



# ***STIC Search Report***

## ***Biotech-Chem Library***

**STIC Database Tracking Number: 126032**

**TO: Terra Gibbs**  
**Location: rem/2d10/2c18**  
**Art Unit : 1635**  
**Wednesday, June 30, 2004**

**Case Serial Number: 10/024369**

**From: Toby Port**  
**Location: Biotech-Chem Library**  
**REM-1A59**  
**Phone: (571) 272-2523**  
**toby.port@uspto.gov**

### **Search Notes**

**THIS PAGE BLANK (USPTO)**



## SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 75%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

**THIS PAGE BLANK (USPIC,**

Schreiber, David

---

126032

**From:** Gibbs, Terra  
**Sent:** Thursday, June 24, 2004 4:48 PM  
**To:** Schreiber, David  
**Subject:** Sequence search request...

Hi David,

I have another request for a score over length search:

I need a length limited nucleotide sequence search of SEQ ID NO:3 in USSN 10/024,369, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched if possible.

*Terra Cotta Gibbs, Ph.D.  
Art Unit 1635  
Remsen Building 2D10  
571-272-0758*

**THIS PAGE BLANK (USPTO)**

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: \_\_\_\_\_ Examiner #: \_\_\_\_\_ Date: \_\_\_\_\_  
 Art Unit: \_\_\_\_\_ Phone Number 30 \_\_\_\_\_ Serial Number: 10 024 369  
 Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (check): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or imply of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

## STAFF USE ONLY

Searcher: <u>P. Schreder</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #: <u>272-2526</u>	NA Sequence (#) <u>15</u>	STN _____
Searcher Location: <u>Kingsen E01P64</u>	AA Sequence (#) _____	Dialog _____
Date Searches Picked Up: _____	Structure (#) _____	Questel/Orbit _____
Rate Completed: <u>6130</u>	Bibliographic _____	Dr. Link _____
Searcher Prep & Review Time: <u>15</u>	Litigation _____	Lexis/Nexis _____
Clerical Prep Time: _____	Fulltext _____	Sequence Systems <u>CompuGen</u>
Online Time: <u>94</u>	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

**(THIS PAGE BLANK (USPTO))**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model1

Run on: June 30, 2004, 08:34:16 ; Search time 12 Seconds  
(without alignments)  
3.427 Million cell updates/sec

Title: US-10-024-369-3

Perfect score: 2247  
Sequence: 1 atgcgcagctcctagctcgc.....ctgcagatgctccgaatga 2247

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 492 seqs, 9152 residues

Total number of hits satisfying chosen parameters: 984

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 495 summaries

Database : rng3.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	41	1.8	41	1	ABZ48393
2	41	1.8	41	1	ABZ50856
3	41	1.8	41	1	ABZ43222
4	31	1.4	31	1	AAI30848
5	28	1.2	28	1	ABK82176
6	28	1.2	28	1	ABL40544
7	27	1.2	27	1	AAT59824
8	27	1.2	27	1	AAT59823
9	27	1.2	27	1	AAV66541
10	27	1.2	27	1	AAV66540
11	26	1.2	26	1	ABK82175
12	24	1.1	24	1	AAZ34534
13	23	1.0	23	1	AAI62374
14	22	1.0	22	1	ABK82236
15	22	1.0	22	1	ABK82237
16	22	1.0	22	1	AAI40543
17	22	1.0	22	1	AAI40542
18	21	0.9	21	1	AAI66003
19	21	0.9	21	1	AAI66004
20	21	0.9	21	1	AAI66011
21	21	0.9	21	1	AAI66007
22	21	0.9	21	1	AAI66006
23	21	0.9	21	1	AAI66009
24	21	0.9	21	1	AAI66010
25	21	0.9	21	1	AAI66005
26	21	0.9	21	1	AAI41089
27	21	0.9	21	1	ABT03924
28	21	0.9	21	1	ACD13527
29	21	0.9	21	1	ADA97828
30	20	0.9	20	1	ABK82235
31	20	0.9	20	1	AAI62402
32	20	0.9	20	1	AAI62413
33	20	0.9	20	1	AAI62423

C 34	20	0.9	20	1	AAI62432	Human ABC transpor
C 35	20	0.9	20	1	AAI62445	Human ABC transpor
C 36	20	0.9	20	1	AAI62449	Human ABC transpor
C 37	20	0.9	20	1	AAI62380	Human ABC transpor
C 38	20	0.9	20	1	AAI62384	Human ABC transpor
C 39	20	0.9	20	1	AAI62385	Human ABC transpor
C 40	20	0.9	20	1	AAI62398	Human ABC transpor
C 41	20	0.9	20	1	AAI62405	Human ABC transpor
C 42	20	0.9	20	1	AAI62426	Human ABC transpor
C 43	20	0.9	20	1	AAI62448	Human ABC transpor
C 44	20	0.9	20	1	AAI62451	Human ABC transpor
C 45	20	0.9	20	1	AAI62401	Human ABC transpor
C 46	20	0.9	20	1	AAI62406	Human ABC transpor
C 47	20	0.9	20	1	AAI62414	Human ABC transpor
C 48	20	0.9	20	1	AAI62437	Human ABC transpor
C 49	20	0.9	20	1	AAI62388	Human ABC transpor
C 50	20	0.9	20	1	AAI62392	Human ABC transpor
C 51	20	0.9	20	1	AAI62397	Human ABC transpor
C 52	20	0.9	20	1	AAI62422	Human ABC transpor
C 53	20	0.9	20	1	AAI62440	Human ABC transpor
C 54	20	0.9	20	1	AAI62442	Human ABC transpor
C 55	20	0.9	20	1	AAI62456	Human ABC transpor
C 56	20	0.9	20	1	AAI62387	Human ABC transpor
C 57	20	0.9	20	1	AAI62395	Human ABC transpor
C 58	20	0.9	20	1	AAI62416	Human ABC transpor
C 59	20	0.9	20	1	AAI62427	Human ABC transpor
C 60	20	0.9	20	1	AAI62441	Human ABC transpor
C 61	20	0.9	20	1	AAI62375	Human ABC transpor
C 62	20	0.9	20	1	AAI62376	Human ABC transpor
C 63	20	0.9	20	1	AAI62389	Human ABC transpor
C 64	20	0.9	20	1	AAI62391	Human ABC transpor
C 65	20	0.9	20	1	AAI62412	Human ABC transpor
C 66	20	0.9	20	1	AAI62434	Human ABC transpor
C 67	20	0.9	20	1	AAI62407	Human ABC transpor
C 68	20	0.9	20	1	AAI62419	Human ABC transpor
C 69	20	0.9	20	1	AAI62431	Human ABC transpor
C 70	20	0.9	20	1	AAI62452	Human ABC transpor
C 71	20	0.9	20	1	AAI62446	Human ABC transpor
C 72	20	0.9	20	1	AAI62447	Human ABC transpor
C 73	20	0.9	20	1	AAI62453	Human ABC transpor
C 74	20	0.9	20	1	AAI62454	Human ABC transpor
C 75	20	0.9	20	1	AAI62409	Human ABC transpor
C 76	20	0.9	20	1	AAI62417	Human ABC transpor
C 77	20	0.9	20	1	AAI62418	Human ABC transpor
C 78	20	0.9	20	1	AAI62421	Human ABC transpor
C 79	20	0.9	20	1	AAI62433	Human ABC transpor
C 80	20	0.9	20	1	AAI62435	Human ABC transpor
C 81	20	0.9	20	1	AAI62450	Human ABC transpor
C 82	20	0.9	20	1	AAI62382	Human ABC transpor
C 83	20	0.9	20	1	AAI62386	Human ABC transpor
C 84	20	0.9	20	1	AAI62436	Human ABC transpor
C 85	20	0.9	20	1	AAI62444	Human ABC transpor
C 86	20	0.9	20	1	AAI62415	Human ABC transpor
C 87	20	0.9	20	1	AAI62439	Human ABC transpor
C 88	20	0.9	20	1	AAI62443	Human ABC transpor
C 89	20	0.9	20	1	AAI62381	Human ABC transpor
C 90	20	0.9	20	1	AAI62394	Human ABC transpor
C 91	20	0.9	20	1	AAI62424	Human ABC transpor
C 92	20	0.9	20	1	AAI62425	Human ABC transpor
C 93	20	0.9	20	1	AAI62429	Human ABC transpor
C 94	20	0.9	20	1	AAI62455	Human ABC transpor
C 95	20	0.9	20	1	AAI62457	Human ABC transpor
C 96	20	0.9	20	1	AAI62396	Human ABC transpor
C 97	20	0.9	20	1	AAI62400	Human ABC transpor
C 98	20	0.9	20	1	AAI62410	Human ABC transpor
C 99	20	0.9	20	1	AAI62383	Human ABC transpor
C 100	20	0.9	20	1	AAI62390	Human ABC transpor
C 101	20	0.9	20	1	AAI62393	Human ABC transpor
C 102	20	0.9	20	1	AAI62403	Human ABC transpor
C 103	20	0.9	20	1	AAI62408	Human ABC transpor
C 104	20	0.9	20	1	AAI62428	Human ABC transpor
C 105	20	0.9	20	1	AAI62438	Human ABC transpor
C 106	20	0.9	20	1	AAI62438	Human ABC transpor

C 107	20	0.9	20	1	AAI62411	Human ABC transpor
C 108	20	0.9	20	1	AAI62420	Human ABC transpor
C 109	20	0.9	20	1	AAI62404	Human ABC transpor
C 110	20	0.9	20	1	AAI62430	Human ABC transpor
C 111	19	0.8	19	1	AAI41088	Primer ON-TAP1-F2
C 112	19	0.8	19	1	AAI82234	Human ATP-binding
C 113	19	0.8	19	1	AAI03523	Human pol kappa 76
C 114	19	0.8	19	1	AAI013526	Human bi-direction
C 115	19	0.8	19	1	AAI97827	Human tumour necro
C 116	18	0.8	18	1	AAI232694	Human MHC Class II
C 117	18	0.8	18	1	AAI76193	Human TAP-1 PCR pr
C 118	18	0.8	18	1	AAI262628	Human Class II regio
C 119	17.2	0.8	22	1	AAI28200	Antisense oligonuc
C 120	17.2	0.8	22	1	AAI18712	Target MMR antisen
C 121	17.2	0.8	22	1	AAI23703	Deletion sequence
C 122	16.8	0.7	20	1	AAI56534	Human PAP-1 antis
C 123	16.8	0.7	20	1	AAI97378	Human NOV-associat
C 124	16.8	0.7	21	1	AAI96716	Human gene single
C 125	16.4	0.7	20	1	AAI60854	CDX4 specific anti
C 126	16.4	0.7	20	1	AAI60835	CDX4 specific anti
C 127	16.4	0.7	21	1	AAI64762	RRV interleukin 6
C 128	16.2	0.7	21	1	AAI073042	Tyrosine-kinase sy
C 129	16.2	0.7	21	1	AAI26604	Human polymorphic
C 130	16.2	0.7	21	1	AAI55721	PCR primer P13. p
C 131	16.2	0.7	21	1	AAI14466	Human src biomarke
C 132	16	0.7	20	1	AAI95793	Capture oligonuclo
C 133	16	0.7	21	1	AAI84244	Chicken glyceralde
C 134	16	0.7	21	1	AAI35649	Chicken glyceralde
C 135	15.8	0.7	19	1	AAI031954	Oligonucleotide PG
C 136	15.8	0.7	19	1	AAI58592	Oligonucleotide PG
C 137	15.8	0.7	19	1	AAI083147	PCR primer used fo
C 138	15.8	0.7	19	1	AAI47527	Matrix metalloprot
C 139	15.8	0.7	20	1	AAI043607	Chlamydia trachoma
C 140	15.8	0.7	20	1	AAI28201	Antisense oligonuc
C 141	15.8	0.7	20	1	AAI18713	Target MMR antisen
C 142	15.8	0.7	20	1	AAI23704	Deletion sequence
C 143	15.8	0.7	20	1	AAI085332	CDNA primer for PA
C 144	15.8	0.7	20	1	AAI085331	CDNA primer for PA
C 145	15.8	0.7	20	1	AAI63984	Human tankyrase2 e
C 146	15.8	0.7	20	1	AAI63985	Human tankyrase2 e
C 147	15.8	0.7	20	1	AAI40440	Mouse caspase 6 an
C 148	15.8	0.7	21	1	AAI659425	Human phosphorilas
C 149	15.8	0.7	21	1	AAI70040	Mycobacterium mari
C 150	15.8	0.7	21	1	AAI81857	M marinum P34 gene
C 151	15.8	0.7	21	1	AAI10097	M. marinum upstrea
C 152	15.4	0.7	17	1	AAI00900	Human GDMLP-1 17-m
C 153	15.4	0.7	17	1	AAI00899	Human GDMLP-1 17-m
C 154	15.4	0.7	17	1	AAI00901	Human GDMLP-1 17-m
C 155	15.4	0.7	17	1	AAI64870	Murine oligonucleo
C 156	15.4	0.7	18	1	AAI62734	Granule bound stear
C 157	15.4	0.7	18	1	AAI89104	p53 binding PG-mot
C 158	15.4	0.7	19	1	AAI84556	Cyclin E ribozyme
C 159	15.4	0.7	19	1	AAI84554	Cyclin E ribozyme
C 160	15.4	0.7	19	1	AAI84555	Cyclin E ribozyme
C 161	15.4	0.7	19	1	AAI859718	Cyclin E ribozyme
C 162	15.4	0.7	19	1	AAI859716	Cyclin E ribozyme
C 163	15.4	0.7	19	1	AAI859717	Cyclin E ribozyme
C 164	15.4	0.7	19	1	AAI293303	Human oligonucleot
C 165	15.2	0.7	20	1	AAI08666	Primer p53-3X7P fo
C 166	15.2	0.7	20	1	AAI99867	Primer for exon 7
C 167	15.2	0.7	20	1	AAI99837	Primer for exon 7
C 168	15.2	0.7	20	1	AAI28203	Antisense oligonuc
C 169	15.2	0.7	20	1	AAI28202	Antisense oligonuc
C 170	15.2	0.7	20	1	AAI237478	Human mdm2 phospho
C 171	15.2	0.7	20	1	AAI205545	PCR primer used to
C 172	15.2	0.7	20	1	AAI18715	Target MMR antisen
C 173	15.2	0.7	20	1	AAI18714	Target MMR antisen
C 174	15.2	0.7	20	1	AAI23705	Deletion sequence
C 175	15.2	0.7	20	1	AAI23706	Deletion sequence
C 176	15.2	0.7	20	1	AAI95547	PCR primer used to
C 177	15.2	0.7	20	1	AAI93890	PCR primer used to
C 178	15.2	0.7	20	1	AAI94024	JNK3-specific prob
C 179	15.2	0.7	20	1	AAI29357	JNK3-specific prob
C 180	15.2	0.7	20	1	AAI97546	Streptomyces albuli
C 181	15.2	0.7	20	1	AAI55792	Human histone deac
C 182	15.2	0.7	20	1	AAI74434	Human biallelic ma
C 183	15.2	0.7	20	1	AAI27482	Human biallelic ma
C 184	15.2	0.7	20	1	AAI62900	JNK antisense olig
C 185	15.2	0.7	20	1	AAI43102	Antisense oligo, t
C 186	15.2	0.7	20	1	AAI80632	Human mdm2 phospho
C 187	15.2	0.7	20	1	AAI07537	Human mdm2 antisen
C 188	15.2	0.7	20	1	AAI83925	ER gene PCR primer
C 189	15.2	0.7	20	1	AAI10981	Murine PAI-1 genot
C 190	15.2	0.7	20	1	AAI54600	Human HLA Class I
C 191	15.2	0.7	20	1	AAI29247	Human mdm2 antisen
C 192	15.2	0.7	20	1	AAI93207	Human oestrogen re
C 193	15.2	0.7	20	1	AAI92551	Adenovirus 5 relat
C 194	15.2	0.7	20	1	AAI39601	Human SR-CYP anti
C 195	15.2	0.7	20	1	AAI93174	Human oestrogen re
C 196	15.2	0.7	20	1	AAI288194	Human oligonucleot
C 197	15.2	0.7	20	1	AAI293288	Human oligonucleot
C 198	15.2	0.7	20	1	AAI33969	Human interleukin
C 199	15.2	0.7	20	1	AAI84008	Toxicologically re
C 200	15.2	0.7	20	1	AAI26604	Human Jun N-termi
C 201	15.2	0.7	20	1	AAI05303	Rat edg1 lysophosp
C 202	15.2	0.7	20	1	AAI99727	Beta-tubulin PCR p
C 203	15.2	0.7	20	1	AAI285679	Human connective t
C 204	15.2	0.7	20	1	AAI88985	Antisense oligonu
C 205	15.2	0.7	20	1	AAI88985	Microsomal triglyc
C 206	15.2	0.7	20	1	AAI21443	Human mdm2 antisen
C 207	15	0.7	15	1	AAI48868	IGFBP3 oligonucleo
C 208	15	0.7	19	1	AAI70949	PCR primer used to
C 209	15	0.7	19	1	AAI16176	Listeria sp. ident
C 210	15	0.7	19	1	AAI89335	Sample member clus
C 211	15	0.7	20	1	AAI62952	Mouse PEPCK-cycto
C 212	15	0.7	20	1	AAI05948	Human diacylglycer
C 213	14.8	0.7	18	1	AAI44610	Human uncoupling p
C 214	14.8	0.7	18	1	AAI93370	KT3 epitope DNA, S
C 215	14.8	0.7	18	1	AAI27570	DNA encoding KT3 e
C 216	14.8	0.7	18	1	AAI71488	DNA encoding prote
C 217	14.8	0.7	18	1	AAI22444	KT3 epitope nucleo
C 218	14.8	0.7	18	1	AAI18351	KT3 epitope DNA.
C 219	14.8	0.7	19	1	AAI17327	Primer used in con
C 220	14.8	0.7	19	1	AAI41791	Human pancreatic c
C 221	14.8	0.7	19	1	AAI27149	Gene 216 SSCP dete
C 222	14.8	0.7	19	1	AAI75002	Human gene 216 pol
C 223	14.8	0.7	19	1	AAI25739	Human REL-A short
C 224	14.8	0.7	19	1	AAI26088	Human REL-A short
C 225	14.8	0.7	19	1	AAI25493	Human PKC-alpha sh
C 226	14.8	0.7	19	1	AAI25368	Human PKC-alpha sh
C 227	14.8	0.7	19	1	AAI23297	Mitogen activated
C 228	14.8	0.7	19	1	AAI30088	Mitogen activated
C 229	14.6	0.6	15	1	AAI16959	Pyridoxal (pyridox
C 230	14.4	0.6	17	1	AAI2677	PCR primer Clamut-
C 231	14.4	0.6	17	1	AAI21561	PCR primer Clamut-
C 232	14.4	0.6	17	1	AAI031733	PCR primer Clamut-
C 233	14.4	0.6	17	1	AAI043301	PCR primer Clamut-
C 234	14.4	0.6	17	1	AAI068674	Primer Clamut-Kan
C 235	14.4	0.6	17	1	AAI62264	Granule bound star
C 236	14.4	0.6	17	1	AAI24820	Oestrogen receptor
C 237	14.4	0.6	17	1	AAI77757	Retinoblastoma mut
C 238	14.4	0.6	17	1	AAI77758	Retinoblastoma mut
C 239	14.4	0.6	17	1	AAI00902	Human GDMLP-1 17-m
C 240	14.4	0.6	17	1	AAI08014	Human GDMLP-1 17-m
C 241	14.4	0.6	17	1	AAI08013	Human GDMLP-1 17-m
C 242	14.4	0.6	17	1	AAI00898	Human GDMLP-1 17-m
C 243	14.4	0.6	17	1	AAI65449	Human pp-GaNTase 1
C 244	14.4	0.6	17	1	AAI65490	Human pp-GaNTase 1
C 245	14.4	0.6	17	1	AAI39140	Tumour suppression
C 246	14.4	0.6	17	1	AAI57647	Human HGPRTMY2-ass
C 247	14.4	0.6	17	1	AAI61070	HCV DNAzyme subst
C 248	14.4	0.6	18	1	AAI651004	Human genotyping p
C 249	14.4	0.6	18	1	AAI53970	Human KfirBeta mu
C 250	14.4	0.6	18	1	AAI24424	PCR primer #1 for
C 251	14.4	0.6	19	1	AAI72326	Human steroid horm
C 252	14.4	0.6	19	1	AAI58297	Human GLUT 10 SSCP



C 253	14.4	0.6	19	1	AAD55156	Goat beta-lac exon
C 254	14.4	0.6	19	1	ADA50311	Human PCR primer r
C 255	14.4	0.6	19	1	ADE29675	Mtogen activated
C 256	14.4	0.6	19	1	ADE29512	Mtogen activated
C 257	14	0.6	14	1	AAQ45287	Sequence of minima
C 258	14	0.6	15	1	AAFA4867	IGFBP3 oligonucleo
C 259	14	0.6	15	1	AAFA4869	IGFBP3 oligonucleo
C 260	14	0.6	16	1	ABA89702	Serial analysis of
C 261	14	0.6	17	1	AAO92210	p53 detection prob
C 262	14	0.6	17	1	AAT81544	Human c-myc hamer
C 263	14	0.6	17	1	AAI65652	Primer for studyn
C 264	14	0.6	17	1	ABN00903	Human GDMWP-1 17-m
C 265	14	0.6	17	1	ABN00904	Human GDMWP-1 17-m
C 266	14	0.6	17	1	ABT39797	Tumour suppression
C 267	14	0.6	17	1	ACD61599	HCV minus strand D
C 268	14	0.6	18	1	AAZ20330	Actinense modulat
C 269	14	0.6	18	1	AAAF76101	CCR5/CCR2b PCR prl
C 270	14	0.6	18	1	AAAF76102	CCR5/CCR2b PCR prl
C 271	14	0.6	18	1	AAFA94632	Rho A antisense ph
C 272	14	0.6	18	1	ABL44589	Human chromosome 1
C 273	13.8	0.6	17	1	AAA24819	Oestrogen receptor
C 274	13.8	0.6	17	1	AAAF02145	Hammerhead ribozym
C 275	13.8	0.6	17	1	AAAF02081	Hammerhead ribozym
C 276	13.8	0.6	17	1	AAAF01721	Hammerhead ribozym
C 277	13.8	0.6	17	1	ABK02015	Human NOGO zinzyme
C 278	13.8	0.6	17	1	ABK00106	Human NOGO Hammer
C 279	13.8	0.6	17	1	ABK01837	Human NOGO zinzyme
C 280	13.8	0.6	17	1	ABN08065	Human GDMWP-1 17-m
C 281	13.8	0.6	17	1	ABN09591	Human GDMWP-1 17-m
C 282	13.8	0.6	17	1	ABN08064	Human GDMWP-1 17-m
C 283	13.8	0.6	17	1	ABN01968	Human GDMWP-1 17-m
C 284	13.8	0.6	17	1	ABN06530	Human GDMWP-1 17-m
C 285	13.8	0.6	17	1	ABN06533	Human GDMWP-1 17-m
C 286	13.8	0.6	17	1	ABN01538	Human GDMWP-1 17-m
C 287	13.8	0.6	17	1	ABN00673	Human GDMWP-1 17-m
C 288	13.8	0.6	17	1	ABN01580	Human GDMWP-1 17-m
C 289	13.8	0.6	17	1	ABN02747	Human GDMWP-1 17-m
C 290	13.8	0.6	17	1	ABN06534	Human GDMWP-1 17-m
C 291	13.8	0.6	17	1	ABN00523	Human GDMWP-1 17-m
C 292	13.8	0.6	17	1	ABN06766	Human GDMWP-1 17-m
C 293	13.8	0.6	17	1	ABN06529	Human GDMWP-1 17-m
C 294	13.8	0.6	17	1	ABO64238	Human KTCM1a portl
C 295	13.8	0.6	17	1	ABV85488	Human pp-GaNTase 1
C 296	13.8	0.6	17	1	ABV85444	Human pp-GaNTase 1
C 297	13.8	0.6	17	1	ABV85800	Human pp-GaNTase 1
C 298	13.8	0.6	17	1	ABV79273	Human HTP1 scannin
C 299	13.8	0.6	17	1	ABK19231	Human ERG Amberzym
C 300	13.8	0.6	17	1	ABK19230	Human ERG Amberzym
C 301	13.8	0.6	17	1	ABV89725	Human POSHL1 scann
C 302	13.8	0.6	17	1	ABV90613	Human POSHL1 scann
C 303	13.8	0.6	17	1	ABV89726	Human POSHL1 scann
C 304	13.8	0.6	17	1	ABV89724	Human POSHL1 scann
C 305	13.8	0.6	17	1	ABV89723	Human POSHL1 scann
C 306	13.8	0.6	17	1	ABL31770	Human HLA genocyp1
C 307	13.8	0.6	17	1	ABL31552	Human HLA genocyp1
C 308	13.8	0.6	17	1	ABK5492	Human CLCA1 gene e
C 309	13.8	0.6	17	1	ABST71929	Human GIP-Rho bind
C 310	13.8	0.6	17	1	ACD00799	G-protein coupled
C 311	13.8	0.6	17	1	ABT36908	Tumour suppression
C 312	13.8	0.6	17	1	ACA09052	NFKB sub-unit modu
C 313	13.8	0.6	17	1	ACA08871	NFKB sub-unit modu
C 314	13.8	0.6	17	1	ACA09051	NFKB sub-unit modu
C 315	13.8	0.6	17	1	ACA06758	NFKB sub-unit modu
C 316	13.8	0.6	17	1	ADA99387	Human MDZ3 scannin
C 317	13.8	0.6	17	1	ADA99540	Human MDZ3 scannin
C 318	13.8	0.6	17	1	ADB00407	Human MDZ3 scannin
C 319	13.8	0.6	17	1	ADB02397	Human MDZ4 scannin
C 320	13.8	0.6	17	1	ABD61560	Human H-Ras DNazym
C 321	13.8	0.6	17	1	ABZ64771	Human HER2 DNazyme
C 322	13.8	0.6	17	1	ABZ65040	Human HER2 DNazyme
C 323	13.8	0.6	17	1	ABZ62176	Human H-Ras DNazym
C 324	13.8	0.6	17	1	ABZ62177	Human H-Ras DNazym
C 325	13.8	0.6	17	1	ABZ61559	Human H-Ras DNazym
C 326	13.8	0.6	17	1	ACD53120	HBV inozyme subctr
C 327	13.8	0.6	17	1	ACD60172	HCY DNazyme subctr
C 328	13.8	0.6	17	1	ACD63300	HCY minus strand D
C 329	13.8	0.6	17	1	ACD51659	HBV hammerhead rib
C 330	13.8	0.6	17	1	ACD61635	HCY minus strand D
C 331	13.8	0.6	17	1	ACD65283	HCY DNAzyme subctr
C 332	13.8	0.6	17	1	ACD57472	Murine oligonucleo
C 333	13.8	0.6	17	1	ACD68479	Murine oligonucleo
C 334	13.8	0.6	17	1	ACC66564	Murine oligonucleo
C 335	13.8	0.6	17	1	ACC64635	Murine oligonucleo
C 336	13.8	0.6	17	1	ADB42925	Tumour suppression
C 337	13.8	0.6	17	1	ADB44878	Tumour suppression
C 338	13.8	0.6	18	1	AAQ65855	PCR primer P-74 fo
C 339	13.8	0.6	18	1	AAV16023	Human cyclooxygena
C 340	13.8	0.6	18	1	AAV15991	Fibroblast growth
C 341	13.8	0.6	18	1	AAV25472	Primer for 307 bp
C 342	13.8	0.6	18	1	AAV25936	Fibroblast growth
C 343	13.8	0.6	18	1	AAV25935	Fibroblast growth
C 344	13.8	0.6	18	1	AAV16023	PCR primer used to
C 345	13.8	0.6	18	1	AAV15991	NBCS (PRC) gene e
C 346	13.8	0.6	18	1	AAV70503	Truncated tpob amp
C 347	13.8	0.6	18	1	AAV81444	Sense oligonucleo
C 348	13.8	0.6	18	1	AAV81445	Sense oligonucleo
C 349	13.8	0.6	18	1	AAV81445	FGF sense oligodeo
C 350	13.8	0.6	18	1	AAV56803	FGF antisense olig
C 351	13.8	0.6	18	1	AAZ44157	Human EGR-1 DNA an
C 352	13.8	0.6	18	1	AAZ23496	Clone vp3.1 hybrid
C 353	13.8	0.6	18	1	AAZ74103	Human biallelic ma
C 354	13.8	0.6	18	1	AAZ43282	Murine Sox2 gene P
C 355	13.8	0.6	18	1	AAO5267	PCR primer C-F use
C 356	13.8	0.6	18	1	AAAS2031	Antisense oligonuc
C 357	13.8	0.6	18	1	AAAS2031	Antisense oligonuc
C 358	13.8	0.6	18	1	AAAF6588	Alzheimer's diseas
C 359	13.8	0.6	18	1	AAAF83006	Human MBSP2 amplif
C 360	13.8	0.6	18	1	AAAF83006	Human MBSP2 amplif
C 361	13.8	0.6	18	1	AAAF83006	Human surfactant p
C 362	13.8	0.6	18	1	AAAF79676	Human Akt-3 antise
C 363	13.8	0.6	18	1	AAAF1452	Human Akt-3 antise
C 364	13.8	0.6	18	1	AAAF1452	Primer JB1133. Sy
C 365	13.8	0.6	18	1	AAAF19762	SNP specific lower
C 366	13.8	0.6	18	1	AAAF76247	Fibroblast growth
C 367	13.8	0.6	18	1	AAAF76247	Human macrophage 1
C 368	13.8	0.6	18	1	AAAF76247	Oat Beta-amylin sy
C 369	13.8	0.6	18	1	AAAF76247	HIV-1 related bind
C 370	13.8	0.6	18	1	ABL89316	HIV-1 related bind
C 371	13.8	0.6	18	1	ABL89316	Endothelial differ
C 372	13.8	0.6	18	1	ABL40468	Endothelial differ
C 373	13.8	0.6	18	1	AAAD40986	Human PI3K p85 ant
C 374	13.8	0.6	18	1	AAK98275	Rat Con-218 R2A ge
C 375	13.8	0.6	18	1	ABK94431	Human MLH1 DNA mis
C 376	13.8	0.6	18	1	ABL46114	Mycobacterium tube
C 377	13.8	0.6	18	1	ABD41843	Fibroblast growth
C 378	13.8	0.6	18	1	ABT06050	Human Igm heavy ch
C 379	13.8	0.6	18	1	ACC46880	Human COB2 related
C 380	13.8	0.6	18	1	ABZ98168	Human CD23 + A1261
C 381	13.8	0.6	18	1	ABT34032	Human pigmentatio
C 382	13.8	0.6	18	1	ABT34032	Human pigmentatio
C 383	13.8	0.6	18	1	ABX95733	Oligonucleotide #2
C 384	13.8	0.6	18	1	ABX95732	Oligonucleotide #1
C 385	13.8	0.6	18	1	ACD27923	Fibroblast growth
C 386	13.8	0.6	18	1	ACD27922	Fibroblast growth
C 387	13.8	0.6	18	1	ACF57054	TM2P cloning forw
C 388	13.8	0.6	18	1	ADC03333	FGF antisense olig
C 389	13.8	0.6	18	1	ADC03332	FGF sense oligonuc
C 390	13.8	0.6	18	1	ADC98362	FGF sense oligonuc
C 391	13.8	0.6	18	1	ADD43511	fosB01 polymorphis
C 392	13.6	0.6	15	1	AA98700	Colony stimulating
C 393	13.6	0.6	15	1	AA98700	Tachykinin recepto
C 394	13.6	0.6	41	1	ABZ48393	Human ATP-binding
C 395	13.6	0.6	41	1	ABZ50855	Human ATP-binding
C 396	13.4	0.6	15	1	ABZ43222	Human ATP-binding
C 397	13.4	0.6	15	1	AAQ11153	3'-terminal noncod
C 398	13.4	0.6	15	1	AAT52346	Mouse ICAM hammerh
C 399	13.4	0.6	15	1	AAT52187	Mouse ICAM hammerh

C	399	13.4	0.6	15	1	AAX64669	Human B7-1 hamsterH
C	400	13.4	0.6	15	1	AAAT97111	Murine p27 wild-type
C	401	13.4	0.6	15	1	AAAT91112	3'-noncoding flank
C	402	13.4	0.6	15	1	AAZ63879	Substrate for hamme
C	403	13.4	0.6	15	1	AAZ56243	V-d5, point mutati-
C	404	13.4	0.6	15	1	AAAS2432	Tdt-expressing Ram
C	405	13.4	0.6	15	1	AAAS5130	Allele specific pr
C	406	13.4	0.6	15	1	AAAF4804	IGFBP3 oligonucleo
C	407	13.4	0.6	15	1	AAAF4804	IGFBP3 oligonucleo
C	408	13.4	0.6	15	1	AAAF48436	IGFBP3 oligonucleo
C	409	13.4	0.6	15	1	AAAF48045	IGFBP3 oligonucleo
C	410	13.4	0.6	15	1	AAAF48043	IGFBP3 oligonucleo
C	411	13.4	0.6	15	1	AAAE50836	IGF-I oligonucleot
C	412	13.4	0.6	15	1	AAAF48558	IGFBP3 oligonucleo
C	413	13.4	0.6	15	1	AAAF45301	IGFBP2 oligonucleo
C	414	13.4	0.6	15	1	AAAF48042	IGFBP3 oligonucleo
C	415	13.4	0.6	15	1	AAAF49257	IGF-I oligonucleot
C	416	13.4	0.6	15	1	AAFE50837	IGF-I oligonucleot
C	417	13.4	0.6	15	1	AAFE50835	IGF-I oligonucleot
C	418	13.4	0.6	15	1	AAAF70355	Human DRD2 allele
C	419	13.4	0.6	15	1	ABK96650	Interleukin-3 (IL-
C	420	13.4	0.6	15	1	ABK961622	Primer used in iso
C	421	13.4	0.6	15	1	ABXO0932	Hepatitis C virus
C	422	13.4	0.6	16	1	AAAD15073	5' PCR primer with
C	423	13.4	0.6	16	1	ABA89678	Serial analysis of
C	424	13.4	0.6	16	1	ABA89770	Serial analysis of
C	425	13.4	0.6	16	1	ABA89672	Serial analysis of
C	426	13.4	0.6	17	1	AAT53360	Rat ICM hammerhea
C	427	13.4	0.6	17	1	AAT53349	Rat ICM hammerhea
C	428	13.4	0.6	17	1	AAT53440	Rat ICM hammerhea
C	429	13.4	0.6	17	1	AAT53555	Rat ICM hammerhea
C	430	13.4	0.6	17	1	AAT53574	Rat ICM hammerhea
C	431	13.4	0.6	17	1	AAT53751	Rat ICM hammerhea
C	432	13.4	0.6	17	1	AAT53494	Rat ICM hammerhea
C	433	13.4	0.6	17	1	AAV20574	Human BRCA1 probe
C	434	13.4	0.6	17	1	AAA18459	Human TIE-2 subscr
C	435	13.4	0.6	17	1	AAA20642	Integrin alpha 6 s
C	436	13.4	0.6	17	1	AAA18460	Human TIE-2 subscr
C	437	13.4	0.6	17	1	AAAX5185	Multiple antisense
C	438	13.4	0.6	17	1	AAA34632	Human adenosine re
C	439	13.4	0.6	17	1	AAAP21457	Human multiple tar
C	440	13.4	0.6	17	1	AAFP20754	Human multiple tar
C	441	13.4	0.6	17	1	AACT0633	Single nucleotide
C	442	13.4	0.6	17	1	AACT0630	Single nucleotide
C	443	13.4	0.6	17	1	AAFO2107	Hammerhead ribozym
C	444	13.4	0.6	17	1	AAFO2109	Hammerhead ribozym
C	445	13.4	0.6	17	1	AAFP2109	Hammerhead ribozym
C	446	13.4	0.6	17	1	AAFO2108	Hammerhead ribozym
C	447	13.4	0.6	17	1	AAFO2108	Hammerhead ribozym
C	448	13.4	0.6	17	1	ABKO2411	Human NCOG Ambery
C	449	13.4	0.6	17	1	ABKO0912	Human NCOG Inozyme
C	450	13.4	0.6	17	1	AAAF26892	Beet necrotic yell
C	451	13.4	0.6	17	1	AAAC22173	Oligomer antiparall
C	452	13.4	0.6	17	1	ABE272318	Gene 216 polymorph
C	453	13.4	0.6	17	1	ABNO6958	Human GDMLP-1 17-m
C	454	13.4	0.6	17	1	ABNO6784	Human GDMLP-1 17-m
C	455	13.4	0.6	17	1	ABNO8015	Human GDMLP-1 17-m
C	456	13.4	0.6	17	1	ABNO0897	Human GDMLP-1 17-m
C	457	13.4	0.6	17	1	ABNO6755	Human GDMLP

472	13.4	0.6	17	1	ABV90561	Human POSH1 scann
473	13.4	0.6	17	1	ABV90559	Human POSH1 scann
474	13.4	0.6	17	1	ABK57194	Human CLCA1 gene e
475	13.4	0.6	17	1	ABK56649	Human CLCA1 gene e
476	13.4	0.6	17	1	ABK56493	Human CLCA1 gene e
477	13.4	0.6	17	1	ABZ97151	Human MTA oligonuc
478	13.4	0.6	17	1	ABZ96448	Human nucleic acid
479	13.4	0.6	17	1	ACD00797	G-protein coupled
480	13.4	0.6	17	1	ACD00798	Tumour suppression
481	13.4	0.6	17	1	ABP38416	Tumour suppression
482	13.4	0.6	17	1	ACA07766	NFKB sub-unit modu
483	13.4	0.6	17	1	ACA07802	NFKB sub-unit modu
484	13.4	0.6	17	1	ACA06237	NFKB sub-unit modu
485	13.4	0.6	17	1	ACA09009	NFKB sub-unit modu
486	13.4	0.6	17	1	ACA06236	NFKB sub-unit modu
487	13.4	0.6	17	1	ABG18128	Human H-Rae DNazym
488	13.4	0.6	17	1	ABZ64627	Human HER2 DNazyme
489	13.4	0.6	17	1	ACD53016	HBV inozyme substr
490	13.4	0.6	17	1	ACD57386	HBV DNazyme substr
491	13.4	0.6	17	1	ACD53015	HBV inozyme substr
492	13.4	0.6	17	1	ABX75171	Human 216 gene all
493	13.4	0.6	17	1	ACC62886	Murine oligonucleo
494	13.4	0.6	17	1	ACC66050	Murine oligonucleo
495	13.4	0.6	17	1	ADB43052	Tumour suppression

ALIGNMENTS

RESULT 1	
ABZ48393	
ID	ABZ48393 standard; DNA; 41 BP.
AC	ABZ48393;
DT	26-JUN-2003 (first entry)
DE	Human ATP-binding cassette ABCB3/TAP1 gene polymorphic site, #5176.
XX	
KW	Human; drug metabolising enzyme; gene; drug metabolism; chromosome 6;
KW	polymorphic site; drug evaluation; drug screening; genotyping;
KW	genetic profiling; therapeutic customisation; adverse reaction;
KW	clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
XX	
OS	Homo sapiens.
XX	
EH	Key
EH	Location/Qualifiers
FT	variation
FT	replac(21,G)
FT	/*tag= a
XX	
PN	WO200252044-A2.
XX	
PD	04-JUL-2002.
XX	
PF	27-DEC-2001; 2001WO-JP011592.
XX	
PR	27-DEC-2000; 2000JP-00399443.
PR	02-MAY-2001; 2001JP-00152526.
PR	27-AUG-2001; 2001JP-00256862.
XX	
PA	(RIKE ) RIKEN KK.
PI	
PI	Nakamura Y, Sekine A, Iida A, Saio S;
XX	
DR	WPI; 2002-583571/62.
PT	
PT	Identifying individuals having a polymorphism, useful for determining the
PT	effectiveness or side effect of a drug or treatment protocol, comprises
PT	detecting at least one polymorphism in the drug metabolizing enzyme
PT	nucleic acid.
XX	
XX	Claim 23; Page 165; 2785pp; English.

XX Sequences AB243217-AB250887 represent polymorphic sites within genes  
 CC encoding enzymes associated with drug metabolism. The invention relates  
 CC to methods and compositions for identifying individuals who have at least  
 CC one polymorphism in such drug metabolizing enzyme-encoding genes. The  
 CC polymorphisms may be identified in a nucleic acid sample using probes or  
 CC primers specific for a sequence selected from AB243217-AB250887 using a  
 CC variety of detection assays, including hybridisation assays, nucleic acid  
 CC arrays and PCR-based methods. The invention also encompasses methods of  
 CC evaluating and screening drugs using genetic polymorphism data. Genetic  
 CC polymorphism data, particularly that relating to single nucleotide  
 CC polymorphisms (SNPs), may be used in studying the relationship between  
 CC DNA sequence variations and human diseases, conditions, and responses to  
 CC drugs. SNPs are also useful as polymorphism markers for discovering genes  
 CC that cause or exacerbate certain diseases. SNPs are particularly useful  
 CC in the above respects as they are stable in populations, occur  
 CC frequently, and have lower mutation rates than other genome variations  
 CC such as repeating sequences. The detection and analysis of polymorphisms  
 CC in genes encoding drug metabolizing enzymes allows the customisation of  
 CC drug therapies based upon the genetic profile of individual patients.  
 CC This would not only take the guesswork out of selecting the drug with the  
 CC greatest therapeutic effect for a particular patient, but would also  
 CC reduce the likelihood of adverse reactions, thereby increasing safety.  
 CC Methods of the invention are also useful in the drug discovery and  
 CC approval processes. For example, individuals could be selected for  
 CC clinical trials only if their genetic profiles indicate that they are  
 CC capable of responding to a particular drug or drug class, and previously  
 CC failed drug candidates could be revived if they were matched with more  
 CC appropriate patient populations. The methods, data and compositions of  
 CC the invention may therefore lead to an increase in the range of  
 CC possible drug targets and decreases in the number of adverse drug  
 CC reactions, failed drug trials, the time taken for a drug to be approved,  
 CC the length of time patients are on medication and the number of different  
 CC medications a patient needs to take before finding an effective therapy

XX SQ Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

XX Query Match 1.8%; Score 41; DB 1; Length 41;  
 Best Local Similarity 100.0%; Pred. No. 0.011;  
 Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCTCACCATTGTCACCTGTATCACCTGCTGCTTTTC 1017  
 Db 1 CCTCACCATTGTCACCTGTATCACCTGCTGCTTTTC 41

RESULT 2  
 AB250856  
 ID AB250856 standard; DNA; 41 BP.  
 AC  
 XX AB250856;  
 DT 26-JUN-2003 (first entry)  
 XX  
 DE Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #7638.  
 XX  
 KM Human: drug metabolizing enzyme; gene; drug metabolism; chromosome 6;  
 KM polymorphic site; drug evaluation; drug screening; genotyping;  
 KM genetic profiling; therapeutic customisation; adverse reaction;  
 KM clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT variation /\*tag= a  
 FT replace(21,G)  
 XX /standard\_name= "Single nucleotide polymorphism (SNP)"  
 PN W0200252044-A2.  
 XX  
 XX 04-JUL-2002.  
 PD  
 XX 27-DEC-2001; 2001WO-JP011592.  
 PF

XX 27-DEC-2000; 2000JP-00399443.  
 PR 02-MAY-2001; 2001JP-00135256.  
 PR 27-AUG-2001; 2001JP-00256862.  
 XX  
 XX (RIKE ) RIKEN KK.  
 XX  
 XX Nakamura Y, Sekine A, Iida A, Saito S;  
 DR WPI; 2002-583571/62.  
 XX  
 XX Identifying individuals having a polymorphism, useful for determining the  
 PT effectiveness or side effect of a drug or treatment protocol, comprises  
 PT detecting at least one polymorphism in the drug metabolizing enzyme  
 PT nucleic acid.

XX Claim 23; Page 223; 2785pp; English.

XX  
 XX Sequences AB243217-AB250887 represent polymorphic sites within genes  
 CC encoding enzymes associated with drug metabolism. The invention relates  
 CC to methods and compositions for identifying individuals who have at least  
 CC one polymorphism in such drug metabolizing enzyme-encoding genes. The  
 CC polymorphisms may be identified in a nucleic acid sample using probes or  
 CC primers specific for a sequence selected from AB243217-AB250887 using a  
 CC variety of detection assays, including hybridisation assays, nucleic acid  
 CC arrays and PCR-based methods. The invention also encompasses methods of  
 CC evaluating and screening drugs using genetic polymorphism data. Genetic  
 CC polymorphism data, particularly that relating to single nucleotide  
 CC polymorphisms (SNPs), may be used in studying the relationship between  
 CC DNA sequence variations and human diseases, conditions, and responses to  
 CC drugs. SNPs are also useful as polymorphism markers for discovering genes  
 CC that cause or exacerbate certain diseases. SNPs are particularly useful  
 CC in the above respects as they are stable in populations, occur  
 CC frequently, and have lower mutation rates than other genome variations  
 CC such as repeating sequences. The detection and analysis of polymorphisms  
 CC in genes encoding drug metabolizing enzymes allows the customisation of  
 CC drug therapies based upon the genetic profile of individual patients.  
 CC This would not only take the guesswork out of selecting the drug with the  
 CC greatest therapeutic effect for a particular patient, but would also  
 CC reduce the likelihood of adverse reactions, thereby increasing safety.  
 CC Methods of the invention are also useful in the drug discovery and  
 CC approval processes. For example, individuals could be selected for  
 CC clinical trials only if their genetic profiles indicate that they are  
 CC capable of responding to a particular drug or drug class, and previously  
 CC failed drug candidates could be revived if they were matched with more  
 CC appropriate patient populations. The methods, data and compositions of  
 CC the invention may therefore lead to an increase in the range of  
 CC possible drug targets and decreases in the number of adverse drug  
 CC reactions, failed drug trials, the time taken for a drug to be approved,  
 CC the length of time patients are on medication and the number of different  
 CC medications a patient needs to take before finding an effective therapy

XX SQ Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

XX Query Match 1.8%; Score 41; DB 1; Length 41;  
 Best Local Similarity 100.0%; Pred. No. 0.011;  
 Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCTCACCATTGTCACCTGTATCACCTGCTGCTTTTC 1017  
 Db 1 CCTCACCATTGTCACCTGTATCACCTGCTGCTTTTC 41

RESULT 3  
 AB243222  
 ID AB243222 standard; DNA; 41 BP.  
 AC  
 XX AB243222;  
 DT 26-JUN-2003 (first entry)  
 XX  
 DE Human ATP-binding cassette ABCB2/TAP2 gene polymorphic site, #6.  
 XX

KW Human; drug metabolising enzyme; gene; drug metabolism; chromosome 6;  
 KW polymorphic site; drug evaluation; drug screening; genotyping;  
 KW genetic profiling; therapeutic customisation; adverse reaction;  
 KW clinical trial; drug approval; single nucleotide polymorphism; SNP; db.  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT replacement(21,G)  
 FT /\*tag= a  
 FT /standard\_name= "single nucleotide polymorphism (SNP)"  
 XX  
 PN MO200252044-A2.  
 XX  
 XX 04-JUL-2002.  
 PD  
 XX 27-DEC-2001; 2001WO-JP011592.  
 PF  
 XX 27-DEC-2000; 2000JP-00399443.  
 PR 02-MAY-2001; 2001JP-00135256.  
 PR 27-AUG-2001; 2001JP-00256862.  
 XX  
 XX (RIKE ) RIKEN KK.  
 PA  
 PI Nakamura Y, Sekine A, Iida A, Saito S;  
 XX  
 XX WPI; 2002-583571/62.  
 DR  
 XX  
 PT Identifying individuals having a polymorphism, useful for determining the  
 PT effectiveness or side effect of a drug or treatment protocol, comprises  
 PT detecting at least one polymorphism in the drug metabolizing enzyme  
 PT nucleic acid.  
 PS  
 XX Claim 23; Page 64; 2785pp; English.  
 XX  
 CC Sequences AB243217-AB250887 represent polymorphic sites within genes  
 CC encoding enzymes associated with drug metabolism. The invention relates  
 CC to methods and compositions for identifying individuals who have at least  
 CC one polymorphism in such drug metabolizing enzyme-encoding genes. The  
 CC polymorphisms may be identified in a nucleic acid sample using probes or  
 CC primers specific for a sequence selected from AB243217-AB250887 using a  
 CC variety of detection assays, including hybridisation assays, nucleic acid  
 CC arrays and PCR-based methods. The invention also encompasses methods of  
 CC evaluating and screening drugs using genetic polymorphism data. Genetic  
 CC polymorphisms (SNPs), may be used in studying the relationship between  
 CC DNA sequence variations and human diseases, conditions, and responses to  
 CC drugs. SNPs are also useful as polymorphism markers for discovering genes  
 CC that cause or exacerbate certain diseases. SNPs are particularly useful  
 CC in the above respects as they are stable in populations, occur  
 CC frequently, and have lower mutation rates than other genome variations  
 CC such as repeating sequences. The detection and analysis of polymorphisms  
 CC in genes encoding drug metabolising enzymes allows the customisation of  
 CC drug therapies based upon the genetic profile of individual patients.  
 CC This would not only take the guesswork out of selecting the drug with the  
 CC greatest therapeutic effect for a particular patient, but would also  
 CC reduce the likelihood of adverse reactions, thereby increasing safety.  
 CC Methods of the invention are also useful in the drug discovery and  
 CC approval processes. For example, individuals could be selected for  
 CC clinical trials only if their genetic profiles indicate that they are  
 CC capable of responding to a particular drug or drug class, and previously  
 CC failed drug candidates could be revived if they were matched with more  
 CC appropriate patient populations. The methods, data and compositions of  
 CC the invention may therefore lead to an increase in the range of  
 CC possible drug targets and decreases in the number of adverse drug  
 CC reactions, failed drug trials, the time taken for a drug to be approved,  
 CC the length of time patients are on medication and the number of different  
 CC medications a patient needs to take before finding an effective therapy  
 CC  
 XX Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;

Query Match 1.8%; Score 41; DB 1; Length 41;  
 Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Oy 977 CCTTCACCATGTCACCCGTGATCACCCGCTGCTTTTC 1017  
 Db 1 CCTTCACCATGTCACCCGTGATCACCCGCTGCTTTTC 41

RESULT 4  
 AI130848  
 ID AI130848 standard; DNA; 31 BP.  
 XX  
 XX AI130848;  
 AC  
 XX  
 XX 18-OCT-2001 (first entry)  
 DT  
 XX Human single nucleotide polymorphism (SNP) TAP1 1.  
 DE  
 XX Human; resequencing; genotype; disease; forensic; paternity testing;  
 KW single nucleotide polymorphism; SNP; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Variation replacement(16,C)  
 FT /\*tag= a  
 FT /standard\_name= "single nucleotide polymorphism"  
 XX  
 PN MO200166800-A2.  
 XX  
 XX 13-SEP-2001.  
 PD  
 XX 07-MAR-2001; 2001WO-US007268.  
 PF  
 XX 07-MAR-2000; 2000US-0187510P.  
 PR 22-MAY-2000; 2000US-0206129P.  
 PR  
 XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.  
 PA  
 PI Cargill M, Ireland JS, Lander ES;  
 XX  
 XX WPI; 2001-522952/57.  
 DR  
 XX  
 PT Nucleic acid molecules from the human genome which include polymorphic  
 PT sites, useful in methods for predicting the presence, absence or severity  
 PT of a particular phenotype or disorder (e.g. diabetes) associated with a  
 PT particular genotype.  
 PS  
 XX Claim 1; Page 112; 145pp; English.  
 XX  
 CC The invention relates to the identification of nucleic acid molecules  
 CC (AA129513-AA131314) from the human genome which include polymorphic sites  
 CC which can predispose individuals to disease. Various genes from a number  
 CC of individuals were resequenced and single nucleotide polymorphisms  
 CC (SNPs) in these genes discovered. The method is useful for predicting the  
 CC presence, absence or severity of a particular phenotype or disorder (e.g.  
 CC diabetes) associated with a particular genotype. The nucleic acids  
 CC containing the polymorphic sites may be useful in forensics and paternity  
 CC testing  
 CC  
 XX Sequence 31 BP; 4 A; 11 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 1.4%; Score 31; DB 1; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 0.44;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 408 CCTTACCGCTTCTGTGTGACGTTATGCAGCG 438  
 Db 1 CCTTACCGCTTCTGTGTGACGTTATGCAGCG 31

RESULT 5  
 ABK82176  
 ID ABK82176 standard; DNA; 28 BP.

```

XX AC ABK82176;
XX DT 27-AUG-2002 (first entry)
XX DE Human ATP-binding cassette (ABC) transporter probe #14.
XX KW Human; ATP-binding cassette transporter; ABC transporter;
XX KM expression rate; drug development; biochemical kinetic; anthelmintic;
XX KW probe; ss.
XX OS Homo sapiens.
XX PN JP2002112775-A.
XX PD 16-APR-2002.
XX PF 03-OCT-2000; 2000JP-00303404.
XX PR 03-OCT-2000; 2000JP-00303404.
XX PA (SAKA ) OTSUKA SEIYAKU KOGYO KK.
XX DR WPI; 2002-458864/49.
XX PS Claim 4; Page 20; 36pp; Japanese.
XX CC The invention describes new probes for identification of human ATP-
XX CC binding cassette (ABC) transporters capable of hybridisation with 33
XX CC regions of genes. Elucidation of expression rate of ABC transporters is
XX CC useful for development of drugs and their biochemical kinetics. This
XX CC sequence represents a probe used to detect human ATP-binding cassette
XX CC (ABC) transporters
XX SQ Sequence 28 BP; 8 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 653 ATGGCTCAGCCGATACCTTCACTCGAAA 680
DB 1 ATGGCTCAGCCGATACCTTCACTCGAAA 28

RESULT 6
AAL40544
ID AAL40544 standard; DNA; 28 BP.
XX AC AAL40544;
XX DT 25-SEP-2002 (first entry)
XX DE Human ABCB2 gene region SEQ ID No 21.
XX KW Human ABCB2 gene region; quenching pigment; human; ABC gene; ds.
XX OS Homo sapiens.
XX PN JP2002181818-A.
XX PD 26-JUN-2002.
XX PF 15-DEC-2000; 2000JP-00381621.
XX PR 15-DEC-2000; 2000JP-00381621.
XX PA (SAKA ) OTSUKA SEIYAKU KOGYO KK.
XX DR WPI; 2002-543426/58.

```

```

XX AC Simultaneous determination of a number of different molecular species of
XX DT protein mRNAs and a kit for the determination composed of primers and
XX DE probes.
XX DE Example 1; Page 14; 23pp; Japanese.
XX CC The invention relates to a method for the simultaneous determination of a
XX CC number of different molecular species of protein mRNAs by the polymerase
XX CC chain reaction (PCR). The kits of the invention comprise of holes each
XX CC containing one primer and probe. The invention particularly comprises a
XX CC combination of a kit of reporter and quencher pigments, for the
XX CC determination of different molecular species. This polynucleotide
XX CC sequence represents a human ABC gene region relating to the invention
XX SQ Sequence 28 BP; 8 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 28; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 653 ATGGCTCAGCCGATACCTTCACTCGAAA 680
DB 1 ATGGCTCAGCCGATACCTTCACTCGAAA 28

RESULT 7
AAT59824/c
ID AAT59824 standard; DNA; 27 BP.
XX AC AAT59824;
XX DT 15-NOV-1997 (first entry)
XX DE TAP-1 antisense oligonucleotide.
XX KW Major histocompatibility complex; MHC class I; antisense; TAP-1;
XX KW tumour specific antigen; cancer; infection; vaccine;
XX KW cytotoxic T lymphocyte; CTL; ss.
XX OS Synthetic.
XX PN WO9707128-A1.
XX PD 27-FEB-1997.
XX PF 20-AUG-1996; 96WO-05013457.
XX PR 21-AUG-1995; 95US-00517373.
XX PA (UYDU-) UNIV DUKE.
XX PI Nair SK, Gilboa E;
XX DR WPI; 1997-165238/15.
XX PT High density presentation of antigens on cells - used in vaccines and to
XX PT generate cytotoxic T cells for treatment of infection and cancer.
XX PS Disclosure; Page 3; 53pp; English.
XX CC An antisense oligonucleotide (AAT59823) is complementary to nucleotides
XX CC 2214-2188 of the human TAP-1 mRNA. It can be used in a novel method of
XX CC altering the presentation of a peptide on a cell. This involves
XX CC inhibiting the activity of an MHC Class I pathway-associated component
XX CC (e.g. TAP, IMP, heat shock protein or proteasome) in a cell using e.g. an
XX CC antisense oligonucleotide, and then contacting the cell with an antigenic
XX CC peptide to produce a potent antigen-presenting cell. Cells loaded with
XX CC the peptides are useful in vaccines for treatment or prevention of
XX CC bacterial or viral infections and, if the peptide is a tumour-specific
XX CC antigen, cancer. The cells can also stimulate proliferation of T cells in
XX CC vitro, generating CTL for treatment of infection and cancer. Inhibition
XX CC of MHC Class I pathway-associated components leads to cells that are

```

CC deficient in endogenous peptide loading, and thus are able to be loaded  
 CC at high density with the peptides, which are presented in the form of a  
 CC MHC-binding epitope, providing powerful APC for stimulation of the immune  
 CC response in vivo or in vitro  
 XX  
 SQ Sequence 27 BP; 9 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 27; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 1.9;  
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1978 AAACCGTGTACTTATCTCGATGAT 2004  
 ||||||||||||||||||||||||||||  
 Db 27 AAACCGTGTACTTATCTCGATGAT 1

RESULT 8  
 AAT59823/C  
 ID AAT59823 standard; DNA; 27 BP.  
 XX AAT59823;  
 AC  
 XX 15-NOV-1997 (first entry)  
 DT  
 XX TAP-1 antisense oligonucleotide.  
 DE  
 XX Major histocompatibility complex; MHC class I; antisense; TAP-1;  
 KM tumour specific antigen; cancer; infection; vaccine;  
 KW cytotoxic T lymphocyte; CTL; ss.  
 XX Synthetic.  
 OS  
 XX WO9707128-A1.  
 PN  
 XX 27-FEB-1997.  
 PD  
 XX 20-AUG-1996; 96WO-US013457.  
 PF  
 XX 21-AUG-1995; 95US-00517373.  
 PR  
 XX (UYDU-) UNIV DUKE.  
 PA  
 XX Nair SK, Gilboa E;  
 PI  
 XX WPI; 1997-165238/15.  
 DR  
 XX High density presentation of antigens on cells - used in vaccines and to  
 PT generate cytotoxic T cells for treatment of infection and cancer.  
 PT  
 XX Disclosure; Page 3; 53pp; English.  
 PS  
 XX An antisense oligonucleotide (AAT59823) is complementary to nucleotides  
 CC 1428-1402 of the human TAP-1 mRNA. It can be used in a novel method of  
 CC altering the presentation of a peptide on a cell. This involves  
 CC inhibiting the activity of an MHC Class I pathway- associated component  
 CC (e.g. TAP, IMP, heat shock protein or proteasome) in a cell using e.g.  
 CC an antisense oligonucleotide, and then contacting the cell with an  
 CC antigenic peptide to produce a potent antigen-presenting cell. Cells  
 CC loaded with the peptides are useful in vaccines for treatment or  
 CC prevention of bacterial or viral infections and, if the peptide is a  
 CC tumour-specific antigen, cancer. The cells can also stimulate  
 CC proliferation of T cells in vitro, generating CTL for treatment of  
 CC infection and cancer. Inhibition of MHC Class I pathway-associated  
 CC components leads to cells that are deficient in endogenous peptide  
 CC loading, and thus are able to be loaded at high density with the  
 CC peptides, which are presented in the form of a MHC-binding epitope,  
 CC providing powerful APC for stimulation of the immune response in vivo or  
 CC in vitro  
 CC  
 SQ Sequence 27 BP; 3 A; 8 C; 6 G; 10 T; 0 U; 0 Other;  
 XX  
 Query Match 1.2%; Score 27; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 1.9;

Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Oy 1192 AAGACTCAACGAGAGGCTGTG 1218  
 ||||||||||||||||||||||||||||  
 Db 27 AAGACTCAACGAGAGGCTGTG 1

RESULT 9  
 AAV6541/C  
 ID AAV6541 standard; DNA; 27 BP.  
 XX AAV6541;  
 AC  
 XX 08-JAN-1999 (first entry)  
 DT  
 XX Antisense oligonucleotide for nucleotides 2214-2188 of human TAP-1.  
 DE  
 XX  
 XX

XX Antisense oligonucleotide; antigen processing protein; TAP; transporter;  
 KM proteasome; antigen-presenting cell; cancer; infection; cytotoxic T cell;  
 KW phosphorothioate; ss.  
 XX Synthetic.  
 OS  
 XX Homo sapiens.  
 XX  
 XX US5831068-A.  
 EN  
 XX 03-NOV-1998.  
 PD  
 XX 20-AUG-1996; 96US-00700035.  
 PP  
 XX 21-AUG-1995; 95US-00517373.  
 PR  
 XX (UYDU-) UNIV DUKE.  
 PA  
 XX Gilboa E, Nair SK;  
 PI  
 XX WPI; 1998-609331/51.  
 DR  
 XX Increasing the presentation of a peptide on a mammalian cell for  
 PT production of antigen-presenting cells and stimulation of immune response  
 PT - by contacting cells with antigen after inactivating the protein  
 PT transporter associated with antigen processing or proteasome.  
 PT  
 XX Example 3; Col 7; 27pp; English.  
 PS  
 XX AAV6537-44 represent antisense oligonucleotides directed against nucleic  
 CC acid encoding antigen processing (TAP) proteins. The oligonucleotides are  
 CC synthesised as phosphorothioate derivatives, and are used in the course  
 CC of the invention. The specification describes a method for increasing the  
 CC presentation of a peptide (antigen) on a mammalian cell. The method  
 CC comprises inhibiting the activity of a transporter associated with TAP or  
 CC proteasome in the cell in vitro before contacting the cell with the  
 CC peptide. Antigen-presenting cells produced as above can be used to  
 CC stimulate an immune response in vitro or in vivo e.g. to treat or prevent  
 CC cancer or infection with a pathogen, e.g. a bacterium or virus. Cytotoxic  
 CC T cells produced as above can also be used for therapy  
 CC  
 SQ Sequence 27 BP; 9 A; 6 C; 5 G; 7 T; 0 U; 0 Other;  
 XX  
 Query Match 1.2%; Score 27; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 1.9;  
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Oy 1978 AAACCGTGTACTTATCTCGATGAT 2004  
 ||||||||||||||||||||||||||||  
 Db 27 AAACCGTGTACTTATCTCGATGAT 1

RESULT 10  
 AAV6540/C  
 ID AAV6540 standard; DNA; 27 BP.  
 XX AAV6540;  
 AC

XX 08-JAN-1999 (first entry)  
 XX Antisense oligonucleotide for nucleotides 1428-1402 of human TAP-1.  
 DE Antisense oligonucleotide; antigen processing protein; TAP; transporter;  
 XX Antisense oligonucleotide; antigen-presenting cell; cancer; infection; cytotoxic T cell;  
 KM phosphorothioate; ss.  
 XX Synthetic.  
 OS Homo sapiens.  
 XX US5831068-A.  
 XX 03-NOV-1998.  
 PD 20-AUG-1996; 96US-00700035.  
 PF 21-AUG-1995; 95US-00517373.  
 XX (UYDU-) UNIV DUKE.  
 PA Gilboa E, Nair SK;  
 PI WPI; 1998-609331/51.  
 XX Increasing the presentation of a peptide on a mammalian cell for  
 PT production of antigen-presenting cells and stimulation of immune response  
 PT - by contacting cells with antigen after inactivating the protein  
 PT transporter associated with antigen processing or proteasome.  
 XX Example 3; Col 7; 27pp; English.  
 CC AAV6537-44 represent antisense oligonucleotides directed against nucleic  
 CC acid encoding antigen processing (TAP) proteins. The oligonucleotides are  
 CC synthesized as phosphorothioate derivatives, and are used in the course  
 CC of the invention. The specification describes a method for increasing the  
 CC presentation of a peptide (antigen) on a mammalian cell. The method  
 CC comprises inhibiting the activity of a transporter associated with TAP or  
 CC proteasome in the cell in vitro before contacting the cell with the  
 CC peptide. Antigen-presenting cells produced as above can be used to  
 CC stimulate an immune response in vitro or in vivo e.g. to treat or prevent  
 CC cancer or infection with a pathogen, e.g. a bacterium or virus. Cytotoxic  
 CC T cells produced as above can also be used for therapy  
 XX Sequence 27 BP; 3 A; 8 C; 6 G; 10 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.2%; Score 27; DB 1; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 1.9;  
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1192 AAGACTCAACGAGAGGCTGTG 1218  
 DB 27 AAGACTCAACGAGAGGCTGTG 1  
 RESULT 11  
 ABR82175  
 ID ABR82175 standard; DNA; 26 BP.  
 AC ABR82175;  
 XX 27-AUG-2002 (first entry)  
 DT Human ATP-binding cassette (ABC) transporter probe #13.  
 DE Human ATP-binding cassette transporter; ABC transporter;  
 KM expression rate; drug development; biochemical kinetic; antihelminthic;  
 KW probe; ss.  
 XX Homo sapiens.  
 OS JP2002112775-A.  
 PN

XX 16-APR-2002.  
 PD 03-OCT-2000; 2000JP-00303404.  
 XX 03-OCT-2000; 2000JP-00303404.  
 PF 03-OCT-2000; 2000JP-00303404.  
 XX (SAKA ) OTSUKA SEIYAKU KOGYO KK.  
 XX WPI; 2002-458864/49.  
 DR Probes for determination of human ATP-binding cassette (ABC) transporters  
 XX capable of hybridization with 33 regions of genes.  
 PT Claim 4; Page 20; 36pp; Japanese.  
 PS The invention describes new probes for identification of human ATP-  
 CC binding cassette (ABC) transporters capable of hybridization with 33  
 CC regions of genes. elucidation of expression rate of ABC transporters is  
 CC useful for development of drugs and their biochemical kinetics. This  
 CC sequence represents a probe used to detect human ATP-binding cassette  
 CC (ABC) transporters  
 XX Sequence 26 BP; 4 A; 7 C; 6 G; 9 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.2%; Score 26; DB 1; Length 26;  
 Best Local Similarity 100.0%; Pred. No. 2.7;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 330 TGCTTGTTCGAGAGCTGATCTCAT 355  
 DB 1 TGCTTGTTCGAGAGCTGATCTCAT 26  
 RESULT 12  
 AA234534  
 ID AA234534 standard; DNA; 24 BP.  
 XX AA234534;  
 AC 01-FEB-2000 (first entry)  
 DT Transporter protein TAP1 exon 9 PCR primer.  
 DE TAP1; transporter associated with antigen protein; TAP; splice variant;  
 KM vaccine; diagnosis; therapy; autoimmune disease; diabetes; cancer; PCR;  
 KW primer; ss.  
 XX Synthetic.  
 OS Homo sapiens.  
 XX W09952928-A1.  
 EN 21-OCT-1999.  
 PD 15-APR-1999; 99WO-US008205.  
 PF 16-APR-1998; 98US-00061764.  
 XX (GEHO ) GEN HOSPITAL CORP.  
 PA Faustman DL;  
 PI WPI; 1999-633819/54.  
 DR Nucleic acid encoding splice variants of transporter associated with  
 XX antigen processing proteins, useful for improving the immune responses.  
 PT Example 2; Page 71; 77pp; English.  
 PS This oligonucleotide is based on exon 9 of the human TAP1 (transporter  
 CC associated with antigen processing 1) gene. It was used as the forward  
 CC primer in the PCR amplification of multiple samples of cDNA from various

CC cell lines in order to determine the pattern of expression of TAP1 and  
 CC its splice variant TAP1iso. The discovery of splice variant TAP subunits  
 CC (see AY32133-34) introduces a cellular mechanism for diversification of  
 CC antigen display to the CD8-positive T cells of the immune system. Methods  
 CC for diagnosis and treatment of diseases or conditions associated with  
 CC abnormal TAP isoform expression, or of expanding the repertoire of  
 CC antigen peptides to which an individual's immune system is capable of  
 CC responding, are also disclosed

XX Sequence 24 BP; 4 A; 8 C; 3 G; 9 T; 0 U; 0 Other;  
 SQ

Query Match 1.1%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 5.5;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1866 TAGTTTCATCTCTGGACTCCTCA 1889  
 |||||  
 1 TAGTTTCATCTCTGGACTCCTCA 24

Db

RESULT 13  
 AAL62374  
 ID AAL62374 standard; DNA; 23 BP.  
 XX  
 AC AAL62374;  
 XX  
 DT 06-OCT-2003 (first entry)  
 XX  
 DE Human ABC transporter MHC I DNA specific forward PCR primer.  
 XX  
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KW PCR; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003051309-A2.  
 XX  
 PD 26-JUN-2003.  
 XX  
 PF 12-DEC-2002; 2002WO-US040101.  
 XX  
 PR 17-DEC-2001; 2001US-00024369.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Borchers AH, Ward DT, Freier SM;  
 XX  
 DR WPI; 2003-577305/54.  
 XX  
 PT New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 XX  
 PS Example 13; Page 78; 112pp; English.  
 XX

CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is human ABC transporter major histocompatibility  
 CC complex I DNA specific PCR primer. This sequence is used to illustrate  
 CC the method of the invention

XX Sequence 23 BP; 7 A; 4 C; 7 G; 5 T; 0 U; 0 Other;  
 SQ

Query Match 1.0%; Score 23; DB 1; Length 23;  
 Best Local Similarity 100.0%; Pred. No. 7.8;  
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 731 TGGGTGACGGGATCTATPACAC 753  
 |||||  
 1 TGGGTGACGGGATCTATPACAC 23

Db

RESULT 14  
 ABR82236  
 ID ABR82236 standard; DNA; 22 BP.  
 XX  
 AC ABR82236;  
 XX  
 DT 27-AUG-2002 (first entry)  
 XX  
 DE Human ATP-binding cassette (ABC) transporter probe #74.  
 XX  
 KW Human; ATP-binding cassette transporter; ABC transporter;  
 KW expression rate; drug development; biochemical kinetic; antihelminthic;  
 KW probe; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN JP2002112775-A.  
 XX  
 PD 16-APR-2002.  
 XX  
 PF 03-OCT-2000; 2000JP-00303404.  
 XX  
 PR 03-OCT-2000; 2000JP-00303404.  
 XX  
 PA (SAKA) OTSUKA SEIYAKU KOGYO KK.  
 XX  
 DR WPI; 2002-458864/49.  
 XX  
 PT Probes for determination of human ATP-binding cassette (ABC) transporters  
 PT capable of hybridization with 33 regions of genes.  
 XX  
 PS Claim 8; Page 27; 36pp; Japanese.  
 XX  
 CC The invention describes new probes for identification of human ATP-  
 CC binding cassette (ABC) transporters capable of hybridisation with 33  
 CC regions of genes. Elucidation of expression rate of ABC transporters is  
 CC useful for development of drugs and their biochemical kinetics. This  
 CC sequence represents a probe used to detect human ATP-binding cassette  
 CC (ABC) transporters  
 XX  
 SQ Sequence 22 BP; 4 A; 8 C; 4 G; 6 T; 0 U; 0 Other;  
 SQ

Query Match 1.0%; Score 22; DB 1; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 11;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 628 CGCCTCACTGACGTGATTCTAC 649  
 |||||  
 1 CGCCTCACTGACGTGATTCTAC 22

Db

RESULT 15  
 ABR82237/C  
 ID ABR82237 standard; DNA; 22 BP.  
 XX  
 AC ABR82237;  
 XX  
 DT 27-AUG-2002 (first entry)  
 XX  
 DE Human ATP-binding cassette (ABC) transporter probe #75.  
 XX



KM Human; ATP-binding cassette transporter; ABC transporter;  
KM expression rate; drug development; biochemical kinetic; anthelmintic;  
KM probe; ss.  
XX  
XX Homo sapiens.  
XX JP2002112775-A.  
XX  
XX PD 16-APR-2002.  
XX  
XX PF 03-OCT-2000; 2000JP-00303404.  
XX PR 03-OCT-2000; 2000JP-00303404.  
XX  
XX (SAKA ) OTSUKA SEIYAKU KOGYO KK.  
XX WPI; 2002-458864/49.  
XX  
XX PT Probes for determination of human ATP-binding cassette (ABC) transporters  
XX capable of hybridization with 33 regions of genes.  
XX  
XX PS Claim 8; Page 27; 36pp; Japanese.  
XX  
XX CC The invention describes new probes for identification of human ATP-  
XX binding cassette (ABC) transporters capable of hybridisation with 33  
XX regions of genes. Elucidation of expression rate of ABC transporters is  
XX useful for development of drugs and their biochemical kinetics. This  
XX sequence represents a probe used to detect human ATP-binding cassette  
XX (ABC) transporters  
XX  
XX SQ Sequence 22 BP; 5 A; 7 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 22; DB 1; Length 22;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 731 TGGGTGACGGGATCTATACAA 752  
DB 22 TGGGTGACGGGATCTATACAA 1  
  
RESULT 16  
AAL40543/c  
ID AAL40543 standard; DNA; 22 BP.  
XX  
XX AC AAL40543;  
XX  
XX DT 25-SEP-2002 (first entry)  
XX  
XX DE Human ABCB2 gene region SEQ ID No 20.  
XX  
XX KM Plural mRNA; kit; reporter; quencher pigment; human; ABC gene; ds.  
XX  
XX OS Homo sapiens.  
XX PN JP2002181818-A.  
XX PD 26-JUN-2002.  
XX  
XX PF 15-DEC-2000; 2000JP-00381621.  
XX PR 15-DEC-2000; 2000JP-00381621.  
XX PA (SAKA ) OTSUKA SEIYAKU KOGYO KK.  
XX  
XX DR WPI; 2002-543426/58.  
XX  
XX PT Simultaneous determination of a number of different molecular species of  
XX protein mRNAs and a kit for the determination composed of primers and  
XX probes.  
XX  
XX PS Example 1; Page 14; 23pp; Japanese.

CC The invention relates to a method for the simultaneous determination of a  
CC number of different molecular species of protein mRNAs by the polymerase  
CC chain reaction (PCR). The kits of the invention comprise of holes each  
CC containing one primer and probe. The invention particularly comprises a  
CC combination of a kit of reporter and quencher pigments, for the  
CC determination of different molecular species. This polynucleotide  
CC sequence represents a human ABC gene region relating to the invention  
XX  
XX SQ Sequence 22 BP; 5 A; 7 C; 3 G; 7 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 22; DB 1; Length 22;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 731 TGGGTGACGGGATCTATACAA 752  
DB 22 TGGGTGACGGGATCTATACAA 1  
  
RESULT 17  
AAL40542  
ID AAL40542 standard; DNA; 22 BP.  
XX  
XX AC AAL40542;  
XX  
XX DT 25-SEP-2002 (first entry)  
XX  
XX DE Human ABCB2 gene region SEQ ID No 19.  
XX  
XX KM Plural mRNA; kit; reporter; quencher pigment; human; ABC gene; ds.  
XX  
XX OS Homo sapiens.  
XX PN JP2002181818-A.  
XX PD 26-JUN-2002.  
XX  
XX PF 15-DEC-2000; 2000JP-00381621.  
XX PR 15-DEC-2000; 2000JP-00381621.  
XX PA (SAKA ) OTSUKA SEIYAKU KOGYO KK.  
XX  
XX DR WPI; 2002-543426/58.  
XX  
XX PT Simultaneous determination of a number of different molecular species of  
XX protein mRNAs and a kit for the determination composed of primers and  
XX probes.  
XX  
XX PS Example 1; Page 14; 23pp; Japanese.  
XX  
XX CC The invention relates to a method for the simultaneous determination of a  
XX number of different molecular species of protein mRNAs by the polymerase  
XX chain reaction (PCR). The kits of the invention comprise of holes each  
XX containing one primer and probe. The invention particularly comprises a  
XX combination of a kit of reporter and quencher pigments, for the  
XX determination of different molecular species. This polynucleotide  
XX sequence represents a human ABC gene region relating to the invention  
XX  
XX SQ Sequence 22 BP; 4 A; 8 C; 4 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 22; DB 1; Length 22;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 628 CGCCTCACTGACTGATTCATC 649  
DB 1 CGCCTCACTGACTGATTCATC 22  
  
RESULT 18  
AAF96003  
ID AAF96003 standard; DNA; 21 BP.

```

XX AC AAF96003;
XX AC 06-JUN-2001 (first entry)
XX DT
XX DE Human gene single nucleotide polymorphism #764.
XX KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX KM polymorphism; vascular disease; coronary artery disease; forensics;
XX KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX KM pulmonary embolism; paternity test; ds.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Variation replace(11,G)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX PD WO200118250-A2.
XX PD 15-MAR-2001.
XX PF 07-SEP-2000; 2000WO-US024503.
XX PR 10-SEP-1999; 99US-0153357P.
XX PR 26-JUL-2000; 2000US-0220947P.
XX PR 16-AUG-2000; 2000US-0225724P.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX DR WPI; 2001-226749/23.
XX PT Nucleic acids comprising single nucleotide polymorphisms, useful in
XX PT applications such as forensics, paternity testing, medicine, genetic
XX PT analysis and phenotype correlations to diseases such as diabetes and
XX PT atherosclerosis.
XX PS Example; Page 101; 242pp; English.
XX CC The present invention provides a method of diagnosing a vascular disease
XX CC in an individual, involving determining the sequence at various
XX CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX CC genes. The sequences at a number of polymorphic sites are also provided
XX CC in the specification. In particular, the method can be used in the
XX CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX CC useful in forensics, paternity testing, genetic analysis and phenotype
XX CC correlations to diseases. The present sequence is an example of one of
XX CC the human gene SNPs shown in the specification
XX SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 706 ATAGCCAGTGCAGTCTGGAG 726
Db 1 ATAGCCAGTGCAGTCTGGAG 21

RESULT 19
AAF96004
ID AAF96004 standard; DNA; 21 BP.
XX AC AAF96004;
XX AC
XX DT 06-JUN-2001 (first entry)
XX DT

```

```

XX DE Human gene single nucleotide polymorphism #765.
XX DE
XX KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX KM polymorphism; vascular disease; coronary artery disease; forensics;
XX KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX KM pulmonary embolism; paternity test; ds.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Variation replace(11,T)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX PD WO200118250-A2.
XX PD 15-MAR-2001.
XX PF 07-SEP-2000; 2000WO-US024503.
XX PR 10-SEP-1999; 99US-0153357P.
XX PR 26-JUL-2000; 2000US-0220947P.
XX PR 16-AUG-2000; 2000US-0225724P.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX DR WPI; 2001-226749/23.
XX PT Nucleic acids comprising single nucleotide polymorphisms, useful in
XX PT applications such as forensics, paternity testing, medicine, genetic
XX PT analysis and phenotype correlations to diseases such as diabetes and
XX PT atherosclerosis.
XX PS Example; Page 101; 242pp; English.
XX CC The present invention provides a method of diagnosing a vascular disease
XX CC in an individual, involving determining the sequence at various
XX CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX CC genes. The sequences at a number of polymorphic sites are also provided
XX CC in the specification. In particular, the method can be used in the
XX CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX CC useful in forensics, paternity testing, genetic analysis and phenotype
XX CC correlations to diseases. The present sequence is an example of one of
XX CC the human gene SNPs shown in the specification
XX SQ Sequence 21 BP; 3 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 ACCCTACGCGCTTGGTGTCA 427
Db 1 ACCCTACGCGCTTGGTGTCA 21

RESULT 20
AAF96011
ID AAF96011 standard; DNA; 21 BP.
XX AC AAF96011;
XX AC
XX DT 06-JUN-2001 (first entry)
XX DT
XX DE Human gene single nucleotide polymorphism #772.
XX DE
XX KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX KM

```

```

KM polymorphism; vascular disease; coronary artery disease; forensics;
KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KM pulmonary embolism; paternity test; ds.
XX
OS Homo sapiens.
FH Key Location/Qualifiers
FT Variation replace(11,T)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200118250-A2.
XX
PD 15-MAR-2001.
XX
PF 07-SEP-2000; 2000WO-US024503.
XX
PR 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILENNIUM PHARM INC.
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis.
XX
PS Example; Page 102; 242pp; English.
XX
CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 6 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1537 CCAAAACGCCAGATGCTTA 1557
Db 1 CCAAAACGCCAGATGCTTA 21
XX
RESULT 21
AAF6007 standard; DNA; 21 BP.
XX
AC AAF6007;
XX
DT 06-JUN-2001 (first entry)
DE Human gene single nucleotide polymorphism #768.
XX
KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KM polymorphism; vascular disease; coronary artery disease; forensics;
KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KM pulmonary embolism; paternity test; ds.
XX

```

```

OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT Variation replace(11,T)
FT /*tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
PN WO200118250-A2.
XX
PD 15-MAR-2001.
XX
PF 07-SEP-2000; 2000WO-US024503.
XX
PR 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILENNIUM PHARM INC.
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
XX applications such as forensics, paternity testing, medicine, genetic
XX analysis and phenotype correlations to diseases such as diabetes and
XX atherosclerosis.
XX
PS Example; Page 101; 242pp; English.
XX
CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 4 A; 3 C; 5 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1245 TAGATTTCAGTATGCTGCT 1265
Db 1 TAGATTTCAGTATGCTGCT 21
XX
RESULT 22
AAF6006 standard; DNA; 21 BP.
XX
AC AAF6006;
XX
DT 06-JUN-2001 (first entry)
DE Human gene single nucleotide polymorphism #767.
XX
KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KM polymorphism; vascular disease; coronary artery disease; forensics;
KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KM pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FT Variation replace(11,G)
XX

```

```

FT      /*tag= a
FT      /standard_name= "single nucleotide polymorphism"
PN      WC200118250-A2.
XX
XX      15-MAR-2001.
XX
XX      07-SEP-2000; 2000WO-US024503.
XX
XX      10-SEP-1999; 99US-0153357P.
PR      26-JUL-2000; 2000US-0220947P.
PR      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA      (MILL-) MILLENNIUM PHARM INC.
PI      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, Mccarthy J;
XX      WPI; 2001-226749/23.
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
PT      applications such as forensics, paternity testing, medicine, genetic
PT      analysis and phenotype correlations to diseases such as diabetes and
PT      atherosclerosis.
XX
XX      Example; Page 101; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
CC      in an individual, involving determining the sequence at various
CC      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC      genes. The sequences at a number of polymorphic sites are also provided
CC      in the specification. In particular, the method can be used in the
CC      diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC      disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC      useful in forensics, paternity testing, genetic analysis and phenotype
CC      correlations to diseases. The present sequence is an example of one of
CC      the human gene SNPs shown in the specification
XX
XX      Sequence 21 BP; 0 A; 7 C; 5 G; 9 T; 0 U; 0 Other;
SQ
QY      Query Match      0.9%; Score 21; DB 1; Length 21;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
      578 TGTGTGTCCTCTCTCTCTG 538
      1 TGTGTGTCCTCTCTCTCTG 21
Db
RESULT 23
AAF96009
ID      AAF96009 standard; DNA; 21 BP.
XX
XX      AAF96009;
XX
XX      06-JUN-2001 (first entry)
XX
XX      Human gene single nucleotide polymorphism #770.
XX
XX      Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW      polymorphism; vascular disease; coronary artery disease; forensics;
KW      myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW      pulmonary embolism; paternity test; ds.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
FT      Variation      replace(11,T)
FT      /*tag= a
FT      /standard_name= "single nucleotide polymorphism"
XX
XX      WC200118250-A2.
PN

```

```

XX      15-MAR-2001.
PD
XX      07-SEP-2000; 2000WO-US024503.
PF
XX      10-SEP-1999; 99US-0153357P.
PR      26-JUL-2000; 2000US-0220947P.
PR      16-AUG-2000; 2000US-0225724P.
XX
XX      (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA      (MILL-) MILLENNIUM PHARM INC.
PI      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, Mccarthy J;
XX      WPI; 2001-226749/23.
XX
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
PT      applications such as forensics, paternity testing, medicine, genetic
PT      analysis and phenotype correlations to diseases such as diabetes and
PT      atherosclerosis.
XX
XX      Example; Page 102; 242pp; English.
XX
XX      The present invention provides a method of diagnosing a vascular disease
CC      in an individual, involving determining the sequence at various
CC      polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC      genes. The sequences at a number of polymorphic sites are also provided
CC      in the specification. In particular, the method can be used in the
CC      diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC      disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC      pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC      useful in forensics, paternity testing, genetic analysis and phenotype
CC      correlations to diseases. The present sequence is an example of one of
CC      the human gene SNPs shown in the specification
XX
XX      Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
SQ
QY      Query Match      0.9%; Score 21; DB 1; Length 21;
      Best Local Similarity 100.0%; Pred. No. 15;
      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
      847 AACATCATGTCTCGGGTAA 867
      1 AACATCATGTCTCGGGTAA 21
Db
RESULT 24
AAF96010
ID      AAF96010 standard; DNA; 21 BP.
XX
XX      AAF96010;
XX
XX      06-JUN-2001 (first entry)
XX
XX      Human gene single nucleotide polymorphism #771.
XX
XX      Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW      polymorphism; vascular disease; coronary artery disease; forensics;
KW      myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW      pulmonary embolism; paternity test; ds.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
FT      Variation      replace(11,G)
FT      /*tag= a
FT      /standard_name= "single nucleotide polymorphism"
XX
XX      WC200118250-A2.
XX
XX      15-MAR-2001.
XX
XX      07-SEP-2000; 2000WO-US024503.
PN

```

```
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI, 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 102; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 3 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 987 GGTCAACCTGATCAGCCGCGC 1007
DB 1 GGTCAACCTGATCAGCCGCGC 21
XX
XX RESULT 25
XX AAF96005
XX ID AAF96005 standard; DNA; 21 BP.
XX AC
XX AAF96005;
XX
XX 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #766.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
XX polymorphism; vascular disease; coronary artery disease; forensics;
XX myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(11,G)
XX FT /*tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
XX 26-JUL-2000; 2000US-0220947P.
XX 16-AUG-2000; 2000US-0225724P.
XX
```

```
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX WPI, 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 101; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
SQ Sequence 21 BP; 1 A; 7 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 15;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 318 CCGCGCGGAGCTTGCTGTT 338
DB 1 CCGCGCGGAGCTTGCTGTT 21
XX
XX RESULT 26
XX AAD41089/C
XX ID AAD41089 standard; DNA; 21 BP.
XX AC
XX AAD41089;
XX
XX 30-OCT-2002 (first entry)
XX
XX Primer ON-TAP1-R2 used for DNA sequencing.
XX
XX Tumour necrosis-factor; TNF; promoter; autoimmune disorder; cancer;
XX therapy; primer; ss.
XX
XX Unidentified.
XX
XX WO200246433-A2.
XX
XX 13-JUN-2002.
XX
XX 07-DEC-2001; 2001WO-EP014412.
XX
XX 08-DEC-2000; 2000US-0254649P.
XX
XX (SAUS/) SAUS J.
XX
XX Saus J;
XX
XX WPI; 2002-519670/55.
XX
XX Novel tumor necrosis-factor inducible promoter useful for identifying
PT candidate compounds for treating/preventing autoimmune disorders/cancer,
PT or for identifying promoters that are regulated by tumor necrosis factor.
XX
XX Example; Page 18; 95pp; English.
XX
```

CC The invention relates to a tumour necrosis-factor TNF inducible promoter.  
 CC The invention is useful for identifying candidate TNF inducible promoters  
 CC by aligning a test sequence consisting of a nucleic acid sequence with a  
 CC comparison sequence selected from the invention, using a gap opening  
 CC penalty of 50 and a gap extension penalty of 3 to define a test  
 CC alignment, shuffling the nucleic sequence of the test sequence at least  
 CC one hundred times, while maintaining its length and composition, to  
 CC produce a series of randomised sequences, aligning the randomised  
 CC sequences with the comparison sequence using a gap opening penalty of 50  
 CC and a gap extension penalty of 3, to produce a series of randomised  
 CC alignments, determining an average alignment quality of the randomised  
 CC alignments, where the average alignment quality of the randomised  
 CC alignments represent an alignment expected by chance, comparing the test  
 CC alignment with the average alignment quality of the randomised alignments  
 CC and identifying a test alignment with a probability value of less than  
 CC 0.05 that the alignment is obtained by chance as a candidate TNF  
 CC inducible promoter. The invention is useful for identifying candidate  
 CC compounds for treating or preventing autoimmune disorders or cancer. The  
 CC present sequence is a primer used in the exemplification of the invention  
 XX  
 SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 15;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678  
 |||||  
 Db 21 TCAGCCGATACCTTCACTCGA 1

RESULT 27  
 ABR03924/C  
 ID ABR03924 standard; DNA; 21 BP.

XX ABR03924;

DT 18-SEP-2002 (first entry)

XX Human pol kappa 76 DNA polymerase sequencing primer #30.

DE Human: pol kappa 76; Goodpasture antigen binding protein; GPBP;

KW chromosome 5q12-13; apoptosis; autoimmune disorder; cancer; cytosolic;

XX Immunosuppressive; PCR; primer; sequencing; ss.

XX Homo sapiens.

XX WO200246378-A2.

XX 13-JUN-2002.

PF 07-DEC-2001; 2001WO-EP014409.

XX 08-DEC-2000; 2000US-0254649P.

PA (SAUS/) SAUS J.

XX Saus J;

XX WPI; 2002-537563/57.

DR Novel isolated pol kappa76 polypeptide, a 76 kDa alternatively spliced

XX variant of DNA polymerase kappa, useful as target for treating a patient

PT with autoimmune disorder or cancer.

XX Example; Page 16; 90pp; English.

CC The present invention provides the protein and coding sequences of human

CC DNA polymerase pol kappa 76. The gene is found on human chromosome 5q12-

CC 13, in a head-to-head arrangement with the Goodpasture antigen binding

CC protein (GPBP). The detection of the coding sequence can be used for

CC diagnosing an autoimmune condition and identifying cells undergoing

CC apoptosis, and the sequences can be used in the treatment of autoimmune

CC diseases and cancer. The present sequence is a sequencing primer

CC described in the invention

XX Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Qy 658 TCAGCCGATACCTTCACTCGA 678  
 |||||  
 Db 21 TCAGCCGATACCTTCACTCGA 1

RESULT 28  
 ACD13527/C

ID ACD13527 standard; DNA; 21 BP.

XX ACD13527;

DT 14-AUG-2003 (first entry)

XX Human bi-directional promoter PCR/sequencing primer ON-TAP1-R2.

DE Human: bi-directional promoter PCR/sequencing primer ON-TAP1-R2.

KW Human; ss; Goodpasture antigen binding protein; GPBP; COL4A3BP;

KW collagen 4 alpha 3 binding protein; DNA polymerase kappa; Pol kappa;

KW Goodpasture disease; cutaneous lupus; polk76; bi-directional promoter;

XX autoimmune disease; cancer; antisense therapy; PCR; primer.

XX Homo sapiens.

XX US2003027165-A1.

XX 06-FEB-2003.

PF 07-DEC-2001; 2001US-00010920.

XX 08-DEC-2000; 2000US-0254649P.

PA (SAUS/) SAUS J.

XX Saus J;

XX WPI; 2003-479531/45.

PT New isolated DNA polymerase, pol kappa 76, useful in identifying

PT autoimmune disorders and in treating cancer and autoimmune disorders by

XX modifying its expression.

XX Example; Page 7; 54pp; English.

XX The invention relates to an isolated pol kappa (K) 76 polypeptide (an

CC alternatively spliced form of DNA polymerase kappa), appearing as

CC ABO07927 (encoded by the cDNA appearing as ACD13492). The gene for

CC POLKappa is located on chromosome 5q12-13 in a head-head arrangement with

CC the gene encoding Goodpasture antigen binding protein (GPBP or collagen 4

CC alpha 3 binding protein (COL4A3BP), associated with autoimmune diseases

CC such as Goodpasture's disease and cutaneous lupus) i.e. has a bi-

CC directional promoter. Also included are a recombinant expression vector

CC comprising the polk76 cDNA, a host cell transfected with the vector,

CC detecting (M1) polk76 (comprising providing a protein sample to be

CC screened, contacting the protein sample to be screened with an anti-

CC polk76 antibody and detecting the formation of an antibody- polypeptide

CC complexes, where the presence of the antibody-polypeptide complexes

CC indicates the presence of polk76), detecting (M2) the polk76 nucleic acid

CC in a sample (comprising contacting the sample with one or more polk76 PCR

CC primer, carrying out PCR to generate PCR products, and identifying the

CC polk76-specific PCR), detecting an autoimmune condition in a patient

CC (comprising providing a tissue or body fluid sample from the patient,

CC providing a control tissue or body fluid sample in which no autoimmune

CC condition is present, and detecting an increase in pol K76 RNA expression

CC in the tissue of body fluid samples compared to the control sample, where

CC the increase indicates the presence of an autoimmune condition) and

CC treating (M3) a patient with an autoimmune disorder or cancer by  
 CC modifying the expression or activity of pol k76 in the patient. Modifying  
 CC the expression or activity of polK76 or polK76 nucleic acid, such as by  
 CC increasing or decreasing their expression or activity using antibodies or  
 CC antisense therapy, is useful for treating an autoimmune disorder or  
 CC cancer. The present sequence is a PCR and/or sequencing primer used in  
 CC the analysis of bi-directional promoters of other genes (and/or of  
 CC polkappa/SPBP), whose structure and sequence were compared to the  
 CC polkappa/SPBP bi-directional promoter  
 XX

SQ Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 658 TCAGCCGATACCTTCACTCGA 678

DB 21 TCAGCCGATACCTTCACTCGA 1

RESULT 29  
 ADA97828/C  
 ID ADA97828 standard; DNA; 21 BP.

XX ADA97828;

XX 20-NOV-2003 (first entry)

XX Human tumour necrosis factor (TNF) inducible promoter PCR primer #30.

XX Human; tumour necrosis factor inducible promoter; TNF;

KW autoimmune disorder; cancer; PCR; immunosuppressive; cytostatic; ss;

XX primer.

XX Homo sapiens.

XX US2003082745-A1.

XX 01-MAY-2003.

XX 07-DEC-2001; 2001US-00008721.

XX 08-DEC-2000; 2000US-0254649P.

XX (SAUS/) SAUS J.

XX Saus J;

XX WPI; 2003-606062/57.

XX New tumor necrosis factor inducible promoters, useful for identifying  
 PT promoters that are regulated by tumor necrosis factor, or for identifying  
 PT candidate compounds for treating or preventing autoimmune disorders or  
 PT cancer.

XX Example; Page 7; 57bp; English.

XX The invention relates to a tumour necrosis factor (TNF) inducible  
 CC promoter. Also disclosed are an expression vector comprising one or more  
 CC tumour necrosis factor inducible promoters and a recombinant host cell  
 CC transfected with one or more expression vectors. The TNF inducible  
 CC promoter, expression vectors and host cells are useful for identifying  
 CC promoters that are regulated by tumour necrosis factor or for identifying  
 CC candidate compounds for treating or preventing autoimmune disorders or  
 CC cancer. This sequence represents a PCR primer used for isolating a tumour  
 CC necrosis factor inducible promoter of the invention.

XX Sequence 21 BP; 5 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 658 TCAGCCGATACCTTCACTCGA 678

DB 21 TCAGCCGATACCTTCACTCGA 1

RESULT 30

ABK82235/C  
 ID ABK82235 standard; DNA; 20 BP.

XX ABK82235;

XX 27-AUG-2002 (first entry)

XX Human ATP-binding cassette (ABC) transporter probe #73.

XX Human; ATP-binding cassette transporter; ABC transporter;

KW expression rate; drug development; biochemical kinetic; anthelmintic;

XX probe; ss.

XX Homo sapiens.

XX JP2002112775-A.

XX 16-APR-2002.

XX 03-OCT-2000; 2000JP-00303404.

XX 03-OCT-2000; 2000JP-00303404.

XX (SAKA ) OTSUKA SEIYAKU KOGYO KK.

XX WPI; 2002-458864/49.

XX Probes for determination of human ATP-binding cassette (ABC) transporters  
 PT capable of hybridization with 33 regions of genes.  
 PT Claim 8; Page 27; 36pp; Japanese.

XX The invention describes new probes for identification of human ATP-  
 CC binding cassette (ABC) transporters capable of hybridization with 33  
 CC regions of genes. Identification of expression rate of ABC transporters is  
 CC useful for development of drugs and their biochemical kinetics. This  
 CC sequence represents a probe used to detect human ATP-binding cassette  
 CC (ABC) transporters

XX Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 412 ACCGCTTCGTTGCTGACTTA 431

DB 20 ACCGCTTCGTTGCTGACTTA 1

RESULT 31

AA162402/C  
 ID AA162402 standard; DNA; 20 BP.

XX AA162402;

XX 06-OCT-2003 (first entry)

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206583.

XX ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;

KW hyperproliferative; autoimmune disorder; antisense gene therapy;

KW inflammation; tumour formation; immunosuppressive; antitubercial; human;

XX phosphorothioate backbone; antisense; ss.

XX Homo sapiens.

```
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX Claim 3; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 740 GGATCTATACACACCATG 759
Db 20 GGATCTATACACACCATG 1
RESULT 32
AAL62413/C
ID AAL62413 standard; DNA; 20 BP.
XX
XX AAL62413;
XX
XX 06-Oct-2003 (first entry)
XX
```

```
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206594.
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX Example 15; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 962 TCTGGGATCAGTGTCCCTC 981
Db 20 TCTGGGATCAGTGTCCCTC 1
```



RESULT 33  
AAL62423/c  
ID AAL62423 standard; DNA; 20 BP.  
XX  
XX AC  
XX AAL62423;  
DT 06-OCT-2003 (first entry)  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206604.  
XX  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorochioate backbone; antisense; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorochioate backbone; All cytidines are 5-methylcytidines"  
FT 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
PN WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
PD  
PP 12-DEC-2002; 2002WO-US040101.  
PR  
PR 17-DEC-2001; 2001US-00024369.  
PA (ISIS-) ISIS PHARM INC.  
PI Borchers AH, Ward DT, Freier SM;  
DR WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.  
PS Claim 3; Page 81; 112pp; English.

The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridises with the nucleic acid molecule and inhibits expression of ATM or specifically hybridises with at least a portion of an active site on the nucleic acid molecule. The invention is useful for inhibiting the expression of ATM in cells or tissues. The invention is useful for treating an animal with hyperproliferative or autoimmune disorder. The invention is useful for diagnostics, therapeutics, prophylaxis, as research reagents and kits, for distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation. The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention

Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

[illegible]

CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1378 GTACTGCTCTCCACTACCC 1397  
DB 20 GTACTGCTCTCCACTACCC 1  
RESULT 35  
AAL62445/C  
ID AAL62445 standard; DNA; 20 BP.  
XX AAL62445;  
AC  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206626.  
XX  
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
FN WO2003051309-A2.  
XX  
PD 26-JUN-2003.  
XX  
PD 12-DEC-2002; 2002WO-US040101.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX  
PT New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
PS Claim 3; Page 81; 112pp; English.  
XX  
CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridises with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridises with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1842 TGCTGACGTAAAGTCTGGGG 1861  
DB 20 TGCTGACGTAAAGTCTGGGG 1  
RESULT 36  
AAL62449/C  
ID AAL62449 standard; DNA; 20 BP.  
XX AAL62449;  
AC  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206630.  
XX  
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
FN WO2003051309-A2.  
XX  
PD 26-JUN-2003.  
XX  
PD 12-DEC-2002; 2002WO-US040101.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX  
PT New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating

PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 PS Claim 3; Page 81; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 XX  
 SQ Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1978 AAACCGGTGTAATTATCCT 1997  
 DB 20 AAACCGGTGTAATTATCCT 1  
 XX  
 RESULT 37  
 AAL62380/C  
 ID AAL62380 standard; DNA; 20 BP.  
 XX  
 AC AAL62380;  
 XX  
 DT 06-OCT-2003 (first entry)  
 XX  
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206561.  
 XX  
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KW phosphorothioate backbone; antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT  
 FT  
 XX WO2003051309-A2.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 12-DEC-2002; 2002WO-US040101.  
 XX  
 XX 17-DEC-2001; 2001US-00024369.  
 XX

PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Borchers AH, Ward DT, Freier SM;  
 XX  
 DR WPI; 2003-577305/54.  
 XX  
 XX  
 PT New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 XX  
 PS Claim 3; Page 80; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 XX  
 SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ATGGCTAGCTCTAGGTGTC 20  
 DB 20 ATGGCTAGCTCTAGGTGTC 1  
 XX  
 RESULT 38  
 AAL62384/C  
 ID AAL62384 standard; DNA; 20 BP.  
 XX  
 AC AAL62384;  
 XX  
 DT 06-OCT-2003 (first entry)  
 XX  
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206565.  
 XX  
 KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KW phosphorothioate backbone; antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT  
 FT  
 XX

```
PN WO2003051309-A2.
XX
XX 26-JUN-2003.
PD
PF 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX WPI; 2003-577305/54.
DR
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
XX Sequence 20 BP; 2 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 219 CGGGGTCTCAGGGCAACGG 238
Db 20 CGGGGTCTCAGGGCAACGG 1
RESULT 39
AAL62385/c
ID AAL62385 standard; DNA; 20 BP.
XX
XX AAL62385;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206566.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
```

```
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT
FT WO2003051309-A2.
PN
XX
XX 26-JUN-2003.
PD
XX
XX 12-DEC-2002; 2002WO-US040101.
PF
XX
XX 17-DEC-2001; 2001US-00024369.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX WPI; 2003-577305/54.
DR
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 225 CCTCAGGGCAACGGTTGGCT 244
Db 20 CCTCAGGGCAACGGTTGGCT 1
RESULT 40
AAL62398/c
ID AAL62398 standard; DNA; 20 BP.
XX
XX AAL62398;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206579.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
```

```

XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
PN WO2003051309-A2.
PD 26-JUN-2003.
PF 12-DEC-2002; 2002MO-US040101.
PR 17-DEC-2001; 2001US-00024369.
PA (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
PI WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX Claim 3; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
SQ
QY Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
644 TTCTACAAGATGGCTCAGCC 663
DB 20 TTCTACAAGATGGCTCAGCC 1
RESULT 41
AAL62405/c
ID AAL62405 standard; DNA; 20 BP.
XX
AC AAL62405;
XX
XX 06-OCT-2003 (first entry)
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206586.
DE

```

```

XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
PN WO2003051309-A2.
PD 26-JUN-2003.
PF 12-DEC-2002; 2002MO-US040101.
PR 17-DEC-2001; 2001US-00024369.
PA (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
PI WPI; 2003-577305/54.
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX Claim 3; Page 80; 112pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
SQ
QY Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
847 AACATCATGTCGTGGTAAC 866
DB 20 AACATCATGTCGTGGTAAC 1
RESULT 42

```

AA62426/C	AA62426 standard; DNA; 20 BP.
XX	AA62426;
AC	AA62426;
XX	AA62426;
XX	AA62426;
DT	06-OCT-2003 (first entry)
XX	
DE	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206607.
XX	
KW	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW	phosphorothioate backbone; antisense; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FT	Key
FT	Location/Qualifiers
FT	modified_base
FT	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note="Phosphorothioate backbone; All cytidines are 5-
FT	methylcytidines"
FT	1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note="2'methoxyethyl nucleotides"
FT	16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note="2'methoxyethyl nucleotides"
XX	
XX	WO2003051309-A2.
XX	
PD	26-JUN-2003.
XX	
PR	12-DEC-2002; 2002MO-US040101.
XX	
PR	17-DEC-2001; 2001US-00024369.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Borchers AH, Ward DT, Freier SM;
XX	
DR	WPI; 2003-577305/54.
XX	
PT	New antisense compound that hybridizes and inhibits the nucleic acid
PT	encoding ABC transporter major histocompatibility complex 1, for treating
PT	diseases or conditions such as a hyperproliferative or autoimmune
PT	disorder.
XX	
PS	Claim 3; Page 81; 112pp; English.
XX	
CC	The invention relates to a compound targeted to a nucleic acid molecule
CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC	where the compound specifically hybridizes with the nucleic acid molecule
CC	and inhibits expression of ATM or specifically hybridizes with at least a
CC	portion of an active site on the nucleic acid molecule. The invention is
CC	useful for inhibiting the expression of ATM in cells or tissues. The
CC	invention is useful for treating an animal with hyperproliferative or
CC	autoimmune disorder. The invention is useful for diagnostics,
CC	therapeutics, prophylaxis, as research reagents and kits, for
CC	distinguishing functions of various members of a biological pathway and
CC	in antisense gene therapy. The invention is also useful prophylactically
CC	e.g., to prevent or delay infection, inflammation or tumour formation.
CC	The present sequence is an antisense oligo targeted to human ABC
CC	transporter MHC I DNA. This sequence is used to illustrate the method of
XX	the invention
SO	Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match	0.9%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 22;

Matches	20	Conservative	0	Mismatches	0	Indels	0	Gaps	0
Oy	1123	CCTAGAGTTGAGAGCTTTGC	1142						
Db	20	CCTAGAGTTGAGAGCTTTGC	1						
RESULT 43									
AAAL62448/c									
ID	AAAL62448	standard; DNA; 20 BP.							
XX									
XX	AAAL62448;								
XX									
XX	06-OCT-2003	(first entry)							
DE									
XX									
KW	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206629.								
KW	ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;								
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;								
KW	inflammation; tumour formation; immunosuppressive; antitubercular; human;								
KW	phosphorothioate backbone; antisense; ss.								
XX									
OS	Homo sapiens.								
XX	Synthetic.								
PH									
FT	Key	Location/Qualifiers							
FT	modified_base	1..20							
FT		/*tag= a							
FT		/mod_base= OTHER							
FT		/note= "phosphorothioate backbone: All cytidines are 5-							
FT		methylcytidines"							
FT	modified_base	1..5							
FT		/*tag= b							
FT		/mod_base= OTHER							
FT		/note= "2'methoxyethyl nucleotides"							
FT	modified_base	15..20							
FT		/*tag= C							
FT		/mod_base= OTHER							
FT		/note= "2'methoxyethyl nucleotides"							
XX									
XX	WO2003051309-A2.								
PD									
XX	26-JUN-2003.								
XX									
PF	12-DEC-2002; 2002WO-US040101.								
XX									
PR	17-DEC-2001; 2001US-00024369.								
XX									
XX	(ISIS-) ISIS PHARM INC.								
PA									
PI	Borchers AH, Ward DT, Freier SW;								
XX									
DR	WPI; 2003-577305/54.								
XX									
PS									
XX	Claim 3; Page 81; 112pp; English.								
CC									
CC	The invention relates to a compound targeted to a nucleic acid molecule								
CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1								
CC	where the compound specifically hybridises with the nucleic acid molecule								
CC	and inhibits expression of ATM or specifically hybridises with at least a								
CC	portion of an active site on the nucleic acid molecule. The invention is								
CC	useful for inhibiting the expression of ATM in cells or tissues. The								
CC	invention is useful for treating an animal with hyperproliferative or								
CC	autoimmune disorder. The invention is useful for diagnostics,								
CC	therapeutics, prophylaxis, as research reagents and kits, for								
CC	distinguishing functions of various members of a biological pathway and								
CC	in antisense gene therapy. The invention is also useful prophylactically								
CC	e.g., to prevent or delay infection, inflammation or tumour formation.								

PT diseases or

XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune

```
PT disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics.
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 714 TGCAGTCTGTGAGTTCTGTG 733
Db 20 TGCAGTCTGTGAGTTCTGTG 1
XX
RESULT 46
AAL62406/c
ID AAL62406 standard; DNA; 20 BP.
XX
AC AAL62406;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206587.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
PA
```

```
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics.
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 866 CAGAGACAGCTCCACCCCTG 885
Db 20 CAGAGACAGCTCCACCCCTG 1
XX
RESULT 47
AAL62414/c
ID AAL62414 standard; DNA; 20 BP.
XX
AC AAL62414;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206595.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
```



```

XX 26-JUN-2003.
PD 12-DEC-2002; 2002MO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 969 ATCAGTGTCCCTCACCATGG 988
Db 20 ATCAGTGTCCCTCACCATGG 1
XX
RESULT 48
AAL62437/c
ID AAL62437 standard; DNA; 20 BP.
XX
AC AAL62437;
XX
DT 06-OCR-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206618.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base 1..5
FT /*tag= b
FT

```

```

FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1506 TGTCCAGTTCACAGATGCT 1525
Db 20 TGTCCAGTTCACAGATGCT 1
XX
RESULT 49
AAL62388/c
ID AAL62388 standard; DNA; 20 BP.
XX
AC AAL62388;
XX
DT 06-OCR-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206569.
XX
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX

```

```
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX PD 26-JUN-2003.
XX PF 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM,
XX WPI; 2003-577305/54.
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX PS Claim 3; Page 80; 112pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
OY Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 294 ATTAGTCGGGCACTGGGCT 313
Db 20 ATTAGTCGGGCACTGGGCT 1
RESULT 50
AAL62392/c
ID AAL62392 standard; DNA; 20 BP.
XX AAL62392;
AC
XX
XX 06-OCT-2003 (first entry)
DT Human ABC transporter MHC I antisense oligonucleotide, ISIS 206573.
XX
```

```
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW hyperproliferative; autoimmune disorder; antisense gene therapy;
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW phosphorothioate backbone; antisense; ss.
XX Homo sapiens.
OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FH /*tag= a
FH /mod_base= OTHER
FH /note= "phosphorothioate backbone; All cytidines are 5-
FH methylcytidines"
FH modified_base 1..5
FH /*tag= b
FH /mod_base= OTHER
FH /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX PD 26-JUN-2003.
XX PF 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM,
XX WPI; 2003-577305/54.
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX PS Claim 3; Page 80; 112pp; English.
XX CC The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
OY Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 391 CTGCACTGGGGAAGTCAACC 410
Db 20 CTGCACTGGGGAAGTCAACC 1
RESULT 51
AAL62397/c
```

ID AAL62397 standard; DNA; 20 BP.  
 XX  
 AC AAL62397;  
 XX  
 DT 06-OCT-2003 (first entry)  
 XX  
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206578.  
 XX  
 KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;  
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KM phosphorothioate backbone; antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key  
 FT modified\_base  
 FT 1. .20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT methylcytidines"  
 FT modified\_base  
 FT 1. .5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base  
 FT 16. .20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 XX  
 PN WO2003051309-A2.  
 XX  
 PD 26-JUN-2003.  
 XX  
 PF 12-DEC-2002; 2002WO-US040101.  
 XX  
 PR 17-DEC-2001; 2001US-00024369.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Borchers AH, Ward DT, Freier SM;  
 XX  
 DR WPI; 2003-577305/54.  
 XX  
 PT New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 XX  
 PS Claim 3; Page 80; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridises with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridises with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutic, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 XX  
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
 Query Match 0.94; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

620 TTACGGGCGGCTCAGTAC 639  
 |||||||||  
 20 TTACGGGCGGCTCAGTAC 1  
 Db  
 RESULT 52  
 AAL62422/c  
 ID AAL62422 standard; DNA; 20 BP.  
 XX  
 AC AAL62422;  
 XX  
 DT 06-OCT-2003 (first entry)  
 XX  
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206603.  
 XX  
 KM ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic;  
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KM phosphorothioate backbone; antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key  
 FT modified\_base  
 FT 1. .20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT methylcytidines"  
 FT modified\_base  
 FT 1. .5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base  
 FT 16. .20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 XX  
 PN WO2003051309-A2.  
 XX  
 PD 26-JUN-2003.  
 XX  
 PF 12-DEC-2002; 2002WO-US040101.  
 XX  
 PR 17-DEC-2001; 2001US-00024369.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Borchers AH, Ward DT, Freier SM;  
 XX  
 DR WPI; 2003-577305/54.  
 XX  
 CC New antisense compound that hybridises and inhibits the nucleic acid  
 CC encoding ABC transporter major histocompatibility complex 1, for treating  
 CC diseases or conditions such as a hyperproliferative or autoimmune  
 CC disorder.  
 XX  
 PS Claim 3; Page 81; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridises with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridises with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutic, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1078 CTGGCAAGTCCAGCCAGGT 1097  
Db 20 CTGGCAAGTCCAGCCAGGT 1  
RESULT 53  
AAL62440/C  
ID AAL62440 standard; DNA; 20 BP.  
XX  
AC AAL62440;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206621.  
XX  
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
PN WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
PD 12-DEC-2002; 2002WO-US040101.  
XX  
PP 17-DEC-2001; 2001US-00024369.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.  
XX  
XX The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridises with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridises with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostic,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 2 A; 9 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1743 GGCTGCAGTGGGACAGAGC 1762  
Db 20 GGCTGCAGTGGGACAGAGC 1  
RESULT 54  
AAL62442/C  
ID AAL62442 standard; DNA; 20 BP.  
XX  
AC AAL62442;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206623.  
XX  
KM ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
PN WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
PD 12-DEC-2002; 2002WO-US040101.  
XX  
PP 17-DEC-2001; 2001US-00024369.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1

CC where the compound specifically hybridizes with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridizes with at least a

CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or

CC autoimmune disorder. The invention is useful for diagnostics,

CC therapeutics, prophylaxis, as research reagents and kits, for

CC distinguishing functions of various members of a biological pathway and

CC in antisense gene therapy. The invention is also useful prophylactically

CC e.g., to prevent or delay infection, inflammation or tumour formation.

CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention

XX

SQ Sequence 20 BP; 4 A; 5 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1773 TGGAGAGAGCTTCAGAAA 1792

DB 20 TGGAGAGAGCTTCAGAAA 1

RESULT 55

AA162456/c

ID AA162456 standard; DNA; 20 BP.

XX

XX AA162456;

DT 06-OCT-2003 (first entry)

XX

DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206637;

XX

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

KM hyperproliferative; autoimmune disorder; antisense gene therapy;

KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;

KM phosphorothioate backbone; antisense; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT methylcytidines"

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

XX

XX WO2003051309-A2.

XX

XX 26-JUN-2003.

XX

XX 12-DEC-2002; 2002WO-US040101.

XX

XX 17-DEC-2001; 2001US-00024369.

XX

XX (ISIS-) ISIS PHARM INC.

XX

PI Borchers AH, Ward DT, Freter SM;

XX WPI; 2003-577305/54.

XX

XX New antisense compound that hybridizes and inhibits the nucleic acid

FT encoding ABC transporter major histocompatibility complex 1, for treating

PT diseases or conditions such as a hyperproliferative or autoimmune

PT disorder.

XX

XX Claim 3; Page 81; 112pp; English.

XX

XX The invention relates to a compound targeted to a nucleic acid molecule

CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1

CC where the compound specifically hybridizes with the nucleic acid molecule

CC and inhibits expression of ATM or specifically hybridizes with at least a

CC portion of an active site on the nucleic acid molecule. The invention is

CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or

CC autoimmune disorder. The invention is useful for diagnostics,

CC therapeutics, prophylaxis, as research reagents and kits, for

CC distinguishing functions of various members of a biological pathway and

CC in antisense gene therapy. The invention is also useful prophylactically

CC e.g., to prevent or delay infection, inflammation or tumour formation.

CC The present sequence is an antisense oligo targeted to human ABC

CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention

XX

SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 22;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2106 CCTCAGCCTGTGTGAGCAGG 2125

DB 20 CCTCAGCCTGTGTGAGCAGG 1

RESULT 56

AA162387/c

ID AA162387 standard; DNA; 20 BP.

XX

XX AA162387;

DT 06-OCT-2003 (first entry)

XX

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206568.

XX

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

KM hyperproliferative; autoimmune disorder; antisense gene therapy;

KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;

KM phosphorothioate backbone; antisense; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT methylcytidines"

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2-methoxyethyl nucleotides"

XX

XX WO2003051309-A2.

XX

```

PD 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
DR
XX
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 270 GGGCTGCTGGCTGCTTTGA 289
Db 20 GGGCTGCTGGCTGCTTTGA 1
RESULT 57
AAL62395/C
ID AAL62395 standard; DNA; 20 BP.
XX
XX AAL62395;
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206576.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
OS
XX Homo sapiens.
OS Synthetic.
XX
XX Key location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER

```

```

FT FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
DR
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 459 GTGGCACAACCTCGGAGCC 478
Db 20 GTGGCACAACCTCGGAGCC 1
RESULT 58
AAL62416/C
ID AAL62416 standard; DNA; 20 BP.
XX
XX AAL62416;
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206597.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
OS
XX Homo sapiens.
OS Synthetic.
XX
XX Key location/Qualifiers
FH

```

```

FT modified_base 1..20
FT /+tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base
FT 1..5
FT /+tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base
FT 16..20
FT /+tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutic, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX SQ Sequence 20 BP; 7 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 995 TGATCACCCTGCTGCTT 1014
XX |||||
XX 20 TGATCACCCTGCTGCTT 1
XX
XX RESULT 59
XX AAL62427/c
XX ID AAL62427 standard; DNA; 20 BP.
XX
XX AC AAL62427;
XX
XX DT 06-OCT-2003 (first entry)
XX
XX DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206608.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;

```

```

KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antidiicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX Key
XX modified_base 1..20
XX /+tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX modified_base
XX 1..5
XX /+tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX modified_base
XX 16..20
XX /+tag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM,
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutic, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1131 TCGAGCTTGGCCAGCAGG 1150
XX |||||
XX 20 TCGAGCTTGGCCAGCAGG 1
XX
XX RESULT 60
XX AAL62441/c
XX ID AAL62441 standard; DNA; 20 BP.

```

```

XX  AAL62441;
AC
XX
XX  06-OCT-2003 (first entry)
DT
XX
XX  Human ABC transporter MHC I antisense oligonucleotide, ISIS 206622.
DE
XX
XX  ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM  hyperproliferative; autoimmune disorder; antisense gene therapy;
KM  inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM  phosphorothioate backbone; antisense; ss.
XX
XX  Homo sapiens.
OS  Synthetic.
XX
XX  Key
FH  Location/Qualifiers
FT  modified_base
FT  1..20
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "Phosphorothioate backbone; All cytidines are 5-
FT  methylcytidines"
FT  1..5
FT  /*tag= b
FT  /mod_base= OTHER
FT  /note= "2' methoxyethyl nucleotides"
FT  16..20
FT  /*tag= c
FT  /mod_base= OTHER
FT  /note= "2' methoxyethyl nucleotides"
XX
XX  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Borchers AH, Ward DT, Freier SM;
PI
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT  encoding ABC transporter major histocompatibility complex 1, for treating
PT  diseases or conditions such as a hyperproliferative or autoimmune
PT  disorder.
XX
XX  Claim 3; Page 81; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC  where the compound specifically hybridises with the nucleic acid molecule
CC  and inhibits expression of ATM or specifically hybridises with at least a
CC  portion of an active site on the nucleic acid molecule. The invention is
CC  useful for inhibiting the expression of ATM in cells or tissues. The
CC  invention is useful for treating an animal with hyperproliferative or
CC  autoimmune disorder. The invention is useful for diagnostics,
CC  therapeutics, prophylaxis, as research reagents and kits, for
CC  distinguishing functions of various members of a biological pathway and
CC  in antisense gene therapy. The invention is also useful prophylactically
CC  e.g., to prevent or delay infection, inflammation or tumour formation.
CC  The present sequence is an antisense oligo targeted to human ABC
CC  transporter MHC I DNA. This sequence is used to illustrate the method of
CC  the invention
XX
SQ  Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

```

```

QY  1756 CAAGAGCCACAGGTATTGG 1775
DB  |||||||||||||||||||
    20 CAAGAGCCACAGGTATTGG 1
    |||||||||||||||||||

RESULT 61
ID  AAL62375/c
ID  AAL62375 standard; DNA; 20 BP.
XX
XX  AAL62375;
AC
XX  06-OCT-2003 (first entry)
DT
XX
XX  Human ABC transporter MHC I DNA specific reverse PCR primer.
DE
XX
XX  ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM  hyperproliferative; autoimmune disorder; antisense gene therapy;
KM  inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM  PCR; primer; ss.
XX
XX  Homo sapiens.
OS
XX
XX  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Borchers AH, Ward DT, Freier SM;
PI
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT  encoding ABC transporter major histocompatibility complex 1, for treating
PT  diseases or conditions such as a hyperproliferative or autoimmune
PT  disorder.
XX
XX  Example 13; Page 78; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC  where the compound specifically hybridises with the nucleic acid molecule
CC  and inhibits expression of ATM or specifically hybridises with at least a
CC  portion of an active site on the nucleic acid molecule. The invention is
CC  useful for inhibiting the expression of ATM in cells or tissues. The
CC  invention is useful for treating an animal with hyperproliferative or
CC  autoimmune disorder. The invention is useful for diagnostics,
CC  therapeutics, prophylaxis, as research reagents and kits, for
CC  distinguishing functions of various members of a biological pathway and
CC  in antisense gene therapy. The invention is also useful prophylactically
CC  e.g., to prevent or delay infection, inflammation or tumour formation.
CC  The present sequence is human ABC transporter major histocompatibility
CC  complex I DNA specific PCR primer. This sequence is used to illustrate
CC  the method of the invention
XX
SQ  Sequence 20 BP; 6 A; 10 C; 1 G; 3 T; 0 U; 0 Other;

```

```

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

RESULT 62
AAL62376
ID  AAL62376 standard; DNA; 20 BP.

```

```

QY  778 TTGCAGGAGAGGCTTTGG 797
DB  |||||||||||||||||||
    20 TTGCAGGAGAGGCTTTGG 1
    |||||||||||||||||||

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```



```

XX AAL62376;
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I DNA specific PCR probe.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX PCR; probe; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1 /*tag= a
XX /mod_base= OTHER
XX /note= "FAM labelled"
XX
XX modified_base 20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "TAMRA labelled"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 13; Page 76; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is human ABC transporter MHC I DNA specific PCR
XX probe. This sequence is used to illustrate the method of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 756 CATGGCCACGTGCACAGCC 775
XX |||||
XX 1 CATGGCCACGTGCACAGCC 20

```

RESULT 63  
AAL62389/c

```

ID AAL62389 standard; DNA; 20 BP.
XX
XX AAL62389;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206570.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1. .20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone; All cytidines are 5-
XX methylcytidines"
XX
XX modified_base 1. .5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2-methoxyethyl nucleotides"
XX
XX modified_base 16. .20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Oy	300	GGCGGCACTGGGCTTGAGCCC	319
Db	20	TGCGGCACACTGGGCTTGAGCCC	1
 RESULT 64			
ID	AAI62391/C		
XX	AAI62391	standard; DNA; 20 BP.	
XX	AAI62391;		
XX	06-OCT-2003	(first entry)	
XX	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206572.		
DE	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;		
XX	hyperproliferative; autoimmune disorder; antisense gene therapy;		
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;		
KW	phosphorothioate backbone; antisense; ss.		
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key	Location/Qualifiers	
FT	modified_base	1..20	
FT		/tag= a	
FT	encoding_base	/mod_base= OTHER	
FT	diseases	/note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"	
FT	modified_base	1..5	
FT		/tag= b	
FT		/mod_base= OTHER	
FT	modified_base	/note= "2'methoxyethyl nucleotides"	
FT		16..20	
FT		/tag= c	
FT		/mod_base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
PN	WO2003051309-A2.		
PD	26-JUN-2003.		
XX	12-DEC-2002; 2002MO-US040101.		
Pf	17-DEC-2001; 2001US-00024369.		
XX	(ISIS-) ISIS PHARM INC.		
PA	Borchers AH, Ward DF, Freier SM;		
PI	WPI; 2003-577305/54.		
DR	New antisense compound that hybridizes and inhibits the nucleic acid		
PT	encoding ABC transporter major histocompatibility complex 1, for treating		
PT	diseases or conditions such as a hyperproliferative or autoimmune		
PT	disorder.		
PS	Claim 3; Page 80; 112pp; English.		
CC	The invention relates to a compound targeted to a nucleic acid molecule		
CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1		
CC	where the compound specifically hybridizes with the nucleic acid molecule		
CC	and inhibits expression of ATM or specifically hybridizes with at least a		
CC	portion of an active site on the nucleic acid molecule. The invention is		
CC	useful for inhibiting the expression of ATM in cells or tissues. The		
CC	invention is useful for treating an animal with hyperproliferative or		
CC	autoimmune disorder. The invention is useful for diagnostics,		
CC	therapeutics, prophylaxis, as research reagents and kits, for		
CC	distinguishing functions of various members of a biological pathway and		
CC	in antisense gene therapy. The invention is also useful prophylactically		
CC	e.g., to prevent or delay infection, inflammation or tumour formation.		
CC	The present sequence is an antisense oligo targeted to human ABC		

CC		transporter MHC I DNA.	This sequence is used to illustrate the method of the invention
CC			
XX	SQ	Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;	
OY		Query Match            0.9%; Score 20; DB 1; Length 20; Best Local Similarity   100.0%; Pred.No. 22; Matches         20; Conservative      0; Mismatches          0; Indels         0; Gaps             0	
Db		334 TTGTTCCGAGACTGCATCTC 353       20 TTGTTCCGAGACTGCATCTC 1	
RESULT 65			
ID	AAL62412/c		
AC	AAL62412 standard; DNA; 20 BP.		
XX	AAL62412;		
DT	06-OCT-2003 (first entry)		
DE	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206593.		
KX	ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;		
KM	hyperproliferative; autoimmune disorder; anticancer gene therapy;		
KW	Inflammation; tumour formation; immunosuppressive; antimicrobial; human;		
KV	phosphorothioate backbone; antisense; ss.		
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key	Location/Qualifiers	
FT	modified_base	1..20	
FT		/tag= a	
FT		/mod_base= OTHER	
FT		/note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"	
FT	modified_base	1..5	
FT		/tag= b	
FT		/mod_base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
FT	modified_base	16..20	
FT		/tag= c	
FT		/mod_base= OTHER	
FT		/note= "2'methoxyethyl nucleotides"	
PN	WO2003051309-A2.		
PD	26-JUN-2003.		
XX			
XX	12-DEC-2002; 2002MO-USO40101.		
PE			
PR	17-DEC-2001; 2001US-00024369.		
PA	(ISIS-) ISIS PHARM INC.		
PI	Borchers AH, Ward DT, Freier SM;		
DR	WPJ; 2003-577305/54.		
PT	New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.		
PS	Example 15; Page 80; 112bp; English.		
CC	The invention relates to a compound targeted to a nucleic acid molecule encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1 where the compound specifically hybridises with the nucleic acid molecule and inhibits expression of ATM or specifically hybridises with at least a portion of an active site on the nucleic acid molecule. The invention is		

CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention

XX SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.9%; Score 20; DB 1; Length 20;  
 XX Best Local Similarity 100.0%; Pred. No. 22;  
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 953 GGATCATGCTCTGGGATCA 972  
 |||||  
 Db 20 GGATCATGCTCTGGGATCA 1

RESULT 66  
 AAL62434/c  
 ID AAL62434 standard; DNA; 20 BP.  
 XX  
 XX AAL62434;  
 XX  
 XX 06-OCT-2003 (first entry)  
 XX  
 XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206615.  
 XX  
 XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
 XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 XX phosphorothioate backbone; antisense; ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 XX modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT methylcytidines"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 PN WO2003051309-A2.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 12-DEC-2002; 2002WO-US040101.  
 XX  
 XX 17-DEC-2001; 2001US-00024369.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Borchers AH, Ward DT, Freier SM,  
 XX  
 XX WPI; 2003-577305/54.  
 XX  
 XX New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.

XX  
 PS Example 15; Page 81; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for creating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention

XX SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.9%; Score 20; DB 1; Length 20;  
 XX Best Local Similarity 100.0%; Pred. No. 22;  
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1431 AATATTTGAGTACCTGGACC 1450  
 |||||  
 Db 20 AATATTTGAGTACCTGGACC 1

RESULT 67  
 AAL62407/c  
 ID AAL62407 standard; DNA; 20 BP.  
 XX  
 XX AAL62407;  
 XX  
 XX 06-OCT-2003 (first entry)  
 XX  
 XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206588.  
 XX  
 XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
 XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 XX phosphorothioate backbone; antisense; ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 XX modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone; All cytidines are 5-  
 FT methylcytidines"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 PN WO2003051309-A2.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 12-DEC-2002; 2002WO-US040101.  
 XX  
 XX 17-DEC-2001; 2001US-00024369.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX

PI Borchers AH, Ward DT, Freier SM;  
XX  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
XX disorder.  
XX  
XX Example 15; Page 80; 112pp; English.  
XX  
XX The invention relates to a compound targetted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridises with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridises with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targetted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 871 GACACGTCACCTGAGTGA 890  
DB 20 GACACGTCACCTGAGTGA 1  
RESULT 68  
AAL62419/C  
ID AAL62419 standard; DNA; 20 BP.  
XX  
XX AAL62419;  
DT 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206600.  
DE  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KW phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX

PD 26-JUN-2003.  
XX  
XX 12-DEC-2002; 2002WO-US040101.  
PF  
XX  
XX 17-DEC-2001; 2001US-00024369.  
PR  
XX  
XX (ISIS-) ISIS PHARM INC.  
FA  
XX  
XX Borchers AH, Ward DT, Freier SM;  
XX  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.  
XX  
XX The invention relates to a compound targetted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridises with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridises with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targetted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1033 GTGGGAAATGTCACAGTT 1052  
DB 20 GTGGGAAATGTCACAGTT 1  
RESULT 69  
AAL62431/C  
ID AAL62431 standard; DNA; 20 BP.  
XX  
XX AAL62431;  
DT 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206612.  
DE  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KW phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT

```

FT /note= "2'methoxyethyl nucleotides"
PT modified_base 16..20
PT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freiler SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1345 CTCACGAGTGCAGTTCAC 1364
DB 20 CTCACGAGTGCAGTTCAC 1

```

```

FT modified_base 1..20
PT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; all cytidines are 5-
FT methylcytidines"
XX
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freiler SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 3 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2020 GATGCAAAACGCCAGTTTACA 2039
DB 20 GATGCAAAACGCCAGTTTACA 1

```

```

RESULT 71
AAL62446/c
ID AAL62446 standard; DNA; 20 BP.
XX
XX AAL62446;
AC
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206627.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX

```

```

KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics, for
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1871 TCATCTCTGACCTCCCTCAG 1890
DB 20 TCATCTCTGACCTCCCTCAG 1

```

```

XX
XX AAL62447;
AC 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206628.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridises and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics, for
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 1879 GGACTCCCTCAGGCGCTATGA 1898  
 |||||  
 DB 20 GGACTCCCTCAGGCGCTATGA 1

RESULT 73  
 AAL62453/c  
 ID AAL62453 standard; DNA; 20 BP.

XX AAL62453;

DT 06-OCT-2003 (first entry)

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206634.

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 XX phosphorothioate backbone; antisense; ss.

OS Homo sapiens.  
 XX Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

XX WO2003051309-A2.

XX 26-JUN-2003.

XX 12-DEC-2002; 2002WO-US040101.

XX 17-DEC-2001; 2001US-00024369.

XX (ISIS-) ISIS PHARM INC.

XX Borchers AH, Ward DT, Freier SM;

XX WPI; 2003-577305/54.

XX New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of

CC the invention  
 XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;  
 SQ

Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2041 GTGAGCAGCTCCTGTACGA 2060  
 |||||  
 DB 20 GTGAGCAGCTCCTGTACGA 1

RESULT 74  
 AAL62454/c  
 ID AAL62454 standard; DNA; 20 BP.

XX AAL62454;

DT 06-OCT-2003 (first entry)

XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206635.

XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 XX phosphorothioate backbone; antisense; ss.

OS Homo sapiens.  
 XX Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidines are 5-

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'methoxyethyl nucleotides"

XX WO2003051309-A2.

XX 26-JUN-2003.

XX 12-DEC-2002; 2002WO-US040101.

XX 17-DEC-2001; 2001US-00024369.

XX (ISIS-) ISIS PHARM INC.

XX Borchers AH, Ward DT, Freier SM;

XX WPI; 2003-577305/54.

XX New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.

XX Claim 3; Page 81; 112pp; English.

XX The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridizes with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridizes with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The

CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 2059 GAAAGCCTGAGCGGTACTC 2078  
Db 20 GAAAGCCTGAGCGGTACTC 1  
RESULT 75  
ID AAL62409/c  
XX AAL62409 standard; DNA; 20 BP.  
XX AAL62409;  
XX  
XX 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206590.  
XX  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
XX modified\_base 1..20  
XX /\*tag= a  
XX /mod\_base= OTHER  
XX /note= "Phosphorothioate backbone; All cytidines are 5-  
XX methylcytidines"  
XX modified\_base 1..5  
XX /\*tag= b  
XX /mod\_base= OTHER  
XX /note= "2' methoxyethyl nucleotides"  
XX modified\_base 16..20  
XX /\*tag= c  
XX /mod\_base= OTHER  
XX /note= "2' methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
XX 12-DEC-2002; 2002WO-US040101.  
XX  
XX 17-DEC-2001; 2001US-00024369.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Borchers AH, Ward DT, Freier SM;  
XX  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
XX encoding ABC transporter major histocompatibility complex 1, for treating  
XX diseases or conditions such as a hyperproliferative or autoimmune  
XX disorder.

PS Claim 3; Page 80; 112pp; English.  
XX  
XX The invention relates to a compound targeted to a nucleic acid molecule  
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
XX where the compound specifically hybridises with the nucleic acid molecule  
XX and inhibits expression of ATM or specifically hybridises with at least a  
XX portion of an active site on the nucleic acid molecule. The invention is  
XX useful for inhibiting the expression of ATM in cells or tissues. The  
XX invention is useful for treating an animal with hyperproliferative or  
XX autoimmune disorder. The invention is useful for diagnostics,  
XX therapeutics, prophylaxis, as research reagents and kits, for  
XX distinguishing functions of various members of a biological pathway and  
XX in antisense gene therapy. The invention is also useful prophylactically  
XX e.g., to prevent or delay infection, inflammation or tumour formation.  
XX The present sequence is an antisense oligo targeted to human ABC  
XX transporter MHC I DNA. This sequence is used to illustrate the method of  
XX the invention  
XX  
SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 915 ATTCTGTGTGTAACCTGTGTC 934  
Db 20 ATTCTGTGTGTAACCTGTGTC 1  
RESULT 76  
ID AAL62417/c  
XX AAL62417 standard; DNA; 20 BP.  
XX AAL62417;  
XX  
XX 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206598.  
XX  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
XX modified\_base 1..20  
XX /\*tag= a  
XX /mod\_base= OTHER  
XX /note= "Phosphorothioate backbone; All cytidines are 5-  
XX methylcytidines"  
XX modified\_base 1..5  
XX /\*tag= b  
XX /mod\_base= OTHER  
XX /note= "2' methoxyethyl nucleotides"  
XX modified\_base 16..20  
XX /\*tag= c  
XX /mod\_base= OTHER  
XX /note= "2' methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
XX 12-DEC-2002; 2002WO-US040101.  
XX  
XX 17-DEC-2001; 2001US-00024369.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Borchers AH, Ward DT, Freier SM;  
XX



```
XX WPI, 2003-577305/54.
DR
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1018 CTCTGCCCAAGAGGTGG 1037
DB 20 CTCTGCCCAAGAGGTGG 1
RESULT 77
AAL62418/c
ID AAL62418 standard; DNA; 20 BP.
XX
XX AAL62418;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206599.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5 /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20 /*tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
PD
```

```
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Borchers AH, Ward DT, Freier SM;
PI
XX
XX WPI, 2003-577305/54.
DR
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 3 A; 8 C; 1 G; 8 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1028 AGAAGGTGGGAAATGCTAC 1047
DB 20 AGAAGGTGGGAAATGCTAC 1
RESULT 78
AAL62421/c
ID AAL62421 standard; DNA; 20 BP.
XX
XX AAL62421;
AC
XX
XX 06-OCT-2003 (first entry)
DT
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206602.
DE
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20 /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5 /*tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX
```

```

FT modified_base 16..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT
XX
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics, for
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1045 TACCAGTTGCTGGAAGTCA 1064
Db 20 TACCAGTTGCTGGAAGTCA 1
RESULT 79
AAL62433/c
ID AAL62433 standard; DNA; 20 BP.
XX
XX AAL62433;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206614.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20

```

```

FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT
XX
XX modified_base 1..5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridises with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridises with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics, for
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1424 CACGAGAAATATTGACTAC 1443
Db 20 CACGAGAAATATTGACTAC 1
RESULT 80
AAL62435/c
ID AAL62435 standard; DNA; 20 BP.
XX
XX AAL62435;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206616.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;

```

KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KM phosphorochioate backbone; antisense; ss.  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX Key  
 FH modified\_base  
 FT 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorochioate backbone; All cytidines are 5-methylcytidines"  
 FT modified\_base  
 FT 1..5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base  
 FT 16..20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 XX  
 XX WO2003051309-A2.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 12-DEC-2002; 2002WO-US040101.  
 XX  
 XX 17-DEC-2001; 2001US-00024369.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Borchers AH, Ward DT, Freier SM;  
 PI  
 XX WPI; 2003-577305/54.  
 DR  
 XX  
 PT New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 PT  
 XX  
 PS Claim 3; Page 81; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridises with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridises with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 CC  
 XX  
 SQ Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1473 TGGTCTGTGACTCCCTTAC 1492  
 DB 20 TGGTCTGTGACTCCCTTAC 1  
 RESULT 81  
 AAL62450/C  
 ID AAL62450 standard; DNA; 20 BP.  
 XX

AC AAL62450;  
 XX  
 XX 06-OCT-2003 (first entry)  
 DT  
 XX  
 XX  
 DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206631.  
 XX  
 XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytotoxic;  
 KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
 KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
 KM phosphorochioate backbone; antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX Key  
 FH modified\_base  
 FT 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorochioate backbone; All cytidines are 5-methylcytidines"  
 FT modified\_base  
 FT 1..5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 FT modified\_base  
 FT 16..20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethyl nucleotides"  
 XX  
 XX WO2003051309-A2.  
 XX  
 XX 26-JUN-2003.  
 XX  
 XX 12-DEC-2002; 2002WO-US040101.  
 XX  
 XX 17-DEC-2001; 2001US-00024369.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Borchers AH, Ward DT, Freier SM;  
 PI  
 XX WPI; 2003-577305/54.  
 DR  
 XX  
 PT New antisense compound that hybridizes and inhibits the nucleic acid  
 PT encoding ABC transporter major histocompatibility complex 1, for treating  
 PT diseases or conditions such as a hyperproliferative or autoimmune  
 PT disorder.  
 PT  
 XX  
 PS Claim 3; Page 81; 112pp; English.  
 XX  
 CC The invention relates to a compound targeted to a nucleic acid molecule  
 CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
 CC where the compound specifically hybridises with the nucleic acid molecule  
 CC and inhibits expression of ATM or specifically hybridises with at least a  
 CC portion of an active site on the nucleic acid molecule. The invention is  
 CC useful for inhibiting the expression of ATM in cells or tissues. The  
 CC invention is useful for treating an animal with hyperproliferative or  
 CC autoimmune disorder. The invention is useful for diagnostics,  
 CC therapeutics, prophylaxis, as research reagents and kits, for  
 CC distinguishing functions of various members of a biological pathway and  
 CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 CC  
 XX  
 SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1988 TACTTATCTGTGATGCC 2007

```
Db          20 TACTTATCTCGATGATGCC 1
|||||
RESULT 82
AAL62382/C
ID  AAL62382 standard; DNA; 20 BP.
XX
XX  AAL62382;
AC
XX
DT  06-OCT-2003 (first entry)
XX
DE  Human ABC transporter MHC I antisense oligonucleotide, ISIS 206563.
XX
XX  ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM  hyperproliferative; autoimmune disorder; antisense gene therapy;
KM  inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW  phosphorothioate backbone; antisense; ss.
XX
OS  Homo sapiens.
XX  Synthetic.
XX
FH  Key
FT  modified_base
FT  1..20
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "phosphorothioate backbone; All cytidines are 5-
FT  methylcytidines"
FT  1..5
FT  /*tag= b
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
FT  16..20
FT  /*tag= c
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
XX
XX  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Borchers AH, Ward DT, Freier SM;
PI
XX
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT  encoding ABC transporter major histocompatibility complex 1, for treating
PT  diseases or conditions such as a hyperproliferative or autoimmune
PT  disorder.
XX
XX  Claim 3; Page 80; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC  where the compound specifically hybridises with the nucleic acid molecule
CC  and inhibits expression of ATM or specifically hybridises with at least a
CC  portion of an active site on the nucleic acid molecule. The invention is
CC  useful for inhibiting the expression of ATM in cells or tissues. The
CC  invention is useful for treating an animal with hyperproliferative or
CC  autoimmune disorder. The invention is useful for diagnostics,
CC  therapeutics, prophylaxis, as research reagents and kits, for
CC  distinguishing functions of various members of a biological pathway and
CC  in antisense gene therapy. The invention is also useful prophylactically
CC  e.g., to prevent or delay infection, inflammation or tumour formation.
CC  The present sequence is an antisense oligo targeted to human ABC
CC  transporter MHC I DNA. This sequence is used to illustrate the method of
CC  the invention
```

```
XX
SQ  Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
      0.9%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 22;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy  90 CGCCGACTGGGTCCTCTCC 109
Db  20 CGCCGACTGGGTCCTCTCC 1
|||||
RESULT 83
AAL62386/C
ID  AAL62386 standard; DNA; 20 BP.
XX
XX  AAL62386;
AC
XX
DT  06-OCT-2003 (first entry)
XX
DE  Human ABC transporter MHC I antisense oligonucleotide, ISIS 206567.
XX
XX
XX  ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM  hyperproliferative; autoimmune disorder; antisense gene therapy;
KM  inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KW  phosphorothioate backbone; antisense; ss.
XX
OS  Homo sapiens.
XX  Synthetic.
XX
FH  Key
FT  modified_base
FT  1..20
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "phosphorothioate backbone; All cytidines are 5-
FT  methylcytidines"
FT  1..5
FT  /*tag= b
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
FT  16..20
FT  /*tag= c
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
XX
XX  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Borchers AH, Ward DT, Freier SM;
PI
XX
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT  encoding ABC transporter major histocompatibility complex 1, for treating
PT  diseases or conditions such as a hyperproliferative or autoimmune
PT  disorder.
XX
XX  Claim 3; Page 80; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
CC  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC  where the compound specifically hybridises with the nucleic acid molecule
CC  and inhibits expression of ATM or specifically hybridises with at least a
CC  portion of an active site on the nucleic acid molecule. The invention is
CC  useful for inhibiting the expression of ATM in cells or tissues. The
CC  invention is useful for treating an animal with hyperproliferative or
```

CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 255 AAACGCGTGTCCAGGGCT 274  
Db 20 AAACGCGTGTCCAGGGCT 1  
RESULT 84  
AAL62436/C  
ID AAL62436 standard; DNA; 20 BP.  
XX AAL62436;  
XX /mod\_base= OTHER  
XX 06-OCT-2003 (first entry)  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206617.  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX Homo sapiens.  
XX Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*cag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methyleytidines"  
FT modified\_base 1..5  
FT /\*cag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*cag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX WO2003051309-A2.  
XX 26-JUN-2003.  
XX 12-DEC-2002; 2002WO-US040101.  
XX 17-DEC-2001; 2001US-00024369.  
XX (ISIS-) ISIS PHARM INC.  
XX Borchers AH, Ward DT, Freier SM;  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
XX encoding ABC transporter major histocompatibility complex 1, for treating  
XX diseases or conditions such as a hyperproliferative or autoimmune  
XX disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.

XX  
CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridizes with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridizes with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1481 TGACTCCCTTACACTTGAG 1500  
Db 20 TGACTCCCTTACACTTGAG 1  
RESULT 85  
AAL62444/C  
ID AAL62444 standard; DNA; 20 BP.  
XX AAL62444;  
XX /mod\_base= OTHER  
XX 06-OCT-2003 (first entry)  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206625.  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
XX hyperproliferative; autoimmune disorder; antisense gene therapy;  
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX Homo sapiens.  
XX Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*cag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methyleytidines"  
FT modified\_base 1..5  
FT /\*cag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*cag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX WO2003051309-A2.  
XX 26-JUN-2003.  
XX 12-DEC-2002; 2002WO-US040101.  
XX 17-DEC-2001; 2001US-00024369.  
XX (ISIS-) ISIS PHARM INC.  
XX Borchers AH, Ward DT, Freier SM;  
XX

DR WPI; 2003-577305/54.  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.  
XX  
CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridizes with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridizes with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;  
Query March 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 1824 TATGAGGAATCACAGCTG 1843  
Db 20 TATGAGGAATCACAGCTG 1  
RESULT 86  
AAL62415/c  
ID AAL62415 standard; DNA; 20 BP.  
XX  
AC AAL62415;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206596.  
DE  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methyleytidines"  
FT 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX

PF 12-DEC-2002; 2002WO-US040101.  
XX  
XX 17-DEC-2001; 2001US-00024369.  
XX  
XX (ISIS-) ISIS PHARM INC.  
PA  
XX Borchers AH, Ward DT, Freier SM;  
XX  
XX WPI; 2003-577305/54.  
DR  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Example 15; Page 81; 112pp; English.  
XX  
CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridizes with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridizes with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;  
Query March 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 979 CTCACATGGTCACCCCTGAT 998  
Db 20 CTCACATGGTCACCCCTGAT 1  
RESULT 87  
AAL62439/c  
ID AAL62439 standard; DNA; 20 BP.  
XX  
AC AAL62439;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206620.  
DE  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
XX phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methyleytidines"  
FT 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT 16..20  
FT modified\_base  
FT

```

FT      /*tag= c
PT      /mod_base= OTHER
FT      /note= "2'methoxyethyl nucleotides"
XX
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM;
XX
XX      WPI; 2003-577305/54.
XX
XX      New antinease compound that hybridizes and inhibits the nucleic acid
PT      encoding ABC transporter major histocompatibility complex 1, for treating
PT      diseases or conditions such as a hyperproliferative or autoimmune
PT      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
CC      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC      where the compound specifically hybridizes with the nucleic acid molecule
CC      and inhibits expression of ATM or specifically hybridizes with at least a
CC      portion of an active site on the nucleic acid molecule. The invention is
CC      useful for inhibiting the expression of ATM in cells or tissues. The
CC      invention is useful for treating an animal with hyperproliferative or
CC      autoimmune disorder. The invention is useful for diagnostics,
CC      therapeutics, prophylaxis, as research reagents and kits, for
CC      distinguishing functions of various members of a biological pathway and
CC      in antinease gene therapy. The invention is also useful prophylactically
CC      e.g., to prevent or delay infection, inflammation or tumour formation.
CC      The present sequence is an antinease oligo targeted to human ABC
CC      transporter MHC I DNA. This sequence is used to illustrate the method of
CC      the invention
XX
XX      Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1537 CCAAACCGCCGATGCTT 1556
DB      20 CCAAACCGCCGATGCTT 1

```

```

FT      /mod_base= OTHER
FT      /note= "Phosphorothioate backbone; All cytidines are 5-
FT      methylcytidines"
XX
XX      modified_base
XX      1..5
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX      modified_base
XX      16..20
XX      /*tag= c
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM;
XX
XX      WPI; 2003-577305/54.
XX
XX      New antinease compound that hybridizes and inhibits the nucleic acid
PT      encoding ABC transporter major histocompatibility complex 1, for treating
PT      diseases or conditions such as a hyperproliferative or autoimmune
PT      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
CC      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC      where the compound specifically hybridizes with the nucleic acid molecule
CC      and inhibits expression of ATM or specifically hybridizes with at least a
CC      portion of an active site on the nucleic acid molecule. The invention is
CC      useful for inhibiting the expression of ATM in cells or tissues. The
CC      invention is useful for treating an animal with hyperproliferative or
CC      autoimmune disorder. The invention is useful for diagnostics,
CC      therapeutics, prophylaxis, as research reagents and kits, for
CC      distinguishing functions of various members of a biological pathway and
CC      in antinease gene therapy. The invention is also useful prophylactically
CC      e.g., to prevent or delay infection, inflammation or tumour formation.
CC      The present sequence is an antinease oligo targeted to human ABC
CC      transporter MHC I DNA. This sequence is used to illustrate the method of
CC      the invention
XX
XX      Sequence 20 BP; 2 A; 4 C; 6 G; 8 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1810 ACCGAGAGCCACTATGGA 1829
DB      20 ACCGAGAGCCACTATGGA 1

```

```

RESULT 88
AAL62443/c
ID      AAL62443 standard; DNA; 20 BP.
XX
XX      AAL62443;
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antinease oligonucleotide, ISIS 206624.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antinease gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antinease; 88.
XX
XX      Homo sapiens.
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      modified_base 1..20
XX      /*tag= a

```

```

RESULT 89
AAL62381/c
ID      AAL62381 standard; DNA; 20 BP.
XX
XX      AAL62381;
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antinease oligonucleotide, ISIS 206562.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antinease gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;

```

```

XX  phosphorothioate backbone; antisense; ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX
FH  Key
FT  modified_base
FT  1. .20
FT  /tag= a
FT  /mod_base= OTHER
FT  /note= "phosphorothioate backbone; All cytidines are 5-
FT  methylcytidines"
FT  modified_base
FT  1. .5
FT  /tag= b
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
FT  modified_base
FT  16. .20
FT  /tag= c
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
XX
PN  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
PI  Borchers AH, Ward DT, Freier SM;
XX
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
XX  encoding ABC transporter major histocompatibility complex 1, for treating
XX  diseases or conditions such as a hyperproliferative or autoimmune
XX  disorder.
XX
PS  Claim 3; Page 80; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
XX  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX  where the compound specifically hybridises with the nucleic acid molecule
XX  and inhibits expression of ATM or specifically hybridises with at least a
XX  portion of an active site on the nucleic acid molecule. The invention is
XX  useful for inhibiting the expression of ATM in cells or tissues. The
XX  invention is useful for treating an animal with hyperproliferative or
XX  autoimmune disorder. The invention is useful for diagnostics,
XX  therapeutics, prophylaxis, as research reagents and kits, for
XX  distinguishing functions of various members of a biological pathway and
XX  in antisense gene therapy. The invention is also useful prophylactically
XX  e.g., to prevent or delay infection, inflammation or tumour formation.
XX  The present sequence is an antisense oligo targeted to human ABC
XX  transporter MHC I DNA. This sequence is used to illustrate the method of
XX  the invention
XX
SQ  Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 49 GGAGCTTCTTCGCATGGCT 68
Db 20 GGAGCTTCTTCGCATGGCT 1
XX
RESULT 90
ID AAL62394/c
XX AAL62394 standard; DNA; 20 BP.
AC AAL62394;
```

```

XX  06-OCT-2003 (first entry)
XX
XX  Human ABC transporter MHC I antisense oligonucleotide, ISIS 206575.
XX
XX
XX  ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX  hyperproliferative; autoimmune disorder; antisense gene therapy;
XX  inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX  phosphorothioate backbone; antisense; ss.
XX
OS  Homo sapiens.
OS  Synthetic.
XX
XX
FH  Key
FT  modified_base
FT  1. .20
FT  /tag= a
FT  /mod_base= OTHER
FT  /note= "phosphorothioate backbone; All cytidines are 5-
FT  methylcytidines"
FT  modified_base
FT  1. .5
FT  /tag= b
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
FT  modified_base
FT  16. .20
FT  /tag= c
FT  /mod_base= OTHER
FT  /note= "2'methoxyethyl nucleotides"
XX
PN  WO2003051309-A2.
XX
XX  26-JUN-2003.
XX
XX  12-DEC-2002; 2002WO-US040101.
XX
XX  17-DEC-2001; 2001US-00024369.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
PI  Borchers AH, Ward DT, Freier SM;
XX
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
XX  encoding ABC transporter major histocompatibility complex 1, for treating
XX  diseases or conditions such as a hyperproliferative or autoimmune
XX  disorder.
XX
PS  Claim 3; Page 80; 112pp; English.
XX
XX  The invention relates to a compound targeted to a nucleic acid molecule
XX  encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX  where the compound specifically hybridises with the nucleic acid molecule
XX  and inhibits expression of ATM or specifically hybridises with at least a
XX  portion of an active site on the nucleic acid molecule. The invention is
XX  useful for inhibiting the expression of ATM in cells or tissues. The
XX  invention is useful for treating an animal with hyperproliferative or
XX  autoimmune disorder. The invention is useful for diagnostics,
XX  therapeutics, prophylaxis, as research reagents and kits, for
XX  distinguishing functions of various members of a biological pathway and
XX  in antisense gene therapy. The invention is also useful prophylactically
XX  e.g., to prevent or delay infection, inflammation or tumour formation.
XX  The present sequence is an antisense oligo targeted to human ABC
XX  transporter MHC I DNA. This sequence is used to illustrate the method of
XX  the invention
XX
SQ  Sequence 20 BP; 1 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 436 GCGGCACTGCCCGACGACG 455
XXXXXXXXXXXXXXXXXXXX
```



Db 20 GCGGACTGCGCGAGCAGC 1

RESULT 91  
AAL62424/C  
ID AAL62424 standard; DNA; 20 BP.  
XX  
XX AAL62424;  
XX  
XX 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206605.  
XX  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
methyletydines"  
FT 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
XX 12-DEC-2002; 2002MO-US040101.  
XX  
XX 17-DEC-2001; 2001US-00024369.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Borchers AH, Ward DT, Freier SM;  
PI  
XX  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.

SQL Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1101 CATTGAGGCTCTGTGCGCA 1120  
DB 20 CATTGAGGCTCTGTGCGCA 1

RESULT 92  
AAL62425/C  
ID AAL62425 standard; DNA; 20 BP.  
XX  
XX AAL62425;  
XX  
XX 06-OCT-2003 (first entry)  
XX  
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206606.  
XX  
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KM hyperproliferative; autoimmune disorder; antisense gene therapy;  
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KM phosphorothioate backbone; antisense; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
methyletydines"  
FT 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
XX WO2003051309-A2.  
XX  
XX 26-JUN-2003.  
XX  
XX 12-DEC-2002; 2002MO-US040101.  
XX  
XX 17-DEC-2001; 2001US-00024369.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Borchers AH, Ward DT, Freier SM;  
PI  
XX  
XX WPI; 2003-577305/54.  
XX  
XX New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
XX Claim 3; Page 81; 112pp; English.

CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1109 CTCTGTCGGCCATGCTACA 1128  
Db 20 CTCTGTCGGCCATGCTACA 1  
RESULT 93  
AAL62429/C  
ID AAL62429 standard; DNA; 20 BP.  
XX  
AC AAL62429;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206610.  
XX  
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KW phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
PN WO2003051309-A2.  
XX  
PD 26-JUN-2003.  
XX  
PF 12-DEC-2002; 2002WO-US040101.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX  
PT New antisense compound that hybridizes and inhibits the nucleic acid  
PT encoding ABC transporter major histocompatibility complex 1, for treating  
PT diseases or conditions such as a hyperproliferative or autoimmune  
PT disorder.  
XX  
PS Claim 3; Page 81; 112pp; English.  
XX

CC The invention relates to a compound targeted to a nucleic acid molecule  
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1  
CC where the compound specifically hybridises with the nucleic acid molecule  
CC and inhibits expression of ATM or specifically hybridises with at least a  
CC portion of an active site on the nucleic acid molecule. The invention is  
CC useful for inhibiting the expression of ATM in cells or tissues. The  
CC invention is useful for treating an animal with hyperproliferative or  
CC autoimmune disorder. The invention is useful for diagnostics,  
CC therapeutics, prophylaxis, as research reagents and kits, for  
CC distinguishing functions of various members of a biological pathway and  
CC in antisense gene therapy. The invention is also useful prophylactically  
CC e.g., to prevent or delay infection, inflammation or tumour formation.  
CC The present sequence is an antisense oligo targeted to human ABC  
CC transporter MHC I DNA. This sequence is used to illustrate the method of  
CC the invention  
XX  
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;  
Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 22;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1218 GGCTATGCACTCAACTCCT 1237  
Db 20 GGCTATGCACTCAACTCCT 1  
RESULT 94  
AAL62455/C  
ID AAL62455 standard; DNA; 20 BP.  
XX  
AC AAL62455;  
XX  
DT 06-OCT-2003 (first entry)  
XX  
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206636.  
XX  
KW ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;  
KW hyperproliferative; autoimmune disorder; antisense gene therapy;  
KW inflammation; tumour formation; immunosuppressive; antimicrobial; human;  
KW phosphorothioate backbone; antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone; All cytidines are 5-  
FT methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'methoxyethyl nucleotides"  
XX  
PN WO2003051309-A2.  
XX  
PD 26-JUN-2003.  
XX  
PF 12-DEC-2002; 2002WO-US040101.  
XX  
PR 17-DEC-2001; 2001US-00024369.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Borchers AH, Ward DT, Freier SM;  
XX  
DR WPI; 2003-577305/54.  
XX

```

XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX  Example 15; Page 81; 112pp; English.
XX
CC  The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ  Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2073 GTACTCCGCTCAGTGCCTTC 2092
      |||||
DB      20 GTACTCCGCTCAGTGCCTTC 1

RESULT 95
AAL62457/C
ID      AAL62457 standard; DNA; 20 BP.
XX
AC      AAL62457;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206638.
XX
KM      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS      Homo sapiens.
OS Synthetic.
XX
FH      Key
FT modified_base
FT      1..20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "phosphorothioate backbone; All cytidines are 5-
FT      methylcytidines"
FT      1..5
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "2'methoxyethyl nucleotides"
FT      16..20
FT      /*tag= c
FT      /mod_base= OTHER
FT      /note= "2'methoxyethyl nucleotides"
XX
PN      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002WO-US040101.
XX

```

```

XX  17-DEC-2001; 2001US-00024369.
PR
XX  (ISIS-) ISIS PHARM INC.
PA
XX  Borchers AH, Ward DT, Freiler SM;
XX  WPI; 2003-577305/54.
XX
XX  New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX  Claim 3; Page 81; 112pp; English.
XX
CC  The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridises with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridises with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ  Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2228 CTGCAGATGCTCCGAGATGA 2247
      |||||
DB      20 CTGCAGATGCTCCGAGATGA 1

RESULT 96
AAL62396/C
ID      AAL62396 standard; DNA; 20 BP.
XX
AC      AAL62396;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206577.
XX
KM      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
OS      Homo sapiens.
OS Synthetic.
XX
FH      Key
FT modified_base
FT      1..20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "phosphorothioate backbone; All cytidines are 5-
FT      methylcytidines"
FT      1..5
FT      /*tag= b
FT      /mod_base= OTHER
FT      /note= "2'methoxyethyl nucleotides"
FT      16..20
FT      /*tag= c
FT

```

```

FT FT /mod_base= OTHER
FT FT /note= "2'methoxyethyl nucleotides"
XX XX WO2003051309-A2.
XX XX
XX XX 26-JUN-2003.
XX PD
XX PD 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM,
XX DR WPI; 2003-577305/54.
XX XX
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
XX PT encoding ABC transporter major histocompatibility complex 1, for treating
XX PT diseases or conditions such as a hyperproliferative or autoimmune
XX PT disorder.
XX PS
XX PS Claim 3; Page 80; 112pp; English.
XX XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX CC where the compound specifically hybridises with the nucleic acid molecule
XX CC and inhibits expression of ATM or specifically hybridises with at least a
XX CC portion of an active site on the nucleic acid molecule. The invention is
XX CC useful for inhibiting the expression of ATM in cells or tissues. The
XX CC invention is useful for treating an animal with hyperproliferative or
XX CC autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX CC distinguishing functions of various members of a biological pathway and
XX CC in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX CC The present sequence is an antisense oligo targeted to human ABC
XX CC transporter MHC I DNA. This sequence is used to illustrate the method of
XX CC the invention
XX XX
XX SQ Sequence 20 BP; 3 A; 9 C; 7 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 475 AGCCTGGGTCGCCGCGG 494
DB 20 AGCCTGGGTCGCCGCGG 1

```

```

FT FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT FT methylcytidines"
XX XX modified_base
XX XX 1..5
XX FT /*cag= b
XX FT /mod_base= OTHER
XX FT /note= "2'methoxyethyl nucleotides"
XX FT 16..20
XX FT /*cag= c
XX FT /mod_base= OTHER
XX FT /note= "2'methoxyethyl nucleotides"
XX XX
XX XX WO2003051309-A2.
XX XX
XX XX 26-JUN-2003.
XX PD
XX PD 12-DEC-2002; 2002WO-US040101.
XX PR 17-DEC-2001; 2001US-00024369.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX PI Borchers AH, Ward DT, Freier SM,
XX DR WPI; 2003-577305/54.
XX XX
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
XX PT encoding ABC transporter major histocompatibility complex 1, for treating
XX PT diseases or conditions such as a hyperproliferative or autoimmune
XX PT disorder.
XX PS
XX PS Claim 3; Page 80; 112pp; English.
XX XX
XX CC The invention relates to a compound targeted to a nucleic acid molecule
XX CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX CC where the compound specifically hybridises with the nucleic acid molecule
XX CC and inhibits expression of ATM or specifically hybridises with at least a
XX CC portion of an active site on the nucleic acid molecule. The invention is
XX CC useful for inhibiting the expression of ATM in cells or tissues. The
XX CC invention is useful for treating an animal with hyperproliferative or
XX CC autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutics, prophylaxis, as research reagents and kits, for
XX CC distinguishing functions of various members of a biological pathway and
XX CC in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX CC The present sequence is an antisense oligo targeted to human ABC
XX CC transporter MHC I DNA. This sequence is used to illustrate the method of
XX CC the invention
XX XX
XX SQ Sequence 20 BP; 5 A; 1 C; 7 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 672 CACTCGAACTTAAGTCTCA 691
DB 20 CACTCGAACTTAAGTCTCA 1

```

```

XX Homo sapiens.
OS Synthetic.
XX Key
FH modified_base
FT 1. .20
FT /*cag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base
FT 1. .5
FT /*cag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base
FT 16. .20
FT /*cag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 920 TGTGTACTGTGTGCGAGGC 939
DB 20 TGTGTACTGTGTGCGAGGC 1

```

```

DT 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206564.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX Key
FH modified_base
FT 1. .20
FT /*cag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base
FT 1. .5
FT /*cag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base
FT 16. .20
FT /*cag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 137 TGTGTGTGCCACCGGCTG 156
DB 20 TGTGTGTGCCACCGGCTG 1

```

```

RESULT 100
AAL62390/c
ID AAL62390 standard; DNA; 20 BP.
XX
XX AAL62390;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206571.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key
XX modified_base
XX      Location/Qualifiers
XX      1..20
XX      /*tag= a
XX      /mod_base= OTHER
XX      /note= "Phosphorothioate backbone; All cytidines are 5-
XX      methylcytidines"
XX      1..5
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX      16..20
XX      /*tag= c
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX W02003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

```

```

Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 304 GCACTGGGCTTGGCCCTTGGCC 323
Db 20 GCACTGGGCTTGGCCCTTGGCC 1

RESULT 101
AAL62393/c
ID AAL62393 standard; DNA; 20 BP.
XX
XX AAL62393;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206574.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytosolic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key
XX modified_base
XX      Location/Qualifiers
XX      1..20
XX      /*tag= a
XX      /mod_base= OTHER
XX      /note= "Phosphorothioate backbone; All cytidines are 5-
XX      methylcytidines"
XX      1..5
XX      /*tag= b
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX      16..20
XX      /*tag= c
XX      /mod_base= OTHER
XX      /note= "2'methoxyethyl nucleotides"
XX
XX W02003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002MO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX
XX WPI; 2003-577305/54.
XX
XX
XX PT New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for

```

CC	distinguishing functions of various members of a biological pathway and in antisense gene therapy. The invention is also useful prophylactically e.g., to prevent or delay infection, inflammation or tumour formation.
CC	The present sequence is an antisense oligo targeted to human ABC transporter MHC I DNA. This sequence is used to illustrate the method of the invention
CC	
CC	
SO	Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match	0.9%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 22;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Oy	425 TCAGTTATGCAGCGGCACTG 444       20 TCAGTTATGCAGCGGCACTG 1
Db	
RESULT 102	
AAI62399/C	
ID	AAI62399 standard; DNA; 20 BP.
AC	
XX	AAI62399;
XX	
DT	06-OCT-2003 (first entry)
DE	
XX	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206580.
KW	ABC transporter; ABC; major histocompatibility complex; MHC; cytostatic; hyperproliferative; autoimmune disorder; antisense gene therapy;
KW	Inflammation; tumour formation; immunosuppressive; antimicrobial; human; phosphorothioate backbone; antisense; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
FT	Key
FT	Location/Qualifiers
FT	1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidines are 5-methylcytidines"
FT	1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'methoxyethyl nucleotides"
FT	16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'methoxyethyl nucleotides"
XX	
PN	WO2003051309-A2.
XX	
PD	26-JUN-2003.
XX	
PF	12-DEC-2002; 2002WO-US040101.
XX	
PR	17-DEC-2001; 2001US-00024369.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
P1	Borchers AH, Ward DT, Freier SM;
XX	
DR	WPI; 2003-577305/54.
XX	
XX	
PT	New antisense compound that hybridizes and inhibits the nucleic acid encoding ABC transporter major histocompatibility complex 1, for treating diseases or conditions such as a hyperproliferative or autoimmune disorder.
XX	
PS	Claim 3; Page 80; 112pp; English.
XX	
CC	The invention relates to a compound targeted to a nucleic acid molecule

CC	encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC	where the compound specifically hybridises with the nucleic acid molecule
CC	and inhibits expression of ATM or specifically hybridises with at least a
CC	portion of an active site on the nucleic acid molecule. The invention is
CC	useful for inhibiting the expression of ATM in cells or tissues. The
CC	invention is useful for treating an animal with hyperproliferative or
CC	autoimmune disorder. The invention is useful for dysproliferative,
CC	therapeutics, prophylaxis, as research reagents and kits, for
CC	distinguishing functions of various members of a biological pathway and
CC	in antisense gene therapy. The invention is also useful prophylactically
CC	e.g., to prevent or delay infection, inflammation or tumour formation.
CC	The present sequence is an antisense oligo targeted to human ABC
CC	transporter MHC I DNA. This sequence is used to illustrate the method of
CC	the invention
SQ	Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match	0.9%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 22;
Matches 20; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Oy	649 CAAGTGGCTCAGCCGATAC 668       
Db	20 CAAGTGCTCAGCCGATAC 1
RESULT 103	
AL62403/C	ID AL62403 standard; DNA; 20 BP.
XX	AA62403;
XX	06-OCT-2003 (first entry)
DT	
XX	
DE	Human ABC transporter MHC I antisense oligonucleotide, ISIS 206584.
XX	
KW	ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KW	hyperproliferative; autoimmune disorder; antisense gene therapy;
KW	inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX	phosphorothioate backbone; antisense; ss.
OS	Homo sapiens.
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..20
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "Phosphorothioate backbone; All cytidines are 5-
FT	methylcytidines"
FT	1..5
FT	/tag= b
FT	/mod_base= OTHER
FT	/note= "2' methoxyethyl nucleotides"
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "2' methoxyethyl nucleotides"
XX	
PN	WO2003051309-A2.
XX	
PD	26-JUN-2003.
XX	
PP	12-DEC-2002; 2002MO-US040101.
PR	17-DEC-2001; 2001US-00024369.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Borchers AH, Ward DT, Freier SM,
XX	
DR	WPI; 2003-577305/54.
XX	

```
PT New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
PS Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 6 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 776 ACTTGACGAGGAGGAGTGT 795
Db 20 ACTTGACGAGGAGGAGTGT 1
RESULT 104
AAL62408/c
ID AAL62408 standard; DNA; 20 BP.
XX
XX AAL62408;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206589.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX W02003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
```

```
PR 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
PI WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
PT encoding ABC transporter major histocompatibility complex 1, for treating
PT diseases or conditions such as a hyperproliferative or autoimmune
PT disorder.
XX
XX Example 15; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
CC where the compound specifically hybridizes with the nucleic acid molecule
CC and inhibits expression of ATM or specifically hybridizes with at least a
CC portion of an active site on the nucleic acid molecule. The invention is
CC useful for inhibiting the expression of ATM in cells or tissues. The
CC invention is useful for treating an animal with hyperproliferative or
CC autoimmune disorder. The invention is useful for diagnostics,
CC therapeutics, prophylaxis, as research reagents and kits, for
CC distinguishing functions of various members of a biological pathway and
CC in antisense gene therapy. The invention is also useful prophylactically
CC e.g., to prevent or delay infection, inflammation or tumour formation.
CC The present sequence is an antisense oligo targeted to human ABC
CC transporter MHC I DNA. This sequence is used to illustrate the method of
CC the invention
XX
SQ Sequence 20 BP; 8 A; 5 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 899 GTGAGAACTGAGCTATT 918
Db 20 GTGAGAACTGAGCTATT 1
RESULT 105
AAL62428/c
ID AAL62428 standard; DNA; 20 BP.
XX
XX AAL62428;
AC
XX
DT 06-OCT-2003 (first entry)
XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206609.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
KM hyperproliferative; autoimmune disorder; antisense gene therapy;
KM inflammation; tumour formation; immunosuppressive; antimicrobial; human;
KM phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
```



```

FT      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002MO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM,
XX
XX      WPI; 2003-577305/54.
XX
XX      New antisense compound that hybridizes and inhibits the nucleic acid
XX      encoding ABC transporter major histocompatibility complex 1, for treating
XX      diseases or conditions such as a hyperproliferative or autoimmune
XX      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX      where the compound specifically hybridizes with the nucleic acid molecule
XX      and inhibits expression of ATM or specifically hybridizes with at least a
XX      portion of an active site on the nucleic acid molecule. The invention is
XX      useful for inhibiting the expression of ATM in cells or tissues. The
XX      invention is useful for treating an animal with hyperproliferative or
XX      autoimmune disorder. The invention is useful for diagnostics,
XX      therapeutics, prophylaxis, as research reagents and kits, for
XX      distinguishing functions of various members of a biological pathway and
XX      in antisense gene therapy. The invention is also useful prophylactically
XX      e.g., to prevent or delay infection, inflammation or tumour formation.
XX      The present sequence is an antisense oligo targeted to human ABC
XX      transporter MHC I DNA. This sequence is used to illustrate the method of
XX      the invention
XX
XX      Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred.No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1157 AAGCCGAGAGTTAGGGA 1176
XX      Db      20 AAGCCGAGAGTTAGGGA 1
XX
XX      RESULT 106
XX      AAL62438/c
XX      ID      AAL62438 standard; DNA; 20 BP.
XX
XX      AAL62438:
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206619.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antisense gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antisense; ss.
XX
XX      Homo sapiens.
XX      OS
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      modified_base 1..20
XX      FT      /mod_base= OTHER
XX      FT      /note= "Phosphorothioate backbone; All cytidines are 5-

```

```

FT      methylcytidines"
XX
XX      modified_base 1..5
XX      FT      /*tag= b
XX      FT      /mod_base= OTHER
XX      FT      /note= "2'methoxyethyl nucleotides"
XX
XX      modified_base 16..20
XX      FT      /*tag= c
XX      FT      /mod_base= OTHER
XX      FT      /note= "2'methoxyethyl nucleotides"
XX
XX      WO2003051309-A2.
XX
XX      26-JUN-2003.
XX
XX      12-DEC-2002; 2002MO-US040101.
XX
XX      17-DEC-2001; 2001US-00024369.
XX
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Borchers AH, Ward DT, Freier SM,
XX
XX      WPI; 2003-577305/54.
XX
XX      New antisense compound that hybridizes and inhibits the nucleic acid
XX      encoding ABC transporter major histocompatibility complex 1, for treating
XX      diseases or conditions such as a hyperproliferative or autoimmune
XX      disorder.
XX
XX      Claim 3; Page 81; 112pp; English.
XX
XX      The invention relates to a compound targeted to a nucleic acid molecule
XX      encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX      where the compound specifically hybridizes with the nucleic acid molecule
XX      and inhibits expression of ATM or specifically hybridizes with at least a
XX      portion of an active site on the nucleic acid molecule. The invention is
XX      useful for inhibiting the expression of ATM in cells or tissues. The
XX      invention is useful for treating an animal with hyperproliferative or
XX      autoimmune disorder. The invention is useful for diagnostics,
XX      therapeutics, prophylaxis, as research reagents and kits, for
XX      distinguishing functions of various members of a biological pathway and
XX      in antisense gene therapy. The invention is also useful prophylactically
XX      e.g., to prevent or delay infection, inflammation or tumour formation.
XX      The present sequence is an antisense oligo targeted to human ABC
XX      transporter MHC I DNA. This sequence is used to illustrate the method of
XX      the invention
XX
XX      Sequence 20 BP; 7 A; 2 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      0.9%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred.No. 22;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1521 TGTCCTTGCTACCCCA 1540
XX      Db      20 TGTCCTTGCTACCCCA 1
XX
XX      RESULT 107
XX      AAL62411/c
XX      ID      AAL62411 standard; DNA; 20 BP.
XX
XX      AAL62411:
XX
XX      06-OCT-2003 (first entry)
XX
XX      Human ABC transporter MHC I antisense oligonucleotide, ISIS 206592.
XX
XX      ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX      hyperproliferative; autoimmune disorder; antisense gene therapy;
XX      inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX      phosphorothioate backbone; antisense; ss.

```

```
OS Homo sapiens.
OS Synthetic.
XX Key
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutic, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 936 AGGCGTATGTCCTTGGGGA 955
XX ||||||||||||||||
DB 20 AGGCGTATGTCCTTGGGGA 1
```

```
XX XX
DE Human ABC transporter MHC I antisense oligonucleotide, ISIS 206601.
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX KM phosphorothioate backbone; antisense; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX Key
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX WO2003051309-A2.
XX 26-JUN-2003.
XX 12-DEC-2002; 2002WO-US040101.
XX 17-DEC-2001; 2001US-00024369.
XX (ISIS-) ISIS PHARM INC.
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX CC therapeutic, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX CC e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
SQ
XX Query Match 0.9%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 22;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1041 ATGGTACCAGTTGCTGAAG 1060
XX ||||||||||||||||
DB 20 ATGGTACCAGTTGCTGAAG 1
```

```

RESULT 109
AAL62404/c
ID AAL62404 standard; DNA; 20 BP.
XX
XX AAL62404;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206585.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*cag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*cag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT /*cag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 80; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX in antisense gene therapy. The invention is also useful prophylactically
XX e.g., to prevent or delay infection, inflammation or tumour formation.
XX The present sequence is an antisense oligo targeted to human ABC
XX transporter MHC I DNA. This sequence is used to illustrate the method of
XX the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX

```

```

* Query Match 0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 839 AGACAGGTAACTCATGTCT 858
Db 20 AGACAGGTAACTCATGTCT 1
XX
XX RESULT 110
XX AAL62430/c
XX ID AAL62430 standard; DNA; 20 BP.
XX
XX AAL62430;
XX
XX 06-OCT-2003 (first entry)
XX
XX Human ABC transporter MHC I antisense oligonucleotide, ISIS 206611.
XX
XX ABC transporter; ABCT; major histocompatibility complex; MHC; cytostatic;
XX hyperproliferative; autoimmune disorder; antisense gene therapy;
XX inflammation; tumour formation; immunosuppressive; antimicrobial; human;
XX phosphorothioate backbone; antisense; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*cag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methyleytidines"
FT modified_base 1..5
FT /*cag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT /*cag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX WO2003051309-A2.
XX
XX 26-JUN-2003.
XX
XX 12-DEC-2002; 2002WO-US040101.
XX
XX 17-DEC-2001; 2001US-00024369.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Borchers AH, Ward DT, Freier SM;
XX WPI; 2003-577305/54.
XX
XX New antisense compound that hybridizes and inhibits the nucleic acid
XX encoding ABC transporter major histocompatibility complex 1, for treating
XX diseases or conditions such as a hyperproliferative or autoimmune
XX disorder.
XX
XX Claim 3; Page 81; 112pp; English.
XX
XX The invention relates to a compound targeted to a nucleic acid molecule
XX encoding ABC transporter (ABCT) major histocompatibility complex (MHC) 1
XX where the compound specifically hybridizes with the nucleic acid molecule
XX and inhibits expression of ATM or specifically hybridizes with at least a
XX portion of an active site on the nucleic acid molecule. The invention is
XX useful for inhibiting the expression of ATM in cells or tissues. The
XX invention is useful for treating an animal with hyperproliferative or
XX autoimmune disorder. The invention is useful for diagnostics,
XX therapeutics, prophylaxis, as research reagents and kits, for
XX distinguishing functions of various members of a biological pathway and
XX
XX

```

CC in antisense gene therapy. The invention is also useful prophylactically  
 CC e.g., to prevent or delay infection, inflammation or tumour formation.  
 CC The present sequence is an antisense oligo targeted to human ABC  
 CC transporter MHC I DNA. This sequence is used to illustrate the method of  
 CC the invention  
 XX  
 SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 22;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1274 GAATCCTCTACATTGCTGGG 1293  
 Db 20 GAATCCTCTACATTGCTGGG 1  
 RESULT 111  
 AAD41088  
 ID AAD41088 standard; DNA; 19 BP.  
 AC AAD41088;  
 XX  
 XX 30-OCT-2002 (first entry)  
 DT  
 XX  
 DE Primer ON-TAP1-F2 used for DNA sequencing.  
 XX  
 KM Tumour necrosis-factor; TNF; promoter; autoimmune disorder; cancer;  
 KM therapy; primer; ss.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200246433-A2.  
 XX  
 PD 13-JUN-2002.  
 XX  
 PF 07-DEC-2001; 2001WO-EP014412.  
 XX  
 PR 08-DEC-2000; 2000US-0254649P.  
 XX  
 PA (SAUS/) SAUS J.  
 XX  
 PI Saus J;  
 XX  
 XX WPI; 2002-519670/55.  
 DR  
 XX  
 PT Novel tumor necrosis-factor inducible promoter useful for identifying  
 PT candidate compounds for treating/preventing autoimmune disorders/cancer,  
 PT or for identifying promoters that are regulated by tumor necrosis factor.  
 XX  
 XX Example; Page 18; 95bp; English.  
 PS  
 XX The invention relates to a tumour necrosis-factor TNF inducible promoter.  
 CC The invention is useful for identifying candidate TNF inducible promoters  
 CC by aligning a test sequence consisting of a nucleic acid sequence with a  
 CC comparison sequence selected from the invention, using a gap opening  
 CC penalty of 50 and a gap extension penalty of 3 to define a test  
 CC alignment, shuffling the nucleic sequence of the test sequence at least  
 CC one hundred times, while maintaining its length and composition, to  
 CC produce a series of randomised sequences, aligning the randomised  
 CC sequences with the comparison sequence using a gap opening penalty of 50  
 CC and a gap extension penalty of 3, to produce a series of randomised  
 CC alignments, determining an average alignment quality of the randomised  
 CC alignments, where the average alignment quality of the randomised  
 CC alignments represent an alignment expected by chance, comparing the test  
 CC alignment with the average alignment quality of the randomised alignments  
 CC and identifying a test alignment with a probability value of less than  
 CC 0.05 that the alignment is obtained by chance as a candidate TNF  
 CC inducible promoter. The invention is useful for identifying candidate  
 CC compounds for treating or preventing autoimmune disorders or cancer. The  
 CC present sequence is a primer used in the exemplification of the invention  
 XX  
 SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 626 GCCGCCCTCACTGACTGGAT 644  
 Db 1 GCCGCCCTCACTGACTGGAT 19  
 RESULT 112  
 ABR82234  
 ID ABR82234 standard; DNA; 19 BP.  
 AC ABR82234;  
 XX  
 XX 27-AUG-2002 (first entry)  
 DT  
 XX  
 DE Human ATP-binding cassette (ABC) transporter probe #72.  
 DE  
 XX Human ATP-binding cassette transporter; ABC transporter;  
 KM Human, ATP-binding cassette transporter; ABC transporter;  
 KM expression rate; drug development; biochemical kinetic; antihelminthic;  
 KM probe; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN JP2002112775-A.  
 XX  
 PD 16-APR-2002.  
 XX  
 PF 03-OCT-2000; 2000JP-00303404.  
 XX  
 PR 03-OCT-2000; 2000JP-00303404.  
 XX  
 PR 03-OCT-2000; 2000JP-00303404.  
 XX  
 PA (SAKA ) OTSUKA SEIYAKU KOGYO KK.  
 XX  
 DR WPI; 2002-458864/49.  
 XX  
 XX  
 PT Probes for determination of human ATP-binding cassette (ABC) transporters  
 PT capable of hybridization with 33 regions of genes.  
 XX  
 XX  
 PS Claim 8; Page 27; 36pp; Japanese.  
 XX  
 XX The invention describes new probes for identification of human ATP-  
 CC binding cassette (ABC) transporters capable of hybridisation with 33  
 CC regions of genes. Flucudation of expression rate of ABC transporters is  
 CC useful for development of drugs and their biochemical kinetics. This  
 CC sequence represents a probe used to detect human ATP-binding cassette  
 CC (ABC) transporters  
 XX  
 SQ Sequence 19 BP; 4 A; 4 C; 6 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 286 TTGAAGCCATTAGCTGCGG 304  
 Db 1 TTGAAGCCATTAGCTGCGG 19  
 RESULT 113  
 ABR03923  
 ID ABR03923 standard; DNA; 19 BP.  
 AC ABR03923;  
 XX  
 XX 18-SEP-2002 (first entry)  
 DT  
 XX Human pol kappa 76 DNA polymerase sequencing primer #29.  
 DE Human, pol kappa 76; Goodpasture antigen binding protein; GPBP;  
 KM Human, pol kappa 76; Goodpasture antigen binding protein; GPBP;  
 KM chromosome Sg12-13; apoptosis; autoimmune disorder; cancer; cytostatic;

```

KM Immunosuppressive; PCR; primer; sequencing; ss.
XX
OS Homo sapiens.
XX
PN WO200246378-A2.
XX
PD 13-JUN-2002.
XX
PS 07-DEC-2001; 2001MO-EP014409.
XX
PR 08-DEC-2000; 2000US-0254649P.
XX
PA (SAUS/) SAUS J.
XX
PI Saus J;
XX
DR WPI; 2002-537563/57.
XX
PT Novel isolated pol kappa76 polypeptide, a 76 kDa alternatively spliced
PT variant of DNA polymerase kappa, useful as target for treating a patient
PT with autoimmune disorder or cancer.
XX
PS Example; Page 16; 90pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC DNA polymerase pol kappa 76. The gene is found on human chromosome 5q12-
CC 13, in a head-to-head arrangement with the Goodpasture antigen binding
CC protein (GPBP). The detection of the coding sequence can be used for
CC diagnosing an autoimmune condition and identifying cells undergoing
CC apoptosis, and the sequences can be used in the treatment of autoimmune
CC diseases and cancer. The present sequence is a sequencing primer
CC described in the invention
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 626 GCCGCTCTACTGACTGAT 644
DB 1 GCCGCTCTACTGACTGAT 19
XX
RESULT 114
ACD13526
ID ACD13526 standard; DNA; 19 BP.
XX
AC ACD13526;
XX
DT 14-AUG-2003 (first entry)
XX
DE Human bi-directional promoter PCR/sequencing primer ON-TAP1-F2.
XX
KM Human; ss; Goodpasture antigen binding protein; GPBP; COL4A3BP;
KM collagen 4 alpha 3 binding protein; DNA polymerase kappa; pol kappa;
KM Goodpasture disease; cutaneous lupus; polK76; bi-directional promoter;
KM autoimmune disease; cancer; antisense therapy; PCR; primer.
XX
OS Homo sapiens.
XX
PN US2003027165-A1.
XX
PD 06-FEB-2003.
XX
PF 07-DEC-2001; 2001US-00010920.
XX
PR 08-DEC-2000; 2000US-0254649P.
XX
PA (SAUS/) SAUS J.
XX
PI Saus J;
XX

```

```

DR WPI; 2003-479531/45.
XX
XX New isolated DNA polymerase, pol kappa 76, useful in identifying
PT autoimmune disorders and in treating cancer and autoimmune disorders by
PT modifying its expression.
XX
PS Example; Page 7; 54pp; English.
XX
CC The invention relates to an isolated pol kappa (k) 76 polypeptide (an
CC alternatively spliced form of DNA polymerase kappa), appearing as
CC AB007327 (encoded by the cDNA appearing as ACD13492). The gene for
CC polkappa is located on chromosome 5q12-13 in a head-head arrangement with
CC the gene encoding Goodpasture antigen binding protein (GPBP or collagen 4
CC alpha 3 binding protein (COL4A3BP)), associated with autoimmune diseases
CC such as Goodpasture's disease and cutaneous lupus) i.e. has a bi-
CC directional promoter. Also included are a recombinant expression vector
CC comprising the polK76 cDNA, a host cell transfected with the vector,
CC detecting (M1) polK76 (comprising providing a protein sample to be
CC screened, contacting the protein sample to be screened with an anti-
CC polK76 antibody and detecting the formation of an antibody-polypeptide
CC complexes, where the presence of the antibody-polypeptide complexes
CC indicates the presence of polK76), detecting (M2) the polK76 nucleic acid
CC in a sample (comprising contacting the sample with one or more polK76 PCR
CC primer, carrying out PCR to generate PCR products, and identifying the
CC polK76-specific PCR), detecting an autoimmune condition in a patient,
CC providing a control tissue or body fluid sample in which no autoimmune
CC condition is present, and detecting an increase in pol K76 RNA expression
CC in the tissue of body fluid samples compared to the control sample, where
CC the increase indicates the presence of an autoimmune condition) and
CC treating (M3) a patient with an autoimmune disorder or cancer by
CC modifying the expression or activity of pol K76 in the patient. Modifying
CC the expression or activity of polK76 or polK76 nucleic acid, such as by
CC increasing or decreasing their expression or activity using antibodies or
CC antisense therapy, is useful for treating an autoimmune disorder or
CC cancer. The present sequence is a PCR and/or sequencing primer used in
CC the analysis of bi-directional promoters of other genes (and/or of
CC polkappa/GPBP), whose structure and sequence were compared to the
CC polkappa/GPBP bi-directional promoter
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 626 GCCGCTCTACTGACTGAT 644
DB 1 GCCGCTCTACTGACTGAT 19
XX
RESULT 115
ADA97827
ID ADA97827 standard; DNA; 19 BP.
XX
AC ADA97827;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human tumour necrosis factor (TNF) inducible promoter PCR primer #29.
XX
KM Human; tumour necrosis factor inducible promoter; TNF;
KM autoimmune disorder; cancer; PCR; immunosuppressive; cytostatic; ss;
KM primer.
XX
OS Homo sapiens.
XX
PN US2003082745-A1.
XX
PD 01-MAY-2003.
XX
PF 07-DEC-2001; 2001US-00008721.
XX

```

```

PR 08-DEC-2000; 2000US-0254649P.
PA (SAUS/) SAUS J.
PI Saus J;
XX WPI; 2003-606062/57.
DR
XX
XX New tumor necrosis factor inducible promoters, useful for identifying
PT promoters that are regulated by tumor necrosis factor, or for identifying
PT candidate compounds for treating or preventing autoimmune disorders or
PT cancer.
PS
XX Example; Page 7, 57pp; English.
XX
XX The invention relates to a tumor necrosis factor (TNF) inducible
CC promoter. Also disclosed are an expression vector comprising one or more
CC tumor necrosis factor inducible promoters and a recombinant host cell
CC transfected with one or more expression vectors. The TNF inducible
CC promoters, expression vectors and host cells are useful for identifying
CC promoters that are regulated by tumor necrosis factor or for identifying
CC candidate compounds for treating or preventing autoimmune disorders or
CC cancer. This sequence represents a PCR primer used for isolating a tumor
CC necrosis factor inducible promoter of the invention.
XX
XX Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 626 GCCGCTCAGTACTGGAT 644
Db 1 GCCGCTCAGTACTGGAT 19
RESULT 116
AAZ32694
ID AAZ32694 standard; DNA; 18 BP.
XX
XX AAZ32694;
AC
XX
XX 21-JAN-2000 (first entry)
DT
XX
XX Human MHC Class II locus TAP1 gene-specific PCR primer TAP1A.
XX
XX Major histocompatibility complex; MHC; Class II; autoimmune disorder;
KM transfection; transgenic animal; animal model; disease; transgene;
KM co-lipofection; yeast artificial chromosome; YAC; lipid; cationic;
KM selectable; TAP1; PCR; primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX US981175-A.
PN
XX
XX 09-NOV-1999.
PD
XX
XX 25-JAN-1994; 94US-00187161.
PF
XX
XX 07-JAN-1993; 93US-00001493.
PR 18-JUN-1993; 93US-00079444.
XX
XX (GENP-) GENPHARM INT INC.
PA
XX
XX Kay RM, Choi T, Loring JF;
PI
XX WPI; 1999-633306/54.
XX
XX Production of transfected mammalian cells by co-lipofection with multiple
PT DNA species, useful for the production of transgenic animals for use as
PT disease models.
XX

```

```

PS Example 4; Col 31; 29pp; English.
XX
XX This sequence represents human TAP1 PCR primer TAP1A, used with primer
CC TAP1B (AAZ32695), to amplify the TAP1 gene in murine embryonic stem cells
CC transfected via a novel method with a YAC (yeast artificial chromosome)
CC containing the human MHC (major histocompatibility complex) Class II
CC locus which contains the TAP1 gene. The novel method of transfection
CC produces a selectable co-lipofected mammalian cell incorporating multiple
CC heterologous DNA species. It comprises forming a co-lipofection complex
CC comprising a cationic lipid, a first polynucleotide larger than 50 kb,
CC and an unlinked second polynucleotide comprising a selectable marker gene
CC expression cassette, and transfecting mammalian cells with it. Both
CC heterologous nucleotides are integrated into the genome, forming
CC selectable co-lipofected mammalian cells which contain incorporated
CC multiple heterologous DNA species. The method can be used for
CC transferring large segments of DNA, such as large YAC clones, into
CC mammalian cells such as embryonic stem cells. The methods can be used to
CC producing mammalian cells which express human TAP1 which can be used to
CC produce transgenic animals as models for autoimmune disorders. The
CC methods can also be used for producing transgenic animals as models for
CC Alzheimer's disease
XX
XX Sequence 18 BP; 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 879 CACCCGTGATGATTCCT 896
Db 1 CACCCGTGATGATTCCT 18
RESULT 117
AAF76193
ID AAF76193 standard; DNA; 18 BP.
XX
XX AAF76193;
AC
XX
XX 05-JUN-2001 (first entry)
DT
XX
XX Human TAP-1 PCR primer, SEQ ID NO:59.
XX
XX Transgenic mouse; immunodeficient; tissue recipient;
KM lymphocyte deficient; human cytokine; interleukin; IL-7; IL-6; SCF; LIF;
KM stem cell factor; leukemia inhibitory factor; GM-CSF; M-CSF;
KM granulocyte macrophage-colony stimulating factor;
KM macrophage-colony stimulating factor; human MHC Class II; DR3;
KM major histocompatibility complex; allergenicity determination;
KM human monoclonal antibody generation; haematopoietic cell development;
KM human immune system animal model; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200115521-A1.
PN
XX
XX 08-MAR-2001.
PD
XX
XX 30-AUG-2000; 2000WO-US023971.
PF
XX
XX 31-AUG-1999; 99US-0151688P.
PR
XX
XX (GENV ) GENENCOR INT INC.
PA
XX
XX Huang MA, Harding FA;
PI
XX WPI; 2001-169001/17.
XX
XX New transgenic mice, useful as non-human mammalian models of human
PT disease, comprise recombination activation gene mutations and donor
PT specific transgenes encoding cytokines.
XX
XX Example 4; Page 47; 68pp; English.
PS

```

XX The invention relates to a transgenic immunodeficient recipient mouse  
CC which is capable of supporting the growth of donor cells. In the mouse,  
CC both alleles of a gene activated in early lymphocyte development are  
CC disrupted, causing it to lack mature B and T cells. In particular, both  
CC alleles of the recombination activation gene-2 (RAG-2) gene are  
CC disrupted, which in turn prevents VDJ recombination. The mouse also  
CC comprises donor (e.g., human) specific transgenes encoding the cytokines  
CC interleukin-7 (IL-7), stem cell factor (SCF), leukemia inhibitory factor  
CC (LIF), granulocyte macrophage-colony stimulating factor (GM-CSF),  
CC macrophage-colony stimulating factor (M-CSF), and IL-6, which enable it  
CC to support the growth of transplanted donor cells. In another embodiment  
CC of the invention, the mouse comprises DNA encoding the human major  
CC histocompatibility complex (MHC) class II DR3 molecule, where the  
CC transgene has naturally linked Drab and Dqb alleles. The transgenic  
CC mouse may be used as a model for determining the allergenicity of non-  
CC donor, e.g., non-human, macromolecules; to determine the effect compounds  
CC have on a human immune system; to generate fully human polyclonal or  
CC monoclonal antibodies to specific antigens; to determine whether  
CC humanised or other monoclonal antibodies will raise a response in a human  
CC immune system; to investigate the human cell mediated response to  
CC pathogens and other immunomodulatory compounds; and to determine the  
CC factors involved in regulating the development and function of human  
CC haematopoietic cells. The transgenic mouse supports the functional  
CC properties of human haematopoietic cells, unlike previous animal models  
CC which produce functionally impaired haematopoietic cells or are  
CC immunologically dysfunctional. In addition the transgenic mouse provides  
CC a unique model system which supports T cell development in a manner which  
CC more closely resembles normal ontogeny, as they possess CD4+ T cells in  
CC the periphery that exhibit MHC-restricted antigen-specific responses.  
CC Sequences AAT76193-AAT76204 represent PCR primers used to determine the  
CC presence of a VNC containing a 550kb segment of the human MHC class II  
CC region in murine embryonic stem (ES) cells

XX Sequence 18 BP, 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 42;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 879 CACCTGAGTGATTCTCT 896

DB 1 CACCTGAGTGATTCTCT 18

RESULT 118

ACC42628  
ID ACC42628 standard; DNA; 18 BP.

AC ACC42628;

XX 26-AUG-2003 (first entry)

DE HLA Class II region Tap 1 gene PCR primer 1069 F.

XX Human; PCR; primer; transgenic mouse; lymphocyte maturation; IL-3; IL-7;  
KW cytokine; interleukin-3; interleukin-6; IL-6; interleukin-7; M-CSF; SCF;  
KW macrophage-colony stimulating factor; stem cell factor; oncostatin M; OM;  
KW granulocyte-colony stimulating factor; GM-CSF; LIF;  
KW leukaemia inhibitory factor; HLA Class II region; Tap 1; ss.

XX Homo sapiens.

XX WO2003018744-A2.

XX 06-MAR-2003.

XX 05-AUG-2002; 2002WO-US024807.

XX 23-AUG-2001; 2001US-00938689.

XX (GEMV ) GENENCOR INT INC.

XX

PI Harding FA, Huang M;  
XX WPI; 2003-278650/27.

XX New recipient mammal, preferably a mouse, useful as a model of human  
PT disease to assess efficacy of therapeutic or prophylactic treatments, or  
PT for facilitating production of donor-specific functional immunity.

PS Example; Page 46; 70pp; English.

XX The present invention relates to a new transgenic mouse, which comprises  
CC a disruption in both alleles of a gene such that lymphocyte maturation  
CC does not occur and exogenous cytokines. The cytokines are selected from:  
CC interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-7 (IL-7),  
CC macrophage-colony stimulating factor (M-CSF), granulocyte-colony  
CC stimulating factor (GM-CSF), stem cell factor (SCF), leukemia inhibitory  
CC factor (LIF) and oncostatin M (OM). The gene disruption is in a gene that  
CC modulates VDJ recombination e.g. a RAG gene. The gene is disrupted by  
CC insertion of a transgene comprising major histocompatibility complex  
CC (MHC, HLA) Class II DR3 and DQ2 genes. The transgenic mouse is useful as  
CC a model of human disease to assess efficacy of therapeutic or  
CC prophylactic treatments, or to assess the antigenic potential of  
CC compounds. The transgenic mouse is also useful for supporting donor  
CC haematopoietic stem cells or facilitating production of donor-specific  
CC functional immunity. PCR primers ACC42571-ACC42639 were used to generate  
CC the transgenic mouse

XX Sequence 18 BP, 3 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 42;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 879 CACCTGAGTGATTCTCT 896

DB 1 CACCTGAGTGATTCTCT 18

RESULT 119

AAV28200/C  
ID AAV28200 standard; DNA; 22 BP.

AC AAV28200;

XX 08-OCT-1998 (first entry)

DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).

XX Purification; oligonucleotide; matrix; affinity unit;

KW affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;  
KW ss.

XX Synthetic.

XX WO9827425-A1.

XX 25-JUN-1998.

XX 18-DEC-1997; 97WO-US023284.

XX 19-DEC-1996; 96US-00769951.

XX (ISIS-) ISIS PHARM INC.

XX Chen D, Srivatsa GS, Cole DL;

XX WPI; 1998-362922/31.

XX Matrix for selective separation of oligo:nucleotide - useful for, e.g.  
PT large scale purification of anti-sense agents from their deletion  
PT derivatives formed during synthesis.  
XX Disclosure; Page 101; 183pp; English.

XX AAV28155-268 represent oligonucleotides which can be purified using the  
 CC method of the invention. The specification describes a matrix that  
 CC comprises a support and an affinity unit that specifically and reversibly  
 CC binds a target oligonucleotide, and comprises a sequence of bases having  
 CC the reverse complement of a hybridising portion of the target of  
 CC oligonucleotide. The matrix is used for affinity purification of  
 CC synthetic oligonucleotides, specifically antisense agents, for treatment  
 CC of hyperproliferative diseases, for treating a non-pathogen, non-  
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression  
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen,  
 CC retrovirus or other viruses

XX  
 SQ Sequence 22 BP, 3 A, 9 C, 4 G, 6 T, 0 U, 0 Other;

QY Query Match 0.8%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 76;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 1617 CAATGGCTCTGGGAAGACACA 1638  
 22 CAGTGGCTGTGGGAAGACACA 1

RESULT 120  
 AAX18712/c  
 ID AAX18712 standard; DNA; 22 BP.  
 XX  
 AC AAX18712;  
 XX  
 DT 10-MAY-1999 (first entry)  
 XX  
 DE Target MDR antisense oligonucleotide #44.  
 XX  
 KM Cellular adhesion protein; proliferation; antisense oligonucleotide;  
 KM alimentary canal; transport; gastrointestinal mucosa; cancer;  
 KM Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;  
 KM inflammation; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9901579-A1.  
 XX  
 PD 14-JAN-1999.  
 XX  
 PF 01-JUL-1998; 98WO-US013574.  
 XX  
 PR 01-JUL-1997; 97US-00866829.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Teng C, Hardee G;  
 XX  
 DR WPI; 1999-106077/09.  
 XX  
 PT Composition comprising nucleic acid and penetration enhancer - used  
 PT particularly for delivering therapeutic antisense oligonucleotides across  
 PT the gastrointestinal mucosa, provides high bioavailability.  
 XX  
 PS Example 2; Page 89; 115pp; English.

XX A pharmaceutical composition has been developed which comprises a nucleic  
 CC acid and at least one penetration enhancer. The compositions are used:  
 CC (i) to treat or prevent any disease or disorder that can be treated with  
 CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,  
 CC malaria, viral infections (including human immune deficiency virus  
 CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate  
 CC the role of a gene or gene product in non-human animals; and (iii) to  
 CC modulate gene expression in cells, tissues or organs. The compositions  
 CC provide bioavailability of at least 15, preferably 17-35%. The  
 CC penetration enhancer improves: (i) transport of the nucleic acid across  
 CC the mucosa of the alimentary canal and into cells; and (ii) increases  
 CC stability of the nucleic acid. Oral administration avoids the

CC complications and expense of intravenous or other methods of  
 CC administration. AAX18669 to AAX18799 and AAX18801 represent antisense  
 CC oligonucleotides which can be used as the nucleic acid in the method of  
 CC the invention

XX  
 SQ Sequence 22 BP, 3 A, 9 C, 4 G, 6 T, 0 U, 0 Other;

QY Query Match 0.8%; Score 17.2; DB 1; Length 22;  
 Best Local Similarity 86.4%; Pred. No. 76;  
 Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 1617 CAATGGCTCTGGGAAGACACA 1638  
 22 CAGTGGCTGTGGGAAGACACA 1

RESULT 121  
 AAX23703/c  
 ID AAX23703 standard; DNA; 22 BP.  
 XX  
 AC AAX23703;  
 XX  
 DT 18-JUN-1999 (first entry)  
 XX  
 DE Deletion sequence oligonucleotide 156.  
 XX  
 KM Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;  
 KM probe; cellular adhesion modulator; cellular proliferation modulator;  
 KM human retrovirus; human immunodeficiency virus; non-human retrovirus;  
 KM HIV; primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9911820-A1.  
 XX  
 PD 11-MAR-1999.  
 XX  
 PF 01-SEP-1998; 98WO-US018084.  
 XX  
 PR 02-SEP-1997; 97US-00923771.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Chen D, Srivatsa GS;  
 XX  
 DR WPI; 1999-205198/17.  
 XX  
 PS Example 9; Page 157; 163pp; English.

XX This invention describes a novel composition comprising a number of  
 CC sensor arrays, where each array comprises a unique probe oligonucleotide,  
 CC which is the reverse complement of part of a unique target  
 CC oligonucleotide present in a mixture of target deletion sequence  
 CC oligonucleotides. The compositions form a method for characterizing a  
 CC sample of target deletion oligonucleotides which are labelled and  
 CC hybridize with the probe oligonucleotides of the sensor arrays. Such  
 CC oligonucleotides and their targets are represented in AAX23548-X23709.  
 CC Oligonucleotides characterized by the method form pharmaceutical  
 CC compositions that are useful for modulating cellular adhesion or  
 CC proliferation, and being active against a eukaryotic pathogen, a human  
 CC retrovirus, a human immunodeficiency virus (HIV), or a non-human  
 CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory  
 CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable  
 CC characterization of deletion sequence oligonucleotides having related,  
 CC but different nucleobase sequences, and quantification of different  
 CC species of deletion sequence ("target") oligonucleotides in a mixture.  
 CC Also, if the specificity of the oligonucleotide's nucleobase sequence for  
 CC its reverse complement is not modified, the method may be performed using  
 CC oligodeoxynucleotides



XX Sequence 22 BP; 3 A; 9 C; 4 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 76;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
1617 CAATGGGCTGGGAGAGACACA 1638  
OY |||||  
DB 22 CAGTGGCTGGGAGAGACACA 1

RESULT 122  
AAS45634/C  
ID AAS45634 standard; DNA; 20 BP.  
XX AAS45634;  
XX 18-DEC-2001 (first entry)  
XX  
XX Human PARP-1 antisense inhibitor ISIS #125995.  
XX  
XX Human; 86; PARP; Poly (ADP-ribose) polymerase; antisense oligonucleotide;  
XX cytoskeletal; neurotrophic; neuroprotective; antiinflammatory; antidiabetic;  
XX immunosuppressant; hyperproliferative disorder; cancer; cellular injury;  
XX oxidative stress; neurological disorder; parkinsonism; apoptosis;  
XX meningitis-associated intracranial complication; ischaemia; probe;  
XX inflammatory disorder; autoimmune disorder; arthritis; diabetes.  
XX  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FT modified\_base 1..20  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
FT modified\_base 1..20  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "All cytidine residues are 5-methyl cytidine"  
FT modified\_base 1..5  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl nucleotides"  
FT modified\_base 16..20  
FT /tag= d  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl nucleotides"  
XX  
XX WO200164955-A1.  
XX  
XX 07-SEP-2001.  
XX  
XX 01-MAR-2001; 2001WO-US006572.  
XX  
XX 02-MAR-2000; 2000US-00517467.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Popoff I, Cowsett LM;  
XX  
XX WPI; 2001-602570/68.  
XX  
XX Antisense compound useful for treating hyperproliferative, neurological,  
XX inflammatory and autoimmune disorders and diabetes inhibits human PARP.  
XX  
XX Claim 3; Page 83; 168pp; English.  
XX  
XX The invention relates to antisense oligonucleotides targeted to human  
XX PARP nucleic acid and inhibiting expression of human PARP. PARP (Poly  
XX (ADP-ribose) polymerase plays an important role in chromatin  
XX decondensation, DNA replication, DNA repair, gene expression, malignant  
XX transformation, cellular differentiation and apoptosis. The antisense

CC oligonucleotide inhibitors are useful for inhibiting the expression of  
CC PARP in human cells or tissues. They are also useful for treating a human  
CC with a disease associated with PARP especially hyperproliferative  
CC disorders (e.g. cancer), cellular injury resulting from oxidative stress,  
CC neurological (e.g. parkinsonism, meningitis-associated intracranial  
CC complications and ischaemia), inflammatory and autoimmune disorders (e.g  
CC arthritis and diabetes. The present sequence is an antisense  
CC oligonucleotide of the invention  
XX  
XX Sequence 20 BP; 0 A; 6 C; 6 G; 8 T; 0 U; 0 Other;  
SQ Query Match 0.7%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 78;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
1193 AGACACTCAACCGAGAGAG 1212  
OY |||||  
DB 20 AGACACCCCAACCGAGAGAG 1

RESULT 123  
ABX97378  
ID ABX97378 standard; DNA; 20 BP.  
XX ABX97378;  
XX 20-MAY-2003 (first entry)  
XX  
XX Human NOV-associated forward primer from primer-probe set Ag3437.  
XX  
XX NOVA; cytoskeletal; cardiant; antiarteriosclerotic; antiasthmatic; cancer;  
XX hypotensive; cardiomyopathy; bronchial asthma; gene therapy; vaccine;  
XX human; PCR; primer; 86.  
XX  
XX Homo sapiens.  
XX  
XX WO200272757-A2.  
XX  
XX 19-SEP-2002.  
XX  
XX 08-MAR-2002; 2002WO-US006908.  
XX  
XX 08-MAR-2001; 2001US-0274101P.  
XX 08-MAR-2001; 2001US-0274194P.  
XX 08-MAR-2001; 2001US-0274281P.  
XX 08-MAR-2001; 2001US-0274322P.  
XX 09-MAR-2001; 2001US-0274849P.  
XX 12-MAR-2001; 2001US-0275235P.  
XX 13-MAR-2001; 2001US-0275578P.  
XX 13-MAR-2001; 2001US-0275579P.  
XX 13-MAR-2001; 2001US-0275601P.  
XX 14-MAR-2001; 2001US-0276000P.  
XX 16-MAR-2001; 2001US-0276776P.  
XX 19-MAR-2001; 2001US-0276994P.  
XX 20-MAR-2001; 2001US-0277239P.  
XX 20-MAR-2001; 2001US-0277321P.  
XX 20-MAR-2001; 2001US-0277327P.  
XX 21-MAR-2001; 2001US-0277791P.  
XX 22-MAR-2001; 2001US-0277833P.  
XX 23-MAR-2001; 2001US-0278152P.  
XX 26-MAR-2001; 2001US-0278894P.  
XX 27-MAR-2001; 2001US-0278999P.  
XX 27-MAR-2001; 2001US-0279036P.  
XX 28-MAR-2001; 2001US-0279344P.  
XX 30-MAR-2001; 2001US-0279358P.  
XX 30-MAR-2001; 2001US-0279959P.  
XX 30-MAR-2001; 2001US-0280233P.  
XX 02-APR-2001; 2001US-0280802P.  
XX 02-APR-2001; 2001US-0280832P.  
XX 02-APR-2001; 2001US-0280900P.  
XX 04-APR-2001; 2001US-0281194P.  
XX 13-APR-2001; 2001US-0283675P.  
XX 30-APR-2001; 2001US-0287424P.

PR 02-MAY-2001; 2001US-0288066P.  
 PR 03-MAY-2001; 2001US-0288342P.  
 PR 03-MAY-2001; 2001US-0288528P.  
 PR 15-MAY-2001; 2001US-0291190P.  
 PR 16-MAY-2001; 2001US-0291099P.  
 PR 16-MAY-2001; 2001US-0291240P.  
 PR 30-MAY-2001; 2001US-0294485P.  
 PR 31-MAY-2001; 2001US-0294889P.  
 PR 31-MAY-2001; 2001US-0299027P.  
 PR 18-JUN-2001; 2001US-0299027P.  
 PR 19-JUN-2001; 2001US-0299303P.  
 PR 10-JUL-2001; 2001US-0304358P.  
 PR 31-JUL-2001; 2001US-0309198P.  
 PR 16-AUG-2001; 2001US-0312903P.  
 PR 10-SEP-2001; 2001US-0318462P.  
 PR 12-SEP-2001; 2001US-0318770P.  
 PR 27-SEP-2001; 2001US-0325430P.  
 PR 27-SEP-2001; 2001US-0325681P.  
 PR 18-OCT-2001; 2001US-0330380P.  
 PR 31-OCT-2001; 2001US-0335301P.  
 PR 14-NOV-2001; 2001US-0332172P.  
 PR 14-NOV-2001; 2001US-0332271P.  
 PR 14-NOV-2001; 2001US-0332272P.  
 PR 14-NOV-2001; 2001US-0333184P.  
 PR 14-NOV-2001; 2001US-0333272P.  
 PR 21-NOV-2001; 2001US-0332094P.  
 PR 03-DEC-2001; 2001US-0337426P.  
 PR 03-DEC-2001; 2001US-0338092P.  
 PR 04-DEC-2001; 2001US-0337185P.  
 PR 03-JAN-2002; 2002US-0345705P.  
 PR 07-MAR-2002; 2002US-00092900.  
 XX  
 XX (CURA-) CURAGEN CORP.  
 XX  
 PI Padigaru M, Spytek KA, Shenoy SG, Taupier RJ, Pena CE, Li L;  
 PI Zehusien BD, Gasev V, Ji W, Gorman L, Miller CE, Kekuda R;  
 PI Patunajan M, Gangoli E, Vernet CM, Guo X, Tchernev V;  
 PI Fernandes ER, Casman SK, Malyankar UM, Gerlach V, Liu Y, Anderson D;  
 PI Spedena SK, Catterton E, Burgess C, Leite M, Zhong H, Alsbrook JP;  
 PI Lepley DM, Rieger DK;  
 XX  
 XX WPI: 2002-723332/78.

XX  
 PT NOXV polypeptides and polynucleotides, useful for preventing or treating  
 PT a disorder associated with aberrant NOXV expression or activity e.g.,  
 PT cancer, hypertension, atherosclerosis, cardiomyopathy or bronchial  
 PT asthma.  
 PT  
 XX  
 XX Example C; Page 762; 1103pp; English.  
 XX  
 PS This invention describes novel human NOXV polypeptides which have  
 CC cytosolic, cardiant, antiatherosclerotic, antiasthmatic and hypotensive  
 CC activity. Pharmaceutical compositions comprising the NOXV proteins or  
 CC nucleic acid molecules or NOXV antibodies are useful for preventing or  
 CC treating a disorder associated with aberrant NOXV expression or activity  
 CC e.g. cancer, hypertension, atherosclerosis, cardiomyopathy or bronchial  
 CC asthma. The products of the invention can be used for gene therapy or in  
 CC a vaccine. ABX13460-ABX13462 and ABX97186-ABX97593 represent PCR primers  
 CC and probes used in the amplification and isolation of the NOXV  
 CC polynucleotides represented in ABX97008-ABX97185 which encode the  
 CC polypeptides represented in ABU65041-ABU65218  
 CC  
 XX  
 SO Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 20;  
 Best Local Similarity 90.0%; Pred. No. 78;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 1259 TGGTGTGAAGTGGGAATC 1278  
 ||||||||||||  
 Db 1 TGGTGTGAAGTGGGAATC 20

RESULT 124  
 AAF96716  
 ID AAF96716 standard; DNA; 21 BP.  
 XX  
 XX AAF96716;  
 AC  
 XX  
 DT 06-JUN-2001 (first entry)  
 DT  
 XX  
 XX Human gene single nucleotide polymorphism #1477.  
 DE  
 XX  
 XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;  
 KW polymorphism; vascular disease; coronary artery disease; forensics;  
 KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;  
 KW pulmonary embolism; paternity test; ds.  
 XX  
 OS Homo sapiens.  
 OS  
 XX  
 FH Key Location/Qualifiers  
 FT Variation replace(11,T)  
 FT /\*tag= a  
 FT /standard\_name= "single nucleotide polymorphism"  
 FT  
 XX  
 XX W0200118250-A2.  
 XX  
 XX 15-MAR-2001.  
 PD  
 XX  
 PF 07-SEP-2000; 2000MO-US024503.  
 PF  
 XX  
 PR 10-SEP-1999; 99US-0153357P.  
 PR 26-JUL-2000; 2000US-0220947P.  
 PR 16-AUG-2000; 2000US-0225724P.  
 PR  
 XX  
 XX  
 PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.  
 PA (MITL-) MILENNITUM PHARM INC.  
 PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;  
 XX  
 XX WPI: 2001-226749/23.

XX  
 PT Nucleic acids comprising single nucleotide polymorphisms, useful in  
 PT applications such as forensics, paternity testing, medicine, genetic  
 PT analysis and phenotype correlations to diseases such as diabetes and  
 PT atherosclerosis.  
 PT  
 XX  
 XX Example; Page 148; 242pp; English.  
 PS  
 XX  
 XX The present invention provides a method of diagnosing a vascular disease  
 CC in an individual, involving determining the sequence at various  
 CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4  
 CC genes. The sequences at a number of polymorphic sites are also provided  
 CC in the specification. In particular, the method can be used in the  
 CC diagnosis of atherosclerosis, myocardial infarction, coronary heart  
 CC disease, stroke, peripheral vascular diseases, venous thromboembolism and  
 CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also  
 CC useful in forensics, paternity testing, genetic analysis and phenotype  
 CC correlations to diseases. The present sequence is an example of one of  
 CC the human gene SNPs shown in the specification  
 CC  
 XX  
 SO Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;  
 Best Local Similarity 90.0%; Pred. No. 84;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1565 AGGGGCTGACATTACCCCTA 1584  
 ||||||||||||  
 Db 2 AGGGGCTGACGTTTACCTA 21  
 RESULT 125  
 AAX60854/C  
 ID AAX60854 standard; DNA; 20 BP.

```

XX AAX60854;
XX
XX 09-AUG-1999 (first entry)
XX
XX CDK4 specific antisense oligo HYB102932.
XX
XX Cyclin-dependent kinase 4; CDK4; antisense; G1/S phase transition;
XX cancerous cell; cyclin D1; p16; tumour growth; ss.
XX
XX Synthetic.
XX
XX WO9927087-A1.
XX
XX 03-JUN-1999.
XX
XX 21-NOV-1997; 97WO-US022234.
XX
XX 21-NOV-1997; 97WO-US022234.
XX
XX (HYBR-) HYBRIDON INC.
XX
XX Morrissey D, Von Hofe E;
XX
XX WPI; 1999-357832/30.
XX
XX Antisense oligonucleotide targeted to cyclin-dependent kinase 4 gene,
XX useful for regulating G1 to S phase transition in a cell.
XX
XX Claim 3; Page 17; 60pp; English.
XX
XX Sequences AAX60831-864 represent synthetic oligonucleotides complementary
XX to a cyclin-dependent kinase 4 (CDK4) nucleic acid. The antisense
XX oligonucleotides are used to regulate G1/S phase transition, especially
XX to inhibit growth of cancerous cells. The oligonucleotides can be
XX administered in the form of a therapeutic composition to treat a mammal
XX afflicted with a tumour associated with aberrant expression of CDK4,
XX cyclin D1, or p16, to reduce tumour growth
XX
XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 92;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 102 GCTGCTCCGACCGCGCT 119
XX 18 GCTGCTCCGACCGAGCT 1
XX
XX Db
XX
XX RESULT 126
XX AAX60835/C
XX ID AAX60835 standard; DNA; 20 BP.
XX
XX AAX60835;
XX
XX 09-AUG-1999 (first entry)
XX
XX CDK4 specific antisense oligo HYB102135.
XX
XX Cyclin-dependent kinase 4; CDK4; antisense; G1/S phase transition;
XX cancerous cell; cyclin D1; p16; tumour growth; ss.
XX
XX Synthetic.
XX
XX WO9927087-A1.
XX
XX 03-JUN-1999.
XX
XX 21-NOV-1997; 97WO-US022234.
XX
XX 21-NOV-1997; 97WO-US022234.
XX
XX 21-NOV-1997; 97WO-US022234.
XX

```

```

PA (HYBR-) HYBRIDON INC.
XX
XX Morrissey D, Von Hofe E;
XX
XX WPI; 1999-357832/30.
XX
XX Antisense oligonucleotide targeted to cyclin-dependent kinase 4 gene,
XX useful for regulating G1 to S phase transition in a cell.
XX
XX Claim 3; Page 16; 60pp; English.
XX
XX Sequences AAX60831-864 represent synthetic oligonucleotides complementary
XX to a cyclin-dependent kinase 4 (CDK4) nucleic acid. The antisense
XX oligonucleotides are used to regulate G1/S phase transition, especially
XX to inhibit growth of cancerous cells. The oligonucleotides can be
XX administered in the form of a therapeutic composition to treat a mammal
XX afflicted with a tumour associated with aberrant expression of CDK4,
XX cyclin D1, or p16, to reduce tumour growth
XX
XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 92;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 102 GCTGCTCCGACCGCGCT 119
XX 19 GCTGCTCCGACCGAGCT 2
XX
XX Db
XX
XX RESULT 127
XX AAC64762/C
XX ID AAC64762 standard; DNA; 21 BP.
XX
XX AAC64762;
XX
XX 28-FEB-2001 (first entry)
XX
XX RRV Interleukin 6 (IL-6) PCR primer SEQ ID NO:171.
XX
XX Macaca mulatta rhadinovirus 17577; RRV; rhesus macaque rhadinovirus;
XX genome; Kaposi's sarcoma-associated herpesvirus; KSHV; interleukin 6;
XX IL-6; macrophage inflammatory protein; MIP; diagnosis; vaccine;
XX cytostatic; anti-HIV; gene therapy; infection; Kaposi's sarcoma;
XX lymphoproliferative disorder; B-cell hyperplasia; lymphadenopathy;
XX splenomegaly; hypergammaglobulinemia; autoimmune haemolytic anaemia;
XX PCR primer; ss.
XX
XX Macaca mulatta rhadinovirus 17577.
XX
XX WO200028040-A2.
XX
XX 18-MAY-2000.
XX
XX 05-NOV-1999; 99WO-US026260.
XX
XX 06-NOV-1998; 98US-0107507P.
XX 20-NOV-1998; 98US-0109409P.
XX
XX (UYOR-) UNIV OREGON HEALTH SCI.
XX
XX Wong SW, Axthelm MK, Searles RP;
XX
XX WPI; 2000-376552/32.
XX
XX New rhesus rhadino virus for producing non-human primate model useful for
XX testing potential treatments and efficacy of the candidate vaccine for
XX conditions associated with RRV infection.
XX
XX Example 14; Page 37; 141pp; English.
XX
XX The present invention describes a novel rhesus macaque rhadinovirus
XX called macaca mulatta rhadinovirus 17577 (RRV). AAC64754 represents the

```

CC RRV genome sequence, and AAB53123 to AAB53204 represent the proteins  
 CC encoded by the genome sequence. The present invention also specifically  
 CC claims the individual open reading frame (ORF) nucleotide sequences from  
 CC the genome which encode the individual proteins, but these sequences are  
 CC not given. A non-human animal infected with RRV can be used for testing  
 CC the efficacy of drug in the treatment of condition associated with  
 CC infection with RRV such as Kaposi's sarcoma, lymphoproliferative  
 CC disorders, B-cell hyperplasia, lymphadenopathy, splenomegaly,  
 CC hypergammaglobulinemia or autoimmune haemolytic anaemia, by  
 CC administering the drug to a immuno-compromised non-human primate  
 CC preferably Rhesus macaque monkey obtained by as a result of infection by  
 CC Simian Immunodeficiency Virus (SIV). RRV is useful for producing non-  
 CC human primate model for testing potential treatments for conditions  
 CC associated with RRV infection. It is also useful for testing the efficacy  
 CC of the candidate vaccine against RRV infection or conditions associated  
 CC with its infection by administering the vaccine to the subject capable of  
 CC infection with RRV, inoculating the subject with RRV and observing the  
 CC effect of vaccine. AAC64755 to AAC64765 and AAB53205 to AAB53213  
 CC represent sequence used in the exemplification of the present invention  
 XX

SQ Sequence 21 BP; 1 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query March 0.7%; Score 16.4; DB 1; Length 21;

Best Local Similarity 94.4%; Pred. No. 98; Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 834 GAACGACAGAGTAACAT 851

Db 18 GAACGACAGCGGAACAT 1

RESULT 128

AAQ73042 ID AAQ73042 standard; DNA; 21 BP.

XX AAQ73042;

XX 25-MAR-2003 (revised)

DT 10-MAR-2003 (revised)

DT 17-JUN-1995 (first entry)

XX Tyrosine-kinase syk DNA probe Z.

XX Tyrosine-kinase; DNA probe Z; ss.

OS Homo sapiens.

XX W09425565-A1.

PD 10-NOV-1994.

PF 25-APR-1994; 94WO-US004540.

PR 23-APR-1993; 93US-00052560.

PA (ARIA-) ARIAD PHARM INC.

PI Brugge J, Morganstern J, Shiu L, Zydowsky L, Zoller M, Pawson A;

XX WPI; 1994-358247/44.

XX Novel DNA encoding human syk tyrosine kinase - its recombinant prod.

XX useful to develop tyrosine activation motif mimics, useful for treating

XX allergies.

XX

XX Disclosure; Fig 1; 63pp; English.

XX The DNA probe is used in the isolation and cloning of human tyrosine-  
 CC kinase (Syk) cDNA. The protein, SH2 domains or fusion proteins can be  
 CC used in the development of tyrosine activation motif mimics or other  
 CC phosphopeptides which can interfere with the signal transduction cascade  
 CC of events leading to allergic responses. These can be used as  
 CC antiinflammatory agents. (Updated on 10-MAR-2003 to add missing OS

CC field.) (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query March 0.7%; Score 16.2; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 1.1e+02; Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 821 AGTTTTCACAGAACGAG 841

Db 1 AGTTTTCACAGAACGAG 21

RESULT 129

AAZ26604/C ID AAZ26604 standard; DNA; 21 BP.

XX AAZ26604;

XX 30-NOV-1999 (first entry)

XX Human polymorphic region 793.

XX Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;

KW cell viability; loss of heterozygosity; precancerous condition; ASI;

KW allele specific inhibitor; somatic cell; diagnosis; prevention;

KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;

KW graft versus host disease; malignant cell removal; bone marrow; ss.

XX Homo sapiens.

XX W09841648-A2.

XX 24-SEP-1998.

PF 19-MAR-1998; 98WO-US005419.

PR 20-MAR-1997; 97US-0041057P.

PA (VARI-) VARIGENICS INC.

PI Housman D, ledley PD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for diagnosis,

PT prevention and treatment of, e.g. cancers, atherosclerotic plaque,

PT dysplastic lesions, endometriosis or graft versus host disease.

XX Disclosure; Fig 7; 605pp; English.

XX This invention describes a novel method for identifying an inhibitor

CC potentially useful for treatment of cancer, where the inhibitor is active

CC on a gene vital for cell growth or viability, and where the gene is

CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

CC used for preventing the development of cancer in a patient having a

CC precancerous condition, by administering to the patient a first allele

CC specific inhibitor (ASI) targeted to an allele of a first essential gene

CC present in cells of the precancerous condition, where the normal somatic

CC cells of the patient are heterozygous for the first gene, the inhibitor

CC is active on at least one but less than all allelic forms of the gene

CC present in a population and targets only one allelic form present in the

CC normal somatic cells, and the first gene. The products and methods can be

CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.

CC cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic

CC lesions, benign tumours, endometriosis, polycystic kidney disease, and

CC graft versus host disease. The method can also be used to remove

CC malignant cells from bone marrow transplants. AAZ25812-226825 represent

CC human polymorphic sites described in the method of the invention

XX Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.2; DB 1; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1389 CATCTACCCGAGTACAGAA 1409  
 21 CTCTCTCCCGAGTGCAGAA 1

Db

RESULT 130  
 AAF55721  
 ID AAF55721 standard; DNA; 21 BP.  
 XX  
 AC AAF55721;  
 XX  
 DT 12-APR-2001 (first entry)  
 XX  
 DE PCR primer F13.  
 XX  
 KM Insecticide; transgenic plant; insect-resistance; PCR primer; probe; ss.  
 XX  
 OS Paecilomyces sp.  
 XX  
 PN WO200100841-A1.  
 XX  
 PD 04-JAN-2001.  
 XX  
 PF 23-JUN-2000; 2000WO-GB002457.  
 XX  
 PR 29-JUN-1999; 99GB-00015215.  
 PR 23-DEC-1999; 99GB-00030536.  
 XX  
 PA (ZENE ) ZENECA LTD.  
 XX  
 PI Griffin J, Carlile AJ, Cayley PJ, Mackay EA, Warner SAJ;  
 PI Vincent JL, Lee MD;  
 PI  
 DR WPI; 2001-123015/13.  
 XX  
 PT Novel insecticidal protein obtained from species of Paecilomyces for  
 PT controlling insects, and for insect-resistant transgenic plant  
 PT production.  
 XX  
 PS Example 6; Page 21; 72pp; English.  
 XX  
 CC The present invention relates to novel insecticidal proteins obtained  
 CC from Paecilomyces sp. (see AAB66899 to AAB66901 and AAB66913). The  
 CC insecticidal proteins can be used to produce transgenic plants, which are  
 CC insect-resistant. Also, the insecticidal proteins are useful for  
 CC controlling insects by providing them at a locus where insects feed. The  
 CC present sequence is a PCR primer used in the present invention  
 CC  
 XX  
 SQ Sequence 21 BP; 1 A; 9 C; 6 G; 5 T; 0 U; 0 Other;  
 OY Query Match 0.7%; Score 16.2; DB 1; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 101 TGCTGCTCCGAGCGCGCTGC 121  
 1 TGCTGCTCCGAGCTTCGCTGC 21

Db

RESULT 131  
 ADD14466  
 ID ADD14466 standard; DNA; 21 BP.  
 XX  
 AC ADD14466;  
 XX  
 DT 01-JAN-2004 (first entry)  
 XX  
 DE Human src biomarker reverse PCR primer SEQ ID NO:655.  
 XX

KM predictor set; protein tyrosine kinase activity modulator;  
 KM protein tyrosine kinase pathway; protein tyrosine kinase; cytostatic;  
 KM gene therapy; drug sensitivity; genetic profile; cancer; human;  
 KM PCR primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003062395-A2.  
 XX  
 PD 31-JUL-2003.  
 XX  
 PF 17-JAN-2003; 2003WO-US001981.  
 XX  
 PR 18-JAN-2002; 2002US-0350061P.  
 XX  
 PA (BRIM ) BRISTOL-MYERS SQUIBB CO.  
 XX  
 PI Huang F, Fairchild CR, Lee FY, Shaw P;  
 PI  
 DR WPI; 2003-636735/60.  
 XX  
 PS Example 2; SEQ ID NO 655; 139pp; English.  
 XX  
 CC The present invention describes a predictor set comprising a plurality of  
 CC polynucleotides or polypeptides whose expression pattern is predictive of  
 CC the response of cells to treatment with a compound that modulates protein  
 CC tyrosine kinase activity or members of the protein tyrosine kinase  
 CC pathway. Also described: (1) predicting whether a compound is capable of  
 CC modulating the activity of cells, comprising obtaining a sample of cells,  
 CC determining whether the cells express a plurality of markers, and  
 CC correlating the expression of the markers to the compound's ability to  
 CC modulate the activity of the cells; (2) a plurality of cell lines for  
 CC identifying polynucleotides and polypeptides whose expression levels  
 CC correlate with compound sensitivity or resistance of cells associated  
 CC with a disease state; and (3) identifying polynucleotides and  
 CC polypeptides that predict compound sensitivity or resistance of cells  
 CC associated with a disease state, comprising subjecting the plurality of  
 CC cell lines to one or more compounds, analysing the expression pattern of  
 CC a microarray of polynucleotides or polypeptides, and selecting  
 CC polynucleotides or polypeptides that predict the sensitivity or  
 CC resistance of cells associated with a disease state by using the  
 CC expression pattern of the microarray. The polynucleotides and  
 CC polypeptides have cytostatic activities, and can be used in gene therapy.  
 CC The polynucleotides and polypeptides are useful in predicting the  
 CC activity of compounds that interact with protein tyrosine kinases and/or  
 CC protein tyrosine kinase pathways. These may be used in determining drug  
 CC sensitivity in patients to allow the development of individualized  
 CC genetic profiles which aid in treating diseases and disorders (e.g.  
 CC cancer) based on patient response at a molecular level. The present  
 CC sequence is used in the exemplification of the present invention.  
 XX  
 SQ Sequence 21 BP; 0 A; 5 C; 4 G; 12 T; 0 U; 0 Other;  
 OY Query Match 0.7%; Score 16.2; DB 1; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1003 CTGCTCTGCTTTCTTCTTG 1023  
 1 CTGCTTTGCTTTTCTTGTG 21

Db

RESULT 132  
 AB195793/C  
 ID AB195793 standard; DNA; 20 BP.  
 XX  
 AC AB195793;  
 XX

DT 16-FEB-2002 (first entry)  
 XX Capture oligonucleotide zip ID#2880 oligo #9.  
 DE  
 XX  
 XX Human: K-ras; PCR primer; probe; capture probe; mutation detection;  
 KW ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;  
 KW infection; 21 hydroxylase deficiency; Turner Syndrome; Obesity; cancer;  
 KW oncogene; tumour suppressor; human papillomavirus; forensic;  
 KW environmental monitoring; food industry; feed industry; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200179548-A2.  
 XX  
 PD 25-OCT-2001.  
 XX  
 XX 04-APR-2001; 2001WO-US010958.  
 PF  
 XX 14-APR-2000; 2000US-0197271P.  
 PR  
 XX (CORR ) CORNELL RES FOUND INC.  
 PA  
 XX Barany F, Zivri M, Gerry NP, Favis R, Kliman R;  
 PI WPI; 2002-034366/04.  
 DR  
 XX  
 XX Designing capture oligonucleotide probes for use on a support to which  
 PT complementary oligonucleotides hybridize with little mismatch.  
 XX  
 PS Example 5; Fig 29; 300pp; English.  
 XX  
 XX The present invention describes a method (M1) for designing capture  
 CC oligonucleotide probes (I) for use on a support to which complementary  
 CC oligonucleotide probes (II) will hybridize with little mismatch, where  
 CC (I) have melting temperatures within a narrow range. The method is useful  
 CC for detecting infectious diseases caused by bacterial infectious agents  
 CC e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal  
 CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and  
 CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytotropic virus,  
 CC Epstein-Barr virus and polio virus, and parasitic infectious agents  
 CC selected from Onchocerca volvulus, Entamoeba histolytica and Dracunculus  
 CC melanosus. The method is also useful for detecting genetic diseases such  
 CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.  
 CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes  
 CC involved in DNA amplification, replication, recombination or repair, the  
 CC cancer is specifically associated with a gene selected from BRCA1 gene,  
 CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The  
 CC method is also used for environmental monitoring, forensics and the food  
 CC and feed industry, detecting composites scanning (using e.g. a scanning  
 CC electron microscope and infrared microscope) the support at the  
 CC particular sites and identifying if ligation of the oligonucleotide probe  
 CC sets occurred and correlating (using a computer) identified ligation to a  
 CC presence or absence of the target nucleotide sequences. AB192074 to  
 CC AB197546 represent oligonucleotide sequences used in the exemplification  
 CC of the present invention  
 XX  
 SQ Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.7%; Score 16; DB 1; Length 20;  
 Db Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 269 AGGCGTGGCTGGCTGC 284  
 Db 19 AGGCGTGGCTGGCTGC 4  
 XX  
 RESULT 133  
 ADB84244/c  
 ID ADB84244 standard; DNA; 21 BP.  
 XX  
 AC ADB84244;  
 XX

DT 04-DEC-2003 (first entry)  
 XX Chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer #2.  
 DE  
 XX  
 XX nucleated red blood cell; nucleic acid isolation;  
 KW high throughput screening assay; genetic analysis;  
 KW avian genetic analysis; fish genetic analysis; reptile genetic analysis;  
 KW amphibian genetic analysis; transgene; chicken;  
 KW glyceraldehyde-3-phosphate dehydrogenase; GAPDH; PCR; primer; ss.  
 XX  
 OS Gallus gallus.  
 XX  
 PN US2003049656-A1.  
 XX  
 PD 13-MAR-2003.  
 XX  
 XX 02-MAY-2002; 2002US-00136942.  
 PF  
 XX 15-JAN-2000; 2000US-0176255P.  
 PR  
 XX 13-JAN-2001; 2001US-00760048.  
 PA  
 XX (HARV/) HARVEY A J.  
 PI Harvey AJ;  
 DR WPI; 2003-677928/64.  
 XX  
 XX Isolation of nucleic acid from nucleated red blood cells involves lysing  
 PT the cells, centrifuging, removing the supernatant, lysing the pellet to  
 PT release nucleic acid, precipitating and washing and drying of the nucleic  
 XX acid.  
 XX  
 PS Example 3; Page 6; 18pp; English.  
 XX  
 XX The invention describes a method of isolating nucleic acid (I) from  
 CC nucleated red blood cells. The method comprises adding a biological  
 CC sample containing the cells to lysis buffer that is confined in a  
 CC container that binds a precipitated nucleic acid, centrifuging, removing  
 CC the supernatant, adding a second lysis buffer to the obtained pellet that  
 CC is incubated in the buffer to release (I), precipitating and washing and  
 CC drying of (I), and dissolving in a solvent. The method is useful for  
 CC extracting DNA from nucleated red blood cells, for a high throughput  
 CC screening assay (e.g. a polymerase chain reaction, ligase chain reaction  
 CC or other conventional DNA detection assay), for detecting a genetic  
 CC sequence in multiple samples and for application towards genetic analysis  
 CC of avians, fish, reptiles and amphibians. The extracted DNA can be used  
 CC for a variety of genetic assays including a high throughput-screening  
 CC assay to identify insertion of a transgene. This sequence represents a  
 CC primer used to isolate DNA encoding chicken glyceraldehyde-3-phosphate  
 CC dehydrogenase (GAPDH) for use as a control in assays for detecting the  
 CC presence of a transgene.  
 XX  
 SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.7%; Score 16; DB 1; Length 21;  
 Db Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1075 TCTCTGGCAAGTCCA 1090  
 Db 21 TCTCTGGCAAGTCCA 6  
 XX  
 RESULT 134  
 ADD35649/c  
 ID ADD35649 standard; DNA; 21 BP.  
 XX  
 AC ADD35649;  
 XX  
 DT 15-JAN-2004 (first entry)  
 XX  
 DE Chicken glyceraldehyde 3-phosphate dehydrogenase (GAPDH) PCR primer #2.  
 XX

KM Chicken; glyceraldehyde 3-phosphate dehydrogenase; GAPDH; PCR; primer;  
 KM ss; nucleated red blood cell.  
 XX  
 OS Gallus gallus.  
 XX  
 PN US6423486-B1.  
 XX  
 PD 23-JUL-2002.  
 XX  
 PF 13-JAN-2001; 2001US-00760048.  
 XX  
 PR 15-JAN-2000; 2000US-0176255P.  
 XX  
 PA (AVIG-) AVIGENICS INC.  
 XX  
 PI Harvey AJ;  
 XX  
 DR WPI; 2003-799767/75.  
 XX  
 PT Isolating nucleic acid such as red blood cells from avian samples, by  
 PT adding to the sample in multi-well plates, lysis buffers which lyse  
 PT plasma membrane and release nucleic acid and precipitating the nucleic  
 PT acid.  
 XX  
 PS Example 3; SEQ ID NO 2; 18pp; English.  
 XX  
 CC The invention relates to a method for isolating a nucleic acid from  
 CC nucleated red blood cells. The method comprises adding a biological  
 CC sample containing the nucleated red blood cells to a first lysis buffer  
 CC to lyse the plasma membranes, where the first lysis buffer is confined in  
 CC a container that binds a precipitated nucleic acid, centrifuging the  
 CC container, removing the supernatant from the pellet in the container,  
 CC adding a second lysis buffer to the pellet in the container, after which  
 CC the pellet is incubated in the second lysis buffer for two hours to  
 CC release a nucleic acid, precipitating the nucleic acid in the container  
 CC with a nucleic acid precipitating solution, washing and drying the  
 CC nucleic acid in the container and dissolving the nucleic acid in the  
 CC container in a solvent. The method is useful for isolating nucleic acids  
 CC from a biological sample, preferably blood, in particular nucleated red  
 CC blood cells obtained from a mammal, bird, reptile, fish or amphibian,  
 CC especially from a bird. The method is useful for extracting DNA from  
 CC avian blood for use in high throughput screening assays, e.g. in an assay  
 CC to detect the insertion of foreign DNA in the genome of a recipient. The  
 CC method facilitates genetic analysis of avians, fish, reptiles and  
 CC amphibians and allows DNA to be extracted rapidly from multiple avian  
 CC samples. This sequence represents a PCR primer used in the method of the  
 CC invention.  
 CC  
 SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 XX  
 XX  
 Query Match 0.7%; Score 16; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1075 TCTCTGCGCAAGTCCA 1090  
 ||||||||||||||||  
 DB 21 TCTCTGCGCAAGTCCA 6  
 RESULT 135  
 AAQ31954  
 ID AAQ31954 standard; DNA; 19 BP.  
 XX  
 AC AAQ31954;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 27-APR-1993 (first entry)  
 XX  
 DE Oligonucleotide PG contg. binding region of plasmid CBE.  
 XX  
 KM P53; DNA-binding; cancer; neoplasia; tumour; concatemer; ss.  
 XX  
 OS Synthetic.

XX  
 PN EP518650-A2.  
 XX  
 PD 16-DEC-1992.  
 XX  
 PF 10-JUN-1992; 92EP-00305333.  
 XX  
 PR 14-JUN-1991; 91US-00715182.  
 PR 31-MAR-1992; 92US-00860758.  
 XX  
 PA (UYJO) UNIV JOHNS HOPKINS.  
 PA (PEAR-) PHARMAGENICS INC.  
 XX  
 PI Vogelstein B, Kinzler KW, Sherman MI;  
 XX  
 DR WPI; 1992-417505/51.  
 XX  
 PT Detection and expression of wild type P53 protein - useful for diagnosing  
 PT and treating cancers, and for screening potential chemotherapeutic  
 PT agents.  
 XX  
 PS Example 12; Page 18; 51pp; English.  
 XX  
 CC Wild-type p53 protein binds specific fragments of human chromosomal DNA.  
 CC To demonstrate that intact p53 can activate expression in human cells  
 CC reporter plasmids were constructed. These comprised part of the  
 CC polyomavirus early promoter and the CAT gene located downstream of DNA  
 CC sequences which could bind p53 in vitro. The p53 binding sequences were  
 CC obtd. using a series of concatemers of PG, which contains the binding  
 CC region of plasmid CBE, previously shown to bind p53 in vitro. The  
 CC reporter and an expression vector coding for the intact human wild type  
 CC protein p53 were transfected together into the human colorectal cancer  
 CC cell line HCT 116. The intact p53 protein was indeed able to activate  
 CC transcription. The level of trans-activation of the CAT gene depended on  
 CC the strength of binding to p53 of the upstream sequences. Thus, the  
 CC longer the number of PG repeats, the greater the binding to p53 in vitro  
 CC and the higher the CAT expression in vivo. See also AAQ31948-84. (updated  
 CC on 25-MAR-2003 to correct PN field.)  
 CC  
 SQ Sequence 19 BP; 1 A; 7 C; 6 G; 5 T; 0 U; 0 Other;  
 XX  
 XX  
 Query Match 0.7%; Score 15.8; DB 1; Length 19;  
 Best Local Similarity 89.5%; Pred. No. 1.1e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 318 CCTGCCGCGACTTGCTTG 336  
 ||||||||||||||||  
 DB 1 CCTGCCGCGACTTGCTTG 19  
 RESULT 136  
 AAX58592  
 ID AAX58592 standard; DNA; 19 BP.  
 XX  
 AC AAX58592;  
 XX  
 DT 16-AUG-1999 (first entry)  
 XX  
 DE Oligonucleotide PG used in p53 cell regulator protein EMSA.  
 XX  
 KM Cell regulatory protein; p53; mouse; cancer; tumour suppressor;  
 KM cell cycle control; apoptosis; cell proliferation; therapy;  
 KM cell differentiation; electrophoretic mobility shift assay; EMSA; ds.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9919357-A2.  
 XX  
 PD 22-APR-1999.  
 XX  
 PF 02-OCT-1998; 98WO-US021992.  
 XX  
 PR 15-OCT-1997; 97US-0062076P.

```

PR 29-MAY-1998; 98US-0087216P.
XX (HARD ) HARVARD COLLEGE.
XX Yang A, Mckeon F;
XX WPI; 1999-277595/23.
XX
XX New isolated p63 cell regulatory protein for, e.g. treatment of tumors.
XX
XX Example 14; Page 114; 161pp; English.
XX
XX This double-stranded oligonucleotide, termed P6, was used in
XX electrophoretic mobility shift assays designed to determine the location
XX of the DNA binding portion of novel p63 cell regulator proteins of the
XX invention. At least 6 different isoforms of p63 exist. These demonstrate
XX divergent activities, such as transactivation of p53 reporter genes and
XX induction of apoptosis. p63 is also implicated in haematopoiesis, muscle
XX wasting (e.g. cachexia) and neuronal differentiation and related
XX degenerative disorders. Human and murine p63 polypeptides (see AY05953-
XX 64), polynucleotides (see AAX58572-83) and anti-p63 antibodies of the
XX invention can be used to identify compounds useful for treating disorders
XX involving such processes, in detection and diagnosis, and in the
XX production of transgenic animals
XX
XX Sequence 19 BP; 1 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 318 CCTGCCGGGACTTGCTTG 336
XX ||||| ||||| ||||| |||||
XX 1 CCTGCCGGGACTTGCTTG 19
XX
XX RESULT 137
XX AAC83147
XX ID AAC83147 standard; DNA; 19 BP.
XX
XX AAC83147;
XX
XX 01-MAR-2001 (first entry)
XX
XX PCR primer used for matrix metalloproteinase DNA amplification SEQ ID 4.
XX
XX Human; membrane-bound matrix metalloproteinase; progelatinase activation;
XX atherosclerosis; Alzheimer's disease; emphysema; rheumatic arthritis;
XX myodystrophy; osteoporosis; neurodegenerative disease; metastasis;
XX cancer infiltration; PCR primer; ss.
XX
XX Synthetic.
XX
XX JP2000270874-A.
XX
XX 03-OCT-2000.
XX
XX 25-MAR-1999; 99JP-00082516.
XX
XX 25-MAR-1999; 99JP-00082516.
XX
XX (FUJY ) FUJY PHARM IND CO LTD.
XX
XX WPI; 2001-011049/02.
XX
XX A new membrane-bound metalloproteinase for treating diseases such as
XX PT atherosclerosis, Alzheimer's disease, emphysema and rheumatic arthritis.
XX
XX Example 1; Page 33; 57pp; Japanese.
XX
XX This invention relates to a human membrane-bound matrix metalloproteinase
XX CC protein. The protein has progelatinase activating ability. The matrix
XX metalloproteinase can be used for the treatment of various diseases such as

```

```

CC atherosclerosis, Alzheimer's disease, emphysema, rheumatic arthritis,
CC myodystrophy, osteoporosis, neurodegenerative diseases and cancer
CC infiltration and metastasis. The present sequence represents a PCR primer
CC specific for DNA encoding human matrix metalloproteinase
XX
XX Sequence 19 BP; 2 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1362 CACCCAGGCTGTGGAGTA 1380
XX ||||| ||||| ||||| |||||
XX 1 CACCCAGGCTGTGGAGTA 19
XX
XX RESULT 138
XX ABK47527
XX ID ABK47527 standard; DNA; 19 BP.
XX
XX ABK47527;
XX
XX 18-JUN-2002 (first entry)
XX
XX Matrix metalloproteinase 19 (MMP-19) associated primer #7.
XX
XX Transgenic animal; matrix metalloproteinase 19; MMP-19;
XX extracellular matrix disorder; chondrogenic failure;
XX osteogenic failure; osteoporosis; arthritis; synovitis; eye disease;
XX malignant tumour; joint disease; bone disease; bone deformation;
XX limb shortening; cranial deformation; defective bite; tooth elongation;
XX primer; ss.
XX
XX Synthetic.
XX
XX WO200211530-A1.
XX
XX 14-FEB-2002.
XX
XX 08-AUG-2001; 2001WO-JP006826.
XX
XX 09-AUG-2000; 2000JP-00241748.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX Yoshimura K, Nishimura A, Nishida M, Hosono K;
XX WPI; 2002-227106/28.
XX
XX Transgenic mammal containing foreign MMP-19 gene for use as a model for
XX PT bone and cartilage diseases.
XX
XX Example 6; Page 21; 46pp; Japanese.
XX
XX The invention describes a non-human transgenic mammal containing a
XX CC recombinant DNA encoding a foreign matrix metalloproteinase 19 (MMP-19)
XX CC gene or its modified form. Identification of agents for the treatment and
XX CC prevention of extracellular matrix disorders including chondrogenic
XX CC failure, osteogenic failure, osteoporosis, arthritis deformans,
XX CC rheumatoid arthritis, synovitis, metabolic arthritis, eye disease,
XX CC malignant tumours, and associated complications. The transgenic mammals
XX CC are a model for joint and bone diseases including deformation and
XX CC shortening of limbs, cranial deformation, defective bite, tooth
XX CC elongation, and defects of lumbar and tail vertebrae. This sequence
XX CC represents a primer associated with the creation of the transgenic animal
XX CC expressing the recombinant MMP-19 protein
XX
XX Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```



QY 1996 CTGATGATGATCCACCACTG 2014  
 |||||  
 DB 1 CTGATGATGATCCACCAAGG 19

RESULT 139  
 AAQ43607  
 ID AAQ43607 standard; DNA; 20 BP.  
 XX  
 AC AAQ43607;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 11-OCT-1993 (first entry)  
 XX  
 XX Chlamydia trachomatis serotype detection probe.  
 DE  
 XX Isolation; amplification; major outer membrane protein gene; MOMP;  
 KW 15 serotypes; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN EP546761-A1.  
 XX  
 PD 16-JUN-1993.  
 XX  
 PF 02-DEC-1992; 92EP-00310998.  
 XX  
 PR 11-DEC-1991; 91US-00806933.  
 XX  
 PA (BECT ) BECTON DICKINSON CO.  
 XX  
 PI Malinowski DP, Fraiser MS, Jurgensen SR;  
 XX WPI; 1993-190117/24.  
 DR

PT Probe for detecting and isolating 15 serotype(s) of Chlamydia trachomatis  
 PT - comprises specific nucleic acid sequences, modified backbone,  
 PT nucleotide, labelled and ribonucleic acid forms, for amplifying major  
 PT outer membrane protein gene.  
 PS  
 XX Claim 1; Page 5; 19pp; English.

CC The sequence is that of a probe based on a unique nucleic acid sequence  
 CC in the Chlamydia trachomatis major outer membrane protein (MOMP) gene  
 CC which is present in all 15 serotypes of C. trachomatis. It corresponds to  
 CC nucleotides 747-766 of the MOMP gene. It may be used for detecting and/or  
 CC amplifying the MOMP gene of C. trachomatis, and can detect all 15  
 CC serotypes of C. trachomatis. Since the MOMP gene is unique for C.  
 CC trachomatis, there will be no cross-hybridisation to nucleic acid from  
 CC other bacteria. (Updated on 25-MAR-2003 to correct PN field.)  
 CC  
 XX

Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 714 TGCAGTCTGAGTTCGTG 732  
 |||||  
 DB 2 TGCAGTCTGAGTTCGTG 20

RESULT 140  
 AAV28201/C  
 ID AAV28201 standard; DNA; 20 BP.  
 XX  
 AC AAV28201;  
 XX  
 DT 08-OCT-1998 (first entry)  
 DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).  
 XX Purification; oligonucleotide; matrix; affinity unit;  
 KW

KW affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;  
 KW ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9827425-A1.  
 XX  
 PD 25-JUN-1998.  
 XX  
 PF 18-DEC-1997; 97MO-US023284.  
 XX  
 PR 19-DEC-1996; 96US-00769951.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Chen D, Srivatsa GS, Cole DL;  
 XX WPI; 1998-362922/31.  
 DR

PT Matrix for selective separation of oligonucleotide - useful for, e.g.  
 PT large scale purification of anti-sense agents from their deletion  
 PT derivatives formed during synthesis.  
 PS  
 XX Disclosure; Page 102; 183pp; English.

CC AAV28155-268 represent oligonucleotides which can be purified using the  
 CC method of the invention. The specification describes a matrix that  
 CC comprises a support and an affinity unit that specifically and reversibly  
 CC binds a target oligonucleotide, and comprises a sequence of bases having  
 CC the reverse complement of a hybridising portion of the target  
 CC oligonucleotide. The matrix is used for affinity purification of  
 CC synthetic oligonucleotides, specifically antisense agents, for treatment  
 CC of hyperproliferative diseases, for treating a non-pathogen, non-  
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression  
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen,  
 CC retrovirus or other viruses  
 XX

Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1620 TGGCTGTGGAGAGACACA 1638  
 |||||  
 DB 19 TGGCTGTGGAGAGACACA 1

RESULT 141  
 AAX18713/C  
 ID AAX18713 standard; DNA; 20 BP.  
 XX  
 AC AAX18713;  
 XX  
 DT 10-MAY-1999 (first entry)  
 DE Target MDR antisense oligonucleotide #45.  
 XX  
 KW Cellular adhesion protein; proliferation; antisense oligonucleotide;  
 KW alimentary canal; transport; gastrointestinal mucosa; cancer;  
 KW Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;  
 KW inflammation; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9901579-A1.  
 XX  
 PD 14-JAN-1999.  
 XX  
 PF 01-JUL-1998; 98MO-US013574.  
 XX  
 PR 01-JUL-1997; 97US-00866829.  
 XX

```

PA (ISIS-)ISIS PHARM INC.
XX
XX Teng C, Hardee G;
XX WPI; 1999-106077/09.
XX
XX Composition comprising nucleic acid and penetration enhancer - used
PT particularly for delivering therapeutic antisense oligonucleotides across
PT the gastrointestinal mucosa, provides high bioavailability.
XX
PS Example 2; Page 89; 115pp; English.
XX
XX A pharmaceutical composition has been developed which comprises a nucleic
CC acid and at least one penetration enhancer. The compositions are used:
CC (i) to treat or prevent any disease or disorder that can be treated with
CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC malaria, viral infections (including human immune deficiency virus
CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC the role of a gene or gene product in non-human animals; and (iii) to
CC modulate gene expression in cells, tissues or organs. The compositions
CC provide bioavailability of at least 15, preferably 17-35,%. The
CC penetration enhancer improves: (i) transport of the nucleic acid across
CC the mucosa of the alimentary canal and into cells; and (ii) increases
CC stability of the nucleic acid. Oral administration avoids the
CC complications and expense of intravenous or other methods of
CC administration. AAX18669 to AAX18799 and AAX18801 represent antisense
CC oligonucleotides which can be used as the nucleic acid in the method of
CC the invention
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1620 TGGGCTCGGGAAGACACA 1638
DB 19 TGGCTGTGGGAAGACACA 1
RESULT 142
AAX23704/C
AAX23704 standard; DNA; 20 BP.
XX
XX AAX23704;
AC
XX 18-JUN-1999 (first entry)
DT
XX Deletion sequence oligonucleotide 157.
DE
XX
XX Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KW probe; cellular adhesion modulator; cellular proliferation modulator;
KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
KW HIV; primer; ss.
XX
XX Synthetic.
OS
XX WO9911820-A1.
PN
XX 11-MAR-1999.
PD
XX
XX 01-SEP-1998; 98WO-US018084.
PF
XX 02-SEP-1997; 97US-00923771.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Chen D, Srivatsa GS;
PI
XX WPI; 1999-205198/17.
PT
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion

```

PT	oligonucleotides.
XX	
PS	Example 9; Page 158; 163pp; English.
CC	This invention describes a novel composition comprising a number of
CC	sensor arrays, where each array comprises a unique probe oligonucleotide,
CC	which is the reverse complement of part of a unique target
CC	oligonucleotide present in a mixture of target deletion sequence
CC	oligonucleotides. The compositions form a method for characterizing a
CC	sample of target deletion oligonucleotides which are labelled and
CC	hybridize with the probe oligonucleotides of the sensor arrays. Such
CC	oligonucleotides and their targets are represented in AXX23548-X23709.
CC	Oligonucleotides characterized by the method form pharmaceutical
CC	compositions that are useful for modulating cellular adhesion or
CC	proliferation, and being active against a eukaryotic pathogen, a human
CC	retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC	retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC	Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC	characterization of deletion sequence oligonucleotides having related,
CC	but different nucleobase sequences, and quantification of different
CC	species of deletion sequence ("target") oligonucleotides in a mixture.
CC	Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC	its reverse complement is not modified, the method may be performed using
CC	oligodeoxynucleotides
XX	
SQ	Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
Query Match	0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity	89.5%; Pred.No. 1.2e+02;
Matches 17; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
Oy	1620 TGGGCTGGGAAGACACA 1638                     19 TGGCGTGGCAAGACACA 1
Db	
RESULT 143	
AAC85332/C	
ID AAC85332 standard; cDNA; 20 BP.	
XX	
AC AAC85332;	
XX	
DT 29-MAR-2001 (first entry)	
XX	
DE cDNA primer for PAPA1A/PAPB2B, PE.	
XX	
KM Human; poly(ADP-ribose) polymerase; hPARP2; oxidative stress; ARDS;	
KM inflammation; ischemic stroke; hemorrhagic shock; myocardial ischemia;	
KM infarction; cerebral vasospasm; rheumatoid arthritis; osteoarthritis;	
KM gouty arthritis; spondylitis; Behcet's disease; sepsis; septic shock;	
KM endotoxic shock; gram negative sepsis; gram positive sepsis; trauma;	
KM toxic shock syndrome; multiple organ injury syndrome; vasculitis;	
KM hemorrhage; conjunctivitis; uveitis; thyroid-associated ophthalmopathy;	
KM eosinophilic granuloma; asthma; chronic bronchitis; allergic rhinitis;	
KM chronic obstructive pulmonary disease; silicosis; reperfusion injury;	
KM pulmonary sarcoidosis; pleurisy; alveolitis; pneumonia; myocardium;	
KM bronchiectasis; pulmonary oxygen toxicity; keloid formation; brain;	
KM scar tissue formation; atherosclerosis; systemic lupus erythematosus;	
KM autoimmune thyroiditis; multiple sclerosis; Reynaud's syndrome;	
KM graft versus host disease; allograft rejection; cystic fibrosis;	
KM chronic glomerulonephritis; inflammatory bowel disease; Crohn's disease;	
KM ulcerative colitis; necrotizing enterocolitis; inflammatory dermatosis;	
KM contact dermatitis; atopic dermatitis; psoriasis; urticaria; fever;	
KM myalgia; meningitis; encephalitis; Sjogren's syndrome;	
KM alcoholic hepatitis; bacterial pneumonia; hypovolemic shock;	
KM Type 1 diabetes mellitus; hypersensitivity; leukocyte dyscrasia;	
KM thermal injury; cytokine-induced toxicity; expressed sequence tag; EST;	
KM RAGE; PCR; amplify; primer; polymerase chain reaction; ss.	
XX	
OS Synthetic.	
XX	
PN WO200077179-A2.	
XX	



```

PR 29-JUN-1999; 99US-0141582P.
XX
XX (ICOS-) ICOS CORP.
XX
PI Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL;
XX WPI; 2001-102896/11.
XX
XX New tankyrase2 polypeptides, useful for treating conditions mediated by
PT poly(denoposite-diphosphate-ribose) polymerase activity e.g. cancers,
PT inflammatory and autoimmune disorders.
XX
XX Example 7; Page 231; 242pp; English.
XX
XX The present invention provides the protein and coding sequence for the
CC human tankyrase2 protein. This is found in two different versions,
CC designated TANK2-LONG and TANK2-SHORT. Tankyrase2 has polyADP-
CC ribosylation activity and is involved in the modification of TRF1, which
CC is a telomere-specific binding protein. The regulation of telomere
CC length, in which TRF1 has a role, is linked to ageing and cancer. The
CC sequences are useful in the treatment of cancers and inflammatory
CC disorders
XX
SQ Sequence 20 BP; 8 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1193 AGACACTCAACCGAGAAGA 1211
Db ||||| ||||| |||||
2 AGACACCCCAACCGAGAAGA 20
RESULT 146
AAF63985/C
ID AAF63985 standard; DNA; 20 BP.
XX
XX AAF63985;
XX
DT 05-APR-2001 (first entry)
XX
XX Human tankyrase2 expression plasmid PCR primer SEQ ID NO: 172.
XX
XX Human; tankyrase2; TANK2; TRF1; telomere; cancer; neoplasm; aging;
KM inflammatory disorder; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200100849-A1.
XX
XX 04-JAN-2001.
XX
XX 28-JUN-2000; 2000WO-US017827.
XX
XX 29-JUN-1999; 99US-0141582P.
XX
XX (ICOS-) ICOS CORP.
XX
XX Christenson E, Demaggio AJ, Goldman PS, Mcelligott DL;
XX WPI; 2001-102896/11.
XX
XX New tankyrase2 polypeptides, useful for treating conditions mediated by
PT poly(denoposite-diphosphate-ribose) polymerase activity e.g. cancers,
PT inflammatory and autoimmune disorders.
XX
XX Example 7; Page 231; 242pp; English.
XX
XX The present invention provides the protein and coding sequence for the
CC human tankyrase2 protein. This is found in two different versions,
CC designated TANK2-LONG and TANK2-SHORT. Tankyrase2 has polyADP-
CC ribosylation activity and is involved in the modification of TRF1, which

```

```

CC is a telomere-specific binding protein. The regulation of telomere
CC length, in which TRF1 has a role, is linked to ageing and cancer. The
CC sequences are useful in the treatment of cancers and inflammatory
CC disorders
XX
SQ Sequence 20 BP; 0 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1193 AGACACTCAACCGAGAAGA 1211
Db ||||| ||||| |||||
19 AGACACCCCAACCGAGAAGA 1
RESULT 147
AAL40440/C
ID AAL40440 standard; DNA; 20 BP.
XX
XX AAL40440;
XX
DT 19-SEP-2002 (first entry)
XX
XX Mouse caspase 6 antisense inhibition related oligo SEQ ID No 159.
XX
XX Muscular; cytosstatic; nootropic; neuroprotective; ophthalmological;
KM antilipemic; osteopathic; caspase 6; Rieger's syndrome; bone metabolism;
KM ataxia telangiectasia; hyperproliferative disorder; cholesterol disorder;
KM haematopoietic disorder; cancer; neurological; Alzheimer's disease;
KM apoptotic; mouse; murine; ds.
XX
XX Mus musculus.
XX
XX WO200229066-A1.
XX
XX 11-APR-2002.
XX
XX 03-OCT-2001; 2001WO-US030871.
XX
XX 04-OCT-2000; 2000US-00679299.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Brown-Driver VL, Zhang H, Watt AT;
XX WPI; 2002-471315/50.
XX
XX An antisense oligonucleotide of 8 to 50 nucleotides in length that
PT inhibits caspase 6, is useful for treating Rieger's syndrome.
XX
XX Claim 3; Page 93; 141pp; English.
XX
XX The invention relates to an antisense oligonucleotide compound of 8 to 50
CC nucleotides in length that is targeted to a nucleic acid molecule
CC encoding caspase 6, where the oligonucleotide specifically hybridises
CC with and inhibits the expression of caspase 6. The oligonucleotide of the
CC invention specifically hybridises to and inhibits expression of caspase 6
CC in cells or tissues. The oligonucleotides can be administered
CC therapeutically or prophylactically to treat an animal having a disease
CC or condition associated with caspase 6, such as Rieger's syndrome or
CC ataxia telangiectasia, hyperproliferative disorder, a haematopoietic
CC disorder, a bone metabolism or cholesterol disorder, various types of
CC cancer, neurological conditions such as Alzheimer's disease and other de-
CC regulated apoptotic pathological conditions. This polynucleotide sequence
CC represents a mouse caspase 6 oligonucleotide relating to the invention.
CC NOTE: This phosphorothioate oligonucleotide sequence has 2'-MOB wings and
CC a deoxy gap
XX
XX Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;

```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1885 CCTCAGGCGCTATGACGAG 1903  
 |||||  
 Db 20 CCTCAGGCGCTATGACGACCG 2

RESULT 148  
 ABK69425/c  
 ID ABK69425 standard; DNA; 20 BP.  
 XX  
 AC ABK69425;  
 XX  
 DT 15-JUL-2002 (first entry)  
 XX  
 DE Human phosphorylase kinase alpha-1 antisense oligonucleotide #9.  
 XX  
 KM Human; rat; antisense; phosphorylase kinase alpha 1; ss;  
 KM antiinflammatory; cytostatic; antimicrobial; antidiabetic;  
 KM metabolic disorder; diabetes; infection; inflammation; tumour; probe.  
 XX  
 OS Homo sapiens.  
 OS Mus sp.  
 OS Synthetic.  
 OS Chimeric.  
 XX

PH Key  
 FT modified\_base 1. .20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = 2'-O-methoxyethyl"  
 FT residues are 5-methyl cytidine"  
 FT modified\_base 1. .5  
 FT /tag= b  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = 2'-O-methoxyethyl"  
 FT modified\_base 5. .15  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = 2' deoxynucleotide"  
 FT modified\_base 15. .20  
 FT /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = 2'-O-methoxyethyl"  
 XX  
 PN WO200220546-A1.  
 XX  
 PD 14-MAR-2002.  
 XX  
 PF 24-AUG-2001; 2001WC-US026608.  
 XX  
 PR 07-SEP-2000; 2000US-00657452.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monica BP, Wyatt JR;  
 XX  
 DR WPI; 2002-351759/38.  
 XX  
 PT New antisense compound which is targeted to nucleic acid encoding  
 PT phosphorylase kinase alpha 1 and inhibits expression of kinase protein,  
 PT useful for treating a condition associated with kinase, e.g. diabetes.  
 XX  
 PS Claim 3; Page 85; 140pp; English.  
 XX  
 CC This invention relates to a novel antisense nucleic acid compound  
 CC targeted to a nucleic acid molecule encoding phosphorylase kinase alpha-1  
 CC which specifically hybridizes with and inhibits expression of  
 CC phosphorylase kinase alpha-1. The compound of the invention is useful for  
 CC inhibiting the expression of phosphorylase kinase alpha-1 in cells or  
 CC tissues, and for treating an animal having a disease condition associated  
 CC with phosphorylase kinase alpha-1, e.g. a metabolic disorder such as  
 CC diabetes. The compounds are also useful prophylactically, e.g. to prevent

CC or delay infection, inflammation or tumour formation. The antisense  
 CC compound are also useful as therapeutic, diagnostic and research  
 CC reagent, for distinguishing functions of various members of a biological  
 CC pathway, and in antisense gene therapy. The present sequence represents  
 CC an antisense oligonucleotide probe used to create the phosphorylase  
 CC kinase alpha-1 inhibiting compound of the invention  
 XX

SQ Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1676 GGGGACAGCTGCTGTGGA 1694  
 |||||  
 Db 19 GGGGACACCTGCGATTGGA 1

RESULT 149  
 ABS70040  
 ID ABS70040 standard; DNA; 21 BP.  
 XX  
 AC ABS70040;  
 XX  
 DT 22-NOV-2002 (first entry)  
 XX  
 DE Mycobacterium marinum capture probe #1.  
 XX  
 KM Mycobacterium differentiation; Mycobacterium detection; us-p34;  
 KM Mycobacterium species-specific; upstream p34 gene region; biochip;  
 KM micro-array; Mycobacterium avium-complex; MAC-complex; TUB; MOTT;  
 KM Mycobacterium tuberculosis-complex; mycobacterial species;  
 KM non-tuberculous mycobacteria; NTM; probe; ss.  
 XX  
 OS Mycobacterium marinum.  
 OS  
 PN EP1233076-A2.  
 XX  
 PD 21-AUG-2002.  
 XX  
 PF 15-FEB-2002; 2002EP-00447026.  
 XX  
 PR 19-FEB-2001; 2001EP-00870030.  
 PR 21-FEB-2001; 2001US-0269848P.  
 PR 23-MAY-2001; 2001US-0292509P.  
 XX  
 PA (UYLO-) UNIV CATHOLIQUE LOUVAIN.  
 XX  
 PI Gala J, Vannuffel P;  
 XX  
 DR WPI; 2002-637887/69.  
 XX  
 PT Detecting/differentially detecting Mycobacterium strain in sample, by  
 PT reacting non-tuberculosis Mycobacterium species-specific upstream p34  
 PT gene region probe with sample and detecting duplexes having the probe.  
 XX  
 PS Claim 17; Page 22; 92pp; English.  
 XX  
 CC The present invention relates to methods for differentiating and  
 CC detecting between Mycobacterium strains in a sample based on species-  
 CC specific upstream p34 gene region (us-p34) sequences. Also provided are  
 CC new us-p34 sequences, primers and probes. The invention also relates to  
 CC methods for detecting and differentiating between Pseudomonas strains. A  
 CC Mycobacterium species-specific us-p34 nucleotide probe or primer is  
 CC useful for producing a biochip or a micro-array for detecting M. avium-  
 CC complex (MAC-complex) Mycobacterium species in a sample, and detecting  
 CC Mycobacterium other than M. tuberculosis-complex (TUB) (MOTT)  
 CC Mycobacterium in a sample. A Mycobacterium us-p34 nucleotide primer is  
 CC useful for detecting new us-p34 sequences in a sample. The method of the  
 CC invention identifies in a single assay, a wide range of mycobacterial  
 CC species that include members of the TUB and non-tuberculous mycobacteria  
 CC (NTM). ABS70027-ABS70068 represent capture probes for Mycobacterium  
 CC strains

```

XX SQ Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1594 GAGGTGACGGCGCTGTCG 1612
DB 3 GAGGTGATGGCGCTGTCG 21

RESULT 150
ABA81857
XX ID ABA81857 standard; DNA; 21 BP.
XX AC ABA81857;
XX XX
XX DT 25-JAN-2002 (first entry)
XX XX
XX DE M marinum P34 gene capture oligonucleotide.
XX KM Microorganism detection; capture oligonucleotide; probe; cancer; biochip;
XX KM polymorphism detection; genetic disease diagnosis; microarray; ss.
XX OS Mycobacterium marinum.
XX PN WO20017372-A2.
XX PD 18-OCT-2001.
XX PF 26-MAR-2001; 2001WO-BE000053.
XX XX
XX PR 24-MAR-2000; 2000EP-00870055.
XX PR 15-SEP-2000; 2000EP-00870204.
XX XX
XX PA (UTMO-) UNIV NOTRE-DAME DE LA PAIX.
XX PI Remacle J, Hamels S, Zammateo N, Lockman L, Dufour S;
XX PI Alexandre I, De Longueville F;
XX DR WPI; 2002-010921/01.
XX PT Identifying or quantifying organisms or genes, useful e.g. for diagnosis,
XX PT by detecting specific nucleotide sequences present among several
XX PT homologous sequences.
XX PS Example 8; Page 33; 56pp; English.
XX CC The present invention provides a method of identifying or quantitating a
XX CC microorganism in a sample by detecting its nucleotide sequence from
XX CC amongst homologous sequences. The method can be used to detect
XX CC microorganisms and polymorphisms, and to diagnosis genetic diseases
XX CC including cancer. The present sequence is a capture oligonucleotide used
XX CC in the exemplification of the invention
XX XX
XX SQ Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1594 GAGGTGACGGCGCTGTCG 1612
DB 3 GAGGTGATGGCGCTGTCG 21

RESULT 151
ABA10097
XX ID ABA10097 standard; DNA; 21 BP.
XX AC ABA10097;
XX XX

```

```

DT DT 23-JAN-2003 (first entry)
XX XX
XX DE M. marinum upstream p34 gene oligonucleotide probe.
XX KM Mycobacterial disease; tuberculosis; leprosy; AIDS; us-p34;
XX KM acquired immunodeficiency syndrome; upstream p34 gene; NTM;
XX KM systemic bacterial opportunistic infection; ss; probe;
XX KM non-tuberculosis Mycobacterium strain.
XX OS
XX PN Mycobacterium marinum.
XX PN JP2002238563-A.
XX PD
XX PD 27-AUG-2002.
XX PF 31-JAN-2001; 2001JP-00024023.
XX PF
XX PR 31-JAN-2001; 2001JP-00024023.
XX PA
XX PA (UYLO-) UNIV CATHOLIQUE LOUVAIN.
XX DR WPI; 2003-003950/01.
XX XX
XX PT Identification of nucleotide sequences specific for mycobacteria and
XX PT development of differential diagnosis strategies for mycobacteria
XX PT species.
XX PS Claim 17; Page 12; 65pp; Japanese.
XX XX
XX CC The invention relates to detection of non-tuberculosis Mycobacterium
XX CC (NTM) strains in a sample comprising: i) providing a NTM species-specific
XX CC upstream p-34 gene region (us-p34) nucleotide probe, (ii) reacting said
XX CC us-p34 nucleotide probe with said sample under conditions that allow for
XX CC the selective formation of nucleotide duplexes between said us-p34
XX CC nucleotide probe and a corresponding NTM nucleic acid target present in
XX CC said sample, and (iii) detecting any nucleotide duplexes containing said
XX CC us-p34 nucleotide probe. Also included is a NTM species-specific us-p34
XX CC nucleotide probe or primer comprising at least 8 continuous nucleotides
XX CC from one of the nucleotide sequences shown in Fig. 3 or its complement or
XX CC the corresponding sequences wherein T has been replaced by U. The method
XX CC is used for the detection of NTM strains in a sample. NTM strains are
XX CC responsible for mycobacterial disease e.g. systemic bacterial
XX CC opportunistic infection (particularly in individuals with AIDS, acquired
XX CC immunodeficiency syndrome), whereas pathogenic strains are responsible
XX CC for leprosy and tuberculosis. The present sequence is a strain specific
XX CC oligonucleotide probe used to detect us-p34 sequences from different
XX CC Mycobacterium strains
XX XX
XX SQ Sequence 21 BP; 2 A; 4 C; 11 G; 4 T; 0 U; 0 Other;
Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1594 GAGGTGACGGCGCTGTCG 1612
DB 3 GAGGTGATGGCGCTGTCG 21

RESULT 152
ABN00900/C
XX ID ABN00900 standard; DNA; 17 BP.
XX AC ABN00900;
XX XX
XX DT 29-MAY-2002 (first entry)
XX XX
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:892.
XX KM Human genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KM skeletal muscle disorder; amplicon; screening; ss.
XX XX

```

OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (ABOM-) AEWOMICA INC.  
 PI Gu Y, JI Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT description ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 892; 214pp; English.  
 XX  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser description ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 0 Other;  
 XX  
 Query Match 0.7%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred.No. 1.1e+00;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1700 AGCCCTTCCCAATAT 1716  
 Db 17 AGCCCTTCCCACTAT 1  
 RESULT 153  
 ABN00899/c  
 ID ABN00899 standard; DNA; 17 BP.

XX  
 AC ABN00899;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:891.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (ABOM-) AEWOMICA INC.  
 PI Gu Y, JI Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT description ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 891; 214pp; English.  
 XX  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser description ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;  
 XX  
 Query Match 0.7%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1701 GCCCCTTCCCAATATG 1717  
17 GCCCCTTCCCAATATG 1

Db

RESULT 154  
ABN00901/c  
ID ABN00901 standard; DNA; 17 BP.  
XX  
AC ABN00901;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:893.  
XX  
KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX  
PN M0200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0268660P.  
XX  
PA (ABOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 893; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acid can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at fcp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 3 A; 1 C; 9 G; 4 T; 0 U; 0 Other;  
XX  
Query Match 0.7%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCAATA 1715  
17 AAGCCCTTCCCACTA 1

Db

RESULT 155  
ACC64870  
ID ACC64870 standard; DNA; 17 BP.  
XX  
AC ACC64870;  
XX  
DT 01-JUL-2003 (first entry)  
XX  
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2117.  
XX  
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
XX schizophrenia; ss.  
XX Mus musculus.  
XX  
PN M02003025176-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004210.  
XX  
PR 17-SEP-2001; 2001FR-00011979.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-333167/31.  
XX  
PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
PS Disclosure; Page 278; 738pp; French.  
XX  
XX The present invention relates to murine oligonucleotides (ACC62754-  
CC ACC68806), which are associated with tumour suppression, tumour  
CC reversion, apoptosis and virus resistance. The oligonucleotides are  
CC useful as (1) as probes and primers for detecting, identifying,  
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia  
XX  
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;  
XX  
Query Match 0.7%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;



QY 996 GATCACCCTGCTCTGC 1012  
 |||||  
 DB 1 GATCTCCCTGCTCTGC 17

RESULT 156  
 ID AAX62734  
 AAX62734 standard; RNA; 18 BP.

XX AAX62734;

XX 16-JUL-1999 (first entry)

DE Granule bound starch synthase hairpin substrate SEQ ID NO:609.

XX Maize; corn; Zea mays; delta-9 desaturase; GBS; target; substrate;  
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;  
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;  
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;  
 KW fruit ripening; flower pigmentation; lignin production; ss.

XX Zea mays.

XX MO9710328-A2.

XX 20-MAR-1997.

XX 12-JUL-1996; 96WO-US011689.

XX 13-JUL-1995; 95US-0001135P.

XX (RIBO-) RIBOZYME PHARM INC.  
 (DOMC) DOWELANCO.

PI Zwack MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA;  
 PI Young SA, Folkerts O, Merlo DJ;

DR WPI; 1997-202224/16.

PT Ribozyme which modulates plant gene expression - preferably modulates  
 PT expression of DELTA-9 desaturase or granule bound starch synthase in  
 PT maize or canola.

PS Claim 42; Page 84; 155pp; English.

XX The present invention describes an enzymatic nucleic acid molecule (I)  
 CC with RNA cleaving activity, which modulates the expression of a plant  
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize  
 CC delta-9 desaturase. (I) can be used to modulate expression of a gene,  
 CC preferably delta-9 desaturase or a granule bound starch synthase (GBS)  
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used to  
 CC modulate caffeine synthesis in a coffee plant, nicotine production in a  
 CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum  
 CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or  
 CC marigold plant or lignin production in a tobacco, aspen, poplar or pine  
 CC plant

XX Sequence 18 BP; 4 A; 6 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 82.4%; Pred. No. 1.2e+02;  
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2178 CCAGCAGCTCATGGAGA 2194  
 |||||  
 DB 2 CCCGACGACUAGGAGA 18

RESULT 157

ID AA289104 standard; DNA; 18 BP.

XX AA289104;

XX 01-JUN-2000 (first entry)  
 DT  
 XX  
 DE p53 binding PG-motif consensus DNA.

XX p53; recombinase; promoter; transcription factor; suicide gene;  
 KW tumor cell; treatment; ss.

XX Unidentified.

XX DE19834430-A1.

XX 03-FEB-2000.

XX 30-JUL-1998; 98DE-01034430.

XX 30-JUL-1998; 98DE-01034430.

XX (VMEI/) VON MELCHNER H.  
 PA (HOEL/) HOELZER D.

PI Von Melchner H, Ebenberger C, Andreu T;

DR WPI; 2000-225128/20.

PT New self-deleting vector, for treatment of tumors, contains a suicide  
 PT gene deleted from normal cells but retained in tumor cells that lack  
 PT functional transcription factor.

XX Disclosure; Page 4; 16pp; German.

XX This invention describes a novel recombinant vector (A) which comprises  
 CC (1) a first transcription cassette containing a recombinase-encoding  
 CC sequence (I), a minimal promoter (MP) that requires a transcription  
 CC factor (TF) for activation, a TF-binding site and optionally a  
 CC polyadenylation sequence; (2) a second transcription cassette containing  
 CC suicide gene (SG), linked to promoter (P) and optionally a  
 CC polyadenylation sequence; and (3) 5' and/or 3'-flanking sequences that  
 CC contain a target sequence for recombinase. Normal cells express  
 CC functional TF, so activate MP, resulting in expression of recombinase and  
 CC deletion of the suicide gene cassette. Tumor cells that are defective in  
 CC functional TF can not do this, so the suicide gene cassette is retained  
 CC and the tumor cell is killed. (A) are used for the treatment of tumors.  
 CC (A) provide targeted and selective killing of tumor cells. This sequence  
 CC represents a PG DNA motif found in p53 binding consensus sequences, and  
 CC which is used in the construction of the vector described in the method  
 CC of the invention

XX Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 94.1%; Pred. No. 1.2e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 318 CCGCGGAGCTTGCT 334  
 |||||  
 DB 1 CCGCGGAGCTTGCT 17

RESULT 158  
 ID AA84556 standard; DNA; 19 BP.

XX AA84556;

XX 04-DEC-2000 (first entry)

DE Cyclin B ribozyme binding site #89.

XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; reestenosis; ss.

XX Mammalia.

XX

PN WO200032765-A2.  
XX  
XX 08-JUN-2000.  
XX  
PF 06-DEC-1999; 99WO-US028772.  
XX  
PR 04-DEC-1998; 98US-0110954P.  
XX  
PA (IMMU-) IMMUSOL INC.  
XX  
PI Tritz R, Welch PJ, Barber JR, Robbins JW;  
XX  
XX WPI; 2000-412314/35.  
XX  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX Disclosure; Page 78; 109pp; English.  
XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AA82415 to AA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX  
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
  
Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1179 GCTGCAAGAAATAAGA 1195  
DB 17 GCTGCAATAATAAGA 1  
  
RESULT 159  
AA84554/C  
ID AA84554 standard; DNA; 19 BP.  
XX  
XX AA84554;  
AC  
XX  
XX 04-DEC-2000 (first entry)  
DT  
XX  
XX Cyclin E ribozyme binding site #87.  
DE  
XX  
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
KM  
XX  
XX Mammalia.  
OS  
XX  
XX WO200032765-A2.  
PN  
XX  
XX 08-JUN-2000.  
PD  
XX  
XX 06-DEC-1999; 99WO-US028772.  
PF  
XX  
XX 04-DEC-1998; 98US-0110954P.  
PR  
XX  
XX (IMMU-) IMMUSOL INC.  
PA  
XX  
XX Tritz R, Welch PJ, Barber JR, Robbins JW;  
PI  
XX  
XX WPI; 2000-412314/35.  
DR  
XX  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX Disclosure; Page 78; 109pp; English.  
PS

XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AA82415 to AA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX  
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
  
Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1179 GCTGCAAGAAATAAGA 1195  
DB 19 GCTGCAATAATAAGA 3  
  
RESULT 160  
AA84555/C  
ID AA84555 standard; DNA; 19 BP.  
XX  
XX AA84555;  
AC  
XX  
XX 04-DEC-2000 (first entry)  
DT  
XX  
XX Cyclin E ribozyme binding site #88.  
DE  
XX  
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
KM  
XX  
XX Mammalia.  
OS  
XX  
XX WO200032765-A2.  
PN  
XX  
XX 08-JUN-2000.  
PD  
XX  
XX 06-DEC-1999; 99WO-US028772.  
PF  
XX  
XX 04-DEC-1998; 98US-0110954P.  
PR  
XX  
XX (IMMU-) IMMUSOL INC.  
PA  
XX  
XX Tritz R, Welch PJ, Barber JR, Robbins JW;  
PI  
XX  
XX WPI; 2000-412314/35.  
DR  
XX  
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX  
XX Disclosure; Page 78; 109pp; English.  
XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AA82415 to AA86787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX  
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
  
Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1179 GCTGCAAGAAATAAGA 1195  
DB 18 GCTGCAATAATAAGA 2

RESULT 161  
AAH59718/c  
ID AAH59718 standard; DNA; 19 BP.  
XX  
AC AAH59718;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Cyclic E ribozyme binding site SEQ ID NO:2142.  
XX  
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
XX recognition site; target; ribozyme binding site; eye disease; vulnery;  
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
XX matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;  
XX antiproliferative; dermatological; anti-seborrheic; antidiabetic; virucide;  
XX antisticking; ophthalmological; keratolytic; gene therapy; viral wart;  
XX atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
XX basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;  
XX sickle cell retinopathy; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX WO200130362-A2.  
XX  
XX 03-MAY-2001.  
XX  
XX 26-OCT-2000; 2000WO-US029500.  
XX  
XX 26-OCT-1999; 99US-0161532P.  
XX  
XX (IMMU-) IMMUSOL INC.  
XX  
XX Robbins JM, Tritz R;  
XX WPI; 2001-300427/31.  
XX  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
XX that cleave RNA encoding cytokines involved in inflammation, matrix  
XX metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
XX Example 1; Page 227; 408pp; English.  
XX  
XX The present invention describes a method for treating a proliferative  
XX skin or eye disease and scarring. The method involves administering a  
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in  
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
XX dependent kinase, growth factor or a reductase, or administering a  
XX nucleic acid molecule (II) comprising a promoter operably linked to a  
XX nucleic acid segment encoding (I). (I) can have antiproliferative,  
XX dermatological, cytosolic, anti-seborrheic, antidiabetic, antisticking,  
XX ophthalmological, vulnery, keratolytic and virucide activities, and  
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
XX in gene therapy. (I) and (II) are useful for treating proliferative skin  
XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
XX squamous or basal cell carcinoma and viral or seboreic wart. They can  
XX also be used for treating proliferative eye diseases such as diabetic  
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
XX prematurity and retinal detachment, and for treating and preventing  
XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
XX scar. AAH57577 to AAH62099 represent sequences used in the  
XX exemplification of the present invention  
XX  
XX Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
XX  
XX Query Match 0.7%; Score 15.4; DB 1; Length 19;  
XX Best Local Similarity 94.1%; Pred. NO. 1.3e+02;  
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX 1179 GCTGCAAGAAATAAGA 1195

Db 17 GCTGCAAGAAATAAGA 1  
|||||  
RESULT 162  
AAH59716/c  
ID AAH59716 standard; DNA; 19 BP.  
XX  
AC AAH59716;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
XX Cyclic E ribozyme binding site SEQ ID NO:2140.  
XX  
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
XX recognition site; target; ribozyme binding site; eye disease; vulnery;  
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
XX matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;  
XX antiproliferative; dermatological; anti-seborrheic; antidiabetic; virucide;  
XX antisticking; ophthalmological; keratolytic; gene therapy; viral wart;  
XX atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
XX basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;  
XX sickle cell retinopathy; ss.  
XX  
XX Homo sapiens.  
XX Synthetic.  
XX  
XX WO200130362-A2.  
XX  
XX 03-MAY-2001.  
XX  
XX 26-OCT-2000; 2000WO-US029500.  
XX  
XX 26-OCT-1999; 99US-0161532P.  
XX  
XX (IMMU-) IMMUSOL INC.  
XX  
XX Robbins JM, Tritz R;  
XX WPI; 2001-300427/31.  
XX  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
XX that cleave RNA encoding cytokines involved in inflammation, matrix  
XX metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
XX Example 1; Page 227; 408pp; English.  
XX  
XX The present invention describes a method for treating a proliferative  
XX skin or eye disease and scarring. The method involves administering a  
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in  
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
XX dependent kinase, growth factor or a reductase, or administering a  
XX nucleic acid molecule (II) comprising a promoter operably linked to a  
XX nucleic acid segment encoding (I). (I) can have antiproliferative,  
XX dermatological, cytosolic, anti-seborrheic, antidiabetic, antisticking,  
XX ophthalmological, vulnery, keratolytic and virucide activities, and  
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
XX in gene therapy. (I) and (II) are useful for treating proliferative skin  
XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
XX squamous or basal cell carcinoma and viral or seboreic wart. They can  
XX also be used for treating proliferative eye diseases such as diabetic  
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
XX prematurity and retinal detachment, and for treating and preventing  
XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
XX scar. AAH57577 to AAH62099 represent sequences used in the  
XX exemplification of the present invention  
XX  
XX Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
XX  
XX Query Match 0.7%; Score 15.4; DB 1; Length 19;  
XX Best Local Similarity 94.1%; Pred. NO. 1.3e+02;  
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1179 GCTGCAAGAAATTAAGA 1195  
 |||||  
 19 GCTGCAATTAATTAAGA 3

## RESULT 163

AAH59717/C  
 ID AAH59717 standard; DNA; 19 BP.

AC AAH59717;  
 XX

DT 10-SEP-2001 (first entry)  
 XX

DE Cyclin E ribozyme binding site SEQ ID NO:2141.  
 XX

Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnery;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;  
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antisticking; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.

OS Homo sapiens.  
 OS Synthetic.  
 XX

PN W0200130362-A2.  
 XX

PD 03-MAY-2001.  
 XX

PF 26-OCT-2000; 2000WO-US029500.  
 XX

PR 26-OCT-1999; 99US-0161532P.  
 XX

PA (IMMU-) IMMUSOL INC.  
 XX

PI Robbins JM, Tritz R;  
 XX

DR WPI; 2001-300427/31.  
 XX

PT Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.

PS Example 1; Page 227; 408pp; English.  
 XX

CC The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,  
 CC dermatological, cytosolic, antiseborrheic, antidiabetic, antisticking,  
 CC ophthalmological, vulnery, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seboreic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX

SQ Sequence 19 BP; 4 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1179 GCTGCAAGAAATTAAGA 1195  
 |||||  
 18 GCTGCAATTAATTAAGA 2

## RESULT 164

ABZ93303  
 ID ABZ93303 standard; DNA; 20 BP.

AC ABZ93303;  
 XX

DT 17-OCT-2003 (first entry)  
 XX

DE Human oligonucleotide sequence.  
 XX

Human; antisense; lung dysfunction; nasal airway dysfunction;  
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
 KW antiaesthetic; hypotensive; immunosuppressive; cytosolic; gene therapy;  
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
 KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.  
 XX

PN W0200285308-A2.  
 XX

PD 31-OCT-2002.  
 XX

PF 23-APR-2002; 2002WO-US013135.  
 XX

PR 24-APR-2001; 2001US-0286137P.  
 XX

PA (EPIC-) EPIGENESIS PHARM INC.  
 XX

PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
 XX Miller S, Tang L, Shahbuddin S;  
 XX

DR WPI; 2003-229219/22.  
 XX

PT Pharmaceutical composition for treating ailments associated with impaired  
 PT respiration, has oligo(s) antisense to specific gene(s) or its  
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
 PT ubiquinone.

PS Disclosure; SEQ ID NO 8545; 872pp; English.  
 XX

CC The invention relates to a novel pharmaceutical composition, which has a  
 CC first active agent comprising an oligonucleotide antisense to the  
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
 CC junctions of genes encoding a polypeptide associated with lung and/or  
 CC nasal airway dysfunction and a second active agent comprising an  
 CC antiinflammatory steroid and ubiquinone. A composition of the invention  
 CC has antiinflammatory, antiallergic, antiaesthetic, hypotensive,  
 CC immunosuppressive, and cytosolic activity. The composition may have a  
 CC use in antisense gene therapy. The composition is useful for treating or  
 CC preventing a respiratory, lung or malignant disease or condition, also  
 CC for enhancing the prophylactic or therapeutic respiratory effect of an  
 CC antiinflammatory steroid in a subject, for reducing or depleting levels  
 CC of, or reducing sensitivity to adenosine, reducing levels of ubiquinone or  
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
 CC lung inflammation, lung allergies, or a respiratory disease or condition.  
 CC Note: The sequence data for this patent is not represented in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences  
 XX

SQ Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2036 TACAGTCGACGAGCTC 2052  
|||||  
Db 2 TACAGATGAGACGAGCTC 18

## RESULT 165

AAT08666  
ID AAT08666 standard; DNA; 20 BP.

XX AAT08666;

XX 05-SEP-1996 (first entry)

DE Primer p53-3X7P for p53 gene exon 7 amplification.

XX primer; PCR; polymerase chain reaction; hierarchy; immunoassay;

KM quantitative assay; fragment length; DNA sequencing; p53; mutation; ss.

XX Synthetic.

XX WO9601909-A1.

PD 25-JAN-1996.

PF 07-JUL-1995; 95MO-US006605.

XX 08-JUL-1994; 94US-00271946.

PR 14-FEB-1995; 95US-00388381.

XX (VIST-) VISIBLE GENETICS INC.

PI Diamandis E, Dunn JM, Stevens JK;

DR WPI; 1996-097638/10.

PT Testing for disease-associated p53 gene mutation(s) using a hierarchy of  
PT assay techniques - e.g. immunoassay, DNA amplification and DNA  
PT sequencing.

PS Claim 22; Page 22; 44pp; English.

XX Rapid and cost effective diagnosis of disease-associated mutations in the  
CC p53 gene is achieved by employing a selected number of diagnostic tools,  
CC in a hierarchy of increasing accuracy and cost per tool, in which each  
CC tool detects essentially no false positives. Tests that may be employed,  
CC in order of increasing accuracy and cost are: (a) immunoassays; (b) DNA  
CC fragment length/quantity analysis; and (c) DNA sequencing of regions  
CC most likely to harbour point mutations. AAT08645-66 are primers used in  
CC DNA fragment length/quantity analysis. The amplification of the eleven  
CC exons is advantageously carried out in 3 multiplex pools, the members of  
CC a pool selected because they all use the same hybridisation temperature  
CC and none of the expected fragment lengths will overlap in an  
CC electrophoresis gel. One of each pair of primers is labeled at the 5' end  
CC with an identifiable marker such as fluorescein, rhodamine or cyanine.  
CC The present sequence is used with AAT08665 to amplify a 286 bp fragment  
CC of exon 7

XX Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1935 GGGTCAGCGACAGCACTGG 1954  
|||||  
Db 1 GGGTCAGCGCGACAGCAAGG 20

## RESULT 166

AAT99867

ID AAT99867 standard; DNA; 20 BP.

XX AAT99867;

XX 07-MAY-1998 (first entry)

DE Primer for exon 7 of p53 gene.

XX PCR primer; amplify; pathogen identification; mutation detection;

KM nucleic acid analysis; microorganism characterisation; human;

XX HLA type determination; p53 gene exon 7; ss.

XX Synthetic.

XX Homo sapiens.

PN WO9741259-A1.

PD 06-NOV-1997.

PF 29-APR-1997; 97MO-US007135.

XX 01-MAY-1996; 96US-00640672.

PR 19-JUL-1996; 96US-00684498.

PR 27-FEB-1997; 97US-00807138.

XX (VIST-) VISIBLE GENETICS INC.

PI Leashner J, Hui M, Dunn JM, Larson MT, Lacroix J, Shipman R;

DR WPI; 1997-549755/50.

PT Nucleic acid sequence determination - comprising synthesising chain  
PT extension products, which are indicative of positions of selected species  
PT of nucleotide in nucleotide sequence.

PS Example 4; Page 20; 69pp; English.

XX This sequence represents a primer for exon 7 of the p53 gene. This  
CC sequence can be used in the method of the invention for determining the  
CC position of at least one selected species of nucleotide, in a region of  
CC interest, in a target nucleic acid polymer, in a sample. The method  
CC comprises combining the sample with a reaction mixture to synthesise  
CC chain extension products indicative of the positions of the species of  
CC nucleotide in the region of interest and evaluating the products  
CC produced, characterised in that the sample, which is combined with the  
CC reaction mixture, and contains target and non-target nucleic acid  
CC polymers in natural abundance. The method can be used to detect  
CC mutations, particularly mutations of medical significance, in samples  
CC derived from a human patient, animal, plant or microorganism, determine  
CC HLA type ancillary to transplant procedures, detect and identify  
CC microorganisms, particularly pathogenic microorganisms, in a sample and  
CC in situ sequencing reactions to produce sequencing fragments in a  
CC histological specimen

XX Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1935 GGGTCAGCGACAGCACTGG 1954  
|||||  
Db 1 GGGTCAGCGCGACAGCAAGG 20

## RESULT 167

AAT99837

ID AAT99837 standard; DNA; 20 BP.

XX AAT99837;

XX 07-MAY-1998 (first entry)

DE Primer for exon 7 of p53 gene.  
 XX PCR primer; amplify; p53 gene exon 7; multiplex amplification reaction;  
 KM nucleic acid analysis; microorganism characterisation; human;  
 KM mutation detection; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 PN WO9741258-A1.  
 XX  
 PD 06-NOV-1997.  
 XX  
 PF 29-APR-1997; 97WO-US007134.  
 XX  
 PR 01-MAY-1996; 96US-00640672.  
 PR 19-JUL-1996; 96US-00684498.  
 XX  
 PA (VIST-) VISIBLE GENETICS INC.  
 XX  
 PI Leushner J, Hui M, Dunn JM, Larson MT, Lacroix J;  
 XX  
 DR WPI; 1997-549754/50.  
 XX  
 PT Analysing nucleic acid containing sample - comprises performing multiplex  
 PT amplification reaction and reacting amplified fragments in sequencing  
 PT reaction mixture.  
 XX  
 PS Example 4; Page 18; 37pp; English.  
 XX  
 CC This sequence represents a primer for exon 7 of the p53 gene. This  
 CC sequence can be used in the method of the invention for analysing a  
 CC nucleic acid containing sample. The method comprises performing a  
 CC multiplex amplification reaction on the nucleic acids in the sample using  
 CC amplification primer pairs, one pair for each region to be analysed, to  
 CC produce a mixture of amplified fragments, and determining the sequence of  
 CC at least one species of amplified fragment, characterised in that the  
 CC sequence is determined by combining the mixture of amplification  
 CC fragments with a sequencing reaction mixture for the production of  
 CC sequencing fragments, and evaluating the sequencing fragments produced.  
 CC The method can be used to analyse regions in the nucleic acids in the  
 CC sample for the presence of mutations, or detect and type microorganisms.  
 CC The method directly performs sequencing reactions on complex DNA mixtures  
 CC  
 XX  
 SQ Sequence 20 BP; 5 A; 4 C; 10 G; 1 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Db Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1935 GGGTCAGCGACAGGCAAGTGG 1954  
 Db 1 GGGTCAGCGCGCAACAGAGG 20  
 XX  
 RESULT 168  
 AAV28203/C  
 ID AAV28203 standard; DNA; 20 BP.  
 XX  
 AC AAV28203;  
 XX  
 DT 08-OCT-1998 (first entry)  
 XX  
 DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).  
 XX  
 KM Purification; oligonucleotide; matrix; affinity unit;  
 KM affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;  
 KM ss.  
 XX  
 OS Synthetic.  
 OS  
 PN WO9827425-A1.  
 XX

PD 25-JUN-1998.  
 XX  
 PF 18-DEC-1997; 97WO-US023284.  
 XX  
 PR 19-DEC-1996; 96US-00769951.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Chen D, Sivatasa GS, Cole DL;  
 XX  
 DR WPI; 1998-362922/31.  
 XX  
 PT Matrix for selective separation of oligo:nucleotide - useful for, e.g.  
 PT large scale purification of anti-sense agents from their deletion  
 PT derivatives formed during synthesis.  
 XX  
 PS Disclosure; Page 104; 183pp; English.  
 XX  
 CC AAV28155-268 represent oligonucleotides which can be purified using the  
 CC method of the invention. The specification describes a matrix that  
 CC comprises a support and an affinity unit that specifically and reversibly  
 CC binds a target oligonucleotide, and comprises a sequence of bases having  
 CC the reverse complement of a hybridising portion of the target  
 CC oligonucleotide. The matrix is used for affinity purification of  
 CC synthetic oligonucleotides, specifically antisense agents, for treatment  
 CC of hyperproliferative diseases, for treating a non-pathogen, non-  
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression  
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen,  
 CC retroviruses or other viruses  
 CC  
 XX  
 SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Db Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1617 CAATGGCTCTGGGAAGCA 1636  
 Db 20 CAGTGGCTGTGGGAAGCA 1  
 XX  
 RESULT 169  
 AAV28202/C  
 ID AAV28202 standard; DNA; 20 BP.  
 XX  
 AC AAV28202;  
 XX  
 DT 08-OCT-1998 (first entry)  
 XX  
 DE Antisense oligonucleotide to multi-drug resistance-1 gene (MDR-1).  
 XX  
 KM Purification; oligonucleotide; matrix; affinity unit;  
 KM affinity purification; antisense; multi-drug resistance-1 gene; MDR-1;  
 KM ss.  
 XX  
 OS Synthetic.  
 OS  
 PN WO9827425-A1.  
 XX  
 PD 25-JUN-1998.  
 XX  
 PF 18-DEC-1997; 97WO-US023284.  
 XX  
 PR 19-DEC-1996; 96US-00769951.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Chen D, Sivatasa GS, Cole DL;  
 XX  
 DR WPI; 1998-362922/31.  
 XX  
 PT Matrix for selective separation of oligo:nucleotide - useful for, e.g.  
 PT large scale purification of anti-sense agents from their deletion

PT derivatives formed during synthesis.  
 XX  
 PS Disclosure, Page 103, 183pp, English.  
 CC  
 CC AAV28155-268 represent oligonucleotides which can be purified using the  
 CC method of the invention. The specification describes a matrix that  
 CC comprises a support and an affinity unit that specifically and reversibly  
 CC binds a target oligonucleotide, and comprises a sequence of bases having  
 CC the reverse complement of a hybridizing portion of the target  
 CC oligonucleotide. The matrix is used for affinity purification of  
 CC synthetic oligonucleotides, specifically antisense agents, for treatment  
 CC of hyperproliferative diseases, for treating a non-pathogen, non-  
 CC hyperproliferative disease, e.g. Alzheimer's, for modulating expression  
 CC of cell surface proteins, and to inhibit a eukaryotic pathogen.  
 CC retrovirus or other viruses  
 XX  
 SQ Sequence 20 BP, 3 A, 9 C, 3 G, 5 T, 0 U, 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17, Conservative 0, Mismatches 3, Indels 0, Gaps 0;  
 QY 1618 AATGGCTCTGGGAAAGACAC 1637  
 DB 20 AGTGGCTGTGGGAAAGACAC 1  
 RESULT 170  
 AA237478/c  
 ID AA237478 standard; DNA, 20 BP.  
 XX  
 AC AA237478;  
 XX  
 DT 07-JAN-2000 (first entry)  
 XX  
 DE Human mdm2 phosphorothioate oligodeoxynucleotide #8.  
 XX  
 KM Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;  
 KM antisense; modulation; oligonucleotide; expression; inhibition;  
 KM hyperproliferation; blood cancer; brain cancer; breast cancer;  
 KM lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;  
 KM restenosis; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 OS  
 PN WO9949065-A1.  
 XX  
 PD 30-SEP-1999.  
 XX  
 PF 26-MAR-1999; 99WO-US006702.  
 XX  
 PR 26-MAR-1998; 98US-00048810.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Miraglia LJ, Nero P, Graham MJ, Montia BP, Cowser LM;  
 DR WPI, 1999-610754/52.  
 XX  
 PT New antisense compounds used to treat eg. hyperproliferative conditions.  
 XX  
 PS Example 2; Page 37, 157pp, English.  
 XX  
 CC AA237473-237738 represent human mdm2 phosphorothioate oligonucleotides.  
 CC AA237471, AA237472, AA237739, AA237740 and AA237741 are used in the  
 CC exemplification of the present invention. The present invention describes  
 CC novel nucleotide antisense compounds, targeted to the 5' untranslated,  
 CC translation termination codon, or 3' untranslated region of a nucleic  
 CC acid encoding human mdm2, that modulates expression of human mdm2. The  
 CC oligonucleotides mediate their effect by antisense inhibition of  
 CC hyperproliferative gene expression. The antisense compound is used to  
 CC treat an animal having a disease or condition associated with mdm2,

CC particularly a hyperproliferative condition, more particularly cancer,  
 CC especially of the blood, brain, breast, lung or soft tissue, or  
 CC psoriasis, fibrosis, atherosclerosis or restenosis  
 XX  
 SQ Sequence 20 BP, 1 A, 4 C, 9 G, 6 T, 0 U, 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17, Conservative 0, Mismatches 3, Indels 0, Gaps 0;  
 QY 243 CTCGAGCGGAAAGCCGAG 262  
 DB 20 CTCGAGCGGAAAGCCCG 1  
 RESULT 171  
 AA205545  
 ID AA205545 standard; DNA, 20 BP.  
 XX  
 AC AA205545;  
 XX  
 DT 07-OCT-1999 (first entry)  
 XX  
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.  
 XX  
 KM Vaccine; eye disease; conventional trachoma; nongonococcal urethritis;  
 KM paratrachoma; inclusion conjunctivitis; genital disease; peritrapatitis;  
 KM nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;  
 KM Bartholinitis; pneumonia; venereal lymphogranulomatosis; ss.  
 XX  
 OS Synthetic.  
 OS Chlamydia trachomatis.  
 OS  
 PN WO9928475-A2.  
 XX  
 PD 10-JUN-1999.  
 XX  
 PF 27-NOV-1998; 98WO-IB001939.  
 XX  
 PR 28-NOV-1997; 97FR-00015041.  
 PR 17-DEC-1997; 97FR-00016034.  
 PR 04-NOV-1998; 98US-0107077P.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 PI Grifffais R;  
 XX  
 DR WPI, 1999-371125/31.  
 XX  
 PT Genome sequence of Chlamydia trachomatis.  
 XX  
 PS Disclosure, Page 1779, 1755pp, English.  
 XX  
 CC PCR primers AA201426-206209 were used to amplify open reading frames  
 CC (ORFs) of the genome of Chlamydia trachomatis (see AA201425). These ORFs  
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines  
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also  
 CC be used to control growth of the microorganism. Chlamydia trachomatis is  
 CC responsible for a large number of diseases, e.g. eye diseases such as  
 CC conventional trachoma, nongonococcal urethritis, paratrachoma, and inclusion  
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,  
 CC epididymitis, cervicitis, salpingitis, peritrapatitis, Bartholinitis;  
 CC pneumonia; in breast feeding infants; and venereal lymphogranulomatosis.  
 CC The polypeptides of the invention may be of use in treating these  
 CC diseases  
 XX  
 SQ Sequence 20 BP, 5 A, 1 C, 9 G, 5 T, 0 U, 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17, Conservative 0, Mismatches 3, Indels 0, Gaps 0;  
 QY 780 GCAGGAGGAGGTGTTGGCG 799

Db 1 GCATGAGAGATGTTGGAG 20

RESULT 172  
AAx18715/c

ID AAX18715 standard; DNA; 20 BP.

AC AAX18715;

DT 10-MAY-1999 (first entry)

DE Target MDR antisense oligonucleotide #47.

Cellular adhesion protein; proliferation; antisense oligonucleotide;  
alimentary canal; transport; gastrointestinal mucosa; cancer;  
Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;  
inflammation; ss.

OS Synthetic.

PN WO9901579-A1.

PD 14-JAN-1999.

PF 01-JUL-1998; 98WO-US013574.

PR 01-JUL-1997; 97US-00886829.

PA (ISIS-) ISIS PHARM INC.

PI Teng C, Hardee G;

DR WPI; 1999-106077/09.

Composition comprising nucleic acid and penetration enhancer - used  
particularly for delivering therapeutic antisense oligonucleotides across  
the gastrointestinal mucosa, provides high bioavailability.

Example 2; Page 90; 115pp; English.

A pharmaceutical composition has been developed which comprises a nucleic  
acid and at least one penetration enhancer. The compositions are used:  
(i) to treat or prevent any disease or disorder that can be treated with  
the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,  
malaria, viral infections (including human immune deficiency virus  
(HIV)), inflammation, in human or animal medicine; (ii) to investigate  
the role of a gene or gene product in non-human animals; and (iii) to  
modulate gene expression in cells, tissues or organs. The compositions  
provide bioavailability of at least 15, preferably 17-35,%. The  
penetration enhancer improves: (i) transport of the nucleic acid across  
the mucosa of the alimentary canal and into cells; and (ii) increases  
stability of the nucleic acid. Oral administration avoids the  
complications and expense of intravenous or other methods of  
administration. AAX18669 to AAX18799 and AAX18801 represent antisense  
oligonucleotides which can be used as the nucleic acid in the method of  
the invention

Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1617 CAATGGCTCTGGGAAGACA 1636

20 CAGTGGCTGTGGGAAGACA 1

RESULT 173

AAx18714/c

ID AAX18714 standard; DNA; 20 BP.

AC AAX18714;

DT 10-MAY-1999 (first entry)

DE Target MDR antisense oligonucleotide #46.

Cellular adhesion protein; proliferation; antisense oligonucleotide;  
alimentary canal; transport; gastrointestinal mucosa; cancer;  
Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;  
inflammation; ss.

OS Synthetic.

PN WO9901579-A1.

PD 14-JAN-1999.

PF 01-JUL-1998; 98WO-US013574.

PR 01-JUL-1997; 97US-00886829.

PA (ISIS-) ISIS PHARM INC.

PI Teng C, Hardee G;

DR WPI; 1999-106077/09.

Composition comprising nucleic acid and penetration enhancer - used  
particularly for delivering therapeutic antisense oligonucleotides across  
the gastrointestinal mucosa, provides high bioavailability.

Example 2; Page 90; 115pp; English.

A pharmaceutical composition has been developed which comprises a nucleic  
acid and at least one penetration enhancer. The compositions are used:  
(i) to treat or prevent any disease or disorder that can be treated with  
the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,  
malaria, viral infections (including human immune deficiency virus  
(HIV)), inflammation, in human or animal medicine; (ii) to investigate  
the role of a gene or gene product in non-human animals; and (iii) to  
modulate gene expression in cells, tissues or organs. The compositions  
provide bioavailability of at least 15, preferably 17-35,%. The  
penetration enhancer improves: (i) transport of the nucleic acid across  
the mucosa of the alimentary canal and into cells; and (ii) increases  
stability of the nucleic acid. Oral administration avoids the  
complications and expense of intravenous or other methods of  
administration. AAX18669 to AAX18799 and AAX18801 represent antisense  
oligonucleotides which can be used as the nucleic acid in the method of  
the invention

Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1618 AATGGCTCTGGGAAGAC 1637

20 AGTGGCTGTGGGAAGACAC 1

RESULT 174

AAx23705/c

ID AAX23705 standard; DNA; 20 BP.

AC AAX23705;

DT 18-JUN-1999 (first entry)

DE Deletion sequence oligonucleotide 158.

Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;  
probe; cellular adhesion modulator; cellular proliferation modulator;



```

KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
XX Synthetic.
XX WO9911820-A1.
XX
XX 11-MAR-1999.
XX
XX
XX 01-SEP-1998; 98WO-US018084.
XX
XX 02-SEP-1997; 97US-00923771.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Chen D, Srivatsa GS;
XX WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
XX Example 9; Page 158; 163pp; English.
XX
XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1618 AATGGCTCTGGAGAGAC 1637
DB 20 AGTGGCTGTGGAGAGAC 1
XX
XX
XX RESULT 175
XX AAX23706/c
XX ID AAX23706 standard; DNA; 20 BP.
XX
XX AAX23706;
XX
XX 18-JUN-1999 (first entry)
XX
XX Deletion sequence oligonucleotide 159.
XX
XX Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KM probe; cellular adhesion modulator; cellular proliferation modulator;
KM human retrovirus; human immunodeficiency virus; non-human retrovirus;
KM HIV; primer; ss.
XX
XX Synthetic.

```

```

XX
XX WO9911820-A1.
XX
XX 11-MAR-1999.
XX
XX
XX 01-SEP-1998; 98WO-US018084.
XX
XX 02-SEP-1997; 97US-00923771.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Chen D, Srivatsa GS;
XX WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
XX Example 9; Page 159; 163pp; English.
XX
XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1617 CAATGGCTCTGGAGAGCA 1636
DB 20 CAGTGGCTGTGGAGAGCA 1
XX
XX
XX RESULT 176
XX AAX95547
XX ID AAX95547 standard; DNA; 20 BP.
XX
XX AAX95547;
XX
XX 13-SEP-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KM neutralising epitope; PCR primer; ss.
XX
XX Synthetic.
XX Chlamydia pneumoniae.
OS
XX WO9927105-A2.
XX
XX 03-JUN-1999.

```

```

XX 20-NOV-1998; 98WO-IB001890.
PF
XX 21-NOV-1997; 97FR-00014673.
PR
XX 04-NOV-1998; 98US-0107078P.
XX
PA (GEST ) GENSET.
XX
PI Griffiths R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae.
PS
XX Page 1756; Disclosure; 1912pp; English.
XX
CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1696 GGGAGGCCCTTCCCAATA 1715
Db 1 GGAAGGCCCTTCCCTAATA 20
XX
RESULT 177
AAX93890
ID AAX93890 standard; DNA; 20 BP.
XX
AC AAX93890;
XX
DT 13-SEP-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW neutralising epitope; PCR primer; ss.
XX
OS Synthetic.
OS Chlamydia pneumoniae.
XX
PN WO9927105-A2.
XX
PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB001890.
XX
XX 21-NOV-1997; 97FR-00014673.
PR
XX 04-NOV-1998; 98US-0107078P.
XX
PA (GEST ) GENSET.
XX
PI Griffiths R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae.
XX

```

```

PS Page 1627; Disclosure; 1912pp; English.
XX
CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1762 CCACAGGTATTGGAGAG 1781
Db 1 CCACAGGTCTTTGAGGAG 20
XX
RESULT 178
AAX94024
ID AAX94024 standard; DNA; 20 BP.
XX
AC AAX94024;
XX
DT 13-SEP-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW neutralising epitope; PCR primer; ss.
XX
OS Synthetic.
OS Chlamydia pneumoniae.
XX
PN WO9927105-A2.
XX
PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB001890.
XX
XX 21-NOV-1997; 97FR-00014673.
PR
XX 04-NOV-1998; 98US-0107078P.
XX
PA (GEST ) GENSET.
XX
PI Griffiths R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae.
PS
XX Page 1637; Disclosure; 1912pp; English.
XX
CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX

```

Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 939 CCTATGTCCTTGGGATCA 958  
1 CCTATGATCTTGGGACCA 20

RESULT 179

AA29357  
ID AAX29357 standard; DNA; 20 BP.

AC AAX29357;

XX 10-JUN-1999 (first entry)

XX JNK3-specific probe ISIS No: 16704.

XX Antisense oligonucleotide; Jun N-terminal kinase; JNK; hybridase; JNK1;

XX JNK2; JNK3; cell cycle progression; phosphorylation; tumour; probe;

XX hyperproliferative disease; human; ss.

XX Synthetic.

XX Homo sapiens.

XX MO9909214-A1.

XX 25-FEB-1999.

XX 07-AUG-1998; 98WO-US016488.

XX 13-AUG-1997; 97US-00910629.

XX (ISIS-) ISIS PHARM INC.

XX McKay R, Dean N, Monia BP, Nero PS, Gaarde WA;

XX WPI; 1999-181060/15.

XX New antisense oligonucleotides that detect and modulate the expression of

XX Jun N-terminal kinase proteins - useful for treating hyperproliferative

XX diseases and inhibiting tumor growth in animals, and for modulating

XX protein phosphorylation by these proteins.

XX Example 5; Page 102; 190pp; English.

XX The invention relates to antisense oligonucleotides that detect and

XX modulate the expression of Jun N-terminal kinase (JNK) proteins. The

XX oligonucleotides specifically hybridize to a nucleic acid encoding a

XX JNK1, JNK2 or JNK3 protein, and which modulate expression of these

XX proteins. The oligonucleotides are useful for modulating JNK protein

XX expression and cell cycle progression in cultured cells or animal cells.

XX The oligonucleotides are also useful for modulating the phosphorylation

XX of a protein that has been phosphorylated by a JNK protein, and the

XX expression of a cellular protein that promotes one or more metastatic

XX events. The oligonucleotides also form pharmaceutical compositions for

XX treating animals with a hyperproliferative disease, and for inhibiting

XX tumor growth in an animal

XX Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

QY Query Match 0.7%; Score 15.2; DB 1; Length 20;

Db Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCGTGGGCTGGGCTG 186  
1 GGGTCGTGGGCTGGGCTG 20

RESULT 180

AA97546  
ID AA97546 standard; DNA; 20 BP.

XX AA97546;

XX 29-JAN-2001 (first entry)

XX Streptomyces albulus strain IF014147 plasmid pNO33 insert PCR primer #4.

XX Plasmid pNO33; Streptomyces albulus strain IF014147;

XX epsilon-polylysine production; detection; PCR primer; ss.

XX Streptomyces albulus.

XX MO200056892-A1.

XX 28-SEP-2000.

XX 21-MAR-2000; 2000MO-JP001698.

XX 23-MAR-1999; 99JP-00077445.

XX (CHCC ) CHISSO CORP.

XX Inoue S, Takagi H, Nakamori S;

XX WPI; 2000-602222/57.

XX Detection of epsilon-polylysine-producing bacteria strain with base

XX sequence originating in plasmid pNO33 by gene amplification or

XX hybridization, for highly-efficient production of epsilon-polylysine.

XX Example 1; Page 12; 25pp; Japanese.

XX The invention relates to a novel method for detecting an epsilon-

XX polylysine-producing bacterium. The method of the invention comprises the

XX detection of a bacterial strain having a base sequence originating in

XX plasmid pNO33. The invention also relates to a process for producing

XX epsilon-polylysine by using the epsilon-polylysine-producing bacterium

XX detected by the method of the invention, and an epsilon-polylysine-

XX producing bacterium comprising a Streptomyces albulus strain IF014147

XX plasmid pNO33 insert sequence. Bacterial strains identified as containing

XX the pNO33 insert sequence using the method of the invention can be used

XX for the efficient production of epsilon-polylysine. Sequences AA97543-

XX AA97549 represent PCR primers used in an exemplification of the

XX invention to amplify portions of the Streptomyces albulus strain IF014147

XX plasmid pNO33 insert sequence

XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

QY Query Match 0.7%; Score 15.2; DB 1; Length 20;

Db Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1795 ATTGCCTAGGCTGACCA 1814  
1 ATTGCCTAGGCTGACCA 20

RESULT 181

AA55792/c  
ID AA55792 standard; DNA; 20 BP.

AC AA55792;

XX 01-SEP-2000 (first entry)

DE Human histone deacetylase HD1 antisense oligonucleotide SEQ ID NO:35.

XX Human; DNA methyltransferase; DNA Metase; antisense oligonucleotide;

XX modulation; inhibition; gene expression; combination therapy; p16;

XX histone deacetylase; HDAC; thymidylate synthase; tumour suppressor;

XX

KW methylation; gene therapy; tumour; cytostatic; antiasthmatic;  
KM antiinflammatory; inflammation; asthma; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200023112-A1.  
PN  
XX 27-APR-2000.  
PD  
XX 19-OCT-1999; 99WO-US024278.  
XX  
XX 19-OCT-1998; 98US-0104804P.  
PR  
XX (METH-) METHYLGENE INC.  
XX  
XX Besterman JM, Macleod AR, Siders WM;  
PI  
XX WPI; 2000-339532/29.  
DR  
XX  
XX Inhibiting gene expression e.g. DNA methyltransferase, by treating cells  
PT with a synergistic amount of antisense oligonucleotide and protein  
PT effectors e.g. 5-aza-cytidine of gene products, useful for gene therapy  
PT of e.g. tumors.  
PS  
XX Disclosure; Page 29; 99pp; English.  
XX  
XX The present invention describes a method for inhibiting the expression of  
CC a gene in a cell comprising contacting the cell with an effective  
CC synergistic amount of an antisense oligonucleotide which inhibits  
CC expression of the gene, and an effective synergistic amount of a protein  
CC effector of a product of the gene. Also described are: (1) a method for  
CC treating a disease responsive to inhibition of a gene in a mammal; (2) a  
CC method for inhibiting tumour growth in mammal; (3) an inhibitor of a gene  
CC comprising an antisense oligonucleotide which inhibits expression of the  
CC gene in operable association with a protein effector of a gene product;  
CC and (4) a pharmaceutical composition comprising the inhibitor of (3). The  
CC methods and compositions are useful as analytical tools for transgenic  
CC studies and as therapeutic tools, e.g. as gene therapy tools for human  
CC diseases including benign and malignant tumours, inflammation or asthma.  
CC The methods, inhibitors and compositions of the invention that inhibit  
CC expression or activity of a gene or gene product may be used to treat  
CC patients having, or predisposed to developing, a disease responsive to  
CC inhibition of the gene. These may also be used to activate silenced genes  
CC to provide missing gene functions and improve a given condition.  
CC Furthermore, the methods and compositions are useful as probes of the  
CC physiological function of a gene product in an experimental cell culture  
CC or animal system; and to evaluate the effect of inhibiting gene activity  
CC or expression. AA55758 to AA55842 represent oligonucleotide sequences  
CC which are used in the exemplification of the present invention  
XX  
SQ Sequence 20 BP; 6 A; 6 C; 8 G; 0 T; 0 U; 0 Other;  
QY  
Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Db 26 CCGCGGGATGCGCGCTGCTC 45  
20 CCGCGTGTGCTGCTGCTC 1  
XX  
RESULT 182  
AA274434  
ID AA274434 standard; DNA; 20 BP.  
XX  
AC AA274434;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Human biallelic marker downstream amplification primer SEQ ID NO:8790.  
XX  
KW Human genome; biallelic marker; high density disequilibrium map;  
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;

KW haplotyping; hybridisation; identification; characterisation;  
KM amplification; single nucleotide polymorphism; SNP; PCR primer;  
KM diagnosis; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO9954500-A2.  
PN  
XX 28-OCT-1999.  
PD  
XX 21-APR-1999; 99WO-IB000822.  
PF  
XX 21-APR-1998; 98US-0082614P.  
PR 23-NOV-1998; 98US-0109732P.  
XX  
XX (GSEST ) GENSET.  
XX  
PI Cohen D, Blumenfeld M, Chumakov I;  
XX  
XX WPI; 2000-013267/01.  
DR  
XX  
XX Novel biallelic markers used to construct a high density disequilibrium  
PT map of the human genome.  
PT  
XX  
XX Claim 8; Page 2104; 2745pp; English.  
PS  
XX  
XX AA265654 to AA269578 represent human biallelic markers from the present  
CC invention, which contain a polymorphic base at position 24 of their  
CC nucleotide sequences. AA269579 to AA277440 represent amplification  
CC primers for the biallelic markers. The biallelic markers of the invention  
CC have a variety of uses: they can be used for high density mapping of the  
CC human genome, and in complex association studies and haplotyping studies  
CC which are useful in determining the genetic basis for disease states.  
CC Compositions and methods of the invention can also be useful for the  
CC identification of the targets for the development of pharmaceutical  
CC agents and diagnostic methods, as well as side effects from  
CC differential efficacious responses to and side effects from  
CC pharmaceutical agents acting on a disease as well as other treatment.  
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and  
CC 3367, are not actually given a sequence in the Sequence listing from the  
CC present invention  
XX  
SQ Sequence 20 BP; 9 A; 1 C; 7 G; 3 T; 0 U; 0 Other;  
QY  
Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Db 1025 CCAGGAAGGTGGGAAATGG 1044  
1 CAAAGTAGGTGCAAAATGG 20  
XX  
RESULT 183  
AA274482/C  
ID AA274482 standard; DNA; 20 BP.  
XX  
XX  
AC AA274482;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Human biallelic marker downstream amplification primer SEQ ID NO:8838.  
XX  
KW Human genome; biallelic marker; high density disequilibrium map;  
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;  
KW haplotyping; hybridisation; identification; characterisation;  
KW amplification; single nucleotide polymorphism; SNP; PCR primer;  
KW diagnosis; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO9954500-A2.  
PN  
XX

PD 28-OCT-1999.  
 XX  
 PF 21-APR-1999; 99WO-IB000822.  
 XX  
 PR 21-APR-1998; 98US-0082614P.  
 PR 23-NOV-1998; 98US-0109732P.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 PI Cohen D, Blumenfeld M, Chumakov I,  
 XX  
 DR WPI; 2000-013267/01.  
 XX  
 PT Novel biallelic markers used to construct a high density disequilibrium  
 map of the human genome.  
 PT  
 PS Claim 8; Page 2115; 2745pp; English.  
 XX  
 CC AA265654 to AA269578 represent human biallelic markers from the present  
 CC invention, which contain a polymorphic base at position 24 of their  
 CC nucleotide sequences. AA269579 to AA277440 represent amplification  
 CC primers for the biallelic markers. The biallelic markers of the invention  
 CC have a variety of uses: they can be used for high density mapping of the  
 CC human genome, and in complex association studies and haplotyping studies  
 CC which are useful in determining the genetic basis for disease states.  
 CC Compositions and methods of the invention can also be useful for the  
 CC identification of the targets for the development of pharmaceutical  
 CC agents and diagnostic methods, as well as the characterization of the  
 CC differential efficacious responses to and side effects from  
 CC pharmaceutical agents acting on a disease as well as other treatment.  
 CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and  
 CC 3267, are not actually given a sequence in the Sequence Listing from the  
 CC present invention  
 XX  
 SQ Sequence 20 BP; 6 A; 0 C; 11 G; 3 T; 0 U; 0 Other;  
 XX  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 688 CTCATGTCATTCACCAT 707  
 DB 20 CTCCTCTCCATCCACCACAT 1  
 XX  
 RESULT 184  
 AAC62900  
 ID AAC62900 standard; DNA; 20 BP.  
 XX  
 AC AAC62900;  
 XX  
 DT 06-FEB-2001 (first entry)  
 XX  
 DE JNK antisense oligonucleotide ISIS #16704.  
 XX  
 XX Antisense; gene therapy; JNK2 protein; apoptosis; cancer;  
 KM cellular hyperproliferation; Alzheimer's; Parkinson's disease;  
 KM amyotrophic lateral sclerosis; retinitis; pigmentosa; epilepsy;  
 KM myocardial infarction; stroke; obstructive jaundice; polycystic kidney;  
 KM diabetes; Jun N-terminal kinase; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200059549-A1.  
 XX  
 PD 12-OCT-2000.  
 XX  
 PF 04-APR-2000; 2000WO-US008880.  
 XX  
 PR 07-APR-1999; 99US-00287796.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX

PI McKay R, Dean NM, Monia BP, Nero PS, Garde WA;  
 XX  
 DR WPI; 2000-638427/61.  
 XX  
 PT Novel methods for reducing apoptosis comprising contacting cells with  
 PT antisense oligonucleotides, useful for treating apoptotic disorders, e.g.  
 PT cancer.  
 XX  
 PS Example 5; Page 138; 160pp; English.  
 XX  
 CC The present invention relates to antisense oligonucleotides (AAC62844-  
 CC C63000, AA269093-A26099 and AA207993) that hybridise specifically to a  
 CC nucleotide encoding a Jun N-terminal kinase (JNK2) protein, resulting in  
 CC decrease of JNK2 expression and leading to induction of apoptosis. The  
 CC present sequence is one such antisense oligonucleotide. The  
 CC oligonucleotides of the present invention are useful for treating  
 CC diseases or conditions with reduced apoptosis, e.g. cancer and cellular  
 CC hyperproliferation. The oligonucleotides may also be used to increase the  
 CC stimulation of apoptotic proteins, e.g. for treating Alzheimer's or  
 CC Parkinson's disease, amyotrophic lateral sclerosis, retinitis,  
 CC pigmentosa, epilepsy, myocardial infarction, stroke, obstructive  
 CC jaundice, polycystic kidney and diabetes. The present sequence may have a  
 CC phosphorothioate backbone  
 XX  
 SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;  
 XX  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 167 GGGTCTGGCGGCGGCTG 186  
 DB 1 GGGTCTGGTGGTGGACATG 20  
 XX  
 RESULT 185  
 AAH43102/c  
 ID AAH43102 standard; DNA; 20 BP.  
 XX  
 AC AAH43102;  
 XX  
 DT 19-SEP-2001 (first entry)  
 XX  
 DE Antisense oligo, target HDAC-1 17-36.  
 XX  
 XX Antisense; histone deacetylase; HDAC-1; HDAC-2; HDAC-4; inhibitor;  
 KM cell proliferation; cancer; restenosis; portalosis; protozoal infection;  
 KM fungal infections; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200138322-A1.  
 XX  
 PD 31-MAY-2001.  
 XX  
 PF 22-NOV-2000; 2000WO-IB001881.  
 XX  
 PR 23-NOV-1999; 99US-0167035P.  
 XX  
 PA (METH-) METHYLENE INC.  
 XX  
 PI Delorme D, Ruel R, Lavoie R, Thibault C, Abou-Khalil E;  
 XX  
 DR WPI; 2001-432601/46.  
 XX  
 PT New inhibitors of histone deacetylase e.g. N-hydroxy-5-(4-  
 PT (benzenesulfonylamino)-phenyl)-4-yn-2-pentanamide for treating cancer,  
 PT restenosis or fungal infections.  
 XX  
 PS Disclosure, Page 40; 147pp; English.  
 XX  
 CC The sequences given in AAH43102-14 are oligonucleotides which are  
 CC antisense to the histone deacetylase gene, HDAC-1. These oligonucleotides

CC may be used in combination with an inhibitor of histone deacetylase  
 CC enzyme function, to given an improved inhibitory effect, thereby reducing  
 CC the amount of inhibitor required to obtain a given inhibitory effect.  
 CC Compounds containing these oligonucleotides may be used to treat cell  
 CC proliferation conditions such as cancer, restenosis or psoriasis. They  
 CC can also be used to treat protozoal and fungal infections

XX Sequence 20 BP; 6 A; 6 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 26 CCCGCGGCTGCGCTGCCTC 45  
 Db 20 CCCGCTGCTGCTGCTCTC 1

RESULT 186

AAAF80632/c

ID AAAF80632 standard; DNA; 20 BP.

XX AAAF80632;

DT 02-MAY-2001 (first entry)

XX Human mdm2 phosphorothioate oligonucleotide #6.

XX Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.

XX Homo sapiens.

XX US6184212-B1.

XX 06-FEB-2001.

XX 26-MAR-1999; 99US-00280805.

XX 26-MAR-1998; 98US-00048810.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;

XX WPI; 2001-190948/19.

XX Novel antisense compound 8-30 nucleobases in length targeted to a nucleic  
 PT acid molecule encoding human mdm-2 useful for modulating the expression  
 PT of human mdm-2 and reducing hyperproliferation of human cells.

XX Example 2; Col 20; 77pp; English.

XX The present invention relates to an antisense compound 8-30 nucleobases  
 CC in length targeted to nucleobases 1-308 of the 5' untranslated region  
 CC 1776-1806 of the translation termination codon region or 1818-2370 of the  
 CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2.  
 CC The invention is useful for reducing hyperproliferation of human cells,  
 CC modulating the expression of mdm2 in human cells or tissues or in vitro.  
 CC The hyperproliferative disorder includes cancer or psoriasis

XX Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 243 CTCGAAGCGGAAAGCGCAG 262

Db 20 CTCGAAGCGGAAAGCGCAG 1

RESULT 187

AAAD07537/c

ID AAAD07537 standard; DNA; 20 BP.

XX AAAD07537;

XX 10-AUG-2001 (first entry)

XX Human mdm2 antisense oligonucleotide (ISIS #16511).

XX Human; mdm2 inhibitor; gene therapy; cell proliferation; therapeutic;

XX tumour; prophylaxis; antisense; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

XX modified\_base 1..20

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

XX modified\_base 1..6

Db 20 CTCGACGCGGAAAACCCCG 1

RESULT 188

AAAC83925 standard; DNA; 20 BP.

AC AAC83925;

XX

XX 02-MAR-2001 (first entry)

DT

XX ER gene PCR primer #2.

DE

XX Osteoporosis; human; polymorphism; vitamin D receptor; VDR;

KM osteogen receptor; apolipoprotein E; ApoE; PCR primer; detection probe;

KM 88.

OS Homo sapiens.

XX

XX EPI054066-A2.

PN

XX 22-NOV-2000.

PD

XX 18-MAY-2000; 2000EP-00110219.

PF

XX 18-MAY-1999; 99JP-00136653.

PR 11-JUN-1999; 99JP-00165642.

XX

XX (NISS-) NISSHO CORP.

PA

XX Shiraki M, Ouchi Y, Hosoi T, Kusaba N, Baba T, Yoshida H;

PI WPI; 2001-018132/03.

XX

XX DR

XX PT Diagnosing sensitivity to a medicine for osteoporosis involves analyzing

PT genetic polymorphisms of vitamin D receptor gene, estrogen receptor gene

and apolipoprotein E gene.

XX

XX PS Claim 18; Page 42; 51pp; English.

XX

XX The present invention relates to a method for anticipating the

CC sensitivity to a medicine for osteoporosis. The method involves analysing

CC combinations of genetic polymorphisms of a vitamin D receptor gene (VDR),

CC an osteogen receptor (ER) gene, and an apolipoprotein E (ApoE) gene from

CC a human genome DNA sample. PCR primers AAC83918-C83926 and AAC83937-

CC C83942 were used in the method of the present invention to amplify the

CC VDR, ER and ApoE genes, and detection probes AAC83927-C83936 were used

CC for detecting VDR, ER and ApoE genetic polymorphism. By relating a

CC combination of the genetic polymorphisms detected using the detection

CC probes described in AAC83927-C83936, a remedy for a bone-associated

CC disease can be selected

CC

XX

XX SQ Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

XX

XX Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CTTGCTGCAGAAATGTGACC 1666

Db 1 CTTGCACCCAGAAATATGTACC 20

XX

XX RESULT 189

XX AAD10981

XX ID AAD10981 standard; DNA; 20 BP.

XX

XX AAD10981;

XX

XX 24-SEP-2001 (first entry)

DT

XX Murine PAI-1 genotype determining common reverse PCR primer.

DE

XX

KM Murine; plasminogen activator inhibitor type-1; PAI-1; antiasthmatic;

KM angiotensin II receptor; antagonist; AIIra; enalapril; captopril; asthma;

KM spirinolactone; imidapril; angiotensin converting enzyme inhibitor; ACEI;

KM chronic obstructive pulmonary disease; COPD; delfibrotide; PCR primer;

KM therapy; 88.

XX

XX Mus sp.

OS

XX W02000151085-A1.

PN

XX 19-JUL-2001.

XX

XX 12-JAN-2001; 2001WO-US001158.

PF

XX 14-JAN-2000; 2000US-0176211P.

PR

XX (TANO-) TANOX INC.

PA

XX Oh CK, Cho SH, Demisseie-Sanders S, Thomas DW, Tan SW;

XX

XX WPI; 2001-451817/48.

DR

XX

XX Treating chronic obstructive pulmonary disease or asthma in a mammal

PT comprises administering a plasminogen activator inhibitor-1 antagonist.

XX

XX Example 10; Page 18; 40pp; English.

PS

XX The invention relates to plasminogen activator inhibitor type-1 (PAI-1)

CC antagonists. PAI-1 antagonists are used in the treatment of asthma and

CC chronic obstructive pulmonary disease (COPD). PAI-1 is highly expressed

CC in the airways of murine asthma model. PAI-1 antagonist can be an

CC antibody, a peptide, a protein, a polynucleotide, a small organic

CC molecule or a polymer. Examples of PAI-1 antagonist are spirinolactone,

CC imidapril, angiotensin converting enzyme inhibitor (ACEI), captopril,

CC enalapril, an angiotensin II receptor antagonist (AIIra) and delfibrotide

CC (a polydeoxyribonucleotide). The present DNA sequence is a common reverse

CC PCR primer which is used for determining murine plasminogen activator

CC inhibitor type-1 (PAI-1) 4G/5G allele genotype. This PCR primer is

CC designed to minimise the dimer-primer formation

CC

XX

XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

XX

XX Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1460 GCTGCCACCCAGTGTCTG 1479

Db 1 GCTGTCCACCCGGTGTCTG 20

XX

XX RESULT 190

XX AAF54600

XX ID AAF54600 standard; DNA; 20 BP.

XX

XX AAF54600;

XX

XX 03-APR-2001 (first entry)

DT

XX Human HLA Class I oligonucleotide probe SEQ ID NO: 45.

DE

XX Human; HLA typing; oligonucleotide array; Class I; gene discovery;

KM expression; polymorphism detection; mapping; probe; PCR primer; 88.

KM

XX Homo sapiens.

OS

XX W0200079006-A1.

PN

XX 28-DEC-2000.

PD

XX 16-JUN-2000; 2000WO-US016722.

PF

XX 17-JUN-1999; 99US-0139843P.

PR

```

XX (HUTC-) HUTCHINSON CANCER RES CENT FRED.
PA (UNIW ) UNIV WASHINGTON.
XX
PI Petersdorf EW, Guo Z, Hansen JA, Hood L;
XX WPI; 2001-102734/11.
XX
XX- Oligonucleotide arrays useful for human leukocyte antigen (HLA) tissue
PT typing, comprises HLA class I oligonucleotide probes representing all
PT known polymorphisms in HLA class I locus, on a solid support.
XX
PS Disclosure; Page 56; 83pp; English.
XX
XX The present invention provides a microarray of oligonucleotides
CC comprising probes for the human HLA Class I genes attached to a solid
CC support. These can be used in HLA typing. Oligonucleotide arrays are also
CC useful in large scale gene discovery, monitoring gene expression,
CC polymorphism detection and gene mapping
XX
SQ Sequence 20 BP; 2 A; 8 C; 9 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 487 CCGCGCGGTCAGCGCGGCTC 506
Db 1 CGCGCGGACACGCGGCTC 20
XX
RESULT 191
AAS29247/C
ID AAS29247 standard; DNA; 20 BP.
XX
AC AAS29247;
XX
DT 21-NOV-2001 (first entry)
XX
XX Human mdm2 antisense oligonucleotide 16511.
XX
XX Human; mdm2; hyperproliferative disorder; cancer; psoriasis;
KW atherosclerosis; tumour; cytostatic; anti psoriatic;
KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= All phosphorothioate linkages,
FT additionally bases 1-6 and bases 15-20 are 2'-O-
FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"
XX
XX US2001016575-A1.
XX
XX 23-AUG-2001.
XX
XX 02-JAN-2001; 2001US-00752983.
XX
XX 26-MAR-1998; 98US-00048810.
XX 26-MAR-1999; 99US-00280805.
XX
XX (MIRA/) MIRAGLIA L J.
PA (NERO/) NERO P.
PA (GRAH/) GRAHAM M J.
PA (MONI/) MONIA B P.
PA (COMS/) COMSERT L M.
XX
PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowser LM;
XX WPI; 2001-535565/59.
XX

```

```

XX An antisense compound, useful for treating e.g. cancer, comprises
PT nucleobases targeted a region (e.g. translation termination codon region)
PT of a nucleic acid encoding human mdm2.
XX
XX Example 2; Page 11; 81pp; English.
XX
XX The present invention relates to antisense compounds, 8-30 nucleobases in
CC length targeted to the 5' untranslated region, translation termination
CC codon region, 3' untranslated region, coding region or translation start
CC site of a nucleic acid encoding human mdm2, where the antisense compound
CC modulates the expression of human mdm2. The antisense oligonucleotides of
CC the invention are useful for encoding human mdm2 and for inhibiting the
CC expression of human mdm2. They may be used for treating an animal having
CC a disease or condition associated with amplification of mdm2 gene or
CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer
CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis,
CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma
CC and chronic myelogenous leukemia. The antisense compound may be
CC administered with a chemotherapeutic agent to overcome drug resistance.
CC The antisense compound reduces hyperproliferation of human cells. The
CC method, which involves the use of the antisense compound, is also useful
CC for detecting the role of mdm2 expression in various cell functions and
CC physiological processes and useful in both clinical research and
CC diagnostic tools. AAS29242-AAS29507 represent the human mdm2 antisense
CC oligonucleotides of the present invention
XX
SQ Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 243 CTCGAAGCGGAAACCGAG 262
Db 20 CTCGAAGCGGAAACCGCG 1
XX
RESULT 192
ABA93207
ID ABA93207 standard; DNA; 20 BP.
XX
AC ABA93207;
XX
DT 17-APR-2002 (first entry)
XX
XX Human oestrogen receptor gene PCR primer SEQ ID NO:16.
XX
XX Human; vitamin D receptor; apolipoprotein E; oestrogen receptor; VDR;
KW ApoE; bone-related disease; polymorphism; detection; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX JP2001333798-A.
XX
XX 04-DEC-2001.
XX
XX 26-MAY-2000; 2000JP-00155871.
XX
XX 26-MAY-2000; 2000JP-00155871.
XX
XX (NISS-) NISSHO KK.
XX
XX WPI; 2002-135948/18.
XX
XX A reagent for detecting simultaneously a gene polymorphism of the vitamin
PT D receptor gene, apolipoprotein E gene and estrogen receptor gene.
XX
XX Claim 3; Page 2; 13pp; Japanese.
XX
XX The present invention describes a reagent for detecting simultaneously
CC the gene polymorphism of the vitamin D receptor (VDR) gene,
CC apolipoprotein E (ApoE) gene and oestrogen receptor (ER) gene. Also
CC

```



CC described is a method for detecting simultaneously the gene polymorphism  
CC of VDR gene, ApoE gene and ER gene in which the reagent is used to detect  
CC the gene polymorphism of VDR, ApoE and ER in a sample. The reagent can be  
CC used for selecting a treating agent for bone-related diseases. The  
CC present sequence represents a specifically claimed PCR primer for the  
CC human ER gene, for use in a reagent of the present invention

XX Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CCTGCTGCAGATCTGTACC 1666

DB 1 CCTGCACCAATATGTACC 20

RESULT 193

ABA92551

ID ABA92551 standard; DNA; 20 BP.

XX ABA92551;

XX 20-MAR-2002 (first entry)

XX Adenovirus 5 related 5' PCR primer E4.

XX Adenovirus 5; adenovirus vector; inflammatory; gene therapy; PCR primer;

XX Mastadenovirus.

XX WO200190392-A1.

XX 29-NOV-2001.

XX 24-MAY-2001; 2001WO-JP004360.

XX 26-MAY-2000; 2000JP-00155603.

XX 08-DEC-2000; 2000JP-00373850.

XX (SUMU) SUMITOMO PHARM CO LTD.

XX Nakai M, Komiya K, Murata M, Tohdoh N, Saito I;

XX WPI; 2002-097660/13.

XX Adenovirus vector with reduced inflammatory side effects for use in gene

XX therapy.

XX Example 6; Page 58; 108bp; Japanese.

XX The present invention describes a recombinant adenovirus vector having  
XX reduced inflammatory activity when administered in vivo. The adenovirus  
XX vector has the adenovirus E1a and E2b genes deleted; a foreign gene is  
XX inserted under the control of a foreign promoter. The expression of an  
XX adenovirus gene is suppressed by insertion of the foreign promoter. The  
XX recombinant virus produces viral particles similar to those of wild-type  
XX adenovirus. Also described are: (1) mammalian cells expressing adenoviral  
XX E1 and E2 genes, and able to proliferate the recombinant adenovirus  
XX vector; (2) a method for the preparation of the viral vector using these  
XX cells; (3) drug compositions containing the recombinant adenovirus vector  
XX; and (4) a method for gene therapy using these drug compositions. The  
XX adenovirus vectors can be used for effective gene therapy of a wide range  
XX of human diseases. The present sequence represents a PCR primer for  
XX adenovirus 5 which is used in an example from the present invention

XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1410 GGCTGTGGCTCCTCAGAGA 1429

DB 1 GGCACTGTCTCTCTCAGCGA 20

RESULT 194

AAD39601/c

ID AAD39601 standard; DNA; 20 BP.

XX AAD39601;

XX 04-OCT-2002 (first entry)

XX Human SR-cyp antisense oligonucleotide, ISIS #123865.

XX Human; antisense; SR-cyp; CLK-associated RS cyclophilin; inflammation;

XX hyperproliferative disorder; cancer; prophylaxis; infection; therapy;

XX tumour; CARS-cyp; phosphorothioate backbone; ss.

XX Homo sapiens.

XX Synthetic.

XX Key

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

XX modified\_base

Location/Qualifiers

1..20

/\*tag= a

/mod\_base= OTHER

/note= "Phosphorothioate backbone"

1..5

/\*tag= b

/mod\_base= OTHER

/note= "2-methoxyethyl nucleotides"

1

/\*tag= d

/mod\_base= m5c

15

/\*tag= e

/mod\_base= m5c

16..20

/\*tag= c

/mod\_base= OTHER

/note= "2-methoxyethyl nucleotides"

17

/\*tag= f

/mod\_base= m5c

19

/\*tag= g

/mod\_base= m5c

WO200236809-A2.

10-MAY-2002.

30-OCT-2001; 2001WO-US047335.

03-NOV-2000; 2000US-00706197.

(ISIS-) ISIS PHARM INC.

(COLD-) COLD SPRING HARBOR LAB.

Bennett CF, Spector DL, Wyatt JR;

WPI; 2002-479763/51.

Novel antisense compounds targeted to nucleic acids encoding SR-cyp, CLK-

associated RS cyclophilin for modulating the gene expression and treating

hyperproliferative disorders such as cancer.

Claim 3; Page 89; 117pp; English.

The invention relates to antisense compounds targeted to a nucleic acid

molecule encoding human SR-cyp (CLK-associated RS cyclophilin) to inhibit

its expression. SR-cyp is also referred to as CARS-cyp. Antisense

Query March	0.7%	Score 15.2	DB 1	Length 20
Best Local Similarity	85.0%	Pred. No. 1.5e+02		
Matches 17	Conservative 0	Mismatches 3	Indels 0	Gaps 0
<p>1269 AGTGGGATCCTCTACATTG 1288         20 AGTGGACTCTCCACATTG 1</p>				
<p>RESULT 195  ABA931174  ID ABA931174 standard; DNA; 20 BP.</p>				
AC	ABA931174			
XX				
DT	17-APR-2002 (first entry)			
XX				
DE	Human oestrogen receptor gene PCR primer SEQ ID NO:8.			
XX				
KW	Human, vitamin D receptor, apolipoprotein E, oestrogen receptor; VDR;			
XX	ApoE; osteoporosis; polymorphism; allele; PCR primer; ss.			
OS	Homo sapiens.			
XX				
FN	JP200133799-A.			
PD	04-DEC-2001.			
XX				
PF	26-MAY-2000; 2000JP-00155993.			
XX				
PR	26-MAY-2000; 2000JP-00155993.			
XX				
PA	(NISS-) NISSHO KK.			
XX				
DR	WPI; 2002-135949/18.			
XX				
PT	Estimate of sensitivity to drugs for osteoporosis and a reagent kit.			
XX				
PS	Example 1; Page 7; 13pp; Japanese.			
XX				
CC	The present invention describes a method for the estimation of			
CC	sensitivity to drugs for osteoporosis in which each gene polymorphism of			
CC	vitamin D receptor (VDR) gene, oestrogen receptor (ER) gene and			
CC	apolipoprotein E3 (ApoE3) allele (2/2, 2/3, 2/4, 3/3, 3/4 or 4/4) are			
CC	analysed from the genomic DNA contained in a sample collected from a			
CC	human and, based on these combinations of gene polymorphisms, it is			
CC	estimated that the sample is derived from an individual showing a			
CC	specific priority on the sensitivity against a plural of treating agents			
CC	for osteoporosis. Also described is a reagent kit for analysing gene			
CC	polymorphisms of VDR, ApoE and ER genes containing primers specific to			
CC	each of the genes and detecting probes for detecting each gene			
CC	polymorphisms. The reagent can be used for selecting an effective drug			
CC	for osteoporosis. The present sequence represents a PCR primer for human			
CC	ER which is used in the exemplification of the present invention			
XX				
XX				
SQ	Sequence 20 BP; 6 A; 7 C; 3 G; 4 T; 0 U; 0 Other;			
Query March	0.7%	Score 15.2	DB 1	Length 20
Best Local Similarity	85.0%	Pred. No. 1.5e+02		
Matches 17	Conservative 0	Mismatches 3	Indels 0	Gaps 0
<p>1647 CCTGCTGCAGATCTGTACC 1666</p>				

Db 1 ||||| ||||| ||||| |||||  
CCTGACCGAGATATTACC 20

RESULT 196  
ABZ88194  
ID ABZ88194 standard; DNA, 20 BP.  
XX AC AC  
XX ABZ88194;  
DT 17-OCT-2003 (first entry)  
XX XX  
DE Human oligonucleotide sequence.

KX Human; antisense; lung dysfunction; nasal airway dysfunction;  
KX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
KX antiasthmatic; hypocensive; immunosuppressive; cycostatic; gene therapy;  
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KM lung inflammation; respiratory disease; ds.  
XX XX  
OS Homo sapiens.  
PM WO200285308-A2.  
PD 31-OCT-2002.  
PF 23-APR-2002; 2002WO-US013135.  
PR 24-APR-2001; 2001US-0286137P.  
XX (EPIG-) EPIGENESIS PHARM INC.  
PA NYce JW, Li Y, Sandraseagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
DR WPI; 2003-229219/22.

PT Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.

PS Disclosure; SEQ ID NO 3436; 872bp; English.

CC The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypocensive,  
CC immunosuppressive, and cycostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

1726 TACTGCACAGCAGGTGGC 1745

```

Db          1  TACCTGCACAGCAGCTGCG 20
|||||
RESULT 197
AB293288
ID  AB293288 standard; DNA, 20 BP.
XX
AC  AB293288;
XX
DT  17-OCT-2003 (first entry)
XX
DE  Human oligonucleotide sequence.
XX
KW  Human; antisense; lung dysfunction; nasal airway dysfunction;
KW  antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW  antidiabetic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW  antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW  adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW  lung inflammation; respiratory disease; ds.
XX
OS  Homo sapiens.
XX
PN  WO200285308-A2.
XX
PD  31-OCT-2002.
XX
PF  23-APR-2002; 2002WO-US013135.
XX
PR  24-APR-2001; 2001US-0286137P.
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI  Miller S, Tang L, Shahabuddin S;
XX
DR  WPI; 2003-229219/22.
XX
PT  Pharmaceutical composition for treating ailments associated with impaired
PT  respiration, has oligo(s) antisense to specific gene(s) or its
PT  corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT  ubiquinone.
XX
PS  Disclosure; SEQ ID NO 8530; 872p; English.
XX
CC  The invention relates to a novel pharmaceutical composition, which has a
CC  first active agent comprising an oligonucleotide antisense to the
CC  initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC  5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC  junctions of genes encoding a polypeptide associated with lung and/or
CC  nasal airway dysfunction and a second active agent comprising an
CC  antiinflammatory steroid and ubiquinone. A composition of the invention
CC  has antiinflammatory, antiallergic, antidiabetic, hypotensive,
CC  immunosuppressive, and cytostatic activity. The composition may have a
CC  use in antisense gene therapy. The composition is useful for treating or
CC  preventing a respiratory, lung or malignant disease or condition, also
CC  for enhancing the prophylactic or therapeutic respiratory effect of an
CC  antiinflammatory steroid in a subject, for reducing or depleting levels
CC  of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC  receptor, producing bronchodilation, increasing levels of ubiquinone or
CC  lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC  lung inflammation, lung allergies, or a respiratory disease or condition.
CC  Note: The sequence data for this patent is not represented in the printed
CC  specification, but was obtained in electronic format directly from WIPO
CC  at ftp.wipo.int/pub/published_pat_sequences
XX
SQ  Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 711 CAGTCAGTCTGAGATTGCG 730

```

```

Db          1  CAGTCAGTCTGAGATTGCG 20
|||||
RESULT 198
ABX33969/C
ID  ABX33969 standard; DNA, 20 BP.
XX
AC  ABX33969;
XX
DT  10-FEB-2003 (first entry)
XX
DE  Human interleukin 12 p40 subunit antisense oligonucleotide ISIS #319142.
XX
KW  Human; ss; antisense; interleukin 12 p40 subunit; antibacterial;
KW  antiinflammatory; cytostatic; infection; inflammation; tumour.
XX
OS  Homo sapiens.
XX
FH  Key
FH  modified_base 1..20
FT  Location/Qualifiers
FT  /*tag= a
FT  /mod_base= OTHER
FT  /note= "All cytosines are 5-methylcytidines and the
FT  nucleotides are linked via a phosphorothioate backbone"
FT  modified_base 1..5
FT  /*tag= b
FT  /mod_base= OTHER
FT  /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT  modified_base 16..20
FT  /*tag= c
FT  /mod_base= OTHER
FT  /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
EN  US6446081-B1.
XX
PD  10-SEP-2002.
XX
PF  07-MAY-2001; 2001US-00851062.
XX
PR  07-MAY-2001; 2001US-00851062.
XX
PA  (ISIS-) ISIS PHARM INC.
XX
PI  Baker BF, Freiler SM;
XX
DR  WPI; 2003-074100/07.
XX
PT  New antisense chimeric oligonucleotide, useful for modulating the
PT  expression of human Interleukin 12 p40 subunit, in treating or preventing
PT  disease states in humans and animals, and as research reagents and
PT  diagnostics.
XX
PS  Example 15; Col 45; 42p; English.
XX
CC  The invention relates to an antisense compound 20-50 nucleobases in
CC  length targeted to a start codon region, coding region, a stop codon
CC  region or a 3'-untranslated region of a nucleic acid molecule encoding
CC  human interleukin 12 p40 subunit. The compound specifically hybridises
CC  with one of the regions and inhibits the expression of human interleukin
CC  12 p40 subunit. The new compound is useful for inhibiting the expression
CC  of human interleukin 12 p40 subunit in cells or tissues and comprises
CC  contacting the cells or tissues in vitro with the compound, so that
CC  expression of the human Interleukin 12 p40 subunit is inhibited. The
CC  antisense compound may also be used as research reagents and diagnostics,
CC  and as treatment or prevention of disease states, e.g. to prevent or
CC  delay infection, inflammation or tumour formation, in animals and humans.
CC  The present sequence is an antisense oligonucleotide of the invention
XX
SQ  Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;

```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1633 AGCACAGTGGCTGCTGCT 1652  
 |||||  
 Db 20 AGGACAGTGGCTGCTGCT 1

RESULT 199  
 AB284008  
 ID AB284008 standard; DNA; 20 BP.  
 XX  
 AC AB284008;  
 XX  
 DT 14-MAY-2003 (first entry)  
 XX  
 DE Toxicologically relevant rat PCR primer #1167.  
 XX  
 KM Toxicologically relevant gene; toxicological response; PCR primer; BS.  
 XX  
 OS Rattus sp.  
 OS Synthetic.  
 XX  
 PN W02003016500-A2.  
 XX  
 PD 27-FEB-2003.  
 XX  
 PF 16-AUG-2002; 2002WO-US026514.  
 XX  
 PR 16-AUG-2001; 2001US-0313080P.  
 XX  
 PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.  
 XX  
 PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kler LD, Schmeiser K;  
 PI Alen P;  
 XX  
 DR WPI; 2003-268322/26.  
 XX  
 PT Determining a toxicological response to an agent, useful for screening of  
 PT drugs, comprises comparing the expression profile of one or more human  
 PT toxic response genes to a reference gene expression profile indicative of  
 PT toxicity.  
 XX  
 PS Claim 1; Page 327; 455pp; English.

CC The present invention describes a method (M1) for determining a  
 CC toxicological response to an agent, which comprises comparing the  
 CC expression profile of one or more human toxic response genes to a  
 CC reference gene expression profile indicative of toxicity, and so  
 CC determining the presence of a toxic response to the agent. Also  
 CC described: (1) an array comprising one or more polynucleotides selected  
 CC from the genes corresponding to the partial sequences given in AB282842  
 CC to AB284764, or their fragments of at least 20 nucleotides, or homologues  
 CC ; and (2) determining if a gene putatively identified to be a toxic  
 CC response gene plays a role on toxic response pathways by determining the  
 CC expression profile of the gene after exposure of cells or a human subject  
 CC to a known toxic pharmaceutical or industrial agent, comprising: (a)  
 CC exposing cells to an agent or isolating cells from a human subject who  
 CC was exposed to an agent; (b) obtaining the test gene expression profile  
 CC for a putatively identified toxic response gene after exposure to a known  
 CC toxic pharmaceutical or industrial agent; and (c) comparing the test  
 CC profile to the expression profile of a gene with a similar function or  
 CC comparing the test profile to the expression profile of that gene after  
 CC exposure to other known toxic compounds. The methods are useful for  
 CC predicting and determining toxicological responses on a cellular, organ  
 CC or system level. The arrays comprising the human genes are useful for  
 CC toxicological screening of drugs, pharmaceutical compounds and chemicals

XX  
 SQ Sequence 20 BP; 0 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1004 TGCTTGTGCTTTCTCTGTG 1023  
 |||||  
 Db 1 TGCTTGTGCTTTCTCTGTG 20

RESULT 200  
 ADA26604  
 ID ADA26604 standard; DNA; 20 BP.  
 XX  
 AC ADA26604;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human Jun N-terminal kinase, JNK3, antisense oligonucleotide ISIS16704.  
 XX  
 KM ss: human; Jun N-terminal kinase; JNK1; JNK2; JNK3; antisense;  
 KM cytosolic; antiinflammatory; apoptosis; prostate cancer;  
 KM prostate tumour; inflammation; fibrosis; fibrotic disease;  
 KM fibrotic scarring; peritoneal adhesion; lung fibrosis;  
 KM conjunctival scarring; hyperproliferative disease; cancer; probe.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..6  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethoxy-modified"  
 FT modified\_base 15..20  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'methoxyethoxy-modified"

US2003004120-A1.  
 XX  
 PD 02-JAN-2003.  
 XX  
 PF 31-JAN-2001; 2001US-00774809.  
 XX  
 PR 13-AUG-1997; 97US-00910629.  
 PR 07-AUG-1998; 98US-00130616.  
 PR 07-APR-1999; 99US-00287796.  
 PR 15-SEP-1999; 99US-00396902.  
 XX  
 PA (MCKA/) MCKAY R.  
 PA (DEAN/) DEAN N M.  
 PA (MONI/) MONIA B P.  
 PA (NERO/) NERO P. P.  
 PA (GAAR/) GAARDE W A.  
 XX  
 PI McKay R, Dean NM, Monia BP, Nero P, Gaarde WA;  
 PI WPI; 2003-311908/30.  
 XX  
 DR WPI; 2003-311908/30.  
 XX  
 PT New oligonucleotides which hybridizes to, and modulates the expression of  
 PT Jun N-terminal kinase, useful for treating a disease or condition  
 PT characterized by a reduction in apoptosis, e.g. prostate cancer,  
 PT inflammation or fibrosis.  
 XX  
 PS Example 5; Page 30; 69pp; English.

XX The invention relates to an oligonucleotide (antisense, AS) comprising 8-  
 XX 30 nucleotides connected by covalent linkages, where the oligonucleotide  
 XX has a sequence specifically hybridizable with a nucleic acid encoding a  
 XX Jun N-terminal kinase (JNK) protein and modulates the expression of the  
 XX JNK protein. Also included are a pharmaceutical composition comprising  
 XX the AS oligonucleotide (or its bioequivalent, and a pharmaceutical  
 XX carrier), treating an animal having/suspected of having/prone to having a  
 XX hyperproliferative disease (by administering to a prophylactic or  
 XX therapeutic amount of the composition of the AS oligonucleotide),  
 XX modulating the expression of a JNK protein in cells or tissues by  
 XX contacting the cells or tissues with the AS oligonucleotide, modulating  
 XX the cell cycle progression (or the phosphorylation of a protein

phosphorylated by a JNK protein, or expression of a cellular protein that promotes one or more metastatic events in cultured cells or the cells of an animal) by administering the oligonucleotide to the cells, inhibiting the growth of a tumour in an animal by administering the oligonucleotide, inducing apoptosis in a cell by contacting a cell with an AS oligonucleotide for JNK2 and treating a human having a disease or condition associated with a JNK protein or characterised by a reduction in apoptosis by administering a prophylactic or therapeutic amount of the AS oligonucleotide. The antisense oligonucleotide is useful for treating a disease or condition characterised by a reduction in apoptosis, such as prostate cancer or prostate tumour, inflammation, fibrosis or fibrotic disease or conjunctival scarring), hyperproliferative disease or fibrosis or conjunctival scarring), hyperproliferative disease or condition, such as cancer. The antisense oligonucleotides may also be used as research agents and diagnostic aids, to detect the presence of JNK protein-specific nucleic acids in a cell or tissue sample, and to study the function of one or more genes in the animal. The present sequence is an antisense oligonucleotide targeting human JNK3.

SO Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGCTGCGGGCTG 166  
DB 1 GGGCTGCTGCTGCGACATG 20

#### RESULT 201

ACF05303 standard; DNA; 20 BP.

AC ACF05303;

DT 06-NOV-2003 (first entry)

DE Rat edg1 lysophospholipid antisense PCR primer.

KW Rat; edg1; lysophospholipid; receptor; hypotensive; cardiant; PCR; primer; ss.

OS Rattus sp.

PN W02003051395-A2.

PD 26-JUN-2003.

PF 28-NOV-2002; 2002MO-EP013429.

PR 30-NOV-2001; 2001US-0334106P.

PA (SOLV ) SOLVAY PHARM GMBH.

PI Molderings Gf, Brues M;

DR WPI; 2003-569116/53.

PT Treatment and/or prophylaxis of hypertension, comprises administering an edg-receptor agonist or its pharmacologically acceptable salt to a mammal.

PS Example; Page 14; 38pp; English.

The present sequence is that of an antisense PCR primer for rat lysophospholipid receptor type edg1. The sense primer is given in ACF05302. PCR was performed to obtain evidence for receptor expression, using cDNA from undifferentiated PC12 cells and genomic DNA prepared from rat whole blood. Edg1 PCR products were obtained from the genomic DNA but not from the cDNA. The invention relates to the treatment and/or prophylaxis of hypertension using an edg-receptor agonist, preferably a highly selective 1/1-receptor agonist that is essentially devoid of alpha2-receptor agonist activity, and having an imidazoline structure.

Screening tools for identifying such compounds are also provided, where the compound is effective with regard to dysfunctions, disorders or diseases of the cardiovascular system including the heart, blood pressure control, e.g. hypertension or vasodilation, myocardial ischemia, ischemic preconditioning, cardioprotective activity and other heart related diseases, nervous system including central nervous system (CNS), and also of glucose and insulin metabolism or with regard to dysfunctions, disorders or diseases related to increased sympathetic tonicity (claimed)

SO Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1182 GCAGGAATGAGACACTCA 1201  
DB 1 GCAGGCAATGAGACACTCA 20

#### RESULT 202

ACC99727/c standard; DNA; 20 BP.

AC ACC99727;

DT 02-SEP-2003 (first entry)

DE Beta-tubulin PCR primer SEQ ID NO:108.

KW Multiplex real-time quantitative PCR; PCR primer; copy number; Alzheimer's disease; ss.

OS Synthetic.

PN W02003048377-A2.

PD 12-JUN-2003.

PF 02-DEC-2002; 2002MO-US038806.

PR 30-NOV-2001; 2001US-0336095P.

PA 19-JUN-2002; 2002US-0397475P.

PI (UVRP ) UNIV ROCHESTER.

PA (THER/) THERIANOS S.

PI Zhu M, Coleman P;

DR WPI; 2003-532841/50.

PT Determining the relative copy number of a group of target nucleic acid molecules present in a sample by performing a first or second PCR in a PCR mixture and quantifying the number of copies of the second target nucleic acid product.

PS Disclosure; Fig 6; 118pp; English.

The present invention describes a multiplex real-time quantitative PCR method for determining the relative copy number of a group of target nucleic acid molecules present in a sample. The method comprises: (1) performing a first PCR in a PCR mixture; (2) performing a second PCR in a PCR mixture; and (3) quantifying the number of copies of the second target nucleic acid product present in the sample containing the target nucleic acid molecule. Also described: (1) quantifying the copy number of a group of target nucleic acids in a sample; and (2) determining whether a subject is at risk of acquiring Alzheimer's disease. The method is useful for determining the relative copy number of a group of target nucleic acid molecules present in a sample for determining whether a subject is at risk of acquiring Alzheimer's disease. ACC99620 to ACC99730 represent PCR primer used in the exemplification of the present invention

SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1349 ACCGATGCACTTCACCGAG 1368  
 |||||  
 20 ACGAGATGAGTTCACCGAG 1  
 Db

RESULT 203  
 ADB25679  
 ID ADB25679 standard; DNA; 20 BP.  
 AC ADB25679;  
 XX  
 DT 20-NOV-2003 (first entry)  
 DE Human connective tissue growth factor antisense oligo DNA (SeqID 72).  
 XX  
 KM antisense; human; ss; connective tissue growth factor; CTGF;  
 KM chromosome 6q23.1; ctgofact; fibroblast inducible secreted protein;  
 KM fisp-12; NOV2;  
 KM insulin-like growth factor binding protein-related protein 2; IGFBP-rp2;  
 KM IGFBP-8; Hcs24; ecogenin; acute lymphoblastic leukaemia; gene therapy;  
 KM hyperproliferative disorder; cancer; pulmonary fibrosis; renal fibrosis;  
 KM scleroderma; atherosclerosis; cystostatic; dermatological;  
 KM antiatherosclerotic.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= phosphorothioate backbone, where 1-5 and  
 16-20 are 2' methoxyethyl nucleotides. All cytidines are  
 5-methylcytidines"  
 FT  
 XX  
 PN WO2003053340-A2.  
 XX  
 PD 03-JUL-2003.  
 XX  
 PF 09-DEC-2002; 2002WO-US038618.  
 XX  
 PR 10-DEC-2001; 2001US-00006191.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Gaarde WA, Watt AT;  
 DR WPI; 2003-559091/52.  
 XX  
 PT New antisense oligonucleotides for modulating connective tissue growth  
 PT factor expression, particularly useful for treating cancers (e.g. breast  
 PT or prostate cancer), pulmonary or renal fibrosis, scleroderma or  
 PT atherosclerosis.  
 XX  
 PS Claim 3; Page 86; 139pp; English.  
 XX  
 CC This invention relates to novel methods for modulating the expression of  
 CC connective tissue growth factor (CTGF) by antisense oligonucleotides.  
 CC CTGF has been mapped to human chromosome region 6q23.1, and is also known  
 CC as ctgofact. fibroblast inducible secreted protein, fisp-12, NOV2,  
 CC insulin-like growth factor binding protein-related protein 2, IGFBP-rp2,  
 CC IGFBP-8, Hcs24 and ecogenin. It is known to stimulate DNA synthesis and  
 CC promote chemotaxis of fibroblasts, however, it is also upregulated in  
 CC acute lymphoblastic leukaemia and in tumour or endothelial cells  
 CC associated with the vasculature. Accordingly, antisense oligonucleotides  
 CC that inhibit the expression of CTGF in cells or tissues can be used in  
 CC gene therapy to treat various conditions including hyperproliferative  
 CC disorders (particularly cancer, e.g. breast, prostate or renal cancer),

CC pulmonary fibrosis, renal fibrosis, scleroderma and atherosclerosis. As  
 CC such, the present invention describes these antisense oligos as having  
 CC cytosatic, dermatological and antiatherosclerotic activities. This  
 CC oligonucleotide sequence is a chimeric phosphorothioate antisense oligo  
 CC with 2' MOE wings and a deoxy gap, which is used to inhibit expression of  
 CC human CTGF of the invention.  
 XX  
 SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 763 CACGTGCACAGCCACTTGA 782  
 |||||  
 1 CACGTGCACGTGACTTGA 20  
 Db

RESULT 204  
 ADB89885/C  
 ID ADB89885 standard; DNA; 20 BP.  
 AC ADB89885;  
 XX  
 DT 04-DEC-2003 (first entry)  
 DE Antisense oligonucleotide targeting human C3 component, ISIS139987.  
 XX  
 KM Human; ss; antisense; complement component C3; inflammation;  
 KM septic shock; multiple organ failure; hyperacute organ failure;  
 KM autoimmune disorder; CNS inflammation; multiple sclerosis;  
 KM atherosclerosis; tumour.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone and all cytosines are 5  
 -methyl cytosines"  
 FT  
 XX  
 FT modified\_base 1..5  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl nucleotides"  
 FT  
 XX  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl nucleotides"  
 FT  
 XX  
 PN US2003096775-A1.  
 XX  
 PD 22-MAY-2003.  
 XX  
 PF 23-OCT-2001; 2001US-00001076.  
 XX  
 PR 23-OCT-2001; 2001US-00001076.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Graham MJ, Watt AT;  
 DR WPI; 2003-606441/57.  
 XX  
 PT New antisense oligonucleotides targeted to a nucleic acid molecule  
 PT encoding complement component C3, useful for treating a disease or  
 PT condition associated with complement component C3, e.g. autoimmune  
 PT disorder or infection.  
 XX  
 PS Claim 3; Page 25; 72pp; English.  
 XX  
 CC The invention relates to a compound 8-50 nucleobases in length targeted  
 CC to a nucleic acid molecule encoding complement component C3. The compound

CC specifically hybridises with the nucleic acid molecule encoding  
 CC complement component C3 and inhibits the expression of complement  
 CC component C3, or specifically hybridises with at least an 8-nucleobase  
 CC portion of an active site on a nucleic acid molecule encoding complement  
 CC component C3. Also included are a composition comprising the compound and  
 CC a pharmaceutical carrier or diluent, inhibiting the expression of  
 CC complement component C3 in cells or tissues (comprising contacting the  
 CC cells or tissues with the compound cited above) and treating an animal  
 CC having a disease or condition associated with complement component C3  
 CC comprising administering to the animal the compound cited above so that  
 CC expression of complement component C3 is inhibited. The antisense  
 CC compounds are useful for inhibiting the expression of complement  
 CC component C3 in cells or tissues, or for treating an animal having a  
 CC disease or condition associated with complement component C3 such as an  
 CC autoimmune disorder (e.g. multiple sclerosis), an infection, or  
 CC atherosclerosis, inflammation, septic shock, multiple organ failure,  
 CC hyperacute organ failure and CNS inflammation. The compounds are also  
 CC useful as research reagents and diagnostics, in distinguishing functions  
 CC of various members of a biological pathway, or for preventing or delaying  
 CC infection, inflammation or tumour formation. The present sequence is an  
 CC antisense oligonucleotide targeting human C3.  
 XX

SQ Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1348 TACCAATGCACTTCACCCA 1367  
 DB 20 TACCAATGCACTTCACCCA 1

RESULT 205  
 ADB68620/C  
 ID ADB68620 standard; DNA; 20 BP.  
 AC ADB68620;  
 XX  
 XX 04-DEC-2003 (first entry)  
 DT  
 XX  
 DE Microsomal triglyceride transfer protein antisense oligonucleotide #36.  
 XX  
 XX microsomal triglyceride transfer protein; antisense oligonucleotide;  
 KM hybridisation; microsomal triglyceride transfer protein inhibitor;  
 KM cardiant; antiarteriosclerotic; antilipemic; antisense gene therapy;  
 KM abnormal lipid metabolism; abnormal cholesterol metabolism;  
 KM atherosclerosis; cardiovascular disease; human; phosphorothioate; ss;  
 KM 2'-O-methoxyethyl.  
 XX  
 XX Synthetic.  
 OS Homo sapiens.  
 XX  
 XX Key Location/Qualifiers  
 FH modified\_base 1..20  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "phosphorothioate linkages, and all cytidine  
 FT residues are 5-methylcytidines"  
 FT 1..5  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "2'-O-methoxyethyls"  
 FT 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-O-methoxyethyls"  
 XX  
 XX WO2003018600-A2.  
 PN 06-MAR-2003.  
 PD 17-JUL-2002; 2002WO-US022799.  
 XX

XX  
 PR 30-JUN-2001; 2001US-00917963.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 PI Crooke RM, Graham MJ;  
 XX  
 XX WPI; 2003-300705/29.  
 DR  
 XX  
 PT New antisense oligonucleotide compounds, useful for diagnosing,  
 PT preventing and/or treating conditions with aberrant activity of the  
 PT microsomal triglyceride transfer protein, such as atherosclerosis and  
 PT heart disease.  
 XX  
 PS Example 15; Page 95; 135pp; English.  
 XX  
 CC The present invention describes compounds (I) comprising 8-50 nucleobases  
 CC in length targeted to a nucleic acid molecule encoding a microsomal  
 CC triglyceride transfer protein, where the compounds specifically hybridise  
 CC with and inhibit the expression of the microsomal triglyceride transfer  
 CC protein. Also described: (1) a compound 8-50 nucleobases in length which  
 CC specifically hybridises with at least an 8-nucleobase portion of an  
 CC active site on a nucleic acid molecule encoding microsomal triglyceride  
 CC transfer protein; (2) a composition comprising (1) and a carrier or  
 CC diluent; (3) inhibiting the expression of microsomal triglyceride  
 CC transfer protein in cells or tissues, comprising contacting the cells or  
 CC tissues with (1) so that expression of microsomal triglyceride transfer  
 CC protein is inhibited; and (4) treating an animal having a disease or  
 CC condition associated with microsomal triglyceride transfer protein.  
 CC comprising administering (1) to the animal so that expression of  
 CC microsomal triglyceride transfer protein is inhibited. (1) have cardiant,  
 CC antiarteriosclerotic and antilipemic activities, and can be used in  
 CC antisense gene therapy. The methods and compositions of the present  
 CC invention are useful for the diagnosis, prevention and/or treatment of  
 CC diseases or conditions associated with aberrant expression or activity of  
 CC microsomal triglyceride transfer protein, such as an abnormal lipid or  
 CC cholesterol metabolism condition like atherosclerosis and cardiovascular  
 CC disease. The present sequence represents a human microsomal triglyceride  
 CC transfer protein chimeric phosphorothioate antisense oligonucleotide,  
 CC which is used in an example from the present invention.  
 XX  
 SQ Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 146 CCACCGGCTGCCACTGCTC 165  
 DB 20 CCACCGGCTGCCACTGCTC 1

RESULT 206  
 ADD21443/C  
 ID ADD21443 standard; DNA; 20 BP.  
 AC ADD21443;  
 XX  
 XX 15-JAN-2004 (first entry)  
 DT  
 XX  
 DE Human mdm2 antisense oligonucleotide #6.  
 XX  
 XX antisense oligonucleotide; human; mdm2; hyperproliferation;  
 KM hyperproliferative disorder; cancer; psoriasis; fibrosis;  
 KM atherosclerosis; restenosis; apoptosis modulation; p21; ss;  
 KM 2'-methoxyethoxy-residue; phosphorothioate backbone.  
 XX  
 XX Homo sapiens.  
 OS  
 XX  
 XX WO2003048315-A2.  
 PN 12-JUN-2003.  
 PD  
 XX



```

PF 02-DEC-2002; 2002WO-US038281.
XX
XX 04-DEC-2001; 2001US-00005344.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY;
PI Manoharan M;
PS WPI; 2003-577263/54.
XX
XX Novel antisense compound targeted to 5' untranslated region, coding
PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
PT mdm2 expression.
XX
XX Example 2; SEQ ID NO 8; 289pp; English.
XX
XX The invention comprises antisense oligonucleotides which are targeted to
CC the human mdm2 gene. The antisense oligonucleotides of the invention are
CC useful for reducing hyperproliferation of human cells. The antisense
CC oligonucleotides are also useful for treating: hyperproliferative
CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
CC restenosis. The antisense oligonucleotides are also useful for modulating
CC apoptosis, and for increasing expression of p21. The present DNA sequence
CC represents a human mdm2 gene antisense oligonucleotide of the invention.
CC The present sequence contains 2'-methoxyethoxy-residues and has a
CC phosphorothioate backbone.
XX
XX Sequence 20 BP; 1 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 243 CTCGACGCGGAAACGAG 262
Db 20 CTCGACGCGGAAACCCCG 1
RESULT 207
AAF48868
ID AAF48868 standard; DNA; 15 BP.
XX
XX AAF48868;
AC
XX
XX 30-MAR-2001 (first entry)
DT
XX
XX IGFBP3 oligonucleotide #2288.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200078341-A1.
PN
XX
XX 28-DEC-2000.
PD
XX
XX 21-JUN-2000; 2000WO-AU000693.
PF
XX
XX 21-JUN-1999; 99US-0140345P.
PR
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
PA
XX
XX Wraight CJ, Werther GA, Edmondson SR;
PI

```

```

DR WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 59; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC P45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
XX Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1643 CTGCGCTGCTGCAGA 1657
Db 1 CTGCGCTGCTGCAGA 15
RESULT 208
AAV70949/c
ID AAV70949 standard; DNA; 19 BP.
XX
XX AAV70949;
AC
XX
XX 04-FEB-1999 (first entry)
DT
XX
XX PCR primer used to amplify the p53 gene.
DE
XX
XX MGE tumour-specific antigen gene; disseminated tumour cell;
XX prostate cancer; non-small or small lung cancer; sarcoma;
XX malignant melanoma; breast cancer; colorectal cancer;
XX tumour adjuvant vaccine; p53; PCR primer; ss.
XX
XX Synthetic.
OS
XX
XX Homo sapiens.
XX
XX WO9846788-A2.
PN
XX
XX 22-OCT-1998.
PD
XX
XX 09-APR-1998; 98WO-EP002081.
PF
XX
XX 11-APR-1997; 97EP-00106026.
PR
XX
XX (MICR-) MICROMET GMBH.
PA
XX
XX Kufer P, Zippelius A;
PI
XX
XX WPI; 1998-594590/50.
DR
XX
XX New MAGE-derived primers detecting disseminated tumour cells - hybridise
PT to nucleic acid complementary to the mRNA of a gene encoding a MAGE
PT tumour-specific antigen, used for tumour adjuvant vaccines.
XX
XX Example 3; Page 26; 65pp; English.
PS

```



XX PCR primers AAV70948-49 are used to amplify the p53 gene in a RT-PCR  
 CC reaction. The specification describes primers specific for MAGE genes  
 CC which are used for detecting disseminated tumour cells which indicate a  
 CC cancerous condition, such as a condition related to prostate cancer, non-  
 CC small or small lung cancer, sarcoma, malignant melanoma, breast cancer or  
 CC colorectal cancer. The PCR products of this detection can be used to  
 CC prepare a tumour adjuvant vaccine  
 XX

Sequence 19 BP; 4 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 15; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 335 TGTTCCGAGAGCTGA 349  
 Db 15 TGTTCCGAGAGCTGA 1

## RESULT 209

AAAD16176  
 ID AAD16176 standard; DNA; 19 BP.

AC AAD16176;

DT 19-NOV-2001 (first entry)

DE *Listeria* sp. Identifying PCR upper primer.

XX Cell isolation; bacterial cell; non-specific ligand; eukaryotic parasite;  
 KM PCR primer; ss.

OS *Listeria* sp.

PN MO200153525-A2.

PD 26-JUL-2001.

PF 22-JAN-2001; 2001MO-GB000240.

PR 21-JAN-2000; 2000GB-00001450.

PA (GENP-) GENPOINT AS.  
 (GARD/) GARDNER R.

PI Refsesh UH, Kolpus T;

DR WPI; 2001-541431/60.

PT Isolating cells from a sample, particularly bacterial cell, comprises  
 binding the cells to a solid support by means of a non-specific ligand  
 PT immobilized on the solid support.

PS Example 2; Page 29; 77pp; English.

XX The present invention relates to a method for isolating cells from a  
 CC sample comprising binding the cells to a solid support using a non-  
 CC specific ligand immobilised on the solid support. The method is useful  
 CC for isolating a wide variety of microorganisms, specifically bacteria, in  
 CC a sample. The method may also be used in the isolation of eukaryotic  
 CC parasites, particularly those which are able to bind the complex  
 CC polysaccharides found on human cell, to isolate simultaneously bacteria  
 CC and other types of microorganism, such as algae, protozoa, fungi or  
 CC viruses, or to capture all types of white blood cells from a blood or  
 CC blood derived sample, from bone marrow or any tissue or fluid containing  
 CC white blood cells. The present sequence is a PCR primer which is used for  
 CC identification of isolated bacteria

Sequence 19 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 1 Other;

Query Match 0.7%; Score 15; DB 1; Length 19;  
 Best Local Similarity 88.2%; Pred. No. 1.5e+02;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1971 GATCCGAAACCGTGG 1987  
 Db 1 GWTCTGAAACCGTGTG 17

## RESULT 210

AAAF89335  
 ID AA89335 standard; DNA; 19 BP.

AC AA89335;

DT 10-DEC-2001 (first entry)

DE Sample member clustering method related human DNA PCR primer #72.

XX Cluster; hierarchical clustering algorithm; population based study;  
 KM clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;  
 KM SNP; single nucleotide polymorphism; ss.

OS *Homo sapiens*.

PN MO200129257-A2.

PD 26-APR-2001.

PF 20-OCT-2000; 2000MO-IB001632.

PR 22-OCT-1999; 99US-0161231P.

PR 07-JUL-2000; 2000US-0216897P.

PA (GEST ) GENSET.

PI Schork N, Skierczynski B;

DR WPI; 2001-316248/33.

PT Genetic clustering by distributing members into optimal numbers of  
 PT clusters determined by a hierarchical clustering algorithm or by paired-  
 PT pair analysis of homozygous pairs in clusters got from non-hierarchical  
 PT clustering.

PS Claim 61; Page 89; 100pp; English.

XX The present invention describes methods of clustering members of a  
 CC sample, involving applying a hierarchical clustering algorithm to the  
 CC sample members, determining the optimal number of clusters based on this  
 CC and distributing the sample members into clusters using non-hierarchical  
 CC clustering. The methods are useful in population based studies such as  
 CC clinical trials, DNA fingerprinting and genetic profile analyses. The  
 CC present sequence was used to demonstrate the method of the invention

Sequence 19 BP; 10 A; 3 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 15; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2185 CTCATGAGAGAAAAG 2199  
 Db 1 CTCATGAGAGAAAAG 15

## RESULT 211

AAAF62952  
 ID AA89335 standard; DNA; 20 BP.

AC AA89335;

DT 08-MAY-2001 (first entry)

DE Mouse PEPCK-cytosolic antisense oligonucleotide ISIS 113352.

```

XX  Mouse; antiinflammatory; cytostatic; antisense gene therapy;
KM  phosphoenol pyruvate carboxykinase-cytosolic; PEPCK-cytosolic; infection;
KM  inflammation; tumour formation; phosphorothioate; ss.
XX
OS  Mus musculus.
XX
PN  US6187545-B1.
XX
PD  13-FEB-2001.
XX
PF  21-JAN-2000; 2000US-00488671.
XX
PR  21-JAN-2000; 2000US-00488671.
XX
PA  (ISIS-) ISIS PHARM INC.
XX
PI  McKay R, Butler MM, Wyatt J, Cowseert LM;
XX  WPI; 2001-190979/19.
XX
PT  Antisense compound capable of modulating the expression of phosphoenol
PT  pyruvate carboxykinase-cytosolic, useful for preventing or delaying
PT  infection, inflammation or tumor formation.
XX
PS  Claim 1; Col 44; 64pp; English.
XX
CC  The present sequence is one of a number of antisense compounds of up to
CC  30 nucleobases in length that are capable of inhibiting the expression of
CC  phosphoenol pyruvate carboxykinase-cytosolic (PEPCK-cytosolic). The
CC  antisense compounds are useful for inhibiting the expression of PEPCK-
CC  cytosolic in cells or tissues. They are commonly used as research
CC  reagents and in diagnostics, e.g. to elucidate the function of particular
CC  genes. They are also useful for distinguishing between functions of
CC  various members of a biological pathway and for research use. The
CC  antisense compounds are also useful prophylactically, e.g. to prevent or
CC  delay infection, inflammation or tumour formation. The present sequence
CC  is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
CC  deoxy gap
XX
SQ  Sequence 20 BP; 9 A; 5 C; 5 G; 1 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      830 AACGAGACGACGACG 844
      |||
      3 AACGAGACGACGACG 17

RESULT 212
AAD05948/c
ID  AAD05948 standard; DNA; 20 BP.
XX
AC  AAD05948;
XX
DT  31-JUL-2001 (first entry)
XX
DE  Human diacylglycerol kinase-zeta intron 13/exon 14 junction sequence.
XX
KM  Human; catalyst; diacylglycerol; DAG; phosphatidic acid; DAG modulator;
KM  diacylglycerol kinase zeta; DGK; ds.
XX
OS  Homo sapiens.
XX
FH  Key
FH  Intron
FT  1. .10
FT  /*tag= a
FT  /number= 13
FT  /partial
FT  11. .20
FT  exon
FT  /*tag= b

```

```

FT  /number= 14
FT  /partial
XX
PN  US6221658-B1.
XX
PD  24-APR-2001.
XX
PF  25-AUG-1999; 99US-00382911.
XX
PR  22-APR-1996; 96US-0016210P.
XX  22-APR-1997; 97US-00841483.
XX
PA  (UTAH ) UNIV UTAH RES FOUND.
XX
PI  Prescott SM, Bunting M, Tang W, Topham M;
XX  WPI; 2001-327248/34.
XX
DR  WPI; 2001-327248/34.
XX
XX
XX  New DNAs of the human diacylglycerol kinase, useful for modulating the
XX  levels of diacylglycerol kinase in cells to catalyze the conversion of
XX  diacylglycerol to phosphatidic acid, therefore increasing phosphatidic
XX  acid levels.
XX
PS  Disclosure; Col 17-18; 74pp; English.
XX
CC  The patent discloses novel human diacylglycerol kinase (DGK) isoforms
CC  namely diacylglycerol kinase epsilon, diacylglycerol kinase zeta,
CC  diacylglycerol kinase kinase zeta-2 and their corresponding cDNAs. Human
CC  diacylglycerol kinase DNA is useful for coding human diacylglycerol
CC  kinase, which is useful for catalyzing the conversion of diacylglycerol
CC  to phosphatidic acid. In particular, the human diacylglycerol kinase and
CC  its DNA are useful for decreasing intracellular levels of diacyl-
CC  glycerol (DAG) and for increasing intracellular levels of phosphatidic
CC  acid in cells. The present DNA sequence is the exon/intron junction
CC  sequence of human diacylglycerol kinase (DGK) zeta gene
XX
SQ  Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1665 CCAGCCACCGGGGG 1679
      |||
      19 CCAGCCACCGGGGG 5

RESULT 213
AAV44610/c
ID  AAV44610 standard; DNA; 18 BP.
XX
AC  AAV44610;
XX
DT  24-NOV-1998 (first entry)
XX
DE  Human uncoupling protein-2 UCP2 gene reverse primer hUCP2g.e6r2.
XX
XX  Uncoupling protein-2; UCP2 gene; human; respiration; thermogenesis;
XX  obesity; hypernatremia; glucose intolerance; diabetes; syndrome X;
XX  hyperthermia; wasting; cachexia; anorexia; inflammation; fever;
XX  hyperthermia; gene therapy; diagnosis; PCR; primer; ss.
XX
OS  Synthetic.
XX  Homo sapiens.
XX
PN  W09831396-A1.
XX
PD  23-JUL-1998.
XX
PF  22-APR-1997; 97MO-US006864.
XX
PR  15-JAN-1997; 97US-0034960P.
XX

```



```

XX PF 29-OCT-1999; 99WO-US025431.
XX PR 30-OCT-1998; 98US-0106308P.
XX PR 26-MAY-1999; 99US-0136078P.
XX PA (CELL-) CELLOMICS INC.
XX PI Giuliano KA, Bright G, Olson K, Burroughs-Tencza S,
XX DR WPI; 2000-365644/31.
XX DR P-PSDB; AAY79581.
XX PT Recombinant nucleic acid encoding a protease biosensor useful for
XX PT fluorescence based cell and molecular biochemical assays for drug
XX PT discovery comprising three operably linked nucleic acid sequences.
XX PS Claim 5; Fig 29A; 218pp; English.
XX XX
XX CC The present sequence is that of DNA encoding the K73 epitope (see
XX CC AAY79581). The DNA can be used in a claimed recombinant nucleic acid
XX CC encoding a protease biosensor. The nucleic acid (see AA27627-43)
XX CC comprises: (1) a sequence (see AAA27568-76) encoding at least 1
XX CC detectable polypeptide signal, such as K73; (2) a sequence (see AAA27577-
XX CC 611) that encodes at least 1 protease recognition site; and (3) a
XX CC sequence (see AAA27611-26) that encodes at least 1 reactant target
XX CC sequence. An expression vector, a genetically engineered host cell and a
XX CC recombinant protease biosensor are also claimed. A claimed method for
XX CC identifying compounds that modify protease activity in a cell involves
XX CC contacting a host cell that possesses the recombinant protease biosensor
XX CC with a test compound, and determining the protease biosensor distribution
XX CC in the host cell, where changes in the distribution of the protease
XX CC biosensor are correlated with modification of protease activity by the
XX CC test compound. Claimed kits for identifying compounds that modify
XX CC the protease activity in a host cell include the recombinant nucleic acid, or
XX CC the recombinant protease biosensor, or the vector, or the host cell. The
XX CC protease biosensor is useful in high content screens to detect in vivo
XX CC activation of enzymatic activity, and to identify specific activity based
XX CC on cleavage of a known recognition motif
XX SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
Db 18 TGTTCCTGTCCTGCTGG 1
RESULT 216
ABST1488/c
ID ABST1488 standard; DNA; 18 BP.
XX AC ABST1488;
XX DT 27-NOV-2002 (first entry)
XX DE DNA encoding protease biosensor signal sequence #3.
XX KM Detection; classification; identification; toxin detection; protease;
XX KM ADP-ribosylating toxin; cytotoxic phospholipase; exfoliative toxin;
XX KM toxic threat agent; ds.
XX OS Synthetic.
XX PN US6416959-B1.
XX PD 09-JUL-2002.
XX PF 25-FEB-2000; 2000US-00513783.
XX XX

```

```

PR 27-FEB-1997; 97US-00810983.
PR 27-FEB-1998; 98US-00031271.
PR 26-FEB-1999; 99US-0122152P.
PR 08-MAR-1999; 99US-0123399P.
PR 12-JUL-1999; 99US-00352171.
PR 31-AUG-1999; 99US-0151797P.
PR 17-SEP-1999; 99US-00398965.
PR 29-OCT-1999; 99US-00430656.
PR 01-DEC-1999; 99US-0168408P.
XX PA (GIULI/) GIULIANO K.
XX PA (KAPU/) KAPUR R.
XX PI Giuliano K, Kapur R;
XX DR WPI; 2002-634730/68.
XX DR P-PSDB; ABG94441.
XX XX
XX PT Automated cell-based toxin detection, classification, and/or
XX PT identification by treating cells involves use of three classes of
XX PT luminescent reporter molecules such as detectors, classifiers or
XX PT identifiers.
XX PS Example 10; Fig 29A-1; 214pp; English.
XX XX
XX CC The invention describes methods of automated detection, classification
XX CC and identification comprising treating cells containing luminescent
XX CC reporter molecules (I) in array of locations with a test substance, where
XX CC (1) are detectors, classifiers or identifiers, imaging cells in each
XX CC location to obtain luminescent signals and converting optical information
XX CC into digital data to interpret presence of toxins in the test substance.
XX CC The method are useful for detection of toxins chosen from proteases, ADP-
XX CC ribosylating toxins, cytotoxic phospholipases, and exfoliative toxins.
XX CC Three classes of cell-based luminescent reporter molecules such as
XX CC detectors, classifiers and identifiers are described and serve as
XX CC reporters of toxic threat agents. The first two levels of
XX CC characterisation ensure a rapid readout of toxin class without
XX CC sacrificing the ability to detect many new mutant toxins or dissect
XX CC several complex mixtures of known toxins. This sequence encodes a
XX CC protease biosensor related signal sequence used in the cell-based
XX CC screening system
XX SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTGCTGG 583
Db 18 TGTTCCTGTCCTGCTGG 1
RESULT 217
ADC2244/c
ID ADC2244 standard; DNA; 18 BP.
XX AC ADC2244;
XX DT 18-DEC-2003 (first entry)
XX DE K73 epitope nucleotide sequence SEQ ID NO:293.
XX KM recombinant fusion protein; fusion protein; binding; detection;
XX KM localisation domain; binding domain;
XX KM subcellular compartment localisation; gene; ds.
XX OS Synthetic.
XX PN WO2003012068-A2.
XX PD 13-FEB-2003.
XX PF
XX XX

```

PF 01-AUG-2002; 2002MO-US024572.  
 XX  
 PR 01-AUG-2001; 2001US-0309395P.  
 PR 13-DEC-2001; 2001US-0341589P.  
 PA (CELL-) CELLOMICS INC.  
 XX  
 PI Bright G, Premkumar DR, Chen Y;  
 XX  
 DR WPI; 2003-248174/24.  
 DR P-PSDB; ADC22443.  
 XX  
 PT New recombinant fusion protein comprising detection and first  
 PT localization domains and a binding domain for the molecule of interest,  
 PT useful for detecting binding of a molecule of interest.  
 XX  
 PS Disclosure; SEQ ID NO 293; 101pp; English.  
 XX  
 CC The present invention describes a recombinant fusion protein (1) for  
 CC detecting binding of a molecule of interest. (1) comprises: (a) a  
 CC detection domain; (b) a first localisation domain; and (c) a binding  
 CC domain for the molecule of interest. The detection domain, the first  
 CC localisation domain and the binding domain for the molecule of interest  
 CC constituting the recombinant fusion protein for detecting binding of a  
 CC molecule of interest are operably linked. The binding domain for the  
 CC molecule of interest is separated from the first localisation domain by 0  
 CC -20 amino acid residues. The first localisation domain and the binding  
 CC domain for the molecule of interest both do not occur in a single non-  
 CC recombinant protein with the same spacing as in the recombinant fusion  
 CC protein for detecting binding of a molecule of interest. Also described:  
 CC (1) a recombinant nucleic acid encoding the recombinant fusion protein;  
 CC (2) a recombinant expression vector comprising the nucleic acid control;  
 CC sequences operably linked to the recombinant nucleic acid molecule; (3) a  
 CC genetically engineered host cell transfected with the recombinant  
 CC expression vector; (4) a kit for detecting binding of the molecule of  
 CC interest; and (5) a method for identifying compounds that alter the  
 CC binding of the molecule of interest. The recombinant fusion protein is  
 CC useful for detecting binding of a molecule of interest. The recombinant  
 CC fusion protein eliminates the need to construct two or more chimeric  
 CC proteins and enables the monitoring of biochemical events in live, intact  
 CC or fixed cells. The present sequence is used in the exemplification of  
 CC the present invention.  
 XX  
 SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;  
 QY  
 Query Match 0.7%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.5e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 DB 566 TGTTCCTGCTCGTGG 583  
 18 TGTTCCTGCTCGTGG 1  
 RESULT 218  
 ID ADC18351/c  
 AC ADC18351 standard; DNA; 18 BP.  
 XX  
 AC ADC18351;  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE K13 epitope DNA.  
 XX  
 KW db; cell based toxin; luminescent reporter molecule; biosensor;  
 KM microchip; drug discovery; MAP4; epitope; affinity tag;  
 XX protease recognition site; caspase; target domain.  
 OS Synthetic.  
 XX  
 PN US2003096322-A1.  
 XX  
 PD 22-MAY-2003.

XX  
 PE 19-MAR-2002; 2002US-00100957.  
 XX  
 PR 27-FEB-1997; 97US-00810983.  
 PR 27-FEB-1998; 98US-00031271.  
 PR 26-FEB-1999; 99US-0122152P.  
 PR 08-MAR-1999; 99US-0123399P.  
 PR 12-JUL-1999; 99US-00352171.  
 PR 31-AUG-1999; 99US-0151787P.  
 PR 17-SEP-1999; 99US-00398965.  
 PR 29-OCT-1999; 99US-00430656.  
 PR 01-DEC-1999; 99US-0168408P.  
 PR 25-FEB-2000; 2000US-00513783.  
 XX  
 PA (CELL-) CELLOMICS INC.  
 XX  
 PI Giuliano K, Kapur R;  
 XX  
 DR WPI; 2003-786988/74.  
 DR P-PSDB; ADC18352.  
 XX  
 PT Cell based toxin characterization method for e.g. in drug discovery  
 PT paradigm, involves treating cells possessing luminescent reporter  
 PT molecules with fluorescence based molecules reagents to detect presence  
 PT of toxins.  
 XX  
 PS Example 10; SEQ ID NO 39; 98pp; English.  
 XX  
 CC The invention relates to characterizing cell based toxins, where the cell  
 CC possessing luminescent reporter molecules (biosensors) are provided on a  
 CC microchip, and are treated with fluorescence based molecular reagents.  
 CC The cells are photographed with fluorescence optics, and the optical  
 CC information is converted into digital data. The presence of the toxin in  
 CC a reagent, is detected using the digital data, based on changes in the  
 CC localisation, distribution structure of identifier, detector and  
 CC classifier in each cell. Also included are a computer readable storage  
 CC medium storing a cell based toxin characterisation program, and a kit for  
 CC cell based toxin detection. The method is used for characterising or  
 CC detecting a biological cell based toxin that affect particular biological  
 CC functions and for preparing molecular biochemical arrays for new drug  
 CC discovery paradigm. It is also used in automated DNA sequencing, PCR  
 CC application, positional cloning, hybridisation arrays and bioinformatics  
 CC using cell based scanning and screening system. The method improves the  
 CC target validation and candidate optimisation by combining many cell  
 CC screening formats with fluorescence based molecular reagents, thereby  
 CC resulting in increased quantity and speed of data collection, shortened  
 CC cycle times and faster evaluation of promising drug candidates. The  
 CC method also provides increased throughput while decreasing the volumes of  
 CC reagent and test compounds required in each assay. The biosensor  
 CC comprises a signal component (fluorescent protein (fused e.g. MAP4,  
 CC tethering it to microtubules) or detectable signal (epitope or affinity  
 CC tag)), a protease recognition site (e.g. for a caspase protein) and a  
 CC target domain (localising the biosensor to a particular cellular  
 CC compartment). The present sequence encodes a signal component of a  
 CC biosensor of the invention.  
 XX  
 SQ Sequence 18 BP; 9 A; 7 C; 2 G; 0 T; 0 U; 0 Other;  
 QY  
 Query Match 0.7%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.5e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 DB 566 TGTTCCTGCTCGTGG 583  
 18 TGTTCCTGCTCGTGG 1  
 RESULT 219  
 ID AAV17327  
 AC AAV17327 standard; DNA; 19 BP.  
 XX  
 AC AAV17327;  
 XX

DT 02-JUN-1998 (first entry)  
 XX  
 DE Primer used in construction of antibody of the invention.  
 XX  
 KM Anti-CEA antibody; carcinoembryonic antigen; 806.077 Ab; cancer therapy;  
 KM cancer diagnosis; complementarity determining region; PCR primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9742329-A1.  
 XX  
 PD 13-NOV-1997.  
 XX  
 PF 29-APR-1997; 97WO-GB001165.  
 XX  
 PR 04-MAY-1996; 96GB-00009405.  
 PR 14-FEB-1997; 97GB-00003103.  
 XX  
 PA (ZENE ) ZENECA LTD.  
 XX  
 PI Copley CG, Edge MD, Emery SC;  
 XX  
 DR WPI; 1997-558987/51.  
 XX  
 PT Anti-carcinoembryonic antigen antibody 806.077 Ab - used for diagnosis  
 PT and therapy of cancer.  
 XX  
 PS Example 48; Page 170; 208pp; English.  
 XX  
 CC This sequence is a primer that was used to construct the antibody of the  
 CC invention. The antibody is an anti-CEA (carcinoembryonic antigen)  
 CC antibody (806.077 Ab). Host cells or transgenic organisms transformed  
 CC with DNA encoding the antibody, are used to make the antibody or  
 CC conjugate. The conjugate is used in a medicament suitable for intravenous  
 CC administration. The conjugate can be used for cancer therapy, selectively  
 CC killing tumour cells. The antibody can be used for in vivo or in vitro  
 CC diagnosis of cancer  
 CC  
 SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;  
 XX  
 XX  
 Query Match 0.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1645 GCCCTGCTGCAGACTCTG 1662  
 | | | | | | | | | | | | | | | | | | | | | |  
 Db 2 GACCTGCTGCAGACTCTG 19  
 RESULT 220  
 AAV41791  
 ID AAV41791 standard; DNA; 19 BP.  
 XX  
 AC AAV41791;  
 XX  
 DT 20-NOV-1998 (first entry)  
 XX  
 DE Human pancreatic carboxypeptidase B primer 677.  
 XX  
 KM ss; primer; PCR; amplification; human; pancreatic carboxypeptidase B;  
 KM insulin; protein sequencing; prodrug therapy.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9835988-A1.  
 XX  
 PD 20-AUG-1998.  
 XX  
 PF 10-FEB-1998; 98WO-GB000415.  
 XX  
 PR 14-FEB-1997; 97GB-00003104.  
 PR 18-OCT-1997; 97GB-00022003.

PR 29-OCT-1997; 97GB-00022727.  
 XX  
 PA (ZENE ) ZENECA LTD.  
 XX  
 PI Edge MD;  
 XX  
 DR WPI; 1998-467168/40.  
 XX  
 XX New modified pro-domain of carboxy-peptidase B - enhances expression of  
 PT co-expressed proteins for production of recombinant carboxy-peptidase or  
 PT its fusions with antibodies, used, e.g. in enzyme prodrug therapy.  
 XX  
 PS Example 1; Page 51; 83pp; English.  
 XX  
 CC The primers AAV41785-V41794 were used in the cloning of human pancreatic  
 CC carboxypeptidase B (CPB). The co-expression of a modified pro-domain of  
 CC CPB from a separate gene enhances recombinant expression. This process  
 CC can be used to produce recombinant CPB in eukaryotic cells, or fusions of  
 CC CPB with antibody chains. CPB is used in insulin production and protein  
 CC sequencing, while its fusions with antibody are useful in antibody-  
 CC directed enzyme prodrug therapy. The Modified pro-domain provide  
 CC increased yields of recombinant CPB, possibly by protecting the C-  
 CC terminus against enzymatic degradation or by increasing intracellular  
 CC trafficking  
 CC  
 SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;  
 XX  
 XX  
 Query Match 0.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1645 GCCCTGCTGCAGACTCTG 1662  
 | | | | | | | | | | | | | | | | | | | | | |  
 Db 2 GACCTGCTGCAGACTCTG 19  
 RESULT 221  
 AB272149/C  
 ID AB272149 standard; DNA; 19 BP.  
 XX  
 AC AB272149;  
 XX  
 DT 03-APR-2003 (first entry)  
 XX  
 DE Gene 216 SSCP detection primer SEQ ID NO 121.  
 XX  
 KM Human; Gene 216; chromosome 20p13-p12; anasthetic; anorectic;  
 KM antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;  
 KM obesity; inflammatory bowel disease; primer; ss.  
 XX  
 OS Synthetic.  
 OS  
 PN WO200178894-A2.  
 XX  
 PD 25-OCT-2001.  
 XX  
 PF 13-APR-2001; 2001WO-US012245.  
 XX  
 PR 13-APR-2000; 2000US-00548797.  
 XX  
 PA (GENO-) GENOME THERAPEUTICS CORP.  
 XX  
 PI Keith T;  
 XX  
 DR WPI; 2001-639428/73.  
 XX  
 PT Isolated genes (Gene 216) from human chromosome 20p13-p12 and the  
 PT proteins they encode, useful for the prevention, diagnosis and treatment  
 PT of asthma, obesity and inflammatory bowel disease.  
 XX  
 PS Example 10; Page 148; 520pp; English.  
 CC The invention relates to isolated genes (Gene 216) from human chromosome

CC 20p13-p12 and the proteins they encode. The nucleic acids and proteins  
 CC may be used in the prevention, diagnosis and treatment of diseases  
 CC associated with inappropriate Gene 216 expression. For example, the  
 CC nucleic acids (or vectors) and proteins may be used to treat disorders  
 CC associated with decreased expression by rectifying mutations or deletions  
 CC in a patient's genome that affect the activity of gene 216 by expressing  
 CC inactive proteins or to supplement the patient's own production of Gene  
 CC 216 proteins. Additionally, the nucleic acids may be used to produce the  
 CC secreted Gene 216 protein, by inserting the nucleic acids into a host  
 CC cell and culturing the cell to express the protein. The nucleic acids and  
 CC complementary sequences may also be used as DNA probes in diagnostic  
 CC assays to detect and quantitate the presence of similar nucleic acid  
 CC sequences in samples and therefore which patients may be in need of  
 CC restorative therapy. The Gene 216 protein may also be used as antigens in  
 CC the production of antibodies against Gene 216 and in assays to identify  
 CC modulators of Gene 216 expression and activity. The anti-Gene 216  
 CC antibodies and antagonists may also be used to down regulate expression  
 CC and activity. The anti-Gene 216 antibodies may also be used as diagnostic  
 CC agents for detecting the presence of Gene 216 proteins in samples (e.g.,  
 CC by enzyme linked immunosorbant assay or ELISA). Disorders that may be  
 CC prevented, diagnosed and/or treated by the above methods include, for  
 CC example asthma, obesity and inflammatory bowel disease. The present  
 CC invention is that of a Gene 216 related primer used in examples of the  
 CC invention. The primers are used in the physical mapping of the gene  
 CC (ABZ72067-ABZ72088), polymorphism identification using single strand  
 CC conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),  
 CC sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)

XX SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGGACACGTCACCT 884

Db 19 AGAGGACACGACGACCT 2

RESULT 222  
 ABX75002/c  
 ID ABX75002 standard; DNA; 19 BP.

XX AC ABX75002;

XX DT 25-MAR-2003 (first entry)

XX DE Human gene 216 polymorphism detection PCR primer #59.

XX KM Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;  
 KM anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;  
 KM gene therapy; respiratory disease; asthma; obesity; PCR;  
 KM bronchial hyper-responsiveness; chronic obstructive pulmonary disease;  
 KM adult respiratory distress syndrome; inflammatory bowel syndrome.

XX OS Homo sapiens.

XX PN WO200283077-A2.

XX PD 24-OCT-2002.

XX PF 15-APR-2002; 2002WO-US012063.

XX PR 13-APR-2001; 2001US-00834597.

XX PR 13-APR-2001; 2001WO-US012245.

XX PA (SCHE ) SCHERING CORP.

XX PI Keith T, Little RD, Van Berdeewegh P, Dupuis J, Del Mastro RG,

XX PI Simon J, Allen K, Pandit S,

XX DR WPI; 2003-092960/08.

XX PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or  
 PT treating a disorder, such as asthma, bronchial hyper-responsiveness,  
 PT chronic obstructive pulmonary disease, obesity or inflammatory bowel  
 PT syndrome.

XX PS Example 10; Page 154; 650pp; English.

XX CC This invention relates to a novel isolated nucleic acid, gene 216,  
 CC identified from human chromosome 20p13-p12. The invention also discloses  
 CC regions of the 216 gene that contain single nucleotide polymorphisms  
 CC (SNPs) which may be used as markers for disease susceptibility or  
 CC severity. The nucleotides of the invention may have antiasthmatic,  
 CC antiinflammatory or anorectic activities and may be used in gene therapy.  
 CC The nucleic acids, antibodies or its fragments are useful for diagnosing,  
 CC preventing or treating a disorder, such as respiratory diseases (e.g.,  
 CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary  
 CC disease or adult respiratory distress syndrome), obesity, or inflammatory  
 CC bowel syndrome. The nucleic acids are also useful for identifying  
 CC increased susceptibility of a subject to the disorders mentioned. The  
 CC nucleic acids can also be used as primers and templates for the  
 CC recombinant production of disorder-associated peptides or polypeptides,  
 CC for chromosome and gene mapping, or for tissue distribution studies. The  
 CC present sequence represents a gene 216 specific PCR primer used in the  
 CC scope of the invention

XX SQ Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGGACACGTCACCT 884

Db 19 AGAGGACACGACGACCT 2

RESULT 223  
 ADA25739/c  
 ID ADA25739 standard; RNA; 19 BP.

XX AC ADA25739;

XX DT 20-NOV-2003 (first entry)

XX DE Human REL-A short interfering nucleic acid SEQ ID NO:87.

XX KM short interfering nucleic acid; siNA; nuclear factor kappa B; NF-kappaB;  
 KM RNA interference; vasotropic; noctropic; antiparkinsonian;  
 KM neuroprotective; cyrotatic; antiinflammatory; antiallergic; virocidic;  
 KM anti-HIV; immunosuppressive; anticonvulsant; nephrotoxic; gene therapy;  
 KM modulation; inhibition; restenosis; central nervous system lesion;  
 KM Alzheimer's disease; Parkinson's disease; Huntington's disease; epilepsy;  
 KM dementia; amyotrophic lateral sclerosis; cancer;  
 KM polycystic kidney disease; inflammatory disease; allergic disease;  
 KM viral infection; HIV; autoimmune disease; transplant rejection; ribozyme;  
 KM human; V-rel reticuloendotheliosis viral oncogene homologue A; REL-A;  
 KM nuclear factor; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO2003070970-A2.

XX PD 28-AUG-2003.

XX PF 20-FEB-2003; 2003WO-US004951.

XX PR 20-FEB-2002; 2002US-0358580P.

XX PR 11-MAR-2002; 2002US-0363124P.

XX PR 06-JUN-2002; 2002US-0386782P.

XX PR 29-AUG-2002; 2002US-0406784P.

XX PR 05-SEP-2002; 2002US-0408378P.







AC ADA25493;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PKC-alpha short interfering nucleic acid SEQ ID NO:224.  
 XX  
 KM short interfering nucleic acid; siNA; protein kinase C alpha; PKC-alpha;  
 KM RNA interference; cytostatic; vasotropic; nephrotropic; modulation;  
 KM inhibition; cancer; breast cancer; ovarian cancer; lung cancer;  
 KM prostate cancer; glioblastoma; proliferative disease; restenosis;  
 KM polycystic kidney disease; human; ribozyme; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO2003070983-A1.  
 XX  
 PD 28-AUG-2003.  
 XX  
 PF 11-FEB-2003; 2003WO-US004034.  
 XX  
 PR 20-FEB-2002; 2002US-0358580P.  
 PR 11-MAR-2002; 2002US-0363124P.  
 PR 06-JUN-2002; 2002US-0386782P.  
 PR 29-AUG-2002; 2002US-0406784P.  
 PR 05-SEP-2002; 2002US-0408378P.  
 PR 09-SEP-2002; 2002US-0409293P.  
 PR 18-SEP-2002; 2002US-0411707P.  
 PR 15-JAN-2003; 2003US-0440129P.  
 PA (SIRN-) SIRNA THERAPEUTICS INC.  
 PI Mcswiggen J, Beigelman L;  
 XX  
 DR WPI; 2003-679891/64.  
 XX  
 PT New short interfering nucleic acid, useful e.g. for treatment and  
 PT diagnosis of cancer and restenosis, downregulates expression of the  
 PT protein kinase C-alpha gene.  
 XX  
 PS Example 3; Page 120; 143pp; English.  
 XX  
 CC The present invention describes a short interfering nucleic acid (siNA)  
 CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)  
 CC gene by RNA interference. Also described: (1) a siNA that modulates  
 CC expression and/or activity of genes for other isoforms of PKC or genes  
 CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of  
 CC siNA; (3) conjugates and/or complexes of siNA; and (4) vectors that  
 CC express siNA. The siNA sequences have cytostatic, vasotropic and  
 CC nephrotropic activities, and can be used in the modulation (inhibition)  
 CC of expression of the PKC-alpha gene by RNA interference. The siNA can be  
 CC used to modulate expression of PKC-alpha genes. They are potentially  
 CC useful in treating a variety of cancers including e.g. breast cancer,  
 CC cancer of the head and neck, ovarian cancer, lung cancer, prostate  
 CC cancer, and glioblastoma and for treating other proliferative diseases  
 CC and conditions, such as restenosis and polycystic kidney disease. The  
 CC siNA may also be useful for diagnosis, drug screening, target  
 CC identification and validation, genetic engineering, studying gene  
 CC function, and for gene mapping (e.g. of single-nucleotide polymorphisms).  
 CC The present sequence represents a human PKC-alpha siNA, which is used in  
 CC the exemplification of the present invention.  
 XX  
 SO Sequence 19 BP; 4 A; 10 C; 5 G; 0 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 226  
 ADA25368  
 ID ADA25368 standard; RNA; 19 BP.  
 XX  
 AC ADA25368;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PKC-alpha short interfering nucleic acid target SEQ ID NO:99.  
 XX  
 KM short interfering nucleic acid; siNA; protein kinase C alpha; PKC-alpha;  
 KM RNA interference; cytostatic; vasotropic; nephrotropic; modulation;  
 KM inhibition; cancer; breast cancer; ovarian cancer; lung cancer;  
 KM prostate cancer; glioblastoma; proliferative disease; restenosis;  
 KM polycystic kidney disease; human; ribozyme; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO2003070983-A1.  
 XX  
 PD 28-AUG-2003.  
 XX  
 PF 11-FEB-2003; 2003WO-US004034.  
 XX  
 PR 20-FEB-2002; 2002US-0358580P.  
 PR 11-MAR-2002; 2002US-0363124P.  
 PR 06-JUN-2002; 2002US-0386782P.  
 PR 29-AUG-2002; 2002US-0406784P.  
 PR 05-SEP-2002; 2002US-0408378P.  
 PR 09-SEP-2002; 2002US-0409293P.  
 PR 18-SEP-2002; 2002US-0411707P.  
 PR 15-JAN-2003; 2003US-0440129P.  
 PA (SIRN-) SIRNA THERAPEUTICS INC.  
 PI Mcswiggen J, Beigelman L;  
 XX  
 DR WPI; 2003-679891/64.  
 XX  
 PT New short interfering nucleic acid, useful e.g. for treatment and  
 PT diagnosis of cancer and restenosis, downregulates expression of the  
 PT protein kinase C-alpha gene.  
 XX  
 PS Example 3; Page 120; 143pp; English.  
 XX  
 CC The present invention describes a short interfering nucleic acid (siNA)  
 CC that downregulates expression of a protein kinase C-alpha (PKC-alpha)  
 CC gene by RNA interference. Also described: (1) a siNA that modulates  
 CC expression and/or activity of genes for other isoforms of PKC or genes  
 CC involved in the PKC pathway; (2) kits for in vitro or in vivo delivery of  
 CC siNA; (3) conjugates and/or complexes of siNA; and (4) vectors that  
 CC express siNA. The siNA sequences have cytostatic, vasotropic and  
 CC nephrotropic activities, and can be used in the modulation (inhibition)  
 CC of expression of the PKC-alpha gene by RNA interference. The siNA can be  
 CC used to modulate expression of PKC-alpha genes. They are potentially  
 CC useful in treating a variety of cancers including e.g. breast cancer,  
 CC cancer of the head and neck, ovarian cancer, lung cancer, prostate  
 CC cancer, and glioblastoma and for treating other proliferative diseases  
 CC and conditions, such as restenosis and polycystic kidney disease. The  
 CC siNA may also be useful for diagnosis, drug screening, target  
 CC identification and validation, genetic engineering, studying gene  
 CC function, and for gene mapping (e.g. of single-nucleotide polymorphisms).  
 CC The present sequence represents a human PKC-alpha siNA target, which is  
 CC used in the exemplification of the present invention.  
 XX  
 SO Sequence 19 BP; 0 A; 5 C; 10 G; 0 T; 4 U; 0 Other;  
 Query Match 0.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 72.2%; Pred. No. 1.6e+02;  
 Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```

Db          2 GCGUGGCGUGUGGCGCUG 19
              ||:|||||:|||||:|
RESULT 227
ADE30297   ID ADE30297 standard; RNA, 19 BP.
XX
XX ADE30297;
DT
XX 29-JAN-2004 (first entry)
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:919.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KM immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KM antipruritic; gastrointestinal; obesity; diabetes; tumour;
KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM psoriasis; inflammatory bowel disease; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
XX WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowira B;
XX
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 919; 164pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipruritic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siNA which is used
CC in the exemplification of the present invention.
XX
XX Sequence 19 BP; 1 A; 10 C; 5 G; 0 T; 3 U; 0 Other;

```

```

Query Match 0.7%; Score 14.6; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 1.6e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Gy 1455 CCCGCGCGCCGCCACCGAG 1472
              ||:|||||:|||||
Db          2 CCGUGGCGUGGCCCGCAG 19
              ||:|||||:|||||
RESULT 228
ADE30088/c ID ADE30088 standard; RNA, 19 BP.
XX
XX ADE30088;
DT
XX 29-JAN-2004 (first entry)
DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:710.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KM cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KM immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KM antipruritic; gastrointestinal; obesity; diabetes; tumour;
KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KM psoriasis; inflammatory bowel disease; drug screening;
KM genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS Synthetic.
XX
XX WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowira B;
XX
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX Example 3; SEQ ID NO 710; 164pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC vectors that express siNA and cells containing these vectors. MAPK siNAs
CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC antiarthritic, antipruritic and gastrointestinal activities. The MAPK
CC siNAs can be used to modulate the expression of MAPK genes, in cells,
CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC and II; a wide range of tumours, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide

```

CC polymorphisms). The present sequence represents a MAPK siNA which is used  
 CC in the exemplification of the present invention.  
 XX  
 CC Sequence 19 BP; 3 A; 5 C; 10 G; 0 T; 1 U; 0 Other;

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Db 1455 CCGCTGCTGCCACCCAG 1472  
 18 CCGTCTGCTGCCACCCAG 1

RESULT 229  
 ABRK16959  
 ID ABRK16959 standard; DNA; 15 BP.  
 AC ABRK16959;  
 XX

DT 26-MAR-2002 (first entry)  
 XX  
 DE Pyridoxal (Pyridoxine, vitamin B6) kinase (PDXK) PCR primer #20.

XX Pyridoxal kinase; pyridoxine; vitamin B6;  
 KM PDXK autoimmune polyglanular disease type 1; transgenic animal;  
 KM gene therapy; allele specific oligonucleotide; ASO; PCR primer; ss.

XX Homo sapiens.

XX WO200190125-A2.

XX 29-NOV-2001.

XX 24-MAY-2001; 2001WO-US016909.

XX 24-MAY-2000; 2000US-0206664P.

XX (GENA-) GENA155ANCE PHARM INC.

XX Chew A, Duda A, Koshy B;

XX WPI; 2002-106169/14.

PT Isolated human pyridoxal (pyridoxine, vitamin B6) kinase polyNTs, useful  
 PT for therapeutic purposes, for studying the expression and function of the  
 PT polyNT, and for expressing pyridoxal protein.  
 XX

PS Claim 17; Page 13; 135pp; English.

XX The invention describes an isolated human pyridoxal (pyridoxine, vitamin  
 CC B6) kinase, (PDXK) polynucleotide. The polynucleotide is useful in  
 CC studying the expression and function of PDXK, and in expressing PDXK  
 CC protein for use in screening for candidate drugs to treat PDXK related  
 CC diseases and for therapeutic purposes. A transgenic animal is useful for  
 CC studying expression of the PDXK isogenes in vivo, for in vivo screening  
 CC and testing of drugs targeted against PDXK protein, and for testing the  
 CC efficacy of therapeutic agents and compounds for autoimmune polyglanular  
 CC disease type 1. The polypeptide is useful for studying the effect of the  
 CC variation on the biological activity of PDXK and the binding affinity of  
 CC candidate drugs targeting PDXK for the treatment of autoimmune  
 CC polyglanular disease type 1. Genotyping and haplotyping is useful for  
 CC improving the efficacy and reliability of several steps in the discovery  
 CC and development of drugs for treating diseases associated with PDXK  
 CC activity, e.g., autoimmune polyglanular disease type 1, to validate PDXK  
 CC as a candidate agent for treating a specific condition or disease  
 CC predicted to be associated with PDXK activity, and in the design of  
 CC clinical trials of candidate drugs. This sequence is one of 37 (see  
 CC ABRK16941-ABRK16977) allele specific oligonucleotide (ASO) PCR primers used  
 CC for detecting PDXK gene polymorphisms, described in the method of the  
 CC invention

XX Sequence 15 BP; 3 A; 4 C; 5 G; 2 T; 0 U; 1 Other;

\*Query Match 0.6%; Score 14.6; DB 1; Length 15;  
 \*Best Local Similarity 93.3%; Pred. No. 1.3e+02;  
 \*Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Query 500 GCGGCTCTGGAACC 514  
 Db 1 GCGGCTCTGGAACC 15

RESULT 230  
 AAQ42677  
 ID AAQ42677 standard; DNA; 17 BP.  
 XX  
 AC AAQ42677;  
 XX

DT 25-MAR-2003 (revised)  
 DT 18-FEB-1999 (first entry)  
 XX

DE PCR primer Clamut-Kan for constructing mycobact'1 integrating plasmid.

XX cytotoxic T-lymphocyte response; transformed Mycobacteria; BCG;  
 KM Mycobacterium smegmatis; vaccine; cell mediated immunity; HIV; pertussis;  
 KM malaria; influenza virus; CTL; herpes virus; ss.

XX Mycobacterium.

XX WO9221374-A1.

XX 10-DEC-1992.

XX 01-JUN-1992; 92WO-US005023.

XX 06-JUN-1991; 91US-00711084.

XX (MED1-) MEDIMUNE INC.

XX Stover CK, Dela Cruz V;

XX WPI; 1992-433378/52.

PT Tetanus vaccination - by provoking an immune response using transformed  
 PT Mycobacteria.  
 XX

PS Example 3; Page 13; 86pp; English.

CC This PCR primer was used with AAQ42678 in order to construct an  
 CC integrating plasmid including mycobacterial promoter expression cassette,  
 CC and the HIV-1 gp120 gene. Plasmid pMV101 was used as template. (updated  
 CC on 25-MAR-2003 to correct PN field.)  
 CC

XX Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Db 1690 TTGATGCGAAGCCCC 1705  
 2 TTGATGCGAAGCCCC 17

RESULT 231  
 AAQ21561  
 ID AAQ21561 standard; DNA; 17 BP.  
 XX  
 AC AAQ21561;  
 XX

DT 03-JUN-1992 (first entry)

DE PCR primer Clamut-Kan for mutagenesis of plasmid pMV101.

XX Polymerase chain reaction; mycobacterial promoter; kanamycin; resistance;

KM BCG; Bacille Calmette-Guerin; site-specific integration; ss.  
 XX Synthetic.  
 OS  
 PN WO9201783-A.  
 XX  
 PD 06-FEB-1992.  
 XX  
 PF 16-JUL-1990; 90US-00553907.  
 XX  
 PR 16-JUL-1990; 90US-00553907.  
 XX  
 PA (YESH ) EINSTEIN A COLLEGE.  
 PA (UPTI-) UNIV OF PITTSBURGH.  
 XX  
 PI Jacobs WR, Hatfull G;  
 XX  
 DR WPI; 1992-064943/08.  
 XX  
 PT DNA site-specific integration into mycobacteria - useful as adjuvant in  
 PT vaccines and as therapeutic agent for malaria, influenza, herpes and  
 PT human immunodeficiency virus.  
 XX  
 PS Example 3; Page 19; 82pp; English.  
 XX  
 CC PCR mutagenesis was performed on plasmid pMV101 (see AAR20991-3) to  
 CC remove the ClaI and HindIII sites in the aph gene. Primer ClaMut-Kan was  
 CC used with primer HindRmut-Kan (see AAQ21562) and the primer pair HindRmut  
 CC -Kan and Bam-Kan (see AAQ21563-4) was used in a separate reaction. The  
 CC amplified products were mixed and a single PCR reaction without primers  
 CC was performed (94 deg.C for 1 min, 72 deg.C for 1 min, 10 cycles).  
 CC Primers ClaMut-Kan and Bam-Kan were added and PCR was resumed. The  
 CC resulting PCR product was ligated to ClaI-digested, end-filled pMV101 and  
 CC the ligation mixture was transformed into E.coli HB101. Kanamycin-  
 CC resistant colonies were screened for plasmids resistant to ClaI and  
 CC HindIII digestion. Such plasmids were designated pMV110  
 XX  
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1690 TTGGATGGGAAGCCCC 1705  
 Db 2 TTGTATGGGAAGCCCC 17  
 RESULT 232  
 AAQ31733  
 ID AAQ31733 standard; DNA; 17 BP.  
 XX  
 AC AAQ31733;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 18-FEB-1999 (first entry)  
 XX  
 DE PCR primer ClaMut-Kan for constructing mycobact'l integrating plasmid.  
 XX  
 KM cytotoxic T-lymphocyte response; transformed Mycobacteria; BCG;  
 KM Mycobacterium smegmatis; vaccine; cell mediated immunity; HIV; pertussis;  
 KM malaria; influenza virus; CTL; herpes virus; ss.  
 XX  
 OS Mycobacterium.  
 XX  
 PN WO9221376-A1.  
 XX  
 PD 10-DEC-1992.  
 XX  
 PF 01-JUN-1992; 92WO-US004538.  
 XX  
 PR 06-JUN-1991; 91US-00711643.  
 XX

PA (MEDI-) MEDIMMUNE INC.  
 XX  
 PI Stover CK, Dela Cruz V;  
 XX  
 DR WPI; 1992-433380/52.  
 XX  
 XX Method of inducing cytotoxic T-lymphocyte response - esp. expression  
 PT products of transformed Mycobacterium are useful as vaccines against HIV,  
 PT pertussis, malaria, influenza virus, herpes virus, etc.  
 XX  
 PS Example 3; Page 14; 86pp; English.  
 XX  
 CC This PCR primer was used with AAQ31734 in order to construct an  
 CC integrating plasmid including mycobacterial promoter expression cassette,  
 CC and the HIV-1 SP120 gene. Plasmid pMV101 was used as template. (Updated  
 CC on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1690 TTGGATGGGAAGCCCC 1705  
 Db 2 TTGTATGGGAAGCCCC 17  
 RESULT 233  
 AAQ41301  
 ID AAQ41301 standard; DNA; 17 BP.  
 XX  
 AC AAQ41301;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 04-JUN-1993 (first entry)  
 XX  
 DE PCR primer ClaMut-Kan for eliminating undesirable restriction sites.  
 XX  
 KM cytotoxic T-lymphocyte response; transformed Mycobacteria; BCG;  
 KM Mycobacterium smegmatis; vaccine; cell mediated immunity; HIV; pertussis;  
 KM malaria; influenza virus; CTL; herpes virus.  
 XX  
 OS Mycobacterium.  
 XX  
 PN WO9307897-A1.  
 XX  
 PD 29-APR-1993.  
 XX  
 PF 21-OCT-1992; 92WO-US009075.  
 XX  
 PR 21-OCT-1991; 91US-00780261.  
 XX  
 PA (MEDI-) MEDIMMUNE INC.  
 XX  
 PI Stover CK;  
 XX  
 DR WPI; 1993-152187/18.  
 XX  
 PT Expression vector for expressing protein or polypeptide in mycobacterium  
 PT - conig DNA sequences encoding lipoprotein secretion signal and peptide  
 PT heterologous to bacteria expressing fusion protein of lipoprotein  
 PT heterologous to bacteria.  
 XX  
 PS Example 1; Page 16; 86pp; English.  
 XX  
 CC This PCR primer was used with AAQ41302 in order to eliminate undesirable  
 CC restriction sites in the aph (kanR) gene. Plasmid pMV101 was used as  
 CC template. (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1690 TTGGATGGGAAGCCCC 1705  
||| ||||| ||||| |||||  
DB 2 TTGTATGGGAAGCCCC 17

## RESULT 234

AA068674  
ID AA068674 standard; DNA; 17 BP.

XX AA068674;

XX 25-MAR-2003 (revised)

DT 20-JAN-1995 (first entry)

XX Primer Clamut-Kan for plasmid pMW110 construction.

XX Primer; Clamut-Kan; pMW110; vaccine; ss.

XX Streptococcus pneumoniae.

XX MO9414318-A1.

PD 07-JUL-1994.

XX 20-DEC-1993; 93MO-US012504.

PR 24-DEC-1992; 92US-00996689.

XX (MEDI-) MEDIMUNE INC.

PA (UABR-) UAB RES FOUND.

PI Briles D, Stover CK;

XX WPI; 1994-234231/28.

XX Protecting an animal against Streptococcus pneumoniae - by administering

PT mycobacteria transformed with DNA which includes a sequence which encodes

XX protein or polypeptide which elicits antibodies against S. pneumoniae.

XX Disclosure; Page 10; 53pp; English.

XX The primer is used in the construction of the mycobacterial expression

CC vector pMW110, specifically for elimination of undesirable restriction

CC sites in the kanamycin-resistance gene of pMW101. pMW10 encodes a

CC protein eliciting antibodies against S. pneumoniae, and transformed

CC Mycobacterium spp. are used in a recombinant vaccine. (Updated on 25-MAR-

XX 2003 to correct PN field.)

XX Sequence 17 BP; 3 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;

XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1690 TTGGATGGGAAGCCCC 1705  
||| ||||| ||||| |||||  
DB 2 TTGTATGGGAAGCCCC 17

RESULT 235  
AA062264  
ID AA062264 standard; RNA; 17 BP.

XX AA062264;

XX 16-JUL-1999 (first entry)

DE Granule bound starch synthase hammerhead substrate SEQ ID NO:139.

XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;

KM granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;  
KM modulation; gene expression; transgenic plant; cleavage; canola plant;  
KM caffeine synthase; coffee plant; nicotine production; tobacco;  
KM fruit ripening; flower pigmentation; lignin production; ss.

XX Zea mays.

XX MO9710328-A2.

XX 20-MAR-1997.

XX 12-JUL-1996; 96MO-US011689.

XX 13-JUL-1995; 95US-0001135P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (DOWC) DOWELANCO.

XX Zwick MG, Edington BE, Mcswiggen JA, Merlo PAO, Guo L, Skokut TA;

XX Young SA, Folkerts O, Merlo DJ;

XX WPI; 1997-202224/18.

XX Ribozyme which modulates plant gene expression - preferably modulates

XX expression of DELTA-9 desaturase or granule bound starch synthase in

XX maize or canola.

XX Claim 41; Page 74; 155pp; English.

XX The present invention describes an enzymatic nucleic acid molecule (1)

XX with RNA cleaving activity, which modulates the expression of a plant

XX gene. Also described is a gene comprising a cDNA sequence encoding maize

XX Delta-9 desaturase. (1) can be used to modulate expression of a gene

XX gene, in a plant (preferably a maize or canola plant). (1) can be used to

XX modulate caffeine synthesis in a coffee plant, nicotine production in a

XX tobacco plant, fruit ripening processes in an apple, tomato, pear, plum

XX or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or

XX marigold plant or lignin production in a tobacco, aspen, poplar or pine

XX plant

XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

QY Query Match 0.6%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 81.2%; Pred. No. 1.6e+02;

XX Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2179 CAGCAGCTCATGAGA 2194  
||| ||||| ||||| |||||  
DB 1 CCGCAGCTCATGAGA 16

RESULT 236  
AAA24820/c  
ID AAA24820 standard; DNA; 17 BP.

XX AAA24820;

XX 19-JUL-2000 (first entry)

XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1318.

XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;

XX hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

XX gene expression modification; cancer; phosphorothioate; endonuclease;

XX anticancer; breast cancer; endometrium cancer; ss.

XX Homo sapiens.

XX WO954459-A2.

XX 28-OCT-1999.

```

PF 19-APR-1999; 99WO-US008547.
XX
XX 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PI Thompson JD, Beigelman L, Mewswigen JA, Karpelesky A, Bellon L,
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P,
PI Matulic-Adamic J;
DR WPI; 2000-013246/01.
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 77; Page 59; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodi(thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A) that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences. AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 540 GGGCTCGAGACGCGC 555
Db 16 GGGCTCGAGACGCGC 1
XX
RESULT 237
ABA77757
ID ABA77757 standard; DNA; 17 BP.
XX
XX ABA77757;
XX
XX 24-JAN-2002 (first entry)
XX
DE Retinoblastoma mutation correcting oligonucleotide SEQ ID NO: 603.
XX
XX Human, gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MHL1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytoskeletal; antistickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX

```

```

EN W0200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US009761.
XX
XX 27-MAR-2000; 2000US-0192176P.
XX 27-MAR-2000; 2000US-0192176P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
XX (UYDE ) UNIV DELAMARE.
XX
XX Kmiec EB, Gamper HB, Rice MC;
PI WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
XX Claim 7; Page 80; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MHL1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1806 CCGAGCCGAGAGCCA 1821
Db 2 CCGAGCCGAGAGCCA 17
XX
RESULT 238
ABA77758/C
ID ABA77758 standard; DNA; 17 BP.
XX
XX ABA77758;
XX
XX 24-JAN-2002 (first entry)
XX
DE Retinoblastoma mutation correcting oligonucleotide SEQ ID NO: 604.
XX
XX Human, gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MHL1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytoskeletal; antistickling; antianaemic; haemostatic;
XX antilipemic; ss.
XX
XX Homo sapiens.
XX

```

```

XX  WO200173002-A2.
PN
XX
XX  04-OCT-2001.
PD
XX
XX  27-MAR-2001; 2001WO-US009761.
PF
XX  27-MAR-2000; 2000US-0192176P.
PR  27-MAR-2000; 2000US-0192179P.
PR  01-JUN-2000; 2000US-0208538P.
PR  30-OCT-2000; 2000US-0244989P.
XX
XX  (UYDE ) UNIV DELAWARE.
PA
XX  Kmlec EB, Gamper HB, Rice MC;
PI
XX  WPI; 2001-639230/73.
DR
XX  Oligonucleotide for targeted alterations of genetic sequences and for
PT  treating cystic fibrosis, comprises at least one mismatch and chemical
PT  modification.
XX
XX  Claim 7; Page 80; 294pp; English.
PS
XX  The present invention provides single-stranded oligonucleotides which can
CC  be used for the targeted alteration of genomic sequences, where the
CC  oligonucleotide has at least one mismatch compared with the genomic
CC  sequence to be altered. In particular, these sequences are directed at
CC  the following genes: adenosine deaminase, p53, beta-globin,
CC  retinoblastoma, BRCA1, BRCA2, CYP2R, cyclin-dependent kinase inhibitor 2A
CC  1 (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
CC  1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC  Apolipoprotein B (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC  (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC  presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC  such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC  haemophilia, hypercholesterolaemia, thalasassaemia, sickle cell anaemia,
CC  Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC  various syndromes. The present sequence is one of the gene correcting
CC  oligonucleotides of the invention
XX
XX  Sequence 17 BP; 1 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 0.64; Score 14.4; DB 1; Length 17;
XX  Best Local Similarity 93.84; Pred. No. 1.6e+02;
XX  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY  1806 CCTGACCCAGAGCCA 1821
DB  16 CCAGACCCAGAGCCA 1
XX
XX  RESULT 239
XX  ABN00902/c
XX  ID ABN00902 standard; DNA; 17 BP.
XX
XX  ABN00902;
AC
XX  29-MAY-2002 (first entry)
DT
XX  Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:894.
XX
XX  Human genome-derived myosin-like protein 1; GDMLP-1, hGDMLP-1, heart;
XX  muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX  skeletal muscle disorder; amplicon; screening; ss.
XX
XX  Homo sapiens.
XX
XX  WO200192524-A2.
XX
XX  06-DEC-2001.
XX
XX  25-MAY-2001; 2001WO-US016981.
XX

```

```

XX  26-MAY-2000; 2000US-0207456P.
PR  21-SEP-2000; 2000US-0234687P.
PR  27-SEP-2000; 2000US-0236359P.
PR  04-OCT-2000; 2000GB-00024263.
PR  30-JAN-2001; 2001WO-US000661.
PR  30-JAN-2001; 2001WO-US000662.
PR  30-JAN-2001; 2001WO-US000663.
PR  30-JAN-2001; 2001WO-US000664.
PR  30-JAN-2001; 2001WO-US000665.
PR  30-JAN-2001; 2001WO-US000666.
PR  30-JAN-2001; 2001WO-US000667.
PR  30-JAN-2001; 2001WO-US000668.
PR  30-JAN-2001; 2001WO-US000669.
PR  30-JAN-2001; 2001WO-US000670.
PR  05-FEB-2001; 2001US-0266860P.
XX
XX  (AEOM-) AEOMICA INC.
PA
XX  Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX  WPI; 2002-179446/23.
DR
XX  New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT  or as specific biomolecule capture probes for surface-enhanced laser
PT  desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX  Disclosure; SEQ ID NO 894; 214pp; English.
PS
XX  The present invention describes a human genome-derived myosin-like
CC  protein 1 (hGDMLP-1). The protein and vaccine production. The hGDMLP-1
CC  1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC  nucleic acids can be used as probes to detect, characterise and quantify
CC  hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC  provide initial substrates for the recombinant engineering of hGDMLP-1
CC  protein variants having desired phenotypic improvements, and for
CC  expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC  used as immunogens to raise antibodies that specifically recognise hGDMLP
CC  -1 proteins, as standards in assays used to determine the concentration
CC  and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC  capture probes for surface-enhanced laser desorption/ionisation, as
CC  therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC  production, and in vaccines or for replacement therapy. The
CC  polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC  disorder associated with the expression of hGDMLP-1, in particular heart
CC  and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC  The present sequence represents an oligomer used in the screening of the
CC  hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC  The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format directly from WIPO
CC  at ftp.wipo.int/pub/published_pct_sequence
XX
XX  Sequence 17 BP; 3 A; 1 C; 10 G; 3 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 0.64; Score 14.4; DB 1; Length 17;
XX  Best Local Similarity 93.84; Pred. No. 1.6e+02;
XX  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY  1699 AAGCCCTTCCCAAT 1714
DB  16 AAGCCCTTCCCACT 1
XX
XX  RESULT 240
XX  ABN08014
XX  ID ABN08014 standard; DNA; 17 BP.
XX
XX  ABN08014;
AC
XX  29-MAY-2002 (first entry)
DT
XX  Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8006.
XX
XX

```



XX	Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;	
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;	
KW	skeletal muscle disorder; amplicon; screening; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200192524-A2.	
PD	06-DEC-2001.	
XX		
PF	25-MAY-2001; 2001WO-US016981.	
XX		
PR	26-MAY-2000; 2000US--0207455P.	
RR	21-SEP-2000; 2000US-0234687P.	
RR	27-SEP-2000; 2000US-0236359P.	
PR	04-OCT-2000; 2000GB-00024263.	
PR	30-JAN-2001; 2001WO-US000661.	
PR	30-JAN-2001; 2001WO-US000662.	
PR	30-JAN-2001; 2001WO-US000663.	
PR	30-JAN-2001; 2001WO-US000664.	
PR	30-JAN-2001; 2001WO-US000665.	
PR	30-JAN-2001; 2001WO-US000666.	
PR	30-JAN-2001; 2001WO-US000667.	
PR	30-JAN-2001; 2001WO-US000668.	
PR	30-JAN-2001; 2001WO-US000669.	
PR	30-JAN-2001; 2001WO-US000670.	
PR	05-FEB-2001; 2001US-0266860P.	
XX		
PA	(AECOM-) AECOMICA INC.	
XX		
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;	
DR	WPI; 2002-179446/23.	
XX		
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,	
PT	or as specific biomolecule capture probes for surface-enhanced laser	
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.	
XX		
PS	Disclosure; SEQ ID NO 8006; 214pp; English.	
XX		
CC	The present invention describes a human genome-derived myosin-like	
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1	
CC	nucleic acids can be used as probes to detect, characterise and quantify	
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to	
CC	provide initial substrates for the recombinant engineering of hGDMLP-1	
CC	protein variants having desired phenotypic improvements, and for	
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP	
CC	-1 proteins, as standards in assays used to determine the concentration	
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule	
CC	capture probes for surface-enhanced laser desorption ionisation, as	
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1	
CC	production, and in vaccines or for replacement therapy. The	
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	
CC	disorder associated with the expression of hGDMLP-1, in particular heart	
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	
CC	The present sequence represents an oligomer used in the screening of the	
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.	
CC	The sequence data for this patent did not form part of the printed	
CC	specification, but was obtained in electronic format directly from WIPO	
CC	at ftp.wipo.int/pub/published_pct_sequence	
XX		
SO	Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;	
QY	Query Match 0.6%; Score 14.4; DB 1; Length 17;	
	Best Local Similarity 93.8%; Pred. No. 1.6e+02;	
	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
db	2038 CAGGTGAGCAGCTTC 2053	
	1 CAGGTGAGCAGCTTC 16	

CC	RESULT 241
XX	ABN08013
XX	ID ABN08013 standard; DNA; 17 BP.
XX	AC ABN08013;
XX	XX ABN08013;
XX	XX 29-MAY-2002 (first entry)
XX	XX
XX	XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8005.
DE	XX
XX	XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW	XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW	XX skeletal muscle disorder; amplicon; screening; ss.
XX	XX
OS	XX Homo sapiens.
XX	XX
PN	XX WO200192524-A2.
XX	XX
PD	XX 06-DEC-2001.
XX	XX
XX	XX 25-MAY-2001; 2001WO-US016981.
XX	XX
XX	XX 26-MAY-2000; 2000US-0207456P.
PR	XX 21-SEP-2000; 2000US-0234687P.
PR	XX 27-SEP-2000; 2000US-0236359P.
PR	XX 04-OCT-2000; 2000GB-0002426P.
PR	XX 30-JAN-2001; 2001WO-US000661.
PR	XX 30-JAN-2001; 2001WO-US000662.
PR	XX 30-JAN-2001; 2001WO-US000663.
PR	XX 30-JAN-2001; 2001WO-US000664.
PR	XX 30-JAN-2001; 2001WO-US000665.
PR	XX 30-JAN-2001; 2001WO-US000666.
PR	XX 30-JAN-2001; 2001WO-US000667.
PR	XX 30-JAN-2001; 2001WO-US000668.
PR	XX 30-JAN-2001; 2001WO-US000669.
PR	XX 30-JAN-2001; 2001WO-US000670.
PR	XX 05-FEB-2001; 2001US-0266860P.
XX	XX
PA	XX (AEOM-.) AEOMICA INC.
XX	XX
PI	XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX	XX
DR	XX WPI; 2002-179446/23.
XX	XX
XX	XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT	XX or as specific biomolecule capture probes for surface-enhanced laser
PT	XX desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX	XX
PS	XX Disclosure; SEQ ID NO 8005; 214pp; English.
XX	XX
XX	XX The present invention describes a human genome-derived myosin-like
CC	XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-1
CC	XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC	XX nucleic acids can be used as probes to detect, characterise and quantify
CC	XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC	XX provide initial substrates for the recombinant engineering of hGDMLP-1
CC	XX protein variants having desired phenotypic improvements, and for
CC	XX expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC	XX used as immunogens to raise antibodies that specifically recognise hGDMLP-
CC	XX -1 proteins, as standards in assays used to determine the concentration
CC	XX and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC	XX capture probes for surface-enhanced laser desorption ionisation, as
CC	XX therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC	XX production, and in vaccines or for replacement therapy. The
CC	XX polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC	XX disorder associated with the expression of hGDMLP-1, in particular heart
CC	XX and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC	XX The present sequence represents an oligomer used in the screening of the
CC	XX hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC	XX The sequence data for this patent did not form part of the printed
CC	XX specification, but was obtained in electronic format directly from WIPO
CC	XX at ftp.wipo.int/pub/published pct sequence



XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;  
SQ  
Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 2038 CAGCTGAGCAGCTCC 2053  
|||  
Db 2 CAGCTGAGCAGCTCC 17  
RESULT 242  
ABN00898/c  
ID ABN00898 standard; DNA; 17 BP.  
XX  
AC ABN00898;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:890.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN NC0200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 890; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterize and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the protein. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 4 A; 1 C; 10 G; 2 T; 0 U; 0 Other;  
XX  
Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1702 CCCCTTCCCAATATG 1717  
|||  
Db 17 CCCCTTCCCAATATG 2  
RESULT 243  
ABV85489/c  
ID ABV85489 standard; DNA; 17 BP.  
XX  
AC ABV85489;  
XX  
DT 11-DEC-2002 (first entry)  
XX  
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:482.  
XX  
KM Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;  
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;  
KM ss.  
XX  
OS Homo sapiens.  
XX  
OS Synthetic.  
XX  
PN EP1243660-A2.  
XX  
PD 25-SEP-2002.  
XX  
PF 25-JAN-2002; 2002EP-00001161.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 30-AUG-2001; 2001US-0315984P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J, Gu Y, Nguyen C;  
XX  
DR WPI; 2002-724954/79.  
XX  
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-  
PT acetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent  
PT and treat disorders associated with reduced or over expression of the  
PT encoded protein.  
XX  
PS Example 2; SEQ ID NO 482; 59pp; English.  
XX  
CC The present invention describes an isolated nucleic acid (1) encoding a  
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-  
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to

CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the  
 CC present invention can be used in therapy, particularly to prevent or  
 CC treat a disorder associated with decreased expression or activity of pp-  
 CC GATase. The sequences given in ABV85011 to ABV86689 and ABP53502 to  
 CC ABP53504 are given in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent is not represented in the printed  
 CC specification but is based on sequence information supplied by the  
 CC European Patent Office  
 CC  
 XX Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1487 CCTTACACTTGAGCG 1502  
 DB 17 CCTTACACTTGAGCG 2  
 RESULT 244  
 ABV85490/c  
 ID ABV85490 standard; DNA; 17 BP.  
 XX  
 AC ABV85490;  
 XX  
 DT 11-DEC-2002 (first entry)  
 XX  
 DE Human pp-GATase 10 scanning 17-mer SEQ ID NO:483.  
 XX  
 KW Human, UDP-GalNAc:polypeptide N-acetylglucosaminyltransferase 10;  
 KM pp-GATase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;  
 KM ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 OS  
 XX EPI243660-A2.  
 PN  
 XX 25-SEP-2002.  
 PD  
 XX  
 PE 25-JAN-2002; 2002EP-00001161.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 30-AUG-2001; 2001US-0315964P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 PA  
 XX Zhang J, Gu Y, Nguyen C;  
 PI  
 XX WPI; 2002-724954/79.  
 DR  
 XX  
 PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-  
 PT cetylglucosaminyltransferase 10 protein is useful to diagnose, prevent  
 PT and treat disorders associated with reduced or over expression of the  
 PT encoded protein.  
 PT  
 XX  
 PS Example 2; SEQ ID NO 483; 59pp; English.  
 XX  
 CC The present invention describes an isolated nucleic acid (I) encoding a  
 CC human UDP-GalNAc:polypeptide N-acetylglucosaminyltransferase 10 (pp-  
 CC GATase 10, EC 2.4.1.41) protein. Human pp-GATase 10 is located to  
 CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the  
 CC present invention can be used in therapy, particularly to prevent or  
 CC treat a disorder associated with decreased expression or activity of pp-

CC GATase. The sequences given in ABV85011 to ABV86689 and ABP53502 to  
 CC ABP53504 are given in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent is not represented in the printed  
 CC specification but is based on sequence information supplied by the  
 CC European Patent Office  
 CC  
 XX Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1487 CCTTACACTTGAGCG 1502  
 DB 16 CCTTACACTTGAGCG 1  
 RESULT 245  
 ABT39140  
 ID ABT39140 standard; DNA; 17 BP.  
 XX  
 AC ABT39140;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID No 4777.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; protein chip; gene therapy; tumour suppression;  
 KM human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 OS  
 XX WO2003025175-A2.  
 PN  
 XX 27-MAR-2003.  
 XX  
 PD 17-SEP-2002; 2002WO-IB004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 PA  
 XX Teلمان A, Amson R, Tuijnder M;  
 PI  
 XX WPI; 2003-313353/30.  
 DR  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 PT  
 XX  
 PS Disclosure; Page 592; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human faktin oligonucleotide of the invention  
XX

SO Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2081 GCTCAGTCTTCAT 2096

DB 1 GATCAGTCTTCAT 16

RESULT 246

ABBS7647/C

ID ABBS7647 standard; DNA, 17 BP.

AC ABBS7647;

DT 14-FEB-2003 (first entry)

DE Human HGPBMY2-associated oligonucleotide SEQ ID 33.  
XX Human; G-protein coupled receptor; HGPBMY1; HGPBMY2; immunosuppressive;  
KM claudin; neuroprotective; antiinflammatory; cytostatic; vulnary;  
KM vaccine; gene therapy; autoimmune; cardiovascular; neural; reproductive;  
KM hematopoietic; pulmonary; gastrointestinal; proliferation; cell cycle;  
KM birth defect; aberrant phosphorylation; acute phase response; primer;  
KM signal transduction; hyperimmune activity; inflammatory; hypercongenital;  
KM necrotic lesion; wound; organ transplant rejection; disorder; PCR; ss.

OS Homo sapiens.

PN WO200268591-A2.

PD 06-SEP-2002.

PF 22-FEB-2002; 2002MO-US005281.

PR 23-FEB-2001; 2001US-0270792P.

PR 23-FEB-2001; 2001US-0270793P.

PR 06-JUN-2001; 2001US-0296427P.

XX (BRIM ) BRISTOL-MYERS SQUIBB CO.

PI Feder J, Ramanathan C, Nelson T, Mintier G, Cacace A, Barber L;

PI Kornacker M, Bol D;

DR WPI; 2003-058304/05.

PT New human HGPBMY1 or HGPBMY2 polynucleotide and polypeptide, useful  
PT preventing, treating or ameliorating a disorder e.g., wound,  
PT cardiovascular disorder or transplant rejection.

PS Disclosure; Page 135; 316pp; English.

XX This invention describes the novel human G-protein coupled receptors  
CC (GPCR's), HGPBMY1 or HGPBMY2 which have immunosuppressive, cardiant,  
CC neuroprotective, antiinflammatory, cytostatic and vulnary activity and  
CC can be used in vaccine or for gene therapy. Pharmaceutical compositions  
CC comprising HGPBMY1 or HGPBMY2 polypeptides or their agonists or  
CC antagonists or modulators, or a HGPBMY1- or HGPBMY2-specific antibody  
CC are useful for preventing, treating or ameliorating a medical condition  
CC comprising autoimmune, cardiovascular, neural, reproductive,  
CC hematopoietic, pulmonary, gastrointestinal or proliferating disorder, a  
CC cell cycle or birth defect, a disorder related to aberrant  
CC phosphorylation, acute phase responses or signal transduction or to  
CC hyperimmune activity, an inflammatory or hypercongenital condition, a  
CC necrotic lesion, a wound, organ transplant rejection or a condition  
CC related to organ transplant rejection. This sequence represents a PCR  
CC primer used in the amplification of the genes encoding the HGPBMY

CC proteins described in the disclosure of the invention  
XX  
SO Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 113 CCGCGCTGCCCCGCAT 128

DB 17 CCGCGCTGCCCCGCAT 2

RESULT 247

ACD61070

ID ACD61070 standard; RNA, 17 BP.

AC ACD61070;

DT 24-SEP-2003 (first entry)

DE HCV DNAzyme substrate sequence #2144.  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KM RNA stability; RNA expression; RNA synthesis; antisense;  
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinczyme;  
KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KM HBV reverse transcriptase; Enhancer I region; viral replication;  
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KM virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

PN WO200281494-A1.

PD 17-OCT-2002.

PF 26-MAR-2002; 2002MO-US009187.

PR 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGGEN J.

PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.

PA (LEEP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

XX Blat L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

DR WPI; 2003-229207/22.

PT Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
PS Claim 1; Page 272; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,  
CC inozymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse

CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNasezyme or minus strand DNasezyme sequences disclosed in the present  
 CC invention  
 XX  
 SQ Sequence 17 BP, 3 A, 7 C, 3 G, 0 T, 4 U, 0 Other;  
 Query Match 0.6%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 68.8%; Pred. No. 1.6e+02;  
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1224 TGCACTCACTCTGCG 1239  
 : |||: |||: |||: |||:  
 Db 1 UCCAGUACAUCUCUGG 16

RESULT 248  
 ABS61004  
 ID ABS61004 standard; DNA, 18 BP.  
 XX  
 AC ABS61004;  
 XX  
 DT 05-NOV-2002 (first entry)  
 XX  
 DE Human genotyping PCR primer #157.  
 XX  
 KW Human; ss; aminopeptidase P; XPNP2; bradykinin receptor B1; primer;  
 KW BDKRB1; tachykinin receptor B1; TACR1; Cl esterase inhibitor; C1NH;  
 KW kallikrein 1; KUK1; bradykinin receptor B2; BDKRB2; gene therapy;  
 KW angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;  
 KW polymorphisms; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;  
 KW cardiovascular disease; angina pectoris; hypertension; heart failure;  
 KW myocardial infarction; ventricular hypertrophy; vascular disease;  
 KW aneurysm; embolism; thrombosis; coronary artery disease; angioedema;  
 KW arteriosclerosis; atherosclerosis; hypersensitivity; sepsis; PCR;  
 KW autoimmune disease; inflammatory arthritis; cancer; wound; genotyping;  
 KW viral infection; bacterial infection; fungal infection; COPD;  
 KW Chronic obstructive pulmonary disease; enterocolitis.  
 KM  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200261131-A2.  
 XX  
 PD 08-AUG-2002.  
 XX  
 PF 03-DEC-2001; 2001WO-US047235.  
 XX  
 PR 04-DEC-2000; 2000US-0251015P.  
 PR 23-JAN-2001; 2001US-0263678P.  
 PR 02-MAR-2001; 2001US-0273037P.  
 XX  
 PA (BRIM ) BRISTOL-MYERS SQUIBB CO.  
 PA (TSUC/) TSUCHIHASHI Z.  
 PA (HUI/) HUI L.  
 PI Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH,  
 PI Swanson BN, Powell JR,  
 XX  
 DR WPI; 2002-619265/66.  
 XX  
 XX New isolated nucleic acid with at least one polymorphic position, useful  
 PT for detecting, diagnosing and treating disorders such as angioedema,  
 PT cancer, viral, bacterial or fungal infection, cardiovascular and  
 PT autoimmune diseases.

PS Example 3; Page 914; 977pp; English.  
 XX  
 CC The invention relates to an isolated nucleic acid from a human gene  
 CC encoding aminopeptidase P (XPNP2), bradykinin receptor B1 (BDKRB1),  
 CC tachykinin receptor B1 (TACR1), Cl esterase inhibitor (C1NH), Kallikrein  
 CC 1 (KUK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme  
 CC 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one  
 CC polymorphic position. Also included are (1) a probe that hybridises to a  
 CC polymorphic position as provided in the detailed summary of single  
 CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic  
 CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising  
 CC obtaining the sample from one or more individuals and determining the  
 CC nucleic acid sequence at one or more polymorphic positions in a gene  
 CC encoding a protein selected from the group above; (3) constructing (M2)  
 CC haplotypes using the genes comprising grouping at least two nucleic acids  
 CC ; (4) identifying (M3) an individual at risk of developing a disorder  
 CC upon administration of an ACE inhibitor and/or vasopressinase inhibitor  
 CC using the polymorphic data; (5) a library of nucleic acids, each of which  
 CC comprises one or more polymorphic positions within a gene encoding a  
 CC human protein selected from the group above; and (6) genotyping (M4) an  
 CC individual comprising obtaining a nucleic acid sample, determining the  
 CC nucleotide present in at least one polymorphic position, and comparing at  
 CC least one position with a known data set. The genes, (M1, M2, M3 and M4)  
 CC and compositions are useful for detecting, diagnosing, treating,  
 CC preventing various disorders such as angioedema and diseases which  
 CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's  
 CC disease, trachomas, and cardiovascular diseases like angina pectoris,  
 CC hypertension, heart failure, myocardial infarction, ventricular  
 CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary  
 CC artery disease, arteriosclerosis and/or atherosclerosis, and  
 CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory  
 CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic  
 CC obstructive pulmonary disease (COPD) and enterocolitis (many other  
 CC diseases and disorders are listed in the specification). The  
 CC polymucleotides are also useful for chromosome identification. Antibodies  
 CC against the proteins may be utilised for immunophenotyping of cell lines  
 CC and biological samples. The present sequence is a genotyping PCR primer  
 CC for the gene encoding one of the proteins listed above  
 XX  
 SQ Sequence 18 BP, 7 A, 2 C, 8 G, 1 T, 0 U, 0 Other;  
 Query Match 0.6%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.7e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2190 GGAGAAAAGCGTGC 2205  
 : |||: |||: |||: |||:  
 Db 2 CGAGAAAAGCGCTGC 17

RESULT 249  
 AAD53970  
 ID AAD53970 standard; DNA, 18 BP.  
 XX  
 AC AAD53970;  
 XX  
 DT 17-JUN-2003 (first entry)  
 XX  
 DE Human KIF1Bbeta mutant DNA fragment.  
 XX  
 KW KIF1B protein, gene therapy; molecular motor protein; kinesin; human;  
 KW Kif1Bbeta gene-associated disease; Charcot-Marie-Tooth disease type 2A;  
 KW muscular; transgenic; mutant; gene; ds.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 OS  
 PH Key Location/Qualifiers  
 FT 1. 18  
 FT CDS /\*tag= a  
 FT /product= "Human KIF1Bbeta mutant peptide"  
 FT /note= "CDS does not include start and stop codon"  
 FT /partial

```

FT mutation replace(14,A)
PT /*tag= b
XX
XX NO200297079-A2.
XX
XX 05-DEC-2002.
XX
XX 29-MAY-2002; 2002WO-JP005226.
XX
XX 29-MAY-2001; 2001US-0293513P.
XX
XX (UYTY ) UNIV TOKYO.
XX
XX Hirokawa N, Hayashi Y;
XX
XX WPI; 2003-167270/16.
XX
XX P-PSDB; AAE35320.
XX
XX New KIF11b polypeptide having motor activity that transports synaptic
XX vesicle precursor, is useful for developing therapeutic or preventive
XX agent for kif11b gene-associated diseases e.g. Charcot-Marie-Tooth
XX disease type 2A.
XX
XX Example 6; Fig 7; 44pp; English.
XX
XX The invention relates to KIF11b protein which belongs to kinesin
XX superfamily of molecular motor proteins (KIFs). KIF11b is useful for
XX screening for a compound binding to it. Composition comprising the
XX selected compound is useful for treating, alleviating, or preventing a
XX KIF11b gene-associated disease, in particular Charcot-Marie-Tooth
XX disease type 2A. Transgenic non-human vertebrate, are useful for
XX screening for a candidate compound for treating, alleviating, or
XX preventing a KIF11b gene-associated disease. KIF11b DNA is useful for
XX gene therapy and for recombinant production of polypeptides. KIF11b
XX antibody is useful for affinity purification of KIF11b and for detecting
XX expression of KIF11b gene at the protein level. The present sequence
XX is human KIF11b gene mutant DNA fragment
XX
XX Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.4; DB 1; Length 18;
XX Best Local Similarity 93.8%; Pred. No. 1.7e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1796 TTGGCTATGGCCGAC 1811
XX |||||
XX 2 TTGCTATGGGCTGAC 17
XX
XX RESULT 250
XX ADA24424/C
XX ID ADA24424 standard; DNA; 18 BP.
XX
XX ADA24424;
XX
XX 20-NOV-2003 (first entry)
XX
XX PCR primer #1 for generating human TSL1 probe.
XX
XX Human tumour suppressor gene; TSL1; hTSL1; cancer; carcinoma;
XX pre-critical stage; cancer therapy; chemical therapy; radiotherapy;
XX TSLC1; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2003109016-A1.
XX
XX 12-JUN-2003.
XX
XX 29-AUG-2002; 2002US-00230335.
XX
XX 11-OCT-2001; 2001JP-00313966.
XX

```

```

PA (PRES-) PRESIDENT NAT CANCER CENT.
PA (BMLB-) BML INC.
XX
XX Murakami Y, Nomura S;
XX
XX WPI; 2003-626209/59.
XX
XX New protein encoded by tumor suppressor gene, designated as TSL1 gene,
XX useful for preventing or treating cancers, predicting of prognosis of
XX cancer therapy, or diagnosing carcinoma in pre-clinical stages.
XX
XX Example; Page 6; 20pp; English.
XX
XX The present invention relates to the isolation of a human tumour
XX suppressor gene, TSL1 (hTSL1), and the encoding protein. The TSL1 gene
XX and protein are useful for preventing and treating cancers. The gene is
XX useful for diagnosing carcinoma in pre-critical stages, qualitative
XX diagnosis of carcinoma, predicting the prognosis of cancer therapy, and
XX forecasting the sensitivity of a carcinoma to chemical therapy, and
XX radiotherapy and gene therapy. The TSL1 protein is homologous the TSLC1
XX protein. The present sequence represents a PCR primer used to generate a
XX probe for human TSL1 cDNA.
XX
XX Sequence 18 BP; 5 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.4; DB 1; Length 18;
XX Best Local Similarity 93.8%; Pred. No. 1.7e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 264 TGCCAGGCGCTGCTG 279
XX |||||
XX 17 TGTCCAGGCGCTGCTG 2
XX
XX RESULT 251
XX AAV72326/C
XX ID AAV72326 standard; DNA; 19 BP.
XX
XX AAV72326;
XX
XX 28-JUL-1999 (first entry)
XX
XX Human steroid hormone binding protein primer 13.
XX
XX Steroid hormone binding protein; membrane bound; hSMBP1; hSMBP2;
XX anti-allergenic; drug screening; treatment; immune disorder; allergy;
XX autoimmune disease; hormone-dependent tumour; primer; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO9924568-A1.
XX
XX 20-MAY-1999.
XX
XX 06-NOV-1998; 98WO-JP005010.
XX
XX 07-NOV-1997; 97JP-00322376.
XX
XX (CHUG-) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX Hirata Y;
XX
XX WPI; 1999-327400/27.
XX
XX New membrane bound steroid binding protein useful in treatment of immune
XX disorders.
XX
XX Example 1; Page 42; 46pp; Japanese.
XX
XX This invention describes a membrane bound steroid binding proteins
XX (hSMBP1 and hSMBP2) of human origin which have anti-allergenic activity.
XX hSMBP1 is used to screen candidate drugs for their ability to bind to it.
XX

```

CC The drugs identified may be used in the treatment of immune disorders  
 CC such as allergy and autoimmune disease, and of hormone-dependent tumours  
 XX  
 SQ Sequence 19 BP; 4 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1258 ATGCTGCTGAAAGTGG 1273  
 |||||  
 Db 16 ATGCTGCTGAAAGTGG 1

RESULT 252  
 ABL58297  
 ID ABL58297 standard; DNA; 19 BP.  
 XX

AC ABL58297;  
 XX  
 DT 15-JUN-2002 (first entry)  
 XX

DE Human GLUT 10 SSCP analysis primer GLUT10 ex2aR.

KM Glucose transporter; GLUT10; insulin; chromosome 20Q12-13.3; human;  
 KM glucose metabolism; single strand conformational polymorphism; PCR;  
 KM type 2 diabetes; SSCP; primer; ss.  
 XX

OS Homo sapiens.

PN WO200218621-A2.

PD 07-MAR-2002.

PF 22-AUG-2001; 2001WO-US026184.

PR 31-AUG-2000; 2000US-00652292.

PA (UYWA-) UNIV WAKE FOREST.

PI Bowden DW, Dawson PA, Fossey SC;

DR WPI; 2002-371828/40.

XX New glucose transporter gene and protein, designated GLUT10, useful for  
 PT studying and analyzing biological processes of glucose metabolism and  
 PT Type 2 diabetes, as well as for screening modulators of glucose  
 PT transporter activity.

PS Example 4; Page 52; 85pp; English.

XX The invention relates to a novel glucose transporter gene and protein,  
 CC designated GLUT10. GLUT 10 is an insulin-responsive glucose transporter  
 CC gene located in the type 2 diabetes linked region of chromosome 20Q12-  
 CC 13.3. The GLUT 10 polypeptide can be expressed by standard recombinant  
 CC methodology. The GLUT 10 glucose transporter gene and protein are useful  
 CC for studying and analyzing biological processes of both glucose  
 CC metabolism and type 2 diabetes. These are also useful in drug screening  
 CC techniques, especially for screening modulators of glucose transporter  
 CC activity or compounds having the ability to be transported across the  
 CC cell membranes. Sequences ABL58290-315 represent primers specific for the  
 CC various regions of the human GLUT 10 glucose transporter gene, used in  
 CC single strand conformational polymorphism (SSCP) analysis of the gene  
 XX  
 SQ Sequence 19 BP; 5 A; 7 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2118 GGAGCAGGCTGACAC 2133  
 |||||  
 Db 2 GGAGCAGGCTGCCAC 17

RESULT 253  
 AAD5156  
 ID AAD5156 standard; DNA; 19 BP.  
 XX

AC AAD5156;

DT 07-AUG-2003 (first entry)

DE Goat beta-lac exon 1 amplifying primer, C.

KM Transgenic; nucleoprotein; recombinase; beta-lac; goat; PCR; primer; ss.

OS Capra hircus.

PN WO2003022220-A2.

PD 20-MAR-2003.

PF 06-SEP-2002; 2002WO-US028763.

PR 07-SEP-2001; 2001US-0317915P.

PA (REGC ) UNIV CALIFORNIA.

PI Mega EA, Anderson GB, Murray JD, Oppenheim SM;

DR WPI; 2003-313182/30.

XX Producing transgenic livestock animal e.g. pig, by introducing  
 PT nucleoprotein made of nucleic acid and recombinase into totipotent or  
 PT pluripotent cell, and growing the resulting recombinant totipotent or  
 PT pluripotent cell.

PS Disclosure; Page 30; 25pp; English.

XX The invention relates to a method for producing transgenic livestock  
 CC animal e.g. pig, by introducing nucleoprotein made of nucleic acid and  
 CC recombinase into totipotent or pluripotent cell, and growing the  
 CC resulting recombinant totipotent or pluripotent cell. The method is  
 CC useful for producing transgenic livestock animal such as pigs, goats,  
 CC sheep, cows or horses, preferably goats and pigs. The present sequence is  
 CC a primer used for amplifying goat beta-lac exon 1. This sequence is used  
 CC to illustrate the method of the invention

XX Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 268 CAGGCGTGGCTGGCTG 283  
 |||||  
 Db 1 CCGGCGTGGCTGGCTG 16

RESULT 254

ID ADA50311/C

XX ADA50311 standard; DNA; 19 BP.

AC ADA50311;

DT 20-NOV-2003 (first entry)

XX

DE Human PCR primer rs1061581r related to abacavir hypersensitivity.  
 XX hypersensitivity reaction; abacavir; 57.1 ancestral haplotype;  
 KM Major Histocompatibility Complex; MHC; human leukocyte antigen; HLA;  
 KM HLA-B\*5701; C4A6; HLA-DR7; Human immunodeficiency virus; HIV;  
 KM immune system; acquired immune deficiency syndrome; AIDS;  
 KM peripheral nervous system; antiviral compound; HIV replication inhibitor;  
 KM antiviral; nucleoside reverse transcriptase inhibitor; NRTI;

KM antiretroviral drug; abacavir; human; sequencing primer; primer; PCR; ss;  
 KM SNP detection; pyrosequence; rs1061581.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003068985-A1.  
 XX  
 PD 21-AUG-2003.  
 XX  
 PF 12-FEB-2003; 2003WO-AU000183.  
 XX  
 PR 12-FEB-2002; 2002AU-00000464.  
 XX  
 PA (EPiP-) EPiPOP PTY LTD.  
 XX  
 PI Mallal S;  
 XX  
 DR WPI; 2003-697530/66.  
 XX  
 PT Method for the identification of subjects hypersensitive to abacavir,  
 PT useful for excluding patients from treatment, comprises detecting the  
 PT presence of the 57.1 ancestral haplotype.  
 XX  
 PS Example 2; Page 23; 43pp; English.  
 XX  
 CC This invention relates to a method for determining whether a patient will  
 CC show a hypersensitivity, or similar, reaction to abacavir by typing the  
 CC patient for presence of the 57.1 ancestral haplotype of the Major  
 CC Histocompatibility Complex (MHC). The ancestral haplotype is defined by  
 CC presence of the human leukocyte antigen (HLA) subtypes HLA-B\*5701, C4A6,  
 CC HLA-D7 and HLA-DQ3. Human immunodeficiency virus (HIV) is the  
 CC aetiological agent of a complex disease that includes progressive  
 CC destruction of the immune system (acquired immune deficiency syndrome,  
 CC AIDS) and degeneration of the peripheral nervous system. It is known that  
 CC some antiviral compounds which act as inhibitors of HIV replication are  
 CC effective agents in the treatment of AIDS. Treatment with an antiviral to  
 CC a person with hypersensitivity may lead to a range of ailments and  
 CC occasionally death. Patients who have the 57.1 ancestral haplotype are at  
 CC a high risk of developing a hypersensitive reaction to abacavir, a  
 CC nucleoside reverse transcriptase inhibitor (NRTI) antiretroviral drug  
 CC often used to treat HIV and AIDS. The identification method of the  
 CC invention may be useful for identifying patients who need to be excluded  
 CC from treatment with abacavir. The present sequence is that of a human  
 CC sequencing and PCR amplification primer which was used for SNP detection  
 CC on the pyrosequencer for identifying the presence or absence of the 57.1  
 CC ancestral haplotype of the MHC of the invention.  
 XX  
 SQ Sequence 19 BP; 3 A; 7 C; 6 G; 3 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.64; Score 14.4; DB 1; Length 19;  
 Db Best Local Similarity 93.84; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1208 AGGAGCTGTGGCTTA 1223  
 | |||||  
 Db 17 ACGAGCTGTGGCTTA 2  
 |||||  
 RESULT 255  
 ADE29675  
 ID ADE29675 standard; RNA; 19 BP.  
 XX  
 AC ADE29675;  
 XX  
 XX 29-JAN-2004 (first entry)  
 XX  
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:297.  
 XX  
 KM short interfering nucleic acid, siNA, downregulation, inhibition;  
 KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;  
 KM cytosolic; anorectic; antidiabetic; antiinflammatory; antiaesthetic;  
 KM immunosuppressive; antibacterial; antineumatic; antiaesthetic;  
 KM antiporiatic; gastrointestinal; obesity; diabetes; tumour;

KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;  
 KM psoriasis; inflammatory bowel disease; drug screening;  
 KM genetic engineering; pharmacogenomic; gene mapping; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO2003072590-A1.  
 XX  
 PD 04-SEP-2003.  
 XX  
 PF 28-JAN-2003; 2003WO-US002510.  
 XX  
 PR 20-FEB-2002; 2002US-0358580P.  
 PR 11-MAR-2002; 2002US-0363124P.  
 PR 06-JUN-2002; 2002US-036782P.  
 PR 29-AUG-2002; 2002US-0406784P.  
 PR 05-SEP-2002; 2002US-0408378P.  
 PR 09-SEP-2002; 2002US-0409293P.  
 PR 15-JAN-2003; 2003US-0440129P.  
 XX  
 PA (SIRN-) SIRNA THERAPEUTICS INC.  
 XX  
 PI Meswigen J, Beigelman L, Usman N, Haerberli P, Chowrira B;  
 XX  
 DR WPI; 2003-689980/65.  
 XX  
 PT New short interfering nucleic acid, useful e.g. for treatment and  
 PT diagnosis of cancer, downregulates expression of mitogen-activated  
 PT protein kinase genes.  
 XX  
 PS Example 3; SEQ ID NO 297; 164pp; English.  
 XX  
 CC The present invention describes a short interfering nucleic acid (siNA)  
 CC that downregulates expression of a mitogen-activated protein kinase  
 CC (MAPK) genes by RNA interference. Also described: (1) a method for  
 CC modulating expression of MAPK genes in cells, tissue explants or  
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo  
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)  
 CC vectors that express siNA and cells containing these vectors. MAPK siNAs  
 CC have cytostatic, anorectic, antidiabetic, antidiabetic, antineumatic,  
 CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,  
 CC antiaesthetic, antipsoriatic and gastrointestinal activities. The MAPK  
 CC siNAs can be used to modulate the expression of MAPK genes, in cells,  
 CC tissue explants or organisms, e.g. for treating obesity, diabetes types I  
 CC and II, a wide range of tumours, and inflammatory diseases (asthma,  
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel  
 CC disease). They can also be used for drug screening; diagnosis; target  
 CC identification and validation; genetic engineering; pharmacogenomics;  
 CC studying gene function and gene mapping (e.g. of single-nucleotide  
 CC polymorphisms). The present sequence represents a MAPK siNA which is used  
 CC in the exemplification of the present invention.  
 XX  
 SQ Sequence 19 BP; 6 A; 1 C; 5 G; 0 T; 7 U; 0 Other;  
 XX  
 QY Query Match 0.64; Score 14.4; DB 1; Length 19;  
 Db Best Local Similarity 56.24; Pred. No. 1.8e+02;  
 Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
 QY 1431 AATATTGAGTACTG 1446  
 ||:|||||:  
 Db 1 AAUAUUUGAGUACUG 16  
 ||:|||||:  
 RESULT 256  
 ADE29512/C  
 ID ADE29512 standard; RNA; 19 BP.  
 XX  
 AC ADE29512;  
 XX  
 XX 29-JAN-2004 (first entry)  
 XX  
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:134.  
 XX



KM short interfering nucleic acid; siNA; downregulation; inhibition;  
 KM mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;  
 KM cytoskeletal; anorectic; antidiabetic; antiinflammatory; antisthmatic;  
 KM immunosuppressive; antibacterial; antirheumatic; antiarthritic;  
 KM antiproliferative; gastrointestinal; obesity; diabetes; tumour;  
 KM inflammatory disease; asthma; septic shock; rheumatoid arthritis;  
 KM psoriasis; inflammatory bowel disease; drug screening;  
 KM genetic engineering; pharmacogenomic; gene mapping; ss.  
 XX Synthetic.  
 OS  
 XX WO2003072590-A1.  
 PN  
 XX 04-SEP-2003.  
 PD  
 XX 28-JAN-2003; 2003WO-US002510.  
 PF  
 XX 20-FEB-2002; 2002US-0358580P.  
 PR 11-MAR-2002; 2002US-0363124P.  
 PR 06-JUN-2002; 2002US-036782P.  
 PR 29-AUG-2002; 2002US-0406784P.  
 PR 05-SEP-2002; 2002US-0408378P.  
 PR 09-SEP-2002; 2002US-0409293P.  
 PR 15-JAN-2003; 2003US-0440129P.  
 PA  
 XX (SIRN-) SIRNA THERAPEUTICS INC.  
 PI  
 XX Mcswigen J, Beigelman L, Usman N, Haeblerli P, Chowitra B;  
 PI WPI; 2003-689980/65.  
 DR  
 XX  
 XX New short interfering nucleic acid, useful e.g. for treatment and  
 PT diagnosis of cancer, downregulates expression of mitogen-activated  
 PT protein kinase genes.  
 XX  
 PS Example 3; SEQ ID NO 134; 164pp; English.  
 XX  
 CC The present invention describes a short interfering nucleic acid (siNA)  
 CC that downregulates expression of a mitogen-activated protein kinase  
 CC (MAPK) genes by RNA interference. Also described: (1) a method for  
 CC modulating expression of MAPK genes in cells, tissue explants or  
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo  
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)  
 CC vectors that express siNA and cells containing these vectors. MAPK siNAs  
 CC have cytostatic, anorectic, antidiabetic, antiinflammatory,  
 CC antiaesthetic, immunosuppressive, antibacterial, antirheumatic,  
 CC antiarthritic, antiproliferative and gastrointestinal activities. The MAPK  
 CC siNAs can be used to modulate the expression of MAPK genes, in cells,  
 CC tissue explants or organisms, e.g. for treating obesity; diabetes types I  
 CC and II; a wide range of tumours, and inflammatory diseases (asthma,  
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel  
 CC disease). They can also be used for drug screening; diagnosis; target  
 CC identification and validation; genetic engineering; pharmacogenomics;  
 CC studying gene function and gene mapping (e.g. of single-nucleotide  
 CC polymorphisms). The present sequence represents a MAPK siNA which is used  
 CC in the exemplification of the present invention.  
 CC  
 XX Sequence 19 BP; 7 A; 5 C; 1 G; 0 T; 6 U; 0 Other;  
 SO  
 Query Match 0.64; Score 14.4; DB 1; Length 19;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 1431 AATATTGAGTACCTG 1446  
 |||||||||  
 Db 19 AATATTGAGTACTTG 4  
 RESULT 257  
 AAQ45287  
 ID AAQ45287 standard; rRNA; 14 BP.  
 XX  
 AC AAQ45287;

XX 25-MAR-2003 (revised)  
 DT 09-OCT-1994 (first entry)  
 XX  
 XX Sequence of minimal sequence required for anti-g10 antibody recognition.  
 KM D10 epitope, g10 antibody; control RNA; loop sequence; ss.  
 KM  
 KM Synthetic.  
 OS  
 XX WO9406934-A1.  
 PN  
 XX 31-MAR-1994.  
 PD  
 XX 31-AUG-1993; 93WO-US008210.  
 PF  
 XX 11-SEP-1992; 92US-00944208.  
 PR 30-SEP-1992; 92US-00956693.  
 PR  
 XX (UYDU-) UNIV DUKE.  
 PA  
 XX  
 PI Keene JD, Kenan DJ, Tsai DE;  
 XX WPI; 1994-118482/14.  
 DR  
 XX  
 XX Generating nucleic acid epitopes cross-reactive with non-nucleic acid  
 PT immunogens, pref. viruses and allergens - used to generate immune  
 PT responses in humans and animals.  
 XX  
 PS Example; Page 34; 56pp; English.  
 XX  
 CC Anti-g10 antibody is specific for proteins contg. a g10 fusion peptide  
 CC (see AAR51052). However, whereas the g10 peptide is a useful epitope tag  
 CC for analysing complexed contg. protein, an RNA epitope tag would be  
 CC equally useful for studying complexes contg. RNA. The anti-g10 serum was  
 CC presented with a degenerate pool of RNA contg. 1,048,576 species  
 CC representing all possible RNA species. The transcripts were  
 CC immunoprecipitated with the anti-g10 serum. A single RNA species, D10,  
 CC was obt'd. The minimal sequence required for antibody recognition is  
 CC AAQ45287, in the context of a stem. (Updated on 25-MAR-2003 to correct PN  
 CC field.)  
 CC  
 XX Sequence 14 BP; 2 A; 3 C; 7 G; 0 T; 2 U; 0 Other;  
 SO  
 Query Match 0.64; Score 14; DB 1; Length 14;  
 Best Local Similarity 85.7%; Pred. No. 1.5e+02;  
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
 Oy 2112 CTTGCTGAGCAGG 2125  
 ||:|||||  
 Db 1 CUGUGUGAGCAGG 14  
 RESULT 258  
 AAF48867  
 ID AAF48867 standard; DNA; 15 BP.  
 XX  
 AC AAF48867;  
 DT 30-MAR-2001 (first entry)  
 DE IGFBP3 oligonucleotide #2287.  
 DE  
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 KM cytoskeletal; dermatological; cardiant; virocid; ophthalmological; keloid;  
 KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;  
 KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 KM growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;  
 KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 KM hyperneovascular condition; hyperplasia; kidney disease;  
 KM neovascular condition of the retina; ss.  
 XX  
 OS Homo sapiens.



```

XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisease nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 59; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisease oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisease
XX CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX CC F5161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 1 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
QY Query Match 0.6%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 1643 CTGCCCTGCTGCAG 1656
2 CTGCCCTGCTGCAG 15
RESULT 259
AAF48869
ID AAF48869 standard; DNA; 15 BP.
XX AC AAF48869;
XX DT 30-MAR-2001 (first entry)
XX DE IGFBP3 oligonucleotide #2289.
XX KW Antisease therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytostatic; dermatological; cardiant; viaricide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.

```

```

XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisease nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 7; Page 59; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisease oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisease
XX CC oligonucleotide of the present invention (see AAF45151 and AAF45153-
XX CC F5161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
QY Query Match 0.6%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 1644 TGCCCTGCTGCAGA 1657
1 TGCCCTGCTGCAGA 14
RESULT 260
ABA89702/c
ID ABA89702 standard; DNA; 16 BP.
XX AC ABA89702;
XX DT 12-FEB-2002 (first entry)
XX DE Serial analysis of ribosomal DNA tag #61.
XX KW Serial analysis of ribosomal DNA; SARD; genetic diversity;
XX KW geochemical exploration; agriculture; bioremediation; forensic science;
XX KW environmental analysis; parasite detection; virus detection; ss.
XX KW Unidentified.
XX OS Homo sapiens.
XX PN WO2000177392-A2.
XX PD 18-OCT-2001.
XX PF 10-APR-2001; 2001WO-US011609.
XX PR 10-APR-2000; 2000US-0196063P.
XX PR 11-APR-2000; 2000US-0196258P.
XX PA (ASHB/) ASHBY M.
XX PI Ashby M;

```

XX	WP1; 2002-010926/01.
DR	
PT	Determining genetic diversity of population by analyzing a specific
PT	polymorphic region characteristic of particular genome in population of
PT	interest, useful for locating mineral deposits or petroleum reserves.
XX	
PS	Example 3; Fig 16; 83pp; English.
XX	
CC	The present invention relates to a method of determining the genetic
CC	diversity of a population, involving amplifying a genome subregion with a
CC	polymorphic site, cleaving amplified fragment close to the polymorphic
CC	site, immobilising the amplified fragment, splitting into two pools,
CC	adding a linker to each pool, digesting the immobilised product to form
CC	tags that are ligated to form digests, and amplifying, cleaving and
CC	ligating to form concatemers and sequencing. The method is known as
CC	serial analysis of ribosomal DNA (SARD). This can be used to determine the
CC	genetic diversity of a population including microbial, viral or immune
CC	cell populations. The microbial population whose genetic diversity can be
CC	determined is from a sample associated with a site for petroleum or
CC	natural gas exploration, i.e., at a site of oil or gas reserves,
CC	associated with a site of mineral exploration, associated with a
CC	agricultural field, of patient sample suspected to have bacterial or
CC	fungal infection, associated with bioremediation site, or of an insect or
CC	parasite. The methods have application in fields of geochemical
CC	exploration, agriculture, bioremediation, environmental analysis,
CC	clinical microbiology, forensic science and medicine. The present
CC	invention is an oligonucleotide described in the exemplification of the
CC	invention
SO	
XX	Sequence 16 BP; 2 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX	
Qy	Query Match 0.6%; Score 14; DB 1; Length 16;
Db	Best Local Similarity 100.0%; Pred. No. 1.7e+02;
	Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
	297 AGCTGCGGCACTGG 310
	16 AGCTGCGGCACTGG 3
RESULT 261	
ID	AA092210/c
XX	AA092210 standard; DNA; 17 BP.
AC	
XX	AA092210;
XX	
DT	12-JAN-1996 (first entry)
XX	
DE	p53 detection probe, (codon 142 del 1 C).
XX	
KW	Primer; polymerase chain reaction; amplify; mutant; K-ras; PCR;
KW	flanking region; amplification; probe; detection; sputum; diagnosis;
KW	benign; malignant; neoplasm; lung; lung cancer; head; neck; ss.
XX	
OS	Synthetic.
XX	
PN	WO9513397-A1.
XX	
PD	18-MAY-1995.
XX	
PF	10-NOV-1994; 94WO-US012947.
XX	
PR	12-NOV-1993; 93US-00152313.
XX	
XX	(UYJO ) UNIV JOHNS HOPKINS SCHOOL MED.
PA	
PI	Sidransky D;
XX	
XX	WP1; 1995-194114/25.
DR	
PT	Detecting target nucleic acid in mammalian sputum - particularly for
PT	diagnosis of lung neoplasia involving mutation(s) in the K-ras oncogene

```

PT or p53 tumour suppressor.
XX
XX Example 1, Page 36; 122pp; English.
XX
CC The sequences given in AA092112-211 are probes which were used in the
CC detection of a mutant p53 gene sequence. The DNA to be detected is
CC amplified using PCR and then these probes which are pref. labeled using
CC 32-P gamma-ATP are used to detect the mutant sequences. The primers and
CC probes given in AA092098-219 are used in the method of the invention for
CC detecting mammalian target DNA in sputum samples. Analysis of the target
CC DNA is used to diagnose benign or malignant neoplasms of the lung. It is
CC also useful for screening people at high risk or for monitoring progress
CC of treatment of lung neoplasms. The method is based on the discovery that
CC mutant target DNA associated with lung cancer is present at detectable
CC levels in sputum. Cells shed into sputum from head and neck cancers may
CC also be detected
CC
SQ Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY 1729 CTGCACAGCGACGCT 1742
DB 16 CTGCACAGCGACGCT 3
CTGCACAGCGACGCT 3
RESULT 262
AAT81544
ID AAT81544 standard; RNA; 17 BP.
AC AAT81544;
XX
XX 14-DEC-1997 (first entry)
DT
DE Human c-myb hammerhead ribozyme target sequence (nt. position 2872).
XX
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
XX coronary angioplasty; ss.
XX
XX Homo sapiens.
OS
XX
XX W09531541-A2.
XX
XX 23-NOV-1995.
ED
XX
XX 18-MAY-1995; 95WO-US006368.
XX
XX 18-MAY-1994; 94US-00245466.
XX
XX 13-JAN-1995; 95US-00373124.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX
XX Stinchcomb Dr, Draper K, Mcawiggen J, Jarvis T;
XX
XX WPI; 1996-010927/01.
XX
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
XX for treating restenosis or cancer.
XX
XX Claim 1, Page 78; 128pp; English.
XX
XX
XX The present sequence represents the preferred target sequence for an
XX enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
XX the human c-myb sequence at the base position indicated in the descriptor
XX line. The c-myb sequence was screened for optimal ribozyme target sites
XX using a computer folding algorithm, and regions of the mRNA which did not
XX form secondary folding structures and contained potential ribozyme
XX cleavage sites were identified. Ribozymes were synthesised and their
XX activities optimised by either varying the length of the binding arms or
XX by modification to prevent degradation by nucleases. The ribozymes cleave

```

CC the c-myb sequence and can be used to prevent smooth muscle cell  
CC hyperproliferation in restenosis, especially after coronary angioplasty,  
CC and in cancers

XX Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 64.3%; Pred. No. 1.9e+02;  
Matches 9; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGATTTCAG 1255  
DB 2 CACTAGATVUCAG 15

RESULT 263  
AA165652/C  
ID AA165652 standard; DNA; 17 BP.

AC AA165652;

XX 03-JAN-2002 (first entry)

DE Primer for studying biallelic polymorphic markers in the IBD1 region.

XX Human; inflammatory bowel disease 1 protein; IBD1, IBD1prox;

KM intestinal inflammatory disease; apoptosis; NF-kappa B; cancer;

KM inflammatory disease; immune disease; cryptogenetic inflammation;

KM hemorrhagic rectocolitis; Crohn's disease; Blau syndrome; PCR primer; ss.

XX Homo sapiens.

OS FR2806739-A1.

PN 28-SEP-2001.

PD 27-MAR-2000; 2000FR-00003832.

PF 27-MAR-2000; 2000FR-00003832.

PR 27-MAR-2000; 2000FR-00003832.

XX (DAUS-) FOND DAUSSET-CEPH JEAN.

PI Hugot JP, Thomas G, Zouali M, Lesage S, Chamallard M;

DR WPI; 2001-608364/70.

XX New human nucleic acids associated with intestinal inflammatory disease,

PT useful for diagnosis, prognosis and control of these diseases, also

PT related proteins.

XX Example 4; Page 85; 97pp; French.

XX Primers AA155647-78 were used to characterise biallelic polymorphic

CC markers in the IBD1 gene region. The IBD1 gene encodes an inflammatory

CC bowel disease 1 (IBD1) polypeptide, which is associated with intestinal

CC inflammatory disease. The specification also describes a polypeptide

CC which is in proximity to IBD1, and is designated IBD1prox. The IBD1 gene

CC is probably involved in regulation of apoptosis and activation of NF-

CC kappa B. The IBD1 and IBD1prox polynucleotides are useful as source of

CC probes and primers, as source of (anti)sense oligonucleotides, for

CC recombinant production of polypeptides, and in screening for interactive

CC compounds. The polypeptides are used to raise specific antibodies which

CC are useful for diagnostic detection or purification of IBD1 and IBD1prox, to

CC screen for specific binding agents, potential therapeutic agents. The

CC IBD1 and IBD1prox polynucleotides and polypeptides are useful for

CC treatment and prevention of inflammatory and/or immune diseases or

CC cancer, where associated with mutations in genes corresponding to IBD1

CC and IBD1prox, especially cryptogenetic inflammation of the intestines

CC (hemorrhagic rectocolitis, Crohn's disease and Blau syndrome)

CC

XX Sequence 17 BP; 3 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 595 CTTGGGAGATGCG 608  
DB 14 CTTGGGAGATGCG 1

RESULT 264  
ABN00903/C  
ID ABN00903 standard; DNA; 17 BP.

AC ABN00903;

XX 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:895.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KM skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

OS WO200192524-A2.

PN 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US016981.

PF 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser

PT desorption ionization, comprises human myosin-like protein hGDMLP-1.

XX Disclosure; SEQ ID NO 895; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence

XX  
 SQ Sequence 17 BP; 2 A; 1 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.9e+02; Mismatches 0; Gaps 0;  
 Matches 14; Conservative 0; Indels 0; Indels 0;

Qy 1699 AAGCCCTTCCCCA 1712  
 |||||  
 Db 15 AAGCCCTTCCCCA 2

RESULT 265  
 ABN0904/C  
 ID ABN0904 standard; DNA; 17 BP.  
 XX  
 AC ABN0904;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:896.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (ABOM-) AEOMICA INC.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 896; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence

XX  
 SQ Sequence 17 BP; 2 A; 1 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.9e+02; Mismatches 0; Gaps 0;  
 Matches 14; Conservative 0; Indels 0; Indels 0;

Qy 1699 AAGCCCTTCCCCA 1712  
 |||||  
 Db 14 AAGCCCTTCCCCA 1

RESULT 266  
 ABR39797  
 ID ABR39797 standard; DNA; 17 BP.  
 XX  
 AC ABR39797;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID NO 5434.  
 XX  
 KW Cyrostatic; vinucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025175-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-313353/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 669; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human leukin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;  
Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;  
Qy 1334 TCACATTGTTCTC 1347  
3 TCACATTGTTCTC 16  
Db  
RESULT 267  
ACD61599/c  
ID ACD61599 standard; RNA; 17 BP.  
XX  
AC ACD61599;  
XX  
DT 23-SEP-2003 (first entry)  
DE HCV minus strand DNAzyme substrate sequence #134.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KM RNA stability; RNA expression; RNA synthesis; antisense;  
KM enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinczyme;  
KM amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KM HBV reverse transcriptase; Enhancer I region; viral replication;  
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KM virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO200281494-A1.  
XX  
PD 17-OCT-2002.  
XX  
PF 26-MAR-2002; 2002MO-US009187.  
XX  
PR 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
PI Blact L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;

XX  
DR WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
PS Claim 1; Page 277; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,  
CC inozymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present  
CC invention  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;  
Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0;  
Qy 1226 CAGTCACTCTCTG 1239  
16 CAGTCACTCTCTG 3  
Db  
RESULT 268  
AAZ20330/c  
ID AAZ20330 standard; DNA; 18 BP.  
XX  
XX AAZ20330;  
AC  
XX  
DT 15-NOV-1999 (first entry)  
DE Antisense modulator of RhoA, ISIS# 25578.  
XX  
XX RhoA; antisense modulator; antisense inhibitor; human; GTPase; cancer;  
KM Alzheimer's disease; wound repair; clotting disorder; diagnosis; therapy;  
KM infection; inflammation; tumour formation; ss.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..18  
FT /\*tag= a  
FT /note= "phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /\*tag= b  
FT /note= "optionally 2'-methoxyethyl nucleotides"  
FT modified\_base 15..18  
FT /\*tag= c  
FT /note= "optionally 2'-methoxyethyl nucleotides"  
PN US5945290-A.  
XX  
XX 31-AUG-1999.  
PD  
XX  
PF 18-SEP-1998; 98US-00156424.  
XX  
PR 18-SEP-1998; 98US-00156424.

```
XX (ISIS-) ISIS PHARM INC.
PA Cowsert IM;
PI WPI; 1999-526254/44.
XX
DR New agent for specific modulation of a GTPase especially useful for
PT prevention of tumor formation.
XX
PS Claim 3; Col 28; 24pp; English.
XX
CC This sequence represents an antisense inhibitor of human RhoA expression
CC of the invention. RhoA is a member of the Rho subfamily of small GTPases,
CC and is thought to be involved in both injury and disease states,
CC including Alzheimer's disease, wound repair, clotting disorders, and the
CC development of cancer. The antisense inhibitors are useful for inhibiting
CC expression of RhoA in human cells or tissues by contacting the cells or
CC tissues with the compound in vitro. They are useful for diagnosis,
CC treatment and prevention of reoccurrence of diseases or disorders caused
CC by aberrant expression of RhoA, and is useful prophylactically e.g. to
CC prevent or delay infection, inflammation or tumour formation. Unlike the
CC antisense sequences, prior art therapeutic agents which inhibit RhoA
CC synthesis are not specific to RhoA
XX
SQ Sequence 18 BP; 5 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1814 AGAAGCCACTATG 1827
Db |||||
15 AGAAGCCACTATG 2
XX
RESULT 269
AAF76101
ID AAF76101 standard; DNA; 18 BP.
XX
AC AAF76101;
XX
DT 22-MAY-2001 (first entry)
XX
DE CCR5/CCR2b PCR primer, SEQ ID:5, used to genotype HIV susceptibility.
XX
KW CC chemokine receptor; beta chemokine receptor; CCR; human; CCR5; CCR2;
KW polymorphism; genotyping; HIV-1 transmission; infection susceptibility;
KW AIDS; acquired immunodeficiency syndrome; disease progression;
KW chromosome 3p21-22; PCR primer; ss.
XX
XX Homo sapiens.
XX OS
XX PN WO200112857-A2.
XX
XX PD 22-FEB-2001.
XX
XX PF 11-AUG-2000; 2000WO-US022255.
XX
XX PR 12-AUG-1999; 99US-0148530P.
XX
XX PA (UABR-) UAB RES FOUND.
XX
XX PI Tang J, Kaslow RA;
XX
XX DR WPI; 2001-211235/21.
XX
XX PT Surveying CC beta chemokine receptor (CCR) genotypes in population,
XX involves amplifying genomic DNA of individuals with experimental and
XX PT control primer combinations, size-separating amplicons and determining
XX CCR genotype.
XX
PS Claim 1; Page 42; 118pp; English.
```

```
XX The invention relates to a method of surveying the CC (beta) chemokine
CC receptor (CCR) genotypes in a population. The method is particularly
CC applied to the human CCR5 and CCR2 genes located on chromosome 3p21-22,
CC which encode co-receptors for HIV-1. The method involves obtaining
CC genomic DNA samples from a representative number of individuals within a
CC population; combining each sample with experimental and control primer
CC combinations to produce primer-annealed DNA; amplifying the DNA to
CC produce amplicons; separating the amplicons by size; determining the CCR
CC genotype based upon the presence of CCR alleles; and compiling the
CC genotypes determined. The method is particularly applied to the human
CC CCR5 and CCR2 genes, which encode co-receptors for HIV-1. Polymorphisms
CC in these genes are associated with a variation in the susceptibility of
CC an individual to infection by HIV-1, or with a variation in the disease
CC progression of AIDS after infection. The invention specifically claims
CC the experimental PCR primers AAF76098-AAF76112, and the control PCR
CC primers AAF76113-AAF76114 for surveying CCR5 and CCR2b genotypes. The
CC method of the invention fulfills a longstanding need for the development
CC of a rapid and informative genotyping strategy that can be readily
CC applied to analyse CCR5, CCR2 and related genetic variants, and to
CC evaluate the relationship of each genotype to HIV transmission and
CC disease progression. The present sequence represents a human CCR5/CCR2b
CC experimental PCR primer for use in the method of the invention
XX
SQ Sequence 18 BP; 7 A; 0 C; 10 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2189 TGGAGAAAAGGGG 2202
Db |||||
4 TGGAGAAAAGGGG 17
XX
RESULT 270
AAF76102
ID AAF76102 standard; DNA; 18 BP.
XX
AC AAF76102;
XX
DT 22-MAY-2001 (first entry)
XX
DE CCR5/CCR2b PCR primer, SEQ ID:6, used to genotype HIV susceptibility.
XX
KW CC chemokine receptor; beta chemokine receptor; CCR; human; CCR5; CCR2;
KW polymorphism; genotyping; HIV-1 transmission; infection susceptibility;
KW AIDS; acquired immunodeficiency syndrome; disease progression;
KW chromosome 3p21-22; PCR primer; ss.
XX
XX Homo sapiens.
XX OS
XX PN WO200112857-A2.
XX
XX PD 22-FEB-2001.
XX
XX PF 11-AUG-2000; 2000WO-US022255.
XX
XX PR 12-AUG-1999; 99US-0148530P.
XX
XX PA (UABR-) UAB RES FOUND.
XX
XX PI Tang J, Kaslow RA;
XX
XX DR WPI; 2001-211235/21.
XX
XX PT Surveying CC beta chemokine receptor (CCR) genotypes in population,
XX involves amplifying genomic DNA of individuals with experimental and
XX PT control primer combinations, size-separating amplicons and determining
XX CCR genotype.
XX
PS Claim 1; Page 42; 118pp; English.
```

The inversion relates to a method of surveying the CC (beta) chemokine receptor (CCR) genotypes in a population. The method is particularly applied to the human CCR5 and CCR2 genes located on chromosome 3p21-22, which encode co-receptors for HIV-1. The method involves obtaining genomic DNA samples from a representative number of individuals within a population; combining each sample with experimental and control primer combinations; to produce primer-annealed DNA; amplifying the DNA to produce amplicons; separating the amplicons by size; determining the CCR genotype based upon the presence of CCR alleles; and compiling the genotypes determined. The method is particularly applied to the human CCR5 and CCR2 genes, which encode co-receptors for HIV-1. Polymorphisms in these genes are associated with a variation in the susceptibility of an individual to infection by HIV-1, or with a variation in the disease progression of AIDS after infection. The invention specifically claims the experimental PCR primers AAF6098-AAF7612, and the control PCR primers AAF7613-AAF7614 for surveying CCR5 and CCR2b genotypes. The method of the invention fulfils a longstanding need for the development of a rapid and informative genotyping strategy that can be readily applied to analyse CCR5, CCR2 and related genetic variants, and to evaluate the relationship of each genotype to HIV transmission and disease progression. The present sequence represents a human CCR5/CCR2b experimental PCR primer for use in the method of the invention

**Seq** Sequence 18 BP; 8 A; 0 C; 9 G; 1 T; 0 U; 0 Other;  
**Query Match** 0.64; Score 14; DB 1; Length 18;  
**Best Local Similarity** 100.0%; Pred. No. 2e+02;  
**Matches** 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	2189	TCGAGAAAAAGGGG	22
Db	4	TGGAGAAAAAGGGG	17

RESULT 271  
AAF94632/c  
ID AAF94632 standard; DNA; 18 BP.

AC AAF94632;

DT 23-MAY-2001 (first entry)

DE Rho A antisense phosphorochloate oligonucleotide SEQ ID 56.

KM Rho; GTP binding protein; phosphoethoxide antisense oligonucleotide;  
KM RhoA; RhoB; RhoC; RhoG; Rac 1; cdc42; hyperproliferative condition;  
KM cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation  
KM 68.

OS Homo sapiens.

PN WO200115739-A1.

PD 08-MAR-2001

PF 18-AUG-2000; 2000WO-US022808.

PR 31-AUG-1999; 99US-00387341.

PA (ISIS-) ISIS PHARM INC.

PI Roberts ML, Cowbert LM,

WPI; 2001-191677/19

PT An antisense compound targeted to a nucleic acid molecule encoding a member of the human Rho family of small GTP binding proteins useful for treating e.g. cancer and ischemia.

PS Example 8; Page 53; 156pp; English.

CC This invention relates to an antisense compound targeted to a nucleic acid molecule encoding a member of the human Rho family of small GTP

CC binding proteins, where the antisense compound inhibits the expression of  
CC the member of the human Rho family. The invention includes antisense  
CC oligonucleotides AAf94180 - AAf94637 which target a RhoA nucleotide  
CC sequence, AAf94645 - AAf94684 which target a RhoB nucleotide sequence,  
CC AAf94686 - AAf94725 which target a RhoC nucleotide sequence, AAf94727 -  
CC AAf94766 which target RhoG nucleotide sequence, AAf94769 - AAf94790 which  
CC target a Rac 1 nucleotide sequence and AAf94795 - AAf94809 which target  
CC cdc42 nucleotide sequence. The antisense compound is useful for treating  
CC hyperproliferative conditions, especially cancer, abnormal wound healing  
CC or clotting conditions and ischaemia/reperfusion or reoxygenation injury.  
CC The compound may also be used to diagnose the above conditions  
XX  
XX Sequence 18 BP; 5 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

Query Match	0.63	Score 14	DB 1	Length 18
Best Local Similarity	100.0%	Pred. No. 2e+02		
Matches 14	Conservative 0	Mismatches 0	Indels 0	Gaps 0

```

QY      1814 AGAAGCCAATATG 1827
          |||||
Db      15 AGAAGCCAATATG 2

```

RESULT 272  
ABL44589  
ID ABL44589 standard; DNA; 18 BP.

AC ABL44589;

DT 11-APR-2002 (first entry)

DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1633.

KM Human; chromosome 1p36-35; genetic analysis; genome;  
KM PCR primer; ss.

OS Homo sapiens.

PN JP2001321190-A.

PD 20-NOV-2001

PF 12-MAR-2001; 2001JP-00068285.

PR 10-MAR-2000; 2000JP-00066716.

PA (RIKA ) RIKAGAKU KENKYUSHO.

XX

DR WPI; 2002-144136/19

PT Arraying genome clones

PS Claim 4; Page 37; 528pp; Japanese.

The present invention describes a method of arraying genome clones. The method comprises: (a) clones of the genomic libraries contained in the multowell plates numbered for discrimination are mixed in each of the multowell plates; (b) a primer designed based on the chromosome marker sequence is added to the mixture to carry out an amplification reaction; (c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multowell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multowell plates; (e) the clones in the multowell plates of the specified discrimination Nos. are mixed respectively in each well of longitudinal and lateral directions; (f) the mixed clones are cultured and the resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multowell plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent



CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634  
 CC represent PCR primers for human chromosome 21q22.1, which are  
 CC specifically claimed for use in the present invention  
 XX  
 SQ Sequence 18 BP; 3 A; 1 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 594 TCTGGGAGATGG 607  
 |||||  
 DB 4 TCTGGGAGATGG 17

RESULT 273  
 AAA24819/c  
 ID AAA24819 standard; DNA; 17 BP.  
 XX  
 AC AAA24819;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1317.  
 XX  
 KM Oestrogen receptor; c-rai; k-raa; bcl-2; ribozyme; cleavage;  
 KM hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
 KM gene expression modification; cancer; phosphorothioate; endonuclease;  
 KM anticancer; breast cancer; endometrium cancer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN MO9954459-A2.  
 XX  
 PD 28-OCT-1999.  
 XX  
 PF 19-APR-1999; 99WO-US008547.  
 XX  
 PR 20-APR-1998; 98US-0082404P.  
 PR 23-JUN-1998; 98US-00103636.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Thompson JD, Beigelman L, Mowsiggen JA, Karpelsky A, Bellon L,  
 PI Reynolds M, Zwick M, Jarvis T, Wolf T, Haeblerl P,  
 PI Matulic-Adamic J;  
 XX  
 DR WPI; 2000-013246/01.  
 XX  
 PT New nucleic acids that interact, and optionally cleave, target sequences,  
 PT used to treat cancer.  
 XX  
 PS Claim 77; Page 59; 148pp; English.  
 XX

The present invention describes nucleic acids (A) that interact stably  
 CC with a target sequence and contain at least one phosphor(di)thioate  
 CC link, having endonuclease activity. (A), and more generally any catalytic  
 CC nucleic acid (A') that modulates expression of the oestrogen receptor  
 CC gene, are used to treat cancer (particularly of breast or endometrium),  
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
 CC for other conditions associated with levels of oestrogen receptor.  
 CC Because of the high selectivity for targeted RNA, (A) can also be used to  
 CC correlate inhibition of gene expression with alterations in phenotype,  
 CC particularly for identification of therapeutic targets, and as research  
 CC reagents (for RNA, in the same way that restriction endonucleases are  
 CC used with DNA). The combination of modifications in (A) improves  
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
 CC AAA24748 to AAA25992 represent their corresponding target sequences.  
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
 CC antisense oligonucleotides used in the exemplification of the present

CC invention  
 XX  
 SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 541 GGCTCGAGACGCCCG 557  
 |||||  
 DB 17 GGCTCGAGACACGCTG 1

RESULT 274  
 AAF02145/c  
 ID AAF02145 standard; DNA; 17 BP.  
 XX  
 AC AAF02145;  
 XX  
 DT 16-FEB-2001 (first entry)  
 XX  
 DE Hammerhead ribozyme substrate #440.  
 XX  
 KM Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KM interferon alpha; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200061729-A2.  
 XX  
 PD 19-OCT-2000.  
 XX  
 PF 11-APR-2000; 2000WO-US009721.  
 XX  
 PR 12-APR-1999; 99US-0129390P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Blatt L, Zwick M, Pavco P, Mowsiggen J;  
 XX  
 DR WPI; 2000-647423/62.  
 XX  
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT interferon alpha and erythropoietin.  
 XX  
 PS Claim 37; Page 66; 164pp; English.  
 XX

The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COP-1, the GATA transcription  
 CC factor gene, IRE-2 and/or the C/EBP displacement protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC interferon alpha  
 CC  
 SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1843 GCTGCACTAAGCTCG 1859  
 |||||  
 DB 17 GCCACGATTAAGTCTGG 1

RESULT 275  
 AAF02081/c  
 ID AAF02081 standard; DNA; 17 BP.  
 XX  
 AC AAF02081;



XX 16-FEB-2001 (first entry)  
 XX Hammerhead ribozyme substrate #376.  
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KW Interferon alpha; ss.  
 XX Homo sapiens.  
 OS WO200061729-A2.  
 PN 19-OCT-2000.  
 PD 11-APR-2000; 2000WO-US009721.  
 PF 12-APR-1999; 99US-0129390P.  
 PR (RIBO-) RIBOZYME PHARM INC.  
 PA Blatt L, Zwick M, Pavco P, McSwiggen J;  
 WPI; 2000-647423/62.  
 DR Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT Interferon alpha and erythropoietin.  
 PS Claim 37; Page 64; 164pp; English.  
 XX The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC Interferon alpha  
 XX Sequence 17 BP; 2 A; 5 C; 8 G; 2 T; 0 U; 0 Other;  
 SQ

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2004 TGGCCACGAGTGGCTCG 2020  
 |||||  
 Db 17 TGCCCCCAGAGCCCTCG 1

RESULT 276  
 AAF01721  
 ID AAF01721 standard; DNA; 17 BP.  
 XX AAF01721;  
 AC 16-FEB-2001 (first entry)  
 XX Hammerhead ribozyme substrate #16.  
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KW Interferon alpha; ss.  
 XX Homo sapiens.  
 OS WO200061729-A2.  
 PN 19-OCT-2000.  
 PD 11-APR-2000; 2000WO-US009721.  
 PR 12-APR-1999; 99US-0129390P.  
 XX

PA (RIBO-) RIBOZYME PHARM INC.  
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;  
 XX WPI; 2000-647423/62.  
 DR Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT Interferon alpha and erythropoietin.  
 PS Claim 37; Page 56; 164pp; English.  
 XX The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC Interferon alpha  
 XX Sequence 17 BP; 1 A; 4 C; 5 G; 7 T; 0 U; 0 Other;  
 SQ

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 949 TTGGGATCATGCTCTG 965  
 |||||  
 Db 1 TTGTGGATCCTGCTCTG 17

RESULT 277  
 ABK02015  
 ID ABK02015 standard; RNA; 17 BP.  
 XX ABK02015;  
 AC 12-MAR-2002 (first entry)  
 XX Human NOD2 zinzyme #337.  
 DE Human NOD2 zinzyme #337.  
 XX Human; ss; antisense therapy; cytoskeletal; antiinflammatory; haemostatic;  
 KW cerebroprotective; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOD2; hammerhead ribozyme;  
 KW DNazyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX WO200159103-A2.  
 PN 16-AUG-2001.  
 PD 09-FEB-2001; 2001WO-US004273.  
 PF 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX

PI Blatt L, Mcswigen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX  
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX  
 PS Claim 88; Page 101; 200pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a  
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) or  
 CC possessing an NGH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably  $Mg^{2+}$ .  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-  
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the  
 CC presence of a divalent cation that is preferably  $Mg^{2+}$ . Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a zynzyme molecule of the invention  
 CC  
 XX  
 SQ Sequence 17 BP; 1 A; 1 C; 9 G; 0 T; 6 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 64.7%; Pred. No. 2e+02;  
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
 OY 784 GGAGAGGTGTTGGGCG 800  
 |||||:::|||||  
 Db 1 GGAGUGGUGUGUGGUC 17  
 RESULT 278  
 ABRK0106  
 ID ABRK0106 standard; RNA; 17 BP.  
 XX  
 AC ABRK0106;  
 XX  
 DT 12-MAR-2002 (first entry)  
 XX  
 DE Human NOGO Hammerhead Ribozyme #106.  
 XX  
 KM Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;  
 KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KM DNazyme; inozyme; G-cleaver; amberzyme; zynzyme; lymphoma; leukemia;  
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;  
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KM inflammatory arthropathy; central nervous system injury;  
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;

KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KM Parkinson's disease; ataxia; Huntington's disease;  
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN MO200159103-A2.  
 XX  
 PD 16-AUG-2001.  
 XX  
 PR 09-FEB-2001; 2001MO-US004273.  
 XX  
 PR 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX  
 PI Blatt L, Mcswigen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 DR  
 XX  
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX  
 PS Claim 88; Page 67; 200pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a  
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) or  
 CC possessing an NGH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably  $Mg^{2+}$ .  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-  
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the  
 CC presence of a divalent cation that is preferably  $Mg^{2+}$ . Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a hammerhead ribozyme of the invention  
 CC  
 XX  
 SQ Sequence 17 BP; 9 A; 3 C; 2 G; 0 T; 3 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 70.6%; Pred. No. 2e+02;  
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;  
 OY 1778 GAAGCTTCAGAAAT 1794  
 |||||:::|||||||:

Db 1 GAACACUCCAGAAAU 17

RESULT 279

ID ABK01837/c

XX ABK01837 standard; RNA, 17 BP.

XX

XX ABK01837;

DT 12-MAR-2002 (first entry)

XX

DE Human NOGO zinzyme #159.

XX

XX Human; ss; antisense therapy; cyostatic; antiinflammatory; haemostatic; KM cerebroprotective; neuroprotective; antiparkinsonian; KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; KM DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia; KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia; KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; KM MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia; KM inflammatory arthropathy; central nervous system injury; KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; KM Parkinson's disease; ataxia; Huntington's disease; KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

XX

OS Homo sapiens.

OS Synthetic.

XX

XX WO200159103-A2.

PN 16-AUG-2001.

XX

PD 09-FEB-2001; 2001WO-US004273.

XX

PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (CHOW/) CHOWRIRA B M.

XX

PI Blatt L, Mcswigen J, Chowrira BM;

XX

DR WPI; 2001-607195/69.

XX

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense PT constructs, which down regulate expression of a CD20 gene or neurite PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and PT central nervous system injury.

XX

PS Claim 88; Page 98; 200PP; English.

XX

XX The invention relates to a nucleic acid molecule which down regulates CC expression of a CD20 gene and a nucleic acid molecule which down CC regulates expression of a neurite growth inhibitor gene (NOGO). The CC nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or CC an amberzyme (cleaving RNA with an NGN tripler), a zinzyme (cleaving RNA CC with a YXY motif). The CD20-targeting nucleic acid is used to cleave RNA CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>. CC Furthermore, it may be contacted with a cell to reduce CD20 activity of CC the cell and treat a patient having a condition associated with the level CC of CD20. The treatment may further comprise the use of one or more CC therapies. In particular, the CD20 targeting nucleic acid may be used to CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non- CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-

CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the CC nucleic acid may be contacted with a cell to reduce NOGO activity of the CC cell and treat a patient having a condition associated with the level of CC NOGO. The treatment may further comprise the use of one or more CC therapies. In particular, the NOGO-targeting nucleic acid may be used to CC treat central nervous system (CNS) injury and cerebrovascular accident CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob CC disease, muscular dystrophy, and/or other neurodegenerative disease CC states which respond to the modulation of NOGO expression. The present CC sequence is a zinzyme molecule of the invention

XX

XX Sequence 17 BP, 3 A, 9 C, 5 G, 0 T, 0 U, 0 Other;

SO

Query Match 0.64; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.24; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 199 GTGCTGTGCTGGGGC 215

Db 17 GGGCTGTGCTGGGGC 1

XX

XX RESULT 280

XX ABN08065

ID ABN08065 standard; DNA, 17 BP.

XX

XX ABN08065;

XX

DT 29-MAY-2002 (first entry)

XX

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8057.

XX

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart; KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; KM skeletal muscle disorder; amplicon; screening; ss.

XX

OS Homo sapiens.

XX

PN WO200192524-A2.

XX

PD 06-DEC-2001.

XX

PR 25-MAY-2001; 2001WO-US016981.

XX

PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US00061.

PR 30-JAN-2001; 2001WO-US00062.

PR 30-JAN-2001; 2001WO-US00063.

PR 30-JAN-2001; 2001WO-US00064.

PR 30-JAN-2001; 2001WO-US00065.

PR 30-JAN-2001; 2001WO-US00066.

PR 30-JAN-2001; 2001WO-US00067.

PR 30-JAN-2001; 2001WO-US00068.

PR 30-JAN-2001; 2001WO-US00069.

PR 30-JAN-2001; 2001WO-US00070.

PR 05-FEB-2001; 2001US-0266860P.

XX

XX (AEOM-) AEOMICA INC.

PA

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX

DR WPI; 2002-179446/23.

XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins, PT or as specific biomolecule capture probes for surface-enhanced laser PT desorption ionization, comprises human myosin-like protein hGDMLP-1.

XX

PS Disclosure; SEQ ID NO 8057; 214pp; English.

XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at [ftp.wipo.int/pub/published\\_pct\\_sequence](http://wipo.int/pub/published_pct_sequence)

XX  
SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
Matches 15; Conservative 0; Indels 2; Indels 0; Gaps 0;

OY 2231 CAGATGCTCCAGAAATGA 2247  
DB 1 CAGATGACCCAGAGA 17  
|||||  
|||||

RESULT 281  
ABN09591  
ID ABN09591 standard; DNA; 17 BP.  
AC ABN09591;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9583.  
DE  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200192524-A2.  
PN  
XX  
XX 06-DEC-2001.  
PD  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
PF  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 03-FEB-2001; 2001US-026860P.  
PR

XX  
PA (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI  
XX WPI; 2002-179446/23.  
XX  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 9583; 214pp; English.

XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at [ftp.wipo.int/pub/published\\_pct\\_sequence](http://wipo.int/pub/published_pct_sequence)

XX  
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
Matches 15; Conservative 0; Indels 2; Indels 0; Gaps 0;

OY 1167 GTTAGGGAAGCTGC 1183  
DB 1 GTCGAGCGAAGAGCTGC 17  
|||||  
|||||

RESULT 282  
ABN08064  
ID ABN08064 standard; DNA; 17 BP.  
AC ABN08064;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8056.  
DE  
XX  
XX Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200192524-A2.  
PN  
XX  
XX 06-DEC-2001.  
PD  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
PF  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR

PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PA (AEOM-) AEOMICA INC.  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 DR  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 8056; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-  
 CC 1-proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 CC  
 XX  
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 1 T; 0 U; 0 Other;  
 Query Match 0.64; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 QY 2230 GCAGATGCTCAGATG 2246  
 Db 1 GCAGATGCTCAGATG 17  
 RESULT 283  
 ABN01968  
 ID ABN01968 standard; DNA; 17 BP.  
 XX  
 AC ABN01968;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1960.  
 XX  
 KM Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KM skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.

XX  
 PN- WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 DR  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 1960; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-  
 CC 1-proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 CC  
 XX  
 SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;  
 Query Match 0.64; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 QY 1832 AATCAGCTGCTGCA 1848  
 Db 1 AATCAGCTGCTGCA 17  
 RESULT 284  
 ABN06530  
 ID ABN06530 standard; DNA; 17 BP.  
 XX

AC ABN06530;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6522.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PA (AEOM-) AEWOMICA INC.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
DR  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 6522; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 2101 CAGCAGCTCAGCCTGT 2117  
|||  
Db 1 CACGACCGCAGCCTGT 17  
RESULT 285  
ID ABN06533 standard; DNA; 17 BP.  
XX  
XX ABN06533;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6525.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PA (AEOM-) AEWOMICA INC.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
DR  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 6525; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.64; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.24; Pred. No. 2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 2104 CACCTGAGCTGTGTA 2120  
1 CACCTGAGCTGTGTA 17  
Db 1 CACCTGAGCTGTGTA 17  
RESULT 286  
ABN01538  
ID ABN01538 standard; DNA; 17 BP.  
AC ABN01538;  
XX  
XX 29-MAY-2002 (first entry)  
DT  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1530.  
XX  
XX Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX MO200192524-A2.  
XX  
XX 06-DEC-2001.  
PD  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX Disclosure; SEQ ID NO 1530; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 1 C; 10 G; 4 T; 0 U; 0 Other;  
Query Match 0.64; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.24; Pred. No. 2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1595 AGGTGACGGCGCTGTG 1611  
1 AGGTGACGGCGCTGTG 17  
Db 1 AGGTGACGGCGCTGTG 17  
RESULT 287  
ABN00673/c  
ID ABN00673 standard; DNA; 17 BP.  
AC ABN00673;  
XX  
XX 29-MAY-2002 (first entry)  
DT  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:665.  
XX  
XX Human, genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX MO200192524-A2.  
XX  
XX 06-DEC-2001.  
PD  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX



```

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 665; 214bp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 7 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 53 CTTCTCGCATGGCTG 69
Db 17 CTTCTCGCTGGCTG 1
RESULT 288
ABN01580/c
ID ABN01580 standard; DNA; 17 BP.
XX
AC ABN01580;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1572.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.

```

```

PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
DE WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX
PS Disclosure; SEQ ID NO 1572; 214bp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 267 CCAGGCTGCTGGCTG 283
Db 17 CCAGAGCAGGCTGGCTG 1
RESULT 289
ABN02747
ID ABN02747 standard; DNA; 17 BP.
XX
AC ABN02747;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2739.
XX
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KM skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX

```



PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 (AEOM-) AEOMICA INC.  
 PI Gu Y, J1 Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PT WPI; 2002-179446/23.  
 DR  
 XX  
 XX  
 PS New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 XX  
 PS Disclosure; SEQ ID NO 2739; 214pp; English.  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 297 AGCTGCGGCACTGGGCT 313  
 |||||  
 DB 1 AGCTGAGGCGCCCTGGGCT 17  
 |||||  
 RESULT 290  
 ABN06534  
 ID ABN06534 standard; DNA; 17 BP.  
 AC ABN06534;  
 XX  
 XX 29-MAY-2002 (first entry)  
 DT Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6526.  
 DE Human, genome-derived myosin-like protein 1, hGDMLP-1, heart;  
 XX  
 KM

KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KM skeletal muscle disorder; amplicon; screening; 88.  
 XX Homo sapiens.  
 OS  
 XX WO200192524-A2.  
 PN  
 XX  
 XX 06-DEC-2001.  
 PD  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 XX  
 PA (AEOM-) AEOMICA INC.  
 PI Gu Y, J1 Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PT WPI; 2002-179446/23.  
 DR  
 XX  
 XX  
 PS New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 XX  
 PS Disclosure; SEQ ID NO 6526; 214pp; English.  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 2105 ACCGACGCTGGGAG 2121  
 |||||  
 DB 1 ACCGACGCTGGGAG 17  
 |||||

RESULT 291  
ABN00523/c  
ID ABN00523 standard; DNA; 17 BP.  
XX  
AC ABN00523;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:515.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0268660P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 515; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX

SEQ Sequence 17 BP; 3 A; 8 C; 5 G; 1 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 160 CTGCTCCGGGCTGGGC 176  
DB 17 CTGCTCAGGGCTGGGGC 1  
RESULT 292  
ABN06766  
ID ABN06766 standard; DNA; 17 BP.  
XX  
AC ABN06766;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6758.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0268660P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 6758; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP, 3 A, 3 C, 8 G, 3 T, 0 U, 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 2041 GTGAGCAGCTCCTGTA 2057  
Db 1 GTGAGCAGCTCCTGGA 17  
RESULT 293  
ABN06529  
ID ABN06529 standard; DNA; 17 BP.  
XX  
AC ABN06529;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6521.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016391.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 6521; 214P; English.  
XX  
XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 protein or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP, 3 A, 9 C, 4 G, 1 T, 0 U, 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 2100 CCAGCAGCTCAGCCTGG 2116  
Db 1 CCAGCAGCAGCAGCCTGG 17  
RESULT 294  
ABQ64238  
ID ABQ64238 standard; DNA; 17 BP.  
XX  
AC ABQ64238;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 951.  
XX  
KM Human; KTOM1a; kidney tumour overexpressed membrane; cytosolic;  
KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
XX

```
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 282; 418bp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (Kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytoskeletal activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 147 CACCGCGCTGCCACTGC 163
Db 1 CACCGAGCAGCCACTGC 17
RESULT 295
ABV85488/c
ID ABV85488 standard; DNA; 17 BP.
XX
AC ABV85488;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:481.
XX
KM Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KM ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 30-JAN-2001; 2001US-00864761.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
```

```
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetylalactosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 481; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (1) encoding a
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to
CC ABP53504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1488 CTTACACTTGAGGCGCC 1504
Db 17 CTTACACTTGTTGGGAC 1
RESULT 296
ABV85444
ID ABV85444 standard; DNA; 17 BP.
XX
AC ABV85444;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mer SEQ ID NO:437.
XX
KM Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KM ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GalNAc:polypeptide N-
PT cetylalactosaminyltransferase 10 protein is useful to diagnose, prevent
```

PT and treat disorders associated with reduced or over expression of the  
PT encoded protein.  
XX  
XX Example 2; SEQ ID NO 437; 59pp; English.  
PS  
XX The present invention describes an isolated nucleic acid (1) encoding a  
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-  
CC GANTase 10, EC 2.4.1.41) protein. Human pp-GANTase 10 is located to  
CC chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the  
CC present invention can be used in therapy, particularly to prevent or  
CC treat a disorder associated with decreased expression or activity of pp-  
CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to  
CC ABP53504 are given in the exemplification of the present invention. N.B.  
CC The sequence data for this patent is not represented in the printed  
CC specification but is based on sequence information supplied by the  
CC European Patent Office  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1421 CCTCAGAGAAAATTT 1437  
Db 1 CCTCAGTGAATAATTT 17  
XX  
RESULT 297  
ABV85800  
ID ABV85800 standard; DNA; 17 BP.  
XX  
AC ABV85800;  
XX  
DT 11-DEC-2002 (first entry)  
XX  
DE Human pp-GANTase 10 scanning 17-mer SEQ ID NO:793.  
XX  
KM Human; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10;  
KW pp-GANTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;  
XX ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
OS  
XX  
XX EP1243660-A2.  
PN  
XX  
XX 25-SEP-2002.  
PD  
XX  
XX 25-JAN-2002; 2002EP-00001161.  
PF  
XX  
XX 30-JAN-2001; 2001WO-US000663.  
PR  
XX 30-JAN-2001; 2001WO-US000664.  
PR  
XX 30-JAN-2001; 2001WO-US000665.  
PR  
XX 30-JAN-2001; 2001WO-US000666.  
PR  
XX 30-JAN-2001; 2001WO-US000667.  
PR  
XX 30-JAN-2001; 2001WO-US000668.  
PR  
XX 30-JAN-2001; 2001WO-US000669.  
PR  
XX 30-JAN-2001; 2001WO-US000670.  
PR  
XX 23-MAY-2001; 2001US-00864761.  
PR  
XX 30-AUG-2001; 2001US-0315984P.  
PR  
XX  
XX (ABOM-) AEOMICA INC.  
PA  
XX  
XX Zhang J, Gu Y, Nguyen C;  
PI  
XX  
XX WPI; 2002-724954/79.  
DR  
XX  
XX Nucleic acid encoding human UDP-GalNAc:polypeptide N-  
PT acetylglactosaminyltransferase 10 protein is useful to diagnose, prevent  
PT and treat disorders associated with reduced or over expression of the  
PT encoded protein.  
XX

PS Example 2; SEQ ID NO 793; 59pp; English.  
XX  
XX The present invention describes an isolated nucleic acid (1) encoding a  
CC human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10 (pp-  
CC GANTase 10, EC 2.4.1.41) protein. Human pp-GANTase 10 is located to  
CC chromosome 7q11.2. (1) can be used in gene therapy. Molecules of the  
CC present invention can be used in therapy, particularly to prevent or  
CC treat a disorder associated with decreased expression or activity of pp-  
CC GANTase. The sequences given in ABV85011 to ABV86689 and ABP53502 to  
CC ABP53504 are given in the exemplification of the present invention. N.B.  
CC The sequence data for this patent is not represented in the printed  
CC specification but is based on sequence information supplied by the  
CC European Patent Office  
XX  
SQ Sequence 17 BP; 1 A; 5 C; 4 G; 7 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 277 CTGCGCTTTGAAACC 293  
Db 1 CTGCGCTTTGAAACC 17  
XX  
RESULT 298  
ABV79273  
ID ABV79273 standard; DNA; 17 BP.  
XX  
XX ABV79273;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 519.  
XX  
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
XX Homo sapiens.  
OS  
OS  
XX  
XX EP1229046-A2.  
PN  
XX  
XX 07-AUG-2002.  
PD  
XX  
XX 28-JAN-2002; 2002EP-00001167.  
PF  
XX  
XX 30-JAN-2001; 2001WO-US000663.  
PR  
XX 30-JAN-2001; 2001WO-US000664.  
PR  
XX 30-JAN-2001; 2001WO-US000665.  
PR  
XX 30-JAN-2001; 2001WO-US000666.  
PR  
XX 30-JAN-2001; 2001WO-US000667.  
PR  
XX 30-JAN-2001; 2001WO-US000668.  
PR  
XX 23-MAY-2001; 2001US-00864761.  
PR  
XX 09-OCT-2001; 2001US-0327998P.  
PR  
XX  
XX (ABOM-) AEOMICA INC.  
PA  
XX  
XX Zhan J;  
PI  
XX  
XX WPI; 2002-676582/73.  
DR  
XX  
XX Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
XX Example 2; Page 131; 718pp; English.  
PS  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and ABP98519 to ABP98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop

CC codon in HTP-L-S (S for short) compared to HTP-L-L (L for long). HTP-L  
 CC shares an overall structure organisation with the Patched protein. The  
 CC shared structural features strongly imply that HTP-L plays a role similar  
 CC to that of Patched, and is a potential tumour suppressor. HTP-L is  
 CC important in regulating male germ cell development, and the HTP-L gene was  
 CC mapped to human chromosome 10p12.1. HTP-L and its coding sequence are  
 CC useful for diagnosing a disorder caused by mutation in HTP-L, and in  
 CC therapy and manufacture of a medicament for treatment or prevention of  
 CC such disorder associated with decreased expression or activity of human  
 CC HTP-L. Such disorders include disorders of testis, or adrenal, adult and  
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
 CC skeletal muscle or colon function. HTP-L proteins and nucleic acids are  
 CC clinically useful diagnostic markers and potential therapeutic agents for  
 CC male infertility and cancer. The present oligonucleotide was used in an  
 CC example from the invention

CC Sequence 17 BP; 0 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 131 TCTCCCTGCTGGGCCC 147  
 Db 1 TCTTCTGCTGGCCCC 17

RESULT 299  
 ABRK19231/C  
 ID ABRK19231 standard; RNA; 17 BP.  
 XX ABRK19231;  
 AC  
 XX  
 DT 09-APR-2002 (first entry)  
 XX  
 DE Human ERG Amberzyme target sequence Seq ID No 1878.  
 XX  
 KM Human; hammerhead ribozyme; cytosstatic; antitumour; antidiabetic;  
 KM ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
 KM vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KM tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KM neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KM angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
 KM Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KM Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;  
 KM amberzyme.

XX Homo sapiens.  
 OS  
 XX  
 PN WO20018124-A2.  
 XX  
 PD 22-NOV-2001.  
 XX  
 PF 16-MAY-2001; 2001WO-US015866.  
 XX  
 PR 16-MAY-2000; 2000US-00572021.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (GLAX ) GLAXO GROUP LTD.  
 XX  
 PI Jarvis T, Von Carlowitz I, Mcswigen JA, McLaughlin F, Randi AM;  
 DR WPI; 2002-082995/11.  
 XX  
 PT Novel polynucleotide which down regulates expression of Ets-related gene,  
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX  
 PS Claim 4; Page 123; 149pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule (I) which down regulates  
 CC expression of an Ets-related gene (ERG). (I) is useful for treating  
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge  
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
 CC treating a patient having a condition associated with the level of ERG,  
 CC by contacting cells of the patient with (I) under conditions suitable for  
 CC the treatment. The method comprises the use of one or more therapies  
 CC under conditions suitable for the treatment. Leukaemia or tumour  
 CC angiogenesis is treated by administering (I) to the patient in  
 CC conjunction with one or more of other therapies such as radiation or  
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABRK17354-ABRK2719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
 CC related PCR primers of the invention

CC Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 345 GCTGATCTCATGGGGAG 361  
 Db 17 GCTGATCTCCTGGGGG 1

RESULT 300  
 ABRK19230/C  
 ID ABRK19230 standard; RNA; 17 BP.  
 XX ABRK19230;  
 AC  
 XX  
 DT 09-APR-2002 (first entry)  
 XX  
 DE Human ERG Amberzyme target sequence Seq ID No 1877.  
 XX  
 KM Human; hammerhead ribozyme; cytosstatic; antitumour; antidiabetic;  
 KM ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
 KM vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KM tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KM neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KM angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
 KM Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KM Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;  
 KM amberzyme.

XX Homo sapiens.  
 OS  
 XX  
 PN WO20018124-A2.  
 XX  
 PD 22-NOV-2001.  
 XX  
 PF 16-MAY-2001; 2001WO-US015866.  
 XX  
 PR 16-MAY-2000; 2000US-00572021.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (GLAX ) GLAXO GROUP LTD.  
 XX  
 PI Jarvis T, Von Carlowitz I, Mcswigen JA, McLaughlin F, Randi AM;  
 DR WPI; 2002-082995/11.  
 XX  
 PT Novel polynucleotide which down regulates expression of Ets-related gene,  
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,

PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX  
 PS Claim 4; Page 123; 149pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule (I) which down regulates  
 CC expression of an Ets-related gene (ERG). (I) is useful for treating  
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, and  
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
 CC vulgaris, angiodioma of tuberous sclerosis, port-wine stains, Sturge  
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu  
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
 CC treating a patient having a condition associated with the level of ERG,  
 CC by contacting cells of the patient with (I) under conditions suitable for  
 CC the treatment. The method comprises the use of one or more therapies  
 CC under conditions suitable for the treatment. Leukaemia or tumour  
 CC angiogenesis is treated by administering (I) to the patient in  
 CC conjunction with one or more of other therapies such as radiation or  
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg<sup>2+</sup>. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
 CC related PCR primers of the invention  
 CC  
 SQ Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 Oy 346 CTGATCTCATGGGAGC 362  
 Db 17 CTGATCTCTGGGGGC 1  
 RESULT 301  
 ABV89725  
 ID ABV89725 standard; DNA; 17 BP.  
 AC ABV89725;  
 XX  
 DT 23-DEC-2002 (first entry)  
 XX  
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 438.  
 XX  
 KM Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
 KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
 KM gene therapy; transgenic; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EPI239051-A2.  
 XX  
 PD 11-SEP-2002.  
 XX  
 PF 28-JAN-2002; 2002EP-00001165.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 23-MAY-2001; 2001US-00864761.  
 PR 10-OCT-2001; 2001US-0328205P.

XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M;  
 XX  
 DR WPI; 2002-684061/74.  
 XX  
 PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL  
 PT -1, useful for treating disorders associated with decreased expression or  
 PT activity of human POSHL1.  
 XX  
 PS Example 2; SEQ ID NO 438; 60pp + Sequence Listing; English.  
 XX  
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling  
 CC protein 1 (POSH) 1 polypeptide (I), comprising a sequence of 730 amino  
 CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),  
 CC (S1) having 95% deviations, especially conservative substitutions or a  
 CC fragment of the sequences comprising at least 8 contiguous amino acids.  
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an  
 CC adaptor protein that interacts with Rho family small GTPases as well as  
 CC downstream components of the signal transduction pathway. (I) is useful  
 CC for identifying a specific binding partner. (I) and nucleic acids (II)  
 CC encoding (I) are useful for diagnosing, monitoring disease and treating  
 CC caused by altered expression of human POSHL1 including diagnosing and  
 CC treating cancer, they are useful in the development of vaccines and (II) is  
 CC useful in gene therapy. (II) is useful for constructing microarrays which  
 CC are useful for measuring and for surveying gene expression and creating  
 CC transgenic non-human animals capable of producing the proteins. The  
 CC present sequence is that of a scanning oligonucleotide useful in examples  
 CC of the invention. Note: The present sequence did not form part of the  
 CC printed specification, but is based on sequence information supplied to  
 CC Derwent by the European Patent Office  
 CC  
 SQ Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 Oy 1103 TTGAGGCTCTGTGGCC 1119  
 Db 1 TTGAGGCGCTGCGGCC 17  
 RESULT 302  
 ABV90613  
 ID ABV90613 standard; DNA; 17 BP.  
 AC ABV90613;  
 XX  
 DT 23-DEC-2002 (first entry)  
 XX  
 DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1326.  
 XX  
 KM Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
 KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
 KM gene therapy; transgenic; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EPI239051-A2.  
 XX  
 PD 11-SEP-2002.  
 XX  
 PF 28-JAN-2002; 2002EP-00001165.  
 XX  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.



```
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
XX
PA (AEOM-) AEOMICA INC.
XX
XX Shannon M;
PI
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 1326; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 3 A; 9 C; 1 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2092 CTCATCACCAGCCACT 2108
Db 1 CTATACACCCGCACT 17
RESULT 303
ABV89726
ID ABV89726 standard; DNA, 17 BP.
XX
XX ABV89726;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 439.
XX
XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
PR
```

```
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
PI
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
XX Example 2; SEQ ID NO 439; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
XX Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1104 TGAGGCTGTGCGCCA 1120
Db 1 TGAAGCGCTCGGCCA 17
RESULT 304
ABV89724
ID ABV89724 standard; DNA, 17 BP.
XX
XX ABV89724;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 437.
XX
XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-00001165.
XX 30-JAN-2001; 2001WO-US000663.
PR
```



PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 10-OCT-2001; 2001US-0328205P.  
XX (AEOM-) AEOMICA INC.  
XX Shannon M;  
XX WPI; 2002-684061/74.  
XX  
XX  
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL  
PT -1, useful for treating disorders associated with decreased expression or  
PT activity of human POSHL1.  
XX  
XX Example 2; SEQ ID NO 437; 60pp + Sequence Listing; English.  
XX  
XX The invention relates to an isolated SH3 domain (POSH)-like signalling  
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino  
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),  
CC (S1) having 95% deviations, especially conservative substitutions or a  
CC fragment of the sequences comprising at least 8 contiguous amino acids.  
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an  
CC adaptor protein that interacts with Rho family small GTPases as well as  
CC downstream components of the signal transduction pathway. (I) is useful  
CC for identifying a specific binding partner. (I) and nucleic acids (II)  
CC encoding (I) are useful for diagnosing, monitoring disease and treating  
CC caused by altered expression of human POSHL1 including diagnosing and  
CC treating cancer, they are useful in the development of vaccines and (II) is  
CC useful in gene therapy. (II) is useful for constructing microarrays which  
CC are useful for measuring and for surveying gene expression and creating  
CC transgenic non-human animals capable of producing the proteins. The  
CC present sequence is that of a scanning oligonucleotide useful in examples  
CC of the invention. Note: The present sequence did not form part of the  
CC printed specification, but is based on sequence information supplied to  
CC Derwent by the European Patent Office  
XX  
XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.64; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Gy 1102 ATTGAGGCTCTGCGG 1118  
Db 1 ATTGAGGCTCTGCGG 17  
RESULT 305  
ABV89723  
ID ABEV89723 standard; DNA; 17 BP.  
XX  
XX ABEV89723;  
XX  
XX 23-DEC-2002 (first entry)  
XX  
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 436.  
XX  
XX Human, POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
KW gene therapy; transgenic; ss.  
XX  
XX Homo sapiens.  
XX  
XX BPI239051-A2.  
XX  
XX 11-SEP-2002.  
XX

PF 28-JAN-2002; 2002EP-00001165.  
XX  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 23-MAY-2001; 2001US-00864761.  
XX 10-OCT-2001; 2001US-0328205P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX Shannon M;  
XX WPI; 2002-684061/74.  
XX  
XX  
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL  
PT -1, useful for treating disorders associated with decreased expression or  
PT activity of human POSHL1.  
XX  
XX Example 2; SEQ ID NO 436; 60pp + Sequence Listing; English.  
XX  
XX The invention relates to an isolated SH3 domain (POSH)-like signalling  
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino  
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),  
CC (S1) having 95% deviations, especially conservative substitutions or a  
CC fragment of the sequences comprising at least 8 contiguous amino acids.  
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an  
CC adaptor protein that interacts with Rho family small GTPases as well as  
CC downstream components of the signal transduction pathway. (I) is useful  
CC for identifying a specific binding partner. (I) and nucleic acids (II)  
CC encoding (I) are useful for diagnosing, monitoring disease and treating  
CC caused by altered expression of human POSHL1 including diagnosing and  
CC treating cancer, they are useful in the development of vaccines and (II) is  
CC useful in gene therapy. (II) is useful for constructing microarrays which  
CC are useful for measuring and for surveying gene expression and creating  
CC transgenic non-human animals capable of producing the proteins. The  
CC present sequence is that of a scanning oligonucleotide useful in examples  
CC of the invention. Note: The present sequence did not form part of the  
CC printed specification, but is based on sequence information supplied to  
CC Derwent by the European Patent Office  
XX  
XX Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.64; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Gy 1101 CATTGAGGCTCTGCGG 1117  
Db 1 CATTGAGGCTCTGCGG 17  
RESULT 306  
ABL31770  
ID ABL31770 standard; DNA; 17 BP.  
XX  
XX ABL31770;  
XX  
XX 21-MAR-2002 (first entry)  
XX  
XX Human HLA genotyping oligonucleotide SEQ ID NO 1259.  
XX  
XX Human, human leukocyte antigen; HLA; genotype; polymorphism;  
KM immunogenetic; transplantation; genetic disease; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200192572-A1.  
XX

```

PD 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-JP004662.
XX
XX 01-JUN-2000; 2000JP-00164798.
XX
XX (NTSN ) NISSHINBO IND INC.
XX
XX (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
XX WPI; 2002-122074/16.
XX
XX
XX
XX The invention relates to a typing kit for judging human leukocyte antigen
XX (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
XX oligonucleotides (ABJ30512-ABJ31809) originating in the sequences of
XX genes e.g. belonging to HLA class I antigens on human genome and
XX containing gene polymorphisms as allantoins have been immobilised as
XX primers for amplification of cleaved nucleic acids relating to gene
XX polymorphisms. The method is useful for judging HLA genotypes of
XX individuals by determining immunogenetic differences before transplanting
XX between them, providing genetic information to decide compatibility of
XX organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
XX pancreas, langerhans islet in pancreas and cornea, susceptibility
XX diagnosis of genetic diseases and identifying individuals
XX
XX Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX
XX
XX Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
XX Matches 15; Conservative 0; Mismatches
XX
XX 370 TCCGCGATAGCACCAG 386
XX ||||| |||||
XX 1 TCCGCGGTACCACGAG 17
XX
XX
XX
XX RESULT 307
XX ABLJ31552
XX ID ABLJ31552 standard; DNA; 17 BP.
XX
XX ABLJ31552;
XX
XX 21-MAR-2002 (first entry)
XX
XX
XX Human HLA genotyping oligonucleotide SEQ ID NO 1041.
XX
XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
XX immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
XX
XX WO200192572-A1.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-JP004662.
XX
XX 01-JUN-2000; 2000JP-00164798.
XX
XX (NTSN ) NISSHINBO IND INC.
XX
XX (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
XX WPI; 2002-122074/16.
XX

```

PT	Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of individuals e.g. by determining immunogenetic differences when transplanting between them.
PT	
XX	
PS	Claim 10; Page 290; 345pp; Japanese.
XX	
CC	The invention relates to a typing kit for judging human leukocyte antigen (HLA) genotype of a sample by hybridising a substrate on which 10-24 base oligonucleotides (ABJ30512-ABJ31809) originating in the sequences of genes e.g. belonging to HLA class I antigens on human genome and containing gene polymorphisms as alloantigens have been immobilised as primers for amplification of cleaved nucleic acids relating to gene polymorphisms. The method is useful for judging HLA genotypes of individuals by determining immunogenetic differences before transplanting between them, providing genetic information to decide compatibility of organ and tissue for transplantation e.g. of bone marrow, kidney, liver, pancreas, Langerhans islet in pancreas and cornea, susceptibility diagnosis of genetic diseases and identifying individuals
CC	
CC	
CC	
CC	
CC	
XX	Sequence 17 BP; 3 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
SQ	
	Query Match 0.6%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 2e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY	490 GGCGGTCAGGCGGCTC 506       1 GGCGGACAGCGGCTC 17
DB	
RESULT 308	
ABK56492/c	
ID	ABK56492 standard; RNA; 17 BP.
XX	
AC	ABK56492;
XX	
DT	02-JUL-2002 (first entry)
XX	
DE	Human CLCA1 gene enzymatic nucleic acid #863.
XX	
KW	Human; chloride channel calcium activated 1; CLCA1; ser; antiasthmatic; antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma; chronic bronchitis; cystic fibrosis; obstructive bowel syndrome; oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic; acetylcholine.
XX	
OS	Homo sapiens.
XX	
PN	WO200211674-A2.
XX	
PD	14-FEB-2002.
XX	
PE	09-AUG-2001; 2001WO-US024970.
XX	
PR	09-AUG-2000; 2000US-0224383P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	(SYNT) SYNTAX USA LLC.
PA	(THOM/) THOMPSON J.
XX	
PI	Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI	Gruppe A;
XX	
DR	WPI, 2002-217145/27.
XX	
XX	
PT	Enzymatic polynucleotide that down regulates expression of chloride channel calcium activated gene, useful for treating Chronic obstructive pulmonary disease (COPD), chronic bronchitis and asthma.
PT	
PS	Claim 4; Page 72; 152pp; English.
XX	
CC	The invention relates to enzymatic nucleic acid molecules that down regulate expression of chloride channel calcium activated 1 (CLCA1) genes

CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
 CC useful as pharmaceutical agents for treating conditions such as chronic  
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
 CC that are related to or will respond to the levels of CLCA1 in a cell or  
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
 CC hence, are useful for treatment of a patient having a condition  
 CC associated with the level of CLCA1, where the invention further comprises  
 CC the use of one or more therapies under conditions suitable for the  
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
 CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The  
 CC nucleic acids of the invention are also used as diagnostic tools to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of CLCA1 RNA in a cell. This sequence represents an  
 CC enzymatic nucleic acid molecule of the invention

SO Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1997 TGGATGATGCCACCACT 2013  
 Db 17 TGGATGATGCCACCACT 1

RESULT 309  
 ABS71929/c  
 ID ABS71929 standard; DNA; 17 BP.  
 AC ABS71929;  
 XX  
 XX 02-DEC-2002 (first entry)  
 DT  
 DE Human GRP-Rho binding protein 2 17mer probe #39.  
 XX  
 KM Human; 88; GRP-Rho binding protein 2; GRBP2; chromosome 19q12; oncogene;  
 KM tumour; liposarcoma; ichthyosis congenita III; probe;  
 KM benign familial infantile convulsion; gene therapy.  
 KM  
 OS Homo sapiens.  
 XX  
 PN BP1231216-A2.  
 XX  
 XX 14-AUG-2002.  
 PD  
 XX 17-JAN-2002; 2002EP-00001026.  
 PF  
 XX 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 29-JUN-2001; 2001US-00895040.  
 PR  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon ME, JI Y;  
 XX  
 DR WPI; 2002-684026/74.  
 XX  
 XX Novel GRP-Rho binding protein 2 and nucleic acids encoding the protein,  
 PT useful for the manufacture of a medicament for treating a disease  
 PT associated with altered expression or activity of human GRBP2 protein.  
 XX  
 XX Example 4; Page 72; 101pp; English.  
 PS  
 CC The invention relates to an isolated GRP-Rho binding protein 2 (GRBP2)  
 CC polypeptide or a fragment of at least 6 amino acids or a sequence in

CC which at least 95% of deviations from GRBP2 sequences are conservative  
 CC substitutions. Also included are an isolated nucleic acid (GRBP2 NA)  
 CC encoding GRBP2 comprising the full length cDNA or CDS, fragments or  
 CC variants, GRBP2 vectors, host cells, antibodies, transgenic non-human  
 CC animals modified to contain GRBP2 NA (or unable to express the endogenous  
 CC orthologue of GRBP2), diagnosing a disease caused by a mutation in human  
 CC GRBP2 or altered expression of GRBP2, anti-agonists of GRBP2, GRBP2  
 CC microarrays, fusion proteins and screening for agents that modulate the  
 CC expression of GRBP2 NA. GRBP2 is useful for identifying binding partners  
 CC of GRBP2. GRBP2 NA and Ab are useful in therapy and in the  
 CC manufacture of a medicament for the treatment or prevention of a disorder  
 CC associated with increased or decreased expression or activity of human  
 CC GRBP2 (e.g. tumour, liposarcoma, ichthyosis congenita III and benign  
 CC familial infantile convulsion, all associated with the chromosomal  
 CC location of GRBP2, 19q12). GRBP2 is useful as a standard in immunoassay  
 CC specific for the proteins, to be used in a therapeutic agent, as  
 CC vaccines, to be and as antigens (e.g. for epitope mapping) or immunogens  
 CC (e.g. for raising antibodies). GRBP2 NA is useful as hybridisation probes,  
 CC to prime synthesis of nucleic acids, to prime first strand cDNA sequence  
 CC on an mRNA template, and to drive in vivo expression of the proteins. The  
 CC vector is useful for shuttling GRBP2 NA between host cells derived from  
 CC disparate organisms, for inserting GRBP2 NA into host cell chromosome,  
 CC for expressing sense or antisense RNA transcripts of GRBP2 NA in vitro or  
 CC within a host cell, and for expressing GRBP2 alone or as fusions to  
 CC heterologous polypeptides. The antibody is useful as an analytical  
 CC reagent for detection and quantification of GRBP2 and as an immuno  
 CC therapeutic agent and is useful for flow cytometric detection, for  
 CC scanning laser cytometric detection, or for fluorescent immunosassay. The  
 CC present sequence is a probe for GRBP2

SO Sequence 17 BP; 1 A; 12 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 206 GGCTGGGGGCGCTGGCGG 222  
 Db 17 GGCTGGGGGCGCGCGG 1

RESULT 310  
 ACD00799/c  
 ID ACD00799 standard; DNA; 17 BP.  
 AC ACD00799;  
 XX  
 XX 28-JUL-2003 (first entry)  
 DT  
 DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1272.  
 XX  
 XX Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;  
 KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.  
 KM  
 OS Homo sapiens.  
 XX  
 PN WO2003031621-A2.  
 XX  
 XX WO2003031621-A2.  
 PN  
 XX 17-APR-2003.  
 PD  
 XX 11-OCT-2002; 2002WO-US032599.  
 PF  
 XX 12-OCT-2001; 2001US-0329000P.  
 PR  
 XX  
 PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
 XX  
 PI Zhang J;  
 XX  
 DR WPI; 2003-381720/36.  
 XX  
 XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,  
 PT investigating and/or treating disorders associated with aberrant  
 PT expression or activity of GPCR-A-1, such as tumors and cancers.

XX Example 2; SEQ ID NO 1296; 156bp; English.  
 XX  
 CC The invention describes an isolated nucleic acid encoding a G protein  
 CC coupled receptor (GPCR), mutations of which cause cancer, comprising a  
 CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a  
 CC 409 residue amino acid sequence, all given in the specification, with or  
 CC without conservative amino acid substitutions, or complements of the  
 CC sequence of them. The encoding nucleic acid is not more than 100 base in  
 CC length. The methods and compositions of the present invention are useful  
 CC for diagnosing, investigating and/or treating disorders associated with  
 CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.  
 CC This sequence represents an oligonucleotide used to analyse the gene  
 CC encoding human G-protein coupled receptor GPCR-A-1  
 XX  
 SQ Sequence 17 BP; 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 859 CCGGTAACAGAGACAC 875  
 Db 17 CAGGTAACAGGGAAC 1  
 RESULT 311  
 ABT36908  
 ID ABT36908 standard; DNA; 17 BP.  
 AC ABT36908;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID NO 2545.  
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrania; protein chip; gene therapy; tumour suppression;  
 KM human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025175-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Ameon R, Tuijnder M;  
 DR WPI; 2003-313353/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 330; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrania. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX  
 SQ Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 996 GATCACCCCTGCCTGTC 1012  
 Db 1 GATCTGCCTGCCTGTC 17  
 RESULT 312  
 ACA09052/C  
 ID ACA09052 standard; RNA; 17 BP.  
 AC ACA09052;  
 XX  
 DT 03-JUN-2003 (first entry)  
 XX  
 DE NFKB sub-unit modulating amberzyme substrate #215.  
 XX  
 KM Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubin; fluorouracil carboxylate; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; achmia; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002177568-A1.  
 XX  
 PD 28-NOV-2002.  
 XX  
 PF 23-MAY-2001; 2001US-00864785.  
 XX  
 PR 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINCHCOMB D T.  
 PA (MCSW/) MCSWIGEN J.  
 PA (DRAP/) DRAPER K G.  
 XX  
 PI Stinchcomb DT, Mcswigen J, Draper KG;  
 DR WPI; 2003-340953/32.  
 XX  
 PT Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX

PS Claim 3; Page 55; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule

XX Sequence 17 BP; 1 A; 9 C; 6 G; 0 T; 1 U; 0 Other;

SO Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 TGGGAGACCCCGGCTC 371  
 17 TGGGAGACCCCGGCTC 1

DB

RESULT 313  
 ACA08871/c  
 ID ACA08871 standard; RNA; 17 BP.

XX ACA08871;  
 AC

XX 03-JUN-2003 (first entry)

DE NFkB sub-unit modulating amberzyme substrate #34.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.  
 XX 28-NOV-2002.  
 XX 23-MAY-2001; 2001US-00864785.  
 XX 07-DEC-1992; 92US-00987132.  
 XX 18-MAY-1994; 94US-00245466.  
 XX 15-AUG-1994; 94US-00291932.

PR 23-DEC-1996; 96US-00777916.

XX (STIN/) STINGHOMB D T.  
 PA (MCSN/) MCSWIGGEN J.  
 PA (DRAE/) DRAPER K G.  
 XX Stinchcomb DT, Mcswiggen J, Draper KG;  
 DR WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 50; 72pp; English.

PS The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule

XX Sequence 17 BP; 5 A; 4 C; 7 G; 0 T; 1 U; 0 Other;

SO Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCTG 579  
 17 CACTGTCCTGCTCTG 1

DB

RESULT 314  
 ACA09051/c  
 ID ACA09051 standard; RNA; 17 BP.

XX ACA09051;  
 AC

XX 03-JUN-2003 (first entry)

DE NFkB sub-unit modulating amberzyme substrate #214.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KM G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;

KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 OS Homo sapiens.  
 XX US2002177566-A1.  
 PN 28-NOV-2002.  
 PD 23-MAY-2001; 2001US-00864785.  
 PF 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX (STIN/) STINCHCOMB D T.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (DRAP/) DRAPER K G.  
 PI Stinchcomb DT, Mcswiggen J, Draper KG;  
 XX WPI; 2003-340953/32.  
 DR Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 PS Claim 3; Page 55; 72pp; English.  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of RBL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, RBL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 0 A; 9 C; 7 G; 0 T; 1 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 356 GGGGAGCCCCCGGGTCC 372  
 |||||  
 |||||  
 Db 17 GGGGAGCCCCCGGGGCC 1  
 |||||  
 |||||  
 RESULT 315  
 ACA06758/c  
 ID ACA06758 standard; RNA; 17 BP.  
 XX  
 AC ACA06758;  
 XX  
 XX 03-JUN-2003 (first entry)

XX  
 DE NFkB sub-unit modulating inozyme substrate #577.  
 XX  
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KW G-cleaver; amberzyme; cancer; RBL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 OS Homo sapiens.  
 XX US2002177566-A1.  
 PN 28-NOV-2002.  
 PD 23-MAY-2001; 2001US-00864785.  
 PF 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX (STIN/) STINCHCOMB D T.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (DRAP/) DRAPER K G.  
 PI Stinchcomb DT, Mcswiggen J, Draper KG;  
 XX WPI; 2003-340953/32.  
 DR Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 PS Claim 3; Page 35; 72pp; English.  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of RBL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, RBL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 356 GGGGAGCCCCCGGGTCC 372  
 |||||  
 |||||  
 Db 17 GGGGAGCCCCCGGGGCC 1  
 |||||  
 |||||

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2162 GGGAGGGGGAGCCAC 2178

Db 17 GGGATGGGGAGCCAC 1

## RESULT 316

ADA99387/C

ID ADA99387 standard; DNA; 17 BP.

AC ADA99387;

XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 376.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;

KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

XX developmental disorder; se.

OS Homo sapiens.

XX EPI281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in

PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MD23,

PT MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 376; 103pp; English.

XX The present invention relates to novel human zinc finger-containing

CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is

CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,

CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,

CC or in manufacturing a medicament for treating or preventing a disorder,

CC associated with decreased or increased expression or activity of MD23,

CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

CC acids and proteins are also useful for diagnosing or monitoring a disease

CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic

CC acids can also be used as probes to detect and characterize gross

CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

CC useful in constructing microarrays for measuring gene expression. The

CC proteins are useful as therapeutic agents for gene therapy or as

CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX Db 17 CACCAGCAGCTCCAGGA 1

## RESULT 317

ADA99540

ID ADA99540 standard; DNA; 17 BP.

XX ADA99540;

XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 529.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;

KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

XX developmental disorder; se.

OS Homo sapiens.

XX EPI281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in

PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MD23,

PT MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 529; 103pp; English.

XX The present invention relates to novel human zinc finger-containing

CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is

CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,

CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,

CC or in manufacturing a medicament for treating or preventing a disorder,

CC associated with decreased or increased expression or activity of MD23,

CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

CC acids and proteins are also useful for diagnosing or monitoring a disease

CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic

CC acids can also be used as probes to detect and characterize gross

CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

CC useful in constructing microarrays for measuring gene expression. The

CC proteins are useful as therapeutic agents for gene therapy or as

CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 5 A; 4 C; 8 G; 0 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX Db 1773 GCCACTTGCAGGAGAG 789

XX 1 GCCACAGCAGCAGAGAG 17

## RESULT 318

ADB00407/C

XX ADB00407 standard; DNA; 17 BP.

XX ADB00407;

XX 20-NOV-2003 (first entry)

DE Human MD23 scanning oligonucleotide SEQ ID 1393.



XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
 KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KM developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EPI281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PF 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 DR WPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MD23,  
 PT MD24, MD27 or MD212, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 1393; 103bp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences; MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.  
 XX  
 SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.64; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 QY 1639 GTGGCTGCCCTGCTGCA 1655  
 Db 17 GTGGCTGCCCTGCTGCA 1  
 RESULT 319  
 ADB02397/c  
 ID ADB02397 standard; DNA; 17 BP.  
 XX  
 AC ADB02397;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human MD24 scanning oligonucleotide SEQ ID 3383.  
 XX  
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
 KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KM developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX

PN EPI281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PD 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 DR WPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MD23,  
 PT MD24, MD27 or MD212, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 3383; 103bp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences; MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.  
 XX  
 SQ Sequence 17 BP; 2 A; 4 C; 6 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.64; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 QY 2176 CACCAGCAGCTCATGGA 2192  
 Db 17 CACCAGCAGCTCATGGA 1  
 RESULT 320  
 AB261560  
 ID AB261560 standard; RNA; 17 BP.  
 XX  
 AC AB261560;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human H-Ras DNAzyme target #351.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HRR2; K-Ras;  
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;  
 KW anti-rheumatic; cancer; AIDS; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W0200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PD 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 PR



XX (RIBO-) RIBOZYME PHARM INC.  
 XX Mcswiggen J;  
 XX WPI; 2003-140484/13.  
 XX Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX Claim 58; Page 117; 185pp; English.  
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
 CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,  
 CC AB266530 - AB266585 represent substrate/target sequences for the human  
 CC ribozymes of the invention  
 XX  
 SO Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 76.5%; Pred. No. 2e+02;  
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 QY 446 CGCGACGAGCCCTGTGG 462  
 | ||||| ||||| : ||  
 1 CAGCAGCUCGCCUCUGG 17  
 DB  
 RESULT 321  
 AB264771/C  
 ID AB264771 standard; RNA; 17 BP.  
 XX  
 AC AB264771;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human HER2 DNAzyme substrate #228.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
 KM anti-rheumatic; cancer; AIDS; ss.  
 OS  
 OS Homo sapiens.  
 XX  
 PN WO200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PF 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Mcswiggen J;  
 XX  
 DR WPI; 2003-140484/13.  
 XX  
 PT Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX

PS Claim 4; Page 137; 185pp; English.  
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
 CC shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,  
 CC AB266530 - AB266585 represent substrate/target sequences for the human  
 CC ribozymes of the invention  
 XX  
 SO Sequence 17 BP; 3 A; 8 C; 3 G; 0 T; 3 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 259 GCAGTGTCCAGGCGTG 275  
 | ||||| ||||| ||  
 17 GTAGGTGACCGAGGCTG 1  
 DB  
 RESULT 322  
 AB265040/C  
 ID AB265040 standard; RNA; 17 BP.  
 XX  
 AC AB265040;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human HER2 DNAzyme substrate #497.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
 KM anti-rheumatic; cancer; AIDS; ss.  
 OS  
 OS Homo sapiens.  
 XX  
 PN WO200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PF 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Mcswiggen J;  
 XX  
 DR WPI; 2003-140484/13.  
 XX  
 PT Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX  
 PS Claim 4; Page 142; 185pp; English.  
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences

```
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
XX ribozymes of the invention
SQ Sequence 17 BP; 5 A; 6 C; 5 G; 0 T; 1 U; 0 Other;

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      269 AGGGCTGCTGCTGCT 285
      |||||
Db      17 AGGGCTGCTGCTGCT 1

RESULT 323
ABZ62176/c
ID ABZ62176 standard; RNA; 17 BP.
XX
AC ABZ62176;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #967.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cyostatic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
XX WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 131; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cyostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2127 TGACCACTCTCTTTC 2143
```

```
Db      17 TGACCACTCTCTTTC 1

RESULT 324
ABZ62177/c
ID ABZ62177 standard; RNA; 17 BP.
XX
AC ABZ62177;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #968.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cyostatic; anti-HIV;
KM anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
XX WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 131; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cyostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2125 GCTGACCACATCTCTT 2141
      |||||
Db      17 GCTGACCACATCTGCTT 1

RESULT 325
ABZ61559
ID ABZ61559 standard; RNA; 17 BP.
XX
AC ABZ61559;
XX
DT 21-MAR-2003 (first entry)
```

```

XX Human H-Ras DNzyme target #350.
DE
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
OS
XX Homo sapiens.
XX
XX NO200297114-A2.
PN
XX
XX 05-DEC-2002.
PD
XX
XX 29-MAY-2002; 2002MO-US016840.
PF
XX
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX MGSWiggen J;
PI
XX
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX Claim 58; Page 117; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and anti-
XX rheumatic activity. The nucleic acid molecules are useful for reducing
XX HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX also useful for treating breast, ovarian, colorectal, lung, prostate,
XX bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX shown in AB259889 - AB262216, AB264544 - AB265531, AB265520 - AB265524,
XX AB265530 - AB265585 represent substrate/target sequences for the human
XX ribozymes of the invention
XX
XX Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 2e+02;
XX Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 443 TGGCCGAGCAGCCCTG 459
DB 1 UGCCAGCAGCCUGCCTG 17

```

```

XX Hepatitis B virus.
OS
XX
XX NO200281494-A1.
PN
XX
XX 17-OCT-2002.
PD
XX
XX 26-MAR-2002; 2002MO-US009187.
PF
XX
XX 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX (BLAT/) BLATT L.
PA
XX
XX (MACE/) MACEJAK D.
PA
XX
XX (MCSW/) MCSWIGGEN J.
PA
XX
XX (MORR/) MORRISSEY D.
PA
XX
XX (PAVC/) PAVCO P.
PA
XX
XX (LEEP/) LEE P.
PA
XX
XX (DRAP/) DRAPER K.
PA
XX
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
DR
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 164; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV, and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HBV
XX ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberzyme sequences
XX disclosed in the present invention
XX
XX Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 2e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 964 TGGGATGAGTGTCCCT 980
DB 17 TGAGATGAGTGTCCCT 1

```



CC	carcinoma. The present sequence represents a substrate for one of the HCV
CC	DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC	invention
XX	
XX	Sequence 17 BP; 1 A; 4 C; 9 G; 0 T; 3 U; 0 Other;
XX	
XX	Query Match 0.6%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity 76.5%; Pred. No. 2e+02; 2; Indels 0; Gaps 0
XX	Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0
XX	
XX	1948 GCAGTGGCGTTGGCCCG 1964
XX	::
XX	1 GCAGGGGUGUGCCCG 17
XX	
XX	RESULT 329
XX	ACD51659/c
XX	ACD51659 standard, RNA; 17 BP.
XX	
XX	ACD51659;
XX	
XX	24-SEP-2003 (first entry)
XX	
XX	HBV hammerhead ribozyme substrate sequence #666.
XX	
XX	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX	RNA stability; RNA expression; RNA synthesis; antisense;
XX	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinczyme;
XX	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX	HBV reverse transcriptase; Enhancer I region; viral replication;
XX	degenerative; disease etracer; HBV infection; HCV infection; cirrhosis;
XX	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX	virucide; antiinflammatory; substrate; ss.
XX	
XX	Hepatitis B virus.
XX	
XX	WO200281494-A1.
XX	
XX	17-OCT-2002.
XX	
XX	26-MAR-2002; 2002WO-US009187.
XX	
XX	26-MAR-2001; 2001US-00817879.
XX	08-JUN-2001; 2001US-00877478.
XX	08-JUN-2001; 2001US-0296876P.
XX	24-OCT-2001; 2001US-0335059P.
XX	05-DEC-2001; 2001US-0337055P.
XX	
XX	(RIBO-) RIBOZYME PHARM INC.
XX	(BLATT) BLATT L.
XX	(MACE/) MACEJAK D.
XX	(MCSW/) MORRISSEY D.
XX	(MORR/) MORRISSEY D.
XX	(PASC/) PAVCO P.
XX	(LEEP/) LEE P.
XX	(DRAP/) DRAPER K.
XX	(ROBE/) ROBERTS E.
XX	
XX	Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P,
XX	Draper K, Roberts E;
XX	
XX	WPI; 2003-229207/22.
XX	
XX	Novel compound useful for treating cirrhosis, liver failure,
XX	hepatocellular carcinoma, or condition associated with hepatitis C virus
XX	infection.
XX	
XX	Example 1; Page 149; 387pp; English.
XX	
XX	The present invention relates to nucleic acid molecules which modulate
XX	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX	and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,

CC	inozymes; zinzymes, amberyymes, and G-cleaver ribozymes. Also disclosed
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV
CC	DNA. The nucleic acids may be used to modulate the expression of HBV
CC	genes and HBV viral replication. Also disclosed is a method for screening
CC	compounds and/or potential therapies directed against HBV, and compounds
CC	that modulate the expression and/or replication of HCV. The compounds and
CC	methods of the invention are useful for the treatment of degenerative and
CC	disease states related to HBV and HCV infection, replication and gene
CC	expression such as cirrhosis, liver failure, and hepatocellular
CC	carcinoma. The present sequence represents a substrate for one of the HBV
CC	ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberyyme sequences
CC	disclosed in the present invention
XX	
SO	Sequence 17 BP; 4 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Qy	Query March 0.6%; Score 13.8; DB 1; Length 17;
Db	Best Local Similarity 88.2%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
	963 CTGGGATCAGTGTCCC 979
	17 CTGAGATGAGTGTCCC 1
RESULT 330	
ACD63635	
XX	ACD63635 standard; RNA; 17 BP.
XX	ACD63635;
XX	30-SEP-2003 (first entry)
DE	HCV minus strand DNAzyme substrate sequence #1162.
KX	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM	RNA stability; RNA expression; RNA synthesis; antisense;
KM	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinzyme;
KM	amberyyme; G-cleaver ribozyme; decoy molecule; aptamer;
KM	HBV reverse transcriptase; Enhancer I region; viral replication;
KM	degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM	vincide; antiinflammatory; substrate; ss.
XX	
OS	Hepatitis C virus.
XX	
FN	WO200281494-A1.
XX	
PD	17-OCT-2002.
XX	
PF	26-MAR-2002; 2002WO-US009187.
XX	
PR	26-MAR-2001; 2001US-00817879.
PR	08-JUN-2001; 2001US-00877478.
PR	08-JUN-2001; 2001US-0296876P.
PR	24-OCT-2001; 2001US-0335059P.
PR	05-DEC-2001; 2001US-0337055P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
PA	(MACE/) MACEJAK D.
PA	(MCSW/) MCSWIGEN J.
PA	(MORR/) MORRISSEY D.
PA	(PAVC/) PAVCO P.
PA	(LEEF/) LEE P.
PA	(DRAP/) DRAPER K.
PA	(ROBE/) ROBERTS E.
XX	
PI	Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P,
PI	Draper K, Roberts E;
PR	WPI; 2003-229207/22.

[illegible]

PA	(MOSM/)	MOSWITGEN J.	
PA	(MOSR/)	MORRISSEY D.	
PA	(PAVC/)	PAVCO P.	
PA	(LEBP/)	LEE P.	
PA	(DRAP/)	DRAPER K.	
PA	(ROBE/)	ROBERTS E.	
XX			
PI	Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;		
PI	Draper K, Roberts E;		
DR	WPI, 2003-229207/22.		
XX			
PT	Novel compound useful for treating cirrhosis, liver failure,		
PT	hepatocellular carcinoma, or condition associated with hepatitis C virus		
XX	infection.		
PS	Claim 1; Page 310; 387pp; English.		
XX			
CC	The present invention relates to nucleic acid molecules which modulate		
CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or		
CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense		
CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,		
CC	ribozymes, zincymes, amberzymes, and G-cleaver ribozymes. Also disclosed		
CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse		
CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well		
CC	as oligonucleotides that specifically bind the Enhancer I region of HBV		
CC	DNA. The nucleic acids may be used to modulate the expression of HBV		
CC	genes and HBV viral replication. Also disclosed is a method for screening		
CC	compounds and/or potential therapies directed against HBV, and compounds		
CC	that modulate the expression and/or replication of HCV. The compounds and		
CC	methods of the invention are useful for the treatment of degenerative and		
CC	disease states related to HBV and HCV infection, replication and gene		
CC	expression such as cirrhosis, liver failure, and hepatocellular		
CC	carcinoma. The present sequence represents a substrate for one of the HCV		
CC	DNAzyme or minus strand DNAzyme sequences disclosed in the present		
XX	invention		
XX			
SQ	Sequence 17 BP; 5 A; 6 C; 3 G; 0 T; 3 U; 0 Other;		
XX			
QY	Query Match 0.6%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;		
Db	Matches 15; Conservative 0;		
	59 TCGCATGGCTGGGACA 75		
	17 TCGCATGGCTGGGATA 1		
RESULT 332			
ID	ACD57472		
AC	ACD57472 standard; RNA; 17 BP.		
XX			
AC	ACD57472;		
XX			
DT	23-SEP-2003 (first entry)		
XX			
DE	HCV DNAzyme substrate sequence #338.		
XX			
KM	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;		
KM	RNA stability; RNA expression; RNA synthesis; antisense;		
KM	enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; ribozyme; zincyme;		
KM	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;		
KM	HBV reverse transcriptase; Enhancer I region; viral replication;		
KM	degenerative; disease state; HBV infection; HCV infection; cirrhosis;		
KM	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;		
KM	virucide; antiinflammatory; substrate; ss.		
XX			
OS	Hepatitis C virus.		
XX			
PM	WO200281494-A1.		
XX			
PD	17-OCT-2002.		
XX			

PF 26-MAR-2002; 2002MO-US009187.  
 XX  
 XX 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (MORA/) MORRISSEY D.  
 PA (PACV/) PAVCO P.  
 PA (LEBP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX  
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PT  
 PS Claim 1, Page 240; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC liozymes, zinczymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNazyme or minus strand DNazyme sequences disclosed in the present  
 CC invention  
 CC  
 SQ Sequence 17 BP; 0 A; 7 C; 6 G; 0 T; 4 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 64.7%; Pred. No. 2e+02; Indels 0; Gaps 0;  
 Matches 11; Conservative 4; Mismatches 2;  
 QY 318 CCTGCGGAGCTTGCT 334  
 Db 1 CCUGCGGCGCTTUCCTU 17  
 XX  
 RESULT 333  
 ACC68479  
 ID ACC68479 standard; DNA; 17 BP.  
 XX  
 AC ACC68479;  
 XX  
 DT 01-JUL-2003 (first entry)  
 XX  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5726.  
 XX  
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KM tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; ss.

XX  
 OS Mus musculus.  
 XX  
 PN MO2003025176-A2.  
 XX  
 XX 27-MAR-2003.  
 PD  
 XX  
 PF 17-SEP-2002; 2002MO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 DR WPI; 2003-333167/31.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumours and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 PT  
 PS Disclosure; Page 700; 738pp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,  
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia  
 CC  
 SQ Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2;  
 QY 996 GATCACCCTGCTCTGCTC 1012  
 Db 1 GATCCTGCTGCTCTGCTC 17  
 XX  
 RESULT 334  
 ACC66564  
 ID ACC66564 standard; DNA; 17 BP.  
 XX  
 AC ACC66564;  
 XX  
 DT 01-JUL-2003 (first entry)  
 XX  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 3811.  
 XX  
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KM tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN MO2003025176-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002MO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-333167/31.  
 XX  
 DR New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 476; 738bp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,  
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia  
 CC  
 XX Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 15; Conservative 0; Indels 2; Indels 0; Gaps 0;  
 QY 996 GATCACCCTGCCTCTGC 1012  
 Db 1 GATCGGCTGCTCTGC 17  
 RESULT 335  
 ACC64635  
 ID ACC64635 standard; DNA, 17 BP.  
 XX  
 AC ACC64635;  
 XX  
 DT 01-JUL-2003 (first entry)  
 XX  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1882.  
 XX  
 KM Cytostatic; vincristine; neuroprotective; neurotropic; neuroleptic; murine;  
 KM tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO2003025176-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-333167/31.  
 XX  
 DE New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 251; 738bp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,  
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia  
 CC  
 XX Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 15; Conservative 0; Indels 2; Indels 0; Gaps 0;  
 QY 1359 GTTACCCAGGCTGTGG 1375  
 Db 1 GATCTCCAGGCTGTGG 17  
 RESULT 336  
 ADB42925  
 ID ADB42925 standard; DNA, 17 BP.  
 XX  
 AC ADB42925;  
 XX  
 DT 18-DEC-2003 (revised)  
 DT 04-DEC-2003 (first entry)  
 XX  
 DE Tumour suppression/reversion associated nucleotide #3248.  
 XX  
 KM Cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;  
 KM primer; probe; tumour suppression; tumour reversion; apoptosis;  
 KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
 KM diagnosis.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003040369-A2.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004219.  
 XX  
 PR 17-SEP-2001; 2001FR-00011981.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-441574/41.  
 XX  
 DE New nucleic acid encoding human prostate membrane-specific antigen,  
 PT useful e.g. for treatment of tumors and viral infection, also related  
 PT polypeptide and antibodies.  
 XX  
 PS Disclosure; Page 411; 771bp; French.  
 XX  
 CC The invention relates to the isolation of 6327 nucleotide sequences,  
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
 CC sequence having at least 80% identity, after optimal alignment, with the  
 CC nucleotides, a sequence that hybridizes under stringent conditions with  
 CC the nucleotides, or the complement, or corresponding RNA, of the  
 CC nucleotides. The nucleotides are used as probes or primers for detecting,  
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
 CC sense and antisense sequences, of nucleotides involved in tumour  
 CC suppression or reversion, apoptosis and/or viral resistance, to produce  
 CC recombinant polypeptides, and to prepare transgenic animals, as  
 CC experimental models. The nucleotides (also vectors containing them and  
 CC cells containing the vectors), the encoded polypeptides and antibodies  
 CC (Ab) against the polypeptide are useful for prevention and/or treatment  
 CC of viral infections or diseases characterized by development of tumours  
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
 CC Analysis of the expression of the nucleotides can be used for diagnosis  
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
 CC also be used to screen for their specific interactive molecules,



CC potentially useful for treating diseases associated with abnormal  
expression of the nucleotides.

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

SO

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 996 GATGACCTGCTCTGC 1012

Db 1 GATGCTCTGCTCTGC 17

RESULT 337

ADB44878

ID ADB44878 standard; DNA; 17 BP.

AC ADB44878;

DT 18-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #5201.

KM cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KM primer; probe; tumour suppression; tumour reversion; apoptosis;

KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

OS Homo sapiens.

PN WO2003040369-A2.

PD 15-MAY-2003.

PF 17-SEP-2002; 2002WO-IB04219.

PR 17-SEP-2001; 2001PR-00011981.

(MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-441574/41.

PT New nucleic acid encoding human prostate membrane-specific antigen,  
useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.

PS Disclosure; Page 640; 771pp; French.

CC The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors) are encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.

CC Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 996 GATGACCTGCTCTGC 1012

Db 1 GATGCTCTGCTCTGC 17

RESULT 338

AAQ56855

ID AAQ56855 standard; DNA; 18 BP.

AC AAQ56855;

DT 25-MAR-2003 (revised)

DT 05-OCT-1994 (first entry)

DE PCR primer P-74 for detection of Norwalk-related virus.

KM Norwalk virus; HucV; Sapporo; pathogen; acute gastroenteritis;

KM food poisoning; seafood contamination; diagnostic assay; PCR primer;

KM human calcivirus; small round virus; polymerase chain reaction; ss.

OS Synthetic.

PN WO9405700-A2.

PD 17-MAR-1994.

PF 07-SEP-1993; 93WO-US008447.

PR 07-SEP-1992; 92US-00941365.

(BAYU ) BAYLOR COLLEGE MEDICINE.

PI Matson DO, Estes MK, Jiang X, Graham DY;

DR WPI; 1994-101125/12.

PT DNA from Norwalk and related viruses - used for preparing probe. for use  
PT in diagnostic assays, detection and vaccines for Norwalk and related  
PT viruses.

PS Claim 49; Page 104; 156pp; English.

CC Sets of PCR primers (see AAQ56835-Q56857) are used as probes to detect  
CC Norwalk-related viruses, e.g. SRSV/KY/89, HucV Sapporo, HucV Houston and  
CC primate calcivirus. Detection of viral RNA is by RT-PCR. (Updated on 25-  
CC MAR-2003 to correct PN field.)

XX Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1639 GTGCTGCTCTGCTCA 1655

Db 2 GAGGCTGCTCTGCTCA 18

RESULT 339

AAQ91475/C

ID AAQ91475 standard; DNA; 18 BP.

AC AAQ91475;

DT 08-FEB-1996 (first entry)

DE Human cyclooxygenase-2 antisense oligonucleotide hCOX-1.1.

KM human; cyclooxygenase-2; COX-2; prostaglandin; thromboxane; inhibition;  
 KM antisense therapy; premature labour; preclampsia; endometriosis;  
 KM rheumatoid arthritis; glomerulitis; ARDS;  
 KM adult respiratory distress syndrome; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN W09516466-A1.  
 XX  
 PD 22-JUN-1995.  
 XX  
 PF 16-DEC-1994; 94WO-US014508.  
 XX  
 PR 17-DEC-1993; 93US-00170089.  
 XX  
 PA (OHIS ) UNIV OHIO STATE.  
 XX  
 PI Kniss DA;  
 XX  
 DR WPI; 1995-231361/30.  
 XX  
 PT Anti:sense oligo:nucleotide(s) binding cyclo:oxygenase and thromboxane A2  
 PT synthase mRNA - used in treatment of diseases involving prostaglandin(s)  
 PT and thromboxane metabolism.  
 XX  
 PS Claim 2; Page 36; 50pp; English.  
 XX  
 CC Antisense oligonucleotides were designed based on the 5'-UTR and 3'-UTR  
 CC sequences of mouse and human cyclooxygenase cDNAs. The phosphorothioate  
 CC derivative, ("S-oligonucleotides") of the different antisense sequences were  
 CC found to be effective for inhibiting translation of cyclooxygenase and  
 CC subsequent production of prostaglandins and thromboxanes. The S-  
 CC oligonucleotide derivs of AAQ1475- AAQ1484 are based on the human  
 CC cyclooxygenase-2 cDNA and are useful for antisense therapy of ARDS,  
 CC glomerulitis, rheumatoid arthritis, premature labour, preclampsia,  
 CC endometriosis, etc  
 XX  
 SQ Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Db Best Local Similarity 88.2%; Pred.No.2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 QY 807 GCGCCAGAGACGAGT 823  
 Db 18 GCGCCATGAGCCGAGT 2  
 XX  
 RESULT 340  
 AAT27721/C  
 ID AAT27721 standard; DNA; 18 BP.  
 XX  
 AC AAT27721;  
 XX  
 DT 10-JAN-1997 (first entry)  
 XX  
 DE Fibroblast growth factor fragment.  
 XX  
 KM Epidermal growth factor; EGF; receptor; proliferation factor; astrocyte;  
 KM multipotent neural stem cell; mammary; neuron; oligodendrocyte; therapy;  
 KM fibroblast growth factor; transforming growth factor alpha; brain injury;  
 KM regulatory factor; neurological disorder; central nervous system;  
 KM scar prevention; spinal cord injury; neural scar tissue; axonal element;  
 KM ds.  
 XX  
 OS Mus cookii.  
 XX  
 PN W09615226-A1.  
 XX  
 PD 23-MAY-1996.  
 XX  
 PF 14-NOV-1995; 95WO-CA000637.  
 XX

PR 14-NOV-1994; 94US-00338730.  
 XX  
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.  
 XX  
 PI Weiss S, Reynolds BA;  
 XX  
 DR WPI; 1996-259834/26.  
 XX  
 PT Regulation of in vitro proliferation of multi-potent neural stem cell(s)  
 PT and their progeny - using compns. contg. biological factors, which can  
 PT prevent scar tissue formn. in patients with brain or spinal cord injury.  
 XX  
 PS Example 3; Page 23; 39pp; English.  
 XX  
 CC This sequence represents a fibroblast growth factor (FGF) fragment. FGF  
 CC can be used as the proliferative factor in the method of the invention  
 CC for regulating in vitro proliferation of multipotent neural stem (MNS)  
 CC cells, and their progeny. The method of the invention comprises  
 CC dissociating mammalian neural tissue containing at least one MNS cell  
 CC which produces progeny which differentiate into neurons, astrocytes and  
 CC oligodendrocytes. The cells are then proliferated in a medium containing  
 CC at least one proliferative factor (e.g. FGF, epidermal growth factor, or  
 CC transforming growth factor alpha) inducing stem cell proliferation and a  
 CC regulatory factor which regulates proliferation of the stem cell. The  
 CC precursor cells can be used for transplantation to treat neurological  
 CC disorders. The method can also be used to test the proliferative or  
 CC regulatory effects of biological factors on mammalian MNS cell  
 CC proliferation in vitro prior to using the factors for the in vivo  
 CC regulation of the proliferation of a patients normally quiescent stem  
 CC cells. A therapeutic composition can also be produced for regulating the  
 CC proliferation of neural stem cells in a patients central nervous system,  
 CC containing a neural stem cell regulatory factor. The composition can be  
 CC used to prevent scar tissue formation, in patients with brain or spinal  
 CC cord injury. This composition reduces neural scar tissue formation at the  
 CC site of injury, and enhances conditions allowing for the reconnection of  
 CC axonal elements  
 XX  
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;  
 XX  
 QY Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Db Best Local Similarity 88.2%; Pred.No.2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 QY 1593 CGAGGTACGCGCGCTGG 1609  
 Db 18 CGAGGTGATGCCGCTGG 2  
 XX  
 RESULT 341  
 AAV25472/C  
 ID AAV25472 standard; DNA; 18 BP.  
 XX  
 AC AAV25472;  
 XX  
 DT 07-JUL-1998 (first entry)  
 XX  
 DE Primer for 307 bp collagen type II gene sequence.  
 XX  
 KM PCR primer; 307 bp collagen type II gene sequence;  
 KM human chondrocyte cDNA library; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN W09804681-A2.  
 XX  
 PD 05-FEB-1998.  
 XX  
 PF 25-JUL-1997; 97WO-US013140.  
 XX  
 PR 25-JUL-1996; 96US-0022801P.  
 PR 25-JUL-1996; 96US-0022810P.  
 PR 26-JUL-1996; 96US-0022711P.  
 XX

```
XX (GENZ ) GENZYME CORP.
PA
XX Mcpherson JM, Yaeger PC, Brown ME, Hanlon JG, Binette F;
PI
XX WPI; 1998-159151/14.
DR
XX Defined cell culture medium - comprises supplement mixture, component
PT mixture, vitamin mixture, inorganic salt mixture and amino acid mixture.
XX
XX Example 7; Page 47; 59pp; English.
XX
XX The present sequence is a primer for a 307 bp collagen type II gene
CC sequence, amplified from a human chondrocyte cDNA library
CC
XX Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 717 AGTGTGAGTCTGCTGG 733
DB 17 AGTGTGAGTCTGCTGG 1
RESULT 342
AAV25936
ID AAV25936 standard; DNA; 18 BP.
XX
XX AAV25936;
AC
XX 25-MAR-2003 (revised)
DT 15-JUL-1998 (first entry)
XX
XX Fibroblast growth factor antisense primer.
DE
XX Epidermal growth factor; receptor; fibroblast growth factor; EGF; FGF;
KM neural cell; genetically modified; neurodegenerative disorder;
KW neurotransmitter; primer; ss.
XX
XX Synthetic.
OS
XX US5750376-A.
PN
XX 12-MAY-1998.
PD
XX 07-JUN-1995; 95US-00483122.
PE
XX
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX
XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
PA
XX Hammang JP, Reynolds B, Baetge EE, Weiss S;
PI
XX WPI; 1998-296768/26.
DR
XX
XX Production of genetically modified neural cells for production of e.g.
PT growth factors - comprises combining mammalian neural tissue cells with
PT serum-free culture medium containing at least one growth factor and
PT inducing proliferation.
XX
```

```
PS Example 43; Col 59; 43pp; English.
XX
XX The present sequence represents a primer used to carry out sense and
CC antisense experiments on fibroblast growth factor (FGF), in an example of
CC the present invention. The present invention describes a method for the
CC production of genetically modified neural cells. The cells can be
CC genetically modified (i) to produce a growth factor product; (ii) to
CC produce a neuropeptide; (iii) to express a growth factor receptor; (iii)
CC to contain a neurotransmitter synthesizing gene; (iv) to express a
CC neurotransmitter receptor; or (v) to express chromaffin granule amine
CC transporter. The cells may be used in the treatment of neurodegenerative
CC disorders. (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-
CC MAR-2003 to correct PA field.)
XX
XX Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTGACGCGCCTGG 1609
DB 1 CGAGGTGATGCCCTGG 17
RESULT 343
AAV25935/C
ID AAV25935 standard; DNA; 18 BP.
XX
XX AAV25935;
AC
XX 25-MAR-2003 (revised)
DT 15-JUL-1998 (first entry)
XX
XX Fibroblast growth factor sense primer.
DE
XX Epidermal growth factor; receptor; fibroblast growth factor; EGF; FGF;
KM neural cell; genetically modified; neurodegenerative disorder;
KW neurotransmitter; primer; ss.
XX
XX Synthetic.
OS
XX US5750376-A.
PN
XX 12-MAY-1998.
PD
XX 07-JUN-1995; 95US-00483122.
PE
XX
XX 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX
XX (NEUR-) NEUROSPHERES HOLDINGS LTD.
PA
XX Hammang JP, Reynolds B, Baetge EE, Weiss S;
PI
XX WPI; 1998-296768/26.
DR
XX
XX Production of genetically modified neural cells for production of e.g.
PT growth factors - comprises combining mammalian neural tissue cells with
PT serum-free culture medium containing at least one growth factor and
PT inducing proliferation.
XX
XX Example 43; Col 59; 43pp; English.
```

XX The present sequence represents a primer used to carry out sense and  
 CC antisense experiments on fibroblast growth factor (FGF), in an example of  
 CC the present invention. The present invention describes a method for the  
 CC production of genetically modified neural cells. The cells can be  
 CC genetically modified (i) to produce a growth factor product; (ii) to  
 CC produce a neuropeptide; (iii) to express a growth factor receptor; (iii)  
 CC to contain a neurotransmitter synthesizing gene; (iv) to express a  
 CC neurotransmitter receptor; or (v) to express chromaffin granule amine  
 CC transporter. The cells may be used in the treatment of neurodegenerative  
 CC disorders. (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-  
 CC MAR-2003 to correct PA field.)

XX SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCGCTGG 1609  
 |||||  
 DB 18 CGAGGTGATGCCGCTGG 2

RESULT 344  
 AAV16023/C  
 ID AAV16023 standard; DNA; 18 BP.

XX AAV16023;  
 AC AAV16023;  
 XX 21-MAY-1998 (first entry)  
 XX PCR primer used to identify Sox-2 gene mutations in mice.  
 DE  
 XX Mutation; Sox-2; mutational screening; recessive; phenotypic alteration;  
 KM mouse model; FGF-4; PCR primer; amplify; ss.  
 XX  
 OS Synthetic.  
 OS Mus sp.  
 XX WO9744485-A1.  
 PN  
 XX 27-NOV-1997.  
 PD  
 XX 16-MAY-1997; 97WO-GB001354.  
 PF  
 XX 17-MAY-1996; 96GB-00010355.  
 PR  
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 PA  
 PI Goodfellow PN;  
 PI  
 XX WPI; 1998-018536/02.  
 DR  
 XX Identification of mutation(s) in genes of interest - without prior  
 PT observation of phenotypic alteration in the mutated organism or cell.  
 PT  
 XX Example 6; Page 43; 66pp; English.

XX PCR primers AAV16019-36 were used to identify mutations in Sox-2 using  
 CC the method of the invention. The method comprises testing a nucleic acid  
 CC sample from a mutated organism for a mutation in a gene of interest  
 CC without the prior observation of a phenotypic alteration in the mutated  
 CC organism resulting from the mutation. Sox-2 is a member of the Sox gene  
 CC family, and is involved in transcriptional regulation of the FGF-4 gene.  
 CC FGF-4 codes for a signalling protein whose expression is essential for  
 CC postimplantation mouse development, and, at later embryonic stages, for  
 CC limb patterning and growth. Mutagenised mice in which a Sox-2 mutation is  
 CC identified can be studied and provide a mouse model for a mutant human  
 CC Sox-2 gene. The method provides mutational screening based on genomic and  
 CC genetic techniques rather than on phenotypic observation. The method  
 CC identifies and characterises genes via mutagenesis to identify genes  
 CC encoding products which may have therapeutic benefit. The method also

CC identifies the presence of mutations in a gene which do not rely solely  
 CC upon prior matching of a gene with a disease. Heterozygotic organisms can  
 CC also be screened to identify those carrying a mutation in a copy of a  
 CC gene of interest even though the gene may be recessive and therefore  
 CC causes no phenotypic alteration

XX SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GGGTCTACTGGCCCAT 2216  
 |||||  
 DB 18 GGGTCTCTGCGCCCAT 2

RESULT 345  
 AAV15991/C  
 ID AAV15991 standard; DNA; 18 BP.

XX AAV15991;  
 AC AAV15991;  
 XX 27-MAY-1998 (first entry)  
 XX NBCCS (PTC) gene exon 20 amplifying primer PTCR25.  
 DE  
 XX Nevroid basal cell carcinoma syndrome; NBCCS; PTC; PATCHED; detection;  
 KM tumour suppressor; human; mutation; Gorlin's syndrome; PCR primer; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX WO9743414-A2.  
 PN  
 XX 20-NOV-1997.  
 PD  
 XX 16-MAY-1997; 97WO-US008433.  
 PF  
 XX 17-MAY-1996; 96US-0017906P.  
 PR  
 XX 21-MAY-1996; 96AU-00000011.  
 PR  
 XX 07-JUN-1996; 96AU-000000363.  
 PR  
 XX 14-JUN-1996; 96US-0019765P.  
 PR  
 XX 16-MAY-1997; 97US-00857636.  
 PR  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 PA  
 XX Dean MF, Hahn H, Wicking C, Christiansen J, Zaphiropoulos PG;  
 PI Galliani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E;  
 PI Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Lefell D;  
 PI Gerrard B, Goldstein A, Mainwright B, Toftegard R, Chevenix-Trench G;  
 PI  
 XX WPI; 1998-008883/01.  
 DR  
 XX Nevroid basal cell carcinoma syndrome tumour suppressor gene - useful for  
 PT detection of pre:disposition to basal cell carcinoma(s).  
 PT  
 XX Claim 3; Page 79; 148pp; English.

XX This primer is used for the PCR amplification of exon 20 of a nevroid  
 CC basal cell carcinoma syndrome (NBCCS) (PTC) protein encoding cDNA. The  
 CC NBCCS nucleic acid specifically hybridises, under stringent conditions,  
 CC to a second nucleic acid consisting of a 6568 (full-length sequence),  
 CC 1732 (exon 1a, b) (AAV15998) or 659 (exon 2a) (AAV15999) base pair  
 CC sequence, in the presence of a human genomic library. The PTC polypeptide  
 CC when presented as an antigen elicits the production of an antibody which  
 CC specifically binds to a polypeptide encoded by the above three sequences.  
 CC The NBCCS gene and its protein product, is a tumour suppressor, and is a  
 CC homologue of the Drosophila PATCHED (PTC) gene. Detection of the NBCCS  
 CC nucleic acid, in particular abnormal sequences, by hybridisation assays  
 CC is useful for detecting a predisposition to NBCCS or to a basal cell  
 CC carcinoma (also known as Gorlin syndrome). Alternatively, detection is of  
 CC the polypeptide and is carried out by immunoassay. Vectors comprising

CC this nucleic acid can be used to treat NBCCS. The PTC polypeptide can  
 CC mitigate symptoms of NBCCS in an organism. The NBCCS nucleic acid  
 CC includes one or more mutations, chosen from Exon-5 693insC, Exon-17  
 CC 2988delBbp, Exon-21 3538delG, Exon-22 G4302T, Exon-12  
 CC 1639insA, Exon-16 2707delC, and Intron-17 3157-2A to G. The mutation may  
 CC be a nonsense or frameshift mutation. Frameshift mutations are chosen  
 CC from 244delCT, 271insA, 464insAC, 693insC, 804del137, 877delG, 929delC,  
 CC 1370del176, 1393insGTCC, 144del6, 1497dup8, 1639insA, 1711insC,  
 CC 2183delTC, 2320insAA, 2392delA, 2574delA, 2583delC, 2596complex,  
 CC 2707delC, 2748insC, 2749dup7, 2988delBbp, 3011insA, 3352delAT, and  
 CC 3338delG. The mutation may be a missense, chosen from G391T, G1148A,  
 CC G1368A, G1555T, C2050T, C3015A, G3193C AND G4302T. Alternatively,  
 CC the mutation alters mRNA splicing and is chosen from A1055-2C, 3157-2A to  
 CC G and 1493-8ins21. All these mutations are claimed but their sequences  
 CC are not provided in the specification

XX  
 SQ Sequence 18 BP; 3 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1461 CTGCCACCCAGTCGTC 1477  
 Db 17 CTGCCACCCAGTCGATC 1

RESULT 346  
 AAV70503/c standard; DNA; 18 BP.  
 XX AAV70503;  
 XX 08-APR-1999 (first entry)  
 XX Truncated rpoB amplicon generating primer 57-119(mismatch).

XX  
 DE Nucleic acid detection; nucleic acid characterisation; hybridisation;  
 KM infection; disease; cancer; forensic; paternity; multiplexing; rpoB;  
 KM PCR primer; truncated; mutated; ss.  
 XX  
 OS Synthetic.  
 OS Mycobacterium tuberculosis.  
 XX  
 PN WO9850403-A1.  
 PD 12-NOV-1998.  
 XX  
 PF 05-MAY-1998; 98MO-US003194.  
 XX  
 PR 05-MAY-1997; 97US-00851588.  
 PR 19-SEP-1997; 97US-00934097.  
 PR 03-MAR-1998; 98US-00034205.  
 XX  
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
 XX  
 PI Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
 PI Anderson TA, Dahlberg JE;  
 PI WPI; 1998-610317/51.  
 DR  
 XX  
 PT Detection and characterisation of nucleic acid sequences - by mixing a  
 PT folded target and one or more probes to form a probe/folded target  
 PT complex and detecting and characterising the complexes.  
 XX  
 PS Example 13; Page 149; 279pp; English.  
 XX  
 CC The invention relates to methods and compositions of detection and  
 CC characterisation of nucleic acid sequences and sequence changes. One  
 CC method of detection and characterisation comprises: (a) providing: (1) a  
 CC folded target having a DNA sequence comprising at least 1 double stranded  
 CC region and at least 1 single stranded region; and (1i) at least 1 probe  
 CC complementary to at least a portion of the folded target; and (b) mixing

CC the target and probes so that the probe hybridises to form a probe  
 CC /folded target complex. Also provided are methods for determination of  
 CC structure formation in nucleic acid targets; for analysing folded nucleic  
 CC acids targets; and for analysis of nucleic acid structures. The methods  
 CC can be used for the detection and characterisation of nucleic acid  
 CC sequences to detect the presence of pathogenic nucleic acid sequences  
 CC indicative of an infection, the presence of variants or alleles of  
 CC mammalian genes associated with disease and cancers, and the  
 CC identification of the source of nucleic acids found in forensic samples,  
 CC as well as in paternity determinations. The methods allow simultaneous  
 CC analysis of both strands (e.g. the sense and antisense strands) and are  
 CC ideal for high-level multiplexing. The products produced are amenable to  
 CC qualitative, quantitative and positional analysis. The methods may be  
 CC performed in solution or in the solid phase (e.g. on a solid support).  
 CC The methods are powerful in that they allow for analysis of longer  
 CC fragments of nucleic acid than current methodologies. The present  
 CC sequence represents a PCR primer used for generating a truncated or  
 CC mutated rpoB amplicon. This is used in exemplifying the method of  
 CC structural analysis of nucleic acid targets

XX  
 SQ Sequence 18 BP; 3 A; 10 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCCCGGGCGTCAGC 499  
 Db 17 GGAGCCCGCGGTCGTGG 1

RESULT 347  
 AAV81444/c  
 ID AAV81444 standard; cDNA; 18 BP.  
 XX AAV81444;  
 XX 16-MAR-1999 (first entry)  
 XX Sense oligonucleotide targeted to RGF sequence.

XX  
 DE Proliferation; differentiation; stem cell; growth factor; drug screening;  
 KM differentiation factor; transplantation; antisense; receptor; ss.  
 XX  
 OS Synthetic.  
 OS US5851832-A.  
 XX  
 PN US5851832-A.  
 PD 22-DEC-1998.  
 XX  
 PF 07-JUN-1995; 95US-00486648.  
 XX  
 PR 08-JUL-1991; 91US-00726812.  
 PR 16-OCT-1992; 92US-00961813.  
 PR 28-OCT-1992; 92US-00967622.  
 PR 29-JAN-1993; 93US-00010829.  
 PR 09-NOV-1993; 93US-00149508.  
 PR 01-APR-1994; 94US-00221655.  
 PR 05-JUL-1994; 94US-00270412.  
 PR 23-SEP-1994; 94US-00311099.  
 PR 14-NOV-1994; 94US-00338730.  
 PR 20-DEC-1994; 94US-00359945.  
 PR 20-JAN-1995; 94US-00376062.  
 PR 07-FEB-1995; 95US-00385404.  
 XX  
 PA (NEUR-) NEUROSPHERES LTD.  
 XX  
 PI Baetge EE, Hamman JP, Weiss S, Reynolds B;  
 DR WPI; 1999-080415/07.  
 XX  
 PT Culture of neural stem cells in vitro - for production of differentiated  
 PT neural cells.

```
XX Example 43; Col 59; 44pp; English.
PS
XX The invention relates to methods for proliferating and differentiating
CC neural stem cells and their progeny by culturing the cells in media
CC containing growth factors and/or differentiation factors. The
CC differentiating neural cells can be used for transplantation or drug
CC screening. Growth factors used to induce proliferation include the
CC proteins activin, bone morphogenetic protein (BMP) 2, transforming growth
CC factor (TGF)-beta, interleukin-2, -6 or -8, macrophage inflammatory
CC protein (MIP)-delta, -1beta or 2, tumour necrosis factor (TNF)-alpha,
CC nerve growth factor (NGF), platelet-derived growth factor (PDGF),
CC epidermal growth factor (EGF) or fibroblast growth factor (FGF).
CC Oligonucleotides AAV81442-V81445 are used in antisense and sense
CC experiments for cell growth induced by FGF. This sequence represents a
CC sense oligonucleotide targeted to the FGF sequence
XX
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTACGCGCGCTGG 1609
Db 18 CGAGGTGATGCCGCTGG 2
RESULT 348
AAV81445
ID AAV81445 standard; cDNA; 18 BP.
XX
AC AAV81445;
XX
DT 16-MAR-1999 (first entry)
XX
DE Antisense oligonucleotide targeted to FGF receptor sequence.
XX
KW Proliferation; differentiation; stem cell; growth factor; drug screening;
KW differentiation factor; transplantation; antisense; receptor; ss.
XX
OS Synthetic.
XX
PN US5851832-A.
XX
PD 22-DEC-1998.
XX
PF 07-JUN-1995; 95US-00486648.
XX
PR 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX
PA (NEUR-) NEUROSPHERES LTD.
XX
PI Baetge EE, Hamang JP, Weiss S, Reynolds B;
XX WPI; 1999-080415/07.
XX
DR WPI; 1999-080415/07.
XX
PT Culture of neural stem cells in vitro - for production of differentiated
PT neural cells.
XX
PS Example 43; Col 59; 44pp; English.
XX
```

```
CC The invention relates to methods for proliferating and differentiating
CC neural stem cells and their progeny by culturing the cells in media
CC containing growth factors and/or differentiation factors. The
CC differentiating neural cells can be used for transplantation or drug
CC screening. Growth factors used to induce proliferation include the
CC proteins activin, bone morphogenetic protein (BMP) 2, transforming growth
CC factor (TGF)-beta, interleukin-2, -6 or -8, macrophage inflammatory
CC protein (MIP)-delta, -1beta or 2, tumour necrosis factor (TNF)-alpha,
CC nerve growth factor (NGF), platelet-derived growth factor (PDGF),
CC epidermal growth factor (EGF) or fibroblast growth factor (FGF).
CC Oligonucleotides AAV81442-V81445 are used in antisense and sense
CC experiments for cell growth induced by FGF. This sequence represents an
CC antisense oligonucleotide targeted to the FGF sequence
XX
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1593 CGAGGTACGCGCGCTGG 1609
Db 1 CGAGGTGATGCCGCTGG 17
RESULT 349
AAA56803/c
ID AAA56803 standard; cDNA; 18 BP.
XX
AC AAA56803;
XX
DT 17-OCT-2000 (first entry)
XX
DE FGF sense oligodeoxynucleotide.
XX
KW Fibroblast growth factor; FGF; nootropic; anticonvulsant;
KW neuroprotective; antiparkinsonian; gene therapy; Alzheimer's disease;
KW neurodegenerative disease; Huntington's disease; Alzheimer's disease;
KW Parkinson's disease; neurological trauma; tissue graft;
KW neural cell proliferation; ss.
XX
OS Unidentified.
XX
PN US6071889-A.
XX
PD 06-JUN-2000.
XX
PF 07-JUN-1995; 95US-00479795.
XX
PR 08-JUL-1991; 91US-00726812.
PR 16-OCT-1992; 92US-00961813.
PR 28-OCT-1992; 92US-00967622.
PR 29-JAN-1993; 93US-00010829.
PR 09-NOV-1993; 93US-00149508.
PR 01-APR-1994; 94US-00221655.
PR 05-JUL-1994; 94US-00270412.
PR 23-SEP-1994; 94US-00311099.
PR 14-NOV-1994; 94US-00338730.
PR 20-DEC-1994; 94US-00359945.
PR 20-JAN-1995; 95US-00376062.
PR 07-FEB-1995; 95US-00385404.
XX
PA (NEUR-) NEUROSPHERES HOLDINGS LTD.
XX
PI Baetge EE, Hamang JP, Reynolds B, Weiss S;
XX WPI; 2000-411199/35.
XX
DR WPI; 2000-411199/35.
XX
PT In vivo transfer of nucleic acid sequence to proliferating neural cells
PT in central nervous system for treating neurodegenerative disorders,
PT involves administering exogenous nucleic acid sequence and growth
PT factor(s).
XX
```



CC by real-time polymerase chain reaction (PCR), results indicated that 60%  
CC inhibition was achieved. When (I) was modified by 2'-O-methoxyethyl-  
CC substitution of the first 4 and last 4 residues, and by replacing any C  
CC in these flanking regions with 5-methyl-C, the degree of inhibition was  
CC increased to 71%. (I) is used to inhibit expression of EGR-1 in cells and  
CC tissues in vitro, for research or diagnosis, e.g. detecting EGR-1  
CC encoding nucleic acid. (I) may also be used to treat or prevent EGR-1-  
CC associated diseases, particularly viral infections, inflammation and  
CC human EGR-1 protein

XX  
SQ Sequence 18 BP; 4 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2054 TGTACGAAAGCCCTGAG 2070  
Db 2 TGTCCGAAAGCCCTGTG 18  
|||||

RESULT 352  
AAA23496/C  
ID AAA23496 standard; DNA; 18 BP.  
XX  
AC AAA23496;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Clone vp3\_1 hybridisation probe, SEQ ID NO:114.  
XX  
XX Human; secreted protein; cancer; tumour; cardiovascular disorder;  
KM blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;  
KM infection; fungal; bacterial; viral; HIV; allergy; arthritis;  
KM neurodegenerative disease; asthma; contraceptive; hybridisation probe;  
KM ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200011015-A1.  
XX  
PD 02-MAR-2000.  
XX  
PF 24-AUG-1999; 99WO-US019351.  
XX  
PR 24-AUG-1998; 98US-0097638P.  
PR 09-SEP-1998; 98US-0087659P.  
PR 09-SEP-1998; 98US-0099618P.  
PR 28-SEP-1998; 98US-0102092P.  
PR 25-NOV-1998; 98US-0109978P.  
PR 23-DEC-1998; 98US-0113645P.  
PR 23-DEC-1998; 98US-0113646P.  
PR 23-AUG-1999; 99US-00379246.  
XX  
PA (ALPH-) ALPHAGENE INC.  
XX  
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Raplejko P;  
XX  
DR WPI; 2000-224657/19.  
XX  
PT New secreted or transmembrane proteins and polynucleotides encoding them,  
PT useful for treating neurodegenerative disorders, autoimmune diseases and  
PT cancer.  
XX  
PS Disclosure; Page 344; 357pp; English.  
XX  
CC The invention relates to 40 human secreted proteins (AA94981-Y95020),  
CC and cDNA sequences encoding them (AAA23423-A23462). The secreted proteins  
CC of the invention include those that are thought to be only partially  
CC secreted, i.e., transmembrane proteins. The proteins of the invention may  
CC exhibit one or more activities selected from the following: cytokine  
CC activity; cell proliferation; differentiation; immune modulation;

CC haematopoiesis regulation; tissue growth activity; activin/inhibin  
CC activity; chemotactic/chemokinetic activity; haemostatic and thrombolytic  
CC activity; anti-inflammatory activity; and tumour inhibition activity. The  
CC proteins may be administered to patients as vaccines, and the nucleotides  
CC may be used as part of a gene therapy regime. Diseases or conditions that  
CC may be treated using the proteins or nucleotides of the invention include  
CC autoimmune diseases; genetic disorders; haemophilia; cardiovascular  
CC diseases; cancer; bacterial, fungal and viral infections, especially HIV;  
CC multiple sclerosis; rheumatoid arthritis; pulmonary inflammation;  
CC Guillain-Barre syndrome; insulin dependent diabetes mellitus; and  
CC allergic reactions such as asthma and anaemia. They may also be used for  
CC treating wounds, burns, ulcers, osteoporosis, osteoarthritis, periodontal  
CC diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease  
CC and amyotrophic lateral sclerosis (ALS). Proteins with activin/inhibin  
CC activity may additionally be useful as contraceptives. Nucleic acid  
CC sequences of the invention may be used in chromosome mapping, and as a  
CC source of diagnostic primers and probes. Sequences AAA23463-A23502  
CC represent hybridisation probes which may be used to isolate the cDNA  
CC clones of the invention

XX  
SQ Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1919 GGAGCCAGCTGTCAGG 1935  
Db 18 GGAGCCAGGTGTCAAG 2  
|||||

RESULT 353  
AAZ74103  
ID AAZ74103 standard; DNA; 18 BP.  
XX  
AC AAZ74103;  
XX  
DT 10-SEP-2001 (first entry)  
XX  
DE Human biallelic marker downstream amplification primer SEQ ID NO:8459.  
XX  
KM Human genome; biallelic marker; high density disequilibrium map;  
KM genomic map; haplotype; phenotype; polymorphic base; genotyping;  
KM haplotyping; hybridisation; identification; characterisation;  
KM amplification; single nucleotide polymorphism; SNP; PCR primer;  
KM diagnosis; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954500-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 21-APR-1999; 99WO-IB000822.  
XX  
PR 21-APR-1998; 98US-0082614P.  
PR 23-NOV-1998; 98US-0109732P.  
XX  
PA (GEST ) GENSET.  
XX  
PI Cohen D, Blumenfeld M, Chumakov I;  
XX  
DR WPI; 2000-013267/01.  
XX  
PT Novel biallelic markers used to construct a high density disequilibrium  
PT map of the human genome.  
XX  
PS Claim 8; Page 2034; 2745pp; English.  
XX  
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present  
CC invention, which contain a polymorphic base at position 24 of their  
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification  
CC primers for the biallelic markers. The biallelic markers of the invention



CC have a variety of uses: they can be used for high density mapping of the  
 CC human genome, and in complex association studies and haplotyping studies  
 CC which are useful in determining the genetic basis for disease states.  
 CC Compositions and methods of the invention can also be useful for the  
 CC identification of the targets for the development of pharmaceutical  
 CC agents and diagnostic methods, as well as the characterisation of the  
 CC differential efficacious responses to and side effects from  
 CC pharmaceutical agents acting on a disease as well as other treatment.  
 CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and  
 CC 3367, are not actually given a sequence in the Sequence Listing from the  
 CC present invention  
 XX  
 SQ Sequence 18 BP; 3 A; 8 C; 1 G; 6 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 77 TACTGCTACTTCTGCCC 93  
 DB 2 TACTGCTACTACTCTCC 18  
 RESULT 354  
 AA243282/C  
 ID AA243282 standard; DNA; 18 BP.  
 XX  
 AC AA243282;  
 XX  
 DT 11-FEB-2000 (first entry)  
 XX  
 DE Murine Sox2 gene PCR primer 5.  
 XX  
 KM Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN US5994075-A.  
 XX  
 PD 30-NOV-1999.  
 XX  
 PF 16-MAY-1997; 97US-00857946.  
 XX  
 PR 17-MAY-1996; 96US-0017824P.  
 XX  
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 XX  
 PI Goodfellow PN;  
 XX  
 PS WPI; 2000-038255/03.  
 DR  
 XX  
 PT Identifying a mutation in a gene of interest in an organism useful for  
 PT identifying genes encoding products which may have therapeutic benefits.  
 XX  
 PS Example 7; Col 69-70; 70pp; English.  
 XX  
 CC This invention describes a novel mutational screening method based on  
 CC genomic and genetic techniques to identify and characterize a mutation in  
 CC a gene of interest without first selecting a phenotypic characteristic.  
 CC The screening methods are useful for identifying genes encoding products  
 CC which may have therapeutic benefit for treating human or animal diseases.  
 CC The method can be used for the DNA mutation screening of a class or a  
 CC family of genes providing a rapid assay for identifying mutant genes. The  
 CC methods produce organisms which can be used for drug discovery e.g.  
 CC providing a model for the study and treatment of a disease state, allow  
 CC in vitro assessment of drug activity and interbreeding of mutants which  
 CC allow investigation of gene interactions in the overall phenotype. A  
 CC range of phenotypes associated with different mutations, and specified  
 CC mutations in a gene of interest can be determined. The method can be  
 CC adapted to screen for a mutation in two or more genes of interest in an  
 CC organism. The methods allow mutations in a gene of interest to be  
 CC identified without having to rely on matching a gene with a disease.  
 CC AA243260-243421 represent PCR primers used in the method of the invention

XX  
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 2200 GGGTCTACTGGGCCAT 2216  
 DB 18 GGGTCTCTCTGGGCCAT 2  
 RESULT 355  
 AAA05267/C  
 ID AAA05267 standard; DNA; 18 BP.  
 XX  
 AC AAA05267;  
 XX  
 DT 19-MAY-2000 (first entry)  
 XX  
 DE PCR primer C-F used in Sox-2 ampilmer generation.  
 XX  
 KM PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; C-Kit; Trp-1;  
 KM Pax-6; mutation detection; therapeutic target identification; mouse;  
 KM mast cell growth factor; ss.  
 XX  
 OS Mus sp.  
 XX  
 PN US6015670-A.  
 XX  
 PD 18-JAN-2000.  
 XX  
 PF 14-NOV-1997; 97US-00970740.  
 XX  
 PR 17-MAY-1996; 96US-0017824P.  
 XX  
 PR 16-MAY-1997; 97US-00857946.  
 XX  
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 XX  
 PI Goodfellow PN;  
 XX  
 PS WPI; 2000-181139/16.  
 DR  
 XX  
 PT Detecting mutations in selected genes, useful e.g. for identifying  
 PT therapeutic targets or products, by analyzing DNA in mutated embryonic  
 PT stem cells without phenotypic characterization.  
 XX  
 PS Example 6; Col 32; 66pp; English.  
 XX  
 CC PCR primers AAA05245-A05406 are used to generate ampimers from the mouse  
 CC Sox-3 gene, Sox-2 gene, T gene, Tyrosinase gene, Trp-1 gene, Sry gene,  
 CC MGF (mast cell growth factor) gene, C-Kit gene, and the Pax-6 gene. The  
 CC primers are used in a method for the identification of a mutation in a  
 CC selected gene in a tissue without the prior observation of a phenotypic  
 CC alteration in the mutated organism or cell. The method is used to  
 CC identify mutations in a selected gene that encode products of potential  
 CC therapeutic activity or that are potential targets, particularly where  
 CC the gene of interest has been identified as a candidate gene by  
 CC positional cloning. Other applications are determining functions of genes  
 CC in detecting the range of phenotypes associated with different mutations  
 CC in a particular gene and identification of particular mutations. Animals  
 CC containing an identified mutation are used as models for studying  
 CC diseases or their treatment, and cells from them for in vitro assessment  
 CC of drug action. Interbreeding of mutant mice is used to investigate  
 CC genetic interaction in the overall phenotype  
 XX  
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 2200 GGGTCTACTGGGCCAT 2216

Db 18 GGGTTCCTGGCCAT 2

RESULT 356  
AAAS2031/C  
ID AAAS2031 standard; cDNA; 18 BP.

XX AAAS2031;

DT 19-DEC-2000 (first entry)

DE Antisense oligonucleotide directed against PI3K p85 subunit.

XX Phosphatidylinositol 3-kinase; PI3K; p85; p110; heterodimer; hormone;  
KW growth factor; receptor; antisense; inhibition; expression; diagnosis;  
KW modulation; growth factor mediated cell transformation; mitogenesis;  
KW protein trafficking; cell survival; cell proliferation; DNA synthesis;  
KW apoptosis; neurite outgrowth; insulin-stimulated glucose transport; ss.

XX Synthetic.

OS US6100090-A.

PN 08-AUG-2000.

XX 25-JUN-1999; 99US-00344521.

XX 25-JUN-1999; 99US-00344521.

XX (ISIS-) ISIS PHARM INC.

PA Monia BP, Cowsett LM;

PI WPI; 2000-542426/49.

DR Antisense compounds targeted to the coding region of human

PT phosphatidylinositol 3-kinase (PI3K) p85 and inhibiting PI3K p85

PT expression, useful for treating disorders associated with PI3K p85

PT expression.

XX Example 15; Col 39; 32pp; English.

XX The phosphatidylinositol 3-kinases (PI3Ks) represent a ubiquitous family  
CC of heterodimeric lipid kinases that are found in association with the  
CC cytoplasmic domain of hormone and growth factor receptor and oncogene  
CC products. PI3Ks act as downstream effectors of these receptors, are  
CC recruited upon receptor stimulation and mediate the activation of second  
CC messenger signaling pathways. The PI3 kinase enzyme consists of a 110KD  
CC catalytic subunit (p110) associated with an 85KD regulatory subunit (p85)  
CC and it is through the SH2 domains of the p85 subunit that the enzyme  
CC associates with the membrane bound receptors. PI3Ks have been implicated  
CC in many cellular activities including growth factor mediated cell  
CC transformation, mitogenesis, protein trafficking, cell survival and  
CC proliferation, DNA synthesis, apoptosis, neurite outgrowth and insulin-  
CC stimulated glucose transport. Antisense compounds directed against PI3K  
CC p85 and which inhibit its expression are useful as diagnostics and  
CC research reagents, and as a component of kits, which can be used for  
CC detecting the level of PI3K p85 in a sample. The compounds may be  
CC administered to an animal or human suspected of having a disease or  
CC disorder which can be treated by modulating the expression of PI3K p85.  
CC The compounds may further be useful prophylactically, e.g., to prevent or  
CC delay infection, inflammation or tumour formation. The target site of  
CC this antisense molecule is nucleotide 1674 of the coding region of the  
CC PI3K p85 subunit (See GENESEQ record AAAS2007)

XX Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1772 TTGAGAGAACTTCAA 1788

Db 17 TTGAGAGAACTTCAA 1

RESULT 357  
AAC67588/C  
ID AAC67588 standard; DNA; 18 BP.

XX AAC67588;

DT 14-FEB-2001 (first entry)

DE Alzheimer's disease-linked mitochondrial SNP PCR primer #288.

XX Human; mitochondrial genome; single nucleotide polymorphism; SNP;  
KW Alzheimer's disease; mtDNA; PCR primer; ss.

XX Homo sapiens.

XX M0200063441-A2.

PN 26-OCT-2000.

XX 19-APR-2000; 2000WO-US010906.

XX 20-APR-1999; 99US-0130447P.

XX 22-OCT-1999; 99US-0160901P.

XX (MITO-) MITOKOR.

PA Herrnschadt C, Davis RE;

PI WPI; 2000-672748/65.

DR Diagnosing a subject at the risk for or having Alzheimer's disease

PT comprises determining at least one single nucleotide polymorphism in

PT mitochondrial DNA associated with the disease in the sample from the

PT subject.

XX Example 9; Page 57; 89pp; English.

XX The present invention describes a novel method for determining the risk

CC of or diagnosing Alzheimer's disease using single nucleotide

CC polymorphisms (SNPs) present in an individual's mitochondrial DNA

CC (mtDNA). In addition, the SNPs identified can be used to identify agents

CC suitable for use in treating Alzheimer's disease. Sequences AAC67301-

CC C67610 are PCR primers used to demonstrate the method of the invention

XX Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 658 TCAGCCGATACCTTCAC 674

Db 18 TCATCCCGCTACTTCAC 2

RESULT 358  
AAF83007/C  
ID AAF83007 standard; DNA; 18 BP.

XX AAF83007;

DT 29-JUN-2001 (first entry)

DE Human MBSBP2 amplifying gene-specific primer 10354784 S2.

XX MBSBP2; cancer; preclampsia; immune system; neurological; cytoskeletal;  
KW gynecological; antiinflammatory; neuroprotective; inotropic; relaxant;  
KW cardiac; dermatological; gene therapy; human; MBSBP2; PCR primer; ss.

```

OS Homo sapiens.
XX
XX WO200127277-A2.
XX
XX 19-APR-2001.
XX
XX PF 13-OCT-2000; 2000WO-US028480.
XX
XX PR 13-OCT-1999; 99US-0159231P.
XX 12-JAN-2000; 2000US-0175670P.
XX 12-OCT-2000; 2000US-00159231.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkels RA, Lichenstein H, Boldog FL;
XX WPI; 2001-282030/29.
XX
XX Novel human polynucleotide sequences and the membrane bound or secreted
XX polypeptides encoded by these sequences, designated MBSPX.
XX
XX Example 1; Page 132; 157pp; English.
XX
XX The invention relates to novel polypeptides, termed MBSPX and
XX polynucleotides encoding the MBSPX polypeptides. The MBSPX polypeptide,
XX nucleic acid and an MBSPX antibody are useful for treating or preventing
XX a pathology associated with the protein especially in humans. The MBSPX
XX nucleic acid can be used to express MBSPX protein (e.g. via a recombinant
XX expression vector in a host cell in gene therapy applications), an to
XX detect MBSPX mRNA in a biological sample or a genetic lesion in a MBSPX
XX gene. Disorders associated with insufficient or excessive production of
XX MBSPX protein include cancer, preclampsia, immune system disorders and
XX inflammation, neurological disorders, cardiovascular disorders, and skin
XX and muscle abnormalities. The anti-MBSPX antibodies can be used to detect
XX and isolate MBSPX proteins and modulate MBSPX activity. Sequences
XX AAF83006-013 represent gene specific PCR primers for amplifying the MBSPX
XX cDNA
XX
XX Sequence 18 BP; 5 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.64; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.24; Pred. No. 2.2e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 197 CCGTCTCTGCTGGG 213
XX Db 17 CCGTCTCTGCTGAGG 1
XX
XX RESULT 359
XX AAF83006
XX ID AAF83006 standard; DNA, 18 BP.
XX
XX AAF83006;
XX
XX 29-JUN-2001 (first entry)
XX
XX Human MBSPX2 amplifying gene-specific primer 10354784 S1.
XX
XX MBSPX; cancer; preclampsia; immune system; neurological; cytostatic;
XX gynecological; antiinflammatory; neuroprotective; inotropic; relaxant;
XX cardant; dermatological; gene therapy; human; MBSPX2; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200127277-A2.
XX
XX 19-APR-2001.
XX
XX 13-OCT-2000; 2000WO-US028480.
XX
XX 13-OCT-1999; 99US-0159231P.
XX 12-JAN-2000; 2000US-0175670P.
XX

```

```

PR 12-OCT-2000; 2000US-00159231.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkels RA, Lichenstein H, Boldog FL;
XX WPI; 2001-282030/29.
XX
XX Novel human polynucleotide sequences and the membrane bound or secreted
XX polypeptides encoded by these sequences, designated MBSPX.
XX
XX Example 1; Page 132; 157pp; English.
XX
XX The invention relates to novel polypeptides, termed MBSPX and
XX polynucleotides encoding the MBSPX polypeptides. The MBSPX polypeptide,
XX nucleic acid and an MBSPX antibody are useful for treating or preventing
XX a pathology associated with the protein especially in humans. The MBSPX
XX nucleic acid can be used to express MBSPX protein (e.g. via a recombinant
XX expression vector in a host cell in gene therapy applications), an to
XX detect MBSPX mRNA in a biological sample or a genetic lesion in a MBSPX
XX gene. Disorders associated with insufficient or excessive production of
XX MBSPX protein include cancer, preclampsia, immune system disorders and
XX inflammation, neurological disorders, cardiovascular disorders, and skin
XX and muscle abnormalities. The anti-MBSPX antibodies can be used to detect
XX and isolate MBSPX proteins and modulate MBSPX activity. Sequences
XX AAF83006-013 represent gene specific PCR primers for amplifying the MBSPX
XX cDNA
XX
XX Sequence 18 BP; 1 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.64; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.24; Pred. No. 2.2e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 197 CCGTCTCTGCTGGG 213
XX Db 2 CCGTCTCTGCTGAGG 18
XX
XX RESULT 360
XX AAS11809
XX ID AAS11809 standard; DNA, 18 BP.
XX
XX AAS11809;
XX
XX 24-OCT-2001 (first entry)
XX
XX Human surfactant protein B, SPB, probe 3'fl.
XX
XX Human surfactant protein B; SPB; Thyroid transcription factor; TTF-1;
XX lung cancer; thyroid cancer; 3'fl; ds; probe; HNF-3; EMSA;
XX electrophoretic mobility shift assay.
XX
XX Homo sapiens.
XX
XX US2001016352-A1.
XX
XX 23-AUG-2001.
XX
XX 26-MAY-1999; 99US-00320337.
XX 18-MAY-1994; 94US-00245356.
XX 17-MAY-1995; 95US-00442809.
XX
XX (BOHL/) BOHINSKI R J.
XX (WHIT/) WHITSETT J A.
XX
XX Bohinski RJ, Whitsett JA;
XX WPI; 2001-513959/56.
XX
XX Oligonucleotide sequences which bind nuclear proteins and surfactants
XX found in lung cells, useful for detecting cancers that originate in the
XX

```

PT lung.  
XX  
XX Example 2; Fig 9a; 76pp; English.  
XX  
CC The invention relates to an oligonucleotide which includes at least 1  
CC nucleic acid sequence which binds to at least 1 nuclear protein found in  
CC lung cells (e.g. the thyroid transcription factor 1, TTF-1, protein). The  
CC oligonucleotide can be expressed in lung cells via a vector and can be  
CC used to target therapeutic agents to kill lung or thyroid cancer cells.  
CC The oligonucleotide can be used to detect or diagnose lung or thyroid  
CC cancer. The oligonucleotides may be designed from the sequences of, for  
CC example, the promoters of lung-specific genes such as those encoding  
CC surfactant proteins. The present sequence is a Human surfactant protein  
CC B, SPB, probe 3' fl based on the SPB-fl probe and is used to identify TTF-  
CC 1 and HNF-3 binding sites in the SPB promoter using EMSA, electrophoretic  
CC mobility shift assay  
XX  
SQ Sequence 18 BP; 5 A; 4 C; 6 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1416 GGGCTCTTCAGAGCAA 1432  
Db 1 GGGCTCTTCAGAGCAA 17  
|||||  
  
RESULT 361  
AAS11811  
ID AAS11811 standard; DNA; 18 BP.  
XX  
AC AAS11811;  
XX  
DT 24-OCT-2001 (first entry)  
XX  
DE Human surfactant protein B, SPB, probe 3'SPB-fl.  
XX  
KW Human; surfactant protein B; SPB; Thyroid transcription factor; TTF-1;  
KW lung cancer; thyroid cancer; 3'SPB-fl; ss; probe; HNF-3; EMSA;  
KW electrophoretic mobility shift assay.  
XX  
OS Homo sapiens.  
XX  
PN US2001016352-A1.  
XX  
PD 23-AUG-2001.  
XX  
PF 26-MAY-1999; 99US-00320337.  
XX  
PR 18-MAY-1994; 94US-00245356.  
PR 17-MAY-1995; 95US-00442809.  
XX  
PA (BOH1/) BOHINSKI R J.  
PA (WHIT/) WHITSETT J A.  
XX  
PI Bohinski RJ, Whiteett JA;  
XX  
DR WPI; 2001-513959/56.  
XX  
PT Oligonucleotide sequences which bind nuclear proteins and surfactants  
PT found in lung cells, useful for detecting cancers that originate in the  
PT lung.  
XX  
XX Example 2; Fig 10a; 76pp; English.  
XX  
CC The invention relates to an oligonucleotide which includes at least 1  
CC nucleic acid sequence which binds to at least 1 nuclear protein found in  
CC lung cells (e.g. the thyroid transcription factor 1, TTF-1, protein). The  
CC oligonucleotide can be expressed in lung cells via a vector and can be  
CC used to target therapeutic agents to kill lung or thyroid cancer cells.  
CC The oligonucleotide can be used to detect or diagnose lung or thyroid  
CC cancer. The oligonucleotides may be designed from the sequences of, for

CC example, the promoters of lung-specific genes such as those encoding  
CC surfactant proteins. The present sequence is a Human surfactant protein  
CC B, SPB, probe 3'SPB-fl and is used to identify TTF-1 and HNF-3 binding  
CC sites in the SPB promoter using EMSA, electrophoretic mobility shift  
CC assay  
XX  
SQ Sequence 18 BP; 5 A; 4 C; 6 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1416 GGGCTCTTCAGAGCAA 1432  
Db 1 GGGCTCTTCAGAGCAA 17  
|||||  
  
RESULT 362  
AAE79676/C  
ID AAE79676 standard; DNA; 18 BP.  
XX  
AC AAE79676;  
XX  
DT 29-MAY-2001 (first entry)  
XX  
DE Human Akt-3 antisense oligonucleotide, SEQ ID NO: 84.  
XX  
DE Human; Akt-3; protein kinase; cytosolic; antiinflammatory; infection;  
KW antisense therapy; inflammation; tumour; ss.  
XX  
OS Homo sapiens.  
XX  
PN US6187586-B1.  
XX  
PD 13-FEB-2001.  
XX  
PF 29-DEC-1999; 99US-00474922.  
XX  
PR 29-DEC-1999; 99US-00474922.  
XX  
PR 29-DEC-1999; 99US-00474922.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Cowseert LM, Roth RA;  
XX  
DR WPI; 2001-264979/27.  
XX  
PT New antisense compounds targeting nucleic acids encoding human Akt-3  
PT useful for treating a disease or condition associated with Akt-3  
PT expression, or in preventing or delaying inflammation or tumor formation.  
XX  
PS Claim 1; Col 40; 37pp; English.  
XX  
CC The present sequence is one of a number of antisense compounds of up to  
CC 30 nucleobases in length targeted to a nucleic acid encoding human Akt-3.  
CC The antisense compounds are useful for inhibiting the expression of human  
CC Akt-3 in human cells or tissues. They are also useful for modulating the  
CC expression of Akt-3, and for treating a human or an animal suspected of  
CC having, or being prone to, a disease or condition associated with Akt-3  
CC expression. The antisense compounds may also be used as research  
CC reagents, in kits and in diagnostics, e.g. to elucidate the function of a  
CC particular gene or to distinguish between functions of various members of  
CC a biological pathway; and as a prophylactic, e.g. to prevent or delay  
CC infection, inflammation or tumour formation  
XX  
SQ Sequence 18 BP; 8 A; 4 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1867 AGTTTCATCTCTGAGCT 1883  
Db 18 AGTTTCATCTCTGAGCT 2  
|||||

RESULT 363  
AAFI7452  
ID AAFI7452 standard; DNA; 18 BP.  
XX  
AC AAFI7452;  
XX  
DT 09-MAR-2001 (first entry)  
XX  
DE Primer UB1133.  
XX  
KM Retrotransposon; genetic defect; cystic fibrosis; ss.  
XX  
OS Synthetic.  
XX  
PN US6150160-A.  
XX  
PD 21-NOV-2000.  
XX  
PF 28-APR-1997; 97US-00847844.  
XX  
PR 16-NOV-1995; 95US-0006831P.  
XX  
PR 15-NOV-1996; 96US-00749805.  
XX  
PA (UYJO ) UNIV JOHNS HOPKINS.  
XX  
PA (UYPE-) UNIV PENNSYLVANIA.  
XX  
PI Moran JV, Dombrowski BA, Kazazian HH, Boeke JD;  
XX  
DR WPI; 2001-060015/07.  
XX  
PT DNAC comprising a promoter P and an L1 cassette sequence having a core  
PT retrotransposon element, useful for random insertion of a heterologous or  
PT homologous DNA sequence into a cell genome and for correcting genetic  
PT defects.  
XX  
PS Example 2; Col 34; 87pp; English.  
XX  
CC The present invention relates to DNA for a promoter and an L1 cassette  
CC sequence having a core retrotransposon element. The invention is useful  
CC for random insertion of a heterologous or homologous DNA sequence into a  
CC cell genome, and for correction of a genetic defect in the cell into  
CC which the insertion is made. Genetic defects which may be corrected  
CC includes cystic fibrosis, mutations in the dystrophin gene, genetic  
CC defects associated with blood clotting and other genetic defects  
XX  
SQ Sequence 18 BP; 7 A; 3 C; 5 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1817 AGCCACTATGAGGAA 1833  
Db 2 AGGCACTATGAGGAA 18  
XX  
RESULT 364  
AAH39762/c  
ID AAH39762 standard; DNA; 18 BP.  
XX  
AC AAH39762;  
XX  
DT 14-AUG-2001 (first entry)  
XX  
DE SNP specific lower PCR primer SEQ ID 2558.  
XX  
KM Single nucleotide polymorphism; SNP; single nucleotide primer extension;  
KM SNPE; genotyping; agammaglobulinemia; diabetes insipidus; cancer;  
KM Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;  
KM polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;  
KM acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;

KM Inflammation; forensic investigation; paternity analysis; PCR primer; ss.  
XX  
XX Homo sapiens.  
XX  
PN WO200129262-A2.  
XX  
XX 26-APR-2001.  
XX  
PD 13-OCT-2000; 2000MO-US028436.  
XX  
PF 15-OCT-1999; 99US-0160096P.  
XX  
PR (ORCH-) ORCHID BIOSCIENCES INC.  
XX  
PA Picoult-Newburg L, Pohl M;  
XX  
PI WPI; 2001-290930/30.  
XX  
DR New genotyping oligonucleotide, useful for detecting the presence,  
XX PT absence or identity of single polymorphic polymorphism in a nucleic  
XX PT acid sample.  
XX  
PS Claim 1; Page 63; 83pp; English.  
XX  
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide  
CC primer extension (SNPE) primers, and the sequences of regions flanking  
CC sites of single nucleotide polymorphisms SNPs. The present invention  
CC includes kits for determining the presence or absence of a SNP, using the  
CC oligonucleotides of the invention. The PCR primers are used to amplify a  
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.  
CC The oligonucleotides are useful for genotyping a nucleic acid sample by  
CC performing a single-nucleotide primer extension reaction. The  
CC oligonucleotides are useful for determining the presence, absence or  
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to  
CC assess by association analysis the genotype of an individual or group of  
CC individuals, having a pathological phenotypic trait suspected of being  
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.  
CC agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular  
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,  
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic  
CC traits also include symptoms of or susceptibility to multifactorial  
CC disease of which a component is or may be genetic such as autoimmune  
CC diseases, including, rheumatoid arthritis, multiple sclerosis,  
CC inflammation, cancer, nervous system diseases and infection by pathogenic  
CC microorganism. The method is also useful in forensic investigations and  
CC paternity analysis. The present sequence represents a PCR primer specific  
CC for a human SNP containing DNA sequence  
XX  
SQ Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 1925 AGCTGTCAGGGGCTCAG 1941  
Db 18 AGCTGTCAGGGGCTCAG 2  
XX  
RESULT 365  
AAD20900/c  
ID AAD20900 standard; DNA; 18 BP.  
XX  
AC AAD20900;  
XX  
DT 15-JAN-2002 (first entry)  
XX  
DE Fibroblast growth factor (FGF) oligonucleotide.  
XX  
XX Proliferation; differentiation; central nervous system; neurosphere;  
XX KM multipotent neural stem cell; neurotransplantation; therapy;  
XX KM neurodegenerative disease; neurological trauma; drug screening;  
XX KM fibroblast growth factor; FGF; regulatory factor; neuroprotective; ss.

```

XX OS Unidentified.
XX PN US6294346-B1.
XX PD 25-SEP-2001.
XX PF 07-JUN-1995; 95US-00484406.
XX PR 08-JUL-1991; 91US-00726812.
XX PR 28-OCT-1992; 92US-00967632.
XX PR 09-NOV-1993; 93US-00149508.
XX PR 03-JUL-1994; 94US-00270412.
XX PR 23-SEP-1994; 94US-00311099.
XX PR 14-NOV-1994; 94US-0038730.
XX PR 20-DEC-1994; 94US-00359945.
XX PR 20-JAN-1995; 95US-00376062.
XX PR 07-FEB-1995; 95US-00385404.
XX PA (NEUR-) NEUROSHERES HOLDINGS LTD.
XX PI Weiss S, Reynolds B, Hammang JP, Baetge EE;
XX WPI; 2001-647262/74.
XX DR WPI; 2001-647262/74.
XX XX
XX PT Screening biological agents affecting proliferation, differentiation or
XX PT survival of central nervous system cells, useful for drug screening,
XX PT comprises contacting a cell culture of a neural cell population with a
XX PT growth factor.
XX PS Example 43; Col 61; 42pp; English.
XX XX
XX CC The present invention relates to a method for screening biological agents
XX CC which affect proliferation, differentiation or survival of central
XX CC nervous system cells, comprises contacting a cell culture of a neural
XX CC cell population with a biological agent, where the neurospheres comprise
XX CC a cluster of multipotent neural stem cells, each capable of producing
XX CC progeny which can differentiate into neurons and glia, including
XX CC astrocytes. The method is useful for generating large numbers of
XX CC (un)differentiated neural cells for neurotransplantation into a host to
XX CC treat neurodegenerative disease and neurological trauma, for non-surgical
XX CC methods and for drug screening applications. The present sequence is a
XX CC fibroblast growth factor (FGF) oligonucleotide which is used for assaying
XX CC striatum-derived neurosphere proliferation in response to various
XX CC combinations of proliferative and regulatory factors
XX CC
XX SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609
Db 18 CGAGGTGATGCGCTGG 2

RESULT 366
AAH76247
ID AAH76247 standard; DNA; 18 BP.
XX AC AAH76247;
XX XX
XX DT 29-OCT-2001 (first entry)
XX XX
XX DE Human macrophage inflammatory protein-2-alpha primer MIP2alpha-F.
XX XX
XX OS Pyrene; gene therapy; antiinflammatory; gene expression; interleukin;
XX OS hemoxygenase-1; prostaglandin G/H synthase-2; RANTES; TNF alpha; p78;
XX OS macrophage inflammatory protein; chemokine; growth regulated protein-1;
XX OS matrix metalloproteinase-9; migration inhibitory factor-related protein;
XX OS lysozyme; GABA(A) receptor-associated protein; interferon; SCO homolog-2;
XX OS transketolase; adenosine A2a receptor; CD37 antigen properdin P factor;

```

```

KW KM G-protein; Nef-associated factor-1; signal peptidase; PCR primer; ss.
XX OS Homo sapiens.
XX XX
XX PN WO200151480-A1.
XX PD 19-JUL-2001.
XX PF 11-JAN-2001; 2001WO-JP000082.
XX PR 13-JAN-2000; 2000JP-00004989.
XX PR 03-OCT-2000; 2000JP-00303711.
XX PA (TAKI ) TAKARA SHUZO CO LTD.
XX PI Enoki T, Yamashita S, Nishimura K, Sagawa H, Kato I;
XX DR WPI; 2001-514436/56.
XX XX
XX PT Agent for correcting gene expression regulation error comprises pyrene
XX PT compound or dihydroxy compound.
XX PS Example 6; Page 72; 93pp; Japanese.
XX XX
XX CC The invention provides an agent comprising a pyrene compound or dihydroxy
XX CC compound of specified formulae given in the specification. The agent is
XX CC used for correcting gene expression regulation errors. Errors in the
XX CC following genes may be corrected: IL-6, IL-10, hemoxygenase-1,
XX CC prostaglandin G/H synthase-2, macrophage inflammatory protein-1-alpha,
XX CC RANTES, IL-1alpha, IL-1beta, TNF alpha, IL-7 receptor, macrophage
XX CC inflammatory protein-1beta, liver and activation-regulated chemokine,
XX CC macrophage-derived chemokine, macrophage inflammatory protein-2-beta,
XX CC macrophage inflammatory protein-2-alpha, growth regulated protein-1,
XX CC matrix metalloproteinase-9, migration inhibitory factor-related protein -
XX CC 8, lysozyme, GABA(A) receptor-associated protein, interferon-induced 17 -
XX CC kDa/15-kDa protein, interferon-inducible protein p78, SCO homolog-2,
XX CC transketolase, adenosine A2a receptor, CD37 antigen properdin P factor,
XX CC regulator of G-protein signaling-2, Nef-associated factor-1, myeloid
XX CC leukemia cell differentiation protein-1, signal peptidase complex, and
XX CC also side-effects caused by them such as inflammation. Sequences AAH76220
XX XX
XX SQ Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 564 GCTGTTCTGCTCCTGG 580
Db 2 GCTGCTCTCTCTCCTGG 18

RESULT 367
AAS09811
ID AAS09811 standard; DNA; 18 BP.
XX AC AAS09811;
XX XX
XX DT 24-OCT-2001 (first entry)
XX XX
XX DE Oat Beta-amylin synthase sequencing primer 53.
XX XX
XX OS Oat; Beta-amylin synthase; triterpenoid; palatability;
XX OS oxidosqualene cyclase; pathogen resistance; transgenic plant;
XX OS fungal disease; sequencing primer; ss.
XX OS
XX OS Avena strigosa.
XX OS
XX PN WO200146391-A2.
XX PD 28-JUN-2001.
XX XX

```

PF 20-DEC-2000; 2000MO-GB004908.  
 XX  
 XX 22-DEC-1999; 99GB-00030394.  
 PR 16-AUG-2000; 2000GB-00020217.  
 XX  
 XX (PLAN-) PLANT BIOSCIENCE LTD.  
 PA  
 XX Oebourn AB, Haralampidis K, Bryan GT;  
 PI WPI; 2001-418055/44.  
 XX  
 XX Novel beta-amyrin synthase encoding nucleic acids useful for influencing  
 PT or affecting triterpene synthesis, and hence resistance to fungal  
 PT pathogen, taste, palatability or nutritional value of plants.  
 XX  
 XX Example 4; Page 59; 69pp; English.  
 PS  
 XX The sequence represents a primer used to sequence nucleic acids encoding  
 CC Oat Beta-amyrin synthase (an oxidogualene cyclase). Beta-amyrin is a  
 CC triterpenoid responsible for palatability to animals and resistance to  
 CC pathogens and predators. The beta-amyrin synthase encoding nucleic acid  
 CC is useful for producing a transgenic plant, by introducing a vector  
 CC containing it into a host cell, optionally causing or allowing  
 CC recombination between the vector and the host cell genome so as to  
 CC transform the host cell, and regenerating a plant from the transformed  
 CC plant cell. The DNA is also useful for identifying, cloning or  
 CC determining the presence of a nucleic acid in a sample and for  
 CC influencing or affecting the quantity or quality of triterpenoid  
 CC synthesis, preferably an oleanane-type triterpene saponin synthesis, in a  
 CC plant, such as altering resistance to a fungal pathogen e.g., an  
 CC ascomycete having a sterol-containing membrane, optionally selected from  
 CC Geunomomyces graminis varis tritici and avenae, Fusarium culmorum, F.  
 CC avenaceum, Stagonopora nodorum or S. avenae, taste, palatability and/or  
 CC nutritional value, of the plant, by causing or allowing expression of the  
 CC DNA within the cells of the plant, following an earlier step of  
 CC introducing the DNA into a cell or its ancestor. The DNA is also useful  
 CC for reducing the level of triterpenoids in the plant, by causing or  
 CC allowing transcription from an antisense molecule in the plant, allowing  
 CC transcription from the DNA, or its part such as to reduce beta-amyrin  
 CC synthase expression by co-suppression, use of a nucleic acid encoding a  
 CC ribozyme specific for the DNA  
 CC  
 XX  
 SQ Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;  
 CC  
 XX  
 QY 941 TATGTCCTTGGGATC 957  
 Db 1 TATGGCTCTTGGGGAAC 17  
 CC  
 XX  
 RESULT 368  
 ABL89316 0.6%; Score 13.8; DB 1; Length 18;  
 ID ABL89316 standard; DNA; 18 BP.  
 XX  
 AC ABL89316;  
 XX  
 DT 22-MAY-2002 (first entry)  
 XX  
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:538.  
 XX  
 KM Binding molecule; HIV-1; human immunodeficiency virus type 1;  
 XX reverse transcriptase; binding group; ss.  
 XX  
 OS Human immunodeficiency virus 1.  
 OS Synthetic.  
 XX  
 PN EP1174518-A1.  
 XX  
 PD 23-JAN-2002.  
 XX

PE 20-JUL-2000; 2000EP-00202611.  
 XX  
 XX 20-JUL-2000; 2000EP-00202611.  
 PR  
 XX  
 XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.  
 PA  
 XX Loukachov VV, Van Gemen B, Goudsmat J;  
 PI WPI; 2002-156696/21.  
 XX  
 XX Collection of binding groups for determining or typing samples,  
 PT especially clinical samples, has groups capable to identify essentially  
 PT all members of the family of nucleic acids of relatively high  
 PT significance.  
 XX  
 XX Disclosure; Page 137; 166pp; English.  
 PS  
 XX The present invention describes a collection of binding groups for a  
 CC family of nucleic acids comprising members of relative high and relative  
 CC low significance, where the binding groups are selected to be capable to  
 CC identify, alone or in combination, essentially all members of the family  
 CC of nucleic acids of relatively high significance. The collection of  
 CC binding groups is useful for typing of nucleic acid in a clinical sample,  
 CC by contacting the nucleic acid with the collection and determining  
 CC whether one or more binding groups bound to the nucleic acid of the  
 CC sample. This method is useful for determining whether the sample  
 CC comprises at least a part of a member of relatively high significance of  
 CC a family of nucleic acids. The collection of binding groups is useful for  
 CC diagnosing the severity of a disease caused by a pathogen containing a  
 CC member of a family of nucleic acids. ABL88779 to ABL89321 represent  
 CC oligonucleotide sequences used in the exemplification of the present  
 CC invention  
 CC  
 XX  
 SQ Sequence 18 BP; 9 A; 6 C; 2 G; 1 T; 0 U; 0 Other;  
 CC  
 XX  
 QY 836 ACCGACAGCTAACATC 852  
 Db 2 ACCGACAGGAAACATC 18  
 CC  
 XX  
 RESULT 369  
 ABL89307 0.6%; Score 13.8; DB 1; Length 18;  
 ID ABL89307 standard; DNA; 18 BP.  
 XX  
 AC ABL89307;  
 XX  
 DT 22-MAY-2002 (first entry)  
 XX  
 DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:529.  
 XX  
 KM Binding molecule; HIV-1; human immunodeficiency virus type 1;  
 XX reverse transcriptase; binding group; ss.  
 XX  
 OS Human immunodeficiency virus 1.  
 OS Synthetic.  
 XX  
 PN EP1174518-A1.  
 XX  
 PD 23-JAN-2002.  
 XX  
 DE 20-JUL-2000; 2000EP-00202611.  
 XX  
 PF 20-JUL-2000; 2000EP-00202611.  
 PR  
 XX  
 XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.  
 PA Loukachov VV, Van Gemen B, Goudsmat J;  
 PI WPI; 2002-156696/21.  
 XX  
 XX

XX Collection of binding groups for determining or typing samples,  
PT especially clinical samples, has groups capable to identify essentially  
PT all members of the family of nucleic acids of relatively high  
PT significance.  
XX  
PS Disclosure; Page 135; 166pp; English.  
XX  
CC The present invention describes a collection of binding groups for a  
CC family of nucleic acids comprising members of relative high and relative  
CC low significance, where the binding groups are selected to be capable to  
CC identify, alone or in combination, essentially all members of the family  
CC of nucleic acids of relatively high significance. The collection of  
CC binding groups is useful for typing of nucleic acid in a clinical sample,  
CC by contacting the nucleic acid with the collection and determining  
CC whether one or more binding groups bound to the nucleic acid of the  
CC sample. This method is useful for determining whether the sample  
CC comprises at least a part of a member of relatively high significance of  
CC a family of nucleic acids. The collection of binding groups is useful for  
CC diagnosing the severity of a disease caused by a pathogen containing a  
CC member of a family of nucleic acids. ABL8779 to ABL9321 represent  
CC oligonucleotide sequences used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 18 BP; 9 A; 6 C; 2 G; 1 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 836 ACCGACAGGTACATC 852  
Db 2 ACCGACAGGAACATC 18  
  
RESULT 370  
ABL40470/c  
ID ABL40470 standard; DNA; 18 BP.  
XX  
AC ABL40470;  
XX  
DT 10-JUN-2002 (first entry)  
XX  
DE Endothelial differentiation gene-1 (EDG-1) sense oligo.  
XX  
KM Angiogenesis; sphingosine-1-phosphate; SPP; EDG-1; EDG-3; antidiabetic;  
KM endothelial differentiation gene; antirheumatic; antiarthritis; cardiant;  
KM antiporiatic; antitumor; vasotropic; vulnerary; cyostatic;  
KM gene therapy; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO200217899-A2.  
XX  
PD 07-MAR-2002.  
XX  
PF 31-AUG-2001; 2001WO-US027064.  
XX  
PR 31-AUG-2000; 2000US-00651846.  
XX  
PA (UYCO-) UNIV CONNECTICUT.  
XX  
PI Hla T, Lee M, Claffey KP, Ancellin N, Thangada S;  
XX  
DR WPI; 2002-269443/31.  
XX  
PT Regulating angiogenesis for treating cancer and diseases and disorders  
PT associated with angiogenesis, comprises affecting endothelial  
PT differentiation gene-1 receptor-mediated signal transduction.  
XX  
PS Example 12; Fig 12; 79pp; English.

CC The invention relates to methods for regulating angiogenesis in vivo. The  
CC method for inducing angiogenesis involves administering a composition  
CC comprising sphingosine-1-phosphate (SPP), its analogue, (salts or  
CC derivatives of SPP or its analogues), or their combination. The method  
CC for inhibiting angiogenesis in vivo, involves administering an antisense  
CC oligonucleotide of an mRNA encoding an endothelial differentiation gene  
CC (EDG-1 or EDG-3) protein receptor. The methods are useful for regulating  
CC (inducing or inhibiting) angiogenesis in vivo. Inducing angiogenesis is  
CC useful for protecting endothelial cells from apoptotic cell death,  
CC increasing at least one of the VE-cadherin, alpha-catenin, beta-catenin  
CC or gamma-catenin at endothelial cell-cell junctions, and modulating  
CC vessel maturation. Inhibiting angiogenesis by administering antagonist of  
CC signal transduction of EDG-1 or EDG-3 or their combination is useful for  
CC treating tumours, rheumatoid arthritis, diabetic retinopathy, Kaposi's  
CC sarcoma, haemangioma or psoriasis, where an additional anti-angiogenic  
CC factor is also administered, and also for treating unwanted angiogenesis  
CC in a human or animal, where a chicken-anti-human-EDG-1 antibody or its  
CC biologically active fragment is also administered with the antagonist of  
CC EDG-1 signal transduction. The methods are useful for promoting vascular  
CC or cardiac endothelial cell growth and morphogenesis. Inducing  
CC angiogenesis is useful to accelerate wound healing in a diabetic ulcers,  
CC stomach and other gastrointestinal ulcers, and to induce new vessels  
CC growth in myocardium of heart suffering from reduced blood supply due to  
CC ischaemic heart disease. The present sequence represents a sense oligo  
CC used in experiments for determining the inhibition of angiogenesis by  
CC phosphothioate oligonucleotides  
XX  
SQ Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1602 GCGCGTGTGGACCCA 1618  
Db 18 GACGCTGTGGCCCA 2  
  
RESULT 371  
ABL40468  
ID ABL40468 standard; DNA; 18 BP.  
XX  
AC ABL40468;  
XX  
DT 10-JUN-2002 (first entry)  
XX  
DE Endothelial differentiation gene-1 (EDG-1) antisense oligo #1.  
XX  
KM Angiogenesis; sphingosine-1-phosphate; SPP; EDG-1; EDG-3; antidiabetic;  
KM endothelial differentiation gene; antirheumatic; antiarthritis; cardiant;  
KM antiporiatic; antitumor; vasotropic; vulnerary; cyostatic;  
KM gene therapy; antisense; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO200217899-A2.  
XX  
PD 07-MAR-2002.  
XX  
PF 31-AUG-2001; 2001WO-US027064.  
XX  
PR 31-AUG-2000; 2000US-00651846.  
XX  
PA (UYCO-) UNIV CONNECTICUT.  
XX  
PI Hla T, Lee M, Claffey KP, Ancellin N, Thangada S;  
XX  
DR WPI; 2002-269443/31.  
XX  
PT Regulating angiogenesis for treating cancer and diseases and disorders  
PT associated with angiogenesis, comprises affecting endothelial  
PT differentiation gene-1 receptor-mediated signal transduction.  
XX  
PS



XX Claim 8; Page 44; 79pp; English.

PS The invention relates to methods for regulating angiogenesis in vivo. The

CC method for inducing angiogenesis involves administering a composition

CC comprising sphingosine-1-phosphate (S1P), its analogue, (salts or

CC derivatives of S1P or its analogues), or their combination. The method

CC for inhibiting angiogenesis in vivo, involves administering an antisense

CC oligonucleotide of an mRNA encoding an endothelial differentiation gene

CC (EDG-1 or EDG-3) protein receptor. The methods are useful for regulating

CC (inducing or inhibiting) angiogenesis in vivo. Inducing angiogenesis is

CC useful for protecting endothelial cells from apoptotic cell death,

CC increasing at least one of the VE-cadherin, alpha-catenin, beta-catenin

CC and gamma-catenin at endothelial cell-cell junctions, and modulating

CC vessel maturation. Inhibiting angiogenesis by administering antagonist of

CC signal transduction of EDG-1 or EDG-3 or their combination is useful for

CC treating tumours, rheumatoid arthritis, diabetic retinopathy, Kaposi's

CC sarcoma, haemangioma or psoriasis, where an additional anti-angiogenic

CC factor is also administered, and also for treating unwanted angiogenesis

CC in a human or animal, where a chicken-anti-human-EDG-1 antibody or its

CC biologically active fragment is also administered with the antagonist of

CC EDG-1 signal transduction. The methods are useful for promoting vascular

CC or cardiac endothelial cell growth and morphogenesis. Inducing

CC angiogenesis is useful to accelerate wound healing in a diabetic ulcers,

CC stomach and other gastrointestinal ulcers, and to induce new vessel

CC growth in myocardium of heart suffering from reduced blood supply due to

CC ischemic heart disease. The present sequence represents a specific

CC example of an antisense oligo specific for the EDG-1 mRNA, used in the

CC method of the invention

XX Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

SQ

Query Match 0.64; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.24; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 GGGCGTGTGGACCCA 1618

Db 1 GACGCTGTGGCCCCA 17

RESULT 372

AA040986/c

ID AAD40986 standard; DNA; 18 BP.

XX

XX AAD40986;

XX

XX 30-OCT-2002 (first entry)

XX

XX Human PI3K p85 antisense oligonucleotide ISIS #28034.

XX

XX Human; antisense; PI3K p85; obesity; type 2 diabetes; cancer; tumour;

KW prophylaxis; hyperproliferative condition; infection; inflammation;

KW therapy; phosphorothioate; ss.

XX

XX Homo sapiens.

OS Synthetic.

OS

XX

XX Key Location/Qualifiers

FT modified\_base 1..18

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "Phosphorothioate backbone"

FT modified\_base 1..14

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-methoxyethyl nucleotides"

FT modified\_base 3

FT /\*tag= d

FT /mod\_base= m5c

FT modified\_base 15..18

FT /\*tag= c

FT /mod\_base= OTHER

FT modified\_base 15

FT /\*tag= e

FT /mod\_base= m5c

PN WO200240637-A2.

XX

XX 23-MAY-2002.

XX

XX 19-NOV-2001; 2001MO-US045006.

XX

XX 20-NOV-2000; 2000US-00715983.

XX

XX (ISIS-) ISIS PHARM INC.

PI Monia BP, Cowseart LM, Murray SF, Butler MM, Dean NM;

XX WPI; 2002-519374/55.

XX

XX Antisense compounds targeted against polynucleotides encoding PI3K p85

PT useful for treating e.g. cancer, Type 2 diabetes, obesity.

XX

XX Example 16; Page 79; 121pp; English.

XX

XX The invention relates to antisense compounds targeted to a nucleic acid

CC molecule encoding PI3K p85 to inhibit its expression. Antisense

CC compounds of the invention are used for treating obesity, Type 2 diabetes

CC and hyperproliferative condition e.g. cancer. They may also be useful

CC prophylactically, e.g. to prevent or delay infection, inflammation or

CC tumour formation. Antisense compounds either alone or in combination with

CC other antisense compounds or therapeutics can be used as tools in

CC differential and/or combinatorial analyses to elucidate expression

CC patterns of a portion of the entire complement of genes expressed within

CC cells and tissues. They are commonly used as research reagents and

CC diagnostics. The present sequence is an antisense oligonucleotide

CC targeted to human PI3K p85 DNA

XX

SQ Sequence 18 BP; 4 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.64; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.24; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1772 TTGAGAGAGCTTCA 1788

Db 17 TTGAGAGAGACTTGA 1

RESULT 373

AAK98275

ID AAK98275 standard; DNA; 18 BP.

XX

XX AAK98275;

XX

XX 28-FEB-2002 (first entry)

XX

XX Rat Con-218 R2A sense PCR primer.

XX

XX Con-218; G protein-coupled receptor; GPCR; anti-HIV; antiparkinsonian;

KW neuroprotective; cytoskeletal; tranquilliser; neuroleptic; antianemic;

KW antidepressant; immunosuppressive; antimigraine; nociceptive; cardiac;

KW antidiabetic; antidiabetic; chromolytic; antipruritic;

KW vasotropic; anticonvulsant; antithyroid; antiinflammatory; nephrologic;

KW hypotensive; antineumatic; antiarthritic; cerebroprotective; vincristine;

KW antileptility; gene therapy; thyroid disorder; renal failure;

KW inflammatory conditions; cell differentiation; homeostasis; CNS disorder;

KW rheumatoid arthritis; autoimmune disorder; movement disorder; stroke;

KW psychotic disorder; neurological disorder; dyskinesia; infection;

KW attention disorder; degenerative disorder; metabolic; cardiovascular;

KW cancer; hyperproliferative disorder; psoriasis; hormonal disorder;

XX sexual dysfunction; schizophrenia; rat; PCR primer; ss.

XX

XX Rattus norvegicus.



XX (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX  
XX  
PI Lymanchev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
XX  
PT Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises identifying  
PT primers that interact with the target to form an extension product under  
PT amplification conditions.  
XX  
PS Example 13; Page 178; 409pp; English.  
XX  
CC The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC which can interact with the folded target nucleic acid. Oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
CC sequences used in the exemplification of the present invention  
XX  
SQ Sequence 18 BP; 3 A; 10 C; 5 G; 0 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 483 GGTGCGCGCGCTCAGG 499  
DB 17 GGGGCGCGCGCTCGG 1  
RESULT 376  
AADD1843/C  
ID AADD1843 standard; DNA; 18 BP.  
XX  
AC AADD1843;  
XX  
DT 04-NOV-2002 (first entry)  
XX  
DE Fibroblast growth factor (FGF) sense oligonucleotide.  
XX  
KM cDNA library; multipotent neural stem cell; neural tissue; neurosphere;  
KM neurological disorder; neurodegenerative disease; neurological trauma;  
KM drug-screening; therapy; fibroblast growth factor; FGF; ss.  
XX  
OS Unidentified.  
XX  
PN US6399369-B1.  
XX  
PD 04-JUN-2002.  
XX  
PF 07-JUN-1995; 95US-00484203.  
XX  
PR 08-JUL-1991; 91US-00726812.  
PR 16-OCT-1992; 92US-00961813.  
PR 28-OCT-1992; 92US-00967622.  
PR 29-JAN-1993; 93US-00010829.  
PR 09-NOV-1993; 93US-00149508.  
PR 01-APR-1994; 94US-00221655.  
PR 05-JUL-1994; 94US-00270412.  
PR 23-SEP-1994; 94US-00311099.  
PR 14-NOV-1994; 94US-00338730.  
PR 20-DEC-1994; 94US-00359945.  
PR 20-JAN-1995; 95US-00376062.  
PR 07-FEB-1995; 95US-00385404.  
XX  
PA (NEUR-) NEUROSPHERES HOLDINGS LTD.

XX  
PI Weise S, Reynolds B;  
XX  
DR WPI; 2002-546286/58.  
XX  
PT Obtaining cDNA library comprises proliferating multipotent neural stem  
PT cells in medium containing growth factor to form neurospheres;  
PT proliferating neurospheres into neural cells and obtaining cDNA library  
PT from the neural cells.  
XX  
PS Example 43; Col 67; 39pp; English.  
XX  
CC The invention relates to a method for obtaining a cDNA library, which  
CC involves proliferating at least one multipotent neural stem cell derived  
CC from mammalian neural tissue in culture medium containing one or more  
CC growth factor(s) that induce multipotent neural stem cell proliferation  
CC into one or more neurospheres, proliferating neurospheres into population  
CC of neural cells and obtaining cDNA library from the neural cells. The  
CC method is useful for obtaining a cDNA library from neural cells that can  
CC be either normal or dysfunctional, allowing for the identification of a  
CC sequence of gene expression during neural development and can be used in  
CC the design of therapies to treat the neurological disorder. It can also  
CC be used to reveal the effects of biological agents on gene expression in  
CC neural cells. The method is useful for generating large numbers of  
CC undifferentiated and differentiated neural cells for neurotransplantation  
CC into a host in order to treat neurodegenerative disease and neurological  
CC trauma, for non-surgical methods of treating neurodegenerative disease  
CC and neurological trauma and for drug-screening applications. The present  
CC sequence is a fibroblast growth factor (FGF) oligonucleotide used in the  
CC exemplification of the invention  
XX  
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1593 CGAGTGACGCGCTCGG 1609  
DB 18 CGAGTGATGCCCTGG 2  
RESULT 377  
ABT06050/C  
ID ABT06050 standard; DNA; 18 BP.  
XX  
AC ABT06050;  
XX  
DT 28-OCT-2002 (first entry)  
XX  
DE Human Igm heavy chain gene related PCR primer SEQ ID No 64.  
XX  
KM Single Primer Amplification; nested oligonucleotide extension reaction;  
KM hairpin; SPA; library; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200248401-A2.  
XX  
PD 20-JUN-2002.  
XX  
PF 10-DEC-2001; 2001WO-US047727.  
XX  
PR 11-DEC-2000; 2000US-0254669P.  
PR 19-SEP-2001; 2001US-0323400P.  
XX  
PA (ALEX-) ALEXION PHARM INC.  
XX  
PI Bowditch KS, Barbas-Frederickson S, Lin Y, McWhirter J, Maruyama T;  
XX WPI; 2002-500537/53.  
XX  
PT Amplifying nucleic acid by synthesizing template nucleic acid containing

PT a predetermined sequence and hairpin structure and using the template for  
PT target amplification by Single Primer Amplification.  
XX  
XX Example 3; Page 22; 54pp; English.  
XX  
CC The invention relates to a method for amplifying a nucleic acid using  
CC Single Primer Amplification (SPA). The method comprises synthesizing a  
CC template nucleic acid containing a predetermined sequence and hairpin  
CC structure with the nested oligonucleotide extension reaction. The method  
CC is useful for amplifying a nucleic acid, preferably for amplifying a  
CC family of related nucleic acid sequences to build a complex library of  
CC polypeptides encoded by the sequences. The engineered nucleic acid strand  
CC is useful for amplifying a nucleic acid strand by providing a nucleic  
CC acid with a predetermined sequence engineered onto its first end, a  
CC structure complementary to the predetermined sequence and a hairpin  
CC structure between them and contacting the engineered nucleic acid strand  
CC with a primer containing at least a portion of the predetermined  
CC sequence. This process is done in the presence of a polymerase and  
CC complementary nucleic acid strand for polymerisation to produce a  
CC complementary nucleic acid strand. The method of the invention is useful  
CC for producing large amounts of a target nucleic acid sequence and for  
CC amplifying simultaneously more than one different target nucleic acid  
CC sequence located on the same or different nucleic acid molecules. This  
CC polynucleotide sequence represents a PCR primer of the invention  
XX  
SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1757 AAGAGCCACAGGTATTT 1773  
Db 17 AAGAACCAACAGGTCTTT 1  
XX  
RESULT 378  
ACC46880  
ID ACC46880 standard; DNA; 18 BP.  
XX  
XX ACC46880;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
XX Human COPD related gene forward PCR primer SEQ ID NO:159.  
XX  
XX Human chronic obstructive pulmonary disease; COPD; chronic lung disease;  
KM PCR primer; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO200297127-A2.  
PN  
XX  
PD 05-DEC-2002.  
XX  
XX 28-MAY-2002; 2002WO-EP005835.  
PF  
XX 31-MAY-2001; 2001GB-00013266.  
PR  
XX (FARB ) BAYER AG.  
PA  
XX  
XX Oellers N, Gehrmann W, Kallabis H, Hall R, Schulze T, Kroegel C;  
PI WPI; 2003-140492/13.  
XX  
XX WPI; 2003-140492/13.  
DR  
XX  
XX Predicting, diagnosing or prognosing chronic lung disease, by detecting a  
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.  
XX  
XX Example 1; Page 213; 214pp; English.  
PS  
XX  
XX The present invention describes a method for predicting, diagnosing or  
CC prognosing chronic lung disease by detecting a chronic obstructive

CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to  
CC ACC46777, which encode the COPD related proteins in ABP96779 to  
CC ABP96806). The method is useful for predicting, diagnosing or prognosing  
CC chronic lung disease in a biological sample. The COPD genes and proteins  
CC encoded by them from the present invention (I) can be used for treating  
CC or preventing chronic lung disease in a mammal. (II) can be used in an  
CC animal model for determining the efficacy, toxicity, or side effects of  
CC treatment with (I), and determining the mechanism of action of (I).  
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used  
CC in an example from the present invention  
XX  
SQ Sequence 18 BP; 0 A; 7 C; 5 G; 6 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 564 GCTGCTCTGCTCTG 580  
Db 2 GCTGCTCTGCTCTG 18  
XX  
RESULT 379  
AB298168/C  
ID AB298168 standard; DNA; 18 BP.  
XX  
XX AB298168;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
XX Human CD23 + A1261 oligonucleotide sequence.  
DE  
XX Human; antisense; lung dysfunction; nasal airway dysfunction;  
KM antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;  
KM antiallergic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KM lung inflammation; respiratory disease; de.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200285308-A2.  
PN  
XX  
XX 31-OCT-2002.  
PD  
XX  
XX 23-APR-2002; 2002WO-US013135.  
PF  
XX 24-APR-2001; 2001US-0286137P.  
PR  
XX (EPIG-) EPIGENESIS PHARM INC.  
PA  
XX  
XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahbuddin S;  
PI WPI; 2003-229219/22.  
XX  
XX  
XX Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
XX  
XX Disclosure; SEQ ID NO 13410; 872pp; English.  
PS  
XX  
XX The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antinflammatory steroid and ubiquinone. A composition of the invention  
CC has antinflammatory, antiallergic, antiallergic, hypotensive,  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC anti-inflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX

Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;  
SQ

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1003 CTGCTCTGCTTTTCTT 1019  
DB 18 CTGACTCTGCTTCTCT 2

RESULT 380  
ABT34032/c  
ID ABT34032 standard; DNA; 18 BP.  
XX  
AC ABT34032;  
XX  
DT 29-MAY-2003 (first entry)  
XX  
DE Human pigmentation trait-related PCR primer - SEQ ID No 131.  
XX  
KM Human, single nucleotide polymorphism; SNP; ss; melanocortin-1 receptor;  
KM genetic pigmentation trait; MC1R; agouti signaling protein; ASIP; race;  
KM hair colour; eye colour; forensic tool; PCR; primer.  
XX  
OS Homo sapiens.  
XX  
PN WC0200297047-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002MO-US016789.  
XX  
PR 25-MAY-2001; 2001US-0293560P.  
PR 21-JUN-2001; 2001US-0300187P.  
PR 07-AUG-2001; 2001US-0310781P.  
PR 17-SEP-2001; 2001US-0323662P.  
PR 26-OCT-2001; 2001US-0344418P.  
PR 15-NOV-2001; 2001US-0334674P.  
PR 02-JAN-2002; 2002US-0346303P.  
XX  
PA (DNAP-) DNAPRINT GENOMICS INC.  
XX  
PI Fridakis T;  
XX  
DR WPI; 2003-239091/23.  
XX  
PT Inferring genetic pigmentation trait such as hair/eye color or shade from  
PT nucleic acid sample of human subject, by identifying a pigmentation-  
PT related haplotype allele of a pigmentation gene in the sample.  
XX  
PS Example 17; Page 245; 396pp; English.  
XX  
CC The invention comprises a method for inferring a genetic pigmentation  
CC trait of a human. The method involves identifying a single nucleotide  
CC polymorphism (SNP) in a pigmentation gene - where the pigmentation gene  
CC is not melanocortin-1 receptor (MC1R) and agouti signaling protein  
CC (ASIP). The method of the invention is useful for inferring a genetic  
CC pigmentation trait of a human, especially for inferring the race of a  
CC human subject. The method is useful for inferring a genetic pigmentation  
CC trait such as hair shade or colour, or eye shade or colour of a human  
CC subject. The method may be used as a forensic tool for obtaining

CC information relating to physical characteristics of a potential crime  
CC victim or a perpetrator of a crime from a nucleic acid sample present at  
CC a crime scene. The present PCR primer is used in the exemplification of  
CC the invention  
XX

Sequence 18 BP; 2 A; 5 C; 6 G; 5 T; 0 U; 0 Other;  
SQ

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1077 TCTGCAAGTCCAGCC 1093  
DB 17 TCCGCAAGTCCAGGC 1

RESULT 381  
ABT34033/c  
ID ABT34033 standard; DNA; 18 BP.  
XX  
AC ABT34033;  
XX  
DT 29-MAY-2003 (first entry)  
XX  
DE Human pigmentation trait-related PCR primer - SEQ ID No 132.  
XX  
KM Human, single nucleotide polymorphism; SNP; ss; melanocortin-1 receptor;  
KM genetic pigmentation trait; MC1R; agouti signaling protein; ASIP; race;  
KM hair colour; eye colour; forensic tool; PCR; primer.  
XX  
OS Homo sapiens.  
XX  
PN WC0200297047-A2.  
XX  
PD 05-DEC-2002.  
XX  
PF 28-MAY-2002; 2002MO-US016789.  
XX  
PR 25-MAY-2001; 2001US-0293560P.  
PR 21-JUN-2001; 2001US-0300187P.  
PR 07-AUG-2001; 2001US-0310781P.  
PR 17-SEP-2001; 2001US-0323662P.  
PR 26-OCT-2001; 2001US-0344418P.  
PR 15-NOV-2001; 2001US-0334674P.  
PR 02-JAN-2002; 2002US-0346303P.  
XX  
PA (DNAP-) DNAPRINT GENOMICS INC.  
XX  
PI Fridakis T;  
XX  
DR WPI; 2003-239091/23.  
XX  
PT Inferring genetic pigmentation trait such as hair/eye color or shade from  
PT nucleic acid sample of human subject, by identifying a pigmentation-  
PT related haplotype allele of a pigmentation gene in the sample.  
XX  
PS Example 17; Page 245; 396pp; English.  
XX  
CC The invention comprises a method for inferring a genetic pigmentation  
CC trait of a human. The method involves identifying a single nucleotide  
CC polymorphism (SNP) in a pigmentation gene - where the pigmentation gene  
CC is not melanocortin-1 receptor (MC1R) and agouti signaling protein  
CC (ASIP). The method of the invention is useful for inferring a genetic  
CC pigmentation trait of a human, especially for inferring the race of a  
CC human subject. The method is useful for inferring a genetic pigmentation  
CC trait such as hair shade or colour, or eye shade or colour of a human  
CC subject. The method may be used as a forensic tool for obtaining  
CC information relating to physical characteristics of a potential crime  
CC victim or a perpetrator of a crime from a nucleic acid sample present at  
CC a crime scene. The present PCR primer is used in the exemplification of  
CC the invention  
XX  
SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1077 TCTGGCAAGTCAGCC 1093  
 |||||  
 Db 17 TCCGGCAAGTCAGGC 1

RESULT 382  
 ABX95733  
 ID ABX95733 standard; DNA; 18 BP.  
 XX ABX95733;  
 AC  
 XX  
 DT 03-JUL-2003 (first entry)  
 XX  
 DE Oligonucleotide #2 for DNA encoding human FGF.  
 XX  
 KM Multipotent neural stem cell progeny; neural tissue; neural stem cell;  
 KM multipotent central nervous system; CNS; cell proliferation; CNS trauma;  
 KM autologous transplantation; neurological disease; neurodegeneration;  
 KM cell differentiation; progenitor cell; fibroblast growth factor; human;  
 KM FGF; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6497872-B1.  
 XX  
 PD 24-DEC-2002.  
 PD  
 XX  
 XX 07-JUN-1995; 95US-00486313.  
 XX  
 PF  
 PR 08-JUL-1991; 91US-00726812.  
 PR 16-OCT-1992; 92US-00961813.  
 PR 28-OCT-1992; 92US-00967622.  
 PR 29-JAN-1993; 93US-00010829.  
 PR 09-NOV-1993; 93US-00149508.  
 PR 01-APR-1994; 94US-00221655.  
 PR 05-JUL-1994; 94US-00270412.  
 PR 23-SEP-1994; 94US-00311099.  
 PR 14-NOV-1994; 94US-00338730.  
 PR 20-DEC-1994; 94US-00359945.  
 PR 20-JAN-1995; 95US-00376062.  
 PR 07-FEB-1995; 95US-00385404.  
 XX  
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.  
 XX  
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;  
 PI  
 XX  
 DR WPI; 2003-401068/38.  
 XX  
 PT Transplanting of multipotent neural stem cell progeny to a host  
 PT comprising obtaining a population of cells derived from mammalian neural  
 PT tissue containing multipotent central nervous system neural stem cells.  
 XX  
 PS Example 43; Col 60; 43pp; English.  
 XX  
 CC The present invention relates to a method of transplanting a multipotent  
 CC neural stem cell progeny to a host by obtaining a population of cells  
 CC derived from mammalian neural tissue containing at least one multipotent  
 CC central nervous system (CNS) neural stem cell, culturing the neural stem  
 CC cell in a culture medium containing growth factor(s) which under culture  
 CC conditions induces multipotent neural stem cell proliferation, inducing  
 CC proliferation of the multipotent neural stem cell to produce neural stem  
 CC cell progeny which includes multipotent neural stem cell progeny cells,  
 CC and transplanting the multipotent neural stem cell progeny to the host.  
 CC The method is useful for transplanting multipotent neural stem cell  
 CC progeny to a host. The method of the invention can be used in autologous  
 CC transplantation to in neurological disease, neurodegeneration, and CNS  
 CC trauma. The method of the invention allows proliferation and  
 CC differentiation of the progenitor cell directly in the host without the

CC need for transplantation. ABX95726-ABX95733 represent oligonucleotides  
 CC used in the examples of the present invention  
 CC  
 XX Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
 SQ

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCTGG 1609  
 |||||  
 Db 1 CGAGGTGATGCCCTGG 17

RESULT 383  
 ABX95732/c  
 ID ABX95732 standard; DNA; 18 BP.  
 XX ABX95732;  
 AC  
 XX  
 DT 03-JUL-2003 (first entry)  
 XX  
 DE Oligonucleotide #1 for DNA encoding human FGF.  
 XX  
 KM Multipotent neural stem cell progeny; neural tissue; neural stem cell;  
 KM multipotent central nervous system; CNS; cell proliferation; CNS trauma;  
 KM autologous transplantation; neurological disease; neurodegeneration;  
 KM cell differentiation; progenitor cell; fibroblast growth factor; human;  
 KM FGF; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6497872-B1.  
 XX  
 PD 24-DEC-2002.  
 PD  
 XX  
 XX 07-JUN-1995; 95US-00486313.  
 XX  
 PF  
 PR 08-JUL-1991; 91US-00726812.  
 PR 16-OCT-1992; 92US-00961813.  
 PR 28-OCT-1992; 92US-00967622.  
 PR 29-JAN-1993; 93US-00010829.  
 PR 09-NOV-1993; 93US-00149508.  
 PR 01-APR-1994; 94US-00221655.  
 PR 05-JUL-1994; 94US-00270412.  
 PR 23-SEP-1994; 94US-00311099.  
 PR 14-NOV-1994; 94US-00338730.  
 PR 20-DEC-1994; 94US-00359945.  
 PR 20-JAN-1995; 95US-00376062.  
 PR 07-FEB-1995; 95US-00385404.  
 XX  
 PA (NEUR-) NEUROSPHERES HOLDINGS LTD.  
 XX  
 PI Weiss S, Reynolds B, Hammang JP, Baetge EE;  
 PI  
 XX  
 DR WPI; 2003-401068/38.  
 XX  
 PT Transplanting of multipotent neural stem cell progeny to a host  
 PT comprising obtaining a population of cells derived from mammalian neural  
 PT tissue containing multipotent central nervous system neural stem cells.  
 XX  
 PS Example 43; Col 60; 43pp; English.  
 XX  
 CC The present invention relates to a method of transplanting a multipotent  
 CC neural stem cell progeny to a host by obtaining a population of cells  
 CC derived from mammalian neural tissue containing at least one multipotent  
 CC central nervous system (CNS) neural stem cell, culturing the neural stem  
 CC cell in a culture medium containing growth factor(s) which under culture  
 CC conditions induces multipotent neural stem cell proliferation, inducing  
 CC proliferation of the multipotent neural stem cell to produce neural stem  
 CC cell progeny which includes multipotent neural stem cell progeny cells,  
 CC and transplanting the multipotent neural stem cell progeny to the host.  
 CC The method is useful for transplanting multipotent neural stem cell

CC progeny to a host. The method of the invention can be used in autologous  
CC transplantation to in neurological disease, neurodegeneration, and CNS  
CC trauma. The method of the invention allows proliferation and  
CC differentiation of the progenitor cell directly in the host without the  
CC need for transplantation. ABX95726-ABX95733 represent oligonucleotides  
CC used in the examples of the present invention  
XX  
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1593 CGAGGTGACGCGCTGG 1609  
Db 18 CGAGGTGATCCCTGG 2  
RESULT 384  
ACD27923  
ID ACD27923 standard; DNA; 18 BP.  
AC 24-SEP-2003 (first entry)  
XX  
XX Fibrinolytic growth factor GGF antisense oligonucleotide.  
XX  
XX Fibrinolytic growth factor; GGF; ss; CNS cell proliferation; antisense;  
XX Fibrinolytic growth factor; CNS cell survival; CNS cell phenotype;  
XX CNS cell function; central nervous system; neurological condition;  
XX Alzheimer's disease; Parkinson's disease; Down's syndrome.  
XX  
XX Unidentified.  
XX  
XX US2003082515-A1.  
XX  
XX 01-MAY-2003.  
XX  
XX 19-JUL-2002; 2002US-00199189.  
XX  
XX 08-JUL-1991; 91US-00726812.  
XX 16-OCT-1992; 92US-00961813.  
XX 28-OCT-1992; 92US-00967622.  
XX 28-JAN-1993; 93US-00010829.  
XX 09-NOV-1993; 93US-00149508.  
XX 01-APR-1994; 94US-00221655.  
XX 05-JUL-1994; 94US-00270412.  
XX 23-SEP-1994; 94US-00311099.  
XX 14-NOV-1994; 94US-00338730.  
XX 20-DEC-1994; 94US-00359945.  
XX 20-JAN-1995; 95US-00376062.  
XX 07-FEB-1995; 95US-00385404.  
XX 07-JUN-1995; 95US-00486313.  
XX  
XX (WEISS) WEISS S.  
XX (REYN) REYNOLDS B.  
XX (HAMM) HAMMANG J P.  
XX (BAET) BAETGE E E.  
XX  
XX Weiss S, Reynolds B, Hammang JP, Baetge EG;  
XX WPI; 2003-567461/53.  
XX  
XX Screening for biological agents affecting proliferation, differentiation,  
XX survival, phenotype or function of central nervous system cells,  
XX comprises contacting a neural stem cell population with at least one  
XX biological agent.  
XX  
XX Example 43; Page 33; 40pp; English.  
XX  
XX The invention relates to a method of screening for biological agents  
XX affecting proliferation, differentiation, survival, phenotype or function

CC of central nervous system (CNS) cells comprising contacting a neural stem  
CC cell population with at least one biological agent and determining if the  
CC agent has an effect on any of the listed cell properties. The method is  
CC useful for screening for biological agents which affect proliferation,  
CC differentiation, survival, phenotype, or function of CNS cells which may  
CC have a therapeutic use in treating neurological conditions (e.g.  
CC Alzheimer's disease, Parkinson's disease or Down's syndrome). The method  
CC allows drug screening to be performed on a cell population consisting  
CC essentially of the progeny of a single multipotent neural stem cell grown  
CC in vitro. The present sequence represents a fibrinolytic growth factor GGF  
XX receptor antisense oligonucleotide used in a striatum derived neurosphere  
XX assay  
SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1593 CGAGGTGACGCGCTGG 1609  
Db 1 CGAGGTGATCCCTGG 17  
RESULT 385  
ACD27922/c  
ID ACD27922 standard; DNA; 18 BP.  
AC 24-SEP-2003 (first entry)  
XX  
XX Fibrinolytic growth factor GGF sense oligonucleotide.  
XX  
XX Fibrinolytic growth factor; GGF; ss; CNS cell proliferation;  
XX CNS cell differentiation; CNS cell survival; CNS cell phenotype;  
XX CNS cell function; central nervous system; neurological condition;  
XX Alzheimer's disease; Parkinson's disease; Down's syndrome.  
XX  
XX Unidentified.  
XX  
XX US2003082515-A1.  
XX  
XX 01-MAY-2003.  
XX  
XX 19-JUL-2002; 2002US-00199189.  
XX  
XX 08-JUL-1991; 91US-00726812.  
XX 16-OCT-1992; 92US-00961813.  
XX 28-OCT-1992; 92US-00967622.  
XX 28-JAN-1993; 93US-00010829.  
XX 09-NOV-1993; 93US-00149508.  
XX 01-APR-1994; 94US-00221655.  
XX 05-JUL-1994; 94US-00270412.  
XX 23-SEP-1994; 94US-00311099.  
XX 14-NOV-1994; 94US-00338730.  
XX 20-DEC-1994; 94US-00359945.  
XX 20-JAN-1995; 95US-00376062.  
XX 07-FEB-1995; 95US-00385404.  
XX 07-JUN-1995; 95US-00486313.  
XX  
XX (WEISS) WEISS S.  
XX (REYN) REYNOLDS B.  
XX (HAMM) HAMMANG J P.  
XX (BAET) BAETGE E E.  
XX  
XX Weiss S, Reynolds B, Hammang JP, Baetge EG;  
XX WPI; 2003-567461/53.  
XX  
XX Screening for biological agents affecting proliferation, differentiation,  
XX survival, phenotype or function of central nervous system cells,  
XX comprises contacting a neural stem cell population with at least one

PT biological agent.  
XX  
PS Example 43; Page 33; 40pp; English.  
XX  
CC The invention relates to a method of screening for biological agents  
CC affecting proliferation, differentiation, survival, phenotype or function  
CC of central nervous system (CNS) cells comprising contacting a neural stem  
CC cell population with at least one biological agent and determining if the  
CC agent has an effect on any of the listed cell properties. The method is  
CC useful for screening for biological agents which affect proliferation,  
CC differentiation, survival, phenotype, or function of CNS cells which may  
CC have a therapeutic use in treating neurological conditions (e.g. the method  
CC allows drug screening to be performed on a cell population consisting  
CC essentially of the progeny of a single multipotent neural stem cell grown  
CC in vitro. The present sequence represents a fibroblast growth factor FGF  
CC sense oligonucleotide used in a striatum derived neurosphere assay  
XX  
SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1593 CGAGCTGACGGCGCTGG 1609  
DB 18 CGAGGTGATGCCGCTGG 2  
RESULT 386  
ACFS7054/C  
ID ACFS7054 standard; DNA; 18 BP.  
XX  
AC ACP57054;  
XX  
DT 13-Oct-2003 (first entry)  
XX  
DE TIMP2 cloning forward PCR primer SEQ ID NO:7.  
XX  
XX Human; human serum albumin; TIMP2; fusion protein; antiinflammatory;  
XX tissue inhibitors of metalloproteinase; cytosolic; antiarthritic;  
XX antiproliferative; ophthalmological; protein therapy; angiogenesis;  
XX arthritis; psoriasis; retinopathy; metastasis; cancer; PCR primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
PN WO2003057884-A1.  
XX  
PD 17-JUL-2003.  
XX  
PF 06-JAN-2003; 2003WO-KR000015.  
XX  
PR 08-JAN-2002; 2002KR-00001057.  
XX  
XX (LEAD-) LEADBIO INC.  
XX (ANGI-) ANGIOLAB INC.  
XX  
PI Kim J, Kim M, Park E, Chang J, Kang H;  
XX  
XX WPI; 2003-569550/53.  
DR  
XX  
XX New human serum albumin-tissue inhibitors of metalloproteinase 2 (TIMP2)  
XX fusion protein, useful for treating diseases related to angiogenesis  
XX (e.g. arthritis, psoriasis or retinopathy) and/or metastasis of cancer  
XX cells.  
XX  
XX Example 1; Page 30; 36pp; English.  
XX  
XX The present invention describes a human serum albumin (HSA)-tissue  
XX inhibitors of metalloproteinase 2 (TIMP2) fusion protein (1). Also  
XX described: (1) a polynucleotide encoding (1); (2) a vector comprising the  
XX polynucleotide; (3) a host cell transformed with the vector; (4) a method

CC of producing (1) by cultivating the transformed host cell in a medium to  
CC produce the fusion protein, and recovering (1); and (5) a pharmaceutical  
CC composition comprising (1), and a pharmaceutical carrier or diluent. (1)  
CC has cytostatic, antiproliferative, antiinflammatory, antipsoriatic and  
CC ophthalmological activities, and can be used in protein therapy. The  
CC fusion protein (1) or polynucleotide encoding it can be used for treating  
CC diseases related to angiogenesis (e.g. arthritis, psoriasis or  
CC retinopathy) and/or metastasis of cancer cells. The present sequence  
CC represents a TIMP2 cloning PCR primer, which is used in an example from  
XX the present invention  
XX  
SQ Sequence 18 BP; 1 A; 7 C; 6 G; 4 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1671 CACCGGGGACAGCTGC 1687  
DB 18 CACCGGGGACAGCTGC 2  
RESULT 387  
ADC03333  
ID ADC03333 standard; DNA; 18 BP.  
XX  
AC ADC03333;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
XX FGF antisense oligonucleotide.  
XX  
XX ss; FGF; multipotent neural stem cell proliferation;  
XX neurological disorder; neurotransplantation; neurodegeneration;  
XX CNS trauma; Alzheimer's disease; Parkinson's disease; stroke;  
XX head injury; depression; epilepsy; schizophrenia.  
XX  
OS Synthetic.  
XX  
XX US2003049837-A1.  
XX  
XX 13-MAR-2003.  
XX  
XX 09-AUG-2001; 2001US-00925911.  
XX  
XX 08-JUL-1991; 91US-00726812.  
XX 16-OCT-1992; 92US-00961813.  
XX 28-OCT-1992; 92US-00967622.  
XX 29-JAN-1993; 93US-00010829.  
XX 09-NOV-1993; 93US-00149508.  
XX 01-APR-1994; 94US-00221655.  
XX 05-JUL-1994; 94US-00270412.  
XX 23-SEP-1994; 94US-00311099.  
XX 14-NOV-1994; 94US-00338730.  
XX 20-DEC-1994; 94US-00359945.  
XX 20-JAN-1995; 95US-00376062.  
XX 07-FEB-1995; 95US-00385404.  
XX 07-JUN-1995; 95US-00484203.  
XX  
XX (WEISS) WEISS S.  
XX (REYN) REYNOLDS B.  
XX (HAMM) HAMMANG J P.  
XX (BAET) BAETGE E E.  
XX  
XX Weiss S, Reynolds B, Hammang JP, Baetge EE;  
XX  
XX WPI; 2003-605757/57.  
DR  
XX  
XX In vitro proliferation of a multipotent neural stem cell, useful for  
XX treating neurological disorders, comprises the use of growth factors to  
XX induce proliferation of the neural stem cell and produce a neural stem  
XX cell progeny.



PS Example 43; Page 33; 42pp; English.

XX The invention relates to a method of in vitro proliferation of a

CC multipotent neural stem cell comprising the use of growth factors to

CC induce proliferation of the neural stem cell and produce a progeny that

CC may be passaged repeatedly to produce a sufficient number of cells to

CC obtain representative nucleic acid samples. The method is useful in

CC proliferating multipotent neural stem cells to produce a progeny that may

CC be used to treat neurological disorders or diagnose genetic disorders.

CC The progeny is used for neurotransplantation in the undifferentiated or

CC differentiated state to alleviate the symptoms of neurologic disease,

CC neurodegeneration and CNS trauma (e.g. Alzheimer's disease, Parkinson's

CC disease, stroke, head injury, depression, epilepsy or schizophrenia).

CC These cells may also be used for drug screening of putative therapeutic

CC agents targeted at the nervous system. The present sequence represents

CC the RGF antisense oligonucleotide.

SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 1 CGAGGTGATGCCGCTGG 17

QY 1593 CGAGGTGACGCGCTGG 1609

RESULT 388

ADC03332/c

ID ADC03332 standard; DNA; 18 BP.

XX ADC03332;

AC 18-DEC-2003 (first entry)

DT FGF sense oligonucleotide.

DE

XX

XX ss: FGF; multipotent neural stem cell proliferation;

KM neurological disorder; neurotransplantation; neurodegeneration;

KM CNS trauma; Alzheimer's disease; Parkinson's disease; stroke;

KM head injury; depression; epilepsy; schizophrenia.

XX Synthetic.

OS

XX US2003049837-A1.

PN 13-MAR-2003.

PD

XX 09-AUG-2001; 2001US-00925911.

PF

XX 08-JUL-1991; 91US-00726812.

PR 16-OCT-1992; 92US-00961813.

PR 28-OCT-1992; 92US-00967622.

PR 29-JAN-1993; 93US-00010829.

PR 09-NOV-1993; 93US-00149508.

PR 01-APR-1994; 94US-00221555.

PR 05-JUL-1994; 94US-00270412.

PR 23-SEP-1994; 94US-00311099.

PR 14-NOV-1994; 94US-00338730.

PR 20-DEC-1994; 94US-00359945.

PR 20-JAN-1995; 95US-00376062.

PR 07-FEB-1995; 95US-00385404.

PR 07-JUN-1995; 95US-00484203.

XX

XX (WEIS/) WEISS S.

PA (REYN/) REYNOLDS B.

PA (HAMM/) HAMMANG J P.

PA (BAET/) BAETGE E E.

PI Weiss S, Reynolds B, Hammang JP, Baetge EE;

XX WPI; 2003-605757/57.

XX In vitro proliferation of a multipotent neural stem cell, useful for

PT treating neurological disorders, comprises the use of growth factors to

PT induce proliferation of the neural stem cell and produce a neural stem

PT cell progeny.

XX Example 43; Page 33; 42pp; English.

XX The invention relates to a method of in vitro proliferation of a

CC multipotent neural stem cell comprising the use of growth factors to

CC induce proliferation of the neural stem cell and produce a progeny that

CC may be passaged repeatedly to produce a sufficient number of cells to

CC obtain representative nucleic acid samples. The method is useful in

CC proliferating multipotent neural stem cells to produce a progeny that may

CC be used to treat neurological disorders or diagnose genetic disorders.

CC The progeny is used for neurotransplantation in the undifferentiated or

CC differentiated state to alleviate the symptoms of neurologic disease,

CC neurodegeneration and CNS trauma (e.g. Alzheimer's disease, Parkinson's

CC disease, stroke, head injury, depression, epilepsy or schizophrenia).

CC These cells may also be used for drug screening of putative therapeutic

CC agents targeted at the nervous system. The present sequence represents

CC the RGF sense oligonucleotide.

SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

QY Query Match 0.6%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

DB 18 CGAGGTGATGCCGCTGG 2

QY 1593 CGAGGTGACGCGCTGG 1609

RESULT 389

ADC98362

ID ADC98362 standard; DNA; 18 BP.

XX ADC98362;

AC 01-JAN-2004 (first entry)

DT FOSB01 polymorphism marker PCR primer B primer seq.

DE

XX

XX low bone mineral density; BMD; bone damage; polymorphism; osteoporosis;

KM single nucleotide polymorphism; SNP; PCR primer; ss; human.

XX Synthetic.

OS

XX Homo sapiens.

OS

XX WO2003054218-A2.

PN 03-JUL-2003.

PD

XX 19-DEC-2002; 2002WO-US040948.

PF

XX 20-DEC-2001; 2001US-0342711P.

PR 04-NOV-2002; 2002US-0423559P.

PR

XX (INCY-) INCYTE GENOMICS INC.

PA

PI Jones KA, Valdes A, Townley DJ, Mangion J, Galwey N, Bennett S;

PI McKay I, Schaffer A;

XX WPI; 2003-559156/52.

DR

XX Determining whether an individual is predisposed to susceptibility to low

PT bone mineral density (BMD) and/or bone damage, involves identifying

PT polymorphisms in associated genes.

XX Example 8; Page 237; 246pp; English.

XX The present invention describes a method of determining whether an

CC individual is predisposed to susceptibility to low bone mineral density  
 CC (BMD) and/or bone damage comprising identifying whether the individual  
 CC has at least one polymorphism in a polynucleotide encoding a protein,  
 CC where the polynucleotide is one of at 200-500 nucleotide sequences (S1),  
 CC see AOC9835 to AOC9835). An agent identified in a method from the of a  
 CC present invention which can be used for the prevention or treatment of a  
 CC disease resulting in susceptibility to low BMD and/or bone damage is  
 CC useful in the manufacture of a medicament for use in modulating the  
 CC susceptibility to low BMD and/or bone damage. The disease associated with  
 CC low BMD and/or bone damage is osteoporosis. The present PCR primer  
 CC sequence is used in the exemplification of the present invention.

SO Sequence 18 BP; 5 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1614 ACCCAATGGCTCTGCGA 1630  
 Db 1 ACCCAATGATCTGCGA 17

RESULT 390  
 ADD43511/c  
 ID ADD43511 standard; DNA; 18 BP.  
 XX AC ADD43511;  
 XX DT 15-JAN-2004 (first entry)  
 DE Human mitochondrial DNA (mtDNA) PCR primer SEQ ID NO:685.  
 XX KM mitochondrial haplogroup; mitochondrial DNA; mtDNA;  
 KM single nucleotide polymorphism; SNP; genetic relationship; antidiabetic;  
 KM neurotrophic; neuroprotective; cytosstatic; gene therapy; genealogy;  
 KM forensic; Alzheimer's disease; cancer; type 2 diabetes mellitus; human;  
 KM PCR primer; ss.  
 XX OS Synthetic.  
 OS Homo sapiens.  
 XX PN WO2003046225-A1.  
 PD 05-JUN-2003.  
 XX PF 25-NOV-2002; 2002WO-US038276.  
 XX PK 26-NOV-2001; 2001US-0333622P.  
 PR 28-MAR-2002; 2002US-0369131P.  
 PR 01-APR-2002; 2002US-0369539P.  
 XX PA (MITO-) MITOKOR.  
 PI Hermaclad C;  
 XX DR WPI; 2003-505214/47.  
 PT Determining single nucleotide polymorphisms in mtDNA or homoplasmic mtDNA  
 PT mutations, useful for diagnosing and treating diseases, such as  
 PT Alzheimer's disease, cancer and type 2 diabetes mellitus.  
 XX PS Example 2; SEQ ID NO 685; 193bp; English.  
 XX The present invention describes a method (M1) for determining the  
 CC mitochondrial haplogroup of a subject, comprising determining in a  
 CC biological sample with mitochondrial DNA (mtDNA) from a subject, the  
 CC presence or absence of at least one mitochondrial single nucleotide  
 CC polymorphism (SNP) that is associated with a mitochondrial haplogroup.  
 CC Also described: (1) determining a genetic relationship between two  
 CC subjects; (2) determining a genetic relationship between an unknown  
 CC source or biological subject from which an unidentified sample is  
 CC obtained, and a known source or biological subject from an identified

CC sample is obtained; and (3) determining the presence of or the risk of  
 CC having a disease associated with a mtDNA SNP. Mitochondrial DNA can have  
 CC antidiabetic, neurotrophic, neuroprotective and cytosstatic activities, and  
 CC can be used in gene therapy. M1 and compositions of the present invention  
 CC are useful for detecting the presence or risk of diseases, treating such  
 CC diseases, determining the haplogroup of an individual, and establishing  
 CC genetic relationships between individuals for genealogical and forensic  
 CC purposes. The diseases include Alzheimer's disease, cancer and type 2  
 CC diabetes mellitus. The present sequence represents a PCR primer used in  
 CC the amplification of human mtDNA in an example from the present  
 CC invention.

SO Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.2e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 658 TCAGCCGATACCTTCAC 674  
 Db 18 TCATCCGCTACCTTCAC 2

RESULT 391  
 AAS98700  
 ID AAS98700 standard; DNA; 15 BP.  
 XX AC AAS98700;  
 XX DT 26-MAR-2002 (first entry)  
 DE Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #6.  
 XX KM Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;  
 KM cytosstatic; gene therapy; malignant histiocytosis; leprose;  
 KM myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;  
 KM genotype; human; allele specific oligonucleotide; ASO; primer; ss.  
 XX OS Homo sapiens.  
 OS WO200179225-A2.  
 XX PN 25-OCT-2001.  
 XX PD 12-APR-2001; 2001WO-US012044.  
 XX PF 12-APR-2001; 2001WO-US012044.  
 XX PR 12-APR-2000; 2000US-0196411P.  
 XX PA (GENA-) GENAISSANCE PHARM INC.  
 XX PI Chew A, Choi JY, Koshy B;  
 XX DR WPI; 2002-075058/10.  
 XX Claim 15; Page 16; 164pp; English.  
 XX The invention describes a novel isolated polynucleotide (I) comprising a  
 CC sequence which is a polymorphic variant (PV) of a reference sequence for  
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the  
 CC polypeptide are useful for improving the discovery and development of  
 CC drugs for treating diseases associated with CSF1R activity, e.g.,  
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders  
 CC and the haplotypes can be used to validate CSF1R as a candidate target  
 CC for treating a specific condition or disease predicted to be associated  
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also  
 CC be used in developing diagnostic tests and therapeutic treatments. (1) is  
 CC useful in studying the expression and function of CSF1R, and in  
 CC expressing CSF1R protein for use in screening for candidate drugs to  
 CC treat diseases related to CSF1R activity and in studying the effect of

CC the variation on the biological activity of CSF1R as well as on the  
CC binding affinity of candidate drugs targeting CSF1R. Antibodies are  
CC useful in a variety of diagnostic and prognostic formats and therapeutic  
CC methods. A transgenic animal is useful in studying expression of the  
CC CSF1R isogenes *in vivo*, for *in vivo* screening and testing of drugs  
CC targeted against CSF1R protein, and for testing the efficacy of  
CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)  
CC are useful as probes and primers, and for assaying a polymorphism in the  
CC target region. Without requiring any *a priori* knowledge of the phenotypic  
CC effect of any particular CSF1R or haplotype the invention provides a  
CC method for identifying lead compounds that are more likely to show  
CC efficacy in clinical trials. This sequence is an allele specific  
CC oligonucleotide primer used for detecting CSF1R gene polymorphisms,  
CC described in the method of the invention

XX  
SQ Sequence 15 BP; 3 A; 3 C; 3 G; 5 T; 0 U; 1 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1648 CTGCTGCAGATCT 1661  
Db 2 CTGCTGCAGATST 15

RESULT 392  
AB564229  
ID AB564229 standard; DNA; 15 BP.  
XX  
AC AB564229;  
XX  
DT 15-NOV-2002 (first entry)

DE Tachykinin receptor gene TACR2, allele-specific primer #39.  
XX  
KM Human; single nucleotide polymorphism; SNP; TACR2; primer; probe; ss;  
XX tachykinin receptor.  
XX  
OS Homo sapiens.  
XX  
PN WO20263046-A1.  
XX  
PD 15-AUG-2002.  
XX  
PF 09-NOV-2001; 2001WO-US047394.  
XX  
PR 09-NOV-2000; 2000US-0247649P.  
XX  
PA (GENA-) GENAISSANCE PHARM INC.  
XX  
PI Cappola G, Chew A, Gilson CR, Koshy B;  
XX  
XX WPI; 2002-636600/68.  
DR  
XX  
PT New genetic variants having polymorphisms in the Tachykinin receptor  
PT (TACR2) protein, useful for studying the function of TACR2, and for  
PT treating disorders associated with abnormal expression or function of  
PT TACR2 isogene.  
XX  
PS Claim 14; Page 15; 139pp; English.  
XX

CC The invention relates to an isolated polypeptide comprising a polymeric  
CC variant of a reference sequence for the Tachykinin receptor (TACR2)  
CC protein. Also described is a method for: (1) haplotyping or genotyping  
CC the TACR2 gene of an individual; (2) predicting a haplotype pair for the  
CC TACR2 gene of an individual; (3) identifying an association between a  
CC trait and at least one haplotype or haplotype pair of the TACR2 gene; and  
CC (4) isolated oligonucleotide for detecting a single nucleotide  
CC polymorphism in the TACR2 gene. Polymorphic variants of the TACR2 gene  
CC are useful in studying the expression and biological function of TACR2,  
CC and in identifying drugs targeting TACR2 protein for treating disorders  
CC associated with abnormal expression or function of TACR2, e.g. asthma or

CC breast cancer. Polynucleotides comprising a polymorphic gene variant or  
CC fragment may be used for therapeutic purposes, where a patient could  
CC benefit from expression or increased expression of a particular TACR2  
CC protein isoform, or an expression vector encoding the isoform may be  
CC administered to the patient. Haplotype information is useful in improving  
CC the efficiency and output of several steps in drug discovery and  
CC development process, including target validation, identifying lead  
CC compounds, and early phase clinical trials. Information on polymorphisms  
CC may be applied in studying biological functions of TACR2 as well as in  
CC identifying drugs targeting this protein for the treatment of disorders  
CC related to its abnormal expression or function. AB564163-AB564302  
CC represent human TACR2 gene allele-specific oligonucleotide probes and  
CC primers used to detect haplotypes of the TACR2 gene of the invention

XX  
SQ Sequence 15 BP; 2 A; 4 C; 6 G; 2 T; 0 U; 1 Other;

Query Match 0.6%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 62 CATGCTGGGACA 75  
Db 1 CATGCTGGGACR 14

RESULT 393  
AB248393/C  
ID AB248393 standard; DNA; 41 BP.  
XX  
AC AB248393;  
XX  
DT 26-JUN-2003 (first entry)

DE Human ATP-binding cassette ABCB3/ABCB1 gene polymorphic site, #5176.  
XX  
KM Human; drug metabolizing enzyme; gene; drug metabolism; chromosome 6;  
XX polymorphic site; drug evaluation; drug screening; genotyping;  
XX genetic profiling; therapeutic customisation; adverse reaction;  
XX clinical trial; drug approval; single nucleotide polymorphism; SNP; de.  
XX  
OS Homo sapiens.  
XX  
PN WO20252044-A2.  
XX  
PD 04-JUL-2002.  
XX  
PF 27-DEC-2001; 2001WO-JP011592.  
XX  
PR 27-DEC-2000; 2000JP-00399443.  
XX  
PR 02-MAY-2001; 2001JP-00335256.  
XX  
PR 27-AUG-2001; 2001JP-00256862.  
XX  
PA (RIKEN) RIKEN KK.  
XX  
PI Nakamura Y, Sekine A, Iida A, Saito S;  
XX  
XX WPI; 2002-583571/62.  
DR  
XX  
PT Identifying individuals having a polymorphism, useful for determining the  
PT effectiveness or side effect of a drug or treatment protocol, comprises  
PT detecting at least one polymorphism in the drug metabolizing enzyme  
PT nucleic acid.  
XX  
PS Claim 23; Page 165; 2785pp; English.  
XX  
XX Sequences AB243217-AB250887 represent polymorphic sites within genes  
XX encoding enzymes associated with drug metabolism. The invention relates  
XX to methods and compositions for identifying individuals who have at least



XX	OS	Hom	sapiens.
XX	XX	Key	Location/Qualifiers
XX	XX	variation	replace(21, G)
XX	XX	/*tag=	a
XX	XX	/standard_name=	"single nucleotide polymorphism (SNP) "
XX	XX	MO200252044-A2.	
XX	XX	04-JUL-2002.	
XX	XX	27-DEC-2001; 2001WO-JP011592.	
XX	XX	27-DEC-2000; 2000JP-00399443.	
XX	XX	PR 02-MAY-2001; 2001JP-00135256.	
XX	XX	PR 27-AUG-2001; 2001JP-00256862.	
XX	XX	(RIKE ) RIKEN KK.	
XX	XX	Nakamura Y, Sekine A, Iida A, Saito S;	
XX	XX	WPI; 2002-583571/62.	
XX	XX	Identifying individuals having a polymorphism, useful for determining the	
XX	XX	effectiveness or side effect of a drug or treatment protocol, comprises	
XX	XX	detecting at least one polymorphism in the drug metabolizing enzyme	
XX	XX	nucleic acid.	
XX	XX	Claim 23; Page 64; 2785pp; English.	
XX	XX	Sequences AB243217-AB250887 represent polymorphic sites within genes	
XX	XX	encoding enzymes associated with drug metabolism. The invention relates	
XX	XX	to methods and compositions for identifying individuals who have at least	
XX	XX	one polymorphism in such drug metabolizing enzyme-encoding genes. The	
XX	XX	polymorphisms may be identified in a nucleic acid sample using probes or	
XX	XX	primers specific for a sequence selected from AB243217-AB250887 using a	
XX	XX	variety of detection assays, including hybridisation assays, nucleic acid	
XX	XX	arrays and PCR-based methods. The invention also encompasses methods of	
XX	XX	evaluating and screening drugs using genetic polymorphism data. Genetic	
XX	XX	polymorphism data, particularly that relating to single nucleotide	
XX	XX	polymorphisms (SNPs), may be used in studying the relationship between	
XX	XX	DNA sequence variations and human diseases, conditions, and responses to	
XX	XX	drugs. SNPs are also useful as polymorphism markers for discovering genes	
XX	XX	that cause or exacerbate certain diseases. SNPs are particularly useful	
XX	XX	in the above respects as they are stable in populations, occur	
XX	XX	frequently, and have lower mutation rates than other genome variations	
XX	XX	such as repeating sequences. The detection and analysis of polymorphisms	
XX	XX	in genes encoding drug metabolising enzymes allows the customisation of	
XX	XX	drug therapies based upon the genetic profile of individual patients.	
XX	XX	This would not only take the guesswork out of selecting the drug with the	
XX	XX	greatest therapeutic effect for a particular patient, but would also	
XX	XX	reduce the likelihood of adverse reactions, thereby increasing safety.	
XX	XX	Methods of the invention are also useful in the drug discovery and	
XX	XX	clinical processes. For example, individuals could be selected for	
XX	XX	clinical trials only if their genetic profiles indicate that they are	
XX	XX	capable of responding to a particular drug or drug class, and previously	
XX	XX	failed drug candidates could be revived if they were matched with more	
XX	XX	appropriate patient populations. The methods, data and compositions of	
XX	XX	the invention may therefore lead to an increase in the range of	
XX	XX	possible drug targets and decreases in the number of adverse drug	
XX	XX	reactions, failed drug trials, the time taken for a drug to be approved,	
XX	XX	the length of time patients are on medication and the number of different	
XX	XX	medications a patient needs to take before finding an effective therapy	
XX	XX	Sequence 41 BP; 5 A; 19 C; 5 G; 12 T; 0 U; 0 Other;	
XX	XX	Query Match 0.6%; Score 13.6; DB 1; Length 41;	
XX	XX	Best Local Similarity 67.9%; Pred. No. 3.8e+02;	
XX	XX	Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0	

```

DB      37 AGCAGAGCGACGGTGATCAGCGTGACCA 10
37:
RESULT 396
AAQ1153
ID      AAQ1153 standard; DNA; 15 BP.
XX
AC      AAQ1153;
XX
DT      25-MAR-2003 (revised)
DT      31-MAY-1991 (first entry)
XX
DE      3'-terminal noncoding sequence of an influenza virus genome.
XX      Influenza virus, ribonucleoprotein complex; RNA polymerase; vaccine;
XX      negative strand RNA template; chimeric virus; ss.
XX
OS      Synthetic.
XX
PN      MO9103552-A.
XX
PD      21-MAR-1991.
XX
PF      28-AUG-1989; 89US-00399728.
XX
PR      28-AUG-1989; 89US-00399728.
PR      21-NOV-1989; 89US-00440053.
PR      22-MAY-1990; 90US-00527237.
XX
PA      (MOUN ) MOUNT SINAI SCHOOL MEDICINE.
XX
PI      Palese P, Parvin JD, Krystal M;
XX
DR      WPI; 1991-102072/14.
XX
PT      Recombinant negative strand RNA template - for RNA polymerase binding
PT      site used to produce expression prods. and chimeric viruses for influenza
PT      vaccines.
XX
PS      Claim 5; Page 87; 114p; English.
XX
CC      This sequence comprises the terminal 15 residues of the 3' non-coding
CC      viral sense flanking region of an influenza genomic segment. It is a
CC      component of a recombinant negative strand RNA template and is used as an
CC      RNA polymerase binding site, in the prepn. of a ribonucleoprotein complex
CC      (RNP). The template also contains a heterologous RNA sequence and opt.
CC      also a 5'-noncoding viral sense flanking sequence of influenza. The
CC      heterologous sequences is selected from e.g. epitopes of HIV, HBsAg or
CC      herpes viruses. A vast repertoire of vaccine formulations can be produced
CC      using the chimeric viruses. This alleviates the problem of host
CC      resistance. See also AAQ1152, AAQ1154-56 and AAQ1192-93. (Updated on
CC      25-MAR-2003 to correct PA field.)
XX
SQ      Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred.No. 2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY      999 CACCTGCTCTGCT 1013
      |||||:|:|:|:|
DB      1 CACCCGUCUCGCU 15
XX
RESULT 397
AA152346
ID      AA152346 standard; RNA; 15 BP.
XX
AC      AA152346;
XX
DT      25-MAR-2003 (revised)
DT      02-APR-1997 (first entry)
XX

```

DE Mouse ICM hammerhead ribozyme target sequence (nt. position 1678).  
 XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
 KW gene expression; downregulation; interleukin-5; IL-5; ICM-1;  
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;  
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
 KW translocation; chronic myelogenous leukaemia; CML; cancer;  
 KW Philadelphia chromosome; inflammation; autoimmune disease;  
 KW atherosclerosis; myocardial infarction; stroke; restenosis;  
 KW transplant rejection; rheumatoid arthritis; psoriasis;  
 KW myocardial ischemia; Kawasaki disease; septic shock; HIV;  
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
 KW ss.  
 OS Mus musculus.  
 XX WO9523225-A2.  
 XX  
 XX 31-AUG-1995.  
 PD  
 XX  
 XX 23-FEB-1995; 95WO-IB000156.  
 PF  
 XX  
 XX 23-FEB-1994; 94US-00201109.  
 PR 29-MAR-1994; 94US-00218934.  
 PR 04-APR-1994; 94US-00222795.  
 PR 07-APR-1994; 94US-00224483.  
 PR 15-APR-1994; 94US-00227958.  
 PR 15-APR-1994; 94US-00228041.  
 PR 18-MAY-1994; 94US-00245736.  
 PR 06-JUL-1994; 94US-00271280.  
 PR 15-AUG-1994; 94US-00291432.  
 PR 16-AUG-1994; 94US-00291433.  
 PR 17-AUG-1994; 94US-00292620.  
 PR 19-AUG-1994; 94US-00293520.  
 PR 02-SEP-1994; 94US-00300000.  
 PR 08-SEP-1994; 94US-00303039.  
 PR 23-SEP-1994; 94US-00311486.  
 PR 23-SEP-1994; 94US-00311749.  
 PR 28-SEP-1994; 94US-00314397.  
 PR 03-OCT-1994; 94US-00316771.  
 PR 07-OCT-1994; 94US-00319492.  
 PR 11-OCT-1994; 94US-00321993.  
 PR 04-NOV-1994; 94US-00334847.  
 PR 10-NOV-1994; 94US-00337608.  
 PR 28-NOV-1994; 94US-00345516.  
 PR 16-DEC-1994; 94US-00357577.  
 PR 23-DEC-1994; 94US-00363233.  
 PR 30-JAN-1995; 95US-00380734.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX  
 XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;  
 PI Grimm S, Kapelsky A, Kisich K, Matulis-Adamec J, Mcswiggen JA;  
 PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;  
 PI Tracz D, Usman N, Wincott FE, Woolf T;  
 XX  
 XX WPI; 1995-351090/45.  
 DR  
 XX Ribozymes having modified bases and methods for producing them - for use  
 PT in inhibiting disease related genes.  
 XX  
 XX Claim 2, Page 178; 407bp; English.  
 PS  
 XX  
 XX The present sequence represents a preferred target sequence for an  
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICM-1 mRNA at the  
 CC nucleotide base position indicated in the DE line. Regions of the mRNA  
 CC that do not form secondary folding structures and that contain potential  
 CC hammerhead and hairpin ribozyme cleavage sites were identified by  
 CC computer analysis. Ribozymes directed against these mRNA sequences were  
 CC designed and synthesised with modifications that improve their nuclease  
 CC resistance. The ribozymes cleave the ICM-1 target sequences and thereby  
 CC inhibit ICM-1 expression, making them useful for reducing transplant  
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,

CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to  
 CC correct PI field.)  
 XX  
 XX Sequence 15 BP; 3 A; 5 C; 5 G; 0 T; 2 U; 0 Other;  
 SQ  
 Query Match 0.64; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 80.04; Pred. No. 2e+02; Indels 0; Gaps 0;  
 Matches 12; Conservative 2; Mismatches 1;  
 QY 2102 AGCACCTCAGCCTGG 2116  
 Db 1 AGCACCTCAGCCTGG 15  
 RESULT 398  
 AAT52187  
 ID AAT52187 standard; RNA; 15 BP.  
 XX  
 AC AAT52187;  
 DT 25-MAR-2003 (revised)  
 DT 01-APR-1997 (first entry)  
 XX  
 XX Mouse ICM hammerhead ribozyme target sequence (nt. position 48).  
 DE  
 XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
 KW gene expression; downregulation; interleukin-5; IL-5; ICM-1;  
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;  
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
 KW translocation; chronic myelogenous leukaemia; CML; cancer;  
 KW Philadelphia chromosome; inflammation; autoimmune disease;  
 KW atherosclerosis; myocardial infarction; stroke; restenosis;  
 KW transplant rejection; rheumatoid arthritis; psoriasis;  
 KW myocardial ischemia; Kawasaki disease; septic shock; HIV;  
 KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
 KW ss.  
 XX  
 OS Mus musculus.  
 XX WO9523225-A2.  
 XX  
 XX 31-AUG-1995.  
 PD  
 XX  
 XX 23-FEB-1995; 95WO-IB000156.  
 PF  
 XX  
 XX 23-FEB-1994; 94US-00201109.  
 PR 29-MAR-1994; 94US-00218934.  
 PR 04-APR-1994; 94US-00222795.  
 PR 07-APR-1994; 94US-00224483.  
 PR 15-APR-1994; 94US-00227958.  
 PR 15-APR-1994; 94US-00228041.  
 PR 18-MAY-1994; 94US-00245736.  
 PR 06-JUL-1994; 94US-00271280.  
 PR 15-AUG-1994; 94US-00291432.  
 PR 16-AUG-1994; 94US-00291433.  
 PR 17-AUG-1994; 94US-00292620.  
 PR 19-AUG-1994; 94US-00293520.  
 PR 02-SEP-1994; 94US-00300000.  
 PR 08-SEP-1994; 94US-00303039.  
 PR 23-SEP-1994; 94US-00311486.  
 PR 23-SEP-1994; 94US-00311749.  
 PR 28-SEP-1994; 94US-00314397.  
 PR 03-OCT-1994; 94US-00316771.  
 PR 07-OCT-1994; 94US-00319492.  
 PR 11-OCT-1994; 94US-00321993.  
 PR 04-NOV-1994; 94US-00334847.  
 PR 10-NOV-1994; 94US-00337608.  
 PR 28-NOV-1994; 94US-00345516.  
 PR 16-DEC-1994; 94US-00357577.  
 PR 23-DEC-1994; 94US-00363233.  
 PR 30-JAN-1995; 95US-00380734.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.

XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;  
 PI Grimm S, Karpelsky A, Kleich K, Matulic-Adamic J, McWiggen JA;  
 PI Modak A, Pavco P, Belgelman L, Sullivan SM, Svedler D, Thompson JD;  
 PI Ttacz D, Ueman N, Wincott FB, Woolf T;  
 XX  
 DR WPI; 1995-351090/45.  
 XX  
 PT Ribozymes having modified bases and methods for producing them - for use  
 PT in inhibiting disease related genes.  
 XX  
 PS Claim 2; Page 177; 407pp; English.  
 XX  
 CC The present sequence represents a preferred target sequence for an  
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the  
 CC nucleotide base position indicated in the DE line. Regions of the mRNA  
 CC that do not form secondary folding structures and that contain potential  
 CC hammerhead and hairpin ribozyme cleavage sites were identified by  
 CC computer analysis. Ribozymes directed against these mRNA sequences were  
 CC designed and synthesized with modifications that improve their nuclease  
 CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby  
 CC inhibit ICAM-1 expression, making them useful for reducing transplant  
 CC rejection and alleviating symptoms in patients with rheumatoid arthritis,  
 CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to  
 CC correct PI field.)  
 XX  
 SQ Sequence 15 BP; 3 A; 5 C; 5 G; 0 T; 2 U; 0 Other;  
 QY  
 Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 80.0%; Pred. No. 2e+02;  
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 DB 2102 AGCACCCTGAGCTGG 2116  
 1 AGGACCCUAGCCTGG 15  
 ID AAX64669 standard; RNA; 15 BP.  
 XX  
 AC AAX64669;  
 XX  
 DT 20-JUL-1999 (first entry)  
 XX  
 DE Human B7-1 hammerhead ribozyme target SEQ ID NO:1301.  
 XX  
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;  
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
 KW streptolysin; synovial membrane; joint; arthritis; osteoarthritis;  
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
 KW diagnosis; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09618736-A2.  
 XX  
 PD 20-JUN-1996.  
 XX  
 PF 22-NOV-1995; 95WO-US015516.  
 XX  
 PR 13-DEC-1994; 94US-00354920.  
 PR 23-DEC-1994; 94US-00363253.  
 PR 23-DEC-1994; 94US-00363254.  
 PR 17-FEB-1995; 95US-00390850.  
 PR 20-APR-1995; 95US-00426124.  
 PR 02-MAY-1995; 95US-00432874.  
 PR 04-MAY-1995; 95US-00434509.  
 PR 07-JUL-1995; 95US-0000951P.  
 PR 07-JUL-1995; 95US-0000974P.  
 PR 07-AUG-1995; 95US-00512861.  
 PR 05-OCT-1995; 95US-00541365.  
 XX

PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 XX Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
 PI Belgelman L, Gustafson J, Ueman N, Wincott F, Matulic-Adamic J;  
 PI McWiggen J, Gustafson J, Ueman N, Wincott F, Matulic-Adamic J;  
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;  
 XX  
 DR WPI; 1996-300653/30.  
 XX  
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used for  
 PT the treatment of arthritis, induction of graft tolerance or treatment of  
 PT auto-immune diseases.  
 XX  
 PS Claim 10; Page 167; 307pp; English.  
 XX  
 CC The present invention describes a novel enzymatic nucleic acid (ENA)  
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
 CC at position 1; (ii) at least 5 ribose residues at position 4 of the ENA; (iii) at least  
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
 CC can inhibit collagenase and stromelysin production in the synovial  
 CC membrane of joints for the treatment or prevention of arthritis,  
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
 CC be used to treat antigen presenting cells of a donor to induce tolerance  
 CC in a recipient to an allograft or for treating autoimmune disease, and for  
 CC enhancing graft tolerance or for treating autoimmune disease, and for  
 CC treating allergies and other inflammatory conditions. The ENA's can also  
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
 CC streptolysin without introducing the non-specific effects upon gene  
 CC expression which accompany treatment with retinoids and dexamethasone.  
 CC The concentration of ribozyme required to affect a therapeutic treatment  
 CC is lower than that required of antisense molecules, and is highly  
 CC specific. The present sequence is used in the exemplification of the  
 CC present invention  
 XX  
 SQ Sequence 15 BP; 3 A; 4 C; 4 G; 0 T; 4 U; 0 Other;  
 QY  
 Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 DB 502 GGCTCTGGAACCT 516  
 15 GGCTCTGGAACCT 1  
 ID AAT97119 standard; DNA; 15 BP.  
 XX  
 AC AAT97119;  
 XX  
 DT 05-MAR-1998 (first entry)  
 XX  
 DE Murine p27 wild-type fragment.  
 XX  
 KW Hypertrophic variant organism; p27; cyclin; inhibitor; hyperplasia;  
 KW proliferation; AIDS; antisense; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN W09726327-A1.  
 XX  
 PD 24-JUL-1997.  
 XX  
 PF 17-JAN-1997; 97WO-US000831.  
 XX  
 PR 18-JAN-1996; 96US-00588595.  
 PR 31-MAY-1996; 96US-00656562.  
 XX  
 PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.  
 XX  
 XX Roberts JM, Coats SR, Fero ML;  
 PI  
 DR WPI; 1997-385332/35.  
 XX



XX Hypertrophic variant organism with inactivated cyclin inhibitor gene -  
PT useful as models for therapy of abnormal cell proliferation diseases,  
PT e.g. hyperplasia.  
XX  
PS Example 3; Page 72; 99pp; English.  
XX  
CC A novel method has been developed for producing a hypertrophic variant  
CC organism. The method comprises functionally inactivating expression of a  
CC cyclin inhibitor gene in an organism where a hypertrophic variant is  
CC produced, the hypertrophy being relative to an organism having the  
CC functional cyclin inhibitor gene. Also produced are: (1) a polynucleotide  
CC targeting a construct, comprising a sequence that is homologous to a  
CC sequence present in a cyclin inhibitor gene and which when integrated at  
CC the corresponding cyclin inhibitor gene locus, functionally inactivates  
CC cyclin inhibitor protein expression; (2) a hypertrophic non-human  
CC organism having a functionally inactivated cyclin inhibitor gene, the  
CC hypertrophy being relative to an organism having the functional cyclin  
CC inhibitor gene; (3) a method for increasing the proportion of dividing  
CC cells in a vertebrate cell population, comprising exposing the cells to a  
CC p27 inhibitor in an amount sufficient to increase the proportion of  
CC dividing cells to non-dividing cells relative to an untreated cell  
CC population; and (4) a p27 inhibitor that comprises an oligonucleotide  
CC that specifically binds to DNA encoding p27, or RNA transcribed from  
CC this, and inhibits expression of the p27 protein. The present sequence  
CC represents a wild-type fragment of murine p27 used in example 3 of the  
CC antisense oligonucleotides can be overcome  
CC  
XX  
SQ Sequence 15 BP; 3 A; 4 C; 7 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 799 GCTGTCTCTGCGCCAG 813  
Db 15 GCTCTCTGCGCCAG 1  
  
RESULT 401  
AAV41112  
ID AAV41112 standard; RNA; 15 BP.  
XX  
AC AAV41112;  
XX  
DT 17-OCT-2003 (revised)  
DT 01-OCT-1998 (first entry)  
XX  
DE 3'-noncoding flanking region of RNA polymerase binding site.  
XX  
KM RNA-directed RNA polymerase; binding site; negative-strand RNA virus;  
KM HIV; chimeric virus; humoral immune response induction; AIDS;  
KM cell-mediated immune response; ss.  
XX  
OS Human immunodeficiency virus 1.  
XX  
PN US5786199-A.  
XX  
PD 28-JUL-1998.  
XX  
PF 14-OCT-1994; 94US-00323192.  
XX  
PR 28-AUG-1989; 89US-00399728.  
PR 21-NOV-1989; 89US-00440053.  
PR 22-MAY-1990; 90US-00527237.  
PR 04-AUG-1992; 92US-00925061.  
PR 01-FEB-1994; 94US-00190698.  
PR 01-JUN-1994; 94US-00252508.  
XX  
PA (MOUN ) MOUNT SINAI SCHOOL MEDICINE.  
XX  
PI Palese P;

XX WPI; 1998-436533/37.  
DR  
XX Chimeric RNA virus containing HIV sequences - contains multi-epitopic  
PT sequences, useful for vaccination against HIV infection.  
XX  
PS Claim 4; Col 94; 83pp; English.  
XX  
CC This sequence represents a 3'-noncoding flanking region that can be used  
CC in the RNA molecule of the invention. The RNA molecule comprises a  
CC binding site specific for an RNA-directed RNA polymerase of a negative-  
CC strand RNA virus, operatively linked to a heterologous RNA sequence  
CC comprising the reverse complement of an HIV coding sequence. A chimeric  
CC virus containing the RNA molecule can be used to induce humoral and cell-  
CC mediated immune responses to HIV (human immunodeficiency virus), the  
CC causative agent of acquired immunodeficiency syndrome (AIDS) e.g.  
CC vaccination against HIV. The RNA molecules are based on sequences which  
CC express heterologous gene products of HIV in the attempt that expression  
CC of the products will induce an immune response in a vaccinated host.  
CC Using a range of different sequences, different epitopes can be produced  
CC in immune responses. Previous attempts at similar procedures have not had  
CC epitopic variety due to lack of availability of negative-strand RNA  
CC molecules that are also infectious. (Updated on 17-OCT-2003 to  
CC standardise OS field)  
CC  
XX  
SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;  
  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 66.7%; Pred. No. 2e+02;  
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 999 CACCCGCTCTGCT 1013  
Db 1 CACCCGCTCTGCT 15  
  
RESULT 402  
AAZ63879  
ID AAZ63879 standard; RNA; 15 BP.  
XX  
AC AAZ63879;  
XX  
DT 28-MAR-2000 (first entry)  
XX  
DE Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 2510.  
XX  
KM Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;  
KM cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;  
KM autoimmune disease; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN W09955847-A2.  
XX  
PD 04-NOV-1999.  
XX  
PF 26-APR-1999; 99WO-US009027.  
XX  
PR 27-APR-1998; 98US-0083217P.  
PR 18-SEP-1998; 98US-0100842P.  
PR 25-FEB-1999; 99US-00257608.  
PR 23-MAR-1999; 99US-00274553.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Blatt L, Meswigen JA, Roberts E, Ravco PA, Macejak D;  
XX WPI; 2000-062023/05.  
DR  
XX Novel ribozymes for the treatment of diseases and conditions related to  
PT hepatitis C infection.  
XX  
PS Claim 1; Page 73; 123pp; English.



XX The present sequence represents the preferred target sequence of an  
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves  
CC the Hepatitis C virus (HCV) RNA sequence at the base position given in  
CC the descriptor line. The HCV sequence was screened for optimal ribozyme  
CC target sites using a computer folding algorithm and regions of the mRNA  
CC which did not form secondary folding structures and contained potential  
CC ribozyme cleavage sites were identified. Ribozymes were synthesized to  
CC target these sites and their activities optimised by either varying the  
CC length of the binding arms or by modification to prevent degradation by  
CC nucleases. The ribozymes of the invention inhibit gene expression and/or  
CC viral replication, and are used to treat diseases associated with  
CC Hepatitis C virus (HCV) infection, e.g. cirrhosis, liver failure and  
CC hepatocellular carcinoma. The ribozymes may be used in combination with  
CC interferon to treat HCV infection, other infectious diseases, autoimmune  
CC diseases, and cancer

SQ Sequence 15 BP; 0 A; 6 C; 1 G; 0 T; 8 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 40.0%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
Matches 6; Conservative 8; Indels 1;

OY 1010 TCGTTTCCTTCGTC 1024  
:||||:|::|:  
1 UGCUUUCUCCUCC 15

Db

RESULT 403  
AAZ56243  
ID AAZ56243 standard; RNA; 15 BP.  
AC AAZ56243;  
XX  
XX 15-MAR-2000 (first entry)  
XX  
XX V-d5' point mutation 3' promoter sequence V-CS SEQ ID NO:12.  
XX  
XX Recombinant negative strand viral RNA template; virus particle;  
KM RNA directed RNA polymerase complex; expression; chimeric virus; vaccine;  
KM packaging; ss.  
XX  
XX Influenza virus.  
OS Synthetic.  
OS  
XX  
XX US6001634-A.  
PN  
XX  
XX 14-DEC-1999.  
PD  
XX  
XX 29-JUN-1998; 98US-00106377.  
PF  
XX  
XX 28-AUG-1989; 89US-0039728.  
PR  
XX 21-NOV-1989; 89US-00440053.  
PR  
XX 22-MAY-1990; 90US-00527237.  
PR  
XX 04-AUG-1992; 92US-00925061.  
PR  
XX 01-FEB-1994; 94US-00190698.  
PR  
XX 01-JUN-1994; 94US-00252508.  
PR  
XX  
XX (PALE/) PALESE P.  
PA (GARC/) GARCIA-SASTRE A.  
PA  
XX  
XX Palese P, Garcia-Sastre A;  
PI  
XX  
XX WPI; 2000-071660/06.  
DR  
XX  
XX Chimeric virus containing influenza virus RNA segments, useful for  
PT expressing heterologous gene products in appropriate host cell systems.  
PT  
XX  
XX Example; Col 61; 67pp; English.  
PS  
XX  
XX The present invention describes a chimeric virus comprising influenza  
CC virus containing a heterologous RNA segment from another strain of  
CC influenza virus or 8 genomic segments from different strains of influenza

CC virus, with each segment comprising the reverse complement of a mRNA  
CC coding sequence operatively linked to a binding site specific for an RNA-  
CC directed RNA polymerase of a negative strand RNA virus. The recombinant  
CC negative strand virus RNA templates may be used to express heterologous  
CC gene products in appropriate host cell systems and/or to construct  
CC recombinant viruses that express, package and/or present the heterologous  
CC gene product. The expression products and chimeric viruses may be used in  
CC vaccine formulations. AAY57746 to AAY57748, and AAZ56234 to AAZ56290,  
CC represent sequences used in the exemplification of the present invention

SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 66.7%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
Matches 10; Conservative 4; Indels 1;

OY 999 CACCCGCTTCGCT 1013  
:||||:|::|:  
1 CACCCGCTTCGCT 15

Db

RESULT 404  
AAZ52432/C  
ID AAZ52432 standard; DNA; 15 BP.  
AC AAZ52432;  
XX  
XX 18-SEP-2000 (first entry)  
XX  
XX Tdt-expressing Ramos cell VH insertion+deletion mutation, F242.  
XX  
XX Lymphoid cell; antibody producing cell; Ramos cell; immunoglobulin M;  
KM IGM; V gene diversity; directed constitutive hypermutation;  
KM target sequence diversification; terminal deoxynucleotidyl transferase;  
KM Tdt; clonal expansion; selection; heavy chain variable region; VH;  
KM mutant; ds.  
XX  
XX Homo sapiens.  
OS Synthetic.  
OS  
XX  
XX WO200022111-A1.  
XX  
XX 20-APR-2000.  
PD  
XX  
XX 08-OCT-1999; 99WO-GB003358.  
PF  
XX  
XX 09-OCT-1998; 98GB-00022104.  
PR  
XX 19-JAN-1999; 99GB-00001141.  
PR  
XX 09-JUN-1999; 99GB-00013435.  
PR  
XX  
XX (MEDI-) MEDICAL RES COUNCIL.  
PA  
XX  
XX Sale JE, Neuberger MS, Cumbers SJ;  
PI  
XX  
XX WPI; 2000-317971/27.  
DR  
XX  
XX Lymphoid cell line preparation useful for producing gene products having  
PT desired activity, involves screening and selecting cells having ongoing  
PT target sequence diversification and higher mutation rates.  
PT  
XX  
XX Example 4; Fig 6; 69pp; English.  
PS  
XX  
XX The invention relates to a method of preparing a lymphoid cell line  
CC capable of capable of directed constitutive hypermutation of a target  
CC nucleic acid region. The method comprises screening a cell population for  
CC ongoing target sequence diversification and selecting a cell in which the  
CC rate of target nucleic acid mutation exceeds that of other nucleic acid  
CC mutation by a factor of 100 or more. The invention also relates to a  
CC method for preparing a gene product with a desired activity, comprising  
CC expressing a nucleic acid encoding the target gene operably linked to a  
CC sequence which directs hypermutation e.g., terminal deoxynucleotidyl  
CC transferase (Tdt), in the lymphoid cell line, and identifying a cell or  
CC cells which express a mutated gene product with the desired activity. One

CC or more clonal populations of the identified cells is established, and  
 CC cells with an improved activity of interest are selected. These steps may  
 CC be iteratively repeated until a gene product with a desired of activity  
 CC is obtained. The cell lines prepared according to the method of the  
 CC invention are used for directed constitutive hypermutation of a nucleic  
 CC acid region in the preparation of a gene product, preferably an enzyme or  
 CC an immunoglobulin (Ig) with a desired activity. In the exemplifications  
 CC of the invention, IgM-secreting Ramos cells were selected for use as they  
 CC undergo hypermutation during clonal expansion. This was determined on the  
 CC basis of the amount of diversity in the heavy chain variable region (VH).  
 CC Sequences AA52366-A52434 represent fragments of Ramos cell VH region DNA  
 CC containing mutations other than single nucleotide substitutions. The  
 CC number assigned to the mutation represents the position in the wild-type  
 CC VH DNA (AA52364) to which the first nucleotide in the mutant fragment  
 CC corresponds. Sequences AA52368-A52434 represent mutations that occur in  
 CC Ramos cells which express Tdt, and sequences AA52366-A52487 represent  
 CC mutations that occur in non-Tdt- expressing control Ramos cells  
 CC  
 SQ Sequence 15 BP; 3 A; 4 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 18 TCCCGCTCCCGCGG 32  
 |||||  
 Db 15 TCTGCTCCCGCGG 1

## RESULT 405

AA55130  
 ID AA55130 standard; DNA; 15 BP.

AC AA55130;

DT 12-JAN-2001 (first entry)

DE Allele specific primer #1 for detection of TNFR1 gene polymorphism.

XX TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;

KM cancer; apoptosis; bacterial infection; primer;

KW allele specific oligonucleotide; ASO; ss.

XX Homo sapiens.

PN W0200050436-A1.

PD 31-AUG-2000.

PF 23-FEB-2000; 2000WO-US004606.

PR 23-FEB-1999; 99US-0121314P.

XX (GENA-) GENASSANCE PHARM INC.

PA (SCHU/) NARBABALAN K.

PA (STEP/) STEPHENS J C.

XX (CHEW/) CHEW A.

PI Nandabalan K, Schulz VP, Stephens JC, Chew A;

XX WPI; 2000-543909/49.

XX polymucleotides comprising polymorphic variants of a reference sequence

PT for tumor necrosis factor receptor 1 (TNFR1), useful for studying the

PT biological function of TNFR1 and identifying drugs targeting the protein

XX for treating disorders.

PS Claim 14; Page 20; 79pp; English.

XX The present invention relates to polymorphic variants of the tumour

CC necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is

CC given in AA55102, AA55103 and AA55104. The polymorphisms were

CC identified by amplifying and sequencing regions of the gene. Twelve  
 CC polymorphic loci were discovered. Of these twelve polymorphisms, four can  
 CC cause a change in the TNFR1 protein. The present sequence is an allele  
 CC specific oligonucleotide (ASO) primer that may be used to detect a TNFR1  
 CC gene polymorphism. The TNFR1 polymorphisms may be useful for studying the  
 CC biological function of TNFR1 as well as for identifying drugs targeting  
 CC the protein for treatment of disorders related to its abnormal expression  
 CC or function such as tumours, apoptosis related disorders and bacterial  
 CC infection  
 CC  
 SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 832 CAGAACGACAGGT 846  
 |||||  
 Db 1 CAGATCCAGACAGGT 15

## RESULT 406

AAF48041/C  
 ID AAF48041 standard; DNA; 15 BP.

AC AAF48041;

DT 30-MAR-2001 (first entry)

DE IGFBP3 oligonucleotide #1461.

XX Antisense therapy; antiproliferative; antiinflammatory; antiposietic;

KM cystostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

KM skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;

KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KM growth factor mediated cell proliferation; ichthyosis; serorhinea; ruba;

KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KM hyperneovascular condition; hyperplasia; kidney disease;

XX Homo sapiens.

PN W0200078341-A1.

PD 28-DEC-2000.

PF 21-JUN-2000; 2000WO-AU000693.

PR 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

PA Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX ameliorating the effects of a disorder, e.g. psoriasis, by administering

PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

PT inhibits or reduces growth factor mediated cell proliferation and/or

XX inflammation.

XX Example 7; Page 53; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of

CC skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation, and

CC inflammation and/or other disorders. The present sequence is an

CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-

CC F45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 CC hyperneovascular condition such as a neovascular condition of the retina,  
 CC brain or skin, growth factor-mediated malignancies, other sclerotic  
 CC disease, kidney disease, hyperproliferation of the inside of blood  
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Qy Query Match 0.6%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1408 AAGGCTGTGGCTCC 1422

15 AAGGCTGTGAGCTCC 1

RESULT 407  
 AAF48044/c  
 ID AAF48044 standard; DNA; 15 BP.

XX AAF48044;

XX 30-MAR-2001 (first entry)

XX IGFBP3 oligonucleotide #1464.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
 XX skin disorder; insulin-like growth factor 1 receptor; IGF-1; ptyriasis;  
 XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;  
 XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 XX hyperneovascular condition; hyperplasia; kidney disease;  
 XX neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 XX inhibits or reduces growth factor mediated cell proliferation and/or  
 XX inflammation.

XX Example 7; Page 53; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of  
 XX skin disorders. The method comprises contacting the skin with an  
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 XX inhibiting or reducing growth factor mediated cell proliferation,  
 XX inflammation and/or other disorders. The present sequence is an  
 XX oligonucleotide which can be used to design the antisense  
 XX oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 XX P4516). The method is useful for ameliorating the effects of psoriasis,  
 XX ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,  
 XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 XX hyperneovascular condition such as a neovascular condition of the retina,  
 XX brain or skin, growth factor-mediated malignancies, other sclerotic  
 XX disease, kidney disease, hyperproliferation of the inside of blood

CC vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Qy Query Match 0.6%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 1405 CAGAGGCTGTGGAC 1419

15 CAGAGGCTGTGAGC 1

RESULT 408  
 AAF48436  
 ID AAF48436 standard; DNA; 15 BP.

XX AAF48436;

XX 30-MAR-2001 (first entry)

XX IGFBP3 oligonucleotide #1856.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
 XX skin disorder; insulin-like growth factor 1 receptor; IGF-1; ptyriasis;  
 XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;  
 XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 XX hyperneovascular condition; hyperplasia; kidney disease;  
 XX neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000MO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 XX inhibits or reduces growth factor mediated cell proliferation and/or  
 XX inflammation.

XX Example 7; Page 56; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of  
 XX skin disorders. The method comprises contacting the skin with an  
 XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
 XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 XX inhibiting or reducing growth factor mediated cell proliferation,  
 XX inflammation and/or other disorders. The present sequence is an  
 XX oligonucleotide which can be used to design the antisense  
 XX oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 XX P4516). The method is useful for ameliorating the effects of psoriasis,  
 XX ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,  
 XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 XX hyperneovascular condition such as a neovascular condition of the retina,  
 XX brain or skin, growth factor-mediated malignancies, other sclerotic  
 XX disease, kidney disease, hyperproliferation of the inside of blood  
 XX vessels or any other hyperplasia

XX Sequence 15 BP; 3 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

```

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy          910 AGCTATTTCGTGG 924
Db          1 AGCTATTTCGTAGG 15

RESULT 409
AAF48045/c
ID AAF48045 standard; DNA; 15 BP.
XX
AC AAF48045;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1465.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PE 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 53; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy          1404 ACAGAGGCTGTGG 1418
Db          15 ACAGAGGCTGTGAG 1

RESULT 410
AAF48043/c
ID AAF48043 standard; DNA; 15 BP.
XX
AC AAF48043;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1463.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PE 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
XX Example 7; Page 53; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

RESULT 411
AAFS0836
ID AAF50836 standard; DNA; 15 BP.
XX
AC AAF50836;
XX
DE 30-MAR-2001 (first entry)
XX
DE IGF-1 oligonucleotide #1796.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 72; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 974 TGTCCCTCACCATGG 988
DB 1 TGACCTCACCATGG 15

```

```

XX
AC AAF48568;
XX
DE 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1988.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 57; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, seborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 4 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 2009 CCAAGTCCCTGGATG 2023
DB 15 CCAAGTCCCTGGATG 1

```

```

RESULT 412
AAFA8568/c
ID AAF48568 standard; DNA; 15 BP.

```

```

RESULT 413
AAFA5301
ID AAF45301 standard; DNA; 15 BP.
XX
AC AAF45301;
XX
DE 30-MAR-2001 (first entry)

```

XX IGFBP2 oligonucleotide #140.  
DE Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;  
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;  
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
KM hyperneovascular condition; hyperplasia; kidney disease;  
KM neovascular condition of the retina; ss.  
XX Homo sapiens.  
OS WO200078341-A1.  
XX 26-DEC-2000.  
XX 21-JUN-2000; 2000WO-AU000693.  
XX 21-JUN-1999; 99US-0140345P.  
XX (MURD-) MURDOCH CHILDRENS RES INST.  
PA Wright CJ, Werther GA, Edmondson SR;  
XX WPI; 2001-041421/05.  
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
PT inhibits or reduces growth factor mediated cell proliferation and/or  
PT inflammation.  
XX Example 6; Page 35; 201pp; English.  
XX The present invention relates to a method for ameliorating the effects of  
CC skin disorders. The method comprises contacting the skin with an  
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
CC inhibiting or reducing growth factor mediated cell proliferation,  
CC inflammation and/or other disorders. The present sequence is an  
CC oligonucleotide which can be used to design the antisense  
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
CC F45161). The method is useful for ameliorating the effects of psoriasis,  
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,  
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
CC hyperneovascular condition such as a neovascular condition of the retina,  
CC brain or skin, growth factor-mediated malignancies, other sclerotic  
CC disease, kidney disease, hyperproliferation of the inside of blood  
CC vessels or any other hyperplasia  
XX Sequence 15 BP; 0 A; 8 C; 5 G; 2 T; 0 U; 0 Other;  
SQ  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 149 CCGCGCTGCCACTGC 163  
DB 1 CCGCGCTGCCACTGC 15  
RESULT 414  
AAF48042/c  
ID AAF48042 standard; DNA; 15 BP.  
XX AAF48042;  
XX 30-MAR-2001 (first entry)  
XX IGFBP3 oligonucleotide #1462.  
DE Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
KM

KM cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;  
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;  
KM keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
KM hyperneovascular condition; hyperplasia; kidney disease;  
KM neovascular condition of the retina; ss.  
XX Homo sapiens.  
OS WO200078341-A1.  
XX 26-DEC-2000.  
XX 21-JUN-2000; 2000WO-AU000693.  
XX 21-JUN-1999; 99US-0140345P.  
XX (MURD-) MURDOCH CHILDRENS RES INST.  
PA Wright CJ, Werther GA, Edmondson SR;  
XX WPI; 2001-041421/05.  
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
PT inhibits or reduces growth factor mediated cell proliferation and/or  
PT inflammation.  
XX Example 7; Page 53; 201pp; English.  
XX The present invention relates to a method for ameliorating the effects of  
CC skin disorders. The method comprises contacting the skin with an  
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
CC inhibiting or reducing growth factor mediated cell proliferation,  
CC inflammation and/or other disorders. The present sequence is an  
CC oligonucleotide which can be used to design the antisense  
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
CC F45161). The method is useful for ameliorating the effects of psoriasis,  
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,  
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
CC hyperneovascular condition such as a neovascular condition of the retina,  
CC brain or skin, growth factor-mediated malignancies, other sclerotic  
CC disease, kidney disease, hyperproliferation of the inside of blood  
CC vessels or any other hyperplasia  
XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1407 GAAGGCTGGGCTC 1421  
DB 15 GAAGGCTGGGCTC 1  
RESULT 415  
AAF49257/c  
ID AAF49257 standard; DNA; 15 BP.  
XX AAF49257;  
XX 30-MAR-2001 (first entry)  
XX IGF-1 oligonucleotide #217.  
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
KM cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;  
KM skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;  
KM IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
KM growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;  
KM

KM		keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KM		hyperneovascular condition; hyperplasia; kidney disease;
KM		neovascular condition of the retina; ss.
XX		
OS	Homo sapiens.	
XX		
PN	WO20078341-A1.	
PD	28-DEC-2000.	
XX		
PF	21-JUN-2000, 2000WO-AU00693.	
XX		
PR	21-JUN-1999; 99US-0140345P.	
XX		
PA	(MURDOCH CHILDRENS RES INST.	
XX		
PI	Wright CJ, Werther GA, Edmondson SR;	
DR	WPI; 2001-041421/05.	
XX		
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antiseptic nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.	
PT		
XX		
PS	Example 8; Page 62; 201pp; English.	
XX		
CC	The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antiseptic oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, CC inflammation and/or other disorders. The present sequence is an CC oligonucleotide which can be used to design the antiseptic CC oligonucleotides of the present invention (see AAF45151 and AAF45153-P4161). The method is useful for ameliorating the effects of psoriasis, CC lichenyosia, pityriasis, rubra, pilaris, seborrhea, keloids, keratosis, CC neoplasm, scleroderma, wart, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, CC brain or skin, growth factor-mediated malignancies, other sclerotic CC disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia	
XX		
SQ	Sequence 15 BP, 3 A; 7 C; 1 G; 4 T; 0 U; 0 Other;	
XX		
Query Match	0.6%; Score 13.4; DB 1; Length 15;	
Best Local Similarity	93.3%; Pred. No. 2e+02;	
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0.	
OY	1366 CAGCGTGTGGAGCTA 1380	
DB	15 CAGGATGTGGAGGTA 1	
RESULT 416		
AAF50837		
ID	AAF50837 standard; DNA, 15 BP.	
XX		
AC	AAF50837;	
XX		
DT	30-MAR-2001 (first entry)	
DE	IGF-I oligonucleotide #1797.	
XX		
KX	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; vitruclide; ophthalmological; keloid; skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; seborrhea; rubra; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.	
XX		

OS Homo sapiens.  
EN WO20078341-A1.  
PD 28-DEC-2000.  
PE 21-JUN-2000; 2000WO-AU000693.  
PR 21-JUN-1999; 99US-0140345P.  
PA (MURD-) MURDOCH CHILDRENS RES INST.  
PI Wraight CJ, Werther GA, Edmondson SR;  
DR WPI; 2001-041421/05.  
XX  
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
PT inhibits or reduces growth factor mediated cell proliferation and/or  
PT inflammation.

Example 8; Page 72; 201pp; English.

The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-P45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, pityriasis, rubea, pilaris, seborrhoea, keloids, keratosis, neoplasias, scleroderma, wart, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query March 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 975 GTCCCTCACCATGCGT 989  
| | | | |  
1 GACCTTCACCATGCGT 15

RESULT 417  
AAF50835  
ID AAF50835 standard; DNA; 15 BP.  
XX  
XX AAF50835;  
XX  
XX 30-MAR-2001 (first entry)  
XX  
XX IGF-I oligonucleotide #1795.  
XX  
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
XX cytostatic; dermatological; cardiant; virocidic; ophthalmological; keloid;  
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;  
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
XX growth factor mediated cell proliferation; ichthyosis; seborrhoea; rubea;  
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
XX hyperneovascular condition; hyperplasia; kidney disease;  
XX neovascular condition of the retina; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO20078341-A1.  
XX



PD 28-DEC-2000.  
 XX  
 XX 21-JUN-2000; 2000MO-AU000693.  
 XX  
 PR 21-JUN-1999; 99US-0140345P.  
 XX  
 PA (MURD-) MURDOCH CHILDRENS RES INST.  
 XX  
 PI Wraight CJ, Werther GA, Edmondson SR;  
 XX WPI; 2001-041421/05.  
 DR  
 XX  
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 PT inhibits or reduces growth factor mediated cell proliferation and/or  
 PT inflammation.  
 XX  
 PS Example 8; Page 72; 201pp; English.  
 XX  
 CC The present invention relates to a method for ameliorating the effects of  
 CC skin disorders. The method comprises contacting the skin with an  
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1  
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 CC inhibiting or reducing growth factor mediated cell proliferation,  
 CC inflammation and/or other disorders. The present sequence is an  
 CC oligonucleotide which can be used to design the antisense  
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 CC F5161). The method is useful for ameliorating the effects of psoriasis,  
 CC ichthyosis, pityriasis, rubra, pilaris, seborrhoea, keloids, keratosis,  
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 CC hyperneovascular condition such as a neovascular condition of the retina,  
 CC brain or skin, growth factor-mediated malignancies, other sclerotic  
 CC disease, kidney disease, hyperproliferation of the inside of blood  
 CC vessels or any other hyperplasia  
 XX  
 SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;  
 QY  
 Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Db 973 GTGTCCCTCACCCAG 987  
 1 GTGACCTCACCCAG 15  
 RESULT 418  
 AAF70395  
 ID AAF70395 standard; DNA; 15 BP.  
 XX  
 AC AAF70395;  
 XX  
 DT 20-APR-2001 (first entry)  
 XX  
 DE Human DRD2 allele specific oligonucleotide primer SEQ ID NO:138.  
 XX  
 KW Human; dopamine receptor D2; DRD2; polymorphism; allele specific;  
 KW drug target isogene; detection; single nucleotide polymorphism; SNP;  
 KW genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;  
 KW probe; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200105832-A1.  
 XX  
 PD 25-JAN-2001.  
 XX  
 PF 19-JUL-2000; 2000MO-US019644.  
 XX  
 PR 19-JUL-1999; 99US-014493P.  
 XX  
 PA (GENA-) GENAISSANCE PHARM INC.  
 XX

PI Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;  
 XX WPI; 2001-091967/10.  
 DR  
 XX  
 PT Polynucleotides comprising single nucleotide polymorphisms in the human  
 PT dopamine receptor D2, useful for detecting mutations associated with,  
 PT e.g. schizophrenia, Parkinson's and myoclonus dystonia.  
 XX  
 XX Claim 15; Page 24; 135pp; English.  
 XX  
 CC The present invention describes polynucleotides comprising single  
 CC nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).  
 CC The polynucleotides may be used in assays to detect and characterise  
 CC polymorphisms in DRD2 that affect its expression and activity and are  
 CC involved in disorders such as schizophrenia, Parkinson's and myoclonus  
 CC dystonia (MD). This information would be useful for studying the  
 CC biological function of DRD2 as well as in identifying drugs targeting  
 CC this protein for the treatment of disorders related to its abnormal  
 CC expression or function. Polymorphisms in the DRD2 gene affect the  
 CC expression of active and functional polypeptides. Therefore it is  
 CC advantageous to detect polymorphisms in the DRD2 gene and how those  
 CC polymorphisms are combined in different copies of the gene. AAF70261 to  
 CC AAF70308 represent human DRD2 allele specific oligonucleotide probes, and  
 CC AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide  
 CC primers which are used in the detection of DRD2 polymorphisms. AAF70405  
 CC to AAF70452 represent oligonucleotide primers for the detection of human  
 CC DRD2 polymorphisms which are given in the exemplification of the present  
 CC invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2  
 CC gene which are used in examples from the present invention  
 XX  
 SQ Sequence 15 BP; 3 A; 8 C; 4 G; 0 T; 0 U; 0 Other;  
 QY  
 Query Match 0.6%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Db 1662 GTACCAAGCCACCGG 1676  
 1 GCACCAAGCCACCGG 15  
 RESULT 419  
 ABR96650/C  
 ID ABR96650 standard; DNA; 15 BP.  
 XX  
 AC ABR96650;  
 XX  
 DT 24-SEP-2002 (first entry)  
 XX  
 DE Interleukin-3 (IL-3) allele specific oligonucleotide primer #1.  
 XX  
 KW Interleukin 3; colony-stimulating factor; IL3; transgenic animal;  
 KW IL3 isogene; central nervous system disorder; multiple sclerosis;  
 KW Alzheimer's disease; Parkinson's disease; CNS injury; immune disorder;  
 KW inflammatory disorder; allele specific oligonucleotide; ASO; PCR; primer;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200244410-A1.  
 XX  
 PD 06-JUN-2002.  
 XX  
 PF 28-NOV-2000; 2000MO-US032381.  
 XX  
 PR 28-NOV-2000; 2000MO-US032381.  
 XX  
 PA (GENA-) GENAISSANCE PHARM INC.  
 XX  
 PI Chew A, Denton RR, Nandabalan K, Stephens JC;  
 XX WPI; 2002-519590/55.  
 DR  
 XX



PT Novel isolated polynucleotide comprising a sequence which is a  
PT polymorphic variant for a reference sequence for interleukin 3 gene  
PT useful for studying the expression and biological function of the  
PT protein.  
PS  
XX Claim 11, Page 16, 62pp; English.  
CC The invention describes an isolated polynucleotide (1) comprising a  
CC sequence which is a polymorphic variant for a reference sequence for  
CC interleukin 3 (colony-stimulating factor) (IL3) gene or its fragment. (1)  
CC is useful for studying the expression and biological function of IL3, as  
CC well as in developing drugs targeting the IL3 protein. A transgenic  
CC animal is useful for studying expression of IL3 isogenes in vivo, for in  
CC vivo screening and testing of drugs targeted against IL3 protein, and for  
CC testing the efficacy of therapeutic agents and compounds for diseases of  
CC the central nervous system e.g. multiple sclerosis, Alzheimer's disease,  
CC Parkinson's disease and CNS injury, and immune or inflammatory disorders.  
CC The method described in the invention is useful in developing diagnostic  
CC tests and therapeutic treatments for diseases of the central nervous  
CC system and immune or inflammatory disorders. This sequence represents an  
CC allele specific oligonucleotide primer for detecting polymorphisms in the  
CC IL-3 gene  
XX  
SQ Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 339 CCGAGAGCTGATCTC 353  
Db 15 CCGAGAGCTGAGCTC 1  
RESULT 420  
ABA91622  
ID ABA91622 standard; DNA; 15 BP.  
XX  
AC ABA91622;  
XX  
DT 23-APR-2002 (first entry)  
XX  
DE Primer used in isometric primer extension reaction.  
XX  
KM Isometric primer extension; nucleic acid detection; rat; primer; ss.  
XX  
OS Ratus SP.  
XX  
PN EP1162278-A2.  
XX  
PD 12-DEC-2001.  
XX  
PF 06-JUN-2001; 2001EP-00304958.  
XX  
PR 08-JUN-2000; 2000US-020987P.  
PR 23-MAY-2001; 2001US-00862417.  
XX  
PA (WANG/) WANG X B.  
PA (MORI/) MORISAWA S.  
PI Wang XB;  
XX  
DR WPI; 2002-149491/20.  
XX  
PT Detecting or quantifying a specific nucleic acid in a sample by  
XX hybridizing primers to the target nucleic acid, extending the primers and  
XX detecting extended primer by label detection or mass spectrometry.  
PS Example 1; Page 6; 10pp; English.  
XX  
CC The present sequence is that of a primer that corresponds to a rat brain  
CC specific cDNA. It was used in an example to demonstrate an isometric  
CC primer extension method of the invention. The method involves carrying

CC out a primer extension reaction in the absence of a free nucleotide so  
CC that the primer extension reaction is stopped where the absent nucleotide  
CC would have been inserted. As the amount of incorporation of a labelled  
CC nucleotide on the primer extended product is detected, the amount of  
CC target RNA or DNA in the sample is measured. The method provides a  
CC faster, cheaper, more sensitive assay which produces less biohazard or  
CC radioisotope waste than northern analysis and RNase protection assays  
XX  
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1322 GTGGAACTTGTCA 1336  
Db 1 GTGGAACTTGTCA 15  
RESULT 421  
ABX00932  
ID ABX00932 standard; RNA; 15 BP.  
XX  
AC ABX00932;  
XX  
DT 23-DEC-2002 (first entry)  
XX  
DE Hepatitis C virus substrate #714 for HCV hammerhead ribozyme #714.  
XX  
KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;  
KM HCV ribozyme; HCV expression; HCV replication; cirrhosis; virology;  
KM liver failure; hepatocellular carcinoma; HCV infection; drug therapy;  
KM type I interferon; interferon alpha; interferon beta; cytostatic;  
KM interferon gamma; consensus interferon; hepatotropic; antiinflammatory;  
KM substrate; hammerhead ribozyme; HH ribozyme; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN US2002082225-A1.  
XX  
PD 27-JUN-2002.  
XX  
PF 23-MAR-1999; 99US-00274553.  
XX  
PR 23-MAR-1999; 99US-00274553.  
XX  
PA (BLATT/) BLATT L.  
PA (MCSW/) MCSWIGEN J A.  
PA (ROBE/) ROBERTS B.  
PA (PAVCO/) PAVCO P A.  
PA (MACE/) MACEJACK D.  
XX  
PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;  
XX  
DR WPI; 2002-617759/66.  
XX  
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral  
PT replication and are useful to treat hepatitis C virus infections and  
PT cirrhosis, liver failure or hepatocellular carcinoma.  
PS Claim 1; Page 42; 80pp; English.  
XX  
CC The present invention relates to enzymatic nucleic acids which  
CC specifically cleave RNA derived from Hepatitis C virus (HCV). The  
CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin  
CC (HP) motif where the binding arms comprise sequences complementary to one  
CC of the substrate sequences defined in the specification. The HCV  
CC ribozymes are useful for modulating the expression and/or replication of  
CC HCV. They can be used to treat cirrhosis, liver failure and/or  
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
CC a condition associated with HCV infection in conjunction with one or more  
CC other drug therapies, particularly type I interferon, especially  
CC interferon alpha, beta or gamma or consensus interferon. The present

CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:  
CC Some of the sequence data for this patent did not form part of the  
CC printed specification. The complete sequence data for this patent was  
CC obtained in electronic format directly from the USPTO web site at  
CC [seqdata.uspto.gov/seispatIDEntry.html](http://seqdata.uspto.gov/seispatIDEntry.html)  
XX  
SQ Sequence 15 BP; 0 A; 6 C; 1 G; 0 T; 8 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 40.0%; Pred. No. 2e+02;  
Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;  
QY 1010 TGCTTTTCCTTCG 1024  
Db :||:||||:|  
1 UGCUUUCUUCUCC 15  
RESULT 422  
AAB15073/C  
ID AAB15073 standard; DNA; 16 BP.  
XX  
AC AAB15073;  
XX  
DT 01-NOV-2001 (first entry)  
XX  
DE 5' PCR primer with parsing bases CTGA.  
XX  
KM Fatty lesion development; atherosclerosis; Alzheimer's disease;  
KM nervous system disorder; Parkinson's disease; immune system disorder;  
KM ischaemia; lymphopoenia; leukocyte adhesion deficiency syndrome;  
KM haemoglobinuria; anaemia; hyperproliferative disorder; Gaucher's disease;  
KM coagulation disorder; blood platelet disorder; autoimmune disorder;  
KM dermatitis; herpes simplex; Addison's disease; rheumatoid arthritis;  
KM Grave's disease; gene therapy; arteriosclerotic; immunostimulant;  
KM cardiovascular; antiviral; PCR Primer; ss.  
XX  
OS Unidentified.  
XX  
PN WO200154651-A2.  
XX  
PD 02-AUG-2001.  
XX  
PF 25-JAN-2001; 2001WO-US002439.  
XX  
PR 25-JAN-2000; 2000US-0177963P.  
XX  
PA (DIGI-) DIGITAL GENE TECHNOLOGIES INC.  
XX  
PI Leonardi A, Sartani A, Glaes JR, Sutcliffe JG, Hasel KM;  
XX  
DR WPI; 2001-514526/56.  
XX  
PT New polynucleotides regulated by fatty lesion development and their  
PT encoded polypeptides, useful for preventing, treating or ameliorating  
PT atherosclerosis, as well as for immune or hyperproliferative disorders.  
XX  
PS Disclosure; Page 162; 189pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid regulated by  
CC fatty lesion development, which comprises any of 55 polynucleotide  
CC sequences from *Oryzotagus cuniculus*. The polynucleotide, polypeptide or  
CC antibody is useful for preventing, treating, modulating or ameliorating a  
CC medical condition, particularly atherosclerosis. The invention is used as  
CC a marker or detector of nervous system disorder or disease (e.g.  
CC Parkinson's disease, Alzheimer's disease, ischaemia, dementia). The  
CC invention may also be useful for treating deficiencies or disorders of  
CC the immune system (e.g. lymphopoenia, leukocyte adhesion deficiency  
CC syndrome or haemoglobinuria, anaemia), hyperproliferative disorders  
CC (e.g. Gaucher's disease), infectious disease (e.g. herpes simplex),  
CC coagulation disorders, blood platelet disorders and autoimmune disorders  
CC (Addison's disease, rheumatoid arthritis, dermatitis, Grave's disease).  
CC The polynucleotide sequence is also used in gene therapy. The present  
CC sequence is a 5' PCR primer with parsing bases CTGA. This primer is used

CC in the invention  
XX  
SQ Sequence 16 BP; 3 A; 4 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 2.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 658 TCAGCCGATACCTTC 672  
Db :||:||||:|  
16 TCAGCCGATACCTTC 2  
RESULT 423  
ABA89678/C  
ID ABA89678 standard; DNA; 16 BP.  
XX  
AC ABA89678;  
XX  
DT 12-FEB-2002 (first entry)  
XX  
DE Serial analysis of ribosomal DNA tag #37.  
XX  
KM Serial analysis of ribosomal DNA; SARD; genetic diversity;  
KM geochemical exploration; agriculture; bioremediation; forensic science;  
KM environmental analysis; parasite detection; virus detection; ss.  
XX  
OS Unidentified.  
XX  
PN WO200177392-A2.  
XX  
PD 18-OCT-2001.  
XX  
PF 10-APR-2001; 2001WO-US011609.  
XX  
PR 10-APR-2000; 2000US-0196063P.  
PR 11-APR-2000; 2000US-0196258P.  
XX  
PA (ASHB/) ASHBY M.  
XX  
PI Ashby M;  
XX  
DR WPI; 2002-010926/01.  
XX  
PT Determining genetic diversity of population by analyzing a specific  
PT polymorphic region characteristic of particular genome in population of  
PT interest, useful for locating mineral deposits or petroleum reserves.  
XX  
PS Example 3; Fig 15; 83pp; English.  
XX  
CC The present invention relates to a method of determining the genetic  
CC diversity of a population, involving amplifying a genome subregion with a  
CC polymorphic site, cleaving amplified fragment close to the polymorphic  
CC site, immobilising the amplified fragment, splitting into two pools,  
CC adding a linker to each pool, digesting the immobilised product to form  
CC tags that are ligated to form concatemers and sequencing. The method is known as  
CC serial analysis of ribosomal DNA (SARD). This can be used to determine the  
CC genetic diversity of a population including microbial, viral or immune  
CC cell populations. The microbial population whose genetic diversity can be  
CC determined is from a sample associated with a site for petroleum or  
CC natural gas exploration, i.e., at a site of oil or gas reserves,  
CC associated with a site of mineral exploration, associated with a  
CC agricultural field, of patient sample suspected to have bacterial or  
CC fungal infection, associated with bioremediation site, or of an insect or  
CC parasite. The methods have application in fields of geochemical  
CC exploration, agriculture, bioremediation, environmental analysis,  
CC clinical microbiology, forensic science and medicine. The present  
CC sequence is an oligonucleotide described in the exemplification of the  
CC invention  
XX  
SQ Sequence 16 BP; 1 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query	Match	0.6%	Score 13.4	DB 1	Length 16
Best Local Similarity	93.3%		Pred. No. 2.2e+02		
Matches 14	Conservative 0	Mismatches 1	Indels 0	Gaps 0	
Qy	297	AGCTGCGGCACTGGG 311			
Db	16	AGCTGCGGCACTGGG 2			
RESULT 424					
ABA89770/C					
ID	ABA89770	standard; DNA; 16 BP.			
XX	ABA89770;				
AC					
XX	12-FEB-2002	(first entry)			
DT					
XX					
DE	Serial analysis of ribosomal DNA tag #129.				
XX					
KW	Serial analysis of ribosomal DNA; SARD; genetic diversity;				
KM	geochemical exploration; agriculture; bioremediation; forensic science;				
XX	environmental analysis; parasite detection; virus detection; ss.				
OS	Unidentified.				
XX					
PN	MO200177392-A2.				
XX					
PD	18-OCT-2001.				
XX					
PF	10-APR-2001; 2001WO-US011609.				
XX					
PR	10-APR-2000; 2000US-0196063P.				
PR	11-APR-2000; 2000US-0196258P.				
XX					
PA	(ASHB/) ASHBY M.				
XX					
P1	Ashby M;				
DR	WPI; 2002-010926/01.				
PT	Determining genetic diversity of population by analyzing a specific				
PT	polymorphic region characteristic of particular genome in population of				
XX	interest, useful for locating mineral deposits or petroleum reserves.				
PS	Example 3; Fig 16; 83pp; English.				
XX					
CC	The present invention relates to a method of determining the genetic				
CC	diversity of a population, involving amplifying a genome subregion with a				
CC	polymorphic site, cleaving amplified fragment close to the polymorphic				
CC	site, immobilising the amplified fragment, splitting into two pools,				
CC	adding a linker to each pool, digesting the immobilised product to form				
CC	tags that are ligated to form digests, and amplifying, cleaving and				
CC	ligating to form concatemers and sequencing. The method is known as				
CC	serial analysis of ribosomal DNA (SARD). This can be used to determine the				
CC	genetic diversity of a population including microbial, viral or immune				
CC	cell populations. The microbial population whose genetic diversity can be				
CC	determined is from a sample associated with a site for petroleum or				
CC	natural gas exploration, i.e., at a site of oil or gas reserves,				
CC	associated with a site of mineral exploration, associated with a				
CC	agricultural field, of patient sample suspected to have bacterial or				
CC	fungal infection, associated with bioremediation site, or of an insect or				
CC	parasite. The methods have application in fields of geochemical,				
CC	exploration, agriculture, bioremediation, environmental analysis,				
CC	clinical microbiology, forensic science and medicine. The present				
CC	invention is an oligonucleotide described in the exemplification of the				
XX					
XX					
SO	Sequence 16 BP; 1 A; 8 C; 5 G; 2 T; 0 U; 0 Other;				
Query Match	0.6%	Score 13.4	DB 1	Length 16	
Best Local Similarity	93.3%	Pred. No. 2.2e+02			
Matches 14	Conservative 0	Mismatches 1	Indels 0	Gaps 0	

QY	297	AGCTGCGGCACTGGG	311
DB	16	AGCTGCGGCACTGGG	2
RESULT 425			
ID	ABA89672/c		
XX	ABA89672 standard; DNA; 16 BP.		
AC	ABA89672;		
XX			
DT	12-FEB-2002 (first entry)		
XX			
DE	Serial analysis of ribosomal DNA tag #31.		
XX			
KW	Serial analysis of ribosomal DNA; SARD; genetic diversity;		
XX	geochemical exploration; agriculture; bioremediation; forensic science;		
KW	environmental analysis; parasite detection; virus detection; ss.		
XX			
OS	Unidentified.		
XX			
PN	WO200177392-A2.		
XX			
PD	18-OCT-2001.		
XX			
PF	10-APR-2001; 2001WO-US011609.		
XX			
PR	10-APR-2000; 2000US-0196063P.		
XX			
PR	11-APR-2000; 2000US-0196258P.		
XX			
PA	(ASHB/) ASHBY M.		
XX			
PI	Ashby M;		
XX			
DR	WPI; 2002-010926/01.		
PT	Determining genetic diversity of population by analyzing a specific		
PT	polymorphic region characteristic of particular genome in population of		
PT	interest, useful for locating mineral deposits or petroleum reserves.		
XX			
XX	Example 3; Fig 15; 83bp; English.		
XX			
XX	The present invention relates to a method of determining the genetic		
CC	diversity of a population, involving amplifying a genome subregion with a		
CC	polymorphic site, cleaving amplified fragment close to the polymorphic		
CC	site, immobilising the amplified fragment, splitting into two pools,		
CC	adding a linker to each pool, digesting the immobilised product to form		
CC	tags that are ligated to form digests, and amplifying, cleaving and		
CC	ligating to form concatemers and sequencing. The method is known as		
CC	serial analysis of ribosomal DNA (SARD). This can be used to determine the		
CC	genetic diversity of a population including microbial, viral or immune		
CC	cell populations. The microbial population whose genetic diversity can be		
CC	determined is from a sample associated with a site for petroleum or		
CC	natural gas exploration, i.e., at a site of oil or gas reserves,		
CC	associated with a site of mineral exploration, associated with a		
CC	agricultural field, of patient sample suspected to have bacterial or		
CC	fungal infection, associated with bioremediation site, or of an insect or		
CC	parasite. The methods have application in fields of geochemical		
CC	exploration, agriculture, bioremediation, environmental analysis,		
CC	clinical microbiology, forensic science and medicine. The present		
CC	invention is an oligonucleotide described in the exemplification of the		
XX			
XX			
SO	Sequence 16 BP; 1 A; 9 C; 4 G; 2 T; 0 U; 0 Other;		
QY	Query Match	0.64; Score 13.4; DB 1; Length 16;	
DB	Best Local Similarity	93.3%; Pred. No. 2.2e+02;	
DB	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	297	AGCTGCGGCACTGGG	311
DB	16	AGCTGCGGCACTGGG	2



```

PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpelsky A, Ksich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Wolf T;
XX
XX WPI, 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407bp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
XX Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 60.0%; Pred. No. 2.3e+02;
XX Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
XX
XX 569 TCCTGTCCTGTCGTCG 583
XX 2 UCCUGUCUCGUGCG 16
XX
XX
XX RESULT 428
XX AAT53480
XX ID AAT53480 standard; RNA; 17 BP.
XX
XX AAT53480;
XX
XX 25-MAR-2003 (revised)
XX 27-MAR-1997 (first entry)
XX
XX Rat ICAM hammerhead ribozyme target sequence (nt. position 735).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
XX intercellular adhesion molecule; rel A; tumour necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translocation; chronic myelogenous leukemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX
XX
XX Rattus rattus.
XX
XX AAT53565
XX ID AAT53565 standard; RNA; 17 BP.
XX
XX

```

```

XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95NO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.
XX 06-JUL-1994; 94US-00271280.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00300000.
XX 08-SEP-1994; 94US-00303039.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-0031497.
XX 03-OCT-1994; 94US-00316771.
XX 07-OCT-1994; 94US-00319492.
XX 11-OCT-1994; 94US-00321993.
XX 04-NOV-1994; 94US-00334847.
XX 10-NOV-1994; 94US-00337608.
XX 28-NOV-1994; 94US-00345516.
XX 16-DEC-1994; 94US-00357577.
XX 23-DEC-1994; 94US-00363233.
XX 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;
XX Grimm S, Karpelsky A, Ksich K, Matulic-Adamic J, Mcswiggen JA;
XX Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
XX Tracz D, Ueman N, Wincott FE, Wolf T;
XX
XX WPI, 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 201; 407bp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
XX Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 0.6%; Score 13.4; DB 1; Length 17;
XX Best Local Similarity 60.0%; Pred. No. 2.3e+02;
XX Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
XX
XX 569 TCCTGTCCTGTCGTCG 583
XX 2 UCCUGUCUCGUGCG 16
XX
XX
XX RESULT 429
XX AAT53565
XX ID AAT53565 standard; RNA; 17 BP.
XX
XX

```

XX	AA153565;
AC	
XX	
DT	25-MAR-2003 (rev15ed)
DT	27-MAR-1997 (first entry)
DE	Rat ICM hammerhead ribozyme target sequence (nt. position 1233).
XX	
KW	Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW	gene expression; downregulation; interleukin-5; IL-5; ICM-1;
KW	intercellular adhesion molecule; rel A; tumor necrosis factor;
KW	TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW	translocation; chronic myelogenous leukaemia; CML; cancer;
KW	Philadelphia chromosome; inflammation; autoimmune disease;
KW	atherosclerosis; myocardial infarction; stroke; restenosis;
KW	transplant rejection; rheumatoid arthritis; psoriasis;
KW	myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW	human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW	SB.
XX	
OS	Rattus rattus.
XX	
PN	WO9523225-A2.
XX	
PD	31-AUG-1995.
XX	
PF	23-FEB-1995; 95WO-1B000156.
XX	
PR	23-FEB-1994; 94US-00201109.
PR	29-MAR-1994; 94US-00218934.
PR	04-APR-1994; 94US-00227795.
PR	07-APR-1994; 94US-00224483.
PR	15-APR-1994; 94US-00227958.
PR	15-APR-1994; 94US-00228041.
PR	18-MAY-1994; 94US-00245736.
PR	06-JUL-1994; 94US-00271280.
PR	15-AUG-1994; 94US-00291932.
PR	16-AUG-1994; 94US-00291433.
PR	17-AUG-1994; 94US-00292620.
PR	19-AUG-1994; 94US-00293520.
PR	02-SEP-1994; 94US-00300000.
PR	08-SEP-1994; 94US-00303039.
PR	23-SEP-1994; 94US-00311486.
PR	23-SEP-1994; 94US-00311749.
PR	28-SEP-1994; 94US-00314397.
PR	03-OCT-1994; 94US-00316771.
PR	07-OCT-1994; 94US-00319492.
PR	11-OCT-1994; 94US-00321993.
PR	04-NOV-1994; 94US-00334847.
PR	10-NOV-1994; 94US-00337608.
PR	28-NOV-1994; 94US-00345516.
PR	16-DEC-1994; 94US-00357577.
PR	23-DEC-1994; 94US-00363233.
PR	30-JAN-1995; 95US-00380734.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PI	Stinchcomb DT, Chowitra B, Dierenzo A, Draper KG, Dudycz LW;
PI	Grimm S, Karpelisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI	Modak A, Pavco P, Belgien L, Sullivan SM, Sweedler D, Thompson JD;
PI	Tracz D, Usman N, Wincott FE, Wolff T;
XX	
DR	WPI, 1995-351090/45.
XX	
PT	Ribozymes having modified bases and methods for producing them - for use
PT	in inhibiting disease related genes.
XX	
PS	Claim 2; Page 202; 407pp; English.
XX	
CC	The present sequence represents a preferred target sequence for an
CC	enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICM-1 mRNA at the
CC	nucleotide base position indicated in the DE line. Regions of the mRNA
CC	that do not form secondary folding structures and that contain potential

CC	hammerhead and hairpin ribozyme cleavage sites were identified by
CC	computer analysis. Ribozymes directed against these mRNA sequences were
CC	designed and synthesised with modifications that improve their nuclease
CC	resistance. The ribozymes cleave the ICM-1 target sequences and thereby
CC	inhibit ICM-1 expression, making them useful for reducing transplant
CC	rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC	asthma and other inflammatory disorders. (updated on 25-MAR-2003 to
CC	correct PI field.)
SO	Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
Qy	Query Match 0.6%; Score 13.4; DB 1; Length 17;
Db	Best Local Similarity 60.0%; Pred. No. 2.3e+02; Indels 0; Gaps 0;
	Matches 9; Conservative 5; Mismatches 1;
	569 TCCTGTCCTCGTGG 583
	:   :   :    :
	2 UCUGAGUCUGUGC 16
RESULT 430	
AAT53574	
ID	AAT53574 standard; RNA; 17 BP.
AC	AAT53574;
XX	
DT	25-MAR-2003 (revised)
DT	27-MAR-1997 (first entry)
XX	
DE	Rat ICM hammerhead ribozyme target sequence (nt. position 1696).
XX	
KM	Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM	gene expression; downregulation; interleukin-5; IL-5; ICM-1;
KM	intercellular adhesion molecule; rel A; tumour necrosis factor;
KM	TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM	translocation; chronic myelogenous leukaemia; CML; cancer;
KM	Philadelphia chromosome; inflammation; autoimmune disease;
KM	atherosclerosis; myocardial infarction; stroke; restenosis;
KM	transplant rejection; rheumatoid arthritis; psoriasis;
KM	myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KM	human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM	89.
OS	Rattus rattus.
XX	
PN	W09523225-A2.
XX	
PD	31-AUG-1995.
XX	
PF	23-FEB-1995; 95WO-IB000156.
XX	
PR	23-FEB-1994; 94US-00201109.
PR	29-MAR-1994; 94US-00218934.
PR	04-APR-1994; 94US-00222795.
PR	07-APR-1994; 94US-00224483.
PR	15-APR-1994; 94US-00227958.
PR	15-APR-1994; 94US-00228041.
PR	18-MAY-1994; 94US-00245736.
PR	06-JUL-1994; 94US-00271280.
PR	15-AUG-1994; 94US-00291932.
PR	16-AUG-1994; 94US-00291433.
PR	17-AUG-1994; 94US-00292620.
PR	19-AUG-1994; 94US-00293520.
PR	02-SEP-1994; 94US-00300000.
PR	08-SEP-1994; 94US-00303039.
PR	23-SEP-1994; 94US-00311486.
PR	28-SEP-1994; 94US-00314397.
PR	07-OCT-1994; 94US-00316771.
PR	11-OCT-1994; 94US-00319492.
PR	04-NOV-1994; 94US-00321993.
PR	10-NOV-1994; 94US-00337608.

```

PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363323.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowitra B, Dizenzo A, Draper KG, Dudycz LM;
PI Grimm S, Karpetsky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 202; 407bp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.3e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
OY 569 TCCTGCTCCTGCTGCG 583
DB 2 UCCUGGUCUGGUCG 16
XX
RESULT 431
AAT53751
ID AAT53751 standard; RNA; 17 BP.
XX
AC AAT53751;
XX
DT 25-MAR-2003 (revised)
DT 03-APR-1997 (first entry)
XX
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 2596).
XX
KM Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KM intercellular adhesion molecule; rel A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukaemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM BB.
XX
XX Rattus rattus.
XX
OS AAT53494
PN WO9523225-A2.
XX
AC AAT53494;
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.

```

```

XX
XX 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363323.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowitra B, Dizenzo A, Draper KG, Dudycz LM;
PI Grimm S, Karpetsky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Belgelman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 204; 407bp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesized with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 2.3e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
OY 569 TCCTGCTCCTGCTGCG 583
DB 2 UCCUGGUCUGGUCG 16
XX
RESULT 432
AAT53494
ID AAT53494 standard; RNA; 17 BP.
XX
AC AAT53494;
XX
DT 25-MAR-2003 (revised)

```

DT 27-MAR-1997 (first entry)  
XX  
XX Rat ICAM hammerhead ribozyme target sequence (nt. position 792).  
XX  
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;  
KM intercellular adhesion molecule; rel A; tumour necrosis factor;  
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
KM translocation; chronic myelogenous leukaemia; CML; cancer;  
KM Philadelphia chromosome; inflammation; autoimmune disease;  
KM atherosclerosis; myocardial infarction; stroke; restenosis;  
KM transplant rejection; rheumatoid arthritis; psoriasis;  
KM myocardial ischemia; Kawasaki disease; septic shock; HIV;  
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
KM ss.  
XX  
XX Rattus rattus.  
OS  
XX MO9523225-A2.  
PN  
XX  
XX 31-AUG-1995.  
PD  
XX  
XX 23-FEB-1995; 95WO-IB000156.  
PF  
XX  
XX 23-FEB-1994; 94US-00201109.  
PR 29-MAR-1994; 94US-00218934.  
PR 04-APR-1994; 94US-00222795.  
PR 07-APR-1994; 94US-00224483.  
PR 15-APR-1994; 94US-00227958.  
PR 15-APR-1994; 94US-00228041.  
PR 18-MAY-1994; 94US-00245736.  
PR 06-JUL-1994; 94US-00271280.  
PR 15-AUG-1994; 94US-00291932.  
PR 16-AUG-1994; 94US-00291433.  
PR 17-AUG-1994; 94US-00292620.  
PR 19-AUG-1994; 94US-00293520.  
PR 02-SEP-1994; 94US-00300000.  
PR 08-SEP-1994; 94US-00303039.  
PR 23-SEP-1994; 94US-00311486.  
PR 23-SEP-1994; 94US-00311749.  
PR 28-SEP-1994; 94US-00311497.  
PR 03-OCT-1994; 94US-00316771.  
PR 07-OCT-1994; 94US-00319492.  
PR 11-OCT-1994; 94US-00321993.  
PR 04-NOV-1994; 94US-00334847.  
PR 10-NOV-1994; 94US-00337608.  
PR 28-NOV-1994; 94US-00345516.  
PR 16-DEC-1994; 94US-00357577.  
PR 23-DEC-1994; 94US-00363233.  
PR 30-JAN-1995; 95US-00380734.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Stinchcomb DT, Chowrira B, Draper KG, Dudycz LM;  
PI Grimm S, Karpelesky A, Kisich K, Matulic-Adamic J, Mewissen JA;  
PI Modak A, Parpo S, Belgelman L, Sullivan K, Swedler D, Thompson JD;  
PI Tracz D, Usman N, Wincott FE, Woolf T;  
XX  
XX WPI; 1995-351090/45.  
DR  
XX  
XX Ribozymes having modified bases and methods for producing them - for use  
PT in inhibiting disease related genes.  
PT  
XX  
XX  
XX Claim 2; Page 201; 407pp; English.  
XX  
XX The present sequence represents a preferred target sequence for an  
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the  
CC nucleotide base position indicated in the DB line. Regions of the mRNA  
CC that do not form secondary folding structures and that contain potential  
CC hammerhead and hairpin ribozyme cleavage sites were identified by  
CC computer analysis. Ribozymes directed against these mRNA sequences were  
CC designed and synthesised with modifications that improve their nuclease  
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby

CC inhibit ICAM-1 expression, making them useful for reducing transplant  
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,  
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to  
CC correct PI field.)  
XX  
SQ Sequence 17 BP; 0 A; 7 C; 5 G; 0 T; 5 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 60.0%; Pred. No. 2.3e+02;  
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;  
XX  
QY 569 TCCTGCGCCGCGCG 583  
DB 2 UCCUGGUCUGGUCG 16  
XX  
RESULT 433  
AAV20574  
ID AAV20574 standard; DNA, 17 BP.  
XX  
XX AAV20574;  
AC  
XX  
DT 02-JUL-1998 (first entry)  
XX  
DE Human BRCA1 probe #8.  
XX  
XX Breast cancer; ovarian cancer; mutation; classification; detection;  
KM tumour; diagnostic; prognostic; probe; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX MO9805677-A1.  
PN  
XX 12-FEB-1998.  
PD  
XX  
XX 04-AUG-1997; 97WO-US013654.  
PF  
XX  
XX 05-AUG-1996; 96US-00233184P.  
PR 05-AUG-1996; 96US-0023187P.  
PR 05-AUG-1996; 96US-0023223P.  
PR 06-AUG-1996; 96US-0022421P.  
XX  
XX (ONCO-) ONCORMED INC.  
PA  
XX  
XX Murphy PD, Allen AC, White MB, Olson SJ, Zeng B;  
PI  
XX WPI; 1998-159166/14.  
DR  
XX  
XX Detection of mutation(s) in the BRCA1 gene - by hybridisation with an  
PT allele-specific oligo:nucleotide or by amplification, useful particularly  
PT for breast or ovarian cancers.  
PT  
XX  
XX Example 10; Page 41; 62pp; English.  
XX  
XX AAV20567-V20574 are probes used in a method to detect mutations in the  
CC human BRCA1 gene. Such mutations are used for classifying a tumour for  
CC diagnostic and prognostic purposes or detecting a predisposition of  
CC higher susceptibility to breast and ovarian cancer in an individual. The  
CC methods can be used for reducing the high incidence and mortality  
CC associated with breast and ovarian cancer through the early detection of  
CC women at high risk. These women, once identified, can be targeted for  
CC more aggressive prevention programmes  
CC  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 454 GCCCTGGGCAAAA 468  
DB 1 GCCATGGGCAAAA 15



RESULT 434  
 AAA18459  
 ID AAA18459 standard; RNA, 17 BP.  
 XX  
 AC AAA18459;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Human TIE-2 substrate sequence SEQ ID NO:1685.  
 XX  
 KM Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KM integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KM hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;  
 KM ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KM dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KM age related macular degeneration; inflammation; neovascular glaucoma;  
 KM myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;  
 KM tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KM Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9950403-A2.  
 XX  
 PD 07-OCT-1999.  
 XX  
 PF 24-MAR-1999; 99WO-US006507.  
 XX  
 PR 27-MAR-1998; 98US-0079678P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mewlissen JA;  
 XX  
 DR WPI; 1999-591315/50.  
 XX  
 PT Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 XX  
 PS Claim 56; Page 96; 305pp; English.  
 XX  
 CC The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 SQ Sequence 17 BP; 1 A; 2 C; 5 G; 0 T; 9 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 46.7%; Pred. No. 2.3e+02;

Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;  
 Oy 909 GAGCTTATTCGTGG 923  
 DB 3 GGGCUCUHUUCUGUG 17  
 RESULT 435  
 AAA20642/C  
 ID AAA20642 standard; RNA, 17 BP.  
 XX  
 AC AAA20642;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3868.  
 XX  
 KM Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KM integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KM hammerhead ribozyme; angiogenic factor; cytoskeletal; antidiabetic;  
 KM ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KM dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KM age related macular degeneration; inflammation; neovascular glaucoma;  
 KM myopic degeneration; psoriasis; verruca vulgaris; angiodiroma;  
 KM tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KM Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9950403-A2.  
 XX  
 PD 07-OCT-1999.  
 XX  
 PF 24-MAR-1999; 99WO-US006507.  
 XX  
 PR 27-MAR-1998; 98US-0079678P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mewlissen JA;  
 XX  
 DR WPI; 1999-591315/50.  
 XX  
 PT Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 XX  
 PS Claim 55; Page 158; 305pp; English.  
 XX  
 CC The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiodiroma of tubercous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3

XX Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;  
 SQ Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 675 TCGAACTTACTCT 689  
 Db 17 TCGAACTGAACTCT 3

RESULT 436  
 AAA18460  
 ID AAA18460 standard; RNA, 17 BP.  
 XX  
 AC AAA18460;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Human TIR-2 substrate sequence SEQ ID NO:1686.  
 XX  
 KM Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KM integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KM hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
 KM ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KM dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KM age related macular degeneration; inflammation; neovascular glaucoma;  
 KM myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KM tubercus sclerosus; poc-wine stain; Sturge Weber syndrome;  
 KM Kippel-Trenauay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 KM  
 XX Homo sapiens.  
 OS  
 PN MO9950403-A2.  
 XX  
 PD 07-OCT-1999.  
 XX  
 PF 24-MAR-1999; 99WO-US006507.  
 XX  
 PR 27-MAR-1998; 98US-0079678P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 XX  
 DR WPI; 1999-591315/50.  
 XX  
 PT Novel ribozymes for modulating the synthesis, expression and/or stability  
 XX of an mRNA encoding an angiogenic factors.  
 XX  
 PS Claim 56; Page 96; 305pp; English.  
 XX  
 CC The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tubercus sclerosus, poc-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenauay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 SQ Sequence 17 BP; 3 A; 2 C; 4 G; 0 T; 8 U; 0 Other;  
 QY Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 46.7%; Pred. No. 2.3e+02;  
 Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;  
 QY 909 GAGCTATTCTGTG 923  
 Db 1 GUCCUAAUUCUGUG 15

RESULT 437  
 AAX5185  
 ID AAX5185 standard; DNA, 17 BP.  
 XX  
 AC AAX5185;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Multiple antisense oligonucleotide 6.  
 XX  
 KM Antisense oligonucleotide; multiple target; antisense treatment;  
 KM impaired respiration; inflammation; lung disease;  
 KM pulmonary vasoconstriction; inflammation; allergic rhinitis;  
 KM acute asthma; allergy; asthma; impeded respiration;  
 KM respiratory distress syndrome; pain; cystic fibrosis;  
 KM pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
 KM chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
 KM colon cancer; breast cancer; lung cancer; pancreatic cancer;  
 KM hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
 KM prostate cancer; ss.  
 KM  
 XX Synthetic.  
 OS  
 PN MO9913886-A1.  
 XX  
 PD 25-MAR-1999.  
 XX  
 PF 17-SEP-1998; 98WO-US019419.  
 XX  
 PR 17-SEP-1997; 97US-0059160P.  
 XX  
 PR 09-JUN-1998; 98US-00093972.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI Nyce JW;  
 XX  
 DR WPI; 1999-229400/19.  
 XX  
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary  
 XX vasoconstriction.  
 XX  
 PS Disclosure; Page 73; 120pp; English.  
 XX  
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)  
 CC directed against at least 2 mRNAs selected from target gene, coding and  
 CC non-coding regions of RNAs corresponding to target gene, gene initiation  
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-  
 CC end and the juxta-section between coding and non-coding regions and all  
 CC segments of RNAs encoding proteins associated with one or more diseases,  
 CC conditions or mixtures. The antisense oligonucleotides may be derived  
 CC from sequences AAX55272-74. These multiple target oligonucleotides  
 CC (specifically AAX55180-271) can be used for the antisense treatment of  
 CC diseases and conditions. Typical diseases and conditions are those  
 CC associated with impaired respiration and inflammation, including lung  
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,  
 CC acute asthma, allergy, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,  
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary  
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.  
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,  
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as  
 CC well as all types of cancers which may metastasize or have metastases  
 CC to the lungs, including breast and prostate cancer  
 XX

SO Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.64; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 565 CTGTCCTGGTCCG 579  
 Db 1 CTGTCCTGGTCCG 15

RESULT 438  
 AAA34632  
 ID AAA34632 standard; DNA; 17 BP.  
 XX  
 AC AAA34632;  
 XX  
 DT 26-JUL-2000 (first entry)  
 XX  
 DE Human adenosine receptor related polynucleotide SEQ ID NO:2121.  
 XX  
 KM Human; adenosine receptor; low adenosine antisense oligonucleotide;  
 KM phosphorothioate; impaired respiration; inhibitor; antiinflammatory;  
 KM allergic disease; bronchoconstriction; inhibitor; antiinflammatory;  
 KM antiallergic; antiaesthetic; cytostatic; analgesic; impaired airway;  
 KM lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;  
 KM respiratory distress syndrome; pain; cystic fibrosis; emphysema;  
 KM pulmonary hypertension; chronic obstructive pulmonary disease; COPD;  
 KM cancer; leukemia; lymphoma; carcinoma; metastasis; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200009525-A2.  
 XX  
 PD 24-FEB-2000.  
 XX  
 PF 03-AUG-1999; 99WO-US017712.  
 XX  
 PR 03-AUG-1998; 98US-0095212P.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI NYCE JW;  
 XX  
 DR WPI; 2000-205971/18.  
 XX  
 PT New antisense oligonucleotides useful for treating e.g. pulmonary  
 PT vasoconstriction, inflammation, allergies, asthma, hypertension, or  
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or  
 PT cancers.  
 XX  
 PS Disclosure; Page 555; 1343pp; English.  
 XX  
 CC The present invention describes a new composition comprising an antisense  
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets  
 CC nucleic acids involved in bronchoconstriction, allergies, and/or  
 CC inflammation. The ON can have antiinflammatory, antiallergic,  
 CC antiaesthetic, cytostatic and analgesic activities. The compositions are  
 CC useful for the treatment of diseases associated with inflammation,  
 CC impaired airways, including lung disease and diseases whose secondary  
 CC effects afflict the lungs of a subject. They can be used for treating  
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
 CC impaired respiration, respiratory distress syndrome, pain, cystic  
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,

CC carcinomas, and cancers which may metastasize to the lungs, including  
 CC breast and prostate cancer. The reduction of the adenosine content of the  
 CC ON reduces side effects. The A-containing ONs break down with the  
 CC release of deoxyadenosine which activates adenosine receptors causing  
 CC bronchoconstriction and inflammation. AAA3313 to AAA3512 represent the  
 CC nucleotide sequences given in the sequence listing from the present  
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA3233 to  
 CC AAA3392) are specifically claimed ONs from the present invention. N.B.  
 CC Sequences given in the disclosure of the present invention do not match  
 CC up with their corresponding SEQ ID NO: sequences given in the sequence  
 CC listing  
 XX

SO Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.64; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 565 CTGTCCTGGTCCG 579  
 Db 1 CTGTCCTGGTCCG 15

RESULT 439  
 AAF21457  
 ID AAF21457 standard; DNA; 17 BP.  
 XX  
 AC AAF21457;  
 XX  
 DT 14-MAR-2001 (first entry)  
 XX  
 DE Human multiple target antisense (MTR) oligonucleotide #3024.  
 XX  
 KM Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
 KM human; airway disorder; bronchoconstriction; lung inflammation;  
 KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
 KM immunosuppressive; antiaesthetic; analgesic; hypotensive; cytostatic;  
 KM respiratory obstruction; pulmonary obstruction; impaired respiration;  
 KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
 KM respiratory distress syndrome; pain; cystic fibrosis; allergies; rhinitis;  
 KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
 KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
 KM cancer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200062736-A2.  
 XX  
 PD 26-OCT-2000.  
 XX  
 PF 24-MAR-2000; 2000WO-US008020.  
 XX  
 PR 06-APR-1999; 99US-0127958P.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI NYCE J W.  
 XX  
 DR WPI; 2000-679539/66.  
 XX  
 PT Low adenosine (A) content antisense oligonucleotides which do not trigger  
 PT adenosine receptors during metabolism, useful e.g. for treating cancers  
 PT and respiratory obstructions.  
 XX  
 PS Disclosure; Page 296; 1592pp; English.  
 XX  
 CC The present invention describes low adenosine (A) content antisense  
 CC oligonucleotides and compositions (I) comprising them. In the antisense  
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

CC immunosuppressive, antiasthmatic, hypotensive and cyostatic activities.  
 CC The antisense oligonucleotides and (I) can be used to down-regulate the  
 CC expression and/or activity of target polypeptides associated with  
 CC lung/respiratory disorders and malignancies, such as stimulating and  
 CC activating peptide factors and transmitters, transcription factors,  
 CC immunoglobulins and antibodies, antibody receptors, cytokines and  
 CC chemokines, endogenously produced specific and non-specific enzymes,  
 CC binding proteins, adhesion molecules and their receptors, cytokine and  
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
 CC nervous system (CNS) and peripheral nervous and non-nervous system  
 CC receptors, CNS and peripheral nervous and non-nervous system peptide  
 CC transmitters, defensins, growth factors, vasoactive peptides and  
 CC receptors, binding proteins and malignancy associated proteins. The  
 CC antisense oligonucleotides may be used in this way to treat disorders  
 CC including respiratory obstruction (especially pulmonary obstruction  
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
 CC surfactant hypoproduction which are associated with a disease or  
 CC condition selected from pulmonary vasoconstriction, inflammation,  
 CC allergies, asthma, impeded respiration, respiratory distress syndrome  
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 CC fragments and antisense oligonucleotides used in the exemplification of  
 CC the present invention

SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. NO. 2.3e+02; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 565 CTGTTCTCGTCTCG 579

Db 1 CTGTCCTCGTCTCG 15

RESULT 440

AAF20754

ID AAF20754 standard; DNA; 17 BP.

XX AAF20754;

DT 14-MAR-2001 (first entry)

DE Human multiple target antisense (MTA) oligonucleotide #2321.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

KM human; airway disorder; bronchoconstriction; lung inflammation;

KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;

KM immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;

KM respiratory obstruction; pulmonary obstruction; impeded respiration;

KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;

KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

KM cancer; ss.

XX Homo sapiens.

PN WO200062736-A2.

XX 26-OCT-2000.

PF 24-MAR-2000; 2000WO-US008020.

PR 06-APR-1999; 99US-0127958P.

PA (UYEC-) UNIV EAST CAROLINA.

XX (UYEC/) NYCE J W.

PI NYce JW;

XX

DR WPI; 2000-679539/66.

XX

XX

PT Low adenosine (A) content antisense oligonucleotides which do not trigger

PT adenosine receptors during metabolism, useful e.g. for treating cancers

PT and respiratory obstructions.

XX

XX

PS

XX

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.  
 PA (AFY-) AFWMETRIX INC.  
 XX  
 PI Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;  
 PI Lipshutz RJ, Pacil N, Sklar P;  
 XX  
 DR WPI; 2000-611722/58.  
 XX  
 PT Nucleic acid selected from one of 106 genes comprising single nucleotide  
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful  
 PT for phenotypic correlations, forensics, paternity testing, medicine and  
 PT genetic analysis.  
 XX  
 PS Claim 8; Fig 5; 214pp; English.  
 XX  
 CC The present invention is concerned with a number of human single  
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human  
 CC genes. These SNPs can be used in disease diagnosis and prediction of an  
 CC individual's susceptibility to disease, in forensic and paternity testing  
 CC and in genetic mapping. In particular, the SNPs of the invention can be  
 CC used to diagnose susceptibility to diseases of the cardiovascular,  
 CC endocrine and neurological systems, such as coronary artery disease,  
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
 CC diseases  
 CC  
 SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 174 GGGCGTGGCCTGAG 188  
 DB 15 GGGGCTGGCCTGAG 1  
 XX  
 RESULT 442  
 AAC70630/c  
 ID AAC70630 standard; DNA; 17 BP.  
 XX  
 AC AAC70630;  
 XX  
 DT 09-FEB-2001 (first entry)  
 XX  
 DE Single nucleotide polymorphism PCR primer #307.  
 XX  
 KW Single nucleotide polymorphism; SNP; human; genetic disease;  
 KM disease susceptibility; cardiovascular system; endocrine system;  
 KM neurological system; forensic testing; paternity testing; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200058519-A2.  
 XX  
 PD 05-OCT-2000.  
 XX  
 PF 30-MAR-2000; 2000MO-US008440.  
 XX  
 PR 31-MAR-1999; 99US-0127248P.  
 XX  
 PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.  
 PA (AFY-) AFWMETRIX INC.  
 XX  
 PI Altschuler D, Cargill M, Daley GO, Ireland JS, Lander ES;  
 PI Lipshutz RJ, Pacil N, Sklar P;  
 XX  
 DR WPI; 2000-611722/58.  
 XX  
 XX Nucleic acid selected from one of 106 genes comprising single nucleotide  
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful  
 PT for phenotypic correlations, forensics, paternity testing, medicine and  
 PT genetic analysis.  
 XX

PS Claim 8; Fig 5; 214pp; English.  
 XX  
 CC The present invention is concerned with a number of human single  
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human  
 CC genes. These SNPs can be used in disease diagnosis and prediction of an  
 CC individual's susceptibility to disease, in forensic and paternity testing  
 CC and in genetic mapping. In particular, the SNPs of the invention can be  
 CC used to diagnose susceptibility to diseases of the cardiovascular,  
 CC endocrine and neurological systems, such as coronary artery disease,  
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's  
 CC diseases  
 CC  
 SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 174 GGGCGTGGCCTGAG 188  
 DB 15 GGGGCTGGCCTGAG 1  
 XX  
 RESULT 443  
 AAF02107/c  
 ID AAF02107 standard; DNA; 17 BP.  
 XX  
 AC AAF02107;  
 XX  
 DT 16-FEB-2001 (first entry)  
 XX  
 DE Hammerhead ribozyme substrate #402.  
 XX  
 KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KM interferon alpha; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200061729-A2.  
 XX  
 PD 19-OCT-2000.  
 XX  
 PF 11-APR-2000; 2000MO-US009721.  
 XX  
 PR 12-APR-1999; 99US-0129390P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Blatt L, Zwack M, Pavco P, Mcswiggen J;  
 XX  
 DR WPI; 2000-647423/62.  
 XX  
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT interferon alpha and erythropoietin.  
 XX  
 PS Claim 37; Page 65; 164pp; English.  
 XX  
 CC The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC interferon alpha  
 XX  
 SQ Sequence 17 BP; 7 A; 3 C; 1 G; 6 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY      1784 TTCAGAGAAATATTG 1798
      |||||
      17  TTCAGAGAAATGTTG 3

RESULT 444
AAFO7421/c
ID  AAF07421 standard; DNA; 17 BP.
XX
XX  AAF07421;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #3678.
DE
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
XX  Homo sapiens.
OS
XX  WO200061729-A2.
PN
XX  19-OCT-2000.
PD
XX  11-APR-2000; 2000WO-US009721.
PF
XX  12-APR-1999; 99US-0129390P.
PR
XX  (RIBO-) RIBOZYME PHARM INC.
PA
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
DR
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT  interferon alpha and erythropoietin.
XX
XX  Claim 54; Page 140; 164pp; English.
XX
XX  The present invention relates to enzymatic and antisense nucleic acid
CC  molecules that act as inhibitors of the expression of repressor genes
CC  encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription
CC  factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC  Inhibition of the repressors removes prevents inhibition (and
CC  consequently increases expression of) genes involved in the production of
CC  erythropoietin, granulocyte colony stimulating factor protein and
CC  interferon alpha
XX
XX  Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      283 GCTTTGAAGCCATT 297
      |||||
      15  GCTCTGAAGCCATT 1

RESULT 445
AAFO2109/c
ID  AAF02109 standard; DNA; 17 BP.
XX
XX  AAF02109;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #404.
DE
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
```

```
OS  Homo sapiens.
XX
XX  WO200061729-A2.
XX
XX  19-OCT-2000.
XX
XX  11-APR-2000; 2000WO-US009721.
XX
XX  12-APR-1999; 99US-0129390P.
XX
XX  (RIBO-) RIBOZYME PHARM INC.
XX
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT  interferon alpha and erythropoietin.
XX
XX  Claim 37; Page 65; 164pp; English.
XX
XX  The present invention relates to enzymatic and antisense nucleic acid
CC  molecules that act as inhibitors of the expression of repressor genes
CC  encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription
CC  factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC  Inhibition of the repressors removes prevents inhibition (and
CC  consequently increases expression of) genes involved in the production of
CC  erythropoietin, granulocyte colony stimulating factor protein and
CC  interferon alpha
XX
XX  Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1784 TTCAGAGAAATATTG 1798
      |||||
      15  TTCAGAGAAATGTTG 1

RESULT 446
AAFO2108/c
ID  AAF02108 standard; DNA; 17 BP.
XX
XX  AAF02108;
XX
XX  16-FEB-2001 (first entry)
XX
XX  Hammerhead ribozyme substrate #403.
DE
XX  Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KM  interferon alpha; ss.
XX
XX  Homo sapiens.
OS
XX  WO200061729-A2.
PN
XX  19-OCT-2000.
PD
XX  11-APR-2000; 2000WO-US009721.
PF
XX  12-APR-1999; 99US-0129390P.
PR
XX  (RIBO-) RIBOZYME PHARM INC.
PA
XX  Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX  WPI; 2000-647423/62.
XX
XX  Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT  useful for producing e.g. granulocyte colony stimulating factor protein,
PT
```

PT Interferon alpha and erythropoietin.  
 XX  
 PS Claim 37; Page 65; 164pp; English.  
 CC The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC Interferon alpha  
 XX  
 SQ Sequence 17 BP; 7 A; 3 C; 1 G; 6 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 1784 TTCAGAAATATG 1798  
 Db 16 TTCAGAAATGTTG 2  
 RESULT 447  
 ID AAF02208  
 XX AAF02208 standard; DNA; 17 BP.  
 AC AAF02208;  
 XX  
 DT 16-FEB-2001 (first entry)  
 OS  
 DE Hammerhead ribozyme substrate #503.  
 XX  
 KM Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
 KM Interferon alpha; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W0200061729-A2.  
 XX  
 PD 19-OCT-2000.  
 XX  
 PF 11-APR-2000; 2000WO-US009721.  
 XX  
 PR 12-APR-1999; 99US-0129390P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;  
 XX  
 DR WPI; 2000-647423/62.  
 XX  
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,  
 PT useful for producing e.g. granulocyte colony stimulating factor protein,  
 PT Interferon alpha and erythropoietin.  
 XX  
 PS Claim 37; Page 67; 164pp; English.  
 XX  
 CC The present invention relates to enzymatic and antisense nucleic acid  
 CC molecules that act as inhibitors of the expression of repressor genes  
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TR-1, the GATA transcription  
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).  
 CC Inhibition of the repressors removes prevents inhibition (and  
 CC consequently increases expression of) genes involved in the production of  
 CC erythropoietin, granulocyte colony stimulating factor protein and  
 CC Interferon alpha  
 XX  
 SQ Sequence 17 BP; 1 A; 11 C; 1 G; 4 T; 0 U; 0 Other;  
 XX  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1384 CTCGCATCTACCCC 1398  
 Db 1 CTCGCCTCTACCCC 15  
 RESULT 448  
 ID ABR02411/c  
 XX ABR02411 standard; RNA; 17 BP.  
 AC ABR02411;  
 XX  
 DT 12-MAR-2002 (first entry)  
 OS  
 DE Human NOGO Ribozyme #83.  
 XX  
 KM Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;  
 KM cerebroprotective; neuroprotective; antiparkinsonian;  
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KM DNAzyme; inozyme; G-cleaver; amberyze; zinczyme; lymphoma; leukaemia;  
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KM inflammatory arthropathy; central nervous system injury;  
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KM Parkinson's disease; ataxia; Huntington's disease;  
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN W0200159103-A2.  
 XX  
 PD 16-AUG-2001.  
 XX  
 PF 09-FEB-2001; 2001WO-US004273.  
 XX  
 PR 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX  
 PI Blatt L, Mcswiggen J, Chowrira B;  
 XX  
 DR WPI; 2001-607195/69.  
 XX  
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukaemia, and  
 PT central nervous system injury.  
 XX  
 PS Claim 88; Page 132; 200pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acid may be enzymatic nucleic acids (e.g., a ribozyme or a  
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberyze (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic



CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is an amberzyme molecule of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 8 C; 5 G; 0 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 201 GCTCTGGCTGGGGGC 215  
 Db 16 GCTCTGGCTGGGGGC 2  
 RESULT 449  
 ID ABRK0912 standard; RNA; 17 BP.  
 XX ABRK0912;  
 AC ABRK0912;  
 XX  
 DT 12-MAR-2002 (first entry)  
 XX  
 DE Human NOGO Inozyme #182.  
 XX  
 XX Human; ss; antisense therapy; cytosstatic; antiinflammatory; haemostatic;  
 KM cerebroprotective; nocrotic; neuroprotective; antiparkinsonian;  
 KM muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KM DNAzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;  
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KM inflammatory arthropathy; central nervous system injury;  
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KM Parkinson's disease; ataxia; Huntington's disease;  
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 KM  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 ID WO200159103-A2.  
 PN  
 XX 16-AUG-2001.  
 PD  
 XX 09-FEB-2001; 2001WO-US004273.  
 PF  
 XX 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLAT L.  
 PA (MCSM/) MCSMIGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX  
 PI Blatt L, Mcswigen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX

PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX  
 XX Claim 88; Page 80; 200pp; English.  
 PS  
 XX  
 XX The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acid may be enzymatic nucleic acids (e.g., a ribozyme or a  
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is an inozyme of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 7 C; 6 G; 0 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 201 GCTCTGGCTGGGGGC 215  
 Db 17 GCTCTGGCTGGGGGC 3  
 RESULT 450  
 ID AAF26892  
 XX AAF26892 standard; DNA; 17 BP.  
 XX  
 AC AAF26892;  
 XX  
 DT 11-SEP-2003 (revised)  
 DT 09-APR-2001 (first entry)  
 XX  
 XX Beet necrotic yellow vein virus RNA-2 PCR primer SEQ ID NO:5.  
 DE  
 XX Beet necrotic yellow vein virus; BNYVV; transformed plant;  
 KM Rhizomania disease-resistant plant; PCR primer; ss.  
 KM  
 XX Beet necrotic yellow vein virus.  
 OS  
 XX JP2000312540-A.  
 PN  
 XX 14-NOV-2000.  
 PD  
 XX 28-APR-1999; 99JP-00122628.  
 PF  
 XX 28-APR-1999; 99JP-00122628.  
 PR  
 XX



XX (HOKK-) HOKKAIDO PREFECTURE.  
PA (HOKK-) HOKKAIDO TENSAN KYOKAI SH.  
XX WPI; 2001-054202/07.  
DR A transformed plant having resistance to beet necrotic yellow vein virus  
PT (BNYVV) comprises a gene derived from BNYVV genome.  
XX  
PS Example 1; Page 5; 11pp; Japanese.  
XX  
CC The present invention describes a method for producing a transformed  
CC plant in which resistance against beet necrotic yellow vein virus (BNYVV)  
CC is given by transforming expressably a gene derived from BNYVV genome or  
CC a DNA corresponding to its part or a DNA substantially same as it in a  
CC plant genome. The vector structure can be used for transforming a plant  
CC or a plant cell having BNYVV resistance. The present sequence represents  
CC a PCR primer for a BNYVV nucleotide sequence which is used in an example  
CC from the present invention. (Updated on 11-SEP-2003 to standardise OS  
CC field)  
XX  
SQ Sequence 17 BP; 4 A; 7 C; 1 G; 5 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 666 TACCTTCACTCGAAA 680  
DB 2 TACCTTCACTCGACA 16  
RESULT 451  
AAC62173/C  
ID AAC62173 standard; DNA; 17 BP.  
XX  
AC AAC62173;  
XX  
DT 06-MAR-2001 (first entry)  
XX  
DE Oligomer antiparallel to human plasminogen antigen activator mRNA.  
XX  
KM Biologically active compound; cellular metabolism; DNA replication;  
KM RNA transcription; RNA translation; RNA elongation; RNA processing;  
KM protein synthesis; protein processing; cellular differentiation;  
KM cell division; ion channel transmission; cellular protein; coxin;  
KM RNA transportation; cellular oxidation; tumour suppressor p53;  
KM plasminogen antigen activator; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX WO200061775-A1.  
XX  
PD 19-OCT-2000.  
XX  
PF 08-APR-1999; 99WO-IB000616.  
XX  
PR 08-APR-1999; 99WO-IB000616.  
XX  
PA (SERG/) SERGEEV P.  
XX  
PI Sergeev P;  
XX  
DR WPI; 2001-006911/01.  
XX  
PT Novel method for the synthesis of biologically active compounds from  
PT inactive precursors in the cells of living organisms, useful for  
PT producing proteins or polynucleotides.  
XX  
PS Example 8; Page 30; 65pp; English.  
XX  
CC The specification describes a method of synthesis of biologically active

CC substances of determined structure directly in the cells of living  
CC organisms containing specific RNA or DNA sequence. The method is based on  
CC the hybridisation of two or more oligomers bound with biologically  
CC inactive substances to specific RNA or DNA in vivo in the cells of living  
CC organisms. After hybridisation of the oligomers, the biologically  
CC inactive precursors bound to the oligomers can interact with each other  
CC to make the active form of the substances. This changing of properties is  
CC due to chemical reactions which bind the biologically inactive precursors  
CC through a chemical bond into a biologically active form of the whole  
CC compound. The methods are useful for producing biologically active  
CC compounds from inactive precursors. These compounds may be inhibitors or  
CC stimulants of cellular metabolism, DNA replication, RNA transcription,  
CC RNA translation, RNA elongation, RNA processing, protein synthesis,  
CC protein processing, cellular differentiation, cell division, ion channel  
CC transmission, cellular protein and RNA transportation, processes of  
CC cellular oxidation, coxin, proteins or RNAs. Oligomers AAC62167-80 are  
CC used to bind peptides AAB30523-36. The peptides are fragments of the  
CC tumour suppressor p53, and the oligomers are antiparallel to human  
CC plasminogen antigen activator mRNA. The method of the invention is used  
CC to produce the tumour suppressor protein p53 from the bound peptides and  
CC oligomers  
XX  
SQ Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 101 TGCTGCTCCGACCG 115  
DB 17 TGCTGCTCCGACCG 3  
RESULT 452  
AB272318  
ID AB272318 standard; DNA; 17 BP.  
XX  
AC AB272318;  
XX  
DT 03-APR-2003 (first entry)  
XX  
DE Gene 216 polymorphism genotyping ASO primer SEQ ID NO 290.  
XX  
KM Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;  
KM antiinflammatory; gastrointestinal, gene therapy; vaccine; asthma;  
KM obesity; inflammatory bowel disease; primer; ss.  
XX  
OS Synthetic.  
XX  
XX WO200178894-A2.  
XX  
XX 25-OCT-2001.  
XX  
PF 13-APR-2001; 2001WO-US012245.  
XX  
PR 13-APR-2000; 2000US-00548797.  
XX  
PA (GENO-) GENOME THERAPEUTICS CORP.  
XX  
PI Keith T;  
XX  
DR WPI; 2001-639428/73.  
XX  
XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the  
XX proteins they encode, useful for the prevention, diagnosis and treatment  
XX of asthma, obesity and inflammatory bowel disease.  
XX  
PS Example 11; Page 156; 520pp; English.  
XX  
XX The invention relates to isolated genes (Gene 216) from human chromosome  
XX 20p13-p12 and the proteins they encode. The nucleic acids and proteins  
XX may be used in the prevention, diagnosis and treatment of diseases  
XX associated with inappropriate Gene 216 expression. For example, the

CC nucleic acids (or vectors) and proteins may be used to treat disorders  
 CC associated with decreased expression by rectifying mutations or deletions  
 CC in a patient's genome that affect the activity of gene 216 by expressing  
 CC inactive proteins or to supplement the patients own production of gene  
 CC 216 proteins. Additionally, the nucleic acids may be used to produce the  
 CC secreted Gene 216 protein, by inserting the nucleic acids into a host  
 CC cell and culturing the cell to express the protein. The nucleic acids and  
 CC complementary sequences may also be used as DNA probes in diagnostic  
 CC assays to detect and quantitate the presence of similar nucleic acid  
 CC sequences in samples and therefore which patients may be in need of  
 CC restorative therapy. The Gene 216 protein may also be used as antigens in  
 CC the production of antibodies against Gene 216 and in assays to identify  
 CC modulators of Gene 216 expression and activity. The anti-Gene 216  
 CC antibodies and antagonists may also be used to down regulate expression  
 CC and activity. The anti-Gene 216 antibodies may also be used as diagnostic  
 CC agents for detecting the presence of Gene 216 proteins in samples (e.g.,  
 CC by enzyme linked immunosorbent assay or ELISA). Disorders that may be  
 CC prevented, diagnosed and/or treated by the above methods include, for  
 CC example asthma, obesity and inflammatory bowel disease. The present  
 CC sequence is that of a Gene 216 related primer used in examples of the  
 CC invention. The primers are used in the physical mapping of the gene  
 CC (ABZ72067-ABZ72088), polymorphism identification using single strand  
 CC conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184).  
 CC sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)  
 CC  
 XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 588 CTCCTCTCTTGGGGA 602  
 Db 2 CTCCTCTCTTGGCGA 16  
 |||||  
 |||||

RESULT 453  
 ABN06958  
 ID ABN06958 standard; DNA; 17 BP.  
 AC  
 XX ABN06958;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6350.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-026860P.

XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 KW New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PR desorption/ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 6950; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP-  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption/ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 89 TCGCCGACTGGCTGC 103  
 Db 3 TCGCCGACTGGCTGC 17  
 |||||  
 |||||

RESULT 454  
 ABN06764  
 ID ABN06764 standard; DNA; 17 BP.  
 AC  
 XX ABN06764;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6756.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.

PR	30-JAN-2001	2001WO-US000661	
PR	30-JAN-2001	2001WO-US000662	
PR	30-JAN-2001	2001WO-US000663	
PR	30-JAN-2001	2001WO-US000664	
PR	30-JAN-2001	2001WO-US000665	
PR	30-JAN-2001	2001WO-US000666	
PR	30-JAN-2001	2001WO-US000667	
PR	30-JAN-2001	2001WO-US000668	
PR	30-JAN-2001	2001WO-US000669	
PR	30-JAN-2001	2001WO-US000670	
PR	05-FEB-2001	2001US-0266860P	
XX			
PA	(AEOM-) AEOMICA INC.		
XX			
F1	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,		
XX			
DR	WPI; 2002-179446/23.		
XX			
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,		
PT	or as specific biomolecule capture probes for surface-enhanced laser		
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.		
XX			
PS	Disclosure; SEQ ID NO 6756; 214pp; English.		
XX			
CC	The present invention describes a human genome-derived myosin-like		
CC	protein 1 (hGMLP-1). The protein and polynucleotide sequences of hGMLP-		
CC	1 can be used in gene therapy and vaccine production. The hGMLP-1		
CC	nucleic acids can be used as probes to detect, characterise and quantify		
CC	hGMLP-1 nucleic acids in samples, as amplification substrates, to		
CC	provide initial substrates for the recombinant engineering of hGMLP-1		
CC	protein variants having desired phenotypic improvements, and for		
CC	expressing the proteins. The hGMLP-1 proteins or polypeptides may be		
CC	used as immunogens to raise antibodies that specifically recognise hGMLP		
CC	-1 proteins, as standards in assays used to determine the concentration		
CC	and/or amount specifically of hGMLP proteins, as specific biomolecule		
CC	capture probes for surface-enhanced laser desorption ionisation, as		
CC	therapeutic supplement in patients having specific deficiency in hGMLP-1		
CC	production, and in vaccines or for replacement therapy. The		
CC	polynucleotide sequences encoding hGMLP-1 may be used for diagnosing a		
CC	disorder associated with the expression of hGMLP-1, in particular heart		
CC	and skeletal muscle disorders. hGMLP-1 is localised to chromosome 22.		
CC	The present sequence represents an oligomer used in the screening of the		
CC	hGMLP-1 sequence in the exemplification of the present invention. N.B.		
CC	The sequence data for this patent did not form part of the printed		
CC	specification, but was obtained in electronic format directly from WIPO		
CC	at ftp.wipo.int/pub/published_pct_sequence		
XX			
SO	Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 U; 0 Other;		
	Query Match	0.6%; Score 13.4; DB 1; Length 17;	
	Best Local Similarity	93.3%; Pred.No.2.3e+02;	
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
Oy	2041 GTGAGACAGCTCCG 2055		
	3 GTGAGAGAGCTCCG 17		
Db			
RESULT 455			
ABN08015			
ID	ABN08015 standard; DNA; 17 BP.		
XX			
AC	ABN08015;		
XX			
DT	29-MAY-2002 (first entry)		
XX			
DE	Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8007.		
XX			
KW	Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;		
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;		
KW	skeletal muscle disorder; amplicon; screening; ss.		
XX			
OS	Homo sapiens		

XX		WO200192524-A2.
PN		
PD	06-DEC-2001.	
PX		
PF	25-MAY-2001; 2001WO-US016981.	
PY		
PR	26-MAY-2000; 2000US-0207456P.	
PS	21-SEP-2000; 2000US-0234687P.	
PT	27-SEP-2000; 2000US-0236359P.	
PP	04-OCT-2000; 2000GB-00024263.	
PR	30-JAN-2001; 2001WO-US000661.	
PR	30-JAN-2001; 2001WO-US000662.	
PR	30-JAN-2001; 2001WO-US000663.	
PR	30-JAN-2001; 2001WO-US000664.	
PR	30-JAN-2001; 2001WO-US000665.	
PR	30-JAN-2001; 2001WO-US000666.	
PR	30-JAN-2001; 2001WO-US000667.	
PR	30-JAN-2001; 2001WO-US000668.	
PR	30-JAN-2001; 2001WO-US000669.	
PR	30-JAN-2001; 2001WO-US000670.	
PR	05-FEB-2001; 2001US-0268660P.	
PB	(AEOM-) AEOMICA INC.	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,	
PJ	WPI; 2002-179446/23.	
PX		
DR	New polypeptide, for raising antibodies that recognize hGDMRP-1 proteins,	
PT	or as specific biomolecule capture probes for surface-enhanced laser	
FT	desorption ionization, comprises human myosin-like protein hGDMRP-1.	
PX		
PS	Disclosure; SEQ ID NO 8007; 21app; English.	
PX		
CC	The present invention describes a human genome-derived myosin-like	
CC	protein I (hGDMRP-1). The protein and polynucleotide sequences of hGDMRP-	
CC	I can be used in gene therapy and vaccine production. The hGDMRP-1	
CC	nucleic acids can be used as probes to detect, characterize and quantify	
CC	hGDMRP-1 nucleic acids in samples, as amplification substrates, to	
CC	provide initial substrates for the recombinant engineering of hGDMRP-1	
CC	protein variants having desired phenotypic improvements, and for	
CC	expressing the protein. The hGDMRP-1 proteins or polypeptides may be	
CC	used as immunogens to raise antibodies that specifically recognise hGDMRP	
CC	-1 proteins, as standards in assays used to determine the concentration	
CC	and/or amount specifically of hGDMRP proteins, as specific biomolecule	
CC	capture probes for surface-enhanced laser desorption/ionisation, as	
CC	therapeutic supplement in patients having specific deficiency in hGDMRP-1	
CC	production, and in vaccines or for replacement therapy. The	
CC	polynucleotide sequences encoding hGDMRP-1 may be used for diagnosing a	
CC	disorder associated with the expression of hGDMRP-1, in particular heart	
CC	and skeletal muscle disorders. hGDMRP-1 is localised to chromosome 22.	
CC	The present sequence represents an oligomer used in the screening of the	
CC	hGDMRP-1 sequence in the exemplification of the present invention. N.B.	
CC	The sequence data for this patent did not form part of the printed	
CC	specification, but was obtained in electronic format directly from WIPO	
CC	at ftp.wipo.int/pub/published_pct_sequence	
PX		
SQ	Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;	
	Query Match 0.6%; Score 13.4; DB 1; Length 17;	
	Best Local Similarity 93.3%; Pred.No. 2.3e+02;	
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	2039 AGGTGGAGCAGCTCC 2053	
DB	1 AGCTGGAGCAGCTCC 15	
RESULT 456		
ABN00897/c		
ID ABN00897 standard; DNA; 17 BP.		
XX		

AC ABN00897;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:889.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
DR  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT description ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 889; 214pp; English.  
XX  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser description ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 5 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1703 CCCTTCCCAATATG 1717  
|||  
Db 17 CCCTTCCCACTATG 3  
RESULT 457  
ABN06765  
ID ABN06765 standard; DNA; 17 BP.  
XX  
AC ABN06765;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6757.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
DR  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT description ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 6757; 214pp; English.  
XX  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser description ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 2041 GTGAGAGAGCTCTG 2055  
Db 2 GTGAGAGAGCTCTG 16  
RESULT 458  
ABN08062  
ID ABN08062 standard; DNA; 17 BP.  
AC ABN08062;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8054.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-026860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
DR WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognise hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT description ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
PS Disclosure; SEQ ID NO 8054; 214P; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 4 C; 4 G; 1 T; 0 U; 0 Other;  
Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 2230 GCAGATGCTCCAGAA 2244  
Db 3 GCAGATGCTCCAGAA 17  
RESULT 459  
ABN08063  
ID ABN08063 standard; DNA; 17 BP.  
AC ABN08063;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8055.  
XX  
KM Human; genome-derived myosin-like protein 1; GDMLP-1; heart;  
KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KM skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-026860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
DR WPI; 2002-179446/23.  
XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 8055; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 2230 GCAGATGCTCCAGAA 2244  
|||  
Db 2 GCAGATGACCCAGAA 16  
  
RESULT 460  
ABN06960  
ID ABR06960 standard; DNA; 17 BP.  
XX  
AC ABR06960;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6952.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
DR  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX  
XX  
PS Disclosure; SEQ ID NO 6952; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 89 TCGCCGACTGGGTGC 103  
|||  
Db 1 TCGCCGACTGGGTGC 15  
  
RESULT 461  
ABN06959  
ID ABR06959 standard; DNA; 17 BP.  
XX  
AC ABR06959;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6951.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX

PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 6951; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 89 TCGCCGACTGGGTC 103  
 |||||  
 Db 2 TCGCCGACTGGGTC 16  
 |||||  
 RESULT 462  
 ABRN08012  
 ID ABRN08012 standard; DNA; 17 BP.  
 AC ABRN08012;  
 XX  
 XX 29-MAY-2002 (first entry)  
 DT  
 XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8004.  
 DE Human; genome-derived myosin-like protein 1; hGDMLP-1; heart;  
 XX

KW muscle; myosin; chromosome 22; Gene therapy; vaccine; heart disease;  
 XX skeletal muscle disorder; amplicon; screening; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 PN W0200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PP 25-MAY-2001; 2001WO-US016981.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 XX (AEOM-) AEOMICA INC.  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX WPI; 2002-179446/23.  
 XX  
 DR WPI; 2002-179446/23.  
 XX  
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
 XX  
 PS Disclosure; SEQ ID NO 8004; 214pp; English.  
 XX  
 CC The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 6 G; 2 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 2038 CAGCTGAGCAGCTC 2052  
 |||||  
 Db 3 CAGCTGAGCAGCTC 17  
 |||||



```
RESULT 463
AB063624
ID AB063624 standard; DNA; 17 BP.
XX
AC AB063624;
XX
XX 20-AUG-2002 (first entry)
XX
XX Human KTOM1a portion (AB063232) probe # 337.
XX
XX Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytosolic;
KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200224750-A2.
XX
XX 28-MAR-2002.
XX
XX 21-SEP-2001; 2001WO-US029656.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 23-MAY-2001; 2001US-00864761.
XX
XX 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 201; 418pp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytosolic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTCG 580
DB 2 TGTTCCTGTCCTCG 16
```

```
RESULT 464
AB063623
ID AB063623 standard; DNA; 17 BP.
XX
AC AB063623;
XX
XX 20-AUG-2002 (first entry)
XX
XX Human KTOM1a portion (AB063232) probe # 336.
XX
XX Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytosolic;
KM gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200224750-A2.
XX
XX 28-MAR-2002.
XX
XX 21-SEP-2001; 2001WO-US029656.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.
XX
XX 23-MAY-2001; 2001US-00864761.
XX
XX 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 201; 418pp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytosolic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 566 TGTTCCTGTCCTCG 580
DB 3 TGTTCCTGTCCTCG 17
```



```

RESULT 465
AB063625
ID AB063625 standard; DNA; 17 BP.
XX
AC AB063625;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (AB063232) probe # 338.
XX
KM Human; KTOM1a; kidney tumour overexpressed membrane; cytostratic;
KM Gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KM kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acid encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 202; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostratic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta.
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (AB063232)
XX
SQ Sequence 17 BP; 0 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 566 TGTTCGTGTCCTGG 580
|||||

```

```

DB 1 TGTTCGTGTCCTGG 15
RESULT 466
ABV85491/c
ID ABV85491 standard; DNA; 17 BP.
XX
AC ABV85491;
XX
DT 11-DEC-2002 (first entry)
XX
DE Human pp-GaNTase 10 scanning 17-mex SEQ ID NO:484.
XX
KM Human; UDP-GaINAc:polypeptide N-acetylglucosaminyltransferase 10;
KM pp-GaNTase 10; EC 2.4.1.41; chromosome 7q11.2; gene therapy; scanning;
KM ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN EP1243660-A2.
XX
PD 25-SEP-2002.
XX
PF 25-JAN-2002; 2002EP-00001161.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 30-AUG-2001; 2001US-0315984P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J, Gu Y, Nguyen C;
XX
DR WPI; 2002-724954/79.
XX
PT Nucleic acid encoding human UDP-GaINAc:polypeptide N-
PT cetylglucosaminyltransferase 10 protein is useful to diagnose, prevent
PT and treat disorders associated with reduced or over expression of the
PT encoded protein.
XX
PS Example 2; SEQ ID NO 484; 59pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) encoding a
CC human UDP-GaINAc:polypeptide N-acetylglucosaminyltransferase 10 (pp-
CC GaNTase 10, EC 2.4.1.41) protein. Human pp-GaNTase 10 is located to
CC chromosome 7q11.2. (I) can be used in gene therapy. Molecules of the
CC present invention can be used in therapy, particularly to prevent or
CC treat a disorder associated with decreased expression or activity of pp-
CC GaNTase. The sequences given in ABV85011 to ABV86689 and ABP3502 to
CC ABP5504 are given in the exemplification of the present invention. N.B.
CC The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office
XX
SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1487 CCTTACCTTGAGG 1501
|||||
DB 15 CCTTACCTTGAGG 1

```

RESULT 467  
ABK19232/c  
ID ABK19232 standard; RNA; 17 BP.  
XX  
AC ABK19232;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Human ERG Amberzyme target sequence Seq ID No 1879.  
XX  
KW Human; hammerhead ribozyme; cytosolic; antitumor; antidiabetic;  
KW ophthalmological; antiarthritic; antipsoriatic; vitamin; osteopathic;  
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
KW angiodioma of tuberous sclerosis; port-wine stain; wound healing;  
KW Sturge Weber syndrome; Kippel-Trenauay-Weber syndrome; leukaemia; ss;  
KW Oslar-Weber-rendu syndrome; leukaemia; osteoporosis; DNzyme; inozyme;  
KW amberzyme.  
XX  
OS Homo sapiens.  
XX  
PN W0200188124-A2.  
XX  
PD 22-NOV-2001.  
XX  
PF 16-MAY-2001; 2001WO-US015866.  
XX  
PR 16-MAY-2000; 2000US-00572021.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PA (GLAXO) GLAXO GROUP LTD.  
XX  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
XX  
DR WPI; 2002-082995/11.  
XX  
PT Novel polynucleotide which down regulates expression of Ets-related gene,  
PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
XX  
PS Claim 4; Page 123; 149pp; English.  
XX  
CC The invention relates to a nucleic acid molecule (I) which down regulates  
CC expression of an Ets-related gene (ERG). (I) is useful for treating  
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
CC vulgaris, angiodioma of tuberous sclerosis, port-wine stains, Sturge  
CC Weber syndrome, Kippel-Trenauay-Weber syndrome, Oslar-Weber-rendu  
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
CC treating a patient having a condition associated with the level of ERG,  
CC by contacting cells of the patient with (I) under conditions suitable for  
CC the treatment. The method comprises the use of one or more therapies  
CC under conditions suitable for the treatment. Leukaemia or tumour  
CC angiogenesis is treated by administering (I) to the patient in  
CC conjunction with one or more of other therapies such as radiation or  
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
CC cation such as Mg<sup>2+</sup>. (I) is useful for diagnosis of conditions and  
CC diseases related to the expression of ERG, and as diagnostic tool to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of ERG RNA in a cell. (I) is useful for specifically  
CC targeting genes that share homology with ERG gene or ERG fusion genes.  
CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
CC related PCR primers of the invention  
XX  
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 345 GCTGATCTCAGGGG 359  
|||  
Db 15 GCTGATCTCCTGGGG 1  
|||  
RESULT 468  
ABK74945  
ID ABK74945 standard; DNA; 17 BP.  
XX  
AC ABK74945;  
XX  
DT 24-DEC-2002 (first entry)  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 471.  
XX  
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
KW dysgenetic pregnancy; primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN US2002102252-A1.  
XX  
PD 01-AUG-2002.  
XX  
PF 06-APR-2001; 2001US-00827998.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
XX  
PA (GUTY/) GU Y.  
XX  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Shannon ME;  
XX  
DR WPI; 2002-697817/75.  
XX  
PT New isolated nucleic acid encoding an isoform of human pregnancy  
PT associated plasma protein E, for preventing or aborting pregnancy.  
XX  
PS Example 2; Page 137; 353pp; English.  
XX  
CC This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
XX  
SQ Sequence 17 BP; 9 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1027 AAGAGGTGGGAAA 1041  
|||  
Db 3 AAGAGGGGGGAAA 17  
|||  
RESULT 469  
ABK74947  
ID ABK74947 standard; DNA; 17 BP.  
XX  
AC ABK74947;

XX 24-DEC-2002 (first entry)  
DT  
XX  
DE Human PAPP-Ea associated 17-mer SEQ ID 473.  
XX  
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
XX dysgenetic pregnancy; primer; ss.  
OS  
XX Homo sapiens.  
PN US2002102252-A1.  
XX  
XX 01-AUG-2002.  
PD  
XX  
XX 06-APR-2001; 2001US-00827998.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX (GUY/) GU Y.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Shannon ME;  
PI  
XX WPI; 2002-697817/75.  
DR  
XX  
XX New isolated nucleic acid encoding an isoform of human pregnancy  
PT associated plasma protein E, for preventing or aborting pregnancy.  
XX  
XX Example 2; Page 137; 353pp; English.  
PS  
XX This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
CC  
XX  
SQ Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1027 AAGAGGTGGGAAA 1041  
DB 1 AAGAGGGGGGAAA 15  
RESULT 470  
ABST4946  
ID ABST4946 standard; DNA; 17 BP.  
XX  
XX  
AC ABST4946;  
XX  
XX 24-DEC-2002 (first entry)  
DE Human PAPP-Ea associated 17-mer SEQ ID 472.  
XX  
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;  
KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;  
XX dysgenetic pregnancy; primer; ss.  
OS  
XX Homo sapiens.  
PN US2002102252-A1.

XX 01-AUG-2002.  
PD  
XX  
XX 06-APR-2001; 2001US-00827998.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX (GUY/) GU Y.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Shannon ME;  
PI  
XX WPI; 2002-697817/75.  
DR  
XX  
XX New isolated nucleic acid encoding an isoform of human pregnancy  
PT associated plasma protein E, for preventing or aborting pregnancy.  
XX  
XX Example 2; Page 137; 353pp; English.  
PS  
XX This invention describes a novel isolated nucleic acid that encodes one  
CC of three new isoforms of human pregnancy associated plasma protein E,  
CC hPAPP-E. The products of the invention have abortive and contraceptive  
CC activity and can be used for gene therapy or in a vaccine. The nucleic  
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be  
CC used in pharmaceutical compositions or vaccines for preventing or  
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of  
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess  
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the  
CC antibodies can be used to assess the expression levels of PAPP-E isoform  
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies  
CC antenatally. This sequence represents an oligomer used in scanning the  
CC human PAPP-E genes described in the disclosure of the invention  
CC  
XX  
SQ Sequence 17 BP; 9 A; 0 C; 8 G; 0 T; 0 U; 0 Other;  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1027 AAGAGGTGGGAAA 1041  
DB 2 AAGAGGGGGGAAA 16  
RESULT 471  
ABV90560  
ID ABV90560 standard; DNA; 17 BP.  
XX  
XX  
AC ABV90560;  
XX  
XX 23-DEC-2002 (first entry)  
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1273.  
XX  
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;  
KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;  
XX gene therapy; transgenic; ss.  
OS  
XX Homo sapiens.  
PN EP1239051-A2.  
XX  
XX 11-SEP-2002.  
PD  
XX  
XX 28-JAN-2002; 2002EP-00001165.  
PF  
XX  
XX 30-JAN-2001; 2001WO-US0000663.  
PR 30-JAN-2001; 2001WO-US0000664.  
XX 30-JAN-2001; 2001WO-US0000665.  
PR 30-JAN-2001; 2001WO-US0000666.  
XX 30-JAN-2001; 2001WO-US0000667.  
PR 30-JAN-2001; 2001WO-US0000668.  
XX 30-JAN-2001; 2001WO-US0000669.  
PR

```
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
PA (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1273; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGGAGAA 2196
DB 2 CAGCCCATGGAGAA 16
XX
RESULT 472
ABV90561
ID ABV90561 standard; DNA; 17 BP.
XX
AC ABV90561;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1274.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
```

```
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
PA (AEOM-) AEOMICA INC.
XX Shannon M;
PI WPI; 2002-684061/74.
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1274; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 6 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2182 CAGCTCATGGAGAA 2196
DB 1 CAGCCCATGGAGAA 15
XX
RESULT 473
ABV90559
ID ABV90559 standard; DNA; 17 BP.
XX
AC ABV90559;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1272.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EPI239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
```

PR	30-JAN-2001	2001MO-US0000664	
PR	30-JAN-2001	2001MO-US0000665	
PR	30-JAN-2001	2001MO-US0000666	
PR	30-JAN-2001	2001MO-US0000667	
PR	30-JAN-2001	2001MO-US0000668	
PR	30-JAN-2001	2001MO-US0000669	
PR	30-JAN-2001	2001MO-US0000670	
PR	23-MAY-2001	2001US-00864761	
PR	10-OCT-2001	2001US-0328205P	
XX			
PA	(AEOM-) AEOMICA INC.		
XX			
PI	Shannon M.		
DR	WPI; 2002-684061/74.		
XX			
PT	Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL		
PT	-1, useful for treating disorders associated with decreased expression or		
PT	activity of human POSHL1.		
XX			
PS	Example 2; SEQ ID NO 1272; 60bp + Sequence Listing; English.		
XX			
CC	The invention relates to an isolated SH3 domain (POSH)-like signalling		
CC	protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino		
CC	acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),		
CC	(SI) having 95% deviations, especially conservative substitutions or a		
CC	fragment of the sequences comprising at least 8 contiguous amino acids.		
CC	Human POSHL1 is a proto-oncogene/oncogene product that functions as an		
CC	adaptor protein that interacts with Rho family small GTPases as well as		
CC	downstream components of the signal transduction pathway. (I) is useful		
CC	for identifying a specific binding partner. (I) and nucleic acids (II)		
CC	encoding (I) are useful for diagnosing, monitoring disease and treating		
CC	caused by altered expression of human POSHL1 including diagnosing and		
CC	treating cancer, they useful in the development of vaccines and (II) is		
CC	useful in gene therapy. (II) is useful for constructing microarrays which		
CC	are useful for measuring and for surveying gene expression and creating		
CC	transgenic non-human animals capable of producing the proteins. The		
CC	present sequence is that of a scanning oligonucleotide useful in examples		
CC	of the invention. Note: The present sequence did not form part of the		
CC	printed specification, but is based on sequence information supplied to		
CC	Derwent by the European Patent Office		
XX			
SO	Sequence 17 BP; 6 A; 6 C; 4 G; 1 T; 0 U; 0 Other;		
QY	Query Match	0.6%; Score 13.4; DB 1; Length 17;	
	Best Local Similarity	93.3%; Pred. No. 2.3e+02;	
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0		
Db	2182 CAGCTCATGGAGAA 2196		
	3 CAGCCCATGGAGAA 17		
RESULT 474			
AC	ABKS7194/C		
XX	ABKS7194 standard; RNA; 17 BP.		
XX			
XX	ABKS7194;		
DT	02-JUL-2002 (first entry)		
XX			
DE	Human CLCA1 gene enzymatic nucleic acid #1565.		
XX			
KM	Human; chloride channel calcium activated 1, CLCA1; sg; antiasthmatic;		
KM	antiinflammatory; chronic obstructive pulmonary disease, COPD; asthma;		
KM	chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;		
KM	oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;		
XX	acetylcycteine.		
XX			
OS	Homo sapiens.		
XX			
XX	WO200211674-A2.		

XX	14-FEB-2002.
PD	
PR	09-AUG-2001; 2001WO-US024970.
XX	
PR	09-AUG-2000; 2000US-0224383P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(SYNT ) SYNTAX USA LLC.
PA	(THOM/) THOMPSON J.
XX	
P1	Thompson J, Mcawiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI	Gruppe A;
XX	
DR	WPI; 2002-217145/27.
PT	
PT	Enzymatic polynucleotide that down regulates expression of chloride
PT	channel calcium activated gene, useful for treating Chronic obstructive
PT	pulmonary disease (COPD), chronic bronchitis and asthma.
XX	
PS	Claim 4; Page 98; 152bp; English.
XX	
CC	The invention relates to enzymatic nucleic acid molecules that down
CC	regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC	by cleaving RNA derived from the genes. The nucleic acid sequences are
CC	useful as pharmaceutical agents for treating conditions such as chronic
CC	obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC	fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC	that are related to or will respond to the levels of CLCA1 in a cell or
CC	tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC	hence, are useful for treatment of a patient having a condition
CC	associated with the level of CLCA1, where the invention further comprises
CC	the use of one or more therapies under conditions suitable for the
CC	treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC	antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC	nucleic acids of the invention are also used as diagnostic tools to
CC	examine genetic drift and mutations within diseased cells or to detect
CC	the presence of CLCA1 RNA in a cell. This sequence represents an
CC	enzymatic nucleic acid molecule of the invention
XX	
SQ	Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
	Query Match            0.6%; Score 13.4; DB 1; Length 17;
	Best Local Similarity   93.3%; Pred. No. 2.3e+02;
	Matches     14; Conservative   0; Mismatches     1; Indels       0; Gaps     0;
Oy	1887 TCAGGCGTATGACAC 1901
Db	15 TCAGGCGCTGTACAC 1
RESULT 475	
ABK56649/c	
ID	ABK56649 standard; RNA; 17 BP.
XX	
AC	ABK56649;
XX	
D7	02-JUL-2002 (first entry)
XX	
DE	Human CLCA1 gene enzymatic nucleic acid #1020.
XX	
KM	Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KM	antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KM	chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KM	oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KM	acetylcycteine.
XX	
OS	Homo sapiens.
XX	
PN	WO200211674-A2.
PD	
PD	14-FEB-2002.
PF	09-AUG-2001; 2001WO-US024970.

XX 09-AUG-2000; 2000US-0224383P.  
PR (RIBO-) RIBOZYME PHARM INC.  
XX (SYNT ) SYNTAX USA LLC.  
PA (THOM/) THOMPSON J.  
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;  
PI Grube A;  
XX WPI; 2002-217145/27.  
DR Enzymatic polynucleotide that down regulates expression of chloride  
XX channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX  
XX Claim 4; Page 77; 152pp; English.  
XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
XX Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;  
SQ  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1887 TCAGGCGCTATGACAC 1901  
Db 16 TCAGGCGCTGACAC 2  
RESULT 476  
ABK56493/C  
ID ABK56493 standard; RNA; 17 BP.  
XX  
XX ABK56493;  
AC  
XX  
XX 02-JUL-2002 (first entry)  
DT  
XX Human CLCA1 gene enzymatic nucleic acid #864.  
XX  
XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;  
KM antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;  
KM chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;  
KM oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;  
KM acetylcysteine.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200211674-A2.  
PN  
XX  
XX 14-FEB-2002.  
PD  
XX  
XX 09-AUG-2001; 2001WO-US024970.  
PF  
XX  
XX 09-AUG-2000; 2000US-0224383P.  
PR  
XX

PA (RIBO-) RIBOZYME PHARM INC.  
PA (SYNT ) SYNTAX USA LLC.  
XX (THOM/) THOMPSON J.  
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;  
PI Grube A;  
XX WPI; 2002-217145/27.  
DR Enzymatic polynucleotide that down regulates expression of chloride  
XX channel calcium activated gene, useful for treating Chronic obstructive  
PT pulmonary disease (COPD), chronic bronchitis and asthma.  
XX  
XX Claim 4; Page 72; 152pp; English.  
XX The invention relates to enzymatic nucleic acid molecules that down  
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes  
CC by cleaving RNA derived from the genes. The nucleic acid sequences are  
CC useful as pharmaceutical agents for treating conditions such as chronic  
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic  
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
CC that are related to or will respond to the levels of CLCA1 in a cell or  
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
CC hence, are useful for treatment of a patient having a condition  
CC associated with the level of CLCA1, where the invention further comprises  
CC the use of one or more therapies under conditions suitable for the  
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The  
CC nucleic acids of the invention are also used as diagnostic tools to  
CC examine genetic drift and mutations within diseased cells or to detect  
CC the presence of CLCA1 RNA in a cell. This sequence represents an  
CC enzymatic nucleic acid molecule of the invention  
XX  
XX Sequence 17 BP; 3 A; 6 C; 4 G; 0 T; 4 U; 0 Other;  
SQ  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1997 TGGATGATGACACCA 2011  
Db 16 TGGATGATGACACCA 2  
RESULT 477  
ABZ97151  
ID ABZ97151 standard; DNA; 17 BP.  
XX  
XX ABZ97151;  
AC  
XX  
XX 17-OCT-2003 (first entry)  
DT  
XX Human MTA oligonucleotide.  
XX  
XX Human; antisense; lung dysfunction; nasal airway dysfunction;  
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiasthmatic;  
KM antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KM lung inflammation; respiratory disease; ds.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200285308-A2.  
PN  
XX  
XX 31-OCT-2002.  
PD  
XX  
XX 23-APR-2002; 2002WO-US013135.  
PF  
XX  
XX 24-APR-2001; 2001US-0286137P.  
PR  
XX (EPIC-) EPICGENESIS PHARM INC.  
PA  
XX

PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahbuddin S;  
XX  
DR WPI; 2003-229219/22.  
XX  
PT Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
PS Disclosure; SEQ ID NO 12393; 872bp; English.  
XX  
CC The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiaschematic, hypotensive,  
CC immunosuppressive, and cyrostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
QY 565 CTGTCCTGTCCTCG 579  
Db 1 CTGTCCTGTCCTCG 15  
XX  
RESULT 478  
AB296448 standard; DNA; 17 BP.  
XX  
AC AB296448;  
XX  
DT 17-OCT-2003 (first entry)  
XX  
DE Human nucleic acid sequence.  
XX  
KW Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
KW antiaschematic; hypotensive; immunosuppressive; cyrostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200285308-A2.  
XX  
PD 31-OCT-2002.  
XX  
PF 23-APR-2002; 2002WO-US013135.  
XX  
PR 24-APR-2001; 2001US-0286137P.  
XX  
PA (EPIG-) EPIGENESIS PHARM INC.  
XX

PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahbuddin S;  
XX  
DR WPI; 2003-229219/22.  
XX  
PT Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
PS Disclosure; SEQ ID NO 11690; 872bp; English.  
XX  
CC The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiaschematic, hypotensive,  
CC immunosuppressive, and cyrostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
QY 565 CTGTCCTGTCCTCG 579  
Db 1 CTGTCCTGTCCTCG 15  
XX  
RESULT 479  
ACD00797/C  
ID ACD00797 standard; DNA; 17 BP.  
XX  
AC ACD00797;  
XX  
DT 28-JUL-2003 (first entry)  
XX  
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1270.  
XX  
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;  
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cyrostatic; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2003031621-A2.  
XX  
PD 17-APR-2003.  
XX  
PF 11-OCT-2002; 2002WO-US032599.  
XX  
PR 12-OCT-2001; 2001US-0329000P.  
XX  
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX  
PI Zhang J;  
XX  
DR WPI; 2003-381720/36.  
XX



PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,  
 PT investigating and/or treating disorders associated with aberrant  
 PT expression or activity of GPCR-A-1, such as tumors and cancers.  
 XX  
 PS Example 2; SEQ ID NO 1294; 156bp; English.  
 XX  
 CC The invention describes an isolated nucleic acid encoding a G protein  
 CC coupled receptor (GPCR), mutations of which cause cancer, comprising a  
 CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a  
 CC 409 residue amino acid sequence, all given in the specification, with or  
 CC without conservative amino acid substitutions, or complements of the  
 CC sequence of them. The encoding nucleic acid is not more than 100 kbase in  
 CC length. The methods and compositions of the present invention are useful  
 CC for diagnosing, investigating and/or treating disorders associated with  
 CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.  
 CC This sequence represents an oligonucleotide used to analyse the gene  
 CC encoding human G-protein coupled receptor GPCR-A-1  
 CC  
 XX Sequence 17 BP, 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 861 GGTACACAGAGACAC 875  
 Db 17 GGTAAACAGAGAAAC 3  
 RESULT 480  
 ACD00798/c  
 ID ACD00798 standard; DNA; 17 BP.  
 XX  
 AC ACD00798;  
 XX  
 DT 28-JUN-2003 (first entry)  
 XX  
 DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1271.  
 XX  
 KM Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;  
 KM G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003031621-A2.  
 XX  
 PD 17-APR-2003.  
 XX  
 PF 11-OCT-2002; 2002WO-US032559.  
 XX  
 PR 12-OCT-2001; 2001US-0329000P.  
 XX  
 PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
 XX  
 PI Zhang J;  
 XX  
 DR WPI; 2003-381720/36.  
 XX  
 PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,  
 PT investigating and/or treating disorders associated with aberrant  
 PT expression or activity of GPCR-A-1, such as tumors and cancers.  
 XX  
 PS Example 2; SEQ ID NO 1295; 156bp; English.  
 XX  
 CC The invention describes an isolated nucleic acid encoding a G protein  
 CC coupled receptor (GPCR), mutations of which cause cancer, comprising a  
 CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a  
 CC 409 residue amino acid sequence, all given in the specification, with or  
 CC without conservative amino acid substitutions, or complements of the  
 CC sequence of them. The encoding nucleic acid is not more than 100 kbase in  
 CC length. The methods and compositions of the present invention are useful  
 CC for diagnosing, investigating and/or treating disorders associated with  
 CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.

CC This sequence represents an oligonucleotide used to analyse the gene  
 CC encoding human G-protein coupled receptor GPCR-A-1  
 XX  
 SQ Sequence 17 BP, 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 861 GGTACACAGAGACAC 875  
 Db 16 GGTAAACAGAGAAAC 2  
 RESULT 481  
 ABT38416  
 ID ABT38416 standard; DNA; 17 BP.  
 XX  
 AC ABT38416;  
 XX  
 DT 12-JUN-2003 (first entry)  
 XX  
 DE Tumour suppression related human fukutin oligo SEQ ID No 4053.  
 XX  
 KM Cyrostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KM schizophrenia; protein chip; gene therapy; tumour suppression;  
 KM human fukutin; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003025175-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004208.  
 XX  
 PR 17-SEP-2001; 2001FR-00011978.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Teلمان A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-313353/30.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 507; 720pp; French.  
 XX  
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention



XX Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 1523 TCTCTTGCTTGCCTACC 1537  
 |||||  
 3 TCTCTCTGCTTACC 17  
 Db  
 RESULT 482  
 ACA07766  
 ID ACA07766 standard; RNA; 17 BP.  
 XX ACA07766;  
 AC  
 XX 03-JUN-2003 (first entry)  
 DT  
 XX NFkB sub-unit modulating zinzyme substrate #165.  
 DE  
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KM G-cleaver; amberszyme; cancer; REL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 KM  
 XX Homo sapiens.  
 OS  
 XX US2002177568-A1.  
 PN  
 XX 28-NOV-2002.  
 PD  
 XX 23-MAY-2001; 2001US-00864785.  
 PF  
 XX 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINGCOMB D T.  
 PA (MCSW/) MCSWIGEN J.  
 PA (DBAP/) DRAPER K G.  
 PI  
 XX Stinchcomb DT, Mcswigen J, Draper KG;  
 DR WPI; 2003-340953/32.  
 XX  
 XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 PT  
 XX Claim 3; Page 40; 72pp; English.  
 PS  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberszyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzyme and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate;  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 CC  
 SQ Sequence 17 BP; 4 A; 6 C; 6 G; 0 T; 1 U; 0 Other;  
 Oy Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 86.7%; Pred. No. 2.3e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 Oy 1362 CACCCAGCGTGTGCA 1376  
 |||||  
 2 CACCCAGCGTGGGCA 16  
 Db  
 RESULT 483  
 ACA07802/C  
 ID ACA07802 standard; RNA; 17 BP.  
 XX ACA07802;  
 AC  
 XX 03-JUN-2003 (first entry)  
 DT  
 XX NFkB sub-unit modulating zinzyme substrate #201.  
 DE  
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;  
 KM G-cleaver; amberszyme; cancer; REL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 KM  
 XX Homo sapiens.  
 OS  
 XX US2002177568-A1.  
 PN  
 XX 28-NOV-2002.  
 PD  
 XX 23-MAY-2001; 2001US-00864785.  
 PF  
 XX 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINGCOMB D T.  
 PA (MCSW/) MCSWIGEN J.  
 PA (DBAP/) DRAPER K G.  
 PI  
 XX Stinchcomb DT, Mcswigen J, Draper KG;  
 DR WPI; 2003-340953/32.  
 XX  
 XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for

PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX Claim 3; Page 40; 72pp; English.  
 XX  
 CC The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 2 A; 9 C; 5 G; 0 T; 1 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 355 TGGGAGCCCCGGG 369  
 |||||  
 16 TGGGAGCCCGGG 2  
 RESULT 484  
 ID ACA06237 standard; RNA; 17 BP.  
 AC ACA06237;  
 XX  
 DT 03-JUN-2003 (first entry)  
 XX  
 DE NFKB sub-unit modulating inozyme substrate #56.  
 XX  
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN US2002177568-A1.  
 XX  
 PD 28-NOV-2002.  
 XX  
 PF 23-MAY-2001; 2001US-00864785.  
 XX  
 PR 07-DEC-1992; 92US-00987132.

PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINGCOMB D T.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (DRAP/) DRAPER K G.  
 PI Stinchcomb DT, Mcswiggen J, Draper KG,  
 DR WPI; 2003-340953/32.  
 XX  
 FT Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 XX  
 PS Claim 3; Page 28; 72pp; English.  
 XX  
 CC The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating REL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of REL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury  
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 XX  
 SQ Sequence 17 BP; 6 A; 4 C; 6 G; 0 T; 1 U; 0 Other;  
 Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 565 CTGTTCTGTCTCTG 579  
 |||||  
 16 CTGTCCTGTCTCTG 2  
 RESULT 485  
 ID ACA09009 standard; RNA; 17 BP.  
 AC ACA09009;  
 XX  
 DT 03-JUN-2003 (first entry)  
 XX  
 DE NFKB sub-unit modulating amberzyme substrate #172.  
 XX  
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;

XX	rhumatoid arthritis; reutenosis; Crohn's disease; obesity; ischaemia;
KW	gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW	transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW	allergic airway inflammation; inflammatory bowel disease; infection; se.
XX	
OS	Homo sapiens.
XX	
PN	US2002177568-A1.
XX	
PD	28-NOV-2002.
XX	
PF	23-MAY-2001; 2001US-00864785.
XX	
PR	07-DEC-1992; 92US-00987132.
PR	18-MAY-1994; 94US-00245466.
PR	15-AUG-1994; 94US-00291933.
PR	23-DEC-1996; 96US-00777916.
XX	
PA	(STIN/) STINCHOMB D T.
PA	(MCSW/) MCSWIGGEN J.
PA	(DRAP/) DRAPER K G.
XX	
PI	Stinchcomb DT, Mcswiggen J, Draper KG;
XX	
DR	WPI, 2003-340953/32.
XX	
PT	Novel enzymatic nucleic acid molecules which down regulates expression of
PT	a sequence encoding a subunit of nuclear factor kappa B useful for
PT	treating cancer, inflammatory disorders and autoimmune diseases.
XX	
PS	Claim 3, Page 54; 72pp; English.
XX	
CC	The invention describes an enzymatic nucleic acid molecule (I) which down
CC	regulates expression of a sequence encoding a subunit of nuclear factor
CC	kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC	confligration. The enzymatic nucleic acid molecule is adapted to treat
CC	cancer and is useful for down-regulating REL-A activity in a cell, for
CC	treating a patient having a condition associated with the level of REL-A.
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC	the presence of a divalent cation, especially Mg <sup>2+</sup> . The enzymatic and
CC	antisense nucleic acid molecules are useful for treating breast, lung,
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC	multidrug resistant cancer. The method involves use of other drug
CC	therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC	cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC	gemtadibine or radiation therapy. The enzymatic and antisense nucleic
CC	acid molecules are also useful for treating inflammatory disease such as
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC	rejection, gene therapy applications, ischaemia/reperfusion injury
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or
CC	infection. This sequence represents the substrate of a novel enzymatic
CC	nucleic acid molecule
XX	
SD	Sequence 17 BP; 3 A; 7 C; 6 G; 0 T; 1 U; 0 Other;
XX	
Query Match	0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity	86.7%; Pred. No. 2, 3e+02;
Matches 13; Conservative	1; Mismatches 1; Indels 0; Gaps 0;
XX	
QY	1362 CACCCAGGCTGTGGA 1376
DB	3 CACCCAGGCTGTGGA 17
XX	
RESULT 486	
ACAA06236/C	
ID ACAA06236 standard; RNA, 17 BP.	
XX	
AC ACAA06236;	

XX 03-JUN-2003 (first entry)  
 XX  
 XX NFKB sub-unit modulating inozyme substrate #55.  
 DE  
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB, inozyme; zinzyme;  
 KM G-cleaver; amberyze; cancer; RBL-A activity; breast cancer; human;  
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;  
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
 KM lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;  
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;  
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 PN US2002177568-A1.  
 PN  
 PD 28-NOV-2002.  
 PD  
 PF 23-MAY-2001; 2001US-00864785.  
 PF  
 XX 07-DEC-1992; 92US-00987132.  
 PR 18-MAY-1994; 94US-00245466.  
 PR 15-AUG-1994; 94US-00291932.  
 PR 23-DEC-1996; 96US-00777916.  
 XX  
 PA (STIN/) STINCCHOMB D T.  
 PA (MCSW/) MCSWIGEN J.  
 PA (DRAP/) DRAPER K G.  
 XX  
 PI Stinchcomb DT, Mcswiggen J, Draper KG;  
 XX  
 XX WPI; 2003-340953/32.  
 DR  
 XX  
 XX Novel enzymatic nucleic acid molecules which down regulates expression of  
 PT a sequence encoding a subunit of nuclear factor kappa B useful for  
 PT treating cancer, inflammatory disorders and autoimmune diseases.  
 PT  
 XX  
 XX Claim 3, Page 28; 72pp; English.  
 XX  
 XX The invention describes an enzymatic nucleic acid molecule (I) which down  
 CC regulates expression of a sequence encoding a subunit of nuclear factor  
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze  
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for  
 CC treating a patient having a condition associated with the level of RBL-A.  
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in  
 CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
 CC antisense nucleic acid molecules are useful for treating breast, lung,  
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
 CC multidrug resistant cancer. The method involves use of other drug  
 CC therapies such as monoclonal antibodies, RBL-A-specific inhibitors or  
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, or  
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
 CC acid molecules are also useful for treating inflammatory disease such as  
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
 CC rejection, gene therapy applications, ischaemia/reperfusion injury,  
 CC central nervous system (CNS) and myocardial, glomerulonephritis,  
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
 CC infection. This sequence represents the substrate of a novel enzymatic  
 CC nucleic acid molecule  
 CC  
 CC Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 565 CTGTTCTGTCGTCG 579  
 Db 17 CTGTCCTGTCCTG 3

RESULT 487  
 ABZ61828  
 ID ABZ61828 standard; RNA; 17 BP.  
 XX  
 AC ABZ61828;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human H-Ras DNAzyme target #619.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;  
 KW anti-rheumatic; cancer; AIDS; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PF 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Mcawiggen J;  
 XX  
 DR WPI; 2003-140484/13.  
 XX  
 PT Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX  
 PS Claim 58; Page 122; 185pp; English.  
 XX  
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytosolic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ6520 - ABZ6524,  
 CC ABZ6530 - ABZ6585 represent substrate/target sequences for the human  
 CC ribozymes of the invention  
 XX  
 SQ Sequence 17 BP; 0 A; 2 C; 10 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 73.3%; Pred. No. 2.3e+02;  
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 QY 167 GGGTCTGGGCGGTGG 181  
 Db 1 GGGUCUGGGCTUGG 15

RESULT 488  
 ABZ64627/c

ID ABZ64627 standard; RNA; 17 BP.  
 XX  
 AC ABZ64627;  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 DE Human HER2 DNAzyme substrate #84.  
 XX  
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;  
 KW anti-rheumatic; cancer; AIDS; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200297114-A2.  
 XX  
 PD 05-DEC-2002.  
 XX  
 PF 29-MAY-2002; 2002WO-US016840.  
 XX  
 PR 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 XX  
 PI Mcawiggen J;  
 XX  
 DR WPI; 2003-140484/13.  
 XX  
 PT Novel short interfering RNA and enzymatic nucleic acid useful for  
 PT treating cancer, modulates the expression of a nucleic acid encoding  
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX  
 PS Claim 4; Page 134; 185pp; English.  
 XX  
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic  
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
 CC acid molecule of the invention has cytosolic, anti-HIV, and anti-  
 CC rheumatic activity. The nucleic acid molecules are useful for reducing  
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ6520 - ABZ6524,  
 CC ABZ6530 - ABZ6585 represent substrate/target sequences for the human  
 CC ribozymes of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1284 CATTGTCGGCAGCT 1298  
 Db 15 CATTGTCGGCAGCT 1

RESULT 489  
 ACD53016/c  
 ID ACD53016 standard; RNA; 17 BP.  
 XX  
 AC ACD53016;  
 XX  
 DT 24-SEP-2003 (first entry)  
 XX  
 DE HBV inozyme substrate sequence #687.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinczyme;

KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KM HBV reverse transcriptase; Enhancer I region; viral replication;  
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KM virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis B virus.  
 PN WO200281494-A1.  
 PD 17-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PS  
 PS Example 1; Page 163; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinczymes, amberyne, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HBV  
 CC ribozyme, inozyme, G-cleaver, zinczyme, DNzyme or amberyne sequences  
 CC disclosed in the present invention  
 XX  
 SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 2162 GGGAGGGGGAGCC 2176  
 Db 15 GGGAGGGGGAGCC 1  
 ACDS7386  
 RESULT 490  
 ACDS7386

ID ACD57386 standard; RNA; 17 BP.  
 XX  
 AC ACD57386;  
 XX  
 DT 23-SEP-2003 (first entry)  
 XX  
 DE HCV DNzyme substrate sequence #308.  
 XX  
 KM Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KM RNA stability; RNA expression; RNA synthesis; antisense;  
 KM enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinczyme;  
 KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KM HBV reverse transcriptase; Enhancer I region; viral replication;  
 KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KM virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis C virus.  
 PN WO200281494-A1.  
 PD 17-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MACE/) MACEJAK D.  
 PA (MCSW/) MCSWIGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PS  
 PS Claim 1; Page 239; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinczymes, amberyne, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HCV  
 CC DNzyme or minus strand DNzyme sequences disclosed in the present  
 CC invention  
 XX  
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

```

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
Oy      59 TCGCATGGCTGGGA 73
      |||:||||:||||
Db      2 UCGCAUGGCUUGGA 16

RESULT 491
ACDS3015/c
ID ACDS3015 standard; RNA; 17 BP.
XX
AC ACDS3015;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #686.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberyyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN W0200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 163; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening

```

```

CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberyyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 0 T; 3 U; 0 Other;
XX

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      2162 GGGAGGGGGAGACC 2176
      |||||
Db      17 GGGAGGGGTGAACC 3

RESULT 492
ABX75171
ID ABX75171 standard; DNA; 17 BP.
XX
AC ABX75171;
XX
DT 25-MAR-2003 (first entry)
XX
DE Human 216 gene allele specific oligonucleotide probe #2.
XX
KW Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
OS Homo sapiens.
XX
PN W0200283077-A2.
XX
PD 24-OCT-2002.
XX
PF 15-APR-2002; 2002WO-US012063.
XX
PR 13-APR-2001; 2001US-00834597.
PR 13-APR-2001; 2001WO-US012245.
XX
PA (SCHE ) SCHERING CORP.
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2003-092960/08.
XX
PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX
PS Example 10; Page 166; 650pp; English.
XX
CC This invention relates to a novel isolated nucleic acid, gene 216,
CC identified from human chromosome 20p13-p12. The invention also discloses
CC regions of the 216 gene that contain single nucleotide polymorphisms
CC (SNP's) which may be used as markers for disease susceptibility or
CC severity. The nucleotides of the invention may have antiasthmatic,
CC antiinflammatory or anorectic activities and may be used in gene therapy.
CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC preventing or treating a disorder, such as respiratory diseases (e.g.
CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC disease or adult respiratory distress syndrome), obesity, or inflammatory
CC bowel syndrome. The nucleic acids are also useful for identifying

```

CC increased susceptibility of a subject to the disorders mentioned. The  
 CC nucleic acids can also be used as primers and templates for the  
 CC recombinant production of disorder-associated peptides or polypeptides,  
 CC for chromosome and gene mapping, or for tissue distribution studies. The  
 CC present sequence represents a gene 216 specific oligonucleotide probe  
 CC used in the scope of the invention

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 588 CTCCTCTCTGGGA 602

Db 2 CTCCTCTCTGGCA 16

RESULT 493

ACC62886/c  
 ID ACC62886 standard; DNA; 17 BP.

XX ACC62886;

XX 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 133.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 XX tumour suppression; tumour reversion; apoptosis; virus resistance;  
 XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 XX schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Teleman A, Amsen R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumours and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.

XX Disclosure; Page 46; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-  
 XX ACC68806), which are associated with tumour suppression, tumour  
 XX reversion, apoptosis and virus resistance. The oligonucleotides are  
 XX useful as (1) as probes and primers for detecting, identifying,  
 XX quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a  
 XX recombinant polypeptides. The oligonucleotides are useful for preparation  
 XX of pharmaceuticals for prevention and/or treatment of viral diseases that  
 XX are characterised by development of tumours or cell degeneration,  
 XX specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 337 TTCGAGAGCTGATC 351

Db 15 TTCCTAGAGCTGATC 1

RESULT 494

ACC66050  
 ID ACC66050 standard; DNA; 17 BP.

XX ACC66050;

XX 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 3297.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 XX tumour suppression; tumour reversion; apoptosis; virus resistance;  
 XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 XX schizophrenia; ss.

XX Mus musculus.

XX WO2003025176-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004210.

XX 17-SEP-2001; 2001FR-00011979.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Teleman A, Amsen R, Tuijnder M;

XX WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumours and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.

XX Disclosure; Page 416; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-  
 XX ACC68806), which are associated with tumour suppression, tumour  
 XX reversion, apoptosis and virus resistance. The oligonucleotides are  
 XX useful as (1) as probes and primers for detecting, identifying,  
 XX quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 XX gene chip; in vitro as (anti)sense reagents; and (2) for production of a  
 XX recombinant polypeptides. The oligonucleotides are useful for preparation  
 XX of pharmaceuticals for prevention and/or treatment of viral diseases that  
 XX are characterised by development of tumours or cell degeneration,  
 XX specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 2 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 976 TTCCTACCATGATC 990

Db 3 TTCCTACCATGATC 17

RESULT 495

ADB43052/c  
 ID ADB43052 standard; DNA; 17 BP.

XX ADB43052;

XX 18-DEC-2003 (revised)

XX Tumour suppression/reversion associated nucleotide #3375.

```

XX cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PE 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijinder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 426; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1181 TGCAGAAATTAAGA 1195
Db      17   TGAAGAATAATAAG 3

```

Search completed: June 30, 2004, 08:34:31  
 Job time : 15 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:30:23 ; Search time 13 Seconds  
(without alignments)  
3.554 Million cell updates/sec

Title: US-10-024-369-3  
Perfect score: 2247  
Sequence: 1 atgcagctcctcagtcgtcc.....ctgcagatgctccagaatga 2247

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 583 seqs, 10281 residues

Total number of hits satisfying chosen parameters: 1166

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 589 summaries

Database : rge3.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	40.6	1.8	41	1	AX513808
2	40.6	1.8	41	1	AX518978
3	40.6	1.8	41	1	AX521440
4	30.6	1.4	31	1	AX249257
5	28	1.2	28	1	BD142943
6	28	1.2	28	1	BD161970
7	27	1.2	27	1	AR052638
8	27	1.2	27	1	AR052639
9	26	1.2	26	1	BD142942
10	22	1.0	22	1	BD143003
11	22	1.0	22	1	BD143004
12	22	1.0	22	1	BD161968
13	22	1.0	22	1	BD161969
14	21	0.9	21	1	AX477614
15	21	0.9	21	1	AX505034
16	20.6	0.9	21	1	AX095590
17	20.6	0.9	21	1	AX095591
18	20.6	0.9	21	1	AX095592
19	20.6	0.9	21	1	AX095593
20	20.6	0.9	21	1	AX095594
21	20.6	0.9	21	1	AX095596
22	20.6	0.9	21	1	AX095597
23	20.6	0.9	21	1	AX095598
24	20	0.9	20	1	BD143002
25	19	0.8	19	1	AX477613
26	19	0.8	19	1	AX505033
27	19	0.8	19	1	BD143001
28	18.2	0.8	24	1	AX057826
29	18.2	0.8	24	1	AX457168
30	17.2	0.8	22	1	AR032131
31	17.2	0.8	22	1	BD192479
32	16.8	0.7	20	1	AR230795
33	16.4	0.7	21	1	AX096303
34	16.4	0.7	21	1	AX097152
35	16.2	0.7	21	1	AR085050
36	16.2	0.7	21	1	AX060422
37	16	0.7	20	1	AX295751
38	15.8	0.7	19	1	AR074584
39	15.8	0.7	19	1	AR157464
40	15.8	0.7	19	1	E39425
41	15.8	0.7	19	1	AX339215
42	15.8	0.7	19	1	BD141673
43	15.8	0.7	20	1	AR032132
44	15.8	0.7	20	1	AR220980
45	15.8	0.7	20	1	AR337234
46	15.8	0.7	20	1	AR361456
47	15.8	0.7	20	1	AR361457
48	15.8	0.7	20	1	AX058352
49	15.8	0.7	20	1	AX058353
50	15.8	0.7	20	1	AX062312
51	15.8	0.7	20	1	AX062313
52	15.8	0.7	20	1	BD192480
53	15.8	0.7	21	1	AX278535
54	15.8	0.7	21	1	AX513092
55	15.8	0.7	21	1	BD171659
56	15.4	0.7	17	1	AX724430
57	15.4	0.7	17	1	AX783932
58	15.4	0.7	18	1	AR039057
59	15.4	0.7	18	1	AR071237
60	15.4	0.7	18	1	E14107
61	15.4	0.7	18	1	AR196144
62	15.4	0.7	18	1	AR300594
63	15.4	0.7	19	1	AX130922
64	15.4	0.7	19	1	AX130923
65	15.4	0.7	19	1	AX130924
66	15.4	0.7	19	1	A62106
67	15.2	0.7	20	1	AR032133
68	15.2	0.7	20	1	AR032134
69	15.2	0.7	20	1	AR084441
70	15.2	0.7	20	1	AR093883
71	15.2	0.7	20	1	AR097398
72	15.2	0.7	20	1	AR116476
73	15.2	0.7	20	1	AR154591
74	15.2	0.7	20	1	BD244905
75	15.2	0.7	20	1	125703
76	15.2	0.7	20	1	AR229022
77	15.2	0.7	20	1	AR243597
78	15.2	0.7	20	1	AR297055
79	15.2	0.7	20	1	AR297103
80	15.2	0.7	20	1	AR312679
81	15.2	0.7	20	1	AR312813
82	15.2	0.7	20	1	AR314336
83	15.2	0.7	20	1	AR323199
84	15.2	0.7	20	1	AX197430
85	15.2	0.7	20	1	AX546286
86	15.2	0.7	20	1	AX546376
87	15.2	0.7	20	1	AX794385
88	15.2	0.7	20	1	BD004726
89	15.2	0.7	20	1	BD074633
90	15.2	0.7	20	1	BD083842
91	15.2	0.7	20	1	BD083881
92	15.2	0.7	20	1	BD103497
93	15.2	0.7	20	1	BD138082
94	15.2	0.7	20	1	BD192481
95	15.2	0.7	20	1	BD192482
96	15.2	0.7	20	1	AX114466
97	15	0.7	19	1	AX202054
98	15	0.7	20	1	AR129704
99	15	0.7	18	1	BD242514
100	14.8	0.7	18	1	BD242514
101	14.8	0.7	18	1	AX766750
102	14.8	0.7	18	1	A51892
103	14.8	0.7	19	1	A67354
104	14.8	0.7	19	1	A87526
105	14.8	0.7	19	1	AR085857
106	14.8	0.7	19	1	AR085857







545	12.8	0.6	17	1	AX727575	ACCESSION:AX727575
546	12.8	0.6	17	1	AX728137	ACCESSION:AX728137
547	12.8	0.6	17	1	AX728606	ACCESSION:AX728606
548	12.8	0.6	17	1	AX728864	ACCESSION:AX728864
549	12.8	0.6	17	1	AX728907	ACCESSION:AX728907
550	12.8	0.6	17	1	AX731757	ACCESSION:AX731757
551	12.8	0.6	17	1	AX732158	ACCESSION:AX732158
552	12.8	0.6	17	1	AX732941	ACCESSION:AX732941
553	12.8	0.6	17	1	AX733047	ACCESSION:AX733047
554	12.8	0.6	17	1	AX733291	ACCESSION:AX733291
555	12.8	0.6	17	1	AX733627	ACCESSION:AX733627
556	12.8	0.6	17	1	AX734653	ACCESSION:AX734653
557	12.8	0.6	17	1	AX734659	ACCESSION:AX734659
558	12.8	0.6	17	1	AX736797	ACCESSION:AX736797
559	12.8	0.6	17	1	AX739468	ACCESSION:AX739468
560	12.8	0.6	17	1	AX739703	ACCESSION:AX739703
561	12.8	0.6	17	1	AX744302	ACCESSION:AX744302
562	12.8	0.6	17	1	AX744303	ACCESSION:AX744303
563	12.8	0.6	17	1	AX745332	ACCESSION:AX745332
564	12.8	0.6	17	1	AX753782	ACCESSION:AX753782
565	12.8	0.6	17	1	AX753783	ACCESSION:AX753783
566	12.8	0.6	17	1	AX756714	ACCESSION:AX756714
567	12.8	0.6	17	1	AX757942	ACCESSION:AX757942
568	12.8	0.6	17	1	AX758903	ACCESSION:AX758903
569	12.8	0.6	17	1	AX759607	ACCESSION:AX759607
570	12.8	0.6	17	1	AX760088	ACCESSION:AX760088
571	12.8	0.6	17	1	AX761127	ACCESSION:AX761127
572	12.8	0.6	17	1	AX761670	ACCESSION:AX761670
573	12.8	0.6	17	1	AX761804	ACCESSION:AX761804
574	12.8	0.6	17	1	AX761929	ACCESSION:AX761929
575	12.8	0.6	17	1	AX781766	ACCESSION:AX781766
576	12.8	0.6	17	1	AX781767	ACCESSION:AX781767
577	12.8	0.6	17	1	AX782300	ACCESSION:AX782300
578	12.8	0.6	17	1	AX782301	ACCESSION:AX782301
579	12.8	0.6	17	1	AX783936	ACCESSION:AX783936
580	12.8	0.6	17	1	AX816806	ACCESSION:AX816806
581	12.8	0.6	17	1	BD067894	ACCESSION:BD067894
582	12.8	0.6	17	1	BD104823	ACCESSION:BD104823
583	12.8	0.6	17	1	BD105166	ACCESSION:BD105166
584	12.8	0.6	17	1	BD202752	ACCESSION:BD202752
585	12.8	0.6	17	1	BD202753	ACCESSION:BD202753
586	12.8	0.6	17	1	BD202918	ACCESSION:BD202918
587	12.8	0.6	17	1	BD203057	ACCESSION:BD203057
588	12.8	0.6	17	1	BD226467	ACCESSION:BD226467
589	12.8	0.6	17	1	AJ587490	ACCESSION:AJ587490

## ALIGNMENTS

RESULT 1  
AX513808 41 bp DNA 1linear PAT 05-OCT-2002  
DEFINITION Sequence 6 from Patent WO02052044.  
ACCESSION AX513808  
VERSION AX513808.1 GI:23559990  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.  
TITLE Detection of genetic polymorphisms  
JOURNAL Patent: WO 02052044-A 6 04-JUL-2002;  
Riken (JP)  
FEATURES  
source 1. 41  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;

Best Local Similarity 97.6%; Pred. No. 0.065;  
Matches 40; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017  
Db 1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

## RESULT 2

AX518978 41 bp DNA 1linear PAT 05-OCT-2002  
LOCUS AX518978  
DEFINITION Sequence 5176 from Patent WO02052044.  
ACCESSION AX518978  
VERSION AX518978.1 GI:23568986  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.  
TITLE Detection of genetic polymorphisms  
JOURNAL Patent: WO 02052044-A 5176 04-JUL-2002;  
Riken (JP)  
FEATURES  
source 1. 41  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;  
Best Local Similarity 97.6%; Pred. No. 0.065;  
Matches 40; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017  
Db 1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

## RESULT 3

AX521440 41 bp DNA 1linear PAT 05-OCT-2002  
LOCUS AX521440  
DEFINITION Sequence 7638 from Patent WO02052044.  
ACCESSION AX521440  
VERSION AX521440.1 GI:23572410  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.  
TITLE Detection of genetic polymorphisms  
JOURNAL Patent: WO 02052044-A 7638 04-JUL-2002;  
Riken (JP)  
FEATURES  
source 1. 41  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.8%; Score 40.6; DB 1; Length 41;  
Best Local Similarity 97.6%; Pred. No. 0.065; 0; Indels 0; Gaps 0;  
Matches 40; Conservative 1; Mismatches 0; Indels 0;

Qy 977 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 1017  
Db 1 CCCTCACCATGTCACCCCTGATCACCCTGCTGCTTTTC 41

RESULT 4  
LOCUS AX249257 31 bp DNA 1linear PAT 28-SEP-2001

DEFINITION Sequence 1336 from Patent WO0166800.  
ACCESSION AX249257  
VERSION AX249257.1 GI:15863880  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Cargill,M., Ireland,J.S. and Lander,E.S.  
TITLE Human single nucleotide polymorphisms  
JOURNAL Patent: WO 0166800-A 1336 13-SEP-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)  
FEATURES  
source  
1. .31  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 30.6; DB 1; Length 31;  
Best Local Similarity 96.8%; Pred. No. 1.6;  
Matches 30; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 408 CCCACGCCCTTCGTTGCTGCTATTCAGCG 438  
|||||  
Db 1 CCTACCGCCTTCGTGTGCTATTCAGCG 31

RESULT 5  
BD142943  
LOCUS BD142943 28 bp DNA linear PAT 17-JAN-2003  
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.  
ACCESSION BD142943  
VERSION BD142943.1 GI:27848701  
KEYWORDS JP 2002112775-A/14.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 28)  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 14 16-APR-2002;  
OTSUKA PHARMACEUTICAL FACTORY INC  
COMMENT OS human ABCB2 gene  
PN JP 2002112775-A/14  
PD 16-APR-2002  
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
PC C12N15/09,C12Q1/68,C12N15/00  
CC Method of assaying human ABC transporter and probe and kit therefor  
FH Key Location/Qualifiers  
FT source 1.28  
/organism='human ABCB2 gene'.  
FEATURES  
source  
1. .28  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 1.2%; Score 28; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 3.6;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 653 ATGGCTCAGCGATACCTTCACTCGAAA 680  
|||||  
Db 1 ATGGCTCAGCGATACCTTCACTCGAAA 28

RESULT 6  
BD161970  
LOCUS BD161970 28 bp DNA linear PAT 17-JAN-2003

DEFINITION Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor.  
ACCESSION BD161970  
VERSION BD161970.1 GI:27867728  
KEYWORDS JP 2002181818-A/21.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 28)  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor  
JOURNAL Patent: JP 2002181818-A 21 26-JUN-2002;  
OTSUKA PHARMACEUTICAL FACTORY INC  
COMMENT OS Human ABCB2 gene  
PN JP 2002181818-A/21  
PD 26-JUN-2002  
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
PC G01N33/53,C12N15/09,C12Q1/48,C12Q1/68,G01N33/566,C12N15/00 CC Simultaneous assay method of a plurality of different molecular species proteins mRNA and kit container used therefor  
FH Key Location/Qualifiers  
FT source 1.28  
/organism='Human ABCB2 gene'.  
FEATURES  
source  
1. .28  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 1.2%; Score 28; DB 1; Length 28;  
Best Local Similarity 100.0%; Pred. No. 3.6;  
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 653 ATGGCTCAGCGATACCTTCACTCGAAA 680  
|||||  
Db 1 ATGGCTCAGCGATACCTTCACTCGAAA 28

RESULT 7  
AR052638/c  
LOCUS AR052638 27 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 4 from patent US 5831068.  
ACCESSION AR052638  
VERSION AR052638.1 GI:5976002  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 27)  
AUTHORS Nair,S.K. and Gilboa,E.  
TITLE Method to increase the density of antigen on antigen presenting cells  
JOURNAL Patent: US 5831068-A 4 03-NOV-1998;  
FEATURES  
source  
1. .27  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 27; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 5;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1192 AAGACACTCAACGAGAGAGGCTGTG 1218  
|||||  
Db 27 AAGACACTCAACGAGAGAGGCTGTG 1

RESULT 8  
AR052639/c  
LOCUS AR052639 27 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 5 from patent US 5831068.  
ACCESSION AR052639  
VERSION AR052639.1 GI:5976003  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Naito,S.K. and Glibbova,E.  
TITLE Method to increase the density of antigen on antigen presenting cells  
JOURNAL Patent: US 5831068-A 5 03-NOV-1998;  
FEATURES  
source  
1. .27  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 27; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 5;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1978 AAACCGTGTACTTATCTCGATGAT 2004  
Db 27 AAACCGTGTACTTATCTCGATGAT 1  
RESULT 9  
BD142942  
LOCUS BD142942 26 bp DNA linear PAT 17-JAN-2003  
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.  
ACCESSION BD142942  
VERSION BD142942.1 GI:27848700  
KEYWORDS JP 2002112775-A/13.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 13 16-APR-2002;  
COMMENT  
OS human ABCB2 gene  
PN JP 2002112775-A/13  
PD 16-APR-2002  
PP 03-OCT-2000 JP 2000303404  
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
PC C12N15/09,C12Q1/68,C12N15/00  
CC Method of assaying human ABC transporter and probe and kit CC  
FH Key Location/Qualifiers  
FT source 1. .26  
/organism="human ABCB2 gene".  
FEATURES  
source  
1. .26  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 1.2%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 6.8;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 330 TGCCTTTTCCGAGAGCTGATTCAT 355  
Db 1 TGCCTTTTCCGAGAGCTGATTCAT 26  
RESULT 10  
BD143003  
LOCUS BD143003 22 bp DNA linear PAT 17-JAN-2003  
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.

ACCESSION BD143003  
VERSION BD143003.1 GI:27848761  
KEYWORDS JP 2002112775-A/74.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 74 16-APR-2002;  
COMMENT  
OS human ABCB2 gene  
PN JP 2002112775-A/74  
PD 16-APR-2002  
PP 03-OCT-2000 JP 2000303404  
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
PC C12N15/09,C12Q1/68,C12N15/00  
CC Method of assaying human ABC transporter and probe and kit CC  
FH Key Location/Qualifiers  
FT source 1. .22  
/organism="human ABCB2 gene".  
FEATURES  
source  
1. .22  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 1.0%; Score 22; DB 1; Length 22;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 628 CGCCTCAGCTGAGTTCATC 649  
Db 1 CGCCTCAGCTGAGTTCATC 22  
RESULT 11  
BD143004  
LOCUS BD143004 22 bp DNA linear PAT 17-JAN-2003  
DEFINITION Method of assaying human ABC transporter and probe and kit therefor.  
ACCESSION BD143004  
VERSION BD143004.1 GI:27848762  
KEYWORDS JP 2002112775-A/75.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 75 16-APR-2002;  
COMMENT  
OS human ABCB2 gene  
PN JP 2002112775-A/75  
PD 16-APR-2002  
PP 03-OCT-2000 JP 2000303404  
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
PC C12N15/09,C12Q1/68,C12N15/00  
CC Method of assaying human ABC transporter and probe and kit CC  
FH Key Location/Qualifiers  
FT source 1. .22  
/organism="human ABCB2 gene".  
FEATURES  
source  
1. .22  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 1.0%; Score 22; DB 1; Length 22;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 TGGGTACGGGATCTATACAA 752  
 |||||||  
 Db 22 TGGGTACGGGATCTATACAA 1

RESULT 12  
 BD161968 22 bp DNA linear PAT 17-JAN-2003  
 LOCUS BD161968  
 DEFINITION Simultaneous assay method of a plurality of different molecular  
 species proteins mRNA and kit container used therefor.  
 BD161968  
 ACCESSION BD161968.1 GI:27867726  
 VERSION JP 2002181818-A/19.  
 KEYWORDS unclassified  
 SOURCE unclassified  
 ORGANISM unclassified.

REFERENCE  
 1 (bases 1 to 22)  
 Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
 TITLE Simultaneous assay method of a plurality of different molecular  
 species proteins mRNA and kit container used therefor  
 JOURNAL Patent: JP 2002181818-A 19 26-JUN-2002;  
 OTSUKA PHARMACEUTICAL FACTORY INC  
 COMMENT OS Human ABCB2 gene  
 PN JP 2002181818-A/19  
 PD 26-JUN-2002  
 PF 15-DEC-2000 JP 2000381621  
 PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
 PC G01N33/53,C12N15/09,C12Q1/48,G01N33/566,C12N15/00 CC  
 Simultaneous assay method of a plurality of different CC  
 molecular species  
 CC proteins mRNA and kit container used therefor FH Key  
 Location/Qualifiers  
 FT source 1..22  
 1..22 /organism='Human ABCB2 gene'.  
 /mol\_type='genomic DNA'  
 /db\_xref='taxon:32644'

Query Match 1.0%; Score 22; DB 1; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 23;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 628 CGCCTCACTGACTGATTCTAC 649  
 |||||||  
 Db 1 CGCCTCACTGACTGATTCTAC 22

RESULT 13  
 BD161969 22 bp DNA linear PAT 17-JAN-2003  
 LOCUS BD161969/c  
 DEFINITION Simultaneous assay method of a plurality of different molecular  
 species proteins mRNA and kit container used therefor.  
 BD161969  
 ACCESSION BD161969.1 GI:27867727  
 VERSION JP 2002181818-A/20.  
 KEYWORDS unclassified  
 SOURCE unclassified  
 ORGANISM unclassified.

REFERENCE  
 1 (bases 1 to 22)  
 Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
 TITLE Simultaneous assay method of a plurality of different molecular  
 species proteins mRNA and kit container used therefor  
 JOURNAL Patent: JP 2002181818-A 20 26-JUN-2002;  
 OTSUKA PHARMACEUTICAL FACTORY INC  
 COMMENT OS Human ABCB2 gene  
 PN JP 2002181818-A/20  
 PD 26-JUN-2002  
 PF 15-DEC-2000 JP 2000381621  
 PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAOKA  
 PC G01N33/53,C12N15/09,C12Q1/48,C12Q1/68,G01N33/566,C12N15/00 CC  
 Simultaneous assay method of a plurality of different CC  
 molecular species  
 CC proteins mRNA and kit container used therefor FH Key  
 Location/Qualifiers  
 FT source 1..22  
 1..22 /organism='Human ABCB2 gene'.  
 /mol\_type='genomic DNA'  
 /db\_xref='taxon:32644'

Simultaneous assay method of a plurality of different CC  
 molecular species  
 CC proteins mRNA and kit container used therefor FH Key  
 Location/Qualifiers  
 FT source 1..22  
 1..22 /organism='Human ABCB2 gene'.  
 /mol\_type='genomic DNA'  
 /db\_xref='taxon:32644'

Query Match 1.0%; Score 22; DB 1; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 23;  
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 TGGGTACGGGATCTATACAA 752  
 |||||||  
 Db 22 TGGGTACGGGATCTATACAA 1

RESULT 14  
 AX477614/c 21 bp DNA linear PAT 12-AUG-2002  
 LOCUS AX477614  
 DEFINITION Sequence 66 from Patent WO0246433.  
 AX477614  
 ACCESSION AX477614.1 GI:22216794  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 REFERENCE  
 1  
 Saus,J.  
 TITLE Tnf-inducible promoters and methods for using  
 JOURNAL Patent: WO 0246433-A 66 13-JUN-2002;  
 Saus, Juan (ES)  
 Location/Qualifiers  
 FT source 1..21  
 1..21 /organism='synthetic construct'  
 /mol\_type='unassigned DNA'  
 /db\_xref='taxon:32630'  
 /note='Primer ON-TAP1-R2'

Query Match 0.9%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 31;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678  
 |||||||  
 Db 21 TCAGCCGATACCTTCACTCGA 1

RESULT 15  
 AX505034/c 21 bp DNA linear PAT 27-SEP-2002  
 LOCUS AX505034  
 DEFINITION Sequence 66 from Patent WO0246378.  
 AX505034  
 ACCESSION AX505034  
 VERSION AX505034.1 GI:23386356  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 REFERENCE  
 1  
 Saus,J.  
 TITLE Alternative pol k nucleotide and amino acid sequence and methods  
 for using  
 JOURNAL Patent: WO 0246378-A 66 13-JUN-2002;  
 Saus, Juan (ES)  
 Location/Qualifiers  
 FT source 1..21  
 1..21 /organism='synthetic construct'  
 /mol\_type='unassigned DNA'  
 /db\_xref='taxon:32630'



/note="Primer ON-TAP1-R2"

Query Match 0.9%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 TCAGCCGATACCTTCACTCGA 678  
|||||  
21 TCAGCCGATACCTTCACTCGA 1

RESULT 16  
AX095590 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 768 from Patent WO0118250.  
ACCESSION AX095590  
VERSION AX095590.1 GI:13511793  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 768 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. 21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 706 ATAGCCAGTGCAGCTGAG 726  
|||||  
1 ATAGCCAGTGCAGCTGAG 21

RESULT 17  
AX095591 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 769 from Patent WO0118250.  
ACCESSION AX095591  
VERSION AX095591.1 GI:13511794  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 769 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. 21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 407 ACCCTACCGCTTGTGTCA 427

Db 1 ACCCTACCGCTTGTGTCA 21  
|||||

RESULT 18  
AX095592 21 bp DNA linear PAT 30-MAR-2001  
LOCUS  
DEFINITION Sequence 770 from Patent WO0118250.  
ACCESSION AX095592  
VERSION AX095592.1 GI:13511795  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 770 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. 21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 578 TGGTGTCCTCTCTCTTG 598  
|||||  
1 TGGTGTCCTCTCTCTTG 21

RESULT 20  
AX095594 21 bp DNA linear PAT 30-MAR-2001  
LOCUS  
DEFINITION Sequence 771 from Patent WO0118250.  
ACCESSION AX095594  
VERSION AX095594.1 GI:13511796  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and  
McCarthy, J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 771 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1. 21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 318 CTTGCCGCGACTGCTTGT 338  
|||||  
1 CTTGCCGCGACTGCTTGT 21

DEFINITION Sequence 772 from Patent WO0118250.  
ACCESSION AX095594  
VERSION AX095594.1 GI:13511797  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 772 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1245 TAGTATTTCAGGATGCTGCT 1265  
Db 1 TAGTATTTCAGGATGCTGCT 21  
RESULT 21  
AX095596 21 bp DNA linear PAT 30-MAR-2001  
LOCUS Sequence 774 from Patent WO0118250.  
ACCESSION AX095596  
VERSION AX095596.1 GI:13511799  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 774 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 847 AACATCATGCTCGGGTACA 867  
Db 1 AACATCATGCTCGGGTACA 21  
RESULT 22  
AX095597 21 bp DNA linear PAT 30-MAR-2001  
LOCUS Sequence 775 from Patent WO0118250.  
ACCESSION AX095597  
VERSION AX095597.1 GI:13511800  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 775 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1537 CCAACCGCCGATGCTCTTA 1557  
Db 1 CCAACCGCCGATGCTCTTA 21  
RESULT 24  
BD143002/c 20 bp DNA linear PAT 17-JAN-2003  
LOCUS Method of assaying human ABC transporter and probe and kit therefor.  
ACCESSION BD143002  
VERSION BD143002.1 GI:27848760  
KEYWORDS JP 2002112775-A/73.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 73 16-APR-2002;  
OS OTSUKA PHARMACEUTICAL FACTORY INC  
COMMENT human ABCB2 gene

REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 775 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 987 GGTACCCCTGATCACCTGCC 1007  
Db 1 GGTACCCCTGATCACCTGCC 21  
RESULT 23  
AX095598 21 bp DNA linear PAT 30-MAR-2001  
LOCUS Sequence 776 from Patent WO0118250.  
ACCESSION AX095598  
VERSION AX095598.1 GI:13511801  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 776 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 36;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 1537 CCAACCGCCGATGCTCTTA 1557  
Db 1 CCAACCGCCGATGCTCTTA 21  
RESULT 24  
BD143002/c 20 bp DNA linear PAT 17-JAN-2003  
LOCUS Method of assaying human ABC transporter and probe and kit therefor.  
ACCESSION BD143002  
VERSION BD143002.1 GI:27848760  
KEYWORDS JP 2002112775-A/73.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.  
TITLE Method of assaying human ABC transporter and probe and kit therefor  
JOURNAL Patent: JP 2002112775-A 73 16-APR-2002;  
OS OTSUKA PHARMACEUTICAL FACTORY INC  
COMMENT human ABCB2 gene

```

PN JP 2002112775-A/73
PD 16-APR-2002
PF 03-OCT-2000 JP 2000303404
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAKA
PC C12N15/09,C12Q1/68,C12N15/00
CC Method of assaying human ABC transporter and probe and kit CC
therefor
FH Key Location/Qualifiers
FT source 1..20 /organism='human ABCB2 gene'.
Location/Qualifiers
1..20 /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 412 ACCGCTTCGTGTCAGTGA 431
|||||
Db 20 ACCGCTTCGTGTCAGTGA 1

RESULT 25
AX477613 19 bp DNA linear PAT 12-AUG-2002
LOCUS AX477613
DEFINITION Sequence 65 from Patent WO246433.
ACCESSION AX477613
VERSION AX477613.1 GI:22216793
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
1
REFERENCE
AUTHORS Saus,J.
TITLE Trf-inducible promoters and methods for using
JOURNAL Patent: WO 0246433-A 65 13-JUN-2002;
Saus, Juan (ES)
FEATURES
source Location/Qualifiers
1..19 /organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/ncbi_xref='Primer ON-TAP1-F2'

Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCGGCTCTGACTGACTGAT 644
|||||
Db 1 GCGGCTCTGACTGACTGAT 19

RESULT 26
AX505033 19 bp DNA linear PAT 27-SEP-2002
LOCUS AX505033
DEFINITION Sequence 65 from Patent WO246378.
ACCESSION AX505033
VERSION AX505033.1 GI:23386355
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
1
REFERENCE
AUTHORS Saus,J.
TITLE Alternative pol k nucleotide and amino acid sequence and methods
for using
JOURNAL Patent: WO 0246378-A 65 13-JUN-2002;
Saus, Juan (ES)
FEATURES
source Location/Qualifiers

```

```

source 1..19
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/ncbi_xref='Primer ON-TAP1-F2'

Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 GCGGCTCTGACTGACTGAT 644
|||||
Db 1 GCGGCTCTGACTGACTGAT 19

RESULT 27
BD143001 19 bp DNA linear PAT 17-JAN-2003
LOCUS BD143001
DEFINITION Method of assaying human ABC transporter and probe and kit
therefor.
ACCESSION BD143001
VERSION BD143001.1 GI:27848759
KEYWORDS JP 2002112775-A/72.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 19)
REFERENCE
AUTHORS Nishimura,M., Yaguchi,H., Naito,S. and Hiraoka,I.
TITLE Method of assaying human ABC transporter and probe and kit therefor
JOURNAL Patent: JP 2002112775-A 72 16-APR-2002;
OTSUKA PHARMACEUTICAL FACTORY INC
OS human ABCB2 gene
PN JP 2002112775-A/72
PD 16-APR-2002
PF 03-OCT-2000 JP 2000303404
PI MASUHIRO NISHIMURA,HIROSHI YAGUCHI,SHINSAKU NAITO,ISAO HIRAKA
PC C12N15/09,C12Q1/68,C12N15/00
CC Method of assaying human ABC transporter and probe and kit CC
therefor
FH Key Location/Qualifiers
FT source 1..19 /organism='human ABCB2 gene'.
Location/Qualifiers
1..19 /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 TTGAAGCCATTAGTCGCG 304
|||||
Db 1 TTGAAGCCATTAGTCGCG 19

RESULT 28
AX057826 24 bp DNA linear PAT 17-JAN-2001
LOCUS AX057826
DEFINITION Sequence 4 from Patent WO0075334.
ACCESSION AX057826
VERSION AX057826.1 GI:12310468
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
1
REFERENCE
AUTHORS Moise,A.R., Jefferies,W.A. and Vitalis,T.Z.
TITLE Apoptosis inhibition by adenovirus e3/6.7k
JOURNAL Patent: WO 0075334-A 4 14-DEC-2000;
UNIVERSITY OF BRITISH COLUMBIA (CA)
FEATURES
source Location/Qualifiers

```

```

SOURCE
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Reverse Primer"

Query Match      0.8%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1990 CTTATCCTGATGATGCCACCAG 2012
          |||||
          2 CTTATCTTGATGTTGCCCCAG 24

RESULT 29
AX457168      24 bp      DNA      linear      PAT 08-JUL-2002
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Reverse Primer"

Query Match      0.8%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred. No. 90;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1990 CTTATCCTGATGATGCCACCAG 2012
          |||||
          2 CTTATCTTGATGTTGCCCCAG 24

RESULT 30
AR032131/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1617 CAATGGGCTGTGGGAAGACACA 1638
          |||||
          22 CAGTGGCTGTGGGAAGACACA 1
```

```

RESULT 31
BD192479/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
PN
PD
PF
PR
PI
PC
FEATURES
source
1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      0.8%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1617 CAATGGGCTGTGGGAAGACACA 1638
          |||||
          22 CAGTGGCTGTGGGAAGACACA 1

RESULT 32
AR230795/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACCAAGAGAG 1212
          |||||
          20 AGACACCCACCAAGAGAG 1

RESULT 33
AX096303
LOCUS
21 bp      DNA      linear      PAT 30-MAR-2001
```

DEFINITION Sequence 1481 from Patent WO0118250.  
ACCESSION AX096303  
VERSION AX096303.1 GI:13512530  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
AUTHORS Lander, E.S., Gargall, M., Ireland, J.S., Bolk, S., Daley, G.Q. and McCarty, J.V.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 1481 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source location/Qualifiers  
1. .21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 16.4; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1565 AGGGGCTGACATTCACCCCTA 1564  
DB 2 AGGGGCTGATGTTACCCCTA 21

RESULT 34  
LOCUS AX097152 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 2330 from Patent WO0118250.  
ACCESSION AX097152  
VERSION AX097152.1 GI:13513456  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
AUTHORS Lander, E.S., Gargall, M., Ireland, J.S., Bolk, S., Daley, G.Q. and McCarty, J.V.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 2330 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)  
FEATURES  
source location/Qualifiers  
1. .21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 16.4; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCGAGGCGGCTGCT 278  
DB 20 GCAGGTGCCGAGGCGGCTGCT 1

RESULT 35  
LOCUS AR085050 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 12 from patent US 5981262.  
ACCESSION AR085050  
VERSION AR085050.1 GI:10011821  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
FEATURES  
source Unclassified.

REFERENCE 1 (bases 1 to 21)  
AUTHORS Brugge, J., Morganstern, J., Shive, L., Zydowsky, L., Zoller, M. and Pawson, A.  
TITLE Human syk  
JOURNAL Patent: US 5981262-A 12 09-NOV-1999;  
FEATURES  
source location/Qualifiers  
1. .21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 1.6e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 821 AGTTTTCACAGAACCA 841  
DB 1 AGTATTTCACAGAACCA 21

RESULT 36  
LOCUS AX060422 21 bp DNA linear PAT 22-JAN-2001  
DEFINITION Sequence 42 from Patent WO0100841.  
ACCESSION AX060422  
VERSION AX060422.1 GI:12405899  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE artificial sequences.  
1  
AUTHORS Griffin, J., Carlile, A.J., Cayley, P.J., Mackay, E.A., Warner, S.A., Vincent, J.L. and Lee, M.D.  
TITLE Insecticidal proteins from psocidomyces and synergistic combinations thereof  
JOURNAL Patent: WO 0100841-A 42 04-JAN-2001;  
ZENECA LIMITED (GB)  
FEATURES  
source location/Qualifiers  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Primers"

Query Match 0.7%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 1.6e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 101 TGCTGCTCCGACCGGCTGC 121  
DB 1 TGCTGCTCCGACCGGCTGC 21

RESULT 37  
LOCUS AX295751 20 bp DNA linear PAT 21-NOV-2001  
DEFINITION Sequence 7513 from Patent WO0179548.  
ACCESSION AX295751  
VERSION AX295751.1 GI:17057440  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE artificial sequences.  
1  
AUTHORS Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kilman, R.  
TITLE Method of designing addressable array for detection of nucleic acid  
JOURNAL Sequence differences using ligase detection reaction  
PATENT: WO 0179548-A 7513 25-OCT-2001;  
CORNELL RESEARCH FOUNDATION, INC. (US)  
FEATURES  
source location/Qualifiers  
1. .20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

```
/note="Hypothetical Probe Sequence"
Query Match      0.7%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      269 AGGCTGCTGCTGCTGC 284
      |||
      19 AGGCTGCTGCTGCTGC 4

Db

RESULT 38
AR074584      19 bp      DNA      linear      PAT 28-AUG-2000
DEFINITION   Sequence 40 from patent US 5955263.
ACCESSION    AR074584
VERSION      AR074584.1 GI:10001337
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Vogelstein,B., Kinzler,K.W. and Sherman,M.I.
TITLE        Sequence specific DNA binding by p53
JOURNAL      Patent: US 5955263-A 40 21-SEP-1999;
FEATURES
source       /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      318 CCGCGCGGACTTGCCTTG 336
      |||
      1 CCGCTGCTGACTTGCCTG 19

Db

RESULT 39
AR157464      19 bp      DNA      linear      PAT 17-OCT-2001
DEFINITION   Sequence 40 from patent US 6245515.
ACCESSION    AR157464
VERSION      AR157464.1 GI:16218405
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Vogelstein,B., Kinzler,K.W. and Sherman,M.I.
TITLE        Sequence specific DNA binding p53
JOURNAL      Patent: US 6245515-A 40 12-JUN-2001;
FEATURES
source       /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      318 CCGCGCGGACTTGCCTTG 336
      |||
      1 CCGCTGCTGACTTGCCTG 19

Db

RESULT 40
E39425      19 bp      DNA      linear      PAT 31-JAN-2002
LOCUS        E39425
DEFINITION   Novel membrane-bound metalloprotease.
ACCESSION    E39425
VERSION      E39425.1 GI:18621534
```

```
KEYWORDS      JP 2000270874-A/3.
SOURCE        synthetic construct
ORGANISM      synthetic construct
REFERENCE     1 (bases 1 to 19)
AUTHORS       Ropesumotin,C., Kuadora,E.J., Pendaau,A.M., Fureihe,J.B., Noki,T.,
              Shinagawa,A. and Iwata,K.
TITLE         Novel membrane-bound metalloprotease
JOURNAL      Patent: JP 2000270874-A 3 03-OCT-2000;
COMMENT       FUJI CHEMICAL INDUSTRIES LTD
              OS Artificial Sequence
              PN JP 2000270874-A/3
              PD 03-OCT-2000
              PF 25-MAR-1999 JP 1999082516
              PR
              PI CARLOS ROPESU-OTIN, ELENA JANO KUADORA, ALBERT M PENDASU, PI
              JOSE B FUREIHE,
              PI TAKANORI NOKI, AKIRA SHINAGAWA, KAZUSHI IWATA
              PC C12N15/09,A61K31/00,A61K31/00,A61K31/00,A61K31/00,A61K31/00,
              PC A61K31/00,A61K31/00,A61K31/00,A61K31/70,A61K38/46,
              PC A61K39/395,
              PC A61K39/395,A61K45/00,A61K48/00,C07K16/40,C12N1/19,C12N1/21, PC
              C12N5/10,C12Q1/68,G01N33/53,G01N33/573//C12P21/08,C12N15/00,
              PC C12N9/50,C12Q1/68,G01N33/53,G01N33/573//C12P21/08,C12N15/00,
              PC A61K37/54,
              PC C12N5/00
              CC
              FH Key
              FT source

FEATURES
source       /organism="Artificial Sequence".
             /organism="synthetic construct"
             /mol_type="genomic DNA"
             /db_xref="taxon:32630"

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1362 CAGCCAGCTGTGAGGTA 1380
      |||
      1 CCCCAGGCTGTGGGGTA 19

Db

RESULT 41
AX339215      19 bp      DNA      linear      PAT 10-JAN-2002
LOCUS        AX339215
DEFINITION   Sequence 9 from Patent WO0196602.
ACCESSION    AX339215
VERSION      AX339215.1 GI:18135476
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Yang A.L. and Pesting,M.
TITLE        Methods and materials to determine the p53 status of a sample by
              determining the binding of p53 to a vector
JOURNAL      Patent: WO 0196602-A 9 20-DEC-2001;
MEDICAL RESEARCH COUNCIL (GB)
FEATURES
source       /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 318 CCTGCCGGGACTTGCCTTG 336  
Db 1 CCTGCCCTGGACTTGCCTGG 19

## RESULT 42

BD141673 19 bp DNA linear PAT 18-SEP-2002  
LOCUS Transgenic animal.  
DEFINITION BD141673  
ACCESSION BD141673.1 GI:23236618  
VERSION WO 0211530-A/7.  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 19)  
Yoshimura, K., Nishimura, A., Nishida, M. and Hosono, K.

AUTHORS Transgenic animal  
TITLE Patent: WO 0211530-A 7 14-FEB-2002;  
JOURNAL TAKEEDA CHEMICAL INDUSTRIES LTD, KOJI YOSHIMURA, ATSUSHI NISHIMURA,  
MAYUMI NISHIDA, KAZUHIRO HOSONO  
FEATURES  
source OS Artificial Sequence  
PN WO 0211530-A/7  
PD 14-FEB-2002  
PF 08-AUG-2001 WO 2001JP06826  
PR 09-AUG-2000 JP 00P 241748  
PI KOJI YOSHIMURA, ATSUSHI NISHIMURA, MAYUMI NISHIDA, KAZUHIRO PI  
HOSONO  
PC A01K67/027, A61K45/00, A61P19/00, A61P19/10, A61P19/02, A61P29/00,  
PC A61P27/02,  
PC A61P35/00, C12N5/16, C12N5/18, C12N15/09, G01N33/15, G01N33/50 CC  
Primer  
FH Key Location/Qualifiers  
FT source 1..19  
FT Location/Qualifiers  
1..19  
/organism="Artificial Sequence".  
/molecule="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.7%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.6e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1996 CTGATGATGCCACCACTG 2014  
Db 1 CTGATGATGCCACCAAGG 19

## RESULT 43

AR032132/c 20 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 2 from patent US 5866699.  
DEFINITION AR032132  
ACCESSION AR032132  
VERSION AR032132.1 GI:5946421  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
Smyth, A.P.  
TITLE Oligonucleotides with anti-MDR-1 gene activity  
JOURNAL Patent: US 5866699-A 2 02-FEB-1999;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/molecule="unassigned DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1620 TGGGTCTGGGAGAGACACA 1638  
Db 19 TGGGTCTGGGAGAGACACA 1

## RESULT 44

AR220980 20 bp DNA linear PAT 26-SEP-2002  
LOCUS Sequence 33 from patent US 6426188.  
DEFINITION AR220980  
ACCESSION AR220980  
VERSION AR220980.1 GI:23327865  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
Wyatt, J.  
TITLE Antisense modulation of phosphorylase kinase alpha 1 expression  
JOURNAL Patent: US 6426188-A 33 30-JUL-2002;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/molecule="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1676 GGGGACAGCTGCTGTTGGA 1694  
Db 19 GGGGACAGCTGCTGTTGGA 1

## RESULT 45

AR37234/c 20 bp DNA linear PAT 17-AUG-2003  
LOCUS Sequence 159 from patent US 6566135.  
DEFINITION AR37234  
ACCESSION AR37234  
VERSION AR37234.1 GI:33723088  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
Watt, A.T.  
TITLE Antisense modulation of caspase 6 expression  
JOURNAL Patent: US 6566135-A 159 20-MAY-2003;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/molecule="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1885 CCTCAGGCGTATGACACAG 1903  
Db 20 CCTCAGGCGTATGACACAG 2

## RESULT 46

AR361456 20 bp DNA linear PAT 17-AUG-2003  
LOCUS Sequence 36 from patent US 6599727.  
DEFINITION AR361456  
ACCESSION AR361456  
VERSION AR361456.1 GI:33769294  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
Christenson, E., Demaggio, A.J., Goldman, P.S. and McElligott, D.L.

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
TITLE      Human poly (ADP-ribose) polymerase 2 materials and methods
JOURNAL    Patent: US 659727-A 36 29-JUL-2003;
FEATURES
  source
    1..20
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        2 AGACACCCACCGAGA 20

RESULT 47
AR361457/c      AR361457      20 bp      DNA      linear      PAT 17-AUG-2003
LOCUS           Sequence 37 from patent US 659727.
ACCESSION       AR361457
VERSION         AR361457.1 GI:33769295
KEYWORDS
SOURCE           .
ORGANISM        Unknown.
REFERENCE        1 (bases 1 to 20)
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Human poly (ADP-ribose) polymerase 2 materials and methods
JOURNAL         Patent: US 659727-A 37 29-JUL-2003;
FEATURES
  source
    1..20
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        19 AGACACCCACCGAGA 1

RESULT 48
AX058352      AX058352      20 bp      DNA      linear      PAT 17-JAN-2001
LOCUS           Sequence 36 from Patent W00077179.
ACCESSION       AX058352
VERSION         AX058352.1 GI:12310812
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
REFERENCE        1
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Human poly(adp-ribose) polymerase 2 materials and methods
JOURNAL         Patent: WO 0077179-A 36 21-DEC-2000;
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        2 AGACACCCACCGAGA 20

RESULT 49
AX058353/c      AX058353      20 bp      DNA      linear      PAT 17-JAN-2001
LOCUS           Sequence 37 from Patent W00077179.
ACCESSION       AX058353
VERSION         AX058353.1 GI:12310813
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
REFERENCE        1
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Human poly(adp-ribose) polymerase 2 materials and methods
JOURNAL         Patent: WO 0077179-A 37 21-DEC-2000;
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        19 AGACACCCACCGAGA 1

RESULT 50
AX062312      AX062312      20 bp      DNA      linear      PAT 24-JAN-2001
LOCUS           Sequence 171 from Patent W00100849.
ACCESSION       AX062312
VERSION         AX062312.1 GI:12540213
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
REFERENCE        1
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Tankyrase2 materials and methods
JOURNAL         Patent: WO 0100849-A 171 04-JAN-2001;
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        2 AGACACCCACCGAGA 20

RESULT 51
AX062313/c      AX062313      20 bp      DNA      linear      PAT 24-JAN-2001
LOCUS           Sequence 172 from Patent W00100849.
ACCESSION       AX062313
VERSION         AX062313.1 GI:12540214
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
```

```
RESULT 49
AX058353/c      AX058353      20 bp      DNA      linear      PAT 17-JAN-2001
LOCUS           Sequence 37 from Patent W00077179.
ACCESSION       AX058353
VERSION         AX058353.1 GI:12310813
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
REFERENCE        1
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Human poly(adp-ribose) polymerase 2 materials and methods
JOURNAL         Patent: WO 0077179-A 37 21-DEC-2000;
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        2 AGACACCCACCGAGA 20

RESULT 50
AX062312      AX062312      20 bp      DNA      linear      PAT 24-JAN-2001
LOCUS           Sequence 171 from Patent W00100849.
ACCESSION       AX062312
VERSION         AX062312.1 GI:12540213
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
REFERENCE        1
AUTHORS         Christenson,E., Demaggio,A.J., Goldman,P.S. and Mcelligott,D.L.
TITLE           Tankyrase2 materials and methods
JOURNAL         Patent: WO 0100849-A 171 04-JAN-2001;
FEATURES
  source
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGA 1211
        ||||| ||||| |||||
        2 AGACACCCACCGAGA 20

RESULT 51
AX062313/c      AX062313      20 bp      DNA      linear      PAT 24-JAN-2001
LOCUS           Sequence 172 from Patent W00100849.
ACCESSION       AX062313
VERSION         AX062313.1 GI:12540214
KEYWORDS
SOURCE           .
ORGANISM        synthetic construct
```



```

REFERENCE
AUTHORS      1
              Christenson, E., Demaggio, A.J., Goldman, P.S. and Mcelligott, D.L.
TITLE        Tenkysaas2 materials and methods
JOURNAL      Patent: WO 0100849-A 172 04-JAN-2001;
              ICOS CORPORATION (US)
FEATURES
SOURCE
              1. .20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Primer"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1193 AGACACTCAACGAGAGGA 1211
Db      19 AGACACCCCAACCGAGAGGA 1

RESULT 52
BD192480/c
LOCUS      BD192480      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION the alimentary canal.
ACCESSION BD192480.1 GI:33002219
VERSION    JP 2002510319-A/45.
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Teng, C.L. and Hardee, G.
TITLE       Compositions and methods for the delivery of oligonucleotides via
JOURNAL     the alimentary canal
JOURNAL     Patent: JP 2002510319-A 45 02-APR-2002;
JOURNAL     ISIS PHARMACEUTICALS INC
COMMENT     OS Artificial Sequence
            PN JP 2002510319-A/45
            PD 02-APR-2002
            PR 01-JUL-1998 JP 1999507295
            PR 01-JUL-1997 US 08/866829
            PI CHING LEOU TENG, GREG HARDEE
            PC C1201/68, A61K9/12, A61K48/00, C07H21/04
            CC Description of Artificial Sequence; Novel Sequence FH Key
FEATURES
SOURCE      Location/Qualifiers
              1. .20
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1620 TGGGCTGGGAAGACACA 1638
Db      19 TGGCTGTGGGAGAGACACA 1

RESULT 53
LOCUS      AX278535      21 bp      DNA      linear      PAT 02-NOV-2001
DEFINITION Sequence 72 from Patent WO0177372.
ACCESSION  AX278535
VERSION    AX278535.1 GI:16605989
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   artificial sequences.

```

```

REFERENCE
AUTHORS      1
              Remacle, J., Hamels, S., Zammateo, N., Lockman, L., Dufour, S.,
              Alexandre, I. and de Longueville, P.
TITLE        Identification of biological (micro) organisms by detection of the
JOURNAL      its homologous nucleotide sequences on arrays
JOURNAL      Patent: WO 0177372-A 72 18-OCT-2001;
JOURNAL      Facultes Universitaires Notre-Dame de la Paix (BE)
FEATURES
SOURCE      Location/Qualifiers
              1. .21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="capture probe"

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGCGCTGTCG 1612
Db      3 GAGGTGATGCGCGCTGTCG 21

RESULT 54
AX513092/c
LOCUS      AX513092      21 bp      DNA      linear      PAT 03-OCT-2002
DEFINITION Sequence 21 from Patent EP1233076.
ACCESSION  AX513092
VERSION    AX513092.1 GI:23504171
KEYWORDS   Mycobacterium marinum
SOURCE     Mycobacterium marinum
ORGANISM   Mycobacterium marinum
            Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales;
            Corynebacterineae; Mycobacteriaceae; Mycobacterium.
REFERENCE   1
AUTHORS     Gala, J.L. and Vannuffel, P.
TITLE       Differential diagnosis for mycobacterial and pseudomonas species
JOURNAL     using species-specific upstream p34 gene region probes
JOURNAL     Patent: EP 1233076-A 21 21-AUG-2002;
JOURNAL     UNIVERSITE CATHOLIQUE DE LOUVAIN (BE)
COMMENT     Location/Qualifiers
            1. .21
            /organism="Mycobacterium marinum"
            /mol_type="unassigned DNA"
            /db_xref="taxon:1781"

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGCGCTGTCG 1612
Db      3 GAGGTGATGCGCGCTGTCG 21

RESULT 55
BD171659/c
LOCUS      BD171659      21 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION Identification of nucleotide sequence specific to mycobacteria and
JOURNAL     development of discrimination and diagnosis of mycobacteria
JOURNAL     species.
ACCESSION  BD171659
VERSION    BD171659.1 GI:28412951
KEYWORDS   JP 2002238563-A/20.
SOURCE     synthetic construct
ORGANISM   synthetic construct
            artificial sequences.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Gara, J.L. and Vannuffel, P.
TITLE       Identification of nucleotide sequence specific to mycobacteria and
JOURNAL     development of discrimination and diagnosis of mycobacteria species
JOURNAL     Patent: JP 2002238563-A 20 27-AUG-2002;
JOURNAL     UNIVERSITE CATHOLIQUE DE LOUVAIN

```

COMMENT OS Artificial Sequence  
PN JP 2002238563-A/20  
PD 27-AUG-2002  
PF 31-JAN-2001 JP 2001024023  
PI JEAN LUC GARA, PASCAL VANNUPPEL,  
PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC  
G01N33/569//  
PC (C12N15/09, C12R1:32), (C12Q1/68, C12R1:32), C12N15/00, C12N15/00,  
PC (C12N15/00, C12R1:32)  
CC Description of Artificial Sequence: oligonucleotide primer FH  
Key Location/Qualifiers  
FT source 1..21  
Location/Qualifiers  
1..21  
/organism='Artificial Sequence'.  
/organism='synthetic construct'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32630'

FEATURES  
source

Query Match 0.7%; Score 15.4; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 GAGGTGACGGCGCTGCTGG 1612  
|||||  
3 GAGGTGATGGCGCTGCTGG 21

Db

RESULT 56  
AX724430 17 bp DNA linear PAT 08-MAY-2003  
LOCUS Sequence 2117 from Patent WO03025176.  
AX724430  
VERSION AX724430.1 GI:30503773  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS 1  
TITLE Telerman, A., Amson, R. and Tuijinder, M.  
JOURNAL Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
PATENT: WO 03025176-A 2117 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

QY 996 GATCACCTGCTCTGC 1012  
|||||  
1 GATCTCCCTGCTCTGC 17

Db

Query Match 0.7%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 57  
AX783932 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Sequence 2263 from Patent WO03050284.  
AX783932  
VERSION AX783932.1 GI:32951781  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
1

AUTHORS Guo, J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 2263 19-JUN-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1631 AGAGCACAGTGTCTGCC 1647  
|||||  
1 AGAGCACAGTGTCTGCC 17

Db

RESULT 58  
AX783933 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Sequence 2264 from Patent WO03050284.  
AX783933  
VERSION AX783933.1 GI:32951782  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Guo, J.  
JOURNAL Human prostate cancer candidate protein 1  
PATENT: WO 03050284-A 2264 19-JUN-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

QY 1632 GAGCACAGTGTCTGCC 1648  
|||||  
1 GAGCACAGTGTCTGCC 17

Db

RESULT 59  
AR039057/c 18 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 23 from patent US 5807730.  
AR039057  
VERSION AR039057.1 GI:5958420  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Ito, K., Yamaki, T., Arai, T., Tsuruoka, M. and Nakamura, T.  
TITLE Nitrite hydratase  
JOURNAL Patent: US 5807730-A 23 15-SEP-1998;  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1.8e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY      2068 GAGCGGTACTCCGCTC 2084
      |||||
      17 GAGCGGTACTCCGCTC 1

RESULT 60
LOCUS   AR071237/c                      18 bp   DNA       linear   PAT 18-FEB-2000
DEFINITION Sequence 23 from patent US 5910432.
ACCESSION AR071237
VERSION  AR071237.1 GI:7222125
KEYWORDS
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS  Ito,K., Yamaki,T., Arai,T., Tsuruoka,M. and Nakamura,T.
TITLE     Nitrite hydratase
JOURNAL   Patent: US 5910432-A 23 08-JUN-1999;
FEATURES  Location/Qualifiers
            source          1..18
                        /mol_type="unknown"
                        /organism="unknown"

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2068 GAGCGGTACTCCGCTC 2084
      |||||
      17 GAGCGGTACTCCGCTC 1

RESULT 61
LOCUS   E14107                      18 bp   DNA       linear   PAT 28-JUN-1999
DEFINITION PCR primer for producing mutated Pseudonocardia nitrilohydrolase.
ACCESSION E14107
VERSION  E14107.1 GI:5708790
KEYWORDS JP 1997275978-A/21.
SOURCE   unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS  Ito,K., Yamaki,T., Arai,T., Tsuruoka,M. and Nakamura,T.
TITLE     NITRILE-HYDRATASE
JOURNAL   Patent: JP 1997275978-A 21 28-OCT-1997;
FEATURES  Location/Qualifiers
            source          1..18
                        /mol_type="unknown"
                        /organism="unknown"

COMMENT   OS None
            OC Artificial sequences.
            PN JP 1997275978-A/21
            PD 28-OCT-1997
            PF 29-JAN-1997 JP 1997015295
            PR 14-FEB-1996 JP 96P 27004
            PI ITO KIYOSHI, YAMAKI TOSHIBUMI, ARAI TERUO, TSURUOKA MIYUKI, PI
            NAKAMURA TAKESHI
            PC C12N9/88,C12N1/21,C12N15/09,(C12N9/88,C12R1:19),(C12N1/21,PC
            C12R1:19);
            CC (C12N15/09,C12R1:01);
            CC strandedness: Single;
            CC topology: Linear;
            CC hypothetical: No;
            CC anti-sense: No;
            FH Key
            FT source          1..18
                        /organism="Artificial sequences".
                        /location/Qualifiers
                        1..18
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"
FEATURES
source          1..18
location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

```

```

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2068 GAGCGGTACTCCGCTC 2084
      |||||
      17 GAGCGGTACTCCGCTC 1

RESULT 62
LOCUS   AR196144                      18 bp   DNA       linear   PAT 20-APR-2002
DEFINITION Sequence 609 from patent US 6350934.
ACCESSION AR196144
VERSION  AR196144.1 GI:20245581
KEYWORDS
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS  Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P Ann Owens,,
TITLE     Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
JOURNAL   Nucleic acid encoding delta-9 desaturase
JOURNAL   Patent: US 6350934-A 609 26-FEB-2002;
FEATURES  Location/Qualifiers
            source          1..18
                        /mol_type="unknown"
                        /organism="unknown"

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2178 CCAGCAGCTCATGAGCA 2194
      |||||
      2 CCAGCAGCTCATGAGCA 18

RESULT 63
LOCUS   AR300594                      18 bp   DNA       linear   PAT 12-JUN-2003
DEFINITION Sequence 1 from patent US 6537805.
ACCESSION AR300594
VERSION  AR300594.1 GI:31688126
KEYWORDS
SOURCE   Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS  Melchner,H.V., Andreu,T. and Ebensperger,C.
TITLE     Self-deleting vectors
JOURNAL   Patent: US 6537805-A 1 25-MAR-2003;
FEATURES  Location/Qualifiers
            source          1..18
                        /mol_type="unknown"
                        /organism="genomic DNA"

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      318 CCGCGCGGAGCTGGCCT 334
      |||||
      1 CCGCGCTGAGCTTGCTT 17

RESULT 64
LOCUS   AX130922/c                      19 bp   DNA       linear   PAT 15-MAY-2001
DEFINITION Sequence 2140 from Patent WO0130362.
ACCESSION AX130922
VERSION  AX130922.1 GI:14137227
KEYWORDS

```

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 2140 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES location/Qualifiers  
SOURCE 1..19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAATAAAGA 1195  
Db 19 GCTGCAATAATAAAGA 3  
|||||  
|||||

RESULT 65  
AX130923/c 19 bp DNA linear PAT 15-MAY-2001  
LOCUS Sequence 2141 from Patent WO0130362.  
DEFINITION AX130923  
ACCESSION AX130923  
VERSION AX130923.1 GI:14137228  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 2141 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES location/Qualifiers  
SOURCE 1..19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAATAAAGA 1195  
Db 18 GCTGCAATAATAAAGA 2  
|||||  
|||||

RESULT 66  
AX130924/c 19 bp DNA linear PAT 15-MAY-2001  
LOCUS Sequence 2142 from Patent WO0130362.  
DEFINITION AX130924  
ACCESSION AX130924  
VERSION AX130924.1 GI:14137229  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye

JOURNAL diseases  
Patent: WO 0130362-A 2142 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES location/Qualifiers  
SOURCE 1..19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin E ribozyme binding site"

Query Match 0.7%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GCTGCAAGAATAAAGA 1195  
Db 17 GCTGCAATAATAAAGA 1  
|||||  
|||||

RESULT 67  
A62106 20 bp DNA linear PAT 09-MAR-1998  
LOCUS Sequence 6 from Patent WO9712970.  
DEFINITION A62106  
ACCESSION A62106  
VERSION A62106.1 GI:3716151  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Balmain,A. and Zhu,J.  
TITLE ANTITUMOUR VECTOR CONSTRUCTS AND METHODS  
JOURNAL Patent: WO 9712970-A 6 10-APR-1997;  
CANCER RES CAMPAIGN TECH (GB)  
COMMENT Other publication AU 7136696 970428  
FEATURES location/Qualifiers  
SOURCE 1..20  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 315 GGCCCTGCGGACTTGCT 334  
Db 1 GGACTTGCTGACTTGCT 20  
|||||  
|||||

RESULT 68  
AR032133/c 20 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 3 from patent US 5866699.  
DEFINITION AR032133  
ACCESSION AR032133  
VERSION AR032133.1 GI:5946422  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1  
AUTHORS Smyth,A.P.  
TITLE Oligonucleotides with anti-MDR-1 gene activity  
JOURNAL Patent: US 5866699-A 3 02-FEB-1999;  
FEATURES location/Qualifiers  
SOURCE 1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1618 AATGGCTGGAGAGACAC 1637  
 Db 20 AGTGGCTGTGGAGAGACAC 1

RESULT 69  
 LOCUS AR032134 20 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 4 from patent US 5866699.  
 ACCESSION AR032134  
 VERSION AR032134.1 GI:5946423  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE  
 1 (bases 1 to 20)  
 Smith,A.P.  
 TITLE Oligonucleotides with anti-MDR-1 gene activity  
 JOURNAL Patent: US 5866699-A 4 02-FEB-1999;  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1617 CAATGGCTGGAGAGCA 1636  
 Db 20 CAGTGGCTGTGGAGAGCA 1

RESULT 70  
 LOCUS AR084441 20 bp DNA linear PAT 01-SEP-2000  
 DEFINITION Sequence 17 from patent US 5981178.  
 ACCESSION AR084441  
 VERSION AR084441.1 GI:10011212  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE  
 1 (bases 1 to 20)  
 Tsui,L.-C., Rommens,J.M. and Kerem,B.-B.  
 TITLE Methods for screening for mutations at various positions in the  
 introns and exons of the cystic fibrosis gene  
 JOURNAL Patent: US 5981178-A 17 09-NOV-1999;  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 TACTTATCTGGATGATGCC 2007  
 Db 20 TAGTTTCTGTGATTTATGCC 1

RESULT 71  
 LOCUS AR093883 20 bp DNA linear PAT 08-SEP-2000  
 DEFINITION Sequence 17 from patent US 6001588.  
 ACCESSION AR093883  
 VERSION AR093883.1 GI:10020629  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
 AUTHORS Tsui,L.-C., Rommens,J.M. and Kerem,B.-B.  
 TITLE Introns and exons of the cystic fibrosis gene and mutations thereof  
 JOURNAL Patent: US 6001588-A 17 14-DEC-1999;  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 TACTTATCTGGATGATGCC 2007  
 Db 20 TAGTTTCTGTGATTTATGCC 1

RESULT 72  
 LOCUS AR097398 20 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 22 from patent US 6071726.  
 ACCESSION AR097398  
 VERSION AR097398.1 GI:12806128  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE  
 1 (bases 1 to 20)  
 Diamandis,E., Dunn,J.M. and Stevens,J.K.  
 TITLE Method, reagents and kit for diagnosis and targeted screening for  
 p53 mutations  
 JOURNAL Patent: US 6071726-A 22 06-JUN-2000;  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1935 GGGTCAGCGACAGCAGTGG 1954  
 Db 1 GGGTCAGCGCGCAAGCAGAGG 20

RESULT 73  
 LOCUS AR116476 20 bp DNA linear PAT 16-MAY-2001  
 DEFINITION Sequence 57 from patent US 6133246.  
 ACCESSION AR116476  
 VERSION AR116476.1 GI:14096798  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE  
 1 (bases 1 to 20)  
 McKay,R., Dean,N., Monia,B.P., Nero,P.S. and Gaarde,W.A.  
 TITLE Antisense oligonucleotide compositions and methods for the  
 modulation of JNK proteins  
 JOURNAL Patent: US 6133246-A 57 17-OCT-2000;  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 167 GGGTCTGGCGGTGGGCTTG 186  
 Db 1 GGGTCTGGCGGTGGGCTTG 186



TITLE Antisense modulation of SR-CYP expression  
JOURNAL Patent: US 6475797-A 47 05-NOV-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1269 AGTGGGAATCCTCTACATTG 1288  
|||||  
20 AGTGAGACTCTCCACATTG 1

RESULT 79  
AR297055 20 bp DNA linear PAT 12-JUN-2003  
LOCUS  
DEFINITION Sequence 8790 from patent US 6537751.  
ACCESSION AR297055  
VERSION AR297055.1 GI:31684339  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Biallelic markers for use in constructing a high density  
disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 8790 25-MAR-2003;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1025 CCAAGAGGTGGGAAATGG 1044  
|||||  
1 CAAAGTAGGTGGAAATGG 20

RESULT 80  
AR297103 20 bp DNA linear PAT 12-JUN-2003  
LOCUS  
DEFINITION Sequence 8838 from patent US 6537751.  
ACCESSION AR297103  
VERSION AR297103.1 GI:31684387  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Biallelic markers for use in constructing a high density  
disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 8838 25-MAR-2003;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 688 CTCATGCCATTCACCAT 707  
|||||  
20 CTCCTCCCATTCACCAT 1

RESULT 81  
AR312679 20 bp DNA linear PAT 12-JUN-2003  
LOCUS  
DEFINITION Sequence 3216 from patent US 6559294.  
ACCESSION AR312679  
VERSION AR312679.1 GI:31706105  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,  
Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 3216 06-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1762 CCACAGGTATTGGAGAG 1781  
|||||  
1 CCACAGGTCTTTGAGAG 20

RESULT 82  
AR312813 20 bp DNA linear PAT 12-JUN-2003  
LOCUS  
DEFINITION Sequence 3350 from patent US 6559294.  
ACCESSION AR312813  
VERSION AR312813.1 GI:31706239  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,  
Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 3350 06-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 939 CCTATGTTCTTGGGATCA 958  
|||||  
1 CCTATGTTCTTGGGATCA 20

RESULT 83  
AR314336 20 bp DNA linear PAT 12-JUN-2003  
LOCUS  
DEFINITION Sequence 4873 from patent US 6559294.  
ACCESSION AR314336  
VERSION AR314336.1 GI:31707762  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffiths,R., Holsech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,  
Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof

```

JOURNAL Patent: US 6559294-A 4873 06-MAY-2003;
FEATURES
    source
        1..20
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
    0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1696 GGGAAGCCCTTCCCAATA 1715
Db 1 GGAAAGCCCTTCCCAATA 20

RESULT 84
AR322199 20 bp DNA linear PAT 17-AUG-2003
LOCUS AR322199
DEFINITION Sequence 8 from patent US 6566064.
ACCESSION AR322199
VERSION AR322199.1 GI:33707763
KEYWORDS
SOURCE
ORGANISM
    .
    unknown.
REFERENCE
    1 (bases 1 to 20)
    Shitaki,M., Ouchi,Y., Hosoi,T., Kusaba,N., Baba,T. and Yoshida,H.
    Method for anticipating sensitivity to medicine for osteoporosis
    JOURNAL Patent: US 6566064-A 8 20-MAY-2003;
FEATURES
    source
        1..20
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match
    0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1647 CCTGCTGCAGATCTGTACC 1666
Db 1 CCTGCACCAAGATATGTACC 20

RESULT 85
AX197430 20 bp DNA linear PAT 29-AUG-2001
LOCUS AX197430
DEFINITION Sequence 7 from Patent W00151085.
ACCESSION AX197430
VERSION AX197430.1 GI:15387821
KEYWORDS
SOURCE
ORGANISM
    .
    synthetic construct
    synthetic construct
    artificial sequences.
REFERENCE
    1
    Oh,C.K., Cho,S.H., Demissie-Sanders,S., Thomas,D.W. and Tan,S.W.
    Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for
    the treatment of asthma and chronic obstructive pulmonary disease
    Patent: WO 0151085-A 7 19-JUL-2001;
JOURNAL Tanox, Inc. (US)
FEATURES
    source
        location/Qualifiers
        1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Synthetic"

Query Match
    0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1460 GCTGCCACCCAGTGTCTG 1479
Db 1 GCTGCCACCCAGTGTCTG 20

```

```

RESULT 86
AX546286/c 20 bp DNA linear PAT 26-NOV-2002
LOCUS AX546286/c
DEFINITION Sequence 35 from Patent EP1243290.
ACCESSION AX546286
VERSION AX546286.1 GI:25811477
KEYWORDS
SOURCE
ORGANISM
    .
    synthetic construct
    synthetic construct
    artificial sequences.
REFERENCE
    1
    Besterman,J.M., Macleod,A.R. and Siders,W.M.
    Modulation of gene expression by combination therapy
    Patent: EP 1243290-A 35 25-SEP-2002;
JOURNAL Methylgene, Inc. (CA)
FEATURES
    source
        location/Qualifiers
        1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Oligonucleotide"

Query Match
    0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 26 CCCGCGGTGCGCTGCCTC 45
Db 20 CCCGCTGCTGCTGCTC 1

RESULT 87
AX546376/c 20 bp DNA linear PAT 26-NOV-2002
LOCUS AX546376/c
DEFINITION Sequence 35 from Patent EP1243289.
ACCESSION AX546376
VERSION AX546376.1 GI:25811567
KEYWORDS
SOURCE
ORGANISM
    .
    synthetic construct
    synthetic construct
    artificial sequences.
REFERENCE
    1
    Besterman,J.M., Macleod,A.R. and Siders,W.M.
    Modulation of gene expression by combination therapy
    Patent: EP 1243289-A 35 25-SEP-2002;
JOURNAL Methylgene, Inc. (CA)
FEATURES
    source
        location/Qualifiers
        1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Oligonucleotide"

Query Match
    0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 26 CCCGCGGTGCGCTGCCTC 45
Db 20 CCCGCTGCTGCTGCTC 1

RESULT 88
AX794385 20 bp DNA linear PAT 04-OCT-2003
LOCUS AX794385
DEFINITION Sequence 6 from Patent W003051395.
ACCESSION AX794385
VERSION AX794385.1 GI:37515463
KEYWORDS
SOURCE
ORGANISM
    .
    synthetic construct
    synthetic construct

```



REFERENCE 1  
AUTHORS Molderings,G.J. and Brueser,M.  
TITLE Ebgg-receptor agonists for the treatment of hypertension  
JOURNAL Patent: WO 03051395-A 6 26-JUN-2003;  
Solvay Pharmaceuticals GmbH (DE)  
FEATURES  
source  
1. .20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="antisense primer sequence"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1182 GCAGAAATTAAGACTCA 1201  
1 GCAGGCAATGAAGACTCA 20

RESULT 89  
BD004726 20 bp DNA linear PAT 31-JAN-2002  
LOCUS  
DEFINITION Vitamin D receptor gene, apolipoprotein E gene and reagent for simultaneously detecting gene polymorphism of estrogen receptor gene, and method for simultaneously detecting the gene polymorphism.

ACCESSION BD004726  
VERSION BD004726.1 GI:18632687  
KEYWORDS JP 2001029088-A/6.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 20)  
Kusaba,N., Baba,T. and Yoshida,H.  
Vitamin D receptor gene, apolipoprotein E gene and reagent for simultaneously detecting gene polymorphism of estrogen receptor gene, and method for simultaneously detecting the gene polymorphism  
Patent: JP 2001029088-A 6 06-FEB-2001;  
NISHIO CORP  
COMMENT OS Homo sapiens (human)  
PN JP 2001029088-A/6  
PD 06-FEB-2001  
PF 16-MAY-2000 JP 2000142951  
PI NORINOBU KUSABA,TOSHIKAKI BABA,HIROSHI YOSHIDA PC  
C12N15/09,C12Q1/68,C12N15/00  
CC  
FH Key Location/Qualifiers  
FT source 1. .20  
location/Qualifiers  
1. .20  
/organism="Homo sapiens (human)".  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

FEATURES  
source  
1. .20  
/organism="Homo sapiens (human)".  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1647 CCGTCTCAGATGTGTACC 1666  
1 CCGTCACCAAGATGTGTACC 20

RESULT 90  
BD074633 20 bp DNA linear PAT 27-AUG-2002  
LOCUS  
DEFINITION Antisense oligonucleotide composition and modulation method of JNK

ACCESSION BD074633  
VERSION BD074633.1 GI:22620236  
KEYWORDS JP 2001514905-A/57.  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS McKay,R., Dean,N., Monia,B.P., Scott,P., Nero and Gaarde,W.A.  
TITLE Antisense oligonucleotide composition and modulation method of JNK  
JOURNAL Protein.  
Patent: JP 2001514905-A 57 18-SEP-2001;  
ISIS PHARMACEUTICALS INC  
COMMENT OS Artificial Sequence  
PN JP 2001514905-A/57  
PD 18-SEP-2001  
PF 07-AUG-1998 JP 2000509875  
PI 13-AUG-1997 US 08/910629  
PI ROBERT MCKAY,NICHOLAS DEAN,BRETT P MONIA,PAMELA SCOTT PI  
NERO, WILLIAM A GAARDE  
PC C12Q1/68,A61K31/7086,A61K48/00,A61P35/00,C12N15/09,C12P19/34,  
PC C12N15/00  
CC antisense sequence  
FH Key Location/Qualifiers  
FT source 1. .20  
location/Qualifiers  
1. .20  
/organism="Artificial Sequence".  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.1e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCTGGCGGCGGCGCTG 186  
1 GGGTCTGTGGTGGGACATG 20

RESULT 91  
BD083842 20 bp DNA linear PAT 27-AUG-2002  
LOCUS  
DEFINITION Method for predicting sensitivity to osteoporosis drug and reagent kit therefor.

ACCESSION BD083842  
VERSION BD083842.1 GI:22629452  
KEYWORDS JP 2001333799-A/8.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 20)  
Shiraki,M., Ouchi,Y. and Hosoi,T.  
Method for predicting sensitivity to osteoporosis drug and reagent kit therefor  
Patent: JP 2001333799-A 8 04-DEC-2001;  
NISHIO CORP  
COMMENT OS Homo sapiens (human)  
PN JP 2001333799-A/8  
PD 04-DEC-2001  
PF 26-MAY-2000 JP 2000155993  
PI MASATAKA SHIRAKI,YASUYOSHI OUCHI,TAKAYUKI HOSOI PC  
C12Q1/68,C12N15/09,G01N33/53,G01N33/56,C12N15/00 CC  
the base sequence of estrogen receptor gene FH Key  
Location/Qualifiers  
FT source 1. .20  
location/Qualifiers  
1. .20  
/organism="Homo sapiens (human)".  
/mol\_type="genomic DNA"

FEATURES  
source  
1. .20  
/organism="Homo sapiens (human)".  
/mol\_type="genomic DNA"

```

                                /db_xref="taxon:9606"
Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1647 CCTGCTGCAAAATCTGTACC 1666
          ||||| ||||| ||||| |||||
          CCTGCACCAAGATATGTACC 20

RESULT 92
BD083881      20 bp DNA linear PAT 27-AUG-2002
LOCUS      Reagent and method for the simultaneous detection of gene
DEFINITION polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene.
ACCESSION   BD083881.1 GI:22629491
KEYWORDS    JP 2001333798-A/16.
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Kusaba,N., Baba,T. and Yoshida,H.
TITLE      Reagent and method for the simultaneous detection of gene
            polymorphisms in vitamin D receptor gene, apolipoprotein E gene and
            estrogen receptor gene
JOURNAL     Patent: JP 2001333798-A 16 04-DEC-2001;
COMMENT     NISSHO CORP
LOCUS      OS Homo sapiens (human)
            PN JP 2001333798-A/16
            PD 04-DEC-2001
            PF 26-MAY-2000 JP 2000155871
            PI NORINORI KUSABA,TOSHIYUKI BABA,HIROSHI YOSHIDA PC
            C12Q1/68,A61K45/00,A61P19/08,C12N15/09,G01N33/15,G01N33/50, PC
            G01N33/53,
            CC Part of base sequence of estrogen receptor gene FH Key
            Location/Qualifiers
            FT source 1..20
            location/organism='Homo sapiens (human)'
FEATURES
    source
        1..20
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1647 CCTGCTGCAAAATCTGTACC 1666
          ||||| ||||| ||||| |||||
          1 CCTGCACCAAGATATGTACC 20

RESULT 93
BD103497      20 bp DNA linear PAT 27-AUG-2002
LOCUS      New recombinant adenovirus vectors with reduced side effects.
DEFINITION   BD103497
ACCESSION   BD103497.1 GI:22649071
KEYWORDS    WO 0190392-A/15.
SOURCE      Synthetic construct
            artificial sequence.
            1 (bases 1 to 20)
REFERENCE   Nakai,M., Komiya,K., Murata,M., Todo,N. and Saito,I.
TITLE      New recombinant adenovirus vectors with reduced side effects
JOURNAL     Patent: WO 0190392-A 15-29-NOV-2001;
            SUMITOMO PHARMACEUTICALS CO LTD,MICHIYO NAKAI,KAZUO KOMIYA,MASASHI

```

```

COMMENT
OS Artificial Sequence
PN WO 0190392-A/15
PD 29-NOV-2001
PF 24-MAY-2001 WO 2001JP004360
PR 26-MAY-2000 JP 00P 155603,08-DEC-2000 JP 00P 373850 PI
MICHIO NAKAI,KAZUO KOMIYA,MASASHI MORATA,NAOKI TODO,IZUMU PI
SAITO
PC C12N15/861,C12N5/10,A61K48/00
CC PCR primer
FH Key Location/Qualifiers
FT source 1..21
location/organism='Artificial Sequence'.

FEATURES
    source
        1..20
        /organism="synthetic construct"
        /mol_type="genomic DNA"
        /db_xref="taxon:32630"

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1410 GGCTGTGGCTCCTCAGAGA 1429
          ||||| ||||| ||||| |||||
          1 GGCAGTGTCTCCTCAGCGA 20

RESULT 94
BD138082/c    20 bp DNA linear PAT 18-SEP-2002
LOCUS      Antisense modulation of human MDM2 expression.
DEFINITION   BD138082
ACCESSION   BD138082.1 GI:23233027
KEYWORDS    JP 2002508944-A/8.
SOURCE      unidentified
            unidentified
            unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Miraglia,L.V., Nero,P., Graham,M.J., Monia,B.P. and Cowseart,L.M.
TITLE      Antisense modulation of human MDM2 expression
JOURNAL     Patent: JP 2002508944-A 8 26-MAR-2002;
            ISTIS PHARMACEUTICALS INC
COMMENT     OS Unidentified
            PN JP 2002508944-A/8
            PD 26-MAR-2002
            PF 26-MAR-1999 JP 2000538025
            PR 26-MAR-1998 US 09/048810
            PI LOREN J MIRAGLIA,PAMELA NERO,MARK J GRAHAM,BRETT P MONIA,LEX M

CONSERT
PI C12N15/09,A61K48/00,A61P9/10,A61P35/00,C07H21/04//
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression FH Key
Location/Qualifiers
    FT source 1..20
    location/organism='Unidentified'.

FEATURES
    source
        1..20
        /organism="unidentified"
        /mol_type="genomic DNA"
        /db_xref="taxon:32644"

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      243 CTCGAAGCGAAACGAG 262
          ||||| ||||| ||||| |||||
          20 CTCGAAGCGAAACCCCG 1

```

```

RESULT 95
BD192481/c
LOCUS
DEFINITION
  BD192481
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
ACCESSION
  BD192481
VERSION
  BD192481.1 GI:33002220
KEYWORDS
  JP 2002510319-A/46.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
REFERENCE
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
  Patent: JP 2002510319-A 46 02-APR-2002;
JOURNAL
  ISIS PHARMACEUTICALS INC
COMMENT
  OS Artificial Sequence
  PN JP 2002510319-A/46
  PD 02-APR-2002
  PF 01-JUL-1998 JP 1999507295
  PR 01-JUL-1997 US 08/886829
  PI CHING LEOU TENG,GREG HARDEE
  PC C1201/68,A61K9/127,A61K48/00,C07H21/04
  CC Description of Artificial Sequence: Novel Sequence FH key
  Location/Qualifiers
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"

Query Match
  0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTCTGGAGAGACAC 1637
Db 20 AGTGGCTGTGGAGAGACAC 1

RESULT 96
BD192482/c
LOCUS
DEFINITION
  BD192482
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
ACCESSION
  BD192482
VERSION
  BD192482.1 GI:33002221
KEYWORDS
  JP 2002510319-A/47.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
REFERENCE
  1 (bases 1 to 20)
  Teng,C.L. and Hardee,G.
  Compositions and methods for the delivery of oligonucleotides via
  the alimentary canal.
  Patent: JP 2002510319-A 47 02-APR-2002;
JOURNAL
  ISIS PHARMACEUTICALS INC
COMMENT
  OS Artificial Sequence
  PN JP 2002510319-A/47
  PD 02-APR-2002
  PF 01-JUL-1998 JP 1999507295
  PR 01-JUL-1997 US 08/886829
  PI CHING LEOU TENG,GREG HARDEE
  PC C1201/68,A61K9/127,A61K48/00,C07H21/04
  CC Description of Artificial Sequence: Novel Sequence FH key
  Location/Qualifiers
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"

Query Match
  0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTCTGGAGAGACAC 1637
Db 20 AGTGGCTGTGGAGAGACAC 1

RESULT 97
AX114466
LOCUS
DEFINITION
  AX114466
  Sequence 135 from Patent WO0129257.
ACCESSION
  AX114466
VERSION
  AX114466.1 GI:14031430
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
  1
  Schork,N. and Skierczynski,B.
  Methods of genetic cluster analysis and use thereof
  Patent: WO 0129257-A 135 26-APR-2001;
JOURNAL
  GENSER (FR)
COMMENT
  Location/Qualifiers
  1..19
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
  primer_bind
  1..19
  /note="downstream amplification primer 4-32 for SEQ 9, in
  complement"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2185 CTCATGGAGAAAAG 2199
Db 1 CTCATGGAGAAAAG 15

RESULT 98
AX202054
LOCUS
DEFINITION
  AX202054
  Sequence 7 from Patent WO0153525.
ACCESSION
  AX202054
VERSION
  AX202054.1 GI:15391837
KEYWORDS
  synthetic construct
  artificial sequences.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1
  Refseth,U.H. and Kolpus,T.G.
REFERENCE
  1
  Refseth,U.H. and Kolpus,T.G.
  Cell Isolation method
  Patent: WO 0153525-A 7 26-JUL-2001;
JOURNAL
  Genpoint AS (NO)
COMMENT
  Location/Qualifiers
  1..19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="primer"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1971 GATCCGAAACCGTGTG 1987

```

```

/db_xref="taxon:32630"

Query Match
  0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1617 CAATGGCTCTGGAGAGCA 1636
Db 20 CAGTGGCTGTGGAGAGCA 1

RESULT 97
AX114466
LOCUS
DEFINITION
  AX114466
  Sequence 135 from Patent WO0129257.
ACCESSION
  AX114466
VERSION
  AX114466.1 GI:14031430
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
  1
  Schork,N. and Skierczynski,B.
  Methods of genetic cluster analysis and use thereof
  Patent: WO 0129257-A 135 26-APR-2001;
JOURNAL
  GENSER (FR)
COMMENT
  Location/Qualifiers
  1..19
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
  primer_bind
  1..19
  /note="downstream amplification primer 4-32 for SEQ 9, in
  complement"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2185 CTCATGGAGAAAAG 2199
Db 1 CTCATGGAGAAAAG 15

RESULT 98
AX202054
LOCUS
DEFINITION
  AX202054
  Sequence 7 from Patent WO0153525.
ACCESSION
  AX202054
VERSION
  AX202054.1 GI:15391837
KEYWORDS
  synthetic construct
  artificial sequences.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  1
  Refseth,U.H. and Kolpus,T.G.
REFERENCE
  1
  Refseth,U.H. and Kolpus,T.G.
  Cell Isolation method
  Patent: WO 0153525-A 7 26-JUL-2001;
JOURNAL
  Genpoint AS (NO)
COMMENT
  Location/Qualifiers
  1..19
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="primer"

Query Match
  0.7%; Score 15; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2.1e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1971 GATCCGAAACCGTGTG 1987

```

Db 1 GWTCTGAACCGTGTG 17

RESULT 99  
LOCUS AR129704  
DEFINITION Sequence 108 from patent US 6187545.  
ACCESSION AR129704  
VERSION AR129704.1 GI:14117601  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
1 (bases 1 to 20)  
AUTHORS McKay, R., Butler, M.M., Myatt, J. and Cowse, L.M.  
TITLE Antisense modulation of pepck-cyclosolic expression  
JOURNAL Patent: US 6187545-A 108 13-FEB-2001;  
FEATURES  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 15; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 AACGAAACGACAG 844  
|||||  
3 AACGAAACGACAG 17

Db

RESULT 100  
LOCUS BD242514/c  
DEFINITION A system for cell based screening.  
ACCESSION BD242514  
VERSION BD242514.1 GI:33052284  
KEYWORDS JP 2002528136-A/20.  
SOURCE  
ORGANISM  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Giuliano, K.A., Bright, G., Olson, K. and Tencza, S.B.  
TITLE A system for cell based screening  
JOURNAL Patent: JP 2002528136-A 20 03-SEP-2002;  
COMMENT OS Artificial Sequence  
PN JP 2002528136-A/20  
PD 03-SEP-2002  
PF 29-OCT-1999 JP 2000579780  
PR 30-OCT-1998 US 60/106308, 26-MAY-1999 US 60/136078 PI  
KENNETH A GUTILIANO, GARY BRIGHT, KEITH OLSON, SARAH BURROUGHS PI  
TENCZA  
PC C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12Q1/02, C12Q1/  
PC 37, G01N3/15,  
PC G01N3/50, C12N15/00, C12N5/00  
CC Description of Artificial Sequence: KT3 epitope FH Key  
Location/Qualifiers  
FT source 1..18  
/organism='Artificial Sequence'.  
FEATURES  
source  
1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCCTGTG 583  
|||||  
18 TGTTCCTGTCCTGTG 1

Db

RESULT 101  
LOCUS AR217439  
DEFINITION Sequence 39 from patent US 6416959.  
ACCESSION AR217439  
VERSION AR217439.1 GI:23317132  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
1 (bases 1 to 18)  
AUTHORS Giuliano, K. and Kapur, R.  
TITLE System for cell-based screening  
JOURNAL Patent: US 6416959-A 39 09-JUL-2002;  
FEATURES  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCCTGTG 583  
|||||  
18 TGTTCCTGTCCTGTG 1

Db

RESULT 102  
LOCUS AX766750/c  
DEFINITION Sequence 39 from Patent EP1314980.  
ACCESSION AX766750  
VERSION AX766750.1 GI:32260514  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE 1  
AUTHORS Giuliano, K.A. and Kapur, R.  
TITLE A system for cell-based screening  
JOURNAL Patent: EP 1314980-A 39 28-MAY-2003;  
CELLCOMICS, Inc. (US)  
FEATURES  
source  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="KT3 epitope"

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCCTGTG 583  
|||||  
18 TGTTCCTGTCCTGTG 1

Db

RESULT 103  
LOCUS A51892  
DEFINITION Sequence 56 from Patent WO9620011.  
ACCESSION A51892  
VERSION A51892.1 GI:2304640  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Blakey, D.C., Davies, D.H., Dowell, R.I., Henman, J.F., Marsham, P.R.,

TITLE Slater, Anthony, M. and Hennequin, L.F.  
JOURNAL CHEMICAL COMPOUNDS CHEMICAL COMPOUNDS  
Patent: WO 9620011-A 56 04-JUL-1996;  
ZENECA LTD (GB)  
COMMENT Other publication AU 4269796 960719.  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGAGCTCG 19

RESULT 104  
LOCUS A67354 19 bp DNA linear PAT 05-MAY-1999  
DEFINITION Sequence 110 from Patent WO9742329.  
ACCESSION A67354  
VERSION A67354.1 GI:4756298  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

REFERENCE 1 (bases 1 to 19)  
AUTHORS Copley, C.G., Edge, M.D. and Emery, S.C.  
TITLE MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY,  
AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM  
JOURNAL Patent: WO 9742329-A 110 13-NOV-1997;  
ZENECA LTD (GB)  
FEATURES Location/Qualifiers

LOCUS A67354 19 bp DNA linear PAT 05-MAY-1999  
DEFINITION Sequence 110 from Patent WO9742329.  
ACCESSION A67354  
VERSION A67354.1 GI:4756298  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGAGCTCG 19

RESULT 105  
LOCUS A87526 19 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 7 from Patent WO9835988.  
ACCESSION A87526  
VERSION A87526.1 GI:6736175  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Edge, M.D.  
TITLE Proteins  
JOURNAL Patent: WO 9835988-A 7 20-AUG-1998;  
ZENECA LTD (GB); EDGE MICHAEL DEREK (GB)  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGAGCTCG 19

RESULT 106  
LOCUS AR085857 19 bp DNA linear PAT 07-SEP-2000  
DEFINITION Sequence 52 from patent US 5985281.  
ACCESSION AR085857  
VERSION AR085857.1 GI:10012623  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Taylorson, C. John., Eggelte, H. Johannes., Tarragona-Piol, A.,  
Rabin, B. Robert., Boyle, F. Thomas., Henman, J. Frederick.,  
Blakey, D. Charles., Marsham, P. Robert., Heaton, D. William.,  
Davies, D. Huw., Slater, A. Michael. and Hennequin, L. Francois. Andre.  
TITLE Chemical compounds  
JOURNAL Patent: US 5985281-A 52 16-NOV-1999;  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGAGCTCG 19

RESULT 107  
LOCUS AX326925/c 19 bp DNA linear PAT 07-JAN-2002  
DEFINITION Sequence 121 from Patent WO0178894.  
ACCESSION AX326925  
VERSION AX326925.1 GI:18097636  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Keith, T.  
TITLE Novel human gene relating to respiratory diseases, obesity, and  
JOURNAL Inflammatory bowel disease  
Patent: WO 0178894-A 121 25-OCT-2001;  
Genome Therapeutics Corp. (US)  
FEATURES Location/Qualifiers  
Source 1..19  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Primer"

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 2.2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 AGAGACACGTCACCT 884  
DB 19 AGAGACACGTCACCT 2

RESULT 108  
AR362307/c

LOCUS AR362307 16 bp DNA linear PAT 03-SEP-2003  
DEFINITION Sequence 15 from patent US 5164485.  
ACCESSION AR362307  
VERSION AR362307.1 GI:34422223  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Modified hepatitis B virus surface antigen p31 and production thereof  
JOURNAL Patent: US 5164485-A 15 17-NOV-1992;  
FEATURES  
source .  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 2.3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 85 CTTCTCGCCGACTGGG 100  
Db 16 CTTCTCGCAGACTGGG 1

RESULT 109  
AR072089/c 17 bp DNA linear PAT 18-FEB-2000  
LOCUS AR072089  
DEFINITION Sequence 10 from patent US 5912337.  
ACCESSION AR072089  
VERSION AR072089.1 GI:7222977  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Tripp,C.Ann., Frank,G.Robert. and Griewe,R.B.  
JOURNAL Parasitic helminth p22u proteins  
FEATURES  
source Patent: US 5912337-A 10 15-JUN-1999;  
1. .17  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGCAGGCTCTGCA 2232  
Db 16 GGTGCAGGATCTGCA 1

RESULT 110  
I31849 17 bp DNA linear PAT 06-FEB-1997  
LOCUS I31849  
DEFINITION Sequence 6 from patent US 5583038.  
ACCESSION I31849  
VERSION I31849.1 GI:1822640  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Stover,C.K.  
JOURNAL Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins  
FEATURES  
source Patent: US 5583038-A 6 10-DEC-1996;  
1. .17  
Location/Qualifiers  
/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1690 TTGGATGGGAAGCCCC 1705  
Db 2 TTGTATGGGAAGCCCC 17

RESULT 111  
I47697/c 17 bp DNA linear PAT 07-OCT-1997  
LOCUS I47697  
DEFINITION Sequence 10 from patent US 5639876.  
ACCESSION I47697  
VERSION I47697.1 GI:2471662  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Tripp,C.Ann., Frank,G.Robert. and Griewe,R.B.  
JOURNAL Nucleic acid molecules encoding novel parasitic helminth proteins  
FEATURES  
source Patent: US 5639876-A 10 17-JUN-1997;  
1. .17  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGCAGGCTCTGCA 2232  
Db 16 GGTGCAGGATCTGCA 1

RESULT 112  
I73119/c 17 bp DNA linear PAT 03-APR-1998  
LOCUS I73119  
DEFINITION Sequence 10 from patent US 5686080.  
ACCESSION I73119  
VERSION I73119.1 GI:3009258  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Tripp,C.Ann., Frank,G.Robert. and Griewe,R.B.  
JOURNAL Parasitic helminth p4 proteins  
FEATURES  
source Patent: US 5686080-A 10 11-NOV-1997;  
1. .17  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2217 GGTGCAGGCTCTGCA 2232  
Db 16 GGTGCAGGATCTGCA 1

RESULT 113  
ARI95674 17 bp DNA linear PAT 20-APR-2002  
LOCUS ARI95674  
DEFINITION Sequence 139 from patent US 6350934.  
ACCESSION ARI95674  
VERSION ARI95674.1 GI:20245111

KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,  
JOURNAL Guo,L., Skokut,T.A., Young,S.A., Folkerds,O. and Merlo,D.J.  
Nucleic acid encoding delta-9 desaturase  
Patent: US 6350934-A 139 26-FEB-2002;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2179 CAGCAGCTCATGGAGA 2194  
1 CCGCAGCTCATGGAGA 16

RESULT 114  
AX263212 17 bp DNA linear PAT 26-OCT-2001  
LOCUS  
DEFINITION Sequence 603 from Patent WO0173002.  
ACCESSION AX263212  
VERSION AX263212.1 GI:16512011  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS Kntec,B.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 603 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1806 CCTGACCCAGAGCCA 1821  
2 CCAGACCCAGAGCCA 17

RESULT 115  
AX263213/c 17 bp DNA linear PAT 26-OCT-2001  
LOCUS  
DEFINITION Sequence 604 from Patent WO0173002.  
ACCESSION AX263213  
VERSION AX263213.1 GI:16512012  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS Kntec,B.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 604 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source Location/Qualifiers

source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1806 CCTGACCCAGAGCCA 1821  
16 CCAGACCCAGAGCCA 1

RESULT 116  
AX544969/c 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 482 from Patent EP1243660.  
ACCESSION AX544969  
VERSION AX544969.1 GI:25810180  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 482 25-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGGG 1502  
17 CCTTACCTTGAGGG 2

RESULT 117  
AX544970/c 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 483 from Patent EP1243660.  
ACCESSION AX544970  
VERSION AX544970.1 GI:25810181  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 483 25-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGGG 1502  
|||||||

Db 16 CCTTACACTGTGTGGG 1

RESULT 118  
LOCUS AX733143 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4777 from Patent WO03025175.  
ACCESSION AX733143  
VERSION AX733143.1 GI:30512486  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Tejerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 4777 27-MAR-2003;  
JOURNAL Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2081 GCTCAGTCTTCTCAT 2096  
Db 1 GATCAGTCTTCTCAT 16  
|||||  
|

RESULT 119  
LOCUS AX783931 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Sequence 2262 from Patent WO03050284.  
ACCESSION AX783931  
VERSION AX783931.1 GI:32951780  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Guo, J.  
Human prostate cancer candidate protein 1  
Patent: WO 03050284-A 2262 19-JUN-2003;  
JOURNAL Amerisham Biosciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1631 AGACACAGTGTCTGC 1646  
Db 2 AGACACAGTGTCTGC 17  
|||||  
|

RESULT 120  
LOCUS AX783934 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Sequence 2265 from Patent WO03050284.  
ACCESSION AX783934  
VERSION AX783934.1 GI:32951783

KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Guo, J.  
Human prostate cancer candidate protein 1  
Patent: WO 03050284-A 2265 19-JUN-2003;  
JOURNAL Amerisham Biosciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1633 AGCAGTGTCTGCC 1648  
Db 1 AGCAGTGTCTGCC 16  
|||||  
|

RESULT 121  
LOCUS AR344485 14 bp DNA linear PAT 17-AUG-2003  
DEFINITION Sequence 12 from patent US 6582902.  
ACCESSION AR344485  
VERSION AR344485.1 GI:33740543  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
Unclassified.

REFERENCE  
AUTHORS 1 (bases 1 to 14)  
TITLE Keene, J.D., Kenan, D.J. and Tsai, D.E.  
Method for deriving epitopes  
JOURNAL Patent: US 6582902-A 12 24-JUN-2003;  
FEATURES  
source Location/Qualifiers  
1..14  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 2.3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2112 CCTGTGTGAGCAGG 2125  
Db 1 CCTGTGTGAGCAGG 14  
|||||  
|

RESULT 122  
LOCUS AR391489 16 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 101 from patent US 6613520.  
ACCESSION AR391489  
VERSION AR391489.1 GI:40114986  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
Unclassified.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Aebly, M.  
Methods for the survey and genetic analysis of populations  
JOURNAL Patent: US 6613520-A 101 02-SEP-2003;  
FEATURES  
source Location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 14; DB 1; Length 16;



Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGGCGCACTGG 310  
|||||  
Db 16 AGCTGGCGCACTGG 3

## RESULT 123

AX281969/c 16 bp DNA linear PAT 02-NOV-2001  
LOCUS Sequence 101 from Patent WO0177392.  
DEFINITION AX281969  
ACCESSION AX281969.1 GI:16609220  
VERSION  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Aebby, M.  
TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: WO 0177392-A 101 18-OCT-2001;  
Aebby, Matthew (US)  
FEATURES  
source Location/Qualifiers  
1.16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="unidentified soil organism"

Query Match 0.6%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGGCGCACTGG 310  
|||||  
Db 16 AGCTGGCGCACTGG 3

## RESULT 124

126890/c 17 bp DNA linear PAT 07-OCT-1996  
LOCUS Sequence 113 from patent US 5561041.  
DEFINITION 126890  
ACCESSION 126890  
VERSION 126890.1 GI:1606760  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Sidransky, D.  
TITLE Nucleic acid mutation detection by analysis of sputum  
JOURNAL Patent: US 5561041-A 113 01-OCT-1996;  
FEATURES  
source Location/Qualifiers  
1.17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCAGGT 1742  
|||||  
Db 16 CTGCACAGCAGGT 3

RESULT 125  
191631/c 17 bp DNA linear PAT 01-DEC-1998  
LOCUS Sequence 113 from patent US 5726019.  
DEFINITION 191631  
ACCESSION 191631  
VERSION 191631.1 GI:3936101

KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Sidransky, D.  
TITLE Analysis of sputum by amplification and detection of mutant nucleic acid sequences  
JOURNAL Patent: US 5726019-A 113 10-MAR-1998;  
FEATURES  
source Location/Qualifiers  
1.17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGCAGGT 1742  
|||||  
Db 16 CTGCACAGCAGGT 3

RESULT 126  
AX259837/c 17 bp DNA linear PAT 26-OCT-2001  
LOCUS Sequence 64 from Patent WO0172822.  
DEFINITION AX259837  
ACCESSION AX259837  
VERSION AX259837.1 GI:16508911  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Hugot, J.P., Thomas, G., Zouali, M., Lesage, S. and Chamailard, M.  
TITLE Genes involved in intestinal inflammatory diseases and use thereof  
JOURNAL Patent: WO 0172822-A 64 04-OCT-2001;  
Fondation Jean Dausset-Ceph (FR)  
FEATURES  
source Location/Qualifiers  
1.17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 595 CTTGGGGAGTGGC 608  
|||||  
Db 14 CTTGGGGAGTGGC 1

RESULT 127  
AX733800 17 bp DNA linear PAT 08-MAY-2003  
LOCUS Sequence 5434 from Patent WO03025175.  
DEFINITION AX733800  
ACCESSION AX733800  
VERSION AX733800.1 GI:30513143  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025175-A 5434 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers

```

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1334 TCACATTGTCTC 1347
| | | | | | | | | |
Db 3 TCACATTGTCTC 16

RESULT 128
AR206689 18 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 5 from patent US 6372435.
ACCESSION AR206689
VERSION AR206689.1 GI:21505368
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Kaslow,R.A. and Tang,J.
TITLE Methods of surveying for CC (Beta) chemokine receptor variants and
their association with HIV-1 transmission and/or disease
progression
JOURNAL Patent: US 6372435-A 5 16-APR-2002;
FEATURES
Location/Qualifiers
1. .18
/mol_type="unassigned DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2189 TGGAGAAAAGGG 2202
| | | | | | | | | |
Db 4 TGGAGAAAAGGG 17

RESULT 129
AR206690 18 bp DNA linear PAT 20-JUN-2002
LOCUS Sequence 6 from patent US 6372435.
ACCESSION AR206690
VERSION AR206690.1 GI:21505369
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Kaslow,R.A. and Tang,J.
TITLE Methods of surveying for CC (Beta) chemokine receptor variants and
their association with HIV-1 transmission and/or disease
progression
JOURNAL Patent: US 6372435-A 6 16-APR-2002;
FEATURES
Location/Qualifiers
1. .18
/mol_type="unassigned DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2189 TGGAGAAAAGGG 2202
| | | | | | | | | |
Db 4 TGGAGAAAAGGG 17

```

```

RESULT 130
AR215508/c 18 bp DNA linear PAT 25-SEP-2002
LOCUS Sequence 56 from patent US 6410323.
DEFINITION AR215508
ACCESSION AR215508
VERSION AR215508.1 GI:23313764
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 18)
AUTHORS Roberts,M.L. and Cowseert,L.M.
TITLE Antisense modulation of human Rho family gene expression
JOURNAL Patent: US 6410323-A 56 25-JUN-2002;
FEATURES
Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1814 AGAGCCACTATG 1827
| | | | | | | | | |
Db 15 AGAGCCACTATG 2

RESULT 131
BD089389 18 bp DNA linear PAT 27-AUG-2002
LOCUS A method of arraying genome clone.
DEFINITION BD089389
ACCESSION BD089389
VERSION BD089389.1 GI:22634999
KEYWORDS JP 2001321190-A/1633.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS Soeda,E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 1633 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT OS Artificial Sequence
PN JP 2001321190-A/1633
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI HICHI SOEDA
PC C12N15/09,C12N15/00,C12M1/68,G01N33/53,G01N33/566,PC
C12N15/00
PC Description of Artificial Sequence:Synthetic DNA FH Key
CC Location/Qualifiers
FT source 1. .18
FT Location/Qualifiers
1. .18
/organism="Artificial Sequence".
FEATURES
Location/Qualifiers
1. .18
/mol_type="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 594 TCTTGGGAGATGG 607
| | | | | | | | | |
Db 4 TCTTGGGAGATGG 17

RESULT 132

```

```
A29720      A29720      17 bp      DNA      linear      PAT 29-JUN-1995
LOCUS       Oligonucleotide probe no.3.
DEFINITION  A29720
ACCESSION   A29720.1 GI:1248989
KEYWORDS    .
SOURCE      .
ORGANISM    .
REFERENCE   1 (bases 1 to 17)
AUTHORS     .
TITLE       .
JOURNAL     .
FEATURES     source
             /organism="synthetic construct"
             /mol_type="unassigned DNA"
             /db_xref="taxon:32630"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1897 GACACAGAGGTAGACA 1913
Db       1 GACACAGACGAGACGA 17

RESULT 133
BD253919    17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS       BD253919
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD253919
VERSION     BD253919.1 GI:33063689
KEYWORDS    UP 2002541795-A/1712.
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1 (bases 1 to 17)
AUTHORS     Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 1712 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/1712
            PD 10-DEC-2002
            PR 11-APR-2000 JP 2000611654
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            CI2N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
            CI2P21/02, PC
            PC CI2P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            CI2R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1.17
            /organism="Eukaryote".

FEATURES     source
             1.17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      949 TTGGGATCATGCTCTG 965
Db       1 TTGTGATCCTGCTCTG 17

RESULT 134
BD254279/c  17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS       BD254279/c
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254279
VERSION     BD254279.1 GI:33064049
KEYWORDS    UP 2002541795-A/2072.
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1 (bases 1 to 17)
AUTHORS     Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 2072 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/2072
            PD 10-DEC-2002
            PR 11-APR-2000 JP 2000611654
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            CI2N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            CI2P21/02, PC
            PC CI2P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            CI2R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1.17
            /organism="Eukaryote".

FEATURES     source
             1.17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2004 TGCCACCATGCTCTG 2020
Db       17 TGCCCCCAGAGCCCTG 1

RESULT 135
BD254343    17 bp      DNA      linear      PAT 17-JUL-2003
LOCUS       BD254343/c
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254343
VERSION     BD254343.1 GI:33064113
KEYWORDS    UP 2002541795-A/2136.
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1 (bases 1 to 17)
AUTHORS     Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE       Regulation of repressor genes using nucleic acid molecules
JOURNAL     Patent: JP 2002541795-A 2136 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS Eukaryote
            PN JP 2002541795-A/2136
            PD 10-DEC-2002
            PR 11-APR-2000 JP 2000611654
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            CI2N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
```

```

C12P21/02,
PC
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02,PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
PC A61K37/02,C12R1:91)
CC C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key
Location/Qualifiers
FT source
1..17
/organism='Eukaryote'.
FEATURES
source
location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1843 GCTGCAGTAAAGTCTCG 1859
Db 17 GCCACAGTAAAGTCTCG 1

RESULT 136
AR286258/c 17 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 630 from patent US 6528640.
ACCESSION AR286258
VERSION AR286258.1 GI:29723854
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS
Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE
Synthetic ribonucleic acids with RNase activity
JOURNAL
Patent: US 6528640-A 630 04-MAR-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCAGGCGCTG 275
Db 17 GTAGGTGACCGAGGCTG 1

RESULT 137
AR286348/c 17 bp RNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 720 from patent US 6528640.
ACCESSION AR286348
VERSION AR286348.1 GI:29723944
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS
Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE
Synthetic ribonucleic acids with RNase activity
JOURNAL
Patent: US 6528640-A 720 04-MAR-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

```

```

/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 AGGGCTGCTGCGCTGCT 285
Db 17 AGGGCTGCTGCTGCT 1

RESULT 138
AR326796/c 17 bp RNA linear PAT 17-AUG-2003
LOCUS
DEFINITION Sequence 4198 from patent US 6566127.
ACCESSION AR326796
VERSION AR326796.1 GI:33712604
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS
Payco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE
Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL
Patent: US 6566127-A 4198 20-MAY-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 977 CCCTCACCATGTCACG 993
Db 1 CGCTCACCATGTCACG 17

RESULT 139
AR398248/c 17 bp RNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 629 from patent US 6617438.
ACCESSION AR398248
VERSION AR398248.1 GI:40135903
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS
Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE
Oligoribonucleotides with enzymatic activity
JOURNAL
Patent: US 6617438-A 629 09-SEP-2003;
FEATURES
source
location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No.2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGGTGCCAGGCGCTG 275
Db 17 GTAGGTGACCGAGGCTG 1

RESULT 140
AR398338/c 17 bp RNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 719 from patent US 6617438.

```

ACCESSION AR398338  
VERSION AR398338.1 GI:40136070  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
Belgeman, L., Burgin, A.B., Beaudry, A., Karpelisky, A.,  
Metulic-Adamc, J., Sweedler, D. and Zinnen, S.  
TITLE Oligoribonucleotides with enzymatic activity  
JOURNAL Patent: US 6617438-A 719 09-SEP-2003;  
FEATURES  
source  
1. 17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 269 AGGCGTGGCTGGCTGCT 285  
Db 17 AGGCGTGGCTGCTGCT 1

RESULT 141  
AX214664 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 106 from Patent WO0159103.  
ACCESSION AX214664  
VERSION AX214664.1 GI:15524707  
KEYWORDS  
SOURCE  
ORGANISM synthetic construct  
REFERENCE  
AUTHORS 1  
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.  
JOURNAL method and reagent for the modulation and diagnosis of cd20 and  
nogo gene expression  
Patent: WO 0159103-A 106 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. 17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1778 GAAGCTTCAGAAAT 1794  
Db 1 GAACACTTCAGAAAT 17

RESULT 142  
AX216395 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 1837 from Patent WO0159103.  
ACCESSION AX216395  
VERSION AX216395.1 GI:15526456  
KEYWORDS  
SOURCE  
ORGANISM synthetic construct  
REFERENCE  
AUTHORS 1  
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.  
JOURNAL method and reagent for the modulation and diagnosis of cd20 and  
nogo gene expression  
Patent: WO 0159103-A 1837 16-AUG-2001;

FEATURES  
source  
1. 17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 199 GTGCTGCTGGGGGC 215  
Db 17 GGCGTGGCTGGGGGC 1

RESULT 143  
AX216573 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 2015 from Patent WO0159103.  
ACCESSION AX216573  
VERSION AX216573.1 GI:15526634  
KEYWORDS  
SOURCE  
ORGANISM synthetic construct  
REFERENCE  
AUTHORS 1  
TITLE Blatt, L., McSwiggen, J. and Chowrira, B.M.  
JOURNAL method and reagent for the modulation and diagnosis of cd20 and  
nogo gene expression  
Patent: WO 0159103-A 2015 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. 17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 784 GGAGAGGTGTTGGGCG 800  
Db 1 GGAGGTGTTGGTGC 17

RESULT 144  
AX423541 17 bp RNA linear PAT 18-JUN-2002  
LOCUS  
DEFINITION Sequence 1877 from Patent WO0188124.  
ACCESSION AX423541  
VERSION AX423541.1 GI:21526923  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
REFERENCE  
AUTHORS 1  
TITLE Uarivis, T., von Carlowitz, I., McSwiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
JOURNAL Method and reagent for the inhibition of erg  
Patent: WO 0188124-A 1877 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. 17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 346 CTGATCTCATTGGGAGC 362  
|||||  
Db 17 CTGATCTCTGGGGGC 1

RESULT 145  
AX423542/c 17 bp RNA linear PAT 18-JUN-2002  
LOCUS AX423542  
DEFINITION Sequence 1878 from Patent WO0188124.  
ACCESSION AX423542  
VERSION AX423542.1 GI:21526924  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Jarvis,T., von Carlwiltz,I., Mcswigen,J.A., McLaughlin,F.G. and  
TITLE Randi,A.M.  
JOURNAL Method and reagent for the inhibition of erg  
PATENT: WO 0188124-A 1878 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 345 GCTGATCTCATTGGGAG 361  
|||||  
Db 17 GCTGATCTCTGGGGGC 1

RESULT 146  
AX475793 17 bp DNA linear PAT 12-AUG-2002  
LOCUS AX475793  
DEFINITION Sequence 1014 from Patent WO0224750.  
ACCESSION AX475793  
VERSION AX475793.1 GI:22215078  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang,J.  
JOURNAL Human kidney tumor overexpressed membrane protein 1  
PATENT: WO 0224750-A 1014 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 147 CACCGCGCTGCCACTGC 163  
|||||  
Db 1 CACCGAGCAGCCACTGC 17

RESULT 147  
AX499212 17 bp DNA linear PAT 27-SEP-2002  
LOCUS AX499212  
DEFINITION Sequence 519 from Patent EP1229046.  
ACCESSION AX499212  
VERSION AX499212.1 GI:23381505  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
JOURNAL Human testis expressed patched like protein  
PATENT: EP 1229046-A 519 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 131 TCTCCTGCTGTGCCCC 147  
|||||  
Db 1 TCTTCTGCTGTGCGCCC 17

RESULT 148  
AX530927 17 bp DNA linear PAT 22-NOV-2002  
LOCUS AX530927  
DEFINITION Sequence 436 from Patent EP1239051.  
ACCESSION AX530927  
VERSION AX530927.1 GI:25253645  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M.  
JOURNAL Human posh-1ike protein 1  
PATENT: EP 1239051-A 436 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1101 CATTGAGGCTGTGCGG 1117  
|||||  
Db 1 CATTGAGGCGCTGCCGG 17

RESULT 149  
AX530928 17 bp DNA linear PAT 22-NOV-2002  
LOCUS AX530928  
DEFINITION Sequence 437 from Patent EP1239051.  
ACCESSION AX530928  
VERSION AX530928.1 GI:25253647  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```

REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 437 11-SEP-2002;
FEATURES
SOURCE
  1.17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
Query Match
  0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1102 ATTGAGGCTCTGTCGCC 1118
  |||||
  1 ATTGAGGCGCTGCCGCC 17
RESULT 150
AX530929 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530929
DEFINITION Sequence 438 from Patent EP1239051.
ACCESSION AX530929
VERSION AX530929.1 GI:25253649
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 438 11-SEP-2002;
FEATURES
SOURCE
  1.17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
Query Match
  0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1103 TTGAGGCTCTGTCGCC 1119
  |||||
  1 TTGAGGCGCTGCCGCC 17
RESULT 151
AX530930 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530930
DEFINITION Sequence 439 from Patent EP1239051.
ACCESSION AX530930
VERSION AX530930.1 GI:25253651
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 439 11-SEP-2002;
FEATURES
SOURCE
  1.17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

```

```

Query Match
  0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1104 TGAGGCTCTGTCGCCA 1120
  |||||
  1 TGAGGCGCTGCCGCCA 17
RESULT 152
AX531817 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531817
DEFINITION Sequence 1326 from Patent EP1239051.
ACCESSION AX531817
VERSION AX531817.1 GI:25255410
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Shannon,M.
TITLE Human posh-1like protein 1
JOURNAL Patent: EP 1239051-A 1326 11-SEP-2002;
FEATURES
SOURCE
  1.17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
Query Match
  0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2092 CTCATCACCAGCAGCCT 2108
  |||||
  1 CTTATCACCCGCACCT 17
RESULT 153
AX544924 17 bp DNA linear PAT 26-NOV-2002
LOCUS AX544924
DEFINITION Sequence 437 from Patent EP1243660.
ACCESSION AX544924
VERSION AX544924.1 GI:25810135
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10
JOURNAL Patent: EP 1243660-A 437 25-SEP-2002;
FEATURES
SOURCE
  1.17
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
Query Match
  0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1421 CCTCAGAGAAATATTT 1437
  |||||
  1 CCTCAGTGAATAATTT 17
RESULT 154
AX544968/c

```

LOCUS AX544968 17 bp DNA linear PAT 26-NOV-2002  
 DEFINITION Sequence 481 from Patent EP1243660.  
 ACCESSION AX544968  
 VERSION AX544968.1 GI:25810179  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
 AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
 TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
 JOURNAL Patent: EP 1243660-A 481 25-SEP-2002;  
 Aeomica, Inc. (US)  
 FEATURES location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 CTGCGCTGCTTGAAGCC 293  
 Db 1 CTGGCTCTTGTGATGCC 17

RESULT 156  
 LOCUS AX579025 17 bp RNA linear PAT 10-JAN-2003  
 DEFINITION Sequence 863 from Patent WO0211674.  
 ACCESSION AX579025  
 VERSION AX579025.1 GI:27648227  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
 AUTHORS Thompson, J., Mcswigen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

TITLE and Grube, A.  
 JOURNAL Method and reagent for the inhibition of calcium activated chloride channel-1 (Clca-1)  
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ; Thompson, James (US)  
 FEATURES location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned RNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1997 TGGATGATGCCACGCT 2013  
 Db 17 TGGATGATGCCACCACT 1

RESULT 157  
 LOCUS AX615974 17 bp DNA linear PAT 20-FEB-2003  
 DEFINITION Sequence 781 from Patent EP1262488.  
 ACCESSION AX615974  
 VERSION AX615974.1 GI:28447020  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
 AUTHORS Gu, Y. and Nguyen, C.T.  
 TITLE Human lcll-domain containing protein  
 JOURNAL Patent: EP 1262488-A 781 04-DEC-2002;  
 Aeomica, Inc. (US)  
 FEATURES location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 918 TCTGTGTACTGTGTC 934  
 Db 17 TCTGTGTGACCTGTGTAC 1

RESULT 158  
 LOCUS AX687644 17 bp DNA linear PAT 31-MAR-2003  
 DEFINITION Sequence 376 from Patent EP1281758.  
 ACCESSION AX687644  
 VERSION AX687644.1 GI:29410340  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
 AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 376 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"



/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2176 CACCAGCAGCTCATGGA 2192  
17 CACCAGCAGCTCCAGGA 1

RESULT 159  
LOCUS AX687797 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 529 from Patent EP1281758.  
ACCESSION AX687797  
VERSION AX687797.1 GI:29410493  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens (human)

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
PATENT: EP 1281758-A 529 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GCCACTTGCAGGCGAG 789  
1 GCCACAGCAGCGAGAG 17

RESULT 160  
LOCUS AX688661/c 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1393 from Patent EP1281758.  
ACCESSION AX688661  
VERSION AX688661.1 GI:29411363  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens (human)

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
PATENT: EP 1281758-A 1393 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1639 GTGGCTGCCCTGCTGCA 1655  
17 GTGGCTGCCCTGCTGCA 1

RESULT 161  
LOCUS AX690651/c 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 3383 from Patent EP1281758.  
ACCESSION AX690651  
VERSION AX690651.1 GI:29413532  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens (human)

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
PATENT: EP 1281758-A 3383 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2176 CACCAGCAGCTCATGGA 2192  
17 CACCAGCAGCTTCAGGA 1

RESULT 162  
LOCUS AX724195 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 1882 from Patent WO03025176.  
ACCESSION AX724195  
VERSION AX724195.1 GI:30503538  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE 1  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
PATENT: WO 03025176-A 1882 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1359 GTTCACCCAGGCTGTG 1375  
1 GATCTCCAGCGTGTG 17

RESULT 163  
LOCUS AX726124 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 3811 from Patent WO03025176.  
ACCESSION AX726124  
VERSION AX726124.1 GI:30505467

KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman,A., Amson,R. and Tuijnder,M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 3811 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match  
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012  
Db 1 GATCGCTGCTCTGC 17

RESULT 164  
AX728039 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 5726 from Patent WO03025176.  
ACCESSION AX728039  
VERSION AX728039.1 GI:30507382  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman,A., Amson,R. and Tuijnder,M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 5726 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match  
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012  
Db 1 GATCGCTGCTCTGC 17

RESULT 165  
AX730911 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2545 from Patent WO03025175.  
ACCESSION AX730911  
VERSION AX730911.1 GI:30510254  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman,A., Amson,R. and Tuijnder,M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03040369-A 3248 15-MAY-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"

TITLE  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 2545 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match  
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 996 GATCACCTGCTCTGC 1012  
Db 1 GATCGCTGCTCTGC 17

RESULT 166  
AX745331/c 17 bp DNA linear PAT 14-MAY-2003  
LOCUS  
DEFINITION Sequence 1296 from Patent WO03031621.  
ACCESSION AX745331  
VERSION AX745331.1 GI:30723998  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
1  
Zhang,J.  
A human G protein coupled receptor  
Patent: WO 03031621-A 1296 17-APR-2003;  
JOURNAL  
Amersham Biosciences (SV) Corp. (US)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match  
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 859 CGGGTAACAGAGAC 875  
Db 17 CAGGTAAAGAGAAC 1

RESULT 167  
AX759927 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 3248 from Patent WO03040369.  
ACCESSION AX759927  
VERSION AX759927.1 GI:32254543  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman,A., Amson,R. and Tuijnder,M.  
Sequences involved in tumoral suppression, tumoral reversion,  
apoptosis and/or viral resistance phenomena and their use as  
medicines  
Patent: WO 03040369-A 3248 15-MAY-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      996 GATCACCCCTGCTCTGC 1012
      1 GATCCTCTCTGCTCTGC 17

RESULT 168
LOCUS      AX761880      17 bp      DNA      linear      PAT 25-JUN-2003
DEFINITION Sequence 5201 from Patent WO03040369.
ACCESSION  AX761880
VERSION     AX761880.1 GI:32256496
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     1
TITLE       Telerman,A., Amson,R. and Tuijnder,M.
            Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
            Patent: WO 03040369-A 5201 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      996 GATCACCCCTGCTCTGC 1012
      1 GATCCTCTCTGCTCTGC 17

RESULT 169
LOCUS      AX783935      17 bp      DNA      linear      PAT 17-JUN-2003
DEFINITION Sequence 2266 from Patent WO03050284.
ACCESSION  AX783935
VERSION     AX783935.1 GI:32951784
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS     1
TITLE       Guo,J.
            Human prostate cancer candidate protein 1
            Patent: WO 03050284-A 2266 19-JUN-2003;
            Amerisham Biosciences (SV) Corp. (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1634 GCACAGTGGCTGCGCTG 1650
      1 GCACAGTGTGTGCGCCCG 17

```

```

RESULT 170
LOCUS      BD104937      17 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION  BD104937
VERSION     BD104937.1 GI:22650511
KEYWORDS    WO 0192572-A/1041.
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
            1 (bases 1 to 17)
REFERENCE
AUTHORS     Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
            Kit and method for determining HLA type
            Patent: WO 0192572-A 1041 06-DEC-2001;
            NISHINO INDUSTRIES INC.,SYSTEM RESEARCH INC.,HIDETOSHI INOKO,
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT
OS      Artificial Sequence
PN      WO 0192572-A/1041
PD      06-DEC-2001
PF      01-JUN-2001 WO 2001JP004662
PR      01-JUN-2000 JP 00P 164798
PI      HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI
            MATSUMURA,
            SHOGO MORIYA,MICHIO NISHIDA
            CC      C12Q1/68,C12M1/00,C12N15/09,G01N33/53
            PC      Description of Artificial Sequence:capture
            FH      Key
            FT      source      1..17
                    /organism='Artificial Sequence'.
                    Location/Qualifiers
                    source      1..17
                    /organism="synthetic construct"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32630"

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      490 GCGGCTCAGGCGGCTC 506
      1 GCGGAGACAGGCGGCTC 17

RESULT 171
LOCUS      BD105155      17 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION  BD105155
VERSION     BD105155.1 GI:22650729
KEYWORDS    WO 0192572-A/1259.
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
            1 (bases 1 to 17)
REFERENCE
AUTHORS     Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
            Kit and method for determining HLA type
            Patent: WO 0192572-A 1259 06-DEC-2001;
            NISHINO INDUSTRIES INC.,SYSTEM RESEARCH INC.,HIDETOSHI INOKO,
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT
OS      Artificial Sequence
PN      WO 0192572-A/1259
PD      06-DEC-2001
PF      01-JUN-2001 WO 2001JP004662
PR      01-JUN-2000 JP 00P 164798
PI      HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI
            MATSUMURA,

```

PI SHOGO MORIYA,MICHIIO NISHIDA  
CC C12Q1/68,C12M1/00,C12N15/09,G01N33/53  
PC Description of Artificial Sequence:capture  
FH Key Location/Qualifiers  
FT source 1..17  
FT Location/Qualifiers  
Location/Qualifiers  
1..17  
/organism="Artificial Sequence".  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 370 TCCGCGGATAGCACCAG 386  
Db 1 TCCGCGGATACCACCAG 17

RESULT 172  
A67603/c  
LOCUS A67603 18 bp DNA linear PAT 05-MAY-1999  
DEFINITION Sequence 23 from Patent WO9744485.  
ACCESSION A67603  
VERSION A67603.1 GI:4756466  
KEYWORDS  
SOURCE  
ORGANISM  
unclassified.  
unclassified.  
unclassified.

REFERENCE  
AUTHORS Goodfellow,P.N.  
TITLE METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST  
JOURNAL Patent: WO 9744485-A 23 27-NOV-1997;  
HEXAGEN TECHNOLOGY LIMITED (GB)  
FEATURES  
source  
1..18  
/organism="unclassified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2200 GGGTGCTACTGGGCAT 2216  
Db 18 GGGTCTCTCTGGGCAT 2

RESULT 173  
AR007264/c  
LOCUS AR007264 18 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 7 from patent US 5750376.  
ACCESSION AR007264  
VERSION AR007264.1 GI:3966748  
KEYWORDS  
SOURCE  
ORGANISM  
Unknown.  
unclassified.  
unclassified.

REFERENCE  
AUTHORS Weis,S., Reynolds,B., Hammang,J.P. and Baetge,E.Edward.  
TITLE In vitro growth and proliferation of genetically modified  
JOURNAL multipotent neural stem cells and their progeny  
FEATURES Patent: US 5750376-A 7 12-MAY-1998;  
source  
1..18  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTGACGCGCTGG 1609  
Db 18 CGAGGTGATGCGCGCTGG 2

RESULT 174  
AR007265  
LOCUS AR007265 18 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 8 from patent US 5750376.  
ACCESSION AR007265  
VERSION AR007265.1 GI:3966749  
KEYWORDS  
SOURCE  
ORGANISM  
Unknown.  
Unknown.  
Unknown.

REFERENCE  
AUTHORS Weis,S., Reynolds,B., Hammang,J.P. and Baetge,E.Edward.  
TITLE In vitro growth and proliferation of genetically modified  
JOURNAL multipotent neural stem cells and their progeny  
FEATURES Patent: US 5750376-A 8 12-MAY-1998;  
source  
1..18  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTGACGCGCTGG 1609  
Db 1 CGAGGTGATGCGCGCTGG 17

RESULT 175  
AR029258/c  
LOCUS AR029258 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 9 from patent US 5859229.  
ACCESSION AR029258  
VERSION AR029258.1 GI:5941231  
KEYWORDS  
SOURCE  
ORGANISM  
Unknown.  
Unknown.  
Unknown.

REFERENCE  
AUTHORS Knise,D.A.  
TITLE Antisense oligonucleotides to suppress eicosanoid formation  
JOURNAL Patent: US 5859229-A 9 12-JAN-1999;  
FEATURES Location/Qualifiers  
1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 807 GCGCCAGAGACGAGT 823  
Db 18 GCGCCATGAGCCGAGT 2

RESULT 176  
AR067989/c  
LOCUS AR067989 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 7 from patent US 5851832.  
ACCESSION AR067989  
VERSION AR067989.1 GI:5999211  
KEYWORDS  
SOURCE  
ORGANISM  
Unknown.  
Unknown.  
Unknown.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

Unclassified.  
1 (bases 1 to 18)  
Weise,S., Reynolds,B., Hammang,J.P. and Baetge,E. Edward  
in vitro growth and proliferation of multipotent neural stem cells  
and their progeny  
Patent: US 5851832-A 7 22-DEC-1998;  
Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609  
Db 18 CGAGGTATGCGCTGG 2

RESULT 177  
AR067990 18 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AR067990  
Sequence 8 from patent US 5851832.  
AR067990  
AR067990.1 GI:5999212  
Unknown.  
Unclassified.  
1 (bases 1 to 18)  
Weise,S., Reynolds,B., Hammang,J.P. and Baetge,E. Edward.  
In vitro growth and proliferation of multipotent neural stem cells  
and their progeny  
Patent: US 5851832-A 8 22-DEC-1998;  
Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609  
Db 1 CGAGGTATGCGCTGG 17

RESULT 178  
AR083518 18 bp DNA linear PAT 01-SEP-2000  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AR083518  
Sequence 57 from patent US 5976873.  
AR083518  
AR083518.1 GI:10010291  
Unknown.  
Unclassified.  
1 (bases 1 to 18)  
Bohinski,R.J. and Whitesett,J.A.  
Nucleic acid sequences controlling lung cell-specific gene  
expression  
Patent: US 5976873-A 57 02-NOV-1999;  
Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGGCTCTCAGAGAAA 1432  
Db 1 GGGCTCTCAGAGAAA 17

RESULT 179  
AR083520 18 bp DNA linear PAT 01-SEP-2000  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AR083520  
Sequence 59 from patent US 5976873.  
AR083520  
AR083520.1 GI:10010293  
Unknown.  
Unclassified.  
1 (bases 1 to 18)  
Bohinski,R.J. and Whitesett,J.A.  
Nucleic acid sequences controlling lung cell-specific gene  
expression  
Patent: US 5976873-A 59 02-NOV-1999;  
Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGGCTCTCAGAGAAA 1432  
Db 1 GGGCTCTCAGAGAAA 17

RESULT 180  
AR084251 18 bp DNA linear PAT 01-SEP-2000  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AR084251  
Sequence 7 from patent US 5980885.  
AR084251  
AR084251.1 GI:10011022  
Unknown.  
Unclassified.  
1 (bases 1 to 18)  
Weise,S. and Reynolds,B.  
Growth factor-induced proliferation of neural precursor cells in  
vivo  
Patent: US 5980885-A 7 09-NOV-1999;  
Location/Qualifiers  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGGTACGCGCTGG 1609  
Db 18 CGAGGTATGCGCTGG 2

RESULT 181  
AR084252 18 bp DNA linear PAT 01-SEP-2000  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

AR084252  
Sequence 8 from patent US 5980885.  
AR084252  
AR084252.1 GI:10011023  
Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 18)  
AUTHORS Weiss,S. and Reynolds,B.  
TITLE Growth factor-induced proliferation of neural precursor cells in vivo  
JOURNAL Patent: US 5980885-A 8 09-NOV-1999;  
FEATURES Location/Qualifiers  
SOURCE 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCCTGG 1609  
Db 1 CGAGGTGATGCCGCTGG 17

RESULT 182  
LOCUS AR089741 18 bp DNA linear PAT 07-SEP-2000  
DEFINITION Sequence 23 from patent US 5994075.  
ACCESSION AR089741 GI:10016496  
VERSION AR089741.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Goodfellow,P.N.  
TITLE Methods for identifying a mutation in a gene of interest without a phenocypic guide  
JOURNAL Patent: US 5994075-A 23 30-NOV-1999;  
FEATURES Location/Qualifiers  
SOURCE 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2200 GGGTGCTACTGGCCCAT 2216  
Db 18 GGGTCTCTCTGGCCCAT 2

RESULT 183  
LOCUS AR096651 18 bp DNA linear PAT 08-SEP-2000  
DEFINITION Sequence 35 from patent US 6008048.  
ACCESSION AR096651  
VERSION AR096651.1 GI:10025638  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Monia,B.P. and Cowser,L.M.  
TITLE Antisense inhibition of EGR-1 expression  
JOURNAL Patent: US 6008048-A 35 28-DEC-1999;  
FEATURES Location/Qualifiers  
SOURCE 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2054 TGTACGAAGCCCTGAG 2070  
Db 1 TGTACGAAGCCCTGAG 2070

Db 2 TGTCCGAAGCCCTGTG 18

RESULT 184  
LOCUS AR097623/c 18 bp DNA linear PAT 14-FEB-2001  
DEFINITION Sequence 7 from patent US 6071889.  
ACCESSION AR097623  
VERSION AR097623.1 GI:12806353  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Weiss,S., Reynolds,B., Hammang,U.P. and Baetge,E.Edward.  
TITLE In vivo genetic modification of growth factor-responsive neural precursor cells  
JOURNAL Patent: US 6071889-A 7 06-JUN-2000;  
FEATURES Location/Qualifiers  
SOURCE 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCCTGG 1609  
Db 18 CGAGGTGATGCCGCTGG 2

RESULT 185  
LOCUS AR097624 18 bp DNA linear PAT 14-FEB-2001  
DEFINITION Sequence 8 from patent US 6071889.  
ACCESSION AR097624  
VERSION AR097624.1 GI:12806354  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Weiss,S., Reynolds,B., Hammang,U.P. and Baetge,E.Edward.  
TITLE In vivo genetic modification of growth factor-responsive neural precursor cells  
JOURNAL Patent: US 6071889-A 8 06-JUN-2000;  
FEATURES Location/Qualifiers  
SOURCE 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGCGCCTGG 1609  
Db 1 CGAGGTGATGCCGCTGG 17

RESULT 186  
LOCUS AR130092/c 18 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 84 from patent US 6187586.  
ACCESSION AR130092  
VERSION AR130092.1 GI:14117989  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Monia,B.P., Cowser,L.M. and Roch,R.A.

TITLE Antisense modulation of AKT-3 expression  
JOURNAL Patent: US 6187586-A 84 13-FEB-2001;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1867 AGTTTCATCTCTGAGT 1863  
Db 18 AGTTTCATCTCTGAGT 2

RESULT 187  
BD270112/c 18 bp DNA linear PAT 17-JUN-2003  
LOCUS Secreted proteins and polynucleotides encoding them.  
DEFINITION BD270112.1 GI:33079880  
ACCESSION BD270112.1 GI:33079880  
VERSION JP 2002537757-A/74.  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Valenzuela, D., Yuan, O., Hoffman, H., Hall, J. and Rapiejko, P.  
TITLE Secreted proteins and polynucleotides encoding them  
JOURNAL Patent: JP 2002537757-A 74 12-NOV-2002;  
ALPHABET INC

OS Artificial Sequence  
PN JP 2002537757-A/74  
PD 12-NOV-2002  
PF 24-AUG-1999 JP 2000566287  
PR 24-AUG-1998 US 60/097638, 24-AUG-1998 US 60/097659 PR  
09-SEP-1998 US 60/099618, 28-SEP-1998 US 60/102092 PR  
25-NOV-1998 US 60/109978, 23-DEC-1998 US 60/113645 PR  
23-DEC-1998 US 60/113646, 23-AUG-1999 US 09/379246 PI DARIO  
VALENZUELA, OLIVE YUAN, HEIDI HOFFMAN, JEFF HALL, PETER PI RAPIEJKO  
PC C12N15/09, A61K38/00, A61K48/00, A61P3/10, A61P11/06, A61P21/00, PC  
A61P29/00,  
PC A61P31/04, A61P31/10, A61P31/12, A61P31/18, A61P35/00, A61P37/00,  
PC C07K14/47,  
PC C12N5/10, C12P21/02, G01N33/15, G01N33/50, C12N15/00, A61K37/02, PC  
C12N5/00  
CC oligonucleotide  
FH key Location/Qualifiers  
FT source 1..18  
/organism="Artificial Sequence".  
FEATURES location/Qualifiers  
source 1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1919 GGAGCCAGCTCTCAGG 1915  
Db 18 GGAGCCAGCTCTCAGG 2

RESULT 188  
AR211763/c 18 bp DNA linear PAT 20-JUN-2002  
LOCUS Sequence 7 from patent US 6399369.  
DEFINITION AR211763  
ACCESSION AR211763.1 GI:21515172  
VERSION AR211763.1 GI:21515172  
KEYWORDS  
SOURCE Unknown.

ORGANISM Unknown.  
REFERENCE Unclassified.  
1 (bases 1 to 18)  
AUTHORS Weiss, S. and Reynolds, B.  
TITLE Multipotent neural stem cell cDNA libraries  
JOURNAL Patent: US 6399369-A 7 04-JUN-2002;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1593 CGAGTGACGCGCTGG 1609  
Db 18 CGAGTGATGCCGCTGG 2

RESULT 189  
AR211764 18 bp DNA linear PAT 20-JUN-2002  
LOCUS AR211764  
DEFINITION Sequence 8 from patent US 6399369.  
ACCESSION AR211764  
VERSION AR211764.1 GI:21515173  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
1 (bases 1 to 18)  
AUTHORS Weiss, S. and Reynolds, B.  
TITLE Multipotent neural stem cell cDNA libraries  
JOURNAL Patent: US 6399369-A 8 04-JUN-2002;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1593 CGAGTGACGCGCTGG 1609  
Db 1 CGAGTGATGCCGCTGG 17

RESULT 190  
AR267617/c 18 bp mRNA linear PAT 10-APR-2003  
LOCUS AR267617  
DEFINITION Sequence 7 from patent US 6497872.  
ACCESSION AR267617  
VERSION AR267617.1 GI:29697719  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
1 (bases 1 to 18)  
AUTHORS Weiss, S., Reynolds, B., Hammang, J.P. and Baetge, E.E.  
TITLE Neural transplantation using proliferated multipotent neural stem  
cells and their progeny  
JOURNAL Patent: US 6497872-A 7 24-DEC-2002;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="mRNA"

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1593 CGAGTGACGCGCTGG 1609

Db 18 CGAGGTGATGCCCTGG 2

RESULT 191  
LOCUS AR267618 18 bp mRNA linear PAT 10-APR-2003  
DEFINITION Sequence 8 from patent US 6497872.  
ACCESSION AR267618  
VERSION AR267618.1 GI:29697720  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 18)  
AUTHORS Weiss,S., Reynolds,B., Hamman,J.P. and Baetge,E.E.  
TITLE Neural transplantation using proliferated multipotent neural stem cells and their progeny  
JOURNAL Patent: US 6497872-A 8 24-DEC-2002;  
FEATURES  
Location/Qualifiers  
1..18  
/organism="unknown"  
/mol\_type="mRNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGGTGACGGCGCTGG 1609  
Db 1 CGAGGTGATGCCCTGG 17

RESULT 192  
LOCUS AR296724 18 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 8459 from patent US 6537751.  
ACCESSION AR296724  
VERSION AR296724.1 GI:31684008  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 18)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 8459 25-MAR-2003;  
FEATURES  
Location/Qualifiers  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TACTGCTACTTCTCGCC 93  
Db 2 TACTGCTACTCTCTCC 18

RESULT 193  
LOCUS AX039910/c 18 bp DNA linear PAT 18-NOV-2000  
DEFINITION Sequence 299 from Patent WO0063441.  
ACCESSION AX039910  
VERSION AX039910.1 GI:11229939  
KEYWORDS  
SOURCE  
ORGANISM  
1. synthetic construct  
2. synthetic construct  
artificial sequences.

AUTHORS Herrstadt,C. and Davis,R.E.  
TITLE Single nucleotide polymorphisms in mitochondrial genes that segregate with Alzheimer's disease  
JOURNAL Patent: WO 0063441-A 299 26-OCT-2000;  
MITOKOR (US)  
FEATURES  
Location/Qualifiers  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="PCR primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 658 TCAGCGATACCTTCAC 674  
Db 18 TCATCCGCTACTTCAC 2

RESULT 194  
LOCUS AX117435/c 18 bp DNA linear PAT 11-MAY-2001  
DEFINITION Sequence 2558 from Patent WO0129262.  
ACCESSION AX117435  
VERSION AX117435.1 GI:14034386  
KEYWORDS  
SOURCE  
ORGANISM  
1. synthetic construct  
2. synthetic construct  
artificial sequences.

REFERENCE  
1  
AUTHORS Picoult-Newbury,J. and Pohl,M.  
TITLE Genotyping reagents, kits and methods of use thereof  
JOURNAL Patent: WO 0129262-A 2558 26-APR-2001;  
Orchid Biosciences, Inc. (US)  
FEATURES  
Location/Qualifiers  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred.No.2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1925 AGCTGTGAGGGGTTCAG 1941  
Db 18 AGCTGTGATGCGCCAG 2

RESULT 195  
LOCUS AX179324 18 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 25 from Patent WO0127277.  
ACCESSION AX179324  
VERSION AX179324.1 GI:14598995  
KEYWORDS  
SOURCE  
ORGANISM  
1. synthetic construct  
2. synthetic construct  
artificial sequences.

REFERENCE  
1  
AUTHORS Shinkets,R.A., Lichenstein,H. and Boldog,F.L.  
TITLE Proteins and polynucleotides encoded thereby  
JOURNAL Patent: WO 0127277-A 25 19-APR-2001;  
Curagen Corporation (US)  
FEATURES  
Location/Qualifiers  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Primer 10354874 S1"



Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 CCGTGTCTGTGGCTGGG 213  
 |||||  
 Db 2 CCGTGTCTGTGGCTGAGG 18

RESULT 196  
 AX179325/c 18 bp DNA linear PAT 03-JUN-2001  
 LOCUS  
 DEFINITION Sequence 26 from Patent WO0127277.  
 ACCESSION AX179325  
 VERSION AX179325.1 GI:14598996  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 .  
 synthetic construct  
 synthetic construct  
 artificial sequences.

REFERENCE 1

AUTHORS Shimketa, R.A., Lichenstein, H. and Boldog, F.L.  
 TITLE Proteins and polynucleotides encoded thereby  
 JOURNAL Patent: WO 0127277-A 26 19-APR-2001;  
 Curagen Corporation (US)

FEATURES  
 source  
 1..18  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Primer 10354784 S2"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 CCGTGTCTGTGGCTGGG 213  
 |||||  
 Db 17 CCGTGTCTGTGGCTGAGG 1

RESULT 197  
 AX180627 18 bp DNA linear PAT 06-AUG-2001  
 LOCUS  
 DEFINITION Sequence 205 from Patent WO0146391.  
 ACCESSION AX180627  
 VERSION AX180627.1 GI:15132513  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 .  
 synthetic construct  
 synthetic construct  
 artificial sequences.

REFERENCE 1  
 AUTHORS Oebourn, A.E., Haralampidis, K. and Bryan, G.T.  
 TITLE Plant gene  
 JOURNAL Patent: WO 0146391-A 205 28-JUN-2001;  
 Plant Bioscience Limited (GB)

FEATURES  
 source  
 1..18  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 941 TATGCTCTTGGGATC 957  
 |||||  
 Db 1 TATGCTCTTGGGATC 17

RESULT 198

AX338227 18 bp DNA linear PAT 09-JAN-2002  
 LOCUS  
 DEFINITION Sequence 9 from Patent WO0181576.  
 ACCESSION AX338227  
 VERSION AX338227.1 GI:18128762  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 .  
 synthetic construct  
 synthetic construct  
 artificial sequences.

REFERENCE 1

AUTHORS Lind, P. and Berthold, M.  
 TITLE G protein-coupled receptor con-218  
 JOURNAL Patent: WO 0181576-A 9 01-NOV-2001;  
 PHARMACIA & UPJOHN COMPANY (US)

FEATURES  
 source  
 1..18  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Primer"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 557 GCCCTGCTGCTGCTGCTG 573  
 |||||  
 Db 1 GCCCTGCTGCTGCTGCTG 17

RESULT 199  
 AX353323 18 bp DNA linear PAT 06-FEB-2002  
 LOCUS  
 DEFINITION Sequence 529 from Patent EP1174518.  
 ACCESSION AX353323  
 VERSION AX353323.1 GI:18618405  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 .  
 synthetic construct  
 synthetic construct  
 artificial sequences.

REFERENCE 1  
 AUTHORS Loukachov, V.V., van Gemen, B. and Goudemil, J.  
 TITLE Collection of binding molecules  
 JOURNAL Patent: EP 1174518-A 529 23-JAN-2002;  
 Amsterdam Support Diagnostics B.V. (NL)

FEATURES  
 source  
 1..18  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 836 ACCGACAGAGTAACATC 852  
 |||||  
 Db 2 ACCGACAGAGTAACATC 18

RESULT 200  
 AX353332 18 bp DNA linear PAT 06-FEB-2002  
 LOCUS  
 DEFINITION Sequence 538 from Patent EP1174518.  
 ACCESSION AX353332  
 VERSION AX353332.1 GI:18618414  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 .  
 synthetic construct  
 synthetic construct  
 artificial sequences.

REFERENCE 1  
 AUTHORS Loukachov, V.V., van Gemen, B. and Goudemil, J.

TITLE Collection of binding molecules  
JOURNAL Patent: EP 1174518-A 538 23-JUN-2002;  
Amsterdam Support Diagnostics B.V. (NL)  
FEATURES  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTACATC 852  
Db 2 ACCGACGAGAAACATC 18  
|||||  
|||||

RESULT 201  
AX363168 18 bp DNA linear PAT 15-FEB-2002  
LOCUS Sequence 529 from Patent WO0208463.  
DEFINITION AX363168  
ACCESSION AX363168  
VERSION AX363168.1 GI:18695308  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
1  
AUTHORS Loukachov, V.V., Goudamit, J. and van Gemen, B.  
TITLE Collection of binding molecules  
JOURNAL Patent: WO 0208463-A 529 31-JUN-2002;  
Amsterdam Support Diagnostics B.V. (NL)  
FEATURES  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTACATC 852  
Db 2 ACCGACGAGAAACATC 18  
|||||  
|||||

RESULT 202  
AX363177 18 bp DNA linear PAT 15-FEB-2002  
LOCUS Sequence 538 from Patent WO0208463.  
DEFINITION AX363177  
ACCESSION AX363177  
VERSION AX363177.1 GI:18695317  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
1  
AUTHORS Loukachov, V.V., Goudamit, J. and van Gemen, B.  
TITLE Collection of binding molecules  
JOURNAL Patent: WO 0208463-A 538 31-JUN-2002;  
Amsterdam Support Diagnostics B.V. (NL)  
FEATURES  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="position 219"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTACATC 852  
Db 2 ACCGACGAGAAACATC 18  
|||||  
|||||

Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 836 ACCGACGAGTACATC 852  
Db 2 ACCGACGAGAAACATC 18  
|||||  
|||||

RESULT 203  
AX419744/c 18 bp DNA linear PAT 18-JUN-2002  
LOCUS AX419744  
DEFINITION Sequence 81 from Patent WO0198537.  
ACCESSION AX419744  
VERSION AX419744.1 GI:21524111  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 81 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCCCCGGCGTCAGG 499  
Db 17 GGGGCCCGCGGCTCTCG 1  
|||||  
|||||

RESULT 204  
AX428594 18 bp DNA linear PAT 20-JUN-2002  
LOCUS AX428594  
DEFINITION Sequence 1 from Patent WO0217899.  
ACCESSION AX428594  
VERSION AX428594.1 GI:21538505  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
1  
AUTHORS Hla, T., Lee, M.J., Claffey, K.P., Ancellin, N. and Thangada, S.  
TITLE Method for regulating angiogenesis  
JOURNAL Patent: WO 0217899-A 1 07-MAR-2002;  
The University of Connecticut (US)  
FEATURES  
source  
1. .18  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 GGGCGTGTGGGACCCA 1618  
Db 1 GAGCGTGTGGGCCCCA 17  
|||||  
|||||

RESULT 205  
AX428596/c 18 bp DNA linear PAT 20-JUN-2002  
LOCUS AX428596  
DEFINITION Sequence 3 from Patent WO0217899.

```

ACCESSION  AX428596
VERSION     AX428596.1  GI:21538507
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE   1
  AUTHORS   Hla,T., Lee,M.J., Claffey,K.P., Ancillin,N. and Thangada,S.
  TITLE     Method for regulating angiogenesis
  JOURNAL   Patent: WO 0217899-A 3 07-MAR-2002;
            The University of Connecticut (US)
            Location/Qualifiers
FEATURES
  source    1..18
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 GCGCGTGTGGACCCA 1618
Db 18 GACGCTGTGGGCCCCA 2

RESULT 206
LOCUS      AX663784 18 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 159 from Patent WO02097127.
ACCESSION  AX663784
VERSION     AX663784.1  GI:29163964
KEYWORDS
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM
REFERENCE   1
  AUTHORS   Koellers,N., Gehrmann,M., Kallabis,H., Hall,R., Schulze,T. and
            Kroegel,C.
  TITLE     Genes and proteins for prevention, prediction, diagnosis, prognosis
            and treatment of chronic lung disease
  JOURNAL   Patent: WO 02097127-A 159 05-DEC-2002;
            Bayer Aktiengesellschaft (DE)
            Location/Qualifiers
FEATURES
  source    1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="M36820 forward sequence"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 564 GCTGTCTCTGCTCTGG 580
Db 2 GCTGTCTCTGCTCTGG 18

RESULT 207
LOCUS      BD085006 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Target-dependent reactions using structure-bridging
            oligonucleotides.
ACCESSION  BD085006
VERSION     BD085006.1  GI:22630616
KEYWORDS
SOURCE      unidentified
            unidentified
            unclassified.
ORGANISM
REFERENCE   1 (bases 1 to 18)
  AUTHORS   Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Nerl,B.P.,

```

```

  TITLE     Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
            Target-dependent reactions using structure-bridging
            oligonucleotides
  JOURNAL   Patent: JP 2001523111-A 81 20-NOV-2001;
            THIRD WAVE TECHNOLOGIES INC
            OS Unidentified
            PN JP 2001523111-A/81
            PD 20-NOV-2001
            PR 05-MAY-1998 JP 1998548047
            PR 05-MAY-1997 US 06/851588,19-SEP-1997 US 08/934097 PR
            PI FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
            PI P NERI,
            PI MARY ANN D BROW,TODD A ANDERSON,JAMES E DAHLBERG PC
            CO7H21/04,CO7H21/02,C12O1/68
            CC Strandedness: Single;
            CC Topology: Linear;
            CC /desc = 'DNA'
            FT Key
            FT source 1..18
            Location/Qualifiers
FEATURES
  source    1..18
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 483 GGTGCGCGGGGTGAG 499
Db 17 GGGGCCCGCGGTCTGG 1

RESULT 208
LOCUS      BD097068 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Therapeutic agents.
ACCESSION  BD097068
VERSION     BD097068.1  GI:22642656
KEYWORDS
SOURCE      synthetic construct
            synthetic construct
            artificial sequences.
ORGANISM
REFERENCE   1 (bases 1 to 18)
  AUTHORS   Enoki,T., Yamaehita,S., Nishimura,K., Sagawa,H. and Kato,I.
  TITLE     Therapeutic agents
  JOURNAL   Patent: WO 0151480-A/27;
            TAKARA SHUZO CO LTD,TATSUJI ENOKI,SHUSAKU YAMASHITA,KAKORI
            NISHIMURA,HIROAKI SAGAWA,IKUNOSHIN KATO
            OS Artificial Sequence
            PN WO 0151480-A/27
            PD 19-JUL-2001
            PR 11-JAN-2001 WO 2001JP000082
            PR 13-JAN-2000 JP 00P 4989,03-OCT-2000 JP 00P 303711 PI
            TATSUJI ENOKI,SHUSAKU YAMASHITA,KAKORI NISHIMURA,HIROAKI SAGAWA,
            PI IKUNOSHIN KATO
            PC C07D309/32,C07D493/08,A61K31/351,A61K31/357,A61P43/00,A61P43/
            PC 111,A61P1/16,
            PC A61P29/00
            CC Designed primer based on nucleotide sequence of human CC
            CC macrophage
            CC inflammatory protein-2-alpha mRNA.
            FH Key
            FT source 1..18
            Location/Qualifiers
FEATURES
  source    1..18
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

```

QY	564	GCTGTTCTCTGTCCTCG	580	0.6%;	Score 13.8;	DB 1;	Length 18;
Db	2	GCTGTCCTCTGTCCTCG	18	0;	Pred. No.2.9e+02;	Mismatches 2;	Indels 0;
Query Match				0.6%;	Score 13.8;	DB 1;	Length 18;
Best Local Similarity				88.2%;	Pred. No.2.9e+02;	Mismatches 2;	Indels 0;
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;
RESULT 209							
BD132439			18 bp	DNA	linear	PAT 18-SEP-2002	
LOCUS	BD132439/c						
DEFINITION	A basal cell carcinoma tumor suppressor gene.						
ACCESSION	BD132439						
VERSION	BD132439.1	GI:23227384					
KEYWORDS	JP 2002504805-A/51.						
SOURCE	synthetic construct						
ORGANISM	synthetic construct						
REFERENCE	artificial sequences.						
AUTHORS	1 (bases 1 to 18)						
	Dean,W.F., Hahn,H., Wicking,C., Christiansen,U.,						
	Zaphiropoulos,P.G., Gallani,M.R., Shanley,S., Chidambaram,A.,						
	Vorechovsky,I., Holmberg,E., Unden,A.B., Gillies,S., Negus,K.,						
	Sweth,I., Pressman,C., Leffell,D.J., Gerrard,B., Goldstein,A.,						
	Wainwright,B., Toftgard,R., Trench,G.C. and Bale,A.E.						
	Patent: JP 2002504805-A 51 12-FEB-2002;						
	A basal cell carcinoma tumor suppressor gene						
	THE GOVERNMENT OF THE UNITED STATES OF AMERICA						
	SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES						
	PN JP 2002504805-A/51						
	PD 12-FEB-2002						
	PF 16-MAY-1997 JP 1997541164						
	PR 17-MAY-1996 US 60/017906,21-MAY-1996 AU PO 0011 PR						
	07-JUN-1996 AU PO 0363,14-JUN-1996 US 60/019765 PI						
	MICHAEL FREDERICK DEAN,HEIDI HAHN,CAROL WICKING,JEFFREY PI						
	CHRISTIANSEN,						
	PI PETER G ZAPHIROPOULOS,MAE R GAILANI,SUSAN SHANLEY,ABIRAMI PI						
	CHIDMBARAM						
	PI IGOR VORECHOVSKY,ERIK HOLMBERG,ANNE BIRGITTE UNDEN,SUSAN PI						
	GILLES,						
	PI KYLIE NEGUS,IAN SMYTH,CAROL PRESSMAN,DAVID J LEEFELL,BERNARD						
	PI GERRARD,						
	PI ALISA GOLDSTEIN,BRANDON WAINWRIGHT,RUNE TOFTGARD,GEORGIA PI						
	CHENEVIX TRENCH,						
	PI ALLEN E BALE						
	PC C12N15/12,C07K14/47,C12N5/10,C12Q1/68,G01N33/50,A61K48/00, PC						
	A61K39/395,						
	PC A61K38/17						
	CC Strandedness: Single;						
	CC Topology: linear;						
	CC /note= 'PCR25 primer'						
	FN key						
	Location/Qualifiers						
	1. 18						
	/organism="synthetic construct"						
	/mol_type="genomic DNA"						
	/db_xref="taxon:32630"						
FEATURES							
source							
QY	1461	CTGCCACCCAGTGTC	1477	0.6%;	Score 13.8;	DB 1;	Length 18;
Db	17	CTGCCACCCAGTGATC	1	0;	Pred. No.2.9e+02;	Mismatches 2;	Indels 0;
Query Match				0.6%;	Score 13.8;	DB 1;	Length 18;
Best Local Similarity				88.2%;	Pred. No.2.9e+02;	Mismatches 2;	Indels 0;
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;
RESULT 210							
LOCUS	AX095593/c		21 bp	DNA	linear	PAT 30-MAR-2001	
DEFINITION	Sequence 771 from Patent WO0118250.						

VERSION	AX095593.1	GI:13511796
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
REFERENCE	Lander, E.S., Gargill, M., Ireland, J.S., Bolk, S., Daley, G.Q. and McCarthy, J.J.	
TITLE	Single nucleotide polymorphisms in genes	
JOURNAL	Patent: WO 0118250-A 771 15-MAR-2001;	
	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium Pharmaceuticals, Inc. (US)	
FEATURES	Location/Qualifiers	
source	1..21	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.6%; Score 13.8;	DB 1;
Best Local Similarity	78.9%; Pred. No. 3.2e+02;	
Matches	15; Conservative	1; Mismatches 3; Indels 0; Gaps 0;
OY	864 AACGAGACACCGTCCACC 882	
Db	20 AAGAGAGAGAGCACACC 2	
RESULT 211		
LOCUS	AX513808	41 bp DNA linear PAT 05-OCT-2002
DEFINITION	Sequence 6 from Patent W002052044.	
ACCESSION	AX513808	
VERSION	AX513808.1 GI:23559990	
KEYWORDS	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1 Nakamura, Y., Sekine, A., Iida, A. and Saito, S.	
AUTHORS	Detection of genetic polymorphisms	
TITLE	Patent: WO 0205204-A 6 04-JUL-2002;	
JOURNAL	Riken (JP)	
FEATURES	Location/Qualifiers	
source	1..41	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.6%; Score 13.6;	DB 1;
Best Local Similarity	67.9%; Pred. No. 3.9e+02;	
Matches	19; Conservative	0; Mismatches 9; Indels 0; Gaps 0;
OY	2105 ACCTCAGCCTGTGGAGCAGGCTGACCA 2132	
Db	37 AGCAGAGGCAGGGTGAYCAGGGTGACCA 10	
RESULT 212		
LOCUS	AX518978	41 bp DNA linear PAT 05-OCT-2002
DEFINITION	Sequence 5176 from Patent W002052044.	
ACCESSION	AX518978	
VERSION	AX518978.1 GI:23568986	
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.	
REFERENCE	1 Nakamura, Y., Sekine, A., Iida, A. and Saito, S.	
AUTHORS	Detection of genetic polymorphisms	
TITLE		

JOURNAL Patent: WO 02052044-A 5176 04-JUL-2002;  
Riken (JP)

FEATURES  
source  
1. .41  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.6; DB 1; Length 41;  
Best Local Similarity 67.94; Pred. No. 3.9e+02;  
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGCAGGCTGACCA 2132  
Db 37 AGCAGAGCAGCGGTGATCAGGCTGACCA 10

RESULT 213  
AX521440 41 bp DNA linear PAT 05-OCT-2002  
LOCUS Sequence 7638 from Patent WO02052044.  
DEFINITION AX521440  
ACCESSION AX521440.1 GI:23572410  
VERSION  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.  
TITLE Detection of genetic polymorphisms  
JOURNAL Patent: WO 02052044-A 7638 04-JUL-2002;  
Riken (JP)

FEATURES  
source  
1. .41  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.6; DB 1; Length 41;  
Best Local Similarity 67.94; Pred. No. 3.9e+02;  
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGCAGGCTGACCA 2132  
Db 37 AGCAGAGCAGCGGTGATCAGGCTGACCA 10

RESULT 214  
AR048008 15 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 12 from patent US 5820871.  
DEFINITION AR048008  
ACCESSION AR048008.1 GI:5970351  
VERSION  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Palés, P. and Garcia-Sastre, A.  
TITLE Recombinant negative strand RNA virus expression systems and vaccines  
JOURNAL Patent: US 5820871-A 12 13-OCT-1998;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.34; Pred. No. 2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 999 CACCCTGCTCTGCT 1013

Db 1 CACCCTGCTCTGCT 15

RESULT 215  
AR056189 15 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 393 from patent US 5837542.  
DEFINITION AR056189  
ACCESSION AR056189.1 GI:5981766  
VERSION  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 393 17-NOV-1998;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.34; Pred. No. 2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2102 AGCAGCTCAGCCTGG 2116  
Db 1 AGCAGCTCAGCCTGG 15

RESULT 216  
AR056452 15 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 656 from patent US 5837542.  
DEFINITION AR056452  
ACCESSION AR056452.1 GI:5982029  
VERSION  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 656 17-NOV-1998;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.64; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.34; Pred. No. 2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2102 AGCAGCTCAGCCTGG 2116  
Db 1 AGCAGCTCAGCCTGG 15

RESULT 217  
AR059760 15 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 10 from patent US 5840520.  
DEFINITION AR059760  
ACCESSION AR059760.1 GI:5986210  
VERSION  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)

AUTHORS Clarke,D.Kirkwood, and Palese,P.M.  
TITLE Recombinant negative strand RNA virus expression systems  
JOURNAL Patent: US 5840520-A 10 24-NOV-1998;  
FEATURES Location/Qualifiers  
SOURCE 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013  
|||||  
Db 1 CACCCTGCTCTGCT 15

RESULT 218  
LOCUS AR068636 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 12 from patent US 5854037.  
ACCESSION AR068636  
VERSION AR068636.1 GI:6000843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Palese,P. and Garcia-Sastre,A.  
JOURNAL Recombinant negative strand RNA virus expression systems and  
FEATURES Location/Qualifiers  
SOURCE 1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 999 CACCCTGCTCTGCT 1013  
|||||  
Db 1 CACCCTGCTCTGCT 15

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013  
|||||  
Db 1 CACCCTGCTCTGCT 15

RESULT 219  
LOCUS AR076280/c 15 bp DNA linear PAT 30-AUG-2000  
DEFINITION Sequence 6 from patent US 5958769.  
ACCESSION AR076280  
VERSION AR076280.1 GI:10003026  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Roberts,J.M., Coats,S.R. and Pero,M.L.  
JOURNAL Compositions and methods for mediating cell cycle progression  
FEATURES Patent: US 5958769-A 6 28-SEP-1999;  
SOURCE Location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 799 GCTGTCTGCGCCAG 813  
|||||  
Db 15 GCTGTCTGCGCCAG 1

RESULT 220  
LOCUS AR094244 15 bp DNA linear PAT 08-SEP-2000  
DEFINITION Sequence 12 from patent US 6001634.  
ACCESSION AR094244  
VERSION AR094244.1 GI:10020989  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Palese,P. and Garcia-Sastre,A.  
JOURNAL Recombinant negative strand RNA viruses  
FEATURES Patent: US 6001634-A 12 14-DEC-1999;  
SOURCE Location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 999 CACCCTGCTCTGCT 1013  
|||||  
Db 1 CACCCTGCTCTGCT 15

RESULT 221

LOCUS AR113947 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 393 from patent US 6132967.  
ACCESSION AR113947  
VERSION AR113947.1 GI:14094269  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of  
FEATURES Inter cellular adhesion molecule-1 (ICAM-1)  
Patent: US 6132967-A 393 17-OCT-2000;  
SOURCE Location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred.No.2.9e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCACTCAGCTTGG 2116  
|||||  
Db 1 AGCACTCAGCTTGG 15

RESULT 222  
LOCUS AR114210 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 656 from patent US 6132967.  
ACCESSION AR114210  
VERSION AR114210.1 GI:14094532  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of

QY 799 GCTGTCTGCGCCAG 813  
|||||  
Db 15 GCTGTCTGCGCCAG 1



```

RESULT 227
BD131298          15 bp  DNA      linear  PAT 18-SEP-2002
-LOCUS
DEFINITION      Isometric primer extension method and kit for detecting and
                  quantitating specific nucleic acids.
ACCESSION      BD131298
VERSION        BD131298.1 GI:23226243
KEYWORDS       JP 2002027993-A/1.
SOURCE         synthetic construct
ORGANISM       artificial sequences.
REFERENCE      1 (bases 1 to 15)
AUTHORS       Wang,X.
TITLE         Isometric primer extension method and kit for detecting and
                  quantitating specific nucleic acids
JOURNAL       Patent: JP 2002027993-A 1 29-JAN-2002;
              XIROBING WANG,SHINKATSU MORISAWA
COMMENT       OS Artificial Sequence
              PN JP 2002027993-A/1
              PD 29-JAN-2002
              PF 01-JUN-2001 JP 2001166477
              PR 08-JUN-2000 US 60/209987,23-MAY-2001 US 09/862417 PI
              XIROBING WANG

FEATURES
source          location/Qualifiers
                1..15 /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1322 GTGGGACCTGTGCA 1336
Db      1 GTGGGACCTGTGCA 15

RESULT 228
BD208457          15 bp  RNA      linear  PAT 17-JUL-2003
-LOCUS
DEFINITION      Enzymatic nucleic acid treatment of diseases or conditions related
                  to hepatitis C virus infection.
ACCESSION      BD208457
VERSION        BD208457.1 GI:33018227
KEYWORDS       JP 2002512791-A/2047.
SOURCE         unidentified
ORGANISM       unidentified
REFERENCE      1 (bases 1 to 15)
AUTHORS       Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE         Enzymatic nucleic acid treatment of diseases or conditions related
                  to hepatitis C virus infection
JOURNAL       Patent: JP 2002512791-A 2047 08-MAY-2002;
              RIBOZYME PHARMACEUTICALS INC
COMMENT       OS Hepatitis virus (hepatitis C virus)
              PN JP 2002512791-A/2047
              PD 08-MAY-2002
              PF 26-APR-1999 JP 2006545991
              PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
              23-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
              LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PI
              PAVCO,

PI      DENNIS MACEJAK
PC      C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC      A61K37/66,
PC      C12N15/00
CC      Enzymatic nucleic acid treatment of diseases or conditions CC

```

```

related to
CC      hepatitis C virus infection.
FH      Key Location/Qualifiers
FT      source 1..15
          virus', /organism="Hepatitis virus (hepatitis C FT

FEATURES
source          location/Qualifiers
                1..15 /organism="unidentified"
                /mol_type="genomic RNA"
                /db_xref="taxon:32644"

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No.2.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1010 TGCTTTCCTTCGTC 1024
Db      1 TGCTTTCCTTC 15

RESULT 229
AR329677          16 bp  RNA      linear  PAT 17-AUG-2003
-LOCUS
DEFINITION      Sequence 7079 from patent US 6566127.
ACCESSION      AR329677
VERSION        AR329677.1 GI:33715485
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS       Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE         Method and reagent for the treatment of diseases or conditions
                  related to levels of vascular endothelial growth factor receptor
JOURNAL       Patent: US 6566127-A 7079 20-MAY-2003;
              Location/Qualifiers
              1..16 /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No.3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      770 ACAGCCACTGCAGG 784
Db      1 ACAGCCACTGCAGG 15

RESULT 230
AR391399/c        16 bp  DNA      linear  PAT 18-DEC-2003
-LOCUS
DEFINITION      Sequence 11 from patent US 6613520.
ACCESSION      AR391399
VERSION        AR391399.1 GI:40114888
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS       Ashby,M.
TITLE         Methods for the survey and genetic analysis of populations
JOURNAL       Patent: US 6613520-A 11 02-SEP-2003;
              Location/Qualifiers
              1..16 /organism="genomic DNA"
              /mol_type="genomic DNA"

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No.3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```



OY 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 231  
LOCUS AR391401 16 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 13 from patent US 6613520.  
ACCESSION AR391401  
VERSION AR391401.1 GI:40114892  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Ashby, M.  
TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: US 6613520-A 13 02-SEP-2003;  
FEATURES  
source 1. 16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 232  
LOCUS AR391465 16 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 77 from patent US 6613520.  
ACCESSION AR391465  
VERSION AR391465.1 GI:40114958  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Ashby, M.  
TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: US 6613520-A 77 02-SEP-2003;  
FEATURES  
source 1. 16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 233  
LOCUS AX281879 16 bp DNA linear PAT 02-NOV-2001  
DEFINITION Sequence 11 from Patent WO0177392.  
ACCESSION AX281879  
VERSION AX281879.1 GI:16609130  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Ashby, M.

TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: WO 0177392-A 11 18-OCT-2001;  
AUTHORS Ashby, Matthew (US)  
FEATURES  
source 1. 16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 234  
LOCUS AX281881 16 bp DNA linear PAT 02-NOV-2001  
DEFINITION Sequence 13 from Patent WO0177392.  
ACCESSION AX281881  
VERSION AX281881.1 GI:16609132  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Ashby, M.  
TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: WO 0177392-A 13 18-OCT-2001;  
FEATURES  
source 1. 16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 235  
LOCUS AX281945 16 bp DNA linear PAT 02-NOV-2001  
DEFINITION Sequence 77 from Patent WO0177392.  
ACCESSION AX281945  
VERSION AX281945.1 GI:16609196  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Ashby, M.  
TITLE Methods for the survey and genetic analysis of populations  
JOURNAL Patent: WO 0177392-A 77 18-OCT-2001;  
FEATURES  
source 1. 16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="unidentified soil organism"

Query Match 0.6%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGCGGCACTGG 311  
|||  
16 AGCTGCGGCACTGG 2

RESULT 236  
A03835 17 bp DNA linear PAT 09-JUL-1993  
LOCUS Artificial sequence (plasmid pMP11) for ENDO II.  
ACCESSION A03835  
VERSION A03835.1 GI:412356  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 17)  
AUTHORS  
TITLE YEAST STRAINS PRODUCING CELLULOXYLIC ENZYMES AND METHODS AND MEANS  
FOR CONSTRUCTING THEM  
JOURNAL Patent: WO 8504672-A 26 24-OCT-1985;  
FEATURES location/Qualifiers  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 965 GGGATCAGTGTCCC 979  
|||  
1 GGGATCAGTGTCCC 15

RESULT 237  
AR057440 17 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 1644 from patent US 5837542.  
ACCESSION AR057440  
VERSION AR057440.1 GI:5983017  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1644 17-NOV-1998;  
FEATURES location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCTGTGG 583  
|||  
2 TCCTGCTCTGTGG 16

RESULT 238  
AR057496 17 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 1700 from patent US 5837542.  
ACCESSION AR057496  
VERSION AR057496.1 GI:5983073

KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1700 17-NOV-1998;  
FEATURES location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCTGTGG 583  
|||  
2 TCCTGCTCTGTGG 16

RESULT 239  
AR057503 17 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 1707 from patent US 5837542.  
ACCESSION AR057503  
VERSION AR057503.1 GI:5983080  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1707 17-NOV-1998;  
FEATURES location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCTGTGG 583  
|||  
2 TCCTGCTCTGTGG 16

RESULT 240  
AR057539 17 bp DNA linear PAT 29-SEP-1999  
LOCUS Sequence 1743 from patent US 5837542.  
ACCESSION AR057539  
VERSION AR057539.1 GI:5983116  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1743 17-NOV-1998;  
FEATURES location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

## RESULT 241

AR057592 17 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 1796 from patent US 5837542.  
ACCESSION AR057592  
VERSION AR057592.1 GI:5983169  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1796 17-NOV-1998;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

RESULT 242  
AR057669 17 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 1873 from patent US 5837542.  
ACCESSION AR057669  
VERSION AR057669.1 GI:5983246  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1873 17-NOV-1998;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

RESULT 243  
AR057730 17 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 1934 from patent US 5837542.  
ACCESSION AR057730  
VERSION AR057730.1 GI:5983107  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1934 17-NOV-1998;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

RESULT 244  
AR115198 17 bp DNA linear PAT 16-MAY-2001  
LOCUS  
DEFINITION Sequence 1644 from patent US 6132967.  
ACCESSION AR115198  
VERSION AR115198.1 GI:14095520  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURNAL Intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1644 17-OCT-2000;  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

RESULT 245  
AR115254 17 bp DNA linear PAT 16-MAY-2001  
LOCUS  
DEFINITION Sequence 1700 from patent US 6132967.  
ACCESSION AR115254  
VERSION AR115254.1 GI:14095576  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURNAL Intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1700 17-OCT-2000;  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGG 583  
|||||  
Db 2 TCCTGCTCTGCTGG 16

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583  
|||  
2 TCCTGCTCTCTGCTG 16

Db

RESULT 246  
LOCUS AR115261 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1707 from patent US 6132967.  
ACCESSION AR115261  
VERSION AR115261.1 GI:14095583  
KEYWORDS  
SOURCE .  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURN. intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1707 17-OCT-2000;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583  
|||  
2 TCCTGCTCTCTGCTG 16

Db

RESULT 247  
LOCUS AR115297 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1743 from patent US 6132967.  
ACCESSION AR115297  
VERSION AR115297.1 GI:14095619  
KEYWORDS  
SOURCE .  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURN. intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1743 17-OCT-2000;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583  
|||  
2 TCCTGCTCTCTGCTG 16

Db

RESULT 248  
LOCUS AR115350 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1796 from patent US 6132967.

ACCESSION AR115350  
VERSION AR115350.1 GI:14095672  
KEYWORDS  
SOURCE .  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURN. intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1796 17-OCT-2000;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583  
|||  
2 TCCTGCTCTCTGCTG 16

Db

RESULT 249  
LOCUS AR115427 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1873 from patent US 6132967.  
ACCESSION AR115427  
VERSION AR115427.1 GI:14095749  
KEYWORDS  
SOURCE .  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURN. intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1873 17-OCT-2000;  
Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGCTCTCTGCTG 583  
|||  
2 TCCTGCTCTCTGCTG 16

Db

RESULT 250  
LOCUS AR115488 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1934 from patent US 6132967.  
ACCESSION AR115488  
VERSION AR115488.1 GI:14095810  
KEYWORDS  
SOURCE .  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 17)  
Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of  
JOURN. intercellular adhesion molecule-1 (ICAM-1)  
FEATURES Patent: US 6132967-A 1934 17-OCT-2000;  
Location/Qualifiers

```
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCGTGTCCTGCTGCG 563
DB 2 TCCGTGTCCTGCTGCG 16

RESULT 251
BD254305/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254305
VERSION BD254305.1 GI:33064075
KEYWORDS JP 2002541795-A/2098.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2098 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2098
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/1129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17
/organism='Eukaryote'.
FEATURES
source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1784 TTCAGAGAAATATTG 1798
DB 17 TTCAGAGAAATATTG 3

RESULT 252
BD254306/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254306
VERSION BD254306.1 GI:33064076
KEYWORDS JP 2002541795-A/2099.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2099 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2099
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/1129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17
/organism='Eukaryote'.
FEATURES
source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
```

```
TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/2099
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/1129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17
/organism='Eukaryote'.
FEATURES
source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1784 TTCAGAGAAATATTG 1798
DB 16 TTCAGAGAAATATTG 2

RESULT 253
BD254307/c 17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254307
VERSION BD254307.1 GI:33064077
KEYWORDS JP 2002541795-A/2100.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2100 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2100
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654
PR 12-APR-1999 US 60/1129390
PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
C12P21/02,
PC
C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
C12R1:91),
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
PC A61K37/02,
PC (C12N5/00, C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1. .17
/organism='Eukaryote'.
FEATURES
source
1. .17
/organism="unidentified"
/mol_type="genomic DNA"
```

```

                                /db_xref="taxon:32644"
Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1784 TTCAAGAAATATG 1798
      |||||
      15 TTCAAGAAATGTTG 1

RESULT 254
BD254406      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD254406
VERSION       BD254406.1 GI:33064176
KEYWORDS      JP 2002541795-A/2199.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt, L., Zwick, M., Pavco, P. and Mcawiggen, J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 2199 10-DEC-2002;
COMMENT       RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/2199
PD      10-DEC-2002
PF      11-APR-2000 JP 2000611654
PR      12-APR-1999 US 60/129390
PI      LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC      C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
C12R1:91),
PC      (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
PC      A61K37/02,
PC      (C12N5/00,C12R1:91)
CC      Regulation of repressor genes using nucleic acid molecules FH
Key      Location/Qualifiers
FT      source      1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1384 CTCCTCATCTACCCC 1398
      |||||
      1 CTCCTCGCTACCCC 15

RESULT 255
BD259619      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD259619
VERSION       BD259619.1 GI:33069389
KEYWORDS      JP 2002541795-A/7412.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt, L., Zwick, M., Pavco, P. and Mcawiggen, J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 7412 10-DEC-2002;
COMMENT       RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/7412
PD      10-DEC-2002
PF      11-APR-2000 JP 2000611654
PR      12-APR-1999 US 60/129390
PI      LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC      C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
C12R1:91)
PC      (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
PC      A61K37/02,
PC      (C12N5/00,C12R1:91)
CC      Regulation of repressor genes using nucleic acid molecules FH
Key      Location/Qualifiers
FT      source      1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      283 GCTTGAAGCATT 297
      |||||
      15 GCTCTGAAGCCATT 1

RESULT 256
ES9892      17 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION    Rhizomania-resisting plant.
ACCESSION     ES9892
VERSION       ES9892.1 GI:18622728
KEYWORDS      JP 2000312540-A/4.
SOURCE        synthetic construct
ORGANISM      artificial sequences.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Nomura, S., Kamitani, G., Saito, M., Kiguchi, T., Xuesu, S. and Soma, C.
TITLE        Rhizomania-resisting plant
JOURNAL      Patent: JP 2000312540-A 4 14-NOV-2000;
COMMENT       GENICHI KAMITANI, SHADANHOJIN HOKKAIDO TENSAI KYOKAI
OS      Artificial Sequence
PN      JP 2000312540-A/4
PD      14-NOV-2000
PF      28-APR-1999 JP 1999122628
PR      SHINGI NOMURA, GENICHI KAMITANI, MINAKO SAITO, TADAHIKO KIGUCHI,
PI      SHUNZO KUSUME,
PI      CHIHIRO SOMA
PC      A61H5/00,C12N5/10,C12N15/09,C12N5/00,C12N15/00 CC
FH      key      Location/Qualifiers
FT      source      1..17
              /organism='Artificial Sequence',
              location/Qualifiers
              1..17
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      666 TACCTTCACTCGAA 680
      |||||
      1 TACCTTCACTCGAA 680
```

```

COMMENT       RIBOZYME PHARMACEUTICALS INC
OS      Eukaryote
PN      JP 2002541795-A/7412
PD      10-DEC-2002
PF      11-APR-2000 JP 2000611654
PR      12-APR-1999 US 60/129390
PI      LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC      C12P21/02,C12P21/02//A61K31/711, (C12N5/10,C12R1:91), (C12P21/02, PC
C12R1:91)
PC      (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
PC      A61K37/02,
PC      (C12N5/00,C12R1:91)
CC      Regulation of repressor genes using nucleic acid molecules FH
Key      Location/Qualifiers
FT      source      1..17
              /organism='Eukaryote',
              location/Qualifiers
              1..17
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

FEATURES
source      1..17
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      666 TACCTTCACTCGAA 680
      |||||
      1 TACCTTCACTCGAA 680
```

Db 2 TACCTCAGTCGACA 16

RESULT 257

LOCUS AR326795 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4197 from patent US 6566127.

ACCESSION AR326795

VERSION AR326795.1 GI:33712603

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4197 20-MAY-2003;

FEATURES

source 1..17

/organism="unknown"

/mol\_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 977 CCCTCACCACCTGCTCA 991

Db 2 CGCTCACCACCTGCTCA 16

RESULT 258

LOCUS AR327103 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4505 from patent US 6566127.

ACCESSION AR327103

VERSION AR327103.1 GI:33712911

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4505 20-MAY-2003;

FEATURES

source 1..17

/organism="unknown"

/mol\_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1991 TTATCCGATGATGANG 2005

Db 3 TTATCCGATGATGCTG 17

RESULT 259

LOCUS AR327353 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 4755 from patent US 6566127.

ACCESSION AR327353

VERSION AR327353.1 GI:33713161

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4755 20-MAY-2003;

FEATURES

source 1..17

/organism="unknown"

/mol\_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2214 CATGTCGACGCTCC 2228

Db 17 CTGTCGACGCTCC 3

RESULT 260

LOCUS AR329223 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 6625 from patent US 6566127.

ACCESSION AR329223

VERSION AR329223.1 GI:33715031

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 6625 20-MAY-2003;

FEATURES

source 1..17

/organism="unknown"

/mol\_type="unassigned RNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 770 ACAGCCACTTGACAG 784

Db 1 ACAGCAACTTGACAG 15

RESULT 261

LOCUS AR434048 17 bp DNA linear PAT 18-DEC-2003

DEFINITION Sequence 471 from patent US 6656700.

ACCESSION AR434048

VERSION AR434048.1 GI:40196891

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Gu, Y. and Shannon, M. E.

TITLE Isoforms of human pregnancy-associated protein-E

JOURNAL Patent: US 6656700-A 471 02-DEC-2003;

FEATURES

source 1..17

/organism="unknown"

/mol\_type="genomic DNA"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1027 AAGAAGTGGGAAA 1041

Db 3 AAGAAGGGGGGAAA 17

```
RESULT 262
AR434049          17 bp  DNA      linear  PAT 18-DEC-2003
LOCUS              Sequence 472 from patent US 6656700.
DEFINITION         AR434049
ACCESSION          AR434049
VERSION            AR434049.1  GI:40196892
KEYWORDS
SOURCE
ORGANISM            Unknown.
                   Unclassified.
REFERENCE            1 (bases 1 to 17)
AUTHORS             Gu, Y. and Shannon, M.E.
TITLE               Isoforms of human pregnancy-associated protein-E
JOURNAL             Patent: US 6656700-A 472 02-DEC-2003;
FEATURES
source              /organism="Unknown"
                   /mol_type="genomic DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1027 AAGAAAGTGGGAAA 1041
Db      2 AAGAAAGGCGGAAA 16

RESULT 263
AR434050          17 bp  DNA      linear  PAT 18-DEC-2003
LOCUS              Sequence 473 from patent US 6656700.
DEFINITION         AR434050
ACCESSION          AR434050
VERSION            AR434050.1  GI:40196893
KEYWORDS
SOURCE
ORGANISM            Unknown.
                   Unclassified.
REFERENCE            1 (bases 1 to 17)
AUTHORS             Gu, Y. and Shannon, M.E.
TITLE               Isoforms of human pregnancy-associated protein-E
JOURNAL             Patent: US 6656700-A 473 02-DEC-2003;
FEATURES
source              /organism="Unknown"
                   /mol_type="genomic DNA"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1027 AAGAAAGTGGGAAA 1041
Db      1 AAGAAAGGCGGAAA 15

RESULT 264
AX215470/c        17 bp  RNA      linear  PAT 07-SEP-2001
LOCUS              Sequence 912 from Patent W00159103.
DEFINITION         AX215470
ACCESSION          AX215470
VERSION            AX215470.1  GI:15525513
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                   synthetic construct
                   artificial sequences.
REFERENCE            1
AUTHORS             Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE               Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL             nogo gene expression
                   Patent: WO 0159103-A 912 16-AUG-2001;
                   RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
```

```
FEATURES
source              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
                   1. .17
                   /organism="synthetic construct"
                   /mol_type="unassigned RNA"
                   /db_xref="taxon:32630"
                   /note="Nucleic Acid"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      201 GCTCTGCTGGGGGC 215
Db      17 GCTCTGCTGGGGGC 3

RESULT 265
AX216969/c        17 bp  RNA      linear  PAT 08-SEP-2001
LOCUS              Sequence 2411 from Patent W00159103.
DEFINITION         AX216969
ACCESSION          AX216969
VERSION            AX216969.1  GI:15527030
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                   synthetic construct
                   artificial sequences.
REFERENCE            1
AUTHORS             Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE               Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL             nogo gene expression
                   Patent: WO 0159103-A 2411 16-AUG-2001;
                   RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
                   McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source              /organism="synthetic construct"
                   /mol_type="unassigned RNA"
                   /db_xref="taxon:32630"
                   /note="Nucleic Acid"

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      201 GCTCTGCTGGGGGC 215
Db      16 GCTCTGCTGGGGGC 2

RESULT 266
AX327094          17 bp  DNA      linear  PAT 07-JAN-2002
LOCUS              Sequence 290 from Patent W00178894.
DEFINITION         AX327094
ACCESSION          AX327094
VERSION            AX327094.1  GI:18097805
KEYWORDS
SOURCE
ORGANISM            synthetic construct
                   synthetic construct
                   artificial sequences.
REFERENCE            1
AUTHORS             Keith, T.
TITLE               Novel human gene relating to respiratory diseases, obesity, and
JOURNAL             inflammatory bowel disease
                   Patent: WO 0178894-A 290 25-OCT-2001;
                   Genome Therapeutics Corp. (US)
FEATURES
source              /organism="synthetic construct"
                   /mol_type="unassigned DNA"
                   /db_xref="taxon:32630"
                   /note="Primer"
```



Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 588 CTCCTCTCTTGGGGA 602  
|||  
2 CTCCTCTCTTGGCGA 16

RESULT 267  
AX423543/c 17 bp RNA linear PAT 18-JUN-2002  
LOCUS  
DEFINITION Sequence 1879 from Patent WO0188124.  
ACCESSION AX423543  
VERSION AX423543.1 GI:21526925  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Jarvis, T., von Carlwiltz, I., Mcawiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 1879 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 345 GCTGATCTCATGGG 359  
|||  
15 GCTGATCTCTGGG 1

RESULT 268  
AX475178 17 bp DNA linear PAT 12-AUG-2002  
LOCUS  
DEFINITION Sequence 399 from Patent WO0224750.  
ACCESSION AX475178  
VERSION AX475178.1 GI:22214463  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 399 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 566 TGTTCCTGCTCTGG 580  
|||  
3 TGTTCCTGCTCTGG 17

RESULT 269

AX475179 17 bp DNA linear PAT 12-AUG-2002  
LOCUS  
DEFINITION Sequence 400 from Patent WO0224750.  
ACCESSION AX475179  
VERSION AX475179.1 GI:22214464  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 400 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 566 TGTTCCTGCTCTGG 580  
|||  
2 TGTTCCTGCTCTGG 16

RESULT 270  
AX475180 17 bp DNA linear PAT 12-AUG-2002  
LOCUS  
DEFINITION Sequence 401 from Patent WO0224750.  
ACCESSION AX475180  
VERSION AX475180.1 GI:22214465  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 401 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 566 TGTTCCTGCTCTGG 580  
|||  
1 TGTTCCTGCTCTGG 15

RESULT 271  
AX531763 17 bp DNA linear PAT 22-NOV-2002  
LOCUS  
DEFINITION Sequence 1272 from Patent EP1239051.  
ACCESSION AX531763  
VERSION AX531763.1 GI:25255305  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1

AUTHORS Shannon,M.  
TITLE Human posh-1like protein 1  
JOURNAL Patent: EP 1239051-A 1272 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2182 CAGCTCATGGAGAA 2196  
|||||  
3 CAGCCCATGGAGAA 17

Db

RESULT 272  
AX531764 17 bp DNA linear PAT 22-NOV-2002  
LOCUS Sequence 1273 from Patent EP1239051.  
DEFINITION AX531764  
ACCESSION AX531764  
VERSION AX531764.1 GI:25255307  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M.  
TITLE Human posh-1like protein 1  
JOURNAL Patent: EP 1239051-A 1273 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2182 CAGCTCATGGAGAA 2196  
|||||  
2 CAGCCCATGGAGAA 16

Db

RESULT 273  
AX531765 17 bp DNA linear PAT 22-NOV-2002  
LOCUS Sequence 1274 from Patent EP1239051.  
DEFINITION AX531765  
ACCESSION AX531765  
VERSION AX531765.1 GI:25255309  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M.  
TITLE Human posh-1like protein 1  
JOURNAL Patent: EP 1239051-A 1274 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2182 CAGCTCATGGAGAA 2196  
|||||  
1 CAGCCCATGGAGAA 15

Db

RESULT 274  
AX544971/c 17 bp DNA linear PAT 26-NOV-2002  
LOCUS Sequence 484 from Patent EP1243660.  
DEFINITION AX544971  
ACCESSION AX544971  
VERSION AX544971.1 GI:25810182  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang,J., Gu,Y. and Nguyen,C.T.  
TITLE Human udb-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 484 25-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACACTTGAGG 1501  
|||||  
15 CCTTACACTTGCTGG 1

Db

RESULT 275  
AX579026/c 17 bp RNA linear PAT 10-JAN-2003  
LOCUS Sequence 864 from Patent WO0211674.  
DEFINITION AX579026  
ACCESSION AX579026  
VERSION AX579026.1 GI:27648228  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.  
and Grupe,A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (Clca-1)  
JOURNAL Patent: WO 0211674-A 864 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1997 TGGATGATGCCACCA 2011  
|||||  
16 TGGATGATGCCACCA 2

Db

```

RESULT 276
AX579182/c
LOCUS      AX579182
DEFINITION Sequence 1020 from Patent WO0211674.
ACCESSION  AX579182
VERSION     AX579182.1 GI:27648384
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Thompson,J., Mcawigsen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
TITLE       Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
JOURNAL     Patent: WO 0211674-A 1020 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      16 TCAGGGCTGTGACAC 2

RESULT 277
AX579727/c
LOCUS      AX579727
DEFINITION Sequence 1565 from Patent WO0211674.
ACCESSION  AX579727
VERSION     AX579727.1 GI:27648929
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Thompson,J., Mcawigsen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
TITLE       Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
JOURNAL     Patent: WO 0211674-A 1565 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      15 TCAGGGCTGTGACAC 1

RESULT 278
AX615975/c
LOCUS      AX615975
DEFINITION Sequence 782 from Patent EPI262488.
ACCESSION  AX615975

```

```

VERSION     AX615975.1 GI:28447021
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y. and Nguyen,C.T.
TITLE       Human lcl-domain containing protein
JOURNAL     Patent: EP 1262488-A 782 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGCTACCTGCT 932
Db      16 TCTGTGCTACCTGCT 2

RESULT 279
AX615976/c
LOCUS      AX615976
DEFINITION Sequence 783 from Patent EPI262488.
ACCESSION  AX615976
VERSION     AX615976.1 GI:28447022
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y. and Nguyen,C.T.
TITLE       Human lcl-domain containing protein
JOURNAL     Patent: EP 1262488-A 783 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES
source      1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.64; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGCTACCTGCT 932
Db      15 TCTGTGCTACCTGCT 1

RESULT 280
AX634510
LOCUS      AX634510
DEFINITION Sequence 1649 from Patent EPI260586.
ACCESSION  AX634510
VERSION     AX634510.1 GI:28470124
KEYWORDS
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
            Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcawigsen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and
            Woolf,T.

```

TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1694 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583  
|||||  
2 TCCTGTCCTGTCG 16

Db

RESULT 281  
AX634541 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1680 from Patent EP1260586.  
ACCESSION AX634541  
VERSION AX634541.1 GI:28470155  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE unclassified.  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,  
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1680 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1680 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583  
|||||  
2 TCCTGTCCTGTCG 16

Db

RESULT 282  
AX634555 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1694 from Patent EP1260586.  
ACCESSION AX634555  
VERSION AX634555.1 GI:28470169  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE unclassified.  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,  
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1694 27-NOV-2002;

FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)  
SOURCE Location/Qualifiers  
1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583  
|||||  
2 TCCTGTCCTGTCG 16

Db

RESULT 283  
AX634626 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1765 from Patent EP1260586.  
ACCESSION AX634626  
VERSION AX634626.1 GI:28470240  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE unclassified.  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,  
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1765 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1765 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGTCG 583  
|||||  
2 TCCTGTCCTGTCG 16

Db

RESULT 284  
AX634635 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1774 from Patent EP1260586.  
ACCESSION AX634635  
VERSION AX634635.1 GI:28470249  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE unclassified.  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,  
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 1774 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGTCCTGCTGTCG 583  
DB 2 TCCTGTCCTGCTGTCG 16

RESULT 285  
AX634691 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1830 from Patent EPI260586.  
ACCESSION AX634691  
VERSION AX634691.1 GI:28470305  
KEYWORDS  
SOURCE  
ORGANISM  
unidentified  
unclassified.

REFERENCE  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpeisky,A., Draper,K.G., Kleich,K., Matulic-Adamic,J.,  
McGawigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Mincott,F.E. and  
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNAL Patent: EP 1260586-A 1830 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1. .17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGTCCTGCTGTCG 583  
DB 2 TCCTGTCCTGCTGTCG 16

RESULT 286  
AX634812 17 bp RNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 1951 from Patent EPI260586.  
ACCESSION AX634812  
VERSION AX634812.1 GI:28470426  
KEYWORDS  
SOURCE  
ORGANISM  
unidentified  
unclassified.

REFERENCE  
AUTHORS 1  
Stinchcomb,D.T., Dudycz,L.W., Chowitra,B., Grimm,S., Dizenzo,A.,  
Karpeisky,A., Draper,K.G., Kleich,K., Matulic-Adamic,J.,  
McGawigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Mincott,F.E. and  
Woolf,T.

TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNAL Patent: EP 1260586-A 1951 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1. .17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 569 TCCTGTCCTGCTGTCG 583  
DB 2 TCCTGTCCTGCTGTCG 16

RESULT 287  
AX722446 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 133 from Patent WO03025176.  
ACCESSION AX722446  
VERSION AX722446.1 GI:30422947  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS 1  
Telerman,A., Amson,R. and Tuijinder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 133 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 337 TTCGAGAGCTGATC 351  
DB 15 TTCGAGAGCTGATC 1

RESULT 288  
AX725610 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 3297 from Patent WO03025176.  
ACCESSION AX725610  
VERSION AX725610.1 GI:30504953  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE  
AUTHORS 1  
Telerman,A., Amson,R. and Tuijinder,M.

TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 3297 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 976 TCCTCACCATGTC 990  
|||||||

Db 3 TCCTCACCCTGCTC 17

RESULT 289  
LOCUS AX732419 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4053 from Patent WO03025175.  
ACCESSION AX732419  
VERSION AX732419.1 GI:30511762  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman,A., Amson,R. and Tuijinder,M.  
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use as medicines  
JOURNAL Patent: WO 03025175-A 4053 27-MAR-2003;  
FEATURES  
source Molecular Engines Laboratories (PR)  
location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1523 TCTCCTTGCTCCTACC 1537  
|||||  
3 TCTCCTTGCTCCTACC 17  
|||||

RESULT 290  
LOCUS AX734744/c 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 334 from Patent WO03025177.  
ACCESSION AX734744  
VERSION AX734744.1 GI:30514021  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman,A., Amson,R. and Tuijinder,M.  
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 334 27-MAR-2003;  
FEATURES  
source Molecular Engines Laboratories (PR)  
location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 2221 CAGGCTCCTGCAGAT 2235  
|||||  
16 CATGCTCTGCAGAT 2  
|||||

RESULT 291  
LOCUS AX737134 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 2724 from Patent WO03025177.

ACCESSION AX737134  
VERSION AX737134.1 GI:30516422  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman,A., Amson,R. and Tuijinder,M.  
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 2724 27-MAR-2003;  
FEATURES  
source Molecular Engines Laboratories (PR)  
location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1334 TCACATTTGTTCTCT 1348  
|||||  
3 TCACATCTGTTCTCT 17  
|||||

RESULT 292  
LOCUS AX745329/c 17 bp DNA linear PAT 14-MAY-2003  
DEFINITION Sequence 1294 from Patent WO03031621.  
ACCESSION AX745329  
VERSION AX745329.1 GI:30723996  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Zhang,J.  
A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 1294 17-APR-2003;  
FEATURES  
source Amerisham Biosciences (SV) Corp. (US)  
location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 861 GGTAACTGAGGACAC 875  
|||||  
17 GTTAACTGAGGAAAC 3  
|||||

RESULT 293  
LOCUS AX745330/c 17 bp DNA linear PAT 14-MAY-2003  
DEFINITION Sequence 1295 from Patent WO03031621.  
ACCESSION AX745330  
VERSION AX745330.1 GI:30723997  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Zhang,J.

TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 1295 17-APR-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 861 GGTACAGAGACAC 875  
16 GGTACAGAGAAC 2

RESULT 294  
AX760054/c 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 3375 from Patent WO03040369.  
ACCESSION AX760054  
VERSION AX760054.1 GI:32254670  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE

1 Teltman, A., Amson, R. and Tuijnder, M.  
Sequences involved in tumoral suppression, tumoral reversion,  
apoptosis and/or viral resistance phenomena and their use as  
medicines  
Patent: WO 03040369-A 3375 15-MAY-2003;  
JOURNAL  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1181 TGCAGAAATTAACA 1195  
17 TGAAGAAATTAACA 3

RESULT 295  
AX783930 17 bp DNA linear PAT 17-JUN-2003  
LOCUS  
DEFINITION Sequence 2261 from Patent WO03050284.  
ACCESSION AX783930  
VERSION AX783930.1 GI:32951779  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

1 Guo, J.  
Human prostate cancer candidate protein 1  
Patent: WO 03050284-A 2261 19-JUN-2003;  
Amersham Biosciences (SV) Corp. (US)  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1631 AGAGCACAGTGTCTG 1645  
3 AGAGCACAGTGTCTG 17

RESULT 296

BD198659 17 bp RNA linear PAT 17-JUN-2003  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response.  
ACCESSION BD198659  
VERSION BD198659.1 GI:33008429  
KEYWORDS JP 2002509721-A/1685.  
SOURCE  
ORGANISM Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
JOURNAL

1 (bases 1 to 17)  
Pavco, P.A., Roberts, E., Jarvis, T., Coeshott, C. and Mcswigen, J.A.  
Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response  
Patent: JP 2002509721-A 1685 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT  
OS Homo sapiens (human)  
PN JP 2002509721-A/1685  
PD 02-APR-2002  
PR 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,  
PI JAMES A MCSWIGEN

PC C12N15/09, A61K31/7088, A61K31/7125, A61K48/00, A61P3/10, A61P17/06, PC  
A61P29/00,  
PC A61P35/00, A61P43/00, C12N5/10, C12N9/00//A61K35/76, C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions CC  
concerning molecule  
CC participating in vasculogenic response  
FH Key Location/Qualifiers  
FT source 1. .17  
FT Location/Qualifiers  
/organism="Homo sapiens (human)".

FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:9606"

Query Match 0.64; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 909 GAGCTATTCTGTG 923  
3 GAGCTATTCTGTG 17

RESULT 297  
BD198660 17 bp RNA linear PAT 17-JUN-2003  
LOCUS  
DEFINITION Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response.  
ACCESSION BD198660  
VERSION BD198660.1 GI:33008430  
KEYWORDS JP 2002509721-A/1686.  
SOURCE  
ORGANISM Homo sapiens (human)

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source  
1 (bases 1 to 17)  
Eukaryota; Metazoa; Chordata; Craniala; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning  
JOURNAL molecule participating in vasculogenic response  
COMMENT Patent: JP 2002509721-A 1686 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/1686  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELIA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC  
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC  
A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions CC  
concerning molecule  
CC participating in vasculogenic response  
FH key Location/Qualifiers  
FT source 1..17  
/organism='Homo sapiens (human)'.  
1..17  
/organism='Homo sapiens'  
/mol\_type='genomic RNA'  
/db\_xref='taxon:9606'  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No.3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 909 GAGCTTATTCTGTG 923  
DB 1 GTGCTATTCTGTG 15  
RESULT 298  
BD200842/c  
LOCUS 17 bp RNA linear PAT 17-JUL-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response.  
ACCESSION BD200842  
VERSION BD200842.1 GI:33010612  
KEYWORDS JP 2002509721-A/3868.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 17)  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning  
molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 3868 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/3868  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELIA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,  
PI JAMES A MCSWIGGEN  
PC  
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC  
A61P29/00,  
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions CC  
concerning molecule  
CC participating in vasculogenic response  
FH key Location/Qualifiers  
FT source 1..17

FT  
FEATURES Location/Qualifiers  
source 1..17  
/organism='Homo sapiens (human)'.  
/mol\_type='genomic RNA'  
/db\_xref='taxon:9606'  
Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No.3.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 675 TCGAACTTACTCT 689  
DB 17 TCGAACTGAACCTCT 3  
RESULT 299  
AR092454/c  
LOCUS 15 bp DNA linear PAT 08-SEP-2000  
DEFINITION Sequence 10 from patent US 5998166.  
ACCESSION AR092454  
VERSION AR092454.1 GI:10019208  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Luo,S.  
JOURNAL CD16-II variance  
PATENT: US 5998166-A 10 07-DEC-1999;  
FEATURES Location/Qualifiers  
1..15  
/mol\_type='unassigned DNA'  
Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No.3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 153 GCTGCCACTGCTC 165  
DB 13 GCTGCCACTGCTC 1  
RESULT 300  
AR092463  
LOCUS 15 bp DNA linear PAT 08-SEP-2000  
DEFINITION Sequence 21 from patent US 5998166.  
ACCESSION AR092463  
VERSION AR092463.1 GI:10019217  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Luo,S.  
JOURNAL CD16-II variance  
PATENT: US 5998166-A 21 07-DEC-1999;  
FEATURES Location/Qualifiers  
1..15  
/organism='unknown'  
/mol\_type='unassigned DNA'  
Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No.3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 153 GCTGCCACTGCTC 165  
DB 3 GCTGCCACTGCTC 15  
RESULT 301



BD266376/c  
LOCUS BD266376 15 bp DNA linear PAT 17-JUL-2003  
DEFINITION Universal arrays.  
ACCESSION BD266376  
VERSION BD266376.1 GI:33076144  
KEYWORDS JP 2002539849-A/376.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE  
1 (bases 1 to 15)  
AUTHORS Fan, J.B., Hirschhorn, J.N., Huang, X., Kaplan, P., Lander, E.S., Lockhart, D.J., Ryder, T. and Sklar, P.  
TITLE Universal arrays  
JOURNAL Patent: JP 2002539849-A 376 26-NOV-2002;  
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC  
OS Artificial Sequence  
PN JP 2002539849-A/376  
PD 26-NOV-2002  
PF 27-MAR-2000 JP 2000608794  
PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI  
JIAN BING FAN, JOEL N HIRSCHHORN, XIAOHUA  
HOANG, PAUL KAPLAN, ERIC  
PI S LANDER,  
PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR  
PC C1201/68, C12M1/00, C12N15/09, C12N15/09, G01N33/53, PC  
G01N33/566,  
PC G01N37/00, C12N15/00, C12N15/00, C12N15/00  
CC Primer  
FM Key  
FT source  
FEATURES  
source location/Qualifiers  
1..15  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 805 CTGGCCAGAGAGA 817  
DB 15 CTGGCCAGAGAGA 3

RESULT 302  
AR226464 15 bp mRNA linear PAT 20-DEC-2002  
LOCUS AR226464  
DEFINITION Sequence 10 from patent US 6444789.  
ACCESSION AR226464  
VERSION AR226464.1 GI:27265001  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 15)  
AUTHORS Luo, S.  
TITLE CD16-II variants  
JOURNAL Patent: US 6444789-A 10 03-SEP-2002;  
FEATURES  
source location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="mRNA"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165  
DB 13 GCTGCCACTGCTC 1

RESULT 303  
AR226473 15 bp mRNA linear PAT 20-DEC-2002  
LOCUS AR226473  
DEFINITION Sequence 21 from patent US 6444789.  
ACCESSION AR226473  
VERSION AR226473.1 GI:27265010  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 15)  
AUTHORS Luo, S.  
TITLE CD16-II variants  
JOURNAL Patent: US 6444789-A 21 03-SEP-2002;  
FEATURES  
source location/Qualifiers  
1..15  
/organism="unknown"  
/mol\_type="mRNA"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165  
DB 3 GCTGCCACTGCTC 15

RESULT 304  
AX362574 15 bp DNA linear PAT 15-FEB-2002  
LOCUS AX362574  
DEFINITION Sequence 8 from Patent WO0208425.  
ACCESSION AX362574  
VERSION AX362574.1 GI:18694718  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
1 Finkel, K. and Koshy, B.  
AUTHORS Haplotypes of the adrb3 gene  
TITLE Patent: WO 0208425-A 8 31-JAN-2002;  
JOURNAL Genaisance Pharmaceuticals, Inc. (US)  
FEATURES  
source location/Qualifiers  
1..15  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 3.3e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 507 TCGAACCCTGTGCG 521  
DB 1 TCGAACCCTGTGCG 15

RESULT 305  
AX377251 15 bp DNA linear PAT 18-MAR-2002  
LOCUS AX377251  
DEFINITION Sequence 13 from Patent WO0212562.  
ACCESSION AX377251  
VERSION AX377251.1 GI:19573539  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE  
1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Kazemi, A., Klien, S.E. and Koshy, B.

TITLE Haplotypes of the pla2g1b gene  
JOURNAL Patent: WO 0212562-A 13 14-FEB-2002,  
Genaisance Pharmaceuticals, Inc. (US)  
FEATURES  
source  
1. .15  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 3.3e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 198 CGTGTCTGCTGGG 212  
|:|||||  
15 CRTGCTGTGCTCGG 1

RESULT 306  
BD005833/c 15 bp DNA linear PAT 31-JAN-2002  
LOCUS Novel probes for the detection of Mycobacteria.  
DEFINITION BD005833  
ACCESSION BD005833.1 GI:18634204  
VERSION JP 2001501825-A/44.  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Stender,H., Lund,K. and Mollerup,T.A.  
TITLE Novel probes for the detection of Mycobacteria  
JOURNAL Patent: JP 2001501825-A 44 13-FEB-2001;  
DAKO AS  
COMMENT OS Unidentified  
PN JP 2001501825-A/44  
PD 13-FEB-2001  
PR 03-OCT-1997 JP 1998517095  
PR 04-OCT-1996 DK 1096/96,18-OCT-1996 DK 1156/96 PR  
05-MAY-1997 DK 0512/97  
PI HENRIK STENDER,KAARE LUND,TINA ANDRESEN MOLLERUP PC  
C12Q1/68,C07K14/00  
CC Strandedness: Single;  
CC Topology: linear;  
FH Key Location/Qualifiers  
FT source 1. .15  
FEATURES  
source 1. .15  
location/Qualifiers  
1. .15  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1962 CCGAGCATTTGATC 1974  
|||||  
13 CCGAGCATTTGATC 1

RESULT 307  
BD208455 15 bp RNA linear PAT 17-JUL-2003  
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related  
DEFINITION to hepatitis C virus infection.  
ACCESSION BD208455  
VERSION BD208455.1 GI:33018225  
KEYWORDS JP 2002512791-A/2045.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 15)

AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.  
TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
JOURNAL Patent: JP 2002512791-A 2045 08-MAY-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT OS Hepatitis virus (hepatitis C virus)  
PN JP 2002512791-A/2045  
PD 08-MAY-2002  
PR 26-APR-1999 JP 2000545991  
PR 27-APR-1999 US 60/083217,18-SEP-1998 US 60/100842 PR  
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI  
LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PI  
PAVCO  
PI DENNIS MACEJAK  
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,  
PC A61K37/66,  
PC C12N15/00  
CC Enzymatic nucleic acid treatment of diseases or conditions CC  
related to  
FH key Location/Qualifiers  
FT source 1. .15  
FEATURES  
source 1. .15  
location/Qualifiers  
1. .15  
/organism="unidentified"  
/mol\_type="genomic RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1010 TGCCTTTCCTTCT 1022  
|||||  
3 TGCCTTTCCTTCT 15

RESULT 308  
BD208456 15 bp RNA linear PAT 17-JUL-2003  
LOCUS Enzymatic nucleic acid treatment of diseases or conditions related  
DEFINITION to hepatitis C virus infection.  
ACCESSION BD208456  
VERSION BD208456.1 GI:33018226  
KEYWORDS JP 2002512791-A/2046.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.  
TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
JOURNAL Patent: JP 2002512791-A 2046 08-MAY-2002;  
RIBOZYME PHARMACEUTICALS INC  
COMMENT OS Hepatitis virus (hepatitis C virus)  
PN JP 2002512791-A/2046  
PD 08-MAY-2002  
PR 26-APR-1999 JP 2000545991  
PR 27-APR-1999 US 60/083217,18-SEP-1998 US 60/100842 PR  
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI  
LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PI  
PAVCO,  
PI DENNIS MACEJAK  
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,  
PC A61K37/66,  
PC C12N15/00  
CC Enzymatic nucleic acid treatment of diseases or conditions CC  
related to  
FH key Location/Qualifiers  
FT source 1. .15

```

FT      /organism='Hepatitis virus (hepatitis C FT
FEATURES
  source      location/Qualifiers
              1. .15
              /organism="unidentified"
              /mol_type="genomic RNA"
              /db_xref="taxon:32644"

Query Match      0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1010 TGCCTTCTCTCT 1022
Db      2 TGCCTTCTCTCT 14

RESULT 309
AR328425/c      16 bp      RNA      linear      PAT 17-AUG-2003
LOCUS      AR328425
DEFINITION      Sequence 5827 from patent US 6566127.
ACCESSION      AR328425
VERSION      AR328425.1 GI:33714233
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5827 20-MAY-2003;
FEATURES      location/Qualifiers
              1. .16
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2216 TGGTGACGGCTCC 2228
Db      16 TGGTGACGGCTCC 4

RESULT 310
AR046237      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046237
DEFINITION      Sequence 1030 from patent US 5817796.
ACCESSION      AR046237
VERSION      AR046237.1 GI:5967702
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1030 06-OCT-1998;
FEATURES      location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1242 CACTAGATTTCGA 1254
Db      5 CACTAGATTTCGA 17

```

```

RESULT 311
AR046239      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046239
DEFINITION      Sequence 1032 from patent US 5817796.
ACCESSION      AR046239
VERSION      AR046239.1 GI:5967704
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1032 06-OCT-1998;
FEATURES      location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1243 ACTAGATTTCAG 1255
Db      1 ACTAGATTTCAG 13

RESULT 312
AR046724/c      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046724
DEFINITION      Sequence 1517 from patent US 5817796.
ACCESSION      AR046724
VERSION      AR046724.1 GI:5968189
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1517 06-OCT-1998;
FEATURES      location/Qualifiers
              1. .17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1050 GTTGCTGGAAGTG 1062
Db      17 GTTGCTGGAAGTG 5

RESULT 313
AR046726/c      17 bp      DNA      linear      PAT 29-SEP-1999
LOCUS      AR046726
DEFINITION      Sequence 1519 from patent US 5817796.
ACCESSION      AR046726
VERSION      AR046726.1 GI:5968191
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL      Patent: US 5817796-A 1519 06-OCT-1998;
FEATURES      location/Qualifiers
              1. .17

```

Query Match	Score	DB	Length	Matches	Conservative	Mismatches	Indels	Gaps
Best Local Similarity	100.0%	Pred. No.	3.6e+02	13	0	0	0	0
Matches	13	Conservative	0	Mismatches	0	Indels	0	Gaps
QY	1050	GTTGCTGGAGTG	1062					
Db	16	GTTGCTGGAGTG	4					
RESULT 314								
LOCUS	AR075049	17 bp	DNA	linear	PAT 28-AUG-2000			
DEFINITION	Sequence 9 from patent US 5955306.							
ACCESSION	AR075049							
VERSION	AR075049.1	GI:10001801						
KEYWORDS								
SOURCE	Unknown.							
ORGANISM	Unknown.							
REFERENCE	1 (bases 1 to 17)							
AUTHORS	Gimeno,C.J. and Errada,P.R.							
TITLE	Genes encoding proteins that interact with the tub protein							
JOURNAL	Patent: US 5955306-A 9 21-SEP-1999;							
FEATURES	Location/Qualifiers							
source	1..17							
	/organism="unknown"							
	/mol_type="unassigned DNA"							
Query Match	0.6%	Score 13	DB 1	Length 17				
Best Local Similarity	100.0%	Pred. No.	3.6e+02	13	0	0	0	0
Matches	13	Conservative	0	Mismatches	0	Indels	0	Gaps
QY	1009	CTGCTTTCCTTC	1021					
Db	16	CTGCTTTCCTTC	4					
RESULT 315								
LOCUS	AR141867	17 bp	DNA	linear	PAT 08-AUG-2001			
DEFINITION	Sequence 9 from patent US 6147192.							
ACCESSION	AR141867							
VERSION	AR141867.1	GI:15101383						
KEYWORDS								
SOURCE	Unknown.							
ORGANISM	Unknown.							
REFERENCE	1 (bases 1 to 17)							
AUTHORS	Gimeno,C.J. and Errada,P.R.							
TITLE	Tub interactor (TI) polypeptides and uses therefor							
JOURNAL	Patent: US 6147192-A 9 14-NOV-2000;							
FEATURES	Location/Qualifiers							
source	1..17							
	/organism="unknown"							
	/mol_type="unassigned DNA"							
Query Match	0.6%	Score 13	DB 1	Length 17				
Best Local Similarity	100.0%	Pred. No.	3.6e+02	13	0	0	0	0
Matches	13	Conservative	0	Mismatches	0	Indels	0	Gaps
QY	1009	CTGCTTTCCTTC	1021					
Db	16	CTGCTTTCCTTC	4					
RESULT 316								
LOCUS	BD254342	17 bp	DNA	linear	PAT 17-JUL-2003			
DEFINITION	Regulation of repressor genes using nucleic acid molecules.							
ACCESSION	BD254342							

VERSION	BD254342.1	GI:33064112
KEYWORDS	JP 2002541795-A/2135.	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.	
TITLE	Regulation of repressor genes using nucleic acid molecules	
JOURNAL	Patent: JP 2002541795-A 2135 10-DEC-2002;	
COMMENT	RIBOZYME PHARMACEUTICALS INC	
OS	Eukaryote	
PN	JP 2002541795-A/2135	
PD	10-DEC-2002	
PF	11-APR-2000 JP 2000611654	
PR	12-APR-1999 US 60/129390	
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN	
PC	PC C12N15/09, A61K38/00, A61P43/00, A61P43/00, C12N5/10, PC C12P21/02,	
PC	C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC C12R1:91),	
PC	(C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,	
PC	A61K37/02,	
PC	C12N5/00, C12R1:91)	
CC	Regulation of repressor genes using nucleic acid molecules	
Key	Location/Qualifiers	
FT	1..17	
FT	source	
FEATURES	location/qualifiers	
source	1..17	
	/organism="Eukaryote".	
	/organism="unidentified"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32644"	
Query Match	0.6%; Score 13; DB 1; Length 17;	
Best local Similarity	100.0%; Pred. NO. 3.6e+02;	
Matches	13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Oy	1847 CAGTAAAGTCTGG 1859	
Db	14 CAGTAAAGTCTGG 2	
RESULT 317		
BD259547	17 bp DNA linear PAR 17-JUL-2003	
LOCUS	BD259547	
DEFINITION	Regulation of repressor genes using nucleic acid molecules.	
ACCESSION	BD259547	
VERSION	BD259547.1 GI:33069317	
KEYWORDS	JP 2002541795-A/7340.	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 17)	
AUTHORS	Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.	
TITLE	Regulation of repressor genes using nucleic acid molecules	
JOURNAL	Patent: JP 2002541795-A 7340 10-DEC-2002;	
COMMENT	RIBOZYME PHARMACEUTICALS INC	
OS	Eukaryote	
PN	JP 2002541795-A/7340	
PD	10-DEC-2002	
PF	11-APR-2000 JP 2000611654	
PR	12-APR-1999 US 60/129390	
PI	LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN	
PC	PC C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC C12P21/02,	
PC	C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC C12R1:91),	
PC	(C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,	
PC	A61K37/02,	
PC	C12N5/00, C12R1:91)	
CC	Regulation of repressor genes using nucleic acid molecules	

Key Location/Qualifiers  
 FT source 1..17  
 /organism="Eukaryote".  
 FEATURES  
 source Location/Qualifiers  
 1..17  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"

Query Match 0.6%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 CTGGGCTTGCCCC 319  
 2 CTGGGCTTGCCCC 14

## RESULT 318

LOCUS 153289 17 bp DNA linear PAT 07-OCT-1997  
 DEFINITION Sequence 1030 from patent US 5646042.  
 ACCESSION 153289  
 VERSION 153289.1 GI:2474492  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 1030 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1..17  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGTATTCA 1254  
 5 CACTAGTATTCA 17

## RESULT 319

LOCUS 153291 17 bp DNA linear PAT 07-OCT-1997  
 DEFINITION Sequence 1032 from patent US 5646042.  
 ACCESSION 153291  
 VERSION 153291.1 GI:2474494  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 1032 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1..17  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1243 ACTAGTATTTCAG 1255  
 1 ACTAGTATTTCAG 13

RESULT 320  
 LOCUS 153776 17 bp DNA linear PAT 07-OCT-1997  
 DEFINITION Sequence 1517 from patent US 5646042.  
 ACCESSION 153776  
 VERSION 153776.1 GI:2474979  
 KEYWORDS  
 SOURCE Unknown.

REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 1517 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1..17  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GTTGCTGGAAGTG 1062  
 17 GTTGCTGGAAGTG 5

## Db

## RESULT 321

LOCUS 153778 17 bp DNA linear PAT 07-OCT-1997  
 DEFINITION Sequence 1519 from patent US 5646042.  
 ACCESSION 153778  
 VERSION 153778.1 GI:2474981  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 1519 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1..17  
 /organism="unknown"  
 /mol\_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 3.6e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GTTGCTGGAAGTG 1062  
 16 GTTGCTGGAAGTG 4

## Db

## RESULT 322

LOCUS ARI86780 17 bp DNA linear PAT 20-APR-2002  
 DEFINITION Sequence 2268 from patent US 6346398.  
 ACCESSION ARI86780  
 VERSION ARI86780.1 GI:20232745  
 KEYWORDS  
 SOURCE Unknown.

REFERENCE 1 (bases 1 to 17)  
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6346398-A 2268 12-FEB-2002;  
 FEATURES Location/Qualifiers

```
source 1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCCATTCTCA 703
|||||
5 ATGTCCATTCTCA 17

RESULT 323
AR186781 17 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 2269 from patent US 6346398.
DEFINITION AR186781
ACCESSION AR186781
VERSION AR186781.1 GI:20232746
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2269 12-FEB-2002;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 324
AR323411 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 813 from patent US 6566127.
DEFINITION AR323411
ACCESSION AR323411
VERSION AR323411.1 GI:33709219
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 813 20-MAY-2003;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCCATTCTCA 703
|||||
5 ATGTCCATTCTCA 17

RESULT 325
AR323412 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 814 from patent US 6566127.
DEFINITION AR323412
ACCESSION AR323412
VERSION AR323412.1 GI:33709220
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 814 20-MAY-2003;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 326
AR327352 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4754 from patent US 6566127.
DEFINITION AR327352
ACCESSION AR327352
VERSION AR327352.1 GI:33713160
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4754 20-MAY-2003;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGGTGACGCTCC 2228
|||||
16 TGGTGACGCTCC 4

RESULT 327
AR327387 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4789 from patent US 6566127.
DEFINITION AR327387
ACCESSION AR327387
VERSION AR327387.1 GI:33713195
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4789 20-MAY-2003;
FEATURES
source 1.17
Location/Qualifiers
```

```
LOCUS AR323412 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 814 from patent US 6566127.
ACCESSION AR323412
VERSION AR323412.1 GI:33709220
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 814 20-MAY-2003;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCCATTCTCA 703
|||||
1 ATGTCCATTCTCA 13

RESULT 326
AR327352 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4754 from patent US 6566127.
DEFINITION AR327352
ACCESSION AR327352
VERSION AR327352.1 GI:33713160
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4754 20-MAY-2003;
FEATURES
source 1.17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGGTGACGCTCC 2228
|||||
16 TGGTGACGCTCC 4

RESULT 327
AR327387 17 bp RNA linear PAT 17-AUG-2003
LOCUS Sequence 4789 from patent US 6566127.
DEFINITION AR327387
ACCESSION AR327387
VERSION AR327387.1 GI:33713195
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 4789 20-MAY-2003;
FEATURES
source 1.17
Location/Qualifiers
```

```

/organism="unknown"
/mol_type="unassigned RNA"

Query Match      0.64; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      328 CTTCCTTGTTC 340
      |||||
Db      16 CTTCCTTGTTC 4

RESULT 328
AR327651      AR327651      17 bp      RNA      linear      PAT 17-AUG-2003
DEFINITION    Sequence 5053 from patent US 6566127.
ACCESSION     AR327651
VERSION       AR327651.1 GI:33713459
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5053 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.64; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
      |||||
Db      2 TGGGAGCCAGCTG 14

RESULT 329
AR327652      AR327652      17 bp      RNA      linear      PAT 17-AUG-2003
DEFINITION    Sequence 5054 from patent US 6566127.
ACCESSION     AR327652
VERSION       AR327652.1 GI:33713460
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5054 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.64; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1917 TGGGAGCCAGCTG 1929
      |||||
Db      1 TGGGAGCCAGCTG 13

RESULT 330
AR327792      AR327792      17 bp      RNA      linear      PAT 17-AUG-2003

```

```

DEFINITION    Sequence 5194 from patent US 6566127.
ACCESSION     AR327792
VERSION       AR327792.1 GI:33713600
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5194 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.64; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCCATTCTCA 703
      |||||
Db      4 ATGTCCATTCTCA 16

RESULT 331
AR327793      AR327793      17 bp      RNA      linear      PAT 17-AUG-2003
DEFINITION    Sequence 5195 from patent US 6566127.
ACCESSION     AR327793
VERSION       AR327793.1 GI:33713601
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5195 20-MAY-2003;
FEATURES      Location/Qualifiers
              1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.64; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCCATTCTCA 703
      |||||
Db      3 ATGTCCATTCTCA 15

RESULT 332
AX672226/c    AX672226      17 bp      DNA      linear      PAT 27-MAR-2003
DEFINITION    Sequence 671 from Patent WO03004526.
ACCESSION     AX672226
VERSION       AX672226.1 GI:29330574
KEYWORDS
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE     1
AUTHORS      Telerman,A., Amson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or resistance to viruses and their use as
              medicines
JOURNAL      Patent: WO 03004526-A 671 16-JAN-2003;
              Molecular Engines Laboratories (FR)

```

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2147 AAGAGGCGCTAT 2159
Db 17 AAGAGGCGCTAT 5

RESULT 333
AX722951 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 638 from Patent WO03025176.
ACCESSION AX722951
VERSION AX722951.1 GI:30423452
KEYWORDS
SOURCE
  Mus musculus (house mouse)
ORGANISM
  Mus musculus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025176-A 638 27-MAR-2003;
  Molecular Engines Laboratories (FR)

JOURNAL
  source
    Location/Qualifiers
      1..17
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

FEATURES
  source

Query Match
  0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 959 TGCTCTGGGGATC 971
Db 13 TGCTCTGGGGATC 1

RESULT 334
AX730455 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2089 from Patent WO03025175.
ACCESSION AX730455
VERSION AX730455.1 GI:30509798
KEYWORDS
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025175-A 2089 27-MAR-2003;
  Molecular Engines Laboratories (FR)

JOURNAL
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

FEATURES
  source

Query Match
  0.6%; Score 13; DB 1; Length 17;

```

```

Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 829 CAACGAACGAGA 841
Db 15 CAACGAACGAGA 3

RESULT 335
AX732634 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 4268 from Patent WO03025175.
ACCESSION AX732634
VERSION AX732634.1 GI:30511977
KEYWORDS
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  Patent: WO 03025175-A 4268 27-MAR-2003;
  Molecular Engines Laboratories (FR)

JOURNAL
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

FEATURES
  source

Query Match
  0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2138 TCTTTCTGAAGG 2150
Db 3 TCTTTCTGAAGG 15

RESULT 336
AX735420 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1010 from Patent WO03025177.
ACCESSION AX735420
VERSION AX735420.1 GI:30514697
KEYWORDS
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
  1
  Telerman,A., Amson,R. and Tuijnder,M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
  Patent: WO 03025177-A 1010 27-MAR-2003;
  Molecular Engines Laboratories (FR)

JOURNAL
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

FEATURES
  source

Query Match
  0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1364 CCCAGGCTGTGGA 1376
Db 15 CCCAGGCTGTGGA 3

```



```

RESULT 337
LOCUS AX735658 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1248 from Patent WO03025177.
ACCESSION AX735658
VERSION AX735658.1 GI:30514935
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
JOURNAL
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2027 ACAGCCAGTTACA 2039
Db 5 ACAGCCAGTTACA 17
|||||
|

RESULT 338
LOCUS AX802040 17 bp DNA linear PAT 24-NOV-2003
DEFINITION Sequence 179 from Patent WO03057913.
ACCESSION AX802040
VERSION AX802040.1 GI:38500964
KEYWORDS
SOURCE Bos taurus (cow)
ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Bovinae; Bos.
REFERENCE
AUTHORS Mabilat,C., Desvarenne,S., Babola,O., Lacroix,B. and bello Pigem,N.
TITLE Method for the detection and/or identification of the original
JOURNAL animal species in animal matter contained in a sample
BIO MEDICUS (FR)
FEATURES
source 1..17
/organism="Bos taurus"
/mol_type="unassigned DNA"
/db_xref="taxon:9913"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 860 GGCTAACAGAGA 872
Db 13 GGCTAACAGAGA 1
|||||
|

RESULT 339
LOCUS BD198661 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION BD198661
molecule participating in vasculogenic response.

```

```

VERSION BD198661.1 GI:33008431
KEYWORDS
SOURCE JP 2002509721-A/1687.
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
COMMENT 1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 1687 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1687
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00/A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism="Homo sapiens (human)".
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 GCTTATTCTGTG 923
Db 2 GCTTATTCTGTG 14
|||||
|

RESULT 340
LOCUS BD198662 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION BD198662
molecule participating in vasculogenic response.
VERSION BD198662.1 GI:33008432
KEYWORDS JP 2002509721-A/1688.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning
JOURNAL molecule participating in vasculogenic response
Patent: JP 2002509721-A 1688 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1688
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,

```

```
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12M5/00, PC
C12M5/00
CC Method and reagent for treating diseases or conditions CC
CC participating molecule
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'
FEATURES
source
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 911 GCTTATTTCGTG 923
Db 1 GCTTATTTCGTG 13

RESULT 341
A31053/C 16 bp DNA linear PAT 21-AUG-1995
LOCUS A31053 primer DNA lpa-7 from patent WO9203550.
ACCESSION A31053
VERSION A31053.1 GI:1249289
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
artificial sequences.
1 (bases 1 to 16)
REFERENCE
AUTHORS RYEGRASS POLLEN ALLERGEN
TITLE Patent: WO 9203550-A 11 05-MAR-1992;
JOURNAL Location/Qualifiers
FEATURES
source
1..16
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACCTGACCGAC 1454
Db 16 AGTACCGGACGAC 1

RESULT 342
AR028650 16 bp DNA linear PAT 29-SEP-1999
LOCUS AR028650
DEFINITION Sequence 18 from patent US 5858740.
ACCESSION AR028650
VERSION AR028650.1 GI:5940623
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Finer,M.H., Roberts,M.R., Dull,T.J., Zeebo,K.M., Qin,L. and
Farrson,D.A.
TITLE Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
JOURNAL Patent: US 5858740-A 18 12-JAN-1999;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

JOURNAL
source
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGGCATTGCCAGT 1514
Db 1 AGGGCATTGCCAGT 16

RESULT 343
AR053743 16 bp DNA linear PAT 29-SEP-1999
LOCUS AR053743
DEFINITION Sequence 18 from patent US 5834256.
ACCESSION AR053743
VERSION AR053743.1 GI:5978605
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Finer,M.H., Roberts,M.R., Dull,T.J., Zeebo,K.M., Qin,L. and
Farrson,D.A.
TITLE Method for production of high titer virus and high efficiency
retroviral mediated transduction of mammalian cells
JOURNAL Patent: US 5834256-A 18 10-NOV-1998;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGGCATTGCCAGT 1514
Db 1 AGGGCATTGCCAGT 16

RESULT 344
AR069284/C 16 bp DNA linear PAT 18-FEB-2000
LOCUS AR069284
DEFINITION Sequence 23 from patent US 5891631.
ACCESSION AR069284
VERSION AR069284.1 GI:7220172
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 16)
REFERENCE
AUTHORS Goldstein,J.L., Brown,M.S., Briggs,M.R. and Wang,X.
TITLE Methods relating tosterol regulatory element binding proteins
JOURNAL Patent: US 5891631-A 23 06-APR-1999;
FEATURES
source
1..16
/organism='unknown'
/mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGAGTGT 795
Db 16 GCAGGAGAGAGTGT 1

RESULT 345
AR126826/C 16 bp DNA linear PAT 16-MAY-2001
LOCUS AR126826
DEFINITION Sequence 16 from patent US 6180368.
ACCESSION AR126826
VERSION AR126826.1 GI:14113419
```

KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,  
Theerakulpitueut,P. and Hough,T.  
JOURNAL Ryegrass pollen allergen  
Patent: US 6180368-A 16 30-JAN-2001;  
FEATURES location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454  
Db 16 AGTACCGGACGCGAC 1

RESULT 346  
ARI37189 16 bp DNA linear PAT 16-JUN-2001  
LOCUS Sequence 16 from patent US 6197313.  
DEFINITION ARI37189  
ACCESSION ARI37189  
VERSION ARI37189.1 GI:14478698  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,  
Theerakulpitueut,P. and Hough,T.  
JOURNAL Ryegrass pollen allergen  
Patent: US 6197313-A 16 06-MAR-2001;  
FEATURES location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454  
Db 16 AGTACCGGACGCGAC 1

RESULT 347  
ARI46243 16 bp DNA linear PAT 08-AUG-2001  
LOCUS Sequence 16 from patent US 6218187.  
DEFINITION ARI46243  
ACCESSION ARI46243  
VERSION ARI46243.1 GI:15109432  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Finer,M.H., Dul,T.J., Zeebo,K.M., Cooke,K. and Parson,D.A.  
JOURNAL Method for production of high titer virus and high efficiency  
retroviral mediated transduction of mammalian cells  
Patent: US 6218187-A 18 17-APR-2001;  
FEATURES location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTTGTCCAGTT 1514  
Db 1 AGGCGCATGTCCAGCT 16

RESULT 348  
ARI56010 16 bp DNA linear PAT 08-AUG-2001  
LOCUS Sequence 16 from patent US 6239269.  
DEFINITION ARI56010  
ACCESSION ARI56010  
VERSION ARI56010.1 GI:15124063  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Singh,M.Bir., Knox,R.Bruce., Smith,P., Avjiloglu,A.,  
Theerakulpitueut,P. and Hough,T.  
JOURNAL Ryegrass pollen allergen  
Patent: US 6239269-A 16 29-MAY-2001;  
FEATURES location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACTGGACCGCAC 1454  
Db 16 AGTACCGGACGCGAC 1

RESULT 349  
ARI78197 16 bp DNA linear PAT 20-APR-2002  
LOCUS Sequence 16 from patent US 6319494.  
DEFINITION ARI78197  
ACCESSION ARI78197  
VERSION ARI78197.1 GI:20219335  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE  
AUTHORS 1 (bases 1 to 16)  
TITLE Capon,D.J., Welles,A., Irving,B.A., Roberts,M.R. and Zeebo,K.  
JOURNAL Chimeric chains for receptor-associated signal transduction  
Patent: US 6319494-A 16 20-NOV-2001;  
FEATURES location/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTTGTCCAGTT 1514  
Db 1 AGGCGCATGTCCAGCT 16

RESULT 350  
I18842 16 bp DNA linear PAT 07-OCT-1996  
LOCUS Sequence 23 from patent US 5498696.  
DEFINITION I18842  
ACCESSION I18842  
VERSION I18842.1 GI:1599197  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 16)  
TITLE Briggner, M.R., Brown, M.S., Goldstein, J.L. and Wang, X.  
JOURNAL Sterol regulatory element binding proteins and their use in screening assays  
PATENT: US 5498696-A 23 12-MAR-1996;  
FEATURES  
LOCATION/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 780 GCAGGAGAGGCTTT 795  
Db 16 GCAGGAGAGGAGCTTT 1

RESULT 351  
LOCUS 122296/c 16 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 23 from patent US 5527690.  
ACCESSION 122296  
VERSION 122296.1 GI:1602650  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 16)  
TITLE Goldstein, J.L., Brown, M.S., Briggner, M.R. and Wang, X.  
METHODS Methods and compositions relating to sterol regulatory element binding proteins  
PATENT: US 5527690-A 23 18-JUN-1996;  
FEATURES  
LOCATION/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 780 GCAGGAGAGGCTTT 795  
Db 16 GCAGGAGAGGAGCTTT 1

RESULT 352  
LOCUS 173322 16 bp DNA linear PAT 03-APR-1998  
DEFINITION Sequence 18 from patent US 5686279.  
ACCESSION 173322  
VERSION 173322.1 GI:3009461  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 16)  
TITLE Finer, M.H., Roberts, M.R., Dull, T.J., Zeebo, K.M., Qin, L. and Farson, D.A.  
METHODS Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells  
PATENT: US 5686279-A 18 11-NOV-1997;  
FEATURES  
LOCATION/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1499 AGGCGCTGTCAGCTT 1514  
Db 1 AGGCGCATGTCAGCT 16

RESULT 353  
LOCUS AR214479 16 bp mRNA linear PAT 25-SEP-2002  
DEFINITION Sequence 16 from patent US 6407221.  
ACCESSION AR214479  
VERSION AR214479.1 GI:23312304  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 16)  
TITLE Capon, D.J., Weiss, A., Irving, B.A., Roberts, M.R. and Zeebo, K.  
METHODS Chimeric chains for receptor-associated signal transduction pathways  
PATENT: US 6407221-A 16 18-JUN-2002;  
FEATURES  
LOCATION/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="mRNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1499 AGGCGCTGTCAGCTT 1514  
Db 1 AGGCGCATGTCAGCT 16

RESULT 354  
LOCUS AR217686 16 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 26 from patent US 6416984.  
ACCESSION AR217686  
VERSION AR217686.1 GI:23317557  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 16)  
TITLE Haseltine, W.A., Ruben, S.M., Wei, Y.-F., Adams, M.D., Fleischmann, R.D., Fraser, C.M., Fuldner, R.A., Kirkness, E.F. and Rosen, C.A.  
METHODS Human DNA mismatch repair proteins  
PATENT: US 6416984-A 26 09-JUL-2002;  
FEATURES  
LOCATION/Qualifiers  
1..16  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2089 CTTCTCATCACCCAGC 2104  
Db 1 CTTCTCAACACCAAGC 16

RESULT 355  
LOCUS AR229701/c 16 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 16 from patent US 6451324.  
ACCESSION AR229701  
VERSION AR229701.1 GI:27269418

```

KEYWORDS      .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Singh,M.B., Knox,R.B., Smith,P., Avjoglou,A., Theerakulpisut,P. and
               Hough,T.
TITLE          Ryegrass pollen allergen
JOURNAL        Patent: US 6451324-A 16 17-SEP-2002;
FEATURES       Location/Qualifiers
               1..16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1439 AGTACTGACGACCGAC 1454
Db      16 AGTACCGGACGCGAC 1

RESULT 356
LOCUS      AR234410
DEFINITION Sequence 64 from patent US 6458567.
ACCESSION  AR234410
VERSION     AR234410.1 GI:27277098
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Barber,U.R., Welch,P.J., Tritz,R., Yei,S. and Yu,M.
TITLE        Hepatitis C Virus ribozymes
JOURNAL      Patent: US 6458567-A 64 01-OCT-2002;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      713 GTGCAGTCTGAGACT 728
Db      1 GTGCAGTCTGAGACT 16

RESULT 357
LOCUS      AR255710
DEFINITION Sequence 24 from patent US 6482606.
ACCESSION  AR255710
VERSION     AR255710.1 GI:27304807
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Adame,M.D., Pleischmann,R.D., Fraser,C.M., Fuldner,R.A.,
               Kirchner,E.F., Habeltine,W.A., Kosen,C.A., Ruden,S. and Wei,Y.-F.
TITLE        Human DNA mismatch repair polynucleotides
JOURNAL      Patent: US 6482606-A 24 19-NOV-2002;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2089 CTTCTCATCACCAGC 2104
Db      1 CTTCTCATCACCAGC 16

RESULT 358
LOCUS      AR274833
DEFINITION Sequence 18 from patent US 6506604.
ACCESSION  AR274833
VERSION     AR274833.1 GI:29707382
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Finer,M.H., Dull,T.J., Zeebo,K.M., Cooke,K. and Pearson,D.A.
TITLE        Method for production of high titer virus and high efficiency
               retroviral mediated transduction of mammalian cells
JOURNAL      Patent: US 6506604-A 18 14-JAN-2003;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGACCTTGTCAGTT 1514
Db      1 AGGACCTTGTCAGTT 16

RESULT 359
LOCUS      AR328356
DEFINITION Sequence 5758 from patent US 6566127.
ACCESSION  AR328356
VERSION     AR328356.1 GI:33714164
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 16)
AUTHORS      Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
               related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6566127-A 5758 20-MAY-2003;
FEATURES     Location/Qualifiers
             1..16
             /organism="unknown"
             /mol_type="unassigned RNA"

Query Match      0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1992 TATCTCGATGATGCC 2007
Db      1 TATCTCGATGATGCC 16

RESULT 360
LOCUS      AR328357
DEFINITION Sequence 5759 from patent US 6566127.
ACCESSION  AR328357
VERSION     AR328357.1 GI:33714165
KEYWORDS
SOURCE      Unknown.

```

```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 5759 20-MAY-2003;
FEATURES
    source
        1..16
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2016 CCTGATGCAACAGC 2031
Db 1 CCTGATGCTGACAGC 16

RESULT 361
LOCUS AR329600 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 7002 from patent US 6566127.
ACCESSION AR329600
VERSION AR329600.1 GI:33715408
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
JOURNAL Patent: US 6566127-A 7002 20-MAY-2003;
FEATURES
    source
        1..16
        /organism="unknown"
        /mol_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1469 CCACTGCTCTGTGC 1484
Db 1 CCACTGGCGCTGATGAC 16

RESULT 362
LOCUS AR364124 16 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 4 from patent US 5256545.
ACCESSION AR364124
VERSION AR364124.1 GI:34426450
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brown,M.S., Goldstein,J.L., Russell,D.W. and Sudhof,T.C.
TITLE Sterol Regulatory Elements
JOURNAL Patent: US 5256545-A 4 26-OCT-1993;
FEATURES
    source
        1..16
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy 780 GCAGGGAGAGGTGTT 795
Db 16 GCAGGGGAGGAGGTTT 1

RESULT 363
LOCUS AR364150 16 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 33 from patent US 5256545.
ACCESSION AR364150
VERSION AR364150.1 GI:34426476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brown,M.S., Goldstein,J.L., Russell,D.W. and Sudhof,T.C.
TITLE Sterol Regulatory Elements
JOURNAL Patent: US 5256545-A 33 26-OCT-1993;
FEATURES
    source
        1..16
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 780 GCAGGGAGAGGTGTT 795
Db 1 GCAGGGGAGGAGGTTT 16

RESULT 364
LOCUS AR382044 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 26 from patent US 6610477.
ACCESSION AR382044
VERSION AR382044.1 GI:40090449
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Haseltine,W.A., Ruben,S.M., Wei,Y.-F., Adams,M.D.,
Fleischmann,R.D., Frazer,C.M., Fuldner,R.A., Kirtness,E.F.,
Rosen,C.A., Vogelstein,B., Kinzler,K.W., Nicolaides,N.C. and
Papadopoulos,N.
TITLE Human DNA mismatch repair proteins
JOURNAL Patent: US 6610477-A 26 26-AUG-2003;
FEATURES
    source
        1..16
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2089 CTTCTCATCACCCAGC 2104
Db 1 CTTCTCAACACCAAGC 16

RESULT 365
LOCUS AR391495 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 107 from patent US 6613520.
ACCESSION AR391495
VERSION AR391495.1 GI:40114993
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

```

```

REFERENCE      Unclassified.
AUTHORS        1 (bases 1 to 16)
TITLE          Methods for the survey and genetic analysis of populations
JOURNAL        Patent: US 6613520-A 107 02-SEP-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             39 CTGCGTCCCGCGAGCT 54
Db             1 CTGCGCGCGCGAGCT 16

RESULT 366
LOCUS          AR399532                16 bp    DNA
DEFINITION     Sequence 24 from patent US 6620619.
ACCESSION      AR399532
VERSION        AR399532.1 GI:40141634
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Haseltine,W.A., Ruben,S., Wei,Y.-F., Adams,M.D., Fleischmann,R.D.,
               Fraser,C.M., Rosen,C.A., Fuldner,R.A. and Kirkness,E.F.
TITLE          Human DNA mismatch repair protein
JOURNAL        Patent: US 6620619-A 24 16-SEP-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             2089 CTTCTCATCACCCAGC 2104
Db             1 CTTCTCAACACCAAGC 16

RESULT 367
LOCUS          AR436078                16 bp    RNA
DEFINITION     Sequence 337 from patent US 6656731.
ACCESSION      AR436078
VERSION        AR436078.1 GI:40199162
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Ecksstein,F., Ludwig,J. and Beigelman,L.
TITLE          Nucleic acid catalysts with endonuclease activity
JOURNAL        Patent: US 6656731-A 337 02-DEC-2003;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unknown"
               /mol_type="unassigned RNA"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             604 ATGGCCATTTCATTCT 619

```

```

Db             16 ATGGCCATTTCATTCT 1

RESULT 368
LOCUS          AX281975                16 bp    DNA
DEFINITION     Sequence 107 from Patent WO0177392.
ACCESSION      AX281975
VERSION        AX281975.1 GI:16609226
KEYWORDS
SOURCE         unidentified
ORGANISM       unidentified
REFERENCE      1
AUTHORS        Aabhy,M.
TITLE          Methods for the survey and genetic analysis of populations
JOURNAL        Patent: WO 0177392-A 107 18-OCT-2001;
FEATURES       Location/Qualifiers
SOURCE         1. .16
               /organism="unidentified"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32644"
               /note="unidentified soil organism"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             39 CTGCGTCCCGCGAGCT 54
Db             1 CTGCGCGCGCGAGCT 16

RESULT 369
LOCUS          AX708805                16 bp    DNA
DEFINITION     Sequence 21 from Patent WO02095071.
ACCESSION      AX708805
VERSION        AX708805.1 GI:29564532
KEYWORDS
SOURCE         synthetic construct
ORGANISM       synthetic construct
REFERENCE      1
AUTHORS        Plassterk,R.H.
TITLE          Means and methods for identifying genes and proteins involved in
               the prevention and/or repair of a replication error
JOURNAL        Patent: WO 02095071-A 21 28-NOV-2002;
FEATURES       Koninklijke Nederlandse Akademie van Wetenschappen (NLS)
SOURCE         Location/Qualifiers
SOURCE         1. .16
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Unc-93 (el500) mutation in C. elegans meh-6"

Query Match    0.64; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             1161 CCAGAGTTTAGGGA 1176
Db             16 CCCGAGATTAGGGA 1

RESULT 370
LOCUS          AX802066                16 bp    DNA
DEFINITION     Sequence 205 from Patent WO03057913.
ACCESSION      AX802066
VERSION        AX802066.1 GI:38500990
KEYWORDS

```

SOURCE Saimo salar (Atlantic salmon)  
ORGANISM Saimo salar  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Actinopterygii; Neopterygii; Teleostei; Euteleostei;  
Protacanthopterygii; Salmoniformes; Salmonidae; Saimo.  
REFERENCE 1  
AUTHORS Mahlat,C., Desvarene,S., Babola,O., Lacroix,B. and bello Pigem,N.  
TITLE Method for the detection and/or identification of the original  
JOURNAL animal species in animal matter contained in a sample  
BIO MERIEUX (FR)  
Patent: WO 03057913-A 205 17-JUL-2003;  
FEATURES  
source location/Qualifiers  
1..16  
/organism="Saimo salar"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:8030"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TACTGCTACTCTCGC 92  
Db 1 TACTTCTACTCTCAGC 16

RESULT 371  
BD166014/C 16 bp DNA linear PAT 17-JAN-2003  
LOCUS Ryegrass pollen allergen.  
DEFINITION BD166014  
ACCESSION BD166014.1 GI:27871826  
VERSION JP 2002159298-A/13.  
KEYWORDS Lolium perenne  
SOURCE Lolium perenne  
ORGANISM Lolium perenne  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Pooidae; Poae; Lolium.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Singh,M.B., Hough,T., Knox,R.B., Theerakulpit,P., Smith,P. and  
Avjiloglu,A.  
TITLE Ryegrass pollen allergen  
JOURNAL Patent: JP 2002159298-A 13 04-JUN-2002;  
COMMENT THE UNIVERSITY OF MELBOURNE  
OS Lolium perenne (perennial ryegrass)  
PN JP 2002159298-A/13  
PD 04-JUN-2002  
PR 05-SEP-2001 JP 2001269054  
PI 17-AUG-1990 AU PK1823  
PI MOHAN BIR SINGH, TERRYN HUGH, ROBERT BRUCE KNOX, PIYADA PI  
THEERAKULPIT,  
PI PENELOPE SMITH, ASIL AVJIOGLU  
PC C12N15/09, A61K38/00, A61K39/36, A61P27/14, A61P37/08, C07K14/415,  
PC C12N1/15,  
PC C12N1/19, C12N1/21, C12N5/10, G01N33/53, C12N15/00, C12N5/00, A61K37/ PC  
02  
CC Ryegrass pollen allergen  
C2 Key location/Qualifiers  
FH source 1..16  
FT /organism="Lolium perenne (perennial ryegrass)"  
location/Qualifiers  
1..16  
/organism="Lolium perenne"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:4522"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACCTGACCGCAGC 1454

Db 16 AGTACCGGACCGCAGC 1

RESULT 372  
BD167992 16 bp DNA linear PAT 17-JAN-2003  
LOCUS Method of constructing mutation DNA library and utilization  
DEFINITION thereof.  
ACCESSION BD167992  
VERSION BD167992.1 GI:27873804  
KEYWORDS WO 0226964-A/39  
SOURCE WO 0226964-A/39  
ORGANISM synthetic construct  
synthetic construct  
artificial sequences.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Tsuji,T. and Yanagawa,H.  
TITLE Method of constructing mutation DNA library and utilization thereof  
JOURNAL Patent: WO 0226964-A 39 04-APR-2002;  
COMMENT MITSUBISHI CHEMICAL CORP, TORU TSUJI, HIROSHI YANAGAWA  
OS Artificial Sequence  
PN WO 0226964-A/39  
PD 04-APR-2002  
PR 26-SEP-2001 WO 2001JP008387  
PR 27-SEP-2001 JP 00P 293692, 06-FEB-2001 JP 01P 029138 PI  
TORU TSUJI, HIROSHI YANAGAWA  
PC C12N15/09, C12P21/02  
CC Description of Artificial Sequence: Synthesized FH Key  
FT location/Qualifiers  
FT source 1..16  
/organism="Artificial Sequence".  
location/Qualifiers  
1..16  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1804 GGCTGACCGCAGAGC 1819  
Db 1 GGCTGACCGCTGAGC 16

RESULT 373  
BD181119 16 bp DNA linear PAT 15-MAY-2003  
LOCUS Human DNA mismatch repair proteins.  
DEFINITION BD181119  
ACCESSION BD181119.1 GI:30792037  
VERSION JP 2002325588-A/23.  
KEYWORDS synthetic construct  
synthetic construct  
artificial sequences.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Haseltine,W.A., Ruben,S.M., Wei,Y.F., Adams,M.D., Fleischmann,R.D.,  
Fraser,C.M., Fuldner,R.A., Kirkness,E.F. and Rosen,C.A.  
TITLE Human DNA mismatch repair proteins  
JOURNAL Patent: JP 2002325588-A 23 12-NOV-2002;  
COMMENT HUMAN GENOME SCIENCES INC  
OS Artificial Sequence  
PN JP 2002325588-A/23  
PD 12-NOV-2002  
PR 25-JAN-2002 JP 2002016830  
PR 27-JAN-1994 US 08/187757, 16-MAR-1994 US 08/210143 PR  
23-AUG-1994 US 08/294312  
PI WILLIAM A HASELTINE, STEVEN M RUBEN, YING FEI WEI, MARK D ADAMS,  
PI ROBERT D FLEISCHMANN, CLAIRE M FRASER, REBECCA A FULDNER, EWEN F  
PI KIRKNESS,  
PI CRAIG A ROSEN  
PC C12N15/09, C07K14/47, C12P21/02, C1201/68// (C12P21/02, C12R1:19),



```

PC C12N15/00
CC hMLH1 sense primer
FH Key Location/Qualifiers
FT source 1..16
   /organism='Artificial Sequence'
   /location/Qualifiers
   1..16
   /organism='synthetic construct'
   /mol_type='genomic DNA'
   /db_xref='taxon:32630'

FEATURES
   source

Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCAGC 2104
Db 1 CTTCTCAACACAGC 16

RESULT 374
LOCUS AR028970 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5858981.
ACCESSION AR028970
VERSION AR028970.1 GI:5940943
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Method of inhibiting phagocytosis
JOURNAL Patent: US 5858981-A 9 12-JAN-1999;
FEATURES
   source
   /location/Qualifiers
   1..17
   /organism='unknown'
   /mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCTGTGGCCATGCC 1124
Db 1 CGCTGTCCATGCC 16

RESULT 375
LOCUS AR046049 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 842 from patent US 5817796.
ACCESSION AR046049
VERSION AR046049.1 GI:5967514
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwigen,J. and Jarvis,T.
TITLE C-myc ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 842 06-OCT-1998;
FEATURES
   source
   /location/Qualifiers
   1..17
   /organism='unknown'
   /mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AAATATTGAGTACT 1445
Db 1 AAATATTGAGTACT 1445

```

```

Db 17 AAATACTGAGTACT 2

RESULT 376
LOCUS AR057432 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1636 from patent US 5837542.
ACCESSION AR057432
VERSION AR057432.1 GI:5983009
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1636 17-NOV-1998;
FEATURES
   source
   /location/Qualifiers
   1..17
   /organism='unknown'
   /mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTGCTCT 578
Db 2 CTCTGTCTCTGTGCTCT 17

RESULT 377
LOCUS AR057439 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1643 from patent US 5837542.
ACCESSION AR057439
VERSION AR057439.1 GI:5983016
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and
Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 1643 17-NOV-1998;
FEATURES
   source
   /location/Qualifiers
   1..17
   /organism='unknown'
   /mol_type='unassigned DNA'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTGCTCT 578
Db 2 CTCTGTCTCTGTGCTCT 17

RESULT 378
LOCUS AR057596 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1800 from patent US 5837542.
ACCESSION AR057596
VERSION AR057596.1 GI:5983173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and

```

Draper,K.G.  
Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 1800 17-NOV-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 CGCTGTCCTGCTCT 578  
Db 2 CTCTGCTCTGCTCT 17

RESULT 379  
LOCUS AR104994 17 bp DNA linear PAT 14-FEB-2001  
DEFINITION Sequence 28 from patent US 6096501.  
ACCESSION AR104994  
VERSION AR104994.1 GI:12818591  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Foxall,P.A. and Berger,D.M.  
JOURNAL Assay for Chlamydia trachomatis by amplification and detection of  
FEATURES Chlamydia trachomatis cryptic plasmid  
source Patent: US 6096501-A 28 01-AUG-2000;  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1679 GACAGCTGCTGTGA 1694  
Db 1 GACAGCTTGTGATGA 16

RESULT 380  
LOCUS AR115190 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1636 from patent US 6132967.  
ACCESSION AR115190  
VERSION AR115190.1 GI:14095512  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of  
FEATURES intercellular adhesion molecule-1 (ICAM-1)  
Patent: US 6132967-A 1636 17-OCT-2000;  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 CGCTGTCCTGCTCT 578  
Db 1 ||||| ||||| |||||

Db 2 CTCTGCTCTGCTCT 17

RESULT 381  
LOCUS AR115197 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1643 from patent US 6132967.  
ACCESSION AR115197  
VERSION AR115197.1 GI:14095519  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of  
FEATURES intercellular adhesion molecule-1 (ICAM-1)  
Patent: US 6132967-A 1643 17-OCT-2000;  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 CGCTGTCCTGCTCT 578  
Db 2 CTCTGCTCTGCTCT 17

RESULT 382  
LOCUS AR115354 17 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 1800 from patent US 6132967.  
ACCESSION AR115354  
VERSION AR115354.1 GI:14095676  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of  
FEATURES intercellular adhesion molecule-1 (ICAM-1)  
Patent: US 6132967-A 1800 17-OCT-2000;  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 CGCTGTCCTGCTCT 578  
Db 2 CTCTGCTCTGCTCT 17

RESULT 383  
LOCUS AR145857 17 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 28 from patent US 6218125.  
ACCESSION AR145857  
VERSION AR145857.1 GI:15109046  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS 1 (bases 1 to 17)  
TITLE Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and  
JOURNAL Ribozyme treatment of diseases or conditions related to levels of  
FEATURES intercellular adhesion molecule-1 (ICAM-1)  
Patent: US 6218125-A 28 01-AUG-2000;  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 563 CGCTGTCCTGCTCT 578  
Db 2 CTCTGCTCTGCTCT 17

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Foxall,P.A. and Berger,D.M.
TITLE Assay for Chlamydia trachomatis by amplification and detection of
JOURNAL Chlamydia trachomatis cryptic plasmid
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1679 GACAGCTGCTGTGGA 1694
Db 1 GACAGCTTGTGATGCA 16

RESULT 384
LOCUS ARI56852 17 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 9 from patent US 6242427.
ACCESSION ARI56852
VERSION ARI56852.1 GI:15125556
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Methode of inhibiting phagocytosis
JOURNAL Patent: US 6242427-A 9 05-JUN-2001;
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1109 CTCGTGCGCCATGCC 1124
Db 1 CGCTGTGAGCCATGCC 16

RESULT 385
LOCUS BD241028 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Process for enzymatically modifying pectin.
ACCESSION BD241028
VERSION BD241028.1 GI:33050798
KEYWORDS JP 2002525071-A/6.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Christensen,T.M.I.E., Pedersen,A.A., Brunstedt,J. and
Mikkelsen,J.D.
TITLE Process for enzymatically modifying pectin
JOURNAL Patent: JP 2002525071-A 6 13-AUG-2002;
COMMENT
    OS Artificial Sequence
    PN JP 2002525071-A/6
    PD 13-AUG-2002
    PR 15-SEP-1999 JP 2000570357
    PR 16-SEP-1998 GB 9820195.7
    PI TOVE MARTEL IDA ELSE CHRISTENSEN,ANETTE
    PI AMSTRUP PEDERSEN,JANNE
    PI BRUNSTEDT,
    PI JOERN DALGAARD MIKKELSEN
    PC C12P19/04,A23L1/05//C12N9/18,C12N15/09,C12N15/09,A23L1/04, PC

```

```

C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence: Primer
FH key Location/Qualifiers
FT source
    1..17
        /organism='Artificial Sequence'.
FEATURES
    source
        Location/Qualifiers
            1..17
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ATTCTCCCTGCTGCTG 144
Db 2 ATTATCCATGCTGCTG 17

RESULT 386
LOCUS BD241330/c 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Methods and products related to genotyping and DNA analysis.
ACCESSION BD241330
VERSION BD241330.1 GI:33051100
KEYWORDS JP 2002525127-A/277.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J.E., Jordan,B., Houseman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 277 13-AUG-2002;
COMMENT
    OS Homo sapiens (human)
    PN JP 2002525127-A/277
    PD 13-AUG-2002 JP 2000572407
    PR 24-SEP-1999 JP 2000572407
    PR 25-SEP-1998 US 60/101757
    PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSEMAN, ALAIN CHAREST
    PC C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
    CC Methods and products related to genotyping and DNA analysis FH
    Key Location/Qualifiers
    FT source
        1..17
            /organism='Homo sapiens (human)'.
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 CCAGGCTGCTGCTGCT 282
Db 16 CCAGAGCTGCTGCTACT 1

RESULT 387
LOCUS BD254112 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254112
VERSION BD254112.1 GI:33063882
KEYWORDS JP 2002541795-A/1905.
SOURCE unidentified

```

```

ORGANISM      unidentified
               unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 1905 10-DEC-2002;
               RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Eukaryote
               PN JP 2002541795-A/1905
               PD 10-DEC-2002
               PR 11-APR-2000 JP 2000611654
               PI 12-APR-1999 US 60/129390
               P1 LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
               C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
               C12P21/02,
               PC
               C12P21/02,C12P21/02//A61K31/71.1, (C12N5/10,C12R1:91), (C12P21/02, PC
               C12R1:91),
               PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
               PC A61K37/02,
               PC (C12N5/00,C12R1:91)
               CC Regulation of repressor genes using nucleic acid molecules FH
               Key Location/Qualifiers
               FT source 1..17
               /organism='Eukaryote'.

FEATURES
source      Location/Qualifiers
             1..17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1700 AGCCCTTCCCATTA 1715
Db      2 AGCCCTTCTCCAGA 17

RESULT 388
BD254113      17 bp DNA linear PAT 17-JUN-2003
LOCUS         BD254113
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD254113
VERSION       BD254113.1 GI:33063883
KEYWORDS      JP 2002541795-A/1906.
SOURCE        unidentified
ORGANISM      unidentified
               unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 1906 10-DEC-2002;
               RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Eukaryote
               PN JP 2002541795-A/1906
               PD 10-DEC-2002
               PR 11-APR-2000 JP 2000611654
               PI 12-APR-1999 US 60/129390
               P1 LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
               C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
               C12P21/02,
               PC
               C12P21/02,C12P21/02//A61K31/71.1, (C12N5/10,C12R1:91), (C12P21/02, PC
               C12R1:91),
               PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
               PC A61K37/02,
               PC (C12N5/00,C12R1:91)
               CC Regulation of repressor genes using nucleic acid molecules FH
               Key Location/Qualifiers
               FT source 1..17
               /organism='Eukaryote'.

```

```

FEATURES
source      Location/Qualifiers
             1..17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1700 AGCCCTTCCCATTA 1715
Db      1 AGCCCTTCTCCAGA 16

RESULT 389
BD254344/c    17 bp DNA linear PAT 17-JUN-2003
LOCUS         BD254344
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD254344
VERSION       BD254344.1 GI:33064114
KEYWORDS      JP 2002541795-A/2137.
SOURCE        unidentified
ORGANISM      unidentified
               unclassified.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE          Regulation of repressor genes using nucleic acid molecules
JOURNAL        Patent: JP 2002541795-A 2137 10-DEC-2002;
               RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Eukaryote
               PN JP 2002541795-A/2137
               PD 10-DEC-2002
               PR 11-APR-2000 JP 2000611654
               PI 12-APR-1999 US 60/129390
               P1 LAWRENCE BLATT, MICHAEL, ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
               C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
               C12P21/02,
               PC
               C12P21/02,C12P21/02//A61K31/71.1, (C12N5/10,C12R1:91), (C12P21/02, PC
               C12R1:91),
               PC (C12P21/02,C12R1:91), (C12P21/02,C12R1:91), C12N15/00,C12N5/00,
               PC A61K37/02,
               PC (C12N5/00,C12R1:91)
               CC Regulation of repressor genes using nucleic acid molecules FH
               Key Location/Qualifiers
               FT source 1..17
               /organism='Eukaryote'.

FEATURES
source      Location/Qualifiers
             1..17
             /organism="unidentified"
             /mol_type="genomic DNA"
             /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1843 GCTCAGTAAAGTCTG 1858
Db      16 GCCACAGTAAAGTCTG 1

RESULT 390
BD254398      17 bp DNA linear PAT 17-JUN-2003
LOCUS         BD254398
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD254398
VERSION       BD254398.1 GI:33064168
KEYWORDS      JP 2002541795-A/2191.
SOURCE        unidentified
ORGANISM      unidentified
               unclassified.

```

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2192 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2191
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PT 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source
location/Qualifiers
1..17
/mol_type='genomic DNA'
/db_xref='taxon:32644'

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1700 AGCCCTTCCTCCAGATA 1715
Db 2 AGCCCTTCCTCCAGATA 17

RESULT 391
BD254399 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254399
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254399
VERSION BD254399.1 GI:33064169
KEYWORDS JP 2002541795-A/2192.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 17)
REFERENCE Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2192 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2192
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PT 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source
location/Qualifiers
1..17
/mol_type='genomic DNA'
/db_xref='taxon:32644'

FEATURES
source
location/Qualifiers
1..17
/mol_type='genomic DNA'
/db_xref='taxon:32644'

```

```

/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1700 AGCCCTTCCTCCAGATA 1715
Db 1 AGCCCTTCCTCCAGATA 16

RESULT 392
BD254560 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254560
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254560
VERSION BD254560.1 GI:33064330
KEYWORDS JP 2002541795-A/2353.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 17)
REFERENCE Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2353 10-DEC-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Eukaryote
PN JP 2002541795-A/2353
PD 10-DEC-2002
PR 11-APR-2000 JP 2000611654
PT 12-APR-1999 US 60/129390
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
C12P21/02,
PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
C12R1:91),
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1:91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1..17
/organism='Eukaryote'.
FEATURES
source
location/Qualifiers
1..17
/mol_type='genomic DNA'
/db_xref='taxon:32644'

QY 1161 CCAGAGTTTAAAGGAA 1176
Db 1 CCAGAGTTTAAAGGAA 16

RESULT 393
BD254561 17 bp DNA linear PAT 17-JUL-2003
LOCUS BD254561
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD254561
VERSION BD254561.1 GI:33064331
KEYWORDS JP 2002541795-A/2354.
SOURCE unidentified
ORGANISM unidentified
unclassified.
1 (bases 1 to 17)
REFERENCE Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
AUTHORS Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 2354 10-DEC-2002;

```

```

TITLE      Regulation of repressor genes using nucleic acid molecules
JOURNAL    Patent: JP 2002541795-A 2354 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT    OS Eukaryote
            PN JP 2002541795-A/2354
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/1129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source      location/Qualifiers
            1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1163 AGAAGTTTAAAGGAAAA 1178
        |||||||
        2 AGAAGTTTAAAGGAAAA 17

Db

RESULT 394
BD254562      17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD254562
VERSION       BD254562.1 GI:33064332
KEYWORDS      JP 2002541795-A/2355.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 2355 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Eukaryote
            PN JP 2002541795-A/2355
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/1129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source      location/Qualifiers
            1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1376 AGTACTGCTCTCCAT 1391
        |||||||
        2 AGTACTGCTCTCCAT 17

Db

RESULT 396
BD259177      17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD259177
VERSION       BD259177.1 GI:33068947
KEYWORDS      JP 2002541795-A/6970.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 6970 10-DEC-2002;

```

```

            /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1163 AGAAGTTTAAAGGAAAA 1178
        |||||||
        1 AGAAGTTTAAAGGAAAA 16

Db

RESULT 395
BD255504      17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD255504
VERSION       BD255504.1 GI:33065274
KEYWORDS      JP 2002541795-A/3297.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 3297 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Eukaryote
            PN JP 2002541795-A/3297
            PD 10-DEC-2002
            PF 11-APR-2000 JP 2000611654
            PR 12-APR-1999 US 60/1129390
            PI LAWRENCE BLATT,MICHAEL,ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
            C12R1:91),
            PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,
            PC A61K37/02,
            PC (C12N5/00,C12R1:91)
            CC Regulation of repressor genes using nucleic acid molecules FH
            Key Location/Qualifiers
            FT source 1..17
            /organism='Eukaryote'.

FEATURES
source      location/Qualifiers
            1..17
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1376 AGTACTGCTCTCCAT 1391
        |||||||
        2 AGTACTGCTCTCCAT 17

Db

RESULT 396
BD259177      17 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION    Regulation of repressor genes using nucleic acid molecules.
ACCESSION     BD259177
VERSION       BD259177.1 GI:33068947
KEYWORDS      JP 2002541795-A/6970.
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE        Regulation of repressor genes using nucleic acid molecules
JOURNAL      Patent: JP 2002541795-A 6970 10-DEC-2002;

```

COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
PN JP 2002541795-A/6970  
PD 10-DEC-2002  
PR 11-APR-2000 JP 2000611654  
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
/organism='Eukaryote'.  
FEATURES  
source  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1162 CAGAACTTGAAGGAAA 1177  
Db 1 CAGAACTTGAAGGAAA 16  
|||||  
|||||

RESULT 397  
BD259430 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Regulation of repressor genes using nucleic acid molecules.  
DEFINITION  
ACCESSION BD259430  
VERSION BD259430.1 GI:33069200  
KEYWORDS UP 2002541795-A/7223.  
SOURCE unidentified  
ORGANISM unidentified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 7223 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
PN JP 2002541795-A/7223  
PD 10-DEC-2002  
PR 11-APR-2000 JP 2000611654  
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
/organism='Eukaryote'.  
FEATURES  
source  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 44 TCCCGGAGCTTCTCT 59  
Db 17 TCCCGGAGATCTCT 2  
|||||  
|||||

RESULT 398  
BD259431 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Regulation of repressor genes using nucleic acid molecules.  
DEFINITION  
ACCESSION BD259431  
VERSION BD259431.1 GI:33069201  
KEYWORDS UP 2002541795-A/7224.  
SOURCE unidentified  
ORGANISM unidentified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.  
TITLE Regulation of repressor genes using nucleic acid molecules  
JOURNAL Patent: JP 2002541795-A 7224 10-DEC-2002;  
RIBOZYME PHARMACEUTICALS INC  
OS Eukaryote  
PN JP 2002541795-A/7224  
PD 10-DEC-2002  
PR 11-APR-2000 JP 2000611654  
PI LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC  
C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC  
C12R1:91),  
PC (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N5/00,C12N5/00,  
PC A61K37/02,  
PC (C12N5/00,C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key Location/Qualifiers  
FT source 1..17  
/organism='Eukaryote'.  
FEATURES  
source  
1..17  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 43 CTCGCCGAGCTTCTC 58  
Db 16 CTCGCCGAGATCTCT 1  
|||||  
|||||

RESULT 399  
BD270691 17 bp DNA linear PAT 17-JUL-2003  
LOCUS Selection system.  
DEFINITION  
ACCESSION BD270691  
VERSION BD270691.1 GI:33080459  
KEYWORDS UP 2002514413-A/18.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Riechmann,L., Kristensen,P., Jestin,J.L. and Winter,G.P.  
TITLE Selection System  
JOURNAL Patent: JP 2002514413-A 18 21-MAY-2002;  
DIVERSYS LTD  
OS Artificial Sequence

```

PN      JP 2002514413-A/18
PF      21-MAY-2002
PR      13-MAY-1999 JP 2000548446
PT      13-MAY-1998 GB 9810222.9, 13-MAY-1998 GB 9810228.8 PI
LUTZ RIECHMANN, PETER KRISTENSEN, JEAN LUC JESTIN, GREGORY PAUL PI
WINTER
PC      C12N15/00, C12N7/02, C12N15/00
CC      Description of Artificial Sequence: PRIMER/POLYPEPTIDE FH
FT      Location/Qualifiers
      source
      1. .17
      /organism="Artificial Sequence".
      /mol_type="synthetic construct"
      /db_xref="taxon:32630"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2203 TGCTACTGGGCGCATGG 2218
Db      2 TGCACCTGGGCGCATGG 17

RESULT 400
BD270691/c
LOCUS      BD270691
DEFINITION Selection system.
ACCESSION      BD270691.1 GI:33080459
VERSION      BD270691.1
KEYWORDS      JP 2002514413-A/18.
SOURCE      synthetic construct
ORGANISM      synthetic construct
REFERENCE      1 (bases 1 to 17)
AUTHORS      Riechmann, L., Kristensen, P., Jestin, J.L. and Winter, G.P.
TITLE      Selection system
JOURNAL      Patent: JP 2002514413-A 18 21-MAY-2002;
COMMENT      DIVERSYS LTD
OS      Artificial Sequence
PN      JP 2002514413-A/18
PD      21-MAY-2002
PR      13-MAY-1999 JP 2000548446
PT      13-MAY-1998 GB 9810222.9, 13-MAY-1998 GB 9810228.8 PI
LUTZ RIECHMANN, PETER KRISTENSEN, JEAN LUC JESTIN, GREGORY PAUL PI
WINTER
PC      C12N15/00, C12N7/02, C12N15/00
CC      Description of Artificial Sequence: PRIMER/POLYPEPTIDE FH
FT      Location/Qualifiers
      source
      1. .17
      /organism="Artificial Sequence".
      /mol_type="synthetic construct"
      /db_xref="taxon:32630"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      755 CCATGGCGCAGTGCA 770
Db      17 CCATGGCGCAGTGCA 2

RESULT 401
E35301
LOCUS      E35301
DEFINITION Assay of Chlamydia trachomatis by amplifying and detecting
Chlamydia trachomatis-latent plasmid.

```

```

ACCESSION      E35301
VERSION      E35301.1 GI:13019028
KEYWORDS      JP 1999221088-A/28.
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE      1 (bases 1 to 17)
AUTHORS      Paul, A.F. and Dororesu, M.B.
TITLE      Assay of Chlamydia trachomatis by amplifying and detecting
JOURNAL      Chlamydia trachomatis-latent plasmid
          Patent: JP 1999221088-A 28 17-AUG-1999;
          BECTON DICKINSON & CO
OS      Unidentified
PN      JP 1999221088-A/28
PD      17-AUG-1999
PR      04-NOV-1998 JP 1998312798
PT      04-NOV-1997 US 08/963927
PI      PAUL A FOKUSOULI, DORORESU M BAGA
PC      C12N15/09, C12Q1/04, C12Q1/68, G01N33/569, G01N33/571, C12N15/00 CC
CC      Strandedness: Single;
      Topology: Linear;
FT      Key
FT      source
      1. .17
      Location/Qualifiers
      /organism="Unidentified".
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

FEATURES
      source
      1. .17
      /organism="unidentified"
      /mol_type="genomic DNA"
      /db_xref="taxon:32644"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1679 GACAGCTGCTGTGGA 1694
Db      1 GACAGCTTGTGATGGA 16

RESULT 402
I46652
LOCUS      I46652
DEFINITION Sequence 631 from patent US 5639612.
ACCESSION      I46652
VERSION      I46652.1 GI:2470617
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Mitsuhashi, M. and Cooper, A.
TITLE      Method for detecting polynucleotides with immobilized
          polynucleotide probes identified based on T.sub.m
          Patent: US 5639612-A 631 17-JUN-1997;
JOURNAL      Location/Qualifiers
FT      source
      1. .17
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      550 ACGGCGCGCTCTGCG 565
Db      2 ACGGCGCGCTCTGCG 17

RESULT 403
E35301/c
LOCUS      E35301
DEFINITION Sequence 842 from patent US 5646042.

```



VERSION 153101.1 GI:2474304  
KEYWORDS  
SOURCE  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 842 08-JUL-1997;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1430 AATATTGAGTACT 1445  
Db 17 AATATTGAGTACT 2

RESULT 404  
LOCUS 184477 17 bp DNA linear PAT 04-APR-1998  
DEFINITION Sequence 1 from patent US 5635940.  
ACCESSION 184477  
VERSION 184477.1 GI:3021997  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Dmanac,R.T. and Crkvenjakov,R.B.  
TITLE Method of sequencing by hybridization of oligonucleotide probes  
JOURNAL Patent: US 5695940-A 1 09-DEC-1997;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1666 CAGCCACCGGGGAC 1681  
Db 17 CAGCCACCGGGGAC 2

RESULT 405  
LOCUS 184484 17 bp DNA linear PAT 04-APR-1998  
DEFINITION Sequence 8 from patent US 5695940.  
ACCESSION 184484  
VERSION 184484.1 GI:3022004  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Dmanac,R.T. and Crkvenjakov,R.B.  
TITLE Method of sequencing by hybridization of oligonucleotide probes  
JOURNAL Patent: US 5695940-A 8 09-DEC-1997;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1666 CAGCCACCGGGGAC 1681  
Db 17 CAGCCACCGGGGAC 2

RESULT 406  
LOCUS ARI86248 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 1736 from patent US 6346398.  
ACCESSION ARI86248  
VERSION ARI86248.1 GI:20232213  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 1736 12-FEB-2002;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 881 CCCGTGATGCTCT 896  
Db 17 CGCTGATGCTCT 2

RESULT 407  
LOCUS ARI86747 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 2235 from patent US 6346398.  
ACCESSION ARI86747  
VERSION ARI86747.1 GI:20232712  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2235 12-FEB-2002;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1637 CAGTGGCTGCTGCT 1652  
Db 1 CAGTGGCTGCTGCT 16

RESULT 408  
LOCUS ARI88407 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 3895 from patent US 6346398.  
ACCESSION ARI88407  
VERSION ARI88407.1 GI:20234372  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Pavco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 3895 12-FEB-2002;
JOURNAL	Location/Qualifiers
FEATURES	1..17 /organism="unknown" /mol_type="unassigned DNA"
source	
Query Match	0.6%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	1430 AAATATTGTGACTACCT 1445       2 AAATTTTGAGCACCT 17
Db	
RESULT 409	
LOCUS	AR188415 17 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 3903 from patent US 6346398.
ACCESSION	AR188415
VERSION	AR188415.1 GI:20234380
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Pavco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 3903 12-FEB-2002;
JOURNAL	Location/Qualifiers
FEATURES	1..17 /organism="unknown" /mol_type="unassigned DNA"
source	
Query Match	0.6%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	91 GCCGACTGGGCTGC 106       17 GCCCAGTGGATGCTGC 2
Db	
RESULT 410	
LOCUS	AR188667 17 bp DNA linear PAT 20-APR-2002
DEFINITION	Sequence 4155 from patent US 6346398.
ACCESSION	AR188667
VERSION	AR188667.1 GI:20234632
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Pavco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 4155 12-FEB-2002;
JOURNAL	Location/Qualifiers
FEATURES	1..17 /organism="unknown" /mol_type="unassigned DNA"
source	
Query Match	0.6%; Score 12.8; DB 1; Length 17; Best Local Similarity 87.5%; Pred.No.3.8e+02;
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	2120	AGCAGGCTGACCATAT	2135
DB	17	AGAGGTGGACCACAT	2
RESULT 411			
LOCUS	ARI90412	17 bp	DNA
DEFINITION	Sequence 5900 from patent US 6346398.		
ACCESSION	ARI90412		
VERSION	ARI90412.1	GI:20236377	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5900 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	1207	AAGAGGCTGTGGCCT	1222
DB	2	AGGAGTCTGTGGCCT	17
RESULT 412			
LOCUS	ARI90474	17 bp	DNA
DEFINITION	Sequence 5962 from patent US 6346398.		
ACCESSION	ARI90474		
VERSION	ARI90474.1	GI:20236439	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5962 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	685	ACTCTCATGTCATTCC	700
DB	2	ACTCTCTTTTCATTTC	17
RESULT 413			
LOCUS	ARI90475	17 bp	DNA
DEFINITION	Sequence 5963 from patent US 6346398.		
ACCESSION	ARI90475		
VERSION	ARI90475.1	GI:20236440	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5963 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	685	ACTCTCATGTCATTCC	700
DB	2	ACTCTCTTTTCATTTC	17
RESULT 414			
LOCUS	ARI90475	17 bp	DNA
DEFINITION	Sequence 5963 from patent US 6346398.		
ACCESSION	ARI90475		
VERSION	ARI90475.1	GI:20236440	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5963 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	685	ACTCTCATGTCATTCC	700
DB	2	ACTCTCTTTTCATTTC	17
RESULT 415			
LOCUS	ARI90475	17 bp	DNA
DEFINITION	Sequence 5963 from patent US 6346398.		
ACCESSION	ARI90475		
VERSION	ARI90475.1	GI:20236440	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5963 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	685	ACTCTCATGTCATTCC	700
DB	2	ACTCTCTTTTCATTTC	17
RESULT 416			
LOCUS	ARI90475	17 bp	DNA
DEFINITION	Sequence 5963 from patent US 6346398.		
ACCESSION	ARI90475		
VERSION	ARI90475.1	GI:20236440	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Payco, P., McSwiggen, J., Stinchcomb, D. and Sacobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor Patent: US 6346398-A 5963 12-FEB-2002;		
JOURNAL FEATURES	Location/Qualifiers 1..17		
source	/organism="unknown" /mol_type="unassigned DNA"		
Query Match	0.6%;	Score 12.8;	DB 1; Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;	
Matches	14;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	685	ACTCTCATGTCATTCC	700
DB	2	ACTCTCTTTTCATTTC	17
RESULT 417			
LOCUS	ARI90475	17 bp	DNA
DEFINITION	Sequence 5963 from patent US 6346398.		
ACCESSION	ARI90475		
VERSION	ARI90475.1	GI:20236440	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS</			

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5963 12-FEB-2002;
FEATURES
    LOCATION/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 685 ACTCTCATGTCATTC 700
Db 1 ACTCTCTTTCATTC 16

RESULT 414
LOCUS AR286467 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 839 from patent US 6528640.
ACCESSION AR286467
VERSION AR286467.1 GI:29724063
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpetsky,A.,
Metulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 839 04-MAR-2003;
FEATURES
    LOCATION/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned RNA"
Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1206 GAAGAGGAGCTGTGCC 1221
Db 17 GAAGGGGCTGTGGGCC 2

RESULT 415
LOCUS AR322879 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 281 from patent US 6566127.
ACCESSION AR322879
VERSION AR322879.1 GI:33708687
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 281 20-MAY-2003;
FEATURES
    LOCATION/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned RNA"
Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 881 CCTGAGTGTCTCT 896

```

```

Db 17 CGCTGAGTGTCTCT 2

RESULT 416
LOCUS AR323378 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 780 from patent US 6566127.
ACCESSION AR323378
VERSION AR323378.1 GI:33709186
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 780 20-MAY-2003;
FEATURES
    LOCATION/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned RNA"
Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGCGTCCCTGCT 1652
Db 1 CAGTGCGTCCAGCT 16

RESULT 417
LOCUS AR324260 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1662 from patent US 6566127.
ACCESSION AR324260
VERSION AR324260.1 GI:33710068
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1662 20-MAY-2003;
FEATURES
    LOCATION/Qualifiers
    1..17
    /organism="unknown"
    /mol_type="unassigned RNA"
Query Match 0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1430 AAATATTGAGTACT 1445
Db 2 AAATTTTGACACCT 17

RESULT 418
LOCUS AR324268 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1670 from patent US 6566127.
ACCESSION AR324268
VERSION AR324268.1 GI:33710076
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)

```

AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 1670 20-MAY-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GCCGACTGGTGCTGC 106  
Db 17 GCCCAGTGGATGCTGC 2

RESULT 419  
AR324520/c 17 bp RNA linear PAT 17-AUG-2003  
LOCUS AR324520  
DEFINITION Sequence 1922 from patent US 6566127.  
ACCESSION AR324520  
VERSION AR324520.1 GI:33710328  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 1922 20-MAY-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2120 AGCAGGCTGACCACT 2135  
Db 17 AGAAGTTGACCACT 2

RESULT 420  
AR325337 17 bp RNA linear PAT 17-AUG-2003  
LOCUS AR325337  
DEFINITION Sequence 2739 from patent US 6566127.  
ACCESSION AR325337  
VERSION AR325337.1 GI:33711145  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 2739 20-MAY-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1207 AAGAGGCTGTGGCCT 1222  
Db 17 AAGAGGCTGTGGCCT 1222

Db 2 AGGAGTCTGTGGCCT 17

RESULT 421  
AR325397 17 bp RNA linear PAT 17-AUG-2003  
LOCUS AR325397  
DEFINITION Sequence 2799 from patent US 6566127.  
ACCESSION AR325397  
VERSION AR325397.1 GI:33711205  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 2799 20-MAY-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 685 ACTCTCATGTCATTC 700  
Db 2 ACTCTCTTTCATTC 17

RESULT 422  
AR325398 17 bp RNA linear PAT 17-AUG-2003  
LOCUS AR325398  
DEFINITION Sequence 2800 from patent US 6566127.  
ACCESSION AR325398  
VERSION AR325398.1 GI:33711206  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 2800 20-MAY-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 685 ACTCTCATGTCATTC 700  
Db 1 ACTCTCTTTCATTC 16

RESULT 423  
AR326829 17 bp RNA linear PAT 17-AUG-2003  
LOCUS AR326829/c  
DEFINITION Sequence 4231 from patent US 6566127.  
ACCESSION AR326829  
VERSION AR326829.1 GI:33712637  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4231 20-MAY-2003;

FEATURES  
SOURCE  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652  
Db 17 CAGTGTCTGCCCTGCT 2

RESULT 424  
AR326830/c 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 4232 from patent US 6566127.  
ACCESSION AR326830  
VERSION AR326830.1 GI:33712638  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4232 20-MAY-2003;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652  
Db 16 CAGTGTCTGCCCTGCT 1

RESULT 425  
AR327109/c 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 4511 from patent US 6566127.  
ACCESSION AR327109  
VERSION AR327109.1 GI:33712917  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4511 20-MAY-2003;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 883 CTGAGTATTCTCTGA 898  
Db 17 CTGAGTATTCTCTCA 2

RESULT 426  
AR327110/c 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 4512 from patent US 6566127.  
ACCESSION AR327110  
VERSION AR327110.1 GI:33712918  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 4512 20-MAY-2003;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 881 CCTGAGTATTCTCT 896  
Db 16 CGTGTGATGCTCT 1

RESULT 427  
AR327761 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 5163 from patent US 6566127.  
ACCESSION AR327761  
VERSION AR327761.1 GI:33713569  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 5163 20-MAY-2003;  
FEATURES  
SOURCE Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1637 CAGTGGCTGCCCTGCT 1652  
Db 2 CAGTGGCTGCCCTGCT 17

RESULT 428  
AR328881/c 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 6283 from patent US 6566127.  
ACCESSION AR328881  
VERSION AR328881.1 GI:33714689  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J. A., Stinchcomb, D. T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions

related to levels of vascular endothelial growth factor receptor  
 Patent: US 6566127-A 6283 20-MAY-2003;

JOURNAL  
 FEATURES  
 source  
 1. .17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GCCGACTGGTGGTGC 106  
 Db 16 GCCCACTGATGCTGC 1

RESULT 429  
 AR329248/c 17 bp RNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 6650 from patent US 6566127.  
 ACCESSION AR329248  
 VERSION AR329248.1 GI:33715056  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE  
 AUTHORS 1 (bases 1 to 17)  
 Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.  
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
 JOURNAL Patent: US 6566127-A 6650 20-MAY-2003;  
 FEATURES Location/Qualifiers  
 source 1. .17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2120 AGCAGGCTGACCACAT 2135  
 Db 16 AGAAGTTGACCACT 1

RESULT 430  
 AR398457/c 17 bp RNA linear PAT 18-DEC-2003  
 DEFINITION Sequence 838 from patent US 6617438.  
 ACCESSION AR398457  
 VERSION AR398457.1 GI:40136287  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE  
 AUTHORS 1 (bases 1 to 17)  
 Beigelman, L., Burgh, A.B., Beaudry, A., Karpelsky, A.,  
 Matulich-Adamic, S., Sweedler, D. and Zinnen, S.  
 TITLE Oligoribonucleotides with enzymatic activity  
 JOURNAL Patent: US 6617438-A 838 09-SEP-2003;  
 FEATURES Location/Qualifiers  
 source 1. .17  
 /organism="unknown"  
 /mol\_type="unassigned RNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1206 GAAGAGGCTGTGGCC 1221  
 Db 17 GAAGGGGCTGTGGCC 2

RESULT 431  
 AR402394/c 17 bp DNA linear PAT 18-DEC-2003  
 DEFINITION Sequence 734 from patent US 6623962.  
 ACCESSION AR402394  
 VERSION AR402394.1 GI:40149844  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE  
 AUTHORS 1 (bases 1 to 17)  
 Akhtar, S., Fell, P. and McSwiggen, J.A.  
 TITLE Enzymatic nucleic acid treatment of diseases related to levels of epidermal growth factor receptors  
 JOURNAL Patent: US 6623962-A 734 23-SEP-2003;  
 FEATURES Location/Qualifiers  
 source 1. .17  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1425 AGAGAAATATTGAG 1440  
 Db 17 AGAGAAATATTATTAG 2

RESULT 432  
 AR403935 17 bp DNA linear PAT 18-DEC-2003  
 DEFINITION Sequence 8 from patent US 6627429.  
 ACCESSION AR403935  
 VERSION AR403935.1 GI:40151859  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE  
 AUTHORS 1 (bases 1 to 17)  
 Christensen, T.M.I.E., Pedersen, A.A., Brunstedt, J. and  
 Mikkelson, J.D.  
 TITLE Process for enzymatically modifying pectin  
 JOURNAL Patent: US 6627429-A 8 30-SEP-2003;  
 FEATURES Location/Qualifiers  
 source 1. .17  
 /organism="unknown"  
 /mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 ATTCTCCCTGCTGTG 144  
 Db 2 ATTATCATGCTGTG 17

RESULT 433  
 AR412050 17 bp DNA linear PAT 18-DEC-2003  
 DEFINITION Sequence 9 from patent US 6638764.  
 ACCESSION AR412050  
 VERSION AR412050.1 GI:40164599  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE  
 AUTHORS 1 (bases 1 to 17)  
 Schreiber, A.D. and Park, J.-G.  
 TITLE Methods of inhibiting phagocytosis  
 JOURNAL Patent: US 6638764-A 9 28-OCT-2003;

FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1109 CTCGTGCGCCATGCC 1124  
DB 1 CGCTGTCAGCCATGCC 16

RESULT 434  
AR434370/c AR434370 17 bp DNA linear PAT 18-DEC-2003  
LOCUS AR434370  
DEFINITION Sequence 793 from patent US 6656700.  
ACCESSION AR434370  
VERSION AR434370.1 GI:40197213  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
JOURNAL Isoforms of human pregnancy-associated protein-E  
PATENT: US 6656700-A 793 02-DEC-2003;  
FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1809 GACCCAGAGCCACT 1824  
DB 17 GACCCAGAGTCACT 2

RESULT 435  
AR434371/c AR434371 17 bp DNA linear PAT 18-DEC-2003  
LOCUS AR434371  
DEFINITION Sequence 794 from patent US 6656700.  
ACCESSION AR434371  
VERSION AR434371.1 GI:40197214  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
JOURNAL Isoforms of human pregnancy-associated protein-E  
PATENT: US 6656700-A 794 02-DEC-2003;  
FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1809 GACCCAGAGCCACT 1824  
DB 16 GACCCAGAGTCACT 1

RESULT 436  
AR434378/c AR434378 17 bp DNA linear PAT 18-DEC-2003  
LOCUS AR434378

DEFINITION Sequence 801 from patent US 6656700.  
ACCESSION AR434378  
VERSION AR434378.1 GI:40197221  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
JOURNAL Isoforms of human pregnancy-associated protein-E  
PATENT: US 6656700-A 801 02-DEC-2003;  
FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 TTCCAACAGAACGAGA 841  
DB 17 TTCTACAGAACGAGA 2

RESULT 437  
AR434379/c AR434379 17 bp DNA linear PAT 18-DEC-2003  
LOCUS AR434379  
DEFINITION Sequence 802 from patent US 6656700.  
ACCESSION AR434379  
VERSION AR434379.1 GI:40197222  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y. and Shannon,M.E.  
JOURNAL Isoforms of human pregnancy-associated protein-E  
PATENT: US 6656700-A 802 02-DEC-2003;  
FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 TTCCAACAGAACGAGA 841  
DB 16 TTCTACAGAACGAGA 1

RESULT 438  
AX010677 AX010677 17 bp DNA linear PAT 06-SEP-2000  
LOCUS AX010677  
DEFINITION Sequence 19 from Patent WO9958655.  
ACCESSION AX010677  
VERSION AX010677.1 GI:9997476  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Kristensen,P., Jeslin,J.L., Winter,G.P. and Riechmann,L.  
JOURNAL Selection system  
PATENT: WO 9958655-A 19 18-NOV-1999;  
KRISTENSEN PETER (DK); JESTIN JEAN LUC (FR); MEDICAL RES COUNCIL (GB); WINTER GREGORY PAUL (GB); RIECHMANN LUTZ (GB)  
FEATURES  
source  
Location/Qualifiers  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"







FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2001 TGATGCCACGAGTCC 2016  
Db 17 TTATTCACGAGTCC 2

RESULT 448  
AX216891 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 2333 from Patent W00159103.  
ACCESSION AX216891  
VERSION AX216891.1 GI:15526952  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
REFERENCE  
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.  
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and  
TITLE nogo gene expression  
JOURNAL Patent: WO 0159103-A 2333 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 541 GGCTCGAGACGCGC 556  
Db 1 GGCTCGAGACGCGC 16

RESULT 449  
AX217378 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 2820 from Patent W00159103.  
ACCESSION AX217378  
VERSION AX217378.1 GI:15527439  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
REFERENCE  
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.  
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and  
TITLE nogo gene expression  
JOURNAL Patent: WO 0159103-A 2820 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1384 CTCCTCATCTACCCCA 1399  
Db 1 CTCCTCATCTACCCCA 16

RESULT 450  
AX217540/c 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 2982 from Patent W00159103.  
ACCESSION AX217540  
VERSION AX217540.1 GI:15527601  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
REFERENCE  
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.  
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and  
TITLE nogo gene expression  
JOURNAL Patent: WO 0159103-A 2982 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2184 GCTCATGAGAAAAG 2199  
Db 16 GCTCATGAGAAAATG 1

RESULT 451  
AX217882/c 17 bp RNA linear PAT 07-SEP-2001  
LOCUS  
DEFINITION Sequence 3324 from Patent W00159103.  
ACCESSION AX217882  
VERSION AX217882.1 GI:15527943  
KEYWORDS  
SOURCE  
ORGANISM  
synthetic construct  
artificial sequences.  
REFERENCE  
1 Blatt, L., McSwiggen, J. and Chowrira, B.M.  
AUTHORS Method and reagent for the modulation and diagnosis of cd20 and  
TITLE nogo gene expression  
JOURNAL Patent: WO 0159103-A 3324 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2184 GCTCATGAGAAAAG 2199  
Db 17 GCTCATGAGAAAATG 2

```

RESULT 452
AX218127/c
LOCUS AX218127
DEFINITION Sequence 3569 from Patent WO0159103.
ACCESSION AX218127
VERSION AX218127.1 GI:15528188
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Blact, L., Mcswiggen, J. and Chowitra, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3569 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1965 AGCATGATCCGGA 1960
17 AGGAGTATCCGGA 2
Db 17

RESULT 453
AX218281/c
LOCUS AX218281
DEFINITION Sequence 3723 from Patent WO0159103.
ACCESSION AX218281
VERSION AX218281.1 GI:15528342
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Blact, L., Mcswiggen, J. and Chowitra, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3723 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blact, Lawrence (US) ;
Mcswiggen, James (US) ; Chowitra, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1045 TACCACTTCTCGAAG 1060
17 TACCAAGTCTCGAAG 2
Db 17

RESULT 454
AX226997
LOCUS AX226997
DEFINITION Sequence 369 from Patent WO0157206.
ACCESSION AX226997
17 bp RNA linear PAT 10-SEP-2001

```

```

VERSION AX226997.1 GI:15556138
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Booher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 369 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2207 ACTGGGCCATGTCGA 2222
1 ACTGGGACTTGTCGA 16
Db 16

RESULT 455
AX227311/c
LOCUS AX227311
DEFINITION Sequence 683 from Patent WO0157206.
ACCESSION AX227311
VERSION AX227311.1 GI:15556452
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Fattaey, A.R., Jarvis, T., Mcswiggen, J., Booher, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk
1) enzyme
JOURNAL Patent: WO 0157206-A 683 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2097 CACCCAGCACCCTCAGC 2112
16 CACCGAGCACCTCGGC 1
Db 16

RESULT 456
AX263388
LOCUS AX263388
DEFINITION Sequence 779 from Patent WO0173002.
ACCESSION AX263388
VERSION AX263388.1 GI:16512187
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Kniiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 779 04-OCT-2001;

```

```

FEATURES
  source
    UNIVERSITY OF DELAWARE (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 917 TTCTGTGGTACCTGCT 932
Db 1 TTCTGTGGTACCTGCT 16

RESULT 457
AX263389/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 780 from Patent W00173002.
ACCESSION AX263389
VERSION AX263389.1 GI:16512188
KEYWORDS
SOURCE
  Homo sapiens (human)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 780 04-OCT-2001;
  JOURNAL UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

FEATURES
  source
    UNIVERSITY OF DELAWARE (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 917 TTCTGTGGTACCTGCT 932
Db 1 TTCTGTGGTACCTGCT 2

RESULT 458
AX265515 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 2906 from Patent W00173002.
ACCESSION AX265515
VERSION AX265515.1 GI:16514314
KEYWORDS
SOURCE
  Homo sapiens (human)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2906 04-OCT-2001;
  JOURNAL UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

FEATURES
  source
    UNIVERSITY OF DELAWARE (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 917 TTCTGTGGTACCTGCT 932
Db 1 TTCTGTGGTACCTGCT 2

RESULT 459
AX265516/c 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 2907 from Patent W00173002.
ACCESSION AX265516
VERSION AX265516.1 GI:16514315
KEYWORDS
SOURCE
  Homo sapiens (human)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 2907 04-OCT-2001;
  JOURNAL UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

FEATURES
  source
    UNIVERSITY OF DELAWARE (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 143 TGCCACCGCGCTGCTC 158
Db 2 TGCCACCGCGCTGCTC 17

RESULT 460
AX265711 17 bp DNA linear PAT 26-OCT-2001
LOCUS
DEFINITION Sequence 3102 from Patent W00173002.
ACCESSION AX265711
VERSION AX265711.1 GI:16514510
KEYWORDS
SOURCE
  Homo sapiens (human)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1
  Kniec,E.B., Gamper,H.B. and Rice,M.C.
  Targeted chromosomal genomic alterations with modified single
  stranded oligonucleotides
  Patent: WO 0173002-A 3102 04-OCT-2001;
  JOURNAL UNIVERSITY OF DELAWARE (US)
  Location/Qualifiers
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

FEATURES
  source
    UNIVERSITY OF DELAWARE (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2179 CAGCAGCTCATGAGAGA 2194
Db 2 CAGCAGCAGCATGAGAGA 17

RESULT 461
AX265712/c
```

```

LOCUS       AX265712                17 bp    DNA             linear    PAT 26-OCT-2001
DEFINITION   Sequence 3103 from Patent WO0173002.
ACCESSION    AX265712
VERSION      AX265712.1  GI:16514511
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1
AUTHORS      Kitec,E.B., Gamper,H.B. and Rice,M.C.
TITLE        Targeted chromosomal genomic alterations with modified single
              stranded oligonucleotides
JOURNAL      Patent: WO 0173002-A 3103 04-OCT-2001;
              UNIVERSITY OF DELAWARE (US)
FEATURES     Location/Qualifiers
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2179 CAGCAGCTCATGGAGA 2194
Db      16 CAGCAGCAGCATCGAGA 1

RESULT 462
LOCUS       AX272955                17 bp    RNA             linear    PAT 29-OCT-2001
DEFINITION   Sequence 524 from Patent WO0162911.
ACCESSION    AX272955
VERSION      AX272955.1  GI:16545692
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1
AUTHORS      Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., Hamblin,P.A. and
              Ellis,J.H.
TITLE        Method and reagent for the inhibition of grid
JOURNAL      Patent: WO 0162911-A 524 30-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES     Location/Qualifiers
              1..17
                /organism="Homo sapiens"
                /mol_type="unassigned RNA"
                /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2223 GGCTCTGCGAGAGTCT 2238
Db      17 GGCTGCTGCGAGTCT 2

RESULT 463
LOCUS       AX421665                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION   Sequence 1 from Patent WO0188124.
ACCESSION    AX421665
VERSION      AX421665.1  GI:21525047
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1
AUTHORS      Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., McLaughlin,P.G. and
              Randi,A.M.
TITLE        Method and reagent for the inhibition of erg
JOURNAL      Patent: WO 0188124-A 715 22-NOV-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES     Location/Qualifiers
              1..17
                /organism="Homo sapiens"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1531 GCCTACCCAAACGCC 1546
Db      17 GCCTACCCAAATGCC 2

RESULT 465
LOCUS       AX422379                17 bp    RNA             linear    PAT 18-JUN-2002
DEFINITION   Sequence 715 from Patent WO0188124.
ACCESSION    AX422379
VERSION      AX422379.1  GI:21525761
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE    1
AUTHORS      Jarvis,T., von Carlwiltz,I., Mcswiggen,J.A., McLaughlin,P.G. and
              Randi,A.M.
TITLE        Method and reagent for the inhibition of erg
JOURNAL      Patent: WO 0188124-A 715 22-NOV-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES     Location/Qualifiers
              1..17
                /organism="Homo sapiens"

```

```

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      347 TGATCTCATGGGAGC 362
      ||||| ||||| |||||
Db      17 TGATCTCCTGGGGGC 2

RESULT 466
LOCUS      AX422704      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1040 from Patent WO0188124.
ACCESSION  AX422704
VERSION     AX422704.1 GI:21526086
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlowitz,I., Mcswigen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 1040 22-NOV-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1906 GTAGACGAGGCTGGGA 1921
      ||||| ||||| |||||
Db      2 GGAGACCGAGGCTGGGA 17

RESULT 467
LOCUS      AX423493      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 1829 from Patent WO0188124.
ACCESSION  AX423493
VERSION     AX423493.1 GI:21526875
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlowitz,I., Mcswigen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 1829 22-NOV-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1030 AAGGTGGGAATGCT 1045
      ||||| ||||| |||||

```

```

Db      2 AAGCGGGAGATGCT 17

RESULT 468
LOCUS      AX423710      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 2046 from Patent WO0188124.
ACCESSION  AX423710
VERSION     AX423710.1 GI:21527092
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlowitz,I., Mcswigen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 2046 22-NOV-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1906 GTAGACGAGGCTGGGA 1921
      ||||| ||||| |||||
Db      1 GGAGACCGAGGCTGGGA 16

RESULT 469
LOCUS      AX423761/c      17 bp      RNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 2097 from Patent WO0188124.
ACCESSION  AX423761
VERSION     AX423761.1 GI:21527143
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Jarvis,T., von Carlowitz,I., Mcswigen,J.A., McLaughlin,F.G. and
            Randi,A.M.
TITLE       Method and reagent for the inhibition of erg
JOURNAL     Patent: WO 0188124-A 2097 22-NOV-2001;
RIBOZYME    PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
SOURCE      location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned RNA"
            /db_xref="taxon:9606"

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1531 GCCTACCCCAACCGCC 1546
      ||||| ||||| |||||
Db      16 GCCTACCCCAATGCC 1

RESULT 470
LOCUS      AX475792      17 bp      DNA      linear      PAT 12-AUG-2002
DEFINITION Sequence 1013 from Patent WO0224750.
ACCESSION  AX475792
VERSION     AX475792.1 GI:22215077

```

KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 1013 28-MAR-2002;  
Aeomica, Inc. (US)

FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 147 CACCGCGCTGCCACTG 162  
Db 2 CACCGAGAGCCACTG 17

RESULT 471  
AX475794 17 bp DNA linear PAT 12-AUG-2002  
LOCUS  
DEFINITION Sequence 1015 from Patent WO0224750.  
ACCESSION AX475794  
VERSION AX475794.1 GI:22215079  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 1015 28-MAR-2002;  
Aeomica, Inc. (US)

FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 148 ACCGCGCTGCCACTGC 163  
Db 1 ACCGAGCAGCCACTGC 16

RESULT 472  
AX494762 17 bp DNA linear PAT 26-SEP-2002  
LOCUS  
DEFINITION Sequence 527 from Patent WO02059256.  
ACCESSION AX494762  
VERSION AX494762.1 GI:23340372  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Tuijnder, M., Tejeran, A., Amsen, R. and Susini, L.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 02059256-A 527 01-AUG-2002;

FEATURES  
source MOLECULAR ENGINES LAB (FR)  
1..17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1139 TTGCCAAGAGAGAGG 1154  
Db 1 TTTCACAGAGAGAGG 16

RESULT 473  
AX498756 17 bp DNA linear PAT 27-SEP-2002  
LOCUS  
DEFINITION Sequence 63 from Patent EP1229046.  
ACCESSION AX498756  
VERSION AX498756.1 GI:23381038  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 63 07-AUG-2002;  
Aeomica, Inc. (US)

FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1009 CTGCTTTCTCTCTGC 1024  
Db 2 CTGCTTTCTCTCTGC 17

RESULT 474  
AX498757 17 bp DNA linear PAT 27-SEP-2002  
LOCUS  
DEFINITION Sequence 64 from Patent EP1229046.  
ACCESSION AX498757  
VERSION AX498757.1 GI:23381039  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 64 07-AUG-2002;  
Aeomica, Inc. (US)

FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1009 CTGCTTTCTCTTGC 1024  
| | | | | | | | | |  
Db 1 CTGCTGTTCTCTCTGC 16

RESULT 475  
LOCUS AX499211 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 518 from Patent EP1229046.  
ACCESSION AX499211  
VERSION AX499211.1 GI:23381504  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 518 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 131 TCTCCCTGCTGTCGC 146  
| | | | | | | | | |  
Db 2 TCTTCCTGCTGCGCC 17

RESULT 476  
LOCUS AX499213 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 520 from Patent EP1229046.  
ACCESSION AX499213  
VERSION AX499213.1 GI:23381506  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 520 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 132 CTCCTGCTGTCGCC 147  
| | | | | | | | | |  
Db 1 CTCCTGCTGTCGCC 16

RESULT 477  
LOCUS AX499242 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 549 from Patent EP1229046.  
ACCESSION AX499242  
VERSION AX499242.1 GI:23381535

KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 549 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 138 GCTGTGCCACCGCG 153  
| | | | | | | | | |  
Db 17 GCCGTGCCACCGCG 2

RESULT 478  
LOCUS AX499243 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 550 from Patent EP1229046.  
ACCESSION AX499243  
VERSION AX499243.1 GI:23381536  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 550 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 138 GCTGTGCCACCGCG 153  
| | | | | | | | | |  
Db 16 GCCGTGCCACCGCG 1

RESULT 479  
LOCUS AX499259 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 566 from Patent EP1229046.  
ACCESSION AX499259  
VERSION AX499259.1 GI:23381552  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 566 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers



```
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TCCTTGCTTACCCCA 1540
|||||
2 TCCTGTACTTACCCCA 17

RESULT 480
AX499260 17 bp DNA linear PAT 29-SEP-2002
LOCUS AX499260
DEFINITION Sequence 567 from Patent EP1229046.
ACCESSION AX499260
VERSION AX499260.1 GI:23381553
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 567 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1525 TCCTTGCTTACCCCA 1540
|||||
1 TCCTGTACTTACCCCA 16

RESULT 481
AX530926 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530926
DEFINITION Sequence 435 from Patent EP1239051.
ACCESSION AX530926
VERSION AX530926.1 GI:25253643
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 435 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 CATTGAGCGCTGTGCG 1116
|||||
```

```
Db 2 CATTGAGCGCGTGC 17

RESULT 482
AX530931 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX530931
DEFINITION Sequence 440 from Patent EP1239051.
ACCESSION AX530931
VERSION AX530931.1 GI:25253653
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 440 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1105 GAGGCTCTGTGCGCA 1120
|||||
1 GAGGCGCTGCGCGCA 16

RESULT 483
AX531054 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531054/c
DEFINITION Sequence 563 from Patent EP1239051.
ACCESSION AX531054
VERSION AX531054.1 GI:25253890
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE
1
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 563 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 307 CTGGGCTTGCCCTGCG 322
|||||
17 CTGGGCTTGCTCTGCG 2

RESULT 484
AX531055/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS AX531055
DEFINITION Sequence 564 from Patent EP1239051.
ACCESSION AX531055
VERSION AX531055.1 GI:25253892
KEYWORDS
SOURCE Homo sapiens (human)
```

```
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 564 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 307 CTGGGCTTGCCCTGC 322
Db 16 CTGGGCTTGCTGCCTGC 1

RESULT 485
AX531704/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1213 from Patent EP1239051.
ACCESSION AX531704
VERSION AX531704.1 GI:25255192
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1213 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1341 TGTTCCTACCATG 1356
Db 17 TGATCTACCATATG 2

RESULT 486
AX531705/c 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1214 from Patent EP1239051.
ACCESSION AX531705
VERSION AX531705.1 GI:25255194
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1214 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
    1..17
    /organism="Homo sapiens"

Query Match
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2093 TCATCACCAGCACT 2108
Db 1 TTATCACCAGCACT 16

RESULT 487
AX531816 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1325 from Patent EP1239051.
ACCESSION AX531816
VERSION AX531816.1 GI:25255408
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1325 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2092 CTCATCACCAGCAC 2107
Db 2 CTTATCACCAGCAC 17

RESULT 488
AX531818 17 bp DNA linear PAT 22-NOV-2002
LOCUS
DEFINITION Sequence 1327 from Patent EP1239051.
ACCESSION AX531818
VERSION AX531818.1 GI:25255412
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1327 11-SEP-2002;
Aeomica, Inc. (US)

FEATURES
source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

RESULT 489  
AX544923 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 436 from Patent EP1243660.  
ACCESSION AX544923  
VERSION AX544923.1 GI:25810134  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 436 25-SEP-2002;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1421 CCTCAGAGAAATTT 1436  
|||||  
2 CCTCAGTGAATAATT 17

RESULT 490  
AX544925 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 438 from Patent EP1243660.  
ACCESSION AX544925  
VERSION AX544925.1 GI:25810136  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 438 25-SEP-2002;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1422 CTCAGAGAAATTT 1437  
|||||  
1 CTCAGTGAATAATT 16

RESULT 491  
AX544967 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 480 from Patent EP1243660.  
ACCESSION AX544967  
VERSION AX544967.1 GI:25810178  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE  
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 480 25-SEP-2002;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1489 TTACACTTGAGGCC 1504  
|||||  
17 TTACACTTGCGGCAC 2

RESULT 492  
AX545279 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 792 from Patent EP1243660.  
ACCESSION AX545279  
VERSION AX545279.1 GI:25810490  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 792 25-SEP-2002;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 277 CTGCTCTTTGAAGC 292  
|||||  
2 CTGCTCTTTGATGC 17

RESULT 493  
AX545281 17 bp DNA linear PAT 26-NOV-2002  
LOCUS  
DEFINITION Sequence 794 from Patent EP1243660.  
ACCESSION AX545281  
VERSION AX545281.1 GI:25810492  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Zhang, J., Gu, Y. and Nguyen, C.T.  
TITLE Human udp-galnac:polypeptide n-acetylglucosaminyltransferase 10  
JOURNAL Patent: EP 1243660-A 794 25-SEP-2002;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers

FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 278 TGGCTGCTTTGAGCC 293  
|||||  
Db 1 TGGCTTTTGATGCC 16

RESULT 494  
AX578253 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 91 from Patent WO0211674.  
ACCESSION AX578253  
VERSION AX578253.1 GI:27647455  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
Patent: WO 0211674-A 238 14-FEB-2002;  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 881 CCTGAGTATTCCT 896  
|||||  
Db 1 CCTGAGTATTCCT 16

RESULT 495  
AX578400 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 238 from Patent WO0211674.  
ACCESSION AX578400  
VERSION AX578400.1 GI:27647602  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
Patent: WO 0211674-A 238 14-FEB-2002;  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

QY 1009 CTGCTTTTCCCTCTGC 1024  
|||||  
Db 2 CAGCTTTTCCCTCTGC 17

RESULT 496  
AX578401 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 239 from Patent WO0211674.  
ACCESSION AX578401  
VERSION AX578401.1 GI:27647603  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
Patent: WO 0211674-A 239 14-FEB-2002;  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1481 TGACTCCCTTACACTT 1496  
|||||  
Db 17 TGCTCCCTGACACTT 2

QY 1009 CTGCTTTTCCCTCTGC 1024  
|||||  
Db 1 CAGCTTTTCCCTCTGC 16

RESULT 497  
AX578890 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 728 from Patent WO0211674.  
ACCESSION AX578890  
VERSION AX578890.1 GI:27648092  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
1  
TITLE Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
Patent: WO 0211674-A 728 14-FEB-2002;  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;  
Thompson, James (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

RESULT 498
AX579181/c
LOCUS AX579181
DEFINITION Sequence 1019 from Patent WO0211674.
ACCESSION AX579181
VERSION AX579181.1 GI:27648383
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
PATENT: WO 0211674-A 1019 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY .1888 CAGGCTATGACACAG 1903
|||||
17 CAGGCTGTGACACTG 2

RESULT 499
AX579898
LOCUS AX579898
DEFINITION Sequence 1736 from Patent WO0211674.
ACCESSION AX579898
VERSION AX579898.1 GI:27649100
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
PATENT: WO 0211674-A 1736 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1683 GCTGCTGTGATGCG 1698
|||||
2 GCTGCTGACGATGCG 17

RESULT 500
AX580127/c
LOCUS AX580127
DEFINITION Sequence 1965 from Patent WO0211674.
ACCESSION AX580127

```

```

VERSION AX580127.1 GI:27649329
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Thompson, J., Mcawiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
PATENT: WO 0211674-A 1965 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1481 TGACTCCCTTACACTT 1496
|||||
16 TGCTTCCCTGACACTT 1

RESULT 501
AX615494/c
LOCUS AX615494
DEFINITION Sequence 301 from Patent EP1262488.
ACCESSION AX615494
VERSION AX615494.1 GI:28446540
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Gu, Y. and Nguyen, C.T.
JOURNAL Human lclcl-domain containing protein
PATENT: EP 1262488-A 301 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
SOURCE
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1009 CTGCTTTCCTTCGC 1024
|||||
17 CTCTTTCCTTCCTTC 2

RESULT 502
AX615495/c
LOCUS AX615495
DEFINITION Sequence 302 from Patent EP1262488.
ACCESSION AX615495
VERSION AX615495.1 GI:28446541
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
TITLE Gu, Y. and Nguyen, C.T.

```

TITLE Human lcc1-domain containing protein  
JOURNML Patent: EP 1262488-A 302 04-DEC-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1009 CTGCTTTCTCTCTGC 1024  
16 CTCTCTTCTCTCTTC 1

RESULT 503  
AX615973/c 17 bp DNA linear PAT 20-FEB-2003  
LOCUS Sequence 780 from Patent EP1262488.  
DEFINITION AX615973  
ACCESSION AX615973.1 GI:28447019  
VERSION  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Gu, Y. and Nguyen, C. T.  
TITLE Human lcc1-domain containing protein  
JOURNML Patent: EP 1262488-A 780 04-DEC-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 919 CTGTGTACTGTGTGC 934  
17 CTGTGGACCTGTGTC 2

RESULT 504  
AX634494 17 bp RNA linear PAT 21-FEB-2003  
LOCUS Sequence 1633 from Patent EP1260586.  
DEFINITION AX634494  
ACCESSION AX634494.1 GI:28470108  
VERSION  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,  
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,  
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,  
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and  
Wolf, T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNML Patent: EP 1260586-A 1633 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"

/db\_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTCTCT 578  
2 CTCTGCTCTGTCTCT 17

RESULT 505  
AX634508 17 bp RNA linear PAT 21-FEB-2003  
LOCUS Sequence 1647 from Patent EP1260586.  
DEFINITION AX634508  
ACCESSION AX634508.1 GI:28470122  
VERSION  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,  
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,  
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,  
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and  
Wolf, T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNML Patent: EP 1260586-A 1647 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTTCTGTCTCT 578  
2 CTCTGCTCTGTCTCT 17

RESULT 506  
AX634643 17 bp RNA linear PAT 21-FEB-2003  
LOCUS Sequence 1782 from Patent EP1260586.  
DEFINITION AX634643  
ACCESSION AX634643.1 GI:28470257  
VERSION  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D. T., Dudycz, L. W., Chowrira, B., Grimm, S., Dizenzo, A.,  
Karpelsky, A., Draper, K. G., Kisich, K., Matulic-Adamic, J.,  
Mcswiggen, J. A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S. M.,  
Sweedler, D., Thompson, J. D., Tracz, D., Usman, N., Wincott, F. E. and  
Wolf, T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNML Patent: EP 1260586-A 1782 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES Location/Qualifiers  
SOURCE 1..17  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"

Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCCT 578  
Db 2 CTCTGCTCTGCTCCT 17

RESULT 507  
LOCUS AX671610/c 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 55 from Patent WO03004526.  
ACCESSION AX671610  
VERSION AX671610.1 GI:29323958  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
Patent: WO 03004526-A 55 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers

FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1330 CTGTGCACATTGTTTC 1345  
Db 16 CTGTGCACGTTTGATC 1

RESULT 508  
LOCUS AX672330 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 775 from Patent WO03004526.  
ACCESSION AX672330  
VERSION AX672330.1 GI:29330678  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
Patent: WO 03004526-A 775 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers

FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 ACCAGCTACTGCACT 397  
Db 2 ATCTGCTACTGCACT 17

RESULT 509  
LOCUS AX673085/c 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1530 from Patent WO03004526.  
ACCESSION AX673085  
VERSION AX673085.1 GI:29331433  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
Patent: WO 03004526-A 1530 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers

FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1263 GCTGAAGTCGGAATC 1278  
Db 16 GCTGAAGTCGGAATC 1

RESULT 510  
LOCUS AX674220 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 2665 from Patent WO03004526.  
ACCESSION AX674220  
VERSION AX674220.1 GI:29332568  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
Patent: WO 03004526-A 2665 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers

FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 905 ATCTGACATTATTTCT 920  
Db 2 ATCTGACATTATTTCT 17

RESULT 511  
LOCUS AX687554/c 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 286 from Patent EP1281758.  
ACCESSION AX687554  
VERSION AX687554.1 GI:29410250

KEYWORDS										
SOURCE										
ORGANISM	Homo sapiens (human)									
REFERENCE	Homo sapiens									
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
TITLE	1									
JOURNAL	Shannon,M., Gu,Y. and Nguyen,C.T.									
FEATURES	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									
source	Patent: EP 1281758-A 286 05-FEB-2003;									
	Aeomica, Inc. (US)									
	Location/Qualifiers									
	1..17									
	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Qy										
Query Match	0.6%; Score 12.8; DB 1; Length 17;									
Best Local Similarity	87.5%; Pred.No.3.8e+02;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
Db	17 GGGTCCAGCTGCTCC 2									
RESULT 512										
LOCUS	AX687555/c 17 bp DNA linear PAT 31-MAR-2003									
DEFINITION	Sequence 287 from Patent EP1281758.									
ACCESSION	AX687555									
VERSION	AX687555.1 GI:29410251									
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1									
TITLE	Shannon,M., Gu,Y. and Nguyen,C.T.									
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									
FEATURES	Patent: EP 1281758-A 287 05-FEB-2003;									
source	Aeomica, Inc. (US)									
	Location/Qualifiers									
	1..17									
	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Qy										
Query Match	0.6%; Score 12.8; DB 1; Length 17;									
Best Local Similarity	87.5%; Pred.No.3.8e+02;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
Db	31 GGGTCCAGCTGCTCC 46									
RESULT 513										
LOCUS	AX687643/c 17 bp DNA linear PAT 31-MAR-2003									
DEFINITION	Sequence 375 from Patent EP1281758.									
ACCESSION	AX687643									
VERSION	AX687643.1 GI:29410339									
KEYWORDS										
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1									
TITLE	Shannon,M., Gu,Y. and Nguyen,C.T.									
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12									

JOURNAL	Patent: EP 1281758-A 375 05-FEB-2003;			
FEATURES	Aeomica, Inc. (US)			
source	Location/Qualifiers			
	1..17			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Qy	2177	ACGACGAGCTCATGGA	2192	
Db	17	ACGACGAGCTCCAGGA	2	
RESULT 514				
LOCUS	AX687645	17 bp	DNA	linear
DEFINITION	Sequence 377 from Patent EP1281758.			
ACCESSION	AX687645			
VERSION	AX687645.1	GI:29410341		
KEYWORDS				
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.			
REFERENCE				
AUTHORS	1			
TITLE	Shannon, M., Gu, Y., and Nguyen, C.T.			
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and			
source	mdz12			
	Patent: EP 1281758-A 528 05-FEB-2003;			
	Aeomica, Inc. (US)			
	Location/Qualifiers			
	1..17			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Query Match	0.6%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	2176	CACGACGAGCTCATGG	2191	
Db	16	CACGACGAGCTCCAGG	1	
RESULT 515				
LOCUS	AX687796	17 bp	DNA	linear
DEFINITION	Sequence 528 from Patent EP1281758.			
ACCESSION	AX687796			
VERSION	AX687796.1	GI:29410492		
KEYWORDS				
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
	Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.			
REFERENCE				
AUTHORS	1			
TITLE	Shannon, M., Gu, Y., and Nguyen, C.T.			
JOURNAL	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and			
source	mdz12			
	Patent: EP 1281758-A 528 05-FEB-2003;			
	Aeomica, Inc. (US)			
	Location/Qualifiers			
	1..17			
	/organism="Homo sapiens"			
	/mol_type="unassigned DNA"			
	/db_xref="taxon:9606"			
Query Match	0.6%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	87.5%;	Pred. No. 3.8e+02;		
Matches 14;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;



Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 773 GCCACTTCGACGGAGA 788  
|||||  
Db 2 GCCACAGCAGGAGA 17

## RESULT 516

LOCUS AX687798 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 530 from Patent EP1281758.  
ACCESSION AX687798  
VERSION AX687798.1 GI:29410494  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 530 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 774 CCACTTCGACGGAG 789  
|||||  
Db 1 CCAACAGCAGGAG 16

RESULT 517  
LOCUS AX687801 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 533 from Patent EP1281758.  
ACCESSION AX687801  
VERSION AX687801.1 GI:29410497  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 533 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 CCGATCACCCTGCT 1008  
|||||  
Db 17 CCGCTCTCCCTGCT 2

## RESULT 518

AX687802/c 17 bp DNA linear PAT 31-MAR-2003  
LOCUS AX687802  
DEFINITION Sequence 534 from Patent EP1281758.  
ACCESSION AX687802  
VERSION AX687802.1 GI:29410498  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 534 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 CCGATCACCCTGCT 1008  
|||||  
Db 16 CCGCTCTCCCTGCT 1

RESULT 519  
LOCUS AX688332 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1064 from Patent EP1281758.  
ACCESSION AX688332  
VERSION AX688332.1 GI:29411032  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1  
AUTHORS Shannon, M., Gu, Y. and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1064 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 381 CACCAGGCTACTGCAC 396  
|||||  
Db 17 CACCAGGCTCCTGCTC 2

RESULT 520  
LOCUS AX688333 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 1065 from Patent EP1281758.  
ACCESSION AX688333  
VERSION AX688333.1 GI:29411033  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
REFERENCE
1 Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS
1 Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1065 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 381 CACCAGGCTCTGCAC 396
Db 16 CACCAGGCTCTGCTC 1

RESULT 521
AX688366/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1098 from Patent EPI281758.
ACCESSION
AX688366
VERSION
AX688366.1 GI:29411066
KEYWORDS
.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1098 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 GAGGGCGAAGCCGAG 1164
Db 17 GAGGAGGAGAGCCGAG 2

RESULT 522
AX688367/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1099 from Patent EPI281758.
ACCESSION
AX688367
VERSION
AX688367.1 GI:29411067
KEYWORDS
.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1099 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1640 TGGCTGCCCTGCTGCA 1655
Db 17 TGGCTGCCCTGCTGCA 2

RESULT 524
AX688662/c 17 bp DNA linear PAT 31-MAR-2003
LOCUS
Sequence 1394 from Patent EPI281758.
ACCESSION
AX688662
VERSION
AX688662.1 GI:29411364
KEYWORDS
.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE
1 Shannon,M., Gu,Y. and Nguyen,C.T.
AUTHORS
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL
Patent: EP 1281758-A 1394 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1639 GTGGCTGCCCTGCTGC 1654
```

Db 16 GTGCTGCGCTGCTGC 1

RESULT 525  
AX690650/c  
LOCUS AX690650 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 3382 from Patent EP1281758.  
ACCESSION AX690650  
VERSION AX690650.1 GI:29413531  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.  
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and  
mdz12  
Patent: EP 1281758-A 3382 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers  
SOURCE 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2176 CACCAGACGCTCAGG 2191  
Db 16 CACCAGACGCTCAGG 1

RESULT 527  
AX690666  
LOCUS AX690666 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 3398 from Patent EP1281758.  
ACCESSION AX690666

VERSION AX690666.1 GI:29413547  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.  
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and  
mdz12  
Patent: EP 1281758-A 3398 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers  
SOURCE 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2040 GTGAGACGCTCCTG 2055  
Db 2 GCTGAGACGCTCCTG 17

RESULT 528  
AX690667  
LOCUS AX690667 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 3399 from Patent EP1281758.  
ACCESSION AX690667  
VERSION AX690667.1 GI:29413548  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.  
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and  
mdz12  
Patent: EP 1281758-A 3399 05-FEB-2003;  
Aeomica, Inc. (US)  
LOCATION/Qualifiers  
SOURCE 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2040 GGTGAGACGCTCCTG 2055  
Db 1 GCTGAGACGCTCCTG 16

RESULT 529  
AX691878  
LOCUS AX691878 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 4610 from Patent EP1281758.  
ACCESSION AX691878  
VERSION AX691878.1 GI:29414819  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS 1  
TITLE Shannon, M., Gu, Y., and Nguyen, C.T.  
JOURNAL Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

JOURNAL mdz12  
 Patent: EP 1281758-A 4610 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2125 GCTGACCACTCTCT 2140  
 Db 2 GCTGCCACAGCCTCT 17

RESULT 530  
 AX691879 17 bp DNA linear PAT 31-MAR-2003  
 LOCUS  
 DEFINITION Sequence 4611 from Patent EP1281758.  
 ACCESSION AX691879  
 VERSION AX691879.1 GI:29414820  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 4611 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2125 GCTGACCACTCTCT 2140  
 Db 1 GCTGCCACAGCCTCT 16

RESULT 531  
 AX691881/c 17 bp DNA linear PAT 31-MAR-2003  
 LOCUS  
 DEFINITION Sequence 4613 from Patent EP1281758.  
 ACCESSION AX691881  
 VERSION AX691881.1 GI:29414822  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 4613 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1206 GAAGAGGCTGTGGCC 1221  
 Db 17 GAGAGAGCTGTGGCC 2

RESULT 532  
 AX691882/c 17 bp DNA linear PAT 31-MAR-2003  
 LOCUS  
 DEFINITION Sequence 4614 from Patent EP1281758.  
 ACCESSION AX691882  
 VERSION AX691882.1 GI:29414823  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
 TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
 JOURNAL Patent: EP 1281758-A 4614 05-FEB-2003;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1206 GAAGAGGCTGTGGCC 1221  
 Db 16 GAGAGAGCTGTGGCC 1

RESULT 533  
 AX701413/c 17 bp DNA linear PAT 03-APR-2003  
 LOCUS  
 DEFINITION Sequence 17 from Patent WO0209095.  
 ACCESSION AX701413  
 VERSION AX701413.1 GI:29537062  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 artificial sequences.  
 REFERENCE 1  
 AUTHORS Barry,A., Bretzel,W., Huemelin,M., Lopez-Ulbarri,R., Mayer,A.F. and Veliseev,A.  
 TITLE Improved isoprenoid production  
 JOURNAL Patent: WO 0209095-A 17 12-DEC-2002;  
 Roche Vitamins AG (CH)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="primer"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1308 TGGGCTGTAAAGCT 1323  
 Db 17 TGGGCTGTAAAGCT 2

RESULT 534  
AX710060 17 bp DNA linear PAT 10-APR-2003  
LOCUS  
DEFINITION Sequence 12 from Patent EP1288314.  
ACCESSION AX710060  
VERSION AX710060.1 GI:29786663  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE  
AUTHORS Eysen,D.J., Rasmussen,R.P., Caplin,B.E., Stevenson,W.R. and Desilva,D.M.  
TITLE Real-time gene quantification with internal standards  
JOURNAL Patent: EP 1288314-A 12 05-MAR-2003;  
The University of Utah Research Foundation (US) ; Idaho Technology, Inc. (US)  
FEATURES  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1936 GGTGAGCGACAGCAG 1951  
|||||  
1 GGTGAGCGCGACAGCAG 16

RESULT 535  
AX723750 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 1437 from Patent WO03025176.  
ACCESSION AX723750  
VERSION AX723750.1 GI:30503093  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 1437 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 582 GGTCTCTCTCTCTT 597  
|||||  
1 GATCTCTCTCTCTT 16

RESULT 536  
AX723821 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 1508 from Patent WO03025176.  
ACCESSION AX723821  
VERSION AX723821.1 GI:30503164  
KEYWORDS

SOURCE Mus musculus (house mouse)  
ORGANISM  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 1508 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2184 GCTCATGAGAAAAG 2199  
|||||  
1 GATCATGAGAAAAG 16

RESULT 537  
AX724325 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2012 from Patent WO03025176.  
ACCESSION AX724325  
VERSION AX724325.1 GI:30503668  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 2012 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 431 ATCGAGCGCACTGCC 446  
|||||  
2 ATCGAGCGCACTGCC 17

RESULT 538  
AX724370 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2057 from Patent WO03025176.  
ACCESSION AX724370  
VERSION AX724370.1 GI:30503713  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 2057 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

JOURNAL  
FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1731 GCACAGCGCGTGGCT 1746  
Db 17 GCACAGCGCGATGGAT 2

RESULT 539  
AX724543 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2230 from Patent WO03025176.  
ACCESSION AX724543  
VERSION AX724543.1 GI:30503886  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 2230 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 CGTGGTGCAGCGGATC 744  
Db 16 CGTAGGTGCAGGATC 1

RESULT 540  
AX724787 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2474 from Patent WO03025176.  
ACCESSION AX724787  
VERSION AX724787.1 GI:30504130  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 2474 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

FEATURES  
source

/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 GCTCATGAGAGAAAAG 2199  
Db 1 GATCATGAGAGAAAAG 16

RESULT 541  
AX725087 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2774 from Patent WO03025176.  
ACCESSION AX725087  
VERSION AX725087.1 GI:30504430  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 2774 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 956 TCATGCTGTGGGATC 971  
Db 16 TCATGCCCTGGAGATC 1

RESULT 542  
AX725274 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 2961 from Patent WO03025176.  
ACCESSION AX725274  
VERSION AX725274.1 GI:30504617  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025176-A 2961 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;



REFERENCE  
AUTHORS  
TITLE  
1  
Telerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 240 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1680 ACAGCTGCTGTGGAT 1695  
Db 17 ACAGCTCCTGTGGAT 2  
|||||  
|||||

RESULT 548  
AX728864/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 498 from Patent WO03025175.  
ACCESSION AX728864  
VERSION AX728864.1 GI:30508207  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 498 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 984 CATGTCACCTGATC 999  
Db 16 CAGGTTACCTGATC 1  
|||||  
|||||

RESULT 549  
AX728907/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 541 from Patent WO03025175.  
ACCESSION AX728907  
VERSION AX728907.1 GI:30508250  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL Patent: WO 03025175-A 541 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 822 GTTTTCCACAGAC 837  
Db 16 GTTTTCCACTGATC 1  
|||||  
|||||

RESULT 550  
AX731757/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 3391 from Patent WO03025175.  
ACCESSION AX731757  
VERSION AX731757.1 GI:30511100  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 3391 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

FEATURES  
source

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1406 AGAAGCTGTGGCTC 1421  
Db 16 AGAAGCTTGGATC 1  
|||||  
|||||

RESULT 551  
AX732158/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS  
DEFINITION Sequence 3792 from Patent WO03025175.  
ACCESSION AX732158  
VERSION AX732158.1 GI:30511501  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
1  
Telerman, A., Amson, R. and Tuijinder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
Patent: WO 03025175-A 3792 27-MAR-2003;  
JOURNAL  
Molecular Engines Laboratories (FR)  
LOCATION/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

FEATURES  
source



```
Query Match      0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1989 ACTTATCTGATGAT 2004
      |||||
      17 ACATATCCTGATGAT 2

RESULT 552
AX732941      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
TITLE
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 4575 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

JOURNAL
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2095 ATCACCAGCAGCTCA 2110
      |||||
      17 bp      DNA      linear      PAT 08-MAY-2003

RESULT 553
AX733047      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
TITLE
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 4681 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

JOURNAL
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2095 ATCACCAGCAGCTCA 2110
      |||||
      17 bp      DNA      linear      PAT 08-MAY-2003

RESULT 554
AX733291      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS
TITLE
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 4925 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

JOURNAL
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2002 GATGCCACGAGTCCC 2017
      |||||
      17 bp      DNA      linear      PAT 08-MAY-2003

RESULT 556
AX734653      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS
DEFINITION
Sequence 243 from Patent WO03025177.
```

ACCESSION AX734653  
VERSION AX734653.1 GI:30513930  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 243 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No.3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1178 AGCTGCAGGAATATA 1193  
Db 2 ATCTGAAGAATAATA 17  
RESULT 557  
AX734659 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX734659  
DEFINITION Sequence 249 from Patent WO03025177.  
ACCESSION AX734659  
VERSION AX734659.1 GI:30513936  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 249 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No.3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 905 ATCTGACTTATTTCT 920  
Db 2 ATCTGACTTATTTT 17  
RESULT 558  
AX736797 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX736797  
DEFINITION Sequence 2387 from Patent WO03025177.  
ACCESSION AX736797  
VERSION AX736797.1 GI:30516085  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 2387 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No.3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 850 ATCATGCTCTGGGTA 865  
Db 2 ATCCTGCTCGGGAA 17  
RESULT 559  
AX739468/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX739468  
DEFINITION Sequence 5058 from Patent WO03025177.  
ACCESSION AX739468  
VERSION AX739468.1 GI:30518765  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5058 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No.3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1680 ACAAGCTGCTGTGGAT 1695  
Db 17 ACAAGCTGCTGTGGAT 2  
RESULT 560  
AX739703 17 bp DNA linear PAT 08-MAY-2003  
LOCUS AX739703  
DEFINITION Sequence 5293 from Patent WO03025177.  
ACCESSION AX739703  
VERSION AX739703.1 GI:30519000  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 5293 27-MAR-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2224 GCTCTGCAAGTCTC 2239  
|||||  
1 GATCCTGACGCTCTC 16

RESULT 561  
AX744302 17 bp DNA linear PAT 14-MAY-2003  
LOCUS  
DEFINITION Sequence 267 from Patent WO03031621.  
ACCESSION AX744302  
VERSION AX744302.1 GI:30722969  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 267 17-APR-2003;  
Amerham BioSciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1623 GTCGGAGAGACACA 1638  
|||||  
2 GTCGGAGAGATACA 17

RESULT 562  
AX744303 17 bp DNA linear PAT 14-MAY-2003  
LOCUS  
DEFINITION Sequence 268 from Patent WO03031621.  
ACCESSION AX744303  
VERSION AX744303.1 GI:30722970  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 268 17-APR-2003;  
Amerham BioSciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1623 GTCGGAGAGACACA 1638

Db  
1 GTCGGAGAGATACA 16  
|||||  
1 GTCGGAGAGATACA 16

RESULT 563  
AX745332/c 17 bp DNA linear PAT 14-MAY-2003  
LOCUS  
DEFINITION Sequence 1297 from Patent WO03031621.  
ACCESSION AX745332  
VERSION AX745332.1 GI:30723999  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE A human G protein coupled receptor  
JOURNAL Patent: WO 03031621-A 1297 17-APR-2003;  
Amerham BioSciences (SV) Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 859 CCGGTACAGAGACA 874  
|||||  
16 CAGGTACAGAGAAA 1

RESULT 564  
AX753782 17 bp DNA linear PAT 23-JUN-2003  
LOCUS  
DEFINITION Sequence 129 from Patent WO03037931.  
ACCESSION AX753782  
VERSION AX753782.1 GI:32166479  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1  
AUTHORS Shannon, M. and Phan, T.  
TITLE Human angiotensin-like protein 1  
JOURNAL Patent: WO 03037931-A 129 08-MAY-2003;  
Amerham BioSciences SV Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 ACGAGAGGCGAAGC 1160  
|||||  
2 ACGAGAGGCCAAGC 17

RESULT 565  
AX753783 17 bp DNA linear PAT 23-JUN-2003  
LOCUS  
DEFINITION Sequence 130 from Patent WO03037931.  
ACCESSION AX753783  
VERSION AX753783.1 GI:32166480  
KEYWORDS

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Shannon,M. and Phan,T.  
TITLE Human angiomotin-like protein 1  
JOURNML Patent: WO 03037931-A 130 08-MAY-2003;  
Amersham Biosciences SV Corp. (US)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1145 ACGAGAGGCGCAAGC 1160  
Db 1 ACGAGAGGCGCAAGC 16  
|||||  
|||||

RESULT 566  
AX756714/c 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 35 from Patent WO03040369.  
ACCESSION AX756714  
VERSION AX756714.1 GI:32251268  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNML Patent: WO 03040369-A 35 15-MAY-2003;  
Molecular Engines Laboratories (FR)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 651 AGATGCTCAGCGAT 666  
Db 17 AGAAGCACAGCCGAT 2  
|||||  
|||||

RESULT 567  
AX757942 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 1263 from Patent WO03040369.  
ACCESSION AX757942  
VERSION AX757942.1 GI:32252558  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines

JOURNML Patent: WO 03040369-A 1263 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 703 ACCATAGCCAGTGCAG 718  
Db 2 ATCATACAGTGCAG 17  
|||||  
|||||

RESULT 568  
AX758903/c 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 2224 from Patent WO03040369.  
ACCESSION AX758903  
VERSION AX758903.1 GI:32253519  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNML Patent: WO 03040369-A 2224 15-MAY-2003;  
Molecular Engines Laboratories (FR)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2188 ATGAGAGAAAAGGGGT 2203  
Db 17 ATGTAGAAAAGGGAT 2  
|||||  
|||||

RESULT 569  
AX759607/c 17 bp DNA linear PAT 25-JUN-2003  
LOCUS  
DEFINITION Sequence 2928 from Patent WO03040369.  
ACCESSION AX759607  
VERSION AX759607.1 GI:32254223  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNML Patent: WO 03040369-A 2928 15-MAY-2003;  
Molecular Engines Laboratories (FR)  
FEATURES location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"



ACCESSION AX761929  
VERSION AX761929.1 GI:32256545  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.  
TITLE Sequences involved in tumoral suppression, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 5250 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 GCTGCGGCTGCTGCT 397  
Db 2 ATCAGGCCACTGCTGCT 17

RESULT 575  
AX781766/c 17 bp DNA linear PAT 17-JUL-2003  
LOCUS AX781766  
DEFINITION Sequence 97 from Patent WO03050284.  
ACCESSION AX781766  
VERSION AX781766.1 GI:32949600  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Guo, J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 97 19-JUN-2003;  
FEATURES Amerisham Biosciences (SV) Corp. (US)  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 GCTGCGGCTGCTGCT 313  
Db 17 GCTGCGGAACTTGCT 2

RESULT 576  
AX781767/c 17 bp DNA linear PAT 17-JUL-2003  
LOCUS AX781767  
DEFINITION Sequence 98 from Patent WO03050284.  
ACCESSION AX781767  
VERSION AX781767.1 GI:32949601  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Guo, J.

TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 98 19-JUN-2003;  
FEATURES Amerisham Biosciences (SV) Corp. (US)  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 GCTGCGGCTGCTGCT 313  
Db 16 GCTGCGGAACTTGCT 1

RESULT 577  
AX782300/c 17 bp DNA linear PAT 17-JUL-2003  
LOCUS AX782300  
DEFINITION Sequence 631 from Patent WO03050284.  
ACCESSION AX782300  
VERSION AX782300.1 GI:32950149  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Guo, J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 631 19-JUN-2003;  
FEATURES Amerisham Biosciences (SV) Corp. (US)  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1605 GCTGCGGAACTTGCT 1620  
Db 17 GCTGATGGAGCCCACT 2

RESULT 578  
AX782301/c 17 bp DNA linear PAT 17-JUL-2003  
LOCUS AX782301  
DEFINITION Sequence 632 from Patent WO03050284.  
ACCESSION AX782301  
VERSION AX782301.1 GI:32950150  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Guo, J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 632 19-JUN-2003;  
FEATURES Amerisham Biosciences (SV) Corp. (US)  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1605 GCTGTGGGACCAAT 1620  
 |||||  
 Db 16 GCTGATGGGACCAAT 1

RESULT 579  
 AX783936 17 bp DNA linear PAT 17-JUN-2003  
 LOCUS Sequence 2267 from Patent WO03050284.  
 DEFINITION AX783936  
 ACCESSION AX783936  
 VERSION AX783936.1 GI:32951785  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
 AUTHORS Guo,J.  
 TITLE Human prostate cancer candidate protein 1  
 JOURNAL Patent: WO 03050284-A 2267 19-JUN-2003;  
 Amerisham Biosciences (SV) Corp. (US)  
 FEATURES  
 source 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1635 CACAGTGGCTGCCCTG 1650  
 |||||  
 Db 1 CACAGTGTCTGCCCG 16

RESULT 580  
 AX816806 17 bp DNA linear PAT 09-DEC-2003  
 LOCUS Sequence 97 from Patent WO03014390.  
 DEFINITION AX816806  
 ACCESSION AX816806  
 VERSION AX816806.1 GI:39647135  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
 AUTHORS Sampson,J.R. and Cheadle,J.P.  
 TITLE Screening methods and sequences relating thereto  
 JOURNAL Patent: WO 03014390-A 97 20-FEB-2003;  
 University of Wales College of Medicine (GB)  
 FEATURES  
 source 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1704 CCTTCCCCCATATGAG 1719  
 |||||  
 Db 1 CCTTCCCCCATATGAG 16

RESULT 581  
 BD067894 17 bp RNA linear PAT 27-AUG-2002  
 LOCUS BD067894  
 DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related

ACCESSION BD067894  
 VERSION BD067894.1 GI:22613497  
 KEYWORDS JP 2001511003-A/734.  
 SOURCE unidentified  
 ORGANISM unidentified  
 unclassified.

REFERENCE  
 AUTHORS Akhtar,S., Fell,P. and Mcawigen,J.A.  
 TITLE Enzymatic nucleic acid treatment of diseases or conditions related  
 JOURNAL to levels of epidermal growth factor receptors  
 Patent: JP 2001511003-A 734 07-AUG-2001;  
 RIBOZYME PHARMACEUTICALS INC,ASTON UNIV  
 OS Unidentified  
 PN JP 2001511003-A/734

COMMENT  
 PD 07-AUG-2001  
 PF 14-JAN-1998 JP 1998532913  
 PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI  
 SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC  
 C12N9/00,C07K14/71  
 CC Strandedness: Single;  
 CC Topology: linear;  
 CC Enzymatic nucleic acid treatment of diseases or conditions CC  
 related to  
 CC levels of epidermal growth factor receptors  
 FH Key Location/Qualifiers  
 FT source 1. .17  
 /organism="Unidentified".  
 /db\_xref="taxon:32644"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1425 AGAGAAATTAATTGAG 1440  
 |||||  
 Db 17 AGAGAAATTAATTGAG 2

RESULT 582  
 BD104823 17 bp DNA linear PAT 27-AUG-2002  
 LOCUS BD104823  
 DEFINITION Kit and method for determining HLA type.  
 ACCESSION BD104823  
 VERSION BD104823.1 GI:22650397  
 KEYWORDS WO 0192572-A/927.  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 artificial sequences.

REFERENCE  
 AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsuura,Y., Moriya,S. and  
 Nishida,M.  
 TITLE Kit and method for determining HLA type  
 JOURNAL Patent: WO 0192572-A 927 06-DEC-2001;  
 NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO  
 KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO  
 NISHIDA  
 OS Artificial Sequence  
 PN WO 0192572-A/927

COMMENT  
 PD 06-DEC-2001  
 PF 01-JUN-2001 WO 2001JP004662  
 PR 01-JUN-2000 JP 00P 164798  
 PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI  
 MATSUMURA,  
 PI SHOGO MORIYA,MICHIO NISHIDA  
 PC C12N01/68,C12M1/00,C12N15/09,G01N31/53  
 CC Description of Artificial Sequence:capture  
 FH Key Location/Qualifiers  
 FT source 1. .17

FEATURES FT /organism='Artificial Sequence',  
source 1. .17  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1911 CGAGCTCGAGCCAG 1926  
Db 1 CGAGCGCGAGCCAG 16

RESULT 583  
BD105166  
LOCUS BD105166 17 bp DNA linear PAT 27-AUG-2002  
DEFINITION Kit and method for determining HLA type.  
ACCESSION BD105166.1 GI:22650740  
VERSION WO 0192572-A/1270.  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.  
TITLE Kit and method for determining HLA type  
JOURNAL Patent: WO 0192572-A 1270 06-DEC-2001;  
NISHINO INDUSTRIES INC, SYSTEM RESEARCH INC, HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO NISHIDA

COMMENT OS Artificial Sequence  
PN WO 0192572-A/1270  
PD 06-DEC-2001  
PF 01-JUN-2001 WO 2001JP004662  
PR 01-JUN-2000 JP 00P 164798  
PI HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA,

FEATURES PI SHOGO MORIYA, MICHIO NISHIDA  
PC C1201/68, C12M1/00, C12N15/09, G01N33/53  
CC Description of Artificial Sequence: capture  
FH Key Location/Qualifiers  
FT source 1. .17  
/organism='Artificial Sequence'.  
FT Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 491 GCGGTACGAGCGGCTC 506  
Db 2 GCGGACAGCGGCTC 17

RESULT 584  
BD202752/c  
LOCUS BD202752 17 bp RNA linear PAT 17-JUN-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD202752.1 GI:33012522  
VERSION JP 2002509721-A/5778.  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens (human)  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.  
1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 5778 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Homo sapiens (human)  
PN JP 2002509721-A/5778  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,  
PI JAMES A MCSWIGEN

FEATURES C12N15/09, A61K31/7088, A61K31/7125, A61K48/00, A61P3/10, A61P17/06, PC  
A61P29/00,  
PC A61P35/00, A61P43/00, C12N5/10, C12N9/00/ A61K35/76, C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions  
CC concerning molecule  
CC participating in vasculogenic response

FEATURES source 1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 541 GCGTCGAGACGGCC 556  
Db 17 GCGTCAGAGTGGCC 2

RESULT 585  
BD202753/c  
LOCUS BD202753 17 bp RNA linear PAT 17-JUN-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD202753.1 GI:33012523  
VERSION JP 2002509721-A/5779.  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswigen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 5779 02-APR-2002;  
RIBOZYME PHARMACEUTICALS INC

COMMENT OS Homo sapiens (human)  
PN JP 2002509721-A/5779  
PD 02-APR-2002  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,  
PI JAMES A MCSWIGEN

FEATURES C12N15/09, A61K31/7088, A61K31/7125, A61K48/00, A61P3/10, A61P17/06, PC  
A61P29/00,  
PC A61P35/00, A61P43/00, C12N5/10, C12N9/00/ A61K35/76, C12N15/00, PC  
C12N5/00  
CC Method and reagent for treating diseases or conditions  
CC concerning molecule  
CC participating in vasculogenic response



```

FEATURES
  source
    FH Key
    FT source
    FT 1.17
    Location/Qualifiers
    1.17
    /organism="Homo sapiens (human)"
    /mol_type="genomic RNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 540 GGGCTCGAGACGCGC 555
Db 16 GGGCTCAGACATGCGC 1

RESULT 586
BD202918
LOCUS
DEFINITION
  BD202918 17 bp RNA linear PAT 17-JUL-2003
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response.
ACCESSION
  BD202918
VERSION
  BD202918.1 GI:33012688
KEYWORDS
  JP 2002509721-A/5944.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1 (bases 1 to 17)
  Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response
  Patent: JP 2002509721-A 5944 02-APR-2002;
JOURNAL
  RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/5944
PD 02-APR-2002
PR 24-MAR-1999 JP 2000541291
PT 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N5/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key
FT source
FT 1.17
Location/Qualifiers
1.17
/organism="Homo sapiens (human)"
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

FEATURES
  source
    1.17
    /organism="Homo sapiens"
    /mol_type="genomic RNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1108 GCTCTGTCGCGCATGC 1123
Db 2 GCTCTGTCGCGCCAGGC 17

RESULT 587
BD203057
LOCUS
DEFINITION
  BD203057 17 bp RNA linear PAT 17-JUL-2003
  Method and reagent for treating diseases or conditions concerning

```

```

  molecule participating in vasculogenic response.
ACCESSION
  BD203057
VERSION
  BD203057.1 GI:33012827
KEYWORDS
  JP 2002509721-A/6083.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
  1 (bases 1 to 17)
  Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  Method and reagent for treating diseases or conditions concerning
  molecule participating in vasculogenic response
  Patent: JP 2002509721-A 6083 02-APR-2002;
JOURNAL
  RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/6083
PD 02-APR-2002
PR 24-MAR-1999 JP 2000541291
PT 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N5/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key
FT source
FT 1.17
Location/Qualifiers
1.17
/organism="Homo sapiens (human)"
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

FEATURES
  source
    1.17
    /organism="Homo sapiens"
    /mol_type="genomic RNA"
    /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 992 CCCGATCACCCTGCC 1007
Db 2 CCGTATCAGCTGCC 17

RESULT 588
BD226467
LOCUS
DEFINITION
  BD226467 17 bp DNA linear PAT 17-JUL-2003
  Method and probes for the detection of chromosome aberrations.
ACCESSION
  BD226467
VERSION
  BD226467.1 GI:33036237
KEYWORDS
  JP 2002513587-A/13.
SOURCE
  synthetic construct
  artificial sequences.
ORGANISM
  artificial sequences.
REFERENCE
  1 (bases 1 to 17)
  Dongen,J.J.M.V., Pluzek,K.J., Nielsen,K.V. and Adelhorst,K.
  Method and probes for the detection of chromosome aberrations
  Patent: JP 2002513587-A 13 14-MAY-2002;
JOURNAL
  DAKO AS
OS Artificial Sequence
PN JP 2002513587-A/13
PD 14-MAY-2002
PR 04-MAY-1999 JP 2000547260
PT 04-MAY-1998 DK 0615/98
PI JACOBS JOHANNES MARIA VAN DONEN,KARL JOHAN PLUZEK,KIRSTEN PI
PI VANG NIELSEN
PI KIM ADELHORST
PC
C12N15/09,C07H21/00,C12Q1/68,G01N33/53,G01N33/566,C12N15/00 CC
Description of Artificial Sequence:PNA probe, mbr, exon CC 4,
position 589-573

```

FEATURES

source	key	Location/Qualifiers
FT	source	1..17
FT		/organism="Artificial Sequence".
		Location/Qualifiers
		1..17
		/organism="synthetic Construct"
		/mol_type="genomic DNA"
		/db_xref="taxon:32630"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1494 CTTGAGGGGCTTGTG 1509  
||| ||||| |||||  
1 CTTGAGGGGCTTGTG 16

RESULT 589  
AJ587490 17 bp DNA linear PLN 23-OCT-2003  
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone  
DEFINITION 283G09.

ACCESSION AJ587490  
VERSION AJ587490.1 GI:37937114  
KEYWORDS left border, T-DNA flanking sequence.  
SOURCE Arabidopsis thaliana (chale cress)  
ORGANISM Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1  
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,  
Chauvin, S., Bechtold, N., Cruaud, C., Derose, R., Pelletier, G.,  
Lepiniec, L., Cabocho, M. and Lecharny, A.  
T-DNA integration into the Arabidopsis genome depends on sequences  
of pre-insertion sites  
EMBO Rep. 3 (12), 1152-1157 (2002)

JOURNAL MEDLINE  
22363535  
PUBMED 12446565  
REFERENCE 2 (bases 1 to 17)

AUTHORS Balzerque, S.  
TITLE Direct Submission  
SUBMITTED (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue  
Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana  
plants from INRA (Versailles). The DNA fragment(s) resulting from  
the PCR were directly sequenced from the left or the right border  
to determine the genomic sequence flanking the insertion. T-DNA  
derived sequences were removed. Information to order the  
corresponding mutant line and a link to a database providing a  
graphical display of the insertion site are available at  
<http://dbgap.versailles.inra.fr/publicines/>. This sequence has  
been generated in the framework of the French plant genomics  
program 'Genoplante' (<http://www.genoplante.com> and  
<http://genoplante-info.infobio.gen.fr>).

FEATURES

source	Location/Qualifiers
	1..17
	/organism="Arabidopsis thaliana"
	/mol_type="genomic DNA"
	/cultivar="wassiljewskij4"
	/db_xref="taxon:3702"
	/clone="283G09"
	/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
	1..17
	/note="T-DNA flanking sequence
	left border"

misc\_feature  
1..17  
/note="T-DNA flanking sequence  
left border"

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 61 GCATGGCTGGGACAG 76

Db 1 GCATGGCGCGACAG 16  
||||| | |||||

Search completed: June 30, 2004, 08:30:39  
Job time : 16 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:41:08 ; Search time 10 Seconds  
(without alignments)  
2.874 Million cell updates/sec

Title: US-10-024-369-3  
Perfect score: 2247  
Sequence: 1 atgcagctcctagctgctc.....ctgcagatgctccagatga 2247

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 374 seqs, 6395 residues

Total number of hits satisfying chosen parameters: 748

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 377 summaries

Database : rn13.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	27	1.2	27	US-08-700-035A-4	Sequence 4, Appl1
2	27	1.2	27	US-08-700-035A-5	Sequence 5, Appl1
3	27	1.2	27	PCT-US96-13457-4	Sequence 4, Appl1
4	27	1.2	27	PCT-US96-13457-5	Sequence 5, Appl1
5	24	1.1	24	US-09-061-764A-20	Sequence 20, Appl1
6	17.2	0.8	22	US-08-276-567A-1	Sequence 1, Appl1
7	17.2	0.8	22	PCT-US95-09011-1	Sequence 1, Appl1
8	16.8	0.7	21	US-09-517-467B-55	Sequence 55, Appl1
9	16.2	0.7	21	US-08-596-319-12	Sequence 12, Appl1
10	15.8	0.7	19	US-08-299-074A-40	Sequence 40, Appl1
11	15.8	0.7	19	US-09-399-773-40	Sequence 40, Appl1
12	15.8	0.7	20	US-08-276-567A-2	Sequence 2, Appl1
13	15.8	0.7	20	US-09-657-452A-33	Sequence 33, Appl1
14	15.8	0.7	20	US-09-679-299A-159	Sequence 159, Appl1
15	15.8	0.7	20	US-09-596-248D-36	Sequence 36, Appl1
16	15.8	0.7	20	US-09-596-248D-37	Sequence 37, Appl1
17	15.8	0.7	20	PCT-US95-09011-2	Sequence 2, Appl1
18	15.4	0.7	17	US-09-866-108A-891	Sequence 891, Appl1
19	15.4	0.7	17	US-09-866-108A-892	Sequence 892, Appl1
20	15.4	0.7	17	US-09-866-108A-893	Sequence 893, Appl1
21	15.4	0.7	18	US-08-800-751-23	Sequence 23, Appl1
22	15.4	0.7	18	US-08-990-818-33	Sequence 33, Appl1
23	15.4	0.7	18	US-08-679-645-609	Sequence 609, Appl1
24	15.4	0.7	18	US-09-508-654-1	Sequence 1, Appl1
25	15.2	0.7	20	US-08-388-381-22	Sequence 22, Appl1
26	15.2	0.7	20	US-08-276-567A-3	Sequence 3, Appl1
27	15.2	0.7	20	US-08-276-567A-4	Sequence 4, Appl1
28	15.2	0.7	20	US-08-910-629A-57	Sequence 57, Appl1
29	15.2	0.7	20	US-08-469-461-17	Sequence 17, Appl1
30	15.2	0.7	20	US-07-890-609-17	Sequence 17, Appl1
31	15.2	0.7	20	US-08-765-626-22	Sequence 22, Appl1
32	15.2	0.7	20	US-09-287-796-57	Sequence 57, Appl1
33	15.2	0.7	20	US-09-280-805-8	Sequence 8, Appl1
34	15.2	0.7	20	US-09-130-616-57	Sequence 57, Appl1
35	15.2	0.7	20	US-09-048-810-8	Sequence 8, Appl1
36	15.2	0.7	20	US-09-851-062-32	Sequence 32, Appl1
37	15.2	0.7	20	US-09-706-197-47	Sequence 47, Appl1
38	15.2	0.7	20	US-09-422-978-8790	Sequence 8790, Appl1
39	15.2	0.7	20	US-09-422-978-8838	Sequence 8838, Appl1
40	15.2	0.7	20	US-09-198-452A-3216	Sequence 3216, Appl1
41	15.2	0.7	20	US-09-198-452A-3350	Sequence 3350, Appl1
42	15.2	0.7	20	US-09-198-452A-4873	Sequence 4873, Appl1
43	15.2	0.7	20	US-09-572-891-8	Sequence 8, Appl1
44	15.2	0.7	20	PCT-US95-08605-22	Sequence 22, Appl1
45	15.2	0.7	20	PCT-US95-09011-3	Sequence 3, Appl1
46	15.2	0.7	20	PCT-US95-09011-4	Sequence 4, Appl1
47	15	0.7	20	US-09-488-671-108	Sequence 108, Appl1
48	14.8	0.7	18	US-09-513-783A-39	Sequence 39, Appl1
49	14.8	0.7	19	US-08-860-882A-52	Sequence 52, Appl1
50	14.8	0.7	19	US-08-860-882A-52	Sequence 52, Appl1
51	14.8	0.7	19	US-09-111-945-110	Sequence 110, Appl1
52	14.8	0.7	19	US-09-011-769A-34	Sequence 34, Appl1
53	14.4	0.6	16	US-09-548-797B-94	Sequence 94, Appl1
54	14.4	0.6	17	5164485-15	Patent No. 5164485
55	14.4	0.6	17	US-07-977-630-6	Sequence 6, Appl1
56	14.4	0.6	17	US-08-109-391A-10	Sequence 10, Appl1
57	14.4	0.6	17	US-08-459-019A-10	Sequence 10, Appl1
58	14.4	0.6	17	US-08-460-428A-10	Sequence 10, Appl1
59	14.4	0.6	17	US-08-458-860A-10	Sequence 10, Appl1
60	14.4	0.6	17	US-08-679-645-139	Sequence 139, Appl1
61	14.4	0.6	17	US-09-866-108A-890	Sequence 890, Appl1
62	14.4	0.6	17	US-09-866-108A-894	Sequence 894, Appl1
63	14.4	0.6	17	US-09-866-108A-895	Sequence 895, Appl1
64	14.4	0.6	19	US-09-866-108A-8006	Sequence 8006, Appl1
65	14.4	0.6	14	US-09-565-808-17	Sequence 17, Appl1
66	14	0.6	16	US-08-862-337-12	Sequence 12, Appl1
67	14	0.6	17	US-09-829-855-101	Sequence 101, Appl1
68	14	0.6	17	US-08-152-313-113	Sequence 113, Appl1
69	14	0.6	17	US-08-579-223-113	Sequence 113, Appl1
70	14	0.6	17	US-09-866-108A-895	Sequence 895, Appl1
71	14	0.6	17	US-09-866-108A-896	Sequence 896, Appl1
72	14	0.6	18	PCT-US94-12947A-113	Sequence 113, Appl1
73	14	0.6	18	US-09-156-424-42	Sequence 42, Appl1
74	14	0.6	18	US-09-638-509C-5	Sequence 5, Appl1
75	14	0.6	18	US-09-387-341-56	Sequence 56, Appl1
76	13.8	0.6	17	US-09-474-432B-730	Sequence 730, Appl1
77	13.8	0.6	17	US-09-474-432B-720	Sequence 720, Appl1
78	13.8	0.6	17	US-09-371-772B-4198	Sequence 4198, Appl1
79	13.8	0.6	17	US-09-476-387-629	Sequence 629, Appl1
80	13.8	0.6	17	US-09-476-387-719	Sequence 719, Appl1
81	13.8	0.6	17	US-09-866-108A-515	Sequence 515, Appl1
82	13.8	0.6	17	US-09-866-108A-665	Sequence 665, Appl1
83	13.8	0.6	17	US-09-866-108A-1530	Sequence 1530, Appl1
84	13.8	0.6	17	US-09-866-108A-1572	Sequence 1572, Appl1
85	13.8	0.6	17	US-09-866-108A-1960	Sequence 1960, Appl1
86	13.8	0.6	17	US-09-866-108A-2739	Sequence 2739, Appl1
87	13.8	0.6	17	US-09-866-108A-6521	Sequence 6521, Appl1
88	13.8	0.6	17	US-09-866-108A-6522	Sequence 6522, Appl1
89	13.8	0.6	17	US-09-866-108A-6525	Sequence 6525, Appl1
90	13.8	0.6	17	US-09-866-108A-6526	Sequence 6526, Appl1
91	13.8	0.6	17	US-09-866-108A-6528	Sequence 6528, Appl1
92	13.8	0.6	17	US-09-866-108A-8057	Sequence 8057, Appl1
93	13.8	0.6	17	US-09-866-108A-8057	Sequence 8057, Appl1
94	13.8	0.6	17	US-09-866-108A-9583	Sequence 9583, Appl1
95	13.8	0.6	18	US-08-483-122-7	Sequence 7, Appl1
96	13.8	0.6	18	US-08-483-122-8	Sequence 8, Appl1
97	13.8	0.6	18	US-08-486-648-7	Sequence 7, Appl1
98	13.8	0.6	18	US-08-486-648-8	Sequence 8, Appl1
99	13.8	0.6	18	US-08-627-254C-9	Sequence 9, Appl1
100	13.8	0.6	18	US-08-442-809A-57	Sequence 57, Appl1
101	13.8	0.6	18	US-08-442-809A-59	Sequence 59, Appl1
102	13.8	0.6	18	US-08-486-307-7	Sequence 7, Appl1
103	13.8	0.6	18	US-08-486-307-8	Sequence 8, Appl1
104	13.8	0.6	18	US-08-857-946-23	Sequence 23, Appl1
105	13.8	0.6	18	US-09-205-921-35	Sequence 35, Appl1
106	13.8	0.6	18	US-08-970-740-23	Sequence 23, Appl1





```
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,035A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-700-035A-4
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1192 AAGACTCAACAGAGAGGCTGTG 1218
Db 27 AAGACTCAACAGAGAGGCTGTG 1
```

```
RESULT 2
US-08-700-035A-5/c
; Sequence 5, Application US/08700035A
; Patent No. 5831068
; GENERAL INFORMATION:
; APPLICANT: Nait, et al., Smita K.
; TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
; TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/700,035A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
```

```
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-700-035A-5
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1978 AACCGTGCTACTATCTCGATGAT 2004
Db 27 AACCGTGCTACTATCTCGATGAT 1
```

```
RESULT 3
PCT-US96-13457-4/c
; Sequence 4, Application PC/TUS9613457
; GENERAL INFORMATION:
; APPLICANT: Duke University
; TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
; TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13457
; FILING DATE: 20-AUG-1996
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/517,373
; FILING DATE: 21-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 06765/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US96-13457-4
```

```
Query Match 1.2%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.3;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1192 AAGACTCAACAGAGAGGCTGTG 1218
Db 27 AAGACTCAACAGAGAGGCTGTG 1
```

```
RESULT 4
PCT-US96-13457-5/c
; Sequence 5, Application PC/TUS9613457
; GENERAL INFORMATION:
```

APPLICANT: Duke University  
TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF  
NUMBER OF SEQUENCES: 16  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: USA  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/13457  
FILING DATE: 20-AUG-1996  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/517,373  
FILING DATE: 21-AUG-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Clark, Paul T.  
REGISTRATION NUMBER: 30,162  
REFERENCE/DOCKET NUMBER: 06765/009W01  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617/542-5070  
TELEFAX: 617/542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
PCT-US96-13457-5

Query Match 1.2%; Score 27; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 0.3;  
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1978 AACCGTGTACTTATCTGGATGAT 2004  
Db 27 AACCGTGTACTTATCTGGATGAT 1

RESULT 5  
US-09-061-764A-20  
Sequence 20, Application US/09061764A  
Patent No. 6284879  
GENERAL INFORMATION:  
APPLICANT: Faubus, Denise L  
TITLE OF INVENTION: TRANSPORT ASSOCIATED PROTEIN SPLICING VARIANTS  
NUMBER OF SEQUENCES: 23  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Yankwich & Associates  
STREET: 130 Bishop Allen Drive  
CITY: Cambridge  
STATE: Massachusetts  
COUNTRY: United States of America  
ZIP: 02139  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44MB storage  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: Windows 95  
SOFTWARE: Microsoft Word 97 SR-1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/061.764A  
FILING DATE: April 16, 1998  
CLASSIFICATION: 424

PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Yankwich, Leon R  
REGISTRATION NUMBER: 30,237  
REFERENCE/DOCKET NUMBER: MGH-002.0 US/MGH-1247.0  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-491-4343  
TELEFAX: 617-491-8801  
INFORMATION FOR SEQ ID NO: 20:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 24 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: synthetic DNA fragment  
US-09-061-764A-20

Query Match 1.1%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 1.2;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1866 TAGTTTCATCTCTGACTCCCTCA 1889  
Db 1 TAGTTTCATCTCTGACTCCCTCA 24

RESULT 6  
US-08-276-567A-1/c  
Sequence 1, Application US/08276567A  
Patent No. 5866699  
GENERAL INFORMATION:  
APPLICANT: Adrienne Smyth  
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Lippin & Kuemer  
STREET: 200 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/276,567A  
FILING DATE:  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Kerner, Ann-Louise  
REGISTRATION NUMBER: 33,523  
REFERENCE/DOCKET NUMBER: HYZ-022  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-330-1300  
TELEFAX: 617-330-1311  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 22 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHEICAL: NO  
ANTI-SENSE: YES  
US-08-276-567A-1

Query Match 0.8%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%; Pred. No. 30;

Matches	19; Conservative	0; Mismatches	3; Indels	0; Gaps
Qy	1617	CAATGGCTCTGGGAAGACACA	1638	
Db	22	CAGTGGCTGTGGGAAGACACA	1	

```

RESULT 7
PCT-US95-09011-1/c
: Sequence 1, Application PC/TUS9509011
: GENERAL INFORMATION:
: APPLICANT: Hybridon, Inc.
: TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
: FILE OF INVENTION: Gene Activity
: NUMBER OF SEQUENCES: 9
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lappin & Kusmer
: STREET: 200 State Street
: CITY: Boston
: STATE: Massachusetts
: COUNTRY: USA
: ZIP: 02109
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: PCT/US95/09011
: FILING DATE:
: CLASSIFICATION:
: ATTORNEY/AGENT INFORMATION:
: NAME: Kerner, Ann-Louise
: REGISTRATION NUMBER: 33,523
: REFERENCE/DOCKET NUMBER: HYZ-022PCT
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 617-330-1300
: TELEFAX: 617-330-1311
: INFORMATION FOR SEQ ID NO: 1:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 22 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: HYPOTHETICAL: NO
: ANTI-SENSE: YES
:
PCT-US95-09011-1

```

Query Match 0.8%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 86.4%;  
Pred. No. 30;  
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0.

```

US-09-517-467B-55/C
: RESULT 8
: Sequence 55, Application US/09517467B
: Patent No. 6451602
: GENERAL INFORMATION:
: APPLICANT: Ian Popoff
: APPLICANT: Lex M. Cowert
: TITLE OR INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
: FILE REFERENCE: RTS 0150
: CURRENT APPLICATION NUMBER: US/09/517,467B
: CURRENT FILING DATE: 2001-03-02
: PRIOR APPLICATION NUMBER: 09/517,467
: PRIOR FILING DATE: 2000-03-02
: NUMBER OF SEQ ID NOS: 345
: SEQ ID NO 55

```

```

; LENGTH: 20
;
; TYPE: DNA
;
; ORGANISM: Artificial Sequence
;
; FEATURE:
;
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-55

```

Query Match	0.7%	Score 16.8;	DB 1;	Length 20;
Best Local Similarity	90.0%	Pred. No. 33;		
Matches 18;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;

```

US-08-596-119-12
: Result 9
: Sequence 12, Application US/08596319
: Patent No. 5981262
: GENERAL INFORMATION:
: APPLICANT: Brugge, Joan
: APPLICANT: Morgenstern, Jay
: APPLICANT: Shue, Lily
: APPLICANT: Zydowsky, Lynne
: APPLICANT: Zoller, Mark
: APPLICANT: Pawson, Anthony
: TITLE OF INVENTION: HUMAN Btk
: NUMBER OF SEQUENCES: 33
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: ARIAD Pharmaceuticals, Inc.
: STREET: 26 Landsdowne Street
: CITY: Cambridge
: STATE: MA
: COUNTRY: USA
: ZIP: 02139
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent In Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/596,319
: FILING DATE: 31-JAN-1996
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: WO US94/04540
: FILING DATE: 25-APR-1994
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/052,560
: FILING DATE: 23-APR-1993
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: BERSTEIN, David L.
: REGISTRATION NUMBER: 31,235
: REFERENCE/DOCKET NUMBER: ARIAD305A-PCT/US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (617) 494-0208
: TELEFAX: (617) 494-0208
: INFORMATION FOR SEQ ID NO: 12:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 21 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
:
US-08-596-319-12

```

Query Match	0.7%;	Score 16.2;	DB 1;	Length 21;
Best Local Similarity	85.7%;	Pred. No. 46;		
Matches 18; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;





```

; REFERENCE/DOCKET NUMBER: HYZ-022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-330-1300
; TELEFAX: 617-330-1311
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHEITICAL: NO
; ANTI-SENSE: YES
; US-08-276-567A-2

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1620 TGGGCTGGGAAGACACA 1638
Db      19   TGGCTGTGGAAAGACACA 1

RESULT 13
US-09-657-452A-33/c
; Sequence 33, Application US/09657452A
; Patent No. 6426188
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHORYLASE KINASE ALPHA 1 EXPRESSION
; FILE REFERENCE: RTS-0125
; CURRENT APPLICATION NUMBER: US/09/657,452A
; CURRENT FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-657-452A-33

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1676 GGGGACAGCTGCTGTGGA 1694
Db      19   GGGGACAGCTGCACTTGA 1

RESULT 14
US-09-679-299A-159/c
; Sequence 159, Application US/09679299A
; Patent No. 6566135
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 6 EXPRESSION
; FILE REFERENCE: RTS-0187
; CURRENT APPLICATION NUMBER: US/09/679,299A
; CURRENT FILING DATE: 2000-10-04
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-679-299A-159
```

```

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1885 CCTGAGGGCTATGACACAG 1903
Db      20   CCTGAGGGCTAGACACCG 2

RESULT 15
US-09-596-248D-36
; Sequence 36, Application US/09596248D
; Patent No. 6599727
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/09/596,248D
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-596-248D-36

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1193 AGACACTCAGCCAGAGGA 1211
Db      2   AGACACCCAGCCGAGAGGA 20

RESULT 16
US-09-596-248D-37/c
; Sequence 37, Application US/09596248D
; Patent No. 6599727
; GENERAL INFORMATION:
; APPLICANT: Christenson, Erik
; APPLICANT: Demaggio, Anthony J
; APPLICANT: Goldman, Phyllis S
; APPLICANT: McElligott, David L
; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and
; FILE REFERENCE: 27866/36544
; CURRENT APPLICATION NUMBER: US/09/596,248D
; CURRENT FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/139,543
; PRIOR FILING DATE: 1999-06-16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-596-248D-37

Query Match          0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 53;
```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1193 AGACACTCAACGAGAGGA 1211  
Db 19 AGACACCCACGAGAGGA 1

## RESULT 17

PCT-US95-09011-2/c  
Sequence 2, Application PC/TUS9509011  
GENERAL INFORMATION:  
APPLICANT: Hybridon, Inc.  
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lappin & Kusner  
STREET: 200 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US95/09011  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Kerner, Ann-Louise  
REGISTRATION NUMBER: 33,523  
REFERENCE/DOCKET NUMBER: HYZ-022PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-330-1300  
TELEFAX: 617-330-1311  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: YES  
PCT-US95-09011-2

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 53;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1620 TGCGCTCGGAGAGCACA 1638

Db 19 TGCGCTCGGAGAGCACA 1

## RESULT 18

US-09-866-108A-891/c  
Sequence 891, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 1575  
SOFTWARE: A60MICA Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 891  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-891

Query Match 0.7%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 55;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GCCCCTTCCCAATATG 1717

Db 17 GCCCCTTCCCAATATG 1

RESULT 19  
US-09-866-108A-892/c  
Sequence 892, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 892
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-892

Query Match      0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 55;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1700 AGCCCTTCCCATAT 1716
Db      17 AGCCCTTCCCATCT 1

RESULT 20
US-09-866-108A-893/c
; Sequence 893, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 893
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-893

Query Match      0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 55;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1699 AAGCCCTTCCCATATA 1715
```

```

Db      17 AAGCCCTTCCCATCTA 1

RESULT 21
US-08-800-751-23/c
; Sequence 23, Application US/08800751
; Patent No. 5807730
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,751
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 8-027004
; FILING DATE: 14-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Teekin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 028022-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
US-08-800-751-23

Query Match      0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2068 GAGCGTACTCCGCTC 2084
Db      17 GAGCGTACTCCGCTC 1

RESULT 22
US-08-990-918-23/c
; Sequence 23, Application US/08990818
; Patent No. 5910432
; GENERAL INFORMATION:
; APPLICANT: ITO, Kiyoshi
; APPLICANT: YAMAKI, Toshifumi
; APPLICANT: ARII, Teruo
; APPLICANT: TSURUOKA, Miyuki
; APPLICANT: NAKAMURA, Takeshi
; TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
; NUMBER OF SEQUENCES: 42
```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/990,818
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/800,751
FILING DATE:
APPLICATION NUMBER: JP 8-027004
FILING DATE: 14-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 028022-007
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-990-818-23

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2068 GAGCGGTACTCCGCTC 2084
DB      17 GAGCGGTACTCCGCTC 1

RESULT 23
US-08-679-645-609
Sequence 609, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggan, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
TITLE OF INVENTION: IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
```

```

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 609:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-609

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 58;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```

QY      2178 CCAGAGCTCATGAGA 2194
DB      2 CCGGAGCUCACUGAGA 18

RESULT 24
US-09-509-654-1
Sequence 1, Application US/09509654
Patent No. 6537805
GENERAL INFORMATION:
APPLICANT: VON MELCHNER, HARALD
APPLICANT: ANDREU, THOMAS
APPLICANT: EBENSPERGER, CHRISTOPHE
TITLE OF INVENTION: SELF-DELETING VECTORS FOR CANCER THERAPY
FILE REFERENCE: 07089,0009U1
CURRENT APPLICATION NUMBER: US/09/509,654
CURRENT FILING DATE: 2000-03-30
PRIOR APPLICATION NUMBER: PCT/EP99/03607
PRIOR FILING DATE: 1999-05-25
PRIOR APPLICATION NUMBER: Germany 198 34 430.9
PRIOR FILING DATE: 1998-07-30
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FaastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of artificial sequence:/note=synthetic
US-09-509-654-1
```

```

Query Match          0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      318 CCGCGCGAGACTGCCT 314
DB      1 CCGCGCGAGACTGCCT 314
```

Db 1 CCTGCTGTGGACTTGCT 17

RESULT 25  
US-08-388-381-22  
; Sequence 22, Application US/08388381  
; Patent No. 5552283  
; GENERAL INFORMATION:  
; APPLICANT: Diamandis, Eleftherios  
; APPLICANT: Dunn, James M.  
; APPLICANT: Stevens, John K.  
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis  
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations  
; NUMBER OF SEQUENCES: 41  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Oppedahl & Larson  
; STREET: 1992 Commerce Street, Suite 309  
; CITY: Yorktown Heights  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10598-4412  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS 5.0  
; SOFTWARE: Word Perfect  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/388,381  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/271,946  
; FILING DATE: 08-JUL-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Marina T. Larson  
; REGISTRATION NUMBER: 32,038  
; REFERENCE/DOCKET NUMBER: VSEN-P-003-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (914) 245-3252  
; TELEFAX: (914) 962-4330  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 22:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 20  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: genomic DNA  
; HYPOTHETICAL: no  
; ANTI-SENSE: no  
; FRAGMENT TYPE: internal  
; ORIGINAL SOURCE:  
; ORGANISM: human  
; FEATURE:  
; NAME/KEY: primer for exon 7 of human p53 gene  
; US-08-388-381-22

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1935 GGGTCAGCGACAGCAGTGG 1954  
|||  
1 GGGTCAGCGCGACAGCAGAGG 20

RESULT 26  
US-08-276-567A-3/c  
; Sequence 3, Application US/08276567A  
; Patent No. 5866699  
; GENERAL INFORMATION:  
; APPLICANT: Adrienne Smyth  
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity

NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lappin & Kusmer  
; STREET: 200 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/276,567A  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kerner, Ann-Louise  
; REGISTRATION NUMBER: 33,523  
; REFERENCE/DOCKET NUMBER: HYZ-022  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-330-1300  
; TELEFAX: 617-330-1311  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 20 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
; US-08-276-567A-3

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTGTGGAGAGCAC 1637  
|||  
20 AGTGGCTGTGGAGAGCAC 1

Db 20 AGTGGCTGTGGAGAGCAC 1

RESULT 27  
US-08-276-567A-4/c  
; Sequence 4, Application US/08276567A  
; Patent No. 5866699  
; GENERAL INFORMATION:  
; APPLICANT: Adrienne Smyth  
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1 Gene Activity  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lappin & Kusmer  
; STREET: 200 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/276,567A  
; FILING DATE:  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kerner, Ann-Louise  
; REGISTRATION NUMBER: 33,523  
; REFERENCE/DOCKET NUMBER: HYZ-022  
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-330-1300  
TELEFAX: 617-330-1311  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHEICAL: NO  
ANTI-SENSE: YES  
US-08-276-567A-4

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1617 CAATGGCTCTGGAGAGCA 1636  
DB 20 CAGTGGCTCTGGAGAGCA 1

RESULT 28  
US-08-910-629A-57  
Sequence 57, Application US/08910629A  
Patent No. 5877309  
GENERAL INFORMATION:  
APPLICANT: Robert A. McKay  
APPLICANT: Nicholas W. Dean

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK  
NUMBER OF SEQUENCES: 86  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Law Offices of Jane Massey Licata  
STREET: 66 East Main Street  
CITY: Marlton  
STATE: NJ  
COUNTRY: USA  
ZIP: 08053

COMPUTER READABLE FORM:  
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB  
MEDIUM TYPE: STORAGE  
COMPUTER: PENTIUM  
OPERATING SYSTEM: WINDOWS 95  
SOFTWARE: WORDPERFECT 6.1

CURRENT APPLICATION NUMBER: US/08/910,629A  
APPLICATION NUMBER: DATA:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257  
REFERENCE/DOCKET NUMBER: ISPH-0215  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (609) 779-2400  
TELEFAX: (609) 779-8488  
INFORMATION FOR SEQ ID NO: 57:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20  
TYPE: Nucleic Acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
ANTI-SENSE: YES  
US-08-910-629A-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 167 GGGTCTGGCGGTGGCCTG 186  
DB 1 GGGTCTGGCGGTGGACATG 20

RESULT 29  
US-08-469-461-17/c  
Sequence 17, Application US/08469461B  
Patent No. 5981178  
GENERAL INFORMATION:  
APPLICANT: Teul, Lap-Chee  
APPLICANT: Rommins, Johanna M.

TITLE OF INVENTION: Introns and Exons of the Cyclic Fibrosis Gene and  
TITLE OF INVENTION: Mutations at Various Positions of the Gene  
FILE REFERENCE: 3477-61, 033477/139840  
CURRENT APPLICATION NUMBER: US/08/469,461B  
CURRENT FILING DATE: 1995-06-06  
NUMBER OF SEQ ID NOS: 33  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 17  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-08-469-461-17

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1988 TACTATCTGGATGATGCC 2007  
DB 20 TACTTCTCTGGATGATGCC 1

RESULT 30  
US-07-890-609-17/c  
Sequence 17, Application US/07890609C  
Patent No. 6001588  
GENERAL INFORMATION:  
APPLICANT: Teul, Lap-Chee  
APPLICANT: Rommins, Johanna M.

TITLE OF INVENTION: Introns and Exons of the Cyclic Fibrosis Gene and  
TITLE OF INVENTION: Mutations at Various Positions of the Gene  
FILE REFERENCE: 3477-61, 033477/139840  
CURRENT APPLICATION NUMBER: US/07/890,609C  
CURRENT FILING DATE: 1992-07-13  
NUMBER OF SEQ ID NOS: 33  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 17  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-07-890-609-17

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1988 TACTATCTGGATGATGCC 2007  
DB 20 TACTTCTCTGGATGATGCC 1

RESULT 31  
US-08-765-626-22  
Sequence 22, Application US/08765626  
Patent No. 6071726  
GENERAL INFORMATION:  
APPLICANT: Visible Genetics Inc.  
APPLICANT: Diamandis, Eleftherios

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1988 TACTATCTGGATGATGCC 2007  
DB 20 TACTTCTCTGGATGATGCC 1

```
; APPLICANT: Dunn, James M.
; APPLICANT: Stevens, John K.
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson
; STREET: 1992 Commerce Street, Suite 309
; CITY: Yorktown Heights
; STATE: NY
; COUNTRY: USA
; ZIP: 10598-4412
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 MB
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,626
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/08605
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/389,381
; FILING DATE: 14-FEB-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN-P-003-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 245-3252
; TELEFAX: (914) 962-4330
; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYPOTHEICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: primer for exon 7 of human p53 gene
; US-08-765-626-22

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1935 GGGTCAGCGACGACGACTGG 1954
Db 1 GGGTCAGCGACGACGACGAGG 20

RESULT 32
US-09-287-796-57
; Sequence 57, Application US/09287796A
; Patent No. 6133246
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monta, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS
; TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS
; FILE REFERENCE: ISPH-0350
```

```
; CURRENT APPLICATION NUMBER: US/09/287,796A
; CURRENT FILING DATE: 1999-04-07
; EARLIER APPLICATION NUMBER: 09/130,616
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
; US-09-287-796-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 GGGTCGCGCGGTGGGCTTG 186
Db 1 GGGTCGTCGCGTGACATG 20
```

```
RESULT 33
US-09-280-805-8/c
; Sequence 8, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monta
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: linear
; ANTI-SENSE: Yes
; US-09-280-805-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```



OY 243 CTCGAGCGGAGGAGGAG 262  
Db 20 CTCGAGCGGAGGAGGAGGAG 1

RESULT 34  
US-09-130-616-57  
Sequence 57, Application US/09130616C  
Patent No. 6221850  
GENERAL INFORMATION:  
APPLICANT: Mckay, Robert A.  
APPLICANT: Dean, Nicholas M.  
APPLICANT: Monia, Brett  
APPLICANT: Nero, Pam  
APPLICANT: Gaarde, William A.  
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS  
FILE REFERENCE: ISPH-0318  
CURRENT APPLICATION NUMBER: US/09/130,616C  
CURRENT FILING DATE: 1998-06-07  
EARLIER APPLICATION NUMBER: 08/910,629  
EARLIER FILING DATE: 1997-06-03  
NUMBER OF SEQ ID NOS: 178  
SEQ ID NO 57  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic Sequence  
US-09-130-616-57

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 167 GGGTCTGGCGGCTGGCGCTG 186  
Db 1 GGGTCTGGCGGCTGGCGCATG 20

RESULT 35  
US-09-048-810-8/C  
Sequence 8, Application US/09048810  
Patent No. 6238921  
GENERAL INFORMATION:  
APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.  
APPLICANT: Graham, Brett P. Monia  
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE  
TITLE OF INVENTION: MODULATION OF HUMAN MDM2 EXPRESSION  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Law Offices of Jane Massey Licata  
STREET: 66 East Main Street  
CITY: Marlton  
STATE: NJ  
COUNTRY: U.S.A.  
ZIP: 08053  
COMPUTER READABLE FORM:  
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE  
COMPUTER: IBM 486  
OPERATING SYSTEM: WINDOWS FOR WORKGROUPS  
SOFTWARE: WORDPERFECT 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/048,810  
FILING DATE: herewith  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Licata, Jane Massey  
REGISTRATION NUMBER: 32,257  
REFERENCE/DOCKET NUMBER: ISPH-0302  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-779-2400  
TELEFAX: 609-810-1454

INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
ANTI-SENSE: Yes  
US-09-048-810-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 243 CTCGAGCGGAGGAGGAG 262  
Db 20 CTCGAGCGGAGGAGGAGGAG 1

RESULT 36  
US-09-851-062-32/C  
Sequence 32, Application US/09851062  
Patent No. 6448081  
GENERAL INFORMATION:  
APPLICANT: Brenda F. Baker  
APPLICANT: Susan M. Freiler  
TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION  
FILE REFERENCE: RTS-0247  
CURRENT APPLICATION NUMBER: US/09/851,062  
CURRENT FILING DATE: 2001-05-07  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 32  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-851-062-32

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1633 AGCAGTGGCTGCTGCTGCT 1652  
Db 20 AGCAGTGGCTGCTGCTGCT 1

RESULT 37  
US-09-706-197-47/C  
Sequence 47, Application US/09706197  
Patent No. 6475797  
GENERAL INFORMATION:  
APPLICANT: C. Frank Bennett  
APPLICANT: David Spector  
APPLICANT: Jacqueline Wyatt  
TITLE OF INVENTION: ANTISENSE MODULATION OF SR-CYP EXPRESSION  
FILE REFERENCE: RTS-0145  
CURRENT APPLICATION NUMBER: US/09/706,197  
CURRENT FILING DATE: 2000-11-03  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 47  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-706-197-47

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1269 AGTGAATCCTCTACATG 1288

```
Db      ||||| ||||| |||||
        20 AGTAGACTCTCCACATTG 1

RESULT 38
US-09-422-978-8790
; Sequence 8790, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1998-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8790
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-18258 for SEQ 925, in compleme
US-09-422-978-8790

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1025 CCAAGAAAGTGGGAAATGG 1044
Db      1 CAAAGTAGGTGGAATAATGG 20

RESULT 39
US-09-422-978-8838/c
; Sequence 8838, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8838
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-18602 for SEQ 973, in compleme
US-09-422-978-8838

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      939 CCTATGCTCTTGGGATCA 958
Db      1 CCAATGATCTTGGGACCA 20

RESULT 42
US-09-198-452A-4873
; Sequence 4873, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      688 CTCATGTCATTCACCAT 707
Db      20 CTCCTCTCATTCACCAT 1

RESULT 40
US-09-198-452A-3216
; Sequence 3216, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; EARLIER FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3216

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1762 CCACAGGTATTGGAAGAG 1781
Db      1 CCACAGGTCTTTGAGGAG 20

RESULT 41
US-09-198-452A-3350
; Sequence 3350, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; EARLIER FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3350
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3350

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      939 CCTATGCTCTTGGGATCA 958
Db      1 CCAATGATCTTGGGACCA 20

RESULT 42
US-09-198-452A-4873
; Sequence 4873, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; FILE REFERENCE: 9710-003-999
```

```

; CURRENT APPLICATION NUMBER: US/09/198.452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4873
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4873

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1696 GGAAGCCCTTCCCAATA 1715
Db      1 GGAAGCCCTTCCCAATA 20

RESULT 43
US-09-572-891-8
; Sequence 8, Application US/09572891
; Patent No. 6566064
; GENERAL INFORMATION:
; APPLICANT: SHIRAKI, MASATAKA
; APPLICANT: OUCHI, YASUYOSHI
; APPLICANT: HOSOI, TAKAYUKI
; APPLICANT: KUSABA, NOBUTAKA
; APPLICANT: BABA, TOSHIKAKI
; APPLICANT: YOSHIDA, HIROSHI
; TITLE OF INVENTION: METHOD FOR ANTICIPATING SENSITIVITY TO MEDICINE FOR
; FILE REFERENCE: NISS-051
; CURRENT APPLICATION NUMBER: US/09/572.891
; CURRENT FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Located on the 6th chromosome; a part of the base sequence
US-09-572-891-8

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1647 CCTGCTGAGAAATCTGTACC 1666
Db      1 CCTGCTGAGAAATCTGTACC 20

RESULT 44
PCT-US95-08605-22
; Sequence 22, Application PC/TUS9508605
; GENERAL INFORMATION:
; APPLICANT: Visible Genetics Inc.
; APPLICANT: Diamandis, Eleftherios
; APPLICANT: Dunn, James M.
; APPLICANT: Stevens, John K.
; TITLE OF INVENTION: Method, Reagents and Kit for Diagnosis
; TITLE OF INVENTION: and Targeted Screening for p53 Mutations
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Opedahl & Larson
; STREET: 1992 Commerce Street, Suite 309
; CITY: Yorktown Heights
; STATE: NY
; COUNTRY: USA
; ZIP: 10596-4412
; COMPUTER READABLE FORM:
```

```

; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 MB
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/08605
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/271,946
; FILING DATE: 08-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/388,381
; FILING DATE: 14-FEB-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN.P-003-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 245-3252
; TELEFAX: (914) 962-4330
; TELEX:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: primer for exon 7 of human p53 gene
PCT-US95-08605-22

Query Match          0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 70;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1935 GGCTCAGCAGCAGCAGTGG 1954
Db      1 GGCTCAGCAGCAGCAGCAGC 20

RESULT 45
PCT-US95-09011-3/C
; Sequence 3, Application PC/TUS9509011
; GENERAL INFORMATION:
; APPLICANT: Hydrion, Inc.
; TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lappin & Kuemer
; STREET: 200 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/09011
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
```

REGISTRATION NUMBER: 33,523  
REFERENCE/DOCKET NUMBER: HYZ-022PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-330-1300  
TELEFAX: 617-330-1311  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: YES  
PCT-US95-09011-3

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1618 AATGGCTGTGGAGAGCAGC 1637  
DB 20 AGTGGCTGTGGAGAGCAGC 1

RESULT 46  
PCT-US95-09011-4/c  
Sequence 4, Application PC/TUS9509011  
GENERAL INFORMATION:  
APPLICANT: Hybridon, Inc.  
TITLE OF INVENTION: Oligonucleotides Having Anti-MDR-1  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lapplin & Kusmer  
STREET: 200 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US95/09011  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Keiner, Ann-Louise  
REGISTRATION NUMBER: 33,523  
REFERENCE/DOCKET NUMBER: HYZ-022PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-330-1300  
TELEFAX: 617-330-1311  
INFORMATION FOR SEQ ID NO: 4:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: YES  
PCT-US95-09011-4

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 70;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1617 CAATGGCTGTGGAGAGCA 1636  
DB 20 AGTGGCTGTGGAGAGCAGC 1

DB 20 CAGTGGCTGTGGAGAGCA 1

RESULT 47  
US-09-488-671-108  
Sequence 108, Application US/09488671A  
Patent No. 6187545  
GENERAL INFORMATION:  
APPLICANT: Robert McKay  
APPLICANT: Madeline M. Butler  
APPLICANT: Jacqueline Wyatt  
APPLICANT: Lex M. Cowsett  
TITLE OF INVENTION: ANTISENSE MODULATION OF PEPCK-CYTOSOLIC EXPRESSION  
FILE REFERENCE: RTS-0123  
CURRENT APPLICATION NUMBER: US/09/488,671A  
CURRENT FILING DATE: 2000-01-21  
NUMBER OF SEQ ID NOS: 177  
SEQ ID NO 108  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-488-671-108

Query Match 0.7%; Score 15; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 77;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 830 AACGAAACGACG 844  
DB 3 AACGAAACGACG 17

RESULT 48  
US-09-513-783A-39/c  
Sequence 39, Application US/09513783A  
Patent No. 6416959  
GENERAL INFORMATION:  
APPLICANT: Giuliano, Kenneth A.  
APPLICANT: Kapur, Ravi  
TITLE OF INVENTION: A System for Cell Based Screening  
FILE REFERENCE: 97-022-11  
CURRENT APPLICATION NUMBER: US/09/513,783A  
CURRENT FILING DATE: 2000-02-25  
NUMBER OF SEQ ID NOS: 180  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 39  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: KT3 epitope  
US-09-513-783A-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 77;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCTGTGTGG 583  
DB 18 TGTTCCTGTCTGTGTGG 1

RESULT 49  
US-08-860-882A-52  
Sequence 52, Application US/08860882A  
Patent No. 5985281  
GENERAL INFORMATION:  
APPLICANT: TAYLORSON, CHRISTOPHER JOHN  
APPLICANT: EGGEITE, HENDRIKUS JOHANNES  
APPLICANT: TARRAGONA-FIOU, ANTONIO  
APPLICANT: RABIN, BRIAN ROBERT

APPLICANT: BOYLE, FRANCIS THOMAS  
APPLICANT: HENNAM, JOHN FREDERICK  
APPLICANT: BLAKLEY, DAVID CHARLES  
APPLICANT: MARSHAM, PETER ROBERT  
APPLICANT: HEATON, DAVID WILLIAM  
APPLICANT: DAVIES, DAVID HUIW  
TITLE OF INVENTION: CHEMICAL COMPOUNDS  
NUMBER OF SEQUENCES: 77  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PILLSBURY, MADISON & SUTRO  
STREET: 1100 NEW YORK AVENUE, N.W.  
CITY: WASHINGTON  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20005  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/860, 882A  
FILING DATE: JUNE 23, 1997  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: DONALD J. BIRD  
REGISTRATION NUMBER: 25,323  
REFERENCE/DOCKET NUMBER: 9901/238653  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 861-3027  
TELEFAX: (202) 822-0944  
TELEX: 6174627 CUSH  
INFORMATION FOR SEQ ID NO: 52:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-860-882A-52

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 81;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 50  
US-09-171-945-110  
Sequence 110, Application US/09171945  
Patent No. 6277599  
GENERAL INFORMATION:  
APPLICANT: Emery, Stephen  
APPLICANT: Copley, Clive Graham  
APPLICANT: Edge, Michael Derek  
TITLE OF INVENTION: Monoclonal Antibody to CEA, Conjugates Comprising Said  
FILE REFERENCE: Monoclonal Antibody to CEA  
CURRENT APPLICATION NUMBER: US/09/171,945  
CURRENT FILING DATE: 1998-10-29  
PRIOR APPLICATION NUMBER: GB9703103.3  
PRIOR FILING DATE: 1997-02-14  
PRIOR APPLICATION NUMBER: GB9609405.7  
PRIOR FILING DATE: 1996-05-04  
PRIOR APPLICATION NUMBER: PCT/GB97/01165  
PRIOR FILING DATE: 1997-04-29  
NUMBER OF SEQ ID NOS: 131  
SOFTWARE: Patent Ver. 2.1  
SEQ ID NO 110  
LENGTH: 19  
TYPE: DNA

ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: humanized  
US-09-171-945-110

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 81;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 51  
US-09-011-769A-34  
Sequence 34, Application US/09011769A  
Patent No. 6436691  
GENERAL INFORMATION:  
APPLICANT: SLATER, Anthony M.  
BLAKLEY, David C.  
DAVIES, David H.  
HENNAM, John F.  
HENNEQUIN, Laurent F.A.  
MARSHAM, Peter R.  
DOWELL, Robert I.  
TITLE OF INVENTION: Chemical Compounds  
NUMBER OF SEQUENCES: 87  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pillsbury Madison & Suto, LLP  
STREET: 1100 New York Ave., N.W.  
CITY: Washington  
STATE: D.C.  
COUNTRY: U.S.A.  
ZIP: 20005  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 1.44 Mb disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/011,769A  
FILING DATE: 13-Feb-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/GB96/01975  
FILING DATE: 13-AUG-1996  
APPLICATION NUMBER: GB 9612295.7  
FILING DATE: 12-JUN-1996  
APPLICATION NUMBER: GB 9611019.2  
FILING DATE: 25-MAY-1996  
APPLICATION NUMBER: GB 9516810.0  
FILING DATE: 16-AUG-1995  
INFORMATION FOR SEQ ID NO: 34:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
SEQUENCE DESCRIPTION: SEQ ID NO: 34:  
US-09-011-769A-34

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 81;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1645 GCCCTGCTGCAGATCTG 1662  
DB 2 GACCTGCTGCAGACTCTG 19

RESULT 52

```
US-09-548-797B-94/c
; Sequence 94, Application US/09548797B
; Patent No. 6683165
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND
; FILE REFERENCE: 2976-4039
; CURRENT APPLICATION NUMBER: US/09/548,797B
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: 60/129,391
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 94
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-548-797B-94

Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 81;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      867 AGAGGACACGTCACCCCT 884
Db      19 AGAGGACACGACGACCCCT 2

RESULT 53
5164485-15/c
; Patent No. 5164485
; APPLICANT: FUJISAWA, YUKIO; ITOH, YASUAKI; NISHIMURA, OSAMU
; FUJII TOMOKO
; TITLE OF INVENTION: MODIFIED HEPATITIS B VIRUS SURFACE
; ANTIGEN P31 AND PRODUCTION THEREOF
; NUMBER OF SEQUENCES: 22
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/547,948
; FILING DATE: 03-JUL-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 898,425
; FILING DATE: 20-AUG-1986
; SEQ ID NO:15
; LENGTH: 16
5164485-15

Query Match          0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      85 CTTCTCGCGGCTGGG 100
Db      16 CTTCTCGGACGACTGG 1

RESULT 54
US-07-977-630-6
; Sequence 6, Application US/07977630
; Patent No. 5583038
; GENERAL INFORMATION:
; APPLICANT: Stover, Charles K.
; TITLE OF INVENTION: BACTERIAL EXPRESSION VECTORS CONTAINING
; TITLE OF INVENTION: DNA ENCODING SECRETION SIGNALS OF LIPOPROTEINS
; NUMBER OF SEQUENCES: 84
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi,
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
```

```
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,630
; FILING DATE: No. 5583038ember 17, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Hertron, Charles J.
; REGISTRATION NUMBER: 28,019
; REFERENCE/DOCKET NUMBER: 469201-174
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: nucleic acid
US-07-977-630-6

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 87;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1690 TTGATGGGGAAGCCCC 1705
Db      2 TTGATGGGAAGCCCC 17

RESULT 55
US-08-109-391A-10/c
; Sequence 10, Application US/08109391A
; Patent No. 5639876
; GENERAL INFORMATION:
; APPLICANT: Tripp, Cynthia A.
; APPLICANT: Frank, Glenn R.
; APPLICANT: Griev, Robert B.
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING NOVEL
; TITLE OF INVENTION: PARASITIC HELMINTH PROTEINS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Sheridan Rose & McIntosh
; STREET: 1700 Lincoln St., Suite 3500
; CITY: Denver
; STATE: CO
; COUNTRY: U.S.A.
; ZIP: 80203
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/109,391A
; FILING DATE: 19-AUG-1993
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Connell, Gary J.
; REGISTRATION NUMBER: 32,020
; REFERENCE/DOCKET NUMBER: 2618-13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 303/863-9700
; TELEFAX: 303/863-0223
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
```

TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 1..17  
OTHER INFORMATION: /label= PRIMER  
US-08-109-391A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 87;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232  
|||||  
DB 16 GGTCAGAGCTCTGCA 1

RESULT 56  
US-08-459-019A-10/C  
Sequence 10, Application US/08459019A  
Patent No. 5686080  
GENERAL INFORMATION:  
APPLICANT: Tripp, Cynthia A.  
APPLICANT: Frank, Glenn R.  
APPLICANT: Griev, Robert B.  
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH P4 PROTEINS  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheridan Ross & McIntosh  
STREET: 1700 Lincoln Street, #3500  
CITY: Denver  
STATE: CO  
COUNTRY: U.S.A.  
ZIP: 80203  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/459,019A  
FILING DATE: 06-JUN-1995  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: Connell, Gary J.  
REGISTRATION NUMBER: 33,020  
REFERENCE/DOCKET NUMBER: 2618-13-1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (303) 863-9700  
TELEFAX: (303) 863-0223  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /desc = "primer"  
US-08-459-019A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 87;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232  
|||||  
DB 16 GGTCAGAGCTCTGCA 1

RESULT 57  
US-08-460-428A-10/C

Sequence 10, Application US/08460428A  
Patent No. 5912337  
GENERAL INFORMATION:  
APPLICANT: Tripp, Cynthia A.  
APPLICANT: Frank, Glenn R.  
APPLICANT: Griev, Robert B.  
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH  
P22U PROTEINS  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheridan Ross P.C.  
STREET: 1700 Lincoln St., Suite 3500  
CITY: Denver  
STATE: CO  
COUNTRY: U.S.A.  
ZIP: 80203  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/460,428A  
FILING DATE: 02-JUN-1995  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: Connell, Gary J.  
REGISTRATION NUMBER: 32,020  
REFERENCE/DOCKET NUMBER: 2618-13-3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 303/863-9700  
TELEFAX: 303/863-0223  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 1..17  
OTHER INFORMATION: /label= PRIMER  
US-08-460-428A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 87;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTCAGAGCTCTGCA 2232  
|||||  
DB 16 GGTCAGAGCTCTGCA 1

RESULT 58  
US-08-458-860A-10/C  
Sequence 10, Application US/08458860A  
Patent No. 6100390  
GENERAL INFORMATION:  
APPLICANT: Frank, Glenn R.  
APPLICANT: Tripp, Cynthia A.  
APPLICANT: Griev, Robert B.  
TITLE OF INVENTION: NOVEL PARASITIC HELMINTH  
P22U NUCLEIC ACID MOLECULES  
NUMBER OF SEQUENCES: 17  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheridan Ross P.C.  
STREET: 1700 Lincoln St., Suite 3500  
CITY: Denver  
STATE: CO  
COUNTRY: U.S.A.  
ZIP: 80203  
COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/458,860A  
FILING DATE: 02-JUN-1995  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: Connell, Gary J.  
REGISTRATION NUMBER: 32,020  
REFERENCE/DOCKET NUMBER: 2618-13-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 303/863-9700  
TELEFAX: 303/863-0223  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc feature  
LOCATION: 1..17  
OTHER INFORMATION: /label= PRIMER  
US-08-458-860A-10

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 87;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2217 GGTGAGGCTCTCTCA 2232  
|||||:|||||  
DB 16 GGTGAGGATCTCTCA 1

RESULT 59  
US-08-679-645-139  
Sequence 139, Application US/08679645  
Patent No. 6350934  
GENERAL INFORMATION:  
APPLICANT: Zwick, Michael G.  
APPLICANT: Edington, Brent B.  
APPLICANT: McSwigen, James A.  
APPLICANT: Merlo, Patricia Ann Owens  
APPLICANT: Guo, Lining  
APPLICANT: Skokut, Thomas A.  
APPLICANT: Young, Scott A.  
APPLICANT: Folckerts, Otto  
APPLICANT: Merlo, Donald J.  
TITLE OF INVENTION: COMPOSITION AND METHODS FOR  
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION  
TITLE OF INVENTION: IN PLANTS  
NUMBER OF SEQUENCES: 1263  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/679,645  
FILING DATE: July 12, 1996  
CLASSIFICATION: 800

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/001,135  
FILING DATE: July 13, 1995  
APPLICATION NUMBER: 08/300,726  
FILING DATE: September 2, 1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Waidburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 219/247  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 139:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-679-645-139

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 81.2%; Pred. No. 87;  
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2179 CAGCAGCTCATGAGA 2194  
|||||:|||||  
DB 1 CCGCAGCTCATGAGA 16

RESULT 60  
US-09-866-108A-890/c  
Sequence 890, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSTIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: ABOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecoma Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 890  
LENGTH: 17  
TYPE: DNA





PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Neomica Sequence Listing Engine  
Patent NO. 6686188  
SEQ ID NO 8006  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8006

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 87;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2038 CAGGTGAGCAGCTCC 2053  
DB 1 CAGCTGAGCAGCTCC 16

RESULT 64  
US-09-565-808-17/c  
Sequence 17, Application US/09565808  
Patent No. 6432674  
GENERAL INFORMATION:  
APPLICANT: Hirata, Yuichi  
TITLE OF INVENTION: STEROID HORMONE BINDING PROTEIN  
FILE REFERENCE: 06501-059001  
CURRENT FILING DATE: US/09/565,808  
PRIOR FILING DATE: 2000-05-05  
PRIOR APPLICATION NUMBER: WO/JP98/05010  
PRIOR FILING DATE: 1998-11-06  
PRIOR APPLICATION NUMBER: JP/9/322376  
PRIOR FILING DATE: 1997-11-07  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 17  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Artificially synthesized primer sequence  
US-09-565-808-17

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 97;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1258 ATGCTGCTGAAGTGG 1273  
DB 16 ATGCTGCTGAAGTGG 1

RESULT 65  
US-08-862-337-12  
Sequence 12, Application US/08862337  
Patent No. 6582902  
GENERAL INFORMATION:  
APPLICANT: Keene, Jack D.  
APPLICANT: Kenan, Daniel J.  
APPLICANT: Tsai, Donald E.  
TITLE OF INVENTION: Nucleic Acid Epitopes and Methods of

TITLE OF INVENTION: Making and Using the Same  
NUMBER OF SEQUENCES: 12  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Kenneth D. Sibley, Bell, Seltzer, Park and  
ADDRESS: Gibson  
STREET: Post Office Drawer 34009  
CITY: Charlotte  
STATE: No. 6582902th Carolina  
COUNTRY: U.S.A.  
ZIP: 28234  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/862,337  
FILING DATE: 23-MAY-1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/447,196  
FILING DATE:  
APPLICATION NUMBER: US/07/956,693  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Sibley, Kenneth D.  
REGISTRATION NUMBER: 31,665  
REFERENCE/DOCKET NUMBER: 5405-69  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 919-881-3140  
TELEFAX: 919-881-3175  
TELEX: 575102  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: rRNA  
US-08-862-337-12

Query Match 0.6%; Score 14; DB 1; Length 14;  
Best Local Similarity 85.7%; Pred. No. 87;  
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2112 CCTGTGAGCAGC 2125  
DB 1 CTUGUGAGCAGC 14

RESULT 66  
US-09-829-855-101/c  
Sequence 101, Application US/09829855  
Patent No. 6613520  
GENERAL INFORMATION:  
APPLICANT: Matthew, Ashby N.  
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
FILE REFERENCE: ASHBY-1  
CURRENT FILING DATE: US/09/829,855  
PRIOR FILING DATE: 2001-04-10  
PRIOR APPLICATION NUMBER: US 60/196063  
PRIOR FILING DATE: 2000-04-10  
PRIOR APPLICATION NUMBER: US 60/196258  
PRIOR FILING DATE: 2000-04-11  
NUMBER OF SEQ ID NOS: 244  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 101  
LENGTH: 16  
TYPE: DNA  
ORGANISM: unknown  
FEATURE:  
OTHER INFORMATION: unidentified soil organism  
US-09-829-855-101

Query Match 0.6%; Score 14; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 297 AGCTGCGGCACTGG 310  
Db 16 AGCTGCGGCACTGG 3

RESULT 67  
US-08-152-313-113/c  
Sequence 113, Application US/08152313  
Patent No. 5561041  
GENERAL INFORMATION:  
APPLICANT: Sidraneky, David  
TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY  
ANALYSIS OF SPUTUM  
NUMBER OF SEQUENCES: 128  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Spensley Horn Jubas & Lubitz  
STREET: 1880 Century Park East, Suite 500  
CITY: Los Angeles  
STATE: California  
COUNTRY: USA  
ZIP: 90067  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/152,313  
FILING DATE: 12-NOV-1993  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Wetherell, Jr., Ph.D., John R.,  
REGISTRATION NUMBER: 31,678  
REFERENCE/DOCKET NUMBER: PD-2912  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 455-5100  
TELEFAX: (619) 455-5110  
INFORMATION FOR SEQ ID NO: 113:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..17  
US-08-152-313-113

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 11e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGGAGGT 1742  
Db 16 CTGCACAGGAGGT 3

RESULT 68  
US-08-579-223-113/c  
Sequence 113, Application US/08579223  
Patent No. 5726019  
GENERAL INFORMATION:  
APPLICANT: Sidraneky, David  
TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY  
ANALYSIS OF SPUTUM  
NUMBER OF SEQUENCES: 128  
CORRESPONDENCE ADDRESS:

ADDRESSEE: Spensley Horn Jubas & Lubitz  
STREET: 1880 Century Park East, Suite 500  
CITY: Los Angeles  
STATE: California  
COUNTRY: USA  
ZIP: 90067

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/579,223  
FILING DATE: 28-DEC-1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/152,313  
FILING DATE: 12-NOV-1993  
ATTORNEY/AGENT INFORMATION:

NAME: Wetherell, Jr., Ph.D., John R.,  
REGISTRATION NUMBER: 31,678  
REFERENCE/DOCKET NUMBER: PD-2912  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (619) 455-5100  
TELEFAX: (619) 455-5110

INFORMATION FOR SEQ ID NO: 113:  
SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:

NAME/KEY: CDS  
LOCATION: 1..17  
US-08-579-223-113

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 11e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1729 CTGCACAGGAGGT 1742  
Db 16 CTGCACAGGAGGT 3

RESULT 69  
US-09-866-108A-895/c  
Sequence 895, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO: 895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-895
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1699 AAGCCCTTCCCA 1712
          |||||||
Db       15 AAGCCCTTCCCA 2
```

```

RESULT 70
US-09-866-108A-896/C
; Sequence 896, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO: 896
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-896
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1699 AAGCCCTTCCCA 1712
          |||||||
Db       14 AAGCCCTTCCCA 1
```

```

RESULT 71
PCT-US94-12947A-113/C
; Sequence 113, Application PC/TUS9412947A
; GENERAL INFORMATION:
; APPLICANT: The Johns Hopkins University School of Medicine
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/12947A
; FILING DATE: 10-NOV-1994
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Ph.D., Lisa A.
; REGISTRATION NUMBER: P-38,347
; REFERENCE/DOCKET NUMBER: PD-2912
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 113:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
; PCT-US94-12947A-113

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      1729 CTGCACAGCAGGT 1742
          |||||||
Db       16 CTGCACAGCAGGT 3
```

```

RESULT 72
US-09-156-424-42/C
; Sequence 42, Application US/09156424
; Patent No. 5945290
; GENERAL INFORMATION:
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF RHOA EXPRESSION
; FILE REFERENCE: RTS-0012
; CURRENT APPLICATION NUMBER: US/09/156,424
; CURRENT FILING DATE: 1998-03-18
; NUMBER OF SEQ ID NOS: 47
```

```
; SEQ ID NO 42
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-156-424-42
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1814 AGAGCCCACTATG 1827
Db      15 AGAGCCCACTATG 2
```

```
RESULT 73
US-09-638-509C-5
; Sequence 5, Application US/09638509C
; Patent No. 6372435
; GENERAL INFORMATION:
; APPLICANT: Tang, Jiaming
; APPLICANT: Kaslow, Richard A.
; TITLE OF INVENTION: Methods of Surveying For CC (Beta) Chemokine
; TITLE OF INVENTION: Receptor Variants and Their Association With HIV-1
; TITLE OF INVENTION: Transmission and/or Disease Progression
; FILE REFERENCE: D6217
; CURRENT APPLICATION NUMBER: US/09/638, 509C
; CURRENT FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/148,530
; PRIOR FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: primer bind
; OTHER INFORMATION: CCR5-5/1S, primer used for typing major
; OTHER INFORMATION: polymorphism in CCR2b, CCR5 and the CCR5 downstream
; OTHER INFORMATION: promoter region
US-09-638-509C-5
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2189 TGGAGAAAAGGCG 2202
Db      4 TGGAGAAAAGGCG 17
```

```
RESULT 74
US-09-638-509C-6
; Sequence 6, Application US/09638509C
; Patent No. 6372435
; GENERAL INFORMATION:
; APPLICANT: Tang, Jiaming
; APPLICANT: Kaslow, Richard A.
; TITLE OF INVENTION: Methods of Surveying For CC (Beta) Chemokine
; TITLE OF INVENTION: Receptor Variants and Their Association With HIV-1
; TITLE OF INVENTION: Transmission and/or Disease Progression
; FILE REFERENCE: D6217
; CURRENT APPLICATION NUMBER: US/09/638, 509C
; CURRENT FILING DATE: 2000-08-11
; PRIOR APPLICATION NUMBER: 60/148,530
; PRIOR FILING DATE: 1999-08-12
; NUMBER OF SEQ ID NOS: 35
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; NAME/KEY: primer bind
; OTHER INFORMATION: CCR5-5/2S, primer used for typing major
; OTHER INFORMATION: polymorphism in CCR2b, CCR5 and the CCR5 downstream
; OTHER INFORMATION: promoter region
US-09-638-509C-6
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      2189 TGGAGAAAAGGCG 2202
Db      4 TGGAGAAAAGGCG 17
```

```
RESULT 75
US-09-387-341-56/c
; Sequence 56, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 56
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-387-341-56
```

```
Query Match          0.6%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1814 AGAGCCCACTATG 1827
Db      15 AGAGCCCACTATG 2
```

```
RESULT 76
US-09-474-432B-630/c
; Sequence 630, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
```

```

; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 630
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-630

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      259 GCAGGTGCCAGGCGCTG 275
Db      17 GTAGGTGACCGAGGCTG 1

RESULT 77
US-09-474-432B-720/c
; Sequence 720, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adams, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-720

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      269 AGGGCTGCGTGGCTGCT 285
Db      17 AGGGCTGCGTCTGCT 1

RESULT 78
US-09-371-772B-4198
; Sequence 4198, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam

```

```

; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4198

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      977 CCTTACCATGCTCACC 993
Db      1 CGTCCACCAUGGUCAGC 17

RESULT 79
US-09-476-387-629/c
; Sequence 629, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adams, Jasenka
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 629
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-629

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      259 GCAGGTGCCAGGCGCTG 275
Db      17 GTAGGTGACCGAGGCGCTG 1

RESULT 80

```

```
US-09-476-387-719/c
; Sequence 719, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Belgelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelesky, Alex
; APPLICANT: Adams, Jasenka Matulic
; APPLICANT: Swedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 719
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-719

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      269 AGGCGTGGCTGGCTGCT 285
Db      17 AGGCGTGGCTGCTGCT 1

RESULT 81
US-09-866-108A-515/c
; Sequence 515, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 515
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-515

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      160 CTGCTCCGGGTGGGC 176
Db      17 CTGCTCAGGCTGGGC 1

RESULT 82
US-09-866-108A-665/c
; Sequence 665, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-665

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

Oy      53      CTTCTCTGCATGGCTG  69
          |||||  |||||
Db      17      CTTCTCTGCATGGCTG  1
          |||||  |||||

RESULT 83
US-09-866-108A-1530
: Sequence 1530, Application US/09866108A
: Patent No. 6686188
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yizhong
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark
: TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
: FILE REFERENCE: AEOmica-7
: CURRENT APPLICATION NUMBER: US/09/866,108A
: PRIOR APPLICATION NUMBER: US/2001-05-25
: PRIOR FILING DATE: 2000-05-26
: PRIOR APPLICATION NUMBER: GB 24263.6
: PRIOR FILING DATE: 2000-10-04
: PRIOR APPLICATION NUMBER: US 60/236,359
: PRIOR FILING DATE: 2000-09-27
: PRIOR APPLICATION NUMBER: PCT/US01/00666
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00667
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00664
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00669
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00665
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00668
: PRIOR FILING DATE: 2001-01-30
: PRIOR APPLICATION NUMBER: PCT/US01/00663
: PRIOR FILING DATE: 2001-01-30
: Remaining Prior Application data removed - See File Wrapper or PALM.
: NUMBER OF SEQ ID NOS: 15755
: SOFTWARE: AeoMica Sequence Listing Engine
: Patent No. 6686188
: SEQ ID NO 1530
: LENGTH: 17
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-866-108A-1530

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1595  AGGTGACGGCGCTGGTG  1611
          |||||  |||||
Db      1      AGGTGATGGGCGCTGGTG  17

RESULT 84
US-09-866-108A-1572/c
: Sequence 1572, Application US/09866108A
: Patent No. 6686188
: GENERAL INFORMATION:
: APPLICANT: GU, Yizhong
: APPLICANT: JI, Yizhong
: APPLICANT: PENN, Sharon G.
: APPLICANT: HANZEL, David K.
: APPLICANT: RANK, David R.
: APPLICANT: CHEN, Wensheng
: APPLICANT: SHANNON, Mark

```

```

/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOmica-7
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 09/866,108A
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 1575
/ SOFTWARE: AeoMica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 1572
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-1572

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      267 CCAGGCGTGGCTGGCTG 283
      ||||| |||||
Db      17 CCAGGCGAGCTGGCTG 1

RESULT 85
US-09-866-108A-1960
/ Sequence 1960, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOmica-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30

```



PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 1960  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-1960

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1832 AAATCAGAGCTGCTGCA 1848  
Db 1 AAAGCTCAGCTGCTGCA 17

RESULT 86  
US-09-866-108A-2739  
Sequence 2739, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 2739  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-2739

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 297 AGCTGGCAGCTGGGCT 313  
Db 1 AGCTGAGCCCTGGGCT 17

RESULT 87  
US-09-866-108A-6521  
Sequence 6521, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 6521  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-6521

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2100 CCAGCAGCTCAGCCTGG 2116  
Db 1 CCAGCAGCAGCAGCCTGG 17

RESULT 88  
US-09-866-108A-6522  
Sequence 6522, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6522
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6522

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2101 CAGCAGCTGCTGTGT 2117
Db      1 CACCGCAGCTGTGT 17

RESULT 89
US-09-866-108A-6525
; Sequence 6525, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6526

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6525

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      2104 CACCTCAGCTGTGTGA 2120
Db      1 CACCGCAGCTGTGTGA 17

RESULT 90
US-09-866-108A-6526
; Sequence 6526, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6526

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2105 ACCGACCTGCTGAG 2121

Db 1 ACCGACCTGCTGAG 17

RESULT 91

US-09-866-108A-6758  
Sequence 6758, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 6758  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-6758

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2041 GTGGAGAGCTCTGTA 2057

Db 1 GTGGAGAGCTCTGTA 17

RESULT 92

US-09-866-108A-8056  
Sequence 8056, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US/09/866,108A  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8056  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8056

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2230 GCAGATCCTCAGATG 2246

Db 1 GCAGATCCTCAGATG 17

RESULT 93

US-09-866-108A-8057  
Sequence 8057, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US/09/866,108A  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30

;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00663  
;; PRIOR FILING DATE: 2001-01-30  
;; Remaining Prior Application data removed - See File Wrapper or PALM.  
;; NUMBER OF SEQ ID NOS: 15755  
;; SOFTWARE: Aecomica Sequence Listing Engine  
;; Patent No. 6686188  
;; SEQ ID NO 8057  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-09-866-108A-8057

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2231 CAGATGCTCGAATGA 2247

Db 1 CAGATGCACGAAAGGA 17

#### RESULT 94

US-09-866-108A-9583  
;; Sequence 9583, Application US/09866108A  
;; Patent No. 6686188  
;; GENERAL INFORMATION:  
;; APPLICANT: GU, Yizhong  
;; APPLICANT: JI, Yizhong  
;; APPLICANT: PENN, Sharon G.  
;; APPLICANT: HANZEL, David K.  
;; APPLICANT: RANK, David R.  
;; APPLICANT: CHEN, Wensheng  
;; APPLICANT: SHANNON, Mark  
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
;; FILE REFERENCE: AECOMICA-7  
;; CURRENT APPLICATION NUMBER: US/09/866,108A  
;; CURRENT FILING DATE: 2001-05-25  
;; PRIOR APPLICATION NUMBER: US 60/207,456  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: GB 24263.6  
;; PRIOR FILING DATE: 2000-10-04  
;; PRIOR APPLICATION NUMBER: US 60/236,359  
;; PRIOR FILING DATE: 2000-09-27  
;; PRIOR APPLICATION NUMBER: PCT/US01/00666  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00667  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00664  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; Remaining Prior Application data removed - See File Wrapper or PALM.  
;; NUMBER OF SEQ ID NOS: 15755  
;; SOFTWARE: Aecomica Sequence Listing Engine  
;; Patent No. 6686188  
;; SEQ ID NO 9583  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-09-866-108A-9583

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1167 GTTAGGGAAGCTGC 1183

Db 1 GTCCAGGGAAGCTGC 17

#### RESULT 95

US-08-483-122-7/c  
;; Sequence 7, Application US/08483122  
;; Patent No. 5750376  
;; GENERAL INFORMATION:  
;; APPLICANT: Weiss, Samuel  
;; APPLICANT: Reynolds, Brent A.  
;; APPLICANT: Hamman, Joseph P.  
;; APPLICANT: Baerge, Edward E.  
;; TITLE OF INVENTION: In Vitro and In Vivo  
;; TITLE OF INVENTION: Proliferation and Use of Multipotent  
;; NUMBER OF SEQUENCES: 8  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESS: Flehr, Hobbach, Test, Albritton  
;; ADDRESS: & Herbert  
;; STREET: Four Embardadero Center, Suite 3400  
;; CITY: San Francisco  
;; STATE: California  
;; COUNTRY: United States  
;; ZIP: 94111-4187  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patentin Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/483,122  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 424  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brunelle, Jan P.  
;; REGISTRATION NUMBER: 35,081  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (415) 781-1989  
;; TELEFAX: (415) 398-3249  
;; TELEX: 910 277299  
;; INFORMATION FOR SEQ ID NO: 7:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 18 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: unknown  
;; TOPOLOGY: unknown  
;; MOLECULE TYPE: cDNA  
US-08-483-122-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1593 CGAGTGACGGCGCTGG 1609

Db 18 CGAGTGATGCGCGCTGG 2

#### RESULT 96

US-08-483-122-8  
;; Sequence 8, Application US/08483122  
;; Patent No. 5750376  
;; GENERAL INFORMATION:  
;; APPLICANT: Weiss, Samuel  
;; APPLICANT: Reynolds, Brent A.  
;; APPLICANT: Hamman, Joseph P.

APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo  
TITLE OF INVENTION: Proliferation and Use of Multipotent  
TITLE OF INVENTION: Neural Stem Cells and their Progeny  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Flehr, Hohbach, Teet, Albritton  
ADDRESSEE: E Herbert  
STREET: Four Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: California  
COUNTRY: United States  
ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/483,122  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-2/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
TELEX: 910 277299  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: CDNA  
US-08-483-122-8

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1593 CGAGGTGACGGCGCTGG 1609  
|||  
Db 1 CGAGGTGATGCCCTGG 17

RESULT 97  
US-08-486-648-7/c  
Sequence 7, Application US/08486648  
Patent No. 5851832  
GENERAL INFORMATION:  
APPLICANT: Weis, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamann, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and  
TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Flehr, Hohbach, Teet, Albritton  
ADDRESSEE: E Herbert  
STREET: Four Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: California  
COUNTRY: United States  
ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/486,648  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-1/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
TELEX: 910 277299  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: CDNA  
US-08-486-648-7

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1593 CGAGGTGACGGCGCTGG 1609  
|||  
Db 18 CGAGGTGATGCCCTGG 2

RESULT 98  
US-08-486-648-8  
Sequence 8, Application US/08486648  
Patent No. 5851832  
GENERAL INFORMATION:  
APPLICANT: Weis, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamann, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and  
TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Flehr, Hohbach, Teet, Albritton  
ADDRESSEE: E Herbert  
STREET: Four Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: California  
COUNTRY: United States  
ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/486,648  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-1/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
TELEX: 910 277299  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown

```
; MOLECULE TYPE: cDNA
US-08-486-648-8

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGGTGACGGCGCTGG 1609
Db 1 CGAGGTGATGCCGCTGG 17

RESULT 99
US-08-627-254C-9/c
Sequence 9, Application US/08627254C
Patent No. 5859229
GENERAL INFORMATION:
APPLICANT: Knies, Douglas A.
TITLE OF INVENTION: Eicosanoid Formation
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: Calfee, Halter & Griwold LLP
STREET: 800 Superior Avenue
CITY: Cleveland
STATE: Ohio
COUNTRY: USA
ZIP: 44114
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/627,254C
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Gollick, Mary E
REGISTRATION NUMBER: 34,829
REFERENCE/DOCKET NUMBER: 18525/00107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (216) 622-8200
TELEFAX: (216) 241-0816
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
ANTI-SENSE: YES
US-08-627-254C-9

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 807 GCGCCAGAGACGAGGT 823
Db 18 GCGCCATGAGCCGAGGT 2

RESULT 100
US-08-442-809A-57
Sequence 57, Application US/08442809A
Patent No. 5976873
GENERAL INFORMATION:
APPLICANT: Bohinski, Robert J.,
APPLICANT: Whitsett, Jeffrey A.
TITLE OF INVENTION: Nucleic Acid Sequences
TITLE OF INVENTION: Controlling Lung Cell -
NUMBER OF SEQUENCES: 76
NUMBER OF SEQUENCES: 76
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
; ADDRESSEE: Cecchi, Stewart & Olstein
; STREET: 6 Becker Farm Road
; CITY: Roseland
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch diskette
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/442,809A
; FILING DATE: 17-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,356
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Olstein, Elliot M.
; REGISTRATION NUMBER: 24,025
; REFERENCE/DOCKET NUMBER: 271010-360
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-442-809A-57

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1416 GGGCTCTTCAGAGAAA 1432
Db 1 GGGCTCTTCAGAGCAA 17

RESULT 101
US-08-442-809A-59
Sequence 59, Application US/08442809A
Patent No. 5976873
GENERAL INFORMATION:
APPLICANT: Bohinski, Robert J.,
APPLICANT: Whitsett, Jeffrey A.
TITLE OF INVENTION: Nucleic Acid Sequences
TITLE OF INVENTION: Controlling Lung Cell -
NUMBER OF SEQUENCES: 76
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carella, Byrne, Bain, Gilfillan,
ADDRESSEE: Cecchi, Stewart & Olstein
STREET: 6 Becker Farm Road
CITY: Roseland
STATE: New Jersey
COUNTRY: USA
ZIP: 07068
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch diskette
COMPUTER: IBM PS/2
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/442,809A
FILING DATE: 17-MAY-1995
CLASSIFICATION: 536
```

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,356  
FILING DATE: 18-MAY-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Olstein, Elliot M.  
REGISTRATION NUMBER: 24,025  
REFERENCE/DOCKET NUMBER: 271010-360  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 201-994-1700  
TELEFAX: 201-994-1744  
INFORMATION FOR SEQ ID NO: 59:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: oligonucleotide  
US-08-442-809A-59

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 GGGCTCTCAGAGAAA 1432  
1 GGGCTCTCAGAGCAA 17

Db 1 GGGCTCTCAGAGCAA 17

RESULT 102  
US-08-486-307-7/c  
Sequence 7, Application US/08486307  
Patent No. 5980885

GENERAL INFORMATION:  
APPLICANT: Weis, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamman, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo  
TITLE OF INVENTION: Proliferation and Use of Multipotent  
TITLE OF INVENTION: Neural Stem Cells and their  
NUMBER OF INVENTIONS: 8  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/486,307  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-3/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown

MOLECULE TYPE: CDNA  
US-08-486-307-7

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGGCGCTGG 1609  
18 CGAGTGATCGCGCTGG 2

Db 18 CGAGTGATCGCGCTGG 2

RESULT 103  
US-08-486-307-8  
Sequence 8, Application US/08486307  
Patent No. 5980885

GENERAL INFORMATION:  
APPLICANT: Weis, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamman, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo  
TITLE OF INVENTION: Proliferation and Use of Multipotent  
TITLE OF INVENTION: Neural Stem Cells and their  
NUMBER OF INVENTIONS: 8  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/486,307  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-3/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: CDNA  
US-08-486-307-8

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGGCGCTGG 1609  
1 CGAGTGATCGCGCTGG 17

Db 1 CGAGTGATCGCGCTGG 17

RESULT 104  
US-08-857-946-23/c  
Sequence 23, Application US/08857946  
Patent No. 5994075

```

; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P.N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 75 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1807
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/857,946
; FILING DATE: 16-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER:
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/05573
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;
US-08-857-946-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2200 GGGTGCTACTGGGCCAT 2216
Db      18 GGGTTCTCTCGGCCAT 2

RESULT 105
US-09-205-921-35
; Sequence 35, Application US/09205921A
; Patent No. 6008048
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF EGR-1 EXPRESSION
; FILE REFERENCE: RTS-0028
; CURRENT APPLICATION NUMBER: US/09/205,921A
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 35
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-09-205-921-35

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      2054 TGTCGAAGCCTTGAG 2070
Db      2 TGTCGAAGCCTTGAG 18

RESULT 106
US-08-970-740-23/C
; Sequence 23, Application US/08970740
; Patent No. 6015670
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P.N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 28 State Street, 28th Floor
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,740
; FILING DATE: 14-NOV-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/857,946
; FILING DATE: 16-MAY-1997
; PRIOR APPLICATION NUMBER:
; FILING DATE: 17-MAY-1996
; APPLICATION NUMBER: 60/017,824
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/59829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-227-7111
; TELEFAX: 617-227-4399
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;
US-08-970-740-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2200 GGGTGCTACTGGGCCAT 2216
Db      18 GGGTTCTCTCGGCCAT 2

RESULT 107
US-08-479-795-7/C
; Sequence 7, Application US/08479795
; Patent No. 6071889
; GENERAL INFORMATION:
; APPLICANT: Weiss, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Hamman, Joseph P.
; TITLE OF INVENTION: Baesge, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo
; TITLE OF INVENTION: Proliferation and Use of Multipotent
; TITLE OF INVENTION: Neural Stem Cells and their Progeny
; NUMBER OF SEQUENCES: 8
```



;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Flehr, Hohbach, Test, Albritton  
;; ADDRESSEE: & Herbert  
;; STREET: Four Embarcadero Center, Suite 3400  
;; CITY: San Francisco  
;; STATE: California  
;; COUNTRY: United States  
;; ZIP: 94111-4187  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patentin Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/479,795  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brunelle, Jan P.  
;; REGISTRATION NUMBER: 35,081  
;; REFERENCE/DOCKET NUMBER: A-61105-6/DJB/JPB  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (415) 781-1989  
;; TELEFAX: (415) 398-3249  
;; TELE: 910 277299  
;; INFORMATION FOR SEQ ID NO: 7:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 18 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: unknown  
;; TOPOLOGY: unknown  
;; MOLECULE TYPE: cDNA  
;; US-08-479-795-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609  
DB 18 CGAGTGATGCGCTGG 2

;; RESULT 108  
;; US-08-479-795-8  
;; Sequence 8, Application US/08479795  
;; Patent No. 6071889  
;; GENERAL INFORMATION:  
;; APPLICANT: Weiss, Samuel  
;; APPLICANT: Reynolds, Brent A.  
;; APPLICANT: Hamman, Joseph P.  
;; APPLICANT: Baetge, Edward E.  
;; TITLE OF INVENTION: In Vitro and In Vivo  
;; TITLE OF INVENTION: Proliferation and Use of Multipotent  
;; TITLE OF INVENTION: Neural Stem Cells and their Progeny  
;; NUMBER OF SEQUENCES: 8  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Flehr, Hohbach, Test, Albritton  
;; ADDRESSEE: & Herbert  
;; STREET: Four Embarcadero Center, Suite 3400  
;; CITY: San Francisco  
;; STATE: California  
;; COUNTRY: United States  
;; ZIP: 94111-4187  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patentin Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/479,795  
;; FILING DATE: 07-JUN-1995  
;; CLASSIFICATION: 435

;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brunelle, Jan P.  
;; REGISTRATION NUMBER: 35,081  
;; REFERENCE/DOCKET NUMBER: A-61105-6/DJB/JPB  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (415) 781-1989  
;; TELEFAX: (415) 398-3249  
;; TELE: 910 277299  
;; INFORMATION FOR SEQ ID NO: 8:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 18 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: unknown  
;; TOPOLOGY: unknown  
;; MOLECULE TYPE: cDNA  
;; US-08-479-795-8

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609  
DB 1 CGAGTGATGCGCTGG 17

;; RESULT 109  
;; US-09-344-521-25/c  
;; Sequence 25, Application US/09344521  
;; Patent No. 6100090  
;; GENERAL INFORMATION:  
;; APPLICANT: Brett P. Monia  
;; APPLICANT: Lex M. Cowart  
;; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3K P85 EXPRESSION  
;; FILE REFERENCE: RTS-0062  
;; CURRENT APPLICATION NUMBER: US/09/344,521  
;; CURRENT FILING DATE: 1999-06-25  
;; NUMBER OF SEQ ID NOS: 47  
;; SEQ ID NO 25  
;; LENGTH: 18  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense Oligonucleotide  
;; US-09-344-521-25

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1772 TTGAGAGAGCTTCAA 1788  
DB 17 TTGAGAGAGCTTCAA 1

;; RESULT 110  
;; US-08-847-844A-135  
;; Sequence 135, Application US/08847844A  
;; Patent No. 6150160  
;; GENERAL INFORMATION:  
;; APPLICANT: KAZAZIAN JR., HAIG H.  
;; APPLICANT: BOEKE, JBF D.  
;; APPLICANT: MORAN, JOHN V.  
;; APPLICANT: DOMBOSKI, BETH A.  
;; TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE OF  
;; TITLE OF INVENTION: MAMMALIAN RETROTRANSPOSONS  
;; NUMBER OF SEQUENCES: 137  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: PANITCH SCHWARZ JACOBS & NADEL, P.C.  
;; STREET: ONE COMMERCE SQUARE, 2005 MARKET STREET, 22ND FL.  
;; CITY: PHILADELPHIA  
;; STATE: PA  
;; COUNTRY: U.S.A.

ZIP: 19103-7086  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/847,844A  
FILING DATE: 28-APR-1997  
CLASSIFICATION: 800  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/749,805  
FILING DATE: 16-NOV-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/006,831  
FILING DATE: 16-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: DOYLE LEARY Ph.D., KATHRYN  
REGISTRATION NUMBER: 36,317  
REFERENCE/DOCKET NUMBER: 9596-2302  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 215-567-2991  
TELEFAX: 215-567-2020  
INFORMATION FOR SEQ ID NO: 135:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-847-844A-135

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1817 AGCCACTATGAGGAA 1833  
DB 2 AGGCAACTATGATGAA 18

RESULT 111  
US-09-474-922A-84/C  
Sequence 84, Application US/09474922A  
Patent No. 6187586  
GENERAL INFORMATION:  
APPLICANT: Brett P. Monia  
APPLICANT: Lex M. Cowseert  
APPLICANT: Richard A. Roth  
TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION  
FILE REFERENCE: RTS-0036  
CURRENT APPLICATION NUMBER: US/09/474,922A  
CURRENT FILING DATE: 1999-12-29  
NUMBER OF SEQ ID NOS: 89  
SEQ ID NO 84  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-474-922A-84

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1867 AGTTTCATCTTGACT 1883  
DB 18 AGTTCTTCTCTGAGT 2

RESULT 112  
US-08-484-406-7/C

Sequence 7, Application US/08484406  
Patent No. 6294346  
GENERAL INFORMATION:  
APPLICANT: Weiss, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamman, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and  
TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Flehr, Hobbach, Teet, Albritton  
ADDRESSER: & Herbert  
STREET: Four Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: California  
COUNTRY: United States  
ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/484,406  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Brunelle, Jan P.  
REGISTRATION NUMBER: 35,081  
REFERENCE/DOCKET NUMBER: A-61105-5/DJB/JPB  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 781-1989  
TELEFAX: (415) 398-3249  
TELEX: 910 277239  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: cDNA  
US-08-484-406-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1593 CGAGTGACGCGCTGG 1609  
DB 18 CGAGTGATGCCGCTGG 2

RESULT 113  
US-08-484-406-8  
Sequence 8, Application US/08484406  
Patent No. 6294346  
GENERAL INFORMATION:  
APPLICANT: Weiss, Samuel  
APPLICANT: Reynolds, Brent A.  
APPLICANT: Hamman, Joseph P.  
APPLICANT: Baetge, Edward E.  
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and  
TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny  
NUMBER OF SEQUENCES: 8  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Flehr, Hobbach, Teet, Albritton  
ADDRESSER: & Herbert  
STREET: Four Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: California  
COUNTRY: United States  
ZIP: 94111-4187

```

: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/484,406
: FILING DATE: 07-JUN-1995
: CLASSIFICATION: 514
: ATTORNEY/AGENT INFORMATION:
: NAME: Brunelle, Jan P.
: REGISTRATION NUMBER: 35,081
: REFERENCE/DOCKET NUMBER: A-61105-5/DJB/JPB
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 781-1989
: TELEFAX: (415) 398-3249
:
: TELEX: 910 277299
: INFORMATION FOR SEQ ID NO: 8:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 18 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: unknown
: TOPOLOGY: unknown
: MOLECULE TYPE: cDNA
:
: US-08-484-406-8
:
Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
:
Qy 1593 CGAGGTGACGCGCTGG 1609
Db 1 CGAGGTGATGCCCTGG 17

RESULT 114
US-08-484-203-7/c
: Sequence 7, Application US/08484203
: Patent No. 6399369
:
: GENERAL INFORMATION:
: APPLICANT: Weis, Samuel
: APPLICANT: Reynolds, Brent A.
: APPLICANT: Hamann, Joseph P.
: APPLICANT: Baetge, Edward E.
: TITLE OF INVENTION: In Vitro and In Vivo Proliferation and
: TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny
: NUMBER OF SEQUENCES: 8
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Flehr, Hohbach, Test, Albritton
: ADDRESSEE: & Herbert
: STREET: Four Embarcadero Center, Suite 3400
: CITY: San Francisco
: STATE: California
: COUNTRY: United States
: ZIP: 94111-4187
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/484,203
: FILING DATE: 07-JUN-1995
: CLASSIFICATION: 514
: ATTORNEY/AGENT INFORMATION:
: NAME: Brunelle, Jan P.
: REGISTRATION NUMBER: 35,081
: REFERENCE/DOCKET NUMBER: A-61105-10/DJB/JPB
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 781-1989
: TELEFAX: (415) 398-3249
:
: TELEX: 910 277299
: INFORMATION FOR SEQ ID NO: 7:

```

```

: SEQUENCE CHARACTERISTICS:
: LENGTH: 18 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: unknown
: TOPOLOGY: unknown
: MOLECULE TYPE: cDNA
:
: US-08-484-203-7
:
Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
:
Qy 1593 CGAGGTGACGCGCTGG 1609
Db 18 CGAGGTGATGCCCTGG 2

RESULT 115
US-08-484-203-8
: Sequence 8, Application US/08484203
: Patent No. 6399369
:
: GENERAL INFORMATION:
: APPLICANT: Weis, Samuel
: APPLICANT: Reynolds, Brent A.
: APPLICANT: Hamann, Joseph P.
: APPLICANT: Baetge, Edward E.
: TITLE OF INVENTION: In Vitro and In Vivo Proliferation and
: TITLE OF INVENTION: Use of Multipotent Neural Stem Cells and their Progeny
: NUMBER OF SEQUENCES: 8
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Flehr, Hohbach, Test, Albritton
: ADDRESSEE: & Herbert
: STREET: Four Embarcadero Center, Suite 3400
: CITY: San Francisco
: STATE: California
: COUNTRY: United States
: ZIP: 94111-4187
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/484,203
: FILING DATE: 07-JUN-1995
: CLASSIFICATION: 514
: ATTORNEY/AGENT INFORMATION:
: NAME: Brunelle, Jan P.
: REGISTRATION NUMBER: 35,081
: REFERENCE/DOCKET NUMBER: A-61105-10/DJB/JPB
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 781-1989
: TELEFAX: (415) 398-3249
:
: INFORMATION FOR SEQ ID NO: 8:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 18 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: unknown
: TOPOLOGY: unknown
: MOLECULE TYPE: cDNA
:
: US-08-484-203-8
:
Query Match 0.64; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.24; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
:
Qy 1593 CGAGGTGACGCGCTGG 1609
Db 1 CGAGGTGATGCCCTGG 17

RESULT 116

```

```
US-08-486-313-7/c
; Sequence 7, Application US/08486313
; Patent No. 6497872
; GENERAL INFORMATION:
; APPLICANT: Weis, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Baetge, Joseph P.
; APPLICANT: Baetge, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation
; TITLE OF INVENTION: and Use of Multipotent Neural Stem Cells and their
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hohbach, Test, Albritton
; STREET: Four Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: United States
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486,313
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Brunelle, Jan P.
; REGISTRATION NUMBER: 35,081
; REFERENCE/DOCKET NUMBER: A-61105-11/DJB/JPB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: cDNA
US-08-486-313-7

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1593 CGAGGTGACGCGCTGG 1609
Db      18 CGAGGTATGCGCGCTGG 2

RESULT 117
; Sequence 8, Application US/08486313
; Patent No. 6497872
; GENERAL INFORMATION:
; APPLICANT: Weis, Samuel
; APPLICANT: Reynolds, Brent A.
; APPLICANT: Hamann, Joseph P.
; APPLICANT: Baetge, Edward E.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation
; TITLE OF INVENTION: and Use of Multipotent Neural Stem Cells and their
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hohbach, Test, Albritton
; STREET: Four Embarcadero Center, Suite 3400
; CITY: San Francisco
```

```
STATE: California
COUNTRY: United States
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,313
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Brunelle, Jan P.
REGISTRATION NUMBER: 35,081
REFERENCE/DOCKET NUMBER: A-61105-11/DJB/JPB
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
US-08-486-313-8

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1593 CGAGGTGACGCGCTGG 1609
Db      1 CGAGGTATGCGCGCTGG 17

RESULT 118
US-09-422-978-8459
; Sequence 8459, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSSET.020C91
; CURRENT APPLICATION NUMBER: US/09/422,978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8459
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-15599 for SEQ 594, in complete
US-09-422-978-8459

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      77 TACTGCTACTTTCGCC 93
Db      11 TACTGCTACTTTCGCC 93
```

Db 2 TACTGCTACTCTCC 18

RESULT 119  
US-08-857-636-51/c  
Sequence 51, Application US/08857636  
Patent No. 6552181  
GENERAL INFORMATION:  
APPLICANT: Dean, Michael Carlton  
APPLICANT: Hahn, Heidi Eve  
APPLICANT: Wicking, Carol  
APPLICANT: Christensen, Jeffrey  
APPLICANT: Zaphiropoulos, Peter G.  
APPLICANT: Gailani, Mae R.  
APPLICANT: Shanley, Susan Mary  
APPLICANT: Chidambaram, Abirami  
APPLICANT: Vorechovsky, Igor  
APPLICANT: Holmberg-Lindstrom, Erika  
APPLICANT: Unden, Anne Birgitte  
APPLICANT: Gillies, Susan Alana  
APPLICANT: Negus, Kylie  
APPLICANT: Smyth, Ian McLeod  
APPLICANT: Pressman, Carol Leah  
APPLICANT: Lefell, David J.  
APPLICANT: Gerrard, Bernard  
APPLICANT: Goldstein, Alisa Miriam  
APPLICANT: Mainwright, Brandon  
APPLICANT: Totfgard, Rune Carl-Magnus  
APPLICANT: Chenevix-Trench, Georgia  
APPLICANT: Bale, Allen E.  
TITLE OF INVENTION: A Basal Cell Carcinoma Tumor Suppressor Gene  
NUMBER OF SEQUENCES: 83  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/857,636  
FILING DATE: 16-MAY-1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/017,906  
FILING DATE: 17-MAY-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: AU P00011  
FILING DATE: 21-MAY-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: AU P00363  
FILING DATE: 07-JUN-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/019,765  
FILING DATE: 14-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Hunter, Tom  
REGISTRATION NUMBER: 38,498  
REFERENCE/DOCKET NUMBER: 015280-278200US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 51:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: DNA  
FEATURE:  
NAME/KEY: -  
LOCATION: 1..18  
OTHER INFORMATION: /note= "PTCR25 primer"  
US-08-857-636-51

Query Match 0.64; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.24; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1461 CTGCCACCCAGTGTC 1477  
Db 17 CTGCCACCCAGTGATC 1

RESULT 120  
US-07-664-989B-121/c  
Sequence 121, Application US/07664989B  
Patent No. 5223409  
GENERAL INFORMATION:  
APPLICANT: Ladner, Robert Charles  
APPLICANT: Guterman, Sonia Kosow  
APPLICANT: Roberts, Bruce Lindsey  
APPLICANT: Markland, William  
APPLICANT: Ley, Arthur Charles  
TITLE OF INVENTION: Directed Evolution of No. 5223409e1  
NUMBER OF SEQUENCES: 121  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Broadway and Neimark  
STREET: 419 Seventh Street, N.W.  
CITY: Washington,  
STATE: DC  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WORDPERFECT 4.2  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/664,989B  
FILING DATE: 19910301  
CLASSIFICATION: 530  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US89/03731  
FILING DATE: 01-SEP-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/487,063  
FILING DATE: 02-MAR-1990  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/240,160  
FILING DATE: 02-SEP-1988  
ATTORNEY/AGENT INFORMATION:  
NAME: Cooper, Iver P.  
REGISTRATION NUMBER: 28005  
REFERENCE/DOCKET NUMBER: LADNER 7  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 121:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: double  
TOPOLOGY: circular  
MOLECULE TYPE: genomic DNA  
US-07-664-989B-121

Query Match 0.64; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 597 TGGGAGATGGCCAT 611  
Db 15 TGGGAGATGACCAT 1

## RESULT 121

US-08-323-192D-13  
Sequence 13, Application US/08323192D  
Patent No. 5786199  
GENERAL INFORMATION:  
APPLICANT: Palese, Peter  
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS  
TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES  
NUMBER OF SEQUENCES: 70  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10036-2711

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/323,192D  
FILING DATE: 14-OCT-1994  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Coruzzi, Laura A.  
REGISTRATION NUMBER: 30,742  
REFERENCE/DOCKET NUMBER: 7682-035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 790-9090  
TELEFAX: (212)869-9741/8864

INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: RNA  
US-08-323-192D-13

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 66.7%; Pred. No. 1.2e+02;  
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 999 CACCCGCTCTGCT 1013  
Db 1 CACCCUGCUCUCGU 15

RESULT 122  
US-08-470-887A-12  
Sequence 12, Application US/08470887A  
Patent No. 5820871

GENERAL INFORMATION:  
APPLICANT: Palese, Peter  
APPLICANT: Garcia-Sastre, Adolfo  
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS  
TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES  
NUMBER OF SEQUENCES: 60  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds  
STREET: 1155 Avenue of the Americas  
CITY: New York

STATE: New York  
COUNTRY: USA  
ZIP: 10036-2711

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/470,887A  
FILING DATE: 06-JUN-1995  
CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:  
NAME: Coruzzi, Laura A.  
REGISTRATION NUMBER: 30,742  
REFERENCE/DOCKET NUMBER: 7682-036  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 790-9090  
TELEFAX: (212) 869-9741/8864

INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: unknown  
MOLECULE TYPE: RNA  
US-08-470-887A-12

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 66.7%; Pred. No. 1.2e+02;  
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Oy 999 CACCCGCTCTGCT 1013  
Db 1 CACCCUGCUCUCGU 15

RESULT 123  
US-08-292-620A-393  
Sequence 393, Application US/08292620A  
Patent No. 5837542

GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620A  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:

PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 393:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-292-620A-393

Query Match 0.64; Score 13.4; DB 1; Length 15;  
Best Local Similarity 80.0%; Pred. No. 1.2e+02;  
Matches 12; Conservatve 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCACCCTCAGCTGG 2116  
Db 1 AGACCTCAGCTGG 15

RESULT 124  
US-08-292-620A-656  
Sequence 656, Application US/08292620A  
Patent No. 5837542  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620A  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435.  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 656:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-292-620A-656

Query Match 0.64; Score 13.4; DB 1; Length 15;  
Best Local Similarity 80.0%; Pred. No. 1.2e+02;  
Matches 12; Conservatve 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCACCCTCAGCTGG 2116  
Db 1 AGACCTCAGCTGG 15

RESULT 125  
US-08-316-439A-10  
Sequence 10, Application US/08316439A  
Patent No. 5840520  
GENERAL INFORMATION:  
APPLICANT: CLARKE, DAVID KIRKWOOD  
APPLICANT: PALSESE, PETER M  
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS EXPRESSION  
TITLE OF INVENTION: SYSTEMS  
NUMBER OF SEQUENCES: 43  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: COOLEY GODWARD CASTRO HUDDLESON & TATUM  
STREET: FIVE PALO ALTO SQUARE  
CITY: PALO ALTO  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94306  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/316,439A  
FILING DATE: September 30, 1994  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/190,678  
FILING DATE: February 1, 1994  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/925,061  
FILING DATE: August 4, 1992  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/527,237  
FILING DATE: May 22, 1990  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/440,053  
FILING DATE: No. 5840520 December 21, 1989  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/399,728  
FILING DATE: August 28, 1989  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: CSERR, LUANN  
REGISTRATION NUMBER: 31,822

```

: REFERENCE/DOCKET NUMBER: AVIR-010/00US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 843-5165
: TELEFAX: (415) 857-0663
: TELEX: 380816 COOLEY PA
: INFORMATION FOR SEQ ID NO: 10:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: SYNTHETIC RNA
US-08-316-439A-10

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      999 CACCTGCTGCTGCT 1013
Db      1 CACCCGCUUCGCU 15

RESULT 126
US-08-252-508B-12
: Sequence 12, Application US/08252508B
: Patent No. 5854037
: GENERAL INFORMATION:
: APPLICANT: Palase, Peter
: APPLICANT: Garcia-Sastre, Adolfo
: TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS
: TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES
: NUMBER OF SEQUENCES: 60
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Pennie & Edmonds
: STREET: 1155 Avenue of the Americas
: CITY: New York
: STATE: New York
: COUNTRY: USA
: ZIP: 10036-2711
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/252,508B
: FILING DATE: 01-JUN-1994
: CLASSIFICATION:
: ATTORNEY/AGENT INFORMATION:
: NAME: Coruzzi, Laura A.
: REGISTRATION NUMBER: 30,742
: REFERENCE/DOCKET NUMBER: 7682-034
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (212) 790-9090
: TELEFAX: (212) 869-9741/8664
: TELEX: 66141 PENNIE
: INFORMATION FOR SEQ ID NO: 12:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: unknown
: MOLECULE TYPE: RNA
US-08-252-508B-12

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      999 CACCTGCTGCTGCT 1013
Db      1 CACCCGCUUCGCU 15
```

```

RESULT 127
US-08-585-684B-163/C
: Sequence 163, Application US/08585684B
: Patent No. 5877021
: GENERAL INFORMATION:
: APPLICANT: Stinchcomb, Daniel T.
: APPLICANT: Jarvis, Thale
: APPLICANT: McSwiggan, James
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
: TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
: NUMBER OF SEQUENCES: 2751
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: FastSeq Version 1.5
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/585,684B
: FILING DATE: January 16, 1996
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/000,951
: FILING DATE: July 7, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/078
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 163:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 15 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
US-08-585-684B-163

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      502 GGCTCTGGAACCT 516
Db      15 GGCTCTGGAACCT 1

RESULT 128
US-08-588-595-6/C
: Sequence 6, Application US/08588595
: Patent No. 5958769
: GENERAL INFORMATION:
: APPLICANT: Robert, James M.
: APPLICANT: Coats, Steven R.
: APPLICANT: Fero, Matthew L.
: TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
: TITLE OF INVENTION: CELL CYCLE PROGRESSION
: NUMBER OF SEQUENCES: 13
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Townsend and Crew
: STREET: One Market Plaza, Stewart Street Tower
```



CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94105-1492  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/588,595  
FILING DATE: 18-JAN-1996  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W.  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 14538A-19  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleotide  
US-08-588-595-6

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 799 GCTGCTCTGCGCCAG 813  
Db 15 GCTCTCTGCGCCAG 1

RESULT 129  
US-09-106-377-12  
Sequence 12, Application US/09106377  
Patent No. 6001634  
GENERAL INFORMATION:  
APPLICANT: Palese, Peter  
APPLICANT: Garcia-Sastre, Adolfo  
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS  
TITLE OF INVENTION: EXPRESSION SYSTEMS AND VACCINES  
NUMBER OF SEQUENCES: 60  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Pennie & Edmonds  
STREET: 1155 Avenue of the Americas  
CITY: New York  
STATE: New York  
COUNTRY: USA  
ZIP: 10036-2711  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/106,377  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/252,508  
FILING DATE: 01-JUN-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Coruzzi, Laura A.  
REGISTRATION NUMBER: 30,742  
REFERENCE/DOCKET NUMBER: 7682-034  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 790-9090

TELEFAX: (212) 869-9741/8864  
TELEX: 66141 PENNIE  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: unknown  
MOLECULE TYPE: RNA  
US-09-106-377-12

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 66.7%; Pred. No. 1.2e+02;  
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 999 CACCCTGCTCTGCT 1013  
Db 1 CACCCTGCTCTGCT 15

RESULT 130  
US-09-071-845-393  
Sequence 393, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 393:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid

STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-393

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 80.0%; Pred. No. 1.2e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCAGCTCAGCCTGG 2116  
|||:|||||:  
Db 1 AGGAGCTCAGCCTGG 15

RESULT 131  
US-09-071-845-656  
Sequence 656, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Diaper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 656:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-656

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 80.0%; Pred. No. 1.2e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2102 AGCAGCTCAGCCTGG 2116  
|||:|||||:  
Db 1 AGGAGCTCAGCCTGG 15

RESULT 132  
US-09-038-073-163/c  
Sequence 163, Application US/09038073  
Patent No. 6194150  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/038,073  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/585,684  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 163:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-038-073-163

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 502 GGCTGTGGAACCT 516  
|||||:  
Db 1 GGCTGTGGAACCT 1

RESULT 133  
5166057-25  
Patent No. 5166057  
APPLICANT: PALASE, PETER, PARVIN, JEFFREY D., KRYSTAL, MARK  
TITLE OF INVENTION: RECOMBINANT NEGATIVE STRAND RNA VIRUS  
EXPRESSION-SYSTEMS  
NUMBER OF SEQUENCES: 43  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/527,237  
FILING DATE: 22-MAY-1990

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440, 053
; FILING DATE: 21-NOV-1989
; APPLICATION NUMBER: 399, 728
; FILING DATE: 28-AUG-1989
; SEQ ID NO:25:
; LENGTH: 15
516057-25

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      999 CACCCGCTCTGCT 1013
DB      1 CACCCGCTCTGCT 15

RESULT 134
US-09-371-772B-7079
; Sequence 7079, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7079
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7079

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      770 ACAGCCACTGCGAG 784
DB      1 ACAGCAACUUGCAG 15

RESULT 135
US-09-829-855-11/c
; Sequence 11, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-11
```

```

; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-11

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      297 AGCTGCGGCACTGGG 311
DB      16 AGCTGCGGCACTGGG 2

RESULT 136
US-09-829-855-13/c
; Sequence 13, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 13
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-13

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      297 AGCTGCGGCACTGGG 311
DB      16 AGCTGCGGCACTGGG 2

RESULT 137
US-09-829-855-77/c
; Sequence 77, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 77
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-77

Query Match      0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGTCGGCGACTGG 311  
|||||  
Db 16 AGTCGGCGACCGG 2

RESULT 139  
US-08-292-620A-1644  
; Sequence 1644, Application US/08292620A  
; Patent No. 5837542  
; GENERAL INFORMATION:  
; APPLICANT: Susan Grimm  
; APPLICANT: Dan T. Stinchcomb  
; APPLICANT: James McSwigen  
; APPLICANT: Sean Sullivan  
; APPLICANT: Kenneth G. Draper  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF  
; TITLE OF INVENTION: DISEASES OR CONDITIONS  
; TITLE OF INVENTION: RELATED TO LEVELS OF  
; TITLE OF INVENTION: INTRACELLULAR ADHESION  
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
; NUMBER OF SEQUENCES: 2390  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/292,620A  
; FILING DATE: August 17, 1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; PRIOR APPLICATION DATA: including application  
; PRIOR APPLICATION DATA: described below:  
; APPLICATION NUMBER: 08/008,895  
; FILING DATE: January 19, 1993  
; APPLICATION NUMBER: 07/989,849  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Waiburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 208/149  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1644:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-292-620A-1644

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 60.0%; Pred. No. 1.4e+02;  
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGTCCTGGTG 583  
:|:|:|:|:|:|:|:|:|  
Db 2 UCCUGGUCUGUG 16

RESULT 139  
US-08-292-620A-1700  
; Sequence 1700, Application US/08292620A  
; Patent No. 5837542  
; GENERAL INFORMATION:  
; APPLICANT: Susan Grimm  
; APPLICANT: Dan T. Stinchcomb  
; APPLICANT: James McSwigen  
; APPLICANT: Sean Sullivan  
; APPLICANT: Kenneth G. Draper  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF  
; TITLE OF INVENTION: DISEASES OR CONDITIONS  
; TITLE OF INVENTION: RELATED TO LEVELS OF  
; TITLE OF INVENTION: INTRACELLULAR ADHESION  
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
; NUMBER OF SEQUENCES: 2390  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/292,620A  
; FILING DATE: August 17, 1994  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; PRIOR APPLICATION DATA: including application  
; PRIOR APPLICATION DATA: described below:  
; APPLICATION NUMBER: 08/008,895  
; FILING DATE: January 19, 1993  
; APPLICATION NUMBER: 07/989,849  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Waiburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 208/149  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1700:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-292-620A-1700

QY 569 TCCTGTCCTGGTG 583  
:|:|:|:|:|:|:|:|:|  
Db 2 UCCUGGUCUGUG 16

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 60.0%; Pred. No. 1.4e+02;  
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

RESULT 140  
US-08-292-620A-1707  
; Sequence 1707, Application US/08292620A  
; Patent No. 5837542  
; GENERAL INFORMATION:  
; APPLICANT: Susan Grimm  
; APPLICANT: Dan T. Stinchcomb

```

; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1707:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1707

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGTCTCTGTGG 583
      :||:||||:|:|:|
Db      2 UCCUGGUCUGGUG 16

RESULT 141
US-08-292-620A-1743
; Sequence 1743, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
```

```

; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1743

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      569 TCCTGTCTCTGTGG 583
      :||:||||:|:|:|
Db      2 UCCUGGUCUGGUG 16

RESULT 142
US-08-292-620A-1796
; Sequence 1796, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
```

```
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEO ID NO: 1796:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1796

Query Match 0.6%, Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Oy 569 TCCTGCTCCTGCTGCG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 143
US-08-292-620A-1873
Sequence 1873, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
```

```
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEO ID NO: 1873:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1873

Query Match 0.6%, Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Oy 569 TCCTGCTCCTGCTGCG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 144
US-08-292-620A-1934
Sequence 1934, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
```

PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1934:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-292-620A-1934

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 60.0%; Pred. No. 1.4e+02;  
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGCTG 583  
Db 2 UCCUGGUCUGGUCG 16

RESULT 145  
US-09-071-845-1644  
Sequence 1644, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwigen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Diaper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE: December 7, 1992  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1644:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-1644

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 60.0%; Pred. No. 1.4e+02;  
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCTGCTGCTG 583  
Db 2 UCCUGGUCUGGUCG 16

RESULT 146  
US-09-071-845-1700  
Sequence 1700, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwigen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Diaper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE: December 7, 1992  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510

```
; INFORMATION FOR SEQ ID NO: 1700:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
US-09-071-845-1700

Query Match
Best Local Similarity 60.0%; Score 13.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCCTGCTG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 147
US-09-071-845-1707
; Sequence 1707, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1707:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
US-09-071-845-1707
```

```
Query Match
Best Local Similarity 60.0%; Score 13.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCCTGCTG 583
Db 2 UCCUGGUCUGGUCG 16

RESULT 148
US-09-071-845-1743
; Sequence 1743, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
US-09-071-845-1743

Query Match
Best Local Similarity 60.0%; Score 13.4; DB 1; Length 17;
Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 569 TCCTGCTCCTGCTG 583
Db 2 UCCUGGUCUGGUCG 16
```



Db 2 UCCUGUCUCUGUG 16

RESULT 149

US-09-071-845-1796

; Sequence 1796, Application US/09071845

; Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/071.845

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/292.620

FILING DATE: August 17, 1994

APPLICATION NUMBER: 08/008.895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989.849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1796:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-071-845-1796

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 60.0%; Pred. No. 1.4e+02;

Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCCTGCTG 583

Db 2 UCCUGUCUCUGUG 16

RESULT 150

US-09-071-845-1873

; Sequence 1873, Application US/09071845

; Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

TITLE OF INVENTION: DISEASES OR CONDITIONS

TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION

TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

NUMBER OF SEQUENCES: 2390

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/071.845

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/292.620

FILING DATE: August 17, 1994

APPLICATION NUMBER: 08/008.895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989.849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1873:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-071-845-1873

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 60.0%; Pred. No. 1.4e+02;

Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 569 TCCTGCTCCTGCTG 583

Db 2 UCCUGUCUCUGUG 16

RESULT 151

US-09-071-845-1934

; Sequence 1934, Application US/09071845

; Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb

APPLICANT: James McSwigen

APPLICANT: Sean Sullivan

APPLICANT: Kenneth G. Draper

TITLE OF INVENTION: RIBOZYME TREATMENT OF

```

; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1934:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1934
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 569 TCCTGCTCTGATG 583
Db 2 UCCUGUCUGUG 16
;
RESULT 152
US-09-371-772B-4197
; Sequence 4197, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT FILING DATE: US/09/371,772B
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR APPLICATION NUMBER: US 08/584,040
;

```

```

; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 1425
; SOFTWARE: Patent version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4197
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 977 CCTCACCAGTGCA 991
Db 2 CGCUCACCAUGUCA 16
;
RESULT 153
US-09-371-772B-4505
; Sequence 4505, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT FILING DATE: US/09/371,772B
; CURRENT APPLICATION NUMBER: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 1425
; SOFTWARE: Patent version 3.0
; SEQ ID NO 4505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4505
;
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.4e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
QY 1991 TTATCTGATGATG 2005
Db 3 UUAUCCUGAUGCUG 17
;
RESULT 154
US-09-371-772B-4755/c
; Sequence 4755, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT FILING DATE: US/09/371,772B
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
;

```

NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 4755  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-4755

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 2214 CATGATGCAGGCTCC 2228  
Db 17 CTGTGTCAGGCTCC 3

RESULT 155  
US-09-371-772B-6625  
Sequence 6625, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: MCSwigen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 6625  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-6625

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 80.0%; Pred. No. 1.4e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Cy 770 ACAGCACTTGACAG 784  
Db 1 ACAGCACTTGACAG 15

RESULT 156  
US-09-827-998-471  
Sequence 471, Application US/09827998  
Patent No. 6656700  
GENERAL INFORMATION:  
APPLICANT: Gu, Yizhong  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
FILE REFERENCE: MDHMOF-8  
CURRENT APPLICATION NUMBER: US/09/827,998  
CURRENT FILING DATE: 2001-04-06  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
NUMBER OF SEQ ID NOS: 1881  
SOFTWARE: Neomica Sequence Listing Engine  
Patent No. 6656700  
SEQ ID NO 471  
LENGTH: 17

TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-827-998-471

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 1027 AAGAAGTGGGAAA 1041  
Db 3 AAGAAGTGGGAAA 17

RESULT 157  
US-09-827-998-472  
Sequence 472, Application US/09827998  
Patent No. 6656700  
GENERAL INFORMATION:  
APPLICANT: Gu, Yizhong  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
FILE REFERENCE: MDHMOF-8  
CURRENT APPLICATION NUMBER: US/09/827,998  
CURRENT FILING DATE: 2001-04-06  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
NUMBER OF SEQ ID NOS: 1881  
SOFTWARE: Neomica Sequence Listing Engine  
Patent No. 6656700  
SEQ ID NO 472  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-827-998-472

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 1027 AAGAAGTGGGAAA 1041  
Db 2 AAGAAGTGGGAAA 16

RESULT 158  
US-09-827-998-473  
Sequence 473, Application US/09827998  
Patent No. 6656700  
GENERAL INFORMATION:  
APPLICANT: Gu, Yizhong  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
FILE REFERENCE: MDHMOF-8  
CURRENT APPLICATION NUMBER: US/09/827,998  
CURRENT FILING DATE: 2001-04-06  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
NUMBER OF SEQ ID NOS: 1881  
SOFTWARE: Neomica Sequence Listing Engine  
Patent No. 6656700  
SEQ ID NO 473  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-827-998-473

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Oy      1027 AAGAAGTGGGAAAA 1041
      |||||
      1 AAGAAGGGGGGAAAA 15

RESULT 159
US-09-866-108A-889/c
; Sequence 889, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 889
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-889

Query March      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
      1703 CCCTTCCCATATG 1717
      |||||
      17 CCCTTCCCATATG 3

RESULT 160
US-09-866-108A-6756
; Sequence 6756, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30

Oy      2041 GTGAGCAGCTCTG 2055
      |||||
      3 GTGAGCAGCTCTG 17

RESULT 161
US-09-866-108A-6757
; Sequence 6757, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6757

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2041 GTGAGCAGCTCTCG 2055
Db      2 GTGAGCAGCTCTCG 16

RESULT 162
US-09-866-108A-6950
; Sequence 6950, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6950

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      89 TCGCCGACTGGTGC 103
Db      3 TCGCCGACTGGTGC 17

RESULT 163
US-09-866-108A-6951
; Sequence 6951, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6951
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6951

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      89 TCGCCGACTGGTGC 103
Db      2 TCGCCGACTGGTGC 16

RESULT 164
US-09-866-108A-6952
; Sequence 6952, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6952
```

APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 6952  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-6952

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 89 TCGCCGACTGGGTC 103  
Db 1 TCGCCGACTGGCTC 15

RESULT 165  
US-09-866-108A-8004  
Sequence 8004, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8004  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8004

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 2038 CAGGTGAGCAGCTC 2052  
Db 3 CAGCTGAGCAGCTC 17

RESULT 166  
US-09-866-108A-8007  
Sequence 8007, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8007  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8007

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2039 AGCTGAGCAGCTCC 2053

Db 1 AGCTGAGCAGCTCC 15

RESULT 167

US-09-866-108A-8054  
Sequence 8054, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: A60MICA Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8054  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8054

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2230 GCAGATGCTCCAGAA 2244

Db 3 GCAGATGCTCCAGAA 17

RESULT 168

US-09-866-108A-8055  
Sequence 8055, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: A60MICA Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8055  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8055

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2230 GCAGATGCTCCAGAA 2244

Db 2 GCAGATGCTCCAGAA 16

RESULT 169

US-08-667-939A-10/c  
Sequence 10, Application US/08667939A  
Patent No. 5998166  
GENERAL INFORMATION:  
APPLICANT: LUC, Shun  
TITLE OF INVENTION: CD16-II VARIANTS  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: BROWDY AND NEWMARK  
STREET: 419 Seventh Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/667,939A  
FILING DATE: 24-JUN-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/433,123  
FILING DATE: 03-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.

REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: LWO-2A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-667-939A-10

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165  
|||||  
Db 13 GCTGCCACTGCTC 1

RESULT 170  
US-08-667-939A-21  
Sequence 21, Application US/08667939A  
Patent No. 5998166  
GENERAL INFORMATION:  
APPLICANT: LWO, Shun  
TITLE OF INVENTION: CD16-II VARIANTS  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/667,939A  
FILING DATE: 24-JUN-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/433,123  
FILING DATE: 03-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: LWO-2A  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 21:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-667-939A-21

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165  
|||||  
Db 3 GCTGCCACTGCTC 15

RESULT 171  
US-08-433-123-10/c  
Sequence 10, Application US/08433123  
Patent No. 6444789  
GENERAL INFORMATION:  
APPLICANT: LWO, Shun  
TITLE OF INVENTION: CD16-II VARIANTS  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/433,123  
FILING DATE:  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: BROWDY, Roger L.  
REGISTRATION NUMBER: 25,618  
REFERENCE/DOCKET NUMBER: LWO-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
TELEX: 248633  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-433-123-10

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 153 GCTGCCACTGCTC 165  
|||||  
Db 13 GCTGCCACTGCTC 1

RESULT 172  
US-08-433-123-21  
Sequence 21, Application US/08433123  
Patent No. 6444789  
GENERAL INFORMATION:  
APPLICANT: LWO, Shun  
TITLE OF INVENTION: CD16-II VARIANTS  
NUMBER OF SEQUENCES: 25  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: BROWDY AND NEIMARK  
STREET: 419 Seventh Street, N.W., Suite 300  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/433,123



```

; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: LEO=2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; TELEX: 248633
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-433-123-21

Query Match 0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 153 GCTGCCACTGCTC 165
| | | | | | | | | |
Db 3 GCTGCCACTGCTC 15

RESULT 173
US-09-371-772B-5827/c
; Sequence 5827, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5827

Query Match 0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGGTGACGGCTCC 2228
| | | | | | | | | |
Db 16 TGGTGACGGCTCC 4

RESULT 174
US-08-373-124A-1030
; Sequence 1030, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
```

```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Marburg, Richard
; REGISTRATION NUMBER: 32,337
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1030:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-1030

Query Match 0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGATTTC 1254
| | | | | | | | | |
Db 5 CACTAGATTTC 17

RESULT 175
US-08-373-124A-1032
; Sequence 1032, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
```

```
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936.422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32.327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1032:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1032

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1243 ACTAGTATTCAG 1255
Db      1 ACUAGUAVUUCAG 13

RESULT 176
US-08-373-124A-1517/c
Sequence 1517, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936.422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32.327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1517:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1517
```

```
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936.422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32.327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1517:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1517

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1050 GTTGCTGGAAGTG 1062
Db      17 GTTGCTGGAAGTG 5

RESULT 177
US-08-373-124A-1519/c
Sequence 1519, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373.124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245.466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192.943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987.132
FILING DATE: August 26, 1992
```

;; FILING DATE: December 7, 1992  
;; APPLICATION NUMBER: 07/936,422  
;; FILING DATE: August 26, 1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 209/035  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510  
;; INFORMATION FOR SEQ ID NO: 1519:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; US-08-373-124A-1519

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GTTCTGGAAGTG 1062  
Db 16 GTTCTGGAAGTG 4

RESULT 179  
US-08-435-628-1030  
; Sequence 1030, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327

;; REFERENCE/DOCKET NUMBER: 209/035  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510  
;; INFORMATION FOR SEQ ID NO: 1030:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; US-08-435-628-1030

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 1.6e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1242 CACTAGTATTTC 1254  
Db 5 CACTAGTATTTC 17

RESULT 179  
US-08-435-628-1032  
; Sequence 1032, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1032:

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1032

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Cy      1243 ACTAGTATTCAG 1255
Db      1 ACUAGUAVUUCAG 13

RESULT 180
US-08-435-628-1517/C
; Sequence 1517, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1517:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1517
```

```

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1050 GTTGCTGGAAGTG 1062
Db      17 GTTGCTGGAAGTG 5

RESULT 181
US-08-435-628-1519/C
; Sequence 1519, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1519:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-1519

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1050 GTTGCTGGAAGTG 1062
```

Db 16 GTGCTTCTTC 4

## RESULT 182

US-08-897-340-9/c  
Sequence 9, Application US/08897340

Patent No. 5955306

GENERAL INFORMATION:

APPLICANT: Gimeno, Carlos J. and Errada, Patrick. R.

TITLE OF INVENTION: Weight Control Pathway Genes and Uses

TITLE OF INVENTION: Therefor

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: LAHIVE & COCKFIELD, LLP

STREET: 28 State Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/897,340

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/715,032

FILING DATE: 17-SEP-1996

ATTORNEY/AGENT INFORMATION:

NAME: Silveri, Jean M.

REGISTRATION NUMBER: 39,030

REFERENCE/DOCKET NUMBER: NMI-005CP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400

TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

US-08-897-340-9

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTGCTTCTTC 1021

Db 16 CTGCTTCTTC 4

## RESULT 183

US-09-252-329-9/c  
Sequence 9, Application US/09252329

Patent No. 6147192

GENERAL INFORMATION:

APPLICANT: Gimeno, Carlos J. and Errada, Patrick. R.

TITLE OF INVENTION: Weight Control Pathway Genes and Uses

TITLE OF INVENTION: Therefor

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSEE: LAHIVE & COCKFIELD, LLP

STREET: 28 State Street

CITY: Boston

STATE: Massachusetts

COUNTRY: USA

ZIP: 02109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/252,329

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/897,340

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Silveri, Jean M.

REGISTRATION NUMBER: 39,030

REFERENCE/DOCKET NUMBER: NMI-005CP

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617)227-7400

TELEFAX: (617)227-5941

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: CDNA

US-09-252-329-9

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTGCTTCTTC 1021

Db 16 CTGCTTCTTC 4

## RESULT 184

US-08-584-040-2268

Sequence 2268, Application US/08584040

Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela

APPLICANT: McSwigen, James

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR

TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL

TITLE OF INVENTION: GROWTH FACTOR

NUMBER OF SEQUENCES: 8502

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/584,040

FILING DATE: January 11, 1996

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995

```

;
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2268:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2268

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches      8; Conservative      5; Mismatches      0; Indels      0; Gaps      0;

Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUTCUCA 17

RESULT 185
US-08-584-040-2269
; Sequence 2269, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Filth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2269:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-371-772B-813
; Sequence 813, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-813

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 1.6e+02;
Matches      8; Conservative      5; Mismatches      0; Indels      0; Gaps      0;

Qy      691 ATGTCATTCTCA 703
Db      5 AUGGCCAUTCUCA 17

RESULT 187
US-09-371-772B-814
; Sequence 814, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
```

ORGANISM: Homo sapiens  
US-09-371-772B-814

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 1.6e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 691 ATGTCATTCTCA 703  
DB 1 AUGUCAUUCUCA 13

RESULT 188

US-09-371-772B-4754/C  
Sequence 4754, Application US/09371772B

PATENT NO. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwigen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
PRIOR FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 4754  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-4754

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2216 TGGTCAGGCTCC 2228  
DB 16 TGGTCAGGCTCC 4

RESULT 189  
US-09-371-772B-4789/C  
Sequence 4789, Application US/09371772B

PATENT NO. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwigen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
PRIOR FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 4789  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens

US-09-371-772B-4789

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 328 CTTCCTTGTTC 340  
DB 16 CTTCCTTGTTC 4

RESULT 190

US-09-371-772B-5053  
Sequence 5053, Application US/09371772B  
PATENT NO. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwigen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
PRIOR FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 5053  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5053

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 1.6e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1917 TGGAGCCAGCTG 1929  
DB 2 TGGAGCCAGCTG 14

RESULT 191

US-09-371-772B-5054  
Sequence 5054, Application US/09371772B  
PATENT NO. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwigen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00, 876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
PRIOR FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 5054  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5054

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 1.6e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGAGGCGAGCTG 1929  
|:|:|:|:|:|:|:|:  
DB 1 UGGAGCGCAGCTG 13

RESULT 192  
US-09-371-772B-5194  
; Sequence 5194, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MEHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5194  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5194

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 1.6e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCATTCGA 703  
|:|:|:|:|:|:|:|:  
DB 4 AUGGCCAUTCUG 16

RESULT 193  
US-09-371-772B-5195  
; Sequence 5195, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MEHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5195  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5195

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 1.6e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCATTCGA 703  
|:|:|:|:|:|:|:|:  
DB 3 AUGGCCAUTCUG 15

RESULT 194  
US-09-866-108A-897/C  
; Sequence 897, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 897  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-897

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1699 AAGCCCTTCCCC 1711  
|:|:|:|:|:|:|:|:  
DB 13 AAGCCCTTCCCC 1

RESULT 195  
US-09-866-108A-9584  
; Sequence 9584, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.



```
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9584
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9584

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAAGCTGC 1183
Db      4 AGGGAAGAAGCTGC 16

RESULT 196
US-09-866-108A-9585
Sequence 9585, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9585
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9585

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGAAGCTGC 1183
Db      3 AGGGAAGAAGCTGC 15

RESULT 197
US-09-866-108A-9586
Sequence 9586, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 9586
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-9586
```

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1171 AGGGAAGCTGC 1183  
|||||  
Db 2 AGGGAAGCTGC 14

## RESULT 198

US-09-866-108A-9587  
; Sequence 9587, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: A60MCA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 9587  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-9587

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1171 AGGGAAGCTGC 1183  
|||||  
Db 1 AGGGAAGCTGC 13

## RESULT 199

US-07-988-194A-16  
; Sequence 16, Application US/07988194A  
; Patent No. 5359046  
; GENERAL INFORMATION:  
; APPLICANT: Capon, Daniel J.  
; APPLICANT: Weiss, Arthur  
; APPLICANT: Irving, Brian A.

APPLICANT: Roberts, Margo R.  
APPLICANT: Zsebo, Krisztina  
TITLE OF INVENTION: Chimeric Chains for Receptor  
TITLE OF INVENTION: Associated Signal Transduction Pathways  
NUMBER OF SEQUENCES: 49  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Flehr, Hohbach, Teet, Albritton &  
ADDRESSEE: Herbert  
STREET: 4 Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA

ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy Disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/988,194A  
FILING DATE: December 9, 1992  
CLASSIFICATION: 536

ATTORNEY/AGENT INFORMATION:  
NAME: Rowland, Bertram I.  
REGISTRATION NUMBER: 20015  
REFERENCE/DOCKET NUMBER: A-55107-1 CELL-0051  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-781-1989  
TELEFAX: 415-398-3249

INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: cDNA  
US-07-988-194A-16

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1499 AGGCGCTTGTCAGTT 1514  
|||||  
Db 1 AGGCGCATGTCAGCT 16

RESULT 200  
US-08-061-697-23/C  
; Sequence 23, Application US/08061697  
; Patent No. 5498696

GENERAL INFORMATION:  
APPLICANT: Brown, Michael S.; Briggs, Michael R.; Wang,  
APPLICANT: Xiaodong, Goldstein, Joseph L.  
TITLE OF INVENTION: Sterol Regulatory Element Binding Proteins  
TITLE OF INVENTION: and Their Use in Screening Assays  
NUMBER OF SEQUENCES: 36  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P. O. Box 4433  
CITY: Houston  
STATE: Texas  
COUNTRY: USA  
ZIP: 77210

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/061,697  
FILING DATE: Concurrently Herewith  
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:  
NAME: Parker, David L.  
REGISTRATION NUMBER: 32,165  
REFERENCE/DOCKET NUMBER: UTSD:347/PAR  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (512) 320-7200  
TELEFAX: (512) 474-7577  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-061-697-23

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 780 GCAGGGAGAGTGT 795  
Db 16 GCAGGGAGAGTGT 1

RESULT 201  
US-08-131-365B-23/C  
Sequence 23, Application US/08131365B  
Patent No. 5527690

GENERAL INFORMATION:  
APPLICANT: Brown, Michael S.  
APPLICANT: Briggs, Michael R.  
APPLICANT: Wang, Xiaodong  
APPLICANT: Goldstein, Joseph L.  
TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING  
TO STEROL REGULATORY ELEMENT BINDING  
TITLE OF INVENTION: PROTEINS  
NUMBER OF SEQUENCES: 64  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P.O. Box 4433  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77210

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/131,365B  
FILING DATE: 01-OCT-1993  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Parker, David L.

REGISTRATION NUMBER: 32,165  
REFERENCE/DOCKET NUMBER: UTSD:372/PAR  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (512) 418-3000  
TELEFAX: (512) 474-7577  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /desc = "DNA"

US-08-131-365B-23

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 780 GCAGGGAGAGTGT 795  
Db 16 GCAGGGAGAGTGT 1

RESULT 202  
US-08-258-152-18

Sequence 18, Application US/08258152  
Patent No. 5686279  
GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
APPLICANT: ROBERTS, MARGO R.  
APPLICANT: DULL, THOMAS J.  
APPLICANT: ZSEBO, KRISZTINA M.

APPLICANT: QIN, LU  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER  
VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION  
TITLE OF INVENTION: OF MAMMALIAN CELLS  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESIS, INC.  
STREET: 322 LAKESIDE DRIVE  
CITY: FOSTER CITY  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94404

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/258,152  
FILING DATE: 10-JUN-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/076,299  
FILING DATE: 11-JUN-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUPEN, KAREN I.

REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131  
TELEFAX: 415-349-7392

INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-258-152-18

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1499 AGGGCCTGTCCAGTT 1514  
Db 1 AGGGCCTGTCCAGTT 16

RESULT 203  
US-08-076-299A-18  
Sequence 18, Application US/08076299A  
Patent No. 5834256

GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
APPLICANT: ROBERTS, MARGO R.  
APPLICANT: DULL, THOMAS J.

```

: APPLICANT: ZSEBO, KRISZTINA M.
: APPLICANT: QIN, LU
: TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
: TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
: TITLE OF INVENTION: OF MAMMALIAN CELLS
: NUMBER OF SEQUENCES: 30
: CORRESPONDENCE ADDRESSES:
: ADDRESS: CELL GENESYS, INC.
: STREET: 322 LAKESIDE DRIVE
: CITY: FOSTER CITY
: STATE: CALIFORNIA
: COUNTRY: USA
: ZIP: 94404
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/076,299A
: FILING DATE: 11-JUN-1993
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER:
: FILING DATE:
: ATTORNEY/AGENT INFORMATION:
: NAME: KRUPEN, KAREN I.
: REGISTRATION NUMBER: 34,647
: REFERENCE/DOCKET NUMBER: CELL 13.0
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 415-358-9600 X131
: TELEFAX: 415-349-7392
: INFORMATION FOR SEQ ID NO: 18:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 16 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
: US-08-076-299A-18

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGCGCTGTCCAGTT 1514
Db      1 AGGCGCATGTCACACT 16

RESULT 204
US-08-438-582-18
: Sequence 18, Application US/08438582
: Patent No. 5858740
: GENERAL INFORMATION:
: APPLICANT: FINER, MITCHELL H.
: APPLICANT: ROBERTS, MARGO R.
: APPLICANT: DULL, THOMAS J.
: APPLICANT: ZSEBO, KRISZTINA M.
: APPLICANT: QIN, LU
: TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
: TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
: NUMBER OF SEQUENCES: 32
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: CELL GENESYS, INC.
: STREET: 322 LAKESIDE DRIVE
: CITY: FOSTER CITY
: STATE: CALIFORNIA
: COUNTRY: USA
: ZIP: 94404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
```

```

: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/438,582
: FILING DATE: 10-MAY-1995
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/258,152
: FILING DATE: 10-JUN-1994
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/076,299
: FILING DATE: 11-JUN-93
: ATTORNEY/AGENT INFORMATION:
: NAME: KRUPEN, KAREN I.
: REGISTRATION NUMBER: 34,647
: REFERENCE/DOCKET NUMBER: CELL 13.2
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 415-358-9600 X131
: TELEFAX: 415-349-7392
: INFORMATION FOR SEQ ID NO: 18:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 16 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
: US-08-438-582-18

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1499 AGGCGCTGTCCAGTT 1514
Db      1 AGGCGCATGTCACACT 16

RESULT 205
US-08-668-123-23/c
: Sequence 23, Application US/08668123
: Patent No. 5891631
: GENERAL INFORMATION:
: APPLICANT: Brown, Michael S.
: APPLICANT: Briggs, Michael R.
: APPLICANT: Wang, Xiaodong
: APPLICANT: Goldstein, Joseph L.
: TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
: TITLE OF INVENTION: TO STEROID REGULATORY ELEMENT BINDING
: NUMBER OF SEQUENCES: 64
: CORRESPONDENCE ADDRESSES:
: ADDRESSEE: Arnold, White & Durkee
: STREET: P O. Box 4433
: CITY: Houston
: STATE: Texas
: COUNTRY: U.S.A.
: ZIP: 77210
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/668,123
: FILING DATE: 14-JUN-1996
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/131,365
: FILING DATE: 01-OCT-1993
: ATTORNEY/AGENT INFORMATION:
: NAME: Parker, David L.
: REGISTRATION NUMBER: 32,165
```

```

?
? TELECOMMUNICATION INFORMATION:
? REFERENCE/DOCKET NUMBER: UTSD:372/PAR
? TELEPHONE: (512) 418-3000
? TELEFAX: (512) 474-5577
? INFORMATION FOR SEQ ID NO: 23:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 16 base pairs
? TYPE: nucleic acid
? STRANDEDNESS: single
? TOPOLOGY: linear
? MOLECULE TYPE: other nucleic acid
? DESCRIPTION: /desc = "DNA"
US-08-668-123-23

```

Query Match	0.6%	Score 12.8 / DB 1	length 16;
Best Local Similarity	87.5%	Pred. No. 1.7e+02;	
Matches 14; Conservative	0;	Mismatches 2;	Indels 0; Gaps 0;

```

Qy      780 GCAGGAGAGCTGTT 795
          ||||| |||||
Db      16 GCAGGGGAGAGTT 1

```

RESULT 206  
 US-08-954-210-64  
 Sequence 64, Application US/08954210  
 Patent No. 6043077  
 GENERAL INFORMATION:  
 APPLICANT: Barber, Jack R.  
 APPLICANT: Welch, Peter J.  
 APPLICANT: Triltz, Richard  
 APPLICANT: Yel, Sompun  
 APPLICANT: Yu, Mang  
 TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES  
 NUMBER OF SEQUENCES: 73  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: SEED AND BERRY LLP  
 STREET: 6300 Columbia Center, 701 Fifth Avenue  
 CITY: Seattle  
 STATE: Washington  
 COUNTRY: USA  
 ZIP: 98104-7092  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/954,210  
 FILING DATE: 20-OCT-1997  
 CLASSIFICATION: 514  
 ATTORNEY/AGENT INFORMATION:  
 NAME: McMaisters, David D.  
 REGISTRATION NUMBER: 33,963  
 REFERENCE/DOCKET NUMBER: 480124.403CL  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (206) 622-6030  
 TELEFAX: (206) 682-6031  
 INFORMATION FOR SEQ ID NO: 64:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 16 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 US-08-954-210-64

Query Match	0.6%	Score 12.8;	DB 1;	Length 16;
Best Local Similarity	62.5%	Pred. NO.1.7e+02;		
Matches	10;	Conservative	4;	Mismatches 2;
				Indels 0;
				Gaps 0;
QY	713	GTCCAGTCTCTGAGTT	728	
	: : : : : : : :			
db	1	GUGCAGUCCUGAAGCU	16	

RESULT 207  
US-08-413-974-16/c  
US-08-413-974-16/c

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

```

APPLICATION NUMBER: US/08/413,974

PRIOR APPLICATION DATA:

FILING DATE: 10/04/2000

FILING DATE:

NAME: Hohenschutz, Liza D.

REGISTRATION NUMBER: 33, 112  
REFERENCE/DOCKET NUMBER: IMPH-0000

TELECOMMUNICATION INFORMATION:  
 (015) ECO 3100

; INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs

Query Match	0.64	Score 12.8	DB 1	Length 16
Best Local Similarity	87.5%	Pred. No. 1.7e+02		
Matches 14	Conservative 0	Mismatches 2	Indels 0	Gaps 0

```

QY      1439 AGTACCTGGACCGCAC 1454
          |||||
Db      16 AGTACCGGACGGCAC 1

```

```

RESULT 208
US-08-434-418-16/c
: Sequence 16, Application US/08434418
: Patent No. 6197313
: GENERAL INFORMATION:
: APPLICANT: Singh, Mohan Bir et al.
: TITLE OF INVENTION: RYSGRASS POLLEN ALLERGEN
: FILE REFERENCE: INT-051CND2
: CURRENT APPLICATION NUMBER: US/08/434,418
: CURRENT FILING DATE: 1995-05-03
: PRIOR APPLICATION NUMBER: 08/202,861
: PRIOR FILING DATE: 1994-25-02
: NUMBER OF SEQ ID NOS: 25

```

SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 16  
LENGTH: 16  
TYPE: DNA  
ORGANISM: Lolium perenne  
US-08-434-418-16

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1439 AGTACCTGGACCGCAGC 1454  
Db 16 AGTACCGGACGCGCAC 1

RESULT 209  
US-09-266-596-18  
Sequence 18, Application US/09266596  
Patent No. 6218187  
GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
APPLICANT: DULL, THOMAS J.  
APPLICANT: ZSEBO, KRISTINA M.  
APPLICANT: COOKE, KEEGAN  
APPLICANT: FARSON, DEBORAH A.  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER  
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION  
TITLE OF INVENTION: OF MAMMALIAN CELLS  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESYS, INC.  
STREET: 322 LAKESIDE DRIVE  
CITY: FOSTER CITY  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94404  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/266,596  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/517,488  
FILING DATE: 21-AUG-1995  
APPLICATION NUMBER: US 08/258,152  
FILING DATE: 10-JUN-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/076,299  
FILING DATE: 11-JUN-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUPEN, KAREN I.  
REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131  
TELEFAX: 415-349-7392  
INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-266-596-18  
Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGGCCTTGTCAGTT 1514  
Db 1 AGGGCATGTCAGCT 16

RESULT 210  
US-08-433-288-16/c  
Sequence 16, Application US/08433288  
Patent No. 6239269  
GENERAL INFORMATION:  
APPLICANT: Singh, Mohan Bir et al.  
TITLE OF INVENTION: RYEGRASS POLLEN ALLERGEN  
FILE REFERENCE: IMI-051CND1  
CURRENT APPLICATION NUMBER: US/08/433,288  
CURRENT FILING DATE: 1995-05-03  
PRIOR APPLICATION NUMBER: 08/413,947  
PRIOR FILING DATE: 1995-03-30  
PRIOR APPLICATION NUMBER: 08/202,861  
PRIOR FILING DATE: 1994-02-25  
PRIOR APPLICATION NUMBER: 07/746,703  
PRIOR FILING DATE: 1991-08-16  
PRIOR APPLICATION NUMBER: 07/585,086  
PRIOR FILING DATE: 1990-10-26  
NUMBER OF SEQ ID NOS: 25  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 16  
LENGTH: 16  
TYPE: DNA  
ORGANISM: Lolium perenne  
US-08-433-288-16

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1439 AGTACCTGGACCGCAGC 1454  
Db 16 AGTACCGGACGCGCAC 1

RESULT 211  
US-08-174-739A-16/c  
Sequence 16, Application US/08174739A  
Patent No. 6265566  
GENERAL INFORMATION:  
APPLICANT: Singh, Mohan Bir  
APPLICANT: Knox, Robert B.  
APPLICANT: Smith, Penelope  
APPLICANT: Aviloglu, Asil  
APPLICANT: Theerakulpisut, Piyada  
APPLICANT: Hough, Terry  
TITLE OF INVENTION: Ryegrass pollen Allergen  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Iahive & Cockfield, LLP  
STREET: 60 State Street, Suite 510  
CITY: Boston  
STATE: MA  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/174,739A  
FILING DATE: 29-DEC-1993  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Mandragouras, Amy E.  
REGISTRATION NUMBER: 36,207

```

; REFERENCE/DOCKET NUMBER: IMI-051DV
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-174-739A-16

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1439 AGTACTGACCGCAGC 1454
Db      16 AGTACCGGACGCGAC 1

RESULT 212
US-08-479-737-16
; Sequence 16, Application US/08479737
; Patent No. 6319494
;
GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J
;           Weiss, Arthur
;           Irving, Brian A
;           Roberts, Margo R
;           Zeebo, Kristina
;
TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
;
NUMBER OF SEQUENCES: 51
;
CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 Lakeside Drive
; CITY: Foster City
; STATE: California
; COUNTRY: USA
; ZIP: 94404
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
;
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/479,737
; FILING DATE: 07-Jun-1995
; CLASSIFICATION: <Unknown>
;
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/238,405
; FILING DATE: 05-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandel, Saralynn
; REGISTRATION NUMBER: 31,853
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-9600
; TELEFAX: (415) 358-0803
;
INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
;
US-08-479-737-16

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

OY      1499 AGGGCCTTGTCCAGT 1514
Db      1 AGGGCAGTTCAGCT 16

RESULT 213
US-08-294-312B-26
; Sequence 26, Application US/08294312B
; Patent No. 6380369
;
GENERAL INFORMATION:
; APPLICANT: Adams et al.
;
TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
;
FILE REFERENCE: P106P2
;
CURRENT APPLICATION NUMBER: US/08/294,312B
;
CURRENT FILING DATE: 1994-08-23
;
PRIOR APPLICATION NUMBER: 08/210,143
;
PRIOR FILING DATE: 1994-03-16
;
PRIOR APPLICATION NUMBER: 08/187,757
;
PRIOR FILING DATE: 1994-01-27
;
NUMBER OF SEQ ID NOS: 78
;
SOFTWARE: Patentin version 3.0
;
SEQ ID NO 26
;
LENGTH: 16
;
TYPE: DNA
;
ORGANISM: Artificial Sequence
;
FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
;
US-08-294-312B-26

Query Match          0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2089 CTCTCATCACCGCAGC 2104
Db      1 CTCTCATCACCGCAGC 16

RESULT 214
US-08-475-442A-16
; Sequence 16, Application US/08475442A
; Patent No. 6407221
;
GENERAL INFORMATION:
; APPLICANT: CAPON, DANIEL J
;           WEISS, ARTHUR
;           IRVING, BRIAN A
;           ROBERTS, MARGO R
;           ZEEBO, KRISTINA
;
TITLE OF INVENTION: CHIMERIC CHAINS FOR
;
NUMBER OF SEQUENCES: 51
;
CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
;
CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,442A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
;
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/238,405
; FILING DATE: 05-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,194
```

```

; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/627,643
; FILING DATE: 14-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09431
; FILING DATE: 12-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL5.5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415)358-9600x131
; TELEFAX: (415)349-7392
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-475-442A-16
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1499 AGGCGCTTGTCAGCTT 1514
Db 1 AGGCGCATGTCAGCT 16
```

```
RESULT 215
US-08-468-024B-26
; Sequence 26, Application US/08468024B
; Patent No. 6416984
; GENERAL INFORMATION:
; APPLICANT: Haseltine et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P3
; CURRENT APPLICATION NUMBER: US/08/468,024B
; CURRENT FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE: OTHER INFORMATION: hmlh1 sense primer
; US-08-468-024B-26
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2089 CTTCTCATCACCCAGC 2104
Db 1 CTTCTCAACACCAAGC 16
```

```
RESULT 216
US-08-434-256-16/c
; Sequence 16, Application US/08434256
; Patent No. 6451324
; GENERAL INFORMATION:
; APPLICANT: Singh, Mohan Bir, Knox, Robert B., Smith, Penelope,
```

```

; APPLICANT: Avtioglu, Asil, Theerakulpisut, Piyada, Hough, Terryn
; TITLE OF INVENTION: Ryegrass Pollen Allergen
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6451324ris
; STREET: 1 Liberty Place, 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/434,256
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Hohenschutz, Liza D.
; REGISTRATION NUMBER: 33,712
; REFERENCE/DOCKET NUMBER: IMPH-0003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215)568-3100
; TELEFAX: (215)568-3949
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-434-256-16
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1439 AGTACTGTGACCGCAC 1454
Db 16 AGTACCGGACGCGCAC 1
```

```
RESULT 217
US-09-431-419A-64
; Sequence 64, Application US/09431419A
; Patent No. 6458567
; GENERAL INFORMATION:
; APPLICANT: Barber, Jack R.
; APPLICANT: Welch, Peter J.
; APPLICANT: Tiltz, Richard
; APPLICANT: Yel, Soomin
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: HEPATITIS C VIRUS RIBOZYMES
; FILE REFERENCE: 480124.403C3
; CURRENT APPLICATION NUMBER: US/09/431,419A
; CURRENT FILING DATE: 1999-11-01
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 64
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Hepatitis C Virus
; US-09-431-419A-64
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 1.7e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 713 GTGCGTGTGAGGTT 728
Db 1 GUGCAGUCUCUGAGCU 16
```



RESULT 218  
US-08-187-757D-24  
Sequence 24, Application US/0818757D  
Patent No. 6482606  
GENERAL INFORMATION:  
APPLICANT: Adams et al.  
TITLE OF INVENTION: Human DNA Mismatch Repair Proteins  
FILE REFERENCE: P1106  
CURRENT APPLICATION NUMBER: US/08/187,757D  
CURRENT FILING DATE: 1994-01-27  
NUMBER OF SEQ ID NOS: 33  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 24  
LENGTH: 16  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: hMLH1 sense primer  
US-08-187-757D-24

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCACG 2104  
DB 1 CTTCTCATCACCACG 16

RESULT 219  
US-09-944-411-18  
Sequence 18, Application US/09944411  
Patent No. 6506604  
GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
DULL, THOMAS J.  
ZSEBO, KRISZTINA M.  
COOKE, KEEGAN  
PARSON, DEBORAH A.  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER  
VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION  
OF MAMMALIAN CELLS  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESYS, INC.  
STREET: 322 LAKESIDE DRIVE  
CITY: FOSTER CITY  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94404  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/944,411  
FILING DATE: 04-Sep-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/914,893  
FILING DATE: <Unknown>  
APPLICATION NUMBER: US 08/258,152  
FILING DATE: 10-JUN-1994  
APPLICATION NUMBER: US 08/076,299  
FILING DATE: 11-JUN-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUPEN, KAREN I.  
REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131

TELEFAX: 415-349-7392  
INFORMATION FOR SEQ ID NO: 18:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 18:  
US-09-944-411-18

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1499 AGGCGCTGTCCAGT 1514  
DB 1 AGGCGCTGTCCAGT 16

RESULT 220  
US-09-371-772B-5758  
Sequence 5758, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: MCSwigen, Jim  
APPLICANT: Scinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00.876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5758  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5758

Query Match 0.6%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 56.2%; Pred. No. 1.7e+02;  
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1992 TATCTGATGATGCC 2007  
DB 1 TATCTGATGATGCC 16

RESULT 221  
US-09-371-772B-5759  
Sequence 5759, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: MCSwigen, Jim  
APPLICANT: Scinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBH00.876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26

```
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5759
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5759

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2016 CTTGGATGCAACAGC 2031
Db 1 CUGGAGUGGUGACAGC 16

RESULT 222
US-09-371-772B-7002
; Sequence 7002, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jacobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-U (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7002
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-7002

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1469 CCAGTGGTCTGTGAC 1484
Db 1 CCAGUGGCGUGAC 16

RESULT 223
US-08-465-679-26
; Sequence 26, Application US/08465679
; Patent No. 6610477
; GENERAL INFORMATION:
; APPLICANT: Haeelint et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P4
; CURRENT APPLICATION NUMBER: US/08/465,679
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: 08/294,312
; PRIOR FILING DATE: 1994-08-23
; PRIOR APPLICATION NUMBER: 08/210,143
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 26
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
; US-08-465-679-26

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCCAGC 2104
Db 1 CTTCTCAACACAGC 16

RESULT 224
US-09-829-855-107
; Sequence 107, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 107
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
; US-09-829-855-107

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 CTGCGTCCCGAGCT 54
Db 1 CTGCGCGCGGAGCT 16

RESULT 225
US-08-210-143C-24
; Sequence 24, Application US/08210143C
; Patent No. 6620619
; GENERAL INFORMATION:
; APPLICANT: Haeelint et al.
; TITLE OF INVENTION: Human DNA Mismatch Repair Proteins
; FILE REFERENCE: PF106P1
; CURRENT APPLICATION NUMBER: US/08/210,143C
; PRIOR FILING DATE: 1994-03-16
; PRIOR APPLICATION NUMBER: 08/187,757
; PRIOR FILING DATE: 1994-01-27
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hMLH1 sense primer
; US-08-210-143C-24

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 16;
```

Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 CTTCTCATCACCACG 2104

Db 1 CTTCTCAGACCAAGC 16

RESULT 226

US-09-479-005A-337/C  
Sequence 337, Application US/09479005A  
Patent No. 6656731  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity  
FILE REFERENCE: MEH80-884-C  
CURRENT APPLICATION NUMBER: US/09/479,005A  
CURRENT FILING DATE: 2000-01-07  
PRIOR APPLICATION NUMBER: US 09/444,209  
PRIOR FILING DATE: 1999-11-19  
PRIOR APPLICATION NUMBER: US 09/159,274  
PRIOR FILING DATE: 1998-09-22  
PRIOR APPLICATION NUMBER: US 60/059,473  
PRIOR FILING DATE: 1997-09-22  
NUMBER OF SEQ ID NOS: 1208  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 337  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-479-005A-337

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 604 ATGCCATTCATCTT 619

Db 16 ATGCCATTCATCTT 1

RESULT 227

5256545-4/C  
Patent No. 5256545  
APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL, DAVID W.; SUDHOF, THOMAS C.  
TITLE OF INVENTION: STEROL REGULATORY ELEMENTS  
NUMBER OF SEQUENCES: 42  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/425,852  
FILING DATE: 20-OCT-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 33,330  
FILING DATE: 30-MAR-1987  
APPLICATION NUMBER: 33,081  
FILING DATE: 30-MAR-1987  
SEQ ID NO: 4  
LENGTH: 16  
5256545-4

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTT 795

Db 16 GCAGGAGAGGTGTT 1

RESULT 228

5256545-33  
Patent No. 5256545  
APPLICANT: BROWN, MICHAEL S.; GOLDSTEIN, JOSEPH L.; RUSSELL,

DAVID W.; SUDHOF, THOMAS C.  
TITLE OF INVENTION: STEROL REGULATORY ELEMENTS  
NUMBER OF SEQUENCES: 42  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/425,852  
FILING DATE: 20-OCT-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 33,330  
FILING DATE: 30-MAR-1987  
APPLICATION NUMBER: 33,081  
FILING DATE: 30-MAR-1987  
SEQ ID NO: 33  
LENGTH: 16  
5256545-33

Query Match 0.6%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTT 795

Db 1 GCAGGAGAGGTGTT 16

RESULT 229

US-08-379-078-631  
Sequence 631, Application US/08379078  
Patent No. 5639612  
GENERAL INFORMATION:  
APPLICANT: Mitsubishi, Masato  
APPLICANT: Cooper, Allan  
TITLE OF INVENTION: Gene Detection System  
NUMBER OF SEQUENCES: 726  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR  
STREET: 620 Newport Center Drive 16th Floor  
CITY: Newport Beach  
STATE: CA  
COUNTRY: USA  
ZIP: 92660  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/379,078  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/974,406  
FILING DATE: 12-NOV-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Altman, Daniel E.  
REGISTRATION NUMBER: 34,115  
REFERENCE/DOCKET NUMBER: HITACHI.011CP2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-760-0404  
TELEFAX: 714-760-9502  
INFORMATION FOR SEQ ID NO: 631:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
MOLECULE TYPE: cDNA to mRNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
US-08-379-078-631

Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 ACGCGCGCCTCTCGC 565  
| | | | | | | | | |  
Db 2 ACGCGCGCCTCTCGC 17

RESULT 230  
US-08-373-124A-842/C  
; Sequence 842, Application US/08373124A  
; Patent No. 5646042  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwigen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08373.124A  
; FILING DATE: January 13, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 842:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-373-124A-842

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AAATATTGAGTACT 1445  
| | | | | | | | | |  
Db 17 AAATACTGAGTACT 2

RESULT 231  
US-08-460-853-1/C  
; Sequence 1, Application US/08460853

; Patent No. 5695940  
; GENERAL INFORMATION:  
; APPLICANT: Drmanac, Radoje T.  
; APPLICANT: Crkvenjakov, Radomir B.  
; TITLE OF INVENTION: Method of sequencing by Hybridization of  
; TITLE OF INVENTION: Oligonucleotide Probes  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/460,853  
; FILING DATE: 06-MAY-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/203,502 CON  
; FILING DATE: 28-FEB-1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/048,152 FWC  
; FILING DATE: 15-APR-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meyers, Thomas C.  
; REGISTRATION NUMBER: 36,989  
; REFERENCE/DOCKET NUMBER: 28110/32735  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 312/474-6300  
; TELEFAX: 312/474-0448  
; TELEX: 25-3856  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; US-08-460-853-1

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CAGCCACCGGAGAC 1681  
| | | | | | | | | |  
Db 17 CAGCCACCGGAGAC 2

RESULT 232  
US-08-460-853-8/C  
; Sequence 8, Application US/08460853  
; Patent No. 5695940  
; GENERAL INFORMATION:  
; APPLICANT: Drmanac, Radoje T.  
; APPLICANT: Crkvenjakov, Radomir B.  
; TITLE OF INVENTION: Method of sequencing by Hybridization of  
; TITLE OF INVENTION: Oligonucleotide Probes  
; NUMBER OF SEQUENCES: 19  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
; STREET: 6300 Sears Tower, 233 South Wacker Drive  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: United States of America  
; ZIP: 60606-6402  
; COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/460,853  
FILING DATE: 06-MAY-1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/203,502 CON  
FILING DATE: 28-FEB-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/048,152 FWC  
FILING DATE: 15-APR-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Meyers, Thomas C  
REGISTRATION NUMBER: 36,989  
REFERENCE/DOCKET NUMBER: 28110/32735  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 312/474-6300  
TELEFAX: 312/474-0448  
TELEX: 25-3856  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-460-853-8

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CAGCCACCGGGGAC 1681  
Db 17 CAGCCACCGGAGGAC 2

RESULT 233  
US-08-435-628-842/c  
Sequence 842, Application US/08435628  
Patent No. 5817796  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TITLE OF INVENTION: TREATMENT OF RHEUMATISM AND  
TITLE OF INVENTION: CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,628  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/373,124

FILING DATE: January 13, 1995  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Waiburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 842:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-628-842

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AAATATTGAGTACT 1445  
Db 17 AAATACTGAGTACT 2

RESULT 234  
US-08-292-620A-1636  
Sequence 1636, Application US/08292620A  
Patent No. 5837542  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620A  
FILING DATE: August 17, 1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993

```

: APPLICATION NUMBER: 07/989,849
: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 208/149
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELE: 67-3510
: INFORMATION FOR SEQ ID NO: 1636:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-292-620A-1636

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      563 CGCTGTCCTGCTCT 578
Db      2 CUUCGUCUCCUGUCCU 17

RESULT 235
US-08-292-620A-1643
: Sequence 1643, Application US/08292620A
: Patent No. 5837542
: GENERAL INFORMATION:
: APPLICANT: Susan Grimm
: APPLICANT: Dan T. Stinchcomb
: APPLICANT: James McSwiggen
: APPLICANT: Sean Sullivan
: APPLICANT: Kenneth G. Draper
: TITLE OF INVENTION: RIBOZYME TREATMENT OF
: TITLE OF INVENTION: DISEASES OR CONDITIONS
: TITLE OF INVENTION: RELATED TO LEVELS OF
: TITLE OF INVENTION: INTRACELLULAR ADHESION
: TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
: NUMBER OF SEQUENCES: 2390
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/292,620A
: FILING DATE: August 17, 1994
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA: including application
: PRIOR APPLICATION DATA: described below:
: APPLICATION NUMBER: 08/008,895
: FILING DATE: January 19, 1993
: APPLICATION NUMBER: 07/989,849
: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 208/149
: TELECOMMUNICATION INFORMATION:
: two
```

```

: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELE: 67-3510
: INFORMATION FOR SEQ ID NO: 1643:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-292-620A-1643

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      563 CGCTGTCCTGCTCT 578
Db      2 CUUCGUCUCCUGUCCU 17

RESULT 236
US-08-292-620A-1800
: Sequence 1800, Application US/08292620A
: Patent No. 5837542
: GENERAL INFORMATION:
: APPLICANT: Susan Grimm
: APPLICANT: Dan T. Stinchcomb
: APPLICANT: James McSwiggen
: APPLICANT: Sean Sullivan
: APPLICANT: Kenneth G. Draper
: TITLE OF INVENTION: RIBOZYME TREATMENT OF
: TITLE OF INVENTION: DISEASES OR CONDITIONS
: TITLE OF INVENTION: RELATED TO LEVELS OF
: TITLE OF INVENTION: INTRACELLULAR ADHESION
: TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
: NUMBER OF SEQUENCES: 2390
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/292,620A
: FILING DATE: August 17, 1994
: CLASSIFICATION: 435
: PRIOR APPLICATION DATA: including application
: PRIOR APPLICATION DATA: described below:
: APPLICATION NUMBER: 08/008,895
: FILING DATE: January 19, 1993
: APPLICATION NUMBER: 07/989,849
: FILING DATE: December 7, 1992
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 208/149
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELE: 67-3510
: INFORMATION FOR SEQ ID NO: 1800:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: two
```

STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-292-620A-1600

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 56.2%; Pred. No. 1.8e+02;  
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 563 CGCGTTCCTGGCTCCT 578  
DB 2 CUCGUCUCGUCGUCU 17

## RESULT 237

US-08-657-884-9  
Sequence 9, Application US/08657884  
Patent No. 5858981  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
APPLICANT: PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: NIXON & VANDERHAYE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/657,884  
FILING DATE: 07-JUN-1996  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4000  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 9:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-657-884-9

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1109 CTCTGTGGCCATGCC 1124  
DB 1 CGCTGTCAGCCATGCC 16

## RESULT 238

US-08-985-162-734/c  
Sequence 734, Application US/08985162  
Patent No. 6057156  
GENERAL INFORMATION:  
APPLICANT: Akhtar, Saghir  
APPLICANT: Fell, Patricia  
APPLICANT: McSwigen, James  
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT  
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED

TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
TITLE OF INVENTION: FACTOR RECEPTORS  
NUMBER OF SEQUENCES: 1877  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage

COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,162  
FILING DATE: 04 December 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/036,476  
FILING DATE: 31 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 230/107  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 734:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-985-162-734

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1425 AGAGAAATTTTGAG 1440  
DB 17 AGAGAAATTTTGTAG 2

## RESULT 239

US-08-963-927-28  
Sequence 28, Application US/08963927  
Patent No. 6096501  
GENERAL INFORMATION:  
APPLICANT: Berger, Dolores M.  
APPLICANT: Foxall, Paul A.  
TITLE OF INVENTION: Assay for Chlamydia Trachomatis by  
TITLE OF INVENTION: Amplification and Detection of Chlamydia Trachomatis  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Richard J. Rodrick - Becton, Dickinson and  
ADDRESS: Company  
STREET: 1 Becton Drive  
CITY: Franklin Lakes  
STATE: NJ  
COUNTRY: USA  
ZIP: 07417  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/963,927
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Highet, David W.
; REGISTRATION NUMBER: 30,265
; REFERENCE/DOCKET NUMBER: P-3889
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 847-5317
; TELEFAX: (201) 848-9228
; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-963-927-28
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1679 GACAGCTGCTGTGGA 1694
      ||||| |||||
DB      1 GACAGCTTGTGATGCA 16
```

```

RESULT 240
US-08-998-099-119/C
; Sequence 119, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 119
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-08-998-099-119
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1053 GCTGAAGTCAGGTG 1068
      ||||| |||||
DB      17 GCTGGAGTACAGGTG 2
```

```

RESULT 241
US-09-071-845-1636
; Sequence 1636, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
```

```

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1636:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1636
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      563 CGCTGTCCTGCGTCT 578
      ||:|:|:|:|:|:|:|
DB      2 CUCUGCUCUGGUCU 17
```

```

RESULT 242
US-09-071-845-1643
; Sequence 1643, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
```





```

;
;   REGISTRATION NUMBER: 30,265
;   REFERENCE/DOCKET NUMBER: P-3889
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (201) 847-5317
;   TELEFAX: (201) 848-9228
;   INFORMATION FOR SEQ ID NO: 28:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
US-09-481-810-28

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1679 GACAGCTGCTTGA 1694
Db      1 GACAGCTTGATGGA 16

RESULT 245
US-09-158-980-9
; Sequence 9, Application US/09158980
; Patent No. 6242427
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHAYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,980
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-158-980-9

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1109 CTCGTGGCGCC 1124
Db      1 CGCTGCGCCATGCC 16
```

```

;
;   REGISTRATION NUMBER: 34,115
;   REFERENCE/DOCKET NUMBER: HITACHI.006CP2
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 714-760-0404
;   TELEFAX: 714-760-9502
;   INFORMATION FOR SEQ ID NO: 631:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 17
;   TYPE: nucleic acid
;   STRANDEDNESS: double
;   TOPOLOGY: linear
;   MOLECULE TYPE: cDNA to mRNA
;   HYPOTHETICAL: NO
;   ANTI-SENSE: NO
US-07-974-409C-631

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      550 ACGGCGCCCTTGC 565
Db      2 ACGGCGCCCTTGC 17

RESULT 247
US-08-584-040-1736/c
; Sequence 1736, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
```

```
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1736:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1736
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 881 CCTGAGTGTCTCTCT 896
Db 17 CGCTGAGTGTCTCTCT 2
```

```
RESULT 248
US-08-584-040-2235
Sequence 2235, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: ESCOBEDO, JAIME
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
```

```
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2235:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2235
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1637 CAGTGCCTGCCCTCTCT 1652
Db 1 CAGTGCCTGCCCTCTCT 16
```

```
RESULT 249
US-08-584-040-3895
Sequence 3895, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: ESCOBEDO, JAIME
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
```

TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 3895:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-3895

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 56.2%; Pred. No. 1.8e+02;  
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1430 AAATATTGAGTACT 1445  
|||:|||||  
Db 2 AAUUUUUGACACCU 17

RESULT 250  
US-08-584-040-3903/c  
; Sequence 3903, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwigen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584, 040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Wardburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 3903:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-3903  
Query Match 0.6%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 91 GCCGACTGGGTCTGC 106  
|||||  
Db 17 GCCCAGTGGATCTGC 2

RESULT 251  
US-08-584-040-4155/c  
; Sequence 4155, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwigen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584, 040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Wardburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 4155:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-4155  
Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 2120 AGCAGCTGACCAT 2135  
|||||  
Db 17 AGAAGTTGACCAT 2  
|||||  
RESULT 252  
US-08-584-040-5900  
; Sequence 5900, Application US/08584040  
; Patent No. 6346398

```

: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/584,040
: FILING DATE: January 11, 1996
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/005,974
: FILING DATE: October 26, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/064
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 5900:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-584-040-5900

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1207 AAGGAGCTGTGGCT 1222
Db 2 AAGGAGCTGTGGCT 17

RESULT 253
US-08-584-040-5962
: Sequence 5962, Application US/08584040
: Patent No. 6346398
: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:

```

```

: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: Word Perfect 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/584,040
: FILING DATE: January 11, 1996
: CLASSIFICATION: 514
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/005,974
: FILING DATE: October 26, 1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 218/064
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 5962:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 17 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-584-040-5962

Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 685 ACTCTCATGTCATTC 700
Db 2 ACUCUCUUCUUCUUC 17

RESULT 254
US-08-584-040-5963
: Sequence 5963, Application US/08584040
: Patent No. 6346398
: GENERAL INFORMATION:
: APPLICANT: Pavco, Pamela
: APPLICANT: McSwiggen, James
: APPLICANT: Stinchcomb, Dan T.
: APPLICANT: Escobedo, Jaime
: TITLE OF INVENTION: METHOD AND REAGENT FOR THE
: TITLE OF INVENTION: TREATMENT OF DISEASES OR
: TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
: TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
: TITLE OF INVENTION: GROWTH FACTOR
: NUMBER OF SEQUENCES: 8502
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: MEDIUM TYPE: storage
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Wardburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5963:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5963
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

OY 685 ACCTCATGTCCTTC 700

Db 1 ACUCUCUUCCAUUC 16

```
RESULT 255
US-09-474-432B-839/C
Sequence 839, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpelsky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MEHB00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
PRIOR FILING DATE: 1999-04-28
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: PatentIn version 3.0
SEQ ID NO 839
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-839
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1206 GAAGAGGCTGTGGCC 1221

Db 17 GAAGGAGGCTGTGGGCC 2

```
RESULT 256
US-09-371-772B-281/C
Sequence 281, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MEHB00,876-D (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 1425
SOFTWARE: PatentIn version 3.0
SEQ ID NO 281
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-281
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 881 CCCTGAGTGTCTCT 896

Db 17 CCCTGAGTGTCTCT 2

```
RESULT 257
US-09-371-772B-780
Sequence 780, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
FILE REFERENCE: MEHB00,876-D (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 1425
SOFTWARE: PatentIn version 3.0
SEQ ID NO 780
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-780
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

OY 1637 CAGTGCTGCCCTGCT 1652

Db 1 CAGUGCUCUCCACGU 16

## RESULT 258

US-09-371-772B-1662  
; Sequence 1662, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1662  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-1662

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 56.2%; Pred. No. 1.8e+02;  
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1430 AATATTGACTACT 1445

DB 2 AAUUUUUGAGCACC 17

## RESULT 259

US-09-371-772B-1670/C  
; Sequence 1670, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1670  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-1670

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCCGACTGGCTGCTGC 106

DB 17 GCCCAGCTGAGTCTGC 2

## RESULT 260

US-09-371-772B-1922/C  
; Sequence 1922, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1922  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-1922

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2120 AGCAGCTGACCAT 2135

DB 17 AGAGGTGACCAT 2

## RESULT 261

US-09-371-772B-2739  
; Sequence 2739, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2739  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-2739

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 1.8e+02;  
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1207 AAGGAGCTGGCT 1222

DB 2 AGGAGUCUGGCGCU 17

## RESULT 262

```
US-09-371-772B-2799
; Sequence 2799, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2799
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2799
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

Oy 685 ACTGTCATGTCATTC 700  
||:|:|:|:|:|:|:|  
Db 2 ACUCUCUUUCCAUUC 17

```
RESULT 263
US-09-371-772B-2800
; Sequence 2800, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2800
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2800
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

Oy 685 ACTGTCATGTCATTC 700  
||:|:|:|:|:|:|:|  
Db 1 ACUCUCUUUCCAUUC 16

```
RESULT 264
US-09-371-772B-4231/c
```

```
; Sequence 4231, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4231
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4231
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1637 CAGTGCCTGCCCTGCT 1652  
||||| ||||| |||||  
Db 17 CAGTGCCTGCCCTGCT 2

```
RESULT 265
US-09-371-772B-4232/c
; Sequence 4232, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4232
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4232
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Oy 1637 CAGTGCCTGCCCTGCT 1652  
||||| ||||| |||||  
Db 16 CAGTGCCTGCCCTGCT 1

```
RESULT 266
US-09-371-772B-4511/c
; Sequence 4511, Application US/09371772B
```



```
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4511
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4511
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 883 CTGAGTGTCTCTGA 898
Db 17 CTGAGTGTCTCTCA 2
```

```
RESULT 267
US-09-371-772B-4512/C
; Sequence 4512, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4512
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4512
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 881 CCTGAGTGTCTCT 896
Db 16 CGCTGAGTGTCTCT 1
```

```
RESULT 268
US-09-371-772B-5163
; Sequence 5163, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5163
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5163
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 1637 CAGTGCTGCCCTGCT 1652
Db 2 CAGUGGCUCCAGCU 17
```

```
RESULT 269
US-09-371-772B-6283/C
; Sequence 6283, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371, 772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6283
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY 91 GCCGACTGGGTGCTGC 106
Db 16 GCCCAGTGTGCTGC 1
```

```
RESULT 270
US-09-371-772B-6650/C
; Sequence 6650, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6650
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6650
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      2120 AGCAGCTGACCACAT 2135
Db      16 AGAGGTTGACCACAT 1
```

```

RESULT 271
US-09-476-387-838/C
; Sequence 838, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zimen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT FILING DATE: 2001-04-04
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 838
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-838
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1206 GAAGAGCTGTGGCC 1221
Db      17 GAAGGGGCTGGGCC 2
```

```

RESULT 272
US-09-401-063-734/C
; Sequence 734, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-734
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1425 AGAGAAATATTGAG 1440
Db      17 AGAGAAATATTAG 2
```

```

RESULT 273
US-09-787-069-8
; Sequence 8, Application US/09787069
; Patent No. 6627429
; GENERAL INFORMATION:
; APPLICANT: Danisco A/S
; APPLICANT: Christensen, Tove MIE
; APPLICANT: Pedersen, Anette A
; APPLICANT: Brunstedt, Janne
; APPLICANT: Mikkelson, Jørn D
; TITLE OF INVENTION: Process
```

```
FILE REFERENCE: P005380WO CTH
CURRENT APPLICATION NUMBER: US/09/787,069
CURRENT FILING DATE: 2001-07-16
PRIOR APPLICATION NUMBER: GB 9820195.7
PRIOR FILING DATE: 1998-09-16
NUMBER OF SEQ ID NOS: 21
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 8
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-787-069-8

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

129 ATTCTCCCTGCTGCTG 144
2 ATTATCCATGCTGCTG 17

Db

RESULT 274
US-09-811-492-9
Sequence 9, Application US/09811492
Patent No. 6638764
GENERAL INFORMATION:
APPLICANT: SCHREIBER, ALAN D.
PARK, JONG-GU
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/811,492
FILING DATE: 19-Jul-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/657,884
FILING DATE: 07-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: WILSON, MARY J.
REGISTRATION NUMBER: 32,955
REFERENCE/DOCKET NUMBER: 555-46
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4100
FAX: (703) 816-4100
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-811-492-9

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
1109 CTCGTGCGCCATGCC 1124
1 CGCTGTGAGCATGCC 16

Db

RESULT 275
US-09-827-998-793/c
Sequence 793, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
SHANNON, MARK
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDHMPF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6656700
SEQ ID NO 794
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-793

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1809 GACCCAGAGCACT 1824
17 GAACCAAGAGCACT 2

Db

RESULT 276
US-09-827-998-794/c
Sequence 794, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
SHANNON, MARK
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
FILE REFERENCE: MDHMPF-8
CURRENT APPLICATION NUMBER: US/09/827,998
CURRENT FILING DATE: 2001-04-06
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
NUMBER OF SEQ ID NOS: 1881
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6656700
SEQ ID NO 794
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-827-998-794

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

1809 GACCCAGAGCACT 1824
16 GAACCAAGAGCACT 1

Db

RESULT 277
US-09-827-998-801/c
```

```
; Sequence 801, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 801
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-801
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      826 TTCCAACGAGACCGA 841
Db      17 TTCTACGAGACCGA 2
```

```
RESULT 278
US-09-827-998-802/c
; Sequence 802, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 802
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-802
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      826 TTCCAACGAGACCGA 841
Db      16 TTCTACGAGACCGA 1
```

```
RESULT 279
US-09-866-108A-514/c
; Sequence 514, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
```

```
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 514
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-514
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      161 TGCTCGGCTCTGGGC 176
Db      17 TGCTCAGGCTCGGGC 2
```

```
RESULT 280
US-09-866-108A-516/c
; Sequence 516, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 516
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-516

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      160 CTGCTCGCGGTCTGGG 175
         ||||| ||||| |||
Db      16 CTGCTCAGCGTCTGGG 1

RESULT 281
US-09-866-108A-664/C
; Sequence 664, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-664
```

```

; Query Match          0.6%; Score 12.8; DB 1; Length 17;
; Best Local Similarity 87.5%; Pred. No. 1.8e+02;
; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      54 TTCTCTGCATGGCTG 69
         ||||| ||||| |||
Db      17 TTCTCTGCTTGGCTG 2

RESULT 282
US-09-866-108A-666/C
; Sequence 666, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-666

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      53 CTCTCTGCATGGCT 68
         ||||| ||||| |||
Db      16 CTCTCTGCTTGGCT 1

RESULT 283
US-09-866-108A-1134/C
; Sequence 1134, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: RANK, David R.
```

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1134
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1134

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1016 TCCTTCTGCCCAAGAA 1031
Db      17  TCCTTCTGCCAGAA 2

RESULT 284
US-09-866-108A-1135/C
; Sequence 1135, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1134
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1135
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1135
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1135

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1016 TCCTTCTGCCCAAGAA 1031
Db      16  TCCTTCTGCCAGAA 1

RESULT 285
US-09-866-108A-1456
; Sequence 1456, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1456
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1456
```

US-09-866-108A-1456

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2176 CACCAGAGCTCATGG 2191  
Db 2 CGCCAGCAGCTCCTGG 17

RESULT 286

US-09-866-108A-1457  
; Sequence 1457, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263,6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 1457  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-1457

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2176 CACCAGAGCTCATGG 2191  
Db 1 CGCCAGCAGCTCCTGG 16

RESULT 287

US-09-866-108A-1529  
; Sequence 1529, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263,6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 1529  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-1529

Query Match 0.6%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1595 AGGTGAGCGGCTGTGT 1610  
Db 2 AGGTGATGGGCTGTGT 17

RESULT 288

US-09-866-108A-1531  
; Sequence 1531, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263,6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1531
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1531

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1596 GGTGACGCGCTGCTG 1611
Db      1 GGTGATGGGCTGCTG 16

RESULT 289
US-09-866-108A-1564/c
; Sequence 1564, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1564
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108A-1564

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      271 GGCTGGCTGGCTGCTT 286
Db      17 GGCTGGCTGGCTCCTT 2

RESULT 290
US-09-866-108A-1565/c
; Sequence 1565, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1565
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1565

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      271 GGCTGGCTGGCTGCTT 286
Db      16 GGCTGGCTGGCTCCTT 1

RESULT 291
US-09-866-108A-1571/c
; Sequence 1571, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```



```

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; ORGANISM: Homo sapiens
; SEQ ID NO 1571
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1571

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 268 CAGGCTGCTGCTG 283
Db 17 CAGAGCAGCTGCTG 2

RESULT 292
US-09-866-108A-1573/C
; Sequence 1573, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1573
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1573

Query Match
Best Local Similarity 87.5%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 267 CCAGGCTGCTGCTG 282
Db 16 CCAGAGCAGCTGCTG 1

RESULT 293
US-09-866-108A-1959
; Sequence 1959, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A60MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1959
; LENGTH: 17
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1959

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1832 AAATCAGCTGCTGC 1847
      ||| ||||| |||
Db       2 AAAGCTCAGCTGCTGC 17

RESULT 294
US-09-866-108A-1961
; Sequence 1961, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1575
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1961
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1961

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1833 AATCAGCTGCTGCA 1848
      ||| ||||| |||
Db       1 AAGCTCAGCTGCTGCA 16

RESULT 295
US-09-866-108A-2445
; Sequence 2445, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1575
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2445
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2445

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1342 GTTCTACCGATGC 1357
      ||| ||||| |||
Db       2 GTTTCTCCGATGC 17

RESULT 296
US-09-866-108A-2446
; Sequence 2446, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2446
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2446

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1342 GTTCTCTACCAAGATC 1357
Db      1 GTTCTCTCCAGATC 16

RESULT 297
US-09-866-108A-2716/c
; Sequence 2716, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2716
```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2716

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1528 TTGGCTTACCAACC 1543
Db      17 TTGGCCACTCAACC 2

RESULT 298
US-09-866-108A-2717/c
; Sequence 2717, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2717
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2717

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1528 TTGGCTTACCAACC 1543
Db      16 TTGGCCACTCAACC 1

RESULT 299
US-09-866-108A-2738
; Sequence 2738, Application US/09866108A
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2738
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2738

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      297 AGCTGCGGCACTGGGC 312
Db      2 AGCTGAGGCGCTGGGC 17

RESULT 300
US-09-866-108A-2740
; Sequence 2740, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2740
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2740

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      298 GCTGCGGCACTGGGCT 313
Db      1 GCTGAGGCGCTGGGCT 16

RESULT 301
US-09-866-108A-6520
; Sequence 6520, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
```

```
/ SEQ ID NO 6520
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-6520

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 1; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2100 CCAGCAGCTCAGCCTGT 2115
Db 2 CACCGCAGCAGCCTGT 17

RESULT 302
US-09-866-108A-6523
/ Sequence 6523, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 6523
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-6523

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 1; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2102 AGCACTCAGCCTGT 2117
Db 1 ACCACCGCAGCCTGT 16

RESULT 303
US-09-866-108A-6524
/ Sequence 6524, Application US/09866108A
```

```
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aeomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 6524
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-6524

Query Match
Best Local Similarity 0.6%; Score 12.8; DB 1; Length 17;
Matches 1; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2104 CACCTCAGCCTGTGTG 2119
Db 2 CACCGCAGCCTGTGTG 17

RESULT 304
US-09-866-108A-6527
/ Sequence 6527, Application US/09866108A
/ Patent No. 6686188
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: PENN, Sharon G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OR INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6527
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6527
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2106 CCTGAGCTCTGTGAG 2121
Db      1 CCGAGCGCTGTGAG 16
```

```
RESULT 305
; Sequence 6759, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 6759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6759
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2042 TGGAGCAGCTCCCTGA 2057
Db      1 TGGAGAGCTCCTGGA 16
```

```
RESULT 306
; Sequence 7938, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

```
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 7938
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7938
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1264 CTGAAGTGGGAATCC 1279
Db      2 CTGAAGTGGGAATCC 17
```

```
RESULT 307
US-09-866-108A-7939
```

```
; Sequence 7939, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7939
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7939

Query Match      0.64; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1264 CTGAAGTGGATCC 1279
Db      1 CTGAAGTGGATCC 16

RESULT 308
; US-09-866-108A-8058
; Sequence 8058, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

; US-09-866-108A-8058
; Sequence 8136, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755

Cy      2232 AGATGCTCAGAAATGA 2247
Db      1 AGATGACACAGAGAGA 16

RESULT 309
; US-09-866-108A-8136
; Sequence 8136, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent NO. 6686188
; SEQ ID NO 8136
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8136

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1053 GCTGGAAGTGCAGCTG 1068
Db      2 GCTGGAATGCAGCTG 17

RESULT 310
US-09-866-108A-8137
; Sequence 8137, Application US/09866108A
; Patent NO. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent NO. 6686188
; SEQ ID NO 8137
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8137

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1053 GCTGGAAGTGCAGCTG 1068
Db      1 GCTGGAATGCAGCTG 16

RESULT 311
```

```
US-09-866-108A-8379
; Sequence 8379, Application US/09866108A
; Patent NO. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent NO. 6686188
; SEQ ID NO 8379
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8379

Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2109 CAGCTGCTGAGCAG 2124
Db      2 CAGCCAGCTGAGCAG 17

RESULT 312
US-09-866-108A-8380
; Sequence 8380, Application US/09866108A
; Patent NO. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
```



```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8380
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8380
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 2109 CAGCTGTGAGGAG 2124

Db 1 CAGCTGTGAGGAG 16

```
RESULT 313
US-09-866-108A-8619
; Sequence 8619, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8619
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8619
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1259 TGCTGTGAGGAGTGG 1274

Db 2 TGCTGTGAGGAGTGG 17

```
RESULT 314
US-09-866-108A-8620
; Sequence 8620, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8620
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8620
```

```
Query Match 0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

OY 1259 TGCTGTGAGGAGTGG 1274

Db 1 TGCTGTGAGGAGTGG 16

```
RESULT 315
US-09-866-108A-9582
; Sequence 9582, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9582
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9582

Query Match          0.6%: Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%: Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1167 GTTAGGAAAAGCTG 1182
Db      2  GTGAGGAAAAGCTG 17

RESULT 316
US-09-866-108A-10081/c
; Sequence 10081, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10081
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10081

Query Match          0.6%: Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%: Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 GCGGCTCTGGAACC 514
Db      17  GCGGCTCTGGAACC 2

RESULT 317
US-09-866-108A-10082/c
; Sequence 10082, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10082
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10082

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      499 GGGGCTCTGGAACC 514
Db      16 GGGGCTCTGGAACC 1

RESULT 318
US-09-866-108A-10318
; Sequence 10318, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10318
```

```
Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      943 TGTCTCTGGGATCA 958
Db      2 TTCTCTCGGGATCA 17
```

```
RESULT 319
US-09-866-108A-10319
; Sequence 10319, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10319
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10319

Query Match      0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      943 TGTCTCTGGGATCA 958
Db      1 TTCTCTCGGGATCA 16

RESULT 320
US-09-866-108A-10320
; Sequence 10320, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263. 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10320
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10320
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      945 TCTCTGGGATCATG 960
Db      2 TCTCTGGGATCAAG 17
```

```
RESULT 321
US-09-866-108A-10321
; Sequence 10321, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263. 6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10321
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10321
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      945 TCTCTGGGATCATG 960
Db      1 TCTCTGGGATCAAG 16
```

```
RESULT 322
PCT-US93-00977-631
; Sequence 631, Application PC/TUS9300977
; GENERAL INFORMATION:
; TITLE OF INVENTION: METHOD AND REAGENT FOR MEASURING MESSENGER RNA
; NUMBER OF SEQUENCES: 711
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobe, Martens, Olson, and Bear
; STREET: 620 Newport Center Dr. Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00977
; FILING DATE: 19930129
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.006H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 631:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US93-00977-631
```

```
Query Match          0.6%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      550 ACGGCGCGCTTCGC 565
Db      2 ACGGCGCGCCCTTCGC 17
```

```
RESULT 323
US-09-513-783A-39
; Sequence 39, Application US/09513783A
; Patent No. 6416959
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Guilliano, Kenneth A.
/ APPLICANT: Kapur, Ravi
/ TITLE OF INVENTION: A System for Cell Based Screening
/ FILE REFERENCE: 97-022-11
/ CURRENT APPLICATION NUMBER: US/09/513.783A
/ CURRENT FILING DATE: 2000-02-25
/ NUMBER OF SEQ ID NOS: 180
/ SOFTWARE: Patent In Ver. 2.0
/ SEQ ID NO 39
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURES:
/ OTHER INFORMATION: Description of Artificial Sequence: K73 epitope
US-09-513-783A-39

Query Match      0.6%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      828 CCAACGACACGACA 843
Db      1 CCACGACACGACGAAA 16

RESULT 324
US-08-700-035A-4
/ Sequence 4, Application US/08700035A
/ Patent No. 5831068
/ GENERAL INFORMATION:
/ APPLICANT: Nair, et al., Smila K.
/ TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
/ TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson P.C.
/ STREET: 225 Franklin Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110-2804
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/700.035A
/ FILING DATE:
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/517,373
/ FILING DATE: 21-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clark, Paul T.
/ REGISTRATION NUMBER: 30,162
/ REFERENCE/DOCKET NUMBER: 06765/009001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617/542-5070
/ TELEFAX: 617/542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 27 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-700-035A-4

Query Match      0.6%; Score 12.8; DB 1; Length 27;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2131 CACATCCTCTTCTGG 2146
Db      1 CACAGCCTCTTCTGG 16

RESULT 325
PCT-US96-13457-4
/ Sequence 4, Application PC/TUS9613457
/ GENERAL INFORMATION:
/ APPLICANT: Duke University
/ TITLE OF INVENTION: A METHOD TO INCREASE THE DENSITY OF
/ TITLE OF INVENTION: ANTIGEN ON ANTIGEN PRESENTING CELLS
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Fish & Richardson P.C.
/ STREET: 225 Franklin Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110-2804
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US96/13457
/ FILING DATE: 20-AUG-1996
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/517,373
/ FILING DATE: 21-AUG-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clark, Paul T.
/ REGISTRATION NUMBER: 30,162
/ REFERENCE/DOCKET NUMBER: 06765/009W01
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617/542-5070
/ TELEFAX: 617/542-8906
/ TELEX: 200154
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 27 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
PCT-US96-13457-4

Query Match      0.6%; Score 12.8; DB 1; Length 27;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2131 CACATCCTCTTCTGG 2146
Db      1 CACAGCCTCTTCTGG 16

RESULT 326
US-08-303-004-19
/ Sequence 19, Application US/08303004
/ Patent No. 5556955
/ GENERAL INFORMATION:
/ APPLICANT: Vergnaud, Gilles
/ TITLE OF INVENTION: Process for Detection of New Polymor-
/ TITLE OF INVENTION: phic loci in an ADN Sequence, Nucleotide Sequences Forming
/ TITLE OF INVENTION: Hybridisation Probes and Their Biological Applications
/ NUMBER OF SEQUENCES: 38
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Ollif & Berridge
/ STREET: P.O. Box 19928
/ CITY: Alexandria
/ STATE: Virginia
```

```

: COUNTRY: U.S.A
: ZIP: 22320
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent in Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/303,004
: FILING DATE:
: CLASSIFICATION: 536
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US/07/931,311B
: FILING DATE: 19920818
: ATTORNEY/AGENT INFORMATION:
: NAME: Berridge, William P.
: REGISTRATION NUMBER: 30,024
: REFERENCE/DOCKET NUMBER: WPB 28264
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (703) 836-6400
: TELEFAX: (703) 836-2787
: TELEX: 90-1799 PTO ALEX
: INFORMATION FOR SEQ ID NO: 19:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 14 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: DNA (genomic)
: HYPOTHEICAL: NO
: ANTI-SENSE: NO
: US-08-303-004-19

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      822 GTTTTCCACAGA 835
Db      1 GTTCTCCACAGA 14

RESULT 327
US-08-985-162-1761/c
: Sequence 1761, Application US/08985162
: Patent No. 6057156
: GENERAL INFORMATION:
: APPLICANT: Akhtar, Saghir
: APPLICANT: Fell, Patricia
: APPLICANT: McSwigen, James
: TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
: TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
: TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
: TITLE OF INVENTION: FACTOR RECEPTORS
: NUMBER OF SEQUENCES: 1877
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Lyon & Lyon
: STREET: 633 West Fifth Street
: STREET: Suite 4700
: CITY: Los Angeles
: STATE: California
: COUNTRY: U.S.A.
: ZIP: 90071-2066
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
: COMPUTER: IBM Compatible
: OPERATING SYSTEM: IBM P.C. DOS 5.0
: SOFTWARE: FASTSEQ for Windows 2.0
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/985,162
: FILING DATE: 04 December 1997
: CLASSIFICATION: 514
```

```

: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/036,476
: FILING DATE: 31 January 1997
: ATTORNEY/AGENT INFORMATION:
: NAME: Warburg, Richard J.
: REGISTRATION NUMBER: 32,327
: REFERENCE/DOCKET NUMBER: 230/107
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (213) 489-1600
: TELEFAX: (213) 955-0440
: TELEX: 67-3510
: INFORMATION FOR SEQ ID NO: 1761:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 14 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: US-08-985-162-1761

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      168 GGTCTGGCGCGTG 181
Db      14 GGTCTGGCGCGCG 1

RESULT 328
US-08-998-099-355
: Sequence 355, Application US/08998099A
: Patent No. 6103890
: GENERAL INFORMATION:
: APPLICANT: JARVIS, THALE
: APPLICANT: MCSWIGEN, JAMES A.
: APPLICANT: STINCHCOMB, DAN T.
: TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
: TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-POS
: FILE REFERENCE: 231/175
: CURRENT APPLICATION NUMBER: US/08/998,099A
: CURRENT FILING DATE: 1997-12-24
: EARLIER APPLICATION NUMBER: 60/037,658
: EARLIER FILING DATE: 1997-01-23
: EARLIER APPLICATION NUMBER: 08/373,124
: EARLIER FILING DATE: 1995-01-13
: EARLIER APPLICATION NUMBER: 08/245,466
: EARLIER FILING DATE: 1994-05-18
: NUMBER OF SEQ ID NOS: 375
: SOFTWARE: FASTSEQ for Windows Version 3.0
: SEQ ID NO 355
: LENGTH: 14
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-08-998-099-355

Query Match          0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 64.3%; Pred. No. 1.8e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1000 ACCCTGCTCTGCT 1013
Db      1 ACCCTGCCUCUCU 14

RESULT 329
US-09-401-063-1761/c
: Sequence 1761, Application US/09401063
: Patent No. 6623962
: GENERAL INFORMATION:
: APPLICANT: Akhtar, Saghir
: APPLICANT: Fell, Patricia
: APPLICANT: McSwigen, James
: TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
```

```

; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1500
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1761:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-1761

Query Match 0.6%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 168 GGTCTGGCGCGTGG 181
DB 14 GGTCTGGCGCGCGG 1

RESULT 330
US-08-093-383-19/c
; Sequence 19, Application US/08093383
; Patent No. 5489529
; GENERAL INFORMATION:
; APPLICANT: DeBoer, Herman A.
; APPLICANT: Heyneker, Herbert L.
; APPLICANT: Seeburg, Peter H.
; TITLE OF INVENTION: DNA for Expression of Bovine Growth Hormone
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/259,148A
; FILING DATE: 13-JUN-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
```

```

; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/093,383
; FILING DATE: 14-JUL-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/619827
; FILING DATE: 28-NOV-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/198824
; FILING DATE: 05-APR-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/632361
; FILING DATE: 19-JUL-1984
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 06/303687
; FILING DATE: 18-SEP-1981
; ATTORNEY/AGENT INFORMATION:
; NAME: Johnston, Sean A.
; REGISTRATION NUMBER: P35,910
; REFERENCE/DOCKET NUMBER: 46C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-3562
; TELEFAX: 415/225-3562
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-093-383-19

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 62 CATGGCTGGGACCA 75
DB 15 CATGGCTGGGACCA 2

RESULT 331
US-08-259-148A-33/c
; Sequence 32, Application US/08259148A
; Patent No. 574190
; GENERAL INFORMATION:
; APPLICANT: Reyes, Gregory R.
; APPLICANT: Bradley, Daniel W.
; APPLICANT: Twu, Jr-Shin
; APPLICANT: Purdy, Michael A.
; APPLICANT: Tam, Albert W.
; APPLICANT: Krawczynski, Krzysztof Z.
; APPLICANT: Yarbough, Patrice D.
; TITLE OF INVENTION: Hepatitis B Virus Vaccine and Method
; NUMBER OF SEQUENCES: 60
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Avenue, Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/259,148A
; FILING DATE: 13-JUN-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
```

```

; APPLICATION NUMBER: US 822,335
; FILING DATE: 17-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 505,888
; FILING DATE: 05-APR-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 420,921
; FILING DATE: 13-OCT-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 367,486
; FILING DATE: 16-JUN-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 336,672
; FILING DATE: 11-APR-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 208,997
; FILING DATE: 17-JUN-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Sholtz, Charles K.
; REGISTRATION NUMBER: 38,615
; REFERENCE/DOCKET NUMBER: 4600-0093.20
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: DNA sequence, Fig. 7
; US-08-259-148A-32

Query Match          0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      173 GGGGCTGGGCGCTG 186
DB      14 GGGGCTGGGCGCTG 1

RESULT 332
; Sequence 426, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
```

```

; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 426:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-426

Query Match          0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      538 CTGGGCTCGGAGAC 551
DB      1 CUGGCTUGGAGAC 14

RESULT 333
; Sequence 25, Application US/08657884
; Patent No. 5858981
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
```



LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-657-884-25

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1111 CTGTGCGCATGCC 1124  
Db 1 CTGTGCGCATGCC 14

RESULT 334  
US-08-657-884-29  
Sequence 29, Application US/08657884  
Patent No. 5858981  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
APPLICANT: PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITTING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: NIXON & VANDERHAYE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/657,884  
FILING DATE: 07-JUN-1996  
CLASSIFICATION: 424  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4000  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-657-884-29

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1111 CTGTGCGCATGCC 1124  
Db 1 CTGTGCGCATGCC 14  
RESULT 335  
US-08-585-684B-162/c  
Sequence 162, Application US/08585684B  
Patent No. 5877021  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale

APPLICANT: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/585,684B  
FILING DATE: January 16, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/000,951  
FILING DATE: July 7, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 162:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-585-684B-162

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 503 GCTCTGGAACCT 516  
Db 15 GCTCTGGAACCT 2

RESULT 336  
US-08-585-684B-1341/c  
Sequence 1341, Application US/08585684B  
Patent No. 5877021  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.

APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage

COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/585,684B  
FILING DATE: January 16, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/000,951  
FILING DATE: July 7, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1341:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-585-684B-1341

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1397 CCAGATACAGAG 1410  
DB 14 CCAGATACAGAG 1

RESULT 337  
US-08-585-684B-2049/c  
Sequence 2049, Application US/08585684B  
Patent No. 5877021  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwigen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/585,684B  
FILING DATE: January 16, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/000,951  
FILING DATE: July 7, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440

TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2049:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-585-684B-2049

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1587 CCTGCGCAGGTGA 1600  
DB 15 CCATGCGCAGGTGA 2

RESULT 338  
US-08-585-684B-2267/c  
Sequence 2267, Application US/08585684B  
Patent No. 5877021  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwigen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FASTSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/585,684B  
FILING DATE: January 16, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/000,951  
FILING DATE: July 7, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2267:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-585-684B-2267

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1372 GTGAGGTACTGCT 1385  
DB 15 GTGAGGTACTGCT 2

RESULT 339  
US-07-876-941A-48/C  
Sequence 48, Application US/07876941A  
Patent No. 5885768  
GENERAL INFORMATION:  
APPLICANT: Reyes, Gregory R.  
APPLICANT: Bradley, Daniel W.  
APPLICANT: Tam, Albert W.  
APPLICANT: Mitchell, Carl  
TITLE OF INVENTION: Hepatitis E Virus Peptide Antigen and  
TITLE OF INVENTION: Antibodies  
NUMBER OF SEQUENCES: 76  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Dehlinger & Associates  
STREET: 350 Cambridge Avenue, Suite 250  
CITY: Palo Alto  
STATE: CA  
COUNTRY: USA  
ZIP: 94306  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/876,941A  
FILING DATE: 01-MAY-1992  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 822,335  
FILING DATE: 17-JAN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 505,888  
FILING DATE: 05-APRIL-1990  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 420,921  
FILING DATE: 13-OCTOBER-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 367,486  
FILING DATE: 16-JUNE-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 336,672  
FILING DATE: 11-APRIL-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 208,997  
FILING DATE: 17-JUNE-1988  
ATTORNEY/AGENT INFORMATION:  
NAME: Sholtz, Charles K.  
REGISTRATION NUMBER: 38,615  
REFERENCE/DOCKET NUMBER: 4600-0093.33  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 324-0880  
TELEFAX: (415) 324-0960  
INFORMATION FOR SEQ ID NO: 48:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA  
HYPOTHEICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
INDIVIDUAL ISOLATE: DNA sequence, Fig. 7  
US-07-876-941A-48

Query Match 0.64; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 173 GGGCGTGGGCTG 186

Db 14 GGGCGTGGGCTG 1  
RESULT 340  
US-08-318-826A-2  
Sequence 2, Application US/08318826A  
Patent No. 5891725  
GENERAL INFORMATION:  
APPLICANT: Soreq, Hermona  
APPLICANT: Zakut, Haim  
APPLICANT: Eckstein, Fritz  
TITLE OF INVENTION: Synthetic Antisense  
TITLE OF INVENTION: Oligodeoxynucleotides and Pharmaceutical Compositions  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Kohn & Associates  
STREET: 30500 No. 5891725thwestern Hwy., Suite 410  
CITY: Farmington Hills  
STATE: Michigan  
COUNTRY: US  
ZIP: 48334  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/318,826A  
FILING DATE:  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Kohn, Kenneth I.  
REGISTRATION NUMBER: 30,955  
REFERENCE/DOCKET NUMBER: 2391.00001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (248) 539-5050  
TELEFAX: (248) 539-5055  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
ANTI-SENSE: YES  
US-08-318-826A-2

Query Match 0.64; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 216 CTGCGGGTCTCTCA 229  
Db 1 CTGCGGGGCTCTCA 14

RESULT 341  
US-08-588-595-1  
Sequence 1, Application US/08588595  
Patent No. 5958769  
GENERAL INFORMATION:  
APPLICANT: Roberts, James M.  
APPLICANT: Coats, Steven R.  
APPLICANT: Fero, Matthew J.  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING  
NUMBER OF SEQUENCES: 13  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Townsend and Townsend and Crew  
STREET: One Market Plaza, Stewart Street Tower  
CITY: San Francisco

STATE: California  
COUNTRY: USA  
ZIP: 94105-1492  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentln Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/588,595  
FILING DATE: 18-JAN-1996  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W.  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 14538A-19  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleotide  
US-08-588-595-1

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 71.4%; Pred. No. 1.9e+02;  
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 798 GGCTGCTCGCGCC 811  
|||:|||||  
Db 2 GGCUCUCUCGCC 15

RESULT 342  
US-08-850-347-5  
Sequence 5, Application US/08850347  
Patent No. 6110742  
GENERAL INFORMATION:  
APPLICANT: Soreq, Hermona  
APPLICANT: Seidman, Shlomo  
APPLICANT: Eckstein, Fritz  
TITLE OF INVENTION: SYNTHETIC ANTISENSE  
TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS  
NUMBER OF INVENTION: CONTAINING THEM  
NUMBER OF SEQUENCES: 16  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Kohn & Associates  
STREET: 30500 No. 6110742thwestern Hwy.  
CITY: Farmington Hills  
STATE: Michigan  
COUNTRY: US  
ZIP: 48334  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentln Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/850,347  
FILING DATE:  
CLASSIFICATION: 514  
ATTORNEY/AGENT INFORMATION:  
NAME: Kohn, Kenneth I.  
REGISTRATION NUMBER: 30,955  
REFERENCE/DOCKET NUMBER: 2391,00057  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (248) 539-5050  
TELEFAX: (248) 539-5055  
INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
ANTI-SENSE: YES  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
US-08-850-347-5

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 216 CTGCGGGGCTCTCA 229  
|||||  
Db 1 CTGCGGGGCTCTCA 14

RESULT 343  
US-09-071-845-426  
Sequence 426, Application US/09071845  
Patent No. 6132867  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwigen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Draper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
TITLE OF INVENTION: DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071,845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292,620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008,895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989,849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 426:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single

```

; TOPOLOGY: linear
; US-09-071-845-426
Query Match      0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      538 CTGGCTCGAGAC 551
      |||||
      1 CUGGCTUGAGAC 14

RESULT 344
US-09-038-073-162/c
; Sequence 162, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 162:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-162

Query Match      0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      503 GCTCTGAAACCT 516
      |||||
      15 GCTCTGAAACCT 2

RESULT 345
US-09-038-073-1341/c
; Sequence 1341, Application US/09038073
; Patent No. 6194150

```

```

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1341:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-1341

Query Match      0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1397 CCAGATACAGAG 1410
      |||||
      14 CCAGATACAGAG 1

RESULT 346
US-09-038-073-2049/c
; Sequence 2049, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

```

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/038,073  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/585,684  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2049:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-038-073-2049

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 CCCTGGCGAGGTGA 1600  
|||  
Db 15 CCATGGCGAGGTGA 2

RESULT 347  
US-09-038-073-2267/C  
Sequence 2267, Application US/09038073  
Patent No. 6194150  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: Jarvis, Thale  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE  
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES  
NUMBER OF SEQUENCES: 2751  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/038,073  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/585,684  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 2267:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-038-073-2267

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1372 GTGGAGTACTGCT 1385  
|||||  
Db 15 GTGGAGTACTGTT 2

RESULT 348  
US-09-158-980-25  
Sequence 25, Application US/09158980  
Patent No. 6242427  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
APPLICANT: PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: NIXON & VANDERHIVE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/158,980  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/657,884  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4000  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-158-980-25

Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1111 CTGTGGCGCATGCC 1124  
|||||  
Db 1 CTGTGACCATGCC 14

RESULT 349  
US-09-158-980-29  
Sequence 29, Application US/09158980  
Patent No. 6242427  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
APPLICANT: PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: NIXON & VANDERHAYE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/158,980  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/657,884  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4000  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-158-980-29  
Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Oy 1111 CTGTCGCGCATGCC 1124  
Db 1 CTGTCGCGCATGCC 14  
RESULT 350  
US-09-042-353-38  
Sequence 38, Application US/09042353  
Patent No. 6255458  
GENERAL INFORMATION:  
APPLICANT: Lomborg, Nils  
APPLICANT: Kay, Robert M.  
TITLE OF INVENTION: Transgenic No. 6255458-Human Animals for  
Producing Heterologous Antibodies  
NUMBER OF SEQUENCES: 421  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Townsend and Townsend and Crew LLP  
STREET: Two Embarcadero Center, Eighth Floor  
CITY: San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94111-3834  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/042,353  
FILING DATE: 13-MAR-1998  
CLASSIFICATION: 800  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/810,279  
FILING DATE: 17-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/853,408  
FILING DATE: 18-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/904,068  
FILING DATE: 23-JUN-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/990,860  
FILING DATE: 16-DEC-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/053,131  
FILING DATE: 26-APR-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/096,762  
FILING DATE: 22-JUL-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/155,301  
FILING DATE: 18-NOV-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/161,739  
FILING DATE: 03-DEC-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/165,699  
FILING DATE: 10-DEC-1993  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/209,741  
FILING DATE: 09-MAR-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/352,322  
FILING DATE: 07-DEC-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/544,404  
FILING DATE: 10-OCT-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/728,463  
FILING DATE: 10-OCT-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US96/16433  
FILING DATE: 10-OCT-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/758,417  
FILING DATE: 02-DEC-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/US97/21803  
FILING DATE: 01-DEC-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Apple, Randolph T.  
REGISTRATION NUMBER: 36,429  
REFERENCE/DOCKET NUMBER: 014643-009040US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 576-0200  
TELEFAX: (415) 576-0300  
INFORMATION FOR SEQ ID NO: 38:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-042-353-38  
Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;

```
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1135 AGCTTGGCAACGA 1148
Db 1 AGCTTGGCAACTA 14

RESULT 351
US-08-758-417A-303
; Sequence 303, Application US/08758417A
; Patent No. 6300129
; GENERAL INFORMATION:
; APPLICANT: Lomborg, Nils
; Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 6300129-Human Animals for
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 417
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,417A
; FILING DATE: 02-Dec-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Serafini, Andrew T.
; REGISTRATION NUMBER: 41,303
; REFERENCE/DOCKET NUMBER: 014643-009030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 303:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 303:
US-08-758-417A-303

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1135 AGCTTGGCAACGA 1148
Db 1 AGCTTGGCAACTA 14

RESULT 352
US-09-081-646-417/c
; Sequence 417, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
; FILE REFERENCE: 01107.74664
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 417
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-417

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2204 GCTACTGGGCATG 2217
Db 14 GCCACTGGGCATG 1

RESULT 353
US-09-081-646-506/c
; Sequence 506, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ma1 and
; FILE REFERENCE: 01107.74664
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 506
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-506

Query Match 0.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 188 GCCGCTGGCCGTG 201
Db 14 GCCGCTGGCCATG 1
```



RESULT 354  
US-09-811-492-25  
Sequence 25, Application US/09811492  
Patent No. 6638764  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: NIXON & VANDERHAYE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/811,492  
FILING DATE: 19-Jul-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/657,884  
FILING DATE: 07-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4100  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 25:  
US-09-811-492-25  
Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1111 CTGTGGCCATGCC 1124  
DB 1 CTGTGACCATGCC 14  
RESULT 355  
US-09-811-492-29  
Sequence 29, Application US/09811492  
Patent No. 6638764  
GENERAL INFORMATION:  
APPLICANT: SCHREIBER, ALAN D.  
PARK, JONG-GU  
TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS  
NUMBER OF SEQUENCES: 31  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: NIXON & VANDERHAYE P.C.  
STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR  
CITY: ARLINGTON  
STATE: VIRGINIA  
COUNTRY: U.S.A.  
ZIP: 22201-4714  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/811,492  
FILING DATE: 19-Jul-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/657,884  
FILING DATE: 07-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4100  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 29:  
US-09-811-492-29

OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/811,492  
FILING DATE: 19-Jul-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/657,884  
FILING DATE: 07-JUN-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: WILSON, MARY J.  
REGISTRATION NUMBER: 32,955  
REFERENCE/DOCKET NUMBER: 555-46  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703) 816-4100  
TELEFAX: (703) 816-4100  
INFORMATION FOR SEQ ID NO: 29:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 29:  
US-09-811-492-29  
Query Match 0.6%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1111 CTGTGGCCATGCC 1124  
DB 1 CTGTGACCATGCC 14  
RESULT 356  
US-07-988-194A-22/C  
Sequence 22, Application US/07988194A  
Patent No. 535046  
GENERAL INFORMATION:  
APPLICANT: Capon, Daniel J.  
APPLICANT: Weiss, Arthur  
APPLICANT: Irving, Brian A.  
APPLICANT: Roberts, Margo R.  
APPLICANT: Zeebo, Krisztina  
TITLE OF INVENTION: Chimeric Chains for Receptor  
TITLE OF INVENTION: Associated Signal Transduction Pathways  
NUMBER OF SEQUENCES: 49  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Flehr, Hobbach, Teet, Albritton &  
ADDRESSEE: Herbert  
STREET: 4 Embarcadero Center, Suite 3400  
CITY: San Francisco  
STATE: CA  
COUNTRY: USA  
ZIP: 94111-4187  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/988,194A  
FILING DATE: December 9, 1992  
CLASSIFICATION: 536  
ATTORNEY/AGENT INFORMATION:  
NAME: Rowland, Berttram I.  
REGISTRATION NUMBER: 20015  
REFERENCE/DOCKET NUMBER: A-55107-1 CELL-0051  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-781-1989  
TELEFAX: 415-398-3249  
INFORMATION FOR SEQ ID NO: 22:  
US-07-988-194A-22/C

SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-07-988-194A-22

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432  
DB 15 CTCCTCAGACAAA 2

RESULT 357  
US-08-311-760A-392/C  
Sequence 392, Application US/08311760A  
Patent No. 5599706  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Newton, Roger S.  
APPLICANT: Ramnarack, Randy  
TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES  
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF  
TITLE OF INVENTION: PLASMA LIPOPROTEIN (a) [LP(a)] BY  
TITLE OF INVENTION: INHIBITING APOLOPROTEIN  
NUMBER OF SEQUENCES: 392  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/311.760A  
FILING DATE: September 23, 1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/155  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 392:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-311-760A-392

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 64 TGCGTGGGACAGT 77

DB 16 TAGCTGGGACAGT 3

RESULT 358  
US-08-258-152-24/C  
Sequence 24, Application US/08258152  
Patent No. 5686279  
GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
APPLICANT: ROBERTS, MARGO R.  
APPLICANT: DULL, THOMAS J.  
APPLICANT: ZSEBO, KRISZTINA M.  
APPLICANT: QIN, LU  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER  
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION  
TITLE OF INVENTION: OF MAMMALIAN CELLS  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESYS, INC.  
STREET: 322 LAKESIDE DRIVE  
CITY: FOSTER CITY  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94404  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/258.152  
FILING DATE: 10-JUN-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/076.299  
FILING DATE: 11-JUN-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUPEN, KAREN I.  
REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131  
TELEFAX: 415-349-7392  
INFORMATION FOR SEQ ID NO: 24:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-258-152-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432  
DB 15 CTCCTCAGACAAA 2

RESULT 359  
US-08-076-299A-24/C  
Sequence 24, Application US/08076299A  
Patent No. 5834256  
GENERAL INFORMATION:  
APPLICANT: FINER, MITCHELL H.  
APPLICANT: ROBERTS, MARGO R.  
APPLICANT: DULL, THOMAS J.  
APPLICANT: ZSEBO, KRISZTINA M.  
APPLICANT: QIN, LU  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER

```

; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESIS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/076,299A
; FILING DATE: 11-JUN-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I.
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELL 13.0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-358-9600 X131
; TELEFAX: 415-349-7392
; INFORMATION FOR SEQ ID NO: 24:
; LENGTH: 16 base pairs
; SEQUENCE CHARACTERISTICS:
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-076-299A-24
;
; Query Match 0.6%; Score 12.4; DB 1; Length 16;
; Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
; Matches 13; Conservative 0; Mismatches 1;
;
; QY 1419 CTCCTCAGAGAAA 1432
; Db 15 CTCCTCAGACAAA 2
;
; RESULT 360
; US-08-292-620A-1615
; Sequence 1615, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C., DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1615
;
; Query Match 0.6%; Score 12.4; DB 1; Length 16;
; Best Local Similarity 71.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
; Matches 10; Conservative 3; Mismatches 1;
;
; QY 153 GCTGCCACTGCTCC 166
; Db 3 GCTGCCCTGCTGCC 16
;
; RESULT 361
; US-08-438-582-24/c
; Sequence 24, Application US/08438582
; Patent No. 5858740
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: ROBERTS, MARGO R.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISZTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESIS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/438,582
; FILING DATE: 10-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/258,152
; FILING DATE: 10-JUN-1994

```

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/076,299  
FILING DATE: 11-JUN-93  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUBEN, KAREN I.  
REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131  
TELEFAX: 415-349-7392  
INFORMATION FOR SEQ ID NO: 24:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-438-582-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1419 CTCTCGAGAAA 1432  
Db 15 CTCTCGAGACAAA 2

RESULT 362  
US-08-173-489C-168  
Sequence 168, Application US/08173489C  
Patent No. 5861244  
GENERAL INFORMATION:  
APPLICANT: WANG, C. -G.  
APPLICANT: HEPBURN, A. G.  
TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
TITLE OF INVENTION: TRIPLE-STRAND FORMATION.  
NUMBER OF SEQUENCES: 365  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
STREET: 510 EAST 73RD STREET,  
CITY: NEW YORK  
STATE: NEW YORK  
COUNTRY: USA  
ZIP: 10021.  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44Mb storage  
COMPUTER: IBM PC/XT/AT  
OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: Wordperfect Version 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959  
INFORMATION FOR SEQ ID NO: 168:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 bases  
TYPE: nucleic acid  
STRANDEDNESS: single stranded  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: third strand derived from Hepatitis B  
DESCRIPTION: isolate a1w sequence region in Seq ID No. 5861244167

HYPOTHETICAL: yes  
ANTI-SENSE: no  
PUBLICATION INFORMATION:  
RELEVANT RESIDUES IN SEQ ID NO: 168 :FROM 1 TO 16  
US-08-173-489C-168

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1009 CTGCTTCTCTCT 1022  
Db 3 CTGCTTCTCTCTT 16

RESULT 363  
US-08-774-310-392/C  
Sequence 392, Application US/08774310  
Patent No. 5877022  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Daniel T.  
APPLICANT: McSwiggen, James  
APPLICANT: Newton, Roger S.  
APPLICANT: Ramharack, Randy

TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES  
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF  
PLASMA LIPOPROTEIN (a) [LP(a)] BY  
TITLE OF INVENTION: INHIBITING APOLIPOPROTEIN

NUMBER OF SEQUENCES: 392  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.

ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/774,310  
FILING DATE: December 23, 1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/311,760  
FILING DATE: September 23, 1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 223/229  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 392:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-774-310-392

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 64 TGGCTGGGACAGT 77  
Db 16 TAGCTGGGACAGT 3

RESULT 364  
US-09-071-845-1615  
Sequence 1615, Application US/09071845  
Patent No. 6132967  
GENERAL INFORMATION:  
APPLICANT: Susan Grimm  
APPLICANT: Dan T. Stinchcomb  
APPLICANT: James McSwiggen  
APPLICANT: Sean Sullivan  
APPLICANT: Kenneth G. Diaper  
TITLE OF INVENTION: RIBOZYME TREATMENT OF  
DISEASES OR CONDITIONS  
TITLE OF INVENTION: RELATED TO LEVELS OF  
TITLE OF INVENTION: INTRACELLULAR ADHESION  
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)  
NUMBER OF SEQUENCES: 2390  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/071.845  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/292.620  
FILING DATE: August 17, 1994  
APPLICATION NUMBER: 08/008.895  
FILING DATE: January 19, 1993  
APPLICATION NUMBER: 07/989.849  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 208/149  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 1615:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-071-845-1615

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 71.4%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;  
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 153 GTCGCCACTGCTCC 166  
||:|||||:|||||  
Db 3 GTCGCCCTCCTCCTCC 16

RESULT 365  
US-09-266-596-24/C  
Sequence 24, Application US/09266596  
Patent No. 6218187  
GENERAL INFORMATION:

APPLICANT: FINER, MITCHELL H.  
APPLICANT: DULL, THOMAS J.  
APPLICANT: ZSEBO, KRISZTINA M.  
APPLICANT: COOKE, KERRAN  
APPLICANT: FARSON, DEBORAH A.  
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER  
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION  
TITLE OF INVENTION: OF MAMMALIAN CELLS  
NUMBER OF SEQUENCES: 48  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESYS, INC.  
STREET: 322 LAKESIDE DRIVE  
CITY: FOSTER CITY  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94404  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/266.596  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/517.488  
FILING DATE: 21-AUG-1995  
APPLICATION NUMBER: US 08/258.152  
FILING DATE: 10-JUN-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/076.299  
FILING DATE: 11-JUN-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: KRUPEN, KAREN I.  
REGISTRATION NUMBER: 34,647  
REFERENCE/DOCKET NUMBER: CELL 13.3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-358-9600 X131  
TELEFAX: 415-349-7392  
INFORMATION FOR SEQ ID NO: 24:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-266-596-24

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1419 CTCCTCAGAGAAA 1432  
|||||  
Db 15 CTCCTCAGACAAA 2

RESULT 366  
US-08-479-737-22/C  
Sequence 22, Application US/08479737  
Patent No. 6319494  
GENERAL INFORMATION:  
APPLICANT: Capon, Daniel J  
APPLICANT: Weis, Arthur  
APPLICANT: Irving, Brian A  
APPLICANT: Roberts, Margo R  
APPLICANT: Zsebo, Krisztina  
TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED  
SIGNAL TRANSDUCTION PATHWAYS  
NUMBER OF SEQUENCES: 51  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CELL GENESYS, INC.

```

: STREET: 322 Lakeside Drive
: CITY: Foster City
: STATE: California
: COUNTRY: USA
: ZIP: 94404
:
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/479,737
: FILING DATE: 07-Jun-1995
: CLASSIFICATION: <Unknown>
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/238,405
: FILING DATE: 05-MAY-1994
: ATTORNEY/AGENT INFORMATION:
: NAME: Mandel, SaraLynn
: REGISTRATION NUMBER: 31,853
: REFERENCE/DOCKET NUMBER: Cell 5.3
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 358-9600
: TELEFAX: (415) 358-0803
: INFORMATION FOR SEQ ID NO: 22:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 16 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-08-479-737-22

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1419 CTCCTCAGAGAAA 1432
Db      15 CTCCTCAGAGAAA 2

RESULT 367
US-08-475-442A-22/c
: Sequence 22, Application US/08475442A
: Patent No. 6407221
: GENERAL INFORMATION:
: APPLICANT: CAPON, DANIEL J
: APPLICANT: WEISS, ARTHUR
: APPLICANT: IRVING, BRIAN A
: APPLICANT: ROBERTS, MARGO R
: APPLICANT: ZSEBO, KRISTINA
: TITLE OF INVENTION: CHIMERIC CHAINS FOR
: NUMBER OF SEQUENCES: 51
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: CELL GENESYS, INC.
: STREET: 322 LAKESIDE DRIVE
: CITY: FOSTER CITY
: STATE: CALIFORNIA
: COUNTRY: USA
: ZIP: 94404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/475,442A
: FILING DATE: 06-JUN-1995
: CLASSIFICATION:
: PRIOR APPLICATION DATA:
```

```

: APPLICATION NUMBER: US 08/238,405
: FILING DATE: 05-MAY-1994
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/988,194
: FILING DATE: 09-DEC-1992
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 07/627,643
: FILING DATE: 14-DEC-1990
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: PCT/US91/09431
: FILING DATE: 12-DEC-1991
: ATTORNEY/AGENT INFORMATION:
: NAME: KRUPEN, KAREN I
: REGISTRATION NUMBER: 34,647
: REFERENCE/DOCKET NUMBER: CELLS.5
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (415) 358-9600x131
: TELEFAX: (415) 349-7392
: INFORMATION FOR SEQ ID NO: 22:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 16 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
US-08-475-442A-22

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1419 CTCCTCAGAGAAA 1432
Db      15 CTCCTCAGAGAAA 2

RESULT 368
US-09-944-411-24/c
: Sequence 24, Application US/09944411
: Patent No. 6506604
: GENERAL INFORMATION:
: APPLICANT: FINER, MITCHELL H.
: DULL, THOMAS J.
: ZSEBO, KRISTINA M.
: COOKE, KEEGAN
: FARSON, DEBORAH A.
: TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION
: OF MAMMALIAN CELLS
: NUMBER OF SEQUENCES: 48
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: CELL GENESYS, INC.
: STREET: 322 LAKESIDE DRIVE
: CITY: FOSTER CITY
: STATE: CALIFORNIA
: COUNTRY: USA
: ZIP: 94404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/944,411
: FILING DATE: 04-Sep-2001
: CLASSIFICATION: <Unknown>
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/914,893
: FILING DATE: <Unknown>
: APPLICATION NUMBER: US 08/258,152
: FILING DATE: 10-JUN-1994
: APPLICATION NUMBER: US 08/076,299
: FILING DATE: 11-JUN-1993
```

```
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-944-411-24

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 1419 CTCTCAGAGAAA 1432
Db 15 CTCTCAGACAAA 2

RESULT 369
US-09-829-855-25/c
Sequence 25, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
PRIOR FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 25
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-25

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 297 AGTCGCGCACTG 310
Db 16 AGTCGCGCACTG 3

RESULT 370
US-09-829-855-30/c
Sequence 30, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
PRIOR FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 34
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-25
```

```
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 30
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-30

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 297 AGTCGCGCACTG 310
Db 16 AGTCGCGCACTG 3

RESULT 371
US-09-829-855-32/c
Sequence 32, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
PRIOR FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 32
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-32

Query Match
Best Local Similarity 92.9%; Score 12.4; DB 1; Length 16;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 297 AGTCGCGCACTG 310
Db 16 AGTCGCGCACTG 3

RESULT 372
US-09-829-855-34/c
Sequence 34, Application US/09829855
Patent No. 6613520
GENERAL INFORMATION:
APPLICANT: Matthew, Ashby N.
TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
FILE REFERENCE: ASHBY-1
CURRENT APPLICATION NUMBER: US/09/829,855
PRIOR FILING DATE: 2001-04-10
PRIOR APPLICATION NUMBER: US 60/196063
PRIOR FILING DATE: 2000-04-10
PRIOR APPLICATION NUMBER: US 60/196258
NUMBER OF SEQ ID NOS: 244
SOFTWARE: PatentIn version 3.1
SEQ ID NO 34
LENGTH: 16
TYPE: DNA
ORGANISM: unknown
FEATURE:
OTHER INFORMATION: unidentified soil organism
US-09-829-855-32
```

```
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-34

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
DB      16 AGCTGCGGCAACAG 3

RESULT 373
US-09-829-855-91/c
; Sequence 91, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 91
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-91

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
DB      16 AGCTTGGGCACTGG 3

RESULT 374
US-09-829-855-92/c
; Sequence 92, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 92
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-92

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      297 AGCTGCGGCACTGG 310
DB      16 AGCTGCGGCAACGG 3

RESULT 375
US-09-829-855-103/c
; Sequence 103, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 103
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-103

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
DB      16 AGCTGCGGCAACGG 3

RESULT 376
US-09-829-855-105/c
; Sequence 105, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; FILE REFERENCE: ASHBY-1
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 105
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-105

Query Match          0.6%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      297 AGCTGCGGCACTGG 310
DB      16 AGCTGCGGCAACGG 3

RESULT 377
US-09-829-855-106/c
```



; Sequence 106, Application US/09829855  
; Patent No. 6613520  
; GENERAL INFORMATION:  
; APPLICANT: Matthew, Leahy N.  
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
; FILE REFERENCE: ASHBY-1  
; CURRENT APPLICATION NUMBER: US/09/829,855  
; CURRENT FILING DATE: 2001-04-10  
; PRIOR APPLICATION NUMBER: US 60/196063  
; PRIOR FILING DATE: 2000-04-10  
; PRIOR APPLICATION NUMBER: US 60/196258  
; PRIOR FILING DATE: 2000-04-11  
; NUMBER OF SEQ ID NOS: 244  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 106  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: unknown  
; FEATURE:  
; OTHER INFORMATION: unidentified soil organism  
US-09-829-855-106.

Query Match 0.6%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 297 AGCTGCGGCACTGG 310  
|||  
Db 16 AGCTGCGGCACTGG 3

Search completed: June 30, 2004, 08:41:20  
Job time : 12 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:50:09 ; Search time 0.001 Seconds  
(without alignments)  
525.798 Million cell updates/sec

Title: US-10-024-369-3  
Perfect score: 2247  
Sequence: 1 atgcctagctcctagctgccc.....ctgcagatgctccagaatga 2247

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 7 seqs, 117 residues

Total number of hits satisfying chosen parameters: 14

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 7 summaries

Database : ref3.seq.\*  
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	15.2	0.7	20	1	ACCESSION:AZ369092
2	14.8	0.7	19	1	ACCESSION:AZ598508
3	14.4	0.6	19	1	ACCESSION:AZ598508
4	12.8	0.6	16	1	ACCESSION:AZ598508
5	12	0.5	16	1	ACCESSION:BO592176
6	11	0.5	13	1	ACCESSION:AI094839
7	10.8	0.5	14	1	ACCESSION:BM395292

## ALIGNMENTS

RESULT 1  
AZ369092 20 bp DNA linear GSS 02-OCT-2000  
LOCUS 1M0119E01R Mouse 10kb plasmid UGCGM library Mus musculus genomic  
DEFINITION clone UGCGM0119E01 R, genomic survey sequence.

ACCESSION AZ369092  
VERSION AZ369092.1 GI:10482792  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 20)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss

University of Utah Genome Center  
University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert length: 10000 Std Error: 0.00  
Plate: 0119 row: E column: 01  
Seq primer: CACACGAGAAACAGCTATGACC  
Class: plasmid ends  
High quality sequence stop: 20.  
Location/Qualifiers

FEATURES  
source

1. 20  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UGCGM0119E01"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/clone\_11b="Mouse 10kb plasmid UGCGM library"  
/note="Vector: PWD42NV, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource  
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (GI:4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best local similarity 85.0%; Pred. No. 0.61;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 632 TCACGACTGATTCACAA 651  
DB 1 TCACAACTGATTCACAA 20

RESULT 2  
AZ598508 19 bp DNA linear GSS 13-DEC-2000  
LOCUS 1M0413B24F Mouse 10kb plasmid UGCGM library Mus musculus genomic  
DEFINITION clone UGCGM0413B24 F, genomic survey sequence.

ACCESSION AZ598508  
VERSION AZ598508.1 GI:11720698  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 19)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts  
JOURNAL Unpublished (2000)  
COMMENT Contact: Robert B. Weiss  
University of Utah Genome Center

University of Utah  
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0413 row: B column: 24  
Seq primer: CGTGTGTAACGACGCGCAGT  
Class: plasmid ends  
High quality sequence stop: 19.

## FEATURES

source

1. 19  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUCGCM0413B24"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/clone\_1lb="Mouse 10kb plasmid UUCGCM library"  
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 0.78;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1111 CTGTGGCCATGCTTACA 1128  
Db 2 CTCTGGCCATGCTTACA 19

RESULT 3  
AZ865832/c 19 bp DNA linear GSS 21-FEB-2001  
LOCUS 2M0176D09F Mouse 10kb plasmid UUCGCM library Mus musculus genomic  
DEFINITION clone UUCGCM0176D09 F, genomic survey sequence.

ACCESSION AZ865832  
VERSION AZ865832.1 GI:13066534  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 19)

REFERENCE  
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacom, T., Duval, B., Hamil, C., Iselm, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.  
TITLE Mouse whole genome scaffolding with paired end reads from 10kb  
JOURNAL Plasmid inserts  
COMMENT Unpublished (2000)  
Contact: Robert B. Weiss  
University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT  
84112, USA  
Tel: 801 585 5606  
Fax: 801 585 7177  
Email: ddunn@genetics.utah.edu  
Insert Length: 10000 Std Error: 0.00  
Plate: 0176 row: D column: 09  
Seq primer: CGTGTGTAACGACGCGCAGT  
Class: plasmid ends  
High quality sequence stop: 19.

## FEATURES

source

1. 19  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UUCGCM0176D09"  
/sex="Male"  
/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"  
/clone\_1lb="Mouse 10kb plasmid UUCGCM library"  
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 0.93;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1896 TGACACACAGGTAGAC 1911  
Db 17 TGACACACAGGTAGAC 2

RESULT 4  
B0592176 16 bp mRNA linear EST 06-DEC-2002  
LOCUS B012696-024-021-004-SP6 MP1Z-ADIS-024-developing root Beta vulgaris  
DEFINITION CDNA clone 024-021-004 5-PRIME, mRNA sequence.

ACCESSION B0592176  
VERSION B0592176.1 GI:26121759  
KEYWORDS EST.  
SOURCE Beta vulgaris  
ORGANISM Beta vulgaris

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Caryophyllales; Amaranthaceae; Beta.  
1 (bases 1 to 16)

REFERENCE  
AUTHORS Herwig, R., Schulz, B., Weishaar, B., Hemmig, S., Steinfath, M., and Radelof, U.  
TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide  
JOURNAL fingerprinting allows access to 25 000 potential sugar beet genes  
MEDLINE Plant J. 32 (5), 845-857 (2002)  
PUBMED 22362189  
12472698

COMMENT Contact: Weishaar B  
ADIS DNA core facility at MP1Z



```

RESULT 7
LOCUS      CA798290
DEFINITION Cac_Bl_611 Cac_Bl (Bean and leaf from Amelonardo type Cacao)
ACCESSION  CA798290
VERSION    CA798290.1 GI:26055376
KEYWORDS
SOURCE
ORGANISM  Theobroma cacao (cacao)
           Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
           Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
           rosids; eurosids II; Malvales; Malvaceae; Byttnerioideae;
           Theobroma.
           1 (bases 1 to 14)
REFERENCE  1 (bases 1 to 14)
AUTHORS   Jones,P.G., Allaway,D., Gilmour,D.M., Harris,C., Rankin,D.,
           Retzel,E.R. and Jones,C.A.
TITLE     Gene discovery and microarray analysis of cacao (Theobroma cacao
           L.) varieties
JOURNAL   Planta 216 (2), 255-264 (2002)
MEDLINE   2237596
PUBMED    12447539
COMMENT   Contact: Jones, Paul
           Masterfoods
           3d Dundee Road, Slough, Berkshire, UK, SL1 4LG
           Tel: +44 1664 416644
           Email: Paul.Jones@eu.efem.com
           Seq primer: T3.
FEATURES
source
location/Qualifiers
     1..14
     /organism="Theobroma cacao"
     /mol_type="mRNA"
     /strain="Amelonado type"
     /db_xref="taxon:3641"
     /clone="Cac Bl 611"
     /tissue_type="Mature leaf and mature bean"
     /dev_stage="maturity"
     /lab_host="XL-1 Blue MRF"
     /clone_1b="Cac_Bl (Bean and leaf from Amelonardo type
     Cacao)"
     /note="Vector: DBK-CMV; Bean and leaf tissue from an
     Amelonado type Cacao tree."

```

```

Query Match      0.5%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 6;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      657 CTCAGCGGATACCT 670
        ||| ||| ||| |||
Db       1 CTCGGCTATACCT 14

```

Search completed: June 30, 2004, 08:50:10  
 Job time : 1 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2004, 08:43:33 ; Search time 11 Seconds  
(without alignments)  
3.377 Million cell updates/sec

Title: US-10-024-369-3

Perfect score: 2247  
Sequence: 1 atgcgcagctcctagctgc.....ctgcagatgctccagatga 2247

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 459 seqs, 8265 residues

Total number of hits satisfying chosen parameters: 918

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 462 summaries

Database : rnmp3.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	40.6	1.8	41	US-10-035-833A-6	Sequence 6, Appl 1
2	40.6	1.8	41	US-10-035-833A-5176	Sequence 5176, Ap
3	40.6	1.8	41	US-10-035-833A-7638	Sequence 7638, Ap
4	30.6	1.4	31	US-09-801-274-1336	Sequence 1336, Ap
5	23	1.0	23	US-10-024-369-4	Sequence 4, Appl 1
6	21	0.9	21	US-10-010-920-66	Sequence 66, Appl 1
7	21	0.9	21	US-10-008-721-66	Sequence 66, Appl 1
8	20	0.9	20	US-10-024-369-5	Sequence 5, Appl 1
9	20	0.9	20	US-10-024-369-6	Sequence 6, Appl 1
10	20	0.9	20	US-10-024-369-10	Sequence 10, Appl 1
11	20	0.9	20	US-10-024-369-11	Sequence 11, Appl 1
12	20	0.9	20	US-10-024-369-12	Sequence 12, Appl 1
13	20	0.9	20	US-10-024-369-13	Sequence 13, Appl 1
14	20	0.9	20	US-10-024-369-14	Sequence 14, Appl 1
15	20	0.9	20	US-10-024-369-15	Sequence 15, Appl 1
16	20	0.9	20	US-10-024-369-16	Sequence 16, Appl 1
17	20	0.9	20	US-10-024-369-17	Sequence 17, Appl 1
18	20	0.9	20	US-10-024-369-18	Sequence 18, Appl 1
19	20	0.9	20	US-10-024-369-19	Sequence 19, Appl 1
20	20	0.9	20	US-10-024-369-20	Sequence 20, Appl 1
21	20	0.9	20	US-10-024-369-21	Sequence 21, Appl 1
22	20	0.9	20	US-10-024-369-22	Sequence 22, Appl 1
23	20	0.9	20	US-10-024-369-23	Sequence 23, Appl 1
24	20	0.9	20	US-10-024-369-24	Sequence 24, Appl 1
25	20	0.9	20	US-10-024-369-25	Sequence 25, Appl 1
26	20	0.9	20	US-10-024-369-26	Sequence 26, Appl 1
27	20	0.9	20	US-10-024-369-27	Sequence 27, Appl 1
28	20	0.9	20	US-10-024-369-28	Sequence 28, Appl 1
29	20	0.9	20	US-10-024-369-29	Sequence 29, Appl 1
30	20	0.9	20	US-10-024-369-30	Sequence 30, Appl 1
31	20	0.9	20	US-10-024-369-31	Sequence 31, Appl 1
32	20	0.9	20	US-10-024-369-32	Sequence 32, Appl 1
33	20	0.9	20	US-10-024-369-33	Sequence 33, Appl 1

C 34	20	0.9	20	1	US-10-024-369-34	Sequence 34, Appl 1
C 35	20	0.9	20	1	US-10-024-369-35	Sequence 35, Appl 1
C 36	20	0.9	20	1	US-10-024-369-36	Sequence 36, Appl 1
C 37	20	0.9	20	1	US-10-024-369-37	Sequence 37, Appl 1
C 38	20	0.9	20	1	US-10-024-369-38	Sequence 38, Appl 1
C 39	20	0.9	20	1	US-10-024-369-39	Sequence 39, Appl 1
C 40	20	0.9	20	1	US-10-024-369-40	Sequence 40, Appl 1
C 41	20	0.9	20	1	US-10-024-369-41	Sequence 41, Appl 1
C 42	20	0.9	20	1	US-10-024-369-42	Sequence 42, Appl 1
C 43	20	0.9	20	1	US-10-024-369-43	Sequence 43, Appl 1
C 44	20	0.9	20	1	US-10-024-369-44	Sequence 44, Appl 1
C 45	20	0.9	20	1	US-10-024-369-45	Sequence 45, Appl 1
C 46	20	0.9	20	1	US-10-024-369-46	Sequence 46, Appl 1
C 47	20	0.9	20	1	US-10-024-369-47	Sequence 47, Appl 1
C 48	20	0.9	20	1	US-10-024-369-48	Sequence 48, Appl 1
C 49	20	0.9	20	1	US-10-024-369-49	Sequence 49, Appl 1
C 50	20	0.9	20	1	US-10-024-369-50	Sequence 50, Appl 1
C 51	20	0.9	20	1	US-10-024-369-51	Sequence 51, Appl 1
C 52	20	0.9	20	1	US-10-024-369-52	Sequence 52, Appl 1
C 53	20	0.9	20	1	US-10-024-369-53	Sequence 53, Appl 1
C 54	20	0.9	20	1	US-10-024-369-54	Sequence 54, Appl 1
C 55	20	0.9	20	1	US-10-024-369-55	Sequence 55, Appl 1
C 56	20	0.9	20	1	US-10-024-369-56	Sequence 56, Appl 1
C 57	20	0.9	20	1	US-10-024-369-57	Sequence 57, Appl 1
C 58	20	0.9	20	1	US-10-024-369-58	Sequence 58, Appl 1
C 59	20	0.9	20	1	US-10-024-369-59	Sequence 59, Appl 1
C 60	20	0.9	20	1	US-10-024-369-60	Sequence 60, Appl 1
C 61	20	0.9	20	1	US-10-024-369-61	Sequence 61, Appl 1
C 62	20	0.9	20	1	US-10-024-369-62	Sequence 62, Appl 1
C 63	20	0.9	20	1	US-10-024-369-63	Sequence 63, Appl 1
C 64	20	0.9	20	1	US-10-024-369-64	Sequence 64, Appl 1
C 65	20	0.9	20	1	US-10-024-369-65	Sequence 65, Appl 1
C 66	20	0.9	20	1	US-10-024-369-66	Sequence 66, Appl 1
C 67	20	0.9	20	1	US-10-024-369-67	Sequence 67, Appl 1
C 68	20	0.9	20	1	US-10-024-369-68	Sequence 68, Appl 1
C 69	20	0.9	20	1	US-10-024-369-69	Sequence 69, Appl 1
C 70	20	0.9	20	1	US-10-024-369-70	Sequence 70, Appl 1
C 71	20	0.9	20	1	US-10-024-369-71	Sequence 71, Appl 1
C 72	20	0.9	20	1	US-10-024-369-72	Sequence 72, Appl 1
C 73	20	0.9	20	1	US-10-024-369-73	Sequence 73, Appl 1
C 74	20	0.9	20	1	US-10-024-369-74	Sequence 74, Appl 1
C 75	20	0.9	20	1	US-10-024-369-75	Sequence 75, Appl 1
C 76	20	0.9	20	1	US-10-024-369-76	Sequence 76, Appl 1
C 77	20	0.9	20	1	US-10-024-369-77	Sequence 77, Appl 1
C 78	20	0.9	20	1	US-10-024-369-78	Sequence 78, Appl 1
C 79	20	0.9	20	1	US-10-024-369-79	Sequence 79, Appl 1
C 80	20	0.9	20	1	US-10-024-369-80	Sequence 80, Appl 1
C 81	20	0.9	20	1	US-10-024-369-81	Sequence 81, Appl 1
C 82	20	0.9	20	1	US-10-024-369-82	Sequence 82, Appl 1
C 83	20	0.9	20	1	US-10-024-369-83	Sequence 83, Appl 1
C 84	20	0.9	20	1	US-10-024-369-84	Sequence 84, Appl 1
C 85	20	0.9	20	1	US-10-024-369-85	Sequence 85, Appl 1
C 86	20	0.9	20	1	US-10-024-369-86	Sequence 86, Appl 1
C 87	20	0.9	20	1	US-10-024-369-87	Sequence 87, Appl 1
C 88	19	0.8	19	1	US-10-010-920-65	Sequence 65, Appl 1
C 89	19	0.8	19	1	US-10-008-721-65	Sequence 65, Appl 1
C 90	19	0.8	19	1	US-10-383-664-74	Sequence 24, Appl 1
C 91	18	0.8	18	1	US-09-398-689-59	Sequence 23, Appl 1
C 92	18	0.8	18	1	US-10-333-664-73	Sequence 23, Appl 1
C 93	16.8	0.7	20	1	US-10-092-900A-550	Sequence 5, App
C 94	16	0.7	21	1	US-10-136-942-2	Sequence 2, Appl 1
C 95	15.8	0.7	19	1	US-09-813-824A-40	Sequence 40, Appl 1
C 96	15.8	0.7	19	1	US-10-648-512-60	Sequence 60, Appl 1
C 97	15.8	0.7	20	1	US-10-369-378-36	Sequence 36, Appl 1
C 98	15.8	0.7	20	1	US-10-369-378-37	Sequence 37, Appl 1
C 99	15.8	0.7	20	1	US-10-199-937-171	Sequence 171, App
C 100	15.8	0.7	20	1	US-10-199-937-172	Sequence 172, App
C 101	15.8	0.7	21	1	US-09-817-014-68	Sequence 68, Appl 1
C 102	15.8	0.7	21	1	US-10-074-246-21	Sequence 21, Appl 1
C 103	15.8	0.7	21	1	US-10-184-085A-855	Sequence 855, App
C 104	15.8	0.7	21	1	US-10-056-229-68	Sequence 68, Appl 1
C 105	15.4	0.7	17	1	US-09-866-108-891	Sequence 891, App
C 106	15.4	0.7	17	1	US-09-866-108-892	Sequence 892, App

C 107	15.4	0.7	17	1	US-09-866-108-693	Sequence 893, App	C 180	14.4	0.6	19	1	US-10-205-309-17	Sequence 17, App1
C 108	15.4	0.7	17	1	US-10-156-306-7105	Sequence 7105, Ap	C 181	14.4	0.6	19	1	US-10-205-309-142	Sequence 342, App
C 109	15.4	0.7	18	1	US-09-969-373-4010	Sequence 4010, Ap	C 182	14	0.6	14	1	US-09-998-780-12	Sequence 12, App1
C 110	15.4	0.7	18	1	US-09-961-077-609	Sequence 609, App	C 183	14	0.6	14	1	US-10-417-393-12	Sequence 12, App1
C 111	15.2	0.7	20	1	US-09-752-983-8	Sequence 8	C 184	14	0.6	16	1	US-09-829-855-101	Sequence 101, App
C 112	15.2	0.7	20	1	US-09-851-771A-8	Sequence 8, App1	C 185	14	0.6	16	1	US-10-607-077A-101	Sequence 101, App
C 113	15.2	0.7	20	1	US-09-774-809-57	Sequence 57, App1	C 186	14	0.6	17	1	US-09-866-108-895	Sequence 895, App
C 114	15.2	0.7	20	1	US-09-917-963-36	Sequence 36, App1	C 187	14	0.6	17	1	US-09-866-108-896	Sequence 896, App
C 115	15.2	0.7	20	1	US-10-345-444B-57	Sequence 57, App1	C 188	14	0.6	17	1	US-09-930-423-1483	Sequence 1483, App
C 116	15.2	0.7	20	1	US-10-642-802-42	Sequence 42, App1	C 189	14	0.6	17	1	US-09-930-423-1484	Sequence 1484, App
C 117	15.2	0.7	20	1	US-09-759-999B-7	Sequence 7, App1	C 190	14	0.6	17	1	US-09-740-332-2411	Sequence 2411, App
C 118	15.2	0.7	20	1	US-10-159-256-20	Sequence 20, App1	C 191	14	0.6	17	1	US-09-745-237A-1483	Sequence 1483, App
C 119	15.2	0.7	20	1	US-10-153-266-56	Sequence 96, App1	C 192	14	0.6	17	1	US-09-745-237A-1484	Sequence 1484, App
C 120	15.2	0.7	20	1	US-10-161-996-127	Sequence 127, App	C 193	14	0.6	17	1	US-09-817-879-2411	Sequence 2411, App
C 121	15.2	0.7	20	1	US-10-161-996-250	Sequence 250, App	C 194	14	0.6	17	1	US-10-156-306-6313	Sequence 6313, App
C 122	15.2	0.7	20	1	US-10-001-076-42	Sequence 42, App1	C 195	14	0.6	17	1	US-10-240-046A-64	Sequence 64, App1
C 123	15.2	0.7	20	1	US-10-145-493B-35	Sequence 35, App1	C 196	14	0.6	17	1	US-10-230-006-2189	Sequence 2189, App
C 124	15.2	0.7	20	1	US-10-005-191-72	Sequence 72, App1	C 197	14	0.6	17	1	US-10-138-674-9170	Sequence 9170, App
C 125	15.2	0.7	20	1	US-10-005-344-8	Sequence 8, App1	C 198	14	0.6	17	1	US-10-287-949A-9170	Sequence 9170, App
C 126	15.2	0.7	20	1	US-10-349-143-8790	Sequence 8790, Ap	C 199	14	0.6	18	1	US-10-178-325-56	Sequence 56, App1
C 127	15.2	0.7	20	1	US-10-349-143-8838	Sequence 8838, Ap	C 200	13.8	0.6	17	1	US-09-866-108-515	Sequence 515, App
C 128	15.2	0.7	20	1	US-10-289-762-2216	Sequence 3216, Ap	C 201	13.8	0.6	17	1	US-09-866-108-655	Sequence 655, App
C 129	15.2	0.7	20	1	US-10-289-762-3350	Sequence 3350, Ap	C 202	13.8	0.6	17	1	US-09-866-108-1532	Sequence 1530, App
C 130	15.2	0.7	20	1	US-10-289-762-4873	Sequence 4873, Ap	C 203	13.8	0.6	17	1	US-09-866-108-1572	Sequence 1572, App
C 131	15.2	0.7	20	1	US-10-210-833-65	Sequence 65, App1	C 204	13.8	0.6	17	1	US-09-866-108-1960	Sequence 1960, App
C 132	15.2	0.7	20	1	US-10-444-206-438	Sequence 438, App	C 205	13.8	0.6	17	1	US-09-866-108-2739	Sequence 2739, App
C 133	15.2	0.7	20	1	US-10-293-998-32	Sequence 32, App1	C 206	13.8	0.6	17	1	US-09-866-108-6521	Sequence 6521, App
C 134	15.2	0.7	20	1	US-10-293-998-58	Sequence 58, App1	C 207	13.8	0.6	17	1	US-09-866-108-6522	Sequence 6522, App
C 135	15.2	0.7	20	1	US-10-296-716-15	Sequence 15, App1	C 208	13.8	0.6	17	1	US-09-866-108-6525	Sequence 6525, App
C 136	15.2	0.7	20	1	US-10-316-667-39	Sequence 39, App1	C 209	13.8	0.6	17	1	US-09-866-108-6526	Sequence 6526, App
C 137	15.2	0.7	20	1	US-10-316-667-63	Sequence 63, App1	C 210	13.8	0.6	17	1	US-09-866-108-6758	Sequence 6758, App
C 138	15	0.7	17	1	US-10-156-306-7106	Sequence 7106, Ap	C 211	13.8	0.6	17	1	US-09-866-108-8056	Sequence 8056, App
C 139	15	0.7	17	1	US-10-156-306-7107	Sequence 7107, Ap	C 212	13.8	0.6	17	1	US-09-866-108-8057	Sequence 8057, App
C 140	15	0.7	17	1	US-10-230-006-741	Sequence 741, App	C 213	13.8	0.6	17	1	US-09-866-108-9583	Sequence 9583, App
C 141	15	0.7	17	1	US-10-230-006-1390	Sequence 1390, Ap	C 214	13.8	0.6	17	1	US-09-895-040A-77	Sequence 77, App1
C 142	14.8	0.7	18	1	US-10-100-957A-39	Sequence 39, App1	C 215	13.8	0.6	17	1	US-09-864-785-577	Sequence 577, App
C 143	14.8	0.7	18	1	US-10-211-088-293	Sequence 293, App	C 216	13.8	0.6	17	1	US-09-864-785-2690	Sequence 2690, App
C 144	14.8	0.7	18	1	US-10-265-689-19	Sequence 39, App1	C 217	13.8	0.6	17	1	US-09-864-785-2870	Sequence 2870, App
C 145	14.8	0.7	19	1	US-09-910-059-110	Sequence 121, App	C 218	13.8	0.6	17	1	US-09-864-785-2871	Sequence 2871, App
C 146	14.8	0.7	19	1	US-10-099-352-22	Sequence 22, App1	C 219	13.8	0.6	17	1	US-09-825-805-629	Sequence 629, App
C 147	14.8	0.7	19	1	US-10-224-005-84	Sequence 84, App1	C 220	13.8	0.6	17	1	US-09-825-805-119	Sequence 119, App
C 148	14.8	0.7	19	1	US-10-224-005-245	Sequence 245, App	C 221	13.8	0.6	17	1	US-09-730-289B-541	Sequence 541, App
C 149	14.8	0.7	19	1	US-10-277-216-121	Sequence 121, App	C 222	13.8	0.6	17	1	US-09-780-533A-106	Sequence 106, App
C 150	14.8	0.7	19	1	US-10-126-022-121	Sequence 121, App	C 223	13.8	0.6	17	1	US-09-780-533A-1837	Sequence 1837, App
C 151	14.8	0.7	19	1	US-10-670-184-94	Sequence 94, App1	C 224	13.8	0.6	17	1	US-09-780-533A-2015	Sequence 2015, App
C 152	14.4	0.6	17	1	US-09-866-108-890	Sequence 890, App	C 225	13.8	0.6	17	1	US-09-877-478-699	Sequence 699, App
C 153	14.4	0.6	17	1	US-09-866-108-894	Sequence 894, App	C 226	13.8	0.6	17	1	US-09-877-478-1441	Sequence 1441, App
C 154	14.4	0.6	17	1	US-09-866-108-8005	Sequence 8005, App	C 227	13.8	0.6	17	1	US-09-930-423-383	Sequence 383, App
C 155	14.4	0.6	17	1	US-09-866-108-8006	Sequence 8006, App	C 228	13.8	0.6	17	1	US-09-930-423-1041	Sequence 1041, App
C 156	14.4	0.6	17	1	US-09-961-077-139	Sequence 139, App	C 229	13.8	0.6	17	1	US-09-930-423-1485	Sequence 1485, App
C 157	14.4	0.6	17	1	US-09-818-875-603	Sequence 603, App	C 230	13.8	0.6	17	1	US-09-930-423-1557	Sequence 1557, App
C 158	14.4	0.6	17	1	US-09-818-875-604	Sequence 604, App	C 231	13.8	0.6	17	1	US-09-930-423-1558	Sequence 1558, App
C 159	14.4	0.6	17	1	US-09-930-423-384	Sequence 384, App	C 232	13.8	0.6	17	1	US-09-864-636A-1682	Sequence 1682, App
C 160	14.4	0.6	17	1	US-09-930-423-385	Sequence 385, App	C 233	13.8	0.6	17	1	US-09-827-395A-35	Sequence 35, App1
C 161	14.4	0.6	17	1	US-09-740-332-2144	Sequence 2144, App	C 234	13.8	0.6	17	1	US-09-827-395A-36	Sequence 36, App1
C 162	14.4	0.6	17	1	US-09-745-237A-384	Sequence 384, App	C 235	13.8	0.6	17	1	US-09-827-395A-79	Sequence 79, App1
C 163	14.4	0.6	17	1	US-09-745-237A-385	Sequence 385, App	C 236	13.8	0.6	17	1	US-09-827-395A-270	Sequence 272, App
C 164	14.4	0.6	17	1	US-09-817-879-2144	Sequence 2144, App	C 237	13.8	0.6	17	1	US-09-827-395A-742	Sequence 742, App
C 165	14.4	0.6	17	1	US-10-081-810-33	Sequence 33, App1	C 238	13.8	0.6	17	1	US-09-740-332-338	Sequence 338, App
C 166	14.4	0.6	17	1	US-10-060-895A-482	Sequence 482, App	C 239	13.8	0.6	17	1	US-09-740-332-1694	Sequence 1694, App
C 167	14.4	0.6	17	1	US-10-060-895A-483	Sequence 483, App	C 240	13.8	0.6	17	1	US-09-740-332-3272	Sequence 3272, App
C 168	14.4	0.6	17	1	US-10-156-306-4759	Sequence 4759, App	C 241	13.8	0.6	17	1	US-09-740-332-4243	Sequence 4243, App
C 169	14.4	0.6	17	1	US-10-156-306-4760	Sequence 4760, App	C 242	13.8	0.6	17	1	US-09-740-332-1247	Sequence 1247, App
C 170	14.4	0.6	17	1	US-10-156-306-7104	Sequence 7104, App	C 243	13.8	0.6	17	1	US-09-745-237A-183	Sequence 183, App
C 171	14.4	0.6	17	1	US-10-209-787-603	Sequence 603, App	C 244	13.8	0.6	17	1	US-09-745-237A-1041	Sequence 1041, App
C 172	14.4	0.6	17	1	US-10-209-787-604	Sequence 604, App	C 245	13.8	0.6	17	1	US-09-745-237A-1485	Sequence 1485, App
C 173	14.4	0.6	17	1	US-10-261-185-603	Sequence 604, App	C 246	13.8	0.6	17	1	US-09-745-237A-1557	Sequence 1557, App
C 174	14.4	0.6	17	1	US-10-261-185-604	Sequence 604, App	C 247	13.8	0.6	17	1	US-09-745-237A-1558	Sequence 1558, App
C 175	14.4	0.6	18	1	US-10-230-335-5	Sequence 5, App1	C 248	13.8	0.6	17	1	US-09-817-879-338	Sequence 338, App
C 176	14.4	0.6	18	1	US-10-005-956-1222	Sequence 1222, App	C 249	13.8	0.6	17	1	US-09-817-879-1694	Sequence 1694, App
C 177	14.4	0.6	19	1	US-10-427-432-11	Sequence 11, App1	C 250	13.8	0.6	17	1	US-09-817-879-3272	Sequence 3272, App
C 178	14.4	0.6	19	1	US-10-164-871-17	Sequence 17, App1	C 251	13.8	0.6	17	1	US-09-817-879-3439	Sequence 3439, App
C 179	14.4	0.6	19	1	US-10-238-042-16	Sequence 16, App1	C 252	13.8	0.6	17	1	US-09-817-879-4247	Sequence 4247, App



253	13.8	0.6	17	1	US-09-864-426A-1682	Sequence 1682, Ap	C 326	13.4	0.6	15	1	US-09-896-095-121	Sequence 121, App
C 254	13.8	0.6	17	1	US-10-342-902-659	Sequence 659, App	C 327	13.4	0.6	15	1	US-10-408-157-6	Sequence 6, App1
C 255	13.8	0.6	17	1	US-10-342-902-1441	Sequence 1441, Ap	C 328	13.4	0.6	15	1	US-10-146-505-71	Sequence 71, App
C 256	13.8	0.6	17	1	US-09-937-046-863	Sequence 863, App	C 329	13.4	0.6	15	1	US-10-440-850-231	Sequence 231, App
C 257	13.8	0.6	17	1	US-10-430-882-35	Sequence 35, App1	C 330	13.4	0.6	15	1	US-10-126-685-121	Sequence 121, App
C 258	13.8	0.6	17	1	US-10-430-882-36	Sequence 36, App1	C 331	13.4	0.6	15	1	US-10-127-028-121	Sequence 121, App
C 259	13.8	0.6	17	1	US-10-430-882-79	Sequence 79, App1	C 332	13.4	0.6	15	1	US-10-126-544-121	Sequence 121, App
C 260	13.8	0.6	17	1	US-10-430-882-270	Sequence 270, App1	C 333	13.4	0.6	16	1	US-09-829-855-11	Sequence 11, App1
C 261	13.8	0.6	17	1	US-10-430-882-742	Sequence 742, App	C 334	13.4	0.6	16	1	US-09-829-855-13	Sequence 13, App1
C 262	13.8	0.6	17	1	US-10-060-830-781	Sequence 781, App	C 335	13.4	0.6	16	1	US-09-829-855-77	Sequence 77, App1
C 263	13.8	0.6	17	1	US-10-060-830-781	Sequence 519, App	C 336	13.4	0.6	16	1	US-10-182-230-68	Sequence 68, App1
C 264	13.8	0.6	17	1	US-10-060-756A-519	Sequence 1690, App	C 337	13.4	0.6	16	1	US-10-138-674-7079	Sequence 7079, Ap
C 265	13.8	0.6	17	1	US-10-287-919-1890	Sequence 437, App	C 338	13.4	0.6	16	1	US-10-287-949A-7079	Sequence 7079, Ap
C 266	13.8	0.6	17	1	US-10-060-895A-437	Sequence 437, App	C 339	13.4	0.6	16	1	US-10-607-077A-11	Sequence 11, App1
C 267	13.8	0.6	17	1	US-10-060-895A-481	Sequence 481, App	C 340	13.4	0.6	16	1	US-10-607-077A-13	Sequence 13, App1
C 268	13.8	0.6	17	1	US-10-060-895A-793	Sequence 793, App	C 341	13.4	0.6	16	1	US-10-607-077A-77	Sequence 77, App1
C 269	13.8	0.6	17	1	US-10-163-552-328	Sequence 232, App	C 342	13.4	0.6	17	1	US-09-866-108-889	Sequence 889, App
C 270	13.8	0.6	17	1	US-10-163-552-497	Sequence 497, App	C 343	13.4	0.6	17	1	US-09-866-108-8756	Sequence 8756, App
C 271	13.8	0.6	17	1	US-10-156-306-4969	Sequence 4969, App	C 344	13.4	0.6	17	1	US-09-866-108-6757	Sequence 6757, App
C 272	13.8	0.6	17	1	US-10-156-306-5001	Sequence 5001, App	C 345	13.4	0.6	17	1	US-09-866-108-6950	Sequence 6950, App
C 273	13.8	0.6	17	1	US-10-238-700-2992	Sequence 2992, App	C 346	13.4	0.6	17	1	US-09-866-108-6951	Sequence 6951, App
C 274	13.8	0.6	17	1	US-10-238-700-2993	Sequence 2993, App	C 347	13.4	0.6	17	1	US-09-866-108-6952	Sequence 6952, App
C 275	13.8	0.6	17	1	US-10-238-700-3609	Sequence 3609, App	C 348	13.4	0.6	17	1	US-09-866-108-8004	Sequence 8004, App
C 276	13.8	0.6	17	1	US-10-238-700-3610	Sequence 3610, App	C 349	13.4	0.6	17	1	US-09-866-108-8007	Sequence 8007, App
C 277	13.8	0.6	17	1	US-10-061-201-436	Sequence 436, App	C 350	13.4	0.6	17	1	US-09-866-108-8054	Sequence 8054, App
C 278	13.8	0.6	17	1	US-10-061-201-437	Sequence 437, App	C 351	13.4	0.6	17	1	US-09-866-108-8055	Sequence 8055, App
C 279	13.8	0.6	17	1	US-10-061-201-438	Sequence 438, App	C 352	13.4	0.6	17	1	US-09-827-998-471	Sequence 471, App
C 280	13.8	0.6	17	1	US-10-061-201-439	Sequence 439, App	C 353	13.4	0.6	17	1	US-09-827-998-472	Sequence 472, App
C 281	13.8	0.6	17	1	US-10-061-201-1326	Sequence 1326, App	C 354	13.4	0.6	17	1	US-09-827-998-473	Sequence 473, App
C 282	13.8	0.6	17	1	US-10-084-839-1682	Sequence 1682, App	C 355	13.4	0.6	17	1	US-09-827-998-473	Sequence 473, App
C 283	13.8	0.6	17	1	US-10-084-839-1682	Sequence 3475, App	C 356	13.4	0.6	17	1	US-09-959-373-7716	Sequence 3716, App
C 284	13.8	0.6	17	1	US-10-230-006-820	Sequence 820, App	C 357	13.4	0.6	17	1	US-09-864-785-55	Sequence 55, App1
C 285	13.8	0.6	17	1	US-10-297-068-1041	Sequence 1041, App	C 358	13.4	0.6	17	1	US-09-864-785-55	Sequence 56, App1
C 286	13.8	0.6	17	1	US-10-297-068-1259	Sequence 1259, App	C 359	13.4	0.6	17	1	US-09-864-785-1585	Sequence 1585, App
C 287	13.8	0.6	17	1	US-10-138-674-4198	Sequence 4198, App	C 360	13.4	0.6	17	1	US-09-864-785-1621	Sequence 1621, App
C 288	13.8	0.6	17	1	US-10-138-674-7439	Sequence 7439, App	C 361	13.4	0.6	17	1	US-09-864-785-2828	Sequence 2828, App
C 289	13.8	0.6	17	1	US-10-138-674-8640	Sequence 8640, App	C 362	13.4	0.6	17	1	US-09-780-533A-2411	Sequence 2411, App
C 290	13.8	0.6	17	1	US-10-287-949A-4158	Sequence 4158, App	C 363	13.4	0.6	17	1	US-09-877-478-1387	Sequence 1387, App
C 291	13.8	0.6	17	1	US-10-287-949A-7439	Sequence 7439, App	C 364	13.4	0.6	17	1	US-09-877-478-1388	Sequence 1388, App
C 292	13.8	0.6	17	1	US-10-287-949A-8640	Sequence 8640, App	C 365	13.4	0.6	17	1	US-09-877-478-2180	Sequence 2180, App
C 293	13.8	0.6	17	1	US-10-712-672-830	Sequence 830, App	C 366	13.4	0.6	17	1	US-09-877-478-2180	Sequence 2180, App
C 294	13.8	0.6	18	1	US-09-320-337-57	Sequence 57, App1	C 367	13.4	0.6	17	1	US-09-877-478-2181	Sequence 2181, App
C 295	13.8	0.6	18	1	US-09-320-337-59	Sequence 59, App1	C 368	13.4	0.6	17	1	US-09-740-332-308	Sequence 308, App
C 296	13.8	0.6	18	1	US-09-925-911-7	Sequence 7, App1	C 369	13.4	0.6	17	1	US-09-817-879-308	Sequence 308, App
C 297	13.8	0.6	18	1	US-09-925-911-8	Sequence 8, App1	C 370	13.4	0.6	17	1	US-10-342-902-1387	Sequence 1387, App
C 298	13.8	0.6	18	1	US-09-882-945A-81	Sequence 81, App1	C 371	13.4	0.6	17	1	US-10-342-902-1388	Sequence 1388, App
C 299	13.8	0.6	18	1	US-09-306-333A-17	Sequence 9, App1	C 372	13.4	0.6	17	1	US-10-342-902-2180	Sequence 2180, App
C 300	13.8	0.6	18	1	US-09-838-028-9	Sequence 9, App1	C 373	13.4	0.6	17	1	US-10-675-685-471	Sequence 471, App
C 301	13.8	0.6	18	1	US-10-308-264-685	Sequence 685, App	C 374	13.4	0.6	17	1	US-10-675-685-472	Sequence 472, App
C 302	13.8	0.6	18	1	US-09-945-353-1	Sequence 1, App1	C 375	13.4	0.6	17	1	US-09-927-046-864	Sequence 864, App
C 303	13.8	0.6	18	1	US-10-156-995-131	Sequence 3, App1	C 376	13.4	0.6	17	1	US-09-927-046-864	Sequence 1020, App
C 304	13.8	0.6	18	1	US-10-156-995-132	Sequence 131, App	C 377	13.4	0.6	17	1	US-09-927-046-1565	Sequence 1565, App
C 305	13.8	0.6	18	1	US-10-037-616-10	Sequence 132, App	C 378	13.4	0.6	17	1	US-09-958-163A-23	Sequence 23, App1
C 306	13.8	0.6	18	1	US-10-199-830-7	Sequence 7, App1	C 379	13.4	0.6	17	1	US-10-430-882-271	Sequence 271, App
C 307	13.8	0.6	18	1	US-10-199-830-8	Sequence 8, App1	C 380	13.4	0.6	17	1	US-10-060-830-782	Sequence 782, App
C 308	13.8	0.6	18	1	US-10-216-122-135	Sequence 135, App	C 381	13.4	0.6	17	1	US-10-060-830-783	Sequence 783, App
C 309	13.8	0.6	18	1	US-10-168-771-84	Sequence 84, App1	C 382	13.4	0.6	17	1	US-10-060-895A-484	Sequence 484, App
C 310	13.8	0.6	18	1	US-10-169-983-27	Sequence 27, App1	C 383	13.4	0.6	17	1	US-10-163-552-84	Sequence 84, App1
C 311	13.8	0.6	18	1	US-10-302-279-51	Sequence 27, App1	C 384	13.4	0.6	17	1	US-10-156-306-4761	Sequence 4761, App
C 312	13.8	0.6	18	1	US-10-168-445-205	Sequence 205, App	C 385	13.4	0.6	17	1	US-10-156-306-5005	Sequence 5005, App
C 313	13.8	0.6	18	1	US-10-349-143-8459	Sequence 8459, App	C 386	13.4	0.6	17	1	US-10-156-306-5013	Sequence 5013, App
C 314	13.8	0.6	18	1	US-10-703-864-25	Sequence 25, App1	C 387	13.4	0.6	17	1	US-10-156-306-5092	Sequence 5092, App
C 315	13.8	0.6	18	1	US-10-628-109-64	Sequence 64, App1	C 388	13.4	0.6	17	1	US-10-156-306-5093	Sequence 5093, App
C 316	13.8	0.6	15	1	US-10-160-358-67	Sequence 67, App1	C 389	13.4	0.6	17	1	US-10-156-306-5184	Sequence 5184, App
C 317	13.8	0.6	41	1	US-10-035-833A-6	Sequence 6, App1	C 390	13.4	0.6	17	1	US-10-156-306-5188	Sequence 5188, App
C 318	13.8	0.6	41	1	US-10-035-833A-5176	Sequence 5176, App	C 391	13.4	0.6	17	1	US-10-156-306-5925	Sequence 5925, App
C 319	13.8	0.6	41	1	US-10-035-833A-7638	Sequence 7638, App	C 392	13.4	0.6	17	1	US-10-156-306-5931	Sequence 5931, App
C 320	13.8	0.6	15	1	US-09-504-231A-714	Sequence 714, App	C 393	13.4	0.6	17	1	US-10-156-306-6960	Sequence 6960, App
C 321	13.8	0.6	15	1	US-09-274-553D-714	Sequence 714, App	C 394	13.4	0.6	17	1	US-10-238-700-3321	Sequence 3321, App
C 322	13.8	0.6	15	1	US-09-781-988-121	Sequence 121, App	C 395	13.4	0.6	17	1	US-10-061-201-1272	Sequence 1272, App
C 323	13.8	0.6	15	1	US-09-879-813-71	Sequence 71, App1	C 396	13.4	0.6	17	1	US-10-061-201-1273	Sequence 1273, App
C 324	13.8	0.6	15	1	US-09-893-878-121	Sequence 121, App	C 397	13.4	0.6	17	1	US-10-061-201-1274	Sequence 1274, App
C 325	13.8	0.6	15	1	US-09-862-417A-1	Sequence 1, App1	C 398	13.4	0.6	17	1	US-10-230-006-1429	Sequence 1429, App

```
399 13.4 0.6 17 1 US-10-277-216-290 Sequence 290, App
400 13.4 0.6 17 1 US-10-126-022-290 Sequence 290, App
401 13.4 0.6 17 1 US-10-138-674-4197 Sequence 4197, App
402 13.4 0.6 17 1 US-10-138-674-4505 Sequence 4505, App
403 13.4 0.6 17 1 US-10-138-674-4755 Sequence 4755, App
404 13.4 0.6 17 1 US-10-138-674-6625 Sequence 6625, App
405 13.4 0.6 17 1 US-10-138-674-7633 Sequence 7633, App
406 13.4 0.6 17 1 US-10-138-674-8874 Sequence 8874, App
407 13.4 0.6 17 1 US-10-287-949A-4197 Sequence 4197, App
408 13.4 0.6 17 1 US-10-287-949A-4505 Sequence 4505, App
409 13.4 0.6 17 1 US-10-287-949A-4755 Sequence 4755, App
410 13.4 0.6 17 1 US-10-287-949A-6625 Sequence 6625, App
411 13.4 0.6 17 1 US-10-287-949A-7633 Sequence 7633, App
412 13.4 0.6 17 1 US-10-287-949A-8874 Sequence 8874, App
413 13.4 0.6 17 1 US-10-712-672-1280 Sequence 1280, App
414 13.4 0.6 17 1 US-10-712-672-1917 Sequence 1917, App
415 13.4 0.6 17 1 US-10-712-672-1977 Sequence 1977, App
416 13 0.6 15 1 US-09-504-231A-712 Sequence 712, App
417 13 0.6 15 1 US-09-504-231A-713 Sequence 713, App
418 13 0.6 15 1 US-09-274-553D-712 Sequence 712, App
419 13 0.6 15 1 US-09-274-553D-713 Sequence 713, App
420 13 0.6 15 1 US-09-748-739A-28 Sequence 28, App
421 13 0.6 15 1 US-10-347-510A-44 Sequence 44, App
422 13 0.6 15 1 US-09-544-934B-44 Sequence 44, App
423 13 0.6 16 1 US-10-138-674-5827 Sequence 5827, App
424 13 0.6 16 1 US-10-287-949A-5827 Sequence 5827, App
425 13 0.6 17 1 US-09-866-108-897 Sequence 897, App
426 13 0.6 17 1 US-09-866-108-9584 Sequence 9584, App
427 13 0.6 17 1 US-09-866-108-9585 Sequence 9585, App
428 13 0.6 17 1 US-09-866-108-9586 Sequence 9586, App
429 13 0.6 17 1 US-09-866-108-9587 Sequence 9587, App
430 13 0.6 17 1 US-09-740-332-641 Sequence 641, App
431 13 0.6 17 1 US-09-740-332-642 Sequence 642, App
432 13 0.6 17 1 US-09-740-332-3913 Sequence 3913, App
433 13 0.6 17 1 US-09-740-332-3914 Sequence 3914, App
434 13 0.6 17 1 US-09-817-879-641 Sequence 641, App
435 13 0.6 17 1 US-09-817-879-642 Sequence 642, App
436 13 0.6 17 1 US-09-817-879-3913 Sequence 3913, App
437 13 0.6 17 1 US-09-817-879-3914 Sequence 3914, App
438 13 0.6 17 1 US-10-156-306-5930 Sequence 5930, App
439 13 0.6 17 1 US-10-156-306-5802 Sequence 5802, App
440 13 0.6 17 1 US-10-230-006-742 Sequence 742, App
441 13 0.6 17 1 US-10-138-674-813 Sequence 813, App
442 13 0.6 17 1 US-10-138-674-814 Sequence 814, App
443 13 0.6 17 1 US-10-138-674-4789 Sequence 4789, App
444 13 0.6 17 1 US-10-138-674-4789 Sequence 4789, App
445 13 0.6 17 1 US-10-138-674-5053 Sequence 5053, App
446 13 0.6 17 1 US-10-138-674-5054 Sequence 5054, App
447 13 0.6 17 1 US-10-138-674-5194 Sequence 5194, App
448 13 0.6 17 1 US-10-138-674-5195 Sequence 5195, App
449 13 0.6 17 1 US-10-138-674-7658 Sequence 7658, App
450 13 0.6 17 1 US-10-138-674-7657 Sequence 7657, App
451 13 0.6 17 1 US-10-138-674-9169 Sequence 9169, App
452 13 0.6 17 1 US-10-287-949A-813 Sequence 813, App
453 13 0.6 17 1 US-10-287-949A-814 Sequence 814, App
454 13 0.6 17 1 US-10-287-949A-4754 Sequence 4754, App
455 13 0.6 17 1 US-10-287-949A-4789 Sequence 4789, App
456 13 0.6 17 1 US-10-287-949A-5053 Sequence 5053, App
457 13 0.6 17 1 US-10-287-949A-5054 Sequence 5054, App
458 13 0.6 17 1 US-10-287-949A-5194 Sequence 5194, App
459 13 0.6 17 1 US-10-287-949A-5195 Sequence 5195, App
460 13 0.6 17 1 US-10-287-949A-7658 Sequence 7658, App
461 13 0.6 17 1 US-10-287-949A-7857 Sequence 7857, App
462 13 0.6 17 1 US-10-287-949A-9169 Sequence 9169, App
```

## ALIGNMENTS

```
RESULT 1
US-10-035-833A-6
; Sequence 6, Application US/10035833A
; Publication No. US20040072156A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-6

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.00058;
Matches 40; Conservative 1; Mismatches 0; Gaps 0;
Indels 0;

Oy 977 CCTCACCATGTCACCCGTGATCACCCTGCTGCTTTTC 1017
Db 1 CCTCACCATGTCACCCCTGTCACCCCTGCTGCTTTTC 41

RESULT 2
US-10-035-833A-5176
; Sequence 5176, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5176
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-5176

Query Match 1.8%; Score 40.6; DB 1; Length 41;
Best Local Similarity 97.6%; Pred. No. 0.00058;
Matches 40; Conservative 1; Mismatches 0; Gaps 0;
Indels 0;

Oy 977 CCTCACCATGTCACCCGTGATCACCCTGCTGCTTTTC 1017
Db 1 CCTCACCATGTCACCCCTGTCACCCCTGCTGCTTTTC 41

RESULT 3
US-10-035-833A-7638
; Sequence 7638, Application US/10035833A
; Publication No. US20040072156A1
; GENERAL INFORMATION:
; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Aritoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035, 833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7638
; LENGTH: 41
```



```
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-024-369-5

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      778 TTGCAGGAGAGGTGTTGG 797
Db      20 TTGCAGGAGAGGTGTTGG 1

RESULT 9
US-10-024-369-6
; Sequence 6, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-10-024-369-6

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      756 CATGGCCACGCTGCACAGCC 775
Db      1 CATGGCCACGCTGCACAGCC 20

RESULT 10
US-10-024-369-10/c
; Sequence 10, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-10
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 ATGGCTAGCTCTAGTGTCC 20
Db      20 ATGGCTAGCTCTAGTGTCC 1

RESULT 11
US-10-024-369-11/c
; Sequence 11, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-11

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      49 CGAGCTTCTCTCGATGGCT 68
Db      20 GGAGCTTCTCTCGATGGCT 1

RESULT 12
US-10-024-369-12/c
; Sequence 12, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-12

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      90 CGCGAGTGGGTGCTGCTCC 109
Db      20 CGCGAGTGGGTGCTGCTCC 1

RESULT 13
US-10-024-369-13/c
; Sequence 13, Application US/10024369
```

```
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-13

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      137 TGCTGTGCCCGCCGCGCTG 156
Db      20 TGCTGTGCCCGCCGCGCTG 1

RESULT 14
US-10-024-369-14/c
; Sequence 14, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-14

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      219 CGGGGTCCTCAGGGCAACG 238
Db      20 CGGGGTCCTCAGGGCAACG 1

RESULT 15
US-10-024-369-15/c
; Sequence 15, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-15

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      225 CCTCAGGGCAACGGTTGGCT 244
Db      20 CCTCAGGGCAACGGTTGGCT 1

RESULT 16
US-10-024-369-16/c
; Sequence 16, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-16

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      255 AAACGACGTCGCCAGGGCT 274
Db      20 AAACGACGTCGCCAGGGCT 1

RESULT 17
US-10-024-369-17/c
; Sequence 17, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-17

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      270 GGGCTGGCTGCTGCTTTGA 289
Db      20 GGGCTGGCTGCTGCTTTGA 1
```

```
RESULT 18
US-10-024-369-18/c
; Sequence 18, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-18
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      294 ATTAGCTGCGGCACTGGGCT 313
      |||||
Db      20 ATTAGCTGCGGCACTGGGCT 1
```

```
RESULT 19
US-10-024-369-19/c
; Sequence 19, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-19
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      300 TGGCGCACTGGGCTTGCC 319
      |||||
Db      20 TGGCGCACTGGGCTTGCC 1
```

```
RESULT 20
US-10-024-369-20/c
; Sequence 20, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
```

```
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-20
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      304 GCACTGGGCTTGCCCTGCC 323
      |||||
Db      20 GCACTGGGCTTGCCCTGCC 1
```

```
RESULT 21
US-10-024-369-21/c
; Sequence 21, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-21
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      334 TTGTTCCGAGAGCTGATCTC 353
      |||||
Db      20 TTGTTCCGAGAGCTGATCTC 1
```

```
RESULT 22
US-10-024-369-22/c
; Sequence 22, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-22
```

```
Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```



Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 620 TTACGGCGCCCTCAGTAC 639  
|||||  
DB 20 TTACGGCGCCCTCAGTAC 1

## RESULT 28

US-10-024-369-28/C  
; Sequence 28, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 28  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-28

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 644 TTCTACAGATGGCTCAGCC 663  
|||||  
DB 20 TTCTACAGATGGCTCAGCC 1

## RESULT 29

US-10-024-369-29/C  
; Sequence 29, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 29  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-29

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 649 CAAGATGGCTCAGCCGATAC 668  
|||||  
DB 20 CAAGATGGCTCAGCCGATAC 1

## RESULT 30

US-10-024-369-30/C  
; Sequence 30, Application US/10024369  
; Publication No. US20030134809A1

; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 30  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-30

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 672 CACTCGAACTTAAGTCTCA 691  
|||||  
DB 20 CACTCGAACTTAAGTCTCA 1

## RESULT 31

US-10-024-369-31/C  
; Sequence 31, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 31  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-31

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 714 TGCAGTGTGAGTTCGTGG 733  
|||||  
DB 20 TGCAGTGTGAGTTCGTGG 1

## RESULT 32

US-10-024-369-32/C  
; Sequence 32, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 32  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence



FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-32

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 740 GGATCTATACACACCATG 759  
DB 20 GGATCTATACACACCATG 1

RESULT 33  
US-10-024-369-33/c  
Sequence 33, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier

TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 33  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-33

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 776 ACTTGACGGAGAGGTGTTT 795  
DB 20 ACTTGACGGAGAGGTGTTT 1

RESULT 34  
US-10-024-369-34/c  
Sequence 34, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier

TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 34  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-34

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 839 AGACAGGAACATCATGCT 858  
DB 20 AGACAGGAACATCATGCT 1

RESULT 35  
US-10-024-369-35/c  
Sequence 35, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier

TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 35  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-35

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 847 AACATCATGTCGGGTAC 866  
DB 20 AACATCATGTCGGGTAC 1

RESULT 36  
US-10-024-369-36/c  
Sequence 36, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier

TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 36  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-36

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 866 CAGAGACAGTCACCCCTG 885  
DB 20 CAGAGACAGTCACCCCTG 1

RESULT 37  
US-10-024-369-37/c  
Sequence 37, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier

TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91

```
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-37

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      871 GACACGTCACCCCTGAGTGA 890
Db      20 GACACGTCACCCCTGAGTGA 1

RESULT 38
US-10-024-369-38/C
; Sequence 38, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-38

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      899 GTGAGATCTGAGCTTATTT 918
Db      20 GTGAGATCTGAGCTTATTT 1

RESULT 39
US-10-024-369-39/C
; Sequence 39, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-39

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      915 ATTTCTGTGTAAGCTGTGTC 934
```

```
Db      20 ATTTCTGTGTAAGCTGTGTC 1

RESULT 40
US-10-024-369-40/C
; Sequence 40, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-40

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      920 TGTGTACTGTGTCGAGGC 939
Db      20 TGTGTACTGTGTCGAGGC 1

RESULT 41
US-10-024-369-41/C
; Sequence 41, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-41

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      936 AGGCTATGTCTCTTGGGGA 955
Db      20 AGGCTATGTCTCTTGGGGA 1

RESULT 42
US-10-024-369-42/C
; Sequence 42, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
```

FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 42  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-42

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 953 GGATCATGCTCTGGGGATCA 972  
DB 20 GGATCATGCTCTGGGGATCA 1

RESULT 43  
US-10-024-369-43/c  
Sequence 43, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 43  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-43

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 962 TCTGGGGATCAGTGTCCCTC 981  
DB 20 TCTGGGGATCAGTGTCCCTC 1

RESULT 44  
US-10-024-369-44/c  
Sequence 44, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 44  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-44

Query Match 0.9%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 ATCAGTGTCCCTCACCCTGG 988  
DB 20 ATCAGTGTCCCTCACCCTGG 1

RESULT 45  
US-10-024-369-45/c  
Sequence 45, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 45  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-45

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 CTCACCATGTGTACCCCTGAT 998  
DB 20 CTCACCATGTGTACCCCTGAT 1

RESULT 46  
US-10-024-369-46/c  
Sequence 46, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Donna T. Ward  
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 46  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-46

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 995 TGATCACCTGTGCTTGTGCTT 1014  
DB 20 TGATCACCTGTGCTTGTGCTT 1

RESULT 47  
US-10-024-369-47/c  
Sequence 47, Application US/10024369  
Publication No. US20030134809A1  
GENERAL INFORMATION:

```
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-47

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1018 CTTCTGCCCAAGAGTGGG 1037
Db 20 CTTCTGCCCAAGAGTGGG 1

RESULT 48
US-10-024-369-48/c
; Sequence 48, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-48

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1028 AGAAGGTGGAAATGTGTAC 1047
Db 20 AGAAGGTGGAAATGTGTAC 1

RESULT 49
US-10-024-369-49/c
; Sequence 49, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide

; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-49

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1033 GTGGGAAATGTGTACAGTT 1052
Db 20 GTGGGAAATGTGTACAGTT 1

RESULT 50
US-10-024-369-50/c
; Sequence 50, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-50

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 ATGGTACCACTGTGTGAG 1060
Db 20 ATGGTACCACTGTGTGAG 1

RESULT 51
US-10-024-369-51/c
; Sequence 51, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-51

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1045 TACCAGTTGCTGGAAGTGA 1064
Db 20 TACCAGTTGCTGGAAGTGA 1

RESULT 52
```

```
US-10-024-369-52/c
; Sequence 52, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-52

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1078 CTGGCAAGTCGACGAGT 1097
|||||
20 CTGGCAAGTCGACGAGT 1

Db

RESULT 53
US-10-024-369-53/c
; Sequence 53, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-53

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1086 GTCCAGCAGGTGCGCATTTG 1105
|||||
20 GTCCAGCAGGTGCGCATTTG 1

Db

RESULT 54
US-10-024-369-54/c
; Sequence 54, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 54

US-10-024-369-55/c
; Sequence 55, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-55

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1101 CATTGAGCTCTGTGCGCCA 1120
|||||
20 CATTGAGCTCTGTGCGCCA 1

Db

RESULT 55
US-10-024-369-55/c
; Sequence 55, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-55

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1109 CTCTGTGCGCCATGCGCTTACA 1128
|||||
20 CTCTGTGCGCCATGCGCTTACA 1

Db

RESULT 56
US-10-024-369-56/c
; Sequence 56, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-024-369-56

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1123 CCTACAGTTGGAAGCTTTGC 1142
|||||
```

```
Db      20 CCTACAGTTGCAAGCTTTGC 1

RESULT 57
US-10-024-369-57/c
; Sequence 57, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-57

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1131 TCGAAGCTTGGCCAAAGAGG 1150
Db      20 TCGAAGCTTGGCCAAAGAGG 1

RESULT 58
US-10-024-369-58/c
; Sequence 58, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-58

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1157 AAGCCGAGAGTTAGGGA 1176
Db      20 AAGCCGAGAGTTAGGGA 1

RESULT 59
US-10-024-369-59/c
; Sequence 59, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353

Db      20 GGCCTATGACGTCACCTCT 1

OY      1218 GGCCTATGACGTCACCTCT 1237
Db      20 GGCCTATGACGTCACCTCT 1

RESULT 60
US-10-024-369-60/c
; Sequence 60, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-60

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1274 GAATCCTCTACATTGGTGGG 1293
Db      20 GAATCCTCTACATTGGTGGG 1

RESULT 61
US-10-024-369-61/c
; Sequence 61, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RRS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-61

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1345 CTCTACGAGTGCAGTTCCAC 1364  
|||||  
Db 20 CTCTACGAGTGCAGTTCCAC 1

RESULT 62  
US-10-024-369-62/c  
; Sequence 62, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 62  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-62

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1378 GTACTGCTCTCCACTACCC 1397  
|||||  
Db 20 GTACTGCTCTCCACTACCC 1

RESULT 63  
US-10-024-369-63/c  
; Sequence 63, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 63  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-63

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1424 CAGAGAAATTTGAGTAC 1443  
|||||  
Db 20 CAGAGAAATTTGAGTAC 1

RESULT 64  
US-10-024-369-64/c  
; Sequence 64, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers

APPLICANT: Donna T. Ward  
APPLICANT: Susan M. Freier  
TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
FILE REFERENCE: RTS-0353  
CURRENT APPLICATION NUMBER: US/10/024,369  
CURRENT FILING DATE: 2001-12-17  
NUMBER OF SEQ ID NOS: 91  
SEQ ID NO 64  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-64

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1431 AATATTGAGTACCTGACC 1450  
|||||  
Db 20 AATATTGAGTACCTGACC 1

RESULT 65  
US-10-024-369-65/c  
; Sequence 65, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 65  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-65

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1473 TGGTCTGTGACCTCCCTTAC 1492  
|||||  
Db 20 TGGTCTGTGACCTCCCTTAC 1

RESULT 66  
US-10-024-369-66/c  
; Sequence 66, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 66  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-024-369-66

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1481 TGACTCCCTTACCTTGAG 1500  
Db 20 TGACTCCCTTACCTTGAG 1

RESULT 67

US-10-024-369-67/c  
; Sequence 67, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 67  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-67

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1506 TGTCAGTTCGAAGATGCT 1525  
Db 20 TGTCAGTTCGAAGATGCT 1

RESULT 68  
US-10-024-369-68/c  
; Sequence 68, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 68  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-68

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1521 TGTCCTTTGGCTACCCAA 1540  
Db 20 TGTCCTTTGGCTACCCAA 1

RESULT 69  
US-10-024-369-69/c

; Sequence 69, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 69  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-69

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1537 CCAACCGCCGAGTGTCTT 1556  
Db 20 CCAACCGCCGAGTGTCTT 1

RESULT 70  
US-10-024-369-70/c  
; Sequence 70, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 70  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-024-369-70

Query Match 0.9%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 8.5;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1743 GGCTGAGTGGGCAAGAGC 1762  
Db 20 GGCTGAGTGGGCAAGAGC 1

RESULT 71  
US-10-024-369-71/c  
; Sequence 71, Application US/10024369  
; Publication No. US20030134809A1  
; GENERAL INFORMATION:  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Donna T. Ward  
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION  
; FILE REFERENCE: RTS-0353  
; CURRENT APPLICATION NUMBER: US/10/024,369  
; CURRENT FILING DATE: 2001-12-17  
; NUMBER OF SEQ ID NOS: 91  
; SEQ ID NO 71  
; LENGTH: 20



```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-71
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1756 CAAGAGCCACGATTTTGG 1775
      |||||||
Db       20 CAAGAGCCACGATTTTGG 1
```

```
RESULT 72
US-10-024-369-72/c
; Sequence 72, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-72
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1773 TGGAGAAGCTTCAAGAA 1792
      |||||||
Db       20 TGGAGAAGCTTCAAGAA 1
```

```
RESULT 73
US-10-024-369-73/c
; Sequence 73, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-73
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1810 ACCCAGAAGCCAACTATGA 1829
      |||||||
Db       20 ACCCAGAAGCCAACTATGA 1
```

```
RESULT 74
US-10-024-369-74/c
; Sequence 74, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-74
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1824 TATGAGGAATCAGACTG 1843
      |||||||
Db       20 TATGAGGAATCAGACTG 1
```

```
RESULT 75
US-10-024-369-75/c
; Sequence 75, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-75
```

```
Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1842 TGCTGCAATAAGTCTGGG 1861
      |||||||
Db       20 TGCTGCAATAAGTCTGGG 1
```

```
RESULT 76
US-10-024-369-76/c
; Sequence 76, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
```

```
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-76

Query March          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1871 TCATCTCTGAGACTCCCTCAG 1890
Db      20 TCATCTCTGAGACTCCCTCAG 1

RESULT 77
US-10-024-369-77/c
; Sequence 77, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-77

Query March          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1879 GGACTCCCTCAGGGCTATGA 1898
Db      20 GGACTCCCTCAGGGCTATGA 1

RESULT 78
US-10-024-369-78/c
; Sequence 78, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-78

Query March          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1885 CCTCAGGGCTATGACACAGA 1904
Db      20 CCTCAGGGCTATGACACAGA 1

RESULT 79
US-10-024-369-79/c
; Sequence 79, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-79

Query March          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1978 AAACCGTGTGACTTATCT 1997
Db      20 AAACCGTGTGACTTATCT 1

RESULT 80
US-10-024-369-80/c
; Sequence 80, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-80

Query March          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1988 TACTTATCTGATGATGCC 2007
Db      20 TACTTATCTGATGATGCC 1

RESULT 81
US-10-024-369-81/c
; Sequence 81, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
```

```

; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-81

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2003 ATGCCACGAGTCCCTGGAT 2022
Db      20 ATGCCACGAGTCCCTGGAT 1

RESULT 82
US-10-024-369-82/c
; Sequence 82, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-82

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2020 GATGCAACAGCCAGTTACA 2039
Db      20 GATGCAACAGCCAGTTACA 1

RESULT 83
US-10-024-369-83/c
; Sequence 83, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-83
```

```

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2041 GTGAGCAGCTCCTGTACGA 2060
Db      20 GTGAGCAGCTCCTGTACGA 1

RESULT 84
US-10-024-369-84/c
; Sequence 84, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-84

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2059 GAAAGCCTGAGCGTACTC 2078
Db      20 GAAAGCCTGAGCGTACTC 1

RESULT 85
US-10-024-369-85/c
; Sequence 85, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-85

Query Match          0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2073 GTACTCCGCTCAGTCTTC 2092
Db      20 GTACTCCGCTCAGTCTTC 1

RESULT 86
US-10-024-369-86/c
; Sequence 86, Application US/10024369
```

```
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-86

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2106 CCTCAGCCTGTGTGAGCAGG 2125
Db      20 CCTCAGCCTGTGTGAGCAGG 1

RESULT 87
US-10-024-369-87/c
; Sequence 87, Application US/10024369
; Publication No. US20030134809A1
; GENERAL INFORMATION:
; APPLICANT: Alexander H. Borchers
; APPLICANT: Donna T. Ward
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF ABC TRANSPORTER MHC 1 EXPRESSION
; FILE REFERENCE: RTS-0353
; CURRENT APPLICATION NUMBER: US/10/024,369
; CURRENT FILING DATE: 2001-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-369-87

Query Match      0.9%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2228 CTGCAGATGCTCCGAGATGA 2247
Db      20 CTGCAGATGCTCCGAGATGA 1

RESULT 88
US-10-010-920-65
; Sequence 65, Application US/10010920
; Publication No. US20030027165A1
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: Alternatively spliced polk nucleotide and amino acid sequences
; FILE REFERENCE: 98,723-E3
; CURRENT APPLICATION NUMBER: US/10/010,920
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/254,649
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 65
```

```
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer ON-TAP1-F2
US-10-010-920-65

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      626 GCCGCTCACTGACTGGAT 644
Db      1 GCCGCTCACTGACTGGAT 19

RESULT 89
US-10-008-721-65
; Sequence 65, Application US/10008721
; Publication No. US20030082745A1
; GENERAL INFORMATION:
; APPLICANT: Saus, Juan
; TITLE OF INVENTION: TNF-Inducible Promoters and Methods for Using
; FILE REFERENCE: 98,723-F1
; CURRENT APPLICATION NUMBER: US/10/008,721
; CURRENT FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/254,649
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 65
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer ON-TAP1-F2
US-10-008-721-65

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      626 GCCGCTCACTGACTGGAT 644
Db      1 GCCGCTCACTGACTGGAT 19

RESULT 90
US-10-383-864-24/c
; Sequence 24, Application US/10383864
; Publication No. US20040081976A1
; GENERAL INFORMATION:
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
; APPLICANT: SIDRANSKY, David
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES
; FILE REFERENCE: JHU1860-1
; CURRENT APPLICATION NUMBER: US/10/383,864
; CURRENT FILING DATE: 2003-07-25
; PRIOR APPLICATION NUMBER: US 60/362,577
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-24

Query Match      0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2016 CCTGATGCAACAGCCAG 2034  
Db 19 CCTGATGCAACAGCCAG 1

RESULT 91  
US-09-938-689-59  
; Sequence 59. Application US/09938689  
; Publication No. US20030028911A1  
; GENERAL INFORMATION:  
; APPLICANT: Huang, Manley  
; APPLICANT: Harding, Fiona  
; TITLE OF INVENTION: TRANSGENIC MAMMAL CAPABLE OF FACILITATING PRODUCTION OF  
; TITLE OF INVENTION: DONOR-SPECIFIC FUNCTIONAL IMMUNITY  
; FILE REFERENCE: 9342-028  
; CURRENT APPLICATION NUMBER: US/09/938,689  
; CURRENT FILING DATE: 2001-08-23  
; PRIOR APPLICATION NUMBER: 09/651,361  
; PRIOR FILING DATE: 2000-08-30  
; PRIOR APPLICATION NUMBER: 60/151,688  
; PRIOR FILING DATE: 1999-08-31  
; NUMBER OF SEQ ID NOS: 72  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 59  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: PCR primer  
US-09-938-689-59

Query Match 0.8%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 879 CACCTGAGTGTCTCT 896  
Db 1 CACCTGAGTGTCTCT 18

RESULT 92  
US-10-383-864-23  
; Sequence 23. Application US/10383864  
; Publication No. US20040081976A1  
; GENERAL INFORMATION:  
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE  
; APPLICANT: SIDRANSKY, David  
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES  
; FILE REFERENCE: JHU1860-1  
; CURRENT APPLICATION NUMBER: US/10/383,864  
; CURRENT FILING DATE: 2003-07-25  
; PRIOR APPLICATION NUMBER: US 60/362,577  
; PRIOR FILING DATE: 2002-03-07  
; NUMBER OF SEQ ID NOS: 127  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 23  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: PCR primer  
US-10-383-864-23

Query Match 0.8%; Score 18; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 21;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 CAGATCTGACGAGCC 1671  
Db 1 CAGATCTGACGAGCC 18

RESULT 93  
US-10-092-900A-550  
; Sequence 550. Application US/10092900A  
; Publication No. US20040043382A1  
; GENERAL INFORMATION:  
; APPLICANT: Padigaru, Muralidhara  
; APPLICANT: Spytek, Kimberly A.  
; APPLICANT: Shenoy, Suresh G.  
; APPLICANT: Taugler Jr., Raymond J.  
; APPLICANT: Pena, Carol E.A.  
; APPLICANT: Li, Li  
; APPLICANT: Zernhusen, Bryan D.  
; APPLICANT: Gusev, Vladimir Y.  
; APPLICANT: Ji, Weizhen  
; APPLICANT: Gorman, Linda  
; APPLICANT: Miller, Charles E.  
; APPLICANT: Kekuda, Ramesh  
; APPLICANT: Patuturajan, Meera  
; APPLICANT: Gangoli, Baha A.  
; APPLICANT: Vernet, Corine A.M.  
; APPLICANT: Guo, Xiaojia Saaha  
; APPLICANT: Tchernev, Vellizar T.  
; APPLICANT: Fernandes, Elma R.  
; APPLICANT: Casman, Stacie J.  
; APPLICANT: Malyankar, Uriel M.  
; APPLICANT: Gerlach, Valerie  
; APPLICANT: Liu, Yi  
; APPLICANT: Anderson, David W.  
; APPLICANT: Spaderna, Steven K.  
; APPLICANT: Catterton, Elina  
; APPLICANT: Leite, Mario W.  
; APPLICANT: Zhong, Haihong  
; APPLICANT: Alsobrook, John P.  
; APPLICANT: Lepley, Denise M.  
; APPLICANT: Rieger, Daniel K.  
; APPLICANT: Burgess, Catherine E.  
; TITLE OF INVENTION: No. US20040043382A1 Proteins and Nucleic Acids Encoding Same  
; FILE REFERENCE: 21402-290C  
; CURRENT APPLICATION NUMBER: US/10/092,900A  
; CURRENT FILING DATE: 2002-03-07  
; PRIOR APPLICATION NUMBER: USSN 60/274,322  
; PRIOR FILING DATE: 2001-03-08  
; PRIOR APPLICATION NUMBER: USSN 60/283,675  
; PRIOR FILING DATE: 2001-04-13  
; PRIOR APPLICATION NUMBER: USSN 60/338,092  
; PRIOR FILING DATE: 2001-12-03  
; PRIOR APPLICATION NUMBER: USSN 60/274,281  
; PRIOR FILING DATE: 2001-03-08  
; PRIOR APPLICATION NUMBER: USSN 60/274,191  
; PRIOR FILING DATE: 2001-03-08  
; PRIOR APPLICATION NUMBER: USSN 60/325,681  
; PRIOR FILING DATE: 2001-09-27  
; PRIOR APPLICATION NUMBER: USSN 60/304,354  
; PRIOR FILING DATE: 2001-07-10  
; PRIOR APPLICATION NUMBER: USSN 60/279,995  
; PRIOR FILING DATE: 2001-03-30  
; PRIOR APPLICATION NUMBER: USSN 60/294,899  
; PRIOR FILING DATE: 2001-05-31  
; PRIOR APPLICATION NUMBER: USSN 60/287,424  
; PRIOR FILING DATE: 2001-04-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 768  
; SEQ ID NO 550  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Forward Primer  
US-10-092-900A-550

Query Match 0.7%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 42;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 TGCTGCTGAAAGTGGGAATC 1278  
DB 1 TGGTGTGCTGAAAGTGGGAATC 20

RESULT 94  
US-10-136-942-2/c  
Sequence 2, Application US/10136942  
Publication No. US20030049656A1  
GENERAL INFORMATION:  
APPLICANT: Avigenics, Inc  
TITLE OF INVENTION: High Throughput Screening Assay for Detecting a DNA Sequence  
FILE REFERENCE: A181 1020  
CURRENT APPLICATION NUMBER: US/10/136,942  
CURRENT FILING DATE: 2002-05-02  
NUMBER OF SEQ ID NOS: 8  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 2  
LENGTH: 21  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Primer chGAPDH-2  
US-10-136-942-2

Query Match 0.7%; Score 16; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1075 TCTCTGCGCAAGTCCA 1090  
DB 21 TCTCTGCGCAAGTCCA 6

RESULT 95  
US-09-813-824A-40  
Sequence 40, Application US/09813824A  
Patent No. US20020164595A1  
GENERAL INFORMATION:  
APPLICANT: Vogelstein, Bert  
Kinzler, Kenneth  
Sherman, Michael  
TITLE OF INVENTION: SEQUENCE SPECIFIC DNA BINDING  
BY PS3  
NUMBER OF SEQUENCES: 41  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Banner & Witcoff  
STREET: 1001 G Street, NW  
CITY: Washington  
STATE: DC  
COUNTRY: USA  
ZIP: 20001  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/813,824A  
FILING DATE: 22-Mar-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/860,758  
FILING DATE: 31-MAR-1992  
APPLICATION NUMBER: 07/715,182  
FILING DATE: 14-JUN-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Kagan, Sarah A  
REGISTRATION NUMBER: 32141  
REFERENCE/DOCKET NUMBER: 01107.47071  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-508-9100

TELEFAX: 202-508-9299  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 40:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 19 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 40:  
US-09-813-824A-40

Query Match 0.7%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 65;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 318 CCGCCGCGACTTGCCCTTG 336  
DB 1 CCGCCGCGACTTGCCCTTG 19

RESULT 96  
US-10-648-512-60  
Sequence 60, Application US/10648512  
Publication No. US20040096922A1  
GENERAL INFORMATION:  
APPLICANT: Hildebrandt, Friedhelm  
APPLICANT: Otto, Edgar  
APPLICANT: Hoeffele, Julia  
APPLICANT: Ruf, Rainer  
APPLICANT: Mueller, Adelheid M.  
APPLICANT: Hiller, Karl S.  
APPLICANT: Wolf, Matthias T.F.  
APPLICANT: Schuermann, Maria J.  
APPLICANT: Becker, Achim  
TITLE OF INVENTION: NHP Nucleic Acids and Proteins  
FILE REFERENCE: UM-08333  
CURRENT APPLICATION NUMBER: US/10/648,512  
CURRENT FILING DATE: 2003-08-26  
NUMBER OF SEQ ID NOS: 102  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 60  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-10-648-512-60

Query Match 0.7%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 65;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1635 CACAGTGGCTGCGCTGCTG 1653  
DB 1 CACAGTGGCTGCTGCTGCTG 19

RESULT 97  
US-10-369-378-36  
Sequence 36, Application US/10369378  
Publication No. US20030170859A1  
GENERAL INFORMATION:  
APPLICANT: Christenson, Erik  
APPLICANT: Demaggio, Anthony J  
APPLICANT: Goldman, Phyllis S  
APPLICANT: McElligott, David L  
TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and  
METHODS  
FILE REFERENCE: 27866/36544  
CURRENT APPLICATION NUMBER: US/10/369,378  
CURRENT FILING DATE: 2003-02-19  
PRIOR APPLICATION NUMBER: US/09/596,248D  
PRIOR FILING DATE: 2000-06-16

;; PRIOR APPLICATION NUMBER: 60/139,543  
;; PRIOR FILING DATE: 1999-06-16  
;; NUMBER OF SEQ ID NOS: 68  
;; SOFTWARE: Patent In Ver. 2.1  
;; SEQ ID NO 36  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-369-378-36

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 AGACACTCAACCGAGAGA 1211  
DB 2 AGACACCCCAACCGAGAGA 20

RESULT 98  
US-10-369-378-37/c  
;; Sequence 37, Application US/10369378  
;; Publication No. US20030170859A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Christenson, Erik  
;; APPLICANT: Demaggio, Anthony J  
;; APPLICANT: Goldman, Phyllis S  
;; APPLICANT: McElligott, David L  
;; TITLE OF INVENTION: Human Poly(ADP-Ribose) Polymerase 2 Materials and  
;; FILE REFERENCE: 27866/36544  
;; CURRENT APPLICATION NUMBER: US/10/369,378  
;; CURRENT FILING DATE: 2003-02-19  
;; PRIOR APPLICATION NUMBER: US/09/596,248D  
;; PRIOR FILING DATE: 2000-06-16  
;; PRIOR APPLICATION NUMBER: 60/139,543  
;; PRIOR FILING DATE: 1999-06-16  
;; NUMBER OF SEQ ID NOS: 68  
;; SOFTWARE: Patent In Ver. 2.1  
;; SEQ ID NO 37  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-369-378-37

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 AGACACTCAACCGAGAGA 1211  
DB 19 AGACACCCCAACCGAGAGA 1

RESULT 99  
US-10-199-937-171  
;; Sequence 171, Application US/10199937  
;; Publication No. US20030190739A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Christenson, Erik  
;; APPLICANT: Demaggio, Anthony J.  
;; APPLICANT: Goldman, Phyllis S.  
;; APPLICANT: McElligott, David L.  
;; TITLE OF INVENTION: TANKYRASE2 MATERIALS AND METHODS  
;; FILE REFERENCE: 27866/36559  
;; CURRENT APPLICATION NUMBER: US/10/199,937  
;; CURRENT FILING DATE: 2002-07-22  
;; PRIOR APPLICATION NUMBER: US/09/606,035  
;; PRIOR FILING DATE: 2000-06-28

;; PRIOR APPLICATION NUMBER: 60/141,582  
;; PRIOR FILING DATE: 1999-06-29  
;; NUMBER OF SEQ ID NOS: 178  
;; SOFTWARE: Patent In Ver. 2.0  
;; SEQ ID NO 171  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: primer  
US-10-199-937-171

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 AGACACTCAACCGAGAGA 1211  
DB 2 AGACACCCCAACCGAGAGA 20

RESULT 100  
US-10-199-937-172/c  
;; Sequence 172, Application US/10199937  
;; Publication No. US20030190739A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Christenson, Erik  
;; APPLICANT: Demaggio, Anthony J.  
;; APPLICANT: Goldman, Phyllis S.  
;; APPLICANT: McElligott, David L.  
;; TITLE OF INVENTION: TANKYRASE2 MATERIALS AND METHODS  
;; FILE REFERENCE: 27866/36559  
;; CURRENT APPLICATION NUMBER: US/10/199,937  
;; CURRENT FILING DATE: 2002-07-22  
;; PRIOR APPLICATION NUMBER: US/09/606,035  
;; PRIOR FILING DATE: 2000-06-28  
;; PRIOR APPLICATION NUMBER: 60/141,582  
;; PRIOR FILING DATE: 1999-06-29  
;; NUMBER OF SEQ ID NOS: 178  
;; SOFTWARE: Patent In Ver. 2.0  
;; SEQ ID NO 172  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: primer  
US-10-199-937-172

Query Match 0.7%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 AGACACTCAACCGAGAGA 1211  
DB 19 AGACACCCCAACCGAGAGA 1

RESULT 101  
US-09-817-014-68  
;; Sequence 68, Application US/09817014  
;; Patent No. US20020106646A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Remacle, Jose  
;; APPLICANT: Hamels, Sandrine  
;; APPLICANT: Zammateo, Nathalie  
;; APPLICANT: Lockman, Laurence  
;; APPLICANT: Dufour, Sophie  
;; APPLICANT: Alexandre, Isabelle  
;; APPLICANT: De Longueville, Francoise  
;; TITLE OF INVENTION: IDENTIFICATION OF BIOLOGICAL  
;; TITLE OF INVENTION: (MICRO)ORGANISMS BY DETECTION OF THEIR HOMOLOGOUS NUCLEOTIDE  
;; FILE REFERENCE: VANM213.001AUS

```

; CURRENT APPLICATION NUMBER: US/09/817,014
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mycobacterium marinum capture probe
; US-09-817-014-68

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGTGTG 1612
          |||||
          3 GAGGTGATGGCGCTGTGTG 21

RESULT 102
US-10-074-246-21
; Sequence 21, Application US/10074246
; Publication No. US20030027174A1
; GENERAL INFORMATION:
; APPLICANT: Universit  Catholique de Louvain
; TITLE OF INVENTION: Identification of nucleotide sequences specific for mycobacterial
; TITLE OF INVENTION: pseudomonas species, development of differential diagnosis strat
; TITLE OF INVENTION: mycobacterial and pseudomonas species
; FILE REFERENCE: UCL-021-US
; CURRENT APPLICATION NUMBER: US/10/074,246
; CURRENT FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: US 60/269,848
; PRIOR FILING DATE: 2001-02-21
; PRIOR APPLICATION NUMBER: US 60/292,509
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: EP 01870030.2
; PRIOR FILING DATE: 2001-02-19
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Mycobacterium marinum
; US-10-074-246-21

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGTGTG 1612
          |||||
          3 GAGGTGATGGCGCTGTGTG 21

RESULT 103
US-10-184-085A-855/c
; Sequence 855, Application US/10184085A
; Publication No. US20030152950A1
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Minna, John D.
; APPLICANT: Lubke, Kevin, J.
; APPLICANT: Balogh, Robert P.
; TITLE OF INVENTION: Identification of Chemically Modified Polymers
; FILE REFERENCE: 119929-1035
; CURRENT APPLICATION NUMBER: US/10/184,085A
; CURRENT FILING DATE: 2002-10-01
```

```

; PRIOR APPLICATION NUMBER: US 60/301,370
; PRIOR FILING DATE: 2001-06-27
; NUMBER OF SEQ ID NOS: 1291
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 855
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-184-085A-855

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      783 GGGAGAGCTGTTGGGCGCT 801
          |||||
          19 GGGAGAGCTGTTGGGCGCT 1

RESULT 104
US-10-056-229-68
; Sequence 68, Application US/10056229
; Publication No. US20030198943A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammateo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De Longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF A LARGE NUMBER OF
; TITLE OF INVENTION: BIOLOGICAL (MICRO)ORGANISMS GROUPS AT DIFFERENT
; TITLE OF INVENTION: LEVELS BY THEIR DETECTION ON A SAME ARRAY
; FILE REFERENCE: VANM213.001CPI
; CURRENT APPLICATION NUMBER: US/10/056,229
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 09/817,014
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mycobacterium marinum capture probe
; US-10-056-229-68

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1594 GAGGTGACGGCGCTGTGTG 1612
          |||||
          3 GAGGTGATGGCGCTGTGTG 21

RESULT 105
US-09-866-108-891/c
; Sequence 891, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```



```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 891
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-891.

Query Match          0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1701 GCCCCTTCCCAATATG 1717
Db      17 GCCCCTTCCCACTATG 1

RESULT 106
US-09-866-108-892/c
; Sequence 893, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 892
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-892

Query Match          0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1700 AGCCCTTCCCAATAT 1716
Db      17 AGCCCTTCCCACTAT 1

RESULT 107
US-09-866-108-893/c
; Sequence 893, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 993
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-893
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1699 AAGCCCTTCCCAATA 1715
Db 17 AAGCCCTTCCCACTA 1
```

```
RESULT 108
US-10-156-306-7105
; Sequence 7105, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7105
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7105
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 70;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 391 CTGCACCTGGGGAAGTCA 407
Db 1 CGGCACUGGGGAAGUCA 17
```

```
RESULT 109
US-09-969-373-4010
; Sequence 4010, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Efiertz, Roger J.
; APPLICANT: Hauege, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT FILING DATE: US/09/969,373
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
```

```
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4010
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-4010
```

```
Query Match 0.7%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2219 TGCAGCTCCTGCAGAT 2235
Db 2 TGCAGCTCCTGCAGAT 18
```

```
RESULT 110
US-09-961-077-609
; Sequence 609, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent B.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
```

SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 609;  
US-09-961-077-609

Query Match 0.7%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 82.4%; Pred. No. 74;  
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2178 CCAGACCTCATGAGA 2194  
|||:|||||  
Db 2 CCGCAGCUCAGGAGA 18

RESULT 111  
US-09-752-983-8/c  
Sequence 8, Application US/09752983  
Patent No. US20010016575A1  
GENERAL INFORMATION:  
APPLICANT: Loren J. Mireaglia, Pamela Nero, Mark J.  
APPLICANT: Graham, Brett P. Monia  
TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2  
TITLE OF INVENTION: EXPRESSION  
NUMBER OF SEQUENCES: 271  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Law Offices of Jane Massey Licata  
STREET: 66 East Main Street  
CITY: Marlton  
STATE: NJ  
COUNTRY: U.S.A.  
ZIP: 08053  
COMPUTER READABLE FORM:  
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE  
COMPUTER: IBM PC  
OPERATING SYSTEM: WINDOWS 95  
SOFTWARE: WORDPERFECT 6.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/752,983  
FILING DATE: 02-Jan-2001  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 09/280,805  
FILING DATE: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Licata, Jane Massey  
REGISTRATION NUMBER: 32,257  
REFERENCE/DOCKET NUMBER: ISPH-0346  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-810-1515  
TELEFAX: 609-810-1454  
INFORMATION FOR SEQ ID NO: 8:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 20 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: Single  
TOPOLOGY: Linear  
ANTI-SENSE: Yes  
US-09-752-983-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 243 CTCGAAGCGAAGACGAG 262  
|||||:|||||  
Db 20 CTCGAAGCGAAGACCGG 1

RESULT 112  
US-09-851-771A-8/c

Sequence 8, Application US/09851771A  
Patent No. US200201511A1

GENERAL INFORMATION:

APPLICANT: Loren J. Mireaglia, Pamela Nero, Mark J.

APPLICANT: Graham, Brett P. Monia

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE  
MODULATION OF HUMAN MDM2 EXPRESSION

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Jane Massey Licata

STREET: 66 East Main Street

CITY: Marlton

STATE: NJ

COUNTRY: U.S.A.

ZIP: 08053

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE

COMPUTER: IBM 486

OPERATING SYSTEM: WINDOWS FOR WORKGROUPS

SOFTWARE: WORDPERFECT 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/851,771A

FILING DATE: 09-May-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/048,810

FILING DATE: 1998-03-26

ATTORNEY/AGENT INFORMATION:

NAME: Licata, Jane Massey

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0302

TELECOMMUNICATION INFORMATION:

TELEPHONE: 609-779-2400

TELEFAX: 609-810-1454

INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

ANTI-SENSE: Yes

SEQUENCE DESCRIPTION: SEQ ID NO: 8;

US-09-851-771A-8

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 243 CTCGAAGCGAAGACGAG 262  
|||||:|||||  
Db 20 CTCGAAGCGAAGACCGG 1

RESULT 113

US-09-774-809-57

Sequence 57, Application US/09774809

Publication No. US20030004120A1

GENERAL INFORMATION:

APPLICANT: McKay, Robert A.

APPLICANT: Dean, Nicholas M.

APPLICANT: Monia, Brett

APPLICANT: Nero, Pam

APPLICANT: Garde, William A.

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS

TITLE OF INVENTION: FOR THE MODULATION OF JNK PROTEINS

FILE REFERENCE: ISPH-0412

CURRENT APPLICATION NUMBER: US/09/774,809

CURRENT FILING DATE: 2001-01-31

PRIOR APPLICATION NUMBER: 09/396,902

PRIOR FILING DATE: 1999-09-15

PRIOR APPLICATION NUMBER: 09/130,616

PRIOR FILING DATE: 1998-08-07

PRIOR APPLICATION NUMBER: 08/910,629

```
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-774-809-57
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Oy      167 GGGTCTGGCGCGTGGCGCTG 186
           ||||| ||||| ||||| |||||
Db      1 GGGTCTGGTGGTGGACATG 20
```

```
RESULT 114
US-09-917-963-36/c
; Sequence 36, Application US/09917963
; Publication No. US20030086912A1
; GENERAL INFORMATION:
; APPLICANT: Roseane M. Crooke
; APPLICANT: Mark J. Graham
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN
; FILE REFERENCE: ISPH-0591
; CURRENT APPLICATION NUMBER: US/09/917,963
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 137
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-917-963-36
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Oy      146 CCACCGCGCTGCCACTGCTC 165
           ||||| ||||| ||||| |||||
Db      20 CCACCTGGCTACCACTGCTC 1
```

```
RESULT 115
US-10-345-444B-57
; Sequence 57, Application US/10345444B
; Publication No. US20040029823A1
; GENERAL INFORMATION:
; APPLICANT: McKay, Robert A.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Monia, Brett
; APPLICANT: Nero, Pam
; APPLICANT: Gaarde, William A.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULA
; TITLE OF INVENTION: OF JNK PROTEINS
; FILE REFERENCE: ISPH-0726
; CURRENT APPLICATION NUMBER: US/10/345,444B
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/774,809
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: US 09/396,902
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: US 09/287,796
; PRIOR FILING DATE: 1999-04-07
; PRIOR APPLICATION NUMBER: US 09/130,616
; PRIOR FILING DATE: 1998-08-07
; PRIOR APPLICATION NUMBER: US 08/910,629
```

```
; PRIOR FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-345-444B-57
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Oy      167 GGGTCTGGCGCGTGGCGCTG 186
           ||||| ||||| ||||| |||||
Db      1 GGGTCTGGTGGTGGACATG 20
```

```
RESULT 116
US-10-642-802-42/c
; Sequence 42, Application US/10642802
; Publication No. US20040043956A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Walt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RFS-0329
; CURRENT APPLICATION NUMBER: US/10/642,802
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US/10/001,076
; PRIOR FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-642-802-42
```

```
Query Match          0.7%: Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Oy      1348 TACCAGATGCAGTTCACCCA 1367
           ||||| ||||| ||||| |||||
Db      20 TACCAGATCCACTTCACCA 1
```

```
RESULT 117
US-09-759-999B-7
; Sequence 7, Application US/09759999B
; Publication No. US20020086838A1
; GENERAL INFORMATION:
; APPLICANT: OH, Chad
; APPLICANT: CHO, Seong
; APPLICANT: DEMISSIS-SANDERS, Sossiena
; APPLICANT: THOMAS, David
; APPLICANT: TAN, Sun
; TITLE OF INVENTION: Use of Antagonists of Plasminogen Activator Inhibitor-1 (PAI-1) Fr
; TITLE OF INVENTION: Treatment of Asthma and Chronic Obstructive Pulmonary Disease
; FILE REFERENCE: 65329.0107
; CURRENT APPLICATION NUMBER: US/09/759,999B
; CURRENT FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: US 60/176,211
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: PAI reverse primer
US-09-759-999B-7

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1460 GCTGCCACCCAGTGTCTG 1479
Db      1 GCTGTCCACCCGCTCTCTG 20

RESULT 118
US-10-159-266-20/c
; Sequence 20, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-266-20

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      66 GCTGGGACAGTACTGCTAC 85
Db      20 GCCGGGACAGACTGCTAC 1

RESULT 119
US-10-159-266-96
; Sequence 96, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
; FILE REFERENCE: RTS-0398
; CURRENT APPLICATION NUMBER: US/10/159,266
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-159-266-96

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      66 GCTGGGACAGTACTGCTAC 85
Db      1 GCCGGGACAGACTGCTAC 20

RESULT 120
US-10-161-996-127/c
; Sequence 127, Application US/10161996
; Publication No. US20030224511A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-996-127

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1875 CTCTGACTCCCTCAGGCT 1894
Db      20 CTCTGACTCCTTCAGGCT 1

RESULT 121
US-10-161-996-250
; Sequence 250, Application US/10161996
; Publication No. US20030224511A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: Brenda F. Baker
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN
; FILE REFERENCE: RTS-0395
; CURRENT APPLICATION NUMBER: US/10/161,996
; CURRENT FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 273
; SEQ ID NO 250
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-161-996-250

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1875 CTCTGACTCCCTCAGGCT 1894
Db      1 CTCTGACTCCTTCAGGCT 20

RESULT 122
US-10-001-076-42/c
; Sequence 42, Application US/10001076
; Publication No. US20030096775A1
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF COMPLEMENT COMPONENT C3 EXPRESSION
; FILE REFERENCE: RTS-0329
; CURRENT APPLICATION NUMBER: US/10/001,076
; CURRENT FILING DATE: 2001-10-23
; NUMBER OF SEQ ID NOS: 179
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-001-076-42

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1348 TACCAGATGCAGTTCACCCA 1367
Db      20 TACCAGATCCACTTCACCCA 1

RESULT 123
US-10-145-493B-35/c
; Sequence 35, Application US/10145493B
; Publication No. US20030096777A1
; GENERAL INFORMATION:
; APPLICANT: Besterman, Jeffrey
; APPLICANT: MacLeod, Robert
; APPLICANT: Siders, William
; TITLE OF INVENTION: Modulation of Gene Expression by Combination Therapy
; FILE REFERENCE: MET-015DV
; CURRENT APPLICATION NUMBER: US/10/145,493B
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 09/420,692
; PRIOR FILING DATE: 1999-10-19
; PRIOR APPLICATION NUMBER: US 60/104,804
; PRIOR FILING DATE: 1998-10-19
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-145-493B-35

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      26 CCCGCGGTGCGCGTCTC 45
Db      20 CCCGCTGTGCTGCTCTC 1

RESULT 124
US-10-006-191-72
; Sequence 72, Application US/10006191
; Publication No. US20030144223A1
; GENERAL INFORMATION:
; APPLICANT: William Gaarde
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION
; FILE REFERENCE: RFS-0274
; CURRENT APPLICATION NUMBER: US/10/006,191
; CURRENT FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 153
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-006-191-72

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      763 CACGTGACAGCCACTTGCA 782
Db      1 CACGTGACAGCCACTTGCA 20
```

```
Db      1 CACGTGACAGCCACTTGCA 20

RESULT 125
US-10-005-344-8/c
; Sequence 8, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglla
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Montia
; APPLICANT: Erich Koller
; APPLICANT: Manjya Chhang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-8

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      243 CTCGAGAGCGGAAACGAG 262
Db      20 CTCGAGCGGAAACCCCG 1

RESULT 126
US-10-349-143-8790
; Sequence 8790, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumentfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8790
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer blind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-18258 for SEQ 925, in compleme
US-10-349-143-8790
```

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1025 CCAAGAGGTGGAAATGG 1044  
DB 1 CCAAGTAGTGGAAATGG 20

RESULT 127  
US-10-349-143-8838/c  
; Sequence 8838, Application US/10349143  
; Publication No. US20040055841  
; GENERAL INFORMATION:  
; APPLICANT: Cohen, Daniel  
; APPLICANT: Blumenfeld, Marla  
; TITLE OF INVENTION: Ballelic markers for use in constructing a high density...  
; FILE REFERENCE: GENSET.020CPI  
; CURRENT APPLICATION NUMBER: US/10/349,143  
; CURRENT FILING DATE: 2003-01-21  
; PRIOR APPLICATION NUMBER: US/09/422,978  
; PRIOR FILING DATE: 1999-10-20  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850  
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732  
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614  
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21  
; NUMBER OF SEQ ID NOS: 11796  
; SEQ ID NO 8838  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
; FEATURE:  
; NAME/KEY: primer\_bind  
; LOCATION: 1..20  
; OTHER INFORMATION: downstream amplification primer 99-18602 for SEQ 973, in compleme  
US-10-349-143-8838

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 688 CTGATGCCATTCACCAT 707  
DB 20 CTCTCTCCATTCACCAT 1

RESULT 128  
US-10-289-762-3216  
; Sequence 3216, Application US/10289762  
; Publication No. US2004006218A1  
; GENERAL INFORMATION:  
; APPLICANT: Grifffais, R.  
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments  
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preven  
; FILE REFERENCE: 9710-003-999  
; CURRENT APPLICATION NUMBER: US/10/289,762  
; CURRENT FILING DATE: 2003-03-27  
; NUMBER OF SEQ ID NOS: 6849  
; SEQ ID NO 3216  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Chlamydia pneumoniae  
US-10-289-762-3216

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1762 CCACAGGTATTGGAGAG 1781

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 939 CCTATGCTCTTGGGATCA 958  
DB 1 CCTATGATCTTGGGACCA 20

RESULT 129  
US-10-289-762-3350  
; Sequence 3350, Application US/10289762  
; Publication No. US2004006218A1  
; GENERAL INFORMATION:  
; APPLICANT: Grifffais, R.  
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments  
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preven  
; FILE REFERENCE: 9710-003-999  
; CURRENT APPLICATION NUMBER: US/10/289,762  
; CURRENT FILING DATE: 2003-03-27  
; NUMBER OF SEQ ID NOS: 6849  
; SEQ ID NO 3350  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Chlamydia pneumoniae  
US-10-289-762-3350

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GGAAGGCCCTTCCCATATA 1715  
DB 1 GGAAGGCCCTTCCCATATA 20

RESULT 130  
US-10-289-762-4873  
; Sequence 4873, Application US/10289762  
; Publication No. US2004006218A1  
; GENERAL INFORMATION:  
; APPLICANT: Grifffais, R.  
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments  
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preven  
; FILE REFERENCE: 9710-003-999  
; CURRENT APPLICATION NUMBER: US/10/289,762  
; CURRENT FILING DATE: 2003-03-27  
; NUMBER OF SEQ ID NOS: 6849  
; SEQ ID NO 4873  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Chlamydia pneumoniae  
US-10-289-762-4873

Query Match 0.7%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 90;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1696 GGAAGGCCCTTCCCATATA 1715  
DB 1 GGAAGGCCCTTCCCATATA 20

RESULT 131  
US-10-210-833-65  
; Sequence 65, Application US/10210833  
; Publication No. US20040023383A1  
; GENERAL INFORMATION:  
; APPLICANT: Sanjay Bhanot  
; APPLICANT: Susan M. Freiler  
; TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION  
; FILE REFERENCE: PUS-0396  
; CURRENT APPLICATION NUMBER: US/10/210,833  
; CURRENT FILING DATE: 2002-07-31  
; NUMBER OF SEQ ID NOS: 165  
; SEQ ID NO 65

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-833-65

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1158 AGCCGAGAGTTTGGGAAA 1177
Db      1 AGCCGAGAGTTTCAAGGACA 20

RESULT 132
US-10-444-206-438
; Sequence 438, Application US/10444206
; Publication No. US20040023917A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karras, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; TITLE OF INVENTION: Modulation of the Expression of B7 Protein
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/444,206
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: 09/851,871
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 444
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 438
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-444-206-438

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1473 TGGTCTGTTGACCTCCCTTAC 1492
Db      1 TGGTCTGTTCACTCTCTTCC 20

RESULT 133
US-10-293-998-32
; Sequence 32, Application US/10293998
; Publication No. US20040091871A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR RE2 EXPRESSION
; FILE REFERENCE: HTS-0026
; CURRENT APPLICATION NUMBER: US/10/293,998
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-998-32

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      816 GACGAGCTTTTCCACAGA 835
Db      1 GACGAGCTTTTCCCCCAGA 20

RESULT 134
US-10-293-998-68/c
; Sequence 68, Application US/10293998
; Publication No. US20040091871A1
; GENERAL INFORMATION:
; APPLICANT: Ming-Yi Chiang
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF G PROTEIN-COUPLED RECEPTOR RE2 EXPRESSION
; FILE REFERENCE: HTS-0026
; CURRENT APPLICATION NUMBER: US/10/293,998
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 82
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-293-998-68

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      816 GACGAGCTTTTCCACAGA 835
Db      20 GACGAGCTTTTCCCCCAGA 1

RESULT 135
US-10-296-716-15
; Sequence 15, Application US/10296716
; Publication No. US20040091456A1
; GENERAL INFORMATION:
; APPLICANT: NAKAI, MICHIO
; APPLICANT: KOMIYA, KAZUO
; APPLICANT: MURATA, MASASHI
; APPLICANT: TOHDOH, NAOKI
; APPLICANT: SAITO, IZUMU
; TITLE OF INVENTION: NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A PROPERTY
; TITLE OF INVENTION: OF REDUCED ADVERSE EFFECT
; FILE REFERENCE: 072860
; CURRENT APPLICATION NUMBER: US/10/296,716
; CURRENT FILING DATE: 2003-07-08
; PRIOR APPLICATION NUMBER: PCT/JP01/04360
; PRIOR FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: JP 2000-155603
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: JP 2000-373850
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-296-716-15

Query Match      0.7%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 90;
```



	Matches	17; Conservative	0;	Mismatches	3;	Indels	0;	Gaps	0;
Qy	1410	GGCTGTGGGCTCCTCAGAGA	1429						
Db	1	GGCACTGGTCTCCTCAGCGA	20						

RESULT 136  
US-10-316-667-39/c  
; Sequence 39, Application US/10316667  
; Publication No. US20040110700A1  
; Inventor: TROST, JAMES

```

1  TITLE:  TITLED INVENTION: MODULATION OF COLD EXPRESSION
2  FILE REFERENCE:  RTS-0349
3  CURRENT APPLICATION NUMBER:  US/10/316,667
4  CURRENT FILING DATE:  2002-12-10
5  NUMBER OF SEQ ID NOS:  69
6  SEQ ID NO 39
7  LENGTH:  20
8  TYPE:  DNA
9  ORGANISM:  Artificial Sequence
10 FEATURE:
11 OTHER INFORMATION:  Antisense Oligonucleotide
12 US-10-316-667-39

```

Query Match	0.7%	Score 15.2	DB 1	Length 20
Best Local Similarity	85.0%	Pred. No. 90		
Matches 17	Conservative 0	Mismatches 3	Indels 0	Gaps 0
Qy	730	GTGGTGACGGAGCTATTA	749	
Db	20	GTGTGTGATGGAGATCTGTA	1	

RESULT 137  
 US-10-316-667-63  
 Sequence 63, Application US/10316667  
 Publication NO. US20040110700A1  
 GENERAL INFORMATION:  
 APPLICANT: C. Frank Bennett  
 APPLICANT: Susan M. Feiler  
 TITLE OF INVENTION: MODULATION OF CPD1 EXPRESSION  
 FILE REFERENCE: RTS-0349  
 CURRENT APPLICATION NUMBER: US/10/316,667  
 CURRENT FILING DATE: 2002-12-10  
 NUMBER OF SEQ ID NOS: 69  
 SEQ ID NO 63  
 LENGTH: 20  
 TYPE: DNA  
 ORGANISM: *H. sapiens*  
 FEATURE:  
 US-10-316-667-63

Query Match	0.7%	Score 15.2	DB 1	Length 20
Best Local Similarity	85.0%	Pred. No. 90		
Matches 17	Conservative 0	Mismatches 3	Indels 0	Gaps 0
Qy	730 GTGGGTACGGGATCTATTAA	749		
Db	1 GTGTGTGATGGGATCTGTTA	20		

RESULT 138  
US-10-156-306-7106  
Sequence 7106, Application US/10156306  
Publication No. US20030119017A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: McGivern, James  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR

```

: FILE REFERENCE: MBBH01-664-A (400/050)
: CURRENT APPLICATION NUMBER: US/10/156,306
: CURRENT FILING DATE: 2002-05-28
: NUMBER OF SEQ ID NOS: 8013
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 7106
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
US-10-156-306-7106

```

	Query Match	0.7%	Score 15	DB 1	Length 17
	Best Local Similarity	86.7%	Pred. No. 85		
	Matches 13; Conservative	2;	Mismatches	0;	Gaps 0;
Qy	393 GCACTGGGGAAGTCA	407			
	:         :				
Dh	2 GCACUGGGGAAGUCA	16			

```

RESULT 139
US-10-156-306-7107
: Sequence 7107, Application US/10156306
: Publication NO. US20030119017A1
: GENERAL INFORMATION:
: APPLICANT: Ribozyme Pharmaceuticals, Inc.
: APPLICANT: McSwiggen, James
: TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
: TITLE OF INVENTION: Levels of IKK-Gamma and p38
: FILE REFERENCE: MBH01-664-A (400/050)
: CURRENT APPLICATION NUMBER: US/10/156,306
: CURRENT FILING DATE: 2002-05-28
: NUMBER OF SEQ ID NOS: 8013
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 7107
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-10-156-306-7107

```

	Query Match	0.7%	Score 15;	DB 1;	Length 17;
	Best Local Similarity	86.7%;	Pred.	No. 85;	
	Matches 13; Conservative	2;	Mismatches	0;	Gaps 0;
OY	393 GCACCTGGGGAAGTCA	407			
	:	:			
Db	1 GCATCGGGGAAGUCA	15			

```

RESULT 140
US-10-230-006-741/c
; Sequence 741, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Fibrozyme Pharmaceuticals, Inc.
; APPLICANT: Roanough, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT
; FILE REFERENCE: 400/056 (NBH001-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 741
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-741

Query Match      0.7%; Score 15; DB 1; Length 17;
Beet Local Similarity 100.0%; Pred. No. 85;

```

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 CGCGGGTCCGCTGC 42  
| | | | | | | | | |  
Db 15 CGCGGGTCCGCTGC 1

RESULT 141  
US-10-230-006-1390/c  
; Sequence 1390, Application US/10230006  
; Publication No. US20030191077A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Fosnaugh, Kathy  
; APPLICANT: MCSwigen, Jim  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC COND  
; FILE REFERENCE: 400/056 (MBH01-1110)  
; CURRENT APPLICATION NUMBER: US/10/230,006  
; CURRENT FILING DATE: 2002-11-18  
; PRIOR APPLICATION NUMBER: US 60/315,315  
; PRIOR FILING DATE: 2001-08-28  
; NUMBER OF SEQ ID NOS: 2678  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1390  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-230-006-1390

Query Match 0.7%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 28 CGCGGGTCCGCTGC 42  
| | | | | | | | | |  
Db 17 CGCGGGTCCGCTGC 3

RESULT 142  
US-10-100-957A-39/c  
; Sequence 39, Application US/10100957A  
; Publication No. US20030096322A1  
; GENERAL INFORMATION:  
; APPLICANT: Giuliano, Kenneth A.  
; APPLICANT: Kapur, Ravi  
; TITLE OF INVENTION: A System for Cell Based Screening  
; FILE REFERENCE: 97-022-11A  
; CURRENT APPLICATION NUMBER: US/10/100,957A  
; CURRENT FILING DATE: 2002-03-19  
; NUMBER OF SEQ ID NOS: 180  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 39  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: K13 epitope  
US-10-100-957A-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 99;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCCTGCTGC 583  
| | | | | | | | | |  
Db 18 TGTTCCTGTCCTGCTGC 1

RESULT 143  
US-10-211-088-293/c  
; Sequence 293, Application US/10211088  
; Publication No. US20030104479A1  
; GENERAL INFORMATION:

; APPLICANT: Bright, Gary R.  
; APPLICANT: Premkumar, D. David  
; APPLICANT: Chen, Yih-Tai  
; TITLE OF INVENTION: No. US20030104479A1el Fusion Proteins And Assays For Molecular Bir  
; FILE REFERENCE: 01-1022-US  
; CURRENT APPLICATION NUMBER: US/10/211,088  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 60/309,395  
; PRIOR FILING DATE: 2001-08-01  
; PRIOR APPLICATION NUMBER: 60/341,589  
; PRIOR FILING DATE: 2001-12-13  
; NUMBER OF SEQ ID NOS: 366  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 293  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Sequence encoding detection domain  
US-10-211-088-293

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 99;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 566 TGTTCCTGTCCTGCTGC 583  
| | | | | | | | | |  
Db 18 TGTTCCTGTCCTGCTGC 1

RESULT 144  
US-10-265-689-39/c  
; Sequence 39, Application US/10265689  
; Publication No. US20030119775A1  
; GENERAL INFORMATION:  
; APPLICANT: SURMIT, RICHARD S.  
; APPLICANT: COLLINS, SHEILA A.  
; APPLICANT: WARDEN, CRAIG H.  
; APPLICANT: SELDIN, MICHAEL F.  
; APPLICANT: BOUILLAUD, FREDERIC  
; TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN  
; FILE REFERENCE: 1579-376  
; CURRENT APPLICATION NUMBER: US/10/265,689  
; CURRENT FILING DATE: 2002-10-08  
; PRIOR APPLICATION NUMBER: US/09/353,645  
; PRIOR FILING DATE: 1999-07-15  
; PRIOR APPLICATION NUMBER: PCT/US97/06864  
; PRIOR FILING DATE: 1997-04-22  
; PRIOR APPLICATION NUMBER: 60/034,960  
; PRIOR FILING DATE: 1997-01-15  
; NUMBER OF SEQ ID NOS: 47  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 39  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:  
; OTHER INFORMATION: Oligonucleotide  
US-10-265-689-39

Query Match 0.7%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 99;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1903 GAGGTAGACGAGCTGGG 1920  
| | | | | | | | | |  
Db 18 GAGGTAGACGAGCTGGG 1

RESULT 145  
US-09-910-059-110

```
/ Sequence 110, Application US/09910059
/ Patent No. US20020142359A1
/ GENERAL INFORMATION:
/ APPLICANT: Copley, Clive G
/ APPLICANT: Edge, Michael Derek
/ APPLICANT: Emery, Stephen Charles
/ TITLE OF INVENTION: Monoclonal Antibody to CRA, Conjugates Comprising Said Antibody,
/ TITLE OF INVENTION: Their Therapeutic use in an Adept System
/ FILE REFERENCE: 1991-209
/ CURRENT APPLICATION NUMBER: US/09/910,059
/ CURRENT FILING DATE: 2001-07-23
/ PRIOR APPLICATION NUMBER: US 09/171,945
/ PRIOR FILING DATE: 1998-10-29
/ PRIOR APPLICATION NUMBER: PCT/GB97/01165
/ PRIOR FILING DATE: 1997-04-29
/ PRIOR APPLICATION NUMBER: GB 9703103.3
/ PRIOR FILING DATE: 1997-02-14
/ PRIOR APPLICATION NUMBER: GB9609405.7
/ PRIOR FILING DATE: 1996-05-04
/ NUMBER OF SEQ ID NOS: 131
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 110
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: PCR primer for preprohCFB
US-09-910-059-110
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1645 GCCCTGCTGCAGATCTG 1662
DB 2 GACCTGCTGCAGATCTG 19
```

```
RESULT 146
US-10-099-352-22/c
/ Sequence 22, Application US/10099352
/ Publication No. US20030082569A1
/ GENERAL INFORMATION:
/ APPLICANT: Johnson, Clayvon H.
/ APPLICANT: McEwen, Joan E.
/ APPLICANT: York, J. Lyndal
/ TITLE OF INVENTION: Histoplasma Capsulation Catalase Sequences and Their Use in the
/ TITLE OF INVENTION: of Histoplasma Capsulation and Histoplasmosis
/ FILE REFERENCE: 40715-255988
/ CURRENT APPLICATION NUMBER: US/10/099,352
/ CURRENT FILING DATE: 2002-03-13
/ PRIOR APPLICATION NUMBER: US 60/275,353
/ PRIOR FILING DATE: 2001-03-13
/ NUMBER OF SEQ ID NOS: 48
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 22
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic primer
US-10-099-352-22
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 290 AGCATAGCTGCGGCAC 307
DB 18 AACCATCAGCTGCGGCAC 1
```

RESULT 147

```
US-10-224-005-84
/ Sequence 84, Application US/10224005
/ Publication No. US20030143732A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Fossnaugh, Kathy
/ TITLE OF INVENTION: RNA interference Mediated Inhibition of Adenosine A1 Receptor (AD
/ TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
/ FILE REFERENCE: 900/041 (MBHB01-1110-A)
/ CURRENT APPLICATION NUMBER: US/10/224,005
/ CURRENT FILING DATE: 2002-08-20
/ PRIOR APPLICATION NUMBER: US 60/315,315
/ PRIOR FILING DATE: 2001-08-28
/ NUMBER OF SEQ ID NOS: 347
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 84
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target sequence/siNA sense r
US-10-224-005-84
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 1e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 205 TGGCTGGGGCCTGCGG 222
DB 1 UGCGUGGGGCAUGCGG 18
```

```
RESULT 148
US-10-224-005-245/c
/ Sequence 245, Application US/10224005
/ Publication No. US20030143732A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Fossnaugh, Kathy
/ TITLE OF INVENTION: RNA interference Mediated Inhibition of Adenosine A1 Receptor (AD
/ TITLE OF INVENTION: Gene Expression Using Short Interfering RNA
/ FILE REFERENCE: 900/041 (MBHB01-1110-A)
/ CURRENT APPLICATION NUMBER: US/10/224,005
/ CURRENT FILING DATE: 2002-08-20
/ PRIOR APPLICATION NUMBER: US 60/315,315
/ PRIOR FILING DATE: 2001-08-28
/ NUMBER OF SEQ ID NOS: 347
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 245
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-224-005-245
```

```
Query Match 0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 205 TGGCTGGGGCCTGCGG 222
DB 19 TGGCTGGGGCCTGCGG 2
```

```
RESULT 149
US-10-277-216-121/c
/ Sequence 121, Application US/10277216
/ Publication No. US20040002470A1
/ GENERAL INFORMATION:
/ APPLICANT: KEITH, TIM
```

```
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 121
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-121
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
        |||||
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 150
US-10-126-022-121/c
; Sequence 121, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 121
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-121
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
        |||||
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 151
US-10-670-184-94/c
; Sequence 94, Application US/10670184
; Publication No. US2004007011A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES AND
; FILE REFERENCE: 2976-4039
```

```
; CURRENT APPLICATION NUMBER: US/10/670,184
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: 60/129,391
; PRIOR FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 170
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 94
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-670-184-94
```

```
Query Match          0.7%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      867 AGAGGACACGTCACCT 884
        |||||
Db       19 AGAGGACACGACGACCT 2
```

```
RESULT 152
US-09-866-108-890/c
; Sequence 890, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOGEN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 890
; LENGTH: 17
```

TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-890

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 CCCCTCCCAATG 1717  
DB 17 CCCCTCCCAATG 2

## RESULT 153

US-09-866-108-894/C  
Sequence 894, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 894  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-894

DB 16 AAGCCCTTCCCACT 1

## RESULT 154

US-09-866-108-8005  
Sequence 8005, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 8005  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8005

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2038 CAGGTGAGCAGCTCC 2053  
DB 2 CAGGTGAGCAGCTCC 17

US-09-866-108-8006

## RESULT 155

US-09-866-108-8006  
Sequence 8006, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8006
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8006

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2038 CAGGTGAGCAGCTCC 2053
DB      1 CAGCTGAGCAGCTCC 16

RESULT 156
US-09-961-077-139
; Sequence 139, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: ZWICK, Michael G.
; Edington, Brent E.
; McSwiggen, James A.
; Merlo, Patricia Ann Owens
; Guo, Lining
; Skokut, Thomas A.
; Young, Scott A.
; Folkerts, Otto
; Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
```

```

; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 139:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 139:
US-09-961-077-139

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      2179 CAGCAGCTCAGGAGA 2194
DB      1 CCGCAGCUCAGGAGA 16

RESULT 157
US-09-818-875-603
; Sequence 603, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
```

```
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-603
```

```
Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1806 CCGAGCCCGAGAGCCA 1821
Db      2 CCAGACCCAGAGCCA 17
```

```
RESULT 158
US-09-818-875-604/c
; Sequence 604, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 604
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-604
```

```
Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1806 CCGAGCCCGAGAGCCA 1821
Db      16 CCAGACCCAGAGCCA 1
```

```
RESULT 159
US-09-930-423-384/c
; Sequence 384, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
```

```
US-09-930-423-384
```

```
Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      360 AGCCCCCGGTCGCG 375
Db      17 AGCCCCCGGTCGCG 2
```

```
RESULT 160
US-09-930-423-385/c
; Sequence 385, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-385
```

```
Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      360 AGCCCCCGGTCGCG 375
Db      16 AGCCCCCGGTCGCG 1
```

```
RESULT 161
US-09-740-332-2144
; Sequence 2144, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2144
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2144
```

```
Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1224 TGCAGTCACTCCTGG 1239
Db      1 UCCAGUCACUCCUGG 16
```

```
RESULT 162
```

```
US-09-745-237A-384/c
; Sequence 384, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 384
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-384
```

```
Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      360 AGCCCCCGGTCGCGC 375
Db      17  AGCCCCCGGTCGCGG  2
```

```
RESULT 163
US-09-745-237A-385/c
; Sequence 385, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 385
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-385
```

```
Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      360 AGCCCCCGGTCGCGC 375
Db      16  AGCCCCCGGTCGCGG  1
```

```
RESULT 164
US-09-817-879-2144
; Sequence 2144, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; APPLICANT: Hepatitis C Virus Infection
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MEBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2144
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2144
```

```
Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1224 TGCAGTCACTCTCG 1239
Db      1    UCCAGUCACUCCUG  16
```

```
RESULT 165
US-10-081-810-33/c
; Sequence 33, Application US/10081810
; Publication No. US20030064438A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; APPLICANT: G-protein coupled receptor nuclear acids, polypeptides, antibodies
; TITLE OF INVENTION: US8 THEREOF
; FILE REFERENCE: D0132 NP
; CURRENT APPLICATION NUMBER: US/10/081,810
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: US 60/270,793
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: US 60/270,792
; PRIOR FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: US 60/296,427
; PRIOR FILING DATE: 2001-06-06
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 33
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-081-810-33
```

```
Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      113 CCGCGTGTCCCGGCAT 128
Db      17  CTTGCTGCCCCGCAT  2
```

```
RESULT 166
US-10-060-895A-482/c
; Sequence 482, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
```



;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00663  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00670  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: US 09/864,761  
;; PRIOR FILING DATE: 2001-05-23  
;; PRIOR APPLICATION NUMBER: US 60/315,984  
;; PRIOR FILING DATE: 2001-08-30  
;; NUMBER OF SEQ ID NOS: 1682  
;; SOFTWARE: Aeomica Sequence Listing Engine  
;; SEQ ID NO 482  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-10-060-895A-482

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGCG 1502  
DB 17 CCTTACCTTGAGCG 2

RESULT 167  
US-10-060-895A-483/C  
;; Sequence 483, Application US/10060895A  
;; Publication No. US20030104403A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Zhang, Jian  
;; APPLICANT: Gu, Yizhong  
;; APPLICANT: Nguyen, Chung-Tuong  
;; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10  
;; FILE REFERENCE: PB0158  
;; CURRENT APPLICATION NUMBER: US/10/060, 895A  
;; CURRENT FILING DATE: 2002-06-10  
;; PRIOR APPLICATION NUMBER: PCT/US01/00666  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00667  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00664  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00663  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00670  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: US 09/864,761  
;; PRIOR FILING DATE: 2001-05-23  
;; PRIOR APPLICATION NUMBER: US 60/315,984  
;; PRIOR FILING DATE: 2001-08-30  
;; NUMBER OF SEQ ID NOS: 1682  
;; SOFTWARE: Aeomica Sequence Listing Engine  
;; SEQ ID NO 483  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-10-060-895A-483

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1487 CCTTACCTTGAGCG 1502  
DB 16 CCTTACCTTGAGCG 1

RESULT 168  
US-10-156-306-4759/C  
;; Sequence 4759, Application US/10156306  
;; Publication No. US20030119017A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
;; APPLICANT: McSwiggen, James  
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
;; FILE REFERENCE: MBH01-664-A (400/050)  
;; CURRENT APPLICATION NUMBER: US/10/156,306  
;; CURRENT FILING DATE: 2002-05-28  
;; NUMBER OF SEQ ID NOS: 8013  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO 4759  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: Homo sapiens  
US-10-156-306-4759

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 214 GCCTGCGGGGTCTCA 229  
DB 17 GCTGCGGGGTCTCA 2

RESULT 169  
US-10-156-306-4760/C  
;; Sequence 4760, Application US/10156306  
;; Publication No. US20030119017A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
;; APPLICANT: McSwiggen, James  
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
;; FILE REFERENCE: MBH01-664-A (400/050)  
;; CURRENT APPLICATION NUMBER: US/10/156,306  
;; CURRENT FILING DATE: 2002-05-28  
;; NUMBER OF SEQ ID NOS: 8013  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO 4760  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: Homo sapiens  
US-10-156-306-4760

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 214 GCCTGCGGGGTCTCA 229  
DB 16 GCTGCGGGGTCTCA 1

RESULT 170  
US-10-156-306-7104  
;; Sequence 7104, Application US/10156306  
;; Publication No. US20030119017A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
;; APPLICANT: McSwiggen, James  
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
;; FILE REFERENCE: MBH01-664-A (400/050)  
;; CURRENT APPLICATION NUMBER: US/10/156,306  
;; CURRENT FILING DATE: 2002-05-28  
;; NUMBER OF SEQ ID NOS: 8013

```
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7104
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-7104

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      391 CTGCACTGGGGAAGTC 406
Db      2 CGGCACUGGGGAAGUC 17

RESULT 171
US-10-209-787-603
; Sequence 603, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-603

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCTGACCCAGAAGCCA 1821
Db      2 CCAGACCCAGAAGCCA 17

RESULT 172
US-10-209-787-604/C
; Sequence 604, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
```

```
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 604
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-604

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCTGACCCAGAAGCCA 1821
Db      16 CCAGACCCAGAAGCCA 1

RESULT 173
US-10-261-185-603
; Sequence 603, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; PRIOR FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 603
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-603

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1806 CCTGACCCAGAAGCCA 1821
Db      2 CCAGACCCAGAAGCCA 17

RESULT 174
US-10-261-185-604/C
; Sequence 604, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
```

FILE REFERENCE: Napro-4CON  
CURRENT APPLICATION NUMBER: US/10/261,185  
CURRENT FILING DATE: 2002-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/09761  
PRIOR FILING DATE: 2001-03-27  
PRIOR APPLICATION NUMBER: US 60/192,176  
PRIOR FILING DATE: 2000-03-27  
PRIOR APPLICATION NUMBER: US 60/192,179  
PRIOR FILING DATE: 2000-03-27  
PRIOR APPLICATION NUMBER: US 60/208,538  
PRIOR FILING DATE: 2000-06-01  
PRIOR APPLICATION NUMBER: US 60/244,989  
PRIOR FILING DATE: 2000-10-30  
NUMBER OF SEQ ID NOS: 4385  
SOFTWARE: Friedman macro Napro4  
SEQ ID NO 604  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-261-185-604

Query Match 0.6%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1806 CCTGACCCAGAGCCA 1821

Db 16 CCAGACCCAGAGCCA 1

## RESULT 175

US-10-230-335-5/C  
Sequence 5, Application US/10230335  
Publication No. US20030109016A1  
GENERAL INFORMATION:  
APPLICANT: MURAKAMI, Yoshihori  
TITLE OF INVENTION: TSL1 GENE  
FILE REFERENCE: 071665  
CURRENT APPLICATION NUMBER: US/10/230,335  
CURRENT FILING DATE: 2002-11-22  
PRIOR APPLICATION NUMBER: JP 2001-313966  
PRIOR FILING DATE: 2001-10-11  
NUMBER OF SEQ ID NOS: 13  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 5  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Gene Amplification Primer  
US-10-230-335-5

Query Match 0.6%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 264 TGCCAGGCGCTGCTG 279

Db 17 TGTCAGGCGCTGCTG 2

## RESULT 176

US-10-005-956-1222  
Sequence 1222, Application US/10005956  
Publication No. US20030113726A1  
GENERAL INFORMATION:  
APPLICANT: Bristol-Myers Squibb Company  
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS  
FILE REFERENCE: D0053NP  
CURRENT APPLICATION NUMBER: US/10/005,956  
CURRENT FILING DATE: 2001-12-03  
PRIOR APPLICATION NUMBER: 60/251,015  
PRIOR FILING DATE: 2000-12-04

PRIOR APPLICATION NUMBER: 60/263,678  
PRIOR FILING DATE: 2001-01-23  
PRIOR APPLICATION NUMBER: 60/273,037  
PRIOR FILING DATE: 2001-03-02  
NUMBER OF SEQ ID NOS: 1579  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1222  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-005-956-1222

Query Match 0.6%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2190 GGAGAAAAGCGCTGC 2205

Db 2 GGAGAAAAGCGCTGC 17

## RESULT 177

US-10-427-432-11  
Sequence 11, Application US/10427432  
Publication No. US2003025260A1  
GENERAL INFORMATION:  
APPLICANT: Snyder, Richard O.  
TITLE OF INVENTION: PRODUCTION OF RECOMBINANT AAV VIRIONS  
FILE REFERENCE: 5853-240  
CURRENT APPLICATION NUMBER: US/10/427,432  
CURRENT FILING DATE: 2003-04-30  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 11  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic Oligonucleotides  
US-10-427-432-11

Query Match 0.6%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1941 GCGACGCGCAGTGGCG 1956

Db 3 GCTACAGCGCAGTGGCG 18

## RESULT 178

US-10-164-871-17/C  
Sequence 17, Application US/10164871  
Publication No. US2002017194A1  
GENERAL INFORMATION:  
APPLICANT: Hirata, Yuichi  
TITLE OF INVENTION: STEROID HORMONE BINDING PROTEIN  
FILE REFERENCE: 06501-059001  
CURRENT APPLICATION NUMBER: US/10/164,871  
CURRENT FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US/09/565,808  
PRIOR FILING DATE: 2000-05-05  
PRIOR APPLICATION NUMBER: WO/99/05010  
PRIOR FILING DATE: 1998-11-06  
PRIOR APPLICATION NUMBER: JP/9/322376  
PRIOR FILING DATE: 1997-11-07  
NUMBER OF SEQ ID NOS: 22  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 17  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:



```

; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 14 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: rRNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-998-780-12

Query Match      0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      2112 CCTGCTGAGCAGG 2125
Db      1 CCUGGUGAGCAGG 14

RESULT 183
US-10-417-393-12
; Sequence 12, Application US/10417393
; Publication No. US2003025024A1
; GENERAL INFORMATION:
;   APPLICANT: Keene, Jack D.
;             Kenan, Daniel J.
;             Tsai, Donald E.
; TITLE OF INVENTION: Nucleic Acid Epitopes and Methods of
;                   Making and Using the Same
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Kenneth D. Sibley; Bell, Seltzer, Park and
;             Gibson
;             STREET: Post Office Drawer 34009
;             CITY: Charlotte
;             STATE: North Carolina
;             COUNTRY: U.S.A.
;             ZIP: 28234
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: PC-DOS/MS-DOS
;   SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/10/417,393
;   FILING DATE: 16-Apr-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US/07/944,208
;   FILING DATE: 1992-09-11
; ATTORNEY/AGENT INFORMATION:
;   NAME: Sibley, Kenneth D.
;   REGISTRATION NUMBER: 31,665
;   REFERENCE/DOCKET NUMBER: 5405-69
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 919-881-3140
;   TELEFAX: 919-881-3175
;   TELEX: 575102
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 14 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
; MOLECULE TYPE: rRNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-417-393-12

Query Match      0.6%; Score 14; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      2112 CCTGCTGAGCAGG 2125
```

```

Db      1 CCUGGUGAGCAGG 14

RESULT 184
US-09-829-855-101/c
; Sequence 101, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
;   APPLICANT: Matthew, Ashby N.
;   TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;   FILE REFERENCE: ASHBY-1
;   CURRENT APPLICATION NUMBER: US/09/829,855
;   CURRENT FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: US 60/196063
;   PRIOR FILING DATE: 2000-04-10
;   PRIOR APPLICATION NUMBER: US 60/196258
;   PRIOR FILING DATE: 2000-04-11
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 101
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;                   microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-101

Query Match      0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      297 AGCTGGCGCACTGG 310
Db      16 AGCTGGCGCACTGG 3

RESULT 185
US-10-607-077A-101/c
; Sequence 101, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
;   APPLICANT: Ashby, Matthew
;   TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
;   FILE REFERENCE: ASHBY/1 DIV
;   CURRENT APPLICATION NUMBER: US/10/607,077A
;   CURRENT FILING DATE: 2003-06-25
;   PRIOR APPLICATION NUMBER: US 09/829855
;   PRIOR FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: PCT/US01/11609
;   PRIOR FILING DATE: 2001-04-10
;   PRIOR APPLICATION NUMBER: US 60/196063
;   PRIOR FILING DATE: 2000-04-10
;   PRIOR APPLICATION NUMBER: US 60/196258
;   PRIOR FILING DATE: 2000-04-11
;   NUMBER OF SEQ ID NOS: 244
;   SOFTWARE: Patentin version 3.1
; SEQ ID NO 101
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
;                   microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-101

Query Match      0.6%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      297 AGCTGGCGCACTGG 310
Db      16 AGCTGGCGCACTGG 3
```

```
Db          16 AGCTGCGGCACTG 3

RESULT 186
US-09-866-108-895/c
; Sequence 895, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-895

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1699 AAGCCCTTCCCA 1712
Db          15 AAGCCCTTCCCA 2

RESULT 187
US-09-866-108-896/c
; Sequence 896, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 896
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-896

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          1699 AAGCCCTTCCCA 1712
Db          14 AAGCCCTTCCCA 1

RESULT 188
US-09-930-423-1483/c
; Sequence 1483, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH800.918-A-400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; PRIOR FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1483
; LENGTH: 17
; TYPE: RNA
```

ORGANISM: Homo Sapiens  
US-09-930-423-1483

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGCTCCG 373  
Db 15 AGCCCCCGGCTCCG 2

RESULT 189

US-09-930-423-1484/c  
; Sequence 1484, Application US/09930423  
; Publication No. US20030092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MHB00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1484  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1484

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGCTCCG 373  
Db 14 AGCCCCCGGCTCCG 1

RESULT 190  
US-09-740-332-2411/c  
; Sequence 2411, Application US/09740332  
; Publication No. US20030125270A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2411  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-2411

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1226 CAGTCACTCCTCG 1239  
Db 16 CAGTCACTCCTCG 3

RESULT 191

US-09-745-237A-1483/c  
; Sequence 1483, Application US/09745237A  
; Publication No. US20030143708A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: 400/007 (MHB00-918-A)  
; CURRENT APPLICATION NUMBER: US/09/745,237A  
; CURRENT FILING DATE: 2002-04-15  
; NUMBER OF SEQ ID NOS: 4550  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1483  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-745-237A-1483

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGCTCCG 373  
Db 15 AGCCCCCGGCTCCG 2

RESULT 192  
US-09-745-237A-1484/c  
; Sequence 1484, Application US/09745237A  
; Publication No. US20030143708A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: 400/007 (MHB00-918-A)  
; CURRENT APPLICATION NUMBER: US/09/745,237A  
; CURRENT FILING DATE: 2002-04-15  
; NUMBER OF SEQ ID NOS: 4550  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1484  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-745-237A-1484

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 360 AGCCCCCGGCTCCG 373  
Db 14 AGCCCCCGGCTCCG 1

RESULT 193  
US-09-817-879-2411/c  
; Sequence 2411, Application US/09817879  
; Publication No. US2003017311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: MHB00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2411  
; LENGTH: 17

```
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2411
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1226 CAGTCACTCTCTGG 1239
          |||||
Db      16  CAGTCACTCTCTGG 3
```

```
RESULT 194
US-10-156-306-6313/C
; Sequence 6313, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6313
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6313
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      216 CTGGGGGTCTCTCA 229
          |||||
Db      17  CTGGGGGTCTCTCA 4
```

```
RESULT 195
US-10-240-046A-64/C
; Sequence 64, Application US/10240046A
; Publication No. US20030190639A1
; GENERAL INFORMATION:
; APPLICANT: HUGOT, JEAN-PIERRE
; APPLICANT: THOMAS, GILLES
; APPLICANT: ZOULALI, MOHAMED
; APPLICANT: LESAGE, SUZANNE
; APPLICANT: CHAMAILLARD, MATHIAS
; TITLE OF INVENTION: GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: 37991-0009
; CURRENT APPLICATION NUMBER: US/10/240,046A
; CURRENT FILING DATE: 2003-04-02
; PRIOR APPLICATION NUMBER: PCT/FR 01/00935
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: FR 00/03832
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 64
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-240-046A-64
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      595 CTTGGGAGATGGC 608
          |||||
Db      14  CTTGGGAGATGGC 1
```

```
RESULT 196
US-10-230-006-2189/C
; Sequence 2189, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBHB01-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-2189
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      29  GCGGGTGCCTGTC 42
          |||||
Db      17  GCGGGTGCCTGTC 4
```

```
RESULT 197
US-10-138-674-9170/C
; Sequence 9170, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9170
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9170
```

```
Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      76  GTACTGCTACTTCT 89
          |||||
Db      15  GTACTGCTACTTCT 2
```

```
RESULT 198
```



US-10-287-949A-9170/c  
; Sequence 9170, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggan, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MEH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 9170  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-267-949A-9170

Query Match 0.6%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 76 GTACTGCTACTTCT 89  
DB 15 GTACTGCTACTTCT 2

RESULT 199  
US-10-178-325-56/c  
; Sequence 56, Application US/10178325  
; Publication No. US20030199467A1  
; GENERAL INFORMATION:  
; APPLICANT: Roberts, M. Luisa  
; APPLICANT: Combert, Lex M.  
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene  
; FILE REFERENCE: ISPH-0404  
; CURRENT APPLICATION NUMBER: US/10/178,325  
; CURRENT FILING DATE: 2002-06-21  
; PRIOR APPLICATION NUMBER: US/09/387,341  
; PRIOR FILING DATE: 1999-08-31  
; PRIOR APPLICATION NUMBER: 09/156,424  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 09/156,979  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 09/156,807  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 09/161,015  
; PRIOR FILING DATE: 1998-09-25  
; NUMBER OF SEQ ID NOS: 233  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 56  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-178-325-56

Query Match 0.6%; Score 14; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1814 AGAGCCACTATG 1827  
DB 15 AGAGCCACTATG 2

RESULT 200

US-09-866-108-515/c  
; Sequence 515, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: Ji, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 515  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-515

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 CTGCTCCGGCTCGGCGC 176  
DB 17 CTGCTCAGGCTCGGCGC 1

RESULT 201  
US-09-866-108-665/c  
; Sequence 665, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: Ji, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-665

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      53 CTTCTCGCATGCGCTG 69
Db      17 CTTCTCGCATGCGCTG 1

RESULT 202
US-09-866-108-1530
; Sequence 1530, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1530
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1530

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1595 AGGTGACGCGCTGGTG 1611
Db      1 AGGTGATGCGGCTGGTG 17

RESULT 203
US-09-866-108-1572/c
; Sequence 1572, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1572

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      267 CCAGGCTGCTGCTGCTG 283
DB      17 CCAGAGCAGCTGCTGCTG 1

```

## RESULT 204

```

US-09-866-108-1960
; Sequence 1960, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1960
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1960

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1832 AAATCAGCTGCTGCA 1848
DB      1 AAAGCTCAGCTGCTGCA 17

```

## RESULT 205

```

US-09-866-108-2739
; Sequence 2739, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2739
; LENGTH: 17
; TYPE: DNA

```

```
; ORGANISM: Homo sapiens
US-09-866-108-2739

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      297 AGCTGCGCAGCTGGGCT 313
Db      1 AGCTGAGGCCCTGGGCT 17

RESULT 206
US-09-866-108-6521
; Sequence 6521, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6521
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6521

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2100 CCAGCAGCTGAGCCTGG 2116
Db      1 CCAGCAGCAGCCTGG 17
```

```
RESULT 207
US-09-866-108-6522
; Sequence 6522, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6522
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6522

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2101 CAGCAGCTGAGCCTGGT 2117
Db      1 CAGCAGCAGCAGCCTGGT 17

RESULT 208
US-09-866-108-6525
; Sequence 6525, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
```

```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6525
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6525

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2104 CACCTGACCTGTGTGGA 2120
Db      1 CACCGACCTGTGTGGA 17

RESULT 209
US-09-866-108-6526
; Sequence 6526, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6526
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6526

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2105 ACCTGACCTGTGTGAG 2121
Db      1 ACCGACCTGTGTGAG 17

RESULT 210
US-09-866-108-6758
; Sequence 6758, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 6758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6758

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```
QY      2041 GTGAGCAGCTCCTGTA 2057
Db      1 GTGAGAGAGCTCCTGGA 17

```

```

RESULT 211
US-09-866-108-8056
; Sequence 8056, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8056
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8056

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```
QY      2230 GCAGATGCTCCAGATG 2246
Db      1 GCAGATGCACCAAGG 17

```

```

RESULT 212
US-09-866-108-8057
; Sequence 8057, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine

```

SEQ ID NO 8057  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8057

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2231 CAGATGCTCCAGATGA 2247  
Db 1 CAGATGACCCAGAGGA 17

RESULT 213  
US-09-866-108-9583  
Sequence 9583, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00660  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 9583  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-9583

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1167 GTTAGGAAAAGCTGC 1183  
Db 1 GTGAGGGAAGAGCTGC 17

RESULT 214  
US-09-895-040A-77/c  
Sequence 77, Application US/09895040A  
Patent No. US20020123474A1  
GENERAL INFORMATION:

APPLICANT: Shannon, Mark  
APPLICANT: JI, Yonggang  
TITLE OF INVENTION: HUMAN GTP-RHO BINDING PROTEIN 2  
FILE REFERENCE: AEOMICA-11  
CURRENT APPLICATION NUMBER: US/09/895,040A  
CURRENT FILING DATE: 2001-06-29  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
NUMBER OF SEQ ID NOS: 180  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 77  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-895-040A-77

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 206 GGCTGGGGGCTGCGGG 222  
Db 17 GGCTGGGGGCGCGGG 1

RESULT 215  
US-09-864-785-577/c  
Sequence 577, Application US/09864785  
Patent No. US2002017568A1  
GENERAL INFORMATION:

APPLICANT: Ribozyne Pharmaceuticals, Inc.  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Draper, Ken  
APPLICANT: McSwiggen, Jim  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
FILE REFERENCE: 400/022 (MBH00-812-D)  
CURRENT APPLICATION NUMBER: US/09/864,785  
CURRENT FILING DATE: 2001-05-23  
NUMBER OF SEQ ID NOS: 3929  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 577  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid

US-09-864-785-577

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2162 GGGAGGGGGGAAACCCAC 2178

DB 17 GGGATGGGGGAGCCAC 1

RESULT 216

US-09-864-785-2690/c  
; Sequence 2690, Application US/09864785  
; Patent No. US2002017568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwigen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; FILE REFERENCE: 400/022 (MBH00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2690  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2690

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 563 CGCTGTCCTGCTCCTG 579

DB 17 CACTGTCTCTGCTCTG 1

RESULT 217

US-09-864-785-2870/c  
; Sequence 2870, Application US/09864785  
; Patent No. US2002017568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwigen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; FILE REFERENCE: 400/022 (MBH00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2870  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2870

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 356 GGGAGAGCCCCGGGTCC 372

DB 17 GGGAGAGCCCCGGGTCC 1

RESULT 218

US-09-864-785-2871/c  
; Sequence 2871, Application US/09864785  
; Patent No. US2002017568A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Draper, Ken  
; APPLICANT: McSwigen, Jim  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; FILE REFERENCE: 400/022 (MBH00-812-D)  
; CURRENT APPLICATION NUMBER: US/09/864,785  
; CURRENT FILING DATE: 2001-05-23  
; NUMBER OF SEQ ID NOS: 3929  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2871  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2871

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 TGGGAGAGCCCCGGGTC 371

DB 17 TGGGAGAGCCCCGGGTC 1

RESULT 219

US-09-825-805-629/c  
; Sequence 629, Application US/09825805  
; Publication No. US20030004122A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Beigelman, Leo  
; APPLICANT: Beaudry, Amber  
; APPLICANT: Karpelsky, Alex  
; APPLICANT: Adams, Jasenka Matulic  
; APPLICANT: Sweedler, Dave  
; APPLICANT: Zinnen, Shawn  
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot  
; FILE REFERENCE: MBH00-831-P (400/009)  
; CURRENT APPLICATION NUMBER: US/09/825,805  
; CURRENT FILING DATE: 2001-09-27  
; PRIOR APPLICATION NUMBER: 09/578,223  
; PRIOR FILING DATE: 2000-05-23  
; PRIOR APPLICATION NUMBER: 09/476,387  
; PRIOR FILING DATE: 1999-12-30  
; PRIOR APPLICATION NUMBER: 09/474,432  
; PRIOR FILING DATE: 1999-12-29  
; PRIOR APPLICATION NUMBER: 09/301,511  
; PRIOR FILING DATE: 1999-04-28  
; PRIOR APPLICATION NUMBER: 09/186,675  
; PRIOR FILING DATE: 1998-11-04  
; PRIOR APPLICATION NUMBER: 60/083,727  
; PRIOR FILING DATE: 1998-04-29  
; PRIOR APPLICATION NUMBER: 60/064,866  
; PRIOR FILING DATE: 1997-11-05  
; NUMBER OF SEQ ID NOS: 1558  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 629  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens



US-09-825-805-629

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 GCAGTGTCCCGAGGCTG 275

Db 17 GTAGTGTACCGAGGCTG 1

RESULT 220

US-09-825-805-719/c

; Sequence 719, Application US/09825805  
; Publication No. US2003004122A1  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpelesky, Alex

; APPLICANT: Adamic, Jasenka Matulic

; APPLICANT: Sweedler, Dave

; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MBH00-831-F (400/009)

; CURRENT APPLICATION NUMBER: US/09/825,805

; PRIOR FILING DATE: 2001-09-27

; PRIOR APPLICATION NUMBER: 09/578,223

; PRIOR FILING DATE: 2000-05-23

; PRIOR APPLICATION NUMBER: 09/476,387

; PRIOR FILING DATE: 1999-12-30

; PRIOR APPLICATION NUMBER: 09/474,432

; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: 09/301,511

; PRIOR FILING DATE: 1999-04-28

; PRIOR APPLICATION NUMBER: 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: 60/083,727

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/064,866

; PRIOR FILING DATE: 1997-11-05

; NUMBER OF SEQ ID NOS: 1558

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 719

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-825-805-719

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 AGGCGTGTGCTGCT 285

Db 17 AGGCGTGTGCTGCT 1

RESULT 221

US-09-730-289B-541/c

; Sequence 541, Application US/09730289B  
; Publication No. US20030050259A1  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease

; FILE REFERENCE: MBH00-864-A (400/006)

; CURRENT APPLICATION NUMBER: US/09/730,289B

; PRIOR FILING DATE: 2000-12-05

; PRIOR APPLICATION NUMBER: US 60/169,100

; PRIOR FILING DATE: 1999-12-06

; NUMBER OF SEQ ID NOS: 3897

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 541

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-730-289B-541

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1465 CCACCAGTGTGTT 1481

Db 17 CTACTAGTGTGTT 1

RESULT 222

US-09-780-533A-106

; Sequence 106, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Chowitra, Bharat

; APPLICANT: Haebertl, Pete

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene

; FILE REFERENCE: MBH00,878-A (400/011)

; CURRENT APPLICATION NUMBER: US/09/780,533A

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: US 60/181,797

; NUMBER OF SEQ ID NOS: 6679

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 106

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-780-533A-106

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 1.5e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1778 GAAGCTTCAGAAAT 1794

Db 1 GAACACUCUCAAATAA 17

RESULT 223

US-09-780-533A-1837/c

; Sequence 1837, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Blatt, Larry

; APPLICANT: McSwiggen, Jim

; APPLICANT: Chowitra, Bharat

; APPLICANT: Haebertl, Pete

; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene

; FILE REFERENCE: MBH00,878-A (400/011)

; CURRENT APPLICATION NUMBER: US/09/780,533A

; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: US 60/181,797

; NUMBER OF SEQ ID NOS: 6679

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1837

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-780-533A-1837

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
ORGANISM: Hepatitis B virus  
US-09-877-478-699

Qy 199 GTGCTGCTGGCTGGGGGC 215  
Db 17 GGAGCTGCTGGGGGC 1

RESULT 224  
US-09-780-533A-2015  
; Sequence 2015, Application US/09780533A  
; Publication No. US2003006011A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Chowitra, Bharat  
; APPLICANT: Haebertl, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MHB00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2015  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-2015

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
ORGANISM: Homo sapiens  
US-09-780-533A-2015

Qy 784 GGAGAGTGTGGGCGC 800  
Db 1 GGAGUGGUGUGGUC 17

RESULT 225  
US-09-877-478-699/c  
; Sequence 699, Application US/09877478  
; Publication No. US20030068301A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Diaper, Kenneth  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Blatt, Larry  
; APPLICANT: Morrissey, Dave  
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication  
; FILE REFERENCE: MHB00-845-H (400/029)  
; CURRENT APPLICATION NUMBER: US/09/877,478  
; PRIOR FILING DATE: 2001-12-31  
; PRIOR APPLICATION NUMBER: US 07/882,712  
; PRIOR FILING DATE: 1992-05-14  
; PRIOR APPLICATION NUMBER: US 09/531,025  
; PRIOR FILING DATE: 2000-03-20  
; PRIOR APPLICATION NUMBER: US 09/636,385  
; PRIOR FILING DATE: 2000-08-09  
; PRIOR APPLICATION NUMBER: US 09/696,347  
; PRIOR FILING DATE: 2000-10-24  
; PRIOR APPLICATION NUMBER: US 08/193,627  
; PRIOR FILING DATE: 1994-02-07  
; PRIOR APPLICATION NUMBER: US 08/433,993  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 08/434,504  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 09/436,430  
; PRIOR FILING DATE: 1999-11-08  
; NUMBER OF SEQ ID NOS: 6586

; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 699  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Hepatitis B virus  
US-09-877-478-699

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
ORGANISM: Hepatitis B virus  
US-09-877-478-699

Qy 963 CTGGGATCAGTGTCCC 979  
Db 17 CTGAGATGAGTGTCCC 1

RESULT 226  
US-09-877-478-1441/c  
; Sequence 1441, Application US/09877478  
; Publication No. US20030068301A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Diaper, Kenneth  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Morrissey, Dave  
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication  
; FILE REFERENCE: MHB00-845-H (400/029)  
; CURRENT APPLICATION NUMBER: US/09/877,478  
; PRIOR FILING DATE: 2001-12-31  
; PRIOR APPLICATION NUMBER: US 07/882,712  
; PRIOR FILING DATE: 1992-05-14  
; PRIOR APPLICATION NUMBER: US 09/531,025  
; PRIOR FILING DATE: 2000-03-20  
; PRIOR APPLICATION NUMBER: US 09/636,385  
; PRIOR FILING DATE: 2000-08-09  
; PRIOR APPLICATION NUMBER: US 09/696,347  
; PRIOR FILING DATE: 2000-10-24  
; PRIOR APPLICATION NUMBER: US 08/193,627  
; PRIOR FILING DATE: 1994-02-07  
; PRIOR APPLICATION NUMBER: US 08/433,993  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 08/434,504  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 09/436,430  
; PRIOR FILING DATE: 1999-11-08  
; NUMBER OF SEQ ID NOS: 6586  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1441  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Hepatitis B virus  
US-09-877-478-1441

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
ORGANISM: Hepatitis B virus  
US-09-877-478-1441

Qy 964 TTGGGATCAGTGTCCC 980  
Db 17 TGAGGATGAGTGTCCC 1

RESULT 227  
US-09-930-423-383/c  
; Sequence 383, Application US/09930423  
; Publication No. US20030092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwigen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MHB00,918-A 400/027

;; CURRENT APPLICATION NUMBER: US/09/930,423  
;; CURRENT FILING DATE: 2001-08-15  
;; NUMBER OF SEQ ID NOS: 4553  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO 383  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: Homo Sapiens  
US-09-930-423-383

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 165 CCGGCTGCGCGGTGG 161  
Db 17 CCGGCTGCGCGGTGG 1

RESULT 228  
US-09-930-423-1041/c  
; Sequence 1041, Application US/09930423  
; Publication No. US2003092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBH00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1041  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1041

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2101 CAGCAGCTCAGCCGTGT 2117  
Db 17 CAGCAGCTCAGCTGT 1

RESULT 229  
US-09-930-423-1485/c  
; Sequence 1485, Application US/09930423  
; Publication No. US2003092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBH00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1485  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1485

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 356 GGGAGCCCCCGGTGC 372

Db 17 GCGCAGCCCCCGGTGC 1

RESULT 230  
US-09-930-423-1557/c  
; Sequence 1557, Application US/09930423  
; Publication No. US2003092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBH00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1557  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1557

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 317 CCTGCGCGGACTTGCC 333  
Db 17 CCTGCGCGGACTTGCC 1

RESULT 231  
US-09-930-423-1558/c  
; Sequence 1558, Application US/09930423  
; Publication No. US2003092003A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blact, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease  
; FILE REFERENCE: MBH00,918-A 400/027  
; CURRENT APPLICATION NUMBER: US/09/930,423  
; CURRENT FILING DATE: 2001-08-15  
; NUMBER OF SEQ ID NOS: 4553  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1558  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-09-930-423-1558

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 316 GCGCTGCGGACTTGC 332  
Db 17 GCGCTGCGGACTTGC 1

RESULT 232  
US-09-864-636A-1682  
; Sequence 1682, Application US/09864636A  
; Publication No. US20030104378A1  
; GENERAL INFORMATION:  
; APPLICANT: Third Wave Technologies  
; APPLICANT: Allwail, Hatim  
; APPLICANT: Bartholomay, Christian  
; APPLICANT: Chehak, LuAnne  
; TITLE OF INVENTION: Detection of RNA Sequences  
; FILE REFERENCE: FORS-04944

```
; CURRENT APPLICATION NUMBER: US/09/864,636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1682
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-1682

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1586 GCCCTGGCGAGGTGACG 1602
Db      1 GCCCTGGCGAGAGACG 17

RESULT 233
US-09-827-395A-35/C
; Sequence 35, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 35
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-35

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      779 TGCAGGAGAGGTGTTT 795
Db      17 TGCAGGAAGAGGTGT 1

RESULT 234
US-09-827-395A-36/C
; Sequence 36, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
```

```
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 36
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-36

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      777 CTGCAGGAGAGGTGT 793
Db      17 CTGCAGGAAGAGGTGT 1

RESULT 235
US-09-827-395A-79/C
; Sequence 79, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 79
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-79

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      178 GTGGGCTGAGCCGCTG 194
Db      17 GTGGGCCAGAGCCGTTG 1

RESULT 236
US-09-827-395A-270/C
; Sequence 270, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 270
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-09-827-395A-270

## Query Match

0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTTG 786

Db 17 GCAGGAGAGGTGTCG 1

## RESULT 237

US-09-827-395A-742/C  
; Sequence 742, Application US/09827395A  
; Publication No. US20030113891A1

GENERAL INFORMATION: Pharmaceuticals, Inc.  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowitra  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C  
; FILE REFERENCE: MHB00-878-C (400/017)  
; CURRENT APPLICATION NUMBER: US/09/827,395A  
; CURRENT FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 742  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-827-395A-742

## Query Match

0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 175 GCGGTGGGCTGACCG 191

Db 17 GCGGTGGGCTGACCG 1

## RESULT 238

US-09-740-332-338  
; Sequence 338, Application US/09740332  
; Publication No. US20030125270A1

GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 338  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-338

## Query Match

0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 318 CTTGCCGCGACTTGCT 334

Db 1 CCUGGCGGCGCCUCCU 17

## RESULT 239

US-09-740-332-1694  
; Sequence 1694, Application US/09740332  
; Publication No. US20030125270A1

GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1694  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-1694

## Query Match

0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.5e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 689 TCATGTCATTCTCACC 705

Db 1 UCAGGUCGACGUCAC 17

## RESULT 240

US-09-740-332-3272  
; Sequence 3272, Application US/09740332  
; Publication No. US20030125270A1

GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3272  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-3272

## Query Match

0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 76.5%; Pred. No. 1.5e+02;  
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1948 GCAGTGGCGTGGCCCG 1964

Db 1 GCAGGCGGUGGCGCCG 17

## RESULT 241

US-09-740-332-3439  
; Sequence 3439, Application US/09740332  
; Publication No. US20030125270A1

; GENERAL INFORMATION:

```
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3439

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

OY 1330 CTGTGCACATTGTTCT 1346
Db 1 CUCGUCACAUUUCUUCU 17

RESULT 242
US-09-740-332-4247/c
; Sequence 4247, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4247
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4247

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 59 TCGCATGCGTGGGACA 75
Db 17 TCGCATGCGTGGGATA 1

RESULT 243
US-09-745-237A-383/c
; Sequence 383, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 383
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-383

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 165 CCGGCTCGGCGGTGG 181
Db 17 CCGGCTCGGCGGTGG 1

RESULT 244
US-09-745-237A-1041/c
; Sequence 1041, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1041
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1041

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2101 CAGACCTCAGCTGT 2117
Db 17 CAGACCTCAGCTGT 1

RESULT 245
US-09-745-237A-1485/c
; Sequence 1485, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MEHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1485
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1485

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 356 GGGAGCCCGCGGTCC 372
Db 17 GGCCAGCCCGCGGTCC 1
```

```
RESULT 246
US-09-745-237A-1557/c
; Sequence 1557, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1557

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 317 CCCTGCCGCGACTTGCC 333
Db 17 CCCTGCCGCGACTTGCC 1

RESULT 247
US-09-745-237A-1558/c
; Sequence 1558, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Biact, Larry
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1558
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1558

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 316 GCCCTGCCGCGACTTGC 332
Db 17 GCCCTGCCGCGACTTGC 1

RESULT 248
US-09-817-879-338
; Sequence 338, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 338
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-338

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 318 CCTGCCGCGACTTGCT 334
Db 1 CCTGCCGCGACTTGCT 17

RESULT 249
US-09-817-879-1694
; Sequence 1694, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; APPLICANT: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1694
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1694

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 689 TCATGTCATTCTCACC 705
Db 1 UCACGUCACATGCTCACC 17

RESULT 250
US-09-817-879-3272
; Sequence 3272, Application US/09817879
; Publication No. US2003017311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3272
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3272

Query Match
Best Local Similarity 0.6%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

Best Local Similarity 76.5%; Pred. No. 1.5e+02;  
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1948 GCAGTGGCTTGCCCG 1964

Db 1 GCAGGGGUGUGGCCCG 17

## RESULT 251

US-09-817-879-3439  
; Sequence 3439, Application US/09817879  
; Publication No. US2003017311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; FILE REFERENCE: MBH00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3439  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3439

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. No. 1.5e+02;  
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1330 CTGTGCATTGTCT 1346

Db 1 CUCGUCACAUUUCU 17

## RESULT 252

US-09-817-879-4247/C  
; Sequence 4247, Application US/09817879  
; Publication No. US2003017311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; FILE REFERENCE: MBH00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4247  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-4247

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 59 TCGCATGCTGGGACA 75

Db 17 TCGCATGCTGGGACA 1

## RESULT 253

US-09-864-426A-1682  
; Sequence 1682, Application US/09864426A  
; Publication No. US20040018489A1  
; GENERAL INFORMATION:  
; APPLICANT: Third Wave Technologies  
; APPLICANT: Ma, Wu Po  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Saiser, Michael  
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences  
; FILE REFERENCE: FORS-04946  
; CURRENT APPLICATION NUMBER: US/09/864,426A  
; CURRENT FILING DATE: 2001-05-24  
; NUMBER OF SEQ ID NOS: 2540  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1682  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-864-426A-1682

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1586 GCCCTGGCGAGTGACG 1602

Db 1 GCCCTGGCGAGGACG 17

## RESULT 254

US-10-342-902-699/C  
; Sequence 699, Application US/10342902  
; Publication No. US20040054156A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwisgen, Jim  
; APPLICANT: Morrissey, Dave  
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication  
; FILE REFERENCE: 400/075 (MBH00-845-1)  
; CURRENT APPLICATION NUMBER: US/10/342,902  
; CURRENT FILING DATE: 2003-01-15  
; PRIOR APPLICATION NUMBER: US 09/877,478  
; PRIOR FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 09/531,025  
; PRIOR FILING DATE: 2000-03-20  
; PRIOR APPLICATION NUMBER: US 09/636,385  
; PRIOR FILING DATE: 2000-08-09  
; PRIOR APPLICATION NUMBER: US 09/696,347  
; PRIOR FILING DATE: 2000-10-24  
; PRIOR APPLICATION NUMBER: US 08/193,627  
; PRIOR FILING DATE: 1994-02-07  
; PRIOR APPLICATION NUMBER: US 07/882,712  
; PRIOR FILING DATE: 1992-05-14  
; PRIOR APPLICATION NUMBER: US 09/436,430  
; PRIOR FILING DATE: 1999-11-08  
; NUMBER OF SEQ ID NOS: 6592  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 699  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Hepatitis B virus  
US-10-342-902-699

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 963 CTGGGATCAGTGTC 979

||| ||||| ||||| |||||



```
Db      17 CTGAGATGAGTGTCCCT 1
RESULT 255
US-10-342-902-1441/C
; Sequence 1441, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirona Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1441
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1441

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      964 TGGGATCAGTGTCCCT 980
Db      17 TGAGATGAGTGTCCCT 1

RESULT 256
US-09-927-046-863/C
; Sequence 863, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grube, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloro
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 863
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-863

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      779 TGCAGGAGAGGTGT 795
Db      17 TGCAGGAAGAGGTGTGT 1

RESULT 257
US-10-430-882-35/C
; Sequence 35, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haebertl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-35

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      779 TGCAGGAGAGGTGT 795
Db      17 TGCAGGAAGAGGTGTGT 1

RESULT 258
US-10-430-882-36/C
; Sequence 36, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blact
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowitra
; APPLICANT: Peter Haebertl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
```

; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 36  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-36

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 777 CTTGACGAGAGAGGTGT 793  
Db 17 CGTGCAGAGAGAGGTGT 1

RESULT 259  
US-10-430-882-79/c  
; Sequence 79, Application US/10430882  
; Publication No. US20030203870A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowitra  
; APPLICANT: Peter Haederli  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor  
; FILE REFERENCE: MHB00-878-H (400/112)  
; CURRENT APPLICATION NUMBER: US/10/430,882  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 09/827,395  
; PRIOR FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: PCT/US01/04273  
; PRIOR FILING DATE: 2001-02-09  
; FILE REFERENCE: MHB00-878-H (400/112)  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: PCT/US02/10512  
; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 79  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-79

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 178 GTGGGCTGAGCCGCTG 194  
Db 17 GTGGGCCAGAGCCGCTG 1

RESULT 260  
US-10-430-882-270/c  
; Sequence 270, Application US/10430882  
; Publication No. US20030203870A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowitra  
; APPLICANT: Peter Haederli  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor  
; FILE REFERENCE: MHB00-878-H (400/112)  
; CURRENT APPLICATION NUMBER: US/10/430,882  
; CURRENT FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 09/827,395  
; PRIOR FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: PCT/US01/04273  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: PCT/US02/10512  
; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 270  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-270

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 780 GCAGGAGAGGTGTTG 796  
Db 17 GCAGGAGAGGTGTTG 1

RESULT 261  
US-10-430-882-742/c  
; Sequence 742, Application US/10430882  
; Publication No. US20030203870A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowitra  
; APPLICANT: Peter Haederli  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor  
; FILE REFERENCE: MHB00-878-H (400/112)  
; CURRENT APPLICATION NUMBER: US/10/430,882  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 09/827,395  
; PRIOR FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: PCT/US01/04273  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: PCT/US02/10512  
; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 742  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-742

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 175 GCGGTGGCTGAGCCG 191  
Db 17 GCGGTGGCCAGAGCCG 1

RESULT 262  
US-10-060-830-781/c  
; Sequence 781, Application US/10060830  
; Publication No. US20030032154A1  
; GENERAL INFORMATION:

```

; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LGCT DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-781

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      918 TCTGTGCTGCTGTGCTC 934
Db      17 TCTGTGCTGCTGTGCTC 1

```

```

RESULT 263
US-10-060-756A-519
; Sequence 519, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 519
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-519

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      131 TCTCCTGCTGTGCTCC 147
Db      1 TCTCCTGCTGTGCTCC 17

```

```

RESULT 264
US-10-287-919-1890/c
; Sequence 1890, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 1890
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (115631)..(115647)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 2404
US-10-287-919-1890

```

```

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      570 CCTGTGCTGTGCTGCTC 586
Db      17 CCTGTGCTGTGCTGCTC 1

```

```

RESULT 265
US-10-060-895A-437
; Sequence 437, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN UDP-GALNAc:POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine

```

```
; SEQ ID NO 437
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-437
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1421 CCTCAGAGAAATATTT 1437
Db      1 CCTCAGTGAAAATTT 17
```

```
RESULT 266
US-10-060-895A-481/C
; Sequence 481, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Nguyen, Cung-Thuong
; TITLE OF INVENTION: HUMAN UDP-GALNAc: POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PR0158
; CURRENT APPLICATION NUMBER: US/10/060, 895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 481
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-481
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1488 CTTACACTTGAGGGCC 1504
Db      17 CTTACACTTGAGGGAC 1
```

```
RESULT 267
US-10-060-895A-793
; Sequence 793, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Thuong
; TITLE OF INVENTION: HUMAN UDP-GALNAc: POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 10
```

```
US-10-060-895A-793
```

```
; FILE REFERENCE: PR0158
; CURRENT APPLICATION NUMBER: US/10/060, 895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 793
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-793
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      277 CTGGCGCTTGAGGCC 293
Db      1 CTGGCTCTTGAGGCC 17
```

```
RESULT 268
US-10-163-552-228/C
; Sequence 228, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level.
; FILE REFERENCE: MEB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 228
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-228
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      259 GCAGTGCCAGGGCTG 275
Db      17 GTAGTGACCAAGGCTG 1
```

```
RESULT 269
US-10-163-552-497/C
; Sequence 497, Application US/10163552
; Publication No. US20030105051A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-497

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      269 AGGCGCTGGCTGCT 285
Db      17 AGGCGCTGGCTGCT 1

RESULT 270
US-10-156-306-4969/C
; Sequence 4969, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4969
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4969

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2106 CCTCAGCCTGGTGGAGC 2122
Db      17 CCTCAGCCTGGTGGAGC 1

RESULT 271
US-10-156-306-5001/C
; Sequence 5001, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5001
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5001
```

```
Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      2224 GCTCCTGCAGATGCTCC 2240
Db      17 GCTCCTGCAGATGCTCC 1

RESULT 272
US-10-238-700-2992
; Sequence 2992, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2992
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2992

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY      443 TGCCCGCAGCAGCCCTG 459
Db      1 UGCCAGCAGCUGCCCTG 17

RESULT 273
US-10-238-700-2993
; Sequence 2993, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MHB01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2993
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2993

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY      446 CCGCAGCAGCCCTGTG 462
Db      1 CAGCAGCUGCCCTG 17
```

RESULT 274  
US-10-238-700-3609/c  
; Sequence 3609, Application US/10238700  
; Publication No. US20030153521A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level  
; FILE REFERENCE: 400/057 (MBH01-1158-A)  
; CURRENT FILING DATE: 2002-09-18  
; PRIOR APPLICATION NUMBER: US/10/238,700  
; PRIOR FILING DATE: 2002-05-28  
; PRIOR APPLICATION NUMBER: PCT/US 02/16840  
; PRIOR FILING DATE: 2002-05-28  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; NUMBER OF SEQ ID NOS: 4666  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3609  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-238-700-3609

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2127 TGACCACTCCTCTTC 2143  
Db 17 TGACCACTCTGCTTC 1

RESULT 275  
US-10-238-700-3610/c  
; Sequence 3610, Application US/10238700  
; Publication No. US20030153521A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level  
; FILE REFERENCE: 400/057 (MBH01-1158-A)  
; CURRENT FILING DATE: 2002-09-18  
; PRIOR APPLICATION NUMBER: US/10/238,700  
; PRIOR FILING DATE: 2002-05-28  
; PRIOR APPLICATION NUMBER: PCT/US 02/16840  
; PRIOR FILING DATE: 2002-05-28  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; NUMBER OF SEQ ID NOS: 4666  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3610  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-238-700-3610

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2125 GCTGACCACTCCTT 2141  
Db 17 GCTGACCACTCTGCTT 1

RESULT 276  
US-10-061-201-436  
; Sequence 436, Application US/10061201  
; Publication No. US20030166229A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1  
; FILE REFERENCE: PB0178

;; CURRENT APPLICATION NUMBER: US/10/061,201  
;; PRIOR FILING DATE: 2002-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00666  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00667  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00664  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00663  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00670  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: US 09/864,761  
;; PRIOR FILING DATE: 2001-05-23  
;; PRIOR APPLICATION NUMBER: US 60/328,205  
;; PRIOR FILING DATE: 2001-10-10  
;; NUMBER OF SEQ ID NOS: 4162  
;; SOFTWARE: Aecomica Sequence Listing Engine  
;; SEQ ID NO 436  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-10-061-201-436

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1101 CATTGAGCTCTGCGG 1117  
Db 1 CATTGAGCGCTGCCG 17

RESULT 277  
US-10-061-201-437  
; Sequence 437, Application US/10061201  
; Publication No. US20030166229A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1  
; FILE REFERENCE: PB0178  
;; CURRENT APPLICATION NUMBER: US/10/061,201  
;; CURRENT FILING DATE: 2002-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00666  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00667  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00664  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00663  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00670  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: US 09/864,761  
;; PRIOR FILING DATE: 2001-05-23  
;; PRIOR APPLICATION NUMBER: US 60/328,205  
;; PRIOR FILING DATE: 2001-10-10  
;; NUMBER OF SEQ ID NOS: 4162  
;; SOFTWARE: Aecomica Sequence Listing Engine  
;; SEQ ID NO 437  
;; LENGTH: 17

TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-061-201-437

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1102 TTGAGGCTGTGCGCC 1118  
DB 1 TTGAGGCGCTGCGGCC 17

RESULT 278  
US-10-061-201-438

Sequence 438, Application US/10061201  
Publication No. US20030166229A1  
GENERAL INFORMATION:  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1  
FILE REFERENCE: PB0178  
CURRENT APPLICATION NUMBER: US/10/061,201  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/328,205  
PRIOR FILING DATE: 2001-10-10  
NUMBER OF SEQ ID NOS: 4162  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 438  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-061-201-438

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1103 TTGAGGCTGTGCGCC 1119  
DB 1 TTGAGGCGCTGCGGCC 17

RESULT 279  
US-10-061-201-439

Sequence 439, Application US/10061201  
Publication No. US20030166229A1  
GENERAL INFORMATION:  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1  
FILE REFERENCE: PB0178  
CURRENT APPLICATION NUMBER: US/10/061,201  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/328,205  
PRIOR FILING DATE: 2001-10-10  
NUMBER OF SEQ ID NOS: 4162  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 439  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-061-201-439

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1104 TGAGGCTGTGCGCCA 1120  
DB 1 TGAGGCGCTGCGGCCA 17

RESULT 280  
US-10-061-201-1326

Sequence 1326, Application US/10061201  
Publication No. US20030166229A1  
GENERAL INFORMATION:  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1  
FILE REFERENCE: PB0178  
CURRENT APPLICATION NUMBER: US/10/061,201  
CURRENT FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/328,205  
PRIOR FILING DATE: 2001-10-10  
NUMBER OF SEQ ID NOS: 4162  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 1326  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-061-201-1326

Query Match 0.6%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2092 CTCATCACCCGACACT 2108  
Db 1 CTTATCACCCGACACT 17

## RESULT 281

US-10-084-839-1682  
; Sequence 1682, Application US/10084839  
; Publication No. US20030186238A1  
; GENERAL INFORMATION:  
; APPLICANT: Third Wave Technologies  
; APPLICANT: Allawi, Hatim  
; APPLICANT: Argue, Brad T.  
; APPLICANT: Bartholomay, Christian T.  
; APPLICANT: Chehak, LuAnne  
; APPLICANT: Curtis, Michelle L.  
; APPLICANT: Eis, Peggy S.  
; APPLICANT: Hall, Jeff G.  
; APPLICANT: IP, Hon S.  
; APPLICANT: Ji, Lin  
; APPLICANT: Kaiser, Michael  
; APPLICANT: Kwiatkowski, Jr., Robert W.  
; APPLICANT: Lukowiak, Andrew A.  
; APPLICANT: Lyamichiev, Victor  
; APPLICANT: Lymaicheva, Natalie E.  
; APPLICANT: Ma, WuPo  
; APPLICANT: Neri, Bruce P.  
; APPLICANT: Olson, Sarah M.  
; APPLICANT: Olson-Munoz, Marilyn C.  
; APPLICANT: Schaefer, James J.  
; APPLICANT: Skrzypczynski, Zbigniew  
; APPLICANT: Takova, Tsetska Y.  
; APPLICANT: Thompson, Lisa C.  
; APPLICANT: Vedvik, Kevin L.  
; TITLE OF INVENTION: RNA Detection Assays  
; FILE REFERENCE: FORS-06666  
; CURRENT APPLICATION NUMBER: US/10/084, 839  
; CURRENT FILING DATE: 2002-02-26  
; NUMBER OF SEQ ID NOS: 4004  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1682  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-084-839-1682

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1586 GCCCTGGCGAGCTACG 1602  
Db 1 GCCCTGGCGAGGACG 17

## RESULT 282

US-10-084-839-3475/C  
; Sequence 3475, Application US/10084839  
; Publication No. US20030186238A1  
; GENERAL INFORMATION:  
; APPLICANT: Third Wave Technologies  
; APPLICANT: Allawi, Hatim  
; APPLICANT: Argue, Brad T.  
; APPLICANT: Bartholomay, Christian T.  
; APPLICANT: Chehak, LuAnne  
; APPLICANT: Curtis, Michelle L.  
; APPLICANT: Eis, Peggy S.  
; APPLICANT: Hall, Jeff G.

; APPLICANT: IP, Hon S.

; APPLICANT: Ji, Lin

; APPLICANT: Kaiser, Michael

; APPLICANT: Kwiatkowski, Jr., Robert W.

; APPLICANT: Lukowiak, Andrew A.

; APPLICANT: Lyamichiev, Victor

; APPLICANT: Lymaicheva, Natalie E.

; APPLICANT: Ma, WuPo

; APPLICANT: Neri, Bruce P.

; APPLICANT: Olson, Sarah M.

; APPLICANT: Olson-Munoz, Marilyn C.

; APPLICANT: Schaefer, James J.

; APPLICANT: Skrzypczynski, Zbigniew

; APPLICANT: Takova, Tsetska Y.

; APPLICANT: Thompson, Lisa C.

; APPLICANT: Vedvik, Kevin L.

; TITLE OF INVENTION: RNA Detection Assays

; FILE REFERENCE: FORS-06666

; CURRENT APPLICATION NUMBER: US/10/084, 839

; CURRENT FILING DATE: 2002-02-26

; NUMBER OF SEQ ID NOS: 4004

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 3475

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-084-839-3475

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 756 CATGGCCACGTGACA 772  
Db 17 CATGGCCACGTGACA 1

## RESULT 283

US-10-230-006-820/C  
; Sequence 820, Application US/10230006  
; Publication No. US20030191077A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: McSnaugh, Jim  
; APPLICANT: Fosnaugh, Kathy  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT  
; FILE REFERENCE: 400/056 (MEHBO1-1110)  
; CURRENT APPLICATION NUMBER: US/10/230, 006  
; CURRENT FILING DATE: 2002-11-18  
; PRIOR APPLICATION NUMBER: US 60/315,315  
; PRIOR FILING DATE: 2001-08-28  
; NUMBER OF SEQ ID NOS: 2678  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 820  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-230-006-820

Query Match 0.6%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 632 TCACGACTGATTCCTA 648  
Db 17 TCACGACTGATTCCTA 1

## RESULT 284

US-10-297-068-1041  
; Sequence 1041, Application US/10297068



```
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; FILE REFERENCE: 13140B1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1041
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1041

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      490 GCGGCTCAGCGCGCTC 506
Db      1 GCGCGACACAGCGCGCTC 17

RESULT 285
US-10-297-068-1259
; Sequence 1259, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 13140B1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1259
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1259

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      370 TCCGCGATGACACACAG 386
Db      1 TCCGCGGATACACACAG 17

RESULT 286
US-10-138-674-4198
; Sequence 4198, Application US/10138674
; Publication No. US20040077565A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 2082
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4198

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY      977 CCTCACCATTGTCACC 993
Db      1 GCCTCACCAUGUCACG 17

RESULT 287
US-10-138-674-7439
; Sequence 7439, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 2082
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7439

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY      1992 TATCCTGATGATGCCA 2008
Db      1 UAUCUGAUGCUGAC 17

RESULT 288
US-10-138-674-8640/c
; Sequence 8640, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
```

```
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 8640
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8640

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1004 TGCCCTGCTTTTCCTT 1020
Db      17 TGGCTCTGCTTCTCTT 1

RESULT 289
US-10-287-949A-4198
; Sequence 4198, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 4198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4198

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Cy      977 CCCACACCATGCTACC 993
Db      1 CGCUCACCAUGGUCAGC 17

RESULT 290
US-10-287-949A-7439
; Sequence 7439, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 7439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7439
```

```
Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Cy      1992 TATCCTGGATGATGCCA 2008
Db      1 UAUCCUGAUGCUGACA 17

RESULT 291
US-10-287-949A-8640/C
; Sequence 8640, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Payco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 8640
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8640

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy      1004 TGCCCTGCTTTTCCTT 1020
Db      17 TGGCTCTGCTTCTCTT 1

RESULT 292
US-10-712-672-830
; Sequence 830, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 830
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-830

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

QY 300 TGGCGCAGCTGGCTTG 316  
:|||||:|||||  
Db 1 UGCGGAGACUGCGCTUG 17

RESULT 293  
US-09-320-337-57  
Sequence 57, Application US/09320337  
Patent No. US20010016352A1  
GENERAL INFORMATION:  
APPLICANT: Bohinski, Robert J.,  
APPLICANT: Whitsett, Jeffrey A.  
TITLE OF INVENTION: Nucleic Acid Sequences Controlling  
TITLE OF INVENTION: Lung Cell - Specific Gene Expression  
NUMBER OF SEQUENCES: 76  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein  
STREET: 6 Becker Farm Road  
CITY: Roseland  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 07068  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch diskette  
COMPUTER: IBM P160  
OPERATING SYSTEM: WINDOWS 95  
SOFTWARE: MS WORD 97  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/320,337  
FILING DATE: 26-MAY-1999  
CLASSIFICATION:  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/442,809  
FILING DATE: 17-MAY-1995  
APPLICATION NUMBER: 08/245,356  
FILING DATE: 18-MAY-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Olstein, Elliot M.  
REGISTRATION NUMBER: 24,025  
REFERENCE/DOCKET NUMBER: 271010-447  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 973-994-1700  
TELEFAX: 973-994-1744  
INFORMATION FOR SEQ ID NO: 157:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: oligonucleotide  
US-09-320-337-57

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1416 GGGCTCTCAGAGAAA 1432  
:|||||:|||||  
Db 1 GGGCTCTCAGAGCAA 17

RESULT 294  
US-09-320-337-59  
Sequence 59, Application US/09320337  
Patent No. US20010016352A1  
GENERAL INFORMATION:  
APPLICANT: Bohinski, Robert J.,  
APPLICANT: Whitsett, Jeffrey A.  
TITLE OF INVENTION: Nucleic Acid Sequences Controlling  
TITLE OF INVENTION: Lung Cell - Specific Gene Expression  
NUMBER OF SEQUENCES: 76  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

STREET: 6 Becker Farm Road  
CITY: Roseland  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 07068  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch diskette  
COMPUTER: IBM P160  
OPERATING SYSTEM: WINDOWS 95  
SOFTWARE: MS WORD 97  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/320,337  
FILING DATE: 26-MAY-1999  
CLASSIFICATION:  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/442,809  
FILING DATE: 17-MAY-1995  
APPLICATION NUMBER: 08/245,356  
FILING DATE: 18-MAY-1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Olstein, Elliot M.  
REGISTRATION NUMBER: 24,025  
REFERENCE/DOCKET NUMBER: 271010-447  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 973-994-1700  
TELEFAX: 973-994-1744  
INFORMATION FOR SEQ ID NO: 59:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 bases  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: oligonucleotide  
US-09-320-337-59

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1416 GGGCTCTCAGAGAAA 1432  
:|||||:|||||  
Db 1 GGGCTCTCAGAGCAA 17

RESULT 295  
US-09-925-911-7/C  
Sequence 7, Application US/09925911  
Patent No. US20030049837A1  
GENERAL INFORMATION:  
APPLICANT: Weiss et al.  
TITLE OF INVENTION: In Vitro and In Vivo Proliferation and Use of  
TITLE OF INVENTION: Multipotent Neural Stem Cells and Their Progeny  
FILE REFERENCE: 17810-705 (CTI-N5 DIV11CON)  
CURRENT APPLICATION NUMBER: US/09/925,911  
CURRENT FILING DATE: 2001-08-09  
PRIORITY APPLICATION NUMBER: 08/484,203  
PRIORITY FILING DATE: 2001-06-07  
PRIORITY APPLICATION NUMBER: 08/270,412  
PRIORITY FILING DATE: 1994-07-05  
PRIORITY APPLICATION NUMBER: 07/726,812  
PRIORITY FILING DATE: 1991-07-08  
PRIORITY APPLICATION NUMBER: 08/385,404  
PRIORITY FILING DATE: 1995-02-07  
PRIORITY APPLICATION NUMBER: 07/961,813  
PRIORITY FILING DATE: 1992-10-16  
PRIORITY APPLICATION NUMBER: 08/359,945  
PRIORITY FILING DATE: 1994-12-20  
PRIORITY APPLICATION NUMBER: 08/221,655  
PRIORITY FILING DATE: 1994-04-01  
PRIORITY APPLICATION NUMBER: 07/967,622  
PRIORITY FILING DATE: 1992-10-28  
PRIORITY APPLICATION NUMBER: 08/376,062  
PRIORITY FILING DATE: 1995-01-20

```
; PRIOR APPLICATION NUMBER: 08/010,829
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: 08/149,508
; PRIOR FILING DATE: 1993-11-09
; PRIOR APPLICATION NUMBER: 08/311,099
; PRIOR FILING DATE: 1994-09-23
; PRIOR APPLICATION NUMBER: 08/338,730
; PRIOR FILING DATE: 1994-11-14
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:chemically
; US-09-925-911-7

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGCGCTGG 1609
Db 18 CGAGTGATGCGCTGG 2

RESULT 296
US-09-925-911-8
; Sequence 8, Application US/09925911
; Publication No. US20030049837A1
; GENERAL INFORMATION:
; APPLICANT: Welles et al.
; TITLE OF INVENTION: In Vitro and In Vivo Proliferation and Use of
; FILE REFERENCE: 17810-705 (CTI-N5 DIVILCON)
; CURRENT APPLICATION NUMBER: US/09/925,911
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 08/484,203
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: 08/270,412
; PRIOR FILING DATE: 1994-07-05
; PRIOR APPLICATION NUMBER: 07/726,812
; PRIOR FILING DATE: 1991-07-08
; PRIOR APPLICATION NUMBER: 08/385,404
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 07/961,813
; PRIOR FILING DATE: 1992-10-16
; PRIOR APPLICATION NUMBER: 08/359,945
; PRIOR FILING DATE: 1994-12-20
; PRIOR APPLICATION NUMBER: 08/221,655
; PRIOR FILING DATE: 1994-04-01
; PRIOR APPLICATION NUMBER: 07/967,622
; PRIOR FILING DATE: 1992-10-28
; PRIOR APPLICATION NUMBER: 08/376,062
; PRIOR FILING DATE: 1995-01-20
; PRIOR APPLICATION NUMBER: 08/010,829
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: 08/149,508
; PRIOR FILING DATE: 1993-11-09
; PRIOR APPLICATION NUMBER: 08/311,099
; PRIOR FILING DATE: 1994-09-23
; PRIOR APPLICATION NUMBER: 08/338,730
; PRIOR FILING DATE: 1994-11-14
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:chemically
```

```
; OTHER INFORMATION: synthesized
; US-09-925-911-8

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1593 CGAGTGACGCGCTGG 1609
Db 1 CGAGTGATGCGCTGG 17

RESULT 297
US-09-882-945A-81/c
; Sequence 81, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: PORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patentn version 3.0
; SEQ ID NO 81
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-882-945A-81

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 483 GGGGCCCGCGGCTCAG 499
Db 17 GGGGCCCGCGGCTCTGG 1

RESULT 298
US-09-306-333A-17/c
; Sequence 17, Application US/09306333A
; Publication No. US20030152918A1
; GENERAL INFORMATION:
; APPLICANT: Academy of Applied Science
; TITLE OF INVENTION: BRCA1 and hMLH1 Gene Primer Sequences and Method for
; FILE REFERENCE: BRCA1
; CURRENT APPLICATION NUMBER: US/09/306,333A
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/IB00/01607
; PRIOR FILING DATE: 2000-11-06
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: Patentn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-306-333A-17

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1166 AGTTTGGGAAAGCTG 1182
Db 17 ACTTTAAGGAAAGCTG 1
```

```
RESULT 299
US-09-838-028-9
; Sequence 9, Application US/09838028
; Publication No. US20030175857A1
; GENERAL INFORMATION:
; APPLICANT: Lind, Peter
; APPLICANT: Berthold, Malin
; TITLE OF INVENTION: No. US20030175857A1e1 G Protein-Coupled Receptor
; FILE REFERENCE: 00125052
; CURRENT APPLICATION NUMBER: US/09/838,028
; CURRENT FILING DATE: 2001-04-19
; PRIOR APPLICATION NUMBER: 60/198,600
; PRIOR FILING DATE: 2000-04-19
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patent version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Primer
US-09-838-028-9

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      557 GCGCTGCTGTTCTG 573
Db      1 GCGCTGCTGTTCTG 17

RESULT 300
US-10-308-264-685/c
; Sequence 685, Application US/10308264
; Publication No. US20040029133A1
; GENERAL INFORMATION:
; APPLICANT: Hermsstad, Corinna
; TITLE OF INVENTION: MITOCHONDRIAL DNA POLYMORPHISM
; FILE REFERENCE: 660088.461
; CURRENT APPLICATION NUMBER: US/10/308,264
; CURRENT FILING DATE: 2002-11-25
; NUMBER OF SEQ ID NOS: 697
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 685
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-308-264-685

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      658 TCAGCCGATACCTTAC 674
Db      18 TCATCCGCTACTTAC 2

RESULT 301
US-09-945-353-1
; Sequence 1, Application US/09945353
; Publication No. US20020142982A1
; GENERAL INFORMATION:
; APPLICANT: University of Connecticut Health Center
; APPLICANT: Hla, Timothy
; APPLICANT: Lee, Meng-Jer
; APPLICANT: Clafey, Kevin P
```

```
; APPLICANT: Ancellin, Nicholas
; APPLICANT: Thangada, Shobha
; TITLE OF INVENTION: Method for regulating Angiogenesis
; FILE REFERENCE: UCT-0012
; CURRENT APPLICATION NUMBER: US/09/945,353
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/152,266
; PRIOR FILING DATE: 1999-09-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patent version 3.2
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; APPLICANT: M.J. Lee, S. Thangada, K.P. Clafey, N. Ancellin, C.H. Liu, M.
; APPLICANT: Kluk, W. Volip, R. Sha-fi and T. Hla
; TITLE: Vacuolar endothelial cell adherens junction assembly and
; TITLE: morphogenesis induced by sphingosine-1-phosphate-
; JOURNAL: Cell
; VOLUME: 99
; ISSUE: 3
; PAGES: 301-312
; DATE: 1999-10-29
; RELEVANT RESIDUES: (1)..(18)
US-09-945-353-1

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCTGTGGGACCA 1618
Db      1 GACGCTGTGGGACCA 17

RESULT 302
US-09-945-353-3/c
; Sequence 3, Application US/09945353
; Publication No. US20020142982A1
; GENERAL INFORMATION:
; APPLICANT: University of Connecticut Health Center
; APPLICANT: Hla, Timothy
; APPLICANT: Lee, Meng-Jer
; APPLICANT: Clafey, Kevin P
; APPLICANT: Ancellin, Nicholas
; APPLICANT: Thangada, Shobha
; TITLE OF INVENTION: Method for regulating Angiogenesis
; FILE REFERENCE: UCT-0012
; CURRENT APPLICATION NUMBER: US/09/945,353
; CURRENT FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/152,266
; PRIOR FILING DATE: 1999-09-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patent version 3.2
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; APPLICANT: Homo sapiens
US-09-945-353-3

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCTGTGGGACCA 1618
Db      18 GACGCTGTGGGACCA 2

RESULT 303
US-10-156-995-131/c
; Sequence 131, Application US/10156995
```

```
; Publication No. US20030211486A1
; GENERAL INFORMATION:
; APPLICANT: DNA Print Genomics, Inc.
; APPLICANT: FRUDAKIS, Tony N.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING POLYMORPHISMS ASSOCIATED W
; TITLE OF INVENTION: PIGMENTATION
; FILE REFERENCE: DNA1140-7
; CURRENT APPLICATION NUMBER: US/10/156,995
; CURRENT FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: US 60/346,303
; PRIOR FILING DATE: 2002-01-02
; PRIOR APPLICATION NUMBER: US 60/334,674
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/344,418
; PRIOR FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: US 60/323,662
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/310,781
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/293,560
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 131
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-156-995-131

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1077 TCTGGCAAGTCCAGCC 1093
          |||||
Db       17 TCCGCAAGTCCAGGC 1

RESULT 304
US-10-156-995-132/c
; Sequence 132, Application US/10156995
; Publication No. US20030211486A1
; GENERAL INFORMATION:
; APPLICANT: DNA Print Genomics, Inc.
; APPLICANT: FRUDAKIS, Tony N.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING POLYMORPHISMS ASSOCIATED W
; FILE REFERENCE: DNA1140-7
; CURRENT APPLICATION NUMBER: US/10/156,995
; CURRENT FILING DATE: 2002-05-28
; PRIOR APPLICATION NUMBER: US 60/346,303
; PRIOR FILING DATE: 2002-01-02
; PRIOR APPLICATION NUMBER: US 60/334,674
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/344,418
; PRIOR FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: US 60/323,662
; PRIOR FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/310,781
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/300,187
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: US 60/293,560
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 132
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-156-995-132

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1077 TCTGGCAAGTCCAGCC 1093
          |||||
Db       17 TCCGCAAGTCCAGGC 1

RESULT 305
US-10-037-616-10
; Sequence 10, Application US/10037616
; Publication No. US20020123148A1
; GENERAL INFORMATION:
; APPLICANT: English, Denis
; APPLICANT: Kovacs, Richard J.
; APPLICANT: Rizzo, Maria T.
; APPLICANT: Silva, Daniel T.
; TITLE OF INVENTION: Sphingolipid Compositions and Methods for Their Therapeutic Use
; FILE REFERENCE: 7042-119
; CURRENT APPLICATION NUMBER: US/10/037,616
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: US 60/243,887
; PRIOR FILING DATE: 2000-10-27
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-037-616-10

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1602 GCGCGTGTGGACCA 1618
          |||||
Db       1 GACGCTGTGGCCCA 17

RESULT 306
US-10-199-830-7/c
; Sequence 7, Application US/10199830
; Publication No. US20030109008A1
; GENERAL INFORMATION:
; APPLICANT: Welles, Samuel
; APPLICANT: Reynolds, Brent
; APPLICANT: Hamman, Joseph P
; APPLICANT: Baetge, E. B.
; TITLE OF INVENTION: Methods of Making cDNA Libraries
; FILE REFERENCE: 17810-705 Div2CON2
; CURRENT APPLICATION NUMBER: US/10/199,830
; CURRENT FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: 08/486,313
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/270,412
; PRIOR FILING DATE: 1994-07-05
; PRIOR APPLICATION NUMBER: 07/726,812
; PRIOR FILING DATE: 1991-07-08
; PRIOR APPLICATION NUMBER: 08/385,404
; PRIOR FILING DATE: 1995-02-07
; PRIOR APPLICATION NUMBER: 07/961,813
; PRIOR FILING DATE: 1992-10-16
; PRIOR APPLICATION NUMBER: 08/359,945
; PRIOR FILING DATE: 1994-12-20
```

PRIOR APPLICATION NUMBER: 08/221,655  
PRIOR FILING DATE: 1994-04-01  
PRIOR APPLICATION NUMBER: 07/967,622  
PRIOR FILING DATE: 1992-10-28  
PRIOR APPLICATION NUMBER: 08/376,062  
PRIOR FILING DATE: 1995-01-20  
PRIOR APPLICATION NUMBER: 08/010,829  
PRIOR FILING DATE: 1993-01-29  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 8  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 7  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: FGF sense  
US-10-199-830-7

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGGTGACGCGCTGG 1609  
Db 18 CGAGGTGATGCGCTGG 2

RESULT 307  
US-10-199-830-8  
Sequence 8, Application US/10199830  
Publication No. US20030109008A1  
GENERAL INFORMATION:  
APPLICANT: Weis, Samuel  
APPLICANT: Reynolds, Brent  
APPLICANT: Hamman, Joseph P  
APPLICANT: Baetge, E. E  
TITLE OF INVENTION: Methods of Making cDNA Libraries  
FILE REFERENCE: 17810-705 DIV12CON2  
CURRENT APPLICATION NUMBER: US/10/199,830  
PRIOR FILING DATE: 2002-07-19  
PRIOR APPLICATION NUMBER: 08/486,313  
PRIOR FILING DATE: 1995-06-07  
PRIOR APPLICATION NUMBER: 08/270,412  
PRIOR FILING DATE: 1994-07-05  
PRIOR APPLICATION NUMBER: 07/726,812  
PRIOR FILING DATE: 1991-07-08  
PRIOR APPLICATION NUMBER: 08/385,404  
PRIOR FILING DATE: 1995-02-07  
PRIOR APPLICATION NUMBER: 07/961,813  
PRIOR FILING DATE: 1992-10-16  
PRIOR APPLICATION NUMBER: 08/359,945  
PRIOR FILING DATE: 1994-12-20  
PRIOR APPLICATION NUMBER: 08/221,655  
PRIOR FILING DATE: 1994-04-01  
PRIOR APPLICATION NUMBER: 07/967,622  
PRIOR FILING DATE: 1992-10-28  
PRIOR APPLICATION NUMBER: 08/376,062  
PRIOR FILING DATE: 1995-01-20  
PRIOR APPLICATION NUMBER: 08/010,829  
PRIOR FILING DATE: 1993-01-29  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 8  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 8  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: FGF anti-sense  
US-10-199-830-8

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1593 CGAGGTGACGCGCTGG 1609  
Db 1 CGAGGTGATGCGCTGG 17

RESULT 308  
US-10-216-122-135  
Sequence 135, Application US/10216122  
Publication No. US20030121063A1  
GENERAL INFORMATION:  
APPLICANT: Kazazian, Haig H.  
APPLICANT: Oesterlag, Eric  
APPLICANT: Debernardinis, Ralph  
TITLE OF INVENTION: COMPOSITIONS AND METHODS OF USE OF MAMMALIAN RETROTRANSPOSONS  
FILE REFERENCE: 053893-5006-03  
CURRENT APPLICATION NUMBER: US/10/216,122  
PRIOR FILING DATE: 2002-08-09  
PRIOR APPLICATION NUMBER: US 09/653,812  
PRIOR FILING DATE: 2000-09-01  
PRIOR APPLICATION NUMBER: US 08/847,844  
PRIOR FILING DATE: 1997-04-28  
PRIOR APPLICATION NUMBER: US 08/749,805  
PRIOR FILING DATE: 1996-11-15  
PRIOR APPLICATION NUMBER: US 60/006,831  
PRIOR FILING DATE: 1995-11-16  
NUMBER OF SEQ ID NOS: 154  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 135  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-216-122-135

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1817 AGCACTATGAGGAA 1833  
Db 2 AGCACTATGATGAA 18

RESULT 309  
US-10-168-771-84/C  
Sequence 84, Application US/10168771  
Publication No. US20030148974A1  
GENERAL INFORMATION:  
APPLICANT: Brett P. Monia  
APPLICANT: Lex M. Cowser  
APPLICANT: Richard A. Roth  
APPLICANT: Isis Pharmaceuticals, Inc.  
TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION  
FILE REFERENCE: RTSP-0322  
CURRENT APPLICATION NUMBER: US/10/168,771  
PRIOR FILING DATE: 2002-06-21  
PRIOR APPLICATION NUMBER: 09/474,922  
PRIOR FILING DATE: 1999-12-29  
NUMBER OF SEQ ID NOS: 89  
SEQ ID NO 84  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-168-771-84

Query Match 0.6%; Score 13.8; DB 1; Length 18;

```
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1867 AGTTTCATCTGACT 1883
    ||||| |||||
Db 18 AGTTTCCTCTGAGCT 2

RESULT 310
US-10-169-983-27
; Sequence 27, Application US/10169983
; Publication No. US20030158250A1
; GENERAL INFORMATION:
; APPLICANT: Takara Shuzo Co., Ltd.
; TITLE OF INVENTION: Therapeutic agents
; FILE REFERENCE: 01-011-PCT
; CURRENT APPLICATION NUMBER: US/10/169,983
; CURRENT FILING DATE: 2002-07-14
; PRIOR APPLICATION NUMBER: JP 2000-4989
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: JP 2000-303711
; PRIOR FILING DATE: 2000-10-03
; NUMBER OF SEQ ID NOS: 61
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Designed primer based on nucleotide sequence of
; OTHER INFORMATION: human macrophage inflammatory protein-2-alpha mRNA.
US-10-169-983-27

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 564 GCTGTCCTGCTGCTCG 580
    ||||| |||||
Db 2 GCTGTCCTGCTGCTCG 18

RESULT 311
US-10-302-279-51/c
; Sequence 0, Application US/10302279
; Publication No. US20030171566A1
; GENERAL INFORMATION:
; APPLICANT: Dean, Michael Carlton
; Hahn, Heidi Eve
; Wickling, Carol
; Christiansen, Jeffrey
; Zaphiropoulos, Peter G.
; Galiani, Mae R.
; Shanley, Susan Mary
; Chidambaram, Abhirami
; Vorechovsky, Igor
; Holmberg-Lindstrom, Erika
; TITLE OF INVENTION: A Basal Cell Carcinoma Tumor Suppressor Gene
; NUMBER OF INVENTIONS: 84
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/302,279
; FILING DATE: 22-No. US20030171566A1-2002
```

```
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/857,636
; FILING DATE: 16-MAY-1997
; APPLICATION NUMBER: US 60/017,906
; FILING DATE: 17-MAY-1996
; APPLICATION NUMBER: AU P00011
; FILING DATE: 21-MAY-1996
; APPLICATION NUMBER: AU P00363
; FILING DATE: 07-JUN-1996
; APPLICATION NUMBER: US 60/019,765
; FILING DATE: 14-JUN-1996
ATTORNEY/AGENT INFORMATION:
; NAME: Hyman, Laurence J.
; REGISTRATION NUMBER: 35, 551
; REFERENCE/DOCKET NUMBER: 015280-278200US
TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: /note= "PTCR25 primer"
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 51:
US-10-302-279-51

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1461 CTGCCACCAAGTGTC 1477
    ||||| |||||
Db 17 CTGCCACCAAGTGATC 1

RESULT 312
US-10-168-445-205
; Sequence 205, Application US/10168445
; Publication No. US20030177518A1
; GENERAL INFORMATION:
; APPLICANT: Osbourn, Anne E
; APPLICANT: Haralampidis, Kosmas
; APPLICANT: Bryan, Gregory T
; TITLE OF INVENTION: Plant Gene
; FILE REFERENCE: 0380-P02892US0
; CURRENT APPLICATION NUMBER: US/10/168,445
; CURRENT FILING DATE: 2002-10-30
; PRIOR APPLICATION NUMBER: PCT/GB00/04908
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: GB 9930394.3
; PRIOR FILING DATE: 1999-12-22
; PRIOR APPLICATION NUMBER: GB 0020217.6
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 219
; SOFTWARE: Patent version 3.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
US-10-168-445-205

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```



QY 941 TATGCTCTGGGATC 957  
|||  
Db 1 TATGGCTTGGGGAC 17  
|||

## RESULT 313

US-10-349-143-8459  
; Sequence 8459, Application US/10349143  
; Publication No. US2004000584A1  
; GENERAL INFORMATION:  
; APPLICANT: Cohen, Daniel  
; APPLICANT: Blumenfeld, Marta  
; APPLICANT: Chumakov, Ilya  
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...  
; FILE REFERENCE: GENSET.020CPI  
; CURRENT APPLICATION NUMBER: US/10/349,143  
; CURRENT FILING DATE: 2003-01-21  
; PRIOR APPLICATION NUMBER: US/09/422,978  
; PRIOR FILING DATE: 1999-10-20  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850  
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732  
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23  
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614  
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21  
; NUMBER OF SEQ ID NOS: 11796  
; SEQ ID NO 8459  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
; FEATURE:  
; NAME/KEY: primer\_bind  
; LOCATION: 1..18  
; OTHER INFORMATION: downstream amplification primer 99-15599 for SEQ 594, in compleme  
US-10-349-143-8459

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 77 TACTGCTACTTCTGCCC 93  
|||  
Db 2 TACTGCTACTCTCTCC 18  
|||

## RESULT 314

US-10-703-864-25/C  
; Sequence 25, Application US/10703864  
; Publication No. US20040077580A1  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; APPLICANT: Lex M. Cowsett  
; APPLICANT: Susan Murray  
; APPLICANT: Madeline M. Butler  
; APPLICANT: Nicholas M. Dean  
; TITLE OF INVENTION: ANTISENSE MODULATION OF PI3K P85 EXPRESSION  
; FILE REFERENCE: ISIS0057-102 (TSPH-0519)  
; CURRENT APPLICATION NUMBER: US/10/703,864  
; CURRENT FILING DATE: 2003-11-10  
; PRIOR APPLICATION NUMBER: US/09/715,993  
; PRIOR FILING DATE: 2000-11-20  
; NUMBER OF SEQ ID NOS: 73  
; SEQ ID NO 25  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-703-864-25

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1772 TTGGAGAGAGCTTCAA 1788  
|||  
Db 17 TTGGAGAGAGCTTCAA 1  
|||

## RESULT 315

US-10-628-109-64/C  
; Sequence 64, Application US/10628109  
; Publication No. US20040101886A1  
; GENERAL INFORMATION:  
; APPLICANT: Bowdlen, Katherine S.  
; APPLICANT: Frederickson, Shana  
; APPLICANT: Lin, Ying-Chi  
; APPLICANT: McWhirter, John  
; APPLICANT: Matuyama, Yoshiaki  
; TITLE OF INVENTION: NESTED OLIGONUCLEOTIDES CONTAINING A HAIRPIN FOR NUCLEIC ACID  
; FILE REFERENCE: 1087-35 DIV  
; CURRENT APPLICATION NUMBER: US/10/628,109  
; CURRENT FILING DATE: 2003-07-28  
; PRIOR APPLICATION NUMBER: US 60/254,669  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 60/323,400  
; PRIOR FILING DATE: 2001-09-19  
; PRIOR APPLICATION NUMBER: US 10/014,012  
; PRIOR FILING DATE: 2001-12-10  
; NUMBER OF SEQ ID NOS: 231  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 64  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; OTHER INFORMATION: primer  
US-10-628-109-64

Query Match 0.6%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1757 AAGAGCCACAGGTATT 1773  
|||  
Db 17 AAGAGCCACAGGTATT 1  
|||

## RESULT 316

US-10-160-358-67  
; Sequence 67, Application US/10160358  
; Publication No. US20030198969A1  
; GENERAL INFORMATION:  
; APPLICANT: Genesbee Pharmaceuticals, Inc.  
; APPLICANT: Bieganski, Karyn  
; APPLICANT: Cappola, Gina-Marie  
; APPLICANT: Koshy, Beena  
; APPLICANT: Monice, Glen  
; TITLE OF INVENTION: HAPLOTYPES OF THE TACR2 GENE  
; FILE REFERENCE: TACR2\_MNH-0225US  
; CURRENT APPLICATION NUMBER: US/10/160,358  
; CURRENT FILING DATE: 2002-05-30  
; PRIOR APPLICATION NUMBER: PCT/US01/47394  
; PRIOR FILING DATE: 2001-11-09  
; PRIOR APPLICATION NUMBER: 60/247,649  
; PRIOR FILING DATE: 2000-11-09  
; NUMBER OF SEQ ID NOS: 139  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 67  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-160-358-67

Query Match 0.6%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.5e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Db 62 CATGCTGGGACA 75  
1 CATGCTGGGACR 14

RESULT 317  
US-10-035-833A-6/c  
; Sequence 6, Application US/10035833A  
; Publication No. US20040072156A1  
; GENERAL INFORMATION:  
; APPLICANT: Nakamura, Yuho  
; APPLICANT: Sekine, Akihiro  
; APPLICANT: Iida, Aritoshi  
; APPLICANT: Saito, Osamu  
; TITLE OF INVENTION: Detection of Genetic Polymorphisms  
; FILE REFERENCE: FORS-06904  
; CURRENT APPLICATION NUMBER: US/10/035, 833A  
; CURRENT FILING DATE: 2001-12-27  
; NUMBER OF SEQ ID NOS: 7669  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 6  
; LENGTH: 41  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-035-833A-6

Query Match 0.6%; Score 13.6; DB 1; Length 41;  
Best Local Similarity 67.9%; Pred. No. 2.7e+02;  
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGACGCTGACCA 2132  
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 318  
US-10-035-833A-5176/c  
; Sequence 5176, Application US/10035833A  
; Publication No. US20040072156A1  
; GENERAL INFORMATION:  
; APPLICANT: Nakamura, Yuho  
; APPLICANT: Sekine, Akihiro  
; APPLICANT: Iida, Aritoshi  
; APPLICANT: Saito, Osamu  
; TITLE OF INVENTION: Detection of Genetic Polymorphisms  
; FILE REFERENCE: FORS-06904  
; CURRENT APPLICATION NUMBER: US/10/035, 833A  
; CURRENT FILING DATE: 2001-12-27  
; NUMBER OF SEQ ID NOS: 7669  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5176  
; LENGTH: 41  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-035-833A-5176

Query Match 0.6%; Score 13.6; DB 1; Length 41;  
Best Local Similarity 67.9%; Pred. No. 2.7e+02;  
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGACGCTGACCA 2132  
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 319  
US-10-035-833A-7638/c  
; Sequence 7638, Application US/10035833A  
; Publication No. US20040072156A1  
; GENERAL INFORMATION:

; APPLICANT: Nakamura, Yuho  
; APPLICANT: Sekine, Akihiro  
; APPLICANT: Iida, Aritoshi  
; APPLICANT: Saito, Osamu  
; TITLE OF INVENTION: Detection of Genetic Polymorphisms  
; FILE REFERENCE: FORS-06904  
; CURRENT APPLICATION NUMBER: US/10/035, 833A  
; CURRENT FILING DATE: 2001-12-27  
; NUMBER OF SEQ ID NOS: 7669  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7638  
; LENGTH: 41  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-035-833A-7638

Query Match 0.6%; Score 13.6; DB 1; Length 41;  
Best Local Similarity 67.9%; Pred. No. 2.7e+02;  
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 2105 ACCTCAGCTGTGTGAGACGCTGACCA 2132  
Db 37 AGCAGAGCAGGCTGATCAGGCTGACCA 10

RESULT 320  
US-09-504-231A-714  
; Sequence 714, Application US/09504231A  
; Patent No. US20020013458A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence  
; APPLICANT: McSwiggen, James  
; APPLICANT: Roberts, Beth  
; APPLICANT: Pavco, Pamela  
; APPLICANT: Macejak, Dennis  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
; FILE REFERENCE: IP1 247/282  
; CURRENT APPLICATION NUMBER: US/09/504, 231A  
; CURRENT FILING DATE: 2000-02-15  
; PRIOR APPLICATION NUMBER: 09/274, 553  
; PRIOR FILING DATE: 1999-03-23  
; PRIOR APPLICATION NUMBER: 09/257, 608  
; PRIOR FILING DATE: 1999-02-24  
; PRIOR APPLICATION NUMBER: 60/100, 842  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 60/083, 217  
; PRIOR FILING DATE: 1998-04-27  
; NUMBER OF SEQ ID NOS: 3242  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 714  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target  
US-09-504-231A-714

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 40.0%; Pred. No. 1.6e+02;  
Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 1010 TGCTTTCCTTCGTC 1024  
Db 1 UGCUUUCUUCUUC 15

RESULT 321  
US-09-274-553D-714  
; Sequence 714, Application US/09274553D  
; Patent No. US20020082225A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence

APPLICANT: McSwiggen, James  
APPLICANT: Roberts, Beth  
APPLICANT: Pavco, Pamela  
APPLICANT: Macejak, Dennis  
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
FILE REFERENCE: rpi 247/282  
CURRENT APPLICATION NUMBER: US/09/274,553D  
CURRENT FILING DATE: 1999-03-23  
PRIOR APPLICATION NUMBER: 09/257,608  
PRIOR FILING DATE: 1999-02-24  
PRIOR APPLICATION NUMBER: 60/100,842  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/083,217  
PRIOR FILING DATE: 1998-04-27  
NUMBER OF SEQ ID NOS: 3148  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 714  
LENGTH: 15  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURES:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target  
US-09-274-553D-714

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 40.0%; Pred. No. 1.6e+02;  
Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1010 TGGCTTTCCTCTGTC 1024  
Db 1 UGCUUUUCCUUC 15

RESULT 322  
US-09-781-988-121/c  
Sequence 121, Application US/09781988  
Patent No. US20020150881A1  
GENERAL INFORMATION:  
APPLICANT: Ladner, Robert Charles  
Guterman, Sonia Kosow  
Roberts, Bruce Lindsey  
Markland, William  
Ley, Arthur Charles  
Kent, Rachel Baribault  
TITLE OF INVENTION: Directed Evolution of No. US20020150881A1  
Binding Proteins  
NUMBER OF SEQUENCES: 121  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Broadway and Newmark  
STREET: 419 Seventh Street, N.W.  
Suite 300  
CITY: Washington,  
STATE: DC  
COUNTRY: USA  
ZIP: 20004  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WORDPERFECT 4.2  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/781,988  
FILING DATE: 14-Feb-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/664,989  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 07/487,063  
FILING DATE: 02-MAR-1990  
APPLICATION NUMBER: 07/240,160  
FILING DATE: 02-SEP-1988  
ATTORNEY/AGENT INFORMATION:

NAME: Cooper, Iver P.  
REGISTRATION NUMBER: 28005  
REFERENCE/DOCKET NUMBER: LADNER 7  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-628-5197  
TELEFAX: 202-737-3528  
INFORMATION FOR SEQ ID NO: 121:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: circular  
MOLECULE TYPE: genomic DNA  
SEQUENCE DESCRIPTION: SEQ ID NO: 121:  
US-09-781-988-121

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.6e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 597 TGGGAGATGGCCAT 611  
Db 15 TGGGAGATGGCCAT 1

RESULT 323  
US-09-879-813-71/c  
Sequence 71, Application US/09879813  
Patent No. US2002015453A1  
GENERAL INFORMATION:  
APPLICANT: Sale, Julian E.  
APPLICANT: Neuberger, Michael S.  
APPLICANT: Cumbers, Sarah J.  
TITLE OF INVENTION: Method of Generating Diversity  
FILE REFERENCE: 18396/2005  
CURRENT APPLICATION NUMBER: US/09/879,813  
CURRENT FILING DATE: 2001-06-11  
PRIOR APPLICATION NUMBER: 09/828,717  
PRIOR FILING DATE: 2001-06-04  
PRIOR APPLICATION NUMBER: PCT/GB99/03358  
PRIOR FILING DATE: 1999-10-08  
NUMBER OF SEQ ID NOS: 87  
SOFTWARE: Patentin version 3.1  
SEQ ID NO 71  
LENGTH: 15  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc feature  
LOCATION: (7)-(9)  
OTHER INFORMATION: F242  
OTHER INFORMATION: The sequence GCA replaces the sequence ACACGCGTGTATTACTGT  
US-09-879-813-71

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.6e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 18 TCCCGCTCCCGCGG 32  
Db 15 TCTCGCTCCCGCGG 1

RESULT 324  
US-09-893-878-121/c  
Sequence 121, Application US/09893878  
Publication No. US20030113717A1  
GENERAL INFORMATION:  
APPLICANT: Ladner, Robert Charles  
Guterman, Sonia Kosow  
Roberts, Bruce Lindsey  
Markland, William  
Ley, Arthur Charles

```

; TITLE OF INVENTION: Directed Evolution of No. US20030113717A1e1
; ORGANISM: Binding Proteins
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
US-09-862-417A-1
;
; ADDRESSER: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/893,878
; FILING DATE: 29-Jun-2001
; CLASSIFICATION: <Unknown>
;
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/009,319
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28605
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
;
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-09-893-878-121
;
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 597 TGGGAGATGGCCAT 611
DB 15 TGGGAGATAGCCAT 1
;
RESULT 325
US-09-862-417A-1
; Sequence 1, Application US/09862417A
; Publication No. US20030148525A1
; GENERAL INFORMATION:
; APPLICANT: Wang, Xiao
; TITLE OF INVENTION: Isomeric Primer Extension Method and Kit for Detection and Quant
; FILE REFERENCE: 55861.00007
; CURRENT APPLICATION NUMBER: US/09/862,417A
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 15

```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic oligonucleotide
US-09-862-417A-1
;
; ADDRESSER: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/893,878
; FILING DATE: 29-Jun-2001
; CLASSIFICATION: <Unknown>
;
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/009,319
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28605
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
;
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-09-893-878-121
;
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 597 TGGGAGATGGCCAT 611
DB 15 TGGGAGATAGCCAT 1
;
RESULT 326
US-09-896-095-121/c
; Sequence 121, Application US/09896095
; Publication No. US20030219886A1
; GENERAL INFORMATION:
; APPLICANT: LADNER, Charles C.
; APPLICANT: GUTERMAN, Sonia K.
; APPLICANT: ROBERTS, Bruce L.
; APPLICANT: MARKLAND, William
; APPLICANT: LEY, Arthur C.
; APPLICANT: KENT, Rachel B.
; TITLE OF INVENTION: DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS
; FILE REFERENCE: LADNER=7L
; CURRENT APPLICATION NUMBER: US/09/896,095
; FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 08/415,922
; PRIOR FILING DATE: 1995-03-04
; PRIOR APPLICATION NUMBER: 08/009,319
; PRIOR FILING DATE: 1993-01-26
; PRIOR APPLICATION NUMBER: 07/664,989
; PRIOR FILING DATE: 1991-03-01
; PRIOR APPLICATION NUMBER: 08/993,776
; PRIOR FILING DATE: 1997-12-18
; NUMBER OF SEQ ID NOS: 274
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic, Epic20 (15-19) DNA
US-09-896-095-121
;
Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 597 TGGGAGATGGCCAT 611
DB 15 TGGGAGATAGCCAT 1
;
RESULT 327
US-10-408-157-6/c
; Sequence 6, Application US/10408157
; Publication No. US20040034878A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, James M.
; APPLICANT: Coats, Steven R.
; APPLICANT: Fero, Matthew L.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MEDIATING
; CELL CYCLE PROGRESSION
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESSES:
; ADDRESSER: Townsend and Townsend and Crew
; STREET: One Market Plaza, Stewart Street Tower
; CITY: San Francisco
; STATE: California

```

```

; COUNTRY: USA
; ZIP: 94105-1492
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/408,157
; FILING DATE: 03-APR-2003
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/556,562
; FILING DATE: 31-MAY-31
; APPLICATION NUMBER: US/08/588,595
; FILING DATE: 18-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W.
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 1453BA-19
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleotide
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-10-408-157-6

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      799 GCTGCTCGCGCCAG 813
Db      15 GCTCTCTCGCGCCAG 1

RESULT 328
; Sequence 71, Application US/10146505
; Publication No. US2003010889A1
; GENERAL INFORMATION:
; APPLICANT: Neuberger, Michael S.
; APPLICANT: Cumbers, Sarah J.
; TITLE OF INVENTION: Method of Generating Diversity
; FILE REFERENCE: 18396/2005B
; CURRENT APPLICATION NUMBER: US/10/146,505
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/828,717
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: 09/879,813
; PRIOR FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: PCT/GB99/03358
; PRIOR FILING DATE: 1999-10-08
; PRIOR APPLICATION NUMBER: GB 9822104.7
; PRIOR FILING DATE: 1998-10-09
; PRIOR APPLICATION NUMBER: GB 9901141.3
; PRIOR FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: GB 9913435.5
; PRIOR FILING DATE: 1999-06-09
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 71
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
```

```

; NAME/KEY: misc feature
; LOCATION: (7)-(9)
; OTHER INFORMATION: F242
; OTHER INFORMATION: The sequence GGA replaces the sequence ACACGCTGTGATTACTGT
US-10-146-505-71

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      18 TCCCGCTCCCGCGG 32
Db      15 TCTGCTCCCGCGG 1

RESULT 329
; Sequence 231, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Revert
; FILE REFERENCE: 250/130 (MEH00-900-A)
; CURRENT APPLICATION NUMBER: US/10/440,850
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US/09/650,012
; PRIOR FILING DATE: 2000-08-28
; PRIOR APPLICATION NUMBER: US 08/585,684
; PRIOR FILING DATE: 1996-01-12
; PRIOR APPLICATION NUMBER: US 60/000,951
; PRIOR FILING DATE: 1995-07-07
; PRIOR APPLICATION NUMBER: US 09/038,073
; PRIOR FILING DATE: 1998-03-11
; NUMBER OF SEQ ID NOS: 2285
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 231
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-10-440-850-231

Query Match      0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      502 GGCTCTGGAAACCT 516
Db      15 GGCTCTGGAAACCT 1

RESULT 330
; Sequence 121, Application US/10126685
; Publication No. US20030219722A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
; APPLICANT: Guterman, Sonia Kosow
; APPLICANT: Roberts, Bruce Lindsey
; APPLICANT: Markland, William
; APPLICANT: Ley, Arthur Charles
; APPLICANT: Kent, Rachel Baribault
; TITLE OF INVENTION: Directed Evolution of No. US20030219722A1e1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
```

```

; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/126,685
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,319
; FILING DATE: 1993-01-26
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-10-126-685-121

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGGAGATGGCCAT 611
Db      15 TGGGGAGATAGCCAT 1

RESULT 331
US-10-127-028-121/c
; Sequence 121, Application US/10127028
; Publication No. US20040005539A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
;            Guterman, Sonia Kosow
;            Roberts, Bruce Lindsey
;            Markland, William
;            Ley, Arthur Charles
;            Kent, Rachel Barbault
; TITLE OF INVENTION: Directed Evolution of No. US20040005539A1e1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/127,028
; FILING DATE: 22-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,319
; FILING DATE: 1993-01-26
; APPLICATION NUMBER: 07/664,989
; FILING DATE: 01-MAR-1991
; APPLICATION NUMBER: PCT/US89/03731
; FILING DATE: 01-SEP-1989
; APPLICATION NUMBER: 07/487,063
; FILING DATE: 02-MAR-1990
; APPLICATION NUMBER: 07/240,160
; FILING DATE: 02-SEP-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Cooper, Iver P.
; REGISTRATION NUMBER: 28005
; REFERENCE/DOCKET NUMBER: LADNER 7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 121:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 121:
US-10-127-028-121

Query Match          0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      597 TGGGGAGATGGCCAT 611
Db      15 TGGGGAGATAGCCAT 1

RESULT 332
US-10-126-544-121/c
; Sequence 121, Application US/10126544
; Publication No. US20040023205A1
; GENERAL INFORMATION:
; APPLICANT: Ladner, Robert Charles
;            Guterman, Sonia Kosow
;            Roberts, Bruce Lindsey
;            Markland, William
;            Ley, Arthur Charles
;            Kent, Rachel Barbault
; TITLE OF INVENTION: Directed Evolution of No. US20040023205A1e1
; Binding Proteins
; NUMBER OF SEQUENCES: 121
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark
; STREET: 419 Seventh Street, N.W.
; Suite 300
; CITY: Washington,
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/126,544
```

;; FILING DATE: 22-Apr-2002  
;; CLASSIFICATION: <Unknown>  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/009,319  
;; FILING DATE: 1993-01-26  
;; APPLICATION NUMBER: 07/664,989  
;; FILING DATE: 01-MAR-1991  
;; APPLICATION NUMBER: PCT/US89/03731  
;; FILING DATE: 01-SEP-1989  
;; APPLICATION NUMBER: 07/487,063  
;; FILING DATE: 02-MAR-1990  
;; APPLICATION NUMBER: 07/240,160  
;; FILING DATE: 02-SEP-1988  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Cooper, Iver P.  
;; REGISTRATION NUMBER: 28005  
;; REFERENCE/DOCKET NUMBER: LADNER 7  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 202-628-5197  
;; TELEFAX: 202-737-3528  
;; INFORMATION FOR SEQ ID NO: 121:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 15 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: double  
;; TOPOLOGY: circular  
;; MOLECULE TYPE: genomic DNA  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 121:  
US-10-126-544-121

Query Match 0.6%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 597 TGGGAGATGCGCAT 611  
DB 15 TGGGAGATGCGCAT 1

RESULT 333  
US-09-829-855-11/c  
; Sequence 11, Application US/09829855  
; Patent No. US20020065609A1  
; GENERAL INFORMATION:  
; APPLICANT: Matthew, Ashby N.  
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
; FILE REFERENCE: ASHBY-1  
; CURRENT APPLICATION NUMBER: US/09/829,855  
; CURRENT FILING DATE: 2001-04-10  
; PRIOR APPLICATION NUMBER: US 60/196063  
; PRIOR FILING DATE: 2000-04-10  
; PRIOR APPLICATION NUMBER: US 60/196258  
; PRIOR FILING DATE: 2000-04-11  
; NUMBER OF SEQ ID NOS: 244  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 11  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: unknown  
; FEATURE:  
; OTHER INFORMATION: unidentified soil organism  
US-09-829-855-11

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGGCGCACTGGG 311  
DB 16 AGCTGGCGCACTGGG 2

RESULT 334

US-09-829-855-13/c  
; Sequence 13, Application US/09829855  
; Patent No. US20020065609A1  
; GENERAL INFORMATION:  
; APPLICANT: Matthew, Ashby N.  
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
; FILE REFERENCE: ASHBY-1  
; CURRENT APPLICATION NUMBER: US/09/829,855  
; CURRENT FILING DATE: 2001-04-10  
; PRIOR APPLICATION NUMBER: US 60/196063  
; PRIOR FILING DATE: 2000-04-10  
; PRIOR APPLICATION NUMBER: US 60/196258  
; PRIOR FILING DATE: 2000-04-11  
; NUMBER OF SEQ ID NOS: 244  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 13  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: unknown  
; FEATURE:  
; OTHER INFORMATION: unidentified soil organism  
US-09-829-855-13

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGGCGCACTGGG 311  
DB 16 AGCTGGCGCACTGGG 2

RESULT 335  
US-09-829-855-77/c  
; Sequence 77, Application US/09829855  
; Patent No. US20020065609A1  
; GENERAL INFORMATION:  
; APPLICANT: Matthew, Ashby N.  
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
; FILE REFERENCE: ASHBY-1  
; CURRENT APPLICATION NUMBER: US/09/829,855  
; CURRENT FILING DATE: 2001-04-10  
; PRIOR APPLICATION NUMBER: US 60/196063  
; PRIOR FILING DATE: 2000-04-10  
; PRIOR APPLICATION NUMBER: US 60/196258  
; PRIOR FILING DATE: 2000-04-11  
; NUMBER OF SEQ ID NOS: 244  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 77  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: unknown  
; FEATURE:  
; OTHER INFORMATION: unidentified soil organism  
US-09-829-855-77

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 AGCTGGCGCACTGGG 311  
DB 16 AGCTGGCGCACTGGG 2

RESULT 336  
US-10-182-230-68/c  
; Sequence 68, Application US/10182230  
; Publication No. US20030215817A1  
; GENERAL INFORMATION:  
; APPLICANT: Leonardi, Amedeo  
; APPLICANT: Sartani, Abraham  
; APPLICANT: Glass, James R.

```
; APPLICANT: Sutcliffe, J. Gregor
; APPLICANT: Hasel, Karl W.
; TITLE OF INVENTION: Modulation of Gene Expression in Formation of Fatty Atherosclerotic
; TITLE OF INVENTION: Lesions
; FILE REFERENCE: 216019-143
; CURRENT APPLICATION NUMBER: US/10/182,230
; CURRENT FILING DATE: 2003-02-03
; PRIOR APPLICATION NUMBER: 60/177,963
; PRIOR FILING DATE: 2000-01-25
; NUMBER OF SEQ ID NOS: 197
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 5' PCR Primer with parsing base
; OTHER INFORMATION: see CTGA
US-10-182-230-68
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      658 TCAGCCGATACCTTC 672
Db      16 TCAGCCGATACCGTC 2
```

```
RESULT 337
US-10-138-674-7079
; Sequence 7079, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7079
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7079
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTCGACG 784
Db      1 ACAGCACTTCGACG 15
```

```
RESULT 338
US-10-287-949A-7079
; Sequence 7079, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```
; FILE REFERENCE: MEB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7079
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7079
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      770 ACAGCCACTTCGACG 784
Db      1 ACAGCACTTCGACG 15
```

```
RESULT 339
US-10-607-077A-11/c
; Sequence 11, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
; APPLICANT: Ashby, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 DIV
; CURRENT APPLICATION NUMBER: US/10/607,077A
; CURRENT FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: PCT/US01/11609
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
; OTHER INFORMATION: microbes in soil sample collected
; OTHER INFORMATION: in Wyoming, USA
US-10-607-077A-11
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      297 AGCTGCGGCACTGGG 311
Db      16 AGCTGCGGCACTGGG 2
```

```
RESULT 340
US-10-607-077A-13/c
; Sequence 13, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
; APPLICANT: Ashby, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 DIV
; CURRENT APPLICATION NUMBER: US/10/607,077A
; CURRENT FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: PCT/US01/11609
; PRIOR FILING DATE: 2001-04-10
```



;; PRIOR APPLICATION NUMBER: US 60/196063  
;; PRIOR FILING DATE: 2000-04-10  
;; PRIOR APPLICATION NUMBER: US 60/196258  
;; PRIOR FILING DATE: 2000-04-11  
;; NUMBER OF SEQ ID NOS: 244  
;; SOFTWARE: PatentIn version 3.1  
;; SEQ ID NO 13  
;; LENGTH: 16  
;; TYPE: DNA  
;; ORGANISM: Unknown  
;; FEATURE:  
;; OTHER INFORMATION: ribosomal DNA sequence tag isolated from  
;; OTHER INFORMATION: microbes in soil sample collected  
;; OTHER INFORMATION: in Wyoming, USA  
US-10-607-077A-13

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 341  
US-10-607-077A-77/C  
;; Sequence 77, Application US/10607077A  
;; Publication No. US20040110183A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ashby, Matthew  
;; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations  
;; FILE REFERENCE: ASHBY/1 Div  
;; CURRENT APPLICATION NUMBER: US/10/607,077A  
;; PRIOR FILING DATE: 2003-06-25  
;; PRIOR APPLICATION NUMBER: US 09/829855  
;; PRIOR FILING DATE: 2001-04-10  
;; PRIOR APPLICATION NUMBER: PCT/US01/11609  
;; PRIOR FILING DATE: 2001-04-10  
;; PRIOR APPLICATION NUMBER: US 60/196063  
;; PRIOR FILING DATE: 2000-04-10  
;; PRIOR APPLICATION NUMBER: US 60/196258  
;; PRIOR FILING DATE: 2000-04-11  
;; NUMBER OF SEQ ID NOS: 244  
;; SOFTWARE: PatentIn version 3.1  
;; SEQ ID NO 77  
;; LENGTH: 16  
;; TYPE: DNA  
;; ORGANISM: Unknown  
;; FEATURE:  
;; OTHER INFORMATION: ribosomal DNA sequence tag isolated from  
;; OTHER INFORMATION: microbes in soil sample collected  
;; OTHER INFORMATION: in Wyoming, USA  
US-10-607-077A-77

Query Match 0.6%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 297 AGCTGCGGCACTGGG 311  
Db 16 AGCTGCGGCACTGGG 2

RESULT 342  
US-09-866-108-889/C  
;; Sequence 889, Application US/09866108  
;; Patent No. US20020048800A1  
;; GENERAL INFORMATION:  
;; APPLICANT: GU, Yizhong  
;; APPLICANT: JI, Yonggang  
;; APPLICANT: PENN, Sharon G.  
;; APPLICANT: HANZEL, David K.

;; APPLICANT: RANK, David R.  
;; APPLICANT: CHEN, Wensheng  
;; APPLICANT: SHANNON, Mark  
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
;; FILE REFERENCE: AEOMICA-7  
;; CURRENT APPLICATION NUMBER: US/09/866,108  
;; CURRENT FILING DATE: 2001-05-25  
;; PRIOR APPLICATION NUMBER: US 60/207,456  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: GB 24263.6  
;; PRIOR FILING DATE: 2000-10-04  
;; PRIOR APPLICATION NUMBER: US 60/236,359  
;; PRIOR FILING DATE: 2000-09-27  
;; PRIOR APPLICATION NUMBER: PCT/US01/00666  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00667  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00664  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00669  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00665  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00668  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00662  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00661  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: PCT/US01/00670  
;; PRIOR FILING DATE: 2001-01-30  
;; PRIOR APPLICATION NUMBER: US 60/234,687  
;; PRIOR FILING DATE: 2000-09-21  
;; PRIOR APPLICATION NUMBER: US 60/266,860  
;; PRIOR FILING DATE: 2001-02-05  
;; NUMBER OF SEQ ID NOS: 15752  
;; SOFTWARE: Aeomica Sequence Listing Engine  
;; SEQ ID NO 889  
;; LENGTH: 17  
;; TYPE: DNA  
;; ORGANISM: Homo sapiens  
US-09-866-108-889

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1703 CCCTCCCAATATG 1717  
Db 17 CCCTCCCAATATG 3

RESULT 343  
US-09-866-108-6756  
;; Sequence 6756, Application US/09866108  
;; Patent No. US20020048800A1  
;; GENERAL INFORMATION:  
;; APPLICANT: GU, Yizhong  
;; APPLICANT: JI, Yonggang  
;; APPLICANT: PENN, Sharon G.  
;; APPLICANT: HANZEL, David K.  
;; APPLICANT: RANK, David R.  
;; APPLICANT: CHEN, Wensheng  
;; APPLICANT: SHANNON, Mark  
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
;; FILE REFERENCE: AEOMICA-7  
;; CURRENT APPLICATION NUMBER: US/09/866,108  
;; CURRENT FILING DATE: 2001-05-25  
;; PRIOR APPLICATION NUMBER: US 60/207,456  
;; PRIOR FILING DATE: 2000-05-26  
;; PRIOR APPLICATION NUMBER: GB 24263.6

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6756
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6756
```

```

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      2041 GTGAGCAGCTCCTG 2055
Db      3 GTGAGCAGCTCCTG 17
```

```

RESULT 344
US-09-866-108-6757
; Sequence 6757, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6757
```

```

OY      2041 GTGAGCAGCTCCTG 2055
Db      2 GTGAGCAGCTCCTG 16
```

```

RESULT 345
US-09-866-108-6950
; Sequence 6950, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6950
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6950

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
Db      3 TCGCCGACTGGGTGC 17

RESULT 346
US-09-866-108-6951
; Sequence 6951, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6951
```

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6951

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
Db      2 TCGCCGACTGGGTGC 16

RESULT 347
US-09-866-108-6952
; Sequence 6952, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6952
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-6952

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      89 TCGCCGACTGGGTGC 103
```

Db 1 TCCTGAGAGCTGC 15

```
RESULT 349
US-09-866-108-8004
; Sequence 8004, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8004
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8004

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8007
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8007

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY 2039 AGGTGAGAGCTCC 2053
Db 1 AGCTGAGAGCTGC 15

RESULT 350
US-09-866-108-8054
; Sequence 8054, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
```

PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 8054  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8054

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2230 GCAGATGCTCCAGAA 2244  
DB 3 GCAGATGCTCCAGAA 17

RESULT 351  
US-09-866-108-8055  
Sequence 8055, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wenheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 8055  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8055

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2230 GCAGATGCTCCAGAA 2244  
DB 2 GCAGATGCTCCAGAA 16

RESULT 352  
US-09-827-998-471  
Sequence 471, Application US/09827998  
Patent No. US20020102252A1  
GENERAL INFORMATION:  
APPLICANT: Gu, Yizhong  
APPLICANT: Shannon, Mark  
TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E  
FILE REFERENCE: NDMORF-8  
CURRENT APPLICATION NUMBER: US/09/827,998  
PRIOR FILING DATE: 2001-04-06  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
NUMBER OF SEQ ID NOS: 1881  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 471  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-827-998-471

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1027 AAGAAGTGGGAAA 1041  
DB 3 AAGAAGTGGGAAA 17

RESULT 353  
US-09-827-998-472  
Sequence 472, Application US/09827998  
Patent No. US20020102252A1

```
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MIMMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; PRIOR FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 472
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-472
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1027 AAGAAGGTGGGAAA 1041
Db       2 AAGAAGGGGGGAAA 16
```

```
RESULT 354
US-09-827-998-473
; Sequence 473, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MIMMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 473
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-473
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1027 AAGAAGGTGGGAAA 1041
Db       1 AAGAAGGGGGGAAA 15
```

```
RESULT 355
US-09-969-373-3716/c
; Sequence 3716, Application US/09969373
; Patent No. US2002013852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Haug, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
```

```
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3716
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3716
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1835 TCACAGCTGCTGAG 1849
Db       15 TCACAGCTGCTGAG 1
```

```
RESULT 356
US-09-864-785-55/c
; Sequence 55, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 55
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-55
```

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      565 CTGTCTCTGCTCTG 579
Db       17 CTGTCTCTGCTCTG 3
```

```
RESULT 357
US-09-864-785-56/c
; Sequence 56, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 56
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-56

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      565 CTGTCCTGGTCCG 579
DB      16 CTGTCCTGGTCCG 2

RESULT 358
US-09-864-785-1585
/ Sequence 1585, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT FILING DATE: 2001-05-23
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1585
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1585

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1362 CACCCAGGCTGTGGA 1376
DB      2 CACCCAGGCTGTGGA 16

RESULT 359
US-09-864-785-1621/c
/ Sequence 1621, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT FILING DATE: 2001-05-23
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1621
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1621

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      355 TGGGAGCCCCCGGG 369
DB      16 TGGGAGCCCCCGGG 2

RESULT 360
US-09-864-785-2828
/ Sequence 2828, Application US/09864785
/ Patent No. US2002017568A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Draper, Ken
/ APPLICANT: McSwiggen, Jim
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
/ FILE REFERENCE: 400/022 (MBH00-812-D)
/ CURRENT FILING DATE: 2001-05-23
/ CURRENT APPLICATION NUMBER: US/09/864,785
/ NUMBER OF SEQ ID NOS: 3929
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 2828
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-2828

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY      1362 CACCCAGGCTGTGGA 1376
DB      3 CACCCAGGCTGTGGA 17

RESULT 361
US-09-780-533A-912/c
/ Sequence 912, Application US/09780533A
/ Publication No. US2003006011A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Blatt, Larry
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Chowrira, Bharat
/ APPLICANT: Haeblerli, Pete
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
/ FILE REFERENCE: MBH00, 878-A (400/011)
/ CURRENT FILING DATE: 2001-02-09
/ PRIOR APPLICATION NUMBER: US 60/181,797
/ NUMBER OF SEQ ID NOS: 6679
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 912
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-780-533A-912

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      201 GCTCTGCTGGGGGC 215
DB      17 GCTCTGCTGGGGGC 3

RESULT 362
```

```
US-09-780-533A-2411/c
; Sequence 2411, Application US/09780533A
; Publication No. US2003006061A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrita, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCO Gene
; FILE REFERENCE: MBH00, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2411
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2411

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      201 GCTCTGGCTGGGGGC 215
Db      16 GCTCTGGCTGGGGGC 2

RESULT 363
US-09-877-478-1387/c
; Sequence 1387, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1387

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      2162 GGGAGGGGGGAACCC 2176
Db      15 GGGAGGGGTGAACCC 1

RESULT 364
US-09-877-478-1388/c
; Sequence 1388, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1388

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      2162 GGGAGGGGGGAACCC 2176
Db      15 GGGAGGGGTGAACCC 1

RESULT 365
US-09-877-478-2180/c
; Sequence 2180, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 1999-11-08
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-08-09
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2180
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2180
```



;; PRIOR APPLICATION NUMBER: US 09/696,347  
;; PRIOR FILING DATE: 2000-10-24  
;; PRIOR APPLICATION NUMBER: US 08/193,627  
;; PRIOR FILING DATE: 1994-02-07  
;; PRIOR APPLICATION NUMBER: US 08/433,993  
;; PRIOR FILING DATE: 1995-05-04  
;; PRIOR APPLICATION NUMBER: US 08/434,504  
;; PRIOR FILING DATE: 1995-05-04  
;; PRIOR APPLICATION NUMBER: US 09/436,430  
;; PRIOR FILING DATE: 1999-11-08  
;; NUMBER OF SEQ ID NOS: 6586  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO: 2180  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: Hepatitis B virus  
US-09-877-478-2180

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2162 GGGAGGGGGGAGCC 2176  
DB 17 GGGAGGGGGTGAACC 3

RESULT 366  
US-09-827-395A-271/c  
;; Sequence 271, Application US/09827395A  
;; Publication No. US20030113891A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
;; APPLICANT: Lawrence Blatt  
;; APPLICANT: James McSwigen  
;; APPLICANT: Bharat Chowitra  
;; TITLE OF INVENTION: Method and Reagent for the Inhibition of NCOG and NCOG Receptor G  
;; FILE REFERENCE: MHB00-878-C (400/017)  
;; CURRENT APPLICATION NUMBER: US/09/827,395A  
;; CURRENT FILING DATE: 2001-04-05  
;; PRIOR APPLICATION NUMBER: 09/780,533  
;; PRIOR FILING DATE: 2001-02-09  
;; PRIOR APPLICATION NUMBER: 60/181,797  
;; PRIOR FILING DATE: 2000-02-11  
;; NUMBER OF SEQ ID NOS: 2617  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO: 271  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: Homo sapiens  
US-09-827-395A-271

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 779 TGCAGGAGAGCTGT 793  
DB 16 TGCAGGAGAGCTGT 2

RESULT 367  
US-09-740-332-308  
;; Sequence 308, Application US/09740332  
;; Publication No. US20030125270A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals Inc.  
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
;; TITLE OF INVENTION: Hepatitis C Virus Infection  
;; FILE REFERENCE: RPI 400/003  
;; CURRENT APPLICATION NUMBER: US/09/740,332  
;; CURRENT FILING DATE: 2001-03-26  
;; NUMBER OF SEQ ID NOS: 9704

;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO: 308  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: artificial sequence  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION:  
;; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-308

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 73.3%; Pred. No. 1.8e+02;  
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 59 TCGCATGCTGGGGA 73  
DB 2 UCGCAUGGCTUGGGA 16

RESULT 368  
US-09-817-879-308  
;; Sequence 308, Application US/09817879  
;; Publication No. US2003017131A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Ribozyme Pharmaceuticals Inc.  
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
;; TITLE OF INVENTION: Hepatitis C Virus Infection  
;; FILE REFERENCE: MHB00-801-F  
;; CURRENT APPLICATION NUMBER: US/09/817,879  
;; CURRENT FILING DATE: 2001-03-26  
;; NUMBER OF SEQ ID NOS: 9703  
;; SOFTWARE: PatentIn version 3.0  
;; SEQ ID NO: 308  
;; LENGTH: 17  
;; TYPE: RNA  
;; ORGANISM: artificial sequence  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION:  
;; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-308

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 73.3%; Pred. No. 1.8e+02;  
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 59 TCGCATGCTGGGGA 73  
DB 2 UCGCAUGGCTUGGGA 16

RESULT 369  
US-10-342-902-1387/c  
;; Sequence 1387, Application US/10342902  
;; Publication No. US20040054156A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Sirna Therapeutics, Inc.  
;; APPLICANT: Draper, Kenneth  
;; APPLICANT: Blatt, Larry  
;; APPLICANT: McSwigen, Jim  
;; APPLICANT: Morrissey, Dave  
;; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication  
;; FILE REFERENCE: 400/075 (MHB00-845-1)  
;; CURRENT APPLICATION NUMBER: US/10/342,902  
;; CURRENT FILING DATE: 2003-01-15  
;; PRIOR APPLICATION NUMBER: US 09/877,478  
;; PRIOR FILING DATE: 2001-06-08  
;; PRIOR APPLICATION NUMBER: US 09/531,025  
;; PRIOR FILING DATE: 2000-03-20  
;; PRIOR APPLICATION NUMBER: US 09/636,385  
;; PRIOR FILING DATE: 2000-08-09  
;; PRIOR APPLICATION NUMBER: US 09/696,347

```
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1387

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      17 GGGAGGGGTGAACCC 3

RESULT 370
US-10-342-902-1388/c
; Sequence 1388, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MHBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1388
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1388

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      15 GGGAGGGGTGAACCC 1
```

```
RESULT 371
US-10-342-902-2180/c
; Sequence 2180, Application US/10342902
; Publication No. US20040054156A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MHBH00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2180
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-2180

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2162 GGGAGGGGGGAACCC 2176
Db      17 GGGAGGGGTGAACCC 3

RESULT 372
US-10-675-685-471
; Sequence 471, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 471
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-471

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      3 AAGAGGGGGGAAA 17
```

```
RESULT 373
US-10-675-685-472
; Sequence 472, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 472
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-472

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      2 AAGAGGGGGGAAA 16

RESULT 374
US-10-675-685-473
; Sequence 473, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 473
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-473

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1027 AAGAGGTGGGAAA 1041
Db      1 AAGAGGGGGGAAA 15

RESULT 375
US-09-927-046-864/C
; Sequence 864, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: MCSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzle, Tim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
```

```
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Symkoweki, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 864
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-864

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1997 TGGATGATGCCACCA 2011
Db      16 TGGATGATGCCACCA 2

RESULT 376
US-09-927-046-1020/C
; Sequence 1020, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: Thompson, Jim
; APPLICANT: MCSwigen, Jim
; APPLICANT: Grupe, Andrew
; APPLICANT: Symkoweki, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1020
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1020

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      16 TCAGGGCTGTGACAC 2

RESULT 377
US-09-927-046-1565/C
; Sequence 1565, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc
; APPLICANT: MCSwigen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzle, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Symkoweki, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
```

```
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1565
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1565

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1887 TCAGGGCTATGACAC 1901
Db      15   TCAGGGCTGTGACAC 1

RESULT 378
US-09-958-163A-23/C
; Sequence 23, Application US/09958163A
; Publication No. US20030104389A1
; GENERAL INFORMATION:
; APPLICANT: Sergeev, Pavel
; TITLE OF INVENTION: Synthesis of biologically active compounds in cells
; FILE REFERENCE: sergeev
; CURRENT APPLICATION NUMBER: US/09/958,163A
; CURRENT FILING DATE: 2001-10-03
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURES:
; OTHER INFORMATION: antisense to the human tissue plasminogen activator mRNA
; PUBLICATION INFORMATION:
; AUTHORS: Degen,S.J., Rajput,B. and Reich,E.
; TITLE: The human tissue plasminogen activator gene
; JOURNAL: Journal of Biological Chemistry
; VOLUME: 261
; ISSUE: 15
; PAGES: 6972-85
; DATE: 1986-05-25
; DATABASE ACCESSION NUMBER: K03021
; DATABASE ENTRY DATE: 1986-04-08
US-09-958-163A-23

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      101 TGTGTCTCCGACCG 115
Db      17   TGTGTCTCCGACCG 3

RESULT 379
US-10-430-882-271/C
; Sequence 271, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwigen
; APPLICANT: Bharat Chowtri
; APPLICANT: Peter Haeblerli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH800-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 271
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-271

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      779 TGCAGGAGAGGTGT 793
Db      16   TGCAGGAGAGGTGT 2

RESULT 380
US-10-060-830-782/C
; Sequence 782, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 782
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-782

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      918 TCTGTGTACTTGCT 932
Db      16   TCTGTGTACTTGCT 2

RESULT 381
US-10-060-830-783/C
```

```
; Sequence 783, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 783
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-783
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 918 TCTGTGCTACTGCT 932
DB 15 TCTGTGCTACTGCT 1
```

```
RESULT 382
US-10-060-895A-484/C
; Sequence 484, Application US/10060895A
; Publication No. US20030104403A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN UDP-GALNA4:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 10
; FILE REFERENCE: PB0158
; CURRENT APPLICATION NUMBER: US/10/060,895A
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/315,984
```

```
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 1682
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 484
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-895A-484
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1487 CCTTACTGTGAGG 1501
DB 15 CCTTACTGTGAGG 1
```

```
RESULT 383
US-10-163-552-84/C
; Sequence 84, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 84
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-84
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1284 CATTGTGGCAGCT 1298
DB 15 CATTGTGGCAGCT 1
```

```
RESULT 384
US-10-156-306-4761/C
; Sequence 4761, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4761
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-4761
```

```
Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 214 GCCTGCGGGCTCCTC 228
DB 15 GCCTGCGGGCTCCTC 1
```

Db 15 GTCTGGGGGTCTC 1

RESULT 385  
US-10-156-306-5005/c  
; Sequence 5005, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: MCSwigen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR  
; FILE REFERENCE: MBH01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5005  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-5005

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 CTGCAGTGGCTCCAG 2242  
Db 16 CTGCAGCTCTCCAG 2

RESULT 386  
US-10-156-306-5013  
; Sequence 5013, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: MCSwigen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR  
; FILE REFERENCE: MBH01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; CURRENT FILING DATE: 2002-05-28  
; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5013  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-5013

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 80.0%; Pred. No. 1.8e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTGAGGG 1936  
Db 3 GCCAGCTGTGAGAG 17

RESULT 387  
US-10-156-306-5092/c  
; Sequence 5092, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: MCSwigen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR  
; FILE REFERENCE: MBH01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; CURRENT FILING DATE: 2002-05-28

; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5092  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-5092

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1945 CAGGCACTGGCGTTG 1959  
Db 17 CAGGCACTGGCGTTG 3

RESULT 388  
US-10-156-306-5093/c  
; Sequence 5093, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: MCSwigen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR  
; FILE REFERENCE: MBH01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; CURRENT FILING DATE: 2002-05-28  
; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5093  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-5093

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1945 CAGGCACTGGCGTTG 1959  
Db 16 CAGGCACTGGCGTTG 2

RESULT 389  
US-10-156-306-5184  
; Sequence 5184, Application US/10156306  
; Publication No. US20030119017A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: MCSwigen, James  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR  
; FILE REFERENCE: MBH01-664-A (400/050)  
; CURRENT APPLICATION NUMBER: US/10/156,306  
; CURRENT FILING DATE: 2002-05-28  
; NUMBER OF SEQ ID NOS: 8013  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5184  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-156-306-5184

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 80.0%; Pred. No. 1.8e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 391 CTGCACCTGGGAGACT 405  
Db 3 CGGCACCTGGGAGAGU 17

```
RESULT 390
US-10-156-306-5889/C
; Sequence 5889, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5889
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5889

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGC 157
DB 15 TGCCACCGCGCTGC 1

RESULT 391
US-10-156-306-5925/C
; Sequence 5925, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5925
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5925

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2228 CTGCAGTGTCTCCAG 2242
DB 15 CTGCAGTGTCTCCAG 1

RESULT 392
US-10-156-306-5931
; Sequence 5931, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5931

Query Match
Best Local Similarity 80.0%; DB 1; Length 17;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTCCAGG 1936
DB 2 GCCAGCTGTCCAGG 16

RESULT 393
US-10-156-306-6960/C
; Sequence 6960, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6960
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-6960

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 TGCCACCGCGCTGC 157
DB 16 TGCCACCGCGCTGC 2

RESULT 394
US-10-238-700-3261
; Sequence 3261, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3261
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-3261

Query Match
Best Local Similarity 93.3%; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 167 GGGTCTGGCGGTGC 181
```





```
US-10-230-006-1429/c
; Sequence 1429, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Fossanugh, Kathy
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
; FILE REFERENCE: 400/056 (MBH001-1110)
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1429
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-1429

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 632 TCACGACTGGATTC 646
Db 16 TCACGACTGGATTC 2

RESULT 399
US-10-277-216-290
; Sequence 290, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-290

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 588 CTCCTCTCTGGGGA 602
Db 2 CTCCTCTCTGGGGA 16

RESULT 400
US-10-126-022-290
; Sequence 290, Application US/10126022
; Publication No. US20040002215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
```

```
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 290
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-290

Query Match
Best Local Similarity 93.3%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 588 CTCCTCTCTGGGGA 602
Db 2 CTCCTCTCTGGGGA 16

RESULT 401
US-10-138-674-4197
; Sequence 4197, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4197

Query Match
Best Local Similarity 73.3%; Score 13.4; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 977 CCCTCACCAGTCA 991
Db 2 CCCTCACCAGTCA 16

RESULT 402
US-10-138-674-4505
; Sequence 4505, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
```

Query Match  
Best Local Similarity 53.3%; Pred. No. 1.8e+02;  
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;  
DB 1991 TTATCTGATGATG 2005  
3 UUAUCCUGAUGCG 17

RESULT 403  
US-10-138-674-4755/c  
Sequence 4755, Application US/10138674  
Publication No. US20040077565A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/138, 674  
CURRENT FILING DATE: 2002-05-03  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 4755  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-138-674-4755

Query Match  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
DB 2214 CATGTCAGGCTCC 2228  
17 CTGTCAGGCTCC 3

RESULT 404  
US-10-138-674-6625  
Sequence 6625, Application US/10138674  
Publication No. US20040077565A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/138, 674  
CURRENT FILING DATE: 2002-05-03  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 6625  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-138-674-6625

Query Match  
Best Local Similarity 80.0%; Pred. No. 1.8e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
DB 770 ACAGCACTTGACAG 784  
1 ACAGCACTTGACAG 15

RESULT 405  
US-10-138-674-7633/c  
Sequence 7633, Application US/10138674  
Publication No. US20040077565A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/138, 674  
CURRENT FILING DATE: 2002-05-03  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 7633  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-138-674-7633

Query Match  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
DB 2214 CATGTCAGGCTCC 2228  
16 CTGTCAGGCTCC 2

RESULT 406  
US-10-138-674-8874  
Sequence 8874, Application US/10138674  
Publication No. US20040077565A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/138, 674  
CURRENT FILING DATE: 2002-05-03  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 8874  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-138-674-8874

Query Match  
Best Local Similarity 80.0%; Pred. No. 1.8e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
DB 770 ACAGCACTTGACAG 784  
3 ACAGCACTTGACAG 17

```

RESULT 407
US-10-287-949A-4197
; Sequence 4197, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4197
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4197

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      977 CCTCACCATTGCTCA 991
Db      2 CGCUCACCAUGGCUCA 16

RESULT 408
US-10-287-949A-4505
; Sequence 4505, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4505
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4505

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 53.3%; Pred. No. 1.8e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      1991 TTATCTGATGATG 2005
Db      3 UUAUCCUGAUGGUG 17

RESULT 409
US-10-287-949A-4755/C
; Sequence 4755, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```

```

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4755
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4755

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2214 CATGTGACGCTCC 2228
Db      17 CTGTGTCAGGCTCC 3

RESULT 410
US-10-287-949A-6625
; Sequence 6625, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6625

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      770 ACAGCCACTTGACG 784
Db      1 ACAGCAACUCCAGG 15

RESULT 411
US-10-287-949A-7633/C
; Sequence 7633, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7633

```

LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-7633

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2214 CATGTCAGGCTCC 2228  
Db 16 CTGTGTCAGGCTCC 2

RESULT 412  
US-10-287-949A-8874  
Sequence 8874, Application US/10287949A  
Publication No. US20040102389A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/287,949A  
CURRENT FILING DATE: 2003-04-11  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 8874  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-8874

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 80.0%; Pred. No. 1.8e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 770 ACAGCCACTGCGAG 784  
Db 3 ACAGCAACUUGCAG 17

RESULT 413  
US-10-712-672-1280  
Sequence 1280, Application US/10712672  
Publication No. US20040102413A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Chowitra, Bharat  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme  
FILE REFERENCE: MHB00-882-C (400/019)  
CURRENT APPLICATION NUMBER: US/10/712,672  
CURRENT FILING DATE: 2003-11-13  
PRIOR APPLICATION NUMBER: US/09/653,225  
PRIOR FILING DATE: 2000-08-31  
PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1280  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-1280

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 86.7%; Pred. No. 1.8e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 437 CGGCGCGCCGCGAG 451  
Db 3 CGGCGCGCCUUCAG 17

RESULT 414  
US-10-712-672-1917/C  
Sequence 1917, Application US/10712672  
Publication No. US20040102413A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Chowitra, Bharat  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme  
FILE REFERENCE: MHB00-882-C (400/019)  
CURRENT APPLICATION NUMBER: US/10/712,672  
CURRENT FILING DATE: 2003-11-13  
PRIOR APPLICATION NUMBER: US/09/653,225  
PRIOR FILING DATE: 2000-08-31  
PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1917  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-1917

Query Match 0.6%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 551 CGGCGCGCCCTCGC 565  
Db 17 CGGCGCGCCGCTGC 3

RESULT 415  
US-10-712-672-1977/C  
Sequence 1977, Application US/10712672  
Publication No. US20040102413A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Chowitra, Bharat  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme  
FILE REFERENCE: MHB00-882-C (400/019)  
CURRENT APPLICATION NUMBER: US/10/712,672  
CURRENT FILING DATE: 2003-11-13  
PRIOR APPLICATION NUMBER: US/09/653,225  
PRIOR FILING DATE: 2000-08-31  
PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1977  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-1977

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2169 GGGAGCCACGACA 2183  
Db 15 GGGAGCCACGACA 1

RESULT 416  
US-09-504-231A-712

; Sequence 712, Application US/09504231A  
; Patent No. US20020013458A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence  
; APPLICANT: McSwigen, James  
; APPLICANT: Roberts, Beth  
; APPLICANT: Pavco, Pamela  
; APPLICANT: Macejak, Dennis  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
; FILE REFERENCE: IP1 247/282  
; CURRENT APPLICATION NUMBER: US/09/504,231A  
; CURRENT FILING DATE: 2000-02-15  
; PRIOR APPLICATION NUMBER: 09/274,553  
; PRIOR FILING DATE: 1999-03-23  
; PRIOR APPLICATION NUMBER: 09/257,608  
; PRIOR FILING DATE: 1999-02-24  
; PRIOR APPLICATION NUMBER: 60/100,842  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 60/083,217  
; NUMBER OF SEQ ID NOS: 3242  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 712  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target  
US-09-504-231A-712

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 38.5%; Pred. No. 1.9e+02;  
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022  
Db 3 UGCUUUCUUCU 15

RESULT 417  
US-09-504-231A-713  
; Sequence 713, Application US/09504231A  
; Patent No. US20020013458A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence  
; APPLICANT: McSwigen, James  
; APPLICANT: Roberts, Beth  
; APPLICANT: Pavco, Pamela  
; APPLICANT: Macejak, Dennis  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
; FILE REFERENCE: IP1 247/282  
; CURRENT APPLICATION NUMBER: US/09/504,231A  
; CURRENT FILING DATE: 2000-02-15  
; PRIOR APPLICATION NUMBER: 09/274,553  
; PRIOR FILING DATE: 1999-03-23  
; PRIOR APPLICATION NUMBER: 09/257,608  
; PRIOR FILING DATE: 1999-02-24  
; PRIOR APPLICATION NUMBER: 60/100,842  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 60/083,217  
; PRIOR FILING DATE: 1998-04-27

; NUMBER OF SEQ ID NOS: 3242  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 713  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target  
US-09-504-231A-713

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 38.5%; Pred. No. 1.9e+02;  
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022  
Db 2 UGCUUUCUUCU 14

RESULT 418  
US-09-274-553D-712  
; Sequence 712, Application US/09274553D  
; Patent No. US2002008225A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence  
; APPLICANT: McSwigen, James  
; APPLICANT: Roberts, Beth  
; APPLICANT: Pavco, Pamela  
; APPLICANT: Macejak, Dennis  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
; FILE REFERENCE: IP1 247/282  
; CURRENT APPLICATION NUMBER: US/09/274,553D  
; CURRENT FILING DATE: 1999-03-23  
; PRIOR APPLICATION NUMBER: 09/257,608  
; PRIOR FILING DATE: 1999-02-24  
; PRIOR APPLICATION NUMBER: 60/100,842  
; PRIOR FILING DATE: 1998-09-18  
; PRIOR APPLICATION NUMBER: 60/083,217  
; PRIOR FILING DATE: 1998-04-27  
; NUMBER OF SEQ ID NOS: 3148  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 712  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target  
US-09-274-553D-712

Query Match 0.6%; Score 13; DB 1; Length 15;  
Best Local Similarity 38.5%; Pred. No. 1.9e+02;  
Matches 5; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1010 TGCTTTCCTTCT 1022  
Db 3 UGCUUUCUUCU 15

RESULT 419  
US-09-274-553D-713  
; Sequence 713, Application US/09274553D  
; Patent No. US2002008225A1  
; GENERAL INFORMATION:  
; APPLICANT: Blact, Lawrence  
; APPLICANT: McSwigen, James  
; APPLICANT: Roberts, Beth  
; APPLICANT: Pavco, Pamela  
; APPLICANT: Macejak, Dennis  
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE  
; FILE REFERENCE: IP1 247/282  
; CURRENT APPLICATION NUMBER: US/09/274,553D

```
; CURRENT FILING DATE: 1999-03-23
; PRIOR APPLICATION NUMBER: 09/257,608
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: 60/100,842
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/083,217
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 3148
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 713
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
US-09-274-553D-713

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 38.5%; Pred. No. 1.9e+02;
Matches 5; Conservative 8; Mismatches 0; Gaps 0; Indels 0;

Qy      1010 TGCTTTCCTCTCT 1022
Db      2 UGCUUUCUUCU 14
      |||::|||::|

RESULT 420
US-09-748-739A-28
; Sequence 28, Application US/09748739A
; Patent No. US20020119489A1
; GENERAL INFORMATION:
; APPLICANT: Lockridge, Oksana
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: Butyrylcholinesterase Variants and
; TITLE OF INVENTION: Methods of Use
; FILE REFERENCE: P-IX 4143
; CURRENT APPLICATION NUMBER: US/09/748,739A
; CURRENT FILING DATE: 2000-12-06
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: human butyrylcholinesterase variant
US-09-748-739A-28

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy      417 CTTGCTGTGCTGCT 429
Db      2 CTTGCTGTGCTGCT 14
      ||||||

RESULT 421
US-10-347-510A-44/C
; Sequence 44, Application US/10347510A
; Publication No. US20040063110A1
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; APPLICANT: Kaare Lund
; APPLICANT: Tina Anderson Hollerup
; TITLE OF INVENTION: No. US20040063110A1 Process For The Detection of Mycobact
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
```

```
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: ASCXI
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/347,510A
; FILING DATE: 21-Jan-2003
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
; NAME: Anthony C. Tridico
; REGISTRATION NUMBER: 45,958
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4173
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 basepairs
; TYPE: nucleic acid basepairs
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-10-347-510A-44

Query Match          0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

Qy      1962 CCGAGCATTTGATC 1974
Db      13 CCGAGCATTTGATC 1
      |||

RESULT 422
US-09-544-934B-44/C
; Sequence 44, Application US/09544934B
; Publication No. US20020137035A1
; GENERAL INFORMATION:
; APPLICANT: Henrik Stender
; APPLICANT: Kaare Lund
; APPLICANT: Tina Anderson Hollerup
; TITLE OF INVENTION: Novel Process For The Detection of Mycobacteria
; NUMBER OF SEQUENCES: 123
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER
; STREET: 1300 I ST. NW
; CITY: Washington
; STATE: District of Columbia
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk 3.5 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: ASCXI
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/544,934B
; FILING DATE: 07-Apr-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/028,392
; FILING DATE: 15-Oct-96
; APPLICATION NUMBER: 60/029,595
; FILING DATE: 23-Oct-96
; APPLICATION NUMBER: 60/045,962
```

```

; FILING DATE: 08-May-97
; APPLICATION NUMBER: 08/943,777
; FILING DATE: 3-Oct-97
; ATTORNEY/AGENT INFORMATION:
;   NAME: Anthony C. Tridico
;   REGISTRATION NUMBER: 45,958
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (202) 408-4173
;     TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 44:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 15 basepairs
;     TYPE: nucleic acid basepairs
;     STRANDEDNESS: single
;     TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 44:
US-09-544-934B-44

Query Match      0.6%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1962 CCGAGCATGATC 1974
DB      13 CCGAGCATGATC 1

RESULT 423
US-10-138-674-5827/C
; Sequence 5827, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
;   APPLICANT: Ribozyme Pharmaceuticals, Inc.
;   APPLICANT: Pavco, Pam
;   APPLICANT: McSwiggan, Jim
;   APPLICANT: Stinchcomb, Dan
;   APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5827

Query Match      0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTGAGGCTCC 2228
DB      16 TGGTGAGGCTCC 4

RESULT 424
US-10-287-949A-5827/C
; Sequence 5827, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;   APPLICANT: Ribozyme Pharmaceuticals, Inc.
;   APPLICANT: Pavco, Pam
;   APPLICANT: McSwiggan, Jim
;   APPLICANT: Stinchcomb, Dan
;   APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
```

```

; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5827
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5827

Query Match      0.6%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTGAGGCTCC 2228
DB      16 TGGTGAGGCTCC 4

RESULT 425
US-09-866-108-897/C
; Sequence 897, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;   APPLICANT: GU, Yizhong
;   APPLICANT: JI, Yonggang
;   APPLICANT: PENN, Sharon G.
;   APPLICANT: HANZEL, David K.
;   APPLICANT: RANK, David R.
;   APPLICANT: CHEN, Wensheng
;   APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 897
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-897

Query Match      0.6%; Score 13; DB 1; Length 17;
```

Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1699 AGGCCCCCTCCCC 1711  
|||  
Db 13 AGCCCCCTCCCC 1

RESULT 426  
US-09-866-108-9584  
; Sequence 9584, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOmica-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263, 6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: AeoMica Sequence Listing Engine  
; SEQ ID NO 9584  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-9584

Query March 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1171 AGGAAAAGCTGC 1183  
|||  
Db 4 AGGAAAAGCTGC 16

RESULT 427  
US-09-866-108-9585

; Sequence 9585, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOmica-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263, 6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: AeoMica Sequence Listing Engine  
; SEQ ID NO 9585  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-9585

Query March 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1171 AGGAAAAGCTGC 1183  
|||  
Db 3 AGGAAAAGCTGC 15

RESULT 428  
US-09-866-108-9586  
; Sequence 9586, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark

RESULT 427  
US-09-866-108-9585



```

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9586
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9586

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGCTGC 1183
Db      2 AGGGAAGCTGC 14

RESULT 429
US-09-866-108-9587
; Sequence 9587, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Menesheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9587
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-9587

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1171 AGGGAAGCTGC 1183
Db      1 AGGGAAGCTGC 13

RESULT 430
US-09-740-332-641
; Sequence 641, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 641
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-09-740-332-641

Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      576 CCGGCGGCTGCTC 588
Db      5 CCGGCGGCTGCTC 17
```

```
RESULT 431
US-09-740-332-642
; Sequence 642, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 642
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-642
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      576 CCTGCTGCTCCTC 588
Db      2 CCUGUGGUCUC 14
```

```
RESULT 432
US-09-740-332-3913/C
; Sequence 3913, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3913
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3913
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      576 CCTGCTGCTCCTC 588
Db      17 CCTGCTGCTCCTC 5
```

```
RESULT 433
US-09-740-332-3914/C
; Sequence 3914, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: RPI 400/003
```

```
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3914
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3914
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      576 CCTGCTGCTCCTC 588
Db      14 CCTGCTGCTCCTC 2
```

```
RESULT 434
US-09-817-879-641
; Sequence 641, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 641
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-641
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 2.2e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      576 CCTGCTGCTCCTC 588
Db      5 CCUGUGGUCUC 17
```

```
RESULT 435
US-09-817-879-642
; Sequence 642, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 642
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
```

NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-642

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 69.2%; Pred. No. 2.2e+02;  
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588  
DB 2 CCUGGUGUCUCC 14

RESULT 436  
US-09-817-879-3913/C  
Sequence 3913, Application US/09817879  
Publication No. US2003017131A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
FILE REFERENCE: MBH00-801-F  
CURRENT APPLICATION NUMBER: US/09/817,879  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9703  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3913  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3913

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588  
DB 17 CCTGGTGTCTC 5

RESULT 437  
US-09-817-879-3914/C  
Sequence 3914, Application US/09817879  
Publication No. US2003017131A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
FILE REFERENCE: MBH00-801-F  
CURRENT APPLICATION NUMBER: US/09/817,879  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9703  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3914  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3914

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 576 CCTGGTGTCTC 588  
DB 14 CCTGGTGTCTC 2

RESULT 438  
US-10-156-306-5930  
Sequence 5930, Application US/10156306  
Publication No. US20030119017A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: MCSwigen, James  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
FILE REFERENCE: MBH01-664-A (400/050)  
CURRENT APPLICATION NUMBER: US/10/156,306  
CURRENT FILING DATE: 2002-05-28  
NUMBER OF SEQ ID NOS: 8013  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5930  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-156-306-5930

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 2.2e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1922 GCCAGCTGTGAG 1934  
DB 5 GCCAGCTGTGAG 17

RESULT 439  
US-10-156-306-6802/C  
Sequence 6802, Application US/10156306  
Publication No. US20030119017A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: MCSwigen, James  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
FILE REFERENCE: MBH01-664-A (400/050)  
CURRENT APPLICATION NUMBER: US/10/156,306  
CURRENT FILING DATE: 2002-05-28  
NUMBER OF SEQ ID NOS: 8013  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 6802  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-156-306-6802

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 217 TGGCGGGTCTCA 229  
DB 17 TGGCGGGTCTCA 5

RESULT 440  
US-10-230-006-742/C  
Sequence 742, Application US/10230006  
Publication No. US20030191077A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Fossnaugh, Kathy  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDIT  
FILE REFERENCE: 400/056 (MBH01-1110)

```
; CURRENT APPLICATION NUMBER: US/10/230,006
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US 60/315,315
; PRIOR FILING DATE: 2001-08-28
; NUMBER OF SEQ ID NOS: 2678
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 742
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-230-006-742

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      28 CGCGGATGCCGCT 40
DB      13 CGCGGATGCCGCT 1

RESULT 441
US-10-138-674-813
; Sequence 813, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-813

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCACTTCTCA 703
DB      5 AUGGCCAUCUCUA 17

RESULT 442
US-10-138-674-814
; Sequence 814, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-10-138-674-814

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      691 ATGTCACTTCTCA 703
DB      1 AUGGCCAUCUCUA 13

RESULT 443
US-10-138-674-4754/c
; Sequence 4754, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4754

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2216 TGGTGACAGCTCC 2228
DB      16 TGGTGACAGCTCC 4

RESULT 444
US-10-138-674-4789/c
; Sequence 4789, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4789

Query Match      0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      328 CTTGCTTGTTC 340
DB      1 CTTGCTTGTTC 340
```

Db 16 CTGCTGTTC 4

RESULT 445  
US-10-138-674-5053  
; Sequence 5053, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5053  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-5053

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 2.2e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGAGCCAGCTG 1929  
:|||||:|  
Db 2 UGGAGCCAGCTG 14

RESULT 446  
US-10-138-674-5054  
; Sequence 5054, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5054  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-5054

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 2.2e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGAGCCAGCTG 1929  
:|||||:|  
Db 1 UGGAGCCAGCTG 13

RESULT 447  
US-10-138-674-5194  
; Sequence 5194, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5194  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-5194

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 2.2e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCATTCTCA 703  
:|||||:|  
Db 4 AUGUCCAUUCUCA 16

RESULT 448  
US-10-138-674-5195  
; Sequence 5195, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5195  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-5195

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 61.5%; Pred. No. 2.2e+02;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCATTCTCA 703  
:|||||:|  
Db 3 AUGUCCAUUCUCA 15

RESULT 449  
US-10-138-674-7658/c  
; Sequence 7658, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwigen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03

```
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7658
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7658
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      328 CTTGCTTGTTC 340
      |||||
Db      13 CTTGCTTGTTC 1
```

```
RESULT 450
US-10-138-674-7857
; Sequence 7857, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7857
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7857
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 84.6%; Pred. No. 2.2e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1917 TGGAGCCAGCTG 1929
      :|||||
Db      4 UCGAGCCAGCTG 16
```

```
RESULT 451
US-10-138-674-9169/C
; Sequence 9169, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9169
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-9169
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
```

```
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      77 TACTGCTACTTCT 89
      |||||
Db      17 TACTGCTACTTCT 5
```

```
RESULT 452
US-10-287-949A-813
; Sequence 813, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 813
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-813
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      691 ATGTCAATCTCA 703
      ||:||||:|
Db      5 AUGGCCAUTCUCA 17
```

```
RESULT 453
US-10-287-949A-814
; Sequence 814, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 814
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-814
```

```
Query Match          0.6%; Score 13; DB 1; Length 17;
Best Local Similarity 61.5%; Pred. No. 2.2e+02;
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      691 ATGTCAATCTCA 703
      ||:||||:|
Db      1 AUGGCCAUTCUCA 13
```

```
RESULT 454
```

US-10-287-949A-4754/c  
; Sequence 4754, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4754  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-4754

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2216 TGGTGCAGGCTCC 2228  
DB 16 TGGTGCAGGCTCC 4

RESULT 455  
US-10-287-949A-4789/c  
; Sequence 4789, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4789  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-4789

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 328 CTTCCTTGTTCC 340  
DB 16 CTTCCTTGTTCC 4

RESULT 456  
US-10-287-949A-5053  
; Sequence 5053, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5053  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-5053

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 2.2e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGGAGCCAGCTG 1929  
DB 2 UGGGAGCCAGCTG 14

RESULT 457  
US-10-287-949A-5054  
; Sequence 5054, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5054  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-5054

Query Match 0.6%; Score 13; DB 1; Length 17;  
Best Local Similarity 84.6%; Pred. No. 2.2e+02;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGGAGCCAGCTG 1929  
DB 1 UGGGAGCCAGCTG 13

RESULT 458  
US-10-287-949A-5194  
; Sequence 5194, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5194  
; LENGTH: 17

TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-5194

Query Match  
Best Local Similarity 61.5%; Score 13; DB 1; Length 17;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCAATTCCTCA 703  
DB 4 AUGUCAUUCUCA 16

RESULT 459  
US-10-287-949A-5195  
Sequence 5195, Application US/10287949A  
Publication No. US20040102389A1  
GENERAL INFORMATION: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/287,949A  
CURRENT FILING DATE: 2003-04-11  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5195  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-5195

Query Match  
Best Local Similarity 61.5%; Score 13; DB 1; Length 17;  
Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 691 ATGTCAATTCCTCA 703  
DB 3 AUGUCAUUCUCA 15

RESULT 460  
US-10-287-949A-7658/C  
Sequence 7658, Application US/10287949A  
Publication No. US20040102389A1  
GENERAL INFORMATION: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/287,949A  
CURRENT FILING DATE: 2003-04-11  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 7658  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-7658

Query Match  
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 328 CTGCTGTGTTCC 340

DB 13 CTGCTGTGTTCC 1

RESULT 461  
US-10-287-949A-7857  
Sequence 7857, Application US/10287949A  
Publication No. US20040102389A1  
GENERAL INFORMATION: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/287,949A  
CURRENT FILING DATE: 2003-04-11  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 7857  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-7857

Query Match  
Best Local Similarity 84.6%; Score 13; DB 1; Length 17;  
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1917 TGGGAGCCAGCTG 1929  
DB 4 UGGAGCCAGCTG 16

RESULT 462  
US-10-287-949A-9169/C  
Sequence 9169, Application US/10287949A  
Publication No. US20040102389A1  
GENERAL INFORMATION: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MHB00-876-N (400/049)  
CURRENT APPLICATION NUMBER: US/10/287,949A  
CURRENT FILING DATE: 2003-04-11  
NUMBER OF SEQ ID NOS: 20822  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 9169  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-287-949A-9169

Query Match  
Best Local Similarity 100.0%; Score 13; DB 1; Length 17;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 TACTGCTACTTCT 89  
DB 17 TACTGCTACTTCT 5

Search completed: June 30, 2004, 08:43:46  
Job time : 13 secs